<SEC-DOCUMENT>0000950170-23-005713.txt : 20230302
<SEC-HEADER>0000950170-23-005713.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302073106
ACCESSION NUMBER:		0000950170-23-005713
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		121
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verve Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001840574
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824800132
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40489
		FILM NUMBER:		23696424

	BUSINESS ADDRESS:	
		STREET 1:		201 BROOKLINE AVENUE
		STREET 2:		SUITE 601
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215
		BUSINESS PHONE:		(978) 501-3026

	MAIL ADDRESS:	
		STREET 1:		201 BROOKLINE AVENUE
		STREET 2:		SUITE 601
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02215
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>verv-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-03-01T20:25:49.2952+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:verv="http://www.vervetx.com/20221231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_61ee6742-2a51-4098-a058-1a9dd746d7b1" name="dei:DocumentFiscalPeriodFocus" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b">FY</ix:nonNumeric><ix:nonFraction id="F_4e655ade-06f9-4904-b02d-66b61f8a751c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="C_966c03b1-7109-4952-a069-3bb673a98824" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_6bd918bc-c341-4101-91d6-aa85e1089ebc" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b">http://www.vervetx.com/20221231#ChangeInFairValueOfSuccessPaymentsLiabilities</ix:nonNumeric><ix:nonFraction id="F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80" name="verv:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_37a3732c-67b8-46fa-a2d3-2aa2597e06dc" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_966c03b1-7109-4952-a069-3bb673a98824" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1581fec8-0bf5-40f2-be75-6ab97ee8bb15" name="us-gaap:CommitmentsAndContingencies" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e0722370-e756-4380-b190-71e49f255f38" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_caa34b87-6d61-41fe-980c-8d45934c3138" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ff5d24c9-5ffa-4c7d-adf1-18e4911abf8a" name="us-gaap:CommitmentsAndContingencies" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_16e89c46-c096-4d76-8afc-fed6bca8d8cc" name="us-gaap:DeferredRevenueAndCreditsNoncurrent" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_e3a6ec9a-5c47-4978-aa82-c8c00b6f48a0" name="dei:EntityCentralIndexKey" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b">0001840574</ix:nonNumeric><ix:nonFraction id="F_8bfc5d9b-0194-447d-8d63-2e05dbf8ee1e" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" contextRef="C_29085c5c-8572-4342-8193-f44746b659b7" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_bfddd2a3-f9a3-4e13-bcf7-0bf43949f96f" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" contextRef="C_bec200da-6561-47c7-ada8-88c14ff8512c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_34d72d37-b190-41b5-ad0e-3ad3cb160e08" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a">http://www.vervetx.com/20221231#ChangeInFairValueOfSuccessPaymentsLiabilities</ix:nonNumeric><ix:nonNumeric id="F_d1f0b311-5b89-4607-814f-03d3a360452f" name="dei:AmendmentFlag" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric id="F_ff58d8b0-898f-4781-8d83-6a9291f25557" name="us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric id="F_57262f8f-91c8-4da2-8965-8ef6140c8e90" name="dei:CurrentFiscalYearEndDate" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" format="ixt:datemonthday">12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="verv-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_57a4273e-e500-4784-b24f-2d7cd8c95f12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10db78b5-9531-4269-b673-ed6a44209efb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1338186f-d03c-4d8a-a4c8-31af991b82fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0cb67e6f-2894-4db6-9521-909923920eff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e543a38-cef8-457e-8d21-0bec7784e4f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bac8d82c-d5da-4a33-90e9-09318020506e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fc34a2a2-051c-4d86-b8ad-adf3902f2be3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c170bb7-edb6-442d-8788-b1811c3e3301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f2608f6-1835-45a9-8887-c4db04550843"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f9a1d59-c482-4313-96a8-40ac3152c220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ThirdLicensedAgentMaterialRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01e0a48b-6d98-43b9-9faa-58583e0071a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59c54d37-04e4-4cc3-9af1-28ee8d5dcf07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyEighteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bec200da-6561-47c7-ada8-88c14ff8512c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c513a636-9c59-4d55-ad2f-c703f327678f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94979cff-1f2a-464c-857e-c9995bec9c94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f3707ed-9eee-4702-833d-a6141f5a0cf1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c63f0f3-4bd5-489e-af2c-513202741f0b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7175e0b6-9535-4c9e-8e30-3ebf8ac9de8f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80d92420-5853-477a-a2f9-78d029bbafe0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0445a9ca-bc9f-4e03-ba8a-fb18a059a14c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aab4db61-ccdc-4683-9f00-31e18b63c0b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_86e5cc33-d110-47af-ada1-8665901d8afd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1eb38d59-c0ac-4039-ba0c-18ac2f3c88af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dbed675-16ab-43ad-92de-56cb1fea30b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_40e18ed5-64dd-4a21-8cc0-7eb7d48b6faf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d68b3a6-6891-4343-9cac-092f95f5b426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70c6c44c-62b4-4951-beb7-990103810b72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_87908575-032d-4129-a33d-db396e918336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_caa34b87-6d61-41fe-980c-8d45934c3138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2b381c95-04aa-4fba-8306-9a71bc42bac3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e417686-fb62-4c06-b6fd-6b68c1256e22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f27beec5-2375-455d-9c1c-624e6dbd8e18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:NovartisLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d8970451-3d27-43fa-9ddd-5d84fc44e22a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d159b9f9-0a0b-4be3-8ded-15481d15c220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_67250595-6ef1-4d88-b28c-b2e432497a69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_101c4b75-a6d1-40e5-b320-d63b7c3de7e7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_37ef4e5c-ee38-4746-8f83-e39d97e60aa9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fa5f0add-d465-41c4-9cb6-bd0f9bb41f41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3188091a-eb34-4e3d-9630-e21db1a73318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e616ea55-8674-4e50-833f-8f6bccf6e730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_63860296-a4f0-4e1a-9241-b6d773d5b067"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e3e444f8-82bf-4a8e-a308-5343180b3425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:NewAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5a628f3e-c8f6-4620-953c-b4cae63925d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0f69b44-4afb-469a-88cb-446f929e64b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_595a69e0-a981-426d-a6f1-79798dc73b95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0bedcb64-f835-4169-aae4-e6de370db89e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57662c72-eee2-4c4f-951b-40edfc12c8d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_279982b2-44db-49b7-a99b-e765968a154b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:AntidilutionRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c9c2b5b-d0e5-4156-b918-deac7e15a723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eab2ba07-0259-4573-8347-1b9098fe2136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f440c691-328c-490a-b5a2-6550bd63dd18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f5c58be5-49fc-43e9-a294-cc491cbf767a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac822c00-7c16-4ab3-98ac-86f18f43dbac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:OfficeFurnitureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_70871dfe-f33d-4493-9391-2c839d284371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50163530-3d32-4277-baac-6dd493e6a3c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ac9284d-7074-4f13-885b-3fd225b5738d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fb1c32eb-3cf9-4efd-b9f9-ef61f34a3d24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1235d3e0-b5c0-47c5-9f20-b1afa841a242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e1ed61d-8951-4d1b-b942-435100437cc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_645da17b-a2fa-4382-926c-98c8f1d57914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_959c970c-a6c2-451b-acea-26466d2da446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a1b1686d-7c2d-471e-b953-e9208218d02c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bf4fef6-d58f-4313-8771-beb6b446dd32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b573d06e-feb8-4e52-95a0-9b02cf165de9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8289e27-62a6-4835-8e99-588f8ef3162f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_24f24102-d3be-4e87-98e7-0dfd0698620a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f6e04a3c-5788-44a1-b5df-375dfe290497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:VertexPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97838a2e-40af-4778-a7e5-dbade0a2d74e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab3f67d4-0906-4241-abd4-7bdebb98d719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d7b83b22-0b4c-4a86-a0f7-f54ef4b0daf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_899016e2-2a07-4bd4-8bcc-57974930a3bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:VertexPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a18baa7c-e6c9-43fd-b0ab-55458b1c2d27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42e3df2c-8ff1-469a-8a07-db72c7a21989"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28918730-6ac5-404a-a56f-497ecef921d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24f6e06a-2bf4-411d-b931-999829f73aa4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6dce68af-09ea-451e-8aa9-bbbf481d2537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51f6cfff-f169-440d-8129-93e247a0bd28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_910510d8-3c53-4144-8d2f-5bf2ee890957"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc3d1cc1-733b-4bd6-a6d6-e0509cce03f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_549dd0a2-a1f7-47be-962d-821373cb96d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69ead165-eb9d-4003-9e73-6dde8148295a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9e4fa60e-e2a1-48fa-9006-8da2fef90e88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79adf0ca-6cf4-4e27-a49b-9bf797059526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8840dc16-dd94-470b-ae47-6f49752ffb5d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e4a312ba-6931-4d91-b541-fb2e420d6d93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5c084e08-8487-4c71-bcce-ce2e7baea2d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-18</xbrli:startDate><xbrli:endDate>2022-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_88c35c5e-d77b-4780-9fe2-eff887d461de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4353a489-6849-4ba4-97a8-7fc091cf5f01"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-05</xbrli:startDate><xbrli:endDate>2022-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5fb7e70-f89c-46e0-8d34-d37cadafb70e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1a914828-67e8-495a-9b12-2c48154e0de5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e91dace-0a68-4bad-a0fd-32815efdc68c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cbafceb-7d5c-4f1a-8167-31d9b2611fff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5632b0e3-72a0-490d-b288-cdfcbada6292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6df26867-2d6b-46b4-b508-092bafb9230e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f3934e3e-c3eb-462e-aef8-a427f8923a25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a7a03b0-4e2c-4c61-8591-8ea00dfc50ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ea5b1c4-02d7-4d08-83fa-e232cce51d59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b22cbc9c-7068-4848-a684-7dd33933fb13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8c752a7-a423-48c6-a1b6-94dbe8e1f488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc740280-5fd2-4e74-a2d7-888d97ae217e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dcad783b-c139-4ff0-8e9c-6423e1ed3d39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_014a8cde-c8d4-4025-be72-d973721b5175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e5b7c24-a5e8-4c36-8628-c7caf3267a19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5533c143-e11b-4687-bab9-616ee25f12a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25b472d9-741d-43a8-b055-7f86620a197c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2029774-b097-49be-abf0-6584c59d9b9d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdcae62d-bb8e-473d-9798-be656594f6aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6c1812ca-014b-4804-9c67-8987654bfa75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2189d68-ff46-4307-87ca-ccad5ed5d257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02d7b42f-eec4-4cd5-861d-bf55e78340ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80a0f724-7529-472e-8067-5943bc65251c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62529372-4437-4f8a-a2e2-7adb297a1ce7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d5267666-4c65-44f3-9936-fcf70ee31d7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eca01a0b-4203-4974-86fd-df6598a8bcb7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84d11930-e66f-4233-9020-576b7dc6f3ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dd1cb871-5f3e-4054-bc64-84e70cd6064d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_467087e6-7c15-4d2a-b5aa-9b131364dec6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_336f1e13-611b-497c-ba64-333f8e899c92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce21619d-19f7-43cd-b8d5-a7b052f3bd59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aea2e412-934b-4a07-a049-22c9f1b5ea0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_80fe8138-eecf-486b-bd60-cbf5bf880dae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">verv:DeliveryTechnologyProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_966c03b1-7109-4952-a069-3bb673a98824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e463725-1023-4ed8-9f1a-3d4cf8b31389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3fdd3360-eab0-4708-a04c-8b89365954ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_808142c2-b5e3-4524-9ea6-da21e029cba1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6c51c82-3c32-4a05-9b39-deffe3ffdec3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_dc7fb957-db9b-4919-85c0-f2b666593c29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17d2fd0e-b2d9-4c3d-8c72-65febc814137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_811d34f0-c7b1-4e6e-ab97-bb9220268914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_69bde097-9b90-4143-bf28-ce208cea2c64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_146d0396-0c40-4489-aa98-b2e85e1a984e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ResearchServicesObligationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4507e5e6-86e5-49af-9e91-39416a49e6de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:FirstLicensedAgentMaterialRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_787fb8f2-564a-4ad4-9e81-6ab4543c8745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c8436e03-c1f0-4e91-a1b2-e9f92451d6ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bcc724c9-3022-47b5-8ad1-b152262e7aba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_042eaa61-5d4c-48a9-bc1a-4987ee4f1dc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1fa2bdd3-e60a-48e3-89d8-47c5490b909e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0d7d5bec-d770-4173-b7fa-5da0ea98f60b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_875f1476-cc60-4a70-a9cc-ff85d743c58f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_199a8315-5928-47de-86f7-85c75d05000c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0561a53b-a5ef-42c6-abb0-89bfc7201442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a76866af-dd3c-4049-b8fe-63fdc94162b1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d29fbc3-5622-4165-a232-e591a91a09ce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a8149ba-0367-4d16-9824-0138611d7cd9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d5b798c-354b-494c-aca5-76cbed28659a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5977f77c-03e7-4fcd-8eb7-0857be233fcb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aa0bb9fe-96a8-4b16-bddc-1ab940b85d65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_830a7292-f023-456a-aa51-b7b87abe1927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_34a36f82-56c7-4f23-aefa-cbf18563b2c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4c419fcc-8948-4d11-ad8c-bc4acd187a2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8d200ccf-3e5b-4292-a74b-e614b3ce55e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_28ec8de1-aead-4024-b68e-b6f0436f3e8c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a90ac7d2-282e-440c-801e-9a2c12563c84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29085c5c-8572-4342-8193-f44746b659b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_38705494-508f-4282-b760-eb63eae1915e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_045cb64e-47d4-4a6a-8f5f-0799d3c6d0ca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_42d8066c-ec6d-457c-92e0-ad6208d5c754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8c22a27c-1726-4bbe-9663-4f3fa7321495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d49a8d56-7215-4b6b-85ee-c2345d8966fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1bf70619-a638-4c23-8216-60415235bbb2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a3dbf855-2073-449b-a0a1-57d11e804ae3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:NovartisLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1a6ad37-f5ef-49b3-be24-86dec915f36d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-18</xbrli:startDate><xbrli:endDate>2022-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_84658634-9c24-4121-9463-34ea37f01b51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b8656ae-4c34-40f1-ae35-56f5f8a895dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_346778ed-ab28-463d-a0c6-1e76673dd790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ac36620-71e8-4db8-856c-7631ba94d156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7f3b431e-5ee8-4828-90a9-812944400c44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5476f53e-8810-4a5b-afa1-3ba7403c605f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ThreeLicensedAgentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_10236809-a80e-4e09-9626-2b295f8196ed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_52a4a369-ae67-4de2-82c2-3426ee972653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a53dba14-9b85-4825-a901-caab2a81e8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d9b46b8-dcc4-4ea7-bf1b-5b347b2d06e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:SecondLicensedAgentMaterialRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_deea9644-67bd-4520-bcd2-358aa23d9d50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ca2fc95-4cb8-4120-8d3b-72c64d65a515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ab5cdc4-68f7-4336-be12-9a43b519475c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d9d32810-8547-4214-94fc-56f99ab953c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06dbfcce-3022-4b09-89dd-3eef6740f46e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_727f645b-7b13-42e1-8111-8ed8a5b4c112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_df58c0aa-a8ae-4c98-9b38-70834ce1e110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-31</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_72c91c7c-a0cb-4506-8c90-233e59c44e9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dd53e7c9-c890-4a7b-9181-75e01d01947a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d7ab199-9fb8-4980-b91e-4d41f59ce3e9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9af85f91-63b3-41d0-b819-c7632790919e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_345d25d5-d53c-4618-b2d5-0ad9f68dc335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66ae070f-26c2-44ff-92ab-c5483d69abea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce0e9729-f513-4bf1-8488-e529d1be5407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0deae6b1-45ca-4fba-96bb-c6dc6d5add88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_43ffe065-4842-415c-88bd-7c2bb5a6e05d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b2ed33c7-4d15-43a9-aa3d-221d32e3b104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f639dd3-36f0-4110-95b1-083a24288e33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c0f7b69c-0978-4971-a704-73743e494290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e3fcf3c5-2b24-43ee-a2b3-55105e54c465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e9d5bc3b-5c96-4d9f-b2f1-b89dbdfe1151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_604ef497-9ecd-45dc-bf27-276566041fda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f7382e3-ab33-42f1-8d80-f3c02882b1e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e2c72aa-22a4-4e86-9784-5469e1b2efbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4ef51bcc-9dfc-45c1-9eee-f5566e195c5b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8d60c32-c672-429e-9168-9e517a3b0c68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69a15539-dd92-45a4-b854-128562acce6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ebb779e-eadf-4f21-b115-8bc997a90a32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ef2c8bcc-a458-4df0-ac7a-cb2750615042"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-18</xbrli:startDate><xbrli:endDate>2022-07-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2df5c335-7703-4efb-9c6f-ac0c13ef2ed0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cbef945b-b67d-4d13-994e-026951a49f6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001840574</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-19</xbrli:startDate><xbrli:endDate>2021-08-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Instalment"><xbrli:measure>verv:Instalment</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>verv:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" fromRefs="F_f13bbc0a-1453-4f66-a849-7ec20406a08c F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e F_ee2714e4-37d2-461d-909b-8a096b25efba F_0a599922-8081-4710-9bde-35868f890597"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" fromRefs="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e F_09a7fb2b-0c8b-414b-a38f-15fe81be641f F_3e8d2871-8d7c-41d2-a82b-315398b036e2"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="border-top:2.25pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Washington, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a527e3c1-99d0-4b89-bd23-8fa38a336953" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b93028c5-c6ba-4f95-8bd8-cf11bec4795d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the fiscal year ended </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_ae3138f1-3b69-4cea-8e7a-2af8cb0cea44" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_38e7ca92-45c0-477c-b131-bc819c515177" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></ix:nonNumeric></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_85d31b85-c9b7-47ae-9709-34c597f111ec" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.01in;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">                     </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commission File Number </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_763ee878-6120-4c16-bb03-bbc6718302e1" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">001-40489</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_cab5972b-04ea-4803-a296-46773c77a64c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE THERAPEUTICS, INC.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Exact name of Registrant as specified in its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_49b15578-ef35-477f-91e6-e8e357c7fade" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_86a4d2ca-ad68-40d6-a049-714ee9d6bc40" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82-4800132</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_38311786-fea5-4d52-9962-e79cdde7d9a0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">201 Brookline Avenue, Suite 601</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_102cc5e4-b08c-4a1c-a20b-7448cd454dad" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_448381ca-19e3-42e8-b8de-0d78f121d6a3" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Massachusetts</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9c8c11b3-b159-4615-a8c7-37cbd2e7f107" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">02215</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_30425964-9aad-4d39-a3bf-8e5781d17d63" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">617</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">) </span><span style="font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_37800150-02f4-4693-aff8-1c49e2aaaa9a" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">603-0070</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Trading</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_14369adc-2df8-429f-94d3-1145d519113e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common stock, par value $0.001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0d38ff46-4c61-4b70-be32-ce9795926485" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERV</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4cd65674-c8db-4413-a049-5bbc0ff032ab" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Securities registered pursuant to Section 12(g) of the Act: </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">     </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f02e2a12-270e-47ba-b13a-74457f118614" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">     </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_bbfd52de-ec9f-463e-af36-a566fe184041" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_87706536-e4ff-4de1-ac07-50a8df1c86bc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">     No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a8ed1cb3-c64d-4e59-b9a6-c35b982b253f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">     No </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:18.898%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:55.843%;"></td>
    <td style="width:1.056%;"></td>
    <td style="width:20.102%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:2.102%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6e9ebc9a-0511-40d0-a3c7-9640d0d5fcde" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_24a22007-e39e-43e1-ba06-774284151ce8" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntitySmallBusiness" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_d12e5ad2-caa2-464d-832a-fce6aefb9ac2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_bf782cd6-4854-45bc-afa8-670697d31ca3" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_0f610a30-1c7b-45ba-91e0-7c137b43d6a8" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#x2019;s executive o&#xfb03;cers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9744;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">     No </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_5c920c8f-10ad-4c16-9a25-995eb7fe159b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate market value of the voting and non-voting common stock held by non-affiliates of the Registrant was $</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4463efea-1505-4014-a07e-b041a1c14406" contextRef="C_fc3d1cc1-733b-4bd6-a6d6-e0509cce03f2" name="dei:EntityPublicFloat" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">557.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million bas</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ed on the closing price of the registrant&#x2019;s common stock on Nasdaq as of June 30, 2022, the last business day of the registrant&#x2019;s most recently completed second quarter.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The number of shares of registrant&#x2019;s common stock outstanding as of February 27, 2023</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was </span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_33b9253e-e9c4-40cc-a55d-911e21181869" contextRef="C_fc740280-5fd2-4e74-a2d7-888d97ae217e" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,833,265</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_99f09b40-7617-4371-9e60-4fc8f5670a69" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2023 Annual Meeting of Stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Annual Report on Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.992%;"></td>
    <td style="width:82.004%;"></td>
    <td style="width:7.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#forward_looking_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#risk_factor_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RISK FACTORS SUMMARY</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART I</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Business</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">74</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Properties</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART II</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">141</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[Reserved]</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">143</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">144</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">157</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 8.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9B.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9C.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">159</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART III</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 10.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 11.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 12.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 13.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 14.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principal Accounting Fees and Services</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART IV</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 15.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibits, Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">161</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;text-indent:6.85pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 16.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">163</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="forward_looking_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This Annual Report on Form 10-K includes forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;might,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the initiation, timing, progress and results of our research and development programs, preclinical studies and clinical trials, including the timing of our submissions of investigational new drug, or IND, applications, and clinical trial applications to regulatory authorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing and conduct of our heart-1 clinical trial, an ongoing Phase 1b clinical trial of VERVE-101, including statements regarding the timing of enrollment and completion of the clinical trials and the period during which the data from clinical trials will become available;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations related to the hold that the U.S. Food and Drug Administration, or FDA, placed on our IND application to conduct a clinical trial evaluating VERVE-101 in the United States, including our plans and expectations for responding to the FDA;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our estimates regarding expenses, future revenue, capital requirements, need for additional financing and the period over which we believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing of and our ability to submit applications for and obtain and maintain regulatory approvals for our current and future product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the potential therapeutic attributes and advantages of our current and future product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations about the translatability of results from studies in non-human primates into clinical trials in humans; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our plans to develop and, if approved, subsequently commercialize any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the rate and degree of market acceptance and clinical utility of our products, if approved; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our estimates regarding the addressable patient population and potential market opportunity for our current and future product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities and strategy; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations regarding our ability to obtain and maintain intellectual property protection; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to identify additional products, product candidates or technologies with significant commercial potential that are consistent with our commercial objectives; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the impact of government laws and regulations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our competitive position and expectations regarding developments and projections relating to our competitors and any competing therapies that are or become available; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments relating to our competitors and our industry; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to establish and maintain collaborations, including our collaborations with Beam Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the impact of the COVID-19 pandemic and of global economic developments, including rising inflation and interest rates, on our business, operations, strategy and goals; and</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our expectations regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#x201c;Risk Factors&#x201d; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments we may make or enter into.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed as exhibits to our other filings with the Securities and Exchange Commission completely and with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Except where the context otherwise requires or where otherwise indicated, the terms &#x201c;we,&#x201d; &#x201c;us,&#x201d; &#x201c;our,&#x201d; &#x201c;our company,&#x201d; &#x201c;the company,&#x201d; and &#x201c;our business&#x201d; in this Annual Report refer to Verve Therapeutics, Inc. and its consolidated subsidiary.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;" id="risk_factor_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe to be the principal risks facing our business, in addition to the risks described more fully in Item 1A, &#x201c;Risk Factors&#x201d; of Part I of this Annual Report on Form 10-K and other information included in this report. The risks and uncertainties described below are not the only risks and uncertainties we face. Additional risks and uncertainties not presently known to us or that we presently deem less significant may also impair our business operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any of the following risks occurs, our business, financial condition and results of operations and future growth prospects could be materially and adversely affected, and the actual outcomes of matters as to which forward-looking statements are made in this report could be materially different from those anticipated in such forward-looking statements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are very early in our development efforts, and we only recently initiated our first clinical trial of a product candidate, VERVE-101, our product candidate targeting PCSK9. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates into and through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The U.S. Food and Drug Administration has placed the investigational new drug, or IND, application to conduct a clinical trial evaluating VERVE-101 in the United States on hold and the IND remains on hold. We cannot be certain that the hold will be lifted on a timely basis, or at all, and we may not be able to initiate our clinical trial of VERVE-101 in the United States;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gene editing, including base editing, is a novel technology in a rapidly evolving field that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products. We are focusing our research and development efforts for VERVE-101 and VERVE-201, our development candidate targeting ANGPTL3, on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing and we may not be able to access or use those technologies, which could materially harm our business;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are seeking to discover and develop new gene editing technologies and may not be successful in doing so;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials and interim or preliminary data from our clinical trials may materially change as participant enrollment continues and more participant data become available;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, including lipid nanoparticles, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we fail to comply with our obligations in our intellectual property license arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery, development and commercialization efforts; and</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do. The market with respect to new products for the treatment of cardiovascular disease, for which the standard of care is well-established, is particularly competitive.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART I</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1. Business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Overview</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile&#x2014;requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access&#x2014;and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. Our initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, or LDL-C. We believe that editing these genes could potently and durably lower LDL-C throughout the lifetime of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach leverages multiple breakthroughs in 21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.025pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> century biomedicine&#x2014;human genetic analysis, gene editing, messenger RNA, or mRNA, -based therapies and lipid nanoparticle, or LNP, delivery&#x2014;to target genes that are predominantly expressed in the liver and disrupt the production of proteins that cause CVD. We are advancing a pipeline of single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes in order to lower blood lipids, thereby reducing the risk of ASCVD. We intend to initially develop these programs for the treatment of patients with familial hypercholesterolemia, or FH, a genetic disease that causes life-long severely elevated blood LDL-C, leading to increased risk of early-onset ASCVD. If our programs are successful in FH, we believe they could also provide a potential treatment for the broader population of patients with established ASCVD. Ultimately, we believe that these treatments could potentially be developed for administration to people at risk for ASCVD as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">High cumulative life-long exposure to LDL-C drives the development of atherosclerotic plaque that results in the hardening of arteries seen in ASCVD. The relationship between lowering of cumulative LDL-C exposure and reduction in the risk of ASCVD is among the best understood relationships in medicine. Studies have shown that lowering LDL-C by 39 mg/dL for five years in patients with established ASCVD reduces the risk of a further event by 21%, whereas a similar degree of LDL-C difference over a lifetime reduces the risk of a first ASCVD event by 88%. This demonstrates that the challenge is not only to substantially reduce LDL-C but also to sustain such a reduction throughout a patient&#x2019;s lifetime. We believe that the cornerstone of the treatment and prevention of ASCVD must be early and aggressive reduction of LDL-C for as long as possible.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The current standard of care is a chronic care model that often fails to sufficiently control overall LDL-C exposure due to the continuous and life-long nature of its treatment approaches and the inherent adherence issues it presents. As a result, a large proportion of patients with established ASCVD have LDL-C levels above the goal recommended by the American Heart Association, or the AHA, and the American College of Cardiology, or the ACC, leaving them at risk for recurrent ASCVD events and the potential for invasive medical procedures or even death. Furthermore, given the silent nature of the damage done by elevated LDL-C, many patients at risk for ASCVD do not properly appreciate the therapeutic benefits of consistent treatment as well as the substantial risk of foregoing treatment, focusing instead on the heavy, life-long medication burden of daily pills, lifestyle changes and other chronic approaches. We believe that single-course gene editing treatments that potently and durably control cumulative LDL-C exposure could fundamentally disrupt the chronic care model for treating patients with or at risk for ASCVD and relieve the significant burden placed on patients, providers and the healthcare system.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our lead product candidate, VERVE-101, is designed to permanently turn off the PCSK9 gene in the liver. PCSK9 is a highly validated target that plays a critical role in controlling blood LDL-C through its regulation of the LDL receptor, or LDLR. Reduction of PCSK9 protein in the blood improves the ability of the liver to clear LDL-C from the blood. VERVE-101 utilizes LNP-mediated delivery to target the liver and base editing technology to make a single base change at a specific site in the PCSK9 gene in order to disrupt PCSK9 protein production.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> proof-of-concept study of a precursor formulation of VERVE-101 in non-human primates, or NHPs, we observed substantial lowering of LDL-C levels that was sustained over an extended period of time following</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">treatment. In this study, following a single intravenous infusion of a base editor targeting PCSK9, we observed an average reduction of blood PCSK9 protein of 89% accompanied by an average reduction of blood LDL-C levels of 59% at two weeks after treatment. This LDL-C reduction was maintained at an average of 71% for two years following treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In an ongoing preclinical study with VERVE-101 in NHPs, we observed 70% mean editing following a single administration of 1.5 mg/kg dose at the PCSK9 target gene site in liver biopsies taken at day 15. In this study, we also observed an average reduction in blood PCSK9 protein of 79% accompanied by an average reduction of blood LDL-C levels of 62% at two weeks after treatment. These reductions were durable when assessed for one year after treatment, with mean reduction in blood PCSK9 protein of 89% and blood LDL-C levels of 68%.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, in our preclinical studies in NHPs, VERVE-101 has been well tolerated following a single administration with only mild elevations in liver function tests that resolved within two weeks. In primary human hepatocytes treated with VERVE-101, we observed on-target editing at the PCSK9 target site and did not observe significant editing at any of approximately 3,000 identified potential off-target sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on our preclinical data, we are advancing VERVE-101 initially for the treatment of heterozygous familial hypercholesterolemia, or HeFH. We plan to expand clinical development of VERVE-101 in a stepwise fashion beyond HeFH for the treatment of patients with established ASCVD, who are not at LDL-C goal on oral therapy, which represents hundreds of millions of potential patients globally. Ultimately, we believe that VERVE-101 may be useful to people at risk for ASCVD as a preventative measure in the general population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The heart-1 trial is designed to enroll approximately 40 adult patients with HeFH who have established ASCVD and evaluate the safety and tolerability of VERVE-101 administration, with additional analyses for pharmacokinetics and reductions in blood PCSK9 protein and LDL-C. The trial includes three parts &#x2013; (A) a single ascending dose portion, followed by (B) an expansion single-dose cohort, in which additional participants will receive the selected potentially therapeutic dose and (C) an optional second-dose cohort, in which eligible participants in lower dose cohorts in Part A have the option to receive a second treatment at the selected potentially therapeutic dose. During our interactions with regulators in New Zealand and the United Kingdom, country-specific protocols have been developed to account for various modifications to eligibility, design, and conduct in each country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have received clearance of our clinical trial applications, or CTAs, for VERVE-101 in New Zealand and the United Kingdom, and in July 2022, we announced that the first patient had been dosed with VERVE-101 in our heart-1 clinical trial. In November 2022, we announced that we completed dosing of VERVE-101 in the first dose cohort of the dose-escalation portion of the heart-1 clinical trial, a global Phase 1b open-label clinical trial. Enrollment efforts are ongoing in New Zealand and the United Kingdom. We plan to report initial safety and pharmacodynamic data from the dose-escalation portion of the heart-1 clinical trial in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We submitted our investigational new drug, or IND, application to conduct a clinical trial evaluating VERVE-101 in patients with HeFH to the U.S. Food and Drug Administration, or FDA, in October 2022 and were subsequently informed by the FDA that our IND application was placed on hold. In December 2022, we received a clinical hold letter from the FDA that outlined the information required to resolve the hold, including additional preclinical data relating to: (i) potency differences between human and non-human cells, (ii) risks of germline editing, and (iii) off-target analyses on non-hepatocyte cell types. Clinical data from the ongoing heart-1 clinical trial in New Zealand and the U.K. were not included in the IND application package submitted to the FDA. In the clinical hold letter, the FDA requested available clinical data from the trial. In addition, the FDA has requested that we modify the trial protocol in the United States to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants. We intend to submit our response to the FDA as expeditiously as possible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-201, our development candidate targeting ANGPTL3,is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism. We believe that disrupting ANGPTL3 protein production may lead to reductions in LDL-C and triglyceride levels through a mechanism distinct from that of PCSK9. We plan to develop this program for the treatment of homozygous familial hypercholesterolemia, or HoFH, which affects approximately 1,300 people in the United States, as well as for refractory hypercholesterolemia defined as people with ASCVD who are not at LDL-C goal on oral therapy and a PCSK9 inhibitor. Ultimately, we believe that VERVE-201 may also be useful to people at risk for ASCVD as a preventative measure in the general population. We are conducting preclinical studies to support a regulatory filing for the initiation of clinical development of VERVE-201 and anticipate initiating a Phase 1b clinical trial in 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For VERVE-201, we plan to utilize internally developed GalNAc-LNP to deliver a base editor targeting the ANGPTL3 gene to the liver. In patients with HoFH, delivery of base editors with standard LNPs to the liver is challenging due to the deficiency of LDLR, which is known to mediate LNP uptake. We have developed proprietary LNPs with a GalNAc ligand designed to bind to asialoglycoprotein receptors, or ASGPR, in the liver, which bypass LDLR, thereby enabling uptake into the liver in HoFH patients.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In our preclinical studies of a precursor formulation of VERVE-201 we used a single treatment of two different formulations of our proprietary GalNAc-LNPs to deliver an ANGPTL3-targeted base editor. We observed approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline. We conducted these studies in an internally developed NHP model of HoFH, which we created by editing the LDLR gene in wild-type NHPs and eliminating LDLR expression in the livers of NHPs using a Cas9 and dual guide RNA strategy encapsulated in standard LNPs. In this model, we achieved nearly 70% whole liver DNA editing at the LDLR gene, resulting in an approximately 94% reduction in LDLR protein in the liver and a six-fold increase in blood LDL-C.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In a proof of concept study of an ANGPTL3 base editor in NHPs (n=4), we observed an approximate 96% reduction in blood ANGPTL3 protein from baseline, with follow-up out to two years. In addition, no long-term impacts were observed on markers of liver toxicity, as measured by alanine aminotransferase and bilirubin levels following treatment administration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have also assessed the potential broad utility of our proprietary GalNAc-LNP approach for delivery of an ANGPTL3-targeted base editor, in a preclinical study evaluating delivery efficiency of our ANGPTL3 base editor using either a GalNAc-LNP or a standard LNP without GalNAc in wild-type NHPs with normal livers. In these studies, we observed that wild-type NHPs treated with our ANGPTL3-targeted base editor delivered via our GalNAc-LNP had an approximately 89% reduction in ANGPTL3 protein compared to an approximately 74% reduction in wild-type NHPs treated with a standard LNP.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are continuing to invest and build out capabilities in the development of novel and optimized GalNAc-targeting ligands, optimal lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We believe GalNAc provides a delivery platform for patients with both forms of FH and potentially may be applicable in other applications where liver-directed delivery is advantageous. We have also generated data where we observed that the GalNac-LNP can efficiently deliver base editors targeting PCSK9 as well. In this study, we observed approximately 87% reduction in blood PCSK9 protein after delivering a base editor targeting PCSK9 using GalNac-PCSK9 LNPs in wild-type NHPs. We believe this data suggests that GalNAc-LNP delivery may have broad utility for liver editing in other indications and are advancing a GalNAc-LNP delivered PCSK9 base editor into preclinical development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are focused on building the preeminent company developing gene editing medicines to treat patients with CVD, the world&#x2019;s leading cause of mortality. We intend to leverage the expertise and capabilities of our team to expand our pipeline beyond PCSK9 and ANGPTL3 and apply our single-course gene editing approach to additional </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> liver gene editing treatments, such as our program targeting lipoprotein(a), or Lp(a), to develop a suite of single-course gene editing medicines that address the root causes of disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our team</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We were founded in 2018 by a team of world-renowned researchers in cardiovascular genetics, pioneers of gene editing and proven business leaders, including Sekar Kathiresan, M.D., Kiran Musunuru, M.D., Ph.D., MPH, J. Keith Joung, M.D., Ph.D., Burt Adelman, M.D., Issi Rozen, MBA, and Barry Ticho, M.D., Ph.D. Since our founding, we have built an organization and culture driven by a talented team of individuals who embody the meaning behind our name&#x2014;vigor, spirit and enthusiasm&#x2014;and who are motivated by a common goal of transforming the care of patients with or at risk for CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Members of our leadership team have extensive collective experience in human genetics, gene editing, CVD care and drug development and commercialization. Our chief executive officer, Dr. Kathiresan, is a preventive cardiologist who has made groundbreaking discoveries of genetic mutations that confer resistance to CVD. Andrew Ashe, J.D., our president, chief operating officer and general counsel, is an accomplished biotech executive with over 20 years of experience in operations and legal management. Andrew Bellinger, M.D., Ph.D., our chief scientific officer and chief medical officer, is a cardiologist with proven expertise in drug delivery, drug development and translational medicine. Allison Dorval, our chief financial officer, has more than 20 years of leadership in finance, accounting, financial reporting and investor relations. Joan Nickerson, our Chief Adminstrative Officer, has over 25 years of experience in human resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have a Scientific Advisory Board, or SAB, comprising leading experts in the fields of cardiology, human genetics, translational medicine, delivery technologies, business and finance, including Eugene Braunwald, M.D., Daniel J. Rader, M.D., Andrew Geall, Ph.D., Anthony Philippakis, M.D., Ph.D, Kiran Musunuru, M.D., Ph.D., MPH, and Penny M. Heaton, M.D. Dr. Braunwald, a cardiovascular medicine specialist at Brigham and Women&#x2019;s Hospital and Hersey Professor of Medicine at Harvard Medical School, serves as chair of our SAB, has been listed as the most frequently cited author in cardiology, and was the first cardiologist elected to the National Academy of Sciences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have in-licensed technologies and intellectual property covering various elements of gene editing, including base editing and CRISPR nucleases, as well as multiple LNPs, with licenses from Beam Therapeutics Inc., or Beam, The Broad Institute, Inc., or Broad, Editas Medicine, Inc., the President and Fellows of Harvard College, or Harvard, Massachusetts General Hospital, Acuitas Therapeutics Inc., or Acuitas, and Novartis Pharma AG, or Novartis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Transforming cardiovascular care</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Despite advances in treatment over the last 50 years, CVD remains a global epidemic. The current paradigm of chronic care is fragile&#x2014;requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access&#x2014;and leaves many patients without adequate care. CVD remains the leading cause of death worldwide, responsible for nearly one in three deaths according to the World Health Organization. It is also a leading contributor to reductions in life expectancy and is one of the most expensive health conditions in the United States. According to the United States Centers for Disease Control and Prevention, or CDC, CVD costs the U.S. healthcare system more than $350 billion per year in annual costs and lost productivity. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach focused on addressing the root causes of this highly prevalent and life-threatening disease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CVD collectively refers to diseases of the heart and blood vessels, which are diagnosed as ASCVD, among others, as depicted in the figure below. In ASCVD, a large subset of CVD, cholesterol drives the development of atherosclerotic plaque, a mixture of cholesterol, cells and cellular debris in the wall of a blood vessel that results in the hardening of the arteries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_0.jpg" alt="img243551639_0.jpg" style="width:633px;height:329px;" />&#160;</p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">High cumulative life-long exposure to blood cholesterol, which is carried in each of low-density lipoprotein, or LDL, triglyceride-rich lipoprotein, or TRL, or Lp(a), is a root cause of ASCVD. The graphic below depicts these liver-produced lipoproteins being secreted into the blood and their typical compositions, comprising cholesterol and triglycerides and with apolipoprotein B, or ApoB, on the surface. Each of these three lipoproteins represents an independent pathway of risk for ASCVD, and we believe that concurrently reducing the blood lipids carried in more than one of these pathways should provide additive benefit for the treatment of ASCVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_1.jpg" alt="img243551639_1.jpg" style="width:335px;height:159px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current treatment approaches to lower LDL-C utilize continuous, life-long treatment, and due to the limitations of this chronic care model, cumulative exposure to LDL-C for many patients with ASCVD remains insufficiently controlled. The most common treatment for patients with ASCVD is daily statin pills in combination with recommended therapeutic lifestyle changes. There are several non-statin daily pills, including ezetimibe, bile acid sequestrants and bempedoic acid, that may be used alone or added sequentially to statin treatment in order to help patients with ASCVD reach recommended LDL-C goals. There are also two FDA-approved monoclonal antibodies, or mAbs, evolocumab and alirocumab, that target and bind to PCSK9 protein and are typically administered via injection twice per month. In addition, inclisiran, a small interfering RNA, or siRNA, that targets PCSK9 and is subcutaneously administered twice per year, was approved by the FDA and the European Medicines Administration, or EMA. Despite these approved treatments, effectively controlling LDL-C levels long-term in patients with or at high risk for ASCVD remains a significant unmet need.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The relationship between lowering of cumulative LDL-C exposure and reduction in the risk of ASCVD is among the best understood relationships in medicine. Human genetic studies have shown that those with FH, a genetic disease, have life-long severely elevated blood LDL-C, which can lead to increased risk of early-onset ASCVD. Conversely, individuals born with resistance mutations that turn off a cholesterol-raising gene expressed in the liver, such as PCSK9, have life-long low levels of LDL-C and rarely suffer from ASCVD. These insights point to the importance of early aggressive treatment to reduce LDL-C exposure over a patient&#x2019;s lifetime. For patients with established ASCVD, such as those who have previously suffered a heart attack, clinical treatment guidelines published by the AHA/ACC recommend lowering blood LDL-C to a goal of less than 70 mg/dL, and the European Society of Cardiology, or ESC, recommends lowering blood LDL-C to a goal of less than 55 mg/dL. If blood LDL-C is maintained low enough for long enough, the risk of a first ASCVD event, including a heart attack, can be dramatically reduced. Studies have shown that lowering LDL-C by 39 mg/dL for five years in patients with established ASCVD reduces the risk of a further event by 21%, whereas a similar degree of LDL-C difference over a lifetime reduces the risk of a first ASCVD event by up to 88%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Despite the availability of statin and non-statin therapies, cumulative exposure to LDL-C is often insufficiently controlled in many patients with ASCVD. As a result, a large proportion of patients with established ASCVD have LDL-C levels above clinical treatment guidelines. In a national registry of outpatient cardiovascular care in the United States, out of 2.6 million patients who had suffered a clinical ASCVD event, 53% had not received any cholesterol-lowering therapy and 72% remained above the LDL-C levels recommended by the AHA/ACC. Further, data from a clinical trial of approximately 6,000 patients in the year following a heart attack showed that among the approximately 3,000 patients for whom the medication was provided for free, only 39% reported full adherence to their statin therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A large proportion of patients with or at risk for ASCVD opt against starting or remaining on treatment due to the heavy, life-long medication burden associated with daily pills or frequent injections. Given the silent nature of the damage done by elevated LDL-C, many patients at risk for ASCVD do not properly appreciate the therapeutic benefits of consistent treatment as well as the substantial risk of foregoing treatment, focusing instead on the heavy, life-long medication burden of chronic approaches. Numerous prior studies of statins and injectable mAb PCSK9 inhibitors showed that treatment discontinuation is frequent. The graphic below illustrates findings from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">two of these studies, which showed that 50% of patients or fewer remain on treatment with PCSK9 inhibitor mAbs or statins over four years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_2.jpg" alt="img243551639_2.jpg" style="width:653px;height:319px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Incomplete adherence to treatment may result in significant oscillation in blood LDL-C levels over a patient&#x2019;s lifetime. The illustrative graphic below depicts the journey of a hypothetical patient with FH who began standard-of-care treatment after suffering a heart attack at age 44, at which point the patient was diagnosed with ASCVD, and the potential consequences of incomplete control of LDL-C over several years due to poor adherence and insufficient healthcare access. Incomplete LDL-C control can lead to recurrent clinical ASCVD events and the need for invasive medical procedures, such as intracoronary stenting and coronary artery bypass surgery, and can be fatal. These recurrent events and procedures place a heavy burden on patients, treating providers and the medical system as a whole, with increased cost and use of healthcare services.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_3.jpg" alt="img243551639_3.jpg" style="width:540px;height:306px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Advantages of our single-course gene editing treatments for ASCVD</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that single-course gene editing treatments for patients with ASCVD have the potential to solve many of the challenges of the chronic care model and create a new paradigm for the treatment of this highly prevalent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and life-threatening disease. By potently and durably controlling cumulative LDL-C exposure throughout a patient&#x2019;s lifetime, we believe our gene editing medicines could fundamentally disrupt the chronic care model for patients with or at risk for ASCVD and relieve the significant burden placed on patients, providers and the healthcare system. The illustrative graphic below depicts the journey of the same hypothetical patient with FH</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">who, in this case, received a single-course gene editing treatment after suffering a heart attack and avoided recurrent ASCVD events as a result.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_4.jpg" alt="img243551639_4.jpg" style="width:534px;height:299px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To achieve our goal of transforming the treatment of ASCVD, we are developing a pipeline of single-course gene editing treatments that leverage multiple breakthroughs of 21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:5.025pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">st</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> century biomedicine&#x2014;human genetic analysis, gene editing, mRNA-based therapies and LNP-mediated delivery. We believe our approach benefits from the following potential advantages:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Validated liver targets implicated in ASCVD risk:    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach specifically targets genes that are predominantly expressed in the liver and have been validated through human genetics research. Naturally occurring mutations in each of these target genes are associated with a reduced risk of ASCVD. Our gene editing programs are designed to mimic these natural resistance mutations to turn off specific genes in the liver implicated in the risks of ASCVD. Such resistance mutations in PCSK9, even in adults with homozygous mutations and complete PCSK9 protein deficiency, do not appear to have any serious adverse health consequences. Furthermore, there is established human pharmacologic proof-of-concept and positive tolerability profiles with other modalities targeting these genes, such as mAbs, siRNA and antisense oligonucleotides. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potent, durable and life-long lowering of blood lipids through a single-course treatment:    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are leveraging gene editing technologies, including base editing, to make a permanent change in the target gene and disrupt the production of specific proteins that cause ASCVD. The durability of a gene editing approach appears to hold true in tissues with cell turnover, such as the liver, since the edit is passed on as cells divide. With VERVE-101, we are leveraging base editing with the goal of potently and permanently reducing blood lipids in order to create the potential for a life-long therapeutic outcome. In a preclinical proof-of-concept study in NHPs using a precursor formulation of VERVE-101, we observed a 59% reduction in blood LDL-C at two weeks after treatment, with LDL-C reduction maintained at an average of 71% at two years. In another preclinical proof-of-concept study in NHPs, we observed that a single administration of a precursor formulation of VERVE-201 targeting ANGPTL3 resulted in a 64% reduction in blood triglycerides at two weeks after treatment, with triglyceride reduction maintained at an average of 69% at ten months. We believe that our gene editing approach has the potential to potently and durably lower blood lipids throughout a patient&#x2019;s lifetime, thereby reducing their risk of ASCVD. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Designed and optimized to reduce or avoid safety risks:    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To optimize the safety profile of our gene editing programs, we utilize non-viral LNP delivery of a gene editor to the liver due to the potentially superior safety profile of LNPs compared with available viral delivery approaches, specifically the minimization of genome integration risk and immunogenicity. In addition, we use base editing for our initial programs, which enables </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">highly precise editing at the single base pair level and minimizes the risks of unwanted DNA modifications associated with double-stranded breaks from nuclease-based editing approaches. Finally, we extensively screen pairs of gene editors with guide RNA, or gRNA, in human cells, mice and NHPs to maximize the likelihood that our gene editing programs will have limited or no off-target editing effects. For VERVE-101, we have identified a base editor paired with a gRNA targeting PCSK9 and have not observed any significant off-target editing in preclinical studies using primary human hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">A suite of complementary single-course gene editing treatments to broadly reduce blood lipids and ASCVD risk:    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are focused on targeting distinct pathways implicated in elevated blood lipid levels and related ASCVD risk. VERVE-101, our lead program, is designed to target the PCSK9 gene, a validated regulator of blood LDL-C levels. VERVE-201 is designed to target the ANGPTL3 gene, a regulator of both cholesterol and triglycerides that contributes to ASCVD risk independent of the PCSK9 pathway. We believe that patients with refractory hypercholesterolemia may benefit from treatment with VERVE-201.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Potential to manufacture our programs in a scalable manner to reach a broad population:    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have designed our single-course treatments as LNPs encapsulating mRNA and gRNA, a similar construction to that used in mRNA-based vaccines approved by the FDA for the prevention of COVID-19. We believe we will benefit from the rapid increase in investment, validation and real-world application of these technologies on a global scale as a result of the COVID-19 pandemic, which should enhance our potential to manufacture our gene editing programs for use with a broad patient population.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that scalable manufacturing is paramount to unlocking the true potential of our single-course gene editing treatments to tackle the worldwide burden of ASCVD. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our strategy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are executing a strategy with the following key elements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Employ a stepwise approach to realize the full potential of VERVE-101and VERVE-201.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> We are pioneering a new approach with single-course gene editing medicines aimed at transforming the care of patients with or at risk for ASCVD. We are initially developing VERVE-101 for the treatment of HeFH, a genetic cardiovascular disorder that causes life-long elevated LDL-C levels and leads to early-onset ASCVD. We are initially developing VERVE-201 for the treatment of HoFH, a genetic cardiovascular disorder that causes extremely elevated LDL-C levels. If we successfully develop VERVE-101 for the treatment of patients with HeFH, we believe it could also be used to treat the broader population of patients with established ASCVD who are not at LDL-C goal on oral therapy. Ultimately, we believe these treatments could be potentially developed for administration to people at risk for ASCVD as a preventative measure. We are currently enrolling HeFH patients in our heart-1 clinical trial in New Zealand and the United Kingdom. We plan to report initial safety and pharmacodynamic data from the dose-escalation portion of the heart-1 clinical trial in the second half of 2023.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Expand our pipeline of gene editing treatments within ASCVD and beyond to additional CVD indications</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are expanding beyond our PCSK9 and ANGPTL3 programs with other early stage discovery programs, including one directed at Lp(a), another root cause of ASCVD, using a novel gene editor tailored to target the LPA gene. We intend to develop a suite of single-course gene editing medicines that comprehensively and robustly address additional independent causes of CVD. We believe our approach may be applicable to additional CVD indications with high unmet need driven by mutations in target genes expressed in the liver. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Expand portfolio of single-course in vivo gene editing programs through strategic relationships. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, we established an exclusive, four-year global research collaboration with Vertex Pharmaceuticals Incorporated, or Vertex, focused on discovering and developing an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing program for a single undisclosed liver disease using a novel gene editor tailored to the gene target. We may enter into additional collaborations intended to develop novel </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing programs for targets of interest.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leverage our expertise and access to multiple gene editing technologies to become the leader in gene editing for CVD.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">   We believe that the deep expertise of our team in human genetics, gene editing and off-target analysis combined with multiple in-licensed technologies, including base editing and CRISPR nucleases, positions us to be able to develop single-course gene editing medicines designed to make a precise, predictable and permanent change in a target gene for the treatment of CVD. For each new target, our expertise allows us to systematically evaluate multiple gene editing technologies, including developing novel gene editing technologies, in primary human hepatocytes, mice and NHPs to identify the optimal approach based on potential efficacy and safety. We believe that our focus on developing gene editing medicines to treat CVD enables us to move rapidly and has culminated in the first ever patient dosed with an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">base editor. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also working to develop novel gene editors tailored to a particular target of interest, including as part of our Vertex collaboration and our research efforts for our Lp(a) program.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Advance LNP delivery technology leveraging both external as well as internal LNP capabilities to deliver gene editors to the liver</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On a target-by-target basis, we evaluate the best options for non-viral delivery from our external partnerships or our internal LNP discovery platform. For our lead program, VERVE-101, we have licensed LNP technology from Acuitas, an established company with a track record of partnering and developing LNPs for clinical use. We have also licensed lipid technology from Novartis which we intend to use in research and development of certain product candidates. Additionally, our internal team&#x2019;s expertise in biodegradable LNP chemistry, formulation and manufacturing has allowed us to develop and screen potent, liver-directed LNPs, including novel liver-targeting GalNAc-LNPs, which may offer superior delivery in certain CVD patient populations. We are utilizing proprietary GalNAc-LNPs in addition to the licensed Novartis lipid technology to deliver VERVE-201 to the liver. We are also evaluating GalNAc-LNPs to deliver a base editor targeting the PCSK9 gene.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Prioritize rapid iteration of product candidates in NHP preclinical models as an early development strategy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.    We believe that studies in NHPs are a powerful predictor of efficacy in humans for gene editing and LNP delivery to the liver. Our preclinical validation approach prioritizes NHP experiments early in the process, enabling us to rapidly optimize drug product development to identify a lead candidate to take into clinical development.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With VERVE-101 and VERVE-201, the bulk of our preclinical studies have been performed in NHPs, allowing us to establish the pharmacodynamic relationship between liver editing and resulting reductions in circulating PCSK9 protein, ANGPTL3 protein, and LDL-C that we believe will translate into humans. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Develop manufacturing capabilities to produce in vivo gene editing medicines at scale.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are currently working with Good Manufacturing Practice, or GMP, vendors to produce all components of our drug candidates for our clinical trial batches. We have successfully executed batches at clinical scale through our vendors. We have also developed proprietary production processes designed to yield high-purity and high-quality mRNA that are crucial for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> liver editing applications. We are continuing to invest in building internal manufacturing capabilities for mRNA and LNP production, in order to fulfill our vision of delivering gene editing medicines to millions of patients with CVD. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Build the leading cardiovascular gene editing company by maintaining a dynamic culture that attracts and retains a talented and collaborative team.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have attracted a talented team of scientists, cardiologists, drug developers and business professionals, as well as experts in the fields of human genetics, gene editing technologies, mRNA biology, off-target analysis and genetic medicine delivery modalities. Developing gene editing medicines that transform the care of CVD requires that we solve many new and complex problems as a natural component of the drug discovery and development process. Our vision, values, talent and strategy are essential to maximizing our ability to address these problems and bring forward a new approach to treating the leading cause of the death in the world. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are employing a tailored approach aimed at developing single-course gene editing medicines to transform treatment for patients with CVD. Our gene editing programs target validated genes in the liver that are supported by extensive human genetics and human pharmacology data and are known to be implicated in CVD. We use base editing, a next-generation gene editing approach that enables precise and efficient editing at the single base level in the genome without making a double-stranded break in the DNA, for our initial programs, including VERVE-101 and VERVE-201. Our gene editing programs consist of LNPs that encapsulate mRNA encoding for a gene or base editor as well as a gRNA targeting the gene of interest expressed in the liver. We believe that the following key elements of our approach will help us achieve our goal of delivering gene editing treatments on a global scale for millions of patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Editor selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We selected gene editing as the core technology to develop our single-course gene editing treatments for CVD because we believe it offers the potential for durability of effect and versatility in the type of genetic modification compared to other genetic medicine approaches, including gene therapy and RNA therapeutics. We have access to multiple gene editing technologies through licenses including base editing and CRISPR nucleases. We are also seeking to discover new gene editing technologies. We believe having the flexibility to apply different gene editing technologies to different single-course treatments for CVD enables us to identify the best potential option for any given therapeutic application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">CRISPR-Cas Editing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CRISPR-Cas is a form of nuclease-based gene editing that enables targeting of genomic DNA sequences with high specificity in human cells by assessing for a match between the gRNA sequence and the DNA sequence. The gRNA allows the Cas protein to recognize a complementary part of the DNA sequence. Once RNA-DNA pairing occurs, the Cas enzyme makes a double-stranded DNA break, and the cell&#x2019;s natural DNA repair mechanisms work to make changes or repair the genome. When the repair is faulty, there can be disruption of a target gene, known as a knockout. CRISPR-Cas is effective at knocking out, or silencing, a targeted gene through disruption. However, potential limitations of standard CRISPR-Cas gene editing include lack of predictability in genetic outcomes and potential toxicities associated with double-stranded DNA breaks.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Base Editing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Base editing is a next-generation gene editing approach that enables precise and efficient editing at the single base level in the genome without making a double-stranded break in the DNA. If CRISPR-Cas gene editing approaches are akin to &#x201c;scissors&#x201d; for the genome, base editors are akin to &#x201c;pencils,&#x201d; erasing and rewriting one letter in a gene.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Through our license agreement with Beam, we have access to two different types of base editors&#x2014;adenine base editors, or ABEs, and cytosine base editors, or CBEs, each of which has a modified Cas9 protein bound to a gRNA, retaining the ability to target a genomic sequence, yet avoiding double-stranded DNA breaks. The base editors are distinguished by the kind of deaminase, the base editing enzyme that carries out the chemical modification, that is fused to Cas9. The deaminase makes a predictable chemical modification, called deamination, of the amine group on either an adenine, or A, base or a cytosine, or C, base as shown in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_5.jpg" alt="img243551639_5.jpg" style="width:503px;height:200px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For VERVE-101 and VERVE-201, we are using an ABE to convert an amine group of A to an inosine, or I, base, which is read by DNA polymerase as a guanine, or G, base, leading ultimately to an A-to-G spelling change. Once the initial modification has occurred, the intermediate DNA consists of an edited strand, containing an I at the target site, and an unedited strand with a thymine, or T, base. The I:T base pair is a mismatch, which the cell will normally attempt to repair in a process that can potentially lose the edit. In order to preserve the editing, our base editors cleave the unedited single strand of the DNA, referred to as nicking, rather than creating double-stranded breaks. The presence of the nick on the unedited strand, however, increases the efficiency of editing by inducing the cell to use the newly edited strand, and not the unedited strand, as the template for repair, resulting in an I:C base pair. Upon DNA repair or replication, the I is read as a G, resulting in a G:C base pair, and the permanent conversion of an A:T base pair to a G:C base pair is completed. This single base pair change at the specific site within the PCSK9 or ANGPTL3 gene alters the gene in such a way that no functional PCSK9 or ANGPTL3 protein is made, disrupting its role in maintaining elevated levels of circulating blood lipids.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Target selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We focus on validated genes in the liver-cardiovascular axis, which are genes predominantly expressed in the liver and where disrupting protein production or introducing a beneficial mutation may effectively treat an underlying cause of CVD. When considering targets for our programs, we evaluate the following criteria:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">human genetic evidence that loss-of-function, or LoF, mutations confer resistance to disease; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">human genetic evidence that LoF mutations do not have adverse effects, and that homozygous LoF, inheriting two mutant alleles, are well tolerated; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">human clinical proof-of-concept data for targeting with other modalities to support the potential safety and efficacy of permanent gene or base editing; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">technical efficiencies, such as liver-predominant expression and known estimates of the pharmacodynamic relationship between target protein and therapeutic effect;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">existence of circulating protein biomarkers for efficacy, clinical biomarkers of disease modulation, and the availability of appropriate preclinical disease models; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">clear unmet medical need and development rationale for the target indications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Evaluating for off-target editing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gene editing enables precise alterations at specific locations in the genome but has the potential to make alterations at undesired locations, known as off-target editing. Base editing has inherently fewer risks for off-target editing than CRISPR-Cas nuclease editing given the precision and efficiency of editing at the single base pair level and ability to make the edit without making a double-stranded DNA break.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach to minimizing off-target editing involves the use of multiple orthogonal assays that provide a comprehensive assessment of the potential for off-target editing with our editors. These include in vitro methods that detect editing at single-nucleotide resolution via DNA sequencing, such as ONE-seq which utilizes a computationally designed synthetic DNA library with sequence similarity to the on-target locus or Digenome-seq where DNA extracted from cells provides an un-biased assessment of edited loci. Both methods provide a complementary and rigorous workflow for candidate site nomination. We have also developed a highly sensitive hybrid capture assay for assessing these nominated candidate sites and assays for assessing structural variants and guide-independent effects across the genome and transcriptome. We believe that our internal expertise in the application of multiple innovative techniques to evaluate off-target editing gives us a leading position in the field and the ability to rapidly advance future programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Lipid nanoparticle delivery selection</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gene editing treatments require intracellular delivery of mRNA and gRNA molecules into the target cell type&#x2014;in our case, hepatocytes in the liver&#x2014;and all of our programs utilize a non-viral approach, LNPs, for delivery. LNPs are well-established, both by approved products and by clinical trials conducted by others with other agents, to preferentially accumulate in the liver after systemic administration. We have chosen non-viral LNP delivery due to the potentially superior safety profile compared with available viral delivery approaches, as well as the high efficiencies of liver editing achievable with LNPs due to their natural tropism to the liver.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-viral delivery to the liver with LNPs confers potential advantages, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">protection of the mRNA and gRNA payloads while in circulation in the blood; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">transient expression of gene editing proteins, allowing more control over the editing process; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">transient expression of the editing protein and rapid completion of the editing process within days, minimizing immunogenicity; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">absence of DNA or viral components, avoiding exogenous DNA capable of inserting into the genome; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">rapid degradation of drug product within one to two weeks, supporting the potential for long-term safety; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">known, manageable infusion-related side effects; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">cost-effective manufacturing with potential to efficiently scale to reach millions of patients. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To date, our LNP discovery platform has yielded novel proprietary ionizable lipids that we have designed, synthesized and evaluated for their potential to deliver gene editing payloads to the liver in mice. We are further optimizing and scaling up such formulations for evaluation in NHPs. We have also developed novel targeting ligands that when added to LNPs allow for more efficient delivery of RNA payloads to the liver.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On a target-by-target basis, we evaluate the optimal LNP delivery options from either external partnerships or our internal LNP discovery platform. For our lead program, VERVE-101, we have licensed LNP technology from Acuitas, an established company with a track record of partnering and developing LNPs for clinical use. Our collaboration with Acuitas included several NHP studies to evaluate various LNP formulations and RNA payloads prior to selecting an Acuitas LNP for VERVE-101. For VERVE-201, we have licensed LNP technology from Novartis and plan to use internally developed GalNAc-LNP technology for delivery.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We view our internal LNP discovery platform as an important source of delivery technology for future therapeutic programs. We are optimizing our internal LNP discovery platform by focusing on:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">strategies to enhance delivery to the liver in certain CVD patient populations, such as patients with HoFH, in whom LNP-mediated delivery may be challenging; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">improved efficiency of delivery to the liver, such that lower doses of RNA payload could be used; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">wider therapeutic indices to optimize the benefit-risk profile of our product candidates; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">improved stability and potential for powder formulation enabling easier storage for commercial application. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that our internal LNP discovery platform will yield improvement in our product candidates for current and future programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are continuing to invest and build out capabilities in the development of novel and optimized GalNAc-targeting ligands, optimal lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We believe GalNAc provides a delivery platform for patients with both forms of FH and potentially may be applicable in other applications where liver-directed delivery is advantageous.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Single-course therapy</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are designing our single-course gene editing treatments to be administered as single-dose regimens through intravenous infusion, which is supported by data generated in our preclinical studies in NHPs. However, an advantage of using LNPs is the potential for split-dosing. In the case of our gene editing programs, we may elect to dose patients using a single, short course consisting of a limited number of split-doses over a short period of time to improve safety, efficacy or both. In patients who may not receive an adequate therapeutic effect with a single course of treatment, our approach may enable the option to re-dose. Patisiran, an approved LNP-encapsulated siRNA, is chronically administered without safety and efficacy concerns for patients with transthyretin amyloidosis, or ATTR. This is in contrast to viral vectors, which face safety and efficacy challenges with re-dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The value of a single-course gene editing treatment will be determined by the safety, potency and durability of its desired effect. We believe a single-course treatment with VERVE-101 could durably lower LDL-C throughout the lifetime of patients with or at risk for ASCVD. Our gene editing treatments are designed to make a permanent change in the DNA of liver cells. With VERVE-101, transient expression of ABE protein in hepatocytes is designed to lead to permanent editing of the PCSK9 gene. Since liver cells turn over predominantly through division of hepatocytes that themselves will carry the PCSK9 edit, we believe that the efficacy resulting from the edit will be durable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This stands in contrast to gene therapy, where the therapeutic benefit has been challenged by a lack of durability. Gene therapies are often designed to express exogenous mRNA by viral delivery or viral expression of mRNA. The durability of therapeutic effect can be limited by the loss of mRNA expression from a viral vector that does not integrate into the genome. This leads to either a reliance on viral integration at unpredictable sites in the genome, which can lead to safety challenges, or on repeat dosing that has its own challenges with viral delivery.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that single-course gene editing treatments could provide durable and transformative outcomes, producing sustained health benefits for patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Scalable manufacturing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By designing our gene editing treatments as LNPs encapsulating mRNA and gRNA, we expect to benefit from the potential for scalable and cost-effective manufacturing processes enabling the opportunity to treat millions of patients with CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our product candidates are similar to two validated and approved drug classes: LNP-encapsulated siRNAs, such as patisiran, and LNP-encapsulated mRNA-based COVID-19 vaccines, which are LNPs containing a long mRNA molecule for the spike protein of SARS-CoV-2. Significant and ongoing investments are being made by multiple organizations to enhance the supply chain for all components and processes related to mRNA production, LNP production and fill-finish, especially in light of the intense worldwide efforts to manufacture massive quantities of COVID-19 vaccines. We believe we will ultimately benefit from the increased global capacity for LNP-encapsulated mRNA production over the next several years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are currently working with GMP vendors to produce all components of our drug candidates for our clinical trial batches. These include plasmid DNA preparation, mRNA production via in vitro transcription reactions, gRNA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">synthesis via solid state synthesis, lipid synthesis and LNP formulation and fill finish. Working closely with these vendors, we have successfully executed batches at clinical scale.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also investing in the buildout of internal process development capabilities in mRNA production and LNP formulation, which we believe will become one of our core competencies in the future. The goals of this internal process development capability are to scale up plasmid DNA, mRNA and LNP production batches, to make improvements in order to enhance quality, consistency and stability, and to reduce costs. Further, we are investing in analytical method development including bioactivity and potency assays that will be critical to further product development, batch comparability assessments and additional manufacturing growth.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our gene editing programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are advancing a pipeline of single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing programs intended to durably turn off genes in the liver implicated in CVD. Our gene editing programs consist of LNPs that encapsulate mRNA encoding for a gene editor as well as a gRNA targeting the gene of interest expressed in the liver. Our pipeline is focused on genes implicated in the control of blood lipids, as well as other liver-mediated targets in and outside of CVD. We are developing our lead programs initially for the treatment of patients with forms of FH, which is a genetic disorder leading to life-long severely elevated blood LDL-C and increased risk of early-onset ASCVD. Patients with FH have mutations predominantly in the LDLR gene that affect the ability of liver cells to remove LDL from the circulation. FH manifests clinically in two forms: the more common heterozygous form, known as HeFH, and the rarer homozygous form, known as HoFH.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following graphic summarizes our pipeline of programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><img src="img243551639_6.jpg" alt="img243551639_6.jpg" style="width:672px;height:289px;" /></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our most advanced product candidate, VERVE-101 targeting the PCSK9 gene, is currently being studied in heart-1, our Phase 1b clinical trial evaluating the safety and tolerability of VERVE-101 administration in a high risk subset of patients with HeFH in New Zealand and the United Kingdom. Genetically defined HeFH affects approximately 1.3 million people in the United States, 2.1 million in the European Union and the United Kingdom and approximately 31 million worldwide. We plan to report initial safety and pharmacodynamic data from the dose-escalation portion of the heart-1 clinical trial in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are strategically developing VERVE-101 initially in patients with HeFH, recognizing that the unmet need is highest in those patients and the benefit-risk profile may be more favorable. We intend to use a stepwise clinical development plan for VERVE-101, evaluating efficacy and safety in higher-risk populations first, and then if successful, expanding into a broader population of patients with established ASCVD who are not at LDL-C goal on oral therapy, and ultimately to those at risk for ASCVD in the general population.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We plan to develop VERVE-201, our development candidate targeting the ANGPTL3 gene, using a similar stepwise approach. We plan to develop this program for the treatment of HoFH, which affects approximately 1,300 people in the United States, as well as people with ASCVD who are not at LDL-C goal on oral therapy and a PCSK9 inhibitor, or refractory hypercholesterolemia. Ultimately, we believe VERVE-201 may also be useful to people at risk for ASCVD as a preventative measure in the general population. We are conducting preclinical</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">studies to support a regulatory filing for the initiation of clinical development of VERVE-201 and anticipate initiating a Phase 1b clinical trial in 2024</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We intend to develop a broad pipeline of gene editing programs targeting distinct pathways implicated with ASCVD risk. Additionally, we believe our gene editing approach could have broader application for additional indications having both high unmet medical needs and validated gene targets expressed in the liver. With a focus on </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing treatments, we plan to develop a suite of single-course gene editing medicines that address root causes of disease.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Familial hypercholesterolemia: our initial focus for our single-course gene editing treatments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FH is a genetic disorder where patients have life-long severely elevated blood LDL-C, which can lead to increased risk of early-onset ASCVD. FH is an autosomal dominant disease often caused by a mutation in the LDLR gene. Individuals with FH may harbor one mutant allele and are thereby heterozygous for the disease, known as HeFH, or two mutated alleles and are therefore homozygous for the disease, known as HoFH. HoFH is typically more severe than HeFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Men and women with untreated HeFH typically have LDL-C levels ranging from approximately 200 to 400 mg/dL and develop ASCVD before age 50 and 60, respectively. The estimated prevalence of genetically defined HeFH is roughly one in 250, which translates to about 1.3 million patients in the United States. Men and women with HoFH have LDL-C levels above 500 mg/dL and typically develop ASCVD before the age of 20 and, without intervention, die before age 30. The estimated prevalence of genetically defined HoFH is roughly one in 250,000, which translates to about 1,300 patients in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">FH can be clinically diagnosed based on a combination of factors, including the concentration of blood LDL-C, physical findings, personal or family history of hypercholesterolemia and early onset of ASCVD. Extensor tendon xanthomas, typically Achilles, subpatellar and hand extensor tendons, with extremely elevated LDL-C levels are considered specific for FH. However, FH is often silent until the development of a heart attack at a young age, at which time a family history of ASCVD and elevated LDL-C levels are often the only findings. In an analysis of the FH phenotype, which typically means LDL-C levels of greater than 190 mg/dL, from six prospective cohort studies with 30-year follow-up, the FH phenotype was associated with up to a five-fold elevated 30-year ASCVD risk. ASCVD development was accelerated in those with the FH phenotype by 10 to 20 years in men and 20 to 30 years in women. In HoFH, patients typically develop atherosclerosis in childhood, initially in the aortic root, causing supravalvular aortic stenosis, and then extending into the coronary arteries. If the LDL-C level is not effectively reduced, people with HoFH die prematurely of ASCVD. The severity of atherosclerosis in FH is proportional to the extent and duration of elevated blood LDL-C levels.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Although the diagnosis of FH can be made on the basis of clinical features, genetic testing may offer additional insight into cardiac risk and diagnosis. Recent analysis of data from more than 26,000 individuals suggests that at any given LDL-C level, having an identified FH mutation is associated with significantly higher ASCVD risk than having the same LDL-C level but no apparent pathogenic FH mutation. In this analysis, individuals with an LDL-C level greater than or equal to 190 mg/dL and no pathogenic FH mutation had a six-fold higher risk of ASCVD than the reference group with an LDL-C level less than or equal to 130 mg/dL. However, individuals with an LDL-C level greater than or equal to 190 mg/dL and a pathogenic FH mutation were at a 22-fold higher risk of ASCVD than the reference group, possibly reflecting greater atherogenicity of life-long LDL-C elevation in FH compared with LDL-C elevation acquired later in life.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While dietary and lifestyle changes are important for LDL-C lowering in patients with FH, multidrug treatment is often required to achieve recommended LDL-C levels. The recommended LDL-C levels for FH patients are similar to those for non-FH patients with ASCVD. Treatment for FH patients tends to start earlier than those with or at risk for ASCVD without FH, and typically follows a more aggressive course with multidrug treatment given the elevated risk of early-onset ASCVD. While FH patients are treated with medicines similar to those used for non-FH patients, the chronic care for FH patients is typically more burdensome with earlier intervention and more drugs. In addition, for many patients, especially those with HoFH, their LDL-C levels remain inadequately controlled and do not reach goals recommended by clinical treatment guidelines.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101: PCSK9 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our lead product candidate, VERVE-101, is designed to be a single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing treatment targeting the PCSK9 gene. We plan to develop VERVE-101 initially for patients with HeFH, and, if successful, to expand development for the broader population of patients who have established ASCVD and are not at LDL-C goal on oral therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In patients with HeFH, a genetic mutation in the LDLR gene down-regulates</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LDLR expression, which limits the ability of liver cells to remove LDL from the bloodstream, resulting in extremely high LDL-C levels in the blood. Over time, high LDL-C builds up in the arteries, leading to formation of atherosclerotic plaque, reduced blood flow or blockage and ultimately heart attack or stroke. We believe that inactivation of the PCSK9 gene will result in lower PCSK9 protein levels, thereby increasing LDLR expression, leading to lower LDL-C levels and reduced risk for ASCVD. Clinical trials conducted by others evaluating PCSK9 inhibitors have suggested that targeting PCSK9 has the potential to work in patients with HeFH regardless of the underlying mutation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 consists of an LNP encapsulating an mRNA encoding an ABE and a gRNA, as depicted in the image below. Four lipid components assemble along with the RNAs to form a dense, stable LNP that is approximately 60 nanometers in diameter.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_7.jpg" alt="img243551639_7.jpg" style="width:309px;height:169px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 is designed to be infused intravenously into the patient over approximately one to two hours, and then accumulates in the liver. Prior to administration of VERVE-101, a pre-medication regimen is given that consists of antihistamines and steroids. Once in the liver, VERVE-101 is brought into hepatocytes and escapes into the cytoplasm where the base editor protein is transiently expressed. The gRNA then binds to the base editor protein, and the complex is carried into the nucleus to locate the gene target specified by the 20-nucleotide spacer sequence of the gRNA. The ABE binds to the DNA and makes a single A-to-G spelling change at the target site, thereby turning off the PCSK9 gene. The ABE mRNA construct is codon-optimized and contains chemical modifications to reduce the potential for mRNA-mediated immune responses. The gRNA sequence has several chemical modifications to enhance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> stability to endonucleases and exonucleases.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PCSK9 as a target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The PCSK9 gene plays a critical role in the regulation of blood LDL-C through its regulation of the LDLR gene. The normal function of PCSK9 is depicted in the figure below on the left. The PCSK9 gene produces a protein in the liver that is released into the blood. LDLR is present on the surface of liver cells and binds to LDL and removes LDL from circulation. The LDL bound to LDLR is taken up by liver cells to enable the breakdown of LDL particles. LDLR is then recycled back to the surface of the cell, enabling the process of LDL uptake to recur. PCSK9 protein in the blood interrupts this LDLR recycling process. Specifically, PCSK9 protein in the blood binds to LDLR and targets LDLR for destruction. In doing so, PCSK9 reduces the number of LDLRs on the liver cell surface, thereby reducing the ability of the liver to clear LDL from the blood. The figure on the right depicts a loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of PCSK9 gene function, which results in less PCSK9 protein and thereby increased LDLR expression and uptake of LDL-C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_8.jpg" alt="img243551639_8.jpg" style="width:628px;height:255px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As reported in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The New England Journal of Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, one study found that adults with naturally occurring LoF mutations in the PCSK9 gene had LDL-C levels that were 38 mg/dL lower than adults without the mutation, and those with the mutation had an 88% lower risk of ASCVD. Human genetic studies also showed that carrying naturally occurring loss-of-function mutations in one or both copies of the PCSK9 gene was not associated with serious adverse health consequences.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to human genetic studies, human pharmacology studies have provided validation for PCSK9 as a target. The impact of PCSK9 inhibition on cardiovascular outcomes has been established by two large, randomized, double-blind, placebo-controlled studies of two approved mAbs that bind to PCSK9 protein and block its activity, the FOURIER trial and the ODYSSEY OUTCOMES trial. The FOURIER trial demonstrated that treatment with evolocumab in addition to background statin therapy over a median of 2.2 years reduced major cardiovascular events by an additional 15% in patients with established ASCVD, with evidence of continued safety and increasing cardiovascular event reduction benefit that accrued over an additional 5.0 years of follow-up in the FOURIER open-label extension study. The ODYSSEY OUTCOMES trial demonstrated that treatment with alirocumab in addition to background statin therapy over a median of 2.8 years reduced major cardiovascular events by an additional 15% in patients with established ASCVD. Treatment with these mAbs demonstrated an approximately 60% reduction in LDL-C on average across clinical trials when compared with placebo treatment. Notably, in both trials, with the exception of injection site reactions, overall adverse event rates were similar between patients treated with placebo or drug, with no observed increase of new-onset diabetes, worsening glycemic control or neurocognitive adverse events.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The PCSK9 target has been further validated by inclisiran, which was approved by the EMA in 2020 and by the FDA in December 2021. In the ORION-9 trial, the pivotal Phase 3 trial of inclisiran in patients with HeFH, the percent change in the PCSK9 level after 510 days was a decrease of 60.7% in the inclisiran-treated group compared with baseline, which led to a reduction in LDL-C after 510 days of 39.7% compared to baseline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe the human genetic studies and the human pharmacology with PCSK9 inhibitors provide substantial evidence that targeting PCSK9 is a potentially safe and effective approach to lower LDL-C and reduce ASCVD risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We discovered VERVE-101 based on extensive screening of a large library of gRNA candidates, evaluation of multiple LNP formulations and optimization of the ABE mRNA construct. We have tested a mouse surrogate of VERVE-101, precursor formulations of VERVE-101, which we refer to as our ABE-PCSK9 precursor formulation, and VERVE-101 itself </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> across multiple animal models. In these studies, we have observed the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">high PCSK9 gene editing activity in the liver by a mouse surrogate of VERVE-101 in both wild type mice and heterozygous LDLR knockout mice, a well-established mouse model of HeFH; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">two year NHP durability data for blood PCSK9 protein and LDL-C reduction following treatment with our ABE-PCSK9 precursor formulation, with average reductions of 90% of PCSK9 protein and 71% for LDL-C; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">dose-responsive liver PCSK9 gene editing, blood PCSK9 protein reduction, and LDL-C reduction in NHPs, with a 1 mg/kg dose of VERVE-101 achieving approximately 71% editing, approximately 85% reduction in blood PCSK9 protein and approximately 64% reduction in LDL-C; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">one year NHP durability data for blood PCSK9 protein and LDL-C reduction following treatment with VERVE-101, with average reductions of 89% of PCSK9 protein and 68% for LDL-C;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 editing occurred predominantly in the liver and within 24 hours of treatment in NHP studies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">evidence that VERVE-101 is potent in NHPs at doses as low as 0.5 mg/kg;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no evidence of germline editing in an analysis conducted in sexually mature male NHPs receiving a 1.5 mg/kg dose of VERVE-101;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no transmissions of the PCSK9 gene edit to the offspring of female mice treated with the murine surrogate of VERVE-101;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sustained editing of the PCSK9 gene in regenerated liver lobes at 95 days post-treatment, as demonstrated in a partial hepatectomy mouse model designed to determine durability of PCSK9 base editing in the liver;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">administration of VERVE-101 to NHPs caused transient, mild elevations in liver function tests that entirely resolved within two weeks; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no significant off-target editing in primary human hepatocytes after evaluation at any of approximately 3,000 potential off-target sites. </span></div></div>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">In vivo validation with ABE-PCSK9 mouse surrogate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our initial target patient population for VERVE-101 is patients with HeFH who produce reduced levels of functional LDLR, which results in increased levels of LDL-C in the blood. We utilized heterozygous LDLR knockout mice to model the HeFH disease state. A mouse surrogate version of VERVE-101 was developed for use in this model comprising a mouse surrogate gRNA targeting the ortholog of the same PCSK9 site, along with two components identical to VERVE-101&#x2014;the ABE mRNA and LNP. As shown in the figure below, we observed that doses of 0.05, 0.1 and 0.5 mg/kg of the mouse surrogate of VERVE-101 administered once to wild-type and heterozygous LDLR knockout mice resulted in similar and robust amounts of PCSK9 editing in the liver.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_9.jpg" alt="img243551639_9.jpg" style="width:413px;height:353px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">NHP validation with ABE-PCSK9 precursor formulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We then applied this approach in an NHP model to establish preclinical proof-of-concept using an ABE-PCSK9 precursor formulation. In this study, which is ongoing, we administered a single dose to healthy NHPs. In the figures below, each treated NHP is represented by a purple bar and each vehicle treated control is represented by a blue bar. Following a single treatment with our ABE-PCSK9 precursor formulation, we observed an average 67% editing of PCSK9 in whole liver tissue sampled through a liver biopsy two weeks after dosing, as shown in the first graph. This was accompanied by an average 89% reduction of blood PCSK9 protein and an average 59% reduction of blood LDL-C concentrations, as shown in the additional two graphs below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_10.jpg" alt="img243551639_10.jpg" style="width:328px;height:374px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_11.jpg" alt="img243551639_11.jpg" style="width:638px;height:324px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Importantly, in this preclinical study, we observed that the reductions in blood PCSK9 protein and blood LDL-C levels were durably maintained. As shown in the figures below, at two years following a single intravenous administration of ABE-PCSK9, we observed that the NHPs continued to exhibit an average 90% reduction in blood PCSK9 protein and an average 71% reduction in blood LDL-C.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img243551639_12.jpg" alt="img243551639_12.jpg" style="width:672px;height:261px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Turnover of mature hepatocytes in the liver is estimated to occur on average every 200 to 300 days. The source of new hepatocytes is not certain, but evidence suggests that mature hepatocytes are responsible for production of new hepatocytes during both homeostatic liver turnover and following liver injury. Less likely, a fraction of hepatocytes with greater regenerative capacity may exist in the liver. In either case, the durability data shown above in our preclinical studies with an ABE-PCSK9 precursor formulation suggest that the liver cells responsible for regeneration are edited at the PCSK9 gene site. In addition, we have not observed evidence of persistent inflammation or liver injury that might suggest more rapid hepatocyte turnover or immune-mediated clearance of edited hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have explored the pharmacodynamics of liver editing and consequent effect on blood PCSK9 protein levels across a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">large number of iterative NHP studies. We have identified a linear relationship between editing of the PCSK9 gene in liver cells and blood PCSK9 protein levels. The figure below shows a best-fit line with confidence intervals representing a large number of data points from individual NHPs. In NHPs, we have achieved a reduction of greater than 60% in PCSK9 protein with a whole liver editing rate of approximately 50% to 55%. We believe that this relationship between whole liver editing and PCSK9 reduction should be similar in humans.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_13.jpg" alt="img243551639_13.jpg" style="width:420px;height:409px;" />&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">VERVE-101 preclinical efficacy data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our preclinical studies of our ABE-PCSK9 precursor formulation led to the development of VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Short-term preclinical study of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In a preclinical dose-response study of VERVE-101 in the figure below, in NHPs, we administered VERVE-101 at four dose levels with three NHPs per dose level. In the figure below each bar represents a different dose group ranging from 0.5 mg/ kg to 3.0 mg/kg. With a dose of 1 mg/kg, we observed whole liver editing levels of approximately 71%, as shown in the figure below, which we believe represents editing of the majority of hepatocytes. We also observed that the level of editing translated into dose-dependent reductions of both blood PCSK9 protein and blood LDL-C. At the 1 mg/kg dose, we observed a PCSK9 protein reduction of approximately 85% and a robust LDL-C reduction of approximately 64%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_14.jpg" alt="img243551639_14.jpg" style="width:561px;height:330px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We observed that editing occurred quickly following dosing of VERVE-101 in NHPs, with the majority of the editing observed within one to two days of dosing. In the study, NHPs (n=2 per group) were administered the same 1 mg/kg dose, and necropsies were serially performed on day one, day two, day seven, day 14 and day 28. We observed high efficiency editing within 24 hours with minimal additional editing at subsequent time points as shown in the figure below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_15.jpg" alt="img243551639_15.jpg" style="width:396px;height:371px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The effects on blood PCSK9 protein and LDL-C reached their peak outcomes within two weeks of dosing. The major component of the LNP, the ionizable lipid, is designed to be biodegradable and to be eliminated from the blood within two weeks, and we observed that it was largely eliminated from the liver, to less than 10% of peak concentration, within two weeks of dosing. ABE mRNA levels in the liver decreased by 97% within one week of dosing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Long-term preclinical study of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In an ongoing long-term NHP study in 36 NHPs, we administered 1.5 mg/kg of VERVE-101 (n=22) and 0.75 mg/kg (n=4) with a control group (n=10). The study was designed to measure whole liver editing, blood PCSK9 protein levels and blood LDL-C levels. This study utilized our final VERVE-101 drug product that was manufactured at our planned clinical manufacturing site. We plan to continue this study in the dosed NHPs for three or more years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With a dose of 1.5 mg/kg (n=22), we observed an average of 70% whole liver editing at the PCSK9 target site at day 15, as shown in the figure below, which we believe represents editing of the majority of hepatocytes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the 1.5 mg/kg dose, we observed a PCSK9 protein reduction of approximately 79% and a robust LDL-C reduction of approximately 62% at two weeks following treatment, which improved to 89% and 68% at one year following treatment. At a 0.75 mg/kg dose level (n=4), we observed a PCSK9 protein reduction of approximately 54% and a robust LDL-C reduction of approximately 38% at two weeks following treatment, which improved to 69% and 50%, respectively, at one year following treatment.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_16.jpg" alt="img243551639_16.jpg" style="width:505px;height:340px;" />&#160;</p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Partial hepatectomy mouse model</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted a durability challenge study in a partial hepatectomy mouse model in order to evaluate whether the level of editing remains following the turnover of liver cells. In this study, a partial hepatectomy that removed two-thirds of the liver or a sham surgery was conducted 11 days after dosing with a mouse surrogate of VERVE-101. In the mice with a partial hepatectomy, the rest of the liver regrows to restore liver weight in approximately nine days. We then performed a necropsy at either 22 days or 95 days post-treatment. We observed sustained editing of PCSK9 in regenerated liver lobes at both 22 days and 95 days post-treatment. We also observed sustained reductions in PCSK9 protein level at both 22 days and 95 days post-treatment. This data supports our belief that as the liver regenerates, the level of editing achieved by VERVE-101 is expected to remain robust and durable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">VERVE-101 biodistribution data</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are using an LNP-based approach to deliver VERVE-101 to the liver. An analysis of the biodistribution of VERVE-101 following administration of a single dose of 1 mg/kg in NHPs indicated that the large majority of editing occurred in the liver in a dose-dependent manner, with lesser rates of editing observed in the spleen and adrenal glands, as shown in the figure below. Other tissues examined showed editing of less than about 2%.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_17.jpg" alt="img243551639_17.jpg" style="width:636px;height:287px;" />&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Tolerability of VERVE-101 in NHPs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 was generally well tolerated in NHP studies. We compared treatment with VERVE-101 to a control, or DPBS, at doses of 1 mg/kg or less and observed transient elevations of alanine aminotransferase, or ALT, consistent with mild acute liver injury within one to two days after dosing, which then peaked two to three days after dosing, with average values around 300 U/L following a 1 mg/kg dose. ALT is a commonly used blood marker of liver injury. Within one week of dosing, the average ALT value was within the normal range, indicating recovery, as shown in the figure below. These findings are consistent with observations from nonclinical studies performed for an approved LNP-based product that is administered intravenously.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_18.jpg" alt="img243551639_18.jpg" style="width:622px;height:232px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The liver enzyme findings, which can be monitored with standard clinical laboratory testing, were consistently transient and mild in nature and fully normalized by one to two weeks. We believe that these findings compare favorably to viral vector delivery approaches, which can lead to unpredictable and acute liver injury.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to assess the long-term liver safety of VERVE-101, we monitored liver enzymes in a long-term durability study of an ABE-PCSK9 precursor formulation. We did not observe evidence of any ongoing inflammation in the livers of NHPs that had undergone high levels of PCSK9 editing in the liver. In contrast, viral vector delivery can have subacute and chronic liver injury as a result of autoimmune reactions to the viral vector.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In our ongoing long-term preclinical study of VERVE-101, we have not observed any long-term effects on liver function tests, and have only observed mild, transient increases in ALT levels, similar to the study described above. In this study, we also evaluated whether glucose homeostasis may be impacted by systemic PCSK9</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">inhibition. We have not observed any impact on glucose homeostasis up to one year following administration of VERVE-101.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In a study of 1.5 mg/kg dose of VERVE-101 in six sexually mature male NHPs, we did not observe evidence of germline editing at the PCSK9 site measured in a targeted amplicon assay at 11 weeks following treatment, which is greater than one full cycle of spermatogenesis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In a study of 436 offspring of female mice treated with the murine surrogate of VERVE-101, genotyping of offspring showed that the PCSK9 gene edit was not transmitted to any of the offspring.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As LNPs are known to stimulate the immune system, we also assessed a panel of common cytokines following administration of a single dose of VERVE-101 in NHPs. At doses of 1 mg/kg or less, we observed mild and transient activation of certain cytokines, such as IP-10 or MCP-1, compared to control animals. This activation was apparent within 24 hours of dosing and fully resolved by the next observation point at one week. Other cytokines, including TNF-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Symbol&quot;, serif;min-width:fit-content;">a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, did not exhibit any changes above those seen in control animals.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also assessed complement activation in NHPs that received single administration of VERVE-101. At doses of 1 mg/kg and less, we observed only minimal activation above that in control animals. This minimal activation was detectable approximately two hours after dosing but resolved by 24 hours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical off-target editing in NHP</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While the human genome is the relevant genome to assess off-target editing, we believe that evaluations of off-target editing in NHPs can support the ability of off-target analysis in primary hepatocytes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> to predict off-target editing in the liver when dosed </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach to the identification of potential off-target sites includes a combination of bioinformatic and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> biochemical techniques, including ABE-Digenome-seq and a state-of-the-art technique called ONE-seq. ONE-seq is a comprehensive and sensitive </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> method to screen for and identify potential sequences where editing may occur. Using ONE-seq, we evaluated the 25,000 sequences in the NHP genome most closely matching the sequence of our on-target site. We prioritized 45 potential sites where editing may occur, of which the PCSK9 target site was identified as the top site.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We then used next-generation DNA sequencing to assess these sites for editing in primary NHP hepatocytes treated with VERVE-101. As shown in the figure below, besides editing at the PCSK9 target site, we did not observe off-target editing at any of the 44 potential off-target sites evaluated, depicted by the purple dots, except for one site designated C5. The C5 site is not present in the human genome.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We then treated NHPs with VERVE-101, took NHP liver samples and sequenced the same sites that we evaluated in primary NHP hepatocytes. In NHP liver samples, we identified off-target editing only at the C5 site. These data support our belief that we have the ability to accurately predict off-target sites </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> based on off-target analysis in primary hepatocytes </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_19.jpg" alt="img243551639_19.jpg" style="width:631px;height:192px;" />&#160;</p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Off-target analysis in primary human hepatocytes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Having established a methodology to connect off-target analysis in cells to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> editing, we turned to evaluation of the human genome for VERVE-101. Using two orthogonal techniques &#x2013; the ONE-seq methodology and ABE-Digenome-seq&#x2014;we prioritized more than 3,000 potential sites and assessed editing in primary human hepatocytes using a highly sensitive hybrid capture assay. As shown in the figure below, we did not observe any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">significant net editing at any of the approximately 3,000 potential off-target sites (black circles) when compared to untreated cells and observed only on-target editing at the PCSK9 target site (purple dot).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2022, we presented data from a comprehensive preclinical assessment of the potential for VERVE-101 to cause unintended, or off-target, DNA edits in primary human liver cells from multiple donors. We used multiple methods consistent with recent guidance from the FDA to identify more than 3,000 sites with the greatest experimental or bioinformatic similarity to the on-target site. We then used a sequencing assay to determine whether administration of VERVE-101 resulted in off-target editing at those sites. We did not observe any statistically significant off-target editing after treatment with VERVE-101 at the identified sites. We also evaluated the potential for off-target editing in non-target cells (spleen cells, adrenal cells, and hematopoietic stem cells) and other cellular contexts (pediatric human liver cells and human liver cell lines) and identified only two sites with statistically significant editing above untreated controls. The two instances of off-target editing occurred at doses greater than the dose we expect to achieve saturation for on-target editing. Based on these assessments, we believe that VERVE-101 has a low risk of off-target genomic modifications that would be expected to have an associated clinical adverse effect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img243551639_20.jpg" alt="img243551639_20.jpg" style="width:672px;height:418px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the above analyses, we have evaluated for two other theoretical risks: editing of RNA by the base editor and translocations of DNA. In primary human hepatocytes, we did not observe any RNA editing above control or any translocations of DNA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical study of multiple doses of VERVE-101</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are developing VERVE-101 as a single-course gene editing medicine. However, given the complexities of treating patients with ASCVD, we believe that some patients may benefit from additional lipid lowering after treatment with any single agent. We conducted a 90-day preclinical study of VERVE-101 in four NHPs to explore the potential to re-dose patients. In this study, we dosed 0.5 mg/kg of a VERVE-101 precursor on days 1, 30 and 60. We measured editing of PCSK9 by liver biopsy on days 14, 46 and 75, and by liver necropsy on day 90. As shown in the figure below, we observed an increase in PCSK9 editing over the course of the study, with an average of 29% at day 14, 36% at day 46, 53% at day 75 and 59% at day 90. We believe that these data suggest that repeat low doses of a PCSK9 base editor could achieve a high level of liver editing. We did not observe evidence of liver injury following any of the doses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img243551639_21.jpg" alt="img243551639_21.jpg" style="width:672px;height:288px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe these data highlight one of the potential key advantages of LNPs as a delivery approach for gene editing medicines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, we have generated data indicating that our proprietary GalNac-LNP can efficiently deliver base editors targeting PCSK9, achieving approximately an 87% reduction in PCSK9 in wild-type NHPs. We are advancing a GalNAc-LNP delivered PCSK9 base editor into preclinical development and believe this data suggests that GalNAc-LNP delivery may have broad utility for liver editing in other indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">heart-1 clinical trial</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The heart-1 clinical trial is designed to enroll approximately 40 adult patients with HeFH who have established ASCVD and evaluate the safety and tolerability of VERVE-101 administration, with additional analyses for pharmacokinetics and reductions in blood PCSK9 protein and LDL-C. The trial includes three parts &#x2013; (A) a single ascending dose portion, followed by (B) an expansion single-dose cohort, in which additional participants will receive the selected potentially therapeutic dose and (C) an optional second-dose cohort, in which eligible participants in lower dose cohorts in Part A have the option to receive a second treatment at the selected potentially therapeutic dose. During our interactions with regulators in New Zealand and the United Kingdom, country-specific protocols have been developed to account for various modifications to eligibility, design, and conduct in each country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have received clearance of our CTAs for VERVE-101 in New Zealand and the United Kingdom, and in July 2022, we announced that the first patient had been dosed with VERVE-101 in our heart-1 clinical trial. We have completed dosing of VERVE-101 in the first dose cohort of the dose-escalation portion of the heart-1 clinical trial. Enrollment efforts are ongoing in New Zealand and the United Kingdom. We plan to report initial safety and pharmacodynamic data for all dose cohorts of the dose-escalation portion of the heart-1 clinical trial in the second half of 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 was recently awarded an Innovation Passport for the treatment of HeFH under the Innovative Licensing and Access Pathway, or ILAP, by the UK Medicines and Healthcare products Regulatory Agency, or the MHRA. The Innovation Passport designation is the entry point to the ILAP, which aims to accelerate time to market and facilitate patient access to medicines in the United Kingdom for life-threatening or seriously debilitating conditions, or conditions for which there is a significant patient or public health need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We submitted our IND application to conduct a clinical trial evaluating VERVE-101 in patients with HeFH to the FDA in October 2022 and were subsequently informed by the FDA that our IND application was placed on hold. In December 2022, we received a clinical hold letter from the FDA that outlined the information required to resolve the hold, including additional preclinical data relating to: (i) potency differences between human and non-human cells, (ii) risks of germline editing, and (iii) off-target analyses on non-hepatocyte cell types. Clinical data from the ongoing heart-1 clinical trial in New Zealand and the U.K. were not included in the IND application package submitted to the FDA. In the clinical hold letter, the FDA requested available clinical data from the trial. In addition,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA has requested that we modify the trial protocol in the United States to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants. We intend to submit our response to the FDA as expeditiously as possible.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-201: ANGPTL3 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-201, our development candidate targeting ANGPTL3, is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism. We plan to develop this program for the treatment of HoFH, which affects approximately 1,300 people in the United States, as well as for refractory hypercholesterolemia defined as people with ASCVD who are not at LDL-C goal on oral therapy and a PCSK9 inhibitor. Ultimately, we believe that VERVE-201 may also be useful to people at risk for ASCVD as a preventative measure in the general population.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are conducting preclinical studies to support a regulatory filing for the initiation of clinical development of VERVE-201 and anticipate initiating a Phase 1b clinical trial in 2024. We plan to utilize internally developed GalNAc-LNP technology in VERVE-201 to deliver a base editor targeting the ANGPTL3 gene to the liver. We have developed proprietary LNPs with a GalNAc ligand designed to bind to ASGPR in the liver, which bypass LDLR, thereby enabling uptake into the liver in HoFH patients.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">ANGPTL3 as a target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The ANGPTL3 gene has recently emerged as a new and promising target for severe hyperlipidemia. The ANGPTL3 protein is produced almost exclusively in the liver and released into the blood. It was first identified as a regulator of cholesterol and triglyceride metabolism through genetic studies of a naturally occurring strain of mice with low cholesterol, low triglycerides and low circulating fatty acids. The main function of the ANGPTL3 protein is the inhibition of lipoprotein lipase, an enzyme on the surface of blood vessels in the heart, skeletal muscle and fat that is responsible for the breakdown and clearance of circulating triglycerides. ANGPTL3 protein has also been shown to regulate LDL-C by a mechanism that does not depend on LDLR expression, which is in contrast to the mechanism by which PCSK9 regulates LDL-C.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Human genetic studies, conducted by our founders, determined that naturally occurring loss-of-function mutations in the ANGPTL3 gene result in extremely low levels of triglycerides, LDL-C and high-density lipoprotein cholesterol. Subsequent studies determined that there were no apparent adverse health consequences observed in patients who naturally lack ANGPTL3 function. Furthermore, individuals completely lacking ANGPTL3 gene function were free from coronary atherosclerotic plaques evaluated by coronary computerized tomography, or CT, scan, compared to matched control family members. Two independent population genetic studies of individuals carrying a single mutated copy of ANGPTL3 demonstrated that partial loss of ANGPTL3 function is protective against ASCVD, with a 34% and 41% lower risk, respectively, compared to individuals without any ANGPTL3 mutations. Collectively, these studies provided strong evidence for ANGPTL3 as a potential therapeutic target for hyperlipidemia and ASCVD risk reduction.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Multiple therapeutic approaches targeting ANGPTL3 have been developed or are being evaluated in the clinic and provide further validation for ANGPTL3 as a target. Evinacumab is a mAb targeting ANGPTL3 that has been shown to effectively lower LDL-C and triglycerides in patients with HoFH and HeFH. The Phase 3 trial for evinacumab in patients with HoFH demonstrated a 49% reduction of LDL-C and a 50% reduction of triglycerides after 24 weeks compared to placebo. Based on these data, evinacumab was approved by the FDA in 2021 for the treatment of patients with HoFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The LDL-C lowering effect of evinacumab has been demonstrated to be additive to that of PCSK9 inhibition. In a late-stage clinical trial of patients with refractory hypercholesterolemia, due to HeFH in the majority of cases, the addition of evinacumab to a PCSK9 inhibitor further reduced LDL-C by 56% compared to placebo. In addition, other investigational agents targeting ANGPTL3 are being evaluated in patients with severe hypertriglyceridemia or CVD, including two different siRNA programs targeting ANGPTL3 from Arrowhead Pharmaceuticals (ARO-ANG3) as well as Eli Lilly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In our early preclinical studies, we evaluated multiple LNP formulations with a view to enabling treatment of patients with all forms of FH, as well as multiple editor and gRNA options. In preclinical data generated to date, and discussed below, we have observed the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">development of a proprietary GalNAc-targeting ligand that when added to an LNP is capable of delivering a base editor to the liver independent of the LDL receptor status in mice, and which may potentially be used to treat patients with HeFH and HoFH; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">proof-of-concept data in NHPs for an ABE-ANGPTL3 precursor formulation demonstrating 60% whole liver editing, 95% reduction in ANGPTL3 and 64% reduction in triglycerides at two weeks after a single treatment; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">durability data in NHPs for an ABE-ANGPTL3 precursor formulation demonstrating an ANGPTL3 reduction of 97% and triglyceride reduction of 71% seen at two years following a single treatment; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">proof-of-concept data in an internally developed NHP model of HoFH using a single treatment of two different formulations of our proprietary GalNAc-LNPs to deliver an ANGPTL3-targeted base editor demonstrating approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, respectively, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline.</span></div></div>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Discovery and validation of LNPs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to nominating VERVE-201 as a development candidate, we used a rigorous process to optimize preclinical safety and efficacy. We performed a number of studies evaluating precursor formulations of an ANGPTL3 targeted base editor as well as multiple precursor formulations of our proprietary GalNAc-LNPs to deliver the editor.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">LNP-mediated delivery to the liver is more challenging in patients with HoFH than in those with HeFH. This is due to the fact that deficiency in the LDLR gene often drives HoFH pathophysiology, and uptake of LNPs into the liver is generally thought to be through a predominantly LDLR-dependent pathway. An approach to bypass the LDLR would be the addition of a targeting ligand to LNPs that works through a receptor other than LDLR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have screened and developed a proprietary GalNAc-targeting ligand that can be incorporated into LNPs. GalNAc ligands bind to the ASGPR in the liver and have been used to enhance delivery of siRNAs to the liver. ASGPR is highly expressed in the liver with rapid turnover in about 15 minutes and high capacity to mediate uptake into the liver independent of LDLR.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted a preclinical study in mice that were entirely deficient in the LDL receptor, or LDLR -/- mice, in order to evaluate the efficacy of our proprietary GalNAc-targeted LNPs. As shown in the graphic below, the addition of the GalNAc ligand onto the LNP increased editing in the liver of LDLR -/- mice. We observed that GalNAc-targeted LNPs have similar apparent potency in wild-type, LDLR +/- mice and LDLR -/- mice.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_22.jpg" alt="img243551639_22.jpg" style="width:459px;height:376px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are continuing to invest and build out capabilities in the development of novel and optimized GalNAc-targeting ligands, optimal lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We believe GalNAc provides a delivery platform for patients with both forms of FH and potentially may be applicable in other applications where liver-directed delivery is advantageous.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">NHP model of HoFH</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to create a model of HoFH in NHPs, we edited the LDLR gene in wild-type NHPs and eliminated LDLR expression in the liver using a Cas9 and dual guide RNA strategy encapsulated in standard LNPs, which led to nearly 70% whole liver DNA editing at the LDLR gene and resulted in an approximately 94% reduction in LDLR protein in the liver and a six-fold increase in blood LDL-C.</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Validation in an NHP model of HoFH using internally developed GalNAc-LNPs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Using this novel NHP model of HoFH, we conducted a preclinical study using two different formulations of our proprietary GalNAc-LNPs to deliver an ANGPTL3-targeted base editor. In this study, we observed that delivery of the base editor using standard LNPs did not achieve effective ANGPTL3 editing in the liver of the NHP model of HoFH. As shown in the figures below, in NHPs treated with an ANGPTL3-targeted base editor delivered with a GalNAc-LNP, we observed approximately 94% (n=3) and 97% (n=3) reduction in blood ANGPTL3 protein, and reductions in LDL-C of nearly 100 mg/dL, which was an approximately 35% reduction from baseline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_23.jpg" alt="img243551639_23.jpg" style="width:627px;height:345px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">GalNAc-LNP delivery to normal livers of NHPs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have also assessed the potential broad utility of our proprietary GalNAc-LNP approach for delivery of an ANGPTL3-targeted base editor, in a preclinical study evaluating delivery efficiency of an ANGPTL3 base editor using both a GalNAc-LNP and a standard LNP without GalNAc in wild-type NHPs with normal livers. In these studies, we observed that wild-type NHPs treated with an ANGPTL3-targeted base editor delivered via our GalNAc-LNP had an approximately 89% reduction in ANGPTL3 protein compared to an approximately 74% reduction in wild-type NHPs treated with a standard LNP. We believe this suggests that GalNAc-LNP delivery may be utilized in indications where LDLR is present.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_24.jpg" alt="img243551639_24.jpg" style="width:597px;height:337px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have completed a large confirmatory dose-response study in 34 wild-type NHPs. In this study, we administered an ANGPTL3 base editor using a GalNAc-LNP at 1.5 mg/kg (n=6) and 3.0 mg/kg (n=16) with a control group (n=12). We observed a 96% reduction in circulating</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ANGPTL3 protein at the 3.0 mg/kg dose group.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">NHP validation with ABE-ANGPTL3 precursor formulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted a preclinical proof-of-concept study using an ABE-ANGPTL3 precursor formulation. In this study, which is ongoing, we administered a single dose to healthy NHPs. In the figure below, each treated NHP is represented by a purple bar and each vehicle treated control is represented by a blue bar. Following a single treatment with our ABE-ANGPTL3 precursor formulation, we observed an average 60% editing of ANGPTL3 in whole liver tissue sampled through a liver biopsy two weeks after dosing. This was accompanied by an average 95% reduction of blood ANGPTL3 protein and an average 64% reduction of blood triglycerides concentrations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_25.jpg" alt="img243551639_25.jpg" style="width:336px;height:420px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Importantly, in this preclinical study, we observed that the reductions in blood ANGPTL3 protein and blood triglycerides levels were durably maintained. As shown in the figure below, at two years following a single intravenous administration of ABE-ANGPTL3, we observed that the NHPs continued to exhibit an average reduction of 97% in blood ANGPTL3 protein and an average reduction of 71% in blood triglycerides.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img243551639_26.jpg" alt="img243551639_26.jpg" style="width:672px;height:250px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our preclinical studies of our ABE-ANGPTL3 precursor formulation as well as precursor formulations of our proprietary GalNAc-LNPs led to the development of VERVE-201.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">VERVE-201 next steps</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to nominating VERVE-201 as a development candidate, we used a rigorous process designed to optimize preclinical safety and efficacy. We selected an optimized configuration and evaluated VERVE-201 in primary human liver cells, which showed potent, on-target editing of the ANGPTL3 gene with no detectable off-target and no detectable structural variants as assessed using high-coverage whole genome optical mapping. We are conducting preclinical studies to support a regulatory filing for the initiation of clinical development of VERVE-201 and anticipate initiating a Phase 1b clinical trial in 2024.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sequential dosing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that patients with very high LDL-C levels or patients with hyperlipidemia that also have high LDL-C levels and high triglyceride levels may benefit from treatment with gene editing medicines that target two lipid pathways, such as PCSK9 and ANGPTL3. We conducted a 90-day preclinical study in four NHPs to assess the potential for sequential dosing of our base editors. In this study, we dosed 1.0 mg/kg of a VERVE-101 precursor on day 1, followed by a 1.0 mg/kg dose of an ANGPTL3 base editor on day 30. As shown in the figure below, we observed a substantial reduction of plasma protein levels of both PCSK9 and ANGPTL3 following sequential dosing. We measured PCSK9 editing by liver biopsy on day 15 and observed an average of 71% editing. We measured ANGPTL3 editing by liver biopsy on day 45 and observed an average of 52% editing. We conducted a liver necropsy on day 90 and observed an average of 69% PCSK9 editing and 63% ANGPTL3 editing. We also monitored plasma PCSK9 and ANGPTL3 protein levels during the study and observed a greater than 90% reduction of plasma PCSK9 protein after the first dose and a greater than 90% reduction of plasma ANGPTL3 protein after the second dose, and observed similar reductions at the end of the study. These data suggest that sequential dosing of a PCSK9 base editor followed by an ANGPTL3 base editor may be able to edit two genes that control two key lipid pathways.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><img src="img243551639_27.jpg" alt="img243551639_27.jpg" style="width:672px;height:293px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lp(a) Program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Lp(a) program is focused on designing an </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> genome-editing medicine to durably inactivate the LPA gene in the liver with a precise DNA change. We plan to develop this program initially for patients with ASCVD and high circulating Lp(a) concentrations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lp(a) is a LDL-like particle with apolipoprotein B covalently linked to apolipoprotein(a) that is produced in the liver and circulates in the blood. The LPA gene target was prioritized based on epidemiologic, human genetic, and pharmacologic studies that have established Lp(a) as an important causal and modifiable driver of risk for ASCVD. This increased risk is most pronounced in individuals with very high Lp(a) concentrations (e.g., &#x2265; 150 nmol/L). An estimated 20% of ASCVD patients have a Lp(a) concentration above this threshold. Lp(a) concentrations are determined almost entirely by inheritance &#x2013; lifestyle therapies and currently approved lipid-lowering therapies have minimal to no impact.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Both human genetics and pharmacologic studies have validated the potential efficacy and safety of a Lp(a)-reducing medicine. DNA variants that cause increased circulating Lp(a) are among the strongest inherited drivers of risk for ASCVD as well as certain heart valvular diseases (e.g., aortic stenosis). By contrast, naturally occurring loss-of-function mutations in one or both copies of the LPA gene are associated with protection from these conditions and no detectable serious adverse health consequences.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to these human genetic studies, recent human pharmacologic studies of investigational therapies targeting LPA expression in the liver can potently lower circulating Lp(a) concentrations by greater than 80%. The potential for these medicines to lower the risk of recurrent ASCVD events in patients with high Lp(a) is being tested in ongoing cardiovascular outcomes trials of the antisense oligonucleotide pelecarsen and the siRNA olpasiran.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that these prior studies &#x2013; alongside our experience in developing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> genome editing medicines to treat ASCVD &#x2013; provide substantial evidence for the potential utility of a single-course medicine to lower Lp(a) in a patient population with both high risk and high unmet need. Our Lp(a) program is in the early research stage.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future opportunities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are investing in the identification of additional </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> liver gene editing treatments and intend to develop a suite of single-course gene editing medicines that address root causes of disease. We plan to continue to focus on programs where the target has biology substantially validated by human genetics and, in many cases, by clinical development programs using other modalities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not currently own or operate manufacturing facilities. We currently rely on third-party contract manufacturing organizations, or CMOs, and suppliers for critical starting materials, drug substances&#x2014;gRNA, mRNA&#x2014;and our drug products. We plan to use third-party CMOs to support our IND-enabling studies and to supply our clinical trials and commercial activities. As we scale manufacturing, we intend to continue to expand and strengthen our network of CMOs. We believe there are multiple sources for all of the materials required for the manufacture of our product candidates, as well as multiple CMOs who could assemble the components of our program candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are continuing to invest in building internal manufacturing capabilities for mRNA production and LNP formulation, including the development of novel and optimized GalNAc-targeting ligands, lipid anchors, optimal compositions and ratios of LNP components, and optimal processes of addition and LNP formation with targeting ligands. We are also investing in analytical method development including bioactivity and potency assays that will be critical to further product development, batch comparability assessments and additional manufacturing growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturing is subject to extensive regulations that impose procedural and documentation requirements. These regulations govern record keeping, manufacturing processes and controls, personnel, quality control and quality assurance. Our CMOs are required to comply with these regulations and are assessed by regular monitoring and formal audits. Our third-party manufacturers are required to manufacture any product candidates we develop under current Good Manufacturing Practice, or cGMP, requirements and other applicable laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have personnel with extensive technical, manufacturing, analytical and quality experience to oversee our contracted manufacturing and testing activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Competition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The biotechnology and biopharmaceutical industries generally, and the CVD field specifically, are characterized by rapid evolution of technologies, sharp competition and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete with existing therapies and new therapies that may become available in the future. While we believe that our technology, development experience and scientific knowledge in CVD, gene editing and manufacturing provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The key competitive factors affecting the success of all of our product candidates that we develop for the treatment of CVD if approved, are likely to be efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium to competitive generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are several approved products for LDL-C lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl. There are several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD. Evolocumab, which is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a mAb marketed as Repatha by Amgen Inc., is approved by the FDA for the treatment of patients with HeFH, patients with HoFH and patients with ASCVD. Alirocumab, which is a mAb marketed as PRALUENT&#174; by both Sanofi and Regeneron Pharmaceuticals, Inc., or Regeneron, is approved by the FDA for the treatment of patients with ASCVD and for the treatment of patients with primary hyperlipidemia, including HeFH. The approved mAb treatments act through extracellular inhibition of the PCSK9 protein. Inclisiran, which is a siRNA marketed as Leqvio&#174; by Novartis, is approved in the United States for the treatment of patients with clinical ASCVD or HeFH who require additional lowering of LDL-C and in Europe for the treatment of patients with hypercholesterolemia, including HeFH, or mixed dyslipidemia. Inclisiran acts by inhibiting the synthesis of PCSK9 within liver cells, which is distinct from extracellular protein inhibition. We are also aware of three orally administered small molecule product candidates that target the PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD in various stages of clinical development. These include MK-0616 from Merck &amp; Co., Inc, which was studied in a recently completed Phase 2b trial of adult patients with hypercholesterolemia with a plan to release results in the first quarter of 2023; an oral small molecule from Serometrix LLC in-licensed by Esperion Therapeutics, which disclosed plans in 2022 to submit an IND in late 2024 or early 2025; and AZD0780, acquired by AstraZeneca from Dogma Therapeutics, which is being evaluated in an ongoing Phase 1 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are aware of two other gene editing programs targeting the PCSK9 gene in preclinical development. Precision Biosciences, Inc., or Precision, has published preclinical data showing long-term stable reduction of PCSK9 and LDL-C levels in NHPs following </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing of the PCSK9 gene using its gene editing platform. In September 2021, Precision entered into a collaboration with iECURE under which iECURE plans to advance Precision&#x2019;s PCSK9 directed nuclease product candidate in to Phase 1 clinical trials for the treatment of FH in 2022. In January 2023, Precision announced that it had decided to cease pursuit of this program with iECURE as a partner, with plans to provide additional guidance on whether and when this medicine will advance into clinical testing in the future. Additionally, in 2022, CRISPR Therapeutics, or CRISPR, announced CTX330, its research stage </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing program targeting PCSK9.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evinacumab, which is a mAb targeting ANGPTL3 protein that is marketed by Regeneron, is approved by the FDA for the treatment of patients with HoFH and has additionally been evaluated in Phase 2 studies of patients with refractory hypercholesterolemia and either ASCVD or HeFH, and severe hypertriglyceridemia. We are aware of several product candidates in clinical development that target ANGPTL3 as a mechanism to lower LDL-C and reduce the risk of ASCVD, including ARO-ANG3, a siRNA targeting ANGPTL3 being evaluated by Arrowhead Pharmaceuticals in Phase 2 clinical trials of patients with HoFH and patients with mixed dyslipidemia. In 2022, Arrowhead announced plans to initiate pivotal Phase 3 studies of ARO-ANG3 in patients with HoFH and patients with HeFH in the second half of 2023. In addition, Eli Lilly and Company is evaluating a siRNA targeting ANGPTL3 protein in a Phase 2 study in adults with mixed dyslipidemia, and in 2022, CRISPR announced CTX310, its gene editing program targeting ANGPTL3, which is in IND-enabling studies with plans for initial patient dosing in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Several investigational medicines designed to reduce Lp(a) are currently in development. These include pelecarsen, an antisense oligonucleotide licensed by Novartis from Ionis Pharmaceuticals in 2019, which is being evaluated in the Phase 3 Lp(a) HORIZON cardiovascular outcomes study in patients with high Lp(a) and cardiovascular disease, with topline results expected in 2025. Olpasiran is an investigational siRNA medicine targeting Lp(a) licensed by Amgen from Arrowhead Pharmaceuticals, which was recently shown to lower Lp(a) concentrations in patients with established ASCVD and high Lp(a) concentrations. The potential for olpasiran to reduce cardiovascular events in patients with existing ASCVD and high Lp(a) will be evaluated in the OCEAN(a) study, which was initiated in 2022 with plans for study completion in 2026. In addition, SLN360 is an investigational siRNA medicine being developed by Silence Therapeutics plc that is being evaluated in an ongoing Phase 2 study of patients with high Lp(a) concentrations and high risk for ASCVD events, and, in 2022, CRISPR announced CTX320, its research stage </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing program targeting Lp(a).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Intellectual Property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We strive to protect the proprietary technologies that we believe are important to our business, including pursuing and maintaining patent protection intended to cover the composition of matter of our product candidates, their methods of use, related technologies and other inventions that are important to our business. In addition to patent protection, we also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection, including certain aspects of our technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and know how related to our business, defend and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">enforce our intellectual property rights, in particular, our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The patent positions for biotechnology and pharmaceutical companies like ours are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, our patent estate covers various aspects of our programs and technology, including our gene editing programs for PCSK9 and ANGPTL3 targets as well as our RNA delivery and other platform technology. Any U.S. or foreign patents issued or pending would be scheduled to expire on various dates from 2041 through 2043, without taking into account any possible patent term adjustments or extensions and assuming payment of all appropriate maintenance, renewal, annuity and other governmental fees. Further details on certain segments of our patent portfolio are included below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PCSK9 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With regard to our VERVE-101 program, as of December 31, 2022, our patent estate includes one pending U.S. patent application and over fifteen foreign application counterparts that we own or control and cover various aspects of our VERVE-101 program, including guide RNA sequences targeting the PCSK9 gene, mRNAs encoding adenine base editors, and compositions thereof, methods of using such compositions for therapeutic indications, methods for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing, formulations, dosing regimens, and combination therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ANGPTL3 program</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With regard to our VERVE-201 program, as of December 31, 2022, our patent estate includes one pending U.S. patent application, one pending international PCT application and over fifteen foreign application counterparts that we own or control and cover various aspects of our VERVE-201 program, including guide RNA sequences targeting the ANGPTL3 gene, mRNAs encoding adenine base editors, and compositions thereof, methods of using such compositions for therapeutic indications, methods for </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing, formulations, dosing regimens, and combination therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and collaboration agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a party to a number of license agreements under which we license patents, patent applications and other intellectual property from third parties. The licensed intellectual property covers, in part, CRISPR-related compositions of matter and their use for base editing. These licenses impose various diligence and financial payment obligations on us. We expect to continue to enter into these types of license agreements in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaboration and license agreement with Beam Therapeutics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2019, we entered into a collaboration and license agreement with Beam, or the Original Beam Agreement, pursuant to which we received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, as well as gene editing and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases, or the licensed products. Upon execution of the Original Beam Agreement and as partial consideration for the rights granted to us thereunder, we issued 276,075 shares of our common stock to Beam.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, we amended and restated the Original Beam Agreement upon entering into the Amended and Restated Collaboration and License Agreement with Beam, or the Amended Beam Agreement. Pursuant to the Amended Beam Agreement, Beam granted us an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology to develop and commercialize products directed towards a third liver-mediated, cardiovascular disease target, in addition to the PCSK9 and ANGPTL3 gene targets licensed under the Original Beam Agreement. We are responsible for the development and commercialization of products targeting the licensed gene targets, in each case subject to Beam&#x2019;s opt-in right. Except as described below, we are fully responsible for the development of licensed products under the Amended Beam Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the ANGPTL3 and PCSK9 gene targets, following the dosing of the final patient in a Phase 1 clinical trial of a licensed product for such gene targets, Beam has the right to opt-in to share 33% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed products in the United States on a 50/50 basis. For the third gene target, following the dosing of the final patient in a Phase 1 clinical trial of a licensed product for such additional gene target, Beam has the right to opt-in to share 35% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share 35% of the profits and expenses of commercializing such licensed product worldwide.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If Beam exercises its opt-in right for a given licensed product, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. With respect to each collaboration product, we and Beam will enter into a subsequent co-promotion agreement prior to the anticipated sale of such collaboration product in the United States, pursuant to which we and Beam will each provide 50% of the promotional effort required to promote the collaboration product. For collaboration products, on a product-by-product basis outside of the United States, we are obligated to pay clinical and regulatory milestones of up to an aggregate of $5.6 million and sales-based milestones of up to an aggregate of $7.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We refer to any licensed products for which Beam has either (i) not elected to exercise its opt-in right or (ii) if Beam has exercised its opt-in right, either we or Beam subsequently elect to opt-out of the payment of shared development and commercialization costs and participating in the commercialization of such licensed product, as a non-collaboration product. For such non-collaboration products, on a product-by-product basis worldwide, we are obligated to pay clinical and regulatory milestones of up to an aggregate of $11.3 million and sales-based milestones of up to an aggregate of $15.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent there are sales of a collaboration product outside of the United States or a non-collaboration product worldwide, we will be required to pay tiered royalties to Beam at rates ranging from the low-to-mid single digit percentage of net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) 10 years after the first commercial sale of such product in such country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under our intellectual property, including under our GalNAc-LNP delivery technology, relating to a preclinical program developed by us. Beam has a non-exclusive license under know-how and patents controlled by us, and an interest in joint collaboration technology, to allow Beam to conduct activities under agreed upon research and development plans, as applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We and Beam each have the right to sublicense our licensed rights, subject to certain restrictions and provided that the sublicense agreement is in compliance and consistent with the terms of the Amended Beam Agreement and any applicable licensed agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Amended Beam Agreement granted Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to our GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe us a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Amended Beam Agreement, Beam controls the prosecution of its respective patent rights, at its sole expense. We have the first right, but not the obligation, to file for, and prosecute and enforce, at our sole expense, product-specific patent rights under the Amended Beam Agreement, to the extent permitted by Beam&#x2019;s applicable in-license agreements, and we have the exclusive right to file for, prosecute and maintain the patent rights under our delivery technology and any other patent rights that we licensed to Beam under the Amended Beam Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With respect to intellectual property rights jointly developed by Beam and Verve arising out of a party&#x2019;s performance of its obligations under the agreement, such intellectual property, depending on its nature, is considered under the agreement as joint collaboration technology and subject to joint ownership by Beam and Verve and we and Beam shall decide in good faith as to who shall bear responsibility for filing for, prosecuting and maintaining the jointly owned patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The term of the Amended Beam Agreement continues until the last to expire of any royalty term for any licensed product. We have the right to terminate the Amended Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired. Beam has the right to terminate the Amended Beam Agreement as to certain products by delivering a 90-day termination notice to us. The Amended Beam Agreement may be terminated by either party upon (i) written notice if the other party is in material breach and fails to cure such breach within the specified cure period or (ii) the other party&#x2019;s bankruptcy or liquidation. Beam may terminate the Amended Beam Agreement, and we may terminate the licenses granted to Beam under the Amended Beam Agreement, immediately if the other party, directly or indirectly, challenges the enforceability, validity or scope of any patent rights underlying the licenses granted under the Amended Beam Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">License agreement for the PCSK9 gene target</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2020, we selected an LNP optimized under a development and option agreement with Acuitas, or the Acuitas Development Agreement, to be a component of our VERVE-101 product candidate. In connection with that selection, we exercised an option with respect to the use of the LNP technology and entered into a non-exclusive, worldwide license with Acuitas, or the Acuitas License Agreement, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop, have developed, make, have made, keep, use and have used, sell, offer for sale, have sold, import and have imported, export and have exported and otherwise commercialize and exploit licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses. Under the Acuitas License Agreement, we are obligated to use diligent efforts to develop and commercialize licensed products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Acuitas retained the right to prosecute and maintain, at its sole expense, patents related to the LNP technology. In the event that Acuitas elects not to file, prosecute or maintain patents related to the LNP technology, it will notify us and we have the right, but not the obligation, to request that Acuitas continue to file, prosecute or maintain such patents, at our expense, and our license to such patents will automatically become irrevocable, perpetual, fully paid-up and royalty free, but such patents will thereafter no longer be part of the licensed technology in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We and Acuitas will enter into a joint patent prosecution and maintenance agreement with respect to the jointly owned patents under the Acuitas License Agreement and as further provided in the Acuitas Development Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We paid Acuitas an upfront license fee of $2.0 million (less previously paid target reservation fees) and are required to pay an annual license maintenance fee of $0.8 million until the achievement of a certain development-based milestone. We are also obligated to reimburse Acuitas quarterly for employee and reasonable external expenses incurred that are related to the transfer of its licensed technology to our CMO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also obligated to pay Acuitas up to an aggregate of $9.8 million in clinical and regulatory milestones and $9.5 million in sales-based milestones. We will be required to pay royalties at a low single digit percentage based on annual net sales of licensed products sold by us, our affiliates or our sublicensees. Such royalty payments are subject to reduction if we obtain a license from a third party under technology relating to the LNP technology. Any such royalty payments are payable, on a country-by-country and licensed product-by-licensed product basis, until the later of (i) the expiration of the last to expire valid claim in the licensed technology that covers the licensed product in such country, (ii) the expiration of the regulatory exclusivity period in such country and (iii) ten years from the first commercial sale of the licensed product in such country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Acuitas License Agreement will terminate on a licensed product-by-licensed product and country-by-country basis upon the last-to-expire royalty term in such country with respect to such licensed product. We may terminate the Acuitas License Agreement without cause upon prior written notice to Acuitas. Either party may terminate the Acuitas License Agreement upon (i) written notice if the other party is in material breach and fails to cure such breach within the specified cure period or (ii) immediately upon notice in the event of the other party&#x2019;s bankruptcy or insolvency. In lieu of terminating the agreement for Acuitas&#x2019; uncured material breach, we have the alternative option, upon written notice to Acuitas, not to terminate the agreement but instead reduce the applicable milestone and royalty payments by a specified percentage.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Novartis license agreement</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, we entered into a license agreement with Novartis to obtain a non-exclusive license to lipid technology that we are using in connection with the research and development of certain product candidates, including VERVE-201. As consideration for the license and rights granted under the agreement, we made a one-time, non-refundable, upfront payment of $0.8 million during the year ended December 31, 2021. The license agreement requires us to pay up to an aggregate of $10.0 million in clinical and regulatory milestones and $35.0 million in sales-based milestones for products that incorporate the licensed lipid technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2022, we amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, we were required to make a one-time, non-refundable upfront payment of $2.8 million to Novartis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2019, we entered into a license agreement with Broad and Harvard for specified patent rights and in December 2019, we entered into an amendment to this license agreement, or, as amended, the Cas9 License Agreement. The licenses granted to us under the Cas9 License Agreement include rights to (i) certain patents and patent applications solely owned by Harvard, or the Harvard Cas9-I Patent Rights, certain patents and patent applications co-owned by the Massachusetts Institute of Technology, or MIT, and Broad, certain patents and patent applications co-owned by The Rockefeller University, or Rockefeller, and Broad, and certain patents and patent applications co-owned by MIT, Broad and Harvard, which patents and patent applications licensed under the Cas9 License Agreement we refer to as the Harvard/Broad Cas9-I Patent Rights and (ii) certain patents and patent applications co-owned by MIT, Broad, Harvard and the University of Iowa Research Foundation, or Iowa, which patents and patent applications licensed under the Cas9 License Agreement we refer to as the Harvard/Broad Cas9-II Patent Rights, and together with the Harvard/Broad Cas9-I Patent Rights, the Harvard/Broad Cas9 Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In February 2017, Broad and Rockefeller entered into an inter-institutional agreement pursuant to which Rockefeller authorized Broad to act as its sole and exclusive agent for the purposes of licensing Rockefeller&#x2019;s rights in such Harvard/Broad Cas9-I Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2014, as amended in August 2016, MIT, Iowa and Broad entered into a joint invention administration agreement pursuant to which Iowa authorized Broad to act as their sole and exclusive agent for the purposes of licensing their rights in such Harvard/Broad Cas9-II Patent Rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">License rights under Cas9 License Agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Cas9 License Agreement, Broad and Harvard granted us a worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9 Patent Rights to make, have made, use, have used, sell, offer for sale, have sold, import and export products directed to PCSK9, ANGPTL3 and two additional targets, in the field of the prevention and treatment of human disease, subject to certain limitations and retained rights. With respect to the Harvard/Broad Cas9-I Patent Rights and certain of the Harvard/Broad Cas9-II Patent Rights, or the Cas 9-II Group A Patent Rights, the license is co-exclusive with Editas Medicine, Inc., or Editas. With respect to certain other of the Harvard/Broad Cas9-II Patent Rights, or the Cas9-II Group B Patent Rights, the license is non-exclusive. The license follows the inclusive innovation strategy developed by Broad, MIT and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Broad and Harvard also granted us a non-exclusive, worldwide, royalty-bearing, sublicensable license to the Harvard/Broad Cas9 Patent Rights for internal research purposes; for research, development and commercialization of products for the prevention or treatment of human disease outside the field of Editas&#x2019; exclusive license agreements with Broad and Harvard; and with respect to the targets, to make, have made, use, have used, sell, offer for sale, have sold, import and export products that are not Cas9 licensed products but is a Cas9 enabled products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The licenses granted by Broad and Harvard to us under the Cas9 License Agreement are subject to retained rights of the U.S. government in the Harvard/Broad Cas9 Patent Rights and the rights retained by Broad, Harvard, MIT, Rockefeller and Iowa on behalf of themselves and other academic, government and non-profit entities, to practice the Harvard/Broad Cas9 Patent Rights, as applicable, for research, educational or teaching purposes. In addition, certain rights granted to us under the Cas9 License Agreement for the Harvard/Broad Cas9-I Patent Rights are further subject to a non-exclusive license to the Howard Hughes Medical Institute for research purposes. Our co-exclusive license rights also are subject to rights retained by Broad, Harvard, MIT, Rockefeller and Iowa, for each of them and for any third party (including non-profit and for-profit entities), to research, develop, make, have made, use, offer for sale, sell, have sold, import or otherwise exploit the Harvard/Broad Cas9 Patent Rights and licensed products as research products or research tools, or for research purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have the right to sublicense our licensed rights, subject to certain restrictions and provided that the sublicense agreement must be in compliance and consistent with the terms of the Cas9 License Agreement. Any sublicense agreement cannot include the right to assign sublicenses without the written consent of Broad and Harvard. In addition, any sublicense agreements must contain certain terms, including a provision requiring the sublicensee to indemnify Harvard, Broad, MIT, Rockefeller, Iowa and Howard Hughes Medical Institute according to the same terms as are provided in the Cas9 License Agreement and a statement that Broad, Harvard, MIT, Rockefeller, Iowa and Howard Hughes Medical Institute are intended third-party beneficiaries of the sublicense agreement for certain purposes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are obligated to use commercially reasonable efforts, or to cause at least one of our affiliates or sublicensees to use commercially reasonable efforts, (i) to research and develop Cas9 licensed products in the licensed field, (ii) to introduce such products in the licensed field into the commercial market, and (iii) to market such products in the licensed field following such introduction into the market and make such products reasonably available to the public. In addition, we, by ourselves or through any of our affiliates or sublicensees, are obligated to achieve certain development milestones within certain time periods. Broad and Harvard have the right to terminate the Cas9 License Agreement if we fail to achieve a development milestone, subject to our right to extend or amend such milestone in accordance with certain procedures. Such termination right will not apply solely with respect to a particular target if, at the time Broad and Harvard elect to terminate the Cas9 License Agreement for failure to achieve a development milestone, we provide evidence reasonably acceptable to Harvard and Broad that we are not in breach of our development milestone diligence obligations with respect to such target and that we are, or one of our affiliates or sublicensees are, (a) researching and developing Cas9 licensed products in the licensed field directed to such target, (b) using commercially reasonable efforts to introduce Cas9 licensed products in the licensed field directed to such target into the commercial market (if applicable), and (c) using commercially reasonable efforts to market Cas9 licensed products in the licensed field directed to such target following such introduction into the market and make such Cas9 licensed products reasonably available to the public (if applicable), and thereafter, for the remainder of the term, we continue, or cause at least one of our affiliates or sublicensees to continue, to develop and commercialize Cas9 licensed products directed to such target in accordance with the foregoing (a)-(c).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Cas9 License Agreement, Broad and Harvard also retained rights to grant further licenses, through its inclusive innovation strategy, under specified circumstances, to third parties, other than specified entities, that wish to develop and commercialize products that target a particular gene outside of the cardiovascular disease field and that otherwise would fall within the scope of our co-exclusive license from Broad and Harvard. If a third party requests a license under the Harvard/Broad Cas9-I Patent Rights for the development and commercialization of a product that would be subject to our co-exclusive license grant from Broad and Harvard under the Cas9 License Agreement, Broad and Harvard may notify us of the request, which we refer to as the Cas9 Third Party Proposed Product Requests. A Cas9 Third Party Proposed Product Request must be accompanied by the third party&#x2019;s bona fide proposal, including the proposed target or category. Broad may not grant a Cas9 Third Party Proposed Product Request (i) if we, directly or indirectly through any of our affiliates or sublicensees, are researching, developing or commercializing a product directed to the same gene target that is the subject of the Cas9 Third Party Proposed Product Request, or the Cas9 Licensee Product, and we can demonstrate such ongoing efforts to Broad&#x2019;s reasonable satisfaction, or (ii) if we, directly or indirectly through any of our affiliates or sublicensees, wish to do so, and we can demonstrate to Broad&#x2019;s reasonable satisfaction that we are interested in researching, developing and commercializing a Cas9 Licensee Product, that we have a commercially reasonable research, development and commercialization plan to do so, and we commence and continue reasonable commercial efforts under such plan. Furthermore, if we, directly or indirectly through any of our affiliates or sublicensees, are not researching, developing or commercializing a Cas9 Licensee Product but wish to grant a sublicense to do so, Broad is obligated to disclose to us the name of the third party and we may enter into a sublicense agreement with the third party. If we, directly or indirectly through any of our affiliates or sublicensees, are not researching, developing or commercializing a Cas9 Licensee Product, are unable to develop and implement a plan reasonably satisfactory to Broad and Harvard, or are unable to enter into a sublicense agreement with the third party, Broad and Harvard have the right to terminate our rights to the specified third-party target or to a specified category and have the right to freely grant to third parties licenses in the licensed field (a) under the patent rights that are exclusively or co-exclusively licensed to us with respect to such specified third party target or (b) under the patent rights that are exclusively or co-exclusively licensed to us within such specified category, provided that such licenses do not grant rights to commercialize products intended for use in the cardiovascular disease field.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Payment terms</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Cas9 License Agreement, we paid Broad and Harvard an upfront license fee of $0.1 million and issued an aggregate of 138,037 shares of our common stock to Broad and Harvard. Broad and Harvard also have anti-dilution rights, pursuant to which we (i) have issued Broad and Harvard an aggregate of an additional 309,278 shares of our common stock in the aggregate following the completion of preferred stock financings and (ii) have issued Broad and Harvard an aggregate of an additional 878,098 shares of common stock upon the closing of our IPO.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also must pay an annual license maintenance fee ranging in dollars from the low- to mid-five figures, depending on the calendar year. A portion of this annual license maintenance fee is creditable against royalties owed on licensed or enabled products in the same year as the maintenance fee is paid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Broad and Harvard, collectively, are entitled to receive (i) clinical and regulatory milestone payments of up to an aggregate of $5.7 million per licensed product in the United States, the European Union and Japan for the prevention or treatment of a human disease that afflicts fewer than a certain number of patients in the United States and (ii) clinical and regulatory milestone payments of up to an aggregate of $17.4 million per licensed product in the United States, the European Union and Japan for the prevention or treatment of a human disease that afflicts at least a certain number of patients in the United States. If we undergo a change of control during the term of the Cas9 License Agreement, certain of these clinical and regulatory milestone payments will increase by a certain percentage. We are also obligated to make additional payments to Broad and Harvard, collectively, of up to an aggregate of $54.0 million upon the occurrence of certain sales-based milestones per licensed product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also obligated to pay to Broad and Harvard tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $10.0 billion, or the Market Cap Success Payments, or sale of our company for consideration in excess of those thresholds, or the Company Sale Success Payments, which with the Market Cap Success Payments, we refer to as the Success Payments. Market Cap Success Payments are payable by us in cash, in shares of our common stock, with such shares being valued for such purpose at the closing price of our common stock as reported on the Nasdaq Stock Market for the trading day immediately preceding the date of such payment if our common stock was then listed on the Nasdaq Stock Market, or a combination of shares and cash. In the event of a change of control of our company or a sale of our company, we are required to pay the related Company Sale Success Payment in cash within a specified period following such event. The Success Payments are cumulative and more than one Success Payment may be due and payable based on the average market capitalization on any trigger date. The maximum aggregate Success Payments that could be payable by us are $31.3 million. Certain of the Success Payments are only payable if a licensed product is or has been evaluated in clinical trials. To the extent we issue shares of our common stock in satisfaction of such Success Payments, we will be obligated to file a registration statement with the SEC to register the resale of such shares by Broad and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In September 2021, we notified Harvard and Broad that our average market capitalization exceeded three specified thresholds as of a relevant measurement date and aggregate success payments of approximately $6.3 million became payable under the Cas9 License Agreement, which we settled in cash in November 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Broad and Harvard, collectively, are entitled to receive mid single-digit percentage royalties on net sales of licensed products, and low single-digit percentage royalties on net sales of other products enabled by the license, made by us, our affiliates or our sublicensees. The royalty percentage depends on the aggregate amount of the net sales for the licensed or enabled products. If we are legally required to pay royalties to a third party on net sales of our licensed products because such third party holds patent rights that cover such licensed product, then we can credit, subject to a floor, up to a certain percentage of the amount paid to such third party against the royalties due to Broad and Harvard in the same period. On a target-by-target basis, if Editas initiates a program that uses technology covered by the Harvard/Broad Cas Patent Rights and is directed to one of the targets, then the milestone and royalty payments for that specific target shall be reduced by a certain percentage. Our obligation to pay royalties will expire on a product-by-product and country-by-country basis upon the later of (i) the expiration of the last to expire valid claim of the Harvard/Broad Cas9 Patent Rights that cover the composition, manufacture or use of each covered product in each country or (ii) the tenth anniversary of the date of the first commercial sale of the licensed or enabled product. If we sublicense any of the Harvard/Broad Cas9 Patent Rights to a third party, Broad and Harvard, collectively, have the right to receive between 10% and 20% of the sublicense income, which percentage shall decrease to a high single-digit after we meet certain clinical milestones.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Prosecution and enforcement provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Broad and Harvard retain control of the prosecution of their respective patent rights. We are obligated to reimburse Broad and Harvard for certain expenses associated with the prosecution and maintenance of the Harvard/Broad Cas9 Patent Rights, including expenses associated with any interference proceedings in the USPTO, any opposition proceedings in the European Patent Office, or any other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or other post grant proceedings in these or other jurisdictions where we are seeking patent protection. Broad and Harvard are required to maintain any application or patent within the Harvard/Broad Patents Rights so long as we meet our obligation to reimburse Broad and Harvard for expenses related to prosecution, there is a good faith basis for doing so and doing so is consistent with Broad or Harvard&#x2019;s patent prosecution strategy. If we cease payment for the prosecution of any Harvard/Broad Cas9 Patent Right, then any license granted to us with respect to such Harvard/Broad Cas9 Patent Right will terminate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have the first right, but not the obligation, to enforce the Harvard/Broad Cas9-I Patent Rights with respect to our licensed products so long as certain conditions are met, such as providing Broad and Harvard with evidence demonstrating a good faith basis for bringing suit against a third party and subject to coordination with Editas. We are solely responsible for the costs of any lawsuits we elect to initiate and cannot enter into a settlement without the prior written consent of Broad and Harvard (and MIT, Rockefeller and Iowa, if applicable). Any sums recovered in such lawsuits will be shared among us, Broad and Harvard.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Termination provisions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unless terminated earlier, the term of the Cas9 License Agreement will expire upon the expiration of the last to expire valid claim of the Harvard/Broad Cas9 Patent Rights. However, our royalty and milestone payment obligations, discussed above, may survive expiration or termination. We have the right to terminate the agreement at will upon four months&#x2019; written notice to Broad and Harvard. Either we or Broad and Harvard may terminate the agreement upon a specified period of notice in the event of the other party&#x2019;s uncured material breach, such notice period varying depending on the nature of the breach. Both Broad and Harvard may terminate the Cas9 License Agreement immediately if we, or our affiliates or sublicensee(s), subject to our ability to cure, challenge the enforceability, validity or scope of any Harvard/Broad Patent Right or assist a third party to do so, or in the event of our bankruptcy or insolvency. Neither Broad nor Harvard acting alone has the right to terminate the Cas9 License Agreement. However, Broad and Harvard may separately terminate the licenses granted to us with respect to their respective patent rights upon the occurrence of the same events that would give rise to the right of both institutions acting collectively to terminate the Cas9 License Agreement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaboration and license agreement with Vertex</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 18, 2022, we entered into a Strategic Collaboration and License Agreement, or the Vertex Collaboration Agreement, with Vertex for an exclusive, four-year worldwide research collaboration focused on developing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, on July 18, 2022, we entered into a Stock Purchase Agreement, or the Stock Purchase Agreement, with Vertex, pursuant to which we agreed to sell and issue shares of our common stock to Vertex in a private placement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Vertex Collaboration Agreement, we will be responsible for discovery, research and certain preclinical development of novel </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing development candidates for the target of interest. Our research activities will be focused on (i) identifying and engineering specific gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Collaboration Agreement. Vertex will reimburse our research expenses consistent with an agreed-upon budget. The research term has an initial term of four years and may be extended by Vertex for up to one additional year.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from our research efforts. We received an upfront payment from Vertex of $25 million on July 20, 2022. We are eligible to receive (i) success payments of up to $22 million for each product candidate (up to a maximum of $66 million) that achieves the applicable development criteria and (ii) up to an aggregate of $340 million in development and commercial milestone payments. We are also eligible to receive tiered single-digit royalties on net sales, subject to specified reductions. Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the first patient dosing of the first Phase 1 clinical trial for the first product candidate developed under the Vertex Collaboration Agreement, we also have the right to opt-in to a profit share arrangement pursuant to which</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we would share the costs and net profits with Vertex for all product candidates emerging from the collaboration. If we exercise our opt-in right, in lieu of milestones and royalties, we will be obligated to pay for a specified percentage of the development and commercialization costs, and we will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time we exercise the option, we may elect a profit/cost share of up to 40% (with Vertex retaining a minimum of 60%). In order to exercise our opt-in right, we are required to pay a fee ranging from $25-70 million, depending on the profit/cost percentage elected by us and the licensed technology of Verve included in the most advanced product candidate at the time Verve exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Vertex Collaboration Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. We and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Collaboration Agreement in its entirety for convenience upon 90 days&#x2019; notice.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the execution of the Vertex Collaboration Agreement, we also entered into the Stock Purchase Agreement with Vertex for the sale and issuance of 1,519,756 shares of our common stock in a private placement to Vertex at a price of $23.03 per share, which was equal to the five-day volume-weighted average share price as of July 15, 2022, for an aggregate purchase price of $35.0 million. The private placement closed on July 20, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Government regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Government authorities in the United States, at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, sales, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting and import and export of pharmaceutical products, including biological products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Licensure and regulation of biologics in the United States</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, any product candidates we may develop would be regulated as biological products, or biologics, under the Public Health Service Act, or PHSA, and the Federal Food, Drug and Cosmetic Act, or FDCA, and its implementing regulations and guidance. The failure to comply with the applicable U.S. requirements at any time during the product development process, including preclinical testing, clinical testing, the approval process, or post-approval process, may subject a sponsor to delays in the conduct of the study, regulatory review and approval and/or administrative or judicial sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA must approve a product candidate for a therapeutic indication before it may be marketed in the United States.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products is referred to as a sponsor. A sponsor seeking approval to market and distribute a new biological product in the United States must satisfactorily complete each of the following steps:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the FDA&#x2019;s Good Laboratory Practices, or GLP regulations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">completion of the manufacture, under cGMP conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">design of a clinical protocol and its submission to the FDA as part of an IND for human clinical testing, which must become effective before human clinical trials may begin; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">performance of adequate and well-controlled human clinical trials to establish the safety, potency and purity of the product candidate for each proposed indication, in accordance with current Good Clinical Practices, or GCP; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation and submission to the FDA of a Biologics License Application, or BLA, for a biologic product requesting marketing for one or more proposed indications, including submission of detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">review of the product by an FDA advisory committee, where appropriate or if applicable; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities, including those of third parties, at which the product, or components thereof, are produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#x2019;s identity, strength, quality and purity; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfactory completion of any FDA audits of the preclinical studies and clinical trial sites to assure compliance with GLP, as applicable, and GCP, and the integrity of clinical data in support of the BLA; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">payment of user Prescription Drug User Fee Act, or PDUFA, securing FDA approval of the BLA and licensure of the new biologic product; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and any post-approval studies or other post-marketing commitments required by the FDA. </span></div></div>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical studies and investigational new drug application</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before testing any biologic product candidate in humans, the product candidate must undergo preclinical testing. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate the potential for efficacy and toxicity in animal studies. These studies are typically referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#x2019;s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved new drug application, or NDA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions about the product or conduct of the proposed clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns before the clinical trials can begin or recommence.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a partial clinical hold might state that a specific protocol or part of a protocol may not proceed, while other parts of a protocol or other protocols may do so. No more than 30 days after the imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following the issuance of a clinical hold or partial clinical hold, a clinical investigation may only resume once the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed or recommence. Occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived by the FDA. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#x2019;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, genetic medicine clinical trials conducted at institutions that receive funding for recombinant DNA research from the U.S. National Institutes of Health, or NIH, also are potentially subject to review by a committee within the NIH&#x2019;s Office of Science Policy called the Novel and Exceptional Technology and Research Advisory Committee, or the NExTRAC. As of 2019, the charter of this review group has evolved to focus public review on clinical trials that cannot be evaluated by standard oversight bodies and pose unusual risks. With certain genetic medicine protocols, FDA review of or clearance to allow the IND to proceed could be delayed if the NExTRAC decides that full public review of the protocol is warranted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Reporting clinical trial results</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the PHSA, sponsors of clinical trials of certain FDA-regulated products, including prescription drugs and biologics, are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the NIH. In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Although sponsors are also obligated to disclose the results of their clinical trials after completion, disclosure of the results can be delayed in some cases for up to two years after the date of completion of the trial. The NIH&#x2019;s final rule on registration and reporting requirements for clinical trials became effective in 2017, and both the NIH and the FDA have recently signaled the government&#x2019;s willingness to begin enforcing those requirements against non-compliant clinical trial sponsors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specifically, the PHSA grants the Secretary of the U.S. Department of Health and Human Services, or HHS, the authority to issue a notice of noncompliance to a responsible party for failure to submit clinical trial information as required. The responsible party, however, is allowed 30 days to correct the noncompliance and submit the required information. The failure to submit clinical trial information to clinicaltrials.gov, as required, is also a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues. In addition to civil monetary penalties, violations may also result in other regulatory action, such as injunction and/or criminal prosecution or disqualification from federal grants. Although the FDA has historically not enforced these reporting requirements due to the HHS&#x2019;s long delay in issuing final implementing regulations, those regulations have now been issued and the FDA has issued several notices of noncompliance since April 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Expanded access to an investigational drug for treatment use</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expanded access, sometimes called &#x201c;compassionate use,&#x201d; is the use of investigational products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or treatment IND application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere with initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There is no obligation for a sponsor to make its drug products available for expanded access; however, as required by the 21st Century Cures Act, or Cures Act, passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial; or 15 days after the investigational drug or biologic receives designation as a breakthrough therapy, Fast Track product, or regenerative medicine advanced therapy.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, on May 30, 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a manufacturer to make its investigational products available to eligible patients as a result of the Right to Try Act.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Human clinical trials in support of a BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trials involve the administration of the investigational product candidate to healthy volunteers or patients with the disease or condition to be treated under the supervision of a qualified principal investigator in accordance with GCP requirements. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A sponsor who wishes to conduct a clinical trial outside the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical trial is not conducted under an IND, the sponsor must ensure that the trial complies with certain regulatory requirements of the FDA in order to use the trial as support for an IND or application for marketing approval. Specifically, the FDA requires that such trials be conducted in accordance with GCP, including review and approval by an independent ethics committee and informed consent from participants. The GCP requirements encompass both ethical and data integrity standards for clinical trials. The FDA&#x2019;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign trials are conducted in a manner comparable to that required for clinical trials in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, each clinical trial must be reviewed and approved by an IRB either centrally or individually at each institution at which the clinical trial will be conducted. The IRB will consider, among other things, clinical trial design, patient informed consent, ethical factors, the safety of human subjects, and the possible liability of the institution. An IRB must operate in compliance with FDA regulations. The FDA, IRB, or the clinical trial sponsor may suspend or discontinue a clinical trial at any time for various reasons, including a finding that the clinical trial is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP rules and the requirements for informed consent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or DSMB. This group may recommend continuation of the trial as planned, changes in trial conduct, or cessation of the trial at designated check points based on certain available data from the trial to which only the DSMB has access.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trials typically are conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may be required after approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or, on occasion, in patients, such as cancer patients. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Phase 3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a biologic; such Phase 3 studies are referred to as &#x201c;pivotal.&#x201d; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#x2019;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">submitted to and reviewed by the FDA. Moreover, as noted above, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#x2019;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In some cases, the FDA may approve a BLA for a product but require the sponsor to conduct additional clinical trials to further assess the product&#x2019;s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication and to document a clinical benefit in the case of biologics approved under accelerated approval regulations. If the FDA approves a product while a company has ongoing clinical trials that were not necessary for approval, a company may be able to use the data from these clinical trials to meet all or part of any Phase 4 clinical trial requirement or to request a change in the product labeling. The failure to exercise due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2022, with the passage of the Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a diversity action plan for each phase 3 clinical trial or any other &#x201c;pivotal study&#x201d; of a new biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. Specifically, action plans must include the sponsor&#x2019;s goals for enrollment, the underlying rationale for those goals, and an explanation of how the sponsor intends to meet them. In addition to these requirements, the legislation directs the FDA to issue new guidance on diversity action plans.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interactions with FDA during the clinical development program</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. When clinical data is submitted to support marketing applications, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, sponsors are given opportunities to meet with the FDA at certain points in the clinical development program. Specifically, sponsors may meet with the FDA prior to the submission of an IND, or pre-IND application meeting, at the end of a Phase 2 clinical trial, or EOP2 meeting, and before an NDA or BLA is submitted, or pre-NDA or pre-BLA meeting. Meetings at other times may also be requested. There are four types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND application and pre-NDA/pre-BLA meetings, as well as Type B end of phase meetings, such as EOP2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. Finally, a type D meeting is focused on a narrow set of issues (should be limited to no more than two focused topics) and should not require input from more than three disciplines or divisions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These meetings provide an opportunity for the sponsor to share information about the data gathered to date with the FDA and for the FDA to provide advice on the next phase of development. For example, at an EOP2 meeting, a sponsor may discuss its Phase 2 clinical results and present its plans for the pivotal Phase 3 clinical trial(s) that it believes will support the approval of the new product. Such meetings may be conducted in person, via teleconference/videoconference or written response only with minutes reflecting the questions that the sponsor posed to the FDA and the FDA&#x2019;s responses. The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#x2019;s failure to follow the FDA&#x2019;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Pediatric Research Equity Act of 2003, or PREA, a BLA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial pediatric study plan within 60 days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. Sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The sponsor, the FDA, and the FDA&#x2019;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the sponsor may request an amendment to the plan at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For investigational products intended to treat a serious or life-threatening disease or condition, the FDA must, upon the request of a sponsor, meet to discuss preparation of the initial pediatric study plan or to discuss deferral or waiver of pediatric assessments. In addition, the FDA will meet early in the development process to discuss pediatric study plans with sponsors and the FDA must meet with sponsors by no later than the end-of-phase 1 meeting for serious or life-threatening diseases and by no later than 90 days after the FDA&#x2019;s receipt of the study plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation. It further requires the FDA to publicly post the PREA Non-Compliance letter and sponsor&#x2019;s response.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation, although the FDA has recently taken steps to limit what it considers abuse of this statutory exemption in the PREA by announcing that it does not intend to grant any additional orphan drug designations for rare pediatric subpopulations of what is otherwise a common disease. The FDA also maintains a list of diseases that are exempt from PREA requirements due to low prevalence of disease in the pediatric population.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Special regulations and guidance governing gene therapy products</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect that the procedures and standards applied to gene therapy products will be applied to any product candidates we may develop. The FDA has defined a gene therapy product as one that seeks to modify or manipulate the expression of a gene or to alter the biological properties of living cells for therapeutic use. The products may be used to modify cells </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or transferred to cells ex vivo prior to administration to the recipient.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Within the FDA, the Center for Biologics Evaluation and Research, or CBER, regulates gene therapy products. Within CBER, the review of gene therapy and related products is consolidated in the Office of Tissues and Advanced Therapies and the FDA has established the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its reviews. The NIH, including the NExTRAC, also advises the FDA on gene therapy issues and other issues related to emerging biotechnologies. The FDA and the NIH have published guidance documents with respect to the development and submission of gene therapy protocols.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA has issued various guidance documents regarding gene therapies, including final guidance documents released in January 2020 relating to chemistry, manufacturing and controls information for gene therapy INDs, long-term follow-up after the administration of gene therapy products, gene therapies for rare diseases and gene therapies for retinal disorders, as well as final guidance in October 2022 for Human Gene Therapy for Neurodegenerative Diseases. Although the FDA has indicated that these and other guidance documents it previously issued are not legally binding, compliance with them is likely necessary to gain approval for any gene therapy product candidate. The guidance documents provide additional factors that the FDA will consider at each of the above stages of development and relate to, among other things: the proper preclinical assessment of gene therapies; the chemistry, manufacturing and control information that should be included in an IND application; the proper design of tests to measure product potency in support of an IND or BLA application; and measures to observe for potential delayed adverse effects in participants who have received investigational gene therapies with the duration of follow-up based on the potential for risk of such effects. For AAV vectors specifically, the FDA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">typically recommends that sponsors continue to monitor participants for potential gene therapy-related adverse events for up to a 5-year period. Other types of gene therapy or gene editing products may require longer follow up, potentially up to a maximum 15-year period.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compliance with cGMP requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. Before approving a BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturers and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug or biologic undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the United States prior to being imported or offered for import into the United States. Inspections must follow a &#x201c;risk&#x2011;based schedule&#x201d; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulatory requirements governing manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA&#x2019;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and drug product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#x201c;risk-based schedule&#x201d; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the NDA sponsor and any third-party manufacturers involved in producing the approved product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Acceptance and review of a BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assuming successful completion of the required clinical testing, the results of the preclinical studies and clinical trials, along with information relating to the product&#x2019;s chemistry, manufacturing, controls, safety updates, patent information, abuse information and proposed labeling, are submitted to the FDA as part of an application requesting approval to market the product candidate for one or more indications. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&#x2019;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of a drug product and the safety, potency and purity of the biological product to the satisfaction of the FDA. The fee required for the submission and review of an</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">application under PDUFA is substantial (for example, for fiscal year 2023 this application fee is approximately $3.3 million), and the sponsor of an approved NDA is also subject to an annual program fee, which for fiscal year 2023 is more than $394,000 per eligible prescription product. These fees, of which the application fee may be waived for products with orphan drug designation, are typically adjusted annually, and exemptions and waivers may be available under certain circumstances, such as where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the sponsor is a small business submitting its first human therapeutic application for review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA conducts a preliminary review of all applications within 60 days of receipt and must inform the sponsor by that time whether an application is sufficiently complete to permit substantive review. In pertinent part, the FDA&#x2019;s regulations state that an application &#x201c;shall not be considered as filed until all pertinent information and data have been received&#x201d; by the FDA. In the event that the FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. Typically, an RTF will be based on administrative incompleteness, such as clear omission of information or sections of required information; scientific incompleteness, such as omission of critical data, information or analyses needed to evaluate safety, purity and efficacy or provide adequate directions for use; or inadequate content, presentation, or organization of information such that substantive and meaningful review is precluded. The FDA may request additional information rather than accept an application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">After the submission is accepted for filing, the FDA begins an in-depth substantive review of the application. The FDA reviews the application to determine, among other things, whether the proposed product is safe and effective for its intended use, whether it has an acceptable purity profile and whether the product is being manufactured in accordance with cGMP. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has ten months from the filing date in which to complete its initial review of a standard application that is a new molecular entity, and six months from the filing date for an application with &#x201c;priority review.&#x201d; The review process may be extended by the FDA for three additional months to consider new information or in the case of a clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. Despite these review goals, it is not uncommon for FDA review of an application to extend beyond the PDUFA goal date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with its review of an application, the FDA will typically submit information requests to the sponsor and set deadlines for responses thereto. The FDA will also conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether the manufacturing processes and facilities comply with cGMPs. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and are adequate to assure consistent production of the product within required specifications.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA also may inspect the sponsor and one or more clinical trial sites to assure compliance with IND applications and GCP requirements and the integrity of the clinical data submitted to the FDA. With passage of FDORA, Congress clarified the FDA&#x2019;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to FDA as well as other persons holding study records or involved in the study process. To ensure cGMP and GCP compliance by its employees and third-party contractors, a sponsor may incur significant expenditure of time, money and effort in the areas of training, record keeping, production and quality control.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, the FDA may refer an application, including applications for novel product candidates which present difficult questions of safety or efficacy, to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendation of an advisory committee, but it considers such recommendations when making final decisions on approval. Data from clinical trials are not always conclusive, and the FDA or its advisory committee may interpret data differently than the sponsor interprets the same data. The FDA may also re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the sponsor during the review process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA also may require submission of a REMS if it determines that a REMS is necessary to ensure that the benefits of the product outweigh its risks and to assure the safe use of the product. The REMS could include medication guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">requirement for a REMS, as well as the specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS is needed, the sponsor of the application must submit a proposed REMS and the FDA will not approve the application without a REMS.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Decisions on BLAs</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The term &#x201c;substantial evidence&#x201d; is defined under the FDCA as &#x201c;evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the product involved, on the basis of which it could fairly and responsibly be concluded by such experts that the product will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling or proposed labeling thereof.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard. This approach was subsequently endorsed by Congress in 1998 with legislation providing, in pertinent part, that &#x201c;If [FDA] determines, based on relevant science, that data from one adequate and well-controlled clinical investigation and confirmatory evidence (obtained prior to or after such investigation) are sufficient to establish effectiveness, FDA may consider such data and evidence to constitute substantial evidence.&#x201d; This modification to the law recognized the potential for the FDA to find that one adequate and well controlled clinical investigation with confirmatory evidence, including supportive data outside of a controlled trial, is sufficient to establish effectiveness. In December 2019, the FDA issued draft guidance further explaining the studies that are needed to establish substantial evidence of effectiveness. It has not yet finalized that guidance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a CRL or an approval letter. To reach this determination, the FDA must determine that the drug is effective and that its expected benefits outweigh its potential risks to patients. This &#x201c;benefit-risk&#x201d; assessment is informed by the extensive body of evidence about the product&#x2019;s safety and efficacy in the NDA or BLA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#x2019; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#x201c;action package,&#x201d; which becomes the record for the FDA&#x2019;s review. The FDA review team then issues a recommendation, and a senior FDA official makes a decision.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time- consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six month extension to respond. The FDA has committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications. That is, the approval will be limited to the conditions of use (e.g., patient population and indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings, or precautions be included in the product labeling; post-approval trials, including Phase 4 clinical trials, be conducted to further assess a product&#x2019;s safety after approval; and/or testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Ensuring Innovation Act, which was signed into law in April 2021, the FDA must publish action packages summarizing its decisions to approve new drugs and biologics within 30 days of approval of such products. To date, CRLs are not publicly available documents.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Expedited review programs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA is authorized to expedite the review of BLAs in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review, accelerated approval or regenerative medicine advanced therapy designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Breakthrough therapy designation.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient drug development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Priority review.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. The FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accelerated approval.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Drug or biologic products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biologic product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to the FDA every six months until the study is completed; and use expedited procedures to withdraw accelerated approval of an NDA or BLA after the confirmatory trial fails to verify the product&#x2019;s clinical benefit. Further, FDORA requires the agency to publish on its website &#x201c;the rationale for why a post-approval study is not appropriate or necessary&#x201d; whenever it decides not to require such a study upon granting accelerated approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regenerative medicine advanced therapy.    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Post-approval regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA have imposed as part of the approval process. The sponsor will be required to report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#x2019;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety, purity, potency and effectiveness of pharmaceutical products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">safety alerts, Dear Healthcare Provider letters, press releases or other communications containing warnings or other safety information about a product;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">mandated modification of promotional materials and labeling and issuance of corrective information;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fines, warning letters or holds on post-approval clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product recall, seizure or detention, or refusal to permit the import or export of products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties; and</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consent decrees, corporate integrity agreements, debarment, or exclusion from federal health care programs.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pharmaceutical products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Although healthcare providers may prescribe products for uses not described in the drug&#x2019;s labeling, known as off-label uses, in their professional judgment, drug manufacturers are prohibited from soliciting, encouraging or promoting unapproved uses of a product. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims about a drug&#x2019;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#x2019;s prescribing information. In September 2021, the FDA published final regulations that describe the types of evidence that the agency will consider in determining the intended use of a drug or biologic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. Moreover, with passage of the Pre-Approval Information Exchange Act, in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Finally, if there are any modifications to the product, including changes in indications, labeling or manufacturing processes or facilities, the sponsor may be required to submit and obtain FDA approval of a new BLA or a BLA supplement, which may require the sponsor to develop additional data or conduct additional preclinical studies and clinical trials. Securing FDA approval for new indications is similar to the process for approval of the original indication and requires, among other things, submitting data from adequate and well-controlled clinical trials to demonstrate the product&#x2019;s safety and efficacy in the new indication. Even if such trials are conducted, the FDA may not approve any expansion of the labeled indications for use in a timely fashion, or at all. There also are continuing, annual user fee requirements that are now assessed as program fees for certain approved drugs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Orphan drug designation and exclusivity</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan drug designation in the United States is designed to encourage sponsors to develop products intended for treatment of rare diseases or conditions. In the United States, a rare disease or condition is statutorily defined as a condition that affects fewer than 200,000 individuals in the United States or that affects more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available the biologic for the disease or condition will be recovered from sales of the product in the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Orphan drug designation qualifies a company for tax credits and market exclusivity for seven years following the date of the product&#x2019;s marketing approval if granted by the FDA. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. A product becomes an orphan when it receives orphan drug designation from the Office of Orphan Products Development at the FDA based on acceptable confidential requests made under the regulatory provisions. The product must then go through the review and approval process like any other product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A sponsor may request orphan drug designation of a previously unapproved product or new orphan indication for an already marketed product. In addition, a sponsor of a product that is otherwise the same product as an already approved orphan drug may seek and obtain orphan drug designation for the subsequent product for the same rare disease or condition if it can present a plausible hypothesis that its product may be clinically superior to the first drug. More than one sponsor may receive orphan drug designation for the same product for the same rare disease or condition, but each sponsor seeking orphan drug designation must file a complete request for designation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#x2019;s marketing application for the same product for the same indication for seven years, except in certain limited circumstances. If a product designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The period of exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the indication for which the product has been designated. The FDA may approve a second application for the same product for a different use or a second application for a clinically superior version of the product for the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">same use. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of the FDA Reauthorization Act of 2017, but have not yet been approved or licensed by the FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the term &#x201c;same disease or condition&#x201d; in the statute means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if a BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#x2019;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of non-patent exclusivity that cover the product are extended by six months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulatory exclusivity governing biologics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">When a biological product is licensed for marketing by the FDA with approval of a BLA, the product may be entitled to certain types of market and data exclusivity barring the FDA from approving competing products for certain periods of time. In March 2010, the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the PPACA, was enacted in the United States and included a subtitle called the Biologics Price Competition and Innovation Act of 2009, or the BPCIA. The BPCIA amended the PHSA to create an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, the FDA has approved a number of biosimilars and the first interchangeable biosimilar product was approved on July 30, 2021 and a second product previously approved as a biosimilar was designated as interchangeable in October 2021. The FDA has also issued numerous guidance documents outlining its approach to reviewing and licensing biosimilars and interchangeable biosimilars under the PHSA, including a draft guidance issued in November 2020 that seeks to provide additional clarity to manufacturers of interchangeable biosimilars.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the BPCIA, a manufacturer may submit an application for a product that is &#x201c;biosimilar to&#x201d; a previously approved biological product, which the statute refers to as a &#x201c;reference product.&#x201d; In order for the FDA to approve a biosimilar product, it must find that there are no clinically meaningful differences between the reference product and the proposed biosimilar product in terms of safety, purity and potency. The biosimilar sponsor may demonstrate that its product is biosimilar to the reference product on the basis of data from analytical studies, animal studies and one or more clinical studies to demonstrate safety, purity and potency in one or more appropriate conditions of use for which the reference product is approved. In addition, the sponsor must show that the biosimilar and reference products have the same mechanism of action for the conditions of use on the label, route of administration, dosage and strength, and the production facility must meet standards designed to assure product safety, purity and potency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the FDA to approve a biosimilar product as interchangeable with a reference product, the FDA must find not only that the product is biosimilar to the reference product but also that it can be expected to produce the same clinical results as the reference product such that the two products may be switched without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Upon licensure by the FDA, an interchangeable biosimilar may be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. Following approval of the interchangeable biosimilar product,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA may not grant interchangeability status for any second biosimilar until one year after the first commercial marketing of the first interchangeable biosimilar product. In December 2022, Congress clarified through FDORA that the FDA may approve multiple first interchangeable biosimilar biological products so long as the products are all approved on the first day on which such a product is approved as interchangeable with the reference product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reference biological product is granted 12 years of exclusivity from the time of first licensure of the product, and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference product until four years after the date of first licensure of the reference product. Even if a product is considered to be a reference product eligible for exclusivity, however, another company could market a competing version of that product if the FDA approves a full BLA for such product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of their product. There have been recent government proposals to reduce the 12-year reference product exclusivity period, but none has been enacted to date. At the same time, since the passage of the BPCIA, many states have passed laws or amendments to laws that address pharmacy practices involving biosimilar products.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent term restoration and extension</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, a patent claiming a new biologic product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent extension of up to five years for patent term lost during product development and FDA regulatory review. Assuming grant of the patent for which the extension is sought, the restoration period for a patent covering a product is typically one-half the time between the effective date of the IND application and the submission date of the BLA, plus the time between the submission date of the BLA and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#x2019;s approval date in the United States. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent for which extension is sought. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The USPTO reviews and approves the application for any patent term extension in consultation with the FDA.</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Federal and state data privacy and security laws</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are multiple privacy and data security laws that may impact our business activities, in the United States and other countries where we conduct our trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials will be regulated by HIPAA&#x2019;s Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#x2019;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the state level, California has enacted legislation that has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020 and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. Additionally, effective starting on January 1, 2023, the California Privacy Rights Act, or CPRA, will significantly modify the CCPA, including by expanding consumers&#x2019; rights with respect to certain sensitive personal information. The CPRA also creates a new state agency that will be vested with authority to implement and enforce the CCPA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and the CPRA. The CCPA and CPRA could impact our business activities depending on how it is interpreted and exemplifies the vulnerability of our business to not only cyber threats but also the evolving regulatory environment related to personal data and individually identifiable health information. These provisions may apply to some of our business activities. In addition, other states, including Virginia and Colorado, have already passed state privacy laws and other states will likely be considering similar laws in the near future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">FDA approval of companion diagnostics</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In August 2014, the FDA issued final guidance clarifying the requirements that will apply to approval of therapeutic products and in vitro companion diagnostics. According to the guidance, for novel drugs, a companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#x2019;s labeling. Approval or clearance of the companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population. In July 2016, the FDA issued a draft guidance intended to assist sponsors of the drug therapeutic and in vitro companion diagnostic device on issues related to co-development of the products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The 2014 guidance also explains that a companion diagnostic device used to make treatment decisions in clinical trials of a biologic product candidate generally will be considered an investigational device, unless it is employed for an intended use for which the device is already approved or cleared. If used to make critical treatment decisions, such as patient selection, the diagnostic device generally will be considered a significant risk device under the FDA&#x2019;s Investigational Device Exemption, or IDE, regulations. Thus, the sponsor of the diagnostic device will be required to comply with the IDE regulations. According to the guidance, if a diagnostic device and a product are to be studied together to support their respective approvals, both products can be studied in the same investigational study, if the study meets both the requirements of the IDE regulations and the IND regulations. The guidance provides that depending on the details of the study plan and subjects, a sponsor may seek to submit an IND alone, or both an IND and an IDE.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2020, the FDA issued additional guidance that describes considerations for the development and labeling of companion diagnostic devices to support the indicated uses of multiple drug or biological oncology products, when appropriate. This guidance builds upon existing policy regarding the labeling of companion diagnostics. In its 2014 guidance, the FDA stated that if evidence is sufficient to conclude that the companion diagnostic is appropriate for use with a specific group of therapeutic products, the companion diagnostic&#x2019;s intended use or indications for use should name the specific group of therapeutic products, rather than specific products. The 2020 guidance expands on the policy statement in the 2014 guidance by recommending that companion diagnostic developers consider a number of factors when determining whether their test could be developed, or the labeling for approved companion diagnostics could be revised through a supplement, to support a broader labeling claim such as use with a specific group of oncology therapeutic products (rather than listing an individual therapeutic product(s)).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the FDCA, in vitro diagnostics, including companion diagnostics, are regulated as medical devices. In the United States, the FDCA and its implementing regulations, and other federal and state statutes and regulations govern, among other things, medical device design and development, preclinical and clinical testing, premarket clearance or approval, registration and listing, manufacturing, labeling, storage, advertising and promotion, sales and distribution, export and import and post-market surveillance. Unless an exemption applies, diagnostic tests require pre-notification marketing clearance or approval from the FDA prior to commercial distribution.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA previously has required in vitro companion diagnostics intended to select the patients who will respond to the product candidate to obtain pre-market approval, or PMA, simultaneously with approval of the therapeutic product candidate. The PMA process, including the gathering of clinical and preclinical data and the submission to and review by the FDA, can take several years or longer. It involves a rigorous premarket review during which the sponsor must prepare and provide the FDA with reasonable assurance of the device&#x2019;s safety and effectiveness and information about the device and its components regarding, among other things, device design, manufacturing and labeling. PMA applications are subject to an application fee. For federal fiscal year 2023, the standard fee is $441,547 and the small business fee is $110,387.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulation and procedures governing approval of medicinal products in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of an MAA and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical trial approval</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2014, the European Union adopted a new Clinical Trials Regulation (EU) No 536/2014. That regulation became effective on January 31, 2022, following confirmation of full functionality of the Clinical Trials Information System through an independent audit by the European Commission in mid-2020.The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the European Union. The main characteristics of the regulation include a streamlined application procedure via a single entry point, the &#x201c;EU portal&#x201d;; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the competent authorities of all European Union member states in which an application for authorization of a clinical trial has been submitted (member states concerned). Part II is assessed separately by each member state concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned European Union member states. However, overall related timelines will be defined by the Clinical Trials Regulation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the European Union at the EudraCT website: https://eudract.ema.europa.eu.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">PRIME designation in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#x2019;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Marketing authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To obtain a marketing authorization for a product under the European Union regulatory system, a sponsor must submit an MAA, either under a centralized procedure administered by the EMA or one of the procedures administered by competent authorities in European Union member states (decentralized procedure, national</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">procedure, or mutual recognition procedure). A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, a sponsor must demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, class waiver or a deferral for one or more of the measures included in the PIP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid for all European Union member states. Pursuant to Regulation (EC) No. 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. Manufacturers must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specifically, the grant of marketing authorization in the European Union for products containing viable human tissues or cells such as gene therapy medicinal products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC lays down specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products, somatic cell therapy medicinal products and tissue engineered products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to EMA which provides an opinion regarding the application for marketing authorization. The European Commission grants or refuses marketing authorization in light of the opinion delivered by EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting an initial assessment of a product. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the CHMP. Accelerated evaluation may be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and, in particular, from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the time limit of 210 days will be reduced to 150 days, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that it is no longer appropriate to conduct an accelerated assessment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">National Authorization Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are also two other possible routes to authorize medicinal products in several European Union member states, which are available for investigational medicinal products that fall outside the scope of the centralized procedure:</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Decentralized procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Using the decentralized procedure, a sponsor may apply for simultaneous authorization in more than one European Union member state of medicinal products that have not yet been authorized in any European Union member state and that do not fall within the mandatory scope of the centralized procedure. The sponsor may choose a European Union member state as the reference member state to lead the scientific evaluation of the application.</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Mutual recognition procedure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. In the mutual recognition procedure, a medicine is first authorized in one European Union member state (which acts as the reference member state), in accordance with the national procedures of that member state. Following this, further marketing authorizations can be progressively sought from other European Union member states in a procedure whereby the members concerned agree to recognize the validity of the original, national marketing authorization produced by the reference European Union member state.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the above-described procedures, before granting the marketing authorization, the EMA or the competent authorities of the European Union member state of the European Economic Area, or the EEA, make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Conditional Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In specific circumstances, E.U. legislation (Article 14&#x2013;a Regulation (EC) No 726/2004 (as amended by Regulation (EU) 2019/5 and Regulation (EC) No 507/2006 on Conditional Marketing Authorizations for Medicinal Products for Human Use) enables sponsors to obtain a conditional marketing authorization prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates (including medicines designated as orphan medicinal products) if (1) the product candidate is intended for the treatment, prevention or medical diagnosis of seriously debilitating or life-threatening diseases; (2) the product candidate is intended to meet unmet medical needs of patients; (3) a marketing authorization may be granted prior to submission of comprehensive clinical data provided that the benefit of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required; (4) the risk-benefit balance of the product candidate is positive, and (5) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Specialized procedures for gene therapies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The grant of marketing authorization in the European Union for gene therapy products is governed by Regulation 1394/2007/EC on advanced therapy medicinal products, read in combination with Directive 2001/83/EC of the European Parliament and of the Council, commonly known as the Community code on medicinal products. Regulation 1394/2007/EC includes specific rules concerning the authorization, supervision and pharmacovigilance of gene therapy medicinal products. Manufacturers of advanced therapy medicinal products must demonstrate the quality, safety and efficacy of their products to the EMA, which provides an opinion regarding the MAA. The European Commission grants or refuses marketing authorization in light of the opinion delivered by the EMA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric studies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to obtaining a marketing authorization in the European Union, sponsors must demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are provided in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. This requirement also applies when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized. The Paediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine for children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when development of a medicine for children is not needed or is not appropriate, such as for diseases that only affect the elderly population. Before an MAA can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with the agreed studies and measures listed in each relevant PIP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulatory data protection in the European Union</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the European Union, new chemical entities approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Regulation (EC) No 726/2004, as amended, and Directive 2001/83/EC, as amended. Data exclusivity prevents regulatory authorities in the European Union from referencing the innovator&#x2019;s data to assess a generic (abbreviated) application for a period of eight years. During the additional two-year period of market exclusivity, a generic marketing authorization application can be submitted, and the innovator&#x2019;s data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to authorization, is held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company may market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent term extensions in the European Union and other jurisdictions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The European Union also provides for patent term extension through Supplementary Protection Certificates, or SPCs. The rules and requirements for obtaining a SPC are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. In certain circumstances, these periods may be extended for six additional months if pediatric exclusivity is obtained, which is described in detail below. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis. Similar patent term extension rights exist in certain other foreign jurisdictions outside the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Periods of authorization and renewals</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A marketing authorization is valid for five years, in principle, and it may be renewed after five years on the basis of a reevaluation of the risk-benefit balance by the EMA or by the competent authority of the authorizing member state. To that end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal period. Any authorization that is not followed by the placement of the drug on the European Union market (in the case of the centralized procedure) or on the market of the authorizing member state within three years after authorization ceases to be valid.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Regulatory requirements after marketing authorization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following approval, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of the medicinal product. These include compliance with the European Union&#x2019;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and additional monitoring obligations can be imposed. In addition, the manufacturing of authorized products, for which a separate manufacturer&#x2019;s license is mandatory, must also be conducted in strict compliance with the EMA&#x2019;s GMP requirements and comparable requirements of other regulatory bodies in the European Union, which mandate the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. Finally, the marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the European Union under Directive 2001/83EC, as amended.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Orphan drug designation and exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An orphan drug designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#x201c;similar medicinal product.&#x201d; A &#x201c;similar medicinal product&#x201d; is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable not to justify market exclusivity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pediatric exclusivity</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a sponsor obtains a marketing authorization in all European Union member states, or a marketing authorization granted in the centralized procedure by the European Commission, and the study results for the pediatric population are included in the product information, even when negative, the medicine is then eligible for an additional six-month period of qualifying patent protection through extension of the term of the Supplementary Protection Certificate, or SPC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Approval of companion diagnostic devices</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the European Union, medical devices such as companion diagnostics must comply with the General Safety and Performance Requirements, or SPRs, detailed in Annex I of the EU Medical Devices Regulation (Regulation (EU) 2017/745), or MDR, which came into force on May 26, 2021 and replaced the previously applicable EU Medical Devices Directive (Council Directive 93/42/EEC). Compliance with SPRs and additional requirements applicable to companion medical devices is a prerequisite to be able to affix the Conformit&#xe8; Europ&#xeb;enne mark of conformity to medical devices, without which they cannot be marketed or sold. To demonstrate compliance with the SPRs, a manufacturer must undergo a conformity assessment procedure, which varies according to the type of medical device and its classification. The MDR is meant to establish a uniform, transparent, predictable, and sustainable regulatory framework across the European Union for medical devices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Separately, the regulatory authorities in the European Union also adopted a new In Vitro Diagnostic Regulation (Regulation (EU) 2017/746), which became effective in May 2022. The new regulation replaces the In Vitro Diagnostics Directive (IVDD) 98/79/EC. Manufacturers wishing to apply to a notified body for a conformity assessment of their in vitro diagnostic medical device had until May 2022 to update their technical documentation to meet the requirements and comply with the new, more stringent regulation. The new regulation will, among other things:</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">strengthen the rules on placing devices on the market and reinforce surveillance once they are available; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish explicit provisions on manufacturers&#x2019; responsibilities for the follow-up of the quality, performance and safety of devices placed on the market; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">improve the traceability of medical devices throughout the supply chain to the end-user or patient through a unique identification number; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">set up a central database to provide patients, healthcare professionals and the public with comprehensive information on products available in the European Union; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">strengthen rules for the assessment of certain high-risk devices, such as implants, which may have to undergo an additional check by experts before they are placed on the market. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Brexit and the regulatory framework in the United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The United Kingdom's withdrawal from the European Union took place on January 31, 2020. The European Union and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, which was applied provisionally beginning on January 1, 2021 and which entered into force on May 1, 2021. The Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products. Thereafter, the European Union and the United Kingdom will form two separate markets governed by two distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of January 1, 2021, the MHRA became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law, the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#x2019;s withdrawal from the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since a significant proportion of the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from EU directives and regulations, Brexit may have a material impact upon the regulatory regime with respect to the development, manufacture, importation, approval and commercialization of our product candidates in the United Kingdom. For example, the United Kingdom is no longer covered by the centralized procedures for obtaining EU-wide marketing authorization from the EMA, and a separate marketing authorization will be required to market our product candidates in the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">United Kingdom. Until December 31, 2023, it is possible for the MHRA to rely on a decision taken by the European Commission on the approval of a new marketing authorization via the centralized procedure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Also, notwithstanding the United Kingdom&#x2019;s withdrawal from the European Union, by operation of the so-called &#x2018;UK GDPR&#x2019; (i.e., the EU General Data Protection Regulation, or GDPR, as it continues to form part of the law of the United Kingdom by virtue of section 3 of the EU (Withdrawal) Act 2018 and as subsequently amended) the GDPR continues to apply in substantially equivalent form to processing operations carried out in the context of an establishment in the United Kingdom and any processing relating to the offering of goods or services to individuals in the United Kingdom and/or monitoring of their behavior in the United Kingdom.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">However, it is still unclear whether transfers of data from the EEA to the United Kingdom will remain lawful under the GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the UK will be treated like a European Union member state in relation to processing and transfers of personal data for four months from January 1, 2021. This may be extended by two further months. After such period, the United Kingdom will be a &#x201c;third country&#x201d; under the GDPR (and transfers of data from the EEA to the United Kingdom will require a &#x2018;transfer mechanism&#x2019; such as the Standard Contractual Clauses) unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. While the European Commission has published draft adequacy decisions in respect of the United Kingdom, these are subject to further review and it remains to be seen whether or when any such decisions will be adopted. The UK government has already determined that it considers all European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European Union and EEA remain unaffected. We may, however, incur liabilities, expenses, costs and other operational losses under GDPR and applicable European Union member states and the United Kingdom privacy laws in connection with any measures we take to comply with them. Furthermore, in general terms, there will now be increasing scope for divergence in application, interpretation and enforcement of the data protection law as between the United Kingdom and EEA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">General Data Protection Regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The collection, use, disclosure, transfer or other processing of personal data in the context of the activities of an establishment in the EEA and/or regarding the offering of goods or services to, and/or the monitoring of the behavior of individuals in the EEA, including health data, is subject to the GDPR, which became effective on May 25, 2018. As noted above, by operation of the so-called &#x2018;UK GDPR,&#x2019; the GDPR continues to apply in substantially equivalent form in the context of the UK, UK establishments and UK-focused processing operations&#x2014;so, when we refer to the GDPR in this section, we are also making reference to the UK GDPR in the context of the United Kingdom, unless the context requires otherwise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The GDPR is wide-ranging in scope and imposes numerous, significant and complex requirements on companies that process personal data, such as: requiring the establishment of a legal basis for processing personal data; broadening the definition of personal data (including to capture &#x2018;pseudonymized&#x2019; or key-coded data that is commonly processed in a clinical trial-related context); creating obligations for controllers and processors to appoint data protection officers in certain circumstances; increasing transparency obligations to data subjects; establishing limitations on the retention of personal data; introducing obligations to honor increased rights for data subjects; formalizing a heightened standard of data subject consent; establishing obligations to implement certain technical and organizational safeguards to protect the security and confidentiality of personal data; introducing obligations to agree to certain specific contractual terms and to take certain measures when working with third-party processors or joint controllers; introducing the obligation to provide notice of certain significant personal data breaches to the relevant supervisory authority(ies) and affected individuals; and mandating the appointment of representatives in the United Kingdom and/or European Union in certain circumstances. In particular, the processing of &#x201c;special category personal data&#x201d; (such as personal data related to health and genetic information), which will be relevant to our operations in the context of clinical trials, imposes heightened compliance burdens under the GDPR and is a topic of active interest among relevant regulators. In addition, the GDPR provides that EEA member states may introduce specific requirements related to the processing of special categories of personal data such as health data that we may process in connection with clinical trials or otherwise. In the United Kingdom, the UK Data Protection Act 2018 complements the UK GDPR in this regard. More broadly, European data protection authorities may interpret the GDPR and national laws differently and impose additional requirements, which contributes to the complexity of processing personal data in or from the EEA and/or United Kingdom. Guidance on implementation and compliance practices is often updated or otherwise revised. This fact may lead to greater divergence on the law that applies to the processing of personal data across the EEA and/or United Kingdom, which may increase our costs and overall compliance risk. Such country-specific regulations could also limit our ability to process relevant personal data in the context of our EEA and/or United Kingdom</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">operations ultimately having an adverse impact on our business, and harming our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The GDPR also imposes strict rules on the transfer of personal data to countries outside Europe, including to the United States, unless the parties to the transfer have implemented specific safeguards to protect the transferred personal data. Certain previously available safeguards have been invalidated, and reliance on alternative safeguards may be complex or not possible in certain circumstances, following a recent ruling of the Court of Justice of the European Union and subsequent regulatory guidance. If we are unable to implement a valid solution for personal data transfers from the EEA and United Kingdom, including, for example, obtaining individuals&#x2019; explicit consent to transfer their personal data to the United States or other countries, we will face increased exposure to regulatory actions, substantial fines and injunctions against transferring personal data from the EEA and United Kingdom. Inability to export personal data from the EEA and United Kingdom may also restrict our activities outside the EEA and United Kingdom; limit our ability to collaborate with partners as well as other service providers, contractors and other companies outside of the EEA and United Kingdom; and/or require us to increase our processing capabilities within the EEA and/or United Kingdom at significant expense or otherwise cause us to change the geographical location or segregation of our relevant systems and operations&#x2014;any or all of which could adversely affect our operations or financial results. Additionally, other countries outside of the EEA and United Kingdom have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The GDPR also provides for more robust regulatory enforcement and permits supervisory authorities to impose greater penalties for violations than under previous European data protection laws, including potential fines of up to &#x20ac;20 million or 4% of annual global revenues for the preceding financial year, whichever is greater. In addition to administrative fines, a wide variety of other potential enforcement powers are available to supervisory authorities in respect of potential and suspected violations of the GDPR, including extensive audit and inspection rights, and powers to order temporary or permanent bans on all or some processing of personal data carried out by noncompliant actors. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR will be a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-US Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-US Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business operations in the European Union.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Coverage, pricing and reimbursement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we may seek regulatory approval by the FDA or other government authorities. In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates. Even if any product candidates we may develop are approved, sales of such product candidates will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for, such product candidates. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover any product candidates we may develop could reduce physician utilization of such product candidates once approved and have a material adverse effect on our sales, results of operations and financial condition. Additionally, a payer&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer&#x2019;s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer. Third-party reimbursement and coverage may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. In addition, any companion diagnostic tests require coverage and reimbursement separate and apart from the coverage and reimbursement for their companion pharmaceutical or biological products. Similar challenges to obtaining coverage and reimbursement, applicable to pharmaceutical or biological products, will apply to any companion diagnostics.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The containment of healthcare costs also has become a priority of federal, state and foreign governments and the prices of pharmaceuticals have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#x2019;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we obtain approval in the future to market in the United States any product candidates we may develop, we may be required to provide discounts or rebates under government healthcare programs or to certain government and private purchasers in order to obtain coverage under federal healthcare programs such as Medicaid. Participation in such programs may require us to track and report certain drug prices. We may be subject to fines and other penalties if we fail to report such prices accurately.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outside the United States, ensuring adequate coverage and payment for any product candidates we may develop will face challenges. Pricing of prescription pharmaceuticals is subject to governmental control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing approval for a product and may require us to conduct a clinical trial that compares the cost effectiveness of any product candidates we may develop to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in our commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies (so called health technology assessments) in order to obtain reimbursement or pricing approval. For example, the European Union provides options for its member states to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other member states allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states, and parallel trade (arbitrage between low-priced and high-priced member states), can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products, if approved in those countries.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Healthcare law and regulation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, patient privacy laws and regulations and other health care laws and regulations that may constrain business and/or financial arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restrictions under applicable federal and state health care laws and regulations include the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; the federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious or fraudulent or knowingly making, using or causing to made or used a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government; HIPAA, which created additional federal criminal statutes that prohibit, among other things, a person from knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; the Foreign Corrupt Practices Act, or FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make, improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; and the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within HHS, information related to payments and other transfers of value made by that entity to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members, and, as of 2022, will require applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Healthcare reform</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2010, the United States Congress enacted the PPACA, which, among other things, includes changes to the coverage and payment for drug products under government health care programs. Other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act, and subsequent legislation, these Medicare sequester reductions were suspended and reduced through June 2022,with the full 2% cut remaining thereafter. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. The U.S. Supreme Court heard this case on November 10, 2020 and, on June 17, 2021, dismissed this action after finding that the plaintiffs do not have standing to challenge the constitutionality of the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Trump administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#x2019; access to health care, and consider actions that will protect and strengthen that access. Under this Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the PPACA; and policies that reduce affordability of coverage or financial assistance, including for dependents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Pharmaceutical prices</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, presidential executive orders, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the prices of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the prices of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries&#x2019; access to evidence-based care.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, in October 2020, the HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, the HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the implementation of which has been delayed until January 1, 2032 by the Inflation Reduction Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 9, 2021, President Biden signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The order directs the HHS to create a plan within 45 days to combat &#x201c;excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging.&#x201d; On September 9, 2021, the HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to make pharmaceutical prices more affordable and equitable for all consumers and throughout the health care system by supporting pharmaceutical price negotiations with manufacturers; improve and promote competition throughout the prescription pharmaceutical industry by supporting market changes that strengthen supply chains, promote biosimilars and generic pharmaceuticals, and increase transparency; and foster scientific innovation to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employees and human capital resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had 204 full-time employees, including 58 employees with M.D., Pharm.D. or Ph.D. degrees. Of these full-time employees, 164 are engaged in research and development activities and 40 are engaged in general and administrative activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have attracted a diverse team of experts in discovery, preclinical research and clinical development, as well as gene editing technologies and the manufacturing and delivery of genetic medicines. Our team is built on several core values that drive our day-to-day activities and inspire our long-term vision:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Grit: we work tenaciously to solve problems and advance science with rigor and care. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Spirit: we act with integrity and inclusion to earn the trust of colleagues, partners, patients and providers. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Drive: we enthusiastically pursue our potential, and we empower those around us to do the same. </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Passion: we are motivated by our mission to reimagine the approach to the treatment of CVD for patients and their families. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and additional employees. We are committed to diversity, equity and inclusion across all aspects of our organization, including in our recruitment, advancement and development practices. Each year, we</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">review employee demographic information to evaluate our diversity efforts across all functions and levels of the company. We conduct annual performance and development reviews for each of our employees to discuss the individual&#x2019;s strengths and development opportunities, career development goals and performance goals. We also regularly survey employees to assess employee engagement and satisfaction. The principal purposes of our equity incentive plans are to attract, retain and motivate selected employees and directors through the granting of stock-based compensation awards. We value our employees and regularly benchmark total rewards we provide, such as short-and long-term compensation, 401(k) contributions, health, welfare and quality of life benefits, paid time o</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ff and personal leave, against our industry peers to ensure we remain competitive and attractive to potential new hires.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Corporate Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We were incorporated under the laws of the state of Delaware on March 9, 2018 under the name Endcadia, Inc. On January 15, 2019, we changed our name to Verve Therapeutics, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our principal executive office is located at 201 Brookline Avenue, Suite 601, Boston, Massachusetts 02215 and our telephone number is (617) 603-0070. Our website address is http://www.vervetx.com. The information contained on, or accessible through, our website does not constitute part of this Annual Report. We have included our website address in this Annual Report solely as an inactive textual reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Available Information</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our Internet address is http://www.vervetx.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. Information on our website is not part of this Annual Report or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at http://www.sec.gov. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1A. Risk Factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our future operating results could differ materially from the results described in this Annual Report on Form 10-K due to the risks and uncertainties described below. You should consider carefully the following information about risks below in evaluating our business. If any of the following risks actually occur, our business, financial conditions, results of operations and future growth prospects would likely be materially and adversely affected. In these circumstances, the market price of our common stock would likely decline. In addition, we cannot assure investors that our assumptions and expectations will prove to be correct. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements. See page 3 of this Annual Report on Form 10-K for a discussion of some of the forward-looking statements that are qualified by these risk factors. Factors that could cause or contribute to such differences include those factors discussed below.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to our financial position and need for additional capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have incurred significant losses since our inception and have no products approved for sale. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical trials, and have incurred significant operating losses. Our net losses were $157.4 million, $120.3 million and $45.7 million for the years ended December 31, 2022, 2021 and 2020, respectively. As of December 31, 2022, we had an accumulated deficit of $344.2 million. We have not generated any revenue from product sales. We have financed our operations primarily through private placements of our preferred stock and common stock and from the sale of common stock in public offerings and payments received in connection with the Strategic Collaboration and License Agreement, or the Vertex Agreement, with Vertex Pharmaceuticals Incorporated, or Vertex, in July 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to continue to incur significant operating expenses and net losses for the foreseeable future. Our operating expenses and net losses may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">conduct our ongoing heart-1 clinical trial for VERVE-101 in New Zealand and the United Kingdom, and if our investigational new drug application, or IND, is cleared, in the United States;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue our current research programs and our preclinical development of product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our existing and future product candidates into clinical development; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek regulatory and marketing approvals for any of our product candidates that we develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">perform research services under the Vertex Agreement and seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">make milestone payments to Beam Therapeutics Inc., or Beam, under our amended and restated collaboration and license agreement with Beam, or the Beam Agreement, milestone payments to Acuitas Therapeutics Inc., or Acuitas, under our non-exclusive license agreement with Acuitas, or the Acuitas Agreement, milestone payments or success payments to The Broad Institute, Inc., or Broad, and the President and Fellows of Harvard College, or Harvard, under our license agreement with Broad and Harvard (as amended, the Cas9 License Agreement), and milestone payments to Novartis Pharma AG, or Novartis, under our license agreement with Novartis, or the Novartis Agreement, and potential payments to other third parties under our other collaboration agreements or any additional future collaboration or license agreements that we obtain; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">further develop our base editing technology and develop novel gene editing technology;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">hire additional personnel including research and development, clinical and commercial personnel; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acquire or in-license products, intellectual property, medicines and technologies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfy any post-approval marketing requirements, such as a cardiovascular outcomes trial, or CVOT, which we expect will be required for VERVE-101 and VERVE-201; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish commercial-scale current good manufacturing practices, or cGMP, capabilities through a third-party or our own manufacturing facility; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, our expenses will further increase if, among other things:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we are required by the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, or other regulatory authorities to perform clinical trials or preclinical studies that are in addition to, or different than, those expected; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">there are any delays in completing our clinical trials or preclinical studies or the development of any of our product candidates; or </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">there are any third-party challenges to our intellectual property or we need to defend against any intellectual property-related claim. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if we obtain marketing approval for, and are successful in commercializing, one or more of our product candidates, we expect to incur substantial additional research and development and other expenditures to develop and market additional product candidates and/or to expand the approved indications of any marketed product. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have never generated revenue from product sales and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have only recently initiated clinical development of our first product candidate and expect that it will be many years, if ever, before we have a product candidate ready for commercialization. To become and remain profitable, we must succeed in developing, obtaining the necessary regulatory approvals for and eventually commercializing a product or products that generate significant revenue. The ability to achieve this success will require us to be effective in a range of challenging activities, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">completing preclinical testing and clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">identifying additional product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtaining marketing approval for these product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">manufacturing, marketing and selling any products for which we may obtain marketing approval; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">achieving market acceptance of products for which we may obtain marketing approval as viable treatment options. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are only in the preliminary stages of these activities and there is no assurance that we will be successful in these activities and, even if we are, may never generate revenues that are significant enough to achieve profitability. We have not yet completed a clinical trial of any product candidate. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to generate revenue or achieve profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. Our revenue will be dependent, in part, upon the size of the markets in the territories for which we gain regulatory approval, the accepted price for the product, the ability to obtain coverage and reimbursement, and whether we own the commercial rights for that territory. If the number of our addressable patients is not as significant as we estimate, the indication approved by regulatory authorities is narrower than we expect, or the treatment population is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from sales of such products, even if approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We will need substantial additional funding. If we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect to devote substantial financial resources to our ongoing and planned activities, particularly as we conduct our ongoing Phase 1b clinical trial of VERVE-101, complete preclinical studies of VERVE-201, continue research, development and preclinical testing, initiate additional clinical trials and potentially seek marketing approval for VERVE-101, VERVE-201, and any other product candidates we may develop. We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance our preclinical activities and our ongoing and planned clinical trials. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution. Furthermore, we expect to continue to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. We currently do not have a credit facility or any committed sources of capital. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the progress, costs and results of our ongoing Phase 1b clinical trial of VERVE-101 and any future clinical development of VERVE-101;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the scope, progress, results and costs of discovery, preclinical and clinical development for any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of developing or acquiring licenses for the delivery modalities that will be used with our future product candidates;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost and timing of completion of commercial-scale manufacturing activities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights, and defending intellectual property-related claims, including claims of infringement, misappropriation or other violation of third-party intellectual property; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs, timing and outcome of regulatory review of the product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of future commercialization activities, either by ourselves or in collaboration with others, including product sales, marketing, manufacturing, and distribution for any product candidates for which we receive marketing approval; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of satisfying any post-approval marketing requirements, such as a CVOT; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the revenue, if any, received from commercial sales of product candidates we may develop for which we receive marketing approval; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the success of our license agreements and our collaborations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to establish and maintain additional collaborations on favorable terms, if at all; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the achievement of milestones or occurrence of other developments that trigger payments under any collaboration or license agreements we enter into; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the extent to which we acquire or in-license products, intellectual property and technologies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of operational, financial and management information systems and associated personnel; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs of operating as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, even if we successfully identify and develop product candidates and those are approved, we may not achieve commercial success. Our commercial revenues, if any, may not be sufficient to sustain our operations. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of approximately $554.8 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. However, we have based</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">this estimate on assumptions that may prove to be wrong, and our operating plan may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect and could be forced to seek additional funding sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize any product candidates. We cannot be certain that additional funding will be available on acceptable terms, or at all. For example, economic and other factors have recently caused significant disruption of global financial markets, which could continue and would reduce our ability to access capital, which could in the future negatively affect our liquidity. We have no committed source of additional capital or external funds and, if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We could be required to seek collaborators for product candidates we may develop at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to product candidates we may develop in markets where we otherwise would seek to pursue development or commercialization ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Until such time, if ever, as we can generate substantial revenues from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. We do not have any source of committed capital or external funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#x2019; interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#x2019; rights as a common stockholder. Any debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures, declaring dividends or encumbering our assets to secure future indebtedness.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we would be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our limited operating history may make it difficult for stockholders to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We commenced operations in 2018 and are a clinical-stage company. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our technology, identifying potential product candidates, securing intellectual property rights, conducting preclinical studies and an early-stage clinical trial. We initiated our first clinical trial, a Phase 1b clinical trial for VERVE-101, in July 2022. Our other research programs, including VERVE-201, are still in the research or preclinical stage of development, and their risk of failure is high. We have not yet demonstrated our ability to complete any clinical trials, obtain marketing approvals, manufacture a clinical development or commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. In part because of this lack of experience, we cannot be certain that our ongoing preclinical studies and clinical trial will be completed on time or if the planned preclinical studies and clinical trials will begin or be completed on time, if at all. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history or a history of successfully developing and commercializing gene editing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our limited operating history, particularly in light of the rapidly evolving genetic medicines field, may make it difficult to evaluate our technology and industry and predict our future performance. Our limited history as an operating company makes any assessment of our future success or viability subject to significant uncertainty. We</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields. If we do not address these risks successfully, our business will suffer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, as our business grows, we may encounter unforeseen expenses, restrictions, difficulties, complications, delays and other known and unknown factors. We will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. We may not be successful in such a transition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our ability to use our net operating losses and research and development tax credit carryforwards to offset future taxable income or taxes may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have a history of cumulative losses and anticipate that we will continue to incur significant losses in the foreseeable future; thus, we do not know whether or when we will generate taxable income necessary to utilize our net operating losses, or NOLs, or research and development tax credit carryforwards. As of December 31, 2022, we had federal NOL carryforwards of $173.6 million and state NOL carryforwards of $157 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In general, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, and corresponding provisions of state law, a corporation that undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset post-change taxable income or taxes. We have not conducted a study to assess whether any such ownership changes have occurred. We may have experienced such ownership changes in the past and may experience such ownership changes in the future as a result of subsequent changes in our stock ownership (which may be outside our control). As a result, if, and to the extent that, we earn net taxable income, our ability to use our pre-change NOLs and research and development tax credit carryforwards to offset such taxable income may be subject to limitations. Our NOLs or credits may also be impaired under state law.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities. As described below in &#x201c;Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition,&#x201d; the Tax Cuts and Jobs Act, or the Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, included changes to U.S. federal tax rates and the rules governing NOL carryforwards that may significantly impact our ability to utilize our NOLs to offset taxable income in the future. For these reasons, even if we attain profitability, we may be unable to use a material portion of our NOLs and other tax attributes.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to discovery and development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are very early in our development efforts, and we have not yet completed a clinical trial of any product candidate. As a result, we expect it will be many years before we commercialize any product candidate, if ever. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval and ultimately commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are very early in our development efforts and have focused our efforts to date primarily on research efforts and preclinical development. We initiated our first clinical trial, a Phase 1b clinical trial for VERVE-101 in July 2022, but we have not yet completed a clinical trial of any product candidate Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development, marketing approval and eventual commercialization of our product candidates, which may never occur. We have not yet generated revenue from product sales, and we may never be able to develop or commercialize a marketable product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commencing clinical trials in the United States is subject to acceptance by the FDA of an IND and finalizing the trial design based on discussions with the FDA and other regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA or other regulatory agencies may require us to complete additional preclinical studies or require us to satisfy other requests prior to commencing clinical trials in the respective countries, which may delay our clinical trials beyond our planned timeline. For example, in November 2022, the FDA placed the IND application to conduct a clinical trial evaluating VERVE-101 in the United States on hold and the IND remains on hold as of the date of this Annual Report on Form 10-K. Even after we receive and incorporate guidance from these regulatory authorities, the FDA or other regulatory authorities could disagree that we have satisfied their requirements to commence any clinical trial, including with respect to VERVE-101, or change their position on the acceptability of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our trial design or the clinical endpoints selected, which may require us to complete additional preclinical studies or clinical trials, delay the enrollment of our clinical trials or impose stricter approval conditions than we currently expect. There are equivalent processes and risks applicable to clinical trial applications in other countries, including countries in the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commercialization of any product candidates we may develop will require preclinical and clinical development; regulatory and marketing approval in multiple jurisdictions, including by the FDA and the EMA; manufacturing supply, capacity and expertise; a commercial organization; and significant marketing efforts. The success of VERVE-101, VERVE-201 and any other product candidates we may identify and develop will depend on many factors, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">effective INDs or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">successful enrollment and completion of clinical trials, including under the FDA&#x2019;s current Good Clinical Practices, or GCPs, current Good Laboratory Practices and any additional regulatory requirements from foreign regulatory authorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">positive results from our ongoing and future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">receipt of marketing approvals from applicable regulatory authorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">commercial launch of any product candidates we may develop, if approved, whether alone or in collaboration with others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acceptance of the benefits and use of our product candidates we may develop, including method of administration, if and when approved, by patients, the medical community and third-party payers; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">effective competition with other therapies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establishment and maintenance of healthcare coverage and adequate reimbursement by payers. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we do not succeed in one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates we may develop, which would materially harm our business. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Gene editing, including base editing, is a novel technology that is not yet clinically validated as being safe and efficacious for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are unproven and may never lead to marketable products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are focused on developing medicines utilizing gene editing technology, which is new and largely unproven. The base editing technologies that we have licensed and that we are utilizing with VERVE-101 and VERVE -201 have not yet been evaluated in any completed clinical trial, nor are we aware of any clinical trials for safety or efficacy having been completed by third parties using our base editing or similar technologies. The scientific evidence to support the feasibility of developing product candidates based on gene editing technologies is both preliminary and limited. Successful development of our product candidates will require us to safely deliver a gene editor into target cells, optimize the efficiency and specificity of such product candidates and ensure the therapeutic selectivity of such product candidates. There can be no assurance that base editing technology, or other gene editing technology will lead to the development of genetic medicines or that we will be successful in solving any or all of these issues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our future success is highly dependent on the successful development of gene editing technologies, delivery technology methods and therapeutic applications of that technology. We may decide to alter or abandon our initial programs as new data become available and we gain experience in developing gene editing therapeutics. We cannot be sure that our technologies will yield satisfactory products that are safe and effective, scalable or profitable in our initial indications or any other indication we pursue. Adverse developments in the clinical development efforts of other gene editing technology companies could adversely affect our efforts or the perception of our product candidates by both investors and regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Similarly, another new gene editing technology that has not been discovered yet may be developed by third parties and may be determined to be more attractive than base editing for the gene targets that we are pursuing with base editing technology.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also are seeking to develop a novel gene editing development candidate as part of our collaboration with Vertex, including seeking to identify and engineer specific gene editing systems and delivery systems directed to a target of interest. We may seek to develop novel gene editing technology for future programs. We have not previously developed novel gene editing technology on our own and have in-licensed gene editing technology from third parties. We cannot be certain that we will be able to successfully develop novel gene editing systems for the target or for any other targets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, we cannot be certain we will be able to obtain any necessary rights to develop other gene editing technologies. Although all of our founders who currently provide consulting and advisory services to us in the area of base editing technologies have assignment of inventions obligations to us with respect to the services they perform for us, these assignment of inventions obligations are subject to limitations and do not extend to their work in other fields or to the intellectual property arising from their employment with their respective academic and research institutions. To obtain intellectual property rights assigned by these founders to such institutions, we would need to enter into license agreements with such institutions, which may not be available on commercially reasonable terms or at all. Any of these factors could reduce or eliminate our commercial opportunity and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Development activities in the field of gene editing are currently subject to a number of risks related to the ownership and use of certain intellectual property rights that are subject to patent interference proceedings in the United States and opposition proceedings in Europe. For additional information regarding the risks that may apply to our and our licensors&#x2019; intellectual property rights, see the section entitled &#x201c;&#x2014;Risks related to our intellectual property&#x201d; for more information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, public perception and related media coverage relating to the adoption of new therapeutics or novel approaches to treatment, as well as ethical concerns related specifically to gene editing, may adversely influence the willingness of subjects to participate in clinical trials, or, if any therapeutic is approved, of physicians and patients to accept these novel and personalized treatments. Physicians, health care providers and third-party payors often are slow to adopt new products, technologies and treatment practices, particularly those that may also require additional upfront costs and training. Physicians may not be willing to undergo training to adopt these novel and potentially personalized therapies, may decide the particular therapy is too complex or potentially risky to adopt without appropriate training, and may choose not to administer the therapy. Further, due to health conditions, genetic profile or other reasons, certain patients may not be candidates for the therapies. In addition, responses by federal and state agencies, Congressional committees and foreign governments to negative public perception, ethical concerns or financial considerations may result in new legislation, regulations or medical standards that could limit our ability to develop or commercialize any product candidates, obtain or maintain regulatory approval or otherwise achieve profitability. New government requirements may be established that could delay or prevent regulatory approval of our product candidates under development. It is impossible to predict whether legislative changes will be enacted, regulations, policies or guidance changed, or interpretations by agencies or courts changed, or what the impact of such changes, if any, may be. Based on these and other factors, health care providers and payors may decide that the benefits of these new therapies do not or will not outweigh their costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The gene editing field is relatively new and is evolving rapidly. We are focusing our research and development efforts on gene editing using base editing technology, but other gene editing technologies may be discovered that provide significant advantages over base editing, which could materially harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To date, we have focused our efforts on gene editing technologies using base editing. Other companies have previously undertaken research and development of gene editing technologies using zinc finger nucleases,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">engineered meganucleases and transcription activator-like effector nucleases, but to date none have obtained marketing approval for a product candidate. There can be no certainty that base editing technology will lead to the development of genetic medicines or that other gene editing technologies will not be considered better or more attractive for the development of medicines. For example, Feng Zhang&#x2019;s group at the Massachusetts Institute of Technology, or MIT, and Broad, and, separately, Samuel Sternberg&#x2019;s group at Columbia University announced the discovery of the use of transposons, or &#x201c;jumping genes.&#x201d; Transposons can insert themselves into different places in the genome and can be programmed to carry specific DNA sequences to specific sites, without the need for making double-stranded breaks in DNA. Beam uses prime editing technology, which utilizes a CRISPR protein to target a mutation site in DNA and to nick a single strand of the target DNA. Guide RNA allows the CRISPR protein to recognize a DNA sequence that is complementary to the guide RNA and also carries a primer for reverse transcription and a replacement template. The reverse transcriptase copies the template sequence in the nicked site, installing the edit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A number of alternative approaches are being developed by others, including, for example, Intellia Therapeutics, Inc., which has reported clinical data from a Phase 1b trial of NTLA-2001, a CRISPR/Cas9-based gene editing product candidate for the treatment of hereditary transthyretin amyloidosis with polyneuropathy and for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy. Similarly, other new gene editing technologies that have not been discovered yet may be more attractive than base editing. Moreover, we cannot be certain we will be able to obtain rights to develop or use other gene editing technologies. Any of these factors could reduce or eliminate our commercial opportunity, and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be successful in our efforts to identify and develop potential product candidates. If these efforts are unsuccessful, we may never become a commercial stage company or generate any revenues.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The success of our business depends primarily upon our ability to identify, develop and commercialize product candidates using gene editing technologies. We have only recently initiated our first clinical trial of VERVE-101 in New Zealand and the United Kingdom. Our research programs may fail to identify potential product candidates for clinical development for a number of reasons. Our research methodology may be unsuccessful in identifying additional potential product candidates, our potential product candidates may be shown to have harmful side effects in preclinical</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> experiments or animal model studies, they may not show promising signals of therapeutic effect in such experiments or studies or they may have other characteristics that may make the product candidates impractical to manufacture, unmarketable or unlikely to receive marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The COVID-19 pandemic may affect our ability to initiate and complete current or future preclinical studies, and clinical trials, disrupt regulatory activities or have other adverse effects on our business and operations. In addition, this pandemic has adversely impacted economies worldwide, which could result in adverse effects on our business, operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The COVID-19 pandemic has caused, and may continue to cause, many governments to implement measures to slow the spread of the pandemic through quarantines, travel restrictions, heightened border scrutiny and other measures. The pandemic and government measures taken in response have also had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The future progression of the pandemic and its effects on our business and operations are uncertain. We and our contract manufacturing organizations, or CMOs, and contract research organizations, or CROs, have experienced a reduction in the capacity to undertake research-scale production and to execute some preclinical studies, and we have faced and may face disruptions that affect our ability to initiate and complete preclinical studies and clinical trials, and disruptions in procuring items that are essential for our research and development activities, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">raw materials and supplies used in the production and purification of messenger RNA, or mRNA, nucleic acids as well as lipids used in the production of lipid nanoparticles, or LNPs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">raw materials and supplies used in the manufacture of any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">laboratory supplies used in our preclinical studies and clinical trials; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">animals that are used for preclinical testing for which there are shortages because of ongoing efforts to address components of the pandemic. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We and our CROs and CMOs may also face disruptions related to our ongoing and future IND-enabling studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals, as well as other delays at clinical trial sites.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The response to the COVID-19 pandemic may also redirect resources with respect to regulatory and intellectual property matters in a way that would adversely impact our ability to progress regulatory approvals and protect our intellectual property, for example by causing interruptions or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines. We have experienced delays with the FDA as a result of the COVID-19 pandemic. In addition, we may face impediments or delays to regulatory meetings and approvals due to measures intended to limit in-person interactions. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business, although for the reasons described above it has the potential to adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The risk of failure for each of our product candidates is high. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. The time required to obtain approval from the FDA, EMA or other comparable foreign regulatory authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. We have only recently initiated a clinical trial for VERVE-101 in New Zealand and the United Kingdom and have not yet completed any clinical trials. Clinical trials may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. Even if initial clinical trials in any of our product candidates we may develop are successful, these product candidates we may develop may fail to show the desired safety and efficacy in later stages of clinical development despite having successfully advanced through preclinical studies and initial clinical trials. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials. Furthermore, even if the clinical trials are successful, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application may cause delays in the approval or rejection of an application.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned INDs and other regulatory filings in the United States and abroad. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates or whether regulatory authorities will accept our proposed clinical programs. As a result, we may not be able to submit an IND in the United States or comparable foreign applications to initiate clinical development on the timelines we expect, if at all, and the submission of these applications may not result in regulatory authorities allowing clinical trials to begin.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For example, in November 2022, the FDA placed our IND application to conduct a clinical trial evaluating</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE-101 in the United States on hold. We received a clinical hold letter from the FDA in December 2022 that outlined the information required to resolve the clinical hold, including additional preclinical data relating to: (i) potency differences between human and non-human cells, (ii) risks of germline editing, and (iii) off-target analyses in non-hepatocyte cell types. The FDA also requested available clinical data from the ongoing heart-1 clinical trial. In addition, the FDA has requested that we modify the trial protocol in the United States to incorporate additional contraceptive measures and to increase the length of the staggering interval between dosing of participants.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to initiating the trial in the United States, we will be required to resolve the hold on the IND application. We cannot be certain that the hold will be lifted on a timely basis, or at all, and we may not be able to initiate our clinical trial of VERVE-101 in the United States. Any delay in our ability, or our inability, to initiate our clinical trial of VERVE-101 in the United States because of the hold may delay our clinical development plans for VERVE-101, may require us to incur additional preclinical or clinical development costs and could impair our ability to ultimately obtain FDA approval for VERVE-101. Delays in the completion of any clinical trial of VERVE-101 could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">increase our costs, slow down our product candidate development and approval process and delay or potentially jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, product candidates are subject to continued preclinical safety studies, which may be conducted concurrently with our clinical testing. The outcomes of these safety studies may delay the launch of or enrollment in future clinical trials and could impact our ability to continue to conduct our clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any of our clinical trials will be conducted as planned or completed on schedule, or at all. A failure of one or more clinical trials can occur at any stage of testing, which may result from a multitude of factors, including, but not limited to, flaws in study design, dose selection issues, placebo effects, patient enrollment criteria and failure to demonstrate favorable safety or efficacy traits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Furthermore, the failure of any of our product candidates to demonstrate safety and efficacy in any clinical trial could negatively impact the perception of our other product candidates and/or cause the FDA, EMA or other regulatory authorities to require additional testing before approving any of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may be unable to demonstrate to the satisfaction of the FDA, EMA or other foreign regulatory authorities that a product candidate is safe, pure and potent or effective for its proposed indication; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA or other foreign regulatory authorities for approval; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may be unable to demonstrate that a product candidate&#x2019;s clinical and other benefits outweigh its safety risks; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a Biologics License Application, or BLA, to the FDA, or similar foreign submission to the EMA or other foreign regulatory authority, to obtain approval in the United States, the European Union or elsewhere; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the FDA, EMA or other foreign regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the approval policies or regulations of the FDA, EMA or other foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA, EMA and other comparable foreign regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be obtained for any product candidate that we develop. Even if we believe the data collected from our ongoing or future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA or any other comparable foreign regulatory authorities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Additionally, outside of the United States, regulatory authorities may not approve the price we intend to charge for our products. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In response to the COVID-19 pandemic, the FDA issued guidance on March 18, 2020, and subsequently updated it on July 2, 2020, January 27, 2021, and August 30, 2021, to address the conduct of clinical trials during the pandemic. The guidance sets out a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruptions by a unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. In its most recent update to this guidance, FDA addresses questions received during the past year from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and handle remote site monitoring visits. There is no assurance that this guidance governing clinical studies during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. On January 30, 2023, the Biden Administration announced that it will end the public health emergency declarations related to COVID-19 on May 11, 2023. On January 31, 2023, the FDA indicated that it would soon issue a Federal Register notice describing how the termination of the public health emergency will impact the agency&#x2019;s COVID-19 related guidance, including the clinical trial guidance and updates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accordingly, our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, slow down or halt our product candidate development and approval process and jeopardize our ability to seek and obtain the marketing approval required to commence product sales and generate revenue, which would cause the value of our company to decline and limit our ability to obtain additional financing if needed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accordingly, the COVID-19 pandemic may continue to significantly impact economies and financial markets worldwide, which could result in adverse effects on our business and operations, impact our ability to raise additional funds through public offerings and impact the volatility of our stock price and trading in our stock. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to adversely affect our business, financial condition, results of operations, and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The outcome of preclinical studies and earlier-stage clinical trials may not be predictive of future results or the success of later preclinical studies and clinical trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have only recently initiated and begun conducting a clinical trial. As a result, our belief in the potential capabilities of our programs is based on research and preclinical studies. However, the results of preclinical studies may not be predictive of the results of later preclinical studies or clinical trials, and the results of any early-stage clinical trials may not be predictive of the results of later clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We have conducted several preclinical studies of our product candidates in non-human primates, but we cannot be certain that the results observed in such studies will translate into similar results in clinical trials of our product candidates in humans. Our ongoing or future clinical trials may not ultimately be successful or support further clinical development of any product candidates we may develop. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators, IRBs, or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators may decide that longer follow-up data are needed before they will consider our marketing application, which would delay our ability to obtain approval; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators may decide the design of our clinical trials is flawed, for example if regulators do not agree with our chosen primary endpoints; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators may decide to slow patient enrollment, resulting in delays to our ability to meet our timelines; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preclinical testing may produce results based on which we may decide, or regulators may require us, to conduct additional preclinical studies before we proceed with certain clinical trials, limit the scope of our clinical trials, halt ongoing clinical trials or abandon product development programs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators, IRBs or ethics committees may require us to perform additional or unanticipated clinical trials to obtain approval or we may be subject to additional post-marketing testing requirements to maintain regulatory approval, such as a CVOT; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of clinical trials of our product candidates may be greater than we anticipate; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate the trials; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulators may withdraw their approval of a product or impose restrictions on its distribution, such as in the form of a risk evaluation and mitigation strategy, or REMS. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We could encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are conducted or their ethics committees, by the data review committee or data safety monitoring board for such trial or by the FDA, EMA or other foreign regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, including those relating to the class of products to which our product candidates belong.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">be delayed in obtaining marketing approval for our product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">not obtain marketing approval at all; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obtain approval with labeling or a REMS that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">be subject to additional post-marketing testing requirements; or </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">have the product removed from the market after obtaining marketing approval. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. We may also determine to change the design or protocol of one or more of our clinical trials, including to add additional patients or arms, which could result in increased costs and expenses and/or delays. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preclinical drug development is uncertain. Some or all of our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain marketing approvals or commercialize these product candidates on a timely basis or at all, which would have an adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to obtain FDA approval to market a new biological product, we must demonstrate product purity (or product quality) as well as proof of safety and potency or efficacy in humans. To satisfy these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support an IND in the United States. We cannot be certain of the timely completion or outcome of our preclinical testing and studies, and we cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of these product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for any preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin. For example, in November 2022, the FDA placed the IND application to conduct a clinical trial evaluating VERVE-101 in the United States on hold.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time may vary substantially according to the type, complexity, novelty and intended use of the product candidate, and often can be several years or more per product candidate. Delays associated with product candidates for which we are conducting preclinical testing and studies ourselves may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain product candidates conducted by our potential partners over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including, for example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">inability to generate sufficient preclinical or other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> data to support the initiation of clinical trials; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delays in reaching a consensus with regulatory agencies on study design. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, even if we do initiate clinical trials for other product candidates, our development efforts may not be successful, and clinical trials that we conduct or that third parties conduct on our behalf may not demonstrate product purity (or quality) as well as proof of safety and potency or efficacy necessary to obtain the requisite marketing approvals for any of our product candidates or product candidates employing our technology. Even if we obtain positive results from preclinical studies or initial clinical trials, we may not achieve the same success in future trials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. In 2022, we initiated our heart-1 clinical trial for VERVE-101 in New Zealand and the United Kingdom under country-specific protocols with various modifications to eligibility in each country. Successful and timely completion of clinical trials will require that we enroll a sufficient number of patients who remain in the trial until its conclusion. We may not be able to initiate or continue additional clinical trials for our product candidates if we are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. Given the large patient population for atherosclerotic cardiovascular disease, or ASCVD, if we expand clinical development of VERVE-101 or VERVE-201 for the treatment of patients with established ASCVD, the number of patients that may be required for clinical trials in order to obtain regulatory approval for that indication could be very high, and we may not be able to enroll a sufficient number of patients and as a result we may not be able to initiate or complete clinical trials of VERVE-101 for the treatment of patients with established ASCVD. Because of the small patient population for homozygous familial hypercholesterolemia, or HoFH, we may have difficulty enrolling patients and we may not be able to initiate or complete clinical trials for VERVE-201 for the treatment of HoFH.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Patient enrollment is affected by a variety of other factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the prevalence and severity of the disease under investigation; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the eligibility criteria for the trial in question; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the perceived risks and benefits of the product candidate under trial; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the requirements of the trial protocols, which for products targeting cardiovascular disease, or CVD, could include up to 15 years of long-term patient follow-up; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability of existing treatments for the indications for which we are conducting clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the ability to recruit clinical trial investigators with the appropriate competencies and experience; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the efforts to facilitate timely enrollment in clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the patient referral practices of physicians; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the ability to monitor patients adequately during and after treatment; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the proximity and availability of clinical trial sites for prospective patients; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">perceived negative public perception of gene editing; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the conduct of clinical trials by competitors for product candidates that treat the same indications or address the same patient populations as our product candidates; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost to, or lack of adequate compensation for, prospective patients. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other pharmaceutical and biotechnology companies have reported experiencing delays in enrollment in their ongoing clinical trials as a result of the COVID-19 pandemic, and we could also experience such delays. Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if we are able to enroll a sufficient number of patients for our future clinical trials, we may have difficulty maintaining patients in our clinical trials. Many of the patients who end up receiving placebo may perceive that they are not receiving the product candidate being tested, and they may decide to withdraw from our clinical trials to pursue alternative therapies rather than continue the trial. If we have difficulty enrolling or maintaining a sufficient number of patients to conduct our clinical trials, we may need to delay, limit or terminate clinical trials, any of which would harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If any of the product candidates we may develop, or the delivery modes we rely on to administer them, cause serious adverse events, undesirable side effects or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We only recently initiated our heart-1 clinical trial for VERVE-101. Moreover, there have been only a limited number of clinical trials involving the use of gene editing technologies and there are no completed clinical trials involving base editing technology similar to the gene editing technology we are using in VERVE-101. Furthermore, there has not been any gene editing product candidate that has received regulatory approval for use in humans. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that gene editing technologies will not cause undesirable side effects, as</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">improper editing of a patient&#x2019;s DNA could lead to lymphoma, leukemia or other cancers or other aberrantly functioning cells.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A significant risk in any gene editing product candidate is that &#x201c;off-target&#x201d; edits may occur, which could cause serious adverse events, undesirable side effects or unexpected characteristics. We cannot be certain that off-target editing will not occur in any of our ongoing or future clinical studies, and the lack of observed side effects in preclinical studies does not guarantee that such side effects will not occur in human clinical studies. There is also the potential risk of delayed or late presentation of adverse events following exposure to gene editors due to the potential permanence of edits to DNA or due to other components of product candidates used to carry the genetic material. Further, because gene editing makes a permanent change, the therapy cannot be withdrawn, even after a side effect is observed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are using LNPs to deliver our gene editors to the liver. LNPs have recently been used to deliver mRNA in humans, including the COVID-19 vaccines developed by Pfizer Inc., or Pfizer, and BioNTech SE and by Moderna, Inc., and LNPs are being used to deliver mRNA for therapeutic use in clinical trials. LNPs have the potential to induce liver injury and/or initiate a systemic inflammatory response, either of which could potentially be fatal. While we aim to continue to optimize our LNPs, there can be no assurance that our LNPs will not have undesired effects. Our LNPs could contribute, in whole or in part, to one or more of the following: liver injury, immune reactions, infusion reactions, complement reactions, opsonization reactions, antibody reactions including IgA, IgM, IgE or IgG or some combination thereof, or reactions to the polyethylene glycol, or PEG, from some lipids or PEG otherwise associated with the LNP. Certain aspects of our investigational medicines may induce immune reactions from either the mRNA or the lipid as well as adverse reactions within liver pathways or degradation of the mRNA or the LNP, any of which could lead to significant adverse events in one or more of our ongoing or future clinical trials. Some of these types of adverse effects have been observed for other LNPs. There may be uncertainty as to the underlying cause of any such adverse event, which would make it difficult to accurately predict side effects in ongoing or future clinical trials and would result in significant delays in our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our GalNAc-LNPs, which we plan to use in VERVE-201, are a novel delivery mechanism for delivery of gene editors to the liver and have not yet been studied in humans.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any product candidates we develop are associated with serious adverse events, undesirable side effects or unexpected characteristics, we may need to abandon their development or limit development to certain uses or subpopulations in which the serious adverse events, undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If in the future we are unable to demonstrate that any of the above adverse events were caused by factors other than our product candidate, the FDA, the EMA or other regulatory authorities could order us to cease further development of, or deny approval of, any product candidates we are able to develop for any or all targeted indications. They could also revoke a marketing authorization if a serious safety concern is identified in any post-marketing follow up studies. Even if we are able to demonstrate that all future serious adverse events are not product-related, such occurrences could affect patient recruitment or the ability of enrolled patients to complete the trial. Moreover, if we elect, or are required, to delay, suspend or terminate any clinical trial of any product candidate we may develop, the commercial prospects of such product candidates may be harmed and our ability to generate product revenues from any of these product candidates may be delayed or eliminated. Any of these occurrences may harm our ability to identify and develop product candidates, and may harm our business, financial condition, result of operations, and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our programs involve editing the human genome. The clinical and commercial success of our product candidates will depend in part on public understanding and acceptance of the use of gene editing therapy for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing is unsafe, unethical or immoral, and, consequently, our product candidates may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, gene editing technology is subject to public debate and heightened regulatory scrutiny due to ethical concerns.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair our development and commercialization of product candidates or demand for any product candidates we may develop. Adverse events in our preclinical studies or clinical trials or those of our licensors, partners or competitors or of academic researchers utilizing gene editing technologies, even if not ultimately attributable to product candidates we may identify and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. Use of gene editing technology by a third party or government to develop biological agents or products that threaten U.S. national security could similarly result in such negative impacts to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more participant data become available and are subject to audit and verification procedures, which could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">From time to time, we may publish or report interim or preliminary results from our clinical trials. Interim results from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as participant enrollment continues and more participant data become available. We also make assumptions, estimations, calculations, and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully evaluate all data. Preliminary, interim or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or interim data we previously published. As a result, preliminary, interim or top-line data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could be material and could significantly harm our reputation and business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Genetic medicines are complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development programs, limit the supply of our product candidates we may develop, or otherwise harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidates we may develop will likely require processing steps that are more complex than those required for most chemical pharmaceuticals. Moreover, unlike chemical pharmaceuticals, the physical and chemical properties of a biologic such as the product candidates we intend to develop generally cannot be fully characterized. As a result, assays of the finished product candidate may not be sufficient to ensure that the product candidate will perform in the intended manner. Problems with the manufacturing process, even minor deviations from the normal process, could result in product defects or manufacturing failures that result in lot failures, product recalls, product liability claims or insufficient inventory or potentially delay progression of our potential IND filings. If we successfully develop product candidates, we may encounter problems achieving adequate quantities and quality of clinical-grade materials that meet FDA, EMA or other comparable applicable foreign standards or specifications with consistent and acceptable production yields and costs. In addition, the product candidates we may develop will require complicated delivery modalities, such as LNPs, which will introduce additional complexities in the manufacturing process.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the FDA, the EMA and other regulatory authorities may require us to submit samples of any lot of any approved product together with the protocols showing the results of applicable tests at any time. Under some circumstances, the FDA, the EMA or other regulatory authorities may require that we not distribute a lot until the agency authorizes its release. Slight deviations in the manufacturing process, including those affecting quality attributes and stability, may result in unacceptable changes in the product that could result in lot failures or product recalls. Lot failures or product recalls could cause us to delay clinical trials or product launches, which could be costly to us and otherwise harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also may encounter problems hiring and retaining the experienced scientific, quality control and manufacturing personnel needed to manage our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable regulatory requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Given the nature of biologics manufacturing, there is a risk of contamination during manufacturing. Any contamination could materially harm our ability to produce product candidates on schedule and could harm our results of operations and cause reputational damage. Some of the raw materials that we anticipate will be required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in the manufacture of any product candidates we may develop could</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially harm our development timelines and our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any problems in our manufacturing process or the facilities with which we contract could make us a less attractive collaborator for potential partners, including larger pharmaceutical companies and academic research institutions, which could limit our access to additional attractive development programs. Problems in third-party manufacturing process or facilities also could restrict our ability to ensure sufficient clinical material for any clinical trials we may be conducting or are planning to conduct and meet market demand for any product candidates we develop and commercialize.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If any of our product candidates receives marketing approval and we, or others, later discover that the drug is less effective than previously believed or causes undesirable side effects that were not previously identified, our ability to market the drug could be compromised.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trials of our product candidates are conducted in carefully defined subsets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects. If one or more of our product candidates receives regulatory approval, and we, or others, later discover that they are less effective than previously believed, or cause undesirable side effects, a number of potentially significant negative consequences could result, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">withdrawal or limitation by regulatory authorities of approvals of such product; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seizure of the product by regulatory authorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recall of the product; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on the marketing of the product or the manufacturing process for any component thereof; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">requirement by regulatory authorities of additional warnings on the label, such as a &#x201c;black box&#x201d; warning or contraindication; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">requirement that we implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">commitment to expensive post-marketing studies as a prerequisite of approval by regulatory authorities of such product; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the product may become less competitive; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">initiation of regulatory investigations and government enforcement actions; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">initiation of legal action against us to hold us liable for harm caused to patients; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">harm to our reputation and resulting harm to physician or patient acceptance of our products. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any of these events could prevent us from achieving or maintaining market acceptance of a particular product candidate, if approved, and could significantly harm our business, financial condition, and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Because we have limited financial and managerial resources, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Failure to allocate resources or capitalize on strategies in a successful manner will have an adverse impact on our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are conducting a clinical trial, and plan to conduct additional clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are conducting and plan to conduct one or more additional clinical trials with one or more trial sites that are located outside the United States, including our ongoing Phase 1b trial of VERVE-101 at trial sites in New Zealand and the United Kingdom. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and be performed by qualified investigators in accordance with ethical principles. The FDA must be able to validate the data from the trial through an onsite inspection, if necessary. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, whether the FDA accepts the data will depend on its determination that the trials also complied with all applicable U.S. laws and regulations. There can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, conducting clinical trials outside the United States could have a significant adverse impact on us. Risks inherent in conducting international clinical trials include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">clinical practice patterns and standards of care that vary widely among countries; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">non-U.S. regulatory authority requirements that could restrict or limit our ability to conduct our clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">administrative burdens of conducting clinical trials under multiple non-U.S. regulatory authority schema; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">foreign exchange fluctuations; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">diminished protection of intellectual property in some countries. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to our dependence on third parties</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We rely, and expect to continue to rely, on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may not perform satisfactorily.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not expect to independently conduct all aspects of our product manufacturing, research and preclinical and clinical testing. We currently rely, and expect to continue to rely, on third parties with respect to many of these items, including CMOs for the manufacturing of any product candidates we test in preclinical or clinical development, as well as CROs for the conduct of our animal testing and research. Any of these third parties may terminate their engagements with us at any time or may face supply chain shortages or otherwise be unable to secure the requisite resources, such as animals used in our preclinical testing, to support our planned development activities. If we need to modify our development plans or enter into alternative arrangements, it could delay our product development activities. Our reliance on these third parties for research and development activities will reduce our control over these activities but will not relieve us of our responsibility to ensure compliance with all required regulations and study protocols. For example, for product candidates that we develop and commercialize on our own, we will remain responsible for ensuring that each of our IND-enabling studies and clinical trials are conducted in accordance with the study plan and protocols.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Although we intend to design the clinical trials for any product candidates we may develop, CROs will conduct some or all of the clinical trials. As a result, many important aspects of our development programs, including their conduct and timing, will be outside of our direct control. Our reliance on third parties to conduct ongoing and future preclinical studies and clinical trials will also result in less direct control over the management of data developed through preclinical studies and clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with outside parties can also be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. Outside parties may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">have staffing difficulties; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fail to comply with contractual obligations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">experience regulatory compliance issues; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">undergo changes in priorities or become financially distressed; or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">form relationships with other entities, some of which may be our competitors. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These factors may materially adversely affect the willingness or ability of third parties to conduct our preclinical studies and clinical trials and may subject us to unexpected cost increases that are beyond our control. If the CROs and other third parties do not perform preclinical studies and ongoing and future clinical trials in a satisfactory manner, breach their obligations to us or fail to comply with regulatory requirements, the development, regulatory approval and commercialization of any product candidates we may develop may be delayed, we may not be able to obtain regulatory approval and commercialize our product candidates or our development programs may be materially and irreversibly harmed. If we are unable to rely on preclinical and clinical data collected by our CROs and other third parties, we could be required to repeat, extend the duration of or increase the size of any preclinical studies or clinical trials we conduct and this could significantly delay commercialization and require greater expenditures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our studies in accordance with regulatory requirements or our stated study plans and protocols, we will not be able to complete, or may be delayed in completing, the preclinical studies and clinical trials required to support future IND submissions and approval of any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Manufacturing biologic products is complex and subject to product loss for a variety of reasons. We contract with third parties for the manufacture of our product candidates for preclinical and clinical testing and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of VERVE-101 and our other product candidates for preclinical and clinical testing, as well as for commercial manufacture if any of our product candidates receive marketing approval. We also rely on these third parties for packaging, labeling, sterilization, storage, distribution and other production logistics. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts. We may be unable to establish any agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reliance on the third party for regulatory compliance and quality assurance; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible breach of the manufacturing agreement by the third party; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We or our third-party manufacturers may encounter shortages in the raw materials or active pharmaceutical ingredients, or API, necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical trials must be manufactured in accordance with cGMP. Our third-party manufacturers are subject to inspection and approval by regulatory authorities before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to ongoing inspection from time to time. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in regulatory actions, such as the issuance of FDA Form 483 notices of observations, warning letters or sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Manufacturing biologic products, such as VERVE-101, is complex, especially in large quantities. Biologic products must be made consistently and in compliance with a clearly defined manufacturing process. Accordingly, it is essential to be able to validate and control the manufacturing process to assure that it is reproducible. The manufacture of biologics is extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, inconsistency in yields, variability in product characteristics and difficulties in scaling the product process. We have not yet scaled up the manufacturing process for any of our product candidates for potential commercialization. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could harm our results of operations and cause potential reputational damage. Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. We do not currently have arrangements in place for redundant supply or a source for bulk drug substance nor do we have any agreements with third-party manufacturers for long-term commercial supply. If any of our future contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement or be unable to reach agreement with an alternative manufacturer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product candidate may increase and commercialization may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of any current or future product candidates that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the quality of the product, then we may not be able to meet the demands of our ongoing or future clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have entered into collaborations, and may enter into additional collaborations, with third parties for the research, development, manufacture and commercialization of programs or product candidates. If these collaborations are not successful, our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of our strategy, we have entered into collaborations and intend to seek to enter into additional collaborations with third parties for one or more of our programs or product candidates. For example, in April 2019, we entered into the Beam Agreement to exclusively license certain of Beam&#x2019;s base editing, gene editing and delivery technology against certain cardiovascular targets for use in our product candidates, which agreement was amended and restated in July 2022; in October 2020, we entered into the Acuitas Agreement to license from Acuitas its LNP delivery technology that we are using in VERVE-101; in October 2021 we entered into the Novartis Agreement to license from Novartis certain lipid technology that we are using in VERVE-201; and in July 2022, we entered into the Vertex Agreement for a four-year worldwide research collaboration focused on developing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. We have under the Beam Agreement, and we may have under any other arrangements that we may enter into with any third parties, limited control over the amount and timing of resources that collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">arrangements may depend on our collaborators&#x2019; abilities to successfully perform the functions assigned to them in these arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaborations that we enter into may not be successful, and any success will depend heavily on the efforts and activities of such collaborators. Collaborations pose a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to these collaborations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may not perform their obligations as expected; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may not pursue development of our product candidates or may elect not to continue or renew development programs based on results of clinical trials or other studies, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may not pursue commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew commercialization programs based on results of clinical trials or other studies, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as an acquisition, that may divert resources or create competing priorities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may delay preclinical studies and clinical trials, provide insufficient funding for a preclinical study or clinical trial program, stop a preclinical study or clinical trial or abandon a product candidate, repeat or conduct new preclinical studies or clinical trials or require a new formulation of a product candidate for preclinical or clinical testing; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may not have access to, or may be restricted from disclosing, certain information regarding product candidates being developed or commercialized under a collaboration and, consequently, may have limited ability to inform our stockholders about the status of such product candidates on a discretionary basis; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates and products if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution or marketing of a product candidate or product; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">disagreements with collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation or the preferred course of development, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">disputes may arise with respect to the ownership of intellectual property developed pursuant to our collaborations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborators may infringe, misappropriate or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">collaborations may be terminated for the convenience of the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner, or at all. If any current or future collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this &#34;Risk Factors&#34; section also apply to the activities of our collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration agreements may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. For example, upon execution of the Beam Agreement, we issued 276,075 shares of our common stock to Beam and in connection with the execution of the Vertex Agreement, we completed a private placement with Vertex pursuant to which we issued 1,519,756 shares of our common stock to Vertex. In addition, under the Cas9 License Agreement, we issued 138,037 shares of our common stock to Broad and Harvard. Broad and Harvard also had anti-dilution rights, pursuant to which we issued Broad and Harvard an additional 309,278 shares of our common stock in the aggregate following the completion of preferred stock financings. We also issued 878,098 additional shares of common stock to Broad and Harvard upon the closing of our IPO pursuant to the Cas9 License Agreement. We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. In September 2021, we notified Harvard and Broad that our average market capitalization exceeded three specified thresholds as of a relevant measurement date and aggregate success payments of approximately $6.3 million became payable under the Cas9 License Agreement, which we settled in cash in November 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We could face significant competition in seeking appropriate collaborators, and the negotiation process is time-consuming and complex. Our ability to reach a definitive collaboration agreement will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator&#x2019;s evaluation of several factors. If we license rights to any product candidates we or our collaborators may develop, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, subject to its contractual obligations to us, if a collaborator of ours is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our perception in the business and financial communities could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are not able to establish or maintain collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans and our business could be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We face significant competition in attracting appropriate collaborators, and a number of more established companies may also be pursuing strategies to license or acquire third-party intellectual property rights that we consider attractive. These established companies may have a competitive advantage over us due to their size, financial resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA, EMA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration agreements, and industry and market conditions generally. The collaborator may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than the one with us for our product candidate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may also be restricted under existing or future license agreements from entering into agreements on certain terms with potential collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaborations are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical and biotechnology companies has reduced the number of potential future collaborators.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We depend on single-source suppliers for some of the components and materials used in our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We depend on single-source suppliers for some of the components and materials used in our product candidates. We cannot ensure that these suppliers or service providers will remain in business, have sufficient capacity or supply to meet our needs or that they will not be purchased by one of our competitors or another company that is not interested in continuing to work with us. Our use of single-source suppliers of raw materials, components, key processes and finished goods exposes us to several risks, including disruptions in supply, price increases or late deliveries. There are, in general, relatively few alternative sources of supply for substitute components. These vendors may be unable or unwilling to meet our future demands for our clinical trials or commercial sale. Establishing additional or replacement suppliers for these components, materials and processes could take a substantial amount of time and it may be difficult to establish replacement suppliers who meet regulatory requirements. Any disruption in supply from any single-source supplier or service provider could lead to supply delays or interruptions, which would damage our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we have to switch to a replacement supplier, the manufacture and delivery of any product candidates we may develop could be interrupted for an extended period, which could adversely affect our business. Establishing additional or replacement suppliers, if required, may not be accomplished quickly. If we are able to find a replacement supplier, the replacement supplier would need to be qualified and may require additional regulatory authority approval, which could result in further delay. While we seek to maintain adequate inventory of the single source components and materials used in our products, any interruption or delay in the supply of components or materials, or our inability to obtain components or materials from alternate sources at acceptable prices in a timely manner, could impair our ability to meet the demand for our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to our intellectual property</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we or our licensors are unable to obtain, maintain, defend and enforce patent rights that cover our gene editing technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our success depends in large part on our ability to obtain, maintain, defend, and enforce protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to proprietary technology and product candidates we develop. It is difficult and costly to protect our gene editing technologies and product candidates, and we may not be able to ensure their protection. Our ability to stop unauthorized third parties from making, using, selling, offering to sell, importing or otherwise commercializing our product candidates we may develop, or operatively similar products, is dependent upon the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business and by in-licensing intellectual property related to our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">technologies and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations and prospects could be materially harmed. Failure to obtain protection including patent protection, may be a result of specific legal and factual circumstances that may preclude the availability of protection for our product candidates in the United States or any given country. For example, inadequate, faulty or erroneous patent prosecution may result in diminution, loss or unavailability of patent rights that adequately cover our products. Patent disclosures and claims that are intended to cover our product candidates that are sufficient or allowable in one country may not be sufficient or allowable in another country. The requirements for filing a patent application in the United States may not be sufficient to support a patent filing in a country or region outside the United States.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, defend or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable over the prior art. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain, enforce and defend the patents, covering technology that we license from third parties. Therefore, these in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended and enforced in a manner consistent with the best interests of our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The patent position of pharmaceutical and biotechnology companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. The field of gene editing especially has been the subject of extensive patenting activity and litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of foreign countries may not protect our rights to the same extent as the laws of the United States or vice versa. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Further, no earlier than the second quarter of 2023, European applications will soon have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court, or the UPC. This will be a significant change in European patent practice. As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we and our licensors are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not published at all. Therefore, neither we nor our licensors can know with certainty whether either we or our licensors were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we or our licensors were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our owned and in-licensed patent rights are highly uncertain. Moreover, our owned and in-licensed pending and future patent applications may not result in patents being issued which protect our technology and product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents and our ability to obtain, protect, maintain, defend and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value or narrow the scope of our patent rights.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, we or our licensors may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize drugs without infringing third-party patent rights. If the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned and in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned or in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned and in-licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our rights to develop and commercialize our gene editing technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We depend on intellectual property licensed from third parties, and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have licensed and are dependent on certain patent rights and proprietary technology from third parties that are important or necessary to the development of our gene editing technology and product candidates. For example, we are a party to the Beam Agreement, the Cas9 License Agreement, the Acuitas Agreement, the Novartis Agreement, and other license agreements, pursuant to which we in-license and have acquired key patents and patent applications for our gene editing technology, LNP technology and product candidates. These license agreements impose various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these obligations, our licensors may have the right to terminate our license, in which event we would not be able to develop or market our gene editing technology or product candidates covered by the intellectual property licensed under these agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our gene editing technology and product candidates in the future. Some licenses and acquired patents granted to us are expressly subject to certain preexisting rights held by the licensor or certain third parties. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in certain territories or fields. If we determine that rights to such excluded fields are necessary to commercialize our product candidates or maintain our competitive advantage, we may need to obtain a license from such third party in order to continue developing, manufacturing or marketing our product candidates. We may not be able to obtain such a license on an exclusive basis, on commercially reasonable terms, or at all, which could prevent us from commercializing our product candidates or allow our competitors or others the chance to access technology that is important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, pursuant to the Cas9 License Agreement, under certain specific circumstances, Harvard and Broad may grant a license to the patents that are the subject of such license agreements to a third party in the same field as such patents are licensed to us. Such third party may then have full rights that are the subject of the Cas9 License Agreement, which could impact our competitive position and enable a third party to commercialize products similar to our potential future product candidates and technology. Any grant of rights to a third party in this scenario would narrow the scope of our exclusive rights to the patents and patent applications we have in-licensed from Harvard and Broad.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not have complete control in the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license or have acquired from third parties. It is possible that our licensors&#x2019; enforcement of patents against infringers or defense of such patents against challenges of validity or claims of enforceability may be less vigorous than if we had conducted them ourselves, or may not be conducted in accordance with our best interests. We cannot be certain that these patents and patent applications will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the best interests of our business. If our licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, our right to develop and commercialize any of our product candidates we may develop that are the subject of such licensed rights could be adversely affected and we may not be able to prevent competitors from making, using and selling competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights to our in-licensed patents, the license granted to us in jurisdictions where the consent of a co-owner is necessary to grant such a license may not be valid and such co-owners may be able to license such patents to our competitors, and our competitors could market competing products and technology. In addition, our rights to our in-licensed patents and patent applications are dependent, in part, on inter-institutional or other operating agreements between the joint owners of such in-licensed patents and patent applications. If one or more of such joint owners breaches such inter-institutional or operating agreements, our rights to such in-licensed patents and patent applications may be adversely affected. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, inventions contained within some of our in-licensed patents and patent applications were made using U.S. government funding. We rely on our licensors to ensure compliance with applicable obligations arising from such funding, such as timely reporting, an obligation associated with our in-licensed patents and patent applications. The failure of our licensors to meet their obligations may lead to a loss of rights or the unenforceability of relevant patents. For example, the U.S. government could have certain rights in such in-licensed patents, including a non-exclusive license authorizing the U.S. government to use the invention or to have others use the invention on its behalf. If the U.S. government decides to exercise these rights, it is not required to engage us as its contractor in connection with doing so. The U.S. government&#x2019;s rights may also permit it to disclose the funded inventions and technology to third parties and to exercise march-in rights to use or allow third parties to use the technology we have licensed that was developed using U.S. government funding. The U.S. government may also exercise its march-in rights if it determines that action is necessary because we or our licensors failed to achieve practical application of the U.S. government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference to U.S. industry. In addition, our rights in such in-licensed U.S. government-funded inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any of the foregoing could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the event any of our third-party licensors determine that, in spite of our efforts, we have materially breached a license agreement or have failed to meet certain obligations thereunder, it may elect to terminate the applicable license agreement or, in some cases, one or more license(s) under the applicable license agreement, and such termination would result in us no longer having the ability to develop and commercialize product candidates and technology covered by that license agreement or license. In the event of such termination of a third-party in-license, or if the underlying patents under a third-party in-license fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. Any of these events could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our owned and in-licensed patents and patent applications and other intellectual property may be subject to priority or inventorship disputes, interferences and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certain of the U.S. patents and one U.S. patent application to which we hold an option are co-owned by Broad and MIT, and in some cases co-owned by Broad, MIT and Harvard, which we refer to together as the Boston Licensing Parties, and were involved in U.S. Interference No. 106,048 with one U.S. patent application co-owned by the University of California, the University of Vienna, and Emmanuelle Charpentier, which we refer to together as CVC. On September 10, 2018, the Court of Appeals for the Federal Circuit, or the CAFC, affirmed the Patent Trial and Appeal Board of the USPTO&#x2019;s, or PTAB&#x2019;s, holding that there was no interference-in-fact. An interference is a proceeding within the USPTO to determine priority of invention of the subject matter of patent claims filed by different parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On June 24, 2019, the PTAB declared a second interference (U.S. Interference No. 106,115) between 14 U.S. patent applications that are co-owned by CVC, and 13 U.S. patents and one U.S. patent application (that are co-owned by the Boston Licensing Parties). In the declared interference, CVC has been designated as the junior party and the Boston Licensing Parties have been designated as the senior party. On February 28, 2022, the PTAB held that the Boston Licensing Parties had priority over CVC with respect to Count 1 of the interference: a single RNA CRISPR-Cas9 system that functions in eukaryotic cells. As a result, CVC&#x2019;s patent applications involved in this interference were deemed unpatentable. In September 2022, the CVC appealed the PTAB&#x2019;s decision at the CAFC and the appeal is ongoing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On December 20, 2020, the PTAB declared an interference (U.S. Interference No. 106,126) between one U.S. patent application owned by Toolgen, Inc. and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Toolgen, Inc. has been designated as the senior party.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The PTAB has currently suspended these subsequent interference proceedings with Toolgen and Sigma-Aldrich, pending the CAFC&#x2019;s decision of the appeal between the CVC and the Boston Licensing Parties over the outcome of the second interference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On June 21, 2021, the PTAB declared an interference (U.S. Interference No. 106,133) between one U.S. patent application owned by Sigma-Aldrich Co., LLC and 14 U.S. patents and two U.S. patent applications that are co-owned by the Boston Licensing Parties. In the declared interference, Boston Licensing Parties have been designated as the junior party and Sigma-Aldrich Co., LLC has been designated as the senior party.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The PTAB has currently suspended these subsequent interference proceedings with Toolgen and Sigma-Aldrich, pending the CAFC&#x2019;s decision of the appeal between the CVC and the Boston Licensing Parties over the outcome of the second interference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result of the declaration of interference, an adversarial proceeding in the USPTO before the PTAB has been initiated, which is declared to ultimately determine priority, specifically and which party was first to invent the claimed subject matter. An interference is typically divided into two phases. The first phase is referred to as the motions or preliminary motions phase while the second is referred to as the priority phase. In the first phase, each party may raise issues including but not limited to those relating to the patentability of a party&#x2019;s claims based on prior art, written description, and enablement. A party also may seek an earlier priority benefit or may challenge whether the declaration of interference was proper in the first place. Priority, or a determination of who first invented the commonly claimed invention, is determined in the second phase of an interference. Although we cannot predict with any certainty how long each phase will actually take, each phase may take approximately a year or longer before a decision is made by the PTAB. It is possible for motions filed in the preliminary motions phase to be dispositive of the interference proceeding, such that the second priority phase is not reached.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There can be no assurance that the current appeal or these pending U.S. interference proceedings will be resolved in favor of the Boston Licensing Parties. If the appeal in the second interference favors CVC, or the 106,126, or 106,133 interference resolves in favor of Toolgen, Inc., or Sigma-Aldrich Co., LLC, respectively, or if the Boston Licensing Parties&#x2019; patents and patent application are narrowed, invalidated, or held unenforceable, we will lose the ability to license the optioned patents and patent application and our ability to commercialize our product candidates may be adversely affected if we cannot obtain a license to relevant third-party patents that cover our product candidates. We may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, we may be unable to commercialize our gene editing technology or product candidates or such commercialization efforts may be significantly delayed, which could in turn significantly harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We or our licensors may also be subject to claims that former employees, collaborators, or other third parties have an interest in our owned patent applications or in-licensed patents or patent applications or other intellectual property as an inventor or co-inventor. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patent applications, such co-owners rights may be subject, or in the future subject, to assignment or license to other third parties, including our competitors. In addition, we may need the cooperation of any such co-owners to enforce any patents that issue from such patent applications against third parties, and such cooperation may not be provided to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we or our licensors are unsuccessful in any interference proceedings or other priority, validity (including any patent oppositions) or inventorship disputes to which we or they are subject, we may lose valuable intellectual</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">property rights through the loss of one or more of our owned, licensed or optioned patents, or such patent claims may be narrowed, invalidated or held unenforceable, or through loss of exclusive ownership of or the exclusive right to use our owned or in-licensed patents. In the event of loss of patent rights as a result of any of these disputes, we may be required to obtain and maintain licenses from third parties, including parties involved in any such interference proceedings or other priority or inventorship disputes. Such licenses may not be available on commercially reasonable terms or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of one or more of the product candidates we may develop. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and product candidates. Even if we or our licensors are successful in an interference proceeding, other similar priority disputes, or inventorship or ownership disputes, it could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could result in a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we fail to comply with our obligations in our intellectual property licenses arrangements with third parties, or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are party to agreements, and we may enter into additional arrangements, with third parties that may impose diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations on us. We have existing agreements, pursuant to which we are obligated to pay royalties on net product sales of product candidates or related technologies to the extent they are covered by the agreements. If we fail to comply with such obligations under current or future agreements, our counterparties may have the right to terminate these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of any product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology, which would have a material adverse effect on our business, financial condition, results of operations and prospects. While we still face all of the risks described herein with respect to those agreements, we cannot prevent third parties from also accessing those technologies. In addition, our licenses may place restrictions on our future business opportunities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disputes may arise regarding intellectual property subject to a licensing agreement, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the scope of rights granted under the agreement and other interpretation related issues; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the sublicensing of patent and other rights under our collaborative development relationships; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our diligence obligations under the agreement and what activities satisfy those diligence obligations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the priority of invention of patented technology. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology and product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our current or future licensors may have relied on third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive owners of the intellectual property or intellectual property rights we in-license. If other third parties have ownership rights to intellectual property or intellectual property rights we in-license, they may be able to license such intellectual property or intellectual property rights to our competitors, and our competitors could market competing products and technology. This could have a</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize product candidates and technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to obtain licenses from third parties on commercially reasonable terms or fail to comply with our obligations under such agreements, our business could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently have rights to intellectual property, through licenses from third parties, to identify and develop product candidates, and we expect to seek to expand our product candidate pipeline in part by in-licensing the rights to key technologies. Although we have succeeded in licensing technologies from third-party licensors including Harvard, Broad, Beam, Acuitas, and Novartis in the past, we cannot assure our stockholders that we will be able to in-license or acquire the rights to any product candidates or technologies from third parties on acceptable terms or at all.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Various third parties practice in competitive technology areas and may have issued patents or patent applications that will issue as patents in the future, which could impede or preclude our ability to commercialize our product candidates. For any third-party patents that could be relevant to our product candidates, we rely in part on the &#x201c;safe harbor&#x201d; or research exemption under 35 U.S.C. &#167; 271(e)(1), which exempts from patent infringement activities related to pursuing FDA approval for a drug product. However, while U.S. patent law provides such a &#x201c;safe harbor&#x201d; to our clinical product candidates under this provision, that exemption expires when an IND or BLA is submitted. Given the uncertainty of clinical trials, we cannot be certain of the timing of their completion and it is possible that we may submit a BLA for one of our product candidates at a time when one or more relevant third-party patents is in force.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It may therefore be necessary for us to use the patented or proprietary technology of third parties to commercialize our products, in which case we would be required to obtain a license from these third parties. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected product candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales or an obligation on our part to pay royalties and/or other forms of compensation. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, there has been extensive patenting activity in the field of gene editing, and pharmaceutical companies, biotechnology companies, and academic institutions are competing with us or are expected to compete with us in the field of gene editing technology and filing patent applications potentially relevant to our business, and there may be third-party patent applications that, if issued, may allow the third party to circumvent our patent rights. Because of the large number of patents issued and patent applications filed in our field, these and other third parties could allege they have patent rights encompassing our product candidates, technologies or methods. In order to market our product candidates, we may find it necessary or prudent to obtain licenses from such third-party intellectual property holders. However, we may be unable to secure such licenses or otherwise acquire or in-license any compositions, methods of use, processes, or other intellectual property rights from third parties that we identify as necessary for product candidates and gene editing technology we may develop. We may also require licenses from third parties for certain gene editing technologies including certain delivery and gene editing compositions and methods that we are evaluating, or may in the future evaluate, for use with product candidates we may develop. In addition, some of our owned patent applications and in-licensed patents and patent applications may be determined to be co-owned with third parties. With respect to any patents co-owned with third parties, we may require licenses to such co-owners&#x2019; interest to such patents. If we are unable to obtain an exclusive license to any such third-party co-owners&#x2019; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, we may collaborate with academic institutions to accelerate our preclinical research or development under written agreements with these institutions. In certain cases, these institutions provide us with an option to negotiate a license to any of the institution&#x2019;s rights in technology resulting from the collaboration. Even if we hold such an option, we may be unable to negotiate a license from the institution within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the licensing or acquisition of third-party intellectual property rights is a highly competitive area, and a number of more established companies are also pursuing strategies to license or acquire third party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are unable to obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology and product candidates, which could harm our business, financial condition, results of operations and prospects significantly.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, if we fail to comply with our obligations under license agreements, our counterparties may have the right to terminate these agreements, in which event we might not be able to develop, manufacture or market, or may be forced to cease developing, manufacturing or marketing, any product that is covered by these agreements or may face other penalties under such agreements. Such an occurrence could materially adversely affect the value of the product candidate being developed under any such agreement. Termination of these agreements or reduction or elimination of our rights under these agreements, or restrictions on our ability to freely assign or sublicense our rights under such agreements when it is in the interest of our business to do so, may result in our having to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual property or technology or impede, or delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The intellectual property landscape around genome editing technology, including base editing, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our commercial success depends upon our ability and the ability of our collaborators to research, develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. The field of genome editing, especially in the area of base editing technology, is still in its infancy, and no such product candidates have reached the market. Due to the intense research and development that is taking place by several companies, including us and our competitors, in this field, the intellectual property landscape is evolving and in flux, and it may remain uncertain for the coming years. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights as well as administrative proceedings for challenging patents, including interference, derivation, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. There may be significant intellectual property related litigation and proceedings relating to our owned and in-licensed, and other third party, intellectual property and proprietary rights in the future. We may be subject to and may in the future become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our gene editing platform technology and any product candidates we may develop, including interference proceedings, post-grant review,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">European Patent Office. Numerous U.S. and foreign issued patents and pending patent applications that are owned by third parties exist in the fields in which we are developing our product candidates and they may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our gene editing technology and product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various types of therapies, products or their methods of use or manufacture. We are aware of certain third-party patent applications that, if issued, may be construed to cover our gene editing technology and product candidates. There may also be third-party patents of which we are currently unaware with claims to technologies, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It is possible that we have failed to identify relevant third-party patents or applications that our product candidates and programs may infringe. Because patent applications can take many years to issue, may be confidential for 18 months or more after filing and can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use, sale or importation of any product candidates we may develop or our technology, and we may not be aware of such patents. Furthermore, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States may remain confidential until a patent issues. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to any product candidates we may develop and our technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may incorrectly conclude that a third-party patent is invalid, unenforceable or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our technologies, any product candidates we may develop or the use of any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could adversely affect our ability to commercialize our product candidates or any other of our product candidates or technologies covered by the asserted third-party patents. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. Our product candidates make use of CRISPR-based gene editing technology, which is a field that is highly active for patent filings. The extensive patent filings related to CRISPR and Cas make it difficult for us to assess the full extent of relevant patents and pending applications that may cover our gene editing technology and product candidates and their use or manufacture. There may be third-party patents or patent applications, including patents held or controlled by our competitors with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our gene editing technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are found to infringe, misappropriate or otherwise violate a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right indemnify our customers</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">or collaborators. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Patents have a limited lifespan. The terms of individual patents depend upon the legal term for patents in the countries in which they are granted. In most countries, including the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest non-provisional filing date in the applicable country. However, the actual protection afforded by a patent varies from country to country, and depends upon many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our product candidates may face competition from biosimilars approved through an abbreviated regulatory pathway.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the PPACA, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-approved reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first approved by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first approved. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#x2019;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of the other company&#x2019;s product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for biosimilar competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for any product candidates we may develop, our business may be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, the patent term of a patent that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under clinical development and regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent applicable to and that covers an approved drug may be extended. Similar provisions are available in Europe, such as supplementary protection certificates,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and certain other non-United States jurisdictions to extend the term of a patent that covers an approved drug. While, in the future, if and when our product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those product candidates, there is no guarantee that the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions. We may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. If we are unable to obtain any patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following the expiration of our patent rights, and our business, financial condition, results of operations and prospects could be materially harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">It is possible that we will not obtain patent term extension under the Hatch-Waxman Act for a U.S. patent covering any of our product candidates that we may identify even where that patent is eligible for patent term extension, or if we obtain such an extension, it may be for a shorter period than we had sought.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our gene editing platform technology and product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As is the case with other biotech and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> review, and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Past U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future. For example, in the case, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Assoc. for Molecular Pathology v. Myriad Genetics, Inc.,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> the U.S. Supreme Court held that claims to certain DNA molecules are not patentable. More recently, in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Amgen Inc. v. Sanofi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Federal Circuit held that claims with functional language may pose high hurdles in fulfilling the enablement requirement for claims with broad</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">functional language. We cannot predict how this and future decisions by the courts, the U.S. Congress or the USPTO may impact the value of our patents. Any similar adverse changes in the patent laws of other jurisdictions could also have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we or one of our licensing partners initiates legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> inter partes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property litigation or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Periodic maintenance, renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we may rely on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency. With respect to our patents, we rely on outside firms and outside counsel to remind us of the due dates and to make payment after we instruct them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, it would have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have limited intellectual property rights outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, and even where such protection is nominally available, judicial and governmental enforcement of such intellectual property rights may be lacking. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furthermore, geo-political actions in the United States and in foreign countries could increase the uncertainties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">108</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">licensors and the maintenance, enforcement or defense of our issued patents or those of any current or future</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">licensors. For example, the United States and foreign government actions related to Russia&#x2019;s invasion of Ukraine</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">may limit or prevent filing, prosecution and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our licensed patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees that have citizenship or nationality in, are registered in, or have a predominantly primary place of business or profit-making activities in the United States and other countries that Russia has deemed unfriendly without consent or compensation. Consequently, we would not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may be subject to claims by third parties asserting that our employees, consultants or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of our employees, consultants and contractors were previously employed at universities or other pharmaceutical or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial conditions, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to seeking patents for our some of our technology and product candidates, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, CROs, CMOs, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to contractual measures, we try to protect the confidential nature of our proprietary information through other appropriate precautions, such as physical and technological security measures. However, trade secrets and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">know-how can be difficult to protect. These measures may not, for example, in the case of misappropriation of a trade secret by an employee or third party with authorized access, provide adequate protection for our proprietary information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and any recourse we might take against this type of misconduct may not provide an adequate remedy to protect our interests fully. In addition, trade secrets may be independently developed by others in a manner that could prevent us from receiving legal recourse. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if any of that information was independently developed by a competitor, our competitive position could be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and adversely harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Intellectual property rights do not necessarily address all potential threats.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any product candidates we may develop will eventually become commercially available in generic or biosimilar product forms; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">others may be able to make gene editing products that are similar to ours but that are not covered by the claims of the patents that we own; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent applications that we license or may own in the future; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we, or our license partners or current or future collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed intellectual property rights; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it is possible that our pending owned and in-licensed patent applications or those we may own or in-license in the future will not lead to issued patents; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it is possible that there are prior public disclosures that could invalidate our owned or in-licensed patents, or parts of our owned or in-licensed patents; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue with claims covering our product candidates or technology similar to ours; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">110</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">it is possible that our owned or in-licensed patents or patent applications omit individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the laws of foreign countries may not protect our proprietary rights or the proprietary rights of license partners or current or future collaborators to the same extent as the laws of the United States; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inventors of our owned or in-licensed patents or patent applications may become involved with competitors, develop products or processes that design around our patents, or become hostile to us or the patents or patent applications on which they are named as inventors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we have engaged in scientific collaborations in the past and will continue to do so in the future and our collaborators may develop adjacent or competing products that are outside the scope of our patent rights; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that any of our patents, or any of our pending patent applications, if issued, or those of our licensors, will include claims having a scope sufficient to protect our product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that any patents issued to us or our licensors will provide a basis for an exclusive market for our commercially viable product candidates or will provide us with any competitive advantages; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that our commercial activities or product candidates will not infringe upon the patents of others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we cannot ensure that we will be able to successfully commercialize our product candidates on a substantial scale, if approved, before our relevant patents that we own or license expire; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may not develop additional proprietary technologies that are patentable; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the patents of others may harm our business; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Should any of these events occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to commercialization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if any of our current or future product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunity for any of such product candidates, if approved, may be smaller than we estimate.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If any of our current or future product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current CVD treatments such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl are well-established in the medical community, and physicians may continue to rely on these treatments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Even if VERVE-101, VERVE-201 or any other product candidate we develop meets its safety and efficacy endpoints in clinical trials, we cannot be certain that success in clinical trials will ensure success as a commercial product. For example, in September 2022, AstraZeneca and Ionis Pharmaceuticals, Inc. determined not to advance an antisense oligonucleotide PCSK9 inhibitor dosed once monthly via subcutaneous administration into Phase 3 clinical development for the treatment of hypercholesterolemia following a Phase 2b clinical trial that met its primary endpoint and achieved a statistically significant 62.3% reduction in low density lipoprotein cholesterol, or LDL-C, after 28 weeks compared to</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">placebo on the basis that the results did not meet AstraZeneca&#x2019;s target product profile criteria to invest in a broad Phase 3 development program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may not be successful. If our current or future product candidates do not achieve</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">111</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our current or future product candidates, if approved for commercial sale, will depend on a number of factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the efficacy and potential advantages of such product candidates compared to the advantages and relative risks of alternative treatments; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the effectiveness of sales and marketing efforts; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of treatment in relation to alternative treatments, including any similar biosimilar treatments; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to offer our products, if approved, for sale at competitive prices; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the clinical indications for which the product is approved; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the convenience and ease of administration compared to alternative treatments; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the strength of marketing and distribution support; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing of market introduction of competitive products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the availability of third-party coverage and adequate reimbursement, and patients&#x2019; willingness to pay out of pocket for required co-payments or in the absence of third-party coverage or adequate reimbursement; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any restrictions on the use of our products, if approved, together with other medications. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our assessment of the potential market opportunity for our current or future product candidates is based on industry and market data that we obtained from industry publications, research, surveys and studies conducted by third parties and our analysis of these data, research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Our estimates of the potential market opportunities for our product candidates include a number of key assumptions based on our industry knowledge, industry publications and third-party research, surveys and studies, which may be based on a small sample size and fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions. If any of our assumptions or estimates, or these publications, research, surveys or studies prove to be inaccurate, then the actual market for any of our product candidates may be smaller than we expect, and as a result our revenues from product sales may be limited and it may be more difficult for us to achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We face substantial competition, which may result in others discovering, developing or commercializing products before us or more successfully than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The development and commercialization of new drug or biologic products is highly competitive. It is particularly competitive with respect to new products for CVD, for which the standard of care is well-established. We face competition with respect to our current product candidates, and will face competition with respect to any product candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the treatment of many of the disease indications for which we are developing our product candidates. Some of these competitive products and therapies are based on scientific approaches that are similar to our approach, and others are based on entirely different approaches. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are several approved products for LDL-C lowering or cardiovascular risk reduction, such as statins, ezetimibe, bempedoic acid, lomitapide, mipomersen and icosapent ethyl. There are several approved products that target PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD. Evolocumab, which is a monoclonal antibody, or mAb, marketed as Repatha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by Amgen Inc., is approved by the FDA for the treatment of patients with heterozygous familial hypercholesterolemia, or HeFH, patients with HoFH and patients with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">112</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASCVD. Alirocumab, which is a mAb marketed as PRALUENT</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> by both Sanofi and Regeneron Pharmaceuticals, Inc., or Regeneron, is approved by the FDA for the treatment of patients with ASCVD and for the treatment of patients with primary hyperlipidemia, including HeFH. The approved mAb treatments act through extracellular inhibition of the PCSK9 protein. Inclisiran, which is a small interfering RNA, or siRNA, marketed as Leqvio</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#174;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">by Novartis, is approved in the United States for the treatment of patients with clinical ASCVD or HeFH who require additional lowering of LDL-C and in Europe for the treatment of patients with hypercholesterolemia, including HeFH, or mixed dyslipidemia. Inclisiran acts by inhibiting the synthesis of PCSK9 within liver cells, which is distinct from extracellular protein inhibition. We are also aware of three orally administered small molecule product candidates that target the PCSK9 protein as a mechanism to lower LDL-C and reduce the risk of ASCVD in various stages of clinical development. These include MK-0616 from Merck &amp; Co., Inc, which was studied in a recently completed Phase 2b trial of adult patients with hypercholesterolemia with a plan to release results in the first quarter of 2023; an oral small molecule from Serometrix LLC in-licensed by Esperion Therapeutics, which disclosed plans in 2022 to submit an IND in late 2024 or early 2025; and AZD0780, acquired by AstraZeneca from Dogma Therapeutics, which is being evaluated in an ongoing Phase 1 clinical trial.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are aware of two other gene editing programs targeting the PCSK9 gene in preclinical development. Precision Biosciences, Inc., or Precision, has published preclinical data showing long-term stable reduction of PCSK9 and LDL-C levels in non-human primates following </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing of the PCSK9 gene using its gene editing platform. In September 2021, Precision entered into a collaboration with iECURE under which iECURE plans to advance Precision's PCSK9 directed nuclease product candidate into Phase 1 clinical trials for the treatment of FH in 2022. In January 2023, Precision announced that it had decided to cease pursuit of this program with iECURE as a partner, with plans to provide additional guidance on whether and when this medicine will advance into clinical testing in the future. Additionally, in 2022, CRISPR Therapeutics, or CRISPR, announced CTX330, its research stage </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing program targeting PCSK9.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evinacumab, which is a mAb targeting ANGPTL3 protein that is marketed by Regeneron is approved by the FDA for the treatment of patients with HoFH and has additionally been evaluated in Phase 2 studies of patients with refractory hypercholesterolemia and either ASCVD or HeFH, and severe hypertriglyceridemia. We are aware of several product candidates in clinical development that target ANGPTL3 as a mechanism to lower LDL-C and reduce the risk of ASCVD, including ARO-ANG3, a siRNA targeting ANGPTL3 being evaluated by Arrowhead Pharmaceuticals in Phase 2 clinical trials of patients with HoFH and patients with mixed dyslipidemia. In 2022, Arrowhead announced plans to initiate pivotal Phase 3 studies of ARO-ANG3 in patients with HoFH and patients with HeFH in the second half of 2023. In addition, Eli Lilly and Company is evaluating a siRNA targeting ANGPTL3 protein in a Phase 2 study in adults with mixed dyslipidemia, and in 2022, CRISPR announced CTX310, its gene editing program targeting ANGPTL3, which is in IND-enabling studies with plans for initial patient dosing in 2023.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Several investigational medicines designed to reduce lipoprotein(a), or LP(a), are currently in development. These include pelecarsen, an antisense oligonucleotide licensed by Novartis from Ionis Pharmaceuticals in 2019, which is being evaluated in the Phase 3 Lp(a) HORIZON cardiovascular outcomes study in patients with high Lp(a) and cardiovascular disease, with topline results expected in 2025. Olpasiran is an investigational siRNA medicine targeting LPA licensed by Amgen from Arrowhead Pharmaceuticals, which was recently shown to lower LP(a) concentrations in patients with established ASCVD and high Lp(a) concentrations. The potential for Olpasiran to reduce cardiovascular events in patients with existing ASCVD and high Lp(a) will be evaluated in the OCEAN(a) study, which was initiated in 2022 with plans for study completion in 2026. In addition, SLN360 is an investigational siRNA medicine being developed by Silence Therapeutics plc that is being evaluated in an ongoing Phase 2 study of patients with high Lp(a) concentrations and high risk for ASCVD events, and, in 2022, CRISPR announced CTX320, its research stage </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing program targeting </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">LPA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. If our product candidates achieve marketing approval, we expect that they will be priced at a significant premium to competitive generic products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Many of the companies against which we are competing or against which we may compete in the future have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">113</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Mergers and acquisitions in the pharmaceutical and biotechnology industry may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and distribution agreements with third parties, we may not be successful in commercializing our current and future product candidates if and when they are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We do not have a sales or marketing infrastructure and have no experience as a company with the commercialization of products. To achieve commercial success for any product for which we have obtained marketing approval, we will need to establish a sales, marketing and distribution organization, either ourselves or through collaborations or other arrangements with third parties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the future, we expect to build a sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own sales, marketing and distribution capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Factors that may inhibit our efforts to commercialize our products on our own include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our inability to recruit, train and retain adequate numbers of effective sales, marketing, coverage or reimbursement, customer service, medical affairs and other support personnel; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inability of reimbursement professionals to negotiate arrangements for coverage, formulary access, reimbursement and other acceptance by payors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inability to price our products at a sufficient price point to ensure an adequate and attractive level of profitability; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restricted or closed distribution channels that make it difficult to distribute our products to segments of the patient population; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unforeseen costs and expenses associated with creating an independent sales and marketing organization. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are unable to establish our own sales, marketing and distribution capabilities and we enter into arrangements with third parties to perform these services, our product revenues and our profitability, if any, are likely to be lower than if we were to market, sell and distribute any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales, marketing and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We currently rely, and expect to continue to rely, on CMOs to manufacture our product candidates. If we are unable to enter into such arrangements as expected or if such organizations do not meet our supply requirements, development and/or commercialization of our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently rely, and expect to continue to rely on third parties to manufacture clinical supplies of our product candidates and commercial supplies of our products, if and when approved for marketing by applicable regulatory authorities, as well as for packaging, sterilization, storage, distribution and other production logistics. If we are unable to enter into such arrangements on the terms or timeline we expect, development and/or commercialization of our product candidates may be delayed. If these third parties do not successfully carry out</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">114</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">their contractual duties, meet expected deadlines or manufacture our product candidates in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities to support commercialization of any of our product candidates for which we obtain marketing approval, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements. These facilities may also be affected by catastrophic events, including pandemics, including the ongoing COVID-19 pandemic, terrorist attacks, wars or other armed conflicts, geopolitical tensions, such as the ongoing conflict between Russia and Ukraine, natural disasters, such as floods or fire, or such facilities could face manufacturing issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, including as a result of additional required FDA approvals, and may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our third-party manufacturers will be subject to inspection and approval by the FDA before we can commence the manufacture and sale of any of our product candidates, and thereafter subject to FDA inspection from time to time. Failure by our third-party manufacturers to pass such inspections and otherwise satisfactorily complete the FDA approval regimen with respect to our product candidates may result in regulatory actions such as the issuance of FDA Form 483 notices of observations, warning letters or injunctions or the loss of operating licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We or our third-party manufacturers may also encounter shortages in the raw materials or API necessary to produce our product candidates in the quantities needed for our clinical trials or, if our product candidates are approved, in sufficient quantities for commercialization or to meet an increase in demand, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API, including shortages caused by the purchase of such raw materials or API by our competitors or others. The failure of us or our third-party manufacturers to obtain the raw materials or API necessary to manufacture sufficient quantities of our product candidates may have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party coverage or reimbursement practices or healthcare reform initiatives, which could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#x2019;s determination that use of a product is:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">a covered benefit under its health plan; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">safe, effective and medically necessary; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">appropriate for the specific patient; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">cost-effective; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">neither experimental nor investigational. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States, there is no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford our product candidates, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for our product candidates, if approved, by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize, our product candidates. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require patient out-of-pocket costs that patients find unacceptably high.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or similar regulatory authorities outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There can be no assurance that our product candidates, even if they are approved for sale in the United States or in other countries, will be considered medically reasonable and necessary for a specific indication or cost-effective by third-party payors, or that coverage and an adequate level of reimbursement will be available or that third-party payors&#x2019; reimbursement policies will not adversely affect our ability to sell our product candidates profitably.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our future growth depends, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties that, if they materialize, could harm our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our future profitability will depend, in part, on our ability to commercialize our product candidates in markets outside of the United States. If we commercialize our product candidates in foreign markets, we will be subject to additional risks and uncertainties, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular economies and markets; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements, many of which vary between countries; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">different medical practices and customs in foreign countries affecting acceptance in the marketplace; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tariffs and trade barriers, as well as other governmental controls and trade restrictions; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">other trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or foreign governments; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">116</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">longer accounts receivable collection times; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">longer lead times for shipping; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">workforce uncertainty in countries where labor unrest is common; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">language barriers for technical training; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reduced protection of intellectual property rights in some foreign countries, and related prevalence of biosimilar alternatives to therapeutics; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">foreign currency exchange rate fluctuations and currency controls; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">differing foreign reimbursement landscapes; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">uncertain and potentially inadequate reimbursement of our products; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If risks related to any of these uncertainties materializes, it could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We will face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in human clinical trials, and we will face an even greater risk if we commercially sell any products that we may develop. While we currently have no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">decreased demand for any product candidates or products that we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">termination of clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">injury to our reputation and significant negative media attention; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">withdrawal of clinical trial participants; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">significant costs to defend any related litigation; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">loss of revenue; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reduced resources of our management to pursue our business strategy; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the inability to commercialize any products that we may develop. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently do not hold any clinical trial liability insurance coverage. We may need to obtain insurance coverage as we expand our clinical trials or if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to regulatory approval and other legal compliance matters</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Gene editing is novel and the regulatory landscape that will govern any product candidates we may develop is uncertain and may change. As a result, we cannot predict the time and cost of obtaining regulatory approval, if we receive it at all, for any product candidates we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The regulatory requirements that will govern any novel gene editing product candidates we develop are not entirely clear and may change. Within the broader genetic medicines field, we are aware of a limited number of gene therapy products that have received marketing authorization from the FDA and the EMA. Even with respect to more established products that fit into the categories of gene therapies or cell therapies, the regulatory</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">117</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">landscape is still developing. Regulatory requirements governing gene therapy products and cell therapy products have changed frequently and will likely continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing gene therapy products and cell therapy products. For example, in the United States, the FDA has established the Office of Tissues and Advanced Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. Gene therapy clinical trials may also be subject to review and oversight by an IBC, a local institutional committee that reviews and oversees basic and clinical research conducted at the institution participating in the clinical trial. Although the FDA decides whether individual gene therapy protocols may proceed, the review process and determinations of other reviewing bodies can impede or delay the initiation of a clinical trial, even if the FDA has reviewed the trial and approved its initiation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The same applies in the European Union. In the European Union, the development and evaluation of a gene therapy medicinal product must be considered in the context of the relevant EU guidelines. The EMA may issue new guidelines concerning the development and marketing authorization for gene therapy medicinal products and require that we comply with these new guidelines. Additionally, for advanced therapy medicinal products, a marketing application authorization undergoes review by the EMA&#x2019;s Committee for Advanced Therapies, or CAT, in addition to review by the Committee for Medicinal Products for Human Use, or CHMP. As a result, the procedures and standards applied to gene therapy products and cell therapy products may be applied to any product candidates we may develop, but that remains uncertain at this point.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adverse developments in post-marketing experience or in clinical trials conducted by others of gene therapy products, cell therapy products, or products developed through the application of a base editing or other gene editing technology may cause the FDA, the EMA, and other regulatory bodies to revise the requirements for development or approval of any product candidates we may develop or limit the use of products utilizing base editing technologies, either of which could materially harm our business. In addition, the clinical trial requirements of the FDA, the EMA, and other regulatory authorities and the criteria these regulators use to determine the safety and efficacy of a product candidate vary substantially according to the type, complexity, novelty, and intended use and market of the potential products. The regulatory approval process for novel product candidates such as the product candidates we may develop can be more expensive and take longer than for other, better known, or more extensively studied pharmaceutical or other product candidates. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of products utilizing base editing technology in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays, or other impediments to our research programs or the commercialization of resulting products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The regulatory review committees and advisory groups described above and the new guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies or trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of these treatment candidates, or lead to significant post-approval limitations or restrictions. As we advance our research programs and develop future product candidates, we will be required to consult with these regulatory and advisory groups and to comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of any product candidates we identify and develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Because we are developing product candidates in the field of genetic medicines, a field that includes gene therapy and gene editing, in which there is little clinical experience, there is increased risk that the FDA, the EMA, or other regulatory authorities may not consider the endpoints of our clinical trials to provide clinically meaningful results and that these results may be difficult to analyze.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the regulatory review process, we will need to identify success criteria and endpoints such that the FDA, the EMA, or other regulatory authorities will be able to determine the clinical efficacy and safety profile of any product candidates we may develop. As we are seeking to identify and develop product candidates to treat diseases in which there is no clinical experience using a gene editing approach, there is heightened risk that the FDA, the EMA, or other regulatory authorities may not consider the clinical trial endpoints that we propose to provide clinically meaningful results (reflecting a tangible benefit to patients). In addition, the resulting clinical data and results may be difficult to analyze. Even if the FDA does find our success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoints to a degree of statistical significance. Further, even if we do achieve the pre-specified criteria, we may produce results that are unpredictable or inconsistent with the results of the non-primary endpoints or other relevant data. The FDA also weighs the benefits of a product against its risks, and the FDA may view the efficacy results in the context of safety as not</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">118</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">being supportive of regulatory approval. Other regulatory authorities in the European Union and other countries may make similar comments with respect to these endpoints and data. Any product candidates we may develop will be based on a novel technology that makes it difficult to predict the time and cost of development and of subsequently obtaining regulatory approval. No gene editing therapeutic product has been approved in the United States or in Europe.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we develop, and our ability to generate revenue will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidates we develop and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States and by comparable authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to the various regulatory authorities for each therapeutic indication to establish the biologic product candidate&#x2019;s safety, purity and potency. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved and the specific disease or condition to be treated. Of the large number of products in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. Even if any product candidates we may develop demonstrate safety and efficacy in clinical trials, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA and comparable authorities in other countries have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we develop, the commercial prospects for those product candidates may be harmed and our ability to generate revenues will be materially impaired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Obtaining and maintaining marketing approval or commercialization of our product candidates in the United States does not mean that we will be successful in obtaining marketing approval of our product candidates in other jurisdictions. Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order to market and sell any product candidates we may develop in the European Union and many other foreign jurisdictions, we or our collaborators must obtain separate marketing approvals and comply with numerous and varying local regulatory requirements. The approval procedure varies among countries and can involve</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">119</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We or these third parties may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize our product candidates in any jurisdiction, which would materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. Following protracted negotiations, the United Kingdom left the European Union on January 31, 2020 and European Union rules and regulations ceased to apply to the United Kingdom starting on January 1, 2021. The Medicines and Healthcare products Regulatory Agency, or the MHRA, is now the sole decision maker for marketing authorizations of pharmaceutical products in the United Kingdom, except for Northern Ireland. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the United Kingdom the body of European Union law governing medicinal products that pre-existed before the United Kingdom&#x2019;s withdrawal from the European Union.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since the regulatory framework for pharmaceutical products in the United Kingdom covering the quality, safety, and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales, and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit and the impact the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business. As a result of Brexit, we expect we will need to submit a separate application to the MHRA for marketing approval in the United Kingdom, in addition to any planned marketing authorization applications for the EMA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">marketing approval outside the United States, including tariffs, trade barriers and regulatory requirements;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; foreign</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">currency fluctuations, which could result in increased operating expenses and reduced revenue, and other</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">obligations incident to doing business in another country; and workforce uncertainty in countries where labor</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unrest is more common than in the United States.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may seek certain designations for our product candidates, including Fast Track, Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Priority Review designations in the United States, Innovative Licensing and Access Pathway designation in the United Kingdom, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If a product candidate is intended for the treatment of a serious or life-threatening condition and the product candidate demonstrates the potential to address unmet medical need for this condition, the sponsor may apply to the FDA for Fast Track designation. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#x2019;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, an applicant may seek designation of its product as a breakthrough therapy, which is a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, a product is eligible for Regenerative Medicine Advanced Therapy, or RMAT, designation if it is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of an RMAT designation are similar to a breakthrough therapy designation, and include early interactions with the FDA to expedite development and review, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, if the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may seek these and other designations for our product candidates. The FDA has broad discretion with respect to whether or not to grant these designations to a product candidate, so even if we believe a particular product candidate is eligible for such designation or status, the FDA may decide not to grant it. Moreover, a Fast Track, breakthrough therapy, or RMAT designation does not necessarily mean a faster regulatory review process or necessarily confer any advantage with respect to approval compared to conventional FDA procedures. As a result, while we may seek and receive these designations for our product candidates, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In addition, the FDA may withdraw these designations if it believes that the designation is no longer supported by data from our clinical development program.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the European Union, we may seek PRIME designation for some of our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA&#x2019;s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the European Union or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the European Union and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME also encourages an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA&#x2019;s grant of a marketing authorization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may equally pursue some of the post-Brexit UK MHRA procedures to prioritize access to new medicines that will benefit patients, such as a 150-day assessment, a rolling review procedure and an innovative licensing and access pathway, or ILAP. ILAP aims to accelerate the time to market and to facilitate patient access to medicines, including new chemical entities, biological medicines, new indications and repurposed medicines. We received our innovation passport, which is the point of entry into the ILAP, from the MHRA on February 14, 2023. Product developers that benefit from ILAP will be provided with advice on clinical trial design to ensure optimal data generation for both regulatory approval and health technology appraisal.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We may not be able to obtain orphan drug exclusivity for any product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. A similar regulatory scheme governs approval of orphan products by the EMA in the European Union. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">121</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States and ten years in the European Union. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation, in particular if the product is sufficiently profitable so that market exclusivity is no longer justified.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In particular, the concept of what constitutes the &#x201c;same drug&#x201d; for purposes of orphan drug exclusivity remains in flux in the context of gene therapies, and the FDA has issued recent final guidance suggesting that it would not consider two genetic medicine products to be different drugs solely based on minor differences in the transgenes or vectors. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA concludes that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2017, the Congress passed the FDA Reauthorization Act of 2017, or the FDARA. FDARA, among other things, codified the FDA&#x2019;s pre-existing regulatory interpretation, to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. Under Omnibus legislation signed by President Trump on December 27, 2020, the requirement for a product to show clinical superiority applies to drugs and biologics that received orphan drug designation before enactment of FDARA in 2017, but have not yet been approved or licensed by FDA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA and Congress may further reevaluate the Orphan Drug Act and its regulations and policies. This may be particularly true in light of a decision from the Court of Appeals for the 11th Circuit in September 2021 finding that, for the purpose of determining the scope of exclusivity, the term &#x201c;same disease or condition&#x201d; means the designated &#x201c;rare disease or condition&#x201d; and could not be interpreted by the FDA to mean the &#x201c;indication or use.&#x201d; Thus, the court concluded, orphan drug exclusivity applies to the entire designated disease or condition rather than the &#x201c;indication or use.&#x201d; Although there have been legislative proposals to overrule this decision, they have not been enacted into law. On January 23, 2023, the FDA announced that, in matters beyond the scope of that court order, the FDA will continue to apply its existing regulations tying orphan-drug exclusivity to the uses or indications for which the orphan drug was approved. Depending on what changes the FDA or Congress may make to its orphan drug regulations and policies, our business could be adversely impacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Negative public opinion of gene editing and increased regulatory scrutiny of gene editing and genetic research may adversely impact public perception of our future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our potential therapeutic products involve introducing genetic material into patients&#x2019; cells. The clinical and commercial success of our potential products will depend in part on public acceptance of the use of gene editing and gene regulation for the prevention or treatment of human diseases. Public attitudes may be influenced by claims that gene editing and gene regulation are unsafe, unethical or immoral, and, consequently, our products may not gain the acceptance of the public or the medical community. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians prescribing, and their patients being willing to receive, treatments that involve the use of product candidates we may develop in lieu of, or in addition to, existing treatments with which they are already familiar and for which greater clinical data may be available.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">More restrictive government regulations or negative public opinion would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of our product candidates or demand for any products once approved. For example, in 2003, trials using early versions of murine gamma-retroviral vectors, which integrate with, and thereby alter, the host cell&#x2019;s DNA, have led to several well-publicized adverse events, including reported cases of leukemia. Adverse events in our clinical trials, even if not ultimately attributable to our product candidates, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates. The risk of cancer remains a concern for gene editing and we cannot</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">122</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">assure that it will not occur in any of our planned or future clinical trials. If any such adverse events occur, commercialization of our product candidates or further advancement of our clinical trials could be halted or delayed, which would have a negative impact on our business and operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Even if we, or any collaborators we may have, obtain marketing approvals for any product candidates we develop, the terms of approvals and ongoing regulation of our products could require the substantial expenditure of resources and may limit how we, or they, manufacture and market our products, which could materially impair our ability to generate revenue.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. For example, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The FDA typically advises that patients treated with genetic medicine undergo follow-up observations for potential adverse events for up to a 15-year period. The holder of an</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to the approved product, product labeling or manufacturing process. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accordingly, assuming we, or any collaborators we may have, receive marketing approval for one or more product candidates we develop, we, and such collaborators, and our and their contract manufacturers will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, and quality control. If we and such collaborators are not able to comply with post-approval regulatory requirements, we and such collaborators could have the marketing approvals for our products withdrawn by regulatory authorities and our, or such collaborators&#x2019;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our business, operating results, financial condition, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any product candidate for which we obtain marketing approval could be subject to restrictions or withdrawal from the market, and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The FDA and other regulatory agencies closely regulate the post-approval marketing and promotion of medicines to ensure that they are marketed only for the approved indications and in accordance with the provisions of the approved labeling. Although physicians may prescribe products for uses not described in the product&#x2019;s labeling, known as off-label uses, in their professional medical judgment, the FDA and other regulatory agencies impose stringent restrictions on manufacturers&#x2019; communications regarding off-label use, and if we market our products, if approved, in a manner inconsistent with their approved labeling, we may be subject to enforcement action for off-label marketing by the FDA and other federal and state enforcement agencies, including the Department of Justice, or DOJ. Violation of the Federal Food, Product, and Cosmetic Act and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may also lead to investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws. In September 2021, the FDA published final regulations that describe the types of evidence that the FDA will consider in determining the intended use of a drug or biologic.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, later discovery of previously unknown problems with our product candidates, manufacturers, or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on such products, manufacturers, or manufacturing processes; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on the labeling or marketing of a medicine; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">restrictions on the distribution or use of a medicine; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">requirements to conduct post-marketing clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">123</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">receipt of warning or untitled letters; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">withdrawal of the medicines from the market; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal to approve pending applications or supplements to approved applications that we submit; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recall of medicines; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fines, restitution, or disgorgement of profits or revenue; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">suspension or withdrawal of marketing approvals; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">suspension of any ongoing clinical trials; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">refusal to permit the import or export of our medicines; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product seizure; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">injunctions or the imposition of civil or criminal penalties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize any product candidates we develop and adversely affect our business, financial condition, results of operations, and prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies&#x2019; operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Separately, in response to the COVID-19 pandemic, a number of companies announced in 2021 receipt of complete response letters due to the FDA&#x2019;s inability to complete required inspections for their applications. Following a period of false starts and temporary suspensions due to the omicron variant, the FDA resumed domestic inspections in February 2022 and indicated that it would conduct foreign inspections beginning in April 2022 on a prioritized basis However, the FDA may not be able to continue its current pace and review timelines could be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">124</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Any relationships we may have with customers, healthcare providers and professionals, and third-party payors, among others, will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to penalties, including criminal sanctions, civil penalties, contractual damages, reputational harm, fines, disgorgement, exclusion from participation in government healthcare programs, curtailment or restricting of our operations, and diminished profits and future earnings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any products for which we are able to obtain marketing approval. Any arrangements we have with healthcare providers, third-party payors and customers will subject us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws and regulations may constrain the business or financial arrangements and relationships through which we conduct clinical research, market, sell and distribute any products for which we obtain marketing approval. These include the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal and state healthcare programs such as Medicare and Medicaid; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the federal civil and criminal false claims laws, including the federal False Claims Act, which can be enforced through civil whistleblower or qui tam actions, and civil monetary penalty laws impose civil and criminal penalties against individuals or entities for knowingly presenting or causing to be presented, to the federal government, claims for payment or approval from Medicare, Medicaid or other government payers that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per-claim penalties; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which prohibits, among other things, knowingly and willfully executing, or attempting to execute, a scheme or artifice to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">HIPAA, as further amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, which imposes certain requirements, including mandatory contractual terms, on covered entities subject to the rule, such as health plans, healthcare clearinghouses and certain healthcare providers, as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security, and transmission of such individually identifiable health information; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the federal transparency requirements under the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report to the Department of Health and Human Services, or HHS, information related to payments and other transfers of value to physicians, as defined by such law, and teaching hospitals and other covered recipients and ownership and investment interests held by physicians and their immediate family members and applicable group purchasing organizations, and, as of January 2022, requires applicable manufacturers to report information regarding payments and other transfers of value provided during the previous year to physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists, anesthesiologist assistants, and certified nurse midwives; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">analogous state laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payers, including private insurers, and certain state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring drug manufacturers to report information related to drug pricing and payments to physicians and other healthcare providers or marketing expenditures and state and local laws that require the registration of sales representatives; and state and foreign laws governing the privacy and security of health information in some circumstances, many of </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">125</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;visibility:hidden;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Efforts to ensure that any business arrangements we have with third parties, and our business generally, will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, disgorgement, contractual damages, reputational harm, and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval and commercialize our product candidates and affect the prices we, or they, may obtain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could, among other things, prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability, or the ability of any collaborators, to profitably sell or commercialize any product candidate for which we, or they, obtain marketing approval. We expect that current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2010, President Obama signed into law the PPACA. In addition, other legislative changes have been proposed and adopted since the PPACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#x2019;s automatic reduction to several government programs. These changes included aggregate reductions to Medicare payments to providers of up to two percent per fiscal year, which went into effect in April 2013 and will remain in effect through 2031. Pursuant to the CARES Act and subsequent legislation, these Medicare sequester reductions were suspended through the end of June 2022 but the full 2% cut resumed thereafter on July 1, 2022. The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since enactment of the PPACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, the Tax Act repealed the &#x201c;individual mandate.&#x201d; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. Further, on December 14, 2018, a U.S. District Court judge in the Northern District of Texas ruled that the individual mandate portion of the PPACA is an essential and inseverable feature of the PPACA, and therefore because the mandate was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. However, on June 17, 2021, the U.S. Supreme Court dismissed the case and sustained the PPACA. Litigation and legislation over the PPACA are likely to continue, with unpredictable and uncertain results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The former Trump presidential administration also took executive actions to undermine or delay implementation of the PPACA, including directing federal agencies with authorities and responsibilities under the PPACA to waive, defer, grant exemptions from, or delay the implementation of any provision of the PPACA that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. On January 28, 2021, however, President Biden revoked those orders and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">126</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">issued a new Executive Order which directs federal agencies to reconsider rules and other policies that limit Americans&#x2019; access to health care, and consider actions that will protect and strengthen that access. Under this Executive Order, federal agencies are directed to re-examine: policies that undermine protections for people with pre-existing conditions, including complications related to COVID-19; demonstrations and waivers under Medicaid and the PPACA that may reduce coverage or undermine the programs, including work requirements; policies that undermine the Health Insurance Marketplace or other markets for health insurance; policies that make it more difficult to enroll in Medicaid and the PPACA; and policies that reduce affordability of coverage or financial assistance, including for dependents. This Executive Order also directs the HHS to create a special enrollment period for the Health Insurance Marketplace in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect that these healthcare reform measures, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. It is also possible that additional governmental action will be taken in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions is subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid. In 2020, President Trump issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations. These regulations include an interim final rule implementing a most favored nation model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, the Centers for Medicare &amp; Medicaid Services, or CMS, issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has been delayed until January 1, 2032 by the Inflation Reduction Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">More recently, on August 16, 2022, the Inflation Reduction Act of 2022, or IRA, was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">127</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond. This provision applies to drug products that have been approved for at least nine years and biologics that have been licensed for 13 years, but it does not apply to drugs and biologics that have been approved for a single rare disease or condition. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#x201c;maximum fair price&#x201d; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product candidates, if approved. In markets outside of the United States and the European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, particularly the countries of the European Union, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are subject to data privacy and protection laws and regulations that apply to the collection, transmission, storage and use of personally-identifying information, which among other things, impose certain requirements relating to the privacy, security and transmission of personal information, including comprehensive regulatory systems in the United States, European Union and United Kingdom. The legislative and regulatory landscape for privacy and data protection continues to evolve in jurisdictions worldwide, and there has been an increasing focus on privacy and data protection issues with the potential to affect our business. Failure to comply with any of these laws and regulations could result in enforcement action against us, including fines, claims for damages by affected individuals, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, financial condition, results of operations or prospects.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">128</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There are numerous U.S. federal and state laws and regulations related to the privacy and security of personal information. In particular, regulations promulgated pursuant to HIPAA establish privacy and security standards that limit the use and disclosure of individually identifiable health information, or protected health information, and require the implementation of administrative, physical and technological safeguards to protect the privacy of protected health information and ensure the confidentiality, integrity and availability of electronic protected health information. Determining whether protected health information has been handled in compliance with applicable privacy standards and our contractual obligations can be complex and may be subject to changing interpretation. These obligations may be applicable to some or all of our business activities now or in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we are unable to properly protect the privacy and security of protected health information, we could be found to have breached certain contracts with our business partners. Further, if we fail to comply with applicable privacy laws, including applicable HIPAA privacy and security standards, we could face civil and criminal penalties. HHS enforcement activity can result in financial liability and reputational harm, and responses to such enforcement activity can consume significant internal resources. In addition, state attorneys general are authorized to bring civil actions seeking either injunctions or damages in response to violations that threaten the privacy of state residents. We cannot be sure how these regulations will be interpreted, enforced or applied to our operations. In addition to the risks associated with enforcement activities and potential contractual liabilities, our ongoing efforts to comply with evolving laws and regulations at the federal and state level may be costly and require ongoing modifications to our policies, procedures and systems.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2018, California passed into law the California Consumer Privacy Act, or the CCPA, which took effect on January 1, 2020 and imposed many requirements on businesses that process the personal information of California residents. Many of the CCPA&#x2019;s requirements are similar to those found in the General Data Protection Regulation, or the GDPR, including requiring businesses to provide notice to data subjects regarding the information collected about them and how such information is used and shared, and providing data subjects the right to request access to such personal information and, in certain cases, request the erasure of such personal information. The CCPA also affords California residents the right to opt-out of &#x201c;sales&#x201d; of their personal information. The CCPA contains significant penalties for companies that violate its requirements. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023 and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agent-the California Privacy Protection Agency-whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities. In addition, other states, including Virginia, Colorado, Utah and Connecticut, already have passed state privacy laws. Virginia&#x2019;s privacy law also went into effect on January 1, 2023, and the laws in the other three stats will go into effect later in the year. Other states will be considering these laws in the future, and Congress has also been debating passing a federal privacy law. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Similar to the laws in the United States, there are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the European Economic Area, or EEA, and the processing of personal data that takes place in the EEA, is regulated by the GDPR, which went into effect in May 2018 and imposes obligations on companies that operate in our industry with respect to the processing of personal data and the cross-border transfer of such data. The GDPR imposes onerous accountability obligations requiring data controllers and processors to maintain a record of their data processing and policies. If our or our partners&#x2019; or service providers&#x2019; privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to 20 million Euros or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The GDPR places restrictions on the cross-border transfer of personal data from the European Union to countries that have not been found by the European Commission to offer adequate data protection legislation, such as the United States. There are ongoing concerns about the ability of companies to transfer personal data from the European Union to other countries. In July 2020, the Court of Justice of the European Union, or CJEU, invalidated the EU-U.S. Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">129</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">to the United States. The CJEU&#x2019;s decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States. While we were not self-certified under the EU-U.S. Privacy Shield, this CJEU decision may lead to increased scrutiny on data transfers from the EEA to the United States generally and increase our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additionally, in October 2022, President Biden signed an executive order to implement the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework in December 2022. It is unclear if and when the framework will be finalized and whether it will be challenged in court. The uncertainty around this issue may further impact our business operations in the European Union.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Following the withdrawal of the United Kingdom from the European Union, the United Kingdom&#x2019;s Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. In relation to data transfers, both the United Kingdom and the European Union have determined, through separate &#x201c;adequacy&#x201d; decisions, that data transfers between the two jurisdictions are in compliance with the UK&#x2019;s Data Protection Act and the GDPR, respectively. Any changes or updates to these adequacy decisions have the potential to impact our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Beyond GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and the sale and distribution of commercial products, through increased compliance costs, costs associated with contracting and potential enforcement actions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While we continue to address the implications of the recent changes to data privacy regulations, data privacy remains an evolving landscape at both the domestic and international level, with new regulations coming into effect and continued legal challenges, and our efforts to comply with the evolving data protection rules may be unsuccessful. It is possible that these laws may be interpreted and applied in a manner that is inconsistent with our practices. We must devote significant resources to understanding and complying with this changing landscape. Failure to comply with laws regarding data protection would expose us to risk of enforcement actions taken by data protection authorities in the EEA and elsewhere and carries with it the potential for significant penalties if we are found to be non-compliant. Similarly, failure to comply with federal and state laws in the United States regarding privacy and security of personal information could expose us to penalties under such laws. Any such failure to comply with data protection and privacy laws could result in government-imposed fines or orders requiring that we change our practices, claims for damages or other liabilities, regulatory investigations and enforcement action, litigation and significant costs for remediation, any of which could adversely affect our business. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are exposed to the risk of fraud or other misconduct by our employees, vendors, consultants and partners, and, for our clinical trials, our principal investigators and CROs. Misconduct by these parties could include intentional failures to comply with FDA regulations or the regulations applicable in the European Union and other jurisdictions, provide accurate information to the FDA, the European Commission, and other regulatory authorities, comply with healthcare fraud and abuse laws and regulations in the United States and abroad, report financial information or data accurately, or disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Such misconduct also could involve the improper use of information obtained in the course of clinical trials or interactions with the FDA or other regulatory authorities, which could result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct applicable to all of our employees, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">130</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, financial condition, results of operations and prospects, including the imposition of significant fines or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are subject to numerous laws and regulations in each jurisdiction outside the United States in which we operate. The creation, implementation and maintenance of international business practices compliance programs is costly and such programs are difficult to enforce, particularly where reliance on third parties is required.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Compliance with the FCPA and other anti-corruption laws potentially applicable to our business is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the compliance with the FCPA and other anti-corruption laws presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also subject to other laws and regulations governing our international operations, including applicable export control laws, economic sanctions on countries and persons, and customs requirements. In addition, various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. Our expansion outside of the United States has required, and will continue to require, us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain drugs and drug candidates outside of the United States, which could limit our growth potential and increase our development costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There is no assurance that we will be completely effective in ensuring our compliance with the FCPA and other applicable anti-corruption, export, sanctions, and customs laws. The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or debarment from government contracting. Violations of these laws, including the FCPA, can result in significant civil and criminal penalties. Indictment alone under the FCPA can lead to suspension of the right to do business with the U.S. government until the pending claims are resolved. Conviction of a violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#x2019;s accounting provisions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">131</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Although we maintain general liability insurance as well as workers&#x2019; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to employee matters and managing growth</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are highly dependent on the research and development, clinical, financial, operational and other business expertise of Sekar Kathiresan, M.D., our chief executive officer, Andrew Ashe, J.D., our president, chief operating officer, and general counsel, Allison Dorval, our chief financial officer, and Andrew Bellinger, M.D., Ph.D., our chief scientific officer and chief medical officer, as well as the other principal members of our management, scientific and clinical teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#x201c;key person&#x201d; insurance for any of our executives or other employees. Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal and sales and marketing personnel will also be critical to our success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. Our success also depends on implementing and maintaining internal controls and the accuracy and timeliness of our financial reporting. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We expect to expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As our development progresses, we expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical, regulatory affairs, manufacturing and quality control and, if any of our product candidates receive marketing approval, sales, marketing and distribution. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities and continue to recruit and train additional</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">132</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Future acquisitions or strategic alliances could disrupt our business and harm our financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may acquire additional businesses, technologies or assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products or product candidates resulting from a strategic alliance or acquisition that may delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure our stockholders that, following any such acquisition, we will achieve the expected synergies to justify the transaction. The risks we face in connection with acquisitions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">diversion of management time and focus from operating our business to addressing acquisition integration challenges; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">coordination of research and development efforts; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">retention of key employees from the acquired company; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">changes in relationships with collaborators as a result of product acquisitions or strategic positioning resulting from the acquisition; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">cultural challenges associated with integrating employees from the acquired company into our organization; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the need to implement or improve controls, procedures and policies at a business that prior to the acquisition may have lacked sufficiently effective controls, procedures and policies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">liability for activities of the acquired company before the acquisition, including intellectual property infringement claims, violation of laws, commercial disputes, tax liabilities and other known liabilities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">unanticipated write-offs or charges; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">litigation or other claims in connection with the acquired company, including claims from terminated employees, customers, former stockholders or other third parties. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our failure to address these risks or other problems encountered in connection with our past or future acquisitions or strategic alliances could cause us to fail to realize the anticipated benefits of these transactions, cause us to incur unanticipated liabilities and harm the business generally. There is also a risk that future acquisitions will result in the incurrence of debt, contingent liabilities, amortization expenses or incremental operating expenses, any of which could harm our financial condition or results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our internal information technology systems, or those of our collaborators, vendors or other contractors or consultants, may fail or suffer security breaches, loss of data and other disruptions, which could result in a material disruption of our product development programs, compromise sensitive information related to our business or prevent us from accessing critical information, trigger contractual and legal obligations, potentially exposing us to liability, reputational harm or otherwise adversely affecting our business and financial results.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are dependent upon information technology systems, infrastructure and data to operate our business. In the ordinary course of business, we collect, store and transmit confidential information, including but not limited to intellectual property, proprietary business information and personal information. It is critical that we, our vendors, collaborators or other contractors or consultants, do so in a secure manner to maintain the availability, security, confidentiality, privacy and integrity of such confidential information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Despite the implementation of security measures, our internal information technology systems and those of any collaborators, vendors, contractors or consultants are vulnerable to damage or interruption from computer viruses, computer hackers, malicious code, employee error, theft or misuse, denial-of-service attacks, sophisticated nation-state and nation-state-supported actors, unauthorized access, natural disasters, terrorism, wars or other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">133</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">armed conflict, telecommunication and electrical failures or other compromise. There could be an increase in cybersecurity attacks generally as a result of the ongoing conflict between Russia and Ukraine and the resulting sanctions imposed by the United States and European governments, together with any additional future sanctions or other actions by them.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations or hostile foreign governments or agencies. We cannot guarantee that the measures we have taken to date, and actions we may take in the future, will be sufficient to prevent any future breaches.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent we experience a material system failure, accident, cyber-attack or security breach, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary or confidential information or other disruptions. For example, the loss of clinical trial data from ongoing or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. If we do not allocate and effectively manage the resources necessary to build and sustain the proper technology and cybersecurity infrastructure, we could suffer significant business disruption, including transaction errors, supply chain or manufacturing interruptions, processing inefficiencies, data loss or the loss of or damage to intellectual property or other proprietary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent that any disruption or security breach were to result in a loss of, or damage to, our or our vendors&#x2019;, collaborators&#x2019; or other contractors&#x2019; or consultants&#x2019; data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, including litigation exposure, penalties and fines, we could become the subject of regulatory action or investigation, our competitive position and reputation could be harmed and the further development and commercialization of our product candidates could be delayed. As a result of such an event, we may be in breach of our contractual obligations. Furthermore, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages. Any of the above could have a material adverse effect on our business, financial condition, results of operations or prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The financial exposure from the events referenced above could either not be insured against or not be fully covered through any insurance that we maintain and could have a material adverse effect on our business, financial condition, results of operations or prospects. In addition, we cannot be sure that our existing insurance coverage will continue to be available on acceptable terms or that our insurers will not deny coverage as to any future claim. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages as a result of the events referenced above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Risks related to ownership of our common stock and our status as a public company</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our executive officers, directors and their affiliates, if they choose to act together, will have the ability to significantly influence all matters submitted to stockholders for approval.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our executive officers and directors and their affiliates, in the aggregate, beneficially owned shares representing approximately 21.0% of our common stock as of January 31, 2023. As a result, if these stockholders were to choose to act together, they would effectively be able to significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This concentration of ownership control may:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delay, defer or prevent a change in control; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">entrench our management and board of directors; or </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">134</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">delay or prevent a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provisions in our restated certificate of incorporation and our amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish a classified board of directors such that only one of three classes of directors is elected each year; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">limit the manner in which stockholders can remove directors from our board of directors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">limit who may call stockholder meetings; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a &#x201c;poison pill&#x201d; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our restated certificate of incorporation or amended and restated bylaws. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">An active trading market for our common stock may not continue to develop or be sustained.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our common stock began trading on the Nasdaq Global Select Market on June 17, 2021. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not continue to develop or be sustained. If an active market for our common stock does not continue to develop or is not sustained, it may be difficult for our stockholders to sell their shares without depressing the market price for the shares, or at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analysts will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">135</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The price of our common stock has been volatile and may fluctuate substantially, which could result in substantial losses for our stockholders.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our stock price has been and is likely to continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, our stockholders may not be able to sell their common stock at or above the price they paid for their shares. The market price for our common stock may be influenced by many factors, including:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">timing and results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors or potential collaborators; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">adverse regulatory decisions, including failure to receive regulatory approvals for any of our product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our success in commercializing our product candidates, if and when approved; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments with respect to competitive products or technologies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">regulatory or legal developments in the United States and other countries; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">developments or disputes concerning patent applications, issued patents or other intellectual property or proprietary rights; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the recruitment or departure of key personnel; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the level of expenses related to any of our product candidates or clinical development programs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the results of our efforts to discover, develop, acquire or in-license products, product candidates, technologies, the costs of commercializing any such products and the costs of development of any such product candidates or technologies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">variations in our financial results or the financial results of companies that are perceived to be similar to us; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">sales of common stock by us, our executive officers, directors or principal stockholders, or others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">changes in the structure of healthcare payment systems; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">market conditions in the pharmaceutical and biotechnology sectors; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">general economic, industry and market conditions, such as the impact of the COVID-19 pandemic on our industry and market conditions; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the other factors described in this &#x201c;Risk factors&#x201d; section. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the past, following periods of volatility in the market price of a company&#x2019;s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management&#x2019;s attention and resources. Furthermore, negative public announcements of the results of hearings, motions or other interim proceedings or developments could have a negative effect on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have broad discretion in the use of our cash, cash equivalents, and marketable securities and may not use them effectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our management has broad discretion in the application of our cash, cash equivalents, and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending their use, we may invest these funds in a manner that does not produce income or that loses value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">136</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">A significant portion of our total outstanding shares are eligible to be sold into the market in the near future, which could cause the market price of our common stock to drop significantly, even if our business is doing well.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Persons who were our stockholders prior to our IPO continue to hold a substantial number of shares of our common stock. If such persons sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, certain of our executive officers, directors and stockholders affiliated with our directors have entered or may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our executive officers, directors and stockholders affiliated with our directors also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Moreover, holders of a substantial number of shares of our common stock have rights, subject to specified conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed registration statements on Form S-8 to register all of the shares of common stock that we were able to issue under our equity compensation plans. Shares registered under these registration statements on Form S-8 can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements, and exercise of options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We are an &#x201c;emerging growth company&#x201d; and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are an &#x201c;emerging growth company,&#x201d; or EGC, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an EGC until the end of 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an EGC as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period. For so long as we remain an EGC, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not EGCs. These exemptions include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">reduced disclosure obligations regarding executive compensation; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We cannot predict whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the JOBS Act permits an EGC to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to &#x201c;opt out&#x201d; of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to &#x201c;opt out&#x201d; of such extended transition period or (ii) no longer qualify as an EGC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">137</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a public company, we have incurred and particularly after we are no longer an EGC, we will continue to incur significant legal, accounting and other expenses that we did not previously incur as a private company. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the Nasdaq Global Select Market and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs, particularly as we hire additional financial and accounting employees to meet public company internal control and financial reporting requirements, and will make some activities more time-consuming and costly compared to when we were a private company. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified members of our board of directors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are evaluating these rules and regulations and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to Section 404, we are required to furnish a report by our management on our internal control over financial reporting beginning with our filing of this Annual Report on Form 10-K. However, while we remain an EGC, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we are engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, including through hiring additional financial and accounting personnel, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses in our internal control over financial reporting, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be our stockholders' sole source of gain.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be our stockholders' sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our restated certificate of incorporation designates the Court of Chancery of the State of Delaware and the federal district courts of the United States of America as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers and employees.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">138</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; or </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.287%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.287%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">any action asserting a claim arising pursuant to any provision of our restated certificate of incorporation or amended and restated bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any claims arising under the Securities Act. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These exclusive forum provisions may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees. If a court were to find either exclusive forum provision contained in our restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could materially adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General risk factors</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in tax law may adversely affect our business or financial condition. On December 22, 2017, the U.S. government enacted the Tax Act, which significantly reformed the Code. The Tax Act, as amended by the CARES Act, among other things, contains significant changes to corporate taxation, including reducing the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and limiting the deduction for NOLs arising in taxable years beginning after December 31, 2017 to 80% of current year taxable income. In addition, beginning in 2022, the Tax Act eliminates the option to deduct research and development expenditures currently and generally requires corporations to capitalize and amortize them over five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition to the CARES Act, as part of Congress&#x2019; response to the COVID-19 pandemic, economic relief legislation has been enacted in 2020 and 2021 containing tax provisions, and the Inflation Reduction Act, or the IRA, which introduced a number of new tax provisions, was signed into law in August 2022. The IRA in particular imposes a 1% excise tax on certain stock repurchases by publicly traded corporations which generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to a de</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">139</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">minimis exception. Thus, the excise tax could apply to certain transactions that are not traditional stock repurchases. Regulatory guidance under the Tax Act, the IRA and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen their impact on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the Tax Act, the IRA and additional tax legislation. We urge prospective investors in our common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Unfavorable global economic conditions could adversely affect our business, financial condition, stock price and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets and uncertainty about economic stability. The global economy and financial markets may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the sanctions relating to Russia, may also adversely impact the financial markets and the global economy, and the economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for any product candidates we may develop and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could impair our ability to achieve our growth strategy, could harm our financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that our current or future service providers, manufacturers or other collaborators may not survive such difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. We cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1b_unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 1B. Unresolved Staff Comments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 2. Properties.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We currently lease 105,182 square feet of office and laboratory space in Boston, Massachusetts under a lease that expires in December</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2032 with an option to extend for an additional five years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, we entered into a sublease agreement with Beam Therapeutics, Inc. for 11,931 square feet of additional office and laboratory space in Cambridge, Massachusetts. The sublease commenced in December 2021 and expired in December 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 3. Legal Proceedings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are currently not a party to any material legal proceedings.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 4. Mine Safety Disclosures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">140</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART II</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_market_for_registrants_common"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Market information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol &#x201c;VERV&#x201d; since June 16, 2021. Prior to that time, there was no public market for our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Holders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of February 27, 2023, there were approximately 17 holders of record of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Dividends</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and expansion of our business and do not anticipate paying any cash dividends to holders of common stock in the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Performance Graph</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following stock performance graph illustrates a comparison from June 17, 2021 (the date our common stock commenced trading on the Nasdaq Global Select Market) through December 31, 2022, of the total cumulative stockholder return on our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The graph assumes an initial investment of $ 100 on June 17, 2021 at the opening trading price of $19.00 per share, and that all dividends were reinvested, although dividends have not been declared on our common stock. The comparisons in the graph are required by the SEC and are not intended to forecast or be indicative of possible future performance of our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">141</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img243551639_28.jpg" alt="img243551639_28.jpg" style="width:583px;height:446px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The performance graph in this Item 5 is not deemed to be &#x201c;soliciting material&#x201d; or to be &#x201c;filed&#x201d; with the SEC for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities under that Section, and shall not be deemed incorporated by reference into any filing of Verve Therapeutics, Inc. under the Securities Act or the Exchange Act, except to the extent we specifically incorporate it by reference into such a filing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recent sales of unregistered securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the period covered by this Annual Report on Form 10-K, we did not issue any unregistered equity securities other than pursuant to transactions previously disclosed in our Current Reports on Form 8-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Use of proceeds from registered securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On June 21, 2021, we completed our IPO of common stock pursuant to a Registration Statement on Form S-1 (File No. 333-256608), which was declared effective by the SEC on June 16, 2021 and Form S-1 (File No. 333-257158), which was filed pursuant to Rule 462(b) of the Securities Act and was declared effective by the SEC on June 16, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The net offering proceeds to us, after deducting underwriting discounts and offering expenses payable by us of $25.1 million, were $281.6 million. As of December 31, 2022, we had not used any of the net proceeds from the IPO. We have invested the net proceeds from the offering in money market funds and short-term investments. There has been no material change in our planned use of the net proceeds from our IPO as described in our final prospectus, dated June 16, 2021, filed with the SEC pursuant to Rule 424(b).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchases of equity securities by the issuer or affiliated purchasers</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Neither we nor any affiliated purchaser or anyone acting on our behalf or on behalf of an affiliated purchaser made any purchases of shares of our common stock during the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">142</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_selected_financial_data"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 6.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">[Reserved.]</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">143</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7_managements_discussion"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7. Management&#x2019;s Discussion </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and Analysis of Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The following discussion and analysis of our financial condition and results of operations should be read together with our consolidated financial statements and related notes appearing at the end of this Annual Report on Form 10-K, or the Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#x201c;Risk factors&#x201d; section of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, or CVD, transforming treatment from chronic management to single-course gene editing medicines. Despite advances in treatment over the last 50 years, CVD remains the leading cause of death worldwide. The current paradigm of chronic care is fragile&#x2014;requiring rigorous patient adherence, extensive healthcare infrastructure and regular healthcare access&#x2014;and leaves many patients without adequate care. Our goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. Our initial two programs target PCSK9 and ANGPTL3, respectively, genes that have been extensively validated as targets for lowering blood lipids, such as low-density lipoprotein cholesterol, or LDL-C. We believe that editing these genes could potently and durably lower LDL-C throughout the lifetimes of patients with or at risk for atherosclerotic cardiovascular disease, or ASCVD, the most common form of CVD.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our approach leverages multiple breakthroughs in 21st century biomedicine&#x2014;human genetic analysis, gene editing, messenger RNA, or mRNA, -based therapies and lipid nanoparticle, or LNP, delivery&#x2014;to target genes that are predominantly expressed in the liver and disrupt the production of proteins that cause CVD. We are advancing a pipeline of single-course </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes in order to lower blood lipids, thereby reducing the risk of ASCVD. We intend to initially develop these programs for the treatment of patients with familial hypercholesterolemia, or FH, a genetic disease that causes life-long severely elevated blood LDL-C, leading to increased risk of early-onset ASCVD. If our programs are successful in FH, we believe they could also provide a potential treatment for the broader population of patients with established ASCVD. Ultimately, we believe that these treatments could potentially be developed for administration to people at risk for ASCVD as a preventative measure similar to the way that certain vaccines offer long-term protection against infectious diseases.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We were incorporated in March 2018 and commenced operations shortly thereafter. Since our inception, we have devoted substantially all of our resources to building our gene editing and LNP technology and advancing development of our portfolio of programs, establishing and protecting our intellectual property, conducting research and development activities, organizing and staffing our company, business planning, raising capital and providing general and administrative support for these operations. To date, we have financed our operations primarily through the sales of our preferred stock and through the sale of our common stock in our initial public offering, or IPO, our follow-on public offering, and our at-the-market, or ATM, equity offering program, and through our strategic partnership with Vertex Pharmaceuticals Incorporated, or Vertex.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Through December 31, 2022, we had raised an aggregate of $861.6 million in gross proceeds from sales of our preferred and common stock in private placements and common stock in public offerings.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are a clinical-stage company. To date, we have not generated any revenue from product sales and do not expect to generate revenue from the sale of products for the foreseeable future. Since our inception, we have incurred significant operating losses. Our net losses for the years ended December 31, 2022, 2021 and 2020 were $157.4 million, $120.3 million and $45.7 million, respectively. As of December 31, 2022, we had an accumulated deficit of $344.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our total operating expenses were $167.6 million, $87.1 million and $40.6 million for the years ended December 31, 2022, 2021 and 2020, respectively. We expect to continue to incur significant expenses and increasing operating losses in connection with ongoing development activities related to our portfolio of programs as we advance VERVE-101 in our ongoing heart-1 clinical trial; continue our preclinical development of other</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">144</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product candidates; advance these product candidates toward clinical development; further develop base editing and novel gene editing technology, delivery technology and manufacturing capabilities; seek to discover and develop additional product candidates including VERVE-201, our development candidate targeting ANGPTL3; maintain, expand enforcement, defend, and protect our intellectual property portfolio; hire research and development and clinical personnel; ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; establish a commercial manufacturing source and secure supply chain capacity sufficient to provide commercial quantities of any product candidates for which we may obtain regulatory approval; and add operational, legal, compliance, financial and management information systems and personnel to support our research, product development, future commercialization efforts and operations as a public company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As a result, we will need substantial additional funding to support our continuing operations and pursue our strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through a combination of equity offerings, debt financings and other sources of capital, which may include collaborations or licensing arrangements with other companies or other strategic transactions. If we are unable to raise capital or obtain adequate funds when needed or on acceptable terms, we may be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve profitability. Even if we are able to generate revenue from product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of $554.8 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. See &#x201c;Liquidity and capital resources.&#x201d;</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Impact of COVID-19 on our business</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2020, COVID-19 was declared a global pandemic by the World Health Organization and to date, the COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic may directly or indirectly impact our business, results of operations and financial condition will depend on future developments that are highly uncertain, subject to change and difficult to predict. We, our contract manufacturing organizations, or CMOs, and our contract research organizations, or CROs, experienced temporary reductions in the capacity to undertake research-scale production and to execute some preclinical studies. While these operations have since normalized, we, together with our CMOs and CROs, are closely monitoring the impact of the COVID-19 pandemic on these operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We also plan to continue to closely monitor the ongoing impact of the COVID-19 pandemic on our employees and our other business operations. In an effort to provide a safe work environment for our employees, we have, among other things, limited employees in our office and lab facilities to those where on-site presence is needed for their job activities, increased the cadence of sanitization of our office and lab facilities, implemented various social distancing measures in our offices and labs including replacing all in-person meetings with virtual interactions, and are providing personal protective equipment for our employees present in our office and lab facilities. Recently, additional employees have returned to our office and lab facilities in limited capacities. We are continuing to monitor the impact and effects of the COVID-19 pandemic and our response to it, and we expect to continue to take actions as may be required or recommended by government authorities or as we determine are in the best interests of our employees and other business partners in light of the pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and collaboration agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have obligations under various license and collaboration agreements to make potentially significant milestone and success payments in the future and to pay royalties on sales of any product candidates covered by those agreements that eventually achieve regulatory approval and commercialization. For information regarding these agreements, see &#x201c;Business&#x2014;License and collaboration agreements&#x201d; included in Part I, Item 1 of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">145</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Components of our results of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022, we recognized $1.9 million of collaboration revenue. We do not expect to generate any revenue from the sale of products in the near future and unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development expenses consist of costs incurred in performing research and development activities, which include:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost to obtain and maintain licenses to intellectual property, such as those with the President and Fellows of Harvard College, or Harvard, The Broad Institute, Inc., or Broad, Beam Therapeutics Inc., or Beam, Acuitas Therapeutics, Inc., or Acuitas, and Novartis Pharma AG, or Novartis, and related future payments should certain development and regulatory milestones be achieved; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">costs incurred related to the research pursuant to the Vertex Agreement;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">personnel-related expenses, including salaries, bonuses, benefits and stock-based compensation for employees engaged in research and development functions; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">expenses incurred in connection with the discovery, preclinical and clinical development of our research programs, including under agreements with third parties, such as consultants, contractors and CROs; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of developing and validating our manufacturing process for use in our preclinical studies and current and future clinical trials, including the cost of raw materials used in our research and development activities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the cost of laboratory supplies and research materials; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities and insurance. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expense research and development costs as incurred. Nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the benefits are consumed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the early phases of development, our research and development costs are often devoted to proof-of-concept studies that are not necessarily allocable to a specific target; therefore, we have not yet begun tracking our expenses on a program-by-program basis.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, develop additional product candidates, build our manufacturing capabilities, and develop our gene editing and LNP technology. We also expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of, and obtain regulatory approval for, any of our product candidates or programs. The successful development of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with product development, including the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing and progress of preclinical and clinical development activities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the number and scope of preclinical and clinical programs we decide to pursue; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">raising additional funds necessary to complete preclinical and clinical development of our product candidates;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the timing of filing and acceptance of investigational new drug, or IND, applications, or comparable foreign applications that allow commencement of planned and future clinical trials for our product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the successful initiation, enrollment and completion of clinical trials; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">146</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to achieve positive results from our ongoing and future clinical programs that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended patient populations of any product candidates we may develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product candidates for the expected indications and patient populations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to hire and retain key research and development personnel; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the costs associated with the development of any additional product candidates we develop or acquire through collaborations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials and commercial manufacturing, if our product candidates are approved; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the terms and timing of any existing or future collaboration, license or other arrangement, including the terms and timing of any milestone payments thereunder; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to establish and obtain intellectual property protection and regulatory exclusivity for our product candidates and enforce and defend our intellectual property rights and claims; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">our ability to maintain a continued acceptable safety, tolerability and efficacy profile of our product candidates following approval; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">the effects of the COVID-19 pandemic. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A change in any of these variables with respect to any of our current or future product candidates could significantly change the costs, timing and viability associated with the development of that product candidate. We may never succeed in obtaining regulatory approval for any product candidate we may develop.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, intellectual property, business development, and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees for accounting, auditing, tax and consulting services, insurance costs, travel, and direct and allocated facility-related expenses and other operating costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities. We also expect to continue to incur increased costs associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq and Securities and Exchange Commission, or SEC, requirements, director and officer insurance costs, and investor and public relations costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Other income (expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Change in fair value of antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of preferred stock financings and other equity financings, which was fully satisfied upon the closing of our IPO. At the inception of the agreements, the liability for the antidilution rights was recorded at fair value with the cost recorded as research and development expense and were remeasured at each reporting period with changes recorded in other income (expense) while the instruments are outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Change in fair value of success payment liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are also obligated to pay to Harvard and Broad tiered success payments in the event our average market capitalization exceeds specified thresholds ascending from a high nine-digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay any related success payment in cash within a specified period following such event. Otherwise, the success payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock.The remaining potential aggregate success payments that could be payable by us are $25.0 million. At inception of the agreements, the success payment liabilities were recorded at fair value with the cost recorded as research and development expense and are being remeasured at each reporting period with charges recorded in other income (expense) while the instrument is outstanding.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">147</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depending on our valuation, the fair value of the success payment liability, and the corresponding changes in fair value that we record in our statements of operations, could fluctuate significantly from period to period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interest and other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest and other income primarily consisted of interest earned on our marketable securities and other miscellaneous income and expenses unrelated to our core operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income tax</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had federal net operating loss, or NOL, carryforwards of $163.9 million and state NOL carryforwards of $148.0 million. The federal NOL carryforwards have an indefinite life and can be utilized to offset 80% of future taxable income, while the state NOL carryforwards will expire at various dates through 2042. We have recorded a full valuation allowance against our net deferred tax assets due to uncertainties as to their ultimate realization.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Results of operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comparison of years ended December 31, 2022 and 2021</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our results of operations for the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.112%;"></td>
    <td style="width:1.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.814%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.952%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.39%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.952%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,941</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,941</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">130,095</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68,202</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61,893</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37,533</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,865</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,668</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">167,628</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">87,067</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80,561</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other (expense) income:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of antidilution rights liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(25,574</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,574</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of success payment liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,486</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(7,815</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,301</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,867</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">142</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,725</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,353</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(33,247</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">41,600</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(157,334</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(120,314</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(37,020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(53</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(53</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(157,387</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(120,314</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(37,073</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">148</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Collaboration Revenue</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration revenue was $1.9 million for the year ended December 31, 2022, all of which related to research services performed under the Vertex Agreement. We did not record any revenue for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:2.267%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our research and development expenses for the years ended December 31, 2022 and 2021:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.052%;"></td>
    <td style="width:1.392%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.752%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.392%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.010000000000002%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.392%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.010000000000002%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee-related expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">46,439</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19,859</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,580</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">External expenses associated with preclinical studies performed by outside consultants, including third-party CROs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,952</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17,681</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,271</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Raw material costs and external expenses associated with manufacturing activities, including third-party CMOs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,584</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,628</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,956</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lab supplies</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,883</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,630</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,253</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Facility-related costs (including depreciation)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,486</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,583</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,903</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and milestone payments</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,515</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,031</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,484</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Clinical trial costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,037</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,037</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other research and development costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,199</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,790</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,409</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">130,095</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68,202</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">61,893</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development expenses were $130.1 million for the year ended December 31, 2022, compared to $68.2 million for the year ended December 31, 2021. The increase of $61.9 million was primarily due to the growth in our research and development organization to support the advancement of our pipeline and included the following:</span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in personnel-related costs of $26.6 million, including an increase in stock-based compensation of $8.7 million, driven by an increase in headcount of employees involved in research and development activities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in external expenses associated with preclinical studies (primarily animal-study costs) performed by outside consulting services, including third-party CROs, of $9.3 million; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in raw material costs and external expenses associated with developing and validating our manufacturing activities, including third-party CMOs, for use in our preclinical studies and clinical trial of $4.0 million;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in lab supplies of $7.3  million due to the increased investment in research and development activities in 2022; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in facility-related costs (including depreciation) and other allocated expenses of $6.9 million due to increased investment in research and development as well as additional space leased at 201 Brookline Avenue; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in research and development expense attributed to license and milestone payments of $2.5 million in 2022;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in clinical trial costs of $3.0 million associated with our heart-1 clinical trial, a Phase 1b clinical trial of VERVE-101; and</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in other research and development costs of approximately $2.3 million, primarily due to an increase in software, IT, and other miscellaneous charges.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We expect that our research and development expenses will continue to increase for the foreseeable future as we advance our programs and product candidates into and through clinical development, and as we continue to develop additional product candidates and invest in our technology and manufacturing capabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">149</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">General and administrative expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative expenses were $37.5 million for the year ended December 31, 2022, compared to $18.9 million for the year ended December 31, 2021. The increase of $18.7 million was primarily attributable to the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase of $12.9 million in personnel, facility and other expenses, including an increase in stock-based compensation of $6.7 million, resulting from an increase in headcount to support our growth; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase of $3.8 million in legal and professional service fees, primarily due to increased professional fees for audit, tax and consulting services; and</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">an increase in other expenses of approximately $2.0 million, including increased insurance expense of $1.3 million for our directors and officers insurance policy and increases in software, IT and other miscellaneous charges.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We anticipate that our general and administrative expenses will increase in the future to support increased research and development activities.</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Other income (expense)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Change in fair value of antidilution rights liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The increase of $25.6 million in fair value of the antidilution rights liability was primarily due to the settlement of the liability during the year ended December 31, 2021 with the issuance of 878,098 shares of our common stock. The settlement amount was $32.5 million and resulted in a fair value adjustment to the antidilution rights liability of $25.6 million due to an increase in the fair value of the shares being issued upon settlement. As the antidilution rights liability was partially satisfied in 2019 and 2020 and was satisfied in full in June 2021 upon the closing of our IPO, there was no further adjustment during the year ended December 31, 2022.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Change in fair value of success payments liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The increase of $9.3 million in fair value of the success payments liability was primarily attributable to the decrease in the fair value of our common stock which resulted in a fair value adjustment of $1.5 million to other expense during the year ended December 31, 2022. During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts due to Harvard and Broad totaled $6.3 million. These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The remaining success payment obligations will continue to be revalued at the end of each reporting period.</span></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Interest and other income (expense), net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The increase of $6.7 million in interest and other income (expense) for the year ended December 31, 2022 was primarily attributable to increasing interest rates on our higher marketable securities balances.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A discussion of changes in our results of operations during the year ended December 31, 2021 compared to the year ended December 31, 2020 has been omitted from this Annual Report on Form 10-K but may be found in &#x201c;Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022, which discussion is incorporated herein by reference and which is available free of charge on the SEC's website at www.sec.gov.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liquidity and capital resources</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Sources of liquidity and capital</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since our inception in 2018, we have incurred significant operating losses. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the preclinical and clinical development of our programs. To date, we have funded our operations primarily through equity offerings. Through December 31, 2022, we had raised an aggregate of $861.6 million in gross proceeds from sales of our preferred stock and common stock in private placements and common stock in our IPO, our follow-on public offering, and our ATM equity offering program. As of December 31, 2022, we had $554.8 million in cash, cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">150</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, we completed our IPO in which we issued 16,141,157 shares of common stock, including 2,105,368 shares of common stock sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a public offering price of $19.00 per share. We received net proceeds from our IPO of $281.6 million, after deducting underwriting discounts and offering expenses payable by us. In June 2021, we issued 878,098 shares of our common stock to Harvard and Broad as final settlement of the antidilution rights liability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 20, 2022, we received $25.0 million as an upfront payment from Vertex pursuant to the Vertex Agreement. Additionally, on July 20, 2022, we sold and issued 1,519,756 shares of our common stock to Vertex at a price of $23.03 per share for an aggregate purchase price of $35.0 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 25, 2022, we issued and sold 9,583,334 shares of our common stock, including 1,250,000 shares of common stock sold pursuant to the underwriters&#x2019; full exercise of their option to purchase additional shares of common stock, at a public offering price of $27.00 per share, for aggregate net proceeds of approximately $242.9 million after deducting underwriting discounts and offering expenses of approximately $15.9 million payable by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, we entered into the Sales Agreement with Jefferies pursuant to which we are entitled to offer and sell, from time to time at prevailing market rates, shares of our common stock. We agreed to pay Jefferies a commission of up to 3.0% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. Any sales under the Sales Agreement will be made pursuant to our registration statement on Form S-3 (File No 333-267578), which became effective on September 23, 2022, with an aggregate offering price of up to $200.0 million. During the year ended December 31, 2022, we sold 1,280,168 shares of common stock under the Sales Agreement for aggregate net proceeds of $42.9 million, after deducting commissions and offering expenses payable by us.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes our sources and uses of cash for each period presented:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.756%;"></td>
    <td style="width:1.611%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.941999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.611%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.079999999999998%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(122,332</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(77,880</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash used in investing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(155,955</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(239,098</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">328,956</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">377,089</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50,669</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">60,111</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.267%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Operating activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022, net cash used in operating activities was $122.3 million, consisting primarily of our net loss of $157.4 million, and a decrease attributable to non-cash items of $1.5 million associated with the fair value change in the success payment liability and $1.0 million associated with amortization of investment premiums. These amounts are partially offset by the following non-cash changes: stock-based compensation of $22.5 million, depreciation expense of $2.8 million, non-cash lease expense of $3.9 million, and a net increase in changes in our operating assets and liabilities of $8.4 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2021, net cash used in operating activities was $77.9 million, consisting primarily of our net loss of $120.3 million and a net decrease in our operating assets and liabilities of $2.9 million. These amounts were partially offset by the following non-cash changes: change in fair value of antidilution rights and success payment liabilities of $33.4 million, depreciation expense of $1.5 million, stock-based compensation of $7.1 million, non-cash lease expense of $1.8 million and amortization of premiums on marketable securities of $1.5 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Investing activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022, net cash used in investing activities was $156.0 million, consisting of purchases of marketable securities of $479.4 million and purchases of property and equipment of approximately $13.3 million, primarily related to lab equipment, which amounts were offset partially by maturities of marketable securities of $336.7 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2021, net cash used in investing activities was $239.1 million, consisting of purchases of marketable securities of $371.5 million and purchases of property and equipment of $4.4 million, primarily related to lab equipment, which amounts were offset partially by maturities of marketable securities of $136.8 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">151</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:2.253%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financing activities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2022, net cash provided by financing activities was $329.0 million, consisting primarily of net proceeds from the sale of our common stock of $286.5 million, net proceeds of $40.0 million from the issuance of 1,519,756 shares to Vertex pursuant to the Stock Purchase Agreement in connection with the Vertex Agreement, proceeds from exercises of stock options of $2.2 million and issuance of shares through our employee stock purchase plan of $1.1 million, offset partially by payment of offering expenses of $0.8 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For the year ended December 31, 2021, net cash provided by financing activities was $377.1 million consisting of the net proceeds from the issuance of Series B Preferred Stock of $93.8 million, net proceeds from the sale of our common stock in our IPO of $285.2 million, proceeds from exercises of stock options of $1.0 million and issuance of shares through our employee stock purchase plan of approximately $0.7 million, offset partially by payment of IPO expenses of $3.6 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Funding requirements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our operating expenses and future funding requirements are expected to increase substantially as we continue to advance our portfolio of programs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specifically, our expenses will increase if and as we:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">conduct our ongoing heart-1 clinical trial for VERVE-101 in New Zealand and the United Kingdom, and if our IND application is cleared, in the United States;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue our current research programs and our preclinical development of product candidates;</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek to identify additional research programs and additional product candidates; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">advance our existing and future product candidates into clinical development; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">initiate preclinical studies and clinical trials for any additional product candidates we identify and develop or expand development of existing programs into additional patient populations; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">seek regulatory and marketing approvals for any of our product candidates that we develop; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">perform research services under the Vertex Agreement and seek to identify, establish and maintain additional collaborations and license agreements, and the success of those collaborations and license agreements; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">make milestone payments to Beam under our amended and restated collaboration and license agreement with Beam, or the Beam Agreement, milestone payments to Acuitas under our non-exclusive license agreement with Acuitas, or the Acuitas Agreement,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:line-through;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">milestone payments or success payments to Broad and Harvard under our license agreement with Broad and Harvard (as amended, the Cas9 License Agreement), and milestone payments to Novartis under our license agreement with Novartis, or the Novartis Agreement, and potential payments to other third parties under our other collaboration agreements or any additional future collaboration or license agreements that we obtain; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ultimately establish a sales, marketing, and distribution infrastructure to commercialize any drug products for which we may obtain marketing approval, either by ourselves or in collaboration with others; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">further develop our base editing technology and develop novel gene editing technology; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">hire additional personnel including research and development, clinical and commercial personnel; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">add operational, financial and management information systems and personnel, including personnel to support our product development; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">acquire or in-license products, intellectual property, medicines and technologies; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">satisfy any post-approval marketing requirements, such as a cardiovascular outcomes trial, or CVOT, which we expect will be required for VERVE-101 and VERVE-201; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">establish commercial-scale current good manufacturing practices, or cGMP, capabilities through a third-party or our own manufacturing facility; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">continue to operate as a public company. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, we had cash, cash equivalents and marketable securities of $554.8 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">152</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">and capital expenditure requirements into the second half of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for several years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our expectation with respect to our ability to fund current planned operations is based on estimates that are subject to risks and uncertainties. Our operating plan may change as a result of many factors currently unknown to management and there can be no assurance that the current operating plan will be achieved in the time frame anticipated by us, and we may need to seek additional funds sooner than planned.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not have any source of committed external funds. Market volatility could also adversely impact our ability to access capital as and when needed. Additional capital raised through the sale of equity or convertible debt securities, may include liquidation or other preferences. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making capital expenditures or declaring dividends and may require the issuance of warrants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed or on terms acceptable to us, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Contractual obligations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We lease certain assets under noncancelable operating leases, which expire through 2032. The leases relate primarily to office space and laboratory space. Our aggregate future minimum commitments under these office and laboratory leases were $119.2 million as of December 31, 2022, excluding any related common area maintenance charges or real estate taxes. For additional information regarding these leases, refer to Note 7, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, to our consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We enter into contracts in the normal course of business with CROs, CMOs and other third parties for clinical trials, preclinical research studies and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable by us upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of our service providers, up to the date of cancellation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have also entered into license agreements under which we may be obligated to make certain payments. For example, in November 2021, we paid success payments of approximately $6.3 million to Broad and Harvard that were triggered under the Harvard/Broad License Agreement. If additional success payments are triggered, we would be obligated to pay Broad and Harvard up to an additional $25.0 million under the Harvard/Broad License Agreement. Our agreements to license intellectual property include potential milestone payments that are dependent upon the development of products using the intellectual property licensed under the agreements and contingent upon the achievement of development or regulatory approval milestones, as well as commercial and success payment milestones. Such payment obligations are contingent upon the occurrence of future events and the timing and likelihood of such potential obligations are not known. For additional information about our license agreements and amounts that could become payable in the future under such agreements, see &#x201c;Business&#x2014;License and collaboration agreements&#x201d; and Note 8, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">License agreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, to our consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Emerging growth company status</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an IPO, an exemption</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">153</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">from the requirement to provide an auditor&#x2019;s report on internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We may remain classified as an EGC until the end of the fiscal year ended December 31, 2026, although if the market value of our common stock that is held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have annual gross revenues of $1.07 billion or more in any fiscal year, we would cease to be an emerging growth company as of December 31 of the applicable year. We also would cease to be an EGC if we issue more than $1 billion of non-convertible debt over a three-year period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Critical accounting policies and significant judgments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This management&#x2019;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which we have prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements and related disclosures requires us to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">While our significant accounting policies are described in more detail in Note 2, Summary of significant accounting policies, to our consolidated financial statements, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">revenue recognition</span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">accrued research and development expenses; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">stock-based compensation and common stock valuation; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">fair value measurements. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We enter into collaboration agreements which are within the scope of Accounting Standards Codification, or ASC, Topic 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, or ASC 606, under which we license rights to certain of our product candidates and perform research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, we perform the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) we satisfy each performance obligation. We only apply the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">154</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The promised goods or services in our arrangements typically consist of license rights to our intellectual property and research and development services. We provide options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. We evaluate the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, we consider factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We estimate the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, we evaluate the number of potential payments and the likelihood that the payments will be received. We utilize either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within our control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, we have not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of our collaboration arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, we have not recognized any consideration related to sales-based royalty revenue resulting from any of our collaboration arrangements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We allocate the transaction price based on the estimated stand-alone selling price of each of the performance obligations. We must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. We utilize key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, we utilize comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts we would expect to receive for the satisfaction of each performance obligation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, we utilize judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. We evaluate the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until we perform our obligations under these arrangements. Amounts are recorded as accounts receivable when our right to consideration is unconditional.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">155</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Accrued research and development expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of the process of preparing our consolidated financial statements, we are required to estimate certain accrued research and development expenses. This process involves estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of the estimates with the service providers and make adjustments if necessary. Examples of estimated accrued research and development expenses include those related to fees paid to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">vendors in connection with discovery and preclinical development activities; </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CROs in connection with clinical trials, preclinical studies and testing; and </span></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:4.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:2.269%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:2.269%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CMOs in connection with the process development and scale up activities and the production of materials. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We base the expense recorded related to contract research and manufacturing on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CROs and CMOs that conduct services and supply materials. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment flows. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses. While the majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; some require advance payments. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. We record these as prepaid expenses on our consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We measure stock options and other stock-based awards granted to employees, directors, consultants or founders based upon their fair value on the date of the grant and recognize stock-based compensation expense over the requisite service period, which is generally the vesting period of the respective award. We recognize forfeitures as they occur.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The stock-based compensation awards are subject to either service or performance-based vesting conditions. We apply the straight-line method of expense recognition to all awards with service-based vesting and recognize stock-based compensation for performance awards based on grant date fair value over the service period using the accelerated attribution method to the extent achievement of the performance condition is probable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We estimate the fair value of each stock option grant on the date of grant using the Black-Scholes option-pricing model, which uses inputs such as the fair value of our common stock, assumptions we make for the volatility of our common stock, the expected term of our stock options, the risk-fee interest rate for a period that approximates the expected term of our stock options and our expected dividend yield. The fair value of our common stock is used to determine the fair value of restricted stock awards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We estimate the fair value of restricted stock unit awards on the date of grant using the closing price of our common stock on that date.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to our IPO in June 2021, there was no public market for our common stock. As a result, prior to our IPO, the estimated fair value of our common stock was determined by our board of directors as of the date of each option grant, with input from management, considering our most recently available third-party valuations of common stock and our board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following our IPO, the fair value of our common stock is determined based on the quoted market price of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">156</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair value measurements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Success payments liability</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are required to make success payments to Harvard and Broad in the event our average market capitalization, since the filing of our first Quarterly Report on Form 10-Q, exceeds specified thresholds ascending from a high nine digit dollar amount to $10.0 billion, or sale of our company for consideration in excess of those thresholds. In the event of a change of control of our company or a sale of our company, we are required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at our option in either cash or shares of our common stock, or a combination of cash and shares of our common stock. The success payments are accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, and were initially recorded at fair value with a corresponding charge to research and development expense. Any subsequent changes in fair value are recognized in other income (expense) in the statement of operations. We will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the success payment obligation. To determine the estimated fair value of the success payments, we used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">See Note 2, &#x201c;Summary of significant accounting policies &#x2013; Recently issued accounting pronouncements&#x201d; in the accompanying notes to our consolidated financial statements included at the end of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_7a_quantitative_and_qualitative"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 7A. Quantitative and Qualitative Disclosures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest rate risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are exposed to market risk related to changes in interest rates. As of December 31, 2022, we had cash and cash equivalents of $115.4 million, which consisted of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. In addition, as of December 31, 2022, we had marketable securities of $439.4 million, which consist of U.S. treasury securities and agency securities. Interest income is sensitive to change in the general level of interest rates, however, due to the short-term maturities of our cash equivalents and the low risk profile of our marketable securities, an immediate 10% change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign currency exchange risk</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we do contract with vendors that are located outside of the United States and may be subject to fluctuations in foreign currency rates. We may enter into additional contracts with vendors located outside of the United States in the future, which may increase our foreign currency exchange risk.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inflation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inflation generally affects us by increasing our cost of labor and target development costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December 31, 2022.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">157</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_8_financial_statements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 8. Financial Statements and Supplementary Data.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The financial statements required pursuant to Item 8 are incorporated by reference herein from the applicable information included in Item 15 of this Annual Report on Form 10-K and are presented beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9_changes_in_and_disagreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9. Changes in and Disagreements</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> With Accountants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9a_controls_and_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9A. Controls and Procedures</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act as of the end of the period covered by this annual report. Based on such evaluation, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Management&#x2019;s Annual Report on Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our principal executive and principal financial officer to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of December 31, 2022. Management based its assessment on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Attestation Report of the Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This annual report does not include an attestation report of our registered public accounting firm due to an exemption provided by the JOBS Act for &#x201c;emerging growth companies.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Changes in Internal Control Over Financial Reporting</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x2011;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15(f) under the Exchange Act) during the three months ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9b_other_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9B. Other Information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_9c_disclosure_regarding"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 9C. Disclosure Re</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">garding Foreign Jurisdictions that Prevent Inspections.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">159</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART III</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_officers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 10. Directors, Executive Officers a</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">nd Corporate Governance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 10 will be included in the sections titled &#x201c;Proposal No. 1&#x2014;Election of Class II Directors,&#x201d; &#x201c;Corporate Governance&#x2014;Code of business conduct and ethics,&#x201d; &#x201c;Corporate Governance&#x2014;Board committees,&#x201d; &#x201c;Corporate Governance&#x2014;Compensation committee interlocks and insider participation,&#x201d; and &#x201c;Delinquent Section 16(a) Reports&#x201d; (if applicable) in our definitive proxy statement to be filed with the Securities and Exchange Commission, or SEC, with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have adopted a written code of business conduct and ethics, or Code, that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the Code is available on the investor section of our website at investors.vervetx.com. We intend to disclose on our website any amendments to, or waivers from, our Code that are required to be disclosed pursuant to SEC rules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 11. Executive Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 11 will be included in the section titled &#x201c;Executive and Director Compensation&#x201d; in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and, other than the information disclosed pursuant to Item 402(v) of Regulation S-K, if required, is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_of_certain"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 12. Security Ownership of Certain</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Beneficial Owners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 12 will be included in the sections titled &#x201c;Executive and Director Compensation&#x2014;Equity compensation plan information&#x201d; and &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 13. Certain Relationships and Related </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Transactions, and Director Independence.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 13 will be included in the sections titled &#x201c;Transactions with Related Persons&#x201d; and &#x201c;Corporate Governance&#x2014;Director independence&#x201d; in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accounting_fees"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 14. Principal Accounting Fees</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and Services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information required by this Item 14 will be included in the section titled &#x201c;Proposal No. 2&#x2014;Ratification of Independent Registered Public Accounting Firm&#x201d; in our definitive proxy statement to be filed with the SEC with respect to our 2023 Annual Meeting of Stockholders and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">160</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">PART IV</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits_financial_statement"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 15. Exhibits, Financial Statement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Schedules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The financial statements of Verve Therapeutics, Inc., together with the report thereon of Ernst &amp; Young LLP, an independent registered public accounting firm (PCAOB ID: 00</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_64beefc9-e5a1-4446-99bf-deceffe645ac" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">42</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">), are included in this Annual Report on Form 10-K beginning on page F-1.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial Statement Schedules.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial statement schedules have been omitted because they are either not required or not applicable or the information is included in the consolidated financial statements or the notes thereto.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.992%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:87.004%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521195234/d188013dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restated Certificate of Incorporation of the Registrant, effective as of June 21, 2021 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K, File No. 001-40489, filed June 21, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312523041486/d447068dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second Amended and Restated Bylaws of the Registrant, effective as of February 14, 2023 (incorporated by reference to exhibit 3.1 to the Registrant's Current Report on Form 8-K, File No. 001-40489, Filed February 17, 2023.)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex41.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, File No. 333-256608, filed May 28,2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex101.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second Amended and Restated Investors&#x2019; Rights Agreement, dated as of January 14, 2021, by and among the Registrant and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022003499/verv-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Description of Securities Registered under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.3 to the Registrant's Annual Report on Form 10-K, filed on March 14, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex102.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex103.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Stock Option Agreement under the 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex104.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022003499/verv-ex10_4.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Stock Option Agreement under the 2021 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant's Annual Report on Form 10-K, filed on March 14, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_5.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of Restricted Stock Unit Agreement under the 2021 Stock Incentive Plan</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex107.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated 2021 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.7*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_7.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Summary of Non-Employee Director Compensation Program</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.8&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022022324/verv-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Collaboration and License Agreement, dated as of July 5, 2022, by and between the Registrant and Beam Therapeutics, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q, filed on November 7, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.9&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1010.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amended and Restated Development and Option Agreement, dated as of October 6, 2020, by and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">between the Registrant and Acuitas Therapeutics, Inc. (incorporated by reference to Exhibit 10.10 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.10&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1011.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-Exclusive License Agreement, dated as of October 14, 2020, by and between the Registrant and Acuitas Therapeutics, Inc. (incorporated by reference to Exhibit 10.11 to the Registrant&#x2019;s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">161</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.992%;"></td>
    <td style="width:2.004%;"></td>
    <td style="width:87.004%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.11&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1012.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cas9 License Agreement, dated as of March 15, 2019, by and among the Registrant, The President and Fellows of Harvard College and The Broad Institute, Inc., as amended (incorporated by reference to Exhibit 10.12 to the Registrant&#x2019;s Registration Statement on Form S-1, File</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.12&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022022324/verv-ex10_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Strategic Collaboration and License Agreement, dated as of July 18, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (incorporated by reference to Exhibit 10.3 to the Registrant's Quarterly Report on Form 10-Q, filed on November 7, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.13</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017021003894/verv-ex10_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease, dated as of August 19, 2021, by and between the Registrant and ARE-MA Region No. 87</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Tenant, LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Quarterly Report on Form 10-Q, filed on November 10, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.14</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022003499/verv-ex10_14.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">First Amendment to Lease, dated as of January 4, 2022, by and between the Registrant and ARE-MA Region No. 87 Tenant, LLC (incorporated by reference to Exhibit 10.14 to the Registrant's Annual Report on Form 10-K, filed on March 14, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.15</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022015737/verv-ex10_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second Amendment to Lease, dated as of June 17, 2022, by and between the Registrant and ARE-MA Region No, 87 Tenant, LLC (incorporated by reference to Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q, filed on August 9, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.16#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex1017.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Form of indemnification agreement between the Registrant and each of its executive officers and</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">directors (incorporated by reference to Exhibit 10.17 to the Registrant&#x2019;s Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.17#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1018.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Sekar Kathiresan, M.D. (incorporated by reference to Exhibit 10.18 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.18#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1019.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Ashe, J.D. (incorporated by reference to Exhibit 10.19 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.19#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521189442/d140009dex1020.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employment Agreement, dated as of June 11, 2021, between the Registrant and Andrew Bellinger, M.D., Ph.D. (incorporated by reference to Exhibit 10.20 to the Registrant&#x2019;s Amendment No. 1 to Registration Statement on Form S-1, File No. 333-256608, filed June 14, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.20#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000095017022003499/verv-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employment Agreement, dated as of November 26, 2021, between the Registrant and Allison Dorval (incorporated by reference to Exhibit 10.19 to the Registrant's Annual Report on Form 10-K, filed on March 14, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312522187258/d370551dex12.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Open Market Sale Agreement</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">SM</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">,dated as of July 1, 2022, by and between the Registrant and Jefferies LLC (incorporated by reference to Exhibit 1.2 to the Registrant&#x2019;s Registration Statement on Form S-3, File No. 333-265996, filed on July 1, 2022)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.22*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex10_22.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock Purchase Agreement, dated as of July 18, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1840574/000119312521176910/d140009dex211.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#x2019;s</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Statement on Form S-1, File No. 333-256608, filed May 28, 2021)</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32.2**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="verv-ex32_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Instance Document &#x2013; the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">162</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.5pt solid;margin-right:80.0%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">** Furnished herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#134; Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"># Indicates management contract or compensatory plan.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_form_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Item 16. Form 10-K Summary</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">163</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.387%;"></td>
    <td style="width:2.698%;"></td>
    <td style="width:5.536%;"></td>
    <td style="width:46.379%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">VERVE THERAPEUTICS, INC.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date: March 2, 2023</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Sekar Kathiresan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sekar Kathiresan</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Executive Officer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Principal Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.472%;"></td>
    <td style="width:1.538%;"></td>
    <td style="width:16.677%;"></td>
    <td style="width:1.538%;"></td>
    <td style="width:31.776%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Name</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Title</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Sekar Kathiresan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Chief Executive Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sekar Kathiresan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;(Principal Executive Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Allison Dorval</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Chief Financial Officer</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Allison Dorval</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;(Principal Financial Officer and Principal Accounting Officer)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Burt Adelman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Burt Adelman</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Lonnel Coats</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lonnel Coats</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Alexander Cumbo</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Alexander Cumbo</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Michael MacLean</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Michael MacLean</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Sheila Mikhail</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sheila Mikhail</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:4.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Krishna Yeshwant</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(255,255,255,0.01);padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;Director</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Krishna Yeshwant</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">164</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:92.321%;"></td>
    <td style="width:7.679%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Page</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Audited Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_of_independent_registered_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Report of independent registered public accounting firm (PCAOB ID No. 0042)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated balance sheets</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmts_of_opr_and_comp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated statements of operations and comprehensive loss</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmt_of_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated statements of convertible preferred stock and stockholders&#x2019; equity (deficit)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_stmt_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated statements of cash flows</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_cons_financial_stmt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notes to consolidated financial statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.75pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="report_of_independent_registered_"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Report of Indep</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">endent Registered Public Accounting Firm</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the Shareholders and the Board of Directors of Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Opinion on the Financial Statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have audited the accompanying consolidated balance sheets of Verve Therapeutics, Inc. (the Company) as of December 31, 2022 and 2021, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders&#x2019; equity (deficit) and cash flows for each of the three years in the period ended December 31, 2022, and the related notes (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2022, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adoption of ASU No. 2016-02</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2021 due to the adoption of Accounting Standards Update (ASU) No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Topic 842), and the related amendments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basis for Opinion</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#x2019;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1030352e-bfef-4404-b077-c54e8b4c6d00" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Ernst &amp; Young LLP</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We have served as the Company&#x2019;s auditor since 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_2a058221-4ceb-4fe1-b951-0fd7e2d49233" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</span></p>
  <p style="text-indent:-2.319%;padding-left:2.267%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated balance sheets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.756%;"></td>
    <td style="width:1.611%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.941999999999998%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.611%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.079999999999998%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current assets:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9851625f-c0f9-4110-985a-89fe6da298d8" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,412</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f54d0f4-04e8-4be5-b274-a57139cc9f69" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81b8ccc3-7a44-4ae3-b322-890fdbc02b95" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439,396</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2002c219-7612-43ba-a08d-2c19e5a4860b" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration receivable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_beced71f-2315-4cb6-9273-4235f39b5ed1" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a4d750a7-5824-427e-ad00-64c8ae587ea9" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:CollaborationReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3aded3a2-7dde-4b75-b8d6-827a1a5e1c80" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bf54e838-d295-463b-bf49-2d31d97f7068" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,686</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_947059e9-a760-470b-8c21-b91faa575f2d" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">563,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab2cf234-dd9c-48b7-b9fc-d8b1c7fcb295" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">367,128</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1c9648bd-1cf6-4dbe-916d-d70561288a8c" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,778</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d0ee4a1a-c408-4bfb-8897-68dbb9b85441" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,224</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52012e07-e356-4166-88aa-21e262daf94a" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,824</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6026aa54-01c6-4542-adf2-eae34ed1d162" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease right-of-use assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8199d238-e4c6-4758-becc-3477f6b8858c" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,877</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f18ad4f-cba9-45ff-9a2c-4fb1dc66b729" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,839</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other long term assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6a283ca-cf1f-4170-ba04-7f592bcc02c8" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">585</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_57d721ac-c2dd-4a01-a3a4-8b6f028a60c1" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,696</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dfbaf8c0-e375-402b-9c7b-63f3fea9d0d7" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ccf52e4-0aa6-44d6-8a0a-42255e6e2335" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities, and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6872a8e3-52c9-489f-a218-4feeb1644241" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc1c7b58-63df-43a8-97f9-d1b1e419a654" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e59a86b4-99cb-4edb-b7f0-7416cae4d4cd" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,767</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7ece1c90-a5dd-44fc-bd08-714df10bb8f7" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,992</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease liability, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_529b3c92-9a0a-417f-bbf3-d6ca1487cbdb" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,904</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12127e48-cba2-498c-aa9c-08f297e603fb" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6fee6a0e-e62c-4424-ae3c-e228a1d79059" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_276787d8-3eff-4232-bc7e-bf5a502c69ed" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Long-term lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb31bef9-ecf6-4283-af01-c65f57a8d71e" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd718b82-f599-473f-91b5-1f1f6c681b0f" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3db9d4cb-c1cd-490c-9119-108248281191" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4a9695c0-a4c2-44b9-96ea-e5b6ab90783c" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred revenue, non-current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6d06b2d1-be82-45e6-8732-022b0a2c111a" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredRevenueAndCreditsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_16e89c46-c096-4d76-8afc-fed6bca8d8cc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other long term liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0fe2656e-75f3-4f6d-90d1-657dfe04a93b" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_111b4c10-edf3-419a-b527-33dc384ae144" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_414c6645-8db6-4a1b-bd95-a512c1247d47" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">128,291</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50d9933b-3d1a-4d62-ba9e-6bff97431d0f" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,772</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_ff5d24c9-5ffa-4c7d-adf1-18e4911abf8a;"><span style="-sec-ix-hidden:F_1581fec8-0bf5-40f2-be75-6ab97ee8bb15;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Commitments and contingencies (See Notes 7 and 8)</span></span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3d7b18a6-c8c3-4904-a15e-c2c6eecfe4b4" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_8d593876-ca3e-4123-8634-da6dedb5d8cb" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38676506-7e61-468f-9334-2b7d85864a5a" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_ab45f6db-d2ee-4efa-a319-a38c68b3cf05" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40553e9e-ba05-4393-8912-193018c96a7b" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_615ee81e-3b14-40bc-b662-97ccf5a3010f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_a179e1b2-b86b-4b68-9fec-0c4d0cc6555e" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_89fd7564-33d9-48cf-b6dd-37e1bc63134f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares issued and outstanding</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d1efc996-a59b-467d-922b-b7b402e8acff" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_83e969f9-d91b-4b7a-b4e3-4ffdee3d1b83" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PreferredStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7292bb0d-0a30-408d-b4b0-92bae6d55ed7" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3"><ix:nonFraction id="F_1f277c11-f977-4241-a884-d353f9101ffe" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3">0.001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;par value; </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_202c4397-e9e6-4c97-834c-e7c8bd5c2821" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_7635ba99-b3b6-427e-8780-7a524774c0b3" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares authorized, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f7da2d67-e681-4b4d-a6d9-5208efc81130" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_6f317949-b895-4b1b-91c7-ef745fef3bcc" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,730,816</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1b1a17dd-7287-474a-9819-0a0f0951ff6f" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_db79e715-924e-468b-a638-7d9f26aea04c" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,511,735</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;shares issued and outstanding at December 31, 2022 and 2021, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e288892d-bc41-4159-9de3-5afb8bd61330" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_29d51bea-29c0-48c6-9941-4dbb85b119c4" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6b8135ff-04b9-4f91-a1df-02422c71faee" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">895,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d93d4f3c-4333-4693-b617-b027f4350bfe" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_79f27d40-0235-4782-bdd7-c53984ebd2a5" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a21e5251-8096-4745-b9c6-cc3694a85878" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d8767003-d2e7-4310-afd9-db9700919abc" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">344,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d2ac2a1-2e3f-4161-9365-66d0f9e7a374" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_638ed02a-8191-4482-9f6a-af4d393b82f5" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">550,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_29dee816-b3b7-4533-b35e-72d27e69e0b2" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities, and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_65f9c83a-b720-4257-869f-eeb021d3b292" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">679,223</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d5e8cee-b37f-4a47-ab1b-ac4b2166da2d" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">384,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmts_of_opr_and_comp"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated statements of operations and comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.184%;"></td>
    <td style="width:1.401%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.838%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.391%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.828%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.391%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.967%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e854c35e-64d7-4a37-ab1d-ed9a41a3551e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:CollaborationsRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,941</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_39328ca9-d15e-4df2-b7ba-543555df3f3c" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:CollaborationsRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b43a995d-b680-4ad8-852b-8ebfc738af77" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:CollaborationsRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e460d576-13bf-42c8-9ea3-b56d8921a117" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">130,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d6ca096-18a2-42b1-aad6-dfc0f53de6b0" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,202</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_89074011-498b-47c6-a78a-b497248b9d42" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,371</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_17726326-e122-41e5-846c-058882168aac" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,533</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4eb26a83-a55d-4369-a985-d87750e7008d" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,865</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6bf8583b-fa89-43bc-b4ae-f78aef2b5201" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c84d1a28-e9d5-47e6-9d90-e294c6788d19" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">167,628</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53b8e2e6-e54a-4577-95e7-f3260698addd" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_879ede04-614d-42ba-81ae-ca2d0b97def8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">40,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss from operations</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81d5c2de-502b-4f65-976b-10bc872af8bb" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">165,687</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6170d16a-5b4d-40ac-bfbd-4cabcb50f125" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">87,067</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5cdbd4e8-c442-4530-9809-e495af17e7a6" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">40,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of preferred stock tranche liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_857bb3c2-f492-4e81-9fb4-79d2eef4a017" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6192b8de-e14f-4736-8237-b38e881e1a66" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2907ea69-7614-4b40-a6ed-4b03ae201a72" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of antidilution rights liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3a5bb4b8-9624-4f1a-8c83-24d58756891c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3353ba66-f29e-452a-8b4f-6d653f903a0c" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2fc1c215-ed56-421f-bef3-38157be95c03" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of success payment liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_608a5bd7-0528-45f1-95e8-c69dbc21cdf0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,486</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fdd82c5a-bb79-46c0-b432-762ecd665000" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c5aef96f-6e4c-4166-abb4-09fe8290f879" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Interest and other income, net</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1aaae682-4e1d-4bc7-8129-1f689c09f9eb" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_da86b3c6-77cb-4888-9686-817d2ebb635e" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3929f763-cf74-4027-80d1-7bce85f59e97" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5e5535aa-4371-4aab-9e2b-859689d53b0f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,353</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_49e9cf9d-c7d5-400e-9d89-8929d641e554" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">33,247</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_57cb69f4-21bd-4e02-a3a5-c715d597be7d" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Loss before provision for income taxes</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_692e480f-41b9-438e-97a4-5f3fe709ebff" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_738b08b1-5139-48cf-9fe6-59653498a1db" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c4c681b9-0a38-4cb9-b765-e4251ade31fe" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9911a604-d5d1-4929-9f96-cab7abba8ccc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dbdc269a-c4d5-4cab-b8c0-19451a4439ba" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c96683b5-06b7-429d-892b-7376501c17e8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50036402-44e9-4157-8a4d-8b484890b0fc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c9ecf0f3-7bbb-49c9-9a36-e2324972ef79" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce006019-11b3-435d-b817-dcd953e04851" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d036191-a4d4-48af-b85a-8c816dab2c1e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_22f0db4b-486b-48b7-8cc3-c92a84dae5a5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.91</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_972b23f0-b1c7-43e0-a4ea-7b71ceb5cdf1" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_4610ec76-8a43-4aaf-adca-f1b77594ae58" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">4.48</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81e3895d-2fbd-48ad-a713-899c738e15c8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_c0abe8f7-1448-4014-bf40-554c27165798" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">20.31</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average common shares used in net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b069a948-20cc-43e3-8c83-74eb57970e3b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_fc27ba8d-b642-4042-a6b9-beaae94f58ea" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">54,023,653</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3d5d4fbf-be06-48e2-a89e-77c4de11771d" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_b91c6a16-5d13-4b37-9e58-2b22ac5eee91" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">26,872,036</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eea929e6-fe6b-47d8-bb4a-f335ac7e226a" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_fd6e8501-24cb-419f-b5fd-9a191e5c96e0" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,250,093</ix:nonFraction></ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive Loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e0d83797-f6d7-4b7a-afe1-11d059314540" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4f3f95f2-afed-4982-b4f6-b34c6d05a2fa" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_796322bf-75a7-4ba9-8709-112034254452" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other comprehensive loss:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized loss on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_22cbcbd9-1132-44de-88f3-812a878abd40" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c25263a7-5890-4e8f-9c2e-5b7873373717" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2b19a85-aaf6-4846-97de-2555e080689d" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b2da8bb-1867-4c51-a641-8717058f864b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,853</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e0bee16f-7650-4e14-b589-ced1e2efa6eb" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,550</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb3701f0-b063-4875-9ded-86b4dfb719fc" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,705</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmt_of_convertible_prefer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consolidated statements of convertible preferred</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> stock and stockholders&#x2019; equity (deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.476%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.872%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:4.612%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.595000000000001%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.463%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0120000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.61%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:6.0120000000000005%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.899%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.26%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Convertible preferred<br />stock</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Common stock</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated<br />other</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share <br />amounts)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">paid-in<br />capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive <br />income</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accumulated<br />deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5185005-ea28-49d6-ab20-a3041c598424" contextRef="C_6dce68af-09ea-451e-8aa9-bbbf481d2537" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">51,421,404</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5c4c84b6-bb64-44ca-9141-d82088cc6528" contextRef="C_6dce68af-09ea-451e-8aa9-bbbf481d2537" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,480</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_72d4deff-5ecd-4eba-bf49-19365d8e0178" contextRef="C_0cb67e6f-2894-4db6-9521-909923920eff" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,854,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_abf2aa3a-8d5f-4bb9-90af-f5445541db2b" contextRef="C_0cb67e6f-2894-4db6-9521-909923920eff" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0d3ef2d5-68b7-4569-a57a-06c0906a1abc" contextRef="C_b1a6ad37-f5ef-49b3-be24-86dec915f36d" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,268</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_149dc535-762d-4807-9261-d24536feaea3" contextRef="C_a76866af-dd3c-4049-b8fe-63fdc94162b1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87636f79-bec2-4555-ab63-52978c8db9c5" contextRef="C_aa0bb9fe-96a8-4b16-bddc-1ab940b85d65" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">20,832</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e43aca8d-0c7a-4c7d-8ccd-54f94f145b0a" contextRef="C_deea9644-67bd-4520-bcd2-358aa23d9d50" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">19,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series A convertible preferred stock and settlement of tranche right liability of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6206bf80-aa4c-4064-bb71-be252e1a9357" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;million, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d500aed-e35d-404f-8404-f344a719cf91" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:IssuanceCostsOfSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d9f2d4f5-0b19-4bae-aeb6-842884d8f76c" contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f" name="verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">49,749,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e2e138c-4d6c-4e5e-94d0-57e5877ce5eb" contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f" name="verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,792</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7b914781-cbf8-4b33-a652-e2d031a2a3f3" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">112</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9c74fe62-9d78-4e9f-9c56-e5514927ba20" contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f" name="verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">78,348,461</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a59ea273-34ab-4e79-9dd4-05ccd954fe88" contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f" name="verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,888</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Additional issuances of common stock to licensor institutions</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f8e0e83e-e4a0-41f1-a873-c5cc755b0de0" contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495" name="verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">187,867</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ed174823-0718-4a8a-bfab-1187bdd42cea" contextRef="C_69a15539-dd92-45a4-b854-128562acce6a" name="verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aa62c320-c389-4691-9a95-ab7ccb5238e2" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04553481-4e2d-491e-b3b6-64584f9555b9" contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,635</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_037c4b7c-a451-4c6e-8213-3c7091acc60f" contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51d04407-56cc-4fcb-8fc2-d5ef6d611820" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0f10f157-19bb-4468-ac9d-f1abae661886" contextRef="C_4ef51bcc-9dfc-45c1-9eee-f5566e195c5b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_951c7c84-46d4-49d2-8feb-8413ca32f50a" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5241b08b-8d2b-4e16-8e70-4208226b6340" contextRef="C_69a15539-dd92-45a4-b854-128562acce6a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0ff598c8-c644-406c-853d-8458f757a1ea" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5569f708-63f8-426a-b2f1-f317cbc96eb3" contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd3a51dc-0bf5-4889-8ac2-4ae63be78e2e" contextRef="C_69a15539-dd92-45a4-b854-128562acce6a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_321cbd70-6d6f-4ff3-a52d-e457f5055eec" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_713eb786-feeb-42ec-b3d3-5613dfad4531" contextRef="C_f0f69b44-4afb-469a-88cb-446f929e64b4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_918e0813-4071-4881-af46-b253c46be841" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2c1b2a1f-c87c-4956-a771-a5c6b1f361f6" contextRef="C_3188091a-eb34-4e3d-9630-e21db1a73318" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">179,519,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ebe6a7cf-a2f5-49da-b8bf-a4ff2eca03f6" contextRef="C_3188091a-eb34-4e3d-9630-e21db1a73318" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125,160</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa96cf6d-bbdd-4781-92df-f65014dca3c3" contextRef="C_959c970c-a6c2-451b-acea-26466d2da446" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,585,789</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_54932679-2480-4b78-bd94-2d0c516a2fb2" contextRef="C_959c970c-a6c2-451b-acea-26466d2da446" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bfa64a8f-f497-480e-b6d3-74842584a687" contextRef="C_dcad783b-c139-4ff0-8e9c-6423e1ed3d39" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a23e70aa-4a48-4cf0-925e-1d72e990b14f" contextRef="C_4e91dace-0a68-4bad-a0fd-32815efdc68c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ddecf8a9-12cc-4125-b4e8-e463df76d3d0" contextRef="C_eab2ba07-0259-4573-8347-1b9098fe2136" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">66,536</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c65dc68f-fbe2-4a49-a2cd-d294ec2921bc" contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">63,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series B convertible preferred stock, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_35031a35-0d36-4c46-acb3-2f82bbea67a3" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:IssuanceCostsOfSeriesBConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">241</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94694d44-ca83-4300-b06f-aa238ce08d07" contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93" name="verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,163,022</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5275c8b9-8d08-488a-9cdd-edf3f03010a4" contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93" name="verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dac2f3d7-ffda-42ae-abce-8fde89d57a3d" contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" sign="-" format="ixt:numdotdecimal">256,682,054</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c16bd781-a17c-4898-a062-bec440feccbc" contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_976e596e-1169-479a-a8bd-78724eca2b8b" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">27,720,923</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a96c5449-3406-4a25-99e8-e34ebe187c36" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ff659e31-b53d-4ab3-b52f-75f37bb667c6" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,891</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6e43854c-583a-4ca8-bcb1-7410bfcef3e5" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from initial public offering, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d9906afd-412a-46aa-a6fb-f5dcaaf3d771" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:IssuanceCostsOfCommonStockFromInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7ec262b9-4f12-42f6-9a41-798573adb005" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">16,141,157</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_803a569d-f3d2-477f-be19-b929a6efb35b" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1454f55b-7fd6-4c26-b845-4be8f00691c1" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281,568</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_03634fc9-d379-4fe1-b05e-709fddd2437f" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">281,584</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock to licensor institutions</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_606a3517-f910-4ef8-8bf4-920de34da201" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="verv:StockIssuedDuringPeriodShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce9b4590-7e0c-4744-88a1-71c2fba7e3ae" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ed04d6e0-c28a-4a5b-8068-0e70d60cebec" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,489</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b5da0a9c-0390-4590-bd7c-0740c054d7d1" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_399d5473-faef-4401-8e86-6bf2a39ccbbd" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e53e2abf-72bd-4eaa-a0e0-c466fad36f02" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">599,838</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c662a1d1-bcd4-474b-a570-13d29ab9201a" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bca1ff08-bd68-4723-9deb-768ba92b508b" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">965</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_11ccc1e4-c211-43f1-83c3-7142a523bc6f" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase of common stock under ESPP</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_79f069c7-a403-4e20-af90-527ab0c0e5f9" contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,297</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d3b62596-df38-41d3-a7a1-2ca4580d46f6" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_8bfc5d9b-0194-447d-8d63-2e05dbf8ee1e;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_37a3732c-67b8-46fa-a2d3-2aa2597e06dc;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ff03cab-fc6e-498f-8ccb-86765c4c82b1" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b65dd60-61aa-4d45-a45c-8ce17fc34ec5" contextRef="C_29085c5c-8572-4342-8193-f44746b659b7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_4e655ade-06f9-4904-b02d-66b61f8a751c;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c661dc4-2795-4589-a1c9-0ca0834ec84b" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9223fca9-8ab0-4d54-9890-c65c5eef6d67" contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1cc073ac-fc6c-4426-8b56-a0709852bc54" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b7f773a0-b6c7-43d4-a5bb-b2d7a40f289d" contextRef="C_966c03b1-7109-4952-a069-3bb673a98824" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc839563-44b9-4272-890e-519297563e56" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_84efc436-065b-4ba9-8073-291872e65a5a" contextRef="C_57a4273e-e500-4784-b24f-2d7cd8c95f12" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">48,511,735</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_184e88e1-5e78-42c6-89d5-5de91a3ed324" contextRef="C_57a4273e-e500-4784-b24f-2d7cd8c95f12" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a250a535-8b85-4415-b98f-5208628a17ae" contextRef="C_bac8d82c-d5da-4a33-90e9-09318020506e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,381</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_10452936-65ab-4f30-8dd9-f8f2e137cfd1" contextRef="C_d8970451-3d27-43fa-9ddd-5d84fc44e22a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b5edcff7-abc8-4a4d-b137-e97d2db6ad3e" contextRef="C_17d2fd0e-b2d9-4c3d-8c72-65febc814137" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">186,850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa5a0706-8ded-457b-bdd9-30fc017f0580" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">357,352</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1882a776-6648-4eaf-be5c-ac163261b87e" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">743,638</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2dc7409d-f23b-4dff-8f21-6e48b4e198c3" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bbe1053c-bcb1-44af-a1c5-85690dcaa9dc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Vesting of restricted stock units</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_34b9eafd-d052-4966-9340-1eaa59806eb0" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,375</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchase of common stock under ESPP</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3abdbe5b-0995-45ab-942f-5a66da60b54c" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">85,810</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bb3bc6c8-90e0-45ee-a058-d34413de8b18" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e662193d-b859-498d-87d8-7a82a1ede38f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock in connection with the Vertex Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9fddaf20-6faa-46b0-8bd1-b99b36148ce7" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="verv:StockIssuedDuringPeriodShareLicensorInstitutions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,519,756</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_878cd9ea-506c-4fe9-be6b-284a64a40dc2" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b4cd3495-3225-4d82-89d4-57087a27aa8e" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,984</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb3a4b1e-eb4f-46e8-a0f9-831e493e29c2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:StockIssuedDuringPeriodValueLicensorInstitutions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock upon follow-on public offering, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_219fea34-b95d-49da-a824-7853a843bce8" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:IssuanceCostsOfCommonStockFromInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,924</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ca432409-d6e3-4bb1-a621-ac55a0614cf1" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,583,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3947ad30-084e-4add-a4d1-c8167e664a2b" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87226227-d06c-4dca-a0cf-71b0ea9fa8ae" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b5f17bba-5611-4376-9283-91652c9665da" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242,826</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock from At-the-Market offering, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b000cfbb-f4d3-4df2-a261-0290ea106a3f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:IssuanceOfCommonStockFromAtTheMarketOffering" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">1,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7314891-c160-4f33-b272-913ac3fb0be9" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,280,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eb982c5a-323d-4880-a973-a9213e70ad05" contextRef="C_84658634-9c24-4121-9463-34ea37f01b51" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8dc82a35-3ff8-4612-9dae-c89caa0c4e2d" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,899</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_e0722370-e756-4380-b190-71e49f255f38;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_bfddd2a3-f9a3-4e13-bcf7-0bf43949f96f;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1d13fae1-2367-4811-b655-4b0632f57f3b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unrealized loss on available-for-sale securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_66f09700-1691-4de0-9ac6-fd906d76f489" contextRef="C_caa34b87-6d61-41fe-980c-8d45934c3138" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f961da72-5947-4c1b-bddd-972e4f2a09cc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">466</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b0d7606a-7ae4-4590-ac71-7403ca6924ec" contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4651f551-6f3b-4e58-8d4d-6148a2e1c39b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:10.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_59d0086d-7768-40d3-9a05-f326403c6b6c" contextRef="C_bec200da-6561-47c7-ada8-88c14ff8512c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38fa8211-8c4c-40b9-b262-85df65062302" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.5pt solid rgba(0,0,0,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ffedc230-2ad6-4061-83b6-d25c40926d38" contextRef="C_2e1ed61d-8951-4d1b-b942-435100437cc4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">61,730,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7a83fc28-a27d-438e-b4a1-7e817eacdff5" contextRef="C_2e1ed61d-8951-4d1b-b942-435100437cc4" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c4a2df5c-cd35-4fff-8214-62f484053026" contextRef="C_80a0f724-7529-472e-8067-5943bc65251c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">895,801</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4091fd1-c2fd-4781-905c-43d3149d1cd3" contextRef="C_06dbfcce-3022-4b09-89dd-3eef6740f46e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dde9cd6b-5b35-4deb-bfeb-b386a9f09600" contextRef="C_5632b0e3-72a0-490d-b288-cdfcbada6292" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">344,237</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f39598ad-32b0-498f-bfd6-f27732e7faec" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">550,932</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="consolidated_stmt_of_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">C</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">onsolidated statements of cash flows</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.562%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.699%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.699%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.341%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:11.017%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
    <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash flows from operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dad2c109-596d-49a0-8916-a063b17c8798" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bafffd2e-0268-40cd-bc41-5c1a384cc37b" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_598406c1-04d3-4c3e-8e7a-4a3bad8a6b30" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Adjustments to reconcile net loss to net cash used in operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5669de4b-3cd9-4ede-acd2-d543ac23b4b9" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eff59e1e-acc3-4f7b-9839-369ab4d56be5" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c8f9a12e-d8d0-4880-b870-582d2467ac89" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,328</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Non-cash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2cf08f2c-b310-4ff8-a76a-e0a34073f19f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ProvisionForLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,907</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b5d6291-4ce0-4911-b5ef-c6718c01c862" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ProvisionForLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,842</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_caa1b79a-0927-4c15-a069-a90ff1dfbfa0" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ProvisionForLeaseLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net amortization of premium (accretion of discount) on marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4cdf0b06-ec3e-433b-a4e6-5920c0c2a75f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_efa157df-dfb0-4a89-9697-1ff5191336c2" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,508</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_27623de9-c21a-41f6-a4d9-e15c953c891b" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">380</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_84db891d-bac2-4836-90d0-06ebf26c294c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,477</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_33570b93-e6a8-427d-9c4c-7147286680bb" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_784e13bf-5508-4155-b8c2-a0b374dd5981" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of preferred stock tranche liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_961e464a-6fb9-4118-93af-cd288cfb3541" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8f320521-507e-4976-ac71-0de7a634527c" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8cbcafab-2fd2-42b7-a303-2b1640b58f40" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfPreferredStockTrancheLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,507</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of antidilution rights</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_93b1e448-d2dc-4501-a58a-365d1097c627" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d00ebd0b-be29-46f3-b876-afd3d68a8b02" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_256e60dd-9bab-4165-b199-a6e421a76b38" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfAntidilutionRights" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value of success payments liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_061d760d-a920-4a70-94a7-d0469355b736" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,486</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_011bafcf-f674-4da1-8b4b-85a669ec024a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_20c50464-7dde-43c3-aefe-0acac705c433" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ChangeInFairValueOfSuccessPaymentsLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,387</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Collaboration receivable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e4381816-7e01-4954-8c51-f7898b67f1d1" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,012</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ec41e7b-afc0-4448-af66-b10ac04b538a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04703dc3-cade-4f46-bef6-9206c53eb841" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6e4ed932-cd8f-4cf6-ba7f-dae727a39d84" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,436</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_95f27264-a487-4f78-81d6-df515823a63d" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,528</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0d06b577-ba48-4b2c-97c6-83c2a1e3081e" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,582</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accounts payable</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_132d39c5-a042-49f1-8be5-690ce9688fa0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,216</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1fc498ed-ceeb-425b-8cd2-d27cc72b41a9" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,829</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aebd1226-dbbb-4b2f-9375-314f5b143091" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,898</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5de46ccf-f3bc-42c3-8611-d62e63e7a467" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,041</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b48ffaf3-f495-4110-a22d-a0fc9e346dcd" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1a8a5637-6e59-41c0-8822-075dc1d9e76c" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,071</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_60e3bb29-a3f6-4a1b-8b31-1915453d929b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ae27e2c-a24c-4137-a4ec-04c702aef090" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf47a255-a5ce-4921-8dc4-6f59eb904f0a" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:SuccessOfPaymentLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6f096d18-e061-4fde-961c-7067ea1d6a07" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,014</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5a798db-4d52-4a61-a9cf-c962092e0e0f" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aa74b251-1fa0-48df-8005-75ac87cd3cbd" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f24941da-d356-42bc-b15b-47996f3b4647" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">3,011</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6bb2b48-d539-4c0a-ad33-05b915db2ce6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6ced8a7d-f547-4ff3-83cc-2d230429420d" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:42.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:42.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred rent liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ee7ffa4-0fc9-47c3-b2e4-7a4313e34971" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7dbf57da-9340-4037-9e64-c63c82685825" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dfb093ba-8cbe-43da-a2a6-f41c5d5121bd" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:56.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ff582de-e38b-4ede-ae1a-f5179965cd7d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">122,332</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef890573-19db-4942-8503-7da88fb82436" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">77,880</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_64fae1f4-79ee-4a8b-8b6c-72fb5f596a82" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">35,265</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash flows from investing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9acb560e-1b03-4033-9ef8-1dd7df39b2b0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,232</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ccbb0a87-c552-4c9e-bd02-e29dacd80331" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,359</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b003221d-4327-459c-83f0-b764ac64365a" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Purchases of marketable securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8e5b0825-460f-427d-8d72-b9e600db55f5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">479,401</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8423f51a-8cda-4913-b46d-3e84e29c0e18" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">371,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e6dfdf9b-cfb7-4e72-b295-54224768ab4b" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">98,484</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Maturities of marketable securities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a47b3633-e2c4-459c-a61f-48bdec0a777d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">336,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_df5e3f13-ea51-4638-b2f3-8a08301c325c" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">136,755</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d235c0a1-d03d-48c2-830f-6ca40d915428" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:MaturitiesOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:56.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash used in investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f578893-df4f-4665-9590-938f8dc745c3" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">155,955</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8517180-8dd8-4727-8d45-9ed0f630e79a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">239,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e9493223-8b79-4733-8a7e-7d26cf8be37e" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,127</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from issuance of Preferred Stock, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e268be3-fbea-4016-b9bf-7b7d0002d879" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_607ce61c-b08d-4afc-927d-d9fc1787e70b" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50363257-ba11-4ef6-8aab-3ade28056b4b" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_27ab7d67-b9c9-464b-ae04-073f7f7607ef" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">286,509</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1aab6fb0-c394-4c97-8fcc-21a1339dd98b" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">285,214</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb95f27b-1fe2-4052-8298-82ad6864cae8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from the issuance of common stock in connection with the Vertex Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_80e00c95-68a6-495f-a748-cea88767b629" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">39,986</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Payment of equity offering costs</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_511d722d-6528-4567-a787-cc2cb805d6b4" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">783</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_69b73bee-b2a8-4fac-b9fe-8b9b30154a46" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,630</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eb5d9e7a-993a-480b-97c6-c7de64c30729" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_78055706-9613-4b72-ac07-a54a1d82e5fd" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5fb61bcb-5e21-4e97-a837-d94f075594d0" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">966</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_99f1e6c9-2058-48fd-8e7b-8d2e6f72f532" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Proceeds from purchase of shares through employee stock purchase plan</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76859f65-f0b8-4e6f-a6f5-008b49a00b75" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,069</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7cbb3916-3008-4bf4-a07c-e201634a57a6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">780</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e8ec729c-56d4-4abf-8bb4-f5cd62a308e9" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:56.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:56.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_88324299-556e-460d-a92b-5d1a3370e2ce" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">328,956</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_90be98a8-c876-4878-a420-9096adcb5cf3" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">377,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6146cdee-eef9-4c6a-82de-9e78fe8beaf2" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">92,627</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_85ec9337-0bfe-4ac2-9146-9c46b2be2e8e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,669</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12d8f849-34ef-440d-9c0e-5f296891c940" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">60,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b73c42b0-190c-4ba8-bc1d-4d68349d6abf" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,235</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash, cash equivalents and restricted cash&#x2014;beginning of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4a941aaa-76d4-46ba-89f9-3c200a8253f7" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_16191e6b-4993-4025-b2a6-20254003b222" contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e8c0797-4a01-42a1-b032-34fbfc0f5bf9" contextRef="C_deea9644-67bd-4520-bcd2-358aa23d9d50" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,221</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash, cash equivalents and restricted cash&#x2014;end of period</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2efae4e4-27e0-47c5-b8ee-c5dbf110efd0" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,236</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4bac0285-d268-4308-bede-0b3c1d95bfcd" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_381ed482-4369-4b1f-b5ce-babce48cb6eb" contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supplemental disclosure of noncash investing and financing activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment additions included in accounts payable and accrued expenses</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2fbad431-4718-4ed0-923c-f3b523f22aa5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c8c46344-597a-485a-8fd4-069d1b36c2a3" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">503</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef8c748e-3203-4dae-b297-09d748524db2" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Settlement of tranche right liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fe6cc1ac-55ff-48a9-b5a5-d2f261d1c166" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ddd98d9-c391-4177-b6f8-88fbb7e441ab" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5b0a5dd8-22bb-49e9-9a42-d37bc0be1697" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:SettlementOfTrancheRightLliability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Conversion of convertible preferred stock to common stock upon closing of initial public offering</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ca49b137-f90b-4928-b2a9-8f32df1b1f75" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c01121fc-30c1-486e-a0fb-f4f1a9eadf68" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">218,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_363045de-8789-47df-a00f-d345532bcc89" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Settlement of derivative liability by issuing common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a00a0f59-e6ed-4939-9cf7-5ba5dc4ce844" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_927041a0-caab-49dd-b4a5-5a58b63a2dc6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c5869e38-4027-41ac-8b0a-7e7c1a39396c" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Right-of-use assets obtained in exchange for new operating lease liabilities</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc3f7eed-61ef-4838-a529-1cbf4abd15ed" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,417</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0b6eac18-f481-40ad-bf81-30177afa26c1" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d0fdb5b0-b6aa-4319-9c50-5a235cee0e34" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">The accompanying notes are an integral part of these consolidated financial statements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="notes_to_cons_financial_stmt"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Notes to consolidated financial statements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_2b67ca67-636b-40c3-bb43-93129b8b12a9" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NatureOfOperations" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Verve&#x201d;) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#x2019;s principal offices are located in Boston, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc1ef3e1-61d2-4d57-9503-1c88cd9b0dc3" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">554.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> as of December 31, 2022, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Basis of presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_e43678ed-c59e-4abb-b295-c321a41ae90a" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ummary of significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a4b241d9-59fc-4ee3-9fde-b48f202e01fd" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ConsolidationPolicyTextBlock" escape="true" continuedAt="F_a4b241d9-59fc-4ee3-9fde-b48f202e01fd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a4b241d9-59fc-4ee3-9fde-b48f202e01fd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_d5779824-712a-4bc5-af4c-79b9c4f5053c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_d5779824-712a-4bc5-af4c-79b9c4f5053c_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_d5779824-712a-4bc5-af4c-79b9c4f5053c_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">circumstances. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the Company's initial public offering (&#34;IPO&#34;)), stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_14c8396f-eff6-4370-848b-41a0e8b2d948" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true" continuedAt="F_14c8396f-eff6-4370-848b-41a0e8b2d948_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_14c8396f-eff6-4370-848b-41a0e8b2d948_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div><ix:nonNumeric id="F_baeb31aa-da6d-4fb1-90ee-11d171ef0018" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_22f473dd-e247-4491-ab7f-690a299cbb0e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" escape="true" continuedAt="F_22f473dd-e247-4491-ab7f-690a299cbb0e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_22f473dd-e247-4491-ab7f-690a299cbb0e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.855%;"></td>
          <td style="width:1.613%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:12.815999999999999%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:1.613%;"></td>
          <td style="width:1.0%;"></td>
          <td style="width:13.103%;"></td>
          <td style="width:1.0%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f253885e-e5ea-4f54-8eeb-f2986d5b268f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,412</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef973bd0-e420-4308-bd58-3b288660dee8" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,330</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4b8448fb-74e1-486a-aa96-8088968cd25f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,824</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_39594492-0036-4c4c-893a-91813a9081a9" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,237</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_047760ee-a6db-473b-a5b8-69dcd638ee6f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">120,236</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_30b696eb-3bd4-4920-9179-b3f9dfda3661" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">69,567</ix:nonFraction></span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></ix:continuation></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:MarketableSecuritiesPolicy" escape="true" continuedAt="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f_1" continuedAt="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f_2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f_2"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p></ix:continuation></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3699f3f7-7e68-4110-9ac3-72b320853792" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">accordance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0b1dbe5f-c5b4-4fc2-810d-2b8b2d841971" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:DeferredOfferingCostsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the stock offerings as other non-current assets until the offerings were consummated. After consummation of the offerings, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_89ccf48a-7074-4b09-91e5-1dbb472231fd" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" escape="true" continuedAt="F_89ccf48a-7074-4b09-91e5-1dbb472231fd_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_89ccf48a-7074-4b09-91e5-1dbb472231fd_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2022, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6f08e60a-898d-4ad2-bbcd-cc6ea68335d5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true" continuedAt="F_6f08e60a-898d-4ad2-bbcd-cc6ea68335d5_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_eec8ab08-69af-401d-81d2-00fddb45e674" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" escape="true" continuedAt="F_eec8ab08-69af-401d-81d2-00fddb45e674_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_eec8ab08-69af-401d-81d2-00fddb45e674_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"></td>
          <td style="width:2.073%;"></td>
          <td style="width:48.958%;"></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e1126bb9-959b-494a-bb20-cc4dd35c1f6b" contextRef="C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Office furniture</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f803d9fc-c89b-4171-9428-f81f316d4012" contextRef="C_ac822c00-7c16-4ab3-98ac-86f18f43dbac" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f8dbdbe0-e1e7-4cda-8820-f7ae20f948f1" contextRef="C_2b381c95-04aa-4fba-8306-9a71bc42bac3" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5 years</span></ix:nonNumeric></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_da8e76d5-2ece-436b-8dc0-a57b0cb91285" contextRef="C_10236809-a80e-4e09-9626-2b295f8196ed" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shorter of useful life or remaining lease term</span></ix:nonNumeric></span></p></td>
         </tr>
        </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_6f08e60a-898d-4ad2-bbcd-cc6ea68335d5_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_59274c14-d6d2-4e3a-a8af-c142e34fc9d2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true" continuedAt="F_59274c14-d6d2-4e3a-a8af-c142e34fc9d2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_59274c14-d6d2-4e3a-a8af-c142e34fc9d2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a4d707ce-7386-4004-a996-b51a6c29ad50" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e1f63fe4-991f-4252-b859-77ab78be2b39" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8b1fd97e-3b5a-42e5-90c1-dd1717d1a801" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_ad52d1f1-6349-4d93-a22d-3aec66761698" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" escape="true" continuedAt="F_ad52d1f1-6349-4d93-a22d-3aec66761698_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities were settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#34;ASC 815&#34;)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f45a659f-4d5d-4933-9187-03f463d62357" contextRef="C_63860296-a4f0-4e1a-9241-b6d773d5b067" name="verv:IssuanceOfAdditionalCommonStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_ad52d1f1-6349-4d93-a22d-3aec66761698_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eda14cfc-83a2-4620-8831-f8fbe5344485" contextRef="C_5533c143-e11b-4687-bab9-616ee25f12a3" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d121da6-eb88-45ac-ba27-fbfbf4fc77a3" contextRef="C_b22cbc9c-7068-4848-a684-7dd33933fb13" name="verv:SuccessLiabilityPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_2ba1e0f6-94bc-4e07-a16f-c261dd71cd7e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:RevenueRecognitionDeferredRevenue" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company enters into collaboration agreements which are within the scope of ASC Topic 606, &#34;Revenue from Contracts with Customers&#34; (&#x201c;ASC 606&#x201d;), under which the Company licenses rights to certain of the Company&#x2019;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The promised goods or services in the Company&#x2019;s arrangements typically consist of license rights to the Company&#x2019;s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company&#x2019;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consideration is unconditional.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f21ffaa4-1411-4d2b-b648-c4bed32a66e2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true" continuedAt="F_f21ffaa4-1411-4d2b-b648-c4bed32a66e2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_f21ffaa4-1411-4d2b-b648-c4bed32a66e2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical, clinical and regulatory expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a95d179f-67b2-4496-9e97-1fde462ca4d2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true" continuedAt="F_a95d179f-67b2-4496-9e97-1fde462ca4d2_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s stock-based compensation program allows for grants of certain equity awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock unit awards. The Company estimates the fair value of the Company&#x2019;s restricted stock unit awards on the date of grant using the closing price of the Company&#x2019;s common stock on that date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_a95d179f-67b2-4496-9e97-1fde462ca4d2_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_685bbf25-bfd8-4172-bf83-fc79a0c7a245" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) using the revised modified retrospective approach, which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fbd807d9-48f5-4382-b5f3-750996494295" contextRef="C_8f639dd3-36f0-4110-95b1-083a24288e33" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_03bab5c8-42a6-4819-8d5b-5009179f4830" contextRef="C_8f639dd3-36f0-4110-95b1-083a24288e33" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was no impact to the Company&#x2019;s results of operations and cash flows from operations.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (&#x201c;ROU&#x201d;) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_7e488b7b-9fb7-413f-8070-61d35d424abe" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true" continuedAt="F_7e488b7b-9fb7-413f-8070-61d35d424abe_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_7e488b7b-9fb7-413f-8070-61d35d424abe_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c1046b2d-a183-4d9b-a77c-67fe050f73e1" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:PercentageOfTaxBenefitRealized" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a59b9e65-c8c7-4235-9624-494499b6f187" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022, 2021 and 2020, the Company&#x2019;s only element of other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss was unrealized losses on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b062ae17-87a1-4e14-bb01-c837d055a161" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true" continuedAt="F_b062ae17-87a1-4e14-bb01-c837d055a161_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_b062ae17-87a1-4e14-bb01-c837d055a161_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6a9ed9e1-bcab-40be-8049-5e6a711f7642" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:SegmentAndGeographicInformationPolicyTextBlock" escape="true" continuedAt="F_6a9ed9e1-bcab-40be-8049-5e6a711f7642_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_6a9ed9e1-bcab-40be-8049-5e6a711f7642_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5ecf37c2-38df-4e0f-b4d9-3ecf025bee5b" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> operating segment operating exclusively in the United States.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_4e39e517-71ef-4a47-aba3-cb2a36836a20" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true" continuedAt="F_4e39e517-71ef-4a47-aba3-cb2a36836a20_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_4e39e517-71ef-4a47-aba3-cb2a36836a20_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1118cb64-e14c-4847-861c-9620047175ef" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company (&#34;EGC&#34;) to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financial Instruments&#x2014;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard became effective for the Company on January 1, 2023. Based on composition of the Company's investment portfolio, current market conditions, and historical credit loss activity, the Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c967e66f-9a3f-4a34-9aa9-3e9b5b9f018c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3. Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1257b10e-7eba-403a-a202-838b0901f7ab" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:MarketableSecuritiesTextBlock" escape="true" continuedAt="F_1257b10e-7eba-403a-a202-838b0901f7ab_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.738%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.414000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.601%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.763%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br />cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br />unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br />unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c0d2203f-399a-481e-a6ac-33c7101a6264" contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228,432</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5004769b-46a4-4df2-913e-14ab18ad3dba" contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0399ab24-ac3a-40e8-9c26-da8aa6e6b539" contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">301</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_969c4db1-1633-425e-97a4-9445eb8d3464" contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228,144</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b8ddb1c7-1c7f-4d9b-913a-436b4f93715b" contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d23320f4-7d5d-417a-bd7b-db1dad8a1a47" contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1922d3a0-5de5-49b3-81f6-38ce7b9ffe57" contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">474</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_85959c45-6b72-4f01-801f-16169ae6bfad" contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d468a87b-d12e-498f-bd5f-0def3d3c2f07" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">440,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c3b05824-c4af-4569-ab8e-547ff94ea9d2" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8fdc89a0-4f59-48b4-a819-ed5144f8e3bf" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">775</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1db5b4b7-7fef-45bd-b1f8-23470d25faa7" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.738%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.414000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.601%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.124%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.763%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br />cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br />unrealized<br />gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br />unrealized<br />losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf28c627-f3a8-47af-8987-af64ee6ae655" contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,559</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_812b7301-7c24-4c0c-bde4-a8fd49ca3a8d" contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9dd1cae9-5188-4b74-8683-d3725a493118" contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">218</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5208ae9a-80c8-4196-b4ff-29356483c63f" contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_011d38fa-5eee-4030-b2f2-16c8101683ea" contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,781</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_21b1f656-88b3-403c-a9ed-2f6463455ae8" contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6544f520-5b46-4417-b987-7294c1097125" contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ec8852d-b5a7-4dd5-8ebc-ab7555a9442e" contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f742011b-354e-4e1c-adbd-b27f24cff40f" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b9060291-3240-4597-87f1-01b78294ff50" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2113f6eb-7eec-4f5c-a6a2-130d011d55e5" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">228</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_85f7e11c-5876-4f63-8ed6-5b639e45e757" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_1257b10e-7eba-403a-a202-838b0901f7ab_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The remaining contractual maturities of all marketable securities were less than 18 months as of December 31, 2022 and 2021.</span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The unrealized losses on the Company&#x2019;s marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2b8f4f30-8873-4d7e-886f-a6e7f5026e57" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d738990-4278-454e-a8f5-9a5570283c61" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">as of December 31, 2022 and 2021, respectively, were caused by interest rate increases which resulted in the decrease in market value of these securities. Because the decline in fair value is attributable to changes in interest rates and not credit quality, and because the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity, the Company does not consider those marketable securities to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">other-than-temporarily </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">impaired at December 31, 2022 or 2021. None of the Company&#x2019;s marketable securities have been in a continuous unrealized loss position for </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_01ffdddb-e434-48cc-aec8-afae36b4fc43" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_f7b1000f-1dcd-4d2b-b4be-2eb6e75d33c2" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12 months</span></ix:nonNumeric></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or greater as of December 31, 2022 or 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0321d383-f688-4d15-8809-bc645fe6a119" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4. P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">roperty and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0f83f37b-b989-42b4-b305-ef34a9c6751d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"></td>
        <td style="width:1.611%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.941999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.611%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.079999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fe1da35a-91b0-43a3-8d26-2c98eb22f33d" contextRef="C_bdcae62d-bb8e-473d-9798-be656594f6aa" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,379</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ea92045-3590-4ad9-bbb8-174231bbd24f" contextRef="C_0d7d5bec-d770-4173-b7fa-5da0ea98f60b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9f5aed75-5f52-4784-b157-ffdc26bbd329" contextRef="C_a53dba14-9b85-4825-a901-caab2a81e8a6" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9b20e52a-c6ce-4d9f-9c12-2acce064c27e" contextRef="C_1338186f-d03c-4d8a-a4c8-31af991b82fc" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5df9103-98bc-4d54-acdc-b15ca6da65c9" contextRef="C_8a7a03b0-4e2c-4c61-8591-8ea00dfc50ed" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,294</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_05e77bb3-92f1-4cd9-8cc1-bf1e5b47b6e3" contextRef="C_8840dc16-dd94-470b-ae47-6f49752ffb5d" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">566</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94e2bdea-0860-4e45-b6b7-1bc1230ac0e1" contextRef="C_25b472d9-741d-43a8-b055-7f86620a197c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">826</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a7423f49-d3da-4b75-a12d-5bc4e68f974e" contextRef="C_7f3b431e-5ee8-4828-90a9-812944400c44" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">158</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9122738e-fe28-45a0-9a38-68a7f9ff865e" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,765</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_242d5ec5-ecb1-4f40-9461-6f9975cb6085" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,557</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0931092d-8558-4411-b09d-4030158e6819" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,987</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bfc3c485-1c81-410c-8452-f668e78fba09" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,333</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_00c9f150-3b8d-4959-9b58-6703c876ab3a" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,778</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1ed17e59-4107-4f98-ae47-14f976f3217e" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,224</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9be33448-1c7b-4a6e-b52d-0621decd7d75" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" escape="true">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.436%;"></td>
        <td style="width:2.257%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.568%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.257%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.568%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:2.257%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:18.657%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1fa55e03-1c1b-4dd3-888c-bf9547d3a4c3" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,804</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4d544f07-ed47-4a9f-a846-22f779089678" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,535</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f3b2aec8-255f-4b08-a30c-c5cfa4e641cf" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:Depreciation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,328</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_5cc0f60f-91f9-4ea3-ae84-85aade2bf62c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5. f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">air value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The antidilution right liability was fully settled in the year ended December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_27e51a39-dc0f-4188-ae31-b9bdfdfe262f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true" continuedAt="F_27e51a39-dc0f-4188-ae31-b9bdfdfe262f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_27e51a39-dc0f-4188-ae31-b9bdfdfe262f_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"></td>
        <td style="width:1.228%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.419%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9b837163-41c6-477a-872a-74180f165243" contextRef="C_0deae6b1-45ca-4fba-96bb-c6dc6d5add88" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea70d8ba-5467-4497-9239-7e25b5112f28" contextRef="C_595a69e0-a981-426d-a6f1-79798dc73b95" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_25bc5f91-8b21-4e0a-ace6-ab4575acab50" contextRef="C_1f7382e3-ab33-42f1-8d80-f3c02882b1e1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7c66b8d-1b05-4e8c-9a7a-7fd1299f285d" contextRef="C_045cb64e-47d4-4a6a-8f5f-0799d3c6d0ca" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_498a3f85-c31c-4e14-bb93-1860201ae6fb" contextRef="C_37ef4e5c-ee38-4746-8f83-e39d97e60aa9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228,144</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_65d3a9ac-d030-44e7-90a0-5730024ff460" contextRef="C_b573d06e-feb8-4e52-95a0-9b02cf165de9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e73446c8-ccdd-44e1-b048-9bc324a5eb4c" contextRef="C_b2ed33c7-4d15-43a9-aa3d-221d32e3b104" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">228,144</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5bca2d4c-9841-4061-baa8-53403299ab8b" contextRef="C_43ffe065-4842-415c-88bd-7c2bb5a6e05d" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8eb804d3-a827-4d5b-b33c-d58ca0ab8cdc" contextRef="C_1bf70619-a638-4c23-8216-60415235bbb2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c93ce3b-dd6e-4df8-be8f-1e77cd702a26" contextRef="C_fa5f0add-d465-41c4-9cb6-bd0f9bb41f41" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_77696267-a3d0-4ed7-ab47-9232b5792575" contextRef="C_7a8149ba-0367-4d16-9824-0138611d7cd9" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">211,252</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_18b513b0-719c-447c-bfb8-83295526518d" contextRef="C_ab3f67d4-0906-4241-abd4-7bdebb98d719" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_45b368f7-e2a1-4151-ba1c-66102b0146b4" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">544,699</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e7ae860-733f-4f07-9eae-3b40a2a641ef" contextRef="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">105,303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5021c6a2-4d94-4bc3-a274-7f72d1c90af4" contextRef="C_1a914828-67e8-495a-9b12-2c48154e0de5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">439,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_78cd3d4d-94b7-4aeb-a092-1067c09360fc" contextRef="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5895f8db-9e1a-4f0b-a4cf-bd11cae09260" contextRef="C_5e543a38-cef8-457e-8d21-0bec7784e4f7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a543e197-4c6e-4cf3-ac8c-fbd0c3dc1a9f" contextRef="C_d7b83b22-0b4c-4a86-a0f7-f54ef4b0daf4" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2077f7a-82f9-47b2-a0be-9bb7a84f7f8e" contextRef="C_3fdd3360-eab0-4708-a04c-8b89365954ae" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7f5dfe82-5927-4a18-9119-e17cc6e5b583" contextRef="C_9dbed675-16ab-43ad-92de-56cb1fea30b1" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b654fc46-0903-45b6-9e63-a34b58f13df1" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f2febaf1-eda8-4ea1-ac6a-0c380f2d065c" contextRef="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94b4a385-a951-42a0-b295-4c945cc844e3" contextRef="C_1a914828-67e8-495a-9b12-2c48154e0de5" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c2423655-f042-498a-9844-f80d70bdefe7" contextRef="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"></td>
        <td style="width:1.228%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.132%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.218%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.419%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br />value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6896f1a-eab3-4ff0-b256-cddda6ba7bb3" contextRef="C_0ca2fc95-4cb8-4120-8d3b-72c64d65a515" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0cf8a642-4b5b-4832-ad96-83520ba68178" contextRef="C_1fa2bdd3-e60a-48e3-89d8-47c5490b909e" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_741c6c86-141e-475b-b619-6f0abd9cf1dc" contextRef="C_8f2608f6-1835-45a9-8887-c4db04550843" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f31b3652-cdf9-49c4-ab15-50c49cea0f11" contextRef="C_2df5c335-7703-4efb-9c6f-ac0c13ef2ed0" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3161836b-69a5-41bf-bbe0-265de40a0ffd" contextRef="C_dc7fb957-db9b-4919-85c0-f2b666593c29" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1a48a6ab-f24b-476e-8343-f3211730cbc4" contextRef="C_0e2c72aa-22a4-4e86-9784-5469e1b2efbb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_010cdd80-9568-4f07-8b64-f46142683e46" contextRef="C_808142c2-b5e3-4524-9ea6-da21e029cba1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,341</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_81c9614b-2d88-4b0f-bc6b-8519e2850d7a" contextRef="C_3ebb779e-eadf-4f21-b115-8bc997a90a32" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_60eaeb50-c8a9-4343-9c49-427331129a0a" contextRef="C_6b8656ae-4c34-40f1-ae35-56f5f8a895dc" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d6ef1a7-8c67-4824-b6a0-f18ae6df158f" contextRef="C_69ead165-eb9d-4003-9e73-6dde8148295a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d28d841-f668-45db-b3d0-2811c90a7982" contextRef="C_9e4fa60e-e2a1-48fa-9006-8da2fef90e88" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,771</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8b82acb9-0c36-4ff8-b15d-86fc74373528" contextRef="C_87908575-032d-4129-a33d-db396e918336" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_770636b5-8ced-4a2b-83df-e3dbd42a4c24" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">354,239</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_92b96805-d483-43cc-88a2-1d19d6aecffe" contextRef="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,127</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c12af2fd-daff-44a4-a027-318dea527b2b" contextRef="C_24f24102-d3be-4e87-98e7-0dfd0698620a" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">296,112</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a621d1b0-25f5-4664-ac66-bc037f00d0f6" contextRef="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_19aa62cc-8436-4221-a9d1-db5e4041713e" contextRef="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd423e60-5861-4583-87fd-c52a267dd08f" contextRef="C_9e463725-1023-4ed8-9f1a-3d4cf8b31389" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb83e825-5cbb-4aea-9a98-d30c480fc281" contextRef="C_e3e444f8-82bf-4a8e-a308-5343180b3425" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76ece1f3-a591-4a1e-aa1f-982715e99c86" contextRef="C_727f645b-7b13-42e1-8111-8ed8a5b4c112" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_df7e6e2a-b8f1-4366-b732-775732d92b76" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_df077667-b880-45cc-a32a-117390aeb214" contextRef="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ed24c70a-5fab-45f2-b009-a2352af4b236" contextRef="C_24f24102-d3be-4e87-98e7-0dfd0698620a" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e3341aa5-f80b-4269-aff8-be50767fce99" contextRef="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47" name="us-gaap:FinancialLiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash Equivalents</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;Cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52843c5e-485c-447d-a537-77cc6beda7c6" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b1e3be7e-12c3-4007-b558-3c9cabd20d96" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:CashEquivalentsAtCarryingValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">58.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> as of December 31, 2022 and 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable Securities&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution Rights&#x2014;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_030be572-0c3e-4185-9d6e-5f6e549e6519" contextRef="C_549dd0a2-a1f7-47be-962d-821373cb96d0" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO in June 2021. Refer to Note 5, Fair value of financial instruments, for additional discussion.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success Payment Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e416d487-2865-46a4-8897-159a72a346b9" contextRef="C_6c1812ca-014b-4804-9c67-8987654bfa75" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="9" decimals="-8" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#x2019;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9fce782-8914-421a-bbf3-31af8cbb8e24" contextRef="C_645da17b-a2fa-4382-926c-98c8f1d57914" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million (after termination of the Broad License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#x2019;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company remeasured the liability at fair value with increases of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_95712f54-898b-4a1b-be09-ea00c3a23455" contextRef="C_1bf4fef6-d58f-4313-8771-beb6b446dd32" name="verv:SuccessPaymentLiabilityPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb08d904-2a65-4ffa-ba1d-76d994cec09d" contextRef="C_10db78b5-9531-4269-b673-ed6a44209efb" name="verv:SuccessPaymentLiabilityPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_741bb4ff-6724-44d5-9bd4-2f61ed31900d" contextRef="C_a8c752a7-a423-48c6-a1b6-94dbe8e1f488" name="verv:SuccessPaymentLiabilityPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> recorded to other expense for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e66db3cf-8399-423a-b2f5-abd65cd0b853" contextRef="C_d8289e27-62a6-4835-8e99-588f8ef3162f" name="verv:SuccessPaymentLiabilityCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1fba3920-306b-4863-b9d7-0693d1a9ae36" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The primary inputs used in valuing the success payments liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.173%;"></td>
        <td style="width:1.356%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.919%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.356%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.919%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.356%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.919%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br />December 31,<br />2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br />December 31,<br />2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br />December 31,<br />2020</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8e8ccf3a-b750-4a5d-b1aa-84d5d1464dc9" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">19.35</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c87da60c-81d4-4f5c-ad3b-5f005da3023c" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">36.87</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d46da72a-83d1-4884-bf4c-b9f0a31bb127" contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012" name="verv:FairValueOfCommonStockPerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">8.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d73ec22f-9590-4b9d-b57c-41afc8b2c1f8" contextRef="C_6df26867-2d6b-46b4-b508-092bafb9230e" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9572fb3d-289f-439e-9bad-520aed09b1eb" contextRef="C_199a8315-5928-47de-86f7-85c75d05000c" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">77</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_19434ca7-2ce2-46ef-9eab-6ad0ce4dd23d" contextRef="C_7c63f0f3-4bd5-489e-af2c-513202741f0b" name="verv:FairValueAssumptionOfEquityVolatilityRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_27a0e8fa-6a6a-4a9a-a460-6079a31b753d" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:CumulativeProbabilityOfTriggeringEvent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">70</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_964d5134-b2df-448f-9d72-60816486c0c6" contextRef="C_5ac36620-71e8-4db8-856c-7631ba94d156" name="verv:FairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.50</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2020 the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company applied a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b20436c0-352e-4016-8408-9b88b6504c14" contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f" name="verv:FairValueInputsProbabilityOfTermination" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% probability of termination of the Broad License Agreement at December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_6d5932fc-b2c9-400d-9132-96213aecfb88" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.061%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.793000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.378%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.804%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.39%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.196%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution<br />rights<br />liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success<br />payment<br />liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd7d88bf-7ead-4f3b-b537-9fac13cf474b" contextRef="C_eca01a0b-4203-4974-86fd-df6598a8bcb7" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,916</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_58b18aeb-40ed-4016-83f9-d3ff0cf7d7bd" contextRef="C_69bde097-9b90-4143-bf28-ce208cea2c64" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,806</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7fabdca3-3f76-4b67-8b55-d58f8654f018" contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_14601ad6-7bf3-41d2-babb-f0345205b5af" contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f6af83e-f3f3-47f5-8164-fe675e28a162" contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_55867969-ed42-4226-a512-15e67ebcb5f6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_913aa5a7-42ed-4d78-84dc-60bb3ac1fe4e" contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd4cdd6f-9023-42ab-8e0a-deee8a3f2f53" contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ea34e681-f9bd-4239-87f6-3c073303ad38" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:CommonStockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,250</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fc6e9847-86ce-4bec-828f-00a7030befb9" contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,574</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e90a82ef-503b-4a23-97f9-a141670f0341" contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc21fcba-459d-443b-bf8f-e4159e47145d" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,389</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7bcbb35c-1b7e-4e96-b8b8-dfa2cd964c0d" contextRef="C_24f6e06a-2bf4-411d-b931-999829f73aa4" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4080fa68-bb03-401a-846e-4b3ef04b46b5" contextRef="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f78e9abc-a529-457d-a1e8-39d1c36a5362" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,371</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_80034555-f040-4401-b8ea-eb974ac489c8" contextRef="C_1235d3e0-b5c0-47c5-9f20-b1afa841a242" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9291e721-0507-42dc-8a6d-e670642f8ab8" contextRef="C_2c9c2b5b-d0e5-4156-b918-deac7e15a723" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_39ec6d80-80d4-43f4-bfbc-0b2907c959fc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b6aa82e9-e1bb-46c9-9d73-2e808424e8c9" contextRef="C_e3fcf3c5-2b24-43ee-a2b3-55105e54c465" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5153d4f-9d20-48fa-874f-fdedd300a01e" contextRef="C_5e543a38-cef8-457e-8d21-0bec7784e4f7" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5899e66-df41-4ef1-ac9d-60306bdb5bc6" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,885</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a5617269-c4fa-4ef4-b077-1cee42841885" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_94286fa0-3890-4112-b3cc-3e176d0cfe1f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.851%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.818%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.613%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.105%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c2a0885c-2fba-49a3-8d7e-b33053afd2d0" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,124</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1af9c2c0-ce9e-4ba5-8d0f-3ada1c761f59" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccruedEmployeeBenefitsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dea098f1-4af0-4a4b-9df4-e1e011a0c49f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:AccruedExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,919</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_580e0786-9ae9-4711-904d-9fe6398e03e9" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:AccruedExternalResearchAndDevelopmentExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,041</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d23d902e-6641-43dc-ac18-9873e77f6b0c" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,193</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f4080458-c94e-4fcb-bb64-b5466fff0fd4" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and milestone payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4fce9de4-79b7-41b9-839c-907a327ac5de" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:LicenseAndMilestonePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">310</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_98d8cd9c-7512-417e-9573-ce559742af74" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,221</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0f89f66d-067b-4154-9015-2e07de6a9418" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">792</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f26c351-8b72-4679-969c-c9dc22a31c29" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,767</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_029093c0-8805-46da-b167-c7f5fafc1dec" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:AccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,992</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_19bfb865-65a1-4923-a7ca-f0581e73ae55" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:LesseeOperatingLeasesTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Boston, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or ROU asset has been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_fb7534bf-e1af-4a84-9412-454503f099a5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"></td>
        <td style="width:1.635%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.477%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.489%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5be36d59-e922-44b5-8bc9-4839e8d70aed" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f14955c0-1616-43a8-9cd5-dd3907ff86b0" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,923</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ceded3dc-6afa-4f63-a956-7c3a5972ed36" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,601</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_51aebbf6-53bb-4d23-a034-39b7be682b47" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1d9e1db0-bfbb-47b9-9503-5c5f49a981ae" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">698</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cc25e3e4-3232-467d-8007-0318919a64ae" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,278</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2b3fa915-ddbe-45e2-b050-e808cd6f95e7" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ac2524e8-3851-46ce-b518-ba4e6d9227a5" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,948</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_14d8a440-bdb2-4b0c-85e8-c5492ceea4a8" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"></td>
        <td style="width:1.635%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.477%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.489%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_13716d9c-134c-47b8-b491-2d6b950e354a" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3670a76f-f422-4c97-b052-5dd4a3bdde30" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company&#x2019;s operating leases were measured using a weighted-average incremental borrowing rate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_82810f5b-da45-47bf-886c-d8eebcac21a5" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:LesseeOperatingLeaseIncrementalBorrowingRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">7.89</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% over a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_23aa5bdb-d623-44dc-9dfb-f54aad354bdb" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#x201c;Landlord&#x201d;), pursuant to which the Company leased approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_638ce54d-df86-4aae-8edf-0a9e6a3598b6" contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">104,933</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#x201c;Boston Lease&#x201d;), further amended in January 2022 to include an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_368c83c0-1e7c-44ad-9f6a-778c875555ba" contextRef="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8" name="verv:AdditionalLesseeOperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">249</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet, for a total of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af8c6c28-b85f-4c57-8400-c8d37bad0fd4" contextRef="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">105,182</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet (the &#x201c;Premises&#x201d;). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Premises were first made available to the Company in August 2022. Upon commencement of the lease, the Company recorded an operating lease ROU asset of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e69f5c29-c4ea-4f2d-95d2-c0ed80d25129" contextRef="C_70871dfe-f33d-4493-9391-2c839d284371" name="verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">91.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and a total lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ee12db91-cd93-4c25-8c94-6a0c34bb4d26" contextRef="C_70871dfe-f33d-4493-9391-2c839d284371" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s obligation for the payment of base rent for the Premises began in January 2023 (the &#x201c;Rent Commencement Date&#x201d;). Base rent is initially $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d89c742a-5631-4f28-a9c0-783846f95efe" contextRef="C_79adf0ca-6cf4-4e27-a49b-9bf797059526" name="us-gaap:PaymentsForRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million per month, and will increase by approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a3acb574-c85f-4da7-9aa6-49bb859464d4" contextRef="C_79adf0ca-6cf4-4e27-a49b-9bf797059526" name="verv:IncreaseDecreaseInRent" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% per annum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Boston Lease has a term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f0a34839-3af8-4bc7-a0ea-910fd9fb7dc7" contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_d44440a6-eb87-434e-b1e9-286bf266dd9e" contextRef="C_cbef945b-b67d-4d13-994e-026951a49f6f" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Under the terms of the Boston Lease, the Landlord made $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a0a4639f-fd0d-48a1-b48d-2e282e115c4a" contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea" name="verv:TenantImprovementsAllowance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in certain tenant improvements to the Premises to suit the Company&#x2019;s use (the &#x201c;Tenant Improvement Allowance&#x201d;), which amount is included in the base rent set forth in the Boston Lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f6777a3c-7924-4e1d-9fc4-ed372df2ff22" contextRef="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e" name="us-gaap:ShortTermBorrowings" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which may be reduced to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_43cb707a-8537-4bac-a77b-d858a510ff47" contextRef="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e" name="verv:ShortTermBorrowingsReducedValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3362e8ab-df17-4eeb-bd2f-8879e9e2e81e" contextRef="C_d159b9f9-0a0b-4be3-8ded-15481d15c220" name="us-gaap:PrepaidRent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which is equal to the first month of base rent. The Landlord has the right to terminate th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e Boston Lease upon customary events of default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022 the Company notified its landlord under its prior lease of its intent to terminate that lease prior to the expiration of the term lease. As of December 31, 2022, there was no remaining ROU and lease liability for the prior lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, the Company entered into a sublease for </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ace36a61-8e8b-48e8-9e5b-634a25a6cbc8" contextRef="C_c8436e03-c1f0-4e91-a1b2-e9f92451d6ed" name="verv:LesseeOperatingLeaseArea" unitRef="U_sqft" decimals="0" format="ixt:numdotdecimal">11,931</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_1bc8cb4f-7281-4c5f-acd2-a28d014f206c" contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165" name="verv:LeaseCommencementDate" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and has an initial noncancelable term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3b48d262-581b-4327-9f26-d206b7e38221" contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165" name="verv:LeaseNoncancelableTerm" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12 months</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_81100b91-937b-47bb-946b-74bb1570b0ed" contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Therefore, this sublease is treated as a short-term lease. The total fixed lease payments over the sublease term were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47c05f77-f004-4450-a44e-28b124ae15a9" contextRef="C_c0f7b69c-0978-4971-a704-73743e494290" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the Company was also required to pay its proportional share of operating expenses.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_9a693a25-3523-40da-a497-a30ec67ba7dc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.936%;"></td>
        <td style="width:1.922%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:16.143%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_aebf1b71-8d3d-463d-8262-e78f38c532f7" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,306</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a503ecbc-bddd-48af-8ab5-2011a8fe8eee" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,563</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_75ba1621-bd60-4d58-99cf-6c9997933d18" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,868</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1f986db2-4a49-4f4c-bb92-25d9d7f12b6f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,183</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_055b9760-6681-4787-9f1c-2755492f5b90" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,506</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0ae794b7-6057-4030-84ee-1924a2e09b77" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,736</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6533c169-8735-4ba8-bf46-53ae8c3b5aa6" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">119,162</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_843c8db3-a9e9-4db8-bff5-5f9358c92a5e" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">37,245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bb0b6029-1f7f-41f2-9281-8d474fc83769" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">81,917</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_81bc5bc4-8f9b-4a90-a702-d08dbc57322d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:LicenseAgreementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> License agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Harvard/Broad license agreement and Broad license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#x201c;license agreements&#x201d;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">agreements without cause upon four months&#x2019; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8527fcc8-0f5b-445d-add1-d5cf8ed68d3f" contextRef="C_910510d8-3c53-4144-8d2f-5bf2ee890957" name="verv:NonRefundableUpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in non-refundable upfront license fees and also issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ca33862-5545-4000-89f5-31d29cdde527" contextRef="C_811d34f0-c7b1-4e6e-ab97-bb9220268914" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5c93566-3272-4110-8058-264d823db1f6" contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. Additional consideration under the license agreements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ef89b253-4c7d-465c-862b-0f07f503df62" contextRef="C_0bedcb64-f835-4169-aae4-e6de370db89e" name="verv:PreferredStockFinancingPartiallySatisfied" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_69514149-ea3f-4bcf-96e7-4aeaa007ef64" contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f" name="verv:PreferredStockFinancingFullySatisfied" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c90e3323-783d-4576-8577-8541b4f8f203" contextRef="C_0bedcb64-f835-4169-aae4-e6de370db89e" name="verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" unitRef="U_USD" decimals="INF" format="ixt:numdotdecimal">121,411</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_06ab9a15-e5b6-44b4-8dd1-d5cabf915e70" contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f" name="verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">187,867</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#x2019;s IPO. The settlement amount totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9fc38b4e-5e23-40a7-86ba-5a6ad69b2ad9" contextRef="C_279982b2-44db-49b7-a99b-e765968a154b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">32.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and was settled through issuance of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_40111d18-0d9b-41fb-b29d-12709aeddac2" contextRef="C_279982b2-44db-49b7-a99b-e765968a154b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company is required to make success payments under the license agreements as further described in Note 5, Fair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">value of financial instruments. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_240815a4-5667-430f-a4c3-bd1578c90679" contextRef="C_d8289e27-62a6-4835-8e99-588f8ef3162f" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_aae41d4f-fdd2-42ad-bc88-30893db37e9b" contextRef="C_6c1812ca-014b-4804-9c67-8987654bfa75" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts were settled in cash in November 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_18dd4035-2f56-4de9-a798-55a7d83c474a" contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">46.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_310c73a4-3b35-415e-8626-e165e1089ee0" contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">108</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and sales-based milestones, respectively. In 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the first milestone was triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e3cf4efc-60cb-4a6e-9a19-423613e99252" contextRef="C_0445a9ca-bc9f-4e03-ba8a-fb18a059a14c" name="us-gaap:DerivativeLiabilities" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts remain payable as of December 31, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Beam license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2019, the Company and Beam Therapeutics, Inc. (&#x201c;Beam&#x201d;) entered into a collaboration and license agreement. Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four initial gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of a final patient in a Phase 1b clinical trial of a given licensed product for the initial gene targe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ts, Beam has the right to opt in to share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_00b67ba0-d0db-46a2-9778-3bf0ba60d22b" contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b" name="verv:PercentageSharesOfDevelopmentExpense" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">33</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product for the initial gene targets, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_42974ac0-e2af-41f3-82e3-1a3ca9397d21" contextRef="C_67250595-6ef1-4d88-b28c-b2e432497a69" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">276,075</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1332dec6-e4d9-470f-ac5a-fac5e17b15c6" contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a34fb85c-046c-4f4b-874e-c9d780ae1900" contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_48848996-244a-4e7d-bf2f-c3f55613b26f" contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. To the extent there are sales</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> of a licensed product, the Company is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dc0f4744-e179-435a-8ff9-646de881207a" contextRef="C_fc34a2a2-051c-4d86-b8ad-adf3902f2be3" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8fd22913-8ada-43e6-853f-be2fd724e32a" contextRef="C_02d7b42f-eec4-4cd5-861d-bf55e78340ce" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. Due to the submission of the Company's clinical trial application in New Zealand, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1acff290-a05b-415b-bdca-2e5117d1cd9d" contextRef="C_aab4db61-ccdc-4683-9f00-31e18b63c0b5" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered in 2022 and subsequently paid by the Company to Beam. Additionally, due to the first patient dosing with VERVE-101 in a clinical trial, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ddf23cc1-5306-4449-b48a-1582557a60a1" contextRef="C_f5c58be5-49fc-43e9-a294-cc491cbf767a" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered and paid by the Company to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The parties have also promised that in further consideration for the licenses granted under the parties&#x2019; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e99a72a5-86fd-43da-b7fd-9efe621f0732" contextRef="C_80fe8138-eecf-486b-bd60-cbf5bf880dae" name="verv:PaymentOfMilestoneDevelopment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7eefc329-57c7-47c0-bd2d-c1ef2a0cd071" contextRef="C_ce21619d-19f7-43cd-b8d5-a7b052f3bd59" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> expense has been recorded for these milestones as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the &#x201c;Amended Beam Agreement&#x201d;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company is responsible for the development and commercialization of products targeting the additional gene target, subject to Beam&#x2019;s opt-in right. Following the dosing of the final patient in a Phase 1b clinical trial of a licensed product for such additional gene target, Beam has the right to opt-in to share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5e2f78be-612f-4de5-a136-8bacfd5228b7" contextRef="C_4353a489-6849-4ba4-97a8-7fc091cf5f01" name="verv:PercentageSharesOfDevelopmentExpense" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_00a1f844-3862-4ce7-a30a-7081cac66b6d" contextRef="C_4353a489-6849-4ba4-97a8-7fc091cf5f01" name="verv:CommercializingProfitsAndExpenses" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">35</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam is entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Amended Beam Agreement also clarified intellectual property rights with respect to the Company's GalNAc-LNP delivery technology; grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology; terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Amended Beam Agreement was not probable as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Development and option agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2019, the Company and Acuitas Therapeutics, Inc. (&#34;Acuitas&#34;) entered into a development and collaboration agreement, whi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ch agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8c9e2b67-3f44-467d-a83e-1e74f33d1230" contextRef="C_e9d5bc3b-5c96-4d9f-b2f1-b89dbdfe1151" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million during the year ended December 31, 2022, and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50e91d14-d427-4e3d-867c-7aa4f3253fb7" contextRef="C_51f6cfff-f169-440d-8129-93e247a0bd28" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the year ended December 31, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. Under the terms of the agreement, the Company allowed the development and option agreement to terminate upon reaching the third anniversary of the agreement in December 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">License agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8f4b2f22-c032-4855-9a54-7792729930f0" contextRef="C_4d7ab199-9fb8-4980-b91e-4d41f59ce3e9" name="verv:NonRefundableUpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent achieved, the Company is also obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ccf1e521-2fc7-478e-988b-aed4e524dbcd" contextRef="C_a1b1686d-7c2d-471e-b953-e9208218d02c" name="verv:ClinicalAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7429ce50-8e06-4b26-bace-f7cf0cbfa361" contextRef="C_a1b1686d-7c2d-471e-b953-e9208218d02c" name="verv:SalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ue to the first patient dosing of VERVE-101 in a clinical trial, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c208566-00e0-4c7f-8917-cc92d51f5819" contextRef="C_a18baa7c-e6c9-43fd-b0ab-55458b1c2d27" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered and paid during the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Novartis license agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, the Company entered into a license agreement with Novartis Pharma AG (&#x201c;Novartis&#x201d;) to obtain a non-exclusive license to lipid technology the Company is using in connection with the research and development of certain product candidates, including VERVE-201. As consideration for the license and rights granted under the agreement, the Company mad</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e a one-time, non-refundable, upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8b774fea-8301-4c57-b8ba-ff8f392cc766" contextRef="C_f27beec5-2375-455d-9c1c-624e6dbd8e18" name="verv:NonRefundableUpfrontLicenseFeesPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million during the year ended December 31, 2021. The license agreement requires the Company to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cd0494cd-4469-41cd-b0ce-b9a1f0816c6b" contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3" name="verv:ClinicalAndRegulatoryMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5d80cde6-f82b-431c-b589-97a883612cf5" contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3" name="verv:PaymentOfSalesBasedMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones for products that incorporate the licensed lipid technology. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e0fedea8-4681-45dd-aa17-95dcf32e4537" contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3" name="verv:MilestoneRelatedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> expense has been recorded for these milestones as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, the Company was required to mak</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e a one-time, non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c73a4f75-c148-4ed8-a3ad-bbabd228b65e" contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3" name="verv:NonRefundableUpfrontLicenseFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to Novartis. This amount was recorded as research and development expense and was paid during the year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div><ix:nonNumeric id="F_a712488b-cb1b-4be2-b683-bb4387701ac5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vertex Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Summary of Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company entered into the Strategic Collaboration and License Agreement (the &#x201c;Vertex Agreement&#x201d;) with Vertex Pharmaceuticals Incorporated (&#x201c;Vertex&#x201d;) for an exclusive, four-year worldwide research collaboration focused on developing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, the Company entered into a stock purchase agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Vertex, pursuant to which the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_735ff689-21f7-4735-a60e-739220c71a8a" contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,519,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bf7c0095-003e-4bd4-ab2e-6f24eb2aff83" contextRef="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">23.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_68f06b91-4c6e-4641-b9df-ed56b3147209" contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3" name="us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Vertex Agreement, the Company is responsible for discovery, research and certain preclinical development of novel </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing development candidates for the target of interest. The Company&#x2019;s research activities are focused on (i) identifying and engineering specific gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex is obligated to reimburse the Company&#x2019;s research expenses consistent with a mutually agreed-upon research plan and budget (&#x201c;Research Plan&#x201d;). The research term has an initial term of four years and may be extended by Vertex for up to one additional year (&#x201c;Research Term&#x201d;). The Research Plan is overseen by a Joint Research Committee (&#x201c;JRC&#x201d;) as detailed in the Vertex Agreement. Any material amendments to the Research Plan are required to be mutually agreed to by the JRC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the Research Term, Vertex may select certain gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> delivery systems directed at the target to become a licensed agent. Upon the designation of the licensed agent, Vertex shall receive a license to exploit the licensed agent, and the licensed agent will continue to be developed under the Research Plan in order to achieve certain development candidate criteria agreed to by the JRC. Following the Research Term, Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the licensed agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company received an upfront payment from Vertex of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_36cad7b6-801c-428e-ba51-35df525bc448" contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3" name="verv:NonRefundableUpfrontPayment" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and is eligible to receive (i) success payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e58115e-b5c1-4dce-9991-d40e3020ddf9" contextRef="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7" name="verv:SuccessPaymentsForEachProduct" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">22</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for each product candidate (up to a maximum of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_20c7e244-9a28-4a3d-a294-cd038ee90e26" contextRef="C_b6c51c82-3c32-4a05-9b39-deffe3ffdec3" name="verv:SuccessPaymentsForEachProduct" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">66</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million) that achieves the applicable development criteria, (ii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f826ae0-2109-4d6f-842c-7f39a1da2334" contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3" name="us-gaap:PaymentsToAcquireCommercialRealEstate" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">175</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development milestones and (iii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_909972f2-2544-4b81-b6a4-30fcb0ffff09" contextRef="C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea" name="us-gaap:PaymentsToAcquireCommercialRealEstate" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">165</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, with the rate dependent upon the type of product and subject to specified reductions. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the first patient dosing of the first Phase 1b clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, it will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_58ce054d-e452-46c1-9a3d-bd1f483d0865" contextRef="C_80d92420-5853-477a-a2f9-78d029bbafe0" name="us-gaap:PercentageOfUnamortizedFilmCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">40</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% (with Vertex retaining a minimum of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_02d14aa9-00d4-4b7c-9f84-e5ce761a4684" contextRef="C_42e3df2c-8ff1-469a-8a07-db72c7a21989" name="us-gaap:PercentageOfUnamortizedFilmCosts" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_08365053-dede-4158-ae7c-74cb727432b5" contextRef="C_5c084e08-8487-4c71-bcce-ce2e7baea2d4" name="us-gaap:InterestAndFeeIncomeLoansCommercial" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d8e10f28-3b87-4336-9e3a-8ff40da06fda" contextRef="C_ef2c8bcc-a458-4df0-ac7a-cb2750615042" name="us-gaap:InterestAndFeeIncomeLoansCommercial" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">70</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, depending on the profit/cost percentage elected by the Company and the Company&#x2019;s licensed technology included in the most advanced product candidate at the time it exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days&#x2019; notice.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company assessed the promised goods and services under the Vertex Agreement, in accordance with ASC 606. At inception, the Vertex Agreement included the following performance obligations: (i) the research services obligation which relates to the research and development services to be provided under the Research Plan (the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x201c;Research Services&#x201d;) and (ii) three licensed agent material rights related to the options to obtain licenses to exploit a licensed agent, at a discount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company identified $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_93696961-877b-4aa1-821d-2cc352af3961" contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9" name="us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of fixed transaction price consisting of the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a7834795-84bd-450a-a814-d977a54c5ec3" contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9" name="us-gaap:ManagementFeeExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million upfront fee offset by a discount of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_417a3ee0-bfff-4467-8eaa-754a869e1888" contextRef="C_0561a53b-a5ef-42c6-abb0-89bfc7201442" name="us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million related to the </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f300d5d-73dd-4c93-b275-5b00269353a6" contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,519,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold to Vertex under the Stock Purchase Agreement when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred associated with the delivery of services under the Research Plan. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7b8b6ba-3dfc-432e-a250-a00ec864d8c0" contextRef="C_0561a53b-a5ef-42c6-abb0-89bfc7201442" name="us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">pany considers this estimate at each reporting date and updates the estimate based on information available. As of December 31, 2022, the estimate of the expected reimbursement is $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7db542e2-6b76-42de-8b69-2105a483f92d" contextRef="C_7ea5b1c4-02d7-4d08-83fa-e232cce51d59" name="us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million based on expectations as of such date. Additional consideration to be paid to the Company upon reachi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ng certain milestones are excluded from the transaction price as that consideration may only be earned subsequent to an option exercise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has concluded that the variable consideration related to the cost reimbursement of the Research Services obligation will be allocated entirely to that obligation as the cost reimbursement relates specifically to the services being performed under the Research Plan. The reimbursement of Research Services is considered to be at a market rate and therefore depicts the estimated amount it would expect to receive for this obligation. As a result, the Company allocated the fixed consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bdf2874d-a81d-4063-8cb5-df2f920fda83" contextRef="C_5476f53e-8810-4a5b-afa1-3ba7403c605f" name="verv:FixedConsiderationAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to the three licensed agent material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">willing to pay an equal amount for each licensed agent license on a standalone basis before being adjusted for the probability of the option becoming exercisable upon the successful completion of research activities to identify the licensed agents. The Company reached this conclusion after considering (i) the downstream economics including success fees, milestones and royalties related to each licensed agent being identical and (ii) that all licensed agents are targeting the same gene. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3fff0d5e-7552-405b-aac1-7ad155e92991" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" escape="true" continuedAt="F_3fff0d5e-7552-405b-aac1-7ad155e92991_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is as follows:</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_3fff0d5e-7552-405b-aac1-7ad155e92991_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.673%;"></td>
        <td style="width:1.994%;"></td>
        <td style="width:1.131%;"></td>
        <td style="width:26.23%;"></td>
        <td style="width:0.972%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research services obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1c969452-1013-43f7-9e2e-cccfd7d4fe90" contextRef="C_146d0396-0c40-4489-aa98-b2e85e1a984e" name="verv:PerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">First licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7de77cf9-8a2a-470c-ae34-e893b70f8ce7" contextRef="C_4507e5e6-86e5-49af-9e91-39416a49e6de" name="verv:PerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second licensed agent material right</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3c1de9db-11d3-405e-9c12-013545818f32" contextRef="C_9d9b46b8-dcc4-4ea7-bf1b-5b347b2d06e3" name="verv:PerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,667</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6be3192b-463e-4f5d-9049-257f516411b6" contextRef="C_1f9a1d59-c482-4313-96a8-40ac3152c220" name="verv:PerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,666</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ecd731b3-1c89-490d-be7a-f9b167f094d4" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:PerformanceObligation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The amount allocated to the Research Services obligation will be recognized on a proportional performance basis over the period of service using input-based measurements of total cost of research incurred to estimate the proportion performed and remeasured at the end of each reporting period. The amount allocated to the licensed agent material rights was recorded as deferred revenue and will commence recognition upon exercise of each option or, if an option is never exercised, it will be recognized in full upon expiry of the Research Term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_46d08463-f32a-4e8c-8606-5aae847c260e" contextRef="C_97838a2e-40af-4778-a7e5-dbade0a2d74e" name="us-gaap:DeferredRevenueRevenueRecognized1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of revenue associated with the Vertex Agreement related to research services performed during the period. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has recorded $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_276c9093-441a-424a-9168-3f72589d65c8" contextRef="C_014a8cde-c8d4-4025-be72-d973721b5175" name="us-gaap:AmountOfDeferredCostsRelatedToLongTermContracts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million as non-current deferred revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Costs incurred relating to the Company&#x2019;s collaboration programs under the Vertex Agreement consist of internal and external research costs, which primarily include: salaries and benefits, and preclinical research studies. These costs are included in research and development expenses in the Company&#x2019;s consolidated statements of operations during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f7403a9b-2c9e-46b7-9cf8-75428665bca1" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:PreferredAndCommonStockTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred and common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">has issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8e788149-df07-4719-98ba-0c4752d2d469" contextRef="C_8d200ccf-3e5b-4292-a74b-e614b3ce55e4" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">101,170,571</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series A preferred, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eeafbb24-bab8-42f8-ab31-85e5a7aeb937" contextRef="C_34a36f82-56c7-4f23-aefa-cbf18563b2c3" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,838,461</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series A-2 preferred, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8453954c-76a8-4acb-86ad-d902226d2aa7" contextRef="C_042eaa61-5d4c-48a9-bc1a-4987ee4f1dc6" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_32aba145-eeca-484c-9ee9-3a41b8086927" contextRef="C_875f1476-cc60-4a70-a9cc-ff85d743c58f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,163,022</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series B preferred and common stock.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company amended and restated its certificate of incorporation to authorize </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_82aff6e5-7ab5-4a5d-8bbc-99d225ac8636" contextRef="C_8d5b798c-354b-494c-aca5-76cbed28659a" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock, which shares of preferred stock are currently undesignated, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8bbd4342-8f52-4788-8908-1a17d702c14d" contextRef="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">200,000,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52f899d7-f5a4-47d6-8d7f-c04e3ceddbb6" contextRef="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="3" format="ixt:numdotdecimal">0.001</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> par value per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8546e994-f208-4ae9-85c4-4aea6a80fd47" contextRef="C_f3934e3e-c3eb-462e-aef8-a427f8923a25" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">16,141,157</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a3c0a434-268c-4197-ac8d-7d6e6ba9e036" contextRef="C_6ab5cdc4-68f7-4336-be12-9a43b519475c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,105,368</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_53ca0415-c9b0-4455-9199-36b13ac3c0df" contextRef="C_0d68b3a6-6891-4343-9cac-092f95f5b426" name="verv:PublicOfferingPrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">19.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4f71c243-50e6-4eea-9a83-2c463a363599" contextRef="C_6ab5cdc4-68f7-4336-be12-9a43b519475c" name="verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">306.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e5ee0eb-ea07-435f-be0d-75f111b44662" contextRef="C_72c91c7c-a0cb-4506-8c90-233e59c44e9f" name="verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">281.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4ca846ac-17a3-4a46-a3c1-25184911a6ff" contextRef="C_fb1c32eb-3cf9-4efd-b9f9-ef61f34a3d24" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">27,720,923</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock, and the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d50ca6e7-bcb5-4127-9cd4-b1701003832d" contextRef="C_e5fb7e70-f89c-46e0-8d34-d37cadafb70e" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">878,098</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_92d4bc5c-653d-44ba-97c3-86d1b3745ca4" contextRef="C_899016e2-2a07-4bd4-8bcc-57974930a3bc" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,519,756</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#x2019;s common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_075a2b47-59d5-4024-9707-51f970306f0b" contextRef="C_899016e2-2a07-4bd4-8bcc-57974930a3bc" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">23.03</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f94b07d1-c7f2-4a00-819a-2f924204a8c4" contextRef="C_f6e04a3c-5788-44a1-b5df-375dfe290497" name="verv:AgreegatePurchasePrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company completed a follow-on public offering of common stock, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b20cb342-314c-4fab-9e9f-d4e668f7123b" contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">9,583,334</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a04e4bb7-4ca2-4e5b-ba5f-d4013ad076b3" contextRef="C_e616ea55-8674-4e50-833f-8f6bccf6e730" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,250,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f82c0071-6d2d-4394-a5c6-3a678b71428b" contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8" name="verv:CommonStockOfferingPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">27.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_632531d6-5d2e-4e7d-9ef1-9a8dfbd981bb" contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">242.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_52020d16-bc3a-4e45-a315-a11954fe7289" contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8" name="us-gaap:InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company entered into an Open Market Sale Agreement (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) as the agent pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of the Company&#x2019;s common stock. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a3ab8473-a617-43a4-963d-dd299406ae2e" contextRef="C_df58c0aa-a8ae-4c98-9b38-70834ce1e110" name="verv:CommissionOnAggregateGrossSaleProceeds" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_90da0151-a32f-4b15-b890-68b596458438" contextRef="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,280,168</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock under the Sales Agreement for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_301f0591-6e24-450a-89db-5b05bdb7e44b" contextRef="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">42.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting commissions and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The holders of c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ommon stock are entitled to one vote for each share of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_5eba59d4-c964-448e-9810-26f64fdf0d5c" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants for the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> issuance or purchase of shares of the Company&#x2019;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d4014bca-e280-48cd-9b2e-f55358d6b783" contextRef="C_59c54d37-04e4-4cc3-9af1-28ee8d5dcf07" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,885,653</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. The shares reserved for issuance pursuant to the 2021 Plan are subject to an annual increase through January 1, 2031. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0cc86586-b562-408e-8dd3-266a04970cd8" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,057,629</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock for issuance of stock options, restricted stock, and restricted stock units, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7e3c155a-640d-410b-8cf3-cc68df78f85e" contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,025,807</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> remained outstanding for future grant under the 2021 Plan. On January 1, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8ce055a3-ac2b-400c-8da5-31e0757626a8" contextRef="C_830a7292-f023-456a-aa51-b7b87abe1927" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,086,541</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f9f13f7f-9a7e-41f9-828a-da710b47aaaa" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.359%;"></td>
        <td style="width:1.406%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.719%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.396%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.719%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.396%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.006%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_31af9e00-5298-40f7-ba53-99e42b1e515f" contextRef="C_57662c72-eee2-4c4f-951b-40edfc12c8d7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,486</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f122ca6d-5e81-47d0-967d-d84c076fd14f" contextRef="C_604ef497-9ecd-45dc-bf27-276566041fda" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,830</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a43a61f0-7ba8-4aa2-bed4-3064c9a39a9f" contextRef="C_3cbafceb-7d5c-4f1a-8167-31d9b2611fff" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">494</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6202f341-4268-4ea2-a7af-9775cf1aad84" contextRef="C_aea2e412-934b-4a07-a049-22c9f1b5ea0f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,991</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_636d72bd-4e44-4995-bf42-fe4d87e63b75" contextRef="C_86e5cc33-d110-47af-ada1-8665901d8afd" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_24dc9c66-c26d-4bae-ad14-9550eb8acb1a" contextRef="C_ce0e9729-f513-4bf1-8488-e529d1be5407" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">356</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9845443a-a81a-4be6-8bb2-dc3c75f93d1a" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,477</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c38a29c1-933e-4c48-9ab3-53d11de2b32a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e583497c-50b5-46a0-a8f8-fd790d9edf55" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">850</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_a6410f78-02df-4d3f-8121-e970ade903c7" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.835%;"></td>
        <td style="width:0.989%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.475%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.989%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.475%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.989%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.247%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br />December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2d51ff62-4beb-49f2-a011-4ba0d66bb987" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_87751413-32a2-44e2-b51f-ec4faea52037" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b6544811-6541-41d6-98f9-948ff168bfdc" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">84.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fcaa3184-841d-4178-b19c-187f7d643412" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d6617667-8296-470b-bb45-b606f57bcf5e" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4224c5d9-8cd3-40fd-8048-71f041f62c18" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_56d47e8f-aa7e-4966-9f13-22977e3dcee8" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_723539be-cb87-463b-8d8b-9442e86bba40" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_d7d9f2a0-f9df-4a02-a772-441b307975f5" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b05dd4c8-8a49-44ca-aa5c-7bc52ee687cc" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_e6148835-322e-4742-bb64-9ba503c14de3" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.143%;"></td>
        <td style="width:0.823%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.238%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.991%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.633000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.823%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.466000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.042%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.839%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of<br />options</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br />average<br />exercise<br />price per<br />share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br />average<br />remaining<br />contractual<br />life (in years)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate<br />intrinsic<br />value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br />(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d15a022f-0e67-4abf-8c9f-b7320801dca1" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,119,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_243a2172-f455-4889-bf6d-3cdddf228bf6" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">9.44</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f682e5cd-1004-4024-a345-40c979c17437" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,561,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_810fd13d-6310-4761-94e3-488759456c1d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">28.49</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e270a080-07e8-41e7-a76c-f581dc2a1982" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">743,638</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_75fa504e-94b1-41b0-9a44-ba8760020af2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">2.92</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_18f8c341-cc10-4ec9-b6c1-6bbe758d694f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">324,131</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8da5c371-86c2-4d9e-9af6-bba004979c59" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76da6e34-8259-4dd1-9d6d-fef59f17f320" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,612,826</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ad1dd59-f2cb-4da0-af2c-886026b03526" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">16.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_3d235212-484b-4e5a-92de-60c509efce7d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3e8d2871-8d7c-41d2-a82b-315398b036e2" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_97311c9c-61b4-4e18-a3f0-2ad32a6c4f61" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,551,841</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_38be8608-8859-4956-9595-0e55be9a3985" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">7.52</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c31804f4-757a-40fc-84fc-127c9515ac06" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_09a7fb2b-0c8b-414b-a38f-15fe81be641f" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected to vest after December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f13bbc0a-1453-4f66-a849-7ec20406a08c" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,060,985</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0a599922-8081-4710-9bde-35868f890597" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2">20.43</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_ee2714e4-37d2-461d-909b-8a096b25efba" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.6</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,495</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><ix:footnote id="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.</span></ix:footnote><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022 the weighted average grant date fair value of the stock options granted </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1c93bcc7-9c60-475a-ac0f-becfd10e8aa2" contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">19.39</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The aggregate intrinsic value of stock options exercised during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8b6d50d0-48af-4d05-8321-fb8f57bc8fb5" contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">21.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million while the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d5cac074-c2cd-4971-8744-2f60cebd80f8" contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in proceeds for the exercise of these options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_32a0ff97-a519-45e8-ac5c-cfd5bd595c0e" contextRef="C_40e18ed5-64dd-4a21-8cc0-7eb7d48b6faf" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">64.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_55391a03-f69a-46a1-9ba7-dec7eba1c73e" contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted stock and restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2018, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ccda87d-46df-46e6-9510-4b03d920ea42" contextRef="C_345d25d5-d53c-4618-b2d5-0ad9f68dc335" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">2,150,537</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of restricted common stock. The restricted shares vested in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_64549902-7136-46ac-9cd3-ffb22dc77e62" contextRef="C_3c170bb7-edb6-442d-8788-b1811c3e3301" name="verv:NumberOfInstallmentsForRestrictedSharesVested" unitRef="U_Instalment" decimals="0" format="ixt:numdotdecimal">48</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_17230d37-f24f-47cb-a8fd-104181155b68" contextRef="C_e4a312ba-6931-4d91-b541-fb2e420d6d93" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">688,700</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_b5e252f1-e8b6-4c17-9355-8c4bfe5cbd9f" contextRef="C_bcc724c9-3022-47b5-8ad1-b152262e7aba" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">four-year</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_db394905-e39e-4aee-8694-0a2d5575d125" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.119%;"></td>
        <td style="width:1.184%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.877%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.077%;"></td>
        <td style="width:1.866%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.877%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-<br />average grant<br />date fair<br />value per share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fd546605-1393-454b-a785-6469fc69293f" contextRef="C_f440c691-328c-490a-b5a2-6550bd63dd18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">32,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fb2c8569-4061-446e-b9ce-0a9590adfd08" contextRef="C_f440c691-328c-490a-b5a2-6550bd63dd18" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">36.58</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_84e0715a-4625-4bc8-ba55-db40d59260dd" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">688,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04da067d-67a5-496c-92bf-a784f9c4bff8" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">22.65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b808e5bd-6911-4218-9726-9bb053e3a134" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,375</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2de18436-4318-4299-a7a9-fae1d95d6339" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">35.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c65b205d-fcad-4525-b00b-de44251f369e" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">36,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b343dc6d-9cd9-4eb7-86a1-49c0558db798" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="verv:WeightedAverageGrantDateFairValueForfeited" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">24.32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7f2f3bf3-ace7-46e3-809b-b522f2e9dba2" contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">677,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_12602417-6890-46b4-bc0c-44f3be6dfc1c" contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:numdotdecimal">23.10</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b183dd08-963c-42cf-bb3c-05e3d71812b1" contextRef="C_4c419fcc-8948-4d11-ad8c-bc4acd187a2f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">13.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of 3</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_c053f0ca-3840-4ce2-be5b-3e9a8e7d31a8" contextRef="C_7175e0b6-9535-4c9e-8e30-3ebf8ac9de8f" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Amended and Restated Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The shares reserved for issuance pursuant to the ESPP are subject to an annual increase through January 1, 2031. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_78ce48a1-0634-4d79-9bb5-596e234fcd3d" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">134,107</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares had been purchased by employees under the ESPP and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cddc92e9-5135-4c1f-8c3f-8ff1c63dd64c" contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84" name="verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">784,326</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares remained available for issuance under the ESPP. On January 1, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_558c5416-0af9-4ca2-a5bc-8e7718b6e9ae" contextRef="C_a90ac7d2-282e-440c-801e-9a2c12563c84" name="verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">617,308</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock were added to the amount reserved for sale under the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_805672b9-e8d4-4cd8-90d9-1eca26080b80" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12. Net loss per share attributable to common stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_57c6bb96-d856-4792-a989-df9a7841e033" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.184%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.838%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.391%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.828%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.391%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.967%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e8640443-3ea8-44e9-a748-a9fbcf872417" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">157,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c1d63082-8072-4f11-b0d7-518fa1f769f3" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">120,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ccd037ac-5a75-41ac-93a4-ff951d97f160" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">45,704</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_70795245-c44a-4a13-8dd3-f465f06773e9" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_cd6cdba3-9572-47f3-9f12-e62b1482bc87" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,023,653</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e8eb7313-3415-474a-9a8c-36873211c36b" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_db255bd4-d5a6-4865-9952-b931e9ddeea6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">26,872,036</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_733d71e0-4a3f-4851-8371-70d3b1206622" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_662aa3c0-3431-440a-97c3-639d70cb5716" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,250,093</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a9ea0d04-5ec1-492c-9cd5-0b253366eed4" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_6b85571b-2059-459e-b0e7-45b837b714af" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">2.91</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_11667e64-9733-4f0f-aa82-f4cb56bb611f" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_1d897b1a-9344-42f4-b40c-7443fc8e047e" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">4.48</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b2c37d5e-1e72-4e8d-b297-51ed2d1aae3e" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EarningsPerShareBasic" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal"><ix:nonFraction id="F_e400fe90-27c7-4bd2-92cd-d9c15e5b9080" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EarningsPerShareDiluted" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" sign="-" format="ixt:numdotdecimal">20.31</ix:nonFraction></ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#x2019;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units, and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_deb2eea3-e480-4f2e-9343-8016bd87cdde" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true" continuedAt="F_deb2eea3-e480-4f2e-9343-8016bd87cdde_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_deb2eea3-e480-4f2e-9343-8016bd87cdde_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.329%;"></td>
        <td style="width:1.007%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.774%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.774%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.085999999999999%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4cfe3138-f788-4b6e-8d5b-a7283f48b493" contextRef="C_5977f77c-03e7-4fcd-8eb7-0857be233fcb" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8726c12-de1f-4c95-90da-91cdbcd54fc5" contextRef="C_787fb8f2-564a-4ad4-9e81-6ab4543c8745" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a884cfb9-541c-4d4a-a019-c0b4b4e7b234" contextRef="C_336f1e13-611b-497c-ba64-333f8e899c92" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,387,544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3ccc0d01-0bd8-4bd6-b26f-3bb661fba63a" contextRef="C_d49a8d56-7215-4b6b-85ee-c2345d8966fc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3da0561d-cd56-4c6f-8c0a-9996a69b4d87" contextRef="C_0e5b7c24-a5e8-4c36-8628-c7caf3267a19" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_89bb5089-5fca-4e4f-a6ec-16bb47267781" contextRef="C_101c4b75-a6d1-40e5-b320-d63b7c3de7e7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">537,633</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_60355410-ee73-43a4-96cd-e88d26fe6822" contextRef="C_01e0a48b-6d98-43b9-9faa-58583e0071a6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">677,825</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_04fefb94-3bff-4d93-a34c-d63fc846e082" contextRef="C_9ac9284d-7074-4f13-885b-3fd225b5738d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">32,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_295bc431-4d67-4ca1-abc9-8136a680aa51" contextRef="C_28ec8de1-aead-4024-b68e-b6f0436f3e8c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_27621f8f-701c-445f-bfec-63b403fd730c" contextRef="C_a2029774-b097-49be-abf0-6584c59d9b9d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,612,826</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_61526d5c-c8ae-4428-b286-095aa1f6c4b1" contextRef="C_dd1cb871-5f3e-4054-bc64-84e70cd6064d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,119,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fac084ea-22d4-45be-b828-dc656f59a118" contextRef="C_346778ed-ab28-463d-a0c6-1e76673dd790" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,888,823</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a4c0ed46-9030-4c35-965e-34c228611a6e" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">8,290,651</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_dd1b979d-62e6-4bb1-8f90-9b519cf518da" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,151,295</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fa53a679-1ae3-46b8-b179-0ee6263acf70" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">23,814,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2022, an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d8dd2350-db46-4d7c-a85c-6a996e1c798e" contextRef="C_94979cff-1f2a-464c-857e-c9995bec9c94" name="verv:SuccessPaymentLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was earned relating to these success payments, which the Company settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_28c35ebb-ce84-498e-92d6-78c7ebcbc095" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true" continuedAt="F_28c35ebb-ce84-498e-92d6-78c7ebcbc095_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company's losses before income taxes consist solely of losses from domestic operations, which totaled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_646dd7ef-1990-4173-8f52-0ee37f863648" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">157.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0623b21a-1e89-473f-8a9a-076b46b28d6a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e9c800cf-ea63-4a11-82a7-2e65663029fa" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">45.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_cdd01b56-fd44-49c9-8cc8-fbe5d76a98c0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income tax expense (benefit) is summarized as follows:</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.662%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.629999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.629999999999999%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.401%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:10.876%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fc4a6355-3a88-4757-90aa-decd3ae25fe5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9e45147e-4150-42c8-853f-c8f2921157fd" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a8420aa0-7a32-499c-8531-79821f1b9204" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d3f18bc-fbc3-4aee-8e7f-e3a84e982882" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ba0bd889-8f76-4bd8-9f90-5150e3a4d143" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f5bfe00b-18b7-44a8-a2f9-359369c596ba" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8d1de571-8382-431d-982a-b7e52a011ed1" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_57ea769d-ee65-416c-a133-dea9ce2def64" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5a7002e3-919f-41d5-93fd-3b9b0a441d36" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_10d942ee-85f8-4611-936c-0276033cd9f8" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5e7d2535-6c41-4feb-9713-8dfcbc813812" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c113d7a8-1cda-4230-8796-f45081285b50" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0df4ac71-3bcf-49cc-8701-750fdbebe9dc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a60ae281-d8a1-4777-8cdf-aa2e89b9ced6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_32cade3f-d6d8-4c85-bc2c-99c2afb57e42" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fdfca671-7079-474b-af79-316b8f7fef97" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_08bc33de-d0f2-4f93-88ba-1974627478c3" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_28872d9c-22a3-4ef4-8a62-53ec39c85035" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ae151fce-8e44-4b12-bed3-8c96b565038d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e05878cc-4844-491c-aa7c-e08a2a6679db" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cb52b461-258d-4bfe-befa-0b89774fd7cb" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5155164f-33e2-4192-a111-878bca103e23" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5749a672-5a3e-4a78-bd57-1876e3a472f9" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_4c04605c-5658-47c3-be9d-abd4b98778a8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">-</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_03ef9407-ffff-489c-b80f-7a6bf637e1c0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.004%;"></td>
        <td style="width:0.984%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.338000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.994%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.338000000000001%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:0.994%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:11.348%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a6bf8734-dd29-44f2-9830-d6e4104d3e65" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ce915678-f911-468f-a79c-26e136be9779" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_44a14dde-3a88-4a40-9fe7-6697c674fc2c" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_eb03c9d8-182a-4393-8adb-4d431a7e6859" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">34.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_46056b0c-17c7-4a34-ae85-3572d75aa38a" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1c4dde36-8c0b-4937-83ca-c756bbc667be" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">29.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d44b11c3-9b48-4cd9-a759-6fa7c7ae510f" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_76a3dd0e-93b8-4519-845e-a1fb4a9a13d6" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2e72ca1d-abf8-48cb-8855-92e17c2321c8" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.3</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Executive compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e7ff60eb-c61a-4fa1-b81a-b271e29372cf" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c1d96cf-4e52-4f0a-b8fd-de711a87a908" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_94fe7169-bb45-4bf8-82cc-05f9d0ffa92d" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_989f04b4-841e-42ad-b717-a0a8eab2fa47" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1437d3cf-73c5-4589-a615-a9f4eaac08fd" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_74f496b8-e7bd-4184-a14d-95de73170163" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:EffectiveIncomeTaxRateReconciliationPermanentItems" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_773f687f-08e6-404c-92d1-f4bdc3ba47a5" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">8.4</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af883616-978c-4683-b84f-8d26a0584514" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5b37fdcf-5c7f-4bb9-bd2b-a8b54014fe38" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9ee549e9-b4ab-4b3f-9bc8-51fc7ce9dca2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f1f48748-f926-43f7-b493-39bb39ac4b70" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5e7a52da-d099-4b88-b7fd-6df246113389" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1f6c0015-a89f-4192-9413-f1ba993802d2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:EffectiveIncomeTaxRateReconciliationOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3f844f8e-1296-42fc-ac11-de9dc8b7a5f5" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="verv:EffectiveIncomeTaxRateReconciliationOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c06222f9-41b7-4235-bf72-d9ddef8bface" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="verv:EffectiveIncomeTaxRateReconciliationOther" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_50952bb5-05e4-4c39-a600-7e00438a28fa" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f9775c3e-fae7-48d0-9dd2-fd990e5438fd" contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ff983ae7-b84b-446a-b512-96ace5729d87" contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2022 and 2021 are comprised of the following</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_78f2bbd6-dae5-4b87-87c3-8d5c99aa47dc" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true" continuedAt="F_78f2bbd6-dae5-4b87-87c3-8d5c99aa47dc_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:continuation id="F_78f2bbd6-dae5-4b87-87c3-8d5c99aa47dc_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"></td>
        <td style="width:1.611%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:12.941999999999998%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.611%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.079999999999998%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fe9089e2-82de-44dd-af59-db461ff44ca1" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,779</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_78d4d0ba-1b86-4c72-8944-f9ffc06bedc0" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized costs&#x2014;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0532ba67-52d3-4020-9eb4-8e691b7906fa" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,095</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8105dcb3-7277-4124-bf79-3fc982738adc" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,395</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7c42cf3b-1e6d-4e2b-9315-c6b85b92f788" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_15bd770e-cad5-4930-ad29-7cb5569faef3" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ab039620-6de0-4aa6-8abb-3b6dc804d655" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,650</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2aafece1-0184-4d36-a49a-da38e52dada6" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:DeferredTaxAssetsStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,669</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d42f7d4-cb16-4e00-a6eb-03032d9fc8dc" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:DeferredTaxAssetsStockBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,117</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1eea6d0f-474f-4daf-aad4-e21b00757b0a" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">174</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3192279b-8bc5-4d27-9bc6-1eb6af271744" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5f10d659-2aed-44a8-a919-09277b73d945" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,285</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_af8df070-6722-4854-8399-6b4a5e05b00b" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">533</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e1c43fc8-e786-40f2-a5e5-0c852f75f7e0" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:DeferredTaxAssetAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,024</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_60887a7d-ce52-4349-9a5d-24454446d54e" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:DeferredTaxAssetAccruedExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6ed11926-7e1e-4968-a081-f3377a504159" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">135,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_b63ba75e-c7eb-4e72-8b54-53303c1fe119" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56,480</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2a390555-4775-437e-9552-160a4e2db0ff" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">881</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_00c30542-18d8-4c61-8799-7a5f51d35c63" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_79291490-2f10-49ba-8aa6-3c75b6d6e623" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="verv:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24,994</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_214a0ddd-a3e5-44e9-8137-806f88c56815" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="verv:DeferredTaxLiabilitiesRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">501</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_7152d2b3-b9d7-4d09-b33a-776695153d55" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,875</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0f40ebaf-80d3-4047-8939-a78635f404bc" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,400</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_899b3e9f-085d-4be3-8fd4-32cd195eca37" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f01728b3-3e8c-41be-86a3-e146d26c0210" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_010c1983-e9d0-40f0-8e1f-e10cc5baf748" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,636</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_84d15b33-298f-4d89-a8d1-dc121003e1e6" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,080</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_0ff3debc-9f6c-4997-8e8f-26a16c9c05da" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_8babecbb-2e85-4e97-bf86-c14346b00e27" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has incurred net operating losses in each year since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s net deferred tax assets, which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#x2019;s history of cumulative net losses in the United States and estimated future tax losses and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2022 and 2021. The valuation allowance increased by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_e900c522-2c2c-4112-b126-ac97732f90b0" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">54.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> in 2022, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. The Company&#x2019;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_f34e87c8-8442-4ecc-8ae6-5cda16abade2" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:ChangeInOwnershipDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_47507c25-78ee-4354-be2f-a53215082af7" contextRef="C_dd53e7c9-c890-4a7b-9181-75e01d01947a" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">163.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ec8be912-2917-4d1c-abbb-8763497af48c" contextRef="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">148.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards The federal net operating losses have an indefinite life and can be utilized to offset </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_d12840a8-b2da-4f1c-aa2f-c117c2012d75" contextRef="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018" name="verv:PercentageOfFutureTaxableIncomeUtilizedToOffset" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of future taxable income, while the state net operating losses will start to expire at various dates through </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0df0e8b7-2337-4044-bd6d-d516a275df84" contextRef="C_62529372-4437-4f8a-a2e2-7adb297a1ce7" name="verv:OperatingLossCarryforwardsExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Additionally, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ec4317c1-1869-4feb-98c1-49451b4d398a" contextRef="C_dd53e7c9-c890-4a7b-9181-75e01d01947a" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_a5e82df4-c171-4a7f-a019-69fad5666f98" contextRef="C_1eb38d59-c0ac-4039-ba0c-18ac2f3c88af" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of Massachusetts tax research and development credits that expire starting in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_446fd862-0ad1-4f79-8f95-3535ade0a892" contextRef="C_b8d60c32-c672-429e-9168-9e517a3b0c68" name="verv:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2042</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_893be8b9-13ac-4055-b712-4bacc9487882" contextRef="C_42d8066c-ec6d-457c-92e0-ad6208d5c754" name="verv:TaxCreditCarryforwardExpirationYear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2037</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_f7b22f09-6203-4443-8736-cdb0c2fa27f3" contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_e7375e70-8b54-4c95-9851-e7f65c6a11e6" contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_ca364bc8-e72b-45d9-b815-a0ac8a182c87" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" unitRef="U_USD" decimals="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_28c35ebb-ce84-498e-92d6-78c7ebcbc095_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, Pennsylvania, and Wisconsin. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_abd2f758-8de1-4f15-9088-083813defb61" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14. Related party transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An executive officer of Beam was a board member of the Company until August 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the years ended December 31, 2022 and 2021, respectively, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1cbd2163-2811-4142-b311-80d37ddc0db1" contextRef="C_467087e6-7c15-4d2a-b5aa-9b131364dec6" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_cf3d249f-23e5-49cc-9439-318d1dbb6ff8" contextRef="C_88c35c5e-d77b-4780-9fe2-eff887d461de" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts, which sublease terminated in December 31, 2022. Total rent payments under this sublease were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_9d01ae64-6dec-4aca-8be3-3fa820400f0d" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="verv:LeaseRentPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_0305bacf-6b59-41f7-9500-3e24ed5d8d06" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15. Employee benefit plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of employment. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_82437b18-6945-4459-a243-7b3f0a5c9869" contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26" name="us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tutorily prescribed limit, equal to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_3da0a082-127d-4c57-bd4c-ba092fce9573" contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">20,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> in 2022 with a catch up contribution limit equal to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_fbe15966-9ce5-46e4-bb0e-245863f02abf" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" unitRef="U_USD" decimals="0" format="ixt:numdotdecimal">6,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Since January 1, 2020 the Company matches </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_abf3499c-2f50-4442-81b8-0364e16ce35e" contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of each participant&#x2019;s annual contribution to the 401(k) plan up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5c55c6af-fddd-487c-b15f-284b40ea6536" contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the participant&#x2019;s salary and then </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_5034f149-290b-409d-bc6e-a9c1ba764e46" contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of each participant&#x2019;s contribution up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_1d721bff-e883-4f6f-b1ba-145ddc742fdd" contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26" name="verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the participant&#x2019;s salary. The match immediately vests </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_6d94f22b-e2e5-4ea6-a5ee-f59cb24f2e3a" contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a" name="us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">100</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%. The matching c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ontributions by the Company to the 401(k) plan were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_bc874398-00e8-414b-8e42-50683c38885f" contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_c647a9c2-cfb6-4061-9f9c-4132a99eb16e" contextRef="C_1f3707ed-9eee-4702-833d-a6141f5a0cf1" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><ix:nonFraction id="F_2071132d-26eb-4dfe-99df-dc75f0a788c4" contextRef="C_38705494-508f-4282-b760-eb63eae1915e" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> December 31, 2022, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;"><ix:nonNumeric id="F_57093492-f965-401f-afe8-0e6a9b0d40c7" contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ubsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">30</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>2
<FILENAME>verv-ex10_5.htm
<DESCRIPTION>EX-10.5
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">		Exhibit 10.5		</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VERVE THERAPEUTICS, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Unit Agreement</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Verve Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) hereby grants the following restricted stock units pursuant to its 2021 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notice of Grant</font></p>
  <table style="margin-left:1.0%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.995%;"></td>
    <td style="width:50.005%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of recipient (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;):</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of restricted stock units (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) granted:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Start Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Schedule:</font></p>
  <table style="margin-left:1.0%;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:49.995%;"></td>
    <td style="width:50.005%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Date:</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Number of RSUs that Vest:</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:28.1pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Verve Therapeutics, Inc.</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">					</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Signature of Participant</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">					</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>Street Address</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</font></p><p style="margin-left:17.1pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of Officer</font></p><p style="margin-left:17.1pt;text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">					</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br>City/State/Zip Code</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Verve Therapeutics, Inc.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Stock Unit Agreement</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Incorporated Terms and Conditions</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Award of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of services rendered and to be rendered to the Company by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and in the Company&#x2019;s 2021 Stock Incentive Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), an award with respect to the number of restricted stock units (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) set forth in the Notice of Grant that forms part of this Agreement (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notice of Grant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  Each RSU represents the right to receive one share of common stock, $0.001</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">par value per share, of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) upon vesting of the RSU, subject to the terms and conditions set forth herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vesting Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)[, provided, however, that upon the Participant&#x2019;s death while the Participant is providing services to the Company as an employee or member of the Company&#x2019;s board of directors, the RSUs will immediately vest].  Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs.  Upon the vesting of the RSU, the Company will deliver to the Participant (or the Participant&#x2019;s Designated Beneficiary, if applicable), for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant (or the Participant&#x2019;s Designated Beneficiary, if applicable) as soon as practicable following each vesting date, but in any event within 30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">days of such date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Forfeiture of Unvested RSUs Upon Cessation of Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">	In the event that the Participant ceases to be an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive awards under the Plan (an &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Eligible Participant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto.  If the Participant provides services to a subsidiary of the Company, any references in this Agreement to provision of services to the Company shall instead be deemed to refer to service with such subsidiary.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on Transfer</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Participant shall not sell, assign, transfer, pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively &#x201c;transfer&#x201d;) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Provisions of the Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Acknowledgments; No Section 83(b) Election</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant&#x2019;s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant&#x2019;s tax liability that may arise in connection with the acquisition, vesting and/or disposition of the RSUs.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), is available with respect to RSUs.   </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Participant acknowledges and agrees that the Company has the right to deduct from payments of any kind otherwise due to the Participant any federal, state, local or other taxes of any kind required by law to be withheld with respect to the vesting of the RSUs.  To the extent the Participant has not previously executed and delivered to the Company effective durable sell-to-cover instructions that by their terms would cover any taxes required by law to be withheld with respect to the vesting of the RSUs, at such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and is not prohibited from doing so by the Company&#x2019;s insider trading policy or otherwise, the Participant shall execute the instructions set forth in </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> attached hereto (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Durable Automatic Sell-to-Cover Instruction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) as the means of satisfying such tax obligation.  If the Participant is required to but does not execute the Durable Automatic Sell-to-Cover Instruction prior to an applicable vesting date, then the Participant agrees that if under applicable law the Participant will owe taxes at such vesting date on the portion of the award then vested the Company shall be entitled to immediate payment from the Participant of the amount of any tax required to be withheld by the Company.  The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Right to Continued Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Participant acknowledges and agrees that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her continued service to the Company, this Agreement does not constitute an express or implied promise of continued service relationship with the Participant or confer upon the Participant any rights with respect to a continued service relationship with the Company or any affiliate of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Participant&#x2019;s Acknowledgments</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Participant acknowledges that he or she:  (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement by legal counsel of the Participant&#x2019;s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is agreeing, in accepting this award, to be bound by any clawback policy that the Company has in place or may adopt in the future; and (iv) is fully aware of the legal and binding effect of this Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall be construed, interpreted and enforced in accordance with the internal laws of the State of Delaware without regard to any applicable conflicts of laws provisions.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Schedule A</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">DURABLE AUTOMATIC SELL-TO-COVER INSTRUCTION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This Durable Automatic Sell-to-Cover Instruction (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Instruction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), which is being delivered to Verve Therapeutics, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) by the undersigned on the date set forth below (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Adoption Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), relates to the Covered RSUs (as defined following my signature below). This Instruction provides for &#x201c;eligible sell-to-cover transactions&#x201d; (as described in Rule 10b5-1(c)(1)(ii)(D)(3) under the Securities Exchange Act of 1934 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exchange Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)) and is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)(1) under the Exchange Act.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I acknowledge that upon vesting and settlement of any Covered RSUs in accordance with the applicable RSU&#x2019;s terms, whether vesting is based on the passage of time or the achievement of performance goals, I will have compensation income equal to the fair market value of the shares of the Company&#x2019;s common stock subject to the RSUs that are settled on such settlement date and that the Company is required to withhold income and employment taxes in respect of that compensation income.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I desire to establish a plan and process to satisfy such withholding obligation in respect of all Covered RSUs through an automatic sale of a portion of the shares of the Company&#x2019;s common stock that would otherwise be issuable to me on each applicable settlement date, such portion to be in an amount sufficient to satisfy such withholding obligation, with the proceeds of such sale delivered to the Company in satisfaction of such withholding obligation.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I understand that the Company has arranged for the administration and execution of its equity incentive programs and the sale of securities by participants thereunder pursuant to a platform administered by a third party (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Administrator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) and the Administrator&#x2019;s designated brokerage partner.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon the settlement of any of my Covered RSUs after the 30</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day following the Adoption Date (or if I am an officer of the Company on the Adoption Date, after the [120</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:super;font-size:8.040000000000001pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> day following the Adoption Date]), I hereby appoint the Administrator (or any successor administrator) to automatically sell such number of shares of the Company&#x2019;s common stock issuable with respect to such RSUs that vested and settled as is sufficient to generate net proceeds sufficient to satisfy the Company&#x2019;s minimum statutory withholding obligations with respect to the income recognized by me in connection with the vesting and settlement of such RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the Company shall receive such net proceeds in satisfaction of such tax withholding obligation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I hereby appoint the Chief Executive Officer, the Chief Financial Officer and the General Counsel (or, if none, the Chief Operating Officer), and any of them acting alone and with full power of substitution, to serve as my attorneys in fact to arrange for the sale of shares of the Company&#x2019;s common stock in accordance with this Instruction. I agree to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares of common stock pursuant to this Instruction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Unless the last box in the definition of Covered RSUs below is checked, if I have previously adopted an automatic sale or sell-to-cover instruction relating to Covered RSUs, this Instruction shall be void </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">ab initio</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> with respect to such Covered RSUs.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">I hereby certify that, as of the Adoption Date:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(i)  I am not prohibited from entering into this Instruction by the Company&#x2019;s insider trading policy or otherwise;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (ii) I am not aware of any material nonpublic information about the Company or its common stock; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> (iii) I am adopting this Instruction in good faith and not as part of a plan or scheme to evade the prohibitions of Rule 10b-5 under the Exchange Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						________________________________</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						Print Name:  _____________________</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">						Date:  __________________________</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Covered RSUs:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The following restricted stock units (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RSUs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) are covered by this Instruction.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check all applicable boxes:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xe0100; The first award of RSUs granted to me on or after ______________ [</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">insert date of grant of current RSUs the grant of which is triggering the execution of this Instruction; if instruction is being executed in advance of a grant of RSUs, insert the Adoption Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">] and any RSUs that may, from time to time following such date, be granted to me by the Company, other than any future granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares for tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xe0100;  Any outstanding RSUs that were granted to me by the Company prior to the Adoption Date that (1) are </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">not</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> subject to any prior automatic sale or sell-to-cover instruction and (2) for which the next vesting date is after the cooling-off period referred to above, other than any previously granted RSUs which by the terms of the applicable award agreement require the Company to withhold shares for tax withholding obligations in connection with the vesting and settlement of such RSUs, and therefore do not permit sell-to-cover transactions.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#xe0100;  With respect to any RSUs, whether or not granted to me by the Company prior to the Adoption Date, that already are subject to an automatic sale or sell-to-cover instruction (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Prior Instruction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), I elect to have such sales effected pursuant to this Instruction and confirm that</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">doing so does not modify or change the amount, price, or timing of such sales from those provided by the Prior Instruction (and, as a result the cooling-off period referred to above is not applicable to sales pursuant to this Instruction that were previously subject to the Prior Instruction).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> IF &#34; DOCVARIABLE &#34;SWDocIDLocation&#34; 1&#34; = &#34;1&#34; &#34; DOCPROPERTY &#34;SWDocID&#34; ACTIVEUS 197965589v.2&#34; &#34;&#34; ACTIVEUS 197965589v.2</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>3
<FILENAME>verv-ex10_7.htm
<DESCRIPTION>EX-10.7
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 10.7</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VERVE THERAPEUTICS, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effective as of January 1, 2023, the non-employee directors of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) shall receive the following compensation for their service as members of the Board of Directors (the &#x201c;Board&#x201d;) of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Director Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Our goal is to provide compensation for our non-employee directors in a manner that enables us to attract and retain outstanding director candidates and reflects the substantial time commitment necessary to oversee the Company&#x2019;s affairs. We also seek to align the interests of our directors and our stockholders and we have chosen to do so by compensating our non-employee directors with a mix of cash and equity-based compensation.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Cash Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The fees that will be paid to our non-employee directors for service on the Board, and for service on each committee of the Board on which the director is then a member, and the fees that will be paid to the chairperson of the Board, if one is then appointed, and the chairperson of each committee of the Board will be as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:76.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.526%;"></td>
    <td style="width:2.629%;"></td>
    <td style="width:2.629%;"></td>
    <td style="width:14.746%;"></td>
    <td style="width:1.321%;"></td>
    <td style="width:2.643%;"></td>
    <td style="width:2.643%;"></td>
    <td style="width:17.543%;"></td>
    <td style="width:1.321%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Member Annual<br>Fee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid rgba(0,0,0,1);padding-right:0.003in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Chairperson Incremental<br>Annual Fee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid rgba(255,255,255,0.01);padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Board of Directors</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">40,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Audit Committee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7,500</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compensation Committee</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6,000</font></p></td>
    <td style="background-color:rgba(204,238,255,1);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nominating and Corporate Governance Committee</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5,000</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;white-space:pre-wrap;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing fees will be payable in arrears in four equal quarterly installments on the last day of each quarter, provided that the amount of such payment will be prorated for any portion of such quarter that the director is not serving on the Board, on such committee or in such position.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Equity Compensation</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Initial Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Upon initial election to the Board, each non-employee director will be granted, automatically and without the need for any further action by the Board, an initial equity award of an option to purchase the number of shares of our common stock that has a Black Scholes value as of the date of the grant equal to $719,754 (as calculated using the same methodology that the Company then uses to calculate the value of stock awards for purposes of the Company&#x2019;s financial statements). The initial award shall have a term of ten years from the date of the award, and shall vest and become exercisable as to 2.7778% of the shares underlying such award at the end of each successive one-month period following the grant date until the third anniversary of the grant date, subject to the non-employee director&#x2019;s continued service to the Company through each applicable vesting date. The vesting shall accelerate as to 100% of the shares upon a change in control of the Company. The exercise price of the option shall be the closing price of our common stock on the date of grant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Annual Grants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. Each non-employee director who has served as a member of the Board for at least six months prior to the date of our annual meeting of stockholders for a particular year will be granted, automatically and without the need for any further action by the Board, an option to purchase the number of shares of our common stock that has a Black Scholes value as of the date of the grant equal to $359,877 (as calculated using the same methodology that the Company then uses to calculate the value of stock awards for purposes of the Company&#x2019;s financial statements) on</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the date of the first Board meeting held after our annual meeting of stockholders for such year. The annual award shall have a term of ten years from the date of the award, and shall vest and become exercisable in full on the one-year anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of stockholders occurring after the grant date), subject to the non-employee director&#x2019;s continued service to the Company through each applicable vesting date. The vesting shall accelerate as to 100% of the shares upon a change in control of the Company. The exercise price of the option shall be the closing price of our common stock on the date of grant.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The foregoing share amounts shall be automatically adjusted in the event of any stock split, reverse stock split, stock dividend, recapitalization, combination of shares, reclassification of shares, spin-off or other similar change in capitalization or event effecting our common stock, or any distribution to holders of our common stock other than an ordinary cash dividend.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The initial awards and the annual awards shall be subject to the terms and conditions of our 2021 Stock Incentive Plan, or any successor plan, and the terms of the option agreements entered into with each director in connection with such awards.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Expenses</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Upon presentation of documentation of such expenses reasonably satisfactory to the Company, each non-employee director shall be reimbursed for his or her reasonable out-of-pocket business expenses incurred in connection with attending meetings of the Board and committees thereof or in connection with other business related to the Board, and each non-employee director shall also be reimbursed for his or her reasonable out-of-pocket business expenses authorized by the Board or a committee of the Board that are incurred in connection with attendance at various conferences or meetings with management of the Company, in accordance with the Company&#x2019;s travel policy, as it may be in effect from time to time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10
<SEQUENCE>4
<FILENAME>verv-ex10_22.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html>
 <head>
  <title>EX-10</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Exhibit 10.22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STOCK PURCHASE AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">This STOCK PURCHASE AGREEMENT (this &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) is made and entered into as of July 18, 2022, by and between Verve Therapeutics, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), and Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">RECITALS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">A.	On the date hereof, the Company and the Investor entered into a Strategic Collaboration and License Agreement (as defined below);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">B.	The Investor wishes to purchase from the Company, and the Company wishes to sell and issue to the Investor, upon the terms and subject to the conditions stated in this Agreement, 1,519,756 shares (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) of the Company&#x2019;s common stock, par value $0.001 per share (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  For the purposes of this Agreement, the following terms shall have the meanings set forth below: </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Affiliate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with such Person.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in the first paragraph.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applicable Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.15.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorizations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.15.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Business Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Change of Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; with respect to the Company: (a) the acquisition by a Third Party, whether in one transaction or a series of related transactions, of direct or indirect beneficial ownership of more than fifty percent (50%) of the outstanding voting equity securities of the Company; (b) a merger or consolidation involving the Company, as a result of which a Third Party acquires direct or indirect beneficial ownership of more than fifty percent (50%) of the voting power of the surviving entity immediately after such merger, reorganization or consolidation; or (c) a sale of all or substantially all of the assets of the Company in one transaction or a series of related transactions to a Third Party.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.1.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Closing Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 3.1.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in the recitals to this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common Stock Equivalents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any securities of the Company which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in the first paragraph.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company&#x2019;s Knowledge</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; (including the terms &#x201c;controlling,&#x201d; &#x201c;controlled by&#x201d; or &#x201c;under common control with&#x201d;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disposition</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; or &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Dispose of</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any (a) pledge, sale, contract to sell, sale of any option or contract to purchase, purchase of any option or contract to sell, grant of any option, right or warrant for the sale of, or other disposition of or transfer of any shares of Common Stock, or any Common Stock Equivalents, including, without limitation, any &#x201c;short sale&#x201d; or similar arrangement, or (b) swap or any other agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of shares of Common Stock, whether any such swap or transaction is to be settled by delivery of securities, in cash or otherwise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EDGAR system</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.8.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.18.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GAAP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.20.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.13.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in the first paragraph.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">LAS</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Nasdaq Notification Form: Listing of Additional Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lock-Up Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall have the meaning set forth in Section 7.4(a).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lock-Up Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the period from and after the date of this Agreement until the date that is 12 months after the Closing Date.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Adverse Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any change, event or occurrence that, individually or in the aggregate, results in a material adverse effect on (a) the assets, liabilities, results of operations, financial condition or business of the Company and its subsidiary taken as a whole, (b) the legality or enforceability of this Agreement or (c) the ability of the Company to perform its obligations under this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Material Contract</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any contract, instrument or other agreement to which the Company is a party or by which it is bound that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Nasdaq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Nasdaq Global Select Market.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Permitted Transferee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means (a) a controlled Affiliate of the Investor that is wholly owned, directly or indirectly, by the Investor, or (b) a controlling Affiliate of the Investor (or any controlled Affiliate of such controlling Affiliate) that wholly owns, directly or indirectly, the Investor, or the acquiring Person in the case of an acquisition of the Investor; it being understood that for purposes of this definition &#x201c;wholly owned&#x201d; shall mean an Affiliate in which the Investor owns, or an Affiliate that owns, as applicable, directly or indirectly, at least ninety-nine percent (99%) of the outstanding capital stock of such Affiliate or the Investor, as applicable.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein, as well as any syndicate or group that would be deemed to be a Person under Section 13(d)(3) of the 1934 Act.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the U.S. Securities and Exchange Commission.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 4.7.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in the recitals to this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shares of Then Outstanding Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means, at any time, the issued and outstanding shares of Common Stock at such time, as well as all capital stock issued and outstanding as a result of any stock split, stock dividend, or reclassification of Common Stock distributable, on a pro rata basis, to all holders of Common Stock.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Strategic Collaboration and License Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Strategic Collaboration and License Agreement, dated as of July 18, 2022, between the Investor and the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Third Party</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means any Person other than the Investor, the Company or any of their respective Affiliates.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Day</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; shall mean each day on which the Nasdaq is open for trading.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; has the meaning set forth in Section 7.2(a).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1933 Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">1934 Act</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d; means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></p>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase and Sale of the Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and the Investor will purchase the Shares for an aggregate purchase price of $34,999,980.68 (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Aggregate Purchase Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), representing a price per share of $23.03, which amount is equal to the daily volume-weighted average per share price of the Common Stock on the Nasdaq over the five Trading Day period ending on and including the last Trading Day prior to the date of this Agreement) as reported by Bloomberg.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">3.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The completion of the purchase and sale of the Shares (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) shall occur remotely via exchange of documents and signatures as promptly as practicable, and in no event later than the third Business Day following the date on which all conditions to closing set forth in Section 6 have been satisfied or waived, or such other place, time and date as may be agreed between the Company and the Investor (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Closing Date</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">3.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On the Closing Date, the Investor shall deliver or cause to be delivered to the Company, via wire transfer of immediately available funds pursuant to the wire instructions delivered to the Investor by the Company on or prior to the Closing Date, the Aggregate Purchase Price.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">3.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">At or before the Closing, the Company shall deliver or cause to be delivered to the Investor the Shares, registered in the name of the Investor (or its nominee in accordance with its delivery instructions).  The Shares shall be delivered to the Investor via a book-entry record through the Company&#x2019;s transfer agent.  </font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Representations and Warranties of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company hereby represents and warrants to the Investor that, except as described in the Company&#x2019;s SEC Filings (as defined below), which qualify these representations and warranties in their entirety:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization, Good Standing and Qualification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties.  The Company is duly qualified to do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect.  The Company&#x2019;s only subsidiary is set forth on Exhibit 21.1 to its most recent Annual Report on Form 10-K, and the Company owns 100% of the outstanding equity of such subsidiary.  The Company&#x2019;s subsidiary is duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts and has all requisite power and authority to carry on its business as now conducted and to own or lease their properties.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company has the requisite corporate power and authority and has taken all requisite corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (a) the authorization, execution and delivery of this Agreement, (b) the authorization of the performance of all obligations of the Company hereunder or thereunder, and (c) the authorization, issuance (or reservation for issuance) and delivery of the Shares.  This Agreement constitutes the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors&#x2019; rights generally and to general equitable principles.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Capitalization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is authorized under its Certificate of Incorporation to issue 200,000,000 shares of Common Stock and 5,000,000 shares of preferred stock, $0.001 par value per share.  The Company&#x2019;s disclosure of its issued and outstanding capital stock in its most recent SEC Filing containing such disclosure was accurate in all material respects as of the date indicated in such SEC Filing.  All of the issued and outstanding shares of the Company&#x2019;s capital stock have been duly authorized and validly issued and are fully paid and nonassessable; none of such shares were issued in violation of any preemptive rights; and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties.  No Person is entitled to preemptive or similar statutory or contractual rights with respect to the issuance by the Company of any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">securities of the Company, including, without limitation, the Shares.  Except for stock options and restricted stock units approved pursuant to Company stock-based compensation plans and employee stock purchase plans described in the SEC Filings, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement.  There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. The issuance and sale of the Shares hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investor) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Valid Issuance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Shares have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by the Investor), except for restrictions on transfer set forth in this Agreement or imposed by applicable securities laws.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Consents</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The execution, delivery and performance by the Company of this Agreement and the offer, issuance and sale of the Shares require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than (i) filings that have been made pursuant to applicable state securities laws, (ii) post-sale filings pursuant to applicable state and federal securities laws and (iii) filings pursuant to the rules and regulations of Nasdaq, each of which the Company has filed or undertakes to file within the applicable time.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Material Adverse Change</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Since December 31, 2021, except as identified and described in the SEC Filings filed at least one Trading Day prior to the date of this Agreement: </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there has not been any change in the consolidated assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2021, except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there has not been any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company has not sold, transferred or otherwise disposed of any material assets or rights;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">the Company has not admitted in writing its inability to pay its debts generally as they become due, filed or consented to the filing against it of a petition in bankruptcy or a petition to take advantage of any insolvency act, made an assignment for the benefit of creditors, consented to the appointment of a receiver for itself or for the whole or any substantial part of its property, or had a petition in bankruptcy filed against it, been adjudicated bankrupt or filed a petition or answer seeking reorganization or arrangement under the federal bankruptcy laws or any other laws of the United States or any other jurisdiction; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">there has not been any other event, change, development, occurrence, circumstance or condition that, individually or in the aggregate, has had or would reasonably be expected to have a Material Adverse Effect.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year period preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SEC Filings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;).  At the time of filing thereof, the SEC Filings complied in all material respects with the requirements of the 1933 Act or the 1934 Act, as applicable, and the rules and regulations of the SEC thereunder.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Conflict, Breach, Violation or Default</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The execution, delivery and performance of this Agreement by the Company and the issuance and sale of the Shares in accordance with the provisions thereof will not, except (solely in the case of clauses (a)(ii) and (b)) for such violations, conflicts or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (a) conflict with or result in a breach or violation of (i) any of the terms and provisions of, or constitute a default under, the Company&#x2019;s Certificate of Incorporation or the Company&#x2019;s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investor through the Electronic Data Gathering, Analysis, and Retrieval system (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">EDGAR system</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;)), or (ii) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or its subsidiary, or any of their assets or properties, or (b) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or its subsidiary or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of, any Material Contract.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiary have paid all federal, state, local and foreign taxes required to be paid by them, except for taxes being contested in good faith. The Company and its subsidiary have filed all tax returns required by law to be filed (taking into account any duly requested extensions thereof) through the date hereof, except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or its subsidiary or any of their respective properties or assets that would reasonably be expected to have a Material Adverse Effect. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title to Properties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiary have good and marketable title to all real properties and all other properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company and its subsidiary hold any leased real or personal property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certificates, Authorities and Permits</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiary possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by them, except where failure to so possess would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect.  The Company and its subsidiary have not received any written notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.12</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Labor Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company is not party to or bound by any collective bargaining agreements or other agreements with labor organizations.  To the Company&#x2019;s Knowledge, the Company has not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees or labor organizations, or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees&#x2019; health, safety, welfare, wages and hours.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company&#x2019;s Knowledge, is threatened or imminent.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.13</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  To the Company&#x2019;s Knowledge, the Company and its subsidiary owns or possesses valid and enforceable licensed rights, or may acquire on reasonable terms sufficient to use, all material patents, patent applications, trademarks, service marks, trade names, Internet domain names, copyrights, proprietary information and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) as described in the SEC Filings (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Intellectual Property</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) necessary for the conduct of its business as currently conducted or as proposed to be conducted, and except where any failure to own, possess or acquire such Intellectual Property would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Company owned Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part. To the Company&#x2019;s Knowledge: (i) there are no third parties who have rights to any Intellectual Property of the Company or its subsidiary, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the SEC Filings as licensed to the Company or its subsidiary; and (ii) there is no infringement by third parties of any Intellectual Property of the Company. Except as disclosed in the SEC Filings, there is no pending or, to the Company&#x2019;s Knowledge, existing threatened-in-writing action, suit or proceeding by others: (A) challenging the Company&#x2019;s or its subsidiary&#x2019;s rights in or to any Intellectual Property of the Company; (B) challenging the validity, enforceability or scope of any Intellectual Property of the Company or its subsidiary; or (C) asserting that the Company or its subsidiary infringes, misappropriates or otherwise violates, or would, upon the commercialization of any product or service described in the SEC Filings as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others. To the Company&#x2019;s Knowledge, the Company has complied with the terms of each agreement pursuant to which Intellectual Property of the Company has been licensed to the Company and its subsidiary, and all such agreements are in full force and effect. To the Company&#x2019;s Knowledge, there are no material defects in any of the patents or patent applications included in the Company-owned Intellectual Property, that would render them unenforceable once issued. To the Company&#x2019;s Knowledge, the patents included in the Intellectual Property of the Company are subsisting and have not lapsed and the patent applications in the Intellectual Property of the Company are subsisting and have not been abandoned. The Company has taken reasonable steps to protect, maintain and safeguard the Intellectual Property of the Company, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignments with its employees, and to the Company&#x2019;s Knowledge, no employee of the Company or its subsidiary is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#x2019;s employment with the Company or its subsidiary.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.14</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Healthcare Regulatory Compliance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is, and at all times has been, in compliance in all material respects with all Health Care Laws to the extent applicable to the Company or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">its business. For purposes of this Agreement, &#x201c;Health Care Laws&#x201d; means: (i) the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act, and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286, 287 and 1349, the health care fraud criminal provisions under HIPAA (42 U.S.C. Section 1320d et seq.), the civil monetary penalties law (42 U.S.C. Section 1320a-7a), the exclusions law (42 U.S.C. Section 1320a-7), and laws governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the HITECH Act (42 U.S.C. Section 17921 et seq.); (iv) the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; (vi) all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company; and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. The Company and its officers, directors, employees and, to the knowledge of the Company, its agents have not engaged in activities which are, as applicable, cause for liability under a Health Care Law. Neither the Company nor its subsidiary have received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#x2019;s Knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company has filed, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions, and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor its employees, officers, directors, or, to the knowledge of the Company, its agents is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority related to activities conducted by or on behalf of the Company. Additionally, neither the Company nor its employees, officers, directors, or, to the knowledge of the Company, its agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.15</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FDA Compliance. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company: (A) is and at all times has been in material compliance with all statutes, rules or regulations of the FDA and other comparable governmental entities with jurisdiction over the Company that are applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Applicable Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other written correspondence or notice from the FDA or any governmental entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorizations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and the Company is not in material violation of any term of any such Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">governmental entity or third party is considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E) has not received written notice that the FDA or any governmental entity has taken, is taking or intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission),</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.16</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tests and Preclinical and Clinical Trials</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The studies, tests and preclinical and clinical trials conducted by or, to the Company&#x2019;s Knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to accepted professional scientific standards and all applicable Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current Good Clinical Practices and Good Laboratory Practices and any applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; and, except to the extent disclosed in SEC Filings, the Company has not received any notices or correspondence from the FDA or any governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.17</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cybersecurity; Data Protection</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company&#x2019;s information technology assets and equipment, including, without limitation, those owned, licensed or otherwise used (excluding any public networks), such as its data communications lines, computers, systems, networks, hardware, servers, software, websites, applications, and databases (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IT Systems</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) are adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company as currently conducted and as proposed to be conducted as described in the Registration Statement and the Prospectus, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has at all times implemented and maintained all reasonably necessary controls, policies, procedures, and safeguards consistent with industry standards and practices for similarly situated companies to maintain and protect the integrity, availability, privacy, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data) (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Company Data</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) used in connection with their business, and there have been no breaches, violations, outages, compromises, or unlawful or unauthorized acquisitions of, disclosures of, uses of or accesses to the same, except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. There are no privacy or security incidents under internal review or investigations relating to the same that would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except in each case as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company is presently and, at all times, has been in compliance with all (i) applicable laws, statutes, judgments, orders, rules and regulations of any court, arbitrator, governmental or regulatory authority; and (ii) internal policies and contractual obligations, each (i) and (ii) relating to the privacy and security of IT Systems and Company Data.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.18</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is not in violation of any statute, rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">environment or human exposure to hazardous or toxic substances (collectively, &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Environmental Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), has not released any hazardous substances regulated by Environmental Law onto any real property that it owns or operates, and has not received any written notice or claim it is liable for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, and to the Company&#x2019;s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.19</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legal Proceedings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  There are no legal, governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or its subsidiary are or may reasonably be expected to become a party or to which any property of the Company or its subsidiary are or may reasonably be expected to become the subject that, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.20</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial Statements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The financial statements included in each SEC Filing comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent restatement) and present fairly, in all material respects, the consolidated financial position of the Company and its subsidiary as of the dates shown and its consolidated results of operations and cash flows for the periods shown, except in the case of unaudited financial statements to normal year-end adjustments, and such consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis during the periods involved (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">GAAP</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial statements, except as permitted by Form 10-Q under the 1934 Act).  Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.21</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Insurance Coverage</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company and its subsidiary have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as the Company reasonably believes are adequate to protect the Company and its subsidiary and their respective businesses; and neither the Company nor its subsidiary has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business in all material respects.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.22</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Compliance with Nasdaq Continued Listing Requirements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is in compliance with applicable Nasdaq continued listing requirements.  There are no proceedings pending or, to the Company&#x2019;s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company&#x2019;s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.23</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brokers and Finders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">into by or on behalf of the Company.  The Investor shall not have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.3 that may be due in connection with the transactions contemplated by this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.24</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No General Solicitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D promulgated under the 1933 Act) in connection with the offer or sale of any of the Shares.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.25</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Integrated Offering</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Neither the Company nor its subsidiary nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or would require registration of the Shares under the 1933 Act.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.26</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Private Placement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Assuming the accuracy of the representations and warranties of the Investor set forth in Section 5, the offer and sale of the Shares to the Investor as contemplated hereby is exempt from the registration requirements of the 1933 Act.  The issuance and sale of the Shares does not contravene the rules and regulations of Nasdaq.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.27</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Internal Controls</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company has established and maintains a system of &#x201c;disclosure controls and procedures&#x201d; (as defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the 1934 Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#x2019;s management as appropriate to allow timely decisions regarding required disclosure.  Since the end of the Company&#x2019;s most recent audited fiscal year, there have been no material weaknesses in the Company&#x2019;s internal control over financial reporting (whether or not remediated) and no change in the Company&#x2019;s internal control over financial reporting that has materially affected, or would reasonably be expected to materially affect, the Company&#x2019;s internal control over financial reporting.  The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or would reasonably be expected to materially affect, the Company&#x2019;s internal control over financial reporting.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.28</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosures</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Neither the Company nor any Person acting on its behalf has provided the Investor or its agents or counsel with any information that constitutes or would reasonably be expected to constitute material nonpublic information concerning the Company or its subsidiary, other than with respect to the transactions contemplated hereby or by the Strategic Collaboration and License Agreement which will be publicly disclosed by 8:30 a.m. (New York City time) on the Business Day immediately following the date this Agreement is executed.  The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.  The Company understands and confirms that the Investor will rely on the foregoing representations in effecting transactions in securities of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.29</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is not required to be registered as, and is not an Affiliate of, and immediately following the Closing will not be required to register as, an &#x201c;investment company&#x201d; within the meaning of the Investment Company Act of 1940, as amended.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.30</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Anti-Bribery and Anti-Money Laundering Laws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. To the Company&#x2019;s Knowledge, each of the Company, its subsidiary and any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with, and its participation in the offering will not violate: (a) the applicable anti-bribery laws of all jurisdictions where the Company or its subsidiary conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions; the U.S. Foreign Corrupt Practices Act of 1977, as amended; the U.K. Bribery Act 2010, or (b) the applicable money laundering laws of all jurisdictions where the Company or its subsidiary conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental agency.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">4.31</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Shell Company Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company is not, and has never been, an issuer identified in Rule 144(i)(1).</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Representations and Warranties of the Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor hereby represents and warrants to the Company that:</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Organization and Existence</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to enter into and consummate the transactions contemplated by this Agreement and to carry out its obligations hereunder and thereunder, and to invest in the Shares pursuant to this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Authorization</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The execution, delivery and performance by the Investor of this Agreement have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors&#x2019; rights generally, and general principles of equity.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Purchase Entirely for Own Account</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Shares to be received by the Investor hereunder will be acquired for the Investor&#x2019;s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to the Investor&#x2019;s right at all times to sell or otherwise dispose of all or any part of the Shares in compliance with applicable federal and state securities laws.  The Shares are being purchased by the Investor in the ordinary course of its business.  Nothing contained herein shall be deemed a representation or warranty by the Investor to hold the Shares for any period of time.  The Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investment Experience</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor acknowledges that it can bear the economic risk and complete loss of its investment in the Shares and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Disclosure of Information</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor has had an opportunity to receive, review and understand all information related to the Company requested by it and to ask questions of and receive </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Shares, and has conducted and completed its own independent due diligence.  The Investor acknowledges that copies of the SEC Filings are available on the EDGAR system.  Based on the information the Investor has deemed appropriate, it has independently made its own analysis and decision to enter into this Agreement.  The Investor is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance of this Agreement, the Shares and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and tax matters.  Neither such inquiries nor any other due diligence investigation conducted by the Investor shall modify, limit or otherwise affect the Investor&#x2019;s right to rely on the Company&#x2019;s representations and warranties contained in this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restricted Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor understands that the Shares are characterized as &#x201c;restricted securities&#x201d; under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain limited circumstances. The Investor represents that it is familiar with Rule 144 as presently in effect. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Legends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  It is understood that, except as provided below, certificates evidencing the Shares (or uncertificated interests in the Shares) may bear the following or any similar legend: </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201c;The securities have not been registered with the Securities and Exchange Commission. They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under the Securities Act of 1933 or an opinion of counsel (which counsel shall be reasonably satisfactory to Verve Therapeutics, Inc.) that such registration is not required or unless sold pursuant to Rule 144 of the Securities Act of 1933.&#x201d; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">These securities are subject to transfer restrictions set forth in a Stock Purchase Agreement by and between Verve Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated, a copy of which is on file with the Secretary of Verve Therapeutics, Inc.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Accredited Investor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor is (a) an &#x201c;accredited investor&#x201d; within the meaning of Rule 501(a) of Regulation D and (b) an &#x201c;Institutional Account&#x201d; as defined in FINRA Rule 4512(c).  The Investor is a sophisticated institutional investor with sufficient knowledge and experience financial and business matters that it is capable of evaluating the risks and merits of its purchase of the Shares. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Brokers and Finders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest or claim against or upon the Company or the Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Investor.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Beneficial Ownership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Other than with respect to the Shares, the Investor does not beneficially own any Common Stock, including any securities into or exchangeable for Common Stock (including any such securities that cannot be converted or exchanged for more than 60 days from the date hereof).  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">5.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No Conflicts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The execution, delivery and performance by the Investor of this Agreement and the consummation by the Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of the Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to the Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of the Investor to perform its obligations hereunder.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditions to Closing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">6.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditions to the Investor&#x2019;s Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The obligation of the Investor to purchase Shares at the Closing is subject to the fulfillment to the Investor&#x2019;s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by the Investor: </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The representations and warranties made by the Company in Section 4 hereof shall be true and correct as of the date hereof and as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in this Section 6.1.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement and the issuance of the Shares, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing this Agreement and related documents on behalf of the Company.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investor shall have received an opinion from Wilmer Cutler Pickering Hale and Dorr LLP, the Company&#x2019;s counsel, dated as of the Closing Date, in form and substance reasonably acceptable to the Investor and addressing such legal matters as the Investor may reasonably request.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There shall have been no Material Adverse Effect with respect to the Company since the date hereof.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with respect to public trading in the Common Stock.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(h)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company shall have executed and delivered Strategic Collaboration and License Agreement and it shall be in full force and effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">6.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Conditions to Obligations of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Company&#x2019;s obligation to sell and issue Shares at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The representations and warranties made by the Investor in Section 5 hereof shall be true and correct as of the date hereof, and shall be true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investor shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investor shall have paid in full the Aggregate Purchase Price to the Company.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Investor shall have executed and delivered the Strategic Collaboration and License Agreement and it shall be in full force and effect.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Covenants and Agreements of the Parties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="margin-left:1.731%;text-indent:6.784%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">7.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Market Listing</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. The Company shall use commercially reasonable efforts to effect the listing of the Shares on Nasdaq, including submitting the LAS to the Nasdaq Stock Market, if required by the Nasdaq Stock Market.</font></div></div>
  <div style="margin-left:1.731%;text-indent:6.784%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">7.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Removal of Legends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In connection with any sale, assignment, transfer or other disposition of the Shares by the Investor pursuant to Rule 144 or pursuant to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall cause the transfer agent for the Common Stock (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transfer Agent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;) to remove any restrictive legends related to the book entry account holding such Shares and make a new, unlegended entry for such book entry Shares sold or disposed of without restrictive legends within three (3) Business Days of any such request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Subject to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares (i) have been sold pursuant to Rule 144 or (ii) are eligible for resale under Rule 144(b)(1) or any successor, the Company shall, in accordance with the provisions of this Section 7.2(b) and within three (3) Business Days of any request therefor from the Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares, and (B) cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933 Act if required by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.  Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account of the Investor&#x2019;s prime broker with the DTC System as directed by such Investor.  The Company shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such issuance.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">7.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Confidentiality After the Date Hereof</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, the Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction), other than to such Person&#x2019;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="margin-left:1.731%;text-indent:6.784%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">7.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Restrictions on Dispositions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lock-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  During the Lock-Up Term, without the prior approval of the Company, the Investor shall not, and shall cause its Affiliates not to, Dispose of (x) any of the Shares, together with any shares of Common Stock issued in respect thereof as a result of any stock split, stock dividend, share exchange, merger, consolidation or similar recapitalization, and (y) any Common Stock issued as (or issuable upon the exercise of any warrant, right or other security that is issued as) a dividend or other distribution with respect to, or in exchange or in replacement of, the shares of Common Stock described in clause (x) of this sentence (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lock-Up Securities</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#x201d;), including, without limitation, any &#x201c;short sale&#x201d; or similar arrangement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, that the foregoing shall not prohibit the Investor from transferring Lock-Up Securities to a Permitted Transferee.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain Tender Offers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Section 7.4 shall not prohibit or restrict any Disposition of Shares of Then Outstanding Common Stock and/or Common Stock Equivalents into (i) a tender offer by a Third Party which is not opposed by the Company&#x2019;s Board of Directors (but only after the Company&#x2019;s filing of a Schedule 14D-9, or any amendment thereto, with the SEC disclosing the recommendation of the Company&#x2019;s Board of Directors with respect to such tender offer) or (ii) an issuer tender offer by the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Termination of Lock-Up</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. This Section 7.4 shall terminate and have no further force or effect, upon the earliest to occur of: (i) the end of the Lock-up Term; (ii) the consummation of a Change of Control; (iii) a liquidation or dissolution of the Company; and (iv) the date on which the Common Stock ceases to be registered pursuant to Section 12 of the 1934 Act. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Effect of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">. No termination pursuant to Section 7.4(c) shall relieve any of the parties (or the Permitted Transferee, if any) for liability for breach of or default under any of their respective obligations or restrictions under any terminated provision of this Agreement, which breach or default arose out of events or circumstances occurring or existing prior to the date of such termination.</font></div></div>
  <div style="text-indent:0.0%;font-size:0;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Miscellaneous</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.1</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The representations and warranties contained in this Agreement shall survive the Closing of the transactions contemplated by this Agreement.  The covenants of the parties hereto shall survive until fully performed and discharged, unless otherwise expressly provided herein</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.2</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may not be assigned by a party hereto without the prior written consent of the other party, provided, however, that the Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Shares in a transaction complying with applicable securities laws without the prior written consent of the Company, provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investor.  The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.  Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#x201c;Company&#x201d; shall be deemed to refer to such Person and the term &#x201c;Shares&#x201d; shall be deemed to refer to the securities </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:0;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">received by the Investor in connection with such transaction.  Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.3</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.  Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.4</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Titles and Subtitles</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.5</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (a) if given by personal delivery, then such notice shall be deemed given upon such delivery, (b) if given by facsimile or e-mail, then such notice shall be deemed given upon receipt of confirmation of complete facsimile transmittal or confirmation of receipt of an e-mail transmission, (c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of such notice by the recipient or (ii) three days after such notice is deposited in first class mail, postage prepaid, and (d) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier.  All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days&#x2019; advance written notice to the other party: </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to the Company:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Verve Therapeutics, Inc.  <br>500 Technology Square, Suite 901</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cambridge, Massachusetts 02139<br>Attention: Andrew Ashe, President and Chief Operating Officer <br>Email: [**]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With a copy (which shall not constitute notice) to:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Wilmer Cutler Pickering Hale and Dorr LLP <br>60 State Street <br>Boston, Massachusetts 02109 <br>Attention: Craig Hilts <br>Email: [**]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If to the Investor:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vertex Pharmaceuticals Incorporated</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attn: Business Development</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50 Northern Avenue</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts 02210</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: [**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Vertex Pharmaceuticals Incorporated</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attn: Corporate Legal</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">50 Northern Avenue</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Boston, Massachusetts 02210</font></p>
  <p style="margin-left:13.2%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Email: [**]</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">With a copy (which shall not constitute notice) to:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Covington &amp; Burling LLP <br>620 Eighth Avenue<br>New York, NY 10018</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Attention: Matthew Gehl<br>Email: [**]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.6</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions contemplated hereby are consummated; it being understood that each of the Company and the Investor has relied on the advice of its own respective counsel.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.7</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Amendments and Waivers</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investor.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.8</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.  To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.9</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entire Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement, including the signature pages and Exhibits, constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.10</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Further Assurances</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:11.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.78457671446162%;">8.11</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.  This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.  Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.  </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">[remainder of page intentionally left blank]</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">COMPANY:	VERVE THERAPEUTICS, INC.</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Andrew Ashe	</font></p>
  <p style="margin-left:51.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:  Andrew Ashe</font></p>
  <p style="margin-left:51.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:  President, Chief Operating Officer,</font></p>
  <p style="margin-left:51.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Counsel and Secretary</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">20</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">INVESTOR:	</font><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">VERTEX PHARMACEUTICALS INCORPORATED</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:40.84%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Reshma Kewalramani	</font></p>
  <p style="margin-left:45.84%;text-indent:-12.058%;padding-left:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name:  Reshma Kewalramani</font></p>
  <p style="margin-left:45.84%;text-indent:-12.058%;padding-left:5.84%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title:  Chief Executive Officer and President</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Investor Information</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Entity Name: Vertex Pharmaceuticals Incorporated</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Address: 50 Northern Avenue</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">City: Boston</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">State: MA	</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Zip Code: 02210</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Telephone:[**]	</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Tax ID #: [**]</font></p>
  <p style="margin-left:0.04%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name in which Shares should be issued: Vertex Pharmaceuticals Incorporated</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>5
<FILENAME>verv-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit 23.1</font></p>
  <p style="margin-left:13.333%;text-indent:7.692%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:bold;font-size:10.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">We consent to the incorporation by reference in the following Registration Statements:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Statement (Form S-3 No. 333-267578) of Verve Therapeutics, Inc.,</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-263518) pertaining to the 2021 Stock Incentive Plan and the Amended and Restated 2021 Employee Stock Purchase Plan of Verve Therapeutics, Inc., and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(3)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Registration Statement (Form S-8 No. 333-257175) pertaining to the 2018 Equity Incentive Plan, 2021 Stock Incentive Plan, and the Amended and Restated 2021 Employee Stock Purchase Plan of Verve Therapeutics, Inc.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of our report dated March 2, 2023, with respect to the consolidated financial statements of Verve Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Ernst &amp; Young LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:13.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">March 2, 2023</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>6
<FILENAME>verv-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I, Sekar Kathiresan, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Verve Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over<br>financial reporting to be designed under our supervision, to provide reasonable assurance<br>regarding the reliability of financial reporting and the preparation of financial statements for<br>external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.406%;"></td>
    <td style="width:1.998%;"></td>
    <td style="width:5.0%;"></td>
    <td style="width:47.596%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Sekar Kathiresan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sekar Kathiresan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>7
<FILENAME>verv-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I, Allison Dorval, certify that:</font></p>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">I have reviewed this Annual Report on Form 10-K of Verve Therapeutics, Inc.;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Designed such internal control over financial reporting, or caused such internal control over<br>financial reporting to be designed under our supervision, to provide reasonable assurance<br>regarding the reliability of financial reporting and the preparation of financial statements for<br>external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div></div>
  <div style="text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.537%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:6.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:47.991%;"></td>
    <td style="width:1.004%;"></td>
    <td style="width:4.583%;"></td>
    <td style="width:46.421%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>8
<FILENAME>verv-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Annual Report on Form 10-K of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Sekar Kathiresan, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.454%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:4.083%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Sekar Kathiresan</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Sekar Kathiresan, M.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>9
<FILENAME>verv-ex32_2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html>
 <head>
  <title>EX-32</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exhibit 32.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with the Annual Report on Form 10K of Verve Therapeutics, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), I, Allison Dorval, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <div style="margin-left:4.528%;text-indent:0.0%;display:flex;margin-top:12.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Arial;justify-content:flex-start;min-width:4.7521786492374725%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.454%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:4.083%;"></td>
    <td style="width:46.463%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Date:  March 2, 2023</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">By:</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.25pt solid rgba(0,0,0,1);padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">/s/ Allison Dorval</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:middle;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Allison Dorval</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Chief Financial Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(Principal Financial Officer)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img243551639_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %* GD# 2(  A$! Q$!_\0
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M/-^)O]W4?^^%_P *]HHH]KY(/K?]Q?<>+^;\3?[NH_\ ?"_X4>;\3?[NH_\
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M/G1_^OY/Y&MNL3Q!_P ?.C_]?R?R-;=4]D7+X4%%%%20%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5B7'_ ".=E_UZ2?\ H0K;K$N/^1SLO^O23_T(4XEPW?HS;HHHI$!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B>(/^/G1_P#K
M^3^1K;K$\0?\?.C_ /7\G\C6W5/9%R^%!1114D!1110 4444 %%%% !1110
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M10 57:R@>_CO2#Y\:&-3GC!Y/%6*X?2=,@\26M[J6J7EPMVMQ)& DY06H4X
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M?^/?X4;?B%_?T;_Q[_"CD\T'L?[R^\[.BN,V_$+^_HW_ (]_A1M^(7]_1O\
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M HHHH **** "BBB@#$;_ )'A/^P<?_1@K;K$;_D>$_[!Q_\ 1@K;JGT+GT]
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MJT*)U5M4M\L 1ALCGW%:L4L<\2RQ2+)&PRK*<@BAIK<3C);H?1112)"BBB@
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M444 %%%% !1110 4444 %%%% 'G_ (\GOO[6MH[5/W:6SN[<=#P:KZL@\B(
M8W:9"?KC%:GC<>7=6C#K-&T/X9'^-1>-+86QLS%T:W:V ]@01_*M*<;.]]ST
M(S3C"-K';1-YD*.1RR@T^D50B*HZ 8I:S//"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBF32K!!),^=L:ECCT S0 ^BN=TV_P!:O8(-3D^Q)83#>8?F
MWI'V.[H3CM0WB^U2W>XEM+J.'R7FA=E_URKR=OOCGFJY6:>RE>R.BI  #D
MUA3>)XXAS87;%(A-.H09A0DX+>Y )Q0?%5M]M,*VUP\(G2 W"@; S@%?_0A1
MRL7LY]C>HK 'BNT\VZC>"9#!"\PS@[U3[V/0_6A?%5OY$SRVMQ"Z+&Z1. &D
M#G"D#ZT<K#V4^QOT5AZQK5QINI6,,=L\Z3)(SH@RWRC-12>+[%4C=(II%,*S
M28 S&IZ9'<]>!Z4<K&J<FDTCH:*Q#XFM5U-;(Q28<D)+QM8[=V/7I56V\4RW
MM[I:0:9.MM?!F$DF 0  <@>G-'*P]E+L=+1114F84444 %%%% !1110 45F>
M(+^;2]"NKV *98@"H8<<L!_6JT?B:U:>ZC:.18[4-YLIQ@%1D\=>_![TU%M7
M+4)-71N45S5SXENE2RDCTRY03SA/+D4;G4J2"O/MWJ3_ (2ZT-O"Z6\S32!V
M:'@,@0[6SDXZ_G3Y6/V4^QT-%<Y)XPM%D_=6MU-%^ZS*B<#S/NCUSVI&\51>
M9 [H]O&K3K<)*OS*8P#V^M'*P]E/L=)16?8:FU[;R3265Q;*HW#S5^\N,Y&/
MY5C7'B]CI)OK+3Y)1YJ( S#D$X]>#[&A1;$J<F[(ZFBL)O%$"-=*;2YS!,+<
M84'S)3C"+ZGFJMUXNAMY+5IE-J@G>*[2<?,F(RPQZYXQ1RL:I3?0Z>BN?F\6
M6MNP$MM.A1%><'&80W3(SR<<X'2M\$$ CH:331,HN.XM%%%(D**** "BBB@
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4A 8$$
M@\$&EJ*YF^S6DTY4L(D9]HZG SB@#)M_#%I;2KY=S>?9D8LEH9OW2D^V,XYZ
M9Q47_"(V!A>&2>[DB,30Q(\@(A5NH3C\.<U@W>MZG(BW4L\*I)ISW");2'Y?
MF&,^XSU^M:3>)[JTN;I;N!4CBC=X8]K%I0JYR&Z$^HZBM+2.IQJ[IFK?>';6
M^F:4SW4)DC$4RPR!1,@Z!N/<],=:4^';$K*H\Q5DN([@J&X#(  ![?**QX_$
M^H"T9Y8(PTBQF"01N%+.<;,=2>>#W]J:?%&I'3HY_LT:E)I8[B78S!-G0[1S
M@]SSC%%I$\E7:YH1>#]/B1D$MR4-O);JI8?*C]0./YYI;G0#=^(--NG1!;:?
M&=K;CND;& ".F!R?QJI'XGO+C4G2UM5EMXYDA8*K%F! RX/0#G./2I->U*\M
MM4E6U+?Z-ITER$'1V)VC([XP31[UPM4O9LVKG38+J]@NI"_F0HZ+@\888.:S
M?^$2T]6A:*2>-HXQ$64J2Z@Y ;*GU[8K*G M=!>_A\07$US+9N^UI5(D.W.5
M';'M4<FKZJ\NC+-;36J/;2L7,RMYI$.1P#Z\\T)/HQQA.VC-P>%K$7@N5DG&
M)FG$88;0Y7:>V>GO4R:!:Q)IBQ2SH=/&V(JXRRXP0W'(.*YO3I9K6V\/RQ:E
M<3S:@%2>"27?N!7)<=UV]:Z/PU=2W>AQ-.Y>2-Y(BYZML<J#^0I2NNI,U.*O
M?^M36HHHJ# **** "BBB@ HHHH JZEI\.J:?-97!<12@!BAP>"#_ $K/E\,6
M,]\UW</-,Q1D".1@!A@C@ _F:VJ*:;12G):)F/!X>AA^S^9>7EQ]GD$D7G2
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M'YT +12;E_O#\Z-R_P!X?G0 M%)N7^\/SHW+_>'YT +12;E_O#\Z-R_WA^=
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MTG_G^U3_ ,"C_A78T4<\NX>WJ_S''?\ "N-)_P"?[5/_  */^%'_  KC2?\
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&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img243551639_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_1.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "? 4\# 2(  A$! Q$!_\0
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M:VMF:WLE/3CAW^I/'T%=+5/30U;Y%RK?K_D%%9UWKVEV,ACGO8Q(.J+EV'U
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=HHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img243551639_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_2.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ HL# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBJNH7T>FV;W4J2NB8RL2%VY..@H&E?1%JB
MN<MO&VEW=R+>&*]:3>$8?9F^4GU]*U[#4[;4C<BW9C]GF:&3(QAAUIN+6Y4J
M<H[HN4444B HK*U3Q%INCRI!<S,;B092&)"[D>N!44/BK29]-N;Z.=C';?ZY
M"A#I]5/-/E9?LY6O8VJ*;&XDC5U^ZP!'T-.I$!1110 454.HVZZHNG'?]H:,
MRCY#MQG'7I5N@;3045%<W,%G;27%S*L4,8RSL< "L2W\::+<W$40FEC$QVQ2
M2PLB.?9B*:3>PU"4E=(Z"BBBD2%%%!.!F@ HK+TCQ#I^N/<I92LSVS[)%9<$
M'G_"DLO$6G:AK%SI=M*SW-L"9!MX&#@\_C3LRG"2OIL:M%%,FE6""29_N1J6
M;'H!FD2/HJMI]_!J>GP7UL289T#H2,'!INI:E;Z38O>73,(4(!*C)Y.*=M;#
MY7>W4MT5%-<1P6KW#D^6B%R<=@,UST7CO19!&[FYBAD("S20,$YZ?-0DWL.,
M)2V1TU%("" 0<@TM(D***KWU[#IUA/>7!(AA0NY R<"@$KZ(L453AU2SGEMX
MDF'FW$(FC0CDIZ_K5R@;36X455U#4(-,M#<W._RPP7Y%+').!P*M Y /K0%G
M:X4452L=5M=1GO(;=F+VDOE2Y&,-C/% 6;U+M%4K+5;6_N[VV@9C)9R".8$8
MPQ&>/6KM --;A1534M1M]*T^6^NBP@B +%1D\G']:M*P= PZ$9% 6=KBT457
M:]MDODLFE47+H9%C[E0<$T"M<L4444 %%%0&]MUOELC*HN6C,@C[E0<9_.@+
M$]%%% !1110 457EO;:"Z@MI956:?/E(>K8&35B@+!1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M '+>&/\ D8O$O_7TO_H-<W]BE;2?$^H17]W!+;7LKQ+#)M4,,<D#K^->B6]A
M:VD]Q/!"J27#;Y6'\1]:B&D6 MKJW%LGE73%YE[.3U)K13U.A5DI-^GX'(:G
M?WU]K6GZ>PNF@:Q6?R[><0M*YZG=W ]!6_X5.I"RGBU#>5CF*P-)('<IZ,1W
M'2KU[HFFZA;Q0W5I'*D(Q'D<H/8]:L65C:Z=;+;VD*0P@Y"J.,TG)-6)G4BX
M<J1RNBRV]KXYUY+]E2\E9&MFD.-T6.BD^]2^*+K3+CP]KB64D#W*1*)S&!GK
MQD]ZW]1T;3M651?6D4^S[I8<K]#3(M!TN#3I+"*RB2UE^_&HQN^OK1S*]Q^T
MC=2UOI^!S4-O/I'B;0%CU"[F2^BD$Z32;E.U 1@=!5*RFO[;PYK.N)>W4]S;
MR3I#"SY1!NQG'<CK7<OI]K)<VMP\*F6U!$+?W,C!Q^%+:Z?:V<$D$$*I%(S,
MZ]B3UI\X_;*VJ_J[.*D#Z.NBW]CK-S>W%W/''+%)-O6=6^\0.V.O%5KB&ZN=
M/\3WW]J7T;V5S(;=8Y2%7 !Z=Z[.S\-Z/I]W]JM=/ABFYPP'W<^GI4XTBP$%
MW +9/+NV+3K_ 'R>N:.=#]M%/3^M3EI=2O%UK2IE=W=M'DF,8/#N #G%/\-6
MJ7EGI^L3Z]=/=S-N=// 1B?^6>S^G6NH32[)+F"X6!1+;Q>3$W]U/2JL7AO1
MX;_[=%I\*W ;<' Z-Z@=,TN96$ZL;66G],R/'R_\2NQDE5FL8[V-KL 9_=]\
M^U:]SJ.B"T@:XN+1H'91""0P+=L"M.2-)8VCD171AAE89!%95KX7T2SNEN;?
M38$E4Y5@OW3[#M2NK69"G%Q2?0X_7[RXG76=1L9=2'V!RBS"Y"HCKC($?<>Y
MK4NEN=4\5:7;M?7,$,FF^=*L#[=YW"MZY\-:->3S33V$3O-_K#_>]S[U;73K
M1+N*Z6%1-%%Y*/W">E5S(T=:-E9' FXU+5K_ %9C]O$MK*8H1#=K$L  X)4]
M<]<FNZTN2[ET:V>_55NC$/-"D$9]>/SJ&]\.Z1J-S]IN["*2;&"Y&"WUQUK2
M1%2-8T4*BC:%'0"E*29%2I&222/)+"ZE\-0?V_!&72>6XM9E'=\DQG\ZN:9;
M7/AS4KZ2-2]^NCFXD)&29"V3GZ?TKT)=%TY+,V8M(_LYE\WRR.-^<Y_.IO[/
MM?M[7WDK]I>/RFD[E>N*IU$S5XE.^F_](X5VDTW2](UBUUNYNKRZFB62)YMR
M3!_O +VQ^E2#?J[^(+N\U6XMI;1Y(HK=)MBQJ%XRO0YKJK;PUHUG>_:[?3X(
MYP20P7[I/7 [4MUX=TB]O#=W-A#).1@N1][MSZTN="]M&YPMO?7G]C>%=,C\
M\6UQ:%W$$HB:1AT7<>GKBI]3748O"FKP7:RBV26(V_G3"5U^894D?UKMI-"T
MR;38M/DLXFM80!'&1]S'IZ4B>']*CT][!+*,6SL&=/[Q'<T^=![>-[VZ_K<7
M4_\ D7KK_KV;_P!!KSL3:Q<>&-&T:[6RM],U +$MT-S,N#D YX!->HR0QRP-
M"ZAHV7:5/<>E5)=%TZ;3$TV2U1K2/&R,]%QTQ4QDD12JJ"U74XEWOK_5]3M<
M7Y%BPA@6WNA$(U X<@]<]<]*N7J:]=V.D&<23,L;?:;6VNQ%)*>S@CJ/:NFO
M?#NDZC,LUW91RRJ N\]2!V)[TZ\T'2[^*&.XLHG6$;8^,;!Z#':GSHKVT=-/
MZ^\Y(:LLG_",-;7EX(3?R0S?:7^;(4_*Q[X--UB[>XD\8QBX,D,=DH50V54[
M3G'I773>'])GTY+"2QA-K&=R1[<!3ZCWIL7AW288;B&*QB2.X01RJHX=?0T<
MR!58+6W]7N<A;:=#)XMT*1[B9"^FK+Q*0,JJX ]O44^WENM.U6*?5Y;]O-N]
ML=Y;W0>!\GY4*=AVKL+C0M,NFM6FLXW:T $)/5 .P_*HHO#6C0WHNX]/A68-
MO#8X#>H'3-'.A^VB]RKXUFEM_"-]+#(T<B[,,IP1\ZUDM:3:MXOU6TDU"\A@
MBM(6"0RE1N(/-==>6=OJ%H]K=1"6%\;D/0X.1^HIL>GVL5Y-=I"HGF14D?NR
MCH*2E9&<*BC&W7_AO\C*\&W4]YX8M9;F5I91N0NQR3AB!FL[PQ<0VWB#Q+;S
MRI%*;SS0KM@E"HY&>U=19V5OI]LMO:Q"*)22%'09.35/4?#^DZK*LM[8Q32J
M,!R,''ID475V'/&\K[,X=[ESIGC*_LYF5)+M/*GC.,X !P:U%CN='\4:.(K^
M\N!>VTS3)-(6#,J!A@=N:ZDZ/IYTS^S1:1+9XQY*KA:E?3[62ZMKIH5,ULK+
M"_= 1@X_"GSHMUD^G]6LCS2]4W_@"ZUFYUBX>\G/[R S?(/GQLV>PYK8U.ZO
M;WQ,=,*7;6T%K&\<5M<"$N2.6)ZG'2NCF\*:%/+-+)IL!>;ESCJ?7ZU9U#0]
M-U01B\M(Y3&,(Q&"H],T^=%>WC^?RV./N9-8;1]*M[J[F@F?4?*69)0SM'SC
M)'!/:I'T6"U^(>F1&[NWQ9O)NDG)8D-TSZ>HKKAH^GK!;0+:QK%;/YD*@<(W
MJ*6\TBPO[F"YNK5))H#F)SU6ESD^V73S..L9+V.V\0:NMW=32V<TX@MRY,8X
M].]0Z4=78:9?VIO)))G4SR3WBM',I^\ N>".V.E=W;6%K9B800J@F<R28_B8
M]2:IVWAO1[2\%W;Z?#',#E64?=/J!T%'.@]M'70XS6KVXGCU75;&74@+.<HL
MWVD!%92 5\ONOO6A)813_$.PN)+B=7EL//($I W!@,#V]JZ*X\,Z-=332S6$
M3/-S(<?>/KCUJ>YT;3KR>VGN+6-Y;;'DN>J8HYT'MHVLC@+C[=_8-YJR:K>I
M<0ZDT<2B3Y%7?C&._7O6PANM&\5/##>W5RDVFO<M'/(7S(IXQZ5T[:+IS6<E
MH;5#!))YK)V+YSG\ZF-A:F^2],*FY2,Q+)W"DYQ0YH'63TMW//--FUJ\T^SU
M6V-X][+(K/))=KY+9/*>7GCCMUK3DM)]4U?Q,)-2O88[788DAE*@'RR<_P#U
MJZ1?#6C)??;%T^$3[M^X#^+UQTS5M-.M(Y;J5(5#W>///]_ P,_A0YKH$J\;
MW2_JYYZ(?[6N_"%W>W4XEN(7$CK*5^Z."/0GOZUZ8.E9DWA[2;BRM[.6RC:"
MW.84/\'TK3    Z"IE*YG5J*=K=/\PHHHJ3(**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHJDVKV"^=FY4F%Q&X'.&(R!]: +M%47UBPC@CF:X
M79)G:0"<XZ\>U7$=98UD1@R,,@CH10 ZBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *KSWL%
MLLADD&8UWLHY./I5BL;4=+N;_4XV=Q]C Y&[!'!R,8YSQW[4 :5I=QWMN)HM
MP4D@AA@@@X(K(ETZZBU2:]@MT=1,CI&&"[QLVD^Q!]:U[.V%I;) "I"]-J[?
MTJ>@#GH;&_M+E[Y;42O.) T D \O<V1R>#TYK4LK.2WTF.T,I60)@NO\)/I]
M,U=HH XOQ(-<TC[%-INHSW4QD8F"0+MD55+$<#T%;WA[Q!:>(=/%S;G;(ORR
MPM]Z-O0TFJ?\AK1?^NTG_HMJY7Q)H]YX;U7_ (2+0AA6/^DP#[K#W'O^E:0B
MIKEZE<\;6EIY_P"?E^7H>@T5D^'_ !!:>(=/%S;-M<<2Q-]Z-O0UK5#36C$T
MXNS"BBBD(**** &N6$;%<;L<9Z9I(BYB4OC>1SMZ9HE&87&W?E3\OK[4EN-M
MO&!'Y>%'R9Z>U $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 453U+38M4M?L\TD\:[@VZ&0HW'N*R/^$,L/^?W5/\ P,>FK=2XJ+6K.CJC
MJ^III&F2WKQ/*$*C8F,DD@#&?K68G@ZP1U87FID@YP;Q\59\3Z?/J>@3V=LI
M:1V3 W;3@.">?H#325QI0YDKZ$4/B>%9)X]0M)]/>&'S\38.Y <$@@GOVI;;
MQ)YLBF?2[ZV@="Z3R(-I &><'(X]:KW/A"V?3;R*&:=KJ>(()[B0R%<$,!],
MBI[6YU^79!/I-O$BH1)(\X97..-H'.#[T_=Z%M0:N@L/$GV\"1=,O([9XVDC
MN& *, ,\X/&?>G6GB:WOGLTMX)6>XB\]QQ^X3U<^_I6)8Z'J,6HI);:8=,BV
M2"X1+K?%-D' 5<\<]^*E\-Z!J'AY;4+%YL5U&%OHVD!:)QG# ]QVQ3:B5*%.
MSL:=EXI@O+F!?L=S%;7+E+>YD4;)2,\#G(S@XS6O<7MK:8^T7$4602-[ 9 Z
MUR%MX;NFU:T46DMI96ER9QON_,7@G 11TS[]*V=7TE]0URRG:VCFMXK>9&WX
M(#-MV\'Z&DU&Y,HPYE9FM%>VL\IBBN(I) -Q57!('K6;I/B2TUB_O+2".16M
MCPS@8E&<;E]LC%8$6@ZGIUK82V-C&+N'3I('VNJGS6*XR>_<Y]J?8>'=:TJ^
MTB<26T\=NA@E2)=C;&Y)))Y(/-'+'N/V<+/4Z/2];L]5MXY(I%21P6\EF&\
M$CD?A5N"]M;EW2"XBD9/O!&!(KC=/\/Z@JZ=!)I<5NUK)))+<K(N95.[Y>.>
M<\YK1\-:9?Z?>NLEKY-FL6Q1*8V<'/0,O)7Z\T.*Z,4Z<%=IG44445!@%1EI
M/M 7">5MSUYS4E0%1]N#>3SLQYN>G/2@">BBB@ HHHH **** "BBB@ K"\3F
M5(+:0&7[.LA\X1W AR,<?,2._:MVN?\ $,J^;;E(V>6W?>$>W>2-\@CL.HH
MT=&'_$KB(25 <D"6;S6QGKNR<U?K+\/1K%I"!2?F=V(\LQA26)("GD =JU*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***;)(D4;22,%11DLQP * '455@U*RN5=H;J)PGWB&''UJUU&
M13::W$I)ZH**BDN8(@2\R*%(4Y/0GH*EI6"Z"BBB@84444 %%%% !1110 57
M.W[>/];N\O\ X!U_G5BH"X^VA/.YV9\K'7GKF@">BBB@ HHHH **** "BBB@
M KF?%*B*:TNEDN_,&Y0D=T84QC))/K735D:^V+:,>;<1@L0?)MQ*3QW!!Q0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!#
M=?\ 'G/_ -<V_E570O\ D!V7_7(5:NO^/.?_ *YM_*JNA?\ (#LO^N0H ODX
M!/I6%>ZEJ$^GW26]E-;W'E,\<C$8'3'/J>>/:MZLS5=4L;22WL;M3(;QA&(P
MN1@G&3Z#)H PAJEW%$UD;BXCN6N(HI))V5_+1P3N!''.,<^M*=0U5(KAEN1+
M%9SF+S<A?,P0?F]>,CCOS6Z-.TBWMYK+R($C9?,DC/<#N?RIUN-*B$-G!]G
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MH"S&-%Q\J9.T<<9 Q6C0 4444 9&J?\ (:T7_KM)_P"BVK7K(U3_ )#6B_\
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MK[CDAJGC./[^@6DO^Y<@?SH/B+Q/'_K/"+G_ '+I3_2NMHHYEV#VD?Y5^/\
MF<E_PENJI_KO"FH#_<(:C_A.2G^M\.ZTG_;OG^M=;11==@YX?R_BSDQ\0--7
M_76.IP^N^V/%*/B+X=SAYYX_]Z!O\*ZK /4"D,<;=44_447CV#FI_P K^_\
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MAUK5DI_R-DO_ %YC_P!#H UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M[/[U_F:RLK#*L"/8TM8+>$-+)RAN8S_LSM2?\(PR?ZC5[^(>@DS_ #HY:?\
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M4A>OOS6C6?HL<D6F()5G$A9F83XW9+$]N,5H4 %%%% &1JG_ "&M%_Z[2?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV84_-Z>]) =UO&?,\S*CY\?>]Z )**** "BBB@ HHHH **** "BBB@ HHHH
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MUIO]V;_O\W^-(WAC3'4JR2E3P09FY_6@#1LO^/"W_P"N2_RJ>FHBQQJBC"J
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M1^5 &7_PDNC?\_\ '^1_PH_X271O^?\ C_(_X5J;%_NC\J-B_P!T?E0!E_\
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M1^5 &7_PDNC?\_\ '^1_PH_X271O^?\ C_(_X5J;%_NC\J-B_P!T?E0!E_\
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M_P"/\C_A6IL7^Z/RHV+_ '1^5 &7_P )+HW_ #_Q_D?\*/\ A)=&_P"?^/\
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ML1GF@#3L+Q;^S2X5&0-GY6[8_G5FJNG69L;)(#)YA!)SC &>P'85:H ****
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M'O@8JQ-)>SZO ER]UYT>H(?)6(^4(QT8-C^M '8T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%9T.LVTINM^8D@8#>_1QG&1Z\@BG6^L6=P$(E"F
M1F5 W\6"1G]* +]%9W]N:=F(+<JWF.(UV@]2"1^''6I#JUB(3+]I3:&V]^OT
MH NT5F/K=LD=FS C[5DKG@  9))J<:M8%@HNDR5W#Z4 7**J6^J65U*(H+A'
M<YP![5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2%[4,@0%@ I7M@8^O>NBLHG@LH8I&W.B ,?>@">BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img243551639_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_3.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# C@# 2(  A$! Q$!_\0
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M !1161<ZI-#XJT_2U5##<6TTK,>H*% ,?]]&@#7HHHH **** "BBB@ HHHH
M**** "BBB@"C/>V$.HK#+(@O/)9E7&6V=\?E^E9!U#PRR-<F.+;&=A?R3\IZ
M8Z4MQX?OYM9.IK?1*ZW"/''Y>?W:C!7=U&0S=N]6FT:9M(O+/S4WSW#RJW.
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MPB+RSGT KS'4OBMJMQ(PT^WAMHNQ<;V_PKF?$>N7'B/6Y;MRQ0ML@C'\*YX
M'J:UHOAMXAEL/M1C@C^7=Y3R8?'\A^==4:<8KWCU:>'I4HIU=V26_P 3O$<,
M@:22WG7NKQX_E7?>%_B!8>()%M)T^R7IZ(QRK_[I_I7E_A_P=JGB2"::R\E8
MX7V,96(RWH,"L[5-)U#0-0^S7D303KAD8'@^A4TY0A+1;FDZ%"HW!:,^D:*Y
MGP-X@;Q!X>26=LW4!\J8^I'0_B*Z:N5JSLSR)P<).+Z!1112)"BBB@ HHHH
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M1#:AR,]>I'Y5Z!96-KIUJEM9P)#"GW408%.52,?@W,:F(I0O[):]R9$6-%1
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M8P*ER.,G&>F:YS^PY9E(:T@A0>5^ZW[@S*<E^G7'%:%]9R2:G'<?98[J$1[
MCOM\MMV=P_"CE7<3BNYI@@DX(XZ^U&1G&1GKUKFET.]>24RK&!(FV0 @!COS
MV'IZU971YUU>28Y:'S-\>TJ %VXV'C./Q[T^5=Q\J[FO-=VUO)$DT\<;2G$8
M9L;C[58K@/B';RRZ=I,$-NPDWD+%'\VWCH,5I>#M/\26<*_VI<J+7'RP2?-(
M/Q[?2G[)<G/<ITUR<US8TR6 ^/+R(66)A:*3<[C\PSTQT_\ U5UE<UIHO_\
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M8/'?(ZU5_=-E)*G;J:M%%%28A7(:[_R/NB_]>5S_ .A1UU]<AKO_ "/NB_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<CKG_ "/NB_\
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MS34G<FK%QF[H*<!2 4ZI,Q:44E.%-"9(OW12T@Z"EJR HHHH **** "BBB@
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M7LD$\5S;QSPN'BD4,C#N#7@FN6GV359 )VG64"82.,,0XW<^_->D_#+4'N=
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MK5?_  .D_P :/^$!TK_GZU7_ ,#I/\:.1ASFUM/H:7!]#6)_P@.E?\_6J_\
M@=)_C44O@O0K=@LVI:A&3T#ZBXS^9HY YSH,'T- 4^AK!/@?15=4-_J09_NJ
M=0?+?3FG_P#"!:5_S]ZK_P"!\G^-'('.;F#Z&C!]#6'_ ,(%I7_/WJO_ ('2
M?XT?\(%I7_/WJO\ X'2?XT<@N<W,'T-&#Z&L/_A M*_Y^]5_\#Y/\:/^$"TK
M_G[U7_P/D_QI\@<YNX/H:,'T-87_  @6E?\ /WJO_@?)_C1_P@6E?\_>J_\
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M1#(D^\!V!]\8K3HH **** "BBB@ HHHH YSQC%?W.EM;V]HT]JT<C7&R4(V
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,4 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img243551639_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_4.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $L A8# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW3()+:PB@E2-&C&W]W]T@=_QI,SFE:]RW1114F84444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15&_U2'3N98KAE"EV>
M.(LJ*.I)%1-K]B+H0AI&4LJ&58R8U9AD MTS0!IUSVH?\CQHW_7O<?\ LM7X
M-<L[B\6V3S 79ECD:,A)"OW@K=#C!_*J&H?\CQHW_7O<?^RT =#1110 4444
M %%%% !15*36--AN)()+ZW66-2[H9!E5'4GTI8]6TZ:%)8[ZW:-SM5A(,$^@
MIV8^5]BY1112$%07=W!8VDEU<R+'#&NYF;L*F9E12S,% ZDG&*\L^)^N^?+;
M:7;3!H OG2E#D,?X?ZU4(\SL:T:3J342KKWQ,U"[F>+2<6MN.!(1F1O?VKFO
M^$GUWS/,_M:ZW>N^NA\)> #KU@-0O;AX+=R1$J#YGQWSV%0R^#K.'QNFB/>N
MMLR[O-< $G'"CU/2NA."T1Z<70@W!+8M:#\3-0M)DBU;%U;G@R 8D7W]Z]8M
M+N"^M([JVD62&1=RLO<5Y'XM\ '0; ZA97#SVR$"17'S)GOGN*T?A7K$@N+G
M2)')C*^=$#V/\0_E43C%KFB<]>E3G#VM(]1HHHK \\**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&UNTU.^:*"V%N;(
MC,ZO*R/)Z+D*<+Z^M5Y-#NV,UJK0"PN+A;B3D[T/!*J,8QD#!XQZ5T-% &!:
M:+=Q3VD4KP_9+.5Y8V4G>Y;. 1C QD]SFLWQ4MX_B;1UT^Y%M<>5,1*4##'R
MY&#78URNN_\ (XZ-_P!<)_\ V6DW971</B0I.NF_>7^U8Q;%-HB$ X;;C.?K
MS54Z5J-S8?9KW7KV1C)O,D.(CC&-O':M>BL/:S.I.VR,T6-[:W_VVTU*X9A%
ML\B=]T;D# )]/?%/7Q+K%M81&\T-Y;QG*E;9P4P/XLGIFK]+3562WU!I/XD5
M6U?7);Z>*+3K>&V"'RII)<DMCC(';-4I-,U'4[.%-7U27S$D+L+0^6K#LI]0
M*V!10ZLN@*T=D4UTG3UDFD^QPEYAB5F7)?ZYJ&;P_I,\"026$/E(Q955< $]
M3Q]*TJ*GFEW'S/N9BIK&F3W=S:737L;KF*RF( 5LCHW8 =J<TOB*\^QR-=P6
M&TYGBC3?NYZ9/M6C2U?M9$Z;V,G_ (1^"5KO[7=7EW'=??CFF)4#.0 !TKS;
MQI81:=X@,%O$(X/)0HHZ8YKU^N2\=:!)JEBEY;(6N+8'*CJR=_Q%:4*K4_>9
MO0J6GJ:WPXU:"^\,Q608"XM,HZ=\9R#^M6[W2IKOQU87P<-!:V[%E9>%)X&/
M<\_E7BNGZC=Z5>I=V4S0S(>H[^Q'<5Z!_P +6;^R,?8!_:73.?W?^]Z_A75*
MFT[Q)JX::FY4];_J;WQ'U:"R\,RV18&XN\*B=\ @D_I7#?#2)W\81LN=J0N6
M/MQ7-:AJ-WJMZ]U>3--.YZGM[ =A7K/PZ\-2:1ITE]=H4NKH#"'JB=L^YZTV
MN2%BY15"@XO=G;4445S'EA1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7*Z[_R..C?]<)__9:ZJN5UW_D<=&_Z
MX3_^RU,_A94/B1>HHHKE.H6BBEH ****8!1110 4M%% !112BF(YO6?!.F:M
M*TZ[K6=N2T0X8^XKE8/A]/-XA;3/MH"+!YWG^4<=<;>O6O3JHV/F_P#"9O\
MZ:GD_8A_HN[YL[OO8].U=%*K/:YJJTXQ=F0Z#\/])T65;APUW<KRKRXPI]A7
M6445;;>YPSG*;O)W"BBBD2%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<KKO_ "..C?\ 7"?_ -EKJJY77?\
MD<=&_P"N$_\ [+4S^%E0^)%ZEI*6N4Z@I:** "BBBF 4"BEH ****8!2T44"
M"LVR:W'CQE^SR?:#89\[=\NW?]W'K6E5*S-U_P )B0+F/[+]B_U&X;MV[[V.
MN*UI?$#^%^ATM%%%:G(%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB1L>&$H;C&>W<>E2+J]BR%UFR,@ !3DY&1@=^*@31(Q(\LDS/(^ 2JA<\8Y
MZGWHN-**>7+:EC/&J*IW 8"J5].X-:6A<KW6R<:O:%G^?Y5V[6'._.>@_ U/
M)?6T5ND[2@QR8V%1G=GT'>LZ/0%,$1DE/VA2&W=5S\WY_>-79-/#06Z12&)[
M<[HW51UP1R/Q-)J/034>@HU2S,OE^>-V,]..F<9]<<XITE_:Q;=\RC=@ >N>
ME5CHZNYWW$C1%_,9,#E\$9S^)XIT.D!)(Y))Y)'C*D' 'W00/YT[1#W24:K9
MF$S"4E-VT':?F/MZU9CECEB61'5D;E6!X-9?]@1X)\XA@^]<+A5XQ]WIS5#Q
ME']D\&2I"=OEO'M*\8.[J,4U&+:2&HQ;21TU9=J;0>/E!CE^UFPX?/R;=W3'
MK7.>#K_Q+<A%NH?-L>TT_P K8]O[W^>:ZJU^V?\ "8+AHOL?V,Y!V[]V[\\?
MI5QAR3M<52/)=7Z'2T4459PA1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 1S([PLL4GEN>CXSC\*Y'3M0TBSU921:F21
MF43QJZ $GG"L,#GK@UV5<7IUD-0GCA9;W["F\0>88QLR><X^8],<]*J.VIM3
MM9W.THI% 50HZ 8I:DQ"N6UW_D<=&_ZX3_\ LM=37+:[_P CCHW_ %PG_P#9
M:F?PLJ'Q(O4M%%<IU!1113 *",@CU&**6@#G([348[1EA,ZM'&P4,W5BQSWY
MXZ430ZI]E58GF8C>R'!!!XVJ?FYYSR:Z.BM.=E\YSQLK[_24C-PI)E?(?&6*
MC9C\:2>VU1'V))/Y!(.[.YMVP>XXW9]JZ.BCG8N=F%+9ZA('+23,S%DX; *%
M/3ZUH65LCZ1:P7$1?9&FY)AD[AZ_C5VBDY-B<FPK+MQ:?\)["6,WVO["=H&-
MFW=^>:U*I6XN_P#A+X2L,1M/LK;I2HWAL] >N*JE\0GL_0Z6BBBMCC"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YW
M1_#\VFW:R/'IS!2W[U(6$ISZDG%:FLP3W.CW4-MGS60A0#@GU&>V1Q67:W$V
MHZQ9O!9W5K':QLLYG&W.0,+C//3.:I;&L+\KLSHJ***DR"N6US_D<=&_ZX3_
M /LM=37+:Y_R..C?]<)__9:F?PLJ'Q(OT445S'4%%%%  *6BB@ HHI:8@HHH
MH ****!BBLJ);;_A.[9FFE%S]C8+&%^4C/7/K6K5"$7'_"86Y6SC:#[*VZX*
M_,ISTSZ5I2^(.C]#IJ***V.,**** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN8),7&3\GMZ5I2^(.C]#J:***V.0**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6US_D<=&_ZX3_ /LM
M=37+:Y_R..C?]<)__9:F?PLJ'Q(OTHI*6N8Z@HHHI@%+110(****!A2TE+0
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MY HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%=TMU"B[MN6<#GTJ99$?&UU;(R,'.17*Q>%]%BM'MA8QO%(V]PY+;F]<T_\
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M;7/^1QT;_KA/_P"RU,MBH?$C0H%%+7.=(4444 %%%% Q:**6@04444 %%%%
M!2T44 %%%%,0444HH *!12T %%%%,04M%%( HHI13 ****!!2T@I:8!1112$
M%%%+0 4444P"EI!2T %%%%,0444M !1110 4444P 4M%% @HHHH *6DI:8!1
M110 HHHI10(44HI*=0 4].],IZ=35(ECZ***HD**** "BBB@ KEM<_Y''1O^
MN$__ ++74URVN?\ (Y:-_P!<)_\ V6IEL5#XD: I:**YSI"BBB@84M)2T %+
M110(**** "BBEH ****8@HHHH *6BB@ %+110 444M,04444 %+110(***!0
M M%%%, HHHI""EHHI@%%%**8!1112$%%%%, I:** "BBBF 4"BEH$%%%% !1
M110 M%%%, I124M @IU(*6@!12T"@4T(6GK313EJD)CJ***9(4444 %%%% &
M%::[-/<6KO;HMG=R/'"P;Y@5SRP]\&L_Q%<06OBW1I+B>*&/R9QOE<*,_+QD
MUKVV@P6UW'*)I6BA9GA@8_+&S9R1Z]3CTS5V[T^SU!%6\M(+A5.5$L88 _C2
M:NK#3L[F'_;.E?\ 04L?_ E/\:/[9TK_ *"EC_X$I_C6C_PC>A_] >P_\!T_
MPK/USPU9/HUS'I>C:?\ ;)%\N-F@0!-QP6Z=@2?PK/V9I[5]C.T_66N6U;5)
M9E71K;*0L!]_8/G?/<9R!]*9H.OP7.DQW6HZI8+-.S2K'YZ#RT)^53SU K0O
MO#;'2=(\/6<2II4;*+LYQF-,$)CON;&?H?6M3_A&]#_Z ]A_X#I_A3]F'M69
MW]LZ5_T%+'_P)3_&E_MG2O\ H*6/_@2G^-:'_"-Z'_T![#_P'3_"JESIOAFT
MNK:VFTNP6:Y8K&OV93G'X<"E[,/:OL1?VUI7_04L?_ E/\:/[:TK_H*6/_@2
MG^-+:VGA:\NC;0Z98E_FVDVJ@/@X.TXYP:O_ /"-Z'_T![#_ ,!T_P */9A[
M5F?_ &UI7_04L?\ P)3_ !H_MK2O^@I8_P#@2G^-:'_"-Z'_ - >P_\  =/\
M*/\ A&]#_P"@/8?^ Z?X4>S#VK*']LZ3_P!!6Q_\"4_QH_MK2?\ H*V/_@2G
M^-7_ /A&]#_Z ]A_X#I_A1_PC>A_] >P_P# =/\ "G[,/:LH_P!LZ5_T%+'_
M ,"4_P :/[9TK_H*6/\ X$I_C5[_ (1O0_\ H#V'_@.G^%176B^';*UDN;C2
MK!(HUW,QMUZ?E1[,7M&5O[9TK_H*6/\ X$I_C1_;.E?]!2Q_\"4_QJ$0^&))
M88X=$@F,L23 Q608!&SM)XXZ&M3_ (1O0_\ H#V'_@.O^%'LP]HRC_;6D_\
M05L/_ E/\:7^VM)_Z"MC_P"!*?XU=_X1O0_^@/8?^ Z?X4?\(WH?_0'L/_ =
M/\*/9A[1E+^VM)_Z"MC_ .!*?XT?VUI/_05L/_ E/\:N_P#"-Z'_ - >P_\
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MA_\ 0'L/_ =/\*/^$;T/_H#V'_@.G^%'('.5O[:TG_H*V'_@2G^-+_;6D_\
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M_P"!*?XTO]N:/_T%K#_P)3_&J%E9^%M0G:&WTNQ+A=PW6JC>N<;EXY&:O_\
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img243551639_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_5.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #( ?8# 2(  A$! Q$!_\0
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M444 (0#U -+110 4F!D' R.]+10 4444 %%%% !1110 4444 %%%% !1110
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ML*P/^$<O;GF_UFX<_P!V+Y14B^#]+',@GD/J\I-&@N:H]H_B;(NK<G GC/\
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MA0":DKHC@F6>%9$((/H<\U)5*RRDUS#SM1\J-F  ?3UJ[0-.Z"BBB@84444
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M10 4444 %%%% %.8F/487.=KJ4X3//7D]JJ7^DB^U2.:8*;<0M&P/7)-:-S
MMQ"4)(YR,''(KG_$M[(OAB]25O*N4502O )R/NFLY13TD:QE)>]'<B7PQ<KI
M\]J95D#W"R!F/51ZU>CTA=,U-[VVCCCA$&TKNQ\V>IK8MCFUA/\ L+_*EFCC
MFA:.50T;## ]"*E4(+8MXFI+23T9!9WOVBP%S(HCZYR>..^?2ET]"MHI8$%B
M6P6W=3ZU61([A5MK10MHO+, "KCNM:2J%4*!@ 8 JXW>YG.RNEU%HHHJS,**
M** "BBB@ HHHH **** "BBB@ JGJ!*"";G$<@) 3<2#Q^%7*;)&LL;1MG:PP
M<&@35T.K'U6RNC?VVHV01Y805,;G 8'W]:LV\QM6^S7&% !\M^<;1TR3WK,\
M82.FF6K1NRDWD0RIQQNH):4U8LZ997;:I/J=ZJ1R.@C6)#G:!ZGUK9KGO"LC
MNVK[W9MM\X&3T'%:=Q<M.QMK5LOG:\B\B/ZT DH(6Q_>37,PSM=\*=^00/3T
MJ[4<,*01+&B@*!T Q4E!25D%%%% PHHHH *BN4,EM(@QDJ<9&?TJ6BA@G8SI
M83J6AM K;6ECV99<8/TJ@_AM3>6%S'(%DM]OF@='P.OUK1;-A.T@4M;R'+8R
MS!C_ $K,T"8R^(-?_>%T69 O.0/E[5DX1E\6YNJLX? ]&#^&4DL;N-A$9YI2
MZRE>5!.:OP7DBZDMC^[=$C^8J>5/O6G5*=K:VF+I"CW3#(50-S4>S4-8Z![6
M5326HLA\W4XE&2(E+,0W0GID5<JO:6YB#/(0TKG+-C''8?A5BKCW,I/H@HHH
MJB0HHHH **** "BBB@ HHHH K:@I>RDVGD#=]W=T]JFB<20HXSA@#R,&GUGH
M3I\IC8$V[M\C<D@GDY]!02]'<=JVG+J5GY1<QNK!T<?PL.AJE!I5Y/?P7.I7
M<<OV?)C2-<#/J:O:I(#HEZ\;9_T=R&4_[)KE_"TTKZO:!Y'8'28F()SSGK0)
MPBW<[6J2?O=5=QDK&FW(?C/ICUI]S=A"88AYDYQ\B]5![GVI]K;_ &>+#$-(
MQR[@8W'UH&]78GHHHH*"BBB@ HHHH KWU[!IUC->7+;885W.V,X%4U\0Z:\-
MA,EP&COGV0,HSN/I[5'XIMIKSPOJ%O;QF262(A4'4FN*A\*ZGI>L:";5'?3?
M-6:6(_\ +"3;\WX&@#TVBL6+Q5I,ERUM)<&WF5BNVX4IGZ$\&M8SPK"9C*@B
M R7W#&/K0!)7-^.6ME\+77VAD4\;-QP<Y'2DF\1W.I2M;>'K;[00<-=R\0I]
M/[U(/"\@BDN[BX6_U4K\CW(S$A] O84!L:-A;K+IT#6E^YB,0565@PSZYJT;
M!';,TDDG(8 MP"*X9&DTR^Q$3H=^QYBD^:TG/L?X<UV&EZG/<6Y_M&U%G,K;
M.7!60^JGN*GE17/(TU547"J /0"EIOF1^9Y>]?,QG;GG'TIU42%%%% !1110
M 4444 %%%% !1110!!>WD.GV4UW<-MAB7<YQG J@/$NE-;6-PMR&BOG\N!E&
M=S>GM1XFMY;KPSJ,$"%Y7A(51U)K@U\):GI][H+6B.]@94FFA/\ RQDQR?H:
M /4J*Q/^$KTN.\>UNGDM9%8J#/&55OH>E:\=Q#+%YL<J/'C.Y6!'YT ++%'-
M&8Y$#H>H-<GXU@BL])@F-P\<8O8W;<V0.:NW7B8SSM9Z';&_N1PT@.(H_JW?
MZ"BV\,M<SK>:[<F_N!RL6,0Q_1>_U- K(SO!L,.H0:I*+IYX7NW&5; 8<<UV
M$<21+M10H]JPKSPPB7!O=&G.G7AY.P?NY/\ >7I5K2;[49#+!JMD+>6(#]\C
M9CD'J/3Z4 DD:U%(648RPYZ<]:3S$VEMZ[1QG- QU%%% !1110 445DZKXAL
MM+<0DM/=M]RVA&YS^';\: -4X R>G>N,T 64_B?7UMKM4<R+L$3C!^7D@=^:
MN#2]7U\[]7F-E9'D64#?,P_VV_H*S]:T@6+C.DJ=/C \JXL/EGM_<_WA2:3W
M&FUL=:;.5L[KN4CC &!T_P :EAM8;?.Q>22<GD\US6@:KJ,DL<7G1:I8L<"Z
M0[9(O:1:Z?[1"8S)YT?EC@MN&!^-'*AN3>A)12 @@$'(/0BEIDA1110 4444
M %%%% !1110 4444 %(RAE*D9!X(I:Q=3\2VME-]DMT>]OCP+>#DC_>/04 +
MK%A''HU^T,CPC[,XPK?*  >U<?X,:&^UNW\J_:41:;&K*IQ@\Y4UT2Z'J.ML
M)M?N-D'5;"W;"#_>/\56[WPKIUPL;VJ&QN8AB*>V^5E^OJ/K0+E1K06T5L@6
M),8&,]3^=35A:?<ZU9W7V358HYX I*WT9VC _OCL:V3/$%1C*FU^%.X?-]/6
M@=K$E%1_:(=KMYL>U#ACN&%^OI3P0P!!!!Z$4 +1110 445G:]]N_L.[_LW'
MVORSLS^N/?% '.ZYK0N;UPDSQZ;IS!IY(SS-+_#$OX]:Z;2IKRXTZ&:_B6*X
M<;FC7^$'H/K7/:#HVGW]MIEW!*S6MLI/V=ASY_\ $S^IKKJ *]W86E]&8[JV
MBF4]G4&N+UCPYI]GKVC6T*RK:74["6V,I,;8&1Q7>5S/B'_D9?#O_7P__H)H
M TM!OX;_ $]F@MQ!'%,\(1>GRG%:E<[X,_Y!%S_U^S?^A5T5 $-U9V]] T%U
M"DT3=5<9%<;\0K+SM.TBRMW:#==JB,O\''%=Q3)(8Y=IDC5]IRNX9P?6@#S[
MPS=:A-X_F@U.,K=6MEY+OVD ;AA]17HE96AWR:O:F_-ND<OF/%D<G"G'6M6@
M HIC2QH<,ZJ?<TGGP_\ /5/^^A0!)14?GP_\]4_[ZH\^'_GJG_?5 $E%1^?%
M_P ]4_[ZH\^+_GHG_?5 $E%1^?%_ST3\Z@NM1BM55F^=2<$J0<4 6Z*;'(DJ
M!T8,I&014=UY_P!DF^S;?/V'R]W3=CC- '.^(;][Z[.BVL_DQJOFW]P#CR8_
M3/J:U="OQJ.F+/';R0P E8?,/+H. WXURNCZ6VL:;':M+L/VAFU97_UDC@\+
M_N_TKNT18XU1%"HHP .@% #)[:"ZC,=Q#'*A_A=017%>*/#>G6,%M+9K+;K-
M=1QR112$(ZD\@BNZKG/&7_'A8_\ 7]#_ .A4 7-$NK9I;ZPM+1;>.QE$6%&
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M7MM8]U=PV^KV>D"TB,-VKNW P"OM0!>TW_D&6O\ UQ3^0JU2 !0   !T I:
M"BF2LZ1,R+O8#A?6J'VS4/\ GP_\?H TJ*S?MNH?] __ ,?H^VZA_P! _P#\
M?H TJ*S?MNH?] \_]]T?;=0_Z!Y_[[H TJ*S?MNH?] \_P#?=(;V_(P=//\
MWW0!IT5A:9=W3:A)"49H\\@MG9^-;M &=K\CQ>']0DC8JZV[D,.H.*Q/",EO
M"RV,-HB,+2*>2;JTC,.<FMGQ%_R+>I?]>[_RK \*?\AD_P#8-M_Y4 =E1110
M!D^)SCPOJ9'_ #[O_*O-(/[2TY/#>FW6^:SDN(Y[:?NH(Y0_2O7W19$*.H96
M&"",@UD&\5O$JZ2;:(PQVPG1BO*G=CCTH \]NCK']D^*OLPMS8_:7\TOG?\
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M]]L&.:[%W6-&=R JC))["N>\.W>D12W5O:ZK;W,MQ</,%5L$9[>] '1T444
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MT->,1:=?-9A9K**.QEU0A[H1$SQX;/Y&O:*3:N,;1CTQ0 B !% .0!UIU%%
M!1110 4444 %%%% !1110 4444 %%%% %74@3I5V "287X'T->5Z#IUZ)_#2
M7MG#;6V\R1W$,1\QF'\+GM7KU)M7 &T<=.* %HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** *VH@G3+L 9)A? 'T->5Z-IU[]H\.I>V<-M:^89$N(
M8SYA8?PN>V:]=I-JX P,#VH 6BBB@ HHHH **** ,C6O$-IHDMI'<!F:XDV#
M:?NC^\?;FJ]YXNTVSU!+0LS?,RR2@?*F!GKWJWJ/AW3-5N#->V_G/Y?EKN)^
M4>WH:IOX-TF23=(LS+R=AD^7)&"<>M #CXPT40QR_:3MD8J $.1CKGTZTU?&
M&EJVV>3RV,A08&X8!QDGM3T\):6MND)21@JLN2W)!Z_RI?\ A$]*VN/*?#@@
M_-[@_P Q0!:LM?TW4+B>"VN [P E^.PZD>M9]UXOM+32X=0DAD\J:;RXAQEE
M[M]*O:?X?L-,EGDMHR/.!!4G( /4"JJ^$M,:*.*Z1KF*'<(4D/"!CG H OPZ
MK#-J;6.UE?RA-&W:1#W%7ZR[#0[>PO!<))(Y6$01ASG8@["M2@ HHHH ****
M "BBB@ HHHH **** "BBB@ K"NO%=A8W=S!="1#"X3(7=N^7<3QZ"K]WJUI9
M7*0328=D,AXX51U)]!62\7AJ^OFE^TQO/<*6XD^\"NTG\J +9\4Z2)C']H.
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,0 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img243551639_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_6.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (L!0T# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BL#QGXH
M3P?X:FUA[1[ORY(XQ"KA-Q=PO4YQC.?\YKSS_A?'_4JW'_@8G^%-1;V1482E
M\*N>Q45X[_POC_J5;C_P,3_"C_A?'_4JW'_@8G^%5[.78KV-3^5GL5%>._\
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M1_POC_J5;C_P,3_"CV<NP>QJ?RL]BHKQW_A?'_4JW'_@8G^%'_"^/^I5N/\
MP,3_  H]G+L'L:G\K/8J*\=_X7Q_U*MQ_P"!B?X4?\+X_P"I5N/_  ,3_"CV
M<NP>QJ?RL]BHKQW_ (7Q_P!2K<?^!B?X4?\ "^/^I5N/_ Q/\*/9R[![&I_*
MSV*BO'?^%\?]2K<?^!B?X4?\+X_ZE6X_\#$_PH]G+L'L:G\K/8J*\=_X7Q_U
M*MQ_X&)_A1_POC_J5;C_ ,#$_P */9R[![&I_*SV*BO'?^%\?]2K<?\ @8G^
M%+_PO<[0W_"*W&"<?\?J?X4>SEV#V-3^5GL-%>._\+X_ZE6X_P# Q/\ "C_A
M?'_4JW'_ (&)_A1[.78/8U/Y6>Q45X[_ ,+X_P"I5N/_  ,3_"C_ (7Q_P!2
MK<?^!B?X4>SEV#V-3^5GL5%>._\ "^/^I5N/_ Q/\*/^%\?]2K<?^!B?X4>S
MEV#V-3^5GL5%>._\+X_ZE6X_\#$_PH_X7Q_U*MQ_X&)_A1[.78/8U/Y6>Q45
MX[_POC_J5;C_ ,#$_P */^%\?]2K<?\ @8G^%'LY=@]C4_E9[%17CO\ POC_
M *E6X_\  Q/\*/\ A?'_ %*MQ_X&)_A1[.78/8U/Y6>Q45X[_P +X_ZE6X_\
M#$_PH_X7Q_U*MQ_X&)_A1[.78/8U/Y6>Q45X[_POC_J5;C_P,3_"C_A?'_4J
MW'_@8G^%'LY=@]C4_E9[%17CO_"^/^I5N/\ P,3_  H_X7Q_U*MQ_P"!B?X4
M>SEV#V-3^5GL5%>._P#"^/\ J5;C_P #$_PH_P"%\?\ 4JW'_@8G^%'LY=@]
MC4_E9[%17CO_  OC_J5;C_P,3_"C_A?'_4JW'_@8G^%'LY=@]C4_E9[%17CO
M_"^/^I5N/_ Q/\*7_A>YV[O^$5N,9Q_Q^I_A1[.78/8U/Y6>PT5X[_POC_J5
M;C_P,3_"C_A?'_4JW'_@8G^%'LY=@]C4_E9[%17CO_"^/^I5N/\ P,3_  H_
MX7Q_U*MQ_P"!B?X4>SEV#V-3^5GL5%>._P#"^/\ J5;C_P #$_PH_P"%\?\
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M[_POC_J5;C_P,3_"C_A?'_4JW'_@8G^%'LY=@]C4_E9[%17CO_"^/^I5N/\
MP,3_  H_X7Q_U*MQ_P"!B?X4>SEV#V-3^5GL5%>._P#"^/\ J5;C_P #$_PH
M_P"%\?\ 4JW'_@8G^%'LY=@]C4_E9[%17CO_  OC_J5;C_P,3_"C_A?'_4JW
M'_@8G^%'LY=@]C4_E9[%17CO_"^/^I5N/_ Q/\*/^%\?]2K<?^!B?X4>SEV#
MV-3^5GL5%>._\+X_ZE6X_P# Q/\ "C_A?'_4JW'_ (&)_A1[.78/8U/Y6>Q4
M5X[_ ,+X_P"I5N/_  ,3_"C_ (7Q_P!2K<?^!B?X4>SEV#V-3^5GL5%>._\
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M3>Y_Z^K;_P!&K7@5=6'V9Z6!^%A11172=P4444 %%%% !1110 4444 %%%%
M!1110 4^'_71_P"\/YTRGP_ZZ/\ WA_.@!I^\?K24I^\?K24 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J1/]5)^'\ZCJ1/\
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MXE8#)0@OE3CD=<@-TQSBOX$GL?"^H:UJ]T;%K:=K>&W\K>T[@XX.X8&<\\\
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M (N>XR<5Y#13<+RO<;HMSYKGT+J5E#'\2Y?$%X"+32='$I89R&+2=!W^4/\
MI6!/+I?C'X7ZG::3)?SRZ:YN ;\(9BV2Y/R=B"X'_P!:O&:*E4O,A8:UM=5;
M\#V_QQ>0:?XP\$W5RX2&-CO<G 4$H,GV&<FK[:7+HGCW7_%M_+!%H\E@ DWF
M ECB,8QUS\GX[E R3QX#11[+2UP^K:)7\OQN>[Z!9:[)'IMI]LLO%'A2ZB&^
M6XB56@"YP,$DDYV]=Q!7'RXS7D?BZVTJT\4WT&B.CZ<C+Y+))YB_=!.&R<C=
MGO6)151ARN]S2G2<)-W"BBBM#8**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "I$_U4GX?SJ.I$_U4GX?SH CHHHH **** "BBB@ H
MKJ?!G@Y/%K7_ )FH_8DLXUD9O(\S(.<\;ATQ6H/AU:W^BG5="\0IJ4$<ZQ3
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M;B#]5KY_U_\ Y&/4_P#K[E_]#-9]%5"GRNY=*@J;;3"BBBM#<**** "BBB@
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M]_9/_C=>[T4>WF'URJ>$?\*5\1_\_NE?]_9/_C='_"E?$?\ S^Z5_P!_9/\
MXW7N]%'MYA]<JGA'_"E?$?\ S^Z5_P!_9/\ XW1_PI7Q'_S^Z5_W]D_^-U[O
M11[>8?7*IX1_PI7Q'_S^Z5_W]D_^-T?\*5\1_P#/[I7_ ']D_P#C=>[T4>WF
M'URJ>$?\*5\1_P#/[I7_ ']D_P#C=.3X+^(UD5C>Z5@$'_6R?_$5[K11[>8?
M7*IX2?@KXC)/^FZ5_P!_9/\ XW2?\*5\1_\ /[I7_?V3_P"-U[O11[>8?7*I
MX1_PI7Q'_P _NE?]_9/_ (W1_P *5\1_\_NE?]_9/_C=>[T4>WF'URJ>$?\
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MW]D_^-U[O11[>8?7*IX1_P *5\1_\_NE?]_9/_C='_"E?$?_ #^Z5_W]D_\
MC=>[T4>WF'URJ>$?\*5\1_\ /[I7_?V3_P"-T?\ "E?$?_/[I7_?V3_XW7N]
M%'MYA]<JGA'_  I7Q'_S^Z5_W]D_^-T?\*5\1_\ /[I7_?V3_P"-U[O11[>8
M?7*IX1_PI7Q'_P _NE?]_9/_ (W3S\%_$9B5?MNE9#$_ZV3V_P!CVKW2BCV\
MP^N53PC_ (4KXC_Y_=*_[^R?_&Z/^%*^(_\ G]TK_O[)_P#&Z]WHH]O,/KE4
M\(_X4KXC_P"?W2O^_LG_ ,;H_P"%*^(_^?W2O^_LG_QNO=Z*/;S#ZY5/"/\
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M[^R?_&Z]WHH]O,/KE4\(_P"%*^(_^?W2O^_LG_QNC_A2OB/_ )_=*_[^R?\
MQNO=Z*/;S#ZY5/"/^%*^(_\ G]TK_O[)_P#&Z23X.>(8XE4WFEYW$\2R>W^Q
M7O%5[K^#\:%7F-8RK<\*_P"%/>(/^?S3/^_LG_Q%'_"GO$'_ #^:9_W]D_\
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M ,_>G?\ ?Q__ (BO8J*/:R#ZS,\=_P"%3Z[_ ,_>G?\ ?Q__ (BC_A4^N_\
M/WIW_?Q__B*]BHH]K(/K,SQW_A4^N_\ /WIW_?Q__B*/^%3Z[_S]Z=_W\?\
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M_P#$T?\ "NM7_P"?FQ_[[?\ ^)KTVBCG8>VD>9?\*ZU?_GYL?^^W_P#B:/\
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M_P#GYL?^^W_^)H_X5UJ__/S8_P#?;_\ Q->FT4<[#VTCS+_A76K_ //S8_\
M?;__ !-'_"NM7_Y^;'_OM_\ XFO3:*.=A[:1YE_PKK5_^?FQ_P"^W_\ B:/^
M%=:O_P _-C_WV_\ \37IM%'.P]M(\R_X5UJ__/S8_P#?;_\ Q-'_  KK5_\
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MX/QJQ5>Z_@_&FAK<K4445184444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1S_ .I:I*CG_P!2U UN4Z***9H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@W'_'S+_OG^=;U8-Q
M_P ?,O\ OG^=7$N&Y'1115FH4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7D/_  M37/\ GTT[_OV__P 71_PM37/^?33O^_;_ /Q='U>8?4:QZ]17D/\
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M4HKRO_A9>L_\^UA_W[?_ .*H_P"%EZS_ ,^UA_W[?_XJCZO,/J=4]4HKRO\
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M)*Y,L/.*NSIZ***S,0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRCJ3PP&!T/;MD5+I?@*+3/"FHZ*M]ODOB=]SY.,#  &W=SC![]ZZO:);[W_
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MH=8LM3O8(TTS5O[-D5LN_P!F6;<,=,-TK*<HN5T_S_5'/5J0E/F3]-_Q33_
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M_:/]W\?^ ?-%%?2]%'UKR#^T?[OX_P# /FBBOI>HY_\ 4M1]:\@_M'^[^/\
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MB98MM62L16UM#:6Z00($C08514M%%8G)N%%%% !1110 4444 %%%% !1110
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M 4444 %%%% !1110 4444 %%%% !5>Z_@_&K%5[K^#\::&MRM1115%A1110
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M"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "J]U_!^-6*KW7\'XTT-;E:BBBJ+"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?\ U+5)4<_^
MI:@:W*=%%%,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *P;C_ (^9?]\_SK>K!N/^/F7_ 'S_ #JXEPW(Z***LU"BBB@
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MA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\
M_P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\
M:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1
M_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O
M^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!
M5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC
M_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_G
MZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %
M5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H Z
MZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%
MF>%O^?J__P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J_
M_P#!5=__ !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__
M !JC_A9GA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9G
MA;_GZO\ _P %5W_\:H ZZBN1_P"%F>%O^?J__P#!5=__ !JC_A9GA;_GZO\
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M ,%=U_\ &Z/^%C>&?^?F^_\ !7=?_&Z NCJJ*Y7_ (6-X9_Y^;[_ ,%=U_\
M&Z/^%C>&?^?F^_\ !7=?_&Z NCJJ*Y7_ (6-X9_Y^;[_ ,%=U_\ &Z/^%C>&
M?^?F^_\ !7=?_&Z NCJJ*Y7_ (6-X9_Y^;[_ ,%=U_\ &Z/^%C>&?^?F^_\
M!7=?_&Z NCJJ*Y7_ (6-X9_Y^;[_ ,%=U_\ &Z/^%C>&?^?F^_\ !7=?_&Z
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MG_@ON/\ XBBZ#VD.Z.@HKG_^$VT/_GM>?^"^X_\ B*/^$VT/_GM>?^"^X_\
MB*+H/:0[HZ"BN?\ ^$VT/_GM>?\ @ON/_B*/^$VT/_GM>?\ @ON/_B*+H/:0
M[HZ"BN?_ .$VT/\ Y[7G_@ON/_B*/^$VT/\ Y[7G_@ON/_B*+H/:0[HZ"BN?
M_P"$VT/_ )[7G_@ON/\ XBC_ (3;0_\ GM>?^"^X_P#B*+H/:0[HZ"BN?_X3
M;0_^>UY_X+[C_P"(H_X3;0_^>UY_X+[C_P"(HN@]I#NCH**Y_P#X3;0_^>UY
M_P""^X_^(H_X3;0_^>UY_P""^X_^(HN@]I#NCH**Y_\ X3;0_P#GM>?^"^X_
M^(H_X3;0_P#GM>?^"^X_^(HN@]I#NCH**Y__ (3;0_\ GM>?^"^X_P#B*/\
MA-M#_P">UY_X+[C_ .(HN@]I#NCH**Y__A-M#_Y[7G_@ON/_ (BC_A-M#_Y[
M7G_@ON/_ (BBZ#VD.Z.@HKG_ /A-M#_Y[7G_ (+[C_XBC_A-M#_Y[7G_ (+[
MC_XBBZ#VD.Z.@HKG_P#A-M#_ .>UY_X+[C_XBC_A-M#_ .>UY_X+[C_XBBZ#
MVD.Z.@HKG_\ A-M#_P">UY_X+[C_ .(H_P"$VT/_ )[7G_@ON/\ XBBZ#VD.
MZ.@HKG_^$VT/_GM>?^"^X_\ B*/^$VT/_GM>?^"^X_\ B*+H/:0[HZ"BN?\
M^$VT/_GM>?\ @ON/_B*/^$VT/_GM>?\ @ON/_B*+H/:0[HZ"BN?_ .$VT/\
MY[7G_@ON/_B*/^$VT/\ Y[7G_@ON/_B*+H/:0[HZ"BN?_P"$VT/_ )[7G_@O
MN/\ XBC_ (3;0_\ GM>?^"^X_P#B*+H/:0[HZ_X6_P#(FM_V$;W_ -*'KM*X
M?X33)<>!_-CW;'O[QE+*5.#.Y'!Y[UW%<S.)[G(_$7_D 6'_ &&+#_TH2NNK
MD?B+_P @"P_[#%A_Z4)774""BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBJ%[K6GZ==06UW<>7-.<1KL8[N<=0..?6G&+D[)7)G.,%S3
M=EYE^BJ$VM:?!JD6FRW&V[E *1[&.<Y[XQV/>K]#BUN@C.,KJ+O;<****104
M444 %%%% !14"WMH]TUJEU"UPHRT0D!<?4=>]3TVFMQ*2>P4444AA145S<PV
M=M)<7$@CAC7<S'L*JZ9K.GZPDCV%QYRQD!CL9<$_4"J4)-<R6A#J04E!M7?3
MJ7Z***DL**@O;VWT^TDNKJ3RX(\%FP3C)QT'/>LY/%&C22!%O,L8C,!Y3_<
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M%%% !65-_KI/]X_SK5K*F_UTG^\?YU<-S"OLAE%%%:G.%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !\,/^11E_["5[_Z425V5<;\,/\ D49?^PE>
M_P#I1)795YSW/=C\*.1^(O\ R +#_L,6'_I0E==7(_$7_D 6'_88L/\ TH2N
MNI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 >._,_X
M2'1O)V>;D;-^=N[>,9QVKOZR=4\/6FKW]I>7$DZR6I!01L #SGG(/I71AJD:
M=3FEYG%F%"=>@Z<-[K\SAM6N-2M/&EO<Z@MHUU# 9%%ONV$!6(Z\TTW>JKX:
M7Q!_;-Y]I-V5\HRGR\>FWIU[=,=J[F[\-V5[K<6JS-*9HU"B/*[&'/4$>Y[U
MG+X!TI=J&XOFMQ+YOV<S#RR?IC/3C.<X[UVQQ5'EC?I;IZZ'DSRW%*<W%W3;
MMK;>UF<W;7>IZSJ6JG^U;RVBBMVNECBE88;;PHYX'/3V_&J[7VKOX776FUF]
M\Y+E;=8UDPNT+G) ZGIR?QS7=P>&+&WO+^YC>8->QM'(N5VJ#_=&./UJ#_A#
MM._L/^R?.NOL_G>=NW+NW8QUVXQ^%)8NE?;33I]XWEN)<7=Z^]U>]]#F;:]U
M+Q)J6H-)J=S9K:VNY$MY"B[@.IQU&<D_TJ)-5GO?#4%S/J.IC4=YM+>&UG*>
M<1@AF&.2-P!/4X'<YKI[CP1ILTYE2XO;=FA$+^1(%WJ!@Y^7G('/8TW_ (0;
M34E@DM[J_MGA38K0S!3WR<XSDY.:/K%#\NG];B^HXS6^K=[N^]WH[>2,19=5
M\)ZEIMQJVH7-Q;W$;"9'E+A&]!D]1E>?K66+[6I/[/>2_P!0=+^1Y3#:2DS!
M <?*.PQNQVX]JZ+7O#^HW%E%I-I'<7L32K,;Z\NE9HCT*XP#C'/'J:9KGAFZ
M?4K!X=.34;"WMQ#]G$PA8$=RV1['OW^M:0JTW9RM=W[=+V]-^O8RK8:NKQ@I
M<JM;?=VOK:[2MT3W.:=M5TBRNI_)GMGO+G9'<W"[;C;R6^;J,_+D^QK6U*YU
M'P[K$U@NJW=W%-8.V992S(VQN1Z8*YX[58T[P4]W=7AOK1M.L)0OEVL=SYC*
MXQ\V[D?WNO\ >-;UEX.TVTN9)Y)+J[=XC#FYDW84C:0, =N/I2J8BBGKK\O2
MVNNP4,#B9+W4UKHVWIJ[Z66_FCC[G5M07PCI$PU"Z$TEQ('<3-N8 ]"<Y(HN
MKO6[&:YGU.\UBUG6<&*1%+6QZ\$9 QTZ9XSP:Z0?#W2MBJ;J_(1LH#*N%]<#
M;W_I4C^!-*9I D][';R.':V28",D>V,_K2^LX=?CT\RGE^->K[)?%V5K_P!/
M[P\6J+[P:]T+AU C27]RQ"29QP0>2.<_E7-P.MEH6E)_;6IH;KYOLEJ-TC<D
M80Y&T>W.2>^..^O-*MKW2&TQM\=L46,",\JHQC&<^E9DW@W3Y8+*-9[R)[-2
ML4T4@5\9SR<>I[ 5A1Q$(PY)=[_@=N+P5:I5]I!*_*ENUK?7\#B&UG4XK;68
M$OM15(RK1_:9")D^<#!.>#@\BK4\FLVT^BJFMWADU6-?,+2$JF\@?*.V P_$
M<5TW_"":7MN1]HO?](4"0F12>"#G)7J2/U-79O"]E/-I<C2W ;3518<,OS;<
M8W<<]!TQ6SQ5&^B_#R_S.2.6XNSYGVMJ_P":[_ XR?4-2T^X\0Z>NIWDL<$0
M>.224EU(D0<-VX8]*J6MS.^KPW+3R-/_ &7(WFER6R(GP<]<UW-SX0T^ZN[^
MY>:Y#WJ;) K+@#<K<?+ZJ/7O3(_!6FQ2K(L]UE;=K<9=?NE2I/W>N":(XJBH
MON_+R">6XIS6NB>FO]YO\CE+;5IIM&TZ.YUK4O->5B8+12\\HR0#O+<#MCGZ
M'MG7>I7D^FZM93SW<L,<Z-&+PDRI\Q&#Z''4>HKN!X&TQ([817-]%);YV31R
MA7Y.<9QVR>GK3?\ A M*\N=!/> 3X+?O%)R#GJ5JHXK#IW\^WF1/+L;**7E;
M=Z^[;\S<T;_D!Z?_ ->T?_H(J[45M EK:PVZ$E(D5%+=2 ,<U+7E2=Y-GTE.
M+C!)]$%%%%26%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5#<?P_C4U0W'\/XTUN3/8@HHHJS$**** "BBB@ HHHH ****
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MC/&XSGYHW:2?1I?9Z>6IW">,]-:UO)GANXI+3!E@DC"R8)"YQG'4CO5<>/\
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M %%%% !3)O\ 5&GTR;_5&FMQ/8JT445J8!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %94W^ND_WC_.M6LJ;_72?[Q_G5PW
M,*^R&4445J<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6-_PE_AG_H8M)_\  V/_ .*H_P"$O\,_]#%I/_@;'_\ %4 ;-%8W_"7^&?\
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M-N.H/J:[*O/_ (G?\PK_ +:_^R5U8**E7BI*ZU_(\W-YRA@YR@[/3;U1S?\
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M_P#Y_P#_ ,@Q_P#Q-85%'L*7\J^Y!]<Q/_/R7WLW?^$RU_\ Y_\ _P @Q_\
MQ-'_  F6O_\ /_\ ^08__B:PJ*/84OY5]R#ZYB?^?DOO9N_\)EK_ /S_ /\
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M]FU_PEFM_P#/[_Y"3_"C_A+-;_Y_?_(2?X5BT4>QI?RK[@^MXC_GX_O9M?\
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ML3PA+)-X4T]I"2P0KD^@8@?H!6W7'4CR2<>QZM&I[6G&IW2?WA1114&AE_\
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M_P"@9>_^ [_X4>TAW#V-3^5_<4**O_V)JW_0,O?_  '?_"C^Q-6_Z!E[_P"
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MMH\&BP0VK7&(YY9)78B/() !R"<@>GZUU5%..(JQM[ST)J8'#SO>"N^J2O\
M>0V=K%8V<-K ,11($4>P]?>IJ**R;;=V=*2BK(****0PHHHH **** "BBB@
MHHHH Y;X@?\ (KM_UV3^M<?J+VE_IFCZ=9:/);ZDZQ_OWB6+S?EQD'^($\Y/
MI[UZ)X@T;^W=+-EY_D9<-OV;NGMD50U+PG]NL=*BCO3!<:>JJDXBR6P .F1C
MD ]:]'#8BG3A%2>MWW[?B>%C\%6K59R@KII+IKKK:^SMU.7G\6ZDTMU&-7CL
MOLJ".-#;^8;AEX)+%3@G'\O<U1N+FZ\1:UI,LUR@>X 0 P*RQ$,0?E/W@<9Y
M]<=J[&3PE=1WEW<:;K,EB+L9F1(0P+<DE3NRO4X[C/6I7\)[M3TV].HS2&R
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M;RKRVMS/.@13O155O+&,@9&!D9-=+=^"Y)+J]DL]5DM(;X?Z1"(@P8YR<<C
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M****U.<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4445SG:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%94W^ND_WC_.M6LJ;_72?[Q_G5PW,*^R&4445J<X4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 'PP_P"11E_["5[_ .E$E=E7&_##_D49?^PE>_\
MI1)795YSW/=C\*.,^)UO%>>%K:VG4M%+JMC&ZAB,J;A 1D<C@U+_ ,*R\)?]
M V;_ ,#KC_XNCXB_\@"P_P"PQ8?^E"5UU(HY'_A67A+_ *!LW_@=<?\ Q='_
M  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;-_X'7'_Q='_"LO"7_0-F_P#
MZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_PK+PE_P! V;_P.N/_ (NNNHH
MY'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.N/\ XNNNHH Y'_A67A+_ *!L
MW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;-_X'7'_Q='_"
MLO"7_0-F_P# ZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_PK+PE_P! V;_P
M.N/_ (NNNHH Y'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.N/\ XNNNHH Y
M'_A67A+_ *!LW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;
M-_X'7'_Q='_"LO"7_0-F_P# ZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_P
MK+PE_P! V;_P.N/_ (NNNHH Y'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.
MN/\ XNNNHH Y'_A67A+_ *!LW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@
M#D?^%9>$O^@;-_X'7'_Q='_"LO"7_0-F_P# ZX_^+KKJ* .1_P"%9>$O^@;-
M_P"!UQ_\71_PK+PE_P! V;_P.N/_ (NNNHH Y'_A67A+_H&S?^!UQ_\ %T?\
M*R\)?] V;_P.N/\ XNNNHH Y'_A67A+_ *!LW_@=<?\ Q='_  K+PE_T#9O_
M  .N/_BZZZB@#D?^%9>$O^@;-_X'7'_Q='_"LO"7_0-F_P# ZX_^+KKJ* .1
M_P"%9>$O^@;-_P"!UQ_\71_PK+PE_P! V;_P.N/_ (NNNHH Y'_A67A+_H&S
M?^!UQ_\ %T?\*R\)?] V;_P.N/\ XNNNHH Y'_A67A+_ *!LW_@=<?\ Q='_
M  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;-_X'7'_Q='_"LO"7_0-F_P#
MZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_PK+PE_P! V;_P.N/_ (NNNHH
MY'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.N/\ XNNNHH Y'_A67A+_ *!L
MW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;-_X'7'_Q='_"
MLO"7_0-F_P# ZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_PK+PE_P! V;_P
M.N/_ (NNNHH Y'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.N/\ XNNNHH Y
M'_A67A+_ *!LW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@#D?^%9>$O^@;
M-_X'7'_Q='_"LO"7_0-F_P# ZX_^+KKJ* .1_P"%9>$O^@;-_P"!UQ_\71_P
MK+PE_P! V;_P.N/_ (NNNHH Y'_A67A+_H&S?^!UQ_\ %T?\*R\)?] V;_P.
MN/\ XNNNHH Y'_A67A+_ *!LW_@=<?\ Q='_  K+PE_T#9O_  .N/_BZZZB@
M#D?^%9>$O^@;-_X'7'_Q=0W'PU\)IMVZ=,,Y_P"7Z?\ ^+KM*KW7\'XTT-;G
M&?\ "M_"O_0.F_\  V?_ .+H_P"%;^%?^@=-_P"!L_\ \775451=D<K_ ,*W
M\*_] Z;_ ,#9_P#XNC_A6_A7_H'3?^!L_P#\77544!9'*_\ "M_"O_0.F_\
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M_P"+KKJCG_U+4 DCC/\ A7OAC_GPE_\  R?_ .+H_P"%>^&/^?"7_P #)_\
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M !=8\W@;P\L\BBSEP&('^ES>O^_7?U@W'_'S+_OG^=5%%0A%[HYK_A"/#_\
MSYR_^!<W_P 71_PA'A__ )\Y?_ N;_XNNAHJ[(T]G#L<]_PA'A__ )\Y?_ N
M;_XNC_A"/#__ #YR_P#@7-_\770T460>SAV.>_X0CP__ ,^<O_@7-_\ %T?\
M(1X?_P"?.7_P+F_^+KH:*+(/9P['/?\ "$>'_P#GSE_\"YO_ (NC_A"/#_\
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M^!<W_P 71_PA'A__ )\Y?_ N;_XNNAHHL@]G#L<]_P (1X?_ .?.7_P+F_\
MBZ/^$(\/_P#/G+_X%S?_ !==#119![.'8Y[_ (0CP_\ \^<O_@7-_P#%T?\
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M$(\/_P#/G+_X%S?_ !='_"$>'_\ GSE_\"YO_BZZ&BBR#V<.QSW_  A'A_\
MY\Y?_ N;_P"+H_X0CP__ ,^<O_@7-_\ %UT-%%D'LX=BW\)X4M_ XAC!$<=_
M>*H))P!.X')KN*XOX6_\B:W_ &$;W_TH>NTKF9Q/<Y'XB_\ ( L/^PQ8?^E"
M5UU<C\1?^0!8?]ABP_\ 2A*Z74;O^S]+N[W9YGV>%Y=F<;MJDXSVZ4+4$KNR
M+-%8?A3Q%_PD^C'4/LOV;]ZT?E^9OZ8YS@>M<Y:?$/4]1COYK'PP9X;')F87
MR@@#)S@KD\ \#-6J<FVNQJJ%1MJVV^J._HKAKKXF647A>UU>"S>6:>8P&U:3
M:58#+?-@Y RO;G<.E='X;UR/Q'H<&I1Q^5YA8-%NW;&!QC.!]?QHE3E%7:%.
MA4A'FDM-C6HHHJ#(**** "BBB@ HHHH **** "BBB@ HHHH *I:QJ*:3H]W?
MR8Q!$S@'N0.!^)P*NURGC[3=6UG18=,TNW,@GG4W#[U4(@YZ$C/.#Q_=JH).
M23-*45*:4GH<;X,US6;+Q781:U?7,UOJMN6B$TK,JEB=I /0DKCC^]4!U2_U
M#7=7M=;\27^BWX;;9Q"1H8 ><!L=%QCGOG.3WV/$GP\OH;>RNM"OM1O;VUD4
M1I=7*'RT'(*$@ 8(''^%2W5GXPNM-NK#5] M=;,BDVUT\L,30%EQT&.0<=,<
MY^8C!KKYH-\RL>ESTY/GC;7T3W\RIK&L>(KB_P!#\-/JD4=S=*KW%[8,?WBL
MQVE3A<?*,\<'Z<56\4:3XQT1;MK/5=2N-)B F%R]Y^\3C!!P=Q_+'>B'X>^(
M-(MM+U.R:&XU.UEWM;;\ +G(4,< _P 6>1U.":Z?3M.\3:QKE]=:V#I^ES6[
M6_\ 9ZSK*'!&,\9 ZDYX/08Q2<HQUBU8ESA"S@TTM_6_]6Z&3J_B*[UO2_"E
MAIU[-!=:DRM<2PR%'4+\K<@],[C_ ,!K)\(66L>*=.U5_P#A)-8ANK=@L&+Q
M]A)!/S#.>W8BM/P%X*U;2/$3WFK0;(K:)H[9O,5LDGJ "2!@MZ?>JMX=TKQI
MX:T_4K>TT!7FNR"DS7<0$>,C.W=SU]1^-%XI.,6AMPC&4*;73MU?^1TWP[\2
M77B#19EOVWW=I)Y;28 WJ1D$X[]1^ JE<?$2[6\U:"T\.R72Z9)(+B07(4!%
M;&[[O?!..P'?G&MX'\+-X6T9X9Y$DNYW\R5DS@<8"CUQS^9KA+!-=?7/&<6C
M:<EXMU/-;REIE0Q$N^&^8C/!;CZ?C"C"4I-;&484IU)M)67R1V4?C>ZU&VL9
M-$\/7=^US&6<E_*CB()!4R$8)R#Z<8]<5ROB3Q]?ZKX9<V5I<:=-#="*XECN
ML&,X.T @ G=AL^FWW%0CP%KUF^FQW.G_ -L6$<;-)9I>B%4D;/<D<C(Y'7'I
M38O /B!?#6K61LHUG:[BEA19E*R*N\':2>/O _-@X]ZN,:2=S6$,-%W36_?S
M]?T-AO$=Q%XDT$:K'J%DS6GF2(FH!H2@W_.Z!3N) SU';TJX/B5(+>/49/#]
MPFBO.85O/.!/UV8_KCJ,FLZ]\,Z_KVMZ5->:7]B@CL6M)V%Q')LX==V 03]X
M' K-L_ 6J0Q)8S>%[*><3$-J,M\_EF/U\M'5OQ].U%J;W_K\1<N':7-:_KZ^
M?^?H=)=_$B:+4=2L[/0GO/L.YWD2Y 7REZO]WCMQS6%JOC75-4UOP[<Z9;7,
M4$K K;K=[!<MN 9&[8!!&3U!S[5I6'A+5K2^\5_Z&!#>64L%H1(N)"00HY8D
M?\"_.LNV\'>)+"W\/7<>F+-<6$[O+;?:$4XWAA\V<<_CCTHBJ2V_K0(+#Q>E
MOO\ +U.@7XB7EQ->?8O#5Q=0V3*ERT=P"Z$YSA I) (;GVR<5T.L^(?[-\+_
M -N6MH;N+8DOEF38=C8YS@],BN!UKPKKVJ37DLGA2R%[<%'CO;2\\ORSD%MR
M,^&;L2 .<GGK7H,.D3R^$QI.I7'VFX>U,,TI).YBN"<GD_7KQFLIJ"LT858T
M8\K7S5_^#_D9"^/[)O$&G:;Y $5W;+.UP9>(RRE@N,<]!SGO7-3>.)M7U;2;
MF"QU")I)F2"WAU$1QSD$8WJ4P<DXZUEI\.=?&@2RFU_XFJW2")//3/DA2"0<
MX')'&>W2MT>#=4MK[P@8+0-%8*K7;"1!L<ON;OD]3TSTK7EI1V-^3#0V:?S\
MF8-GXC\02^%_$<A>[*K(A%U]M.ZV.\?(HSG!R1D<5TN@?$"X']A:?J&E3HEX
MB0QWKW&YI6&$W%<9Y;U/?/-94?A7Q-9Z/K^CII"S1WTJO%<K<Q@':X(^4G/(
M]<8J]/X4UIY_!C+99&G>7]J_>I^[PZD]^> >F:)>S>CM_2*G["5T[;]_+_,]
M+HHHKC/)"BBB@ HHHH **** "BBL3Q5XA_X1G13J/V7[3B14\OS-G7OG!II-
MNR*C%R:BMV;=%<;<?$"WC\&0^(8+/SM\HADM_.VF-^<C=M.>@[="*Z*?7-+M
M"B7FI6=K*Z!_+FN%1L'O@D4W"2Z%2I3CNOZ1H455@U*PNKAK>WO;::95#M''
M*K,%.,$@'..1S[U"VNZ0D3RMJMBL:2>4SFX0!7Y.TG/!X/'M2LR>678T**YK
MQ+XQMM"T*#5;2.+4899Q"#%< +T8D[@"#C;C%:&N:U_8WAV?5OL_G>4BOY6_
M;G) ZX/KZ4^26GF5[*>FF^AJT5Q^E^*_$&K6]O=V_A/-I.>)O[1CX7."<$ ^
MM7?$?C"PT+3[B:*2VO+J!E#VB7*JZY(!)')&,CM3]G*]ANA/FY;:^J.CHKCF
M\=>4)9)[.TB@6P6[5FU&/>S&-7$?E_>&2V <<\''-:.@^+M.UC0$U2>>ULN2
M)HGN5/DG<0NXG&,XR,@4.G)*]@E0J15VCH**HQZUI4UK+<Q:G9/;PX\R59U*
M)GIDYP*EMM1L;V22.UO+>=X\;UBE5BN>F0#Q4V9GRM="S1112$%%%% !7#_$
M/Q5?>&?[-^Q16\GVCS=_G*QQMV8Q@C^\:[BO*_C-_P P3_MO_P"TZUH).HDS
MIPD5*M&,MO\ @&)_PM37/^?33O\ OV__ ,71_P +4US_ )]-._[]O_\ %UPU
M%>A[*'8]OZM1_E/0++XJZB+R+[=9VAM<_O/(5@X'J,L17J%G>6^H6D5U:RK+
M!*-R.O>OF^ND\)>+;CPW=['W2V$I_>PYZ?[2^_\ /\B,JM!-7B<V(P491O35
MF>YT5!9WEOJ%I%=6LJRP2C<CKWJ>N(\EJVC"BBB@04444 %%%% !1110 444
M4 %%%% !1110 4444 %1S_ZEJDJ.?_4M0-;E.BBBF:!1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %8-Q_Q\R_[Y_G6]6#<?
M\?,O^^?YU<2X;D=%%%6:A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 3VEG->SB*%<GN3T ]36_%X9@"#SIY&;OLP!^N:F\.
MP+'IHE ^:5B2?8''^-6EU>Q;5I-+^T 7D<0F:(J1\GJ#C!_"L)U+.QSRE.3:
M@MBG_P (U9?\]9_^^A_A44NAZ7 <37CQGKAY5'\Q56_\<Z+'81RVVH*3.3Y;
M")VPH.&?:!G YYZ$BHGUKPMIWD+<W:7,UT@E5C&TQ=6Z,< X'Y5E]8C_ #&G
MU;&;>SE]SZ;].AIKX;L64,LTY!&00R\_I2_\(U9?\]9_^^A_A699:_H]A]OG
MBO NF0./,)1@(GR0RXQGJ%[?Q5?;QEH*:@MBU^!,6"?ZMMJL>BEL8!]B:;K)
M/XB8T,7*]H2TWT?3_AT1W/AD!"UK,2P_AD[_ (US[HT;LCJ593@@]J] !R >
M>?6N9\30*ES#,!@R*0?<C'^-;0FV[,FE4;?*S#HHHK4Z HHHH **** "BBB@
M"_\ "W_D36_["-[_ .E#UVE<7\+?^1-;_L(WO_I0]=I7*SSWN<C\1?\ D 6'
M_88L/_2A*V_$?_(L:M_UY3?^@&L3XB_\@"P_[#%A_P"E"5UDD<<T3Q2HKQNI
M5D89# ]01W%-.SN$79IGG?PSUK2K#PH8;S4[.VE^T.VR:=4;&!S@FL+P1I&I
MZNNO06.M'3H6D\N91;+*9 V\=205XST]:]._X1C0/^@'IG_@)'_A5RTTZQL#
M(;.SM[;S#E_)B5-Q]\#GJ:V=5:M=3LEB8^\XK67>QY'#I#V7B^#2-*T]]9BT
MF)GGC>980\KJ S9/ ZJ .ORCDX)K7^&-Q/I>KZKX<O8V@E0^>D3.&VD8##(X
M/!7IZ5Z+!I]E:W$UQ;V=O#-,<RR1QA6D/7+$#)_&C^SK'[?]N^Q6_P!LQC[1
MY2^9C&/O8STXHE6YDTT*>*4XN+73\2S1116!QA1110 4444 %%%% !1110 4
M444 %%%% !1110 4R::*WA>::1(HD&YW=@JJ/4D]*?6+XN_Y$_5_^O23_P!!
M--*[L5!<TDC5M[F"[@2>VFCFA?[LD;!E;Z$<4RVU"RO))H[6[MYWA.V58I Q
MC//# 'CH>OH:\=TW7?$7A_PWH=['?QG3YYWB2T\E3\BMR2V,\G=WXP/PM1>)
M=5TVU\775E';+)!>QQB1+6-"BL\HW':HW'(4?-GK]:W>'>MG_5SL>"EK9^GW
MV/7998X(GEED6.-%+.[G 4#DDGL*;;7,%Y;K/:SQSPO]V2)PRMSC@CBO#Y[F
M?Q+J4TEY>/K,5OI4TIF\@P"V<1LPX7 .& &3P<^U6-,U_P 1>'O"VD7T-_'_
M &>]R\26AA4Y4'));&>26'MQ^#>'=M]1O NVDM?Z_KH>S75Y:V,!GO+F&WB!
MP9)G"+GZFF6]M8VOG7-M!;0^>?-EEC15\SON8CKU)R?6N5^*7_(E2_\ 7>/^
M=<]_;OB+1;C1;>_OXKRRU2U&(1"J>3N&  0,G&5Y/7GZU$:3E&Z9E3P[G#FB
M^_X'IMI?6FH0F:RNH+F(-M+PR!U!],COR*L5X?X9U_4['0]/T;1YDM[J_P!1
M<&=T#!!B,#@@CN<\=JVK[QOK_AJ[UG2=0N([ZZA13;7/DJF-VWDJO'1LX]1Z
M53P\KV1<L%/FY8O^MCU:H+N]M;"'SKRYAMXLXWS2!%SZ9->;2>)O$OAJZT2Y
MU?4(]0L]2AW-$($0QGCH5 )QN7GW/'>L+6]4\0:_X*FU>^OH6L7O!&MHL(&S
M'((8<^V#FE&@VU=Z"A@Y-J[5GU/9Y+NVBM3=27$26X7>9F<!-OKGIBBUN[:]
M@6>TN(KB%L@21.'4XZ\CBN7US_DEDO\ V#H__05J#X>NT7PYBD0X91,P/H0S
M5')[O-YV,O8KV;G?K8[6H)KZTM[B&WGNH(IICB*-Y K2'_9!Y/X5Y-;>)O&,
M_A&?Q$-8B,5I.L+PFVCRX)&6)QZNHP.WIWU?".I2^(_$>M^(I!"LEM:)';+,
MQ$<65)//894Y/^T:MT6DVWL:/"2BG*3T7;O_ $STNH+:]M+WS/LMU#/Y;;'\
MJ0-L;T..A]J\CO\ QSK&GK'/'XIM+^X%P1+90V6(@H)Z2%06' ''//!/6NF,
MO]E_%:U,("0ZS9[ID'3>H8@_7Y1^9I.BUN#PDHK7L_P]3O:***Q.0**** "B
MBB@ HHHH **** "N)^*O_(F-_P!?$?\ 6NVJ"[LK6_A\F\MH;B+.=DT8=<^N
M#50ERR3-*4^2:D^AXAXXTBX\,7]U8P C2;]Q/"O967/RCW&XCZ$5>A.E'7/%
MI\0F,S^2XM?/ZX_AV9_BQLQCG'MFO7[S3K'445+ZSM[I4.56>)7 /MD5#<Z'
MI-[+YMUI=E/)@+OEMT8X'09(K=5]+,[%C4XI26O?[O\ (\5TNXOO"]EI?B-$
M8K/'/; $=<#Y#SVR?_'*0:9<Z9J6@)=BQV3VYN5_M,M]G+ON)WX[X"?D,\5[
MA<:;8W=JEK<V5M-;QXV121*R+@8& 1@8'%+=:=8WT*0W=E;W$2'*)-$KJIQC
M@$<4_K'D/Z\KWY?ZZ?F>#:G T'A^^\J]L9[9M2C)CLQ+Y<;[)>%+J 1CT)Z"
MO6/''_).[_\ ZXQ_^A+6XVBZ4UFMFVF61M4;>L!@78&YY"XQGD\^]69[6WNK
M9K>X@BF@8 -%(@92/<'BHE64FGV,JF*4Y1=MG?\ +_(\T\()IL&A6-T/%EQ%
M>K&Q73WU%%B#\@*8SVZ'%<<O]D?\(#=_:/+_ +<-^,;_ /6[<?GM^]GWQGM7
MMJ^&M!1@RZ)IJL#D$6J @_E4DFA:1-)-))I5B\DW^M9K="9.0?F..>0#SZ52
MKI.YI'%Q4F]=7<\<:!+C5[]7B63;X?C=05S@BWC((]QUJONTX^'_  LLA@^S
MBZ?^TQ%C?_K?E\S'/W-VW/;.*]OCTG389_/BT^T2;RQ'YBPJ&V  !<XZ8 &/
M05$OA_14ADA72+!8I""Z"V0*Q&<$C'.,G\Z?UA=AK&QTT>G^5CQS73:#7?$?
M]@^7_9AM%\WR /*SNCZ8X^]Z>^.*]*^'VFVEGX2L;B&!%GN8]\TNWYG.3U/H
M*W(]$TJ&VEMHM,LD@FQYL2VZA7QTR,8/XU:@@AMH$@MXDBB086.-0JJ/8#I6
M<ZO-'E1C6Q*G3Y%_6A)1116)R!1110 5Y7\9O^8)_P!M_P#VG7JE>5_&;_F"
M?]M__:=;8?\ B(Z\#_'C\_R/*Z***],^@"I[*RN-0O([2TB:6>0X55[T65E<
M:A>1VEI$TL\APJKWKVSPEX2M_#=GN;;+?R#][-CI_LK[?SK*K54%YG-B,1&C
M'S)O"7AP>&])^SM,TLTAWRG)V!L=%']>_P#+>HHKSVW)W9X<Y.<G)[A1112)
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.?_4M4E1S_P"I:@:W*=%%
M%,T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *P;C_CYE_WS_.MZL&X_P"/F7_?/\ZN)<-R.BBBK-0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .RT+_D#0?\  O\ T(U@
M^-/#>I:I-:W^BR1Q7\:/;R,[8#1."#^6>/K5WP[J"*ILY6P2<QD]_:NBKDK4
MU*\68TJ]3"U_:0WUWV=SS?6?!MUIE[:7FG)Y]G%8K9RQ+=M;-Q_%N7J#GD>M
M7=!T3^P_$5O>N8+>S_LM8 @F+X<ONP">HZ\UW3*&4JP!!&"#WK(?3[FR8BR2
M.XMV.?(F/W?H?3_.#6*P\%*Z.B>;XB=)TYZJUKZ_CK:_G;U.1O\ P^MSXO,T
M5[;C1+N>.ZNH=WS-*F<#'H3@G_ZU4O\ A%;E=6O;5XTO;"ZO?M&\7[Q!-S?Q
M1CAF'8_K7HEA92I'(]YY3RRMNV(OR1CLH]?KZU;\B'C]TG'3Y1Q0\-3;*AG.
M*BDM-DONV>C3O_D2=JYWQ1_RZ?\  _\ V6NA)"@DD #DDUQ^M7RWM[^[.8HQ
MM4^OJ:ZJ:U//HIN5S-HHHK<[ HHHH **** "BBB@"_\ "W_D36_["-[_ .E#
MUVE<7\+?^1-;_L(WO_I0]=I7*SSWN<C\1?\ D 6'_88L/_2A*ZZN1^(O_( L
M/^PQ8?\ I0E==0(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J6KZ?\ VKH]YI_F^5]HB:+?MW;<C&<9&:NT4)VU&FT[HX>Y^'?V
MCPYI.D?VKM_L^1Y/-^SY\S<Q;&-W'7U-87B?P/?Z?87\UF)-22^ODN)HX8<2
M1*"_W>3N_P!9CIQUQZ>JT5K&M-,Z(8NI%[W_ *N>2'3M=U;48;+2YO%4-I-&
M\=X^M<H$8;3M!(#'#'CKT(Z9'07'PX^T>&=.T;^U=OV.9Y?.^SYW[B3C&[CK
MZUW=%-UI:6T'+%S=N72QC^)M 7Q)I']G/<&!#(KLZKN. >@Y_6N?M?A]*-0M
M+K4];EOTLH/)M8C (Q'C[I)!.[&?J<#G Q7<45"J22LC*-:<(\L7H>?1?"]8
M=*M;>+6'CO;6Z:XBNTM\8R%XV[NQ0$'/KQ4Z_#:*X35)=5U22]O[Y0!<^2$\
ML@@@A02#R!Z<#'%=U15>VGW+^M5>YPUI\.Y#?V$^L:U)J4%C'L@@, C  Z9(
M8YQ^? YXJI+\+I6T^;3H_$,Z:>9C-%;FW!"-TY.X;N..W/->B44>VGW#ZU5O
M>_X(P-:T^,>#VTJ:=TB,"V[7"0E]@  W%0<XX_#/IS7(6&FZMHVF?8+?Q!>Q
M6D88RP/I"_NU;)RS;B<-GMDC)R!@X].HK/GFM$_P*I8A0CRR5^O3_)_U\[^-
M:;X6EDT8V-QJFIVMBTPENK9].8;,<!SDY /08#= 2.#C?L/#QTSQ!>V LKP:
M'K=F$#)&2T# 8PY .T\MC/J/0UZ-15^UGKS,NIC'.]E:_P#78\ZD^&%U-HL6
ME2^)&-K#)YD4:V:JH8YR3ALL>>"3QS5_3].N]4^()U::">&STRW%M;M+$8S,
MQ!!8 ]OF;GZ5VU%-U9/<R>)FT^;^K[A11161SA1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57NOX/QJQ5>Z_
M@_&FAK<K4445184444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %1S_ZEJDJ.?\ U+4#6Y3HHHIF@4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !6#<?\?,O^^?YUO5@W'_'S+_OG^=7
M$N&Y'1115FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !5V+5[^%-J7+8']X!OYU2HI-7$TGN:/]NZE_P _/_CB_P"%']NZ
ME_S\_P#CB_X5G44<J["Y(]C1_MW4O^?G_P <7_"C^W=2_P"?G_QQ?\*SJ*.5
M=@Y(]BU<:C=W2[9IV9?[O0?D*JT44#22V"BBBF,**** "BBB@ HHHH O_"W_
M )$UO^PC>_\ I0]=I7%_"W_D36_["-[_ .E#UVE<K//>YQGQ.2:3PO:I;S"&
M9M5L0DI3?L8W"8.,C.#@XJ;^PO&G_0ZVW_@F3_XY2?$7_D 6'_88L/\ TH2N
MNH$<E_87C3_H=;;_ ,$R?_'*/["\:?\ 0ZVW_@F3_P".5UM% ')?V%XT_P"A
MUMO_  3)_P#'*/["\:?]#K;?^"9/_CE=;10!R7]A>-/^AUMO_!,G_P <H_L+
MQI_T.MM_X)D_^.5UM% ')?V%XT_Z'6V_\$R?_'*/["\:?]#K;?\ @F3_ ..5
MUM% ')?V%XT_Z'6V_P#!,G_QRC^PO&G_ $.MM_X)D_\ CE=;10!R7]A>-/\
MH=;;_P $R?\ QRC^PO&G_0ZVW_@F3_XY76T4 <E_87C3_H=;;_P3)_\ '*/[
M"\:?]#K;?^"9/_CE=;10!R7]A>-/^AUMO_!,G_QRC^PO&G_0ZVW_ ()D_P#C
ME=;10!R7]A>-/^AUMO\ P3)_\<H_L+QI_P!#K;?^"9/_ (Y76T4 <E_87C3_
M *'6V_\ !,G_ ,<H_L+QI_T.MM_X)D_^.5UM% ')?V%XT_Z'6V_\$R?_ !RC
M^PO&G_0ZVW_@F3_XY76T4 <E_87C3_H=;;_P3)_\<H_L+QI_T.MM_P""9/\
MXY76T4 <E_87C3_H=;;_ ,$R?_'*/["\:?\ 0ZVW_@F3_P".5UM% ')?V%XT
M_P"AUMO_  3)_P#'*/["\:?]#K;?^"9/_CE=;10!R7]A>-/^AUMO_!,G_P <
MH_L+QI_T.MM_X)D_^.5UM% ')?V%XT_Z'6V_\$R?_'*/["\:?]#K;?\ @F3_
M ..5UM% ')?V%XT_Z'6V_P#!,G_QRC^PO&G_ $.MM_X)D_\ CE=;10!R7]A>
M-/\ H=;;_P $R?\ QRC^PO&G_0ZVW_@F3_XY76T4 <E_87C3_H=;;_P3)_\
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M_P <H_L+QI_T.MM_X)D_^.5UM% ')?V%XT_Z'6V_\$R?_'*/["\:?]#K;?\
M@F3_ ..5UM% ')?V%XT_Z'6V_P#!,G_QRC^PO&G_ $.MM_X)D_\ CE=;10!R
M7]A>-/\ H=;;_P $R?\ QRC^PO&G_0ZVW_@F3_XY76T4 <E_87C3_H=;;_P3
M)_\ '*/["\:?]#K;?^"9/_CE=;10!R7]A>-/^AUMO_!,G_QRC^PO&G_0ZVW_
M ()D_P#CE=;10!R7]A>-/^AUMO\ P3)_\<H_L+QI_P!#K;?^"9/_ (Y76T4
M<E_87C3_ *'6V_\ !,G_ ,<J&?0O&7R[O&EN>O\ S!T_^.5V=0W'\/XTUN*3
MLKHXS^PO&/\ T.5O_P""A/\ XY1_87C'_H<K?_P4)_\ '*ZRBKL9\\NYR?\
M87C'_H<K?_P4)_\ '*/["\8_]#E;_P#@H3_XY76446#GEW.3_L+QC_T.5O\
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MV"%_^.5U],F_U1H2U$ZDK;G%?V%XM_Z&^#_P4K_\71_87BW_ *&^#_P4K_\
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MA_\ !8O_ ,71_8'B;_H:H?\ P6+_ /%UU-%:^SB8_7<1_,<M_8'B;_H:H?\
MP6+_ /%T?V!XF_Z&J'_P6+_\774T4>SB'UW$?S'+?V!XF_Z&J'_P6+_\71_8
M'B;_ *&J'_P6+_\ %UU-%'LXA]=Q'\QRW]@>)O\ H:H?_!8O_P 71_8'B;_H
M:H?_  6+_P#%UU-%'LXA]=Q'\QRW]@>)O^AJA_\ !8O_ ,71_8'B;_H:H?\
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M\%B__%T?V!XF_P"AJA_\%B__ !==311[.(?7<1_,<M_8'B;_ *&J'_P6+_\
M%T?V!XF_Z&J'_P %B_\ Q==311[.(?7<1_,<M_8'B;_H:H?_  6+_P#%T?V!
MXF_Z&J'_ ,%B_P#Q==311[.(?7<1_,<M_8'B;_H:H?\ P6+_ /%T?V!XF_Z&
MJ'_P6+_\774T4>SB'UW$?S'+?V!XF_Z&J'_P6+_\71_8'B;_ *&J'_P6+_\
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MDQR^I*]J3TW]WM\O,M3Z+ ZGR28V[<Y%84L3PRM'(,,IP177@Y ///K6-K,
M>ZML<-)\GZC_ !KHHU7>S/-Q6'BH\T58H6EA/><H $'5FZ5?&@''-S_XY_\
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M4(P<%=]K^EGZ&TLNJSK1JRLKOWDNJO==-7?=Z'&>!)K>WT+69;LK]G7&\,<
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M9G;YL8;&<9QGZ5>J&X_A_&JBVG=$5(J46F97]B:3_P! RR_\!T_PH_L32?\
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M'J7_ ,%<'^%=;10!R7_".^+O^AZE_P#!7!_A1_PCOB[_ *'J7_P5P?X5UM%
M')?\([XN_P"AZE_\%<'^%'_".^+O^AZE_P#!7!_A76T4 <E_PCOB[_H>I?\
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M6E_T?[L%PQ_U?HK'^[Z'M].F57#V5XG-B,$HQYJ9ZI1117*>:%%%% !1110
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M=@Q_D.WZ#I:**\V3YG<\&<N>3EW"BBBD0%%%% !1110 4444 %%%% !1110
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M.&!!Y'_Z^ARO^$7\2_\ 0_:G_P" -I_\;KKJ*!'(_P#"+^)?^A^U/_P!M/\
MXW1_PB_B7_H?M3_\ ;3_ .-UUU% '(_\(OXE_P"A^U/_ , ;3_XW1_PB_B7_
M *'[4_\ P!M/_C===10!R/\ PB_B7_H?M3_\ ;3_ .-T?\(OXE_Z'[4__ &T
M_P#C===10!R/_"+^)?\ H?M3_P# &T_^-T?\(OXE_P"A^U/_ , ;3_XW7744
M <C_ ,(OXE_Z'[4__ &T_P#C='_"+^)?^A^U/_P!M/\ XW7744 <C_PB_B7_
M *'[4_\ P!M/_C='_"+^)?\ H?M3_P# &T_^-UUU% '(_P#"+^)?^A^U/_P!
MM/\ XW1_PB_B7_H?M3_\ ;3_ .-UUU% '(_\(OXE_P"A^U/_ , ;3_XW1_PB
M_B7_ *'[4_\ P!M/_C===10!R/\ PB_B7_H?M3_\ ;3_ .-T?\(OXE_Z'[4_
M_ &T_P#C===10!R/_"+^)?\ H?M3_P# &T_^-T?\(OXE_P"A^U/_ , ;3_XW
M7744 <C_ ,(OXE_Z'[4__ &T_P#C='_"+^)?^A^U/_P!M/\ XW7744 <C_PB
M_B7_ *'[4_\ P!M/_C='_"+^)?\ H?M3_P# &T_^-UUU% '(_P#"+^)?^A^U
M/_P!M/\ XW1_PB_B7_H?M3_\ ;3_ .-UUU% '(_\(OXE_P"A^U/_ , ;3_XW
M1_PB_B7_ *'[4_\ P!M/_C===10!R/\ PB_B7_H?M3_\ ;3_ .-T?\(OXE_Z
M'[4__ &T_P#C===10!R/_"+^)?\ H?M3_P# &T_^-T?\(OXE_P"A^U/_ , ;
M3_XW7744 <C_ ,(OXE_Z'[4__ &T_P#C='_"+^)?^A^U/_P!M/\ XW7744 <
MC_PB_B7_ *'[4_\ P!M/_C='_"+^)?\ H?M3_P# &T_^-UUU% '(_P#"+^)?
M^A^U/_P!M/\ XW1_PB_B7_H?M3_\ ;3_ .-UUU% '(_\(OXE_P"A^U/_ , ;
M3_XW1_PB_B7_ *'[4_\ P!M/_C===10!R/\ PB_B7_H?M3_\ ;3_ .-T?\(O
MXE_Z'[4__ &T_P#C===10!R/_"+^)?\ H?M3_P# &T_^-T?\(OXE_P"A^U/_
M , ;3_XW7744 <C_ ,(OXE_Z'[4__ &T_P#C='_"+^)?^A^U/_P!M/\ XW77
M44 <C_PB_B7_ *'[4_\ P!M/_C='_"+^)?\ H?M3_P# &T_^-UUU% '(_P#"
M+^)?^A^U/_P!M/\ XW1_PB_B7_H?M3_\ ;3_ .-UUU% '(_\(OXE_P"A^U/_
M , ;3_XW1_PB_B7_ *'[4_\ P!M/_C===10!R/\ PB_B7_H?M3_\ ;3_ .-T
M?\(OXE_Z'[4__ &T_P#C===10!R/_"+^)?\ H?M3_P# &T_^-T?\(OXE_P"A
M^U/_ , ;3_XW7744 <C_ ,(OXE_Z'[4__ &T_P#C='_"+^)?^A^U/_P!M/\
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M_P#C='_"$Z[_ -#UJ7_@%:__ !NNVHHNPNSB?^$)UW_H>M2_\ K7_P"-T?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img243551639_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_7.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "H 38# 2(  A$! Q$!_\0
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M2/.#Q@J?0BH<6CDG2G"]T7Z***DS"BBB@ HHHH **** "BBB@ HHHH ****
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M:;#?[S@QPQR >IV8_F*71S_9QO7F)7RH8V?ZXR?U-1W,*75W'.TA4  .@Z.
M<@'\:2:!KB_,K2@6[[3+'W8KT_"A-IJW3]0:4D[]=_E;_@D^@+(NHW-S/_K!
M&&8GL7.X_IBJ,NGV?BKQ#YM[ '@0$KV.P<#\SS5@_:9KR[ME4QP7#JSS?[&
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M93&GF*"%;;R >O-"A)-.XIUZ4HM*-FR2BBBMCD"BBB@ HHHH **** "BBB@
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img243551639_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_8.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  G4# 2(  A$! Q$!_\0
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MM#KZ***@P"BBB@ HHHH **** "BBB@ HHHH *R=3UP:=?6]FEE<74\R-(%A
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MCIZ=:?+'N/V=-[/^K'6/J=C&L+/=PA9O]62XPWTJO#KVFSR7J+=(ILW"3%N
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M7X=2O[FV2Q4WJ1AFDD8^4RK@X '/6H]-T+4]!OS]A2VN+9H(86:60JPV9R<
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M_P#)4?XT6C_-^8>QC_.OQ_R.YHKAO[ \7?\ 0X?^2H_QH_L#Q=_T.'_DJ/\
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M-"5S-#)AGQGG^O/-.R#E7<WF8*I9B !U).*6N=ETW6)XGBDN-P92#F3Y2,#
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MT9W8*JC))["EK \7QW%UHZ6-K.(I;N=(>G4$\_3BA*["$>:2B;J.LD:NARK
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M^'V>6WAD\^:(XE FR5/N.U)<>#H$8S:9=36DXZ'>2#]?:ES(I0@GH_P-6D)
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MICOK&N7&L.I%N@\JW![^I_+(_'VK17OY"E+=]$OQM8WJ***9PA1110 4444
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M&N4U+0Y89O/C9HY%QB>,=?J*UTJ*W4F$U3O&7P_E_P  [FL'Q/X5L_$UELE
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MCZMZ_EG\Q705!9VD-C:1VUNNV-!@>I]S[U/4F%22E+38****1 4444 %%%%
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MJT$R7%O'/'G9(H=<C!P1FKY'"*1QXN$J:C%K3]22BBBD<04444 %& >"***
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M^??7!W32_P!!["M, !=H  '8=**7H92J*W+%604444&84444 %%%% !1110
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M_P#@'G__  L30_2[_P"_!H_X6)H?I=_]^#7H&T>@HVCT%'M%V#]S_*_O_P"
M>?\ _"Q-#]+O_OP:/^%B:'Z7?_?@UZ!M'H*-H]!1[1=@_<_RO[_^ >?_ /"Q
M-#]+O_OP:KW'C7PO=D&XM996'0O:Y(_'%>D;1Z"C:/04>T78:=);1?W_ / /
M,H_%OA&)PZ6#AAT)M,D?I5S_ (6)H?\ T]_]^#7H.T>@HVCT%'M%V!ND]XO[
M_P#@'G__  L30_2[_P"_!H_X6)H?I=_]^#7H&T>@HVCT%'M%V%^Y_E?W_P#
M//\ _A8FA^EW_P!^#1_PL30_2[_[\&O0-H]!1M'H*/:+L'[G^5_?_P  \_\
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MKK_OP:]!VCT%&T>@JO:+L9-TGO%_?_P#S_\ X6)H?I=_]^#1_P +$T/TN_\
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M#S__ (6)H?I=_P#?@T?\+$T/TN_^_!KT#:/04;1Z"CVB[!^Y_E?W_P# //\
M_A8FA^EW_P!^#6:=?L]?\=>'6L5FQ"[[R\97J./Y5ZEM'H*,#T%'M%V*C.G!
/WC%W]?\ @"T445D8G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img243551639_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_9.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &) <H# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ K
MUS5KFQNQ%$X1/(,BD0F0LP/0@?='O^M;]4+W2HKRX\\330R[/+9HFQN3K@T
M4&U'4+@3M;M!']F@21U(W!V9=Q .>!6JM]#_ &:E_*?+A,0E8GG:",U4DT&U
M=52-YH8_+$;I&Y D4= ?\:TE150(J@(!@#'&* ,J/Q1HLLJ1I?(7=@J@JPR3
MT'2M>L+Q2B#2X"%4'[9!T'_305NT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &'
MXJ_Y!<'_ %^0?^C!6Y6'XJ_Y!<'_ %^0?^C!6Y0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/Q5_R"X/\
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M%7H->?BX\M6WH>KE\^:A?I=_=<****YCN"BBB@ HHHH **** ,/Q5_R"X/\
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M4375TY$TBW!^=/[6C0=,$8]*]!/2N)U"QMYY;R2QCTIK>[M]^^6/#0JHPS
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M ->I_G79UQFK?\CU#_UZG^=&&^)^C'C/AC_B1?HHHJQ!1110!GZ9_P CX?\
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MR_Q,*XJ__P"1^D_Z]17:UQ5__P C])_UZBC#;R]&&,VA_B7ZFC1115@%%%%
M%#1O^1ZN?^O8?TKLZXS1O^1ZN?\ KV']*[.HQ/Q+T08+X)?XF%<1<?\ (]WG
M_7NO]*[>N(N/^1[O/^O=?Z48;>7H&,^Q_B7Y,TZ***L HHHH H^'O^1TU/\
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M /D?I/\ KU%=K7%7_P#R/TG_ %ZBC#;R]&&,VA_B7ZFC1115@%%%% %#1O\
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MAO8<YZ<5UE !1110 4444 %%%% !1110 4444 %%%% !1110 4F ,8 XI:*
M$  Z 4  #  %+10 4444 %%%% !2$ ]1FEHH ,#THHHH **** "BBB@ I,#.
M<#-+10 FT9!P..E+110 4444 %%%%  0",'FDP/2EHH 3:,8P,>E*  , 8%%
M% !1110 4444 %)@9S@9I:* # ]**** "BBB@ HHHH *3:.>!SUI:* $P,YP
M,^M+110 4444 %%%% !1110 4444 %%%% !1110 5G:GK5OI4EO%+#<323EM
MB01[R<<FM&L/4_\ D:=$^D__ *"* #_A)XO^@7JO_@*?\:/^$GB_Z!>J_P#@
M*?\ &MRB@##_ .$GB_Z!>J_^ I_QH_X2>+_H%ZK_ . I_P :W** ,/\ X2>+
M_H%ZK_X"G_&C_A)XO^@7JO\ X"G_ !K5^V6WGRP^>GFPJ'D7/*J>Y]J8=2L@
MD#_:8MMQ_JCN^_QGC\* ,W_A)XO^@7JO_@*?\:/^$GB_Z!>J_P#@*?\ &M6&
M]M;EPD,Z2,4$@"G.5/?Z4Y;B%KEK<2*9D4,R9Y /0T 9'_"3Q?\ 0+U7_P !
M3_C1_P )/%_T"]5_\!3_ (U9E\1:/!,T,NHVZ2*=I4MR#6DK!U#*<J1D'UH
MQ/\ A)XO^@7JO_@*?\:/^$GB_P"@7JO_ ("G_&MRB@##_P"$GB_Z!>J_^ I_
MQH_X2>+_ *!>J_\ @*?\:U!?6IO39>?']I"[S%GYMOKBHSJM@'G0W<.Z A91
MN^X3T!H S_\ A)XO^@7JO_@*?\:/^$GB_P"@7JO_ ("G_&MRB@##_P"$GB_Z
M!>J_^ I_QH_X2>+_ *!>J_\ @*?\:W** ,/_ (2>+_H%ZK_X"G_&C_A)XO\
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M]5_\!3_C1_PD\7_0+U7_ ,!3_C6O%<0S/(D<BNT9PX!^Z>O-2T 8?_"3Q?\
M0+U7_P !3_C1_P )/%_T"]5_\!3_ (UN'@9JM;W]I=N4M[B.5@H?"G/RGH:
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M444 %8>I_P#(TZ)])_\ T$5N5A:JRIXHT0LP48GY)Q_"* -VBH_M$'_/:/\
M[Z%'VB#_ )[1_P#?0H DHJ/[1!_SVC_[Z%'VB#_GM'_WT* .2\6)-;:O!-;H
MS?VA ;%]HZ$L""?P+52TNUE75I; H_DZ+;RI$S#AM_W2/^ UW)GMSUEB./\
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M_P! RW_[YH_X1?0_^@9;_P#?-:U% &3_ ,(OH?\ T#+?_OFC_A%]#_Z!EO\
M]\UK44 9/_"+Z'_T#+?_ +YH_P"$7T/_ *!EO_WS6M10!D_\(OH?_0,M_P#O
MFC_A%]#_ .@9;_\ ?-:U% &3_P (OH?_ $#+?_OFC_A%]#_Z!EO_ -\UK44
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M?\(OH?\ T#+?_OFM:B@#)_X1?0_^@9;_ /?-'_"+Z'_T#+?_ +YK6HH R?\
MA%]#_P"@9;_]\T?\(OH?_0,M_P#OFM:B@#)_X1?0_P#H&6__ 'S1_P (OH?_
M $#+?_OFM:B@#)_X1?0_^@9;_P#?-'_"+Z'_ - RW_[YK6HH R?^$7T/_H&6
M_P#WS1_PB^A_] RW_P"^:UJ* *=EI-AIK.UG:10,XPQ08S5RBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img243551639_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_10.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &> 6T# 2(  A$! Q$!_\0
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M#7M<O^J?_=->2>"_^03<?]?4G\ZUINT6SKP[<82:\OU'_P#".7G_ $,.I?\
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MN/\ KZD_G6L/A9U4/X<OE^IT= ZT4#K2&1_"W_CPU?\ Z_G_ *UWU<#\+?\
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M_P#U_/\ UKOJ53XF9XG^*SR;0?\ D.>(O^OY_P#T(UOU@:#_ ,ASQ%_U_/\
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MQOI\WF6I<M:1D%.1P3GH?Z4 =A1110 4444 85W_ ,CIIW_7I-_-:W:PKO\
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M^%O_ !X:O_U_/_6N^K@?A;_QX:O_ -?S_P!:[ZE4^)F>)_BL\FT'_D.>(O\
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MM<K#9W5IXRLA<ZA)>%K67:70+MY7TKJJ "BBB@ HHHH **** "BBB@ HHHH
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 V7_5/_NFO)/!?_()N/\
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M(Q/Q+T1YAJG_ "5>\_Z\T_D*U:RM4_Y*O>?]>:?R%:M5+IZ&T]H^B"LK2?\
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MW%M%=*BR@D(XD7!QR.E344 4(]'LXKH7"J^0Q=4+DHK'J0O0&K]%% &%=_\
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M  K_ ,E/U'_KR'\UKTJO-?"O_)3]1_Z\A_-:]*HJ;HC$_$O1'F&J?\E7O/\
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MQ_\ ?0H%S;Y_U\?_ 'V*U-9\.::MSI8M]*@VF[42[(AC;@]?:M;_ (1G0_\
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M[&NGJ!K.U9BS6T))ZDH* *G_  D&C?\ 04L_^_R_XT?\)!HW_04L_P#O\O\
MC5O[#:?\^L/_ '[%'V&T_P"?6'_OV* *G_"0:-_T%+/_ +_+_C1_PD&C?]!2
MS_[_ "_XU;^PVG_/K#_W[%'V&T_Y]8?^_8H J?\ "0:-_P!!2S_[_+_C1_PD
M&C?]!2S_ ._R_P"-6_L-I_SZP_\ ?L4?8;3_ )]8?^_8H J?\)!HW_04L_\
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KES%.JV+AC&P8 [U]*VOL-I_SZP_]^Q3H[>"%BT4,:$\950* ):*** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img243551639_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_11.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %# GX# 2(  A$! Q$!_\0
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MJ"Z4M;S1R@'!*,&Q^52U+5MRDT]4%%%% PHHHH **** "BBB@ HHHH ****
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M.N#N[:"#6M%,4*1DW)SM&,\5WE95J<86<>IOAZLYN2G;3MZ!1116!TA1110
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M]5^2"BBBN8[ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"0LG'*Y&0/R-34 %%%% !1110 53U2].GZ=+<J@9EP &.!DG&2>PJY6=KC7
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MTFN98Y[,M<2>8V8SP<8XIUGXCU^\\2?V,KV2OY'G>88VQ],4M4=#_P"2G?\
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M5F158;<CC.2:WFQM.3@8Z^E8'A0*EK/&MIY #A@2Y8L",C)/<"N@(!&",@T
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MU;_T(UZ3J7_(+N_^N#_^@FO-O"G_ "+=K]6_]"-:1^%G51_AOU7ZFS5'0_\
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M !7\R>L[7_\ D 7W_7%JT:SM?_Y %]_UQ:JCN:0^)':>%O\ D4])_P"O2/\
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M'_T8M:]8_B8C^PY.?^6L/_HQ:V* "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 5=2_Y!=W_ -<'_P#037FWA3_D6[7ZM_Z$:])U+_D%W?\
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M^1HU;_KC;_\ L];% !1110 4444 %%%% !1110 4444 %%%% %74O^07=_\
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M\.7JOU-RJ&F?\E-L?^O.3^1J_5#3/^2FV/\ UYR?R-4NI<=I>C/1Y/\ 5/\
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MMS3R26JW$:P6Q+[Q+*0K$#Y<E.?PKHESM&[KCF@@,,$ CWH Y"2Y6=&EN3-
MXMXVLD#MG=SG'KSCKV-='<W%[#9Q/#9?:9SC>@D"8XY.3[U<(!() )'3VI:
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MC\!6E63KNHSZ;#%)%+:H&;:1/NRQ[!0H)- ">'X6-I)?32,]S=MOD)7;C'
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M%%% !1110 4444 5=2_Y!=W_ -<'_P#037FWA3_D6[7ZM_Z$:])U+_D%W?\
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MZEQVEZ,])HHHK$X@HHHH *RM4L;V:_L[RR:WWP!QMF!Q\V.1CZ5JU3O]-BU
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M]9/YUU?A;_D4])_Z](__ $$5RGC#_D?]%_Z]9/YTH_$_F12_BR^98K-\0_\
M(N:C_P!<&K2K-\0_\BYJ/_7!J<=T7#XD=MX8_P"17TS_ *]D_E6M63X8_P"1
M7TS_ *]D_E6M64MSEJ?&PHHHI$!1110 56N[^VL0AN)=F_.T!2Q..O JS6#J
MFFWT[PLLKSA6<Y1A"Z9&  P[>M &A)K&GQ>5ON5Q(H92 2,'N2.GXU>KFUTJ
M_MX)8D@AD-S;I$Y#;5B*@CIW'.?K6Q<-=VEI$MG;"Z=<*0T@3@#KF@"G8_\
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M4J.%+6WF]7!'RY^3C\JU]4TO4-3U:#S([81+!*N\@NHRRX],-@&M'^T]1_Z
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MVH5'12?<_P JP9++5=NGK<6LX>V@FMV:. 3 C*[<9[$=_:NH_M/4?^@%<_\
M?Z+_ .*H_M/4?^@%<_\ ?Z+_ .*H YJ'3[ZUN;5GM)XU%C%&?+MA-\P9L@YZ
M=1^=:^J:?J5]>:=N\A?+E<^8L7F*JE>-P..:O?VGJ/\ T KG_O\ 1?\ Q5']
MIZC_ - *Y_[_ $7_ ,50!C1:-_8MX3)82:G;M#L0A%8QMDEAM/0'/:F:A87"
MWR3V6FS+,R1+Y4D:20D#L3_!CU%;G]IZC_T KG_O]%_\51_:>H_] *Y_[_1?
M_%4 8=EI5[!K%Q<W5N\MO//,B*HYM]W\8]0>F>U/\/:7>6VKI(8FBMK>W:'<
M\(C,G(QG!.[IUK9_M/4?^@%<_P#?Z+_XJC^T]1_Z 5S_ -_HO_BJ ,PVLTOB
MBUFBT]XHH9'+DQJJ\@C>''+$YZ4_4+/49M5DDBFNTB\^)5$;X781\YK0_M/4
M?^@%<_\ ?Z+_ .*H_M/4?^@%<_\ ?Z+_ .*H YG49-0LK21+FXO5$<,PMRD@
M#;@[!2WJ-NW%7K^SU.[@2ZM(_P#2_M,0B,H.%55(W'VR2?QK4DO+N9E:7P[*
M[(<J6DB)7Z?-4G]IZC_T KG_ +_1?_%4 <QJ%Q>6T"B66^B<6Z^6HD&?,W8;
M=ZY[>U=?J.?[%NL]?(;/_?-4WN[N219'\.RLZ?=9I(B5^AW4R\O=3N;*>!=#
MN TD;*"9HL<C_>H T-)_Y UC_P!>\?\ Z"*N56T^)[?3;6&08>.%$8>A  -6
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img243551639_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_12.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"@17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0>NH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA=&4@36]R
M;F5A=6QT     >H<  <   @,   (;      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MU=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!
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M0?\ @5.-.-U?_ARZ>&I*<;K2Z^=UT]&>CW7CO2K.*T\V&^-S=1F5+-+5FG5
M2-S)_".#UJMKWB^U;P/_ &YHNI^3"TBJ)UM_-*G."I0D<UR&M7=DWQ"_MF?6
M[W3-*U&Q M=0L\@.5(!0_*>ZD_EZU#KEE86OP=OI]*EOYK>\U!9_,OE"LY)
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MH **** "BBB@ HHHH **** (OLT'_/&/_O@4]D1UVNJL/0C-.HH'=B,H=2K
M,#U!%*    , =!110(0(JL2J@%NI ZT%5+ E02O0D=*6B@!%14&$4*"<X Q1
ML4.7"C<1@MCFEHH *0HI8,5!8="1R*6B@ IJ1I&,1HJCT48IU% "*BJ254 M
MR2!UI!&@<N$4,>K8YIU% "*BIG8H7)R<#&:S_$&EG6_#U[IJRB$W41C$A7=M
MSWQ6C133:=RHR<6I(S]#TL:/H=C8,ZRO:VZ0F4+C=M&/P^E7PBABP4!CU(')
MI:*&[NXI2<G=B,BL064':<C(Z4$!E(8 @]0:6BD(:8T9 C(I4=%(XI6177#J
M&'H1FEHH ;L0/N"KNQC..:54522J@;CDX'6EHH **** "BBB@ HHHH ****
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MFU&'4;.&TN;"Z%NZP7!F1LQ1RA@Q1#TE QCM0!K4444 %%%% !1110 4444
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MF3.9)'\D9=B<DGU)JS>^']'U&YAN-0TNTN9H0%CDFA5F4 Y !(Z9 /UK1HH
M*PO#_P#R'/%/_853_P!(K:MVL+P__P ASQ3_ -A5/_2*VH W:*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH B:V@=BSPQLQZDH#FGF*,A044A/NC'W?I3J* "N;L?^2I
MZ[_V!=-_]'WU=)7-V/\ R5/7?^P+IO\ Z/OJ .DHHHH **** "BBB@ HHHH
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MD5M6[6%X?_Y#GBG_ +"J?^D5M0!NT444 %%%% !1110 4444 %%%% !1110
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MF++@*3@8%1>'=,U[2+>UM)]+T^14D)DN3-F3YF)+=.HS^E=E10\3)KE:5O\
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ML),^,=7CC.46"W+^S_/_ .RX_2MJL_2-.:PAE>X<27=U(9KB1>A8\ #_ &0
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M_;OJ4M@KL;F&)9738V K$@'.,'E3P#GBJZ:[I\FGV=ZDSFWO9%B@;R7!9F.
M",97IU( K0HH KI?V\E_/9H[&>WC221=C8"MNVG.,'[IX![5!'K=A)96-VDK
MF&_=4MV\EP7+ D9&,KP#R<5?HH JKJ5J]Y=6RNQFM$5YE\MOE# D8.,'[IZ9
MJ)-;L)+73[A)7,6HLJVQ\E_G)4L,C&5X!^]BK]% %4:E:M/=PAVWV:JTX\MO
ME!&X8./FX';-1C6;$PZ?*)6V:B0+8^4_SY0N,C'R_*"?FQZ=:O44 4_[5L]]
M\OF-G3P#<?NF^3*[^./F^7^[GTZT@U>R/V#$C?\ $Q_X]OW3?/\ (7YX^7Y0
M3\V/3K5VB@"DVK6:K?L9&QIW_'S^Z;Y/D#\<?-\I!^7/IUIQU2T$ME&9&W7X
M)MQY;?-A=QSQ\O'KCTZU;HH HOK5BEOJ$S2N(]-)%T?*?Y,*'.!C+?*0?ES^
M=2-J5JMQ:0%V\R\5F@'EM\P R<G&%X/?%6J* *#ZU8QVE_<O*XBT]F6Y;R7^
M0JH8X&,MP1]W-3/J-M'>VUH[L)KI&>%?+;#!<9R<8'WAUQ5FB@#/DUW3XK"]
MO'F<06#M'<-Y+DHRXS@8RW4<@&K#W]O'?P6;NPGN(WDC78V"JXW'.,#[PX)[
MU8HH SY-=T^+3[N^>5Q;V<C13MY+DJRG!P,9//< BK#W]NFI16#.PN98FE1=
MC8*J0"=V,#EAQG-6** ,\Z[IZZ=/?&9_L]O*T,C>2^0ZOL(VXR?FXR!COTJP
M;ZW74DL"[?:7B,RKL;&P$ G=C'4CC.:L44 9[:[IZZ;)?M*XMHYC S^2^0XD
M\O&W&?O<9QCOTYJQ]OM_[3&G[V^TF'S]FQL;,[<[L8Z]LYJQ10!GC7=/.F#4
M!*_V8S>1N\E\[_,\O&W&?O<9QCOTYJP+ZW.I&P#M]I$(F*[&QL)(SNQCJ#QG
M-6** ,Y=>TYM-BOQ,_V:680(_DODN7\O&W&1\W&2,=^G-65O[=M2>P5V^TQQ
M+,R;&P$8D [L8ZJ>,YJQ10!GKKE@^GV]ZLKFWN95AB;R7R79MH&,9'/<C'X5
M82^MWU"6Q5V-Q#&LKKL; 5B0#G&#]T\ YXJQ10!GIKNGR:?9WJ3.;>]D6*!O
M)<%F8X (QE>G4@"IX]0MI;^XLD=C/;(CRKL8 *V=N#C!^Z>A-6:* *":W826
M5C=I*YAOW5+=O)<%RP)&1C*\ \G%2KJ5J]Y=6JNQFM$5YE\MOE# D8.,'H>F
M:M44 4$UNPDM;"X65S%J+*ML?*?YR5+#(QE> ?O8J1=3M&N+R!9&,ED%,X\M
MOE!7<,'&&X],U;HH I+K%D\-A*LC%-1(%L?*?Y\H7&>/E^4$_-CTZTO]JV>^
M^7S&SIX!N/W3?)E=_''S<?W<^G6KE% %(:O9'[!B5O\ B8?\>W[IOG^0OSQ\
MOR@GYL>G6AM6LU6_8R-C3_\ CY_=-\GR!^./F^4@_+GTZU=HH J?VI:>991^
M8VZ^!, \MOFPNXYX^7CUQ3'UJQ2#4)FE<1Z:2+H^4_R84.<#&6^4@_+G\ZO4
M4 5&U.U2YL[=I&\R]5F@'EMA@H!.3C"\$=<4Q]:L8[2_N7E<1:>S+<MY3_(5
M4,<#&6X(^[FKU% "*P=0R]",CBEHHH **** "BBB@ IKNL:%Y&5$49+,< "G
M5R'CC2]'>V74=?M+S6%5XX;73$E(C>5VVK\@(#$D]7S@=,4 =):ZMIU_(T=C
M?VMRZ_>6&97(_ &K=>46%EX6OI-(%]X'CT>6^O+FR$]E,%:TN(68!2\>TY/E
MM@C(R.XYKU&SMS:6<4#3RW!C7;YLQ!=O<D 9/O0!-1110 4444 %<.TEQXF\
M=>(]*EOKVRM]%M[86WV:X>$&25'<R,5(W@84;6RO!XKN*PM3\*6VH:G+?P7U
M[IUQ<0BWN6LW1?M$8)PK;E;!&X_,N&YZT 9/AWQ?J=YX"T35I-#OM5GN[<M<
M/9- @C*G&YA)(GWN3A0W0\#C/(Z-XVU"3QT;^6)'-^(;26)5Z1H[E /<&5S[
M[N>@QZS86-MIFGV]C8Q+#;6\:QQ1KT50, 5SEIHNF6OQ%F>"SB1A8I.N!PKF
M1@6 Z X Z5W86=*,9JI&^FAY&8TL3.I2=&IRJ^OG_GML:\>N>9IMA>?V7J2?
M;95C\AK?$L&[/S2+GY5&.3SC(JPFH;[^\M?L=TOV6-'\YHL1S;@>$.?F(V\C
MMD>M7**X3US-CUG?8Z=<_P!FZ@OV]U3RF@Q);[E)S*,_*!C!/."14PU'-U?0
M_8[L?8U5MYB^6?*DXC.?F(Q@^Y%7** ,X:OFVTV;^S[\?V@RC88/FMMR%LRC
M/R 8P>O) I_]J?OM1C^PWO\ H*AMWD\7&4W8B.?F(Z=N>*O44 9ZZMN73#_9
M]\/[0&<&'_CV^0O^]Y^3IM[_ #<4K:KC^TO] O3]@&>(?^/GY _[KGY^NWM\
MP(J_10!1_M/]YIZ?8KS_ $X$[O*XM\)NQ+S\OIWYXIK:OMMM2F_L^^/]GEAL
M$/S7.$#?NAGY\YVCIR"*T** *1U/%S80_8KP_;59MXB^6#"AL2'/RDYP.O-0
MOK6RQU*Y_LW4&^P.R>4L&7N=J@YB&?G!S@'C)!K3HH J/J&R^L[;[)=-]J1W
M\U8\I#M .'.?E)W<#O@^E5Y-:\O3K^[_ +-U%_L4CQ^2L&9)]N/FC7/S YX/
M&<&M.B@"I+?^7JEO9?9+I_/C>3[0D>8H]N/E9L\$[N!WP:K2:YY>F7M[_9>I
M-]CF:+R%M\RS[6 W1KGYE.<@]Q6I10!5>^V:M%8_9;EO,A:7[0(_W*X(&TMV
M8YR!Z U6?6]FEW-[_9FHMY$[0^0+?][)A]F]%SRI^\#_ '>:TZ* *IO<:LMC
M]FN#N@,WVCR_W(PP&S=_>YSCT!JJVM[='?4/[,U([9C#]F%O^^/[SR]X7/W?
MXL_W>:U** *OV[_B;_8/LMS_ *CSOM/E_N?O;=F[^]WQZ55&N9TF._\ [+U(
M>9.(?LYM_P!\O[S9O*YX7^+/]WFM2B@"L+W.K-8_9K@;8!-]H,?[DY8C8&_O
M#&<>A%54UO?I=M>_V9J*_:)UA\AK?$L67V[W7/"C[Q/IS6G10!52^WZM+8?9
M;E?+A67[0T>(6R2-H;NPQDCT(JK'KGF:997O]EZDOVR98O(:WQ+!N8C=(N?E
M48R3V%:E% %1+_?J5S9_9+I?L\:2>>T>(Y=V?E1NY&WD=LCUJO'K7F:=I]W_
M &;J*?;I$3R6@Q);[@?FE7/R@8Y/.,BM.B@"FNH;KV\M_LET/LJ(_FF+Y)MP
M)Q&<_,1CD=LBH5UG=9:;<?V=J ^WNB^48/GMMRELRC/R 8P>N"0*TJ* *0U/
M-S?P_8KP?8E5MYB^6?*EL1G/S$8P?>HUUC=#IDG]G7X_M#'RF#YK;*%OWHS\
MF,;>_) K1HH HG5,2:BOV&\_T$ Y\GBXRF[]US\W]WMSQ2#5,G3O]!O1]O&>
M8?\ CW^0O^]Y^7IM[_-Q5^B@"@=5Q'J3_8+X_P!GY^40\W.$#_NN?GZ[>WS
MBE_M3]]IT?V&]_TY2V[R>+?";L2G/RD]._/%7J* ,U]9VVNIS_V=J#?V>S+Y
M8@^>YP@;,0S\X.<#IR"*F;4=MU90?8[L_:T9O,$7R0[0#B0Y^4G.![@U<HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <;\1)KB>UTO1+6'37;5[LP[]3A\V%-L;2
M#Y>[$J /<US_ (!UO4KOQ#I/V^_T:6/4-*+I%I]H$EA$9'[ER#\@0R' Z$A^
MF.>J\;ZG]BATNWM]$CUF_NKY190S.L:1RH"XD+GH5"DC')Z5C^%F_L[QM):Z
MSX0T_1M4U&"2>.^L9%D%P%9?,4\ J<LI]#]10!Z!1110 4444 %%<KJWC5M(
MM[[4)]'NO[*T^<07%TQ".>0"Z1D9= 6QG(S@X!I^H^,Q;3ZHNG:;+J$.CQ++
M?21R!=H*[]J _?8)\Q''4#.>* .GKA?#S#_A<'BQ<\[8?_1$/^-=G8WL&HZ?
M;WMG()+>YB66)Q_$K#(/Y&N)\/<?&;Q5[K'^D%O_ (UO1^UZ')B=Z?\ B7ZG
M>T445@=84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M807D0D56ZKGJI]P<C\*XN[X_:'@/_4'MQ_X]>G^E;T/B?H_R9R8S^&O\4/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 <?\0].U.ZM=,U#1AI2SZ9=&X,FJN5A0;"IS
M]=WMC@@@BHO!VK:]J]^9;I?"\VGJI#3:/=&9U;L/3'6E^(VG-J4.C+%'8WTD
M5Z9%TJ^F\M+_ !&PV@G@L,[@#QP<U2\(^'=17Q8FM3>%M/\ "5O%:R6[VEG.
MDC73,RD%O+ 0!=IQWYH ]!HHHH **** "BBB@ K@M)^7XO:P?[TS#_R4M#7>
MUP.G<?%K4C_>NI ??_0[2MZ/Q/T?Y')B_@C_ (H_FCOJ***P.L**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1^)\LL7
M@:9K?R4F^TV_EW$S%5M6\U<3''/R'YO3CD$9%==7->/KC3[?PI(=4TI=762:
M**"Q9@HFF9@J L>%&3U/2@#-T63Q2VJ6OV_Q9H5]:EAYD5O %DE&/X3NZ_A7
M;UY7HFEV_A_Q5I7]M^ ]+TIKR8Q6=]8W(E,4VPL%92 >0K?,./SKU2@ HHHH
M **** "BBB@ KSK6OE^+ZOZ0Z4N?K)J%>BUYUK_'Q4+>B:-^L]^/ZUO0_B+^
MNAR8S^ _E^:/1:***P.L**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#S'QQXBT37=0@T&7Q"WA^\L]2*M/(D.8V2
M+S%DW.P**<[0PP225Z&M3PE)NUQ5_P"%DV_B/]TW^@Q_9\G_ &OD.[C^M;FN
M>&/"U_<IJWB'2].EDM@2;BZC7&,%<.3PP / ;(!Y'-.T;2/"EO<+=>'M/T>*
M9H@ZS6,,08QMT(9!G:<=>AQ0!N4444 %%%% !1110 5P5GQ\5;LG^*_F _\
M &SKO:X&VX^*4Q_ZB<X_\I]H?Z5O0^)^C_)G)C/X:_Q0_P#2D=]1116!UA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MR7Q-N[6S\!WCZC!:7%HSQK-!=!L2IN&54J05? ^4Y # 5UM<%XRL?'::Y'=^
M$I[>>RFEM=]O-,R&(HY+=./+8$;N^!P* ,3P9JGPN/B6R;1+^ZNM7DS':+>_
M:9##N'*J7&U>!C.?;/->L5R>EW'C]]4@76+'0([$M^^:VGE:0+_L@C&:ZR@
MHHHH **** "BBB@ KSKQ%Q\2+I_[D.BMGT_TF^KT6O.O$O'CK57Z;+/1F_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\3:V^@Z/]J@M?M=
MQ)-';P0F01J\DC!5W,?NC)ZUKUR/Q O)K;3[:"70XM<TR^<VMQ9D@2/*Q7R<
M$D +NSD\D<$=#0!6TOQKJ;3:/'J]A:I]OO[K3IFMYB?*FB9PN >64^6V3QCC
MZ5V]>+Z?:6NBW>CMX/\ "UK8^)KR[N+9X]7NY+A+-HXR\@5@QY93PPZYYKUC
M0-5_MSP_8ZGY1A-U"LC1$YV,1RN>^#D9H T**** "BBJU^][':EM,M[>XN,C
M$=Q.T*$=_F".?TH KZWK^E^'+%+O6KM;6"25849E+%G;HH !)/7\ 34>J>)=
M*T:<0W]PZRE/-9(H))3&F<;WV*=B\'YFP..M>:_$S^VKG2]1O-:T*=(+86D5
MD\%Q#) C&>)I7)+JY+$!%.P8 R<;CC;M]3AT+Q[XEOO$^;&#5;*S>RBNBN6"
M(ZO""I(9]Q^ZI).X8S0!Z##-'<01S02++%(H='0Y5E(R"#W%>>^*>/%GB!_[
MFFZ.W_DW>5>\)>&]87X=^'[.;6]2T2ZMK;]ZEK';LS;CE5?SHGP5'&!CJ<YX
MQAZO87.G:KXLCN]6O-5?^RM)D$]XD*LH^UW7R_NHT7'&>1GD\] -\/\ QH>J
M.3'?[K4_PO\ (]3K-\0?\@=O^N\/_HU*TJS?$'_(';_KO#_Z-2HI_''U-<1_
M!GZ/\C2HHHK,V"BBB@ HHHH **** "BBB@ HHHH ANKR"RA\VZDV)G&<$\_A
M4-EJ]CJ+%;*X$I W<*1QT[BKE9OA[_D V_\ P+_T(UHE'D;ZF$I3]JHIJUGT
M[6\_/L:59L__ "-5A_UY7/\ Z'!6E6;/_P C58?]>5S_ .AP44]_D_R'7^%>
MJ_-&E11169L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!P?Q4U5-+TO2_M>N76C6$]YLNYK$E;A
MDVG&P@'&&VD]\9QGH<SP#J/A2Y\3B/0O'?B/7+KR7(M-1GE>(KQEL-&HR/K7
M1>.]2U6U.C:=HNIPZ1+JE[]F-_+"LHC/ELRJ%;@EV4*,^O%<O\/_ !)K&H^(
MM,AU3QDFL_;-/DGFT^*RAB:SE78&24K\PP6(&1S@\#C(!ZK1110 4444 1S6
M\-P$%Q#'*(W$B;U#;6'1AGH1ZU'/86=U-%-=6D$TL)S&\D89D/L3TJQ10 5P
M1X\=3L.O_"0 ?GIUO7>UP,O'B^Y;I_Q4L8S]=/@K>A\?R?Y,Y,9_!^<?_2D=
M]1116!UA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5S7C]M(7P=<_P!O-=K;[X_+:QS]H$V\>7Y6/X]V,?KQ72US?CZV
MAN?!]R+G6(=%CC=)#?2PB3R2K J5&1AMV,$'.<8H \SL-'@OM:LQHMK\0M(U
M0%E@U+5;,300NX(DE<,WWF7*DC'8XR*]AT/2(- T&RTJU9GALX5A5GZM@8R?
M<]:\V\,>)9+KQ)8V[?%>'6%>3;]A71$B,_'W=XY'KGVKUB@ HHHH **** "B
MBB@ KSSQ6N[7?%X_Z@6F'_R9O*]#K@/$B[O$/C ?]2]IQ_\ (][6U#2M'U7Y
MG+C%?#5%_=?Y'?*VY%;U&:SO$'_(';_KO#_Z-2KEH=UE ?6-3^E4_$'_ "!V
M_P"N\/\ Z-2IIZ5%ZE5G>A)^3_(TJ**CGD:&!GCA>=E'$<94,WTW$#\S6>YN
MW97)**S;#5WOYVC&F7D"H[1O)*T6U6';Y7)_(5I54HN+LR83C45XA1114EA1
M110 5ALNJ_VV+0:H!&T!E_X]EXPP&/UK<K-;_D:H_P#KR;_T-:UINUSGKQNH
MZO==6OR-*BBBLCH"LWP]_P @&W_X%_Z$:TJS?#W_ " ;?_@7_H1K1?PWZK]3
M&7\:/H_S1I5FS_\ (U6'_7E<_P#H<%:59L__ "-5A_UY7/\ Z'!13W^3_(*_
MPKU7YHTJ*R-8DU*WDA>SNX8XY9HXMCV^XC<<$YW#^5:=NLR0*MS*LLH^\ZIL
M!_#)_G2<;13N.-3FFXV>GI_F24445!J%%%9\NOZ3!,T,VH6Z2*2&4N,@CK51
MC*6R(E4A#63L:%%(C*Z*Z$,K#(([BEJ2PHHHH **** "BBB@ HHHH *H76N:
M=9W'D7-R(Y,XVE&/.,^GI5^LW5O^/W2/^OT_^B9:NFHMV9C6E.,;Q[K\[=T7
MX9DN(5EA;<CC*G&,BGT45!JKVU"BBB@84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <QX
MVU.]LHM+M=+TNSU"[OKU8X3?MMAA=5,BN3@_-E/EQSGIS57PS8>)+;Q!-=:Q
MHGANR2Y4F>YTW=Y\K=MQ*C(^IKG9?!>F^-?B!K4EUIRG2K6;R+J1[V<2S7&Q
M7^5%8(J@,O4<]:L^'?#=KX2^*/V/[&JPWEK+)IUPEW-(P5-@=)%=B,_,""*
M/2J*** "BBB@ HHHH *X*YX\2W;=O^$IMQ^=A!7>UP5Y_P AV]/IXKM?_2*
M?UK>A_$7]=#DQG\!_+\T=[1116!UA1110 4444 %%%% !1110 4444 %%%%
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MVE;X?^+'U.3&_P"[5/1G?4445@=84444 %%%% !1110 4444 %%%% !1110
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M["QE.E3;5TXN[7>5FSR_P;X9UJ'QA&\D$ELME)_I#MTQC[H]<@]NQS7IL_\
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MCE>A4<<&M2LW0O\ CRN/^OVY_P#1SUI5G4MSM)&^'NZ47)W;"BBBLS<****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M:UWQ%K^F:F;?2O"-SJUOL#?:8[N.,9/48;GBNEKSKQ+]E\1>.+O1M?U]]*TC
M3[2&06T5V+<W<DI?)9NI50@^4=R#0!'=S^*/$WBSPW+=^$;G2[;3KTSS3R7<
M4@P4*]%.>]>DUYA8V^F>$?%.BIX3\1->V.HW1L[K39+X7"C,;LLJ<DJ05P?7
M(KT^@ HHHH **** "BBB@ KF['_DJ>N_]@73?_1]]725S=C_ ,E3UW_L"Z;_
M .C[Z@"UH5C:3:%:236L,CE.6:,$]3WK81$C0)&JHJ\!5& *S_#W_(O6?^Y_
M4UI5K5;<WZG/AHI4HM+HOR"HYY&A@:2.&2=EZ1QE0S?3<0/S-245D;O5&-HT
MEY'/<1W.EW5NLUP\HD=XBJ@] =KDYX["MFBBKG+F=[$4Z?LX\M[^O_ L%%%%
M0:&?K6BV>OZ:UE?JQC)#*RG#(P[CWY/YUB^#=#T_0=!%_&)&EN(@\LC#<0/0
M #I^M='=V5M?1"*\A29 =P5QD9]:CLM*L-.8FQM(H"PP2BXR*Z(UFJ3IW=GT
M.*>&C+$*ORJZ5K]?R_7J9ND:E;OJNI*!.#<W8>(M;R*& @C7.2N!RI'/I5MO
M^1JC_P"O)O\ T-:TJQ6BUHZP+P6=AM6$Q!3>OD@L#G_5>W2A-2;:TT[A*,J<
M4I:ZWT3[W\RQJ_\ Q\Z7_P!?H_\ 1;USOQ$\,OK&GKJ$$RI)8QNS(^<.G4X]
M^*Z2[T.QOKCS[F.5I 0P(N)% .,9 # #BH]1TB2[TXV-M>-;6[1-$P*>82#[
ML<U=&JJ<XRB[-&6*PSKTJE.<;J6UGKY=OS*G@[PVWAK1VMIIEFGE?S)"F=H.
M,8&?IUK=E3S8G3<R;@1N0X(]P:BM(KB&(K=7/VEB<AO+"8'I@5/6%2<IS<Y.
M[.NA1A2I*G!62Z&;:Z)':7;7"7EX[NP9P\V0Y P,C'H!1/\ \C58?]>5S_Z'
M!6E6;/\ \C58?]>5S_Z'!51DY2N^S_(BI3C3A:*ZK\T:59NO23?V5<6]O9SW
M+SP2(OE!<*2N!G)'K6E16<9<LDS>I'G@XWM<PKW3E\2^'9=.N[>XLOE4*\@7
M(8=" "<C\JP_ _@Y=*DN-1:Z\R?=-;1X3 3;(R%O?.WI7<UFZ#_R#9?^OV[_
M /2B2NF->:I2A%V39P3P=&6)A4FKR2>OHU;\V1VVE7T&H273:IYGF[!(AMU&
MX+GCKQUJ2Z_Y&33O^N,__M.M*LVZ_P"1DT[_ *XS_P#M.LHR<I7?9_D=$Z<:
M<+1[KJW]I=S-\-RQV%_K.ERNJ"WO#-&&.,)*-P _'-1^-_% T#2(_L\:SS7F
MY$)/RJ .2<=>HXK/\46D$7C33I9X(Y$U#RH3O0'YTG0]_521]*76;"V\37$N
MFVD20:5I0=I9(4"[I\'Y%XP .K>]=L84W4C5GL]7^7YGD5*U:-&IAJ6DD[+Y
MN_X1ZE/P;=/XPF5M6VF'24C$5JBD(S$$!VR>2-O3I716VD65_I.IVLMI$Z/=
MS87;CY@3@Y'0CUJ;PIHMEHVA0"RC(:XC665V.6=B/7T&>!5G1?\ 5WO_ %^S
M?^A5G7K)SDZ>B5K?UZG1@\,XTH1KV<FG=]_^&6AX_HM[K=OXRMD\^Y^V&=89
M%F<DL,XVMGMC->P7_P#R&M*_WY?_ $6:SM5TB/6=6U*V+>5,+.U>&8=8I!).
M58?C^E1:?J[:G<:6;M1#>6TLT5W&>-CK&<GZ'J*VQ%15[32M9:_-')@L.\&I
M4I2;YI)KY2L_GU\_D0_$'Q(FCZ.UBL/FS:A%)'DG 12,$^YYX%:/A/Q-'XGT
MMIQ%Y$T3;)8\Y /8@^AKF_$5J/&-I>ZF,QZ;I=O,;651\US(!DGG^ ;<>]:%
MI8'P"Q:+?<Z-,09W*@R6SXQO.!RG\OYS*G2^KJ'_ "\_K3[K:?J7#$8CZ[*L
MW^YLONUU[VO?7MKMJ=C2,P52S$!0,DGM49NK=;47+3QB J&$I<!<'H<]*Y_Q
M-K5M/H<EEI=[;SW=\ZVL:Q2JQ&\X)X/89K@ITY3DDCV:U>%*#DWTO;N2>$5-
MU;WNLR []3N#(F>HB7Y4'Y G\:OZM_Q^Z1_U^G_T3+5RTMH[*RAM8!B.&-8U
M'L!BLS5/[1EO[0VVGB6.UN/-WF=5W#RV7IVY;]*TYN>JVO/\K(QY'1P\8/5Z
M7LKZWNWI\S9KG?')AC\*S7,K,DMLZ2V[H,E90?E/^/MFM^%G>%&EC\IR/F3=
MG:?3-5]4TRVUC39K&]4M#,,':<$=P0?4&HI24*BD]DS;$P=6A*$=VG:_X'(>
M _&*ZK<2Z;<P>5.[RW"NIRK;G+$8[8W5W5>>Z/X5FT)7UC0F:ZN;>>:%[:8#
M$L:N5PIQPWRYS_D]KI6JVNLV"W5FQ*D[71AAHV'56'8BNG&1IN;G2V_4\_*Z
ME9452Q+][IYK_@=2[166WB"V6Y\@V]]YF"VT6DG(!QGITK4KCE&4=T>I"I"=
M^5WL%%%%2:!1110 4444 %%%% !1110!FWG_ ",&F?[DW\EK2K-O/^1@TS_<
MF_DM:5:2VCZ?JS&G\4_7]$5[N_M+!%:]N(X%8X4NV,TVSU*RU$,;&ZBGV8W>
M6V<9Z5-<_P#'K+_N'^55=$_Y &G_ /7M'_Z"*+1Y+]0YI^U4=+6_KK^A>HHH
MK,V"L_7_ /D6]3_Z])?_ $ UH5GZ_P#\BWJ?_7I+_P"@&KI_&O4RK_PI>C+T
M7^I3_=%.IL7^I3_=%.J#1;!1110,**** "BBB@ HHHH **** .'TBZ%[\2M:
MDU;6989].<06>EF8)'Y+1JWG%?XR26Y[8QZ4RPEAL_B_/;Z/J;7L6HV<EQJ-
MKY@D6TD0HL; C[NX%AM/U]*Y_P <_;?$5QK5^GA_0K[2O#;&.;[<'^TS[(UE
MD".N-@ ;@<Y//M7H/A;2-$TS18)?#VFP6$%W$DV(T 9@5R-QZDX/<T ;5%%%
M !1110 45PFH?$=K;^V+BUL[26UT:Z^RW$4MX8[J0Y )2+8002<+EOGP>E:%
M_P",+M;S5DT?2TO(=%B5[UI;@Q.S%=YCC7:<L$YY(&2!ZD '5UQ&H '2?'F?
M^?U3_P"25M77:;J%OJVE6NHV3%[>[A6:)B,$JPR,CL>:Y2Z!.F^/<?\ /U_[
M8VU:T?XL?5'/BM</->3_ ".NLCFPMSUS$O/X5-573#NTBS(Z&!#_ ..BK51+
MXF:TW>"84445)84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 5AZMX:\,:K?&YUK2].NKG:%,ES$C-@=!D]JW*Y[6O 7ACQ%J)O
MM:TB*[N2@3S'9@<#H."* .=U73O#WASQ5X8&@Z)H\4M[?&*26.W7?&!&3E2.
MAXZUZ'7+Z;\-_".D:E#?Z;HD,%U VZ.57<E3^)KJ* "BBB@ HHHH **X37?B
M ^G:WK-A%+IMH^E0I(L-_(RR7Q9-V(\8XR0H(W$MVZ9MQ>+=4UB^N;/0;""*
MYL+&"ZNX;XMN629"ZP87[K8'+<XR.#0!V%<I'<-;?$[7'2WFN#_8^FC9"!G_
M %U]SR16SX=UN#Q'X<L=7M%9(KR(2!&ZH>ZGZ'(_"LVQ_P"2IZ[_ -@73?\
MT??4UN)IM61=\.R3IIL-K<V5Q;O$G+2A=IYZ#!-:]%%.<N:3D12A[."A>]@H
MHHJ30**** "BBB@ HHHH **** "BBB@ HHHH *SI/#VD2S&633K=I&))8IR<
M\FM&BJC*4=F1.G"?Q*X !0 !@#@4445)85FZ#_R#9?\ K]N__2B2M*LW0?\
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M1I?)_P!,\;!2QM*I4J8C6+>RW6BZ>EEI?8Z*Y_X]9?\ </\ *JNB?\@#3_\
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ML[=849C->@L0H S@ 9]A795S=C_R5/7?^P+IO_H^^H Z2BBB@ HHHH ****
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MFL#GC<,X& ?QK;#8:=::5M#ES#,*6%I2ES>\NBLW]QZ;:SM<P[WMY;<YQLE
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M*** "BBB@ HHHH **** "N;L?^2IZ[_V!=-_]'WU=)7-V/\ R5/7?^P+IO\
MZ/OJ .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***#G!QP: ,V#_D:K[_KRMO_ $.>M*LB'2]2CU-[QM3A
M9I(XXW7[)C*H6(Q\_!^<UKUI4M?1WV_(PH<W*U)6U?;JV^C84445F;A1110
M4444 %%%% !1110 4444 %%%% !1110 5BZ]=X\B%+6[E9+F&1C%;NZ[0X)Y
M QT%;5%7"2C*[,JL'4@XIVN1V\ZW,"RJDB!OX94*,/J#S4A 92&&0>"#WHJ*
MYN8+. S74JQ1KC+.< 5.[T+O:-Y,S?#5M!;:;/\ 9X(XLWER#Y:!<XG<#IZ
M 5KUA^&]2LKBVE@AN8WE-U<N$#<[3.Y!_(@_C6Y6E9/VCN885Q="'+V04445
MD=)'<_\ 'K+_ +A_E571/^0!I_\ U[1_^@BG:G>V]G:,;F39O4JORDY./:JW
MAV\@N=%M(H7W/#;QK(I4C:=OO]*UY7[.]NIS.<?;J-];/]#5KC[3P;HT'C6:
M>.W($4,=Q'%N^179G&0/^ C KL*S8O\ D:KO_KR@_P#0Y:JE4G!2Y7;0G$4:
M=65/GBG9_HS2K/U__D6]3_Z])?\ T UH5D>)[ZTM/#]]'=74,,DUK*L222!2
MYV'@ ]>HZ>M123<TEW-,1)1HR;[,U8O]2G^Z*Y[7?^)/K5IKJ?+ V+6]] C'
MY'/^ZWZ&MG3[^SO[<-8W4%RJ !C#('VG'0XJ2]M(;ZQFM;E=T4R%''L13A+V
M<_>^9-6'MJ7N/7=/S7]:^1EQ2ZTVL26;WE@4CACF+"R<%@S,,?ZWC[G7WZ5M
M5YWX7\7V<6MBQU"<O((DLX[D#*2['?:V>HR&7GZUZ)6N)IRISM)&&7XBG7IN
M<'?776]O(****Y3T HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y:PN3
M;ZEXJ"V\\YDU-5 A3=C_ $*VZUU-87A__D.>*?\ L*I_Z16U-.SNR9)N-D[#
MM#MK:?3+>.YTLQ30PQJYN+< L=N#@]^E:YMX3C,,9P,#Y1P*DHJI3<G<BG24
M(J(BJ%4!0 !T %))%'-&4FC61#U5ER*=14&EE:Q#%96L#%H;:&,D8)2,#(IP
MMX5;<L,8/J%%244[L2C%;(*S=6\/:5KAC.J6:SM']UMQ4CVR"#CVK2HIQE*#
MO%V8JE.%2/+-)KL]2L=.LCIXL6M86M54*(2@*X'M7.^+O#UH/"LSZ590P75J
M ]N\($;)\PW8(QU&>.Y]ZZNFR1I-&4E170]589!K2G5E":E?K<QKX:G6IR@T
MM5;T_P"&/&O EIK%SK,L&G7KV$;1D3R% W3L%/4Y_$<U+8?#W5'\4&RN=BP0
M%)99UD',9) ('7)V-],?2O6X["TA;=#:P1MSRL8!YJJGA[18Y%>/2+!'4@JR
MVR @^HXKT99E)RE**M==CP89!!4X0F^;E;>[2MVM9_U^!8^'M(TW'V'3K>)A
MT<("W_?1YJKXDT^?5+46L>G6UTF58232X*$-S@;3V&,Y[UMT5YJJR4^=ZL]^
M6'INFZ25D^R7^16L%D2S5)+6*TV?*L4+[E5>V.!CZ8I-2L;;4M-GM+X P2J5
M8],>X/8BK5,EBCGB:*>-9(VX9'4$'\#4<SYN8T<$X<CU."\,^!-(BU.\>\F6
M_$$IABB<#:1M!W$9Y/S8_#\NA;P/X=9MRZ<L;>L4KH?T(K4@TK3[:82VUA;0
MR#H\<*J1VZ@5;KIJXJK.7,I/\OR.'#Y=AZ5/D=./W7_,\B\4>"+X:^_]CVUS
M/;/M&YPS;#CGYCG(]_PKL=)\(O'I-LAUS6H"L8!C2<(JGN I4D"NLHJZF.JS
M@H/H8T<GPU&K*JOM=.WI8XGQ+X,U"[T62*QUF_O'4AQ;W<JD/CMG Y],\5F?
M#CPI<VUX^K:E!&(]A2!7 8[MPRP],8(_&O0[JU6[A\MY)HQG.89"A_,57T_2
M8-,&+:2X*XP$DG9U'.> 3@4UC)^P=.^_D3+*J3Q<,0EMY_=O_F7J***X#V@K
M@/B5X9FOH(]4TZWC+0*QN=H 8KC(;WQ@^]=_69KRWD^E7%I8VHG:X@DC+&4)
ML)7 Z]>M=&&JRI55*)PYAAX8C#2IS7W;WZ')^$/#_BC1])9H+BT@\Y]_V6Z0
ML!QURIX)]*VKG4_$ME:RM>:+;W2*C%I+.\VD #D@,,_ES6Y8R7,D/^EVOV=E
MP /,#Y]^*L.N^-EW%=P(RIP1]*NIB'.HY3BG_7DS*A@52HJ%&<E9?UHU_D>,
M:+XPU@^(8-\ES>))*%6T^TN 23P 2?7UR*]'^V>++G_4:5I]B/\ IZN3(?R0
M?UHL?!&DZ?J:W]J)EG5MP.X8_+'>NAK;%8FC.2=."^9R9=@,51A*->H]^EOS
MM<\J\:>&/$]]?0WDZIJ!*!,6B$"+GI@G..>M='X<\"VL6CVW_"00M<W2Y/E2
M3,R1#/ "@XKLJ*B>.JRIJFM+=M#:GE&'A7E7E>3?1ZHI/8V]GI\D-CIUNR,N
MTVZ*J*X/!!XQTK)\-:2=)FG T>*T\Z1V,J2JQ"DY5?7 &*Z.BN959*+CW]3T
M)8>#J1GMR[:+_(IW>D:=?Y^VV%M.?62)6/YUY7XD\&B/Q$Z:42MK(_*F"7$!
MQSR%.1Z8S7L%%;8?%5*#NCDQV6T<9%*22=][:_H<O8^&;VVT^W73?$FH1(L:
MA1+$CJ!CLK#('L>E4/$]OXLLO#UR\6JQWB #>8K;RI0O<C:3^/M7;U%<QS2P
ME;:?R'SP^P-^AI1Q,N=2DD_5+_*Y53 4W2<(.2TMI)_DW8\H^'T6MW]Q<6]G
MJ-Q9V.W=+(J!QN]%W="<]1Z5WT7@W2O,$M^)]3F'_+2^F,OZ?=_2KFE:9<Z:
MOER7QN(LLP0Q!<%F+$Y'U-:5:8G%2G4<H:+R_I,PP&6PHT(PK+F:[ZV]%=I'
M')X*T1?&9E6V(185N!"&_=A]Q'3TXZ=/PXKL:QUT[5QJ1O#J-D6,8B*BQ?&T
M$G_GKUYK8K&M4<[7E>R\SKPE&-%2Y8<MW?I^@4445SG:17,?G6DL7EI+O0KL
MD/RMD=#UXKD-!\$'1M>-_P#9K4KNS&/M#MY((YP"@R>O4_XUVE%;0K3IQ<8[
M,Y:V%I5IQJ36L=@JC=:+IM]/YUW90S2<?,ZY/'2KU%9*3B[IG1*$9JTE<CM[
M>*U@6&WC6.)?NHHP!69XHL+#4M!FMM5NH[2%B-L[N%"-V//'X5KT549N,E+J
M14I1G3=-K1JQP7P^T32K"YFN8=4@O;T^9&(XW7*('QNP"3S@'/H?QKO:**NO
M6E6FYR,<)A886BJ4.G]=V8=U=7/]OV\Z:5>O%!%-&S*$^8LR8(^;I\IK;4[E
M!(*Y&<'J*6BHE+F25MC:G3<&W>]REJUW%:V,@E\S,B,JA(F?)Q_L@XJ'1+F"
M\T>&#8Y,<")*DL+*/NXQ\P&>E:=%',N6PG"3J<U]-K6_X/Z'-W?AC["LUUX:
MN9-.EP6:W3YH93CIL['MD8Q7FFE^*=8/B"W8S7=RK3 "S^V2A6)/"@EL_F2/
M7->WD9!'KZ5@V_@S1K74A?PQ2K<AMWF><V<]SU[]_6N_#XN$(R557OL>-CLL
MJ5)PEAI<J3U73Y+;]'U&_:_%EQ_J=,TZR'_3Q<M)C_O@"N1\=:-XEOH[1[DK
M?%=W[FQMGQ'G'/?->G45A2Q3I34XQ6AV8G+EB:3ISJ2=_/\ 161YYX*T+Q%;
M:-((]1;3,REOLT]EOSP.<L1C/MZ5T1M?%L8/EZEILQZCS+9ES[<-70T$9!'2
ME4Q4JDW)I:^2*H9?3HTE3C*6G]Y_E>QXAI;^(/\ A.8^;C^TO.'G!\_=SSN_
MV<?ABO;ZRH]!CCO/M0OKXRE54EILY"DD \=.3^=:M7C,1&NXM*UD8Y7@9X.,
MU*3=W?7^M^X4445Q'KA1110 4444 %%%% !1110 4444 %%%% !1110 5S=C
M_P E3UW_ + NF_\ H^^KI*YNQ_Y*GKO_ &!=-_\ 1]]0!TE%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !6;%_R-5W_P!>4'_H<M:1Z>E94>A&.]-U_:E^TK*J-EH\
M,JDD#[G^T?SK2%K.[,*O->/*KV?Z&K11169N%(RAU*MR",&EH)P* /,;/X;^
M7XO:&2\#6D 2X'R_.P+-A3V_@.37IU8,.H@^(II_L=^(I+>*)6-I(!N#R$]O
M]H5O5UXJK5J->TZ(\S+\-A\/&7L5NW^>@4445R'IA1110 4444 %%%% !111
M0 4444 %4YM7L(-6M],ENXEOKE6>*WS\[*HR3CL/<T:A/J$*I_9ME#=DD[Q+
M<>5M],?*V:X+6]3T2U^,'AIXKZPA2.*^^T,LR*%D95^_SPQ(/7GB@#M;GQ-H
MUIJ)L;G4(DN%=8W!SB-FQM5FZ*3D8!()R,=:+_Q+H^F7AM;Z_BAE4*S@Y(B#
M'"ER!A 2."V,UYI<W$$'@GQOHNH21OJ^H:E<-;6NX>;=>=M,#(O5@1C!' VG
MTJ9;B/1]'\>:;XDGC.I7H8P0NV)+Q7ME2,1]W^8%>.AH ]9K"\/_ /(<\4_]
MA5/_ $BMJCTVQ\00>%=$MH+ZSMKN"RBCNS=VCW&^0(H."LJ8Y#9SG.1T[Y.A
MVOB<ZQXD$6KZ2KC4D$I;2I6#-]DM^0/M VC;M&#GD$YYP #MZ*POLGBW_H-Z
M+_X)Y?\ Y)H^R>+?^@WHO_@GE_\ DF@#=HK"^R>+?^@WHO\ X)Y?_DFJEY_P
MF5M=6$46H:3.EU<&*61='FQ HB=]Y_TD\;D5><<N.>Q .HHK"^R>+?\ H-Z+
M_P"">7_Y)H^R>+?^@WHO_@GE_P#DF@#=HK"^R>+?^@WHO_@GE_\ DFJ&N3^+
M=%\.ZCJG]JZ+-]AM9;CRO[)E7?L0MMS]I.,XQG!H ZRBL+[)XM_Z#>B_^">7
M_P"2:/LGBW_H-Z+_ .">7_Y)H W:*POLGBW_ *#>B_\ @GE_^2:/LGBW_H-Z
M+_X)Y?\ Y)H W:*Y>S_X3*YNK^*74-)@2UN!%%(VCS8G4Q(^\?Z2.-SLO&>4
M//86_LGBW_H-Z+_X)Y?_ ))H W:*POLGBW_H-Z+_ .">7_Y)H^R>+?\ H-Z+
M_P"">7_Y)H W:*Y.:?Q;%XBL]+_M713]IM9[CS?[)E^7RGB7;C[3SGSLYSQM
M[YXO_9/%O_0;T7_P3R__ "30!NT5A?9/%O\ T&]%_P#!/+_\DT?9/%O_ $&]
M%_\ !/+_ /)- &[17+ZK_P )EI^C7MY;:AI-Y-;V\DL=M'H\VZ9E4D(,7).2
M1CH>O2K?V3Q;_P!!O1?_  3R_P#R30!NT5A?9/%O_0;T7_P3R_\ R31]D\6_
M]!O1?_!/+_\ )- &[16%]D\6_P#0;T7_ ,$\O_R35#3Y_%M_?:I;_P!JZ+'_
M &?=+;[O[)E/F9ABEW8^T\?ZW&.>F>^* .LHK"^R>+?^@WHO_@GE_P#DFC[)
MXM_Z#>B_^">7_P"2: -VBL+[)XM_Z#>B_P#@GE_^2:J2?\)DFLVUFNH:2T,U
MO+*]R-'FVQLC1A4/^DXRP=B.?X#P>P!U%%87V3Q;_P!!O1?_  3R_P#R31]D
M\6_]!O1?_!/+_P#)- &[16%]D\6_]!O1?_!/+_\ )-4-<G\6Z+X>U'5/[5T6
M;[#:RW'E?V3*N_8A;;G[2<9QC.#0!UE%87V3Q;_T&]%_\$\O_P DT?9/%O\
MT&]%_P#!/+_\DT ;M%87V3Q;_P!!O1?_  3R_P#R31]D\6_]!O1?_!/+_P#)
M- &[17+Z;_PF5[:O+<:AI-HZW$T0C?1YLLJ2LBOS<CA@H8>S#D]:M_9/%O\
MT&]%_P#!/+_\DT ;M%87V3Q;_P!!O1?_  3R_P#R31]D\6_]!O1?_!/+_P#)
M- &[17)S3^+8O$-GI?\ :NBG[3:SW'F_V3+\OEO$NW'VGG/FYSGC;WSQ?^R>
M+?\ H-Z+_P"">7_Y)H W:*POLGBW_H-Z+_X)Y?\ Y)H^R>+?^@WHO_@GE_\
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MKVG:MH%M!XXUQDU+4'M9B]O8$JHM9YLKBVX.Z)1SG@GZC7_X1?5_^A[\0?\
M?C3_ /Y%H Z2BN;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^
M1: .DHKC=:\.>*(- U"70_&FN7.IQVLC6<,L.GA))@I**W^C#@M@'D?45>_X
M1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>
M_$'_ 'XT_P#^1: .DHKF_P#A%]7_ .A[\0?]^-/_ /D6LC1M,U[4=6\06L_C
MC7%33=02UA*6]@"RFU@FRW^C<G=*PXQP!]2 =W17-_\ "+ZO_P!#WX@_[\:?
M_P#(M'_"+ZO_ -#WX@_[\:?_ /(M '245S?_  B^K_\ 0]^(/^_&G_\ R+5&
M_P##GBB.]TQ=/\::Y+;R73+?.\.GYBA\F0AE_P!&'/F")>_#'CN #LJ*YO\
MX1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2BN;_ .$7U?\
MZ'OQ!_WXT_\ ^1:R/%FF:]H7@O6]7M/'&N/<:?I\]U$LMO8%&9(V8!@+8'&1
MS@B@#NZ*YO\ X1?5_P#H>_$'_?C3_P#Y%H_X1?5_^A[\0?\ ?C3_ /Y%H Z2
MBN;_ .$7U?\ Z'OQ!_WXT_\ ^1:/^$7U?_H>_$'_ 'XT_P#^1: .DHKB=+T/
MQ+=:EK,-[XR\00P6EZL-F_V2Q7SHC;PN6R;7#?O'D7(X^7'4&M+_ (1?5_\
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MMDF\>9)(TDASD]7=CCMG P*\P\87KZ>FK:2VE65C/)#9O<WFG,51[1Y]C*_
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MPR"/0UDZ7X6T?1KD3Z?:LDBQF*,R3R2B%"<[(P[$1KP/E7 X'I6O10 4444
M%%%% !1110!E:YX:TWQ'#Y.K+=2PE"C0Q7LT*.#V94<!OQ!J#_A#]'-C%:-'
M>.D,GFPR/J%PTL+;=OR2%]Z#'&%('7UK<HH R'\+:,^DQ:;]B"VT,GG1;)'6
M1).<R"0'>'.3ELY.3SS5O3-*LM'M#;:=#Y4;.9')8NTCGJS,Q+,Q]22:N44
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M-.TVTTFQ2TTZ!8($)(4$DDDY))/)))R2>2:M44 %%%% !1110 $9&#R*P(?
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MT_3;V_U'RH=3C\VV_<NS,F,[BH!*@ ]357P1XY@\21);74T1U"03SQK"A"/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5G
M7>@:7?ZO::I>64<U[9 BWF?),>>N!T_&M&B@ HHHH *SH] TN+7Y=;2RC&I3
M1B)[GDL5&./;H.E:-% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
5%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img243551639_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_13.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '% =,# 2(  A$! Q$!_\0
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M;I=UMC1D3FWD]\=5/KVK:H:&XVU"BBBD2%%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4R5_*B>3:S;03M49)^E/HH YC5?$*RZ1>1_V7J:[H7&YK8@#@]:V])_Y ]E_
MUP3^0INM?\@._P#^O=__ $$T[2?^0/9?]<$_D* .-\=>!?[4SJ^D#RM3C^9E
M3CS<=QZ-_.E\!^.?[74:3JK>7J<7RAFX\W'_ +-7>UY]X[\#&^9M:T8&/48_
MG=$X\S'<?[7\ZUC)27+(ZZ=2-2/LJOR?;_@'H-%<-X$\<+K<0TW4F$>IQ#'S
M<>:!_P"S>HKN:B47%V9SU*<J<N610U?3WU*P:&*XDMYU(>*5#C:XZ9]1ZBGZ
M9-=RV,1U"%8;L B1%;()!QD>QZ_C5RLC6],N+HPWVGR^7J-KDQ;C\L@/5&]C
M^E):Z!%W]UFO14<,OF+ABHE4#S$#9VG'2I*1 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%,66-W=%=69" R@\KWYH ?11
M10 4R6011/(P8A020HR?P%/HH YC5?$MG+I%Y&MM?@O"Z@M:.!R#U.*V])_Y
M ]E_UP3^0INM?\@._P#^O>3_ -!-4_#6KVNHZ9%#$62>WC5989!M=>.#CT/8
MT6&DVKFU1110(\Z\=^!WN'.NZ(#%?Q'?)''QOQ_$/]K^=:'@7QNGB" 6-\1'
MJ<0Y!X\T#N/?U%=K7FWCCP3*LY\0: &BO(CYDL47!8C^)??U'>M8R4ERR.NG
M4C5C[*I\F>DT5QW@?QM%XCM?LEV5CU.(?.O02#^\/ZBNQK.47%V9SU*<J<N6
M1CW6DS)K4.J:?(L<K82[C?.V9.Q_WAV-:D%Q#=1"6"5)8R2-R-D9'6I*Q8].
MCT74+K48[E8=/E4R7$!7A7_OKZ9[BC<+\RL]S:HID4L<T22Q.KQN RLIR"*?
M2("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,'Q/I,
M6JV\&^\%O)"Q9 [[5D]0W(./I67X2TJ"WU2]N7@$$^X+$HNO-#+M&2.>1GUK
M=UW1++6K6-;S"^2X='_N^N?4&I++0M*L)Q<6EC!#+C =%P<&@#1HHHH *9+(
ML,3R.<*@)) SQ3Z* .9U7Q1I,VD7D:3R%GA=0/(<<D'VJ]8:;:S6VFZ@8A]K
MAMU5) 2"05Z''45:UH#^P[_C_EW?_P!!-.TG_D#V7_7!/Y"@:;6Q4TK6_MES
M)87L/V34HN6A)R'7^^A[C^5:]130"169-J3;"J2[02F?2LW1[S46EEL-5MR+
MF$ BYC'[N=?4>A]13WU132>J->BBBD0>9^./!4UM<'Q%X?#17,3>9+%%P<_W
MU_J*WO!/C6#Q+:"WN"L6I1+^\CZ!Q_>7^HKKJ\Q\;>"I[*Z/B/P[NBGB/F2Q
M1<$'NRC^8K6,E-<LCLA.-:/LZF_1_HSTZD95=2K*&4C!!&017)^"?&D'B:S\
MF8K%J40_>1]-X_O+76UFTXNS.:<)0ERRW,.VAM?"T$BRW;+82S@0(XX@+?PY
M_NYZ9Z5N5#=6L%[:R6US&LD,BE75NA%9MK/;Z(UEH\]S-(\BL()9A]['\&[U
MQ^>*-_4'[VO4V****1 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% %74@ATVX$EM]I38<PY W^V3TKCM+CU%9W?2]4M(L#<FF"?S@?4%CT_"
MNF\1O;+H-TEW<K;QRH4#GGD]!@<GZ5@^&([>XUEY;22S$4&]MJ0F.;Y\8!!
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M=I]ZT-)_Y ]E_P!<$_D*HZOI6GIHM\RV-L&$#D$1#@[35[2?^0/9?]<$_D*
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M+X^ZV.Q[&MNAJPG&P4444B0HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3BQ<P-L\X#Y9QV<?U'K6G2>A+5G8****!!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!E
MZY!$]BUQ->7=M' "[&V?:6]NG-9.@R(+Z+S;C5!+)YBK#=2JZ_+C.<#KR*W-
M:DAAT:[>XB\Z(1G='G&X?7M]:YCPZ+:'Q"ZQB>='\Q(9Y9]^&7:7P,=.0,^U
M ':T444 %!.!DT4V2-)HFCD4,C A@>XH H:S+&=#OP)$_P"/=_XA_=-2Z3_R
M![+_ *X)_(5CZMX8T6'1[V2/3H5=('92!T(!K8TG_D#V7_7!/Y"@"Y1110 4
M444 %%%% !1110 4444 (5#8R.G0^E8^GOJMGJ+V-\K75LV7@O% ! _N./7T
M(ZULTUT62-D<95@01ZBFF4G;0=4<\$5S \$\:R12 JR,,@BL?3[2YT%YTENU
MDT=$+QM,Q,D'JN>Z_J*V8I8YHEEB=7C<95E.010U8&K/0\@UG2-2^'&NKJ^D
MEI-,E;#(>@']QOZ&O3M UZR\1:8E[9OD'AXS]Z-O0U>NK6"]MI+:YB66&1=K
MHPR"*\BU72]3^&NN#5-++3:7,V&5N1C^XW]#6JM45GN=::Q*Y9?&OQ/4M9T^
M74+(+;7+V]U$PDAD4\!AV([@]"*GT^:YFL87O(!!=%?WD08$ ].#Z=ZK:%KM
MGXATR.^LGRK<.A^\C=P:BUG3+F6>#4=-D"7]OP%<X29#U1OZ'L:S\F<UG\$M
M#8HJ.*=)2R!T,J8\Q%8$H2,X-25)F%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %'6+AK
M31[N=85F*1$^6PR#]?:N;\/74PU>*U=].*H)4$5M!M:/!'/7@'/XUJ>([ZZM
MY["TMKR"S^TL^^:900 JYQSQS6/X=U&XGU>RGEO+:=M0AD:6*-%!AV8P,CG'
M/>@#MJ*** "BBF2QK-$\3C*."I'M0!4UK_D!W_\ U[O_ .@FG:3_ ,@>R_ZX
M)_(5BZKX6TB'2+R5+4ATA=E/F-P0#[UM:3_R![+_ *X)_(4 7**** "BBB@
MHHHH **** "BBB@ HHHH 1E5U*L RD8((X-8T-C#X:@O+F%KA['_ %@M(UW^
M6>^P=<=\5M44TRE*VG0@L[RWU"UCNK65989!E64TMW:07UI+:W42RPRJ5=&&
M016=/:?V+;W=UI%@)999!++ K[0WJ5'0''YU;TS5+75K,7-JY*YVLK##(PZJ
MP[$46ZH;5O>CL>3ZC8:I\,]>&H:>7GTF9L%3T(_NM[^AKU31=:L]>TV.^LI
MT;#YE[H>X/O5B]LK?4;.2UNXEE@D&&1AP:\CO;/5?ACKPO;(M/I$[8*GH1_=
M;T8=C6NE1>9U)K$JS^-?C_P3TV]T5GU6'5+"<6UV"%FXRL\?HP]1V/:KUI?V
MM\9EMIED:&0QR*."C#L14&C:S9Z[IL=]92!XW'([J>X/O39='@&L)JL+217
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M08:-QU4U?J7H0TT[,****!!1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!')+$CI'(ZAI,A58_>]:S;"XTR/4)
M;6SM%@<LP,B0A%D9?O#(ZD5#XF6YDM8HXD<QL3O:.+S&! ^7 [<]^U)H^CRV
M5RMS,H=Y$RQ9R6C8XR .ASZ]>.<T ;M%%% !113)8Q+$\99E# C*G!'T- %3
M6O\ D!W_ /U[R?\ H)IVD_\ ('LO^N"?R%8FJ^'88M(O)!J&I-MA<X:Z8@\'
MJ*V])_Y ]E_UP3^0H N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !63K&C-?/%>6<WV;4H/]5-U!'=6'=36M133L.,G%W15@O89+AK-IHS>1HK2
MQJ>F>X]J34M-M=7T^6RO(A)!*,$'M[CT-0:EHT.H3V]TLCV]Y;MF.>/[V.ZG
MU!]#3[75[6YU&XT\%X[J#[T<@P67^\OJ*/-%6^U$\I5M5^%WB#8VZYT>Y;CT
M8?T8?K7K>G:C:ZK8Q7EG*)8)1E6'\C[U'JVDV>MZ=+8WL0>&0?BI[$'L:\H@
MGU3X7^(?L\^^XT>X;((Z,/4>C#T[UKI47F=6F)7]]?C_ ,$]3U>+4!;";2GC
M6XC?S&B8#$X[J3V/O5G3[PW]C%<F"6!G'S12KAE/0@TMC?6VI645W:2K+!*N
MY66J&LVFH.T-]I<Y%S;Y_P!'=OW<ZGJI]#Z&L_)G*M?=>AKT5'!(9849T,;E
M06C)!*D]CBI*D@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,K6-2N;.2TM;&&.2[NF98_-8A%"C))QS6?H/B
M"^O;J*WU&WMU,PD,4D!.-R'#*0?YU/XHACEMK=KFPDNK5'+2O"Q$L/\ M+CD
MCKFJ^AO:7-[ =)L%&G6L;1K>/G+DGD)GD\]2: .FHHHH ***9*ADB= [(6!&
MY>H]Q0!4UK_D!W__ %[O_P"@FG:3_P @>R_ZX)_(5AZIH$T6D7CG6]2<+"YV
MM*,'@\'BMS2?^0/9?]<$_D* +E%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %4[K3+2\N;:YEC_ ']LVZ*120P]1D=1[5<HH&FUL96G:VMU
M?SZ?=0FUOHB2(F.1(G9U/<?RJ;6='L]=TV2QOH@\3C@]U/8@]C5B>UBED6;R
MXS<1AA%(RY*$BL[1]6N)[B73M2@\G4(1N)0'RY4[.I_IVJO-%_WH:6/,[6ZU
M7X8:\;6Z#7&D3MD$="/[P]&'<5ZY97MOJ-G%=VDJRP2KN5U[U7UK1;/7M-DL
M;V,-&_W6[H>Q'O7E=A?:I\,M>-A?;Y])G;(8="/[R^A]16FE1>9TM+$JZ^-?
MC_P3TS4M*N&OXM4TV417JX21')\N://W6'J.QK2ANH;AI4BE1WB;9(JG)5O0
MT6EW!?6L=U;2K+#(NY'4\$51GT93K$6IVDQMYQ\LX4?+.GHP]1V-9>3.6]])
M=#4HJI8:E:ZDDC6TFXQ.8Y%(PR,.Q':K=(EIK1A1110(**** "BBB@ HHHH
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M@8.<<5N:3_R![+_K@G\A0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU8_M?6/^A=G_ / F+_&@#;HK$_M?6/\ H79__ F+_&C^U]8_Z%V?_P "8O\
M&@#;HK$_M?6/^A=G_P# F+_&C^U]8_Z%V?\ \"8O\: -NBL3^U]8_P"A=G_\
M"8O\:/[7UC_H79__  )B_P : -NBL3^U]8_Z%V?_ ,"8O\:/[7UC_H79_P#P
M)B_QH VZ*YV7Q%J,-U!;2:!.)9]WEKY\?..3WJ?^U]8_Z%V?_P "8O\ &@#;
MHK$_M?6/^A=G_P# F+_&C^U]8_Z%V?\ \"8O\: -NBL3^U]8_P"A=G_\"8O\
M:/[7UC_H79__  )B_P : -NBL3^U]8_Z%V?_ ,"8O\:/[7UC_H79_P#P)B_Q
MH VZ*Q/[7UC_ *%V?_P)B_QH_M?6/^A=G_\  F+_ !H VZ*YQ/$>HO>R6:Z!
M.9XT#LOGQ\ ].<^U6/[7UC_H79__  )B_P : -NBL3^U]8_Z%V?_ ,"8O\:/
M[7UC_H79_P#P)B_QH VZ*Q/[7UC_ *%V?_P)B_QH_M?6/^A=G_\  F+_ !H
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MIS6C6;!K5O+(T<D<]LPC,H\]-NY!U(_SFEL]9MKR=(5CFB:1=\1E3:)%]5H
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5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img243551639_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_14.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %P F\# 2(  A$! Q$!_\0
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M%CD^@'- &A16+_PE%CYQA\F]\T+N*?97SCIGI3;CQ9IUI T]S'>0PK]YWMG
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M,]D95]H^GZGE7A[_ %^L_P#81F_G6W6)X>_U^L_]A&;^=;=5+<VJ_&S.MO\
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MY_J2UE>)O^19U'_KBU:M97B;_D6=1_ZXM3CNBZ?QKU.^\/\ _(N:9_UZ1?\
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M!--?Q!K_ 'E^K$JMJ/\ R#+O_KB_\C5FJVH_\@R[_P"N+_R-);A'='0> O\
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MIC_KYB_G4%"^%"A_"7J_T ]#]*L?#'_D3U_Z^9?_ $(U7/0_2K'PQ_Y$]?\
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MZUZ-<_\ 'K-_N'^53/H8U]X^GZGEWA+_ ) (_P"N\O\ Z%6Y6'X2_P"0"/\
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M_81D_I4OQ+_Y%JW_ .OZ'^M1?#7_ (\M9_[",G]*E^)?_(M6_P#U_0_UI?\
M+PG_ )B?F5QT'TILG^J?_=/\J<.@^E-D_P!4_P#NG^5 BY\-/^1/3_KXE_\
M0JK?$?[WA[_L(K_Z":L_#3_D3T_Z^)?_ $*JWQ'^]X>_["*_^@FFOX@U_O+]
M6)5;4?\ D&7?_7%_Y&K-5M1_Y!EW_P!<7_D:2W".Z.@\!?\ (DZ9_P!<OZFL
M/QO_ ,C?X>_[:?RK<\!?\B3IG_7+^IK#\;_\C?X>_P"VG\J%\;^8H?QY?/\
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MF@ HHHH RO$O_(M:C_UP;^5:<?\ JD_W169XE_Y%K4?^N#?RK3C_ -4G^Z*
M/,K7_D</$?\ U\#^5:M95K_R.'B/_KX'\JU:VEN=U3?Y+\C)O?\ D;?#7_7W
M_2O4*\OO?^1M\-?]??\ 2O4*F>R,J^T?3]3RKP]_K]9_[",W\ZVZQ/#W^OUG
M_L(S?SK;JI;FU7XV9UM_R4;1_P#KA)_6O1KG_CUF_P!P_P J\YMO^2C:/_UP
MD_K7HUS_ ,>LW^X?Y5,^AC7WCZ?J>7>$O^0"/^N\O_H5;E8?A+_D C_KO+_Z
M%6Y52^)FM7XV5?#O_)2[C_L'#_T*NTU[_D7M2_Z]9?\ T$UQ?AW_ )*7<?\
M8.'_ *%7::]_R+VI?]>LO_H)J9?$C*M_$CZ(\_\ #/\ R+=C_P!<ZUJR?#/_
M "+=C_USK6JI;LTJ?&_4A\%?\CKK_P#USB_K7H%>?^"O^1UU_P#ZYQ?UKT"H
MJ;F.)^/Y+\@HHHJ# **** "N8\37\/VRUL)5BP27*W,)>.08[$=Q73UC>(-6
M_LF"&411,68C?*<*H'7GU/:@"]I;B33(&41!=O A4J@'L#5NJNG78O[&.Y5-
MBN6P,YX#$ _CC/XU:H **** ,=/^1QE_Z\$_]&-6Q6.G_(XR_P#7@G_HQJV*
M (KG_CUF_P!QOY5G>&/^19T__KB*T;G_ (]9O]P_RK.\,?\ (LZ?_P!<15?9
M+7P/U_S-:N-^)?\ R+5O_P!?T/\ 6NRKC?B7_P BU;_]?T/]:</B1>'_ (L2
MN.@^E-D_U3_[I_E3AT'TILG^J?\ W3_*J-2Y\-/^1/3_ *^)?_0JK?$?[WA[
M_L(K_P"@FK/PT_Y$]/\ KXE_]"JM\1_O>'O^PB/_ $$TU_$&O]Y?JS,O[^^L
MHYIA8PR01\[O/()'TVTD\M[)I]X+FUBB3[.Y!2;><X],"GZY_P @6[_W*GU#
M_D%77_7!O_0:$6FK+0Z#P%_R).F?]<OZFL/QO_R-_A[_ +:?RK<\!?\ (DZ9
M_P!<OZFL/QO_ ,C?X>_[:?RI+XW\S.'\>7S_ %):RO$W_(LZC_UQ:M6LKQ-_
MR+.H_P#7%J<=T73^->IWWA__ )%S3/\ KTB_]!%:-9WA_P#Y%S3/^O2+_P!!
M%:-9/<XY_$S&UZ'4I/(?3HQ(RK(KJ9=GWEP#^!I=#AU%&G?4(1#N"*B"7?T7
M!/XFKFJ_:/[,G^S/LEQPVX+QGG!/ .,\U0\-RW<UK(;J3=C:JAI5D88'))'J
M:1)MT444 %9.J_\ (5T;_KX?_P!%M6M63JO_ "%=&_Z^'_\ 1;4 7[W_ (\+
MC_KDW\J\Q\(?\BS:_P"\_P#Z&:].O?\ CPN/^N3?RKS#PDZIX8M"S*OS/]XX
M_C-:1^%G51_AOU7ZES3/]?J'_7R?Y"I_"W_)1M3_ .O*.JNF2Q>?J'[U.;D_
MQ#T%6O"W_)1M3_Z\HJM]366TO3_(ZWQ1_P BMJ?_ %[/_*N)\/\ _(O6'_7$
M5VWBC_D5M3_Z]G_E7$^'_P#D7K#_ *XBIC\)G2_A/U_0TJC\"?\ (S^)/]Z'
M^1J2H_ G_(S^)/\ >A_D:/LL?_+N7I^J-KQ__P B+JW_ %R'_H0K!T__ )!M
MK_UR7^5;WC__ )$75O\ KD/_ $(5@Z?_ ,@VU_ZY+_*B/P"I_P +Y_HBR.HI
M/AOUUW_K]_I2CJ*3X;]==_Z_?Z4?98W_  I?+\R?XG?\BF/^OF+^=05/\3O^
M13'_ %\Q?SJ"A?"A0_A+U?Z >A^E6/AC_P B>O\ U\R_^A&JYZ'Z58^&/_(G
MK_U\R_\ H1H?PL)_PGZK]3LJ***R.0**** "H;L7#6L@M619\?(7&1GWJ:B@
M#F] TJ\LY8I+FTBA.UMVRX9@"?1>E=)7(:'=W0UEHKB[4KO8NS7"L)#M  4?
M4$XKKZ "BBB@#*\2_P#(M:C_ -<&_E6G'_JD_P!T5F>)?^1:U'_K@W\JTX_]
M4G^Z* /,K7_D</$?_7P/Y5JUE6O_ ".'B/\ Z^!_*M6MI;G=4W^2_(R;W_D;
M?#7_ %]_TKU"O+[W_D;?#7_7W_2O4*F>R,J^T?3]3RKP]_K]9_[",W\ZVZQ/
M#W^OUG_L(S?SK;JI;FU7XV9UM_R4;1_^N$G]:]&N?^/6;_</\J\YMO\ DHVC
M_P#7"3^M>C7/_'K-_N'^53/H8U]X^GZGEWA+_D C_KO+_P"A5N5A^$O^0"/^
MN\O_ *%6Y52^)FM7XV5?#O\ R4NX_P"P</\ T*NTU[_D7M2_Z]9?_037%^'?
M^2EW'_8.'_H5=IKW_(O:E_UZR_\ H)J9?$C*M_$CZ(\_\,_\BW8_]<ZUJR?#
M/_(MV/\ USK6JI;LTJ?&_4A\%?\ (ZZ__P!<XOZUZ!7G_@K_ )'77_\ KG%_
M6O0*BIN8XGX_DOR"BBBH, HHHH *P?$PD,5J6,_V0.?/\@C=T^7@]>:WJYWQ
M28XQ8S.Z[HW8K&T)DW_+@\#TH F\-#4%MG%Z[O&0K1&0@D9SD9'H OZUN51T
M:02Z3;NJJH((VK&4 P2/NGI5Z@ HHHH QT_Y'&7_ *\$_P#1C5L5CI_R.,O_
M %X)_P"C&K8H BN?^/6;_</\JSO#'_(LZ?\ ]<16C<_\>LW^X?Y5G>&/^19T
M_P#ZXBJ^R6O@?K_F:U<;\2_^1:M_^OZ'^M=E7&_$O_D6K?\ Z_H?ZTX?$B\/
M_%B5QT'TILG^J?\ W3_*G#H/I39/]4_^Z?Y51J7/AI_R)Z?]?$O_ *%5;XC_
M 'O#W_817_T$U9^&G_(GI_U\2_\ H55OB/\ >\/?]A%?_0337\0:_P!Y?JS.
MUS_D"W?^Y4^H?\@JZ_ZX-_Z#4&N?\@6[_P!RI]0_Y!5U_P!<&_\ 0:%T*6R]
M?\CH/ 7_ ").F?\ 7+^IK#\;?\CAX>_[:?RK<\!?\B3IG_7+^IK#\;_\C?X>
M_P"VG\J2^-_,B'\>7S_4I3ZU';G]Y9WH&[8&\K@GMCFJFN7?VKPSJ?\ H]Q%
MMA/^M3;GZ<U=UG_CT@_Z^8_YU%XG_P"1:U'_ *XM5*UT:PM>.G4[[P__ ,BY
MIG_7I%_Z"*T:SO#_ /R+FF?]>D7_ *"*T:Q>YPS^)F5XA7SM)DMQ'(YDQ@I'
MO P0>1Z<5#X<W?9YMT$<7S#A+<19X]!UJSK\:R:)<HTBH"!RP)!Y'&!R<],>
M]5O#;1FVDV1VT9.UBL$13&1D9!I$FW1162NO1/YXCMY6*2K%&.!YI89!'H/<
MT :U9.J_\A71O^OA_P#T6U7;*\6\A9]C1NCE)$;&58=1D<51U1E;5='PP/\
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MY*-J?_7E'5FJWA;_ )*-J?\ UY1U2V9:^&7I^J.M\4?\BMJ?_7L_\JXGP_\
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MAEZ?JCK?%'_(K:G_ ->S_P JXGP__P B]8?]<17;>*/^16U/_KV?^5<3X?\
M^1>L/^N(I1^$FE_"?K^AI5'X$_Y&?Q)_O0_R-25'X$_Y&?Q)_O0_R-'V6/\
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M ,BOJ'_7+^M;"_<'TI]"W\"]7^@M%%%(@P_%'_'C9_\ 7[#_ .A5N5A^*/\
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M7>$O^0"/^N\O_H5;E8?A+_D C_KO+_Z%6Y52^)FM7XV5?#O_ "4NX_[!P_\
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M^2C:G_UY1U9JMX6_Y*-J?_7E'5+9EKX9>GZHZWQ1_P BMJ?_ %[/_*N)\/\
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MO_H51^&?^1;L?^N=2:/_ *BY_P"OJ7_T*K?4WGO+U+?@K_D==?\ ^N<7]:]
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M_'A<?]<F_E7F/A'_ )%BU_WG_P#0S7IU[_QX7'_7)OY5YCX1_P"18M?]Y_\
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M5ZQ]@LL_\>D'_?L?X5C:+96K:GK0:UA(%T ,QCCY!6O/%W=CJ]O3ES2L_O\
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M **** "BBB@ HHHH *R=5_Y"NC?]?#_^BVK6K)U7_D*Z-_U\/_Z+:@"_>_\
M'A<?]<F_E7F/A'_D6+7_ 'G_ /0S7IU[_P >%Q_UR;^5>8^$?^18M?\ >?\
M]#-:1^%G51_AOU7ZFW5;PM_R4;4_^O*.K-5O"W_)1M3_ .O*.J6S+7PR]/U1
MUOBC_D5M3_Z]G_E7$^'_ /D7K#_KB*[;Q1_R*VI_]>S_ ,JXGP__ ,B]8?\
M7$4H_"32_A/U_0TJC\"?\C/XD_WH?Y&I*C\"?\C/XD_WH?Y&C[+'_P NY>GZ
MHVO'_P#R(NK?]<A_Z$*P=/\ ^0;:_P#7)?Y5O>/_ /D1=6_ZY#_T(5@Z?_R#
M;7_KDO\ *B/P"I_POG^B+(ZBD^&_77?^OW^E*.HI/AOUUW_K]_I1]EC?\*7R
M_,G^)W_(IC_KYB_G4%3_ !._Y%,?]?,7\Z@H7PH4/X2]7^@'H?I5CX8_\B>O
M_7S+_P"A&JYZ'Z58^&/_ ")Z_P#7S+_Z$:'\+"?\)^J_4[*BBBLCD"BBB@ H
MHHH **** "BBB@#*\2_\BUJ/_7!OY5IQ_P"J3_=%9GB7_D6M1_ZX-_*M./\
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M_P!_TJ ZW?B^6T_L=_-:,R >>O3.* -VBLG^T=4_Z S_ /?]*/[1U3_H#/\
M]_TH UJ*R?[1U3_H#/\ ]_TJ%-;OWO);5='D\V-%=AYZ]&SC^1H W**R?[1U
M3_H#/_W_ %H_M'5/^@,__?\ 2@#6HK)_M'5/^@,__?\ 2H(=<OY[B>!-'<O
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B,"@"?3()[;2[:&Z??.D85VSG)Q5NBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img243551639_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_15.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %S 8T# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#$N/^1TL?^O*7_P!"2MNL2X_Y'2Q_
MZ\I?_0DK;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q+C_D=+'_ *\I?_0DK;K$N/\ D=+'_KRE_P#0DK;H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M -"2MN@ HHHH **** "BHYIX;>,R3RI$@_B=@!^M$,\-Q&)()4E0]&1@1^E
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M %\TX;,>'VGZ?JC;HHHH*"BBB@"K\._^1B\2_P#79?YM7HE>=_#O_D8O$O\
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MQ_R.EC_UY2_^A)6W6)<?\CI8_P#7E+_Z$E;= !7ED?\ R4/Q#]$KU.O+(_\
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M3^M>B5YW\//^1D\2?]=$_K7HE*I\1&)_B?)?D%>56'_(Z>)O^OFO5:\JL/\
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MC_Y*'XA^B5I3ZG3A]I>GZHV:***"@HHHH I^ _\ D=?$?^['_,UZ-7G/@/\
MY'7Q'_NQ_P S7HU%3XB,3_$^2_(*\KM_^1_\2?\ 71?Y"O5*\KM_^1_\2?\
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M%HYK>Y;<(E'(P3R>>E6=,T)I;J:XO["&VB<*/L:D.A8?\M/8]OIUKI0 !@#
M':@ HHHH **** "H;NX%I:2W!C>01J6*H,DCVJ/4KY--TZ>\>-Y%B7.Q!R?8
M5EW4\?B;P^PTZX42MAO+<X.0>4<=1Z4 9^M:W)>V\ L#:RV=S&2OFM@38Y9<
MY^7 _'-/TG394U.RO[=;K[)<VY6:&Z;=Y0'*@'J>?TJ?2]":2YN+F_L8;>*0
MJ5L@0Z*XZOZ GVKI ,# Z4 %%%% !1110 5%=3_9K66?8TGEJ6VIU./2H-1U
M*'3+=9)0[L[!(XXQEI&/0 5G7$H\2^'I5LG,,Q/,<AP0RMRK8Z XQ0!F:SKD
ME]#"+(6TUC/'N E;'G8Y9=V?E*X^N2*GTC398=4M[V$71M+JVQ-%=')BQ@H/
M4]3^%2:7H1DO9KR_L(+:-MNVS4AT#CK)Z GI_.NEH **** "BBB@ HHHH **
M** "BBB@ HHHH *HZEJUII2(UR[9<D(D:%V;'7 'I5ZH)+:(W N_*#7"(41O
M0'DC]!0!Q5]JE_#X@DO=(EEO#<PI)#:D$I)%CDC^Z01^.<5UT5I!=R6NHRP%
M+I8^"<J0".0?_KUE^%+#4K2Q1M0*Q;4V1VZ@':,DY)]3GIVKHJ "BBB@ HHH
MH *IZGJ=KI%DUW=LRQ*0I*J2<GVJY6?K=C+J&DS6\!03\-&7Z;@<C/M0!R.I
MW-Y_;45Y]J1(Y)?,L[EKG$'E*N2I4=2?>NHTY4UBRT_5+NU$5VJEEP2"N>/R
M(YP:IZ/X6BL&EDNFCN1.1(T#1 QQR>J ]!71=* "BBB@ HHHH **** &M&C,
MK,BEE.5)'(^E4;'36L=1OYTD'D73K((\?=?&&/XX%:%% !1110 4444 %%%%
M ')ZW#J\$VHW#M]HTJ9!&T"C+Q+MP9%]<'DBKNA^'HK"==3:YDFO)X@)I,!5
MD';Y<<8K?HH **** "BBB@ IDS,D+NB;W5257.-Q]*?10!Q%^+DSVZ:]=HJS
M0O.I4;#:R <;2.3UQ5_PSH,]E.E[<)!$1 (E6 D^;DY+N3W/IVS6Q=Z-97VI
M6U]<QF26V!$:D_*">^/6M"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img243551639_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_16.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA=&4@36]R
M;F5A=6QT    !9 #  (    4   0J) $  (    4   0O)*1  (    #-C$
M )*2  (    #-C$  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#(Z,34@,3 Z,3DZ,#8 ,C R,SHP
M,CHQ-2 Q,#HQ.3HP-@   $L 80!T &4 ( !- &\ <@!N &4 80!U &P =
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" +B!$@# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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ML_"4MB-1MYVBO)"@FC VQD8^]DCL<_@:WY)4AA>65@J(I9F/8#J:X_XJ:/\
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MN/ ( ))()! '?%$:47%/EO?S'3P\)0A)0O??7;4[+6OB%I.C:3IVJ;)[NPU
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI^TM;5K[G;T^YM>84445B=(4444 %%%% !1110 4444 %%%% !1110 4444
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M$-CXPTV_B:-;G59'@D="-K!5VN/49_,9%;4N77F.K#N"4N=:&UH>I7=SX_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH I6'_ !^ZG_U]+_Z)CJ[5*P_X_=3_ .OI?_1,=7: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0!M0 [,GINS7'OXCUF=KSQ#;ZKMLX+T06]EC_CX7(^4#UVD'UZ]* /4:***
M"BBB@ HHHH **** "BBB@ HHHH **** *5A_Q^ZG_P!?2_\ HF.N;N?^0_JW
M_7PG_HB*NDL/^/W4_P#KZ7_T3'7-W/\ R']6_P"OA/\ T1%0 5I^%?N:I_U^
MC_T3%696GX5^YJG_ %^C_P!$Q4 4M8_Y&J;_ *\H/_0YJAJ;6/\ D:IO^O*#
M_P!#FJ&@"[X;_P"0YJ/_ %[V_P#Z%-4&L?\ (U3?]>4'_H<U3^&_^0YJ/_7O
M;_\ H4U0:Q_R-4W_ %Y0?^AS4 0U=\-_\AS4?^O>W_\ 0IJI5=\-_P#(<U'_
M *][?_T*:@#I**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#!\6R:"FDJ/$H#0,_[M1G=N_V<<UST7BCP1;V=K;Q0R>59R>="
MGE,</@_-R>3SWK8\5VTW]K:)J*69O8+6=TEA S_K %#8YZ$9KF[QKZS#:)::
M%(U_%>F2TOEC^4(9-^<XZ8.TC.,?2@#TNBBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@"E8?\?NI_\ 7TO_ *)CKF[G_D/ZM_U\)_Z(BKI+#_C]U/\ Z^E_
M]$QUS=S_ ,A_5O\ KX3_ -$14 %:?A7[FJ?]?H_]$Q5F5I^%?N:I_P!?H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?\: "P_X_=3_ .OI?_1,=<W<_P#(?U;_ *^$_P#1$5;%EJ^FI=Z@6U"U4/<
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MK2O^@G9_^!"_XT?VUI7_ $$[/_P(7_&@"[15+^VM*_Z"=G_X$+_C1_;6E?\
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MVCY(^@?#?_(JZ3_UY0_^@"O$/$G_ "-6K?\ 7[-_Z&:]O\-_\BKI/_7E#_Z
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M@Z+_ -&2UBOX[.:/^^2]/T1QU=A\+?\ D=Y/^P=+_P"C(JX^NP^%O_([R?\
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M2NW^+?\ R+>G_P#817_T3+7$>!?^2@:-_P!=9?\ T1)7;_%O_D6]/_["*_\
MHF6HG_&C_7<SK?[U#T_S/*JWO O_ "4#1_\ KI+_ .B)*P:WO O_ "4#1_\
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MA_ZYK_*I:BM?^/.'_KFO\JEKJ/2>Y[SX/_Y$C0_^P?!_Z+6O$];_ .1EU?\
M["%S_P"C6KVSP?\ \B1H?_8/@_\ 1:UXGK?_ ",NK_\ 80N?_1K5R4/CD>7@
M_P"+/^NI2KV;X:?\B!8_]=;C_P!'O7C->S?#3_D0+'_KK<?^CWJ\3\'S-<?_
M  5Z_P"9Y-K?_(RZO_V$+G_T:U4JNZW_ ,C+J_\ V$+G_P!&M5*MUL=D?A1[
M-\-/^2?V/_76X_\ 1[UYQX[_ .2@:Q_UTB_]$1UZ/\-/^2?V/_76X_\ 1[UY
MQX[_ .2@:Q_UTB_]$1URTOXTOG^9YV'_ -ZJ?/\ ,P*]F^&G_(@6/_76X_\
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M^+?_ -'I0!C5#<?>M?\ K]MO_1R5-4-Q]ZU_Z_;;_P!')0!TOB/_ )%;5?\
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MCTGXE?\ )/[_ /ZZ0?\ H^.O&*]G^)7_ "3^_P#^ND'_ */CKQBLL-\'S.7
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MW'_H]ZO$_!\S7'_P5Z_YG%?%/_D=8O\ L'Q?^C):XZNQ^*?_ ".L7_8/B_\
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M]$QU=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K!\5?<TO\
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M&M7B->W?#W_D0]/_ .VO_HUJZ,V_@+U_1G'PS_ODO\+_ #1X_K7_ ",FK_\
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M%_Z,EK%?QV<T?]\EZ?HCCJ[#X6_\CO)_V#I?_1D5<?78?"W_ )'>3_L'2_\
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M^#_T6M>#5[SX/_Y$C0_^P?!_Z+6JQ/PHO,/@7J> VO\ QYP_]<U_E4M16O\
MQYP_]<U_E4M=1Z3W/>?!_P#R)&A_]@^#_P!%K7B>M_\ (RZO_P!A"Y_]&M7M
MG@__ )$C0_\ L'P?^BUKQ/6_^1EU?_L(7/\ Z-:N2A\<CR\'_%G_ %U*5>S?
M#3_D0+'_ *ZW'_H]Z\9KV;X:?\B!8_\ 76X_]'O5XGX/F:X_^"O7_,\FUO\
MY&75_P#L(7/_ *-:J57=;_Y&75_^PA<_^C6JE6ZV.R/PH]F^&G_)/['_ *ZW
M'_H]Z\X\=_\ )0-8_P"ND7_HB.O1_AI_R3^Q_P"NMQ_Z/>O./'?_ "4#6/\
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M15TG_KRA_P#0!6F;_P ./J8\,?QJGHOS/GZBBBO:/DCZ!\-_\BKI/_7E#_Z
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MP=+_ .C(JVJ_ SIQ'\*7H=+\6_\ D6]/_P"P@O\ Z)EKRJO5?BW_ ,BWI_\
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M -'+7KGQ*_Y)_?\ _72#_P!'QTJO\2!.)_CT_7]4>+U<T?\ Y&+2?^PA;?\
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M"/\ Y%W4?^P@?_1,5<Y\4_\ D=HO^P?%_P"C):PC_'9QT_\ ?)''5ZI\(_\
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MH **** "BBB@ HHHH **** *5A_Q^ZG_ -?2_P#HF.KM4K#_ (_=3_Z^E_\
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M?^1WD_[!TO\ Z,BKCZ[#X6_\CO)_V#I?_1D5;5?@9TXC^%+T-/XO?\?FB?\
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M .NDO_HB2L&M[P+_ ,E T?\ ZZ2_^B)*WG\#]#LJ_P .7H_R/2?B5_R3^_\
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M $6M5B?A1>8? O4\!M?^/.'_ *YK_*I:BM?^/.'_ *YK_*I:ZCTGN>\^#_\
MD2-#_P"P?!_Z+6O$];_Y&75_^PA<_P#HUJ]L\'_\B1H?_8/@_P#1:UXGK?\
MR,NK_P#80N?_ $:U<E#XY'EX/^+/^NI2KV;X:?\ (@6/_76X_P#1[UXS7LWP
MT_Y$"Q_ZZW'_ */>KQ/P?,UQ_P#!7K_F>3:W_P C+J__ &$+G_T:U4JNZW_R
M,NK_ /80N?\ T:U4JW6QV1^%'LWPT_Y)_8_]=;C_ -'O7G'CO_DH&L?]=(O_
M $1'7H_PT_Y)_8_]=;C_ -'O7G'CO_DH&L?]=(O_ $1'7+2_C2^?YGG8?_>J
MGS_,P*]F^&G_ "(%C_UUN/\ T>]>,U[-\-/^1 L?^NMQ_P"CWJ\3\'S-<?\
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M%_Z(CK"'\:7]=CCH_P"]3]/\C KT+X0_\?VM_P#7.V_G-7GM>A?"'_C^UO\
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MJFJ&[_X\I_\ KFW\JZCT5N?2P^Z/I7S5:_\ 'G#_ -<U_E7TJ/NCZ5\U6O\
MQYP_]<U_E7'A>IY67[3^7ZDM>\^#_P#D2-#_ .P?!_Z+6O!J]Y\'_P#(D:'_
M -@^#_T6M5B?A1>8? O4\!M?^/.'_KFO\JEJ*U_X\X?^N:_RJ6NH])[GO/@_
M_D2-#_[!\'_HM:\3UO\ Y&75_P#L(7/_ *-:O;/!_P#R)&A_]@^#_P!%K7B>
MM_\ (RZO_P!A"Y_]&M7)0^.1Y>#_ (L_ZZE*O9OAI_R(%C_UUN/_ $>]>,U[
M-\-/^1 L?^NMQ_Z/>KQ/P?,UQ_\ !7K_ )GDVM_\C+J__80N?_1K52J[K?\
MR,NK_P#80N?_ $:U4JW6QV1^%'LWPT_Y)_8_]=;C_P!'O7G'CO\ Y*!K'_72
M+_T1'7H_PT_Y)_8_]=;C_P!'O7G'CO\ Y*!K'_72+_T1'7+2_C2^?YGG8?\
MWJI\_P S KV;X:?\B!8_]=;C_P!'O7C->S?#3_D0+'_KK<?^CWJ\3\'S-<?_
M  5Z_P"9Q7Q3_P"1UB_[!\7_ *,EKCJ['XI_\CK%_P!@^+_T9+7'5I2^!&^'
M_A1]#U3X1_\ (NZC_P!A _\ HF*N<^*?_([1?]@^+_T9+71_"/\ Y%W4?^P@
M?_1,5<Y\4_\ D=HO^P?%_P"C):PC_'9QT_\ ?)''5ZI\(_\ D7=1_P"P@?\
MT3%7E=>J?"/_ )%W4?\ L('_ -$Q5I7_ (;-\;_!9G?%[_C\T3_<N?YQ5YY7
MH?Q>_P"/S1/]RY_G%7GE.C_#1>$_@1^?YL]"^$/_ !_ZW_URMOYRUZ?7F'PA
M_P"/_6_^N5M_.6O3ZY*_\1GE8S^._E^2"BBBL#D"BBB@ HHHH **** "BBB@
M#@?&&O6.IBPBL?$"V]IYQ^UFW<[\$#:<#DCKD>X.#BJ']F>'_P#H=KG_ +_5
ML>)=/T+1([:*S\/6]Y?7CE(( N,XZD^PR*9KEEHFA7%B]SX<@:QG.V>X5?\
M4,<8S[=?\\4 =Q1110!Q5SIWBZVUZ^NM%2PB@N'R58_ZS' 8@]&QZ8SWK4T+
M_A*O[0/]O_8_LOEG'D?>W9&/PZUARZ4OC'Q1JMMJVHSPPV,@CALX7"DC'W\$
M'.?7']*L^&D;0_&%SX?MK][VR%J)U$C;FMV! VY'L<]NH_$ [2BBB@ HHHH
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M''U,>&/XU3T7YGS]1117M'R1] ^&_P#D5=)_Z\H?_0!7B'B3_D:M6_Z_9O\
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M!1O>!?\ DH&C?]=9?_1$E=O\6_\ D6]/_P"PBO\ Z)EKB/ O_)0-&_ZZR_\
MHB2NW^+?_(MZ?_V$5_\ 1,M1/^-'^NYG6_WJ'I_F>55O>!?^2@:/_P!=)?\
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M +>_]M"OH'PW_P BKI/_ %Y0_P#H KY^KZ!\-_\ (JZ3_P!>4/\ Z *TS?\
MAQ]3'AC^-4]%^9\_4445[1\D?0/AO_D5=)_Z\H?_ $ 5XAXD_P"1JU;_ *_9
MO_0S7M_AO_D5=)_Z\H?_ $ 5XAXD_P"1JU;_ *_9O_0S7@Y9_'J?UU/L\_\
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MS+!?P4;W@7_DH&C?]=9?_1$E=O\ %O\ Y%O3_P#L(K_Z)EKB/ O_ "4#1O\
MKK+_ .B)*[?XM_\ (MZ?_P!A%?\ T3+43_C1_KN9UO\ >H>G^9Y56]X%_P"2
M@:/_ -=)?_1$E8-;W@7_ )*!H_\ UTE_]$25O/X'Z'95_AR]'^1Z3\2O^2?W
M_P#UT@_]'QUXQ7L_Q*_Y)_?_ /72#_T?'7C%98;X/F<N _@OU_1%S1_^1BTG
M_L(6W_HY:]<^)7_)/[__ *Z0?^CXZ\CT?_D8M)_["%M_Z.6O7/B5_P D_O\
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MF^&G_(@6/_76X_\ 1[U>)^#YFN/_ (*]?\SR;6_^1EU?_L(7/_HUJI5=UO\
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M7_KRF_\ 0#6!0!3U?_D"7W_7O)_Z":ZOQ'_R*NJ_]>4W_H!KE-7_ .0)??\
M7O)_Z":ZOQ'_ ,BKJO\ UY3?^@&M*?QQ]3'$?P9^C_(^?J***^Y/QX^DZ^;*
M^DZ^;*\#)_M_+]3[/BG_ )<_]O?^VA7T#X;_ .15TG_KRA_] %?/U?0/AO\
MY%72?^O*'_T 5IF_\./J8\,?QJGHOS/GZBBBO:/DCZ!\-_\ (JZ3_P!>4/\
MZ *\0\2?\C5JW_7[-_Z&:]O\-_\ (JZ3_P!>4/\ Z *\0\2?\C5JW_7[-_Z&
M:\'+/X]3^NI]GG_^YT/ZZ&;7MWP]_P"1#T__ +:_^C6KQ&O;OA[_ ,B'I_\
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M6/\ KI%_Z(CK"'\:7]=CCH_[U/T_R,"O0OA#_P ?VM_]<[;^<U>>UZ%\(?\
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M:U6)^%%YA\"]3P&U_P"/.'_KFO\ *I:BM?\ CSA_ZYK_ "J6NH])[GO/@_\
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M4   $UW-% &;XC_Y%;5?^O*;_P! -8%;_B/_ )%;5?\ KRF_] -8% %/5_\
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MO)_V#I?_ $9%6G\7O^/S1/\ KG<_SAK-_P =&$O]\CZ?HSSRNP^%O_([R?\
M8.E_]&15Q]=A\+?^1WD_[!TO_HR*MJOP,Z<1_"EZ'2_%O_D6]/\ ^P@O_HF6
MO*J]5^+?_(MZ?_V$%_\ 1,M>55&'_AF6"_@HWO O_)0-&_ZZR_\ HB2NW^+?
M_(MZ?_V$5_\ 1,M<1X%_Y*!HW_767_T1)7;_ !;_ .1;T_\ ["*_^B9:B?\
M&C_7<SK?[U#T_P SRJM[P+_R4#1_^NDO_HB2L&M[P+_R4#1_^NDO_HB2MY_
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M-/\ D0+'_KK<?^CWJ\3\'S-<?_!7K_F<5\4_^1UB_P"P?%_Z,EKCJ['XI_\
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M110 4444 %%%% !1110!2L/^/W4_^OI?_1,=7:I6'_'[J?\ U]+_ .B8ZNT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% %35K1[_ $6]M(2JR7%O)$I8\ LI S[<US_]CZY_SPT__P "W_\
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M_ C\_P V=A\+?^1WD_[!TO\ Z,BK3^+W_'YHG_7.Y_G#69\+?^1WD_[!TO\
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M&^#YG+@/X+]?T1<T?_D8M)_["%M_Z.6O7/B5_P D_O\ _KI!_P"CXZ\CT?\
MY&+2?^PA;?\ HY:]<^)7_)/[_P#ZZ0?^CXZ57^) G$_QZ?K^J/%ZN:/_ ,C%
MI/\ V$+;_P!'+5.KFC_\C%I/_80MO_1RUT/8[Y;,]N\6_P#(E:W_ -@^X_\
M1;5X+7O7BW_D2M;_ .P?<?\ HMJ\%KFPWPL\_+_@?J0W?_'E/_US;^5>_P#B
MS_D2-;_[!T__ *+:O +O_CRG_P"N;?RKW_Q9_P B1K?_ &#I_P#T6U%?>/\
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M!1O>!?\ DH&C?]=9?_1$E=O\6_\ D6]/_P"PBO\ Z)EKB/ O_)0-&_ZZR_\
MHB2NW^+?_(MZ?_V$5_\ 1,M1/^-'^NYG6_WJ'I_F>55O>!?^2@:/_P!=)?\
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M3_\ 7-OY5U'HK<^EA]T?2OFJU_X\X?\ KFO\J^E1]T?2OFJU_P"/.'_KFO\
M*N/"]3RLOVG\OU):]Y\'_P#(D:'_ -@^#_T6M>#5[SX/_P"1(T/_ +!\'_HM
M:K$_"B\P^!>IX#:_\></_7-?Y5+45K_QYP_]<U_E4M=1Z3W/>?!__(D:'_V#
MX/\ T6M>)ZW_ ,C+J_\ V$+G_P!&M7MG@_\ Y$C0_P#L'P?^BUKQ/6_^1EU?
M_L(7/_HUJY*'QR/+P?\ %G_74I5[-\-/^1 L?^NMQ_Z/>O&:]F^&G_(@6/\
MUUN/_1[U>)^#YFN/_@KU_P SR;6_^1EU?_L(7/\ Z-:J57=;_P"1EU?_ +"%
MS_Z-:J5;K8[(_"CV;X:?\D_L?^NMQ_Z/>O./'?\ R4#6/^ND7_HB.O1_AI_R
M3^Q_ZZW'_H]Z\X\=_P#)0-8_ZZ1?^B(ZY:7\:7S_ #/.P_\ O53Y_F8%>S?#
M3_D0+'_KK<?^CWKQFO9OAI_R(%C_ -=;C_T>]7B?@^9KC_X*]?\ ,XKXI_\
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MC7MWP]_Y$/3_ /MK_P"C6KLS;^ O7]&>9PS_ +Y+_"_S1TM%%%?,GZ %%%%
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M8?\ A1]#T+X0_P#']K?_ %SMOYS5G?%/_D=H_P#L'1?^C):T?A#_ ,?VM_\
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M\OU):]Y\'_\ (D:'_P!@^#_T6M>#5[SX/_Y$C0_^P?!_Z+6JQ/PHO,/@7J>
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M444 %%%% %*P_P"/W4_^OI?_ $3'5VJ5A_Q^ZG_U]+_Z)CJ[0 4444 %%%%
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MB5K?_8/N/_1;5X+7O7BW_D2M;_[!]Q_Z+:O!:YL-\+//R_X'ZD-W_P >4_\
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M(%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 4K#_C]U/_KZ7_T3'5VJ5A_Q^ZG_ -?2_P#HF.KM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)KM+L12.R2)"8N&8L01N;)R3SQQCCN;K5(2A9,VQ=>E4I\L'=W\_,\X^*?\
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M/=PS&6>>="QEY7"CG@#:?7J:T?$G@X:WJ$.HV5])I]]" OFH,Y Z=""#SUH
MY7X@VVLP:-;-K&IV]RK3_+#% $VG:><]2.WXU-\2SG0=$SZ'_P!!6M2^^'LN
MHZ;LOM:GNK[S PN)E+*B@'*JN>,Y!//85>\3>$)/$.FV%M]L6!K08+>7N#\
M=,\=* .HKA/B;?.UK9:1;I)+)<R>:\<0RQ1>V/<\_P# :[NL(>'&?QH=>N;E
M9%2'RH(?+QY?&,YS[MV_BH X[Q'K]QK/AQ].7PQ?P!-ICD9&(CV_\!],C\:T
MO#NI_P!H?"K4(G;,EG:SPMGTV$K^AQ^%=X1D8/(KD-*\#R:5'K$$-^IMM2A>
M)8_*.8\Y"G.><!C]: (OA=#&GA:655 >2Y;<W<X Q5'X<?+K_B!5X7S1P/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img243551639_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_17.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $? GT# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_7\]=M45/B9SXC^*PHHHJ#$**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHJ*ZF^SVDTV-WEH6QZX&:$KB;LKDM%<C;
M^+-3N;=)XM%+1N,J1*.:NZ3XBN;[5OL%U8?9G\OS =^>*WEAZD4V^GFCGCBZ
M4FDKZ^3.AHK+U#4[FVU""SM;07$DJ,_S2;  ,?XU!)X@9+*1Q9L+N*9(7MV<
M##,>#GT]ZA4I-)KJ6Z\(MIO8VZ*P)_$-Q:+/'<V&RZC5&5!*"KAFV]>W-2+K
MLD,EQ'?V?DO% 9_W<@D#*./P-/V,Q?6:=[7_  9MT5F:;J5U>N#)8B.%UW)*
MDP<?0XZ&B[U26.]-E96ANKA5#R?.$5 >F3ZGTJ?9RO8KVT.7F_1FG15!=5BC
MLTGOE-FS$KY<IYR/3'44^75;&&..22ZC"2J60YSN ZXI<DNQ7M(=RY16:VN6
M(N[6W$P8W*ED9>1C_P"O4JZMI[0/.+N(Q(0&;/ /I]:?)+L)58/JB[16<^KP
M;[/[.5F2YE,>Y3]TX)_I6C4N+6Y49QELPHHHI%!1110!D>)',>CR.D:R2KDQ
MJ9O+R=I[]^_%9OAKF^=E$2+Y7*B]\]B<^G85L:Y!<3:5,;5RLT:EU C#[R ?
MEP?6L;PW*\FHL$G:XB\@&1C:B+8^?NY Y^E '54444 %97B7_D6M1_ZX-6K6
M5XE_Y%K4?^N#4 :47^I3_=%/ID7^I3_=%/H XOXF?\@"Q_[",/\ ,UF#1M-\
MT/\ 8HMV<YYS6G\3/^0!8_\ 81A_F:B'WA]:U3]U'9!M4E;S'_#7C3=3'_3\
M]=M7$_#;_D':G_U_/7;5-3XF8XC^*PHHHJ#$**** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]B:>QN(4QN>-E&?4BIZ
M*:=G<35U8XBST?Q+96<5LD-D5C7:"9#FKVCZ3JT6O?;]02!5\DQ@1-FNIHK>
M6)E)/1:G+#!PBUJ]#&U*VOQK%K?6<$<PCB=&5Y-O4C_"JEQH=Y>6L[W'EFXN
MIXGD1&PJ(IZ ^N,UTE%1&M*-K=#26'C)N_7_ "L8&H^'HO[*G@L+=3-(R%O,
M<_, 0<$FH;#2;VWO)IXK.VM$: IY/F&19&SP3["NEHIJO+ELQ/#4^926ASNE
MZ3=0:LET;2"QC5&$D<,A82D]#CH,5:N;2_M=4EOK!(IA.BK+%(VW!7H0:V**
M3JR;NQQP\8QY5WO_ %T,*:SU-I[2_>*VFN(U='AW84!NA!/<8Q3++19X+FQD
ME6)EC\YI%'1"YR H]!7044>VE:W]?UJ'U>%[O^MO\CGK;2KRU;37$43&!IED
M&[&%=L@CZ>E-31;J'2=/5(X6N+24R-$3\LG7OZ\UT=%/VTOZ^?\ F)8:"_KT
M_P D<[#H]X;V*[D2*,M=^>\2-PB[=OXFNBHHJ)S<]S2G2C3O;J%%%%0:!111
M0!EZVM[LLY;*!YVAN [QI($++M8=3QU(K/T&+5Q=0&_MI84BMRC,\P?>Q;.>
M#Z5NWLDT5C<26Z;YUC8QI_>;' _.L/P[JEW?3O%(\DR1AM\CPF/#;N!^7:@#
M>N9TM;:2>3.R-2QP,GBN5M=;N;J2YB%\A:6XA52F#Y".O('XC&3WKKZK26%K
M-YWF0JWGX\S/\6!@4 5]+FE,MW;2RM,+>0*LK8R01G!QW%97B35P='U&V^PW
MW^K9?,\@[/KGTKH+:UALX?*@C")G..N3ZDGJ:H>)?^1:U'_K@U &E%_J4_W1
M3Z9%_J4_W13Z .+^)G_( L?^PC#_ #-1#[P^M2_$S_D 6/\ V$8?YFHA]X?6
MM5\*.N/\*/S'_#;_ )!VI_\ 7\]=M7$_#;_D':G_ -?SUVU34^)F6(_BL***
M*@Q"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *
M.L2K'I-R/M"P.\3I&[/LPVTXY[5B>%WM6N&6&*%91&-[)?\ GY_#M]:WM3\P
M:9=-"@:98F:,%=WS8...]9'AUMTK$RWK/Y8W+/;+&H/?! % '14444 %97B7
M_D6M1_ZX-6K65XE_Y%K4?^N#4 :47^I3_=%/ID7^I3_=%/H XOXF?\@"Q_["
M,/\ ,U$/O#ZU+\3/^0!8_P#81A_F:B'WA]:U7PHZX_PH_,?\-O\ D':G_P!?
MSUVU<3\-O^0=J?\ U_/7;5-3XF98C^*PHHHJ#$**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH HZQ<16^F3^9=+;&1#&DK9^5B#@
MUS_A.3?=R(LL"I&C8BBF,F[+9W=.!_C70:P;3^RKA+V=889$,9D;L2"./>L#
MPS.;O5YVWM,MO"(1*MOY*>O(/)..?2@#K:*.@IBRQNA=9$*#JP88% #ZRO$O
M_(M:C_UP:M165U#(P93T(.0:R_$O_(M:C_UP:@#2B_U*?[HI],B_U*?[HI]
M'%_$S_D 6/\ V$8?YFHA]X?6I?B9_P @"Q_[",/\S40^\/K6J^%'7'^%'YC_
M (;?\@[4_P#K^>NVKB?AM_R#M3_Z_GKMJFI\3,L1_%84445!B%%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBH;JZALX#-
M,V%R ,#))/0 >M $U97B7_D6M1_ZX-5VTO(;V(O$3\K%65A@J1V(JEXE_P"1
M:U'_ *X-0!I1?ZE/]T4^F1?ZE/\ =%/H XOXF?\ ( L?^PC#_,U$/O#ZU+\3
M/^0!8_\ 81A_F:B'WA]:U7PHZX_PH_,?\-O^0=J?_7\]=M7$_#;_ )!VI_\
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M4 %%%% !1110 4444 %%%% !113'FBC(#R(I/9F H ?134=)%W(RL/53FG4
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M&%PR-*"&&.AXJKI7A"U;2+-EOKY T*':LN ,@=.*ZT@,I5@"#P0:%4*H50
M, #M1<+M:'-P>#+2UO7O(+Z_2Y=-C2";DKZ=*N_V#)_T&-3_ ._P_P *V**
M;;W,?^PI/^@QJ?\ W^'^%<YHO@^QN[2_C:ZO%C^URHRK+@-SU/'6NZ=UC1G=
M@JJ,DGH!38A%LW1!-K_-E>ASWHN"DUL<V? ]@9X)S>7YEMSNB;SN4/MQ5_\
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MZ[N-PQMG?<![CBKU%%(D**** "BBB@ HHHH *0D*,D@#U-1O<PQSQP/*BRR
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M=(UW.P49QDG% !)(D2%Y'5%'4L<"N7\2W.IP7*QLMDVCW"^6[3QL0C'^\0>
M?7'%;,MQ::C-=Z;+ 988TQ.[ ; 3SMZYSCFJ-KI&I1S+:7%XLNE1<HK+F20=
MD?/! _7B@"7P[;:M9VKVVI202QH?]'>-RQV^A)'./6MJD "@   #@ 4M !67
MJ^J):PRV\#12W[1EH[8N S#V'?Z5!JGB*"RANUCXN+<KN612 JG^/'4J/:L2
MWT^;Q!.TSO IR#,4W J>JNO)PV!TSQF@#1\.P75JD:VDZWFF3$R&65R)(FQ@
MKCN,CIVKI:9%$D*!44 =^.I]3[T^@ JCJE^VGP)(D8F8O@Q!L.R]]H[D>E2W
MMXEE;/(WS.%8I&#\TA S@>IKF(;N^U35HKBUBC2[6V*D7,;*@4L?F3OD=#D#
M.* $MM3U&[UWS83<R0,Y\H(/W,D9Z9./EQSG)SGC%=C56PL4L8"HP9'.Z5P,
M;W[G'09JU0 5'//';0/-,X2-%+,Q[ 4[S$\WRMZ^9C=MSSCUQ7*Z]J"W;&T=
M7^6012V;865\D;9(SWQU].N: (-2U9]1G,MK->+!&@-O]GC.1.,Y64$9 QCK
M@8)KH]%OI=1TN*XFC"2DE6VG*D@XR/8XXI+33$5&>\6*:ZDC\J:0+@2J.FX=
M,XJ^B+&BHBA548"@8 % #J*K7]_;Z=;F>X8A<[551EF)Z  <DUAW6KQZKY5I
M&6AM;N-E69LJ3(/^69_NGUSU[4 1:KJLTQ2TD,ENJ'=<FV<^9LS\KH<<KTW8
MY%;NF+>)9A+R6.9U.$E3CS$[$CL:QO#^A2VTGG7</E!#NC@)!$;_ ,3*1T4^
MGYUTU !117.ZKX@:.6ZT^U3_ $R/!&U@24/WF4=V']TT 6]4UM+27[+ 0UV6
M51O1BBD] Q XR*J^'[FYCU"^T^\@:%\_:8U+[QM8\X/INZ52L=!>_NVO);^6
M:"2,;+A"H,R],,,<, ,9&,BNJ2"*-]Z1J&VA-V.<#H,T 24450U/4UT]8T2(
MSW,S;88%8 N>_)]!0 NK:DFEV$EP5WLHX7MD\ GT&>IK&TDZJVI.\DS>=OS<
MP2-F(QG.UXFQZ<8JH&OM;N(VBB_>)*0+D@#RD_CBE3//I[\&NLM;6&RMDMX%
MVQ)PJY)Q[<T 3445!>WD.GV<MU<-MBC&2?Z4 /GF2")I'R0H)PHR3[ =S7)0
MWNIZE?1W<4IA:1=UFBL6@D4?>23C(?\ E27E]>:K-):OI\N\JKQP[U66!OX9
M5;."OKW%=)I=A]AM_G*-<28:=T&U7?'+ =LT 75R5&X -CD#UI:*:TB(RJSJ
M&;H">3]* "21(HWDD8*B LS$\ #O7*7^K+JE[#';WD\%HO!EA!5TD/W"X(Y0
M^O0U%J5X^I3J]K;W*QW4;PKO8>7=(,Y Y^5NI!/6MS2M+EMYA>7=R\\YA6)=
MR!-B#G!QU.>] %ZR^U?9(Q>^7]H PYC^Z?>K%%,DECA4-+(J*2 "QP,GI0 3
M3)!"\LC;4098^@KF=5\0R3"[L[&&<3P%6;85W21\9,?J>?PI^LG58M8\](P;
M2.-3%))<>7#&W.XR#JW; J/1-*BU.T2[NXD,#NTB08.U'W$;D/4*PYVF@#4\
M/2W4FG8NO-;:V$DF&UG'7I@' Z<]<9K6HHH *R=;U;[!:R"'RFF50SA\E8T)
MQN8#G'M4>J>((;9+ZWMMSWUM&)&C\MCA3CYO< <\>E96B1G5KR6[\Z*7>-MQ
MB(&.:,_=#<XWCVZ=#0!9\,_:Q+*%B$%NK%9K<G*QR=<Q'H5/<=C735'!;PVL
M*PP1)%$HPJ(, 5)0 4444 %%%% !1110 4444 4M3TR#5+;RI=RNIW12H<-&
MW8@U!IFG7<):?4KL75R<!<+A$ X! [$YY-:E% !4-U<QV=I+<RY\N)"[8]!4
MU(Z*Z,CJ&5A@@]"* ./O_$9O;2*!9(XII) TEM!*6E:'K@,. ^.V<^E6O#=C
M'<%]1W2M$6*P&5]S/'V#]<D'.,\BKR>'H$OH73RXK.!A)%:Q1A1YG]XGJ:UH
MH8X0PBC5 S%B%&,D]30 ^D)"@DG '))I:Q]8UA;6WG2UE@:YB ,H8Y\I?[Q7
M.3_]<4 0>(&6ZLK&Y1&N].68/<)#\V],'!P.H!P2*S]+L7U347F>6:2SB ,4
MAA,(1L_<C!YV;< YZU8\,BZ:::0*D,)8B:)3NC+]=\9[9[CUKIZ &1Q1PQB.
M)%1!T51@"GT5GZGJ'V!8RK0LY.?)9@'D'<(,\F@!EWK5O;R21 JVW*%B>%D_
MA0^F?7I7)Z79PZE=QVY,DOFQ.TXCS&UDQZIGNI)/RGZU+!!-JUX\T<4LDMQ*
M0\[\V[V_]QESPPZ8QD&NTM;:.TMTACW%5  +')./4]Z *VBVUQ9Z3;V]TVZ6
M)=F<Y.T'Y<GUQBK]%% %+5)+Y+)AIT2/=.=JF0X5/]H^H'I7(2V][JWV>W96
MGN+5#'=V\\F)%8G(D4],'ID=!7>4SR8_/\[RU\W;MWXYQUQF@"I8Z>L!6YG5
M6O#&%=P20/89Z#^=7J*KW=W%:1%Y#T[#D]<9^G/6@"Q7':M?RWL=Q:%Q-"9B
ML)7Y 7'_ "QD!Z>H/0X%)J.NWEU;7*/'#;I %\R,2'S9,GAXF'!'0CKGI6QI
M>D3Q7LE_?S1RW#QK&#&A4,HY#..[>_:@"+P]HS62FYG\P2D;(UD;YUC[*Q'#
M8[>G2M^BB@ KGM<U>$@6D#),RR W"*"7$8Y8IQ@L/8Y%1:_JTAN(K;3KPP3Q
MR#=(RYA8G_EFS=F/Z5'H^CS2WK7Q:XMH?-+"WF0;U.<E0V?N$_GB@"6PT!9W
M>:XN9)[>38R.DA'GH.5\P=R..>_>NEH  & ,"B@ JM?VTEW920Q7$EO(1\LL
M?53V_"K-% ')6.D3ZG<3S:L9H]5MW"B9!B/R_1!T*D=0:ZF&"*WC$<$21H.B
MH,"I** "L;6=82&UO;:PN[?^U(HMZ0N03Z].YQ5K5;UK.U!BFMDN&8"-)WVB
M0_W1[FL.\TNR\3*M_;11QZA"?+GAG7KZHXZ_0T 4H[R_\0PF Q1O(Z(YC9MA
M@;^&:-NZ^W7/%==96,=G'GA[AP/-FV@-(0.II-/TZWTRSCMK9"L<8(4,VX@9
MSC)[5;H **** ,S5M*^W>7<6\GD7\',$P[?[)]5/<4:;8W(/VK4VBEO6Z!%^
M6$?W5/7ZUIT4 %%%% &5KFCG5+=&@G:WO8"6MYU_@8C'([BLWP]H+P2R75Y9
MQ6Y*"/R%;?O8'/F,>[$]/05T]% !2$@ D]!2T4 <W)K,>HWSPVE]#$$A6:WD
M9\!WRRE6'&0,#BJUCH]SJ&3,5AMC=&X>,J?,63OL<'E2>0?3BM";PM8R:T=0
M$,6V52MQ"\897]&'H?YUMQQI#&L<:A44850. * %50JA5  '84M%4M2U&/3[
M=F)#3LK&*,]9"!G H @U?64TF2V\Q-Z2,0^W)9%_O;1_".Y[5SEDMYK-\T5X
MMTZEB0XX2/G*RH^,=,  =><T^U:]UG55DAU*W,PM=WGP1[E56/,; ]^X[\<U
MU>GV,.FV,5I #LC&.>Y[G\Z )HXQ&N.K?Q-CECZFGT4R57:%UB<)(5(5B,X/
M8XH BO9WM[<O$B.^1A&;;N]<>^.@KEK_ %*;5-HMX9'D+E;<!2T,RGAHY1_"
M1WS^%07L&I:QJ"6]Q;PO<VT86>%GV*ZDY$D;>AQ@]^,5T6GZ5-:7[73S)^\A
M5)4C7 >0?Q$?3B@"WI]BMC:QQ!F?8,*7.XJ/[H/4@5;HHH *Y=[B#3?$%[<:
ME:323,0;.9(6D&S;C8N =ISGTSFNHHH P]&T:.%(;V>%XKD@OY'F$QPLW7:N
M< UN44R::.WA:65@J*,DGM0 2R+#"\KYVHI8X&3@>U<]J.L&_P#L]KIJ03+<
MQF57FR%D _@4CH_UZ59OM?:"]>"UM3=+!&);C:V&5#T*C^+UHM]$LI;G[9 V
M;.?$WV<K\HDZAU[J?6@"OHDTER&TV^@>:%8Q+&;A/F49QL?/!8$<'N!FNB
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MBWF215"M*WWGQTR>]+86?V&T6'S6E;)+.W&2?;L/:K5 !1110 4444 %%%%
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M3])EU!UN1>7!!!Q<L=EQ"XX:,^JG],5UD,201+%&H5%& !3@ !P*6@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** (;RUCO;.:UE&8Y4*-]"*XS0
M?#<EP)5N6-M#;R?9WMD&4GV_QL#P,C'2NYHH 9##';PK%"BQQH,*JC  I]%%
M !1110 4444 %%%% !1110 5Q/B2+6EO+BVEN89--OOEA\V/Y8G[*2.1ST/2
MNVI"H888 CWH PM%T".T@BDN8E\P8=86PP@?^+8?0GG':MZBB@ K"\2Z?J-U
M##<Z9>313VY+&*-@!*.XY[^E;M% '*>'M",C?VC=2;R\AEB(C,3@-]Y'7H1G
MG%=4    , = *6B@ HHHH **** "L36M=33KN*TW0QET,DDLS[55,XXQR6]!
M6W5:\LHKM.4C$R_ZN5HPQC/J,T <9 U]J]\L,+17UBT+PF2Z1AN&<[7 '# =
M#WKL-.TRVTV$I;Q[2P&XEBQ.!QR>PHTW3H]-@9%D>621B\LLGWG8]S5R@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K&U?67M8+F*WB8W2#*@C)*]W _B ]!6?JOB&)IKFW%
MVMDEN^P3[LNTHYP$ R5]:KZ59ZAJS2O>"*)!<F:.6,MO7(&#&W0J?2@#5T^.
M34;5K;4T@U"U(#PW6T;90?5>S"MB""&VA6&")(HUX5$& *6.*.&,1Q(J(.BJ
M,"GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110!EW^BQW;-);M':SR_+-.D*F1T[C=V^M7[
H:WBM+:*WA7;%&H51Z 5+10 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img243551639_18.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_18.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #H FX# 2(  A$! Q$!_\0
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M0 4444 %%4-7OI+"Q\R%%::218HPYPH9CC)]A56PO;^/4Q8:A);3&2(RQRP
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M-9/A[_D'S?\ 7W/_ .C&K6K)\/?\@^;_ *^Y_P#T8U &M1110 4444 %%%%
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MO>3_ -!--T;_ ) 6G_\ 7M'_ .@BK]H^6W0V^L/V?);3L)I>L6&LVWGV,ZR
M<,O1D/HPZ@U?K#U7PQ;WUQ]NLY7T_4A]VY@XW>SKT8?6J</B.[TB5;7Q+;K"
M"=J7\()@D_WNZ'ZU'+?8QY%+6'W=?^"=1134D26-7C971AD,IR"*=4F04444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6MQ]214J^+?#[=-8L_QE J%[+7&^\-(?_>@;_&H6TG4W^_9:$_UMS1[./?\
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M / 6=[17!'1_$2?ZNYUD?[U[$W_LM LO%J?=NM2_%X6_I1[%]U]Z#VM+N_\
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M_C0!KT5D?\(Y:?\ /S?_ /@4_P#C1_PCEI_S\W__ (%/_C0!KT5D?\(Y:?\
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MG_QJS9:7#82,\4MRY88(EF9Q^1-267J*** "BBB@ HHHH 1F5$+NP55&22>
M*KVE_:WRL;699-I^;'&*;JEJ][I=S;1D!Y(RJYZ9]_:JUC'<R:C)=SVWV=?)
M6(*6!+$$DGCMSQ^- &I1110 4444 %%%% !1110!5N]1M+$H+F81F3.T8))Q
MUZ4V75;&!XEEN$1I0"H.>0>Y]/QJMJ]L\LD$L<%Q(Z!@#!,$(R/?K5!['4DB
MN$>W6YDO($C9RXPC#(^;UZ]O2@#I**9"ABACC+%BJA<GO@4^@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***X>VUK57TFQ:2*78U\$:Y\Q3O7>?EQU]J .XH
MKE/^$HNUA\]HK<I+%+)$B,2T>S^_]:GE\07+WXM;1;=RTD*!F8X&]&8]/3%
M'245B:7K%Q=ZI/:721Q,NXQH 22H;&=W0_TK&MKG5FO+F[B^V/%;WDWF%Y$\
MIHE+?*J_>STH [2BN6'B/4/*.V"VFDD@6>,0N3L!.,-ZG^=2Z5JUY?Z[&#/"
M;5K3?L52IWAR#UYS0!TE%<JNK:BFH7%M T<CR7LL:^<3A%6,-QBJ<NO:DTRZ
MAOC6".R$Q@!."Q?:230!VU%<O>^);F&YND@BA:"";8TO+;5V@\@<GD]1TI%U
MRY.H3VUN\699\)).Q\M%$2M@<=\_SH ZFBN2_P"$HOI8C/#;P+'';QS2!V.3
MN<J=OMQD&NL4[E#>HS0 M%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img243551639_19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_19.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #  G8# 2(  A$! Q$!_\0
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MNG?UI2B,<LJDXQDCM5>TUV-GB-=$<5X=T;4+R'0+ZZ^Q0V]G 'B\A3YDFY,
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M%=[&UEW;X$;>06R.I%/EMH9H1%)$C1CHI' ^E2T478^5=B 6=LJ!!"@4*5
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+G[TG<]/I0!T5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXZ,R@D5+5#66F339)()6C="IRHY(R.*EO;BZ@"?9K,W.?O8D"[?SH S/#=K
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M:* (YH8KB(Q31I)&W57&0:6**."-8XD6-%X"J, 4^B@+ACF@C/6BB@ QSFD
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M)9EF\Z>9VZM-(6_3H/P% %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img243551639_20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_20.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" /N!E(# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRV=U/F%7SGF=D/RGK@CA1CW"POK?4].MK^SD\RUNHDFA?:1N1@"IP>1D$=:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM
M_P"20Z[_ -N__I1'7H%>?_&W_DD.N_\ ;O\ ^E$= 'H%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y_P#&W_DD.N_]N_\
MZ41UZ!7G_P ;?^20Z[_V[_\ I1'0!Z!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>?_&W_ ))#KO\ V[_^E$=>@5Y_\;?^
M20Z[_P!N_P#Z41T >@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#I1'7H%>?_ !M_Y)#KO_;O_P"E
M$= 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_ &[_ /I1'0!Z!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>?\ QM_Y
M)#KO_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T >@4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7G_QM_P"20Z[_ -N__I1'
M7H%>?_&W_DD.N_\ ;O\ ^E$= 'H%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5Y_P#&W_DD.N_]N_\ Z41UZ!7G_P ;?^20
MZ[_V[_\ I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>/
M_P##1W@__H&ZY_WXA_\ CM>P5'//#:V\MQ<2QPP1(7DDD8*J*!DDD\  <YH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\S^.^MS:/\,KB&#S ^HW$=F9$D*%%(+MTZ@K&4(XR&/T
M/IE<GXN\&S>*=9\-WJZO):0:->B\>V$1=;EE9"N?F ! 5@#@XWG\0#8\-Z)#
MX<\-:;HT'EE+.W2(ND8C$C ?,^T="S98\GDGDUC^)]+\%Z]X@T73_$26EUJB
M.SV%I)*VXY!=B8U.&0B$\N"ORX[X/65R_C?P19^-=.MHI;J>QOK*7[197UL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !7G_P ;?^20Z[_V[_\ I1'7H%>?
M_&W_ ))#KO\ V[_^E$= 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5Y_\;?^20Z[_P!N_P#Z41UZ!7G_ ,;?^20Z[_V[
M_P#I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MASQCH_BA6%A*ZW"+O>WF7:ZKG&>,AATY4G&1G!.*'"25[ Z4U'F:T-^BL/\
MX2S2_P#A+/\ A&]TOV[9NSL^3=MW[,]<[?FZ8[9SQ4OB/Q'8^&-+^WWXE:,R
M"-$B4%G8@G R0!P">2.GK@4<KO:PN25TK;FO15&35[6VT0:M>E[.V\E97%PN
MUX\@?*R\_-DXP,G/ S7&Q?%_P]).L36NI1 D!G:.,A!ZD*Y.![ GVIJ$I;(<
M:4Y7Y4>@44R&:.XACFAD22*10Z.C JRGD$$=13Z@S"BBB@ HHHH **9++';P
MO--(D<4:EW=V 55')))Z"F6MW;7ULES:7$5Q ^=LL+AU;!P<$<'D$4#MU)J*
M**!!1110 4444 %%,EECMX7FFD2.*-2[N[ *JCDDD]!4-EJ-EJ4)FL+RWNHE
M;87@E5U#<'&0>O(_.BP[.URS1110(**SM=UFW\/Z-/J=U'+)##M#+" 6.Y@H
MQD@=6'>D37M-_L:SU6YNHK.UNXTDC:ZD6/[R[@I).,X[9[&GRNURE"35TC2H
MHHI$A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7G_ ,;?^20Z[_V[_P#I1'7H%>?_ !M_Y)#KO_;O_P"E
M$= 'H%%%8OBKQ!%X:T*:^?F4_N[=-I8-*02H/3C@D\C@'OBFDV[(<8N3LA_B
M'Q+IWAFR6YOW8EVVQPQ@%Y#WP"1P.Y/'XD \;/\ &#3UNXUM]*N9+8X\R221
M4=>><*,@\?[0S[=:\JOKZYU*]EO+R9IKB5MSNW4G^@[ = *KUVQP\4O>/4IX
M*"7O:L]]T+X@Z%KUVUK%)+:S<;%NPJ>:2<84AB"<XXZG/&><=37RS7M7PV\7
M2:W9/IE_,TFH6R[E=EYDBX&2W=@3@YQD$=3DUE5H\JO$PQ&%Y%S0V.\KD_B7
M_P D_P!2_P!Z#_T<E=97)_$O_DG^I?[T'_HY*QI_&O4Y:/\ $CZHQ/!NM>&H
MOAU;66L7^FL$\YIK2X='8XF=A^[.23T(&,GC%<MH%S<Z9X7\8:SI"FVT^1X[
M:V#Y\R/=)@8(;*LB2CGG)(Y^4YZ/P/X'\.ZSX0LK^_L&FN96EWO]IE7.)74<
M*P'0"NK\3>'4OO!5[HVEP16^4#P0PHJ*65Q(% X W$8SVSFMG.*DUW>OWG6Z
MD(S<>[UOMN9GPOTF/3_!\-UY+)<7SM+(74 E02J <9V[0&'7[Y(ZU+9>"VTO
MQ]_;6F26]IIKVQ26UCC RQP-JJ  J_*C9SG<#V:L?X:^+-(M_"B:??7]K92V
MLC[?M$P3S4=BX8;L#JQ& 3C )QD5?3QMJ&J^+)K'P[90ZCIMK;NT\OW2\@5]
MH20MM"LP102#GYB,J,U,E/FD1.-7VD[?TCD?#.H6WPX\2WVFZU8,6?"17Z)F
M3RMV VW)_=D?,=N2""#N( 7KM,LO"7B/Q3%KVBZD8K^V)9X($6+S.NYWC=-Q
MW>9M+_3G(HTSQEX?\3V=Q!XDM=.L)K:?'V349%89 QN'F*HW [E(QD8YZBN/
MU.UT:Q\=Z!'X,;SI?,1Y!!=F6,_/TW@LP^4/OZ@+@XZYNSDW?1_@:-.;=TU*
MWR+%_?VNF?'&6]O9UAMH6W.[=O\ 0_U)/  Y).!3_#VJ6_CCXC"YU2XD$=H6
METVUR%4%6! /S??P Y SN*GD*H!J:WI,.N?&F33K@XAEGB+]>56W5RO!!&0I
M7.>,Y[5T/Q#T7^Q?[/\ %.BP16\^GR(DJQC8K)PJ9P1P.(R ,E7QG"U3:T75
MHIN/NQZN*_KYE?XQB4QZ*&:X2R+RB5HU+!6PFTXR 7V^9@$C/S<CFNJU>'PQ
M)X'N7:.R;1HHI'C-HL95&^89B_A$FXD#_:-5/$OB3P_/X)MK_4K6YO-+U%D7
MR8"-X;E\-AQ@J4((!ZC%<Y)X1\!:!!#KESJDM_ -SPPM-#(MT5.-JA5!?!(R
M,X_O<9K-:Q2=]#*.L(J5U9OYE_X0:JUUH%UIDC%FLY0Z$ ;0DF3@'J3O60\^
MHY[#M->U>+0=#N]3F7<MNF53)&]B<*N0#C+$#..,YKE?A/I$FG>$C<SQ(DE[
M+YB-M(<Q!0JYR.F0S#J,/GN:G^*.G27_ (->:/<393I<E%3=N7!1OH '+$^B
M_B)DDZMNA%11EB+=+F)_:?Q$_LC_ (2GS],^P>1]I^P[/^66W[V,9Z?/CS,^
MW\-;6K^++BZ^&$GB+2R]G<-L"[@KE&\X1N!D$$?>P2.F#@&FZ5XFT6#X:P/)
M<V=R;73DAEM)954O((B/**GNVQ@.#D<C(KC=.M9K?X'ZO)*OR3WT<D39'SJ)
M(4)]OF1ASZ5HHIO56U-5%2>L;6DEZFC#XD\?ZCX<37[9;2&PLH1))NV,]WLX
MD)'8 HQ(&S@X!8X-=_X8\1VWBC1UO[=&C96\N:)N?+D !(SW&""#Z'L<@9/_
M #1S_N7_ /VWKC?!'AZ]U[PC,+'7;S2I8=1DRT#-MD!BBX8*RDD8&#GC)XYX
MEJ,DWM9DRC"<6VE&S.F^*8UA?#?GV%XL.GH-E]%G#RAW15 .T\<MD9&0<<]*
MSOAL->LO#YU&>=;C0DM[AK>Q@0-/Y@D).!M&22'P-Q^\/P=K7A35M*\":^ES
MKMUK#2)#*HG+#REBDWN1N=OX>>,?=[U9\(:JVG?"%[VT5+BXLH[EC&"#L82.
MWSC(X (8C.<=,DC+T]G9:ZCT]CRQL];?U_F5X#\2M>\S4+6YM]'MY'(BL[F,
M!T4<?Q1,WXG&3D@ $5M?#WQ;)XHT:07>W[?:E5E*C'F*P^5R,8!.&! [J3P"
M!7#:?X?TGQ#H3^)_%OB:;+.\>-Z Q%2Q*?,&R2/F5%5< \ Y%:/P9,9GUXPJ
M5B(@**S!BHS+@$@ $CU &?04YQ7(_+R_JY56$?9R=MO*WX]2KHWBSQSXIL+>
MTT9X_M$ 4WEZ\<2D,[R;>#QLVA?NINRI_'=U#Q%XE\0^)[[1/"LUK:Q6'^MN
MY4)W.#M9<E& ^8D ;>?+)#8XH^#7_(HW?_7\?_145<JTTX\=:[=Z'JFG:!+'
M-)#(VH7:XF)D;>4W(>"4#$<[2>#@X#LG-I):%.,74DE%:?KW_0T_#;M+X]U3
M4O%5Y*FJ:+;EU"*?+:-$9)'QMSMPRN -N3(2!S@78/$OC3Q9<SWOAN"VMM-M
M)&"I/L+3D!3Y;YR=Q!!^7:!N(WY -3:%X;MFT#Q++:ZO9:UKFHVLBRM:O&5C
M>16.T$'C<Y/)V@[5X&*Y?P=X0\*^(]&DN;[4[BWO8?,>XC$L* 1C!\P!E)V8
M906/<&CW7=OIY?H#Y&W)]++;]#;O_%&M>)/"6M:<#:Z?JVG"4ZA&"-LUN%D6
M14!WG<" #@XZ$,-V!#\*;;7G=KBVO8$T-+IQ<VS ;W?REP1\F<<I_$.AX]9?
M#OAW19[+Q/\ \(V=4N)DLY]/1[EHO(F9P?\ 5LH /*J<DCA@>]:/P=GB?PYJ
M$2R(9%O2Y0'Y@K1I@D=0#M/Y'THDTH220JCC&G)17],[S4+V/3=-NK^97:*V
MA>9P@!8JH).,]^*\[TC5?B+X@LDUVR;2$M0'5+-E(%P5R"><D'=D#+J,J,C'
M)[S7K^VTS0KR\O+26[M8X_WT$48<LAX;*D@$ $DYXP#7F-GX1TO48+C6_"/B
ME].58"\T,DA5X.2=DDBL&1/EQR&^[NRW%94TK-LPH*/*W)?-JYT.NZY?7_PJ
MNK^[T_['?*T<<T%S:94-YR#(25<$$$$<'&<9)%<=XV&NS>#M$O+N>T&BO!;"
M*W@0(XD-N26("X'\8 4@ ;>*T&\1:EXB^$.LRZGF2:"YAC$^U5W@R1-@@8^8
M9_N@8*]3FIO&L,DOP<\.-'&[K'';,Y520H-NR@GT&6 ^I'K6T%RM+S.FDN1I
M6^T_R.A76M>\':#=WGBVZM=0=I%2R6U&&=R&)1CL50N%SG!/WNO K(_MGXB1
MZ1_PDV-,EL)8/.^R;?\ 4Q;=WF8R#T&<;V/S?=["S\6T:]\'V5W:2--;BX5\
MQX:,JR,%<G'3) !S@[^YQC'E\#> H]"?65UV[EM%4XV30!F?;N\L H/WA'\)
MP:F*C;F:W\C.FH.*E):M]OZL>FZ#J\6O:'::G"NU9TRR9)V.#AER0,X8$9QS
MC-:-<OX!T[3['PPDNF#4%M[R1K@"_"B3D!0?E&,$(".N0<]ZZBN>22DTCCJ)
M*;2"BBBI("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/.1U..!@#G/8457M)7O<KVU2]^9A1114&84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "O/_C;_ ,DAUW_MW_\ 2B.O0*\_^-O_ "2'7?\ MW_]*(Z /0**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKA[_XO^!-,U&YL+S7?+NK
M65X9D^R3G:ZDAAD)@X(/2@#N**X_1/BEX-\1ZQ!I.DZS]HOI]WEQ?99DW;5+
M'ED ' )Y-=)JNJV.AZ7<:GJ=S';6=NF^65^BC^9).  .22 ,DT 7**\W3XY>
M"3>,DEQ?16/(BU%[*3R)G4(61< ON <9RHQZ\C/HD$\-U;Q7%O+'-!*@>.2-
M@RNI&001P01SF@"2O/\ XV_\DAUW_MW_ /2B.O0*\_\ C;_R2'7?^W?_ -*(
MZ /0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBHYYX;6WEN+B6.&")"\DDC!510,DDG@ #G- 'F?Q\T>XU7X:M+;O BZ?=I=R
M^=*$W(%=,*3P6RXP,\]!DX!T/!/C[P$?"6GQ6&J:5I$,,2HUA-<B(P/M#,N9
M-I?!8Y?!W')R3FI/&MMX)\>>%84U3Q/:0Z7%>J5N[6_A53,$;Y"[;ESM<G'7
MH:\[_P"%6?"#_H??_*Q:?_$4 >R0>-/"MU<16]OXET::>5PD<<=_$S.Q.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S?XW>&-4\4> 1#I$'VBX
ML[M;MH%^_(BHZD(/XF^<''?!QDX!YO3?VBM-@MVM_$F@ZE::I YBFCM45EW*
M &R'960[MPVG.,#DUZQXCU^Q\+>'[S6M2:06EJ@9_+7<S$D*J@>I8@<X'/)
MYKPR^^(=YXC\?:(FI> =*&D:K=PVUE=:QI9>>2W9U&Y9&.T_?W *"!O'7J0
MO]>U'XX>.=*LM!LI[#1-)E2XFOV"QW,62-S"0;MC';A%4G)7<>!\GT/7F^F>
M/K#0_B!+X"NM"_L:!I0-)>...*&1&4DD@-CYI P4KG)8*0K Y](H *Y?XC7F
MJ6'PZUZZT8?Z=%:,58/L,:?\M'4Y&&5-S#!Z@<'H>HHH \G^ UMX6_X0N*XT
ME8)-:3<FHS/$%G5F.0IY)\O"KC!VMMS@-N R_P!H72O#,/AJ+4Y[:.+Q!/<*
MEM+!M5Y@ -_F]W0*H&>2I*#@$YL>*/V>=%UG5'OM'U*31Q,[/+;BW$L0)Q_J
MQN4H,[CC)'.!M Q1X7_9YT71M42^UC4I-8$+J\5N;<11$C/^L&YBXSM.,@<8
M.X'% 'J'AJ:^N?"ND3ZH)!J$EE"]T)(]C"4H"^5P-IW9XP,5J444 %%%% !1
M110 4444 %>?_&W_ ))#KO\ V[_^E$=>@5Y_\;?^20Z[_P!N_P#Z41T >@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.N_]N_\ Z41UZ!7G_P ;?^20Z[_V[_\ I1'0!Z!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@$X]C75_\)MXB_X:-_X13^T/^))_SZ^3'_SZ>9]_;N^_SU]NE'[1W_)/-/\
M^PK'_P"BI: /5-)LYM.T:QLKB[DO)[>WCBDN9,[IF50"YR2<DC/4]>IJY7/^
M!/\ DGGAK_L%6O\ Z*6N@H **** "BBB@ HHHH *\_\ C;_R2'7?^W?_ -*(
MZ] KS_XV_P#)(==_[=__ $HCH ] HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+:YJ.I:/<0:WI$UW<W:6+OYQBC.=J$-MDX&,)$Q&5Z<\@'G'VSXC_P#"Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \O\4W'BGQ/\2H?"&G7U]H6B16GVF[O8HC')=[
M6C++!+STWQKD8P2^[<,*<?Q%\++CP=H>J^)/"?BW7+?4X,W]S]KN@Z70CW.V
M\*HW-R2-VX'D$?,2/:*\O\>^+O\ A(OM?P_\(-]MUZ\W6UY*H_<V,/ E:1RI
M!X)3"Y()(X8*I .P\#^)/^$N\%Z7KAC\N2ZB_>H%P!(I*/M&3\NY6QDYQC/-
M=!67X;T2'PYX:TW1H/+*6=ND1=(Q&)& ^9]HZ%FRQY/)/)K4H *\_P#C;_R2
M'7?^W?\ ]*(Z] KS_P"-O_)(==_[=_\ THCH ] HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %>?_ !M_Y)#KO_;O_P"E$=>@5Y_\;?\ DD.N_P#;O_Z41T >@5P_
MB_X@_P!D:BWA[P_IL^M>)I(@Z6L"[H[;<5"M.V1L7Y@?IC)4,&K#?7_%?Q,=
MX/"32:#X:WRQMKTJAI;H!=N(8CAE&XGYL@_+]Y64H>T\)^"]"\%:<UGHMIY7
MF[3/,[%Y)F48!9C^)P,*"3@#)H /".G^(+'3KN3Q-J,%[J5W=O.5M@PAMT(5
M5BCW<[0%ST'+'.3ECT%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]P\UIX:BVO%&1A4::13B4X#''(^;J 62O2(((;6WBM[>*.&") D<<:A510,
M #@ #C%244 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*<<DCUKUZO/_ (V_\DAUW_MW_P#2B.@#T"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\_^-O\ R2'7?^W?_P!*(Z] KS_X
MV_\ )(==_P"W?_THCH ] HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHJG'JVFS:I-I<6H6CZA"F^6T693*B\<LF<@?,O)'<>M %RBBB@
M KS_ .-O_)(==_[=_P#THCKT"O/_ (V_\DAUW_MW_P#2B.@#T"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** .3\;:EXK@2UTSPEI4<]Y?)(
M&U">0+%8 ,@WL",,<.2%Z_*3M8 BO,_AKH/_  C7Q^\0Z2;V>^DBTH/+=3G+
MS2.;=W8_5F8\DGU)/)]XKQ_P]_R=#XL_[!4?_H-K0![!1110 5Y_\;?^20Z[
M_P!N_P#Z41UZ!7D/Q@\:>']0\!:_H%KJ'F:FKI&8/)D&&CF0N-Q7;P%;OSCB
M@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .7\2:YXJT
MS48X=#\'?VU:M$':X_M.*VVOD@IM<9.  <^_M7F^G67Q#L/BAJWC3_A ?,_M
M"T6V^Q_VQ;CR\"(;M_?_ %73:/O>W/N%% &/X;U'6=3TZ2;7-!_L6Z64HMO]
ML2YW)@$/N08&22,>WO6Q110 5Y_\;?\ DD.N_P#;O_Z41UZ!7G_QM_Y)#KO_
M &[_ /I1'0!Z!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %>?\ QM_Y)#KO_;O_ .E$=>@5Y_\ &W_DD.N_]N__ *41T >@
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEL %E;BMD> _'L5A>6D7A2%],DNXITL9KZ#>I++(Z+ABGE!D9<$ _O <'Y@
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M9+#DD'!4US=S\</$-U874]GX<L-*6S9?M%SJ%S)<1KG \O;&BMORRYZ[<$$
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MN!48 !R<G''^'/ 7CWP]<6DVIZ&UQ8)"[R+!<QRR0/\ =#%=Q+L$0* F?E;
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M0. O6LGPOX)^(MIKTA_LBW:RF ADGO;@18\L-R0&=@6<DDA6#%B02#NK=L/
M'CB[\,W=C<6.D68N1.D4,U^^^WC<L%4[(V4@ \8(XP,#% "77QPU^WDAL_\
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M 5Y_\;?^20Z[_P!N_P#Z41UZ!7G_ ,;?^20Z[_V[_P#I1'0!Z!1110 4444
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MD:3X6T/0[F2YT[388)Y 5\P LR(2#Y:$YV1Y PBX4=@*UZ** "BBB@ HHHH
M**** ,:^\(^'=4OVO;_1+"ZN'&'>:!7\S@ %@1AB , G)4$@8!.=GI110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D/Q@U7Q!/X"U^RNO#/V;3
MZ*-1^WQOE5F38WE@;OF(48[;N>E>O5S_ (V\,?\ "8^$+[0/MGV/[5Y?[_RO
M,V[9%?[N1G.W'7O0!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>=W\FOV?Q2\+QWNL.]K
M?SZ@5LK?Y(4A2(>6&[R/_$2Q(#'"@ 9(!Z)1110 4444 %%%% !1110 4444
M %%%% !1110 45YQXDTN^T3P9+J5WXGU/_A)G\DP2)<.T<ET N((K=-J,KE2
M "A.&+-G!KT. RM;QFX1$F*@R)&Y=5;'(#$ D9[X'T% $E%%% !1110 4444
M %%%% !1110 445R/C"72=*GBUCQ'KVH6>E[1:PVUK+-$OG,68NS0G>Q*J
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MG=0I:1"4=L#@ LI(]B.!TH Z&BBB@ HHHH **9,95@D,"(\P4E$=RJLV. 2
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M:!::Q)J=[K6LP6MG-=P6\,=E!(93"D>]OGDP S%I7'RC "CD]:Z"B@ HHHH
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M\]-^_=^F,?C75R7_ (QLV-X-$AU""YB1Q81W21SV4OEG=&7(V2)O ^;((W'
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M!>O\.,9Z'/M76RZ;>OJFG>*H]+1=56P-K=V37/S!&*OM1\%&96# 9VAMW+*
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MXR 2.U>I44 <1X7OO%,5[%::AX,>S@G9GN]2EU:&9V?;]YE51DG"J ,!1@
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M]"]_Y.W'_P <KT"B@#S_ /X4E\//^A>_\G;C_P".4?\ "DOAY_T+W_D[<?\
MQRO0** //_\ A27P\_Z%[_R=N/\ XY1_PI+X>?\ 0O?^3MQ_\<KT"B@#S_\
MX4E\//\ H7O_ "=N/_CE'_"DOAY_T+W_ ).W'_QRO0** //_ /A27P\_Z%[_
M ,G;C_XY71VW@W0+.UAMH+#9#"BQQKYTAPH& ,EL]*W:* ,?_A%=%_Y\O_(K
M_P"-'_"*Z+_SY?\ D5_\:V** ,?_ (171?\ GR_\BO\ XT?\(KHO_/E_Y%?_
M !K8HH Q_P#A%=%_Y\O_ "*_^-'_  BNB_\ /E_Y%?\ QK8HH Q_^$5T7_GR
M_P#(K_XT?\(KHO\ SY?^17_QK8HH Q_^$5T7_GR_\BO_ (T?\(KHO_/E_P"1
M7_QK8HH Q_\ A%=%_P"?+_R*_P#C1_PBNB_\^7_D5_\ &MBB@#'_ .$5T7_G
MR_\ (K_XU%<^#= O+6:VGL-\,R-'(OG2#*D8(R&STK=HH \__P"%)?#S_H7O
M_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRO0** //_P#A27P\_P"A>_\ )VX_^.4?
M\*2^'G_0O?\ D[<?_'*] HH \_\ ^%)?#S_H7O\ R=N/_CE'_"DOAY_T+W_D
M[<?_ !RO0** //\ _A27P\_Z%[_R=N/_ (Y1_P *2^'G_0O?^3MQ_P#'*] H
MH \__P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_QRO0** //_P#A27P\
M_P"A>_\ )VX_^.5+;?!KP#:74-S!H.R:%UDC;[9.<,#D'!?UKNZ* ,?_ (17
M1?\ GR_\BO\ XT?\(KHO_/E_Y%?_ !K8HH Q_P#A%=%_Y\O_ "*_^-'_  BN
MB_\ /E_Y%?\ QK8HH Q_^$5T7_GR_P#(K_XT?\(KHO\ SY?^17_QK8HH Q_^
M$5T7_GR_\BO_ (T?\(KHO_/E_P"17_QK8HH Q_\ A%=%_P"?+_R*_P#C1_PB
MNB_\^7_D5_\ &MBB@#'_ .$5T7_GR_\ (K_XUC:M\*_!>N72W.HZ-Y\R((U;
M[5,N%!)QA7'<FNQHH \__P"%)?#S_H7O_)VX_P#CE'_"DOAY_P!"]_Y.W'_Q
MRO0** //_P#A27P\_P"A>_\ )VX_^.4?\*2^'G_0O?\ D[<?_'*] HH \_\
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M?_'*] HH \__ .%)?#S_ *%[_P G;C_XY1_PI+X>?]"]_P"3MQ_\<KT"O/\
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M7SI!E2,$9#>E,TOQMX=UKQ%>Z!I^H>=JEEO^T0>3(NS8P1OF*A3AB!P3704
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MB_\ /E_Y%?\ QK8 P,"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img243551639_21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_21.jpg
M_]C_X  02D9)1@ ! 0$ -@ V  #_X2<J17AI9@  34T *@    @ "0 +  (
M   F   (A@$2  ,    !  $   $:  4    !   (K $;  4    !   (M $H
M  ,    !  (   $Q  (    F   (O $R  (    4   (XH=I  0    !   (
M]NH<  <   @,    >@  $9(<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0
M    -@    $    V     5=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 ,C R,CHP,CHQ," Q,3HS,SHQ,   ") #  (    4   1:) $
M  (    4   1?)*1  (    #.#,  )*2  (    #.#,  * !  ,    !  $
M * "  0    !   "T* #  0    !   !E>H<  <   @,   )7      <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         #(P,C(Z,#(Z,3 @,3 Z
M-3$Z,3@ ,C R,CHP,CHQ," Q,#HU,3HQ.      & 0,  P    $ !@   1H
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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MTZT +#]HCBN&?1X6+E5V1I@,IR3D'\,_7VIT%WJ$;$II*('=LA%*D@ ;2?\
M/:@#0TZ]EO5F:6W: QR% K YX[]/Y4V^FU".9!:11/$%S(7!)'T Z^N* ,N6
M749Y6:32+:4[,>8\1X']W!Y//8<5).]Q'9HBZ+'+(L!905RJNQ.5QUY[_6@!
MPU._MK?YM*(1$;B,$!<'  'N,&MF"0RV\<C#:S*&(YXR/>@"2B@ HH J7]K-
M=1HL%R8&5PVX#.?:JR:?J&V43:FS[U(7"!0I..?YT 0-IVKJT 75B1N_>9C&
M2,'^N*NZ=#>0^:+NZ$_("$+C' S^M %ZB@!&Y4@'&1UK'73-25=JZLX7)/\
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7J,\]:F5%-7IO7L92PD*B;H.[7V7O\NY])T5&N&7(Y!IU<IY8ZBBB@ HHHH
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M#C"\\+P<GFFK\%=&_P"%I1^.Y+N[GU2$N886$.R(O%Y3#>(Q*R[2<(TA4'D
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M @'!(S6+_P *A\#KS_PA^@_^"R#_ .)JUR6U-H^SM[UR?_A:G@W_ *&O1/\
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M9()P,XKWL7.C+"P49:GVF9UL//+J,*=2[73_ #1ZO3J6BO!/BPHHHH ****
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M0/$3:VLZ!63RL&(1Y+AL_)R,;>]>JW]E%&D<BAM_GQGEV(YD7MG% &G1110
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M^I\5C/\ >:O^)_F.HHHK$XPHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P!6WTIU-D_U;?2FMQK<_//X?_\ 'QXN_P"QBOO_ $,5UU<C\/\ _CX\7?\
M8Q7W_H8KKJ^GGN?HE3XA" P((R#U%-BA2! D2+&@[* !^0I]%3>W4SN]D%%%
M% 7?0****!/S+OP*_P"3K+/_ +%F7_T>*^T?2OB[X%?\G66?_8LR_P#H\5]H
M^E>3COXB]#YS./X\?\*'4445YYX04444 %%%% ">M?#/Q"_Y.F^)7_7'3_\
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M &+]Q_Z4Q5QE?04?X4?0^WPO^[4_3]0HHHK4Z0HHHI@%%%%(#G/B+_R(>O\
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MDY. . /:J]=ZV/;C?E]XN_ K_DZRS_[%F7_T>*^T?2OB[X%?\G66?_8LR_\
MH\5]H^E>7COXB]#Y[./X\?\ "AU%%%>>>$%%%% !1110 GK7PS\0O^3IOB5_
MUQT__P!)4K[F]:^&?B%_R=-\2O\ KCI__I*E>E@/CEZ?JCW\F_BU/\/ZHGHH
MHKTSZ$]?^$\&BZW%::;-I.G*<-]HDU!MUQ<Y5L>2,<!2O.#P/?FNHTOP3H&@
MV=A";331)?7,H\O5AOE<;FVQ*<G! P"1D9'0E@:\LT7XK:KH^GVEJ;:RO39Y
M%K/=0[I( 0!A3D8&!Z9[9/ IVF_%S6;.';<0V>INL[W$,MW &>&1B22N",<D
MD<<9P.,"N"5*HW='BU,-7E*3B]/4]'T_P3X;U[27T:&VLK6[@*B94??=PR+*
M1)ER.5*\*2 #GH.,>8?$SP[<:'KQD:VM+:SN,BV2S(9%"'85)P,N,#.>Y/-5
M+?Q]JUJDQA>-+BXO%O9[D+\\KJ<A3VV \@  9]N*9XN\;7WC*:W:ZBMK:.#>
M8XK:/:H9FR[')Y)(R<_S))UIPJ1E?H;T:-:G43;NCGZYW4?^2H_"S_L9+;_T
M):Z*N=U'_DJ/PL_[&2V_]"6NQ=?1_D>LMI>C_(_0%?NCZ4M(OW1]*6OF#\\"
MBBB@ HHHH **** /E+]I;_DN7A[_ +%^X_\ 2F*N,KL_VEO^2Y>'O^Q?N/\
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MN]'LH]__ &2?^3>_"?\ NW/_ *4RUZ__ (5Y!^R3_P F]^$_]VY_]*9:]?\
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M/EQM?Y1P=_\ LBF6^CZM''IZSZ]+.85(N3]EB7[22N < ?)@\X&: /@[X?\
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M9H&>YNGB6$I)&" 7DRN'!SP  PV\]>O'++;]GC1(TL1->W,S11[;E@ GGMM
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MX958AU8#C((Z]Q@U>M?&GA^_MKV>VUS3KBWL@3=2Q7<;+!UR7(.%Z'KBO._
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MM&N[N6SG@LI;/4[6X2T5E\V3S(8T$JY.1F5F()Q[T ?6=%%% !1110 4444
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MVHZA:V%D,?Z1=3+''ST^9B!S]:^?_B)\(=:\8:AJUII_AF\TB+69XKB>Z37
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MFHF]B,4OFDA0 #D<C )X).!FM2+Q?H,VES:E'K6GOI\+%);M;N,Q1L.JEP<
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img243551639_22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_22.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y <H# 2(  A$! Q$!_\0
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MM;N&\1W@;<J2-&W&,,IP14V,VFMR>BL*^\0RQZG)IVF:=+J%S"H:;:X1(\]
M6/<^E7+75XI--6\O4;3\DJR71"%2/?H:?*RG"25S1HK+N=;B@U/3;2-1,M\)
M"LJ." %7=^.:S-+\:6FJ:)J-^D#)-8J[R6[-R0H)!!]#BGRO<:I3:O8Z>BN;
MU?Q='I6D6%[]CDGDO%#K"C<JNW<QS["MO[?:BR2\>XBCMW4,)'<*N#TY-+E8
MG"25VBS140N8GM3<0NDL>TL&1@0?H:RM,\0+J$5I,8%AAN+=IRSS+\F#C&.I
M]<]*+,2BVKFU151=2M)EE^S7,$\D:;RD<JD].,\\5'%JMO\ 8+>YN98;<SJ"
MJ/,IR?0'.#^%%F+E9?HJAHVIC6-*AOEB,0EW?(3G&&(Z_A5^DU8&FG9A1110
M(*P=0T&6[OY9UE@Q+L^>2,M)%M_N'/%;U% &+)HL[-+;K<I]AFE\Z12I\S/!
M(!SC!(]*TKRQM=0@\B[A6:+(.UAQD58HH Y:ZT?3],\1:*]E:1P,\L@8H,9'
MEFNIK#UC_D/Z%_UVD_\ 19K<H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \OUW3O$-MXXO\
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MT;+O^A=HHHJ20SFL+QA_R+%U]5_G6[6%XP_Y%BZ^J_SJH_$BZ7QQ]3TK1_\
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M-%%%4,****!D'@/_ )!EW_U\M_(5U=<IX#_Y!EW_ -?+?R%=766)_BR'@O\
M=XD-Y_QY3_\ 7-OY5Y3X)_Y%[_MO)_2O5KS_ (\I_P#KFW\J\I\$_P#(O?\
M;>3^E3#X6>K1_A2]5^IT5%%%( J&[_X\KC_KD_\ (U-4-W_QY7'_ %R?^1IH
M%N7_ (7_ /(CVW_767_T(UV-<=\+_P#D1[;_ *ZR_P#H1KL:FI\3,L1_%EZA
M1114&(4444 %%%% !1110!S/Q _Y$?4_]P?^A"N>TC_D#6/_ %P3^5=#\0/^
M1'U/_<'_ *$*Y[2/^0-8_P#7!/Y5K'X#KI_P?G^A=HHHI %87C#_ )%BZ^J_
MSK=K"\8?\BQ=?5?YU4?B1=+XX^IZ5H__ "!+#_KWC_\ 015VJ6C_ /($L/\
MKWC_ /015VLGN<4MV%%%%(0$ C!Z5SS^((K'STATBY,$,QB,D2J%+9QQSZFN
MAKBFMOMFLW!AM'^RK=_O(FO@J/(#R^SZ\^] '6V5Y%?V<5U#NV2#(##!'L15
MBH;2UBLK9+>$$1H,#)R:FH **** ,/6/^0_H7_7:3_T6:W*P]8_Y#^A?]=I/
M_19K<H *XJY_Y'V]_P"O=/Y"NUKBKG_D?;W_ *]T_D*Z<-O+T_5''C/L?XE^
M3-&BBBK ****!E+PY_R-^J_]<U_I78UQWAS_ )&_5?\ KFO]*[&L\3\:]%^0
ML%_#?J_S"O*+'_D>O$__ %V%>KUY18_\CUXG_P"NPK.GLSU</M/T_5&[1110
M4%'>BCO0!7^'/_(:\2_]?(_FU>A5Y[\.?^0UXE_Z^1_-J]"I5/B,\3_$?R_(
M*X+0/]9J?_7TW]:[VN"T#_6:G_U]-_6M\/\ !/Y'EXG^+3^?Y&S1115#"BBB
M@9!X#_Y!EW_U\M_(5U=<IX#_ .09=_\ 7RW\A75UEB?XLAX+_=XD-Y_QY3_]
M<V_E7E/@G_D7O^V\G]*]6O/^/*?_ *YM_*O*?!/_ "+W_;>3^E3#X6>K1_A2
M]5^IT5%%%( J&[_X\KC_ *Y/_(U-4-W_ ,>5Q_UR?^1IH%N7_A?_ ,B/;?\
M767_ -"-=C7'?"__ )$>V_ZZR_\ H1KL:FI\3,L1_%EZA1114&(4444 %%%%
M !1110!S/Q _Y$?4_P#<'_H0KGM(_P"0-8_]<$_E70_$#_D1]3_W!_Z$*Y[2
M/^0-8_\ 7!/Y5K'X#KI_P?G^A=HHHI %87C#_D6+KZK_ #K=K"\8?\BQ=?5?
MYU4?B1=+XX^IZ5H__($L/^O>/_T$5=JEH_\ R!+#_KWC_P#015VLGN<4MV%%
M%%(1'.S+;R,K*K!20S=!QU-<"MUIUQ??:A=Z3)*;D!E2!C(S;@,CGGZUWMP'
M-M*(]Q?8=NW&<X[9X_.N(MY+J"1I]FIQ0I=!)6#V^T.6 .<<XR><4 =Y1110
M 4444 8>L?\ (?T+_KM)_P"BS6Y6'K'_ "']"_Z[2?\ HLUN4 %<5<_\C[>_
M]>Z?R%=K7%7/_(^WO_7NG\A73AMY>GZHX\9]C_$OR9HT4458!1110,I>'/\
MD;]5_P"N:_TKL:X[PY_R-^J_]<U_I78UGB?C7HOR%@OX;]7^85Y18_\ (]>)
M_P#KL*]7KRBQ_P"1Z\3_ /785G3V9ZN'VGZ?JC=HHHH*"CO11WH K_#G_D->
M)?\ KY'\VKT*O/?AS_R&O$O_ %\C^;5Z%2J?$9XG^(_E^05P6@?ZS4_^OIOZ
MUWM<%H'^LU/_ *^F_K6^'^"?R/+Q/\6G\_R-FBBBJ&%%%% R#P'_ ,@R[_Z^
M6_D*ZNN4\!_\@R[_ .OEOY"NKK+$_P 60\%_N\2&\_X\I_\ KFW\J\I\$_\
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M;?\ 767_ -"-=C7'?"__ )$>V_ZZR_\ H1KL:FI\3,L1_%EZA1114&(4444
M%%%% !1110!S/Q _Y$?4_P#<'_H0KGM(_P"0-8_]<$_E70_$#_D1]3_W!_Z$
M*Y[2/^0-8_\ 7!/Y5K'X#KI_P?G^A=HHHI %87C#_D6+KZK_ #K=K"\8?\BQ
M=?5?YU4?B1=+XX^IZ5H__($L/^O>/_T$5=JEH_\ R!+#_KWC_P#015VLGN<4
MMV%%%%(05QRSFTU:[6'4Y([<W)=P;)67<6 *ALYZD FNOD9EB=D3>X!*KG&X
M^F:X.0&6^:^ETV\CM5N@DT8NHS&)"XR<=<;L$X[T =]1110 4444 8>L?\A_
M0O\ KM)_Z+-;E8>L?\A_0O\ KM)_Z+-;E !7%7/_ "/M[_U[I_(5VM<5<_\
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MK'_K@G\JZ'X@?\B/J?\ N#_T(5SVD?\ (&L?^N"?RK6/P'73_@_/]"[1112
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MEOY"NKKE/ ?_ "#+O_KY;^0KJZRQ/\60\%_N\2&\_P"/*?\ ZYM_*O*?!/\
MR+W_ &WD_I7JUY_QY3_]<V_E7E/@G_D7O^V\G]*F'PL]6C_"EZK]3HJ***0!
M4-W_ ,>5Q_UR?^1J:H;O_CRN/^N3_P C30+<O_"__D1[;_KK+_Z$:[&N.^%_
M_(CVW_767_T(UV-34^)F6(_BR]0HHHJ#$**** "BBB@ HHHH YGX@?\ (CZG
M_N#_ -"%<]I'_(&L?^N"?RKH?B!_R(^I_P"X/_0A7/:1_P @:Q_ZX)_*M8_
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MQJB6_P!HN=IA+YW\]:Z6LQ[B$>(8T,J!O(*XSWSTK:%6H[ZF-3#T5;3JBO\
M\(Q;?\_5W_WW5?4- @M=/GG2YNB\:%@"_%='5+6/^0->?]<C2A6FY+4=3#4E
M!M1Z&YX9);PU8$DDF(<FM6LGPQ_R+.G_ /7$5K5PU?XDO5GHT/X4?1?D<S\0
M/^1'U/\ W!_Z$*Y[2/\ D#6/_7!/Y5T/Q _Y$?4_]P?^A"N>TC_D#6/_ %P3
M^5./P'H4_P"#\_T+M%%%( K"\8?\BQ=?5?YUNUA>,/\ D6+KZK_.JC\2+I?'
M'U/2M'_Y EA_U[Q_^@BKM4M'_P"0)8?]>\?_ *"*NUD]SBENPHHHI""BBB@
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MI_\ 7TW]:[VN"T#_ %FI_P#7TW]:WP_P3^1Y>)_BT_G^1LT4450PHHHH&0>
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MXJY_Y'V]_P"O=/Y"NUKBKG_D?;W_ *]T_D*Z<-O+T_5''C/L?XE^3-&BBBK
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M./J>E:/_ ,@2P_Z]X_\ T$5=JEH__($L/^O>/_T$5=K)[G%+=A1112$%%%%
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MFO\ A#+7_H(ZA_W^'^%'_"&6O_01U#_O\/\ "NEHHN%V<U_PAEK_ -!'4/\
MO\/\*BN/ >GW<#0W%[?R1MU5I00?TKJJ*=V',UU,&/PR(HUCCU?4U1 %51/P
M /PI_P#PCK?]!G5/^_\ _P#6K;HI"*MA9FQMS$;F>X^;.^=MS?3-6J** "BB
MB@ HHHH **** "BBB@ K*OM?M+"]^R/%<RS! Y6&(O@'@9K5K#M_^1UO?^O*
M+_T)J %_X2>V_P"?+4?_  &-'_"3VW_/EJ/_ (#&MNB@#$_X2>V_Y\M1_P#
M8T?\)/;?\^6H_P#@,:VZ* ,3_A)[;_GRU'_P&-'_  D]M_SY:C_X#&MHD 9)
MQ1D<\CB@#%_X2>V_Y\M1_P# 8T?\)/;?\^6H_P#@,:V/-CSCS%S]:?0!B?\
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M:H ;(ZQQL[?=4$GZ"L.+Q993Q++%:W[QN,JPMC@BM>\_X\;C_KFW\JH^&?\
MD6-,_P"O=/Y4 0_\)/;?\^6H_P#@,:/^$GMO^?+4?_ 8UMT4 8G_  D]M_SY
M:C_X#&C_ (2>V_Y\M1_\!C6V3@9/2D+*HR6 'J30!B_\)/;?\^6H_P#@,:/^
M$GMO^?+4?_ 8UM;EVYR,>N:&=5^\P'U- &+_ ,)/;?\ /EJ/_@,:/^$GMO\
MGRU'_P !C6WG(R*0D @$@$]/>@#%_P"$GMO^?+4?_ 8T?\)/;?\ /EJ/_@,:
MVZ* ,3_A)[;_ )\M1_\  8TR3Q990QF26VOXT'5FMR /K6]6-XK_ .17U#_K
MG_44 ;"L&4,.A&12U'!_Q[Q_[H_E4E !1110 4444 %%%% !1110 4444 %8
M=O\ \CK>_P#7E%_Z$U;E84+*OC6]R0/]"BZG_::@#=HIOF)_?7\Z/,3^^OYT
M .HIOF)_?7\Z/,3^^OYT 4->M'OM"O((B1*8RT9!P=PY'ZBN(DU"\O5:Z4RA
M-;Q:Q@9_=["%)]LC>:]&\Q/[Z_G3 MN H B 4Y4<<'VH YB;1K%?&-E%Y&4:
MU>1OF;!<,,'KUKK*CS$7#Y3<!@'C-.\Q/[Z_G0 ZBF^8G]]?SH\Q/[Z_G0 Z
MBF^8G]]?SH\Q/[Z_G0!BZ'_R%==_Z^Q_Z M;E8>A$'5-=(((^UCI_N+6Y0 5
MA^&^FJ_]A"7^E;E87AQU7^U<L!_Q,)>I^E &[13?,3^^OYT>8G]]?SH IZT2
M-"U @D'[/)C'^Z:YC4+^SNO!ME&MTDFQK83A7Y5=PSG]:[(O&P(+(0>"":B$
M%F%*B* *W4!1@T </J36T2:JNCRL; 68:;8Y*++O&-I]<=<5>UVYAU)-&CLS
M%>_O]KQB7"D[,X)'2NL"VXB\H+$(S_!@8_*D2*UCQL2%<'/R@#F@##\)"7^Q
M9Y$"HSSN5MF9B(#TV$GG_P#73/.U1M-GMKKRTEN;@PQ%68D GD\CH!FNB4Q*
M25*#<<G&.32DQ,5)*$KR"<<4 06DDI:2%[-H(HL+&Q=2''L >/QJU3?,3^^O
MYT>8G]]?SH =2/\ <;Z4GF)_?7\Z:\B;&^=>GK0!D^$O^17L?]T_^A&MJL7P
ME_R*]C_NG_T(UM4 07G_ !XW'_7-OY51\,_\BQIG_7NG\JO7G_'C<?\ 7-OY
M5G^&G0>&=-!=?^/=._M0!KT4WS$_OK^='F)_?7\Z *.O$CP_J!4D'[.^,=?N
MFN<U&_L+S0M'C:ZCDB6> 7&'Z#:<[L5V!:-E*LR$'@@D5"+>R"E1#;[3U&T8
M- '"ZC)#%!JHTN5SIB" [@Y*++O&=I/MUK2\0W$6IZGI?V*./4$'G9B$NU6(
M7/4=ZZO;;^5Y6V+R_P"Y@8_*A([6,@QI"F.FT 8H Q/##2Q>&1,BF=V=W2 /
MS'S_ *O+>G3FI'N+FXU(3+9.[V<(/D"1<^8YZ9SC(4?^/5LJ84!"%%!.3C Y
MI0T2DD% 6Y)&.: ")F>)&>,QL0"4)!VGTXI]-\Q/[Z_G1YB?WU_.@!U8WBO_
M )%?4/\ KG_45K^8G]]?SK'\5.A\+WX#+GR_7W% &M!_Q[Q_[H_E4E1P?\>\
M?^Z/Y5)0 4444 %%%% !1110 4444 %%%% !6=?:%IFI3B>\LXYI0NT,V<X]
M*T:* ,;_ (1/0O\ H&Q?F?\ &C_A$]"_Z!L7YG_&MFB@#&_X1/0O^@;%^9_Q
MH_X1/0O^@;%^9_QK9HH QO\ A$]"_P"@;%^9_P :/^$3T+_H&Q?F?\:V:* ,
M;_A$]"_Z!L7YG_&C_A$]"_Z!L7YG_&MFB@#&_P"$3T+_ *!L7YG_ !H_X1/0
MO^@;%^9_QK9HH QO^$3T+_H&Q?F?\:/^$3T+_H&Q?F?\:V:* *EAIEEID31V
M5ND*.VY@O<^M6Z** "LF?PSHUS/)/-I\32R-N=CGD^O6M:B@#&_X1/0O^@;%
M^9_QH_X1/0O^@;%^9_QK9HH QO\ A$]"_P"@;%^9_P :/^$3T+_H&Q?F?\:V
M:* ,;_A$]"_Z!L7YG_&C_A$]"_Z!L7YG_&MFB@#&_P"$3T+_ *!L7YG_ !H_
MX1/0O^@;%^9_QK9HH QO^$3T+_H&Q?F?\:/^$3T+_H&Q?F?\:V:* ,;_ (1/
M0O\ H&Q?F?\ &C_A$]"_Z!L7Z_XULT4 16UM#9VT=O;QB.&,81%Z 5+110 C
M*'4JPRI&"*QAX2T$# TR$#\?\:VJ* ,;_A$]"_Z!L7YG_&C_ (1/0O\ H&Q?
MF?\ &MFB@#&_X1/0O^@;%^9_QH_X1/0O^@;%^9_QK9HH QO^$3T+_H&Q?F?\
M:/\ A$]"_P"@;%^9_P :V:* ,;_A$]"_Z!L7YG_&C_A$]"_Z!L7YG_&MFB@#
M&_X1/0O^@;%^9_QH_P"$3T+_ *!L7YG_ !K9HH QO^$3T+_H&Q?F?\:/^$3T
>+(/]FP\<]_\ &MFB@!  H  P!P*6BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img243551639_23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_23.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %9 G,# 2(  A$! Q$!_\0
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M:I_.V?89MOFA-^Y,;2N=_7H#QCKGMBK5 !1110 4444 %%%% !1110 4444
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MUS,$EN-WEC!.=HR>G3 ]:25]@2;T1<HK.77]*;3VOUOX3:(VQI0W ;T/YBM
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MY&N[ETS79)G>&XE$3,2@%\5P.W'E\?2M:V$A#:7?\#GPF;5:U^:F[I+;SO\
MA:QN2ZUID%U]FEO[=)LX*%QP?0^E36^H6UW<W-O#)NEMF"RK@C!/2O/?$CV,
MD)^S/:;HW47:8Q.\@X)#%>1ZGUYKH=*9?^$RE,2,B3:='(R-U!&T#/OBIGAH
MJGS:WM_D72S*<Z_LW:UTM.SO^37YZ'54445Q'LA1110 4444 %%%% !1110
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M15'1]135M'M+],8FC#$#LW0C\#D5>K-JSL)IIV84444A!1110 4444 %%%%
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MZ%J;F$7!&1$7&\CZ=: )JS]._P"/W5O^OL?^B8JT*S]._P"/W5O^OL?^B8J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O.?'6JRVGBBUMI-=GTVV^R>8#!!YAWEB.>1U ]>W3FO1J\_\<ZAJT&K
M>5:7;6MK#:+.S);B0L/,VN<G^Z&!Q_C0!N^"_LTFA+<07C7Q=RK7+P^6[8/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!@3&,;P/][K5BB@ K/T[_C]U;_K['_HF*M"L_3O^/W5O^OL?^B8J -"BBB@
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M!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5Y)H/BC4(M7T^^NM8M18WT\B2V>]5
M%NHZ$C^'V/MWS7K9.!D]*\>DL]"N=(DU#3O"CO&UXEM;>9<R_O\ .[)&&XY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:DVI^&K9Y"?/@'D3 ]0R\<^^,'\:WJYY*SL=<XN,G%] HHHI$A1110 4444
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MM;'5HA_%$WE2'\\#\@:ZVBE[1O?4?MY/XDGZ_P">YRB>/+*!Q'JUC?:9(?\
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MZWI7_>B?_"J]E5ZPO\O\C19MA)?'*/WV_P B#_A.-'NK.0VFH00W*C(2[1E
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M_P"-T :%%9_]GW?_ $&;W_OB'_XW56Z@OH;NRB76+O;/*R-F.'H$9N/D]0*
M-JBL_P#L^[_Z#-[_ -\0_P#QNC^S[O\ Z#-[_P!\0_\ QN@#0JGI7_(*MO\
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M?WD_4\/_ ,^X_<BH?".@G_F')_WVW^-(?!V@'_F'K_W\?_&KG]GW?_09O?\
MOB'_ .-T?V?=_P#09O?^^(?_ (W1[>K_ #/[Q?4L+_S[C]R*)\&: ?\ EP_\
MC2?_ !5(?!6@'_ER(_[;/_C4NGV]]=6SR2:Q=@B>:,8CAZ+(RC^#T JU_9]W
M_P!!F]_[XA_^-T_K%7^9_>Q?4,)_SZC]R,X^"=!/_+HX_P"VK?XTT^!]"/\
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M@"CJVJVNC6)N[LOY88(JHI9F8\  =S60OC/16LIK^59XI;:3[.T,L.)U9OX
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M?O?I0!V5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>img243551639_24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_24.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %1 E4# 2(  A$! Q$!_\0
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M+GV'.>] %ZBJAN;O<0+!B-SC/FKT'W3_ ,"_3O2"YO"1FP89,>?WJ\;OO?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5=6<)/W58$F8NN7MQ:WNF)!*466;:X 'S#*_XU7\2ZG>:=<69M7(!#,Z8R&
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MX<LKV*[M].V3Q.'1_/D.".^"V*N6'AK1M+OI+VRL(X;AP07!)P#UP"<+^&*
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MT]5M4@:SD4[5B \ME/7@<8.:Q%\)>&+**;3UMHH3J *E#,=\@7YL+DYXX/%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME_UDB1A6?ZD=:L44 %9^A?\ (O:;_P!>L7_H K0K/T+_ )%[3?\ KUB_] %
M&A1110 4444 %%%% '!WUN^FZ[>P1?+N(U"V^H^^/YG_ ("*[:UN$N[6*XC^
M[(H8>WM6%XNA:&WM=6C7=)8R@N/[T;<,/Y?K4OAV987N-.#;DC(E@;^]&W(_
MF/SKKJ_O*2GU_K_@'#A?W=2=#L[KT>OX.Z^XWJ***Y#N"BBB@ HHHH ****
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M\I:^<V?PR<_F![5[%HMGXACNC+J=QIT5MAO]$LX3M+$YW%CSG.?KFM_:/04
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M0U%5:W[G5%IJZ"BBBLR@HHHH **** "BBB@ HHHH ***1T5T*.H92,$$9!H
M6BJ%O9VPO+@BWB!1UVX0?+\H/%7Z;5@"BBBD 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 57OO^0?<_\ 7)OY&K%5[[_D'W/_ %R;^1IQ
MW0$Z_='TI:1?NCZ4M( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M $;[C?2O&]&N/ $VF1OJ]D(+TD[XX6N"H&>,?,>V.]>R,,J0?2O+?!FHV"W-
MGI$NA(]E<O*+2^N(U9I2I).>/PXZ<4 =[X9.E'0+<Z(I&GY;R@=V?O'/WN>N
M:UJCA@BMHA%!$D4:]$10H'X"I* "J6J:7#JUNL$\EQ&JOO!@E,9S@CJ.W-7:
M* .<_P"$?NKGQ/>7][)$]DUG]DMD5B70'&XG(QD\\Y-9FA^#=0L=2TU[Z[MI
M;/2EE%J(E8.^\GE\\#&>WH*[:B@"M-IUC<R&2>RMY9#P6>)6/YD5!H(QX>TP
M#I]DB_\ 0!6A6?H7_(O:;_UZQ?\ H H T**** "BBB@ HHHH **** "F31)/
M#)#(NY)%*L/4'@T^B@32:LSC=,MY+C0K_1)"3=:=*?*/<CDJ1]>1^(KI=*O1
MJ&F07'\3+A_9AP:Q]1_XE7B^ROQQ!?+]FF]-W\)_D/P-6=/_ .)=KUW8'B*X
M_?P_7^(?Y]*ZZOOKF777_/\ $XL$W&+HO>#M\MU^!IG4+('!O+?/IYJ_XU8!
M! (.0>A%5W_Y"4/_ %QD_FE6:Y7;H=P4444@"BBB@ HHHH **** "BBFNZ1(
MSR,J(HR68X % ;$$'_'W=_[R_P#H(JS6;:ZE8O>W"K>V[,[J% E4ECM'3FM*
MJDFGJ3&<9?"[A1114E!1110 4444 %%%% !3)?-V_N@A;/\ 'G%/HH JVLUQ
M,"TBQ! S+\I).02/Z5:JM8_\>[?]=9/_ $-JLTY;@%%%%( HHHH **** "BB
MHIKF"W7,TT<8]78"BUP):KWW_(/N?^N3?R-4)?$NF1MM25YW_NQ(6S_2L3Q!
MJM]<VB>7:7-K;$X9G&TOZ#Z=:VIT9.2OH)M'8K]T?2EK"\*S7<VF,;EG90^(
MV?J1_A6[6<X\LG$$[A116*D^OFZ"M:6RP,_WMV2BY[\\G%$8W&;5%4-6MA<6
MN]KR:V2++LT38R,=ZXX:E=)82Q+>RJS_ +TM)(=P4?=5?<]3CM6E.CSJZ8F[
M'H%%<M+)/)IEE?Q7FY8HD5U\PY\S()Z?>)Z8/K6UI+K):%_M*SRNQ:0JV0K'
ML/0"IE3Y5<$R_16#_P )!,)KS-EFWM9&624..@SCCU)%5X_%H,$SRVRAEC#H
M%?(.2!@\<'FG["?8.9'345R(U>[MM0O[J>/YDMXV$'F$J,E1G]:T)O$GV>6=
M9( 5B@248;EBV./UINA/H',C>HKF-5U35!I+NUK]E.Y?WJ29X//'\C33J\EC
MJ5S-=1R>8ELI,0ERF25 P,>_7ZT*A)H.8ZFBN<?Q-+##<B:T5;B$(VP/D%6Q
MW_$5>TS59KV\N;:>V$+PA6P'W<&I=*:5V%T:M%%%9C$(RI'J*\;GT6STVT2=
M?&LWDV%P8(S#;.1#(P+$+A^,X.2*]D8;E(.1D8XKR1+'6M(M!HJZ)INHP17!
MF@N#* &;G#/\PS@$C#4 >A^%&9_#5H[7T]]N#,+F="C."QQP23]/:MFL3PCI
MDFC^&+.QEE262,,69&RH)8G /MG%;= !116?J.HS6$L"QZ?<W22$[Y(<8B''
M+9.>YZ>E &A17BV@ZG?)K=E="XEEDN6N-DJS%VN#@A5DCW'8,\]._MFM/PG>
MS'7=!D@OY[BZO4N#J4;REL8)VDC^'H,?_7H ]6K/T+_D7M-_Z]8O_0!4L[:@
M)3]GCM6C[&21@?T!J+0<_P#"/:9GK]DB_P#0!0!H4444 %%%% !1110 4444
M %%%% &3XET\ZEH5Q$@/G(/-B(Z[EYX^O(_&LV>[;4-!T_781F>W(9P._9Q^
M8_*NHKE]&C2QUG5="E'[B7-Q"IZ%&X8#Z<#\#732E>#7;7Y;,X:O[O$QGTE[
MK]5JOU7W&XLJ37MM+&<H]N[*?4$I5RN:T2Y%M?#3;F11);>9&A8XW E2N/UK
MI:RJ1Y78[4PHHHK,844UG1?O,H^IJ-KNV7[UQ$/JXIV8$U%56U.P7[U];#ZR
MK_C43:UIB];Z#\'!I\DNP7+]%9C>(=*7K>I^ )_I4;>)]('_ "]$_2-O\*?L
MY]F*Z->BL7_A*=,/W6E?_=C--?Q/;"-FCM;MR 2/W6!^)S3]C/L%T7++_D*Z
MG_UTC_\ 0!6A7":7XFNEU:>2:/S4G8%TB3YAA<#'Y5T/_"36H^]:WJ_6'_Z]
M:5:$U+;HOR,J37+\W^;-JBL7_A*-.'WO/7ZQ&G#Q3I)ZW##ZQM_A6?LI]C6Z
M-BBLH>)-(;I>#\48?TIXU_2FZ7L?XY%+V<^S"Z-*BJ(UK3&Z7T'XN!3QJFGM
MTOK8_P#;5?\ &ER2[#N6Z*@%]:-TNH#])!3Q<0MTEC/T84K,"2BD# ]"#]*9
M//%;0O-,X2-!EF/:D!%8_P#'NW_763_T-JLUDZ9JUA-;2%;J-=LCL=YVX!8D
M'GV-+-XCTN$[1<>:_98E+9_I6CIR<FK"NC5HK$_MF_N/^/+1YR#T><A!_G\:
M/(\077^LNK:T4]HDW']?\:/9M;M(+FWTJE<:OI]KGS;R($=@VX_D*H_\(Y'-
MS>WMU='T9\+^57;?1].M<>59Q CNR[C^9HM36[N&I3/B2&4XLK.ZNCZI'A?S
MI/M&OW7^JL[>T4]YGW']/\*VP,# Z44<\5M$+&)_8^H7'_'YK$V#U2!0@_/_
M .M4L/AO3(FW- 9G_O2L6S_2M:BCVL^X61'%;PVZ[88HXQZ(H'\JCO\ G3KG
M_KDW\C5BL_6'N(]-NGA\K8L#E@^<G@],5,=9(4Y*,6V7UX4?2EJ"V^T%,W'E
M<@;?+S^N:GI-68T[JX4444AE:^LTU"S>VE=U1\9*$ \'/>H)-%LI;$6K1# 0
M)YH4;\#WQUXK0HJE.2T3"Q071[588(<,8X5("\ ,2,;C@<G'?WI^GZ=%IR.L
M;R.7QEG(S@# ' '0"KE%#G)JUPL4(M(MHUO%.]UNW+R!CW/ICZU77P[:BVD@
M>>ZEC90@#R9V '(P.E:]%/VDNXK(QE\-V@68//<R&:,1L7<$X!!&./84L?AJ
MR42AY)Y?-C$;>8^>!C!''7@5L44_:S[A9&3_ ,(_;-92VTDUQ()-N7=\L-O0
M#C%(/#MH3(999YC)$(F,C@G ((/3KP*UZ*7M)]PLC&'AJS-O-$\MP[2[=TC.
M"V!T'3I5VWTV&VO9[M&<R3!0P)&!@8XXJY10ZDGNPL@HHHJ!B-C:<],5\^7D
MN@ZEJZ1VEN-(TY3S*QDFD8?3)&?;]:^@R< D<UXOJ_CGQ'<QW"R7$6E/'@"U
M6%EE?)QP2#C'U% 'I_A-=,3PS:+I$DDED P1Y 0S'<=Q.??-;597ARU^Q:#;
M0_V@=0P&8W);.\EB>N3ZXZ]JU: "BBB@"G#I.G6UTUU!86L5PV<RI"JL<]>0
M,U)#86=M/)/!:0132_ZR1(PK/]2.M6** "L_0O\ D7M-_P"O6+_T 5H5GZ%_
MR+VF_P#7K%_Z * -"BBB@ HHHH **** "BBB@ HHHH *YOQ0#876G:X@/^BR
M^7-CO&W!_P ^]=)5;4+--0T^XM)/NRH5SZ'L?P-:4IJ$TWMU]#GQ5)U:3C'?
M=>JU7XG#W.@ZI)KGEJ\;B<M,LXZ;<C)ZY_B%=,- E('F:QJ#'OB7 JAX8O'N
M7LX)N+BT@GMY0>H*O%C],?E755O7J3BU%]#/"3C5A[1=?\D8O_"-0'[]]?O]
M9O\ ZU'_  B^GG[[7#_[TIK:HK#VL^YUV1CKX7T@=;9F^LC?XU(OAS25Z6:_
MBS'^M:E%+VL^["R,]=#TM>EC#^*YJ1=*TY>EC;?]^E_PJVS*@RS #U)JM)J=
MA%_K+ZV3_>E4?UH3F]KBE*,?B=AZV5HOW;6$?2,5(L,2_=C0?116=)XDT6+[
MVI6Q_P!U]W\JJ2>,]!C_ .7TL?18G/\ 2K5&K+:+^XPEC,-'XJD5\T;]'6N<
M_P"$TT]O]3:W\_\ US@S_,TR7Q3=M"YMM U(D*2K21;1FG]6J]C-YAANDK^E
MW^1=TS3[2#6=1>*W161T"D#[N4!./2MFO+-$\3:JFM&5O.O!.<RPHF2V!U '
M3 'Z5V(\::8AQ=17EH?^FT!'\LUMB,+54N^B.7!YMAJL&V^75[Z>>^QT5(45
MNJ@_45EP>)=%N,;-2@&?[[;/_0L5HQ7$,XS#-'(/5&!_E7+*$H_$K'I0K4ZG
MP23]&(;:!NL$9^J"F&PLVZVD!^L8_P *L45-V:E,Z5IS=;"V_P"_2_X4PZ)I
MC=;&#\%Q5^BGSR[A8S#X?TINME'^!(_K3#X:T@_\N8'TD;_&M:BG[2?=BLC&
M/A;23T@<?21O\:KW?A.UDM76V>1)?X=[DKGWKH:CFB\Y-N^1.<Y1L&J5::>X
MFM-$<OH?AE0[SWZQR*"46,$GD'!)_*NGAM;>V&(((XQ_L*!5#1H"+=I3-,Y\
MZ9<,^1Q(PZ?A6I3K3E*3NR:3YHJ5K7"BBBL30**** "BBB@ HHHH *I:Q_R!
M+_\ Z]I/_035VJ6L?\@2_P#^O:3_ -!-5#XD9U?X<O1EN/\ U:_04ZFQ_P"K
M7Z"G5)H@HHK%?Q9HJ7,EN;S]XC[" C')SC@XYJHPE/X5<RJ5J=*WM))7[NQM
M45DZ_K::%8I.83,\CA$3=M&>N2>PXK'_ .$W$5C=27%B5N()%CV)*&1BP)'S
M#C^$^M:0P]2<>:*T,*V/P]&;IU)6:UV?J==17+?\);+&E[#<6 BO;95?RQ+N
M0JQ4;MP' &X$U=T?7WU>6)([8 !"UPX;(0Y(4#CG.,_2B6'J17,UH$,?AYS4
M(O5]+/O;^OO-RBJEUJ=C92K%=744+LI8!VQD#O\ I31J^G&Z2U%[ 9W *IO&
M3GD5GR2M>QT.M33LY*_J7:*P-7\46UA-%!;O#<3F=8I(P_* ]ZT3K.G!2QO(
MMHE\DG=_'_=^M4Z,TD[;F<<51E)Q4E=;EZBJ#ZWI<<\D#7\ EC!+KO&1CK^5
M8L?C%;G3([JV@B\TW"PO%),!M4@X;)QZ=*<:%26J1-3&T*;LY*^NVNV^QU-%
M4QJVGF^^Q"\A-SG'E[QG/I]?:HX]=TJ6=(4OX&E=MBJ'Y+>E3[.?8U]O2_F7
M;<T****@U"J]Y86>H1>5>6L-Q'_=E0,!^=6** *VGZ?:Z79I:64(AMT)*H"2
M!DDGK[DU9HHH *1F"(68X &2:6J&HZ3!JA@,TMPGDMN7R9F3/3KCKTH PM.\
M>6E]<VPELYK:UN_,%M<.RD/L^]D Y7\:DTCQM:ZKJ5O:_8[BWCNPYM)I,;9@
MA(/ Z=#67:^ 9'UE+F^73H[>(R%?L<91YB_ W \+@= *FT/P;J%CJ6FO?7=M
M+9Z4LHM1$K!WWD\OG@8SV]!0!V+W,$3;9)XT;T9P#530O^1>TS_KTB_] %6I
M+2VF??+;Q.Q_B9 3570N/#VF?]>D7_H H T**** "BBB@ HHHH **** "BBB
M@ HHHH \FGUF_LO%EW=6R^5,TS(8@N0PSC!'O@5VWV[Q5)]S1[2'_KI.&_D:
MLS1HWB"WN#I;&402?,1'N)#)@YW=N?SK9!R <8]C7=7Q$9*-H+8\;"9?5IRJ
M)U79OI;UZI]^ECG=OB^7K)I4 ]@Y/]:/[,\3R_ZS788AZ1VRG^=='16'MWT2
M^Y';]2B_BG)_]O-?E8YS_A'=3D_UWB2\/_7-0G\C1_PB$3_\?&K:I,?]JXX_
ME71T4?6*G1_@@_L_#]8W]6W^;.=7P3HF<R0S2GU>9OZ8JS'X4T.+[NG1'_>+
M-_,ULT4GB*KWD_O*C@<+':G'[D4(]$TJ+[FFV@/KY*Y_E5N.WAB_U<,:?[J@
M5)16;E)[LWC2A'X4D%%%%2696G6T$6L:H\<,:/O0;E4 \H"?UK4(# @@$'L:
MH67_ "%=3_ZZ1_\ H K0K2HW?Y+\C*BDHM+N_P V49]&TRYSYVGVSD]S$,_G
M6=+X,T20[DMGA;^]%*P_KBM^BB-:I':3(GA*%3XX)_)'.?\ "*S0_P#'EKNH
MPCLKR;U_+BC[!XIM_P#4ZQ:W('03P;?Y UT=%7]8F][/U2,_J%%?!>/I)K\+
MV.<^W>*K?_6Z3:7('4P3;?\ T(T?\)3<0?\ '[H.HQ#N8T\P#\>*Z.BCVL'O
M!?*Z#ZM5C\%5_-)_HG^)S\7C/1';;)<20-_=EB8?R!K1@UO2[G'DZA;,3V\T
M _E5N6"*==LL22#T=0:SY_#>BW&?,TVW&?[B[/Y8HO1?1K[G_D%L9'K&7R:_
M5FFK!@"I!![BEKG6\%Z6I+6TEW:GUAG(_GFLW7-"U.UTB<V^MW=PA&#!,<EQ
MW ;/Z=Z<:5.;24_O7_#D5,3B:<7*5*]NSO\ FDSI=&96L&*D$?:)^A_Z:M5^
MO,?"5AK$D\ZVEZU@A&&9HPV\@] I].>:ZO\ X1[57_UOB6Z/_7.,)_(UI7H0
MA4:<U^)A@\;6JT(R5%_>K?BT_P #HZ*YS_A$R_\ K];U:3_MOC^AH_X0K2F_
MUKW<W_728FLN2EUE^'_!.KVV)>U)?.7^29O/=6\7^LGB3_><"JSZUI<?W]2M
M%]C,O^-9Z>#=!3_EQW'U:5S_ %JRGAK18_NZ;;G_ 'DW?SHM1[O[E_F'-C']
MF*^;?Z(:_BC1(_O:E"?]W+?RJL_C704Z7C.?]F)_ZBM1-)TV+_5Z?:I_NPJ/
MZ592&./_ %<:+_NJ!1>BNC^]?Y!RXQ_:BODW_P"W(Y__ (3/3V_U5K?S?]<X
M,_UH_P"$IG?_ %.@:HX]6AVBNCHHYZ72'XA['$O>K]T5^K9SG]O:W)_JO#4W
MUDG"_P!*P?%>H>(7T]!<V)LK9F(?RI0^[T#$=!_.O0:H:Q!'+I=VSJ25@?')
M'\)K2C7A&:?(OQ_S.?%8*K4HRBZTMO+]$G^)C^!I[Z?17-XTCH),0M)R2N/7
MN,UT]0V\$<"8C!&0,Y)/\ZFK"K-3FY)6N=N%HNC1C3;O9;A57^S;'S%D^Q6^
M]&+*WE+D$\Y!QUJU14)M;&LHQENCGO%NF7NJ6-O':(LJI*'DA+!2X]B>G?\
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M?:O-3++Z8)S[TZ7P_K?F2VZ62M!_:/VD2B502O(Z$^E>@45?UZIV7X_YF/\
M8U#^:7X?Y?\ !.,T70KZRG%I=:7:RQ+,\AO9&#$J1C '7/'>J$/A[6%T2.P.
MFJLD5ZDWF"5/G7# ]^W'YUZ%12^N3O>R_'_,K^R*/*HW>E^VSMIMY>IP$?A?
M55U". V\?E)>_:?MOF#)7CC'7MGZTMKX9U*)+-VLE$L>I><[;TR(OEP<YZ<'
MBN^HI_7:GD)9-AUK=_AY>7EZA1117&>L%%%% !1110 4444 %%%% !6?H7_(
MO:;_ ->L7_H K0K/T+_D7M-_Z]8O_0!0!H4444 %%%% !1110 4444 %%%%
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M/B1G5^!EM?N#Z4M0V[7!4B>)(\8QLDW9_05-2:LRXNZN%%%%(84444 %%%%
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M]C_WR_\ C6A10!GXU?\ OV/_ 'R_^-&-7_OV/_?+_P"-:%% &?C5_P"_8_\
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M7CK6C:7=O?6J7-K,DT$@RKH<@T 5<:O_ '['_OE_\:,:O_?L?^^7_P :T**
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M^RP-#'O\J3(^]_='&<UVNAVDUAH-A:7#9FAMT1^<\@ $5?HH **** "BBB@
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%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>img243551639_25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_25.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &D 5 # 2(  A$! Q$!_\0
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B:W_ ,A;0O\
MK[;_ -%M6W6)K?\ R%M"_P"OMO\ T6U &W1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45G:AJPT[<TEK.\2@9D0 CGCUI#K=LMUY)278)!$TVSY%
M<_PDT :58FM_\A;0O^OMO_1;5MUB:W_R%M"_Z^V_]%M0!MT444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 9]_:2WEY9J<?98G\V3)Y9A]T?GS5!M,OM
MLMBJQFVDN?.,Q;D+D$C'K[UOT4 5KZR6_MC \LT0)!W0N4;\Q7.7>CQ:=K>B
M2)=7DQ:Y9<3SEP/W;= :ZRL36_\ D+:%_P!?;?\ HMJ -NBBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<A?S-S GYL'@#D?+[4 =''()8ED7.U@",TZD4$* 3D@<XI: "BBB@ K$UO\
MY"VA?]?;?^BVK;K$UO\ Y"VA?]?;?^BVH VZ*** "BBB@ HHHH **** "BBB
M@ HHHH #T->2>%?O:M_U_/7K9Z&O)/"OWM6_Z_GK2'PLZJ'P2^1T-*.HI*4=
M10,K?#7_ )"'B/\ Z^A_*O0J\]^&O_(0\1_]?0_E7H5*I\1GB?XK^7Y'E5G_
M ,CSXD_Z[+_(5MUB6?\ R//B3_KLO\A6W5RW.BKNO1?D%4?!O_)0]:_Z]TJ]
M5'P;_P E#UK_ *]TH6S$O@GZ?JCTBO,=7_Y*M<_]>2?RKTZO,=7_ .2K7/\
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MZ=7F.K_\E6N?^O)/Y5-/KZ&6&WEZ&I1110496G?\E5L?^O-O_9J]/KS#3O\
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M +-7I]>8:=_R56Q_Z\V_]FKT^BIT]"<3O'T/-_%__)2='_Z]&_F:O51\7_\
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MD%JTHF:W &TN/?KCCI6K10 UXTE7;(BNOHPR*PM7MX8M7T,Q0QH3=MRJ@?\
M+-JWZQ-;_P"0MH7_ %]M_P"BVH VZ*** "BBB@ HHHH **** "BBB@ HHHH
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MEN=%7=>B_(*H^#?^2AZU_P!>Z5>JCX,Y^(>M'_I@E"V8E\$_3]4>D5YCJ_\
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MB@HRM._Y*K8_]>;?^S5Z?7F&G?\ )5;'_KS;_P!FKT^BIT]"<3O'T/-_%_\
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M!1E:=_R56Q_Z\V_]FKT^O,-._P"2JV/_ %YM_P"S5Z?14Z>A.)WCZ'F_B_\
MY*3H_P#UZ-_,U>JCXO\ ^2DZ/_UZ-_,U>JGLC1_!'T_5A6)=?\C]X:_WV_G6
MW6)=?\C]X:_WV_G1'<JGN_1_D>JT445B< 4444 %%%% !167X@$O]CS/%</"
M4PQ*<$\CC-933RE9;\W4BW:7@B6'=\NW(&S;[@YS0!U-8FM_\A;0O^OMO_1;
M5I7UQ-:VQE@M9+IP0/+C(!/YUSEWJ%W=ZWHB7&ESVBBY8AY'4@GRVXX- '64
M444 %%%% !1110 4444 %%%% !1110 'H:\D\*_>U;_K^>O6ST->2>%?O:M_
MU_/6D/A9U4/@E\CH:4=124HZB@96^&O_ "$/$?\ U]#^5>A5Y[\-?^0AXC_Z
M^A_*O0J53XC/$_Q7\OR/*K/_ )'GQ)_UV7^0K;K$L_\ D>?$G_79?Y"MNKEN
M=%7=>B_(*I>"O^1_US_KC'5VJ7@K_D?]<_ZXQT+9DKX)^GZH]'KS'5_^2K7/
M_7DG\J].KS'5_P#DJUS_ ->2?RJ:?7T,\-O+T-2BBB@HRM._Y*K8_P#7FW_L
MU>GUYAIW_)5;'_KS;_V:O3Z*G3T)Q.\?0\W\7_\ )2='_P"O1OYFKU4?%_\
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MJSS6QU*SC^(]G?/<*+5+5D:4@[0?FX_6O0?^$KT+_H)P?F:T_LMO_P \(O\
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MKO\ SZ6?_?TTS0G6.QO78X5;RX)/MO-.LO$FF7\T<44[!Y?]5YB%1)_ND]:
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MN05 P/0$G\:Q5TS5X3IHN+:Z<V22P&2SD"LRDC:03VP*Z/\ X2G1_P#G[/\
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M3HP  NL ?],V_P *:_B;1)4*27 =3U5HF(/Z4 5O")1EU)XH3%"UT=B%MP'
MZ&K6H_\ (SZ+_P!MO_0*1/$VB1($CN BCHJQ, /TJHVJ6FI^)])^R2&3RQ,7
M.PC&4]Q0!TU%%% !1110 4444 %%%% !1110 8HP/2BB@ P/2C ]*** # ]*
M,#THHH ,#THP/2BB@ P/2C ]*** # HHHH *,#THHH ,#THP/2BB@ P/2C ]
M*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/
32C ]*** # ]*,444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>img243551639_26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_26.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#X17AI9@  34T *@    @ ! $[  (
M   /   (2H=I  0    !   (6IR=  $    >   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $MA=&4@36]R
M;F5A=6QT    !9 #  (    4   0J) $  (    4   0O)*1  (    #,S,
M )*2  (    #,S,  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                         #(P,C,Z,#(Z,34@,3 Z,3@Z,#0 ,C R,SHP
M,CHQ-2 Q,#HQ.#HP-    $L 80!T &4 ( !- &\ <@!N &4 80!U &P =
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" '>!0<# 2(  A$! Q$!_\0 'P
M 04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%! 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **\]O+C6]2\:
M:K8V>OC3H+78463&#E1P*DTC6-9MM1UC2KS48]26WLGG2ZB _=L!P,CZ]#GI
M7;]4ERW4E>R=M>IY*S2'/RN#M=J^FZOYWZ=COJ*Y7P]XDBMO =GJGB"]^9RZ
MF1QEG(D8  #J<#]*U=)\2:9K,\D%G,PN(QEX)4*.!ZX/4<_K6$Z%2+>FB=KG
M72QE&HH>\DY)-*^NJN:M%8$WC?0H+MX'NF(C?RWF6)C&C>A8#%6M4\2Z9HY@
M6[G+27 S%'"AD9QZ@#M2]C5NERO4KZWA[.7.K+?5&K17)>&]=DU?QAK"17;3
MV,<<;0*1@+D#/'4'.>#4_BJPUR5I+W2=8^Q006Q+0A,[F7<2<^XP/PJ_8-5%
M"3M_P3)8Q3HNM3BY)-K2W1VOO:QTU%><^'KO6SI$/B35===M.C8F:W\O)8!M
MO;WK;O\ Q?I5]HT\EK?7EHB*KFYBMSP"P& 2,$Y.#^-7+"SC+E6O32^C,:>9
M4IT^>2Y=+I-J[7??\SJZ*Q[[Q)INCPVB7EP[RW" QHD9=W&.N!61J_C&TO?#
MVJMH5U(+FTB5_,"%=N6 XS6<,/4FU9:/K^!T5<;0IIWDKI7M=7VO^1U]%8/A
MWQ!!?PVEA++(VH+8PSR[TQOW(I+ ]#RU3_\ "3Z5NU'?<;$TT[;F1E.U3G&
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M'U"*PATP(KRM )&FD(/4'@#(/3T]ZYWQ+K=_K?@19YIOL\EM=FUO((U^69@
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MVR];WU_ [J-+$+$*<F[<TNKMRVTTVW-NBBBN ]D**** "BBB@ HHHH ****
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M65S7(^=7@DHZ=$[ZZZ_AW.(\(74%[X\\07-H"(951D)7&X?WOH>OXUUNL?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4451?6]*BU1=-DU.S2_<96U:X4
M2L/9,Y_2@"]15.ZUC3+&\AM+W4;2WN;C_4PRSJCR?[JDY/X5<H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** (+V>6VL9Y[>W>ZECC9D@0@-*P'"@G@$].:Y*
MY\:7WA_6M.L_%4%I%'J-G<7(:U9B;8PQ^8ZOG[PVYPPQR.E=;?/=)83-IT4<
MUT$/E1RN41F[9(!('X5PVE>#]4N[R\N?&%M!>7VHVTEK/>)=DK;1.I'EPQ;
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH PO W_)//#O_ &"K;_T4M;M87@;_ ))YX=_[!5M_Z*6MV@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,+P_P#\ASQ3_P!A5/\ TBMJW:PO#_\ R'/%/_853_TBMJW:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA'I714; TT[,****!!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7_["R_RBKE] \37?AY;N.""UNK:\0)<6UW%OCDP<J2 0<C)[]ZZ>+X@^'8=
MFT2/P7C3IIO.DA_M63YGXYW;<_PCC/:N:T^]T(>+%O;_ $^:+2ED,@L86\T\
M?=0LY&1GJ?2IBG:7,O,RIQE:?/!V;OT\NSW/1+.[U!H=->X,%IKVMQ+::9;P
M1D1Z;9_Q2!<\$CD9.>!Z$5S5_P"$= N=-UT^'KG43>:$V9_M?EF.90Q5BFT
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M+:W4/E21 ' !3^'IT],5>JGI5I=6.EP6U_?/J%Q&I#W+QA#(<]2HX'I^%7*
M"BBB@ HHHH \X^!G_).P.PN3_P"BHS_6O1Z\X^!^1X#<'J+A>/8V\->CU=3X
MC:O_ !&%%%%08A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:\;TZZTSPG/H^HV)UOQ9*;&>6V5BB"PMU(\XA"!\^?E(Z\8],^P03QW-O'/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-HUQI6F336ES?:;::C'/?VMJ"7DB"M@[1RP5RC%?;/:NQI&8*I9B H&22>E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<$&LY4W%)]+F52C*FHNVES6T[_D%VG_7%/\ T$5)<W"VMI-<2!BD*,[!1DD
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MHT$>UBQW$YY"X'OQ753^%=/N+B2:2XU8/(Y=A'K-VB@DYX590%'L  .U;-%
M'G/@,XUO0@!PW@ZR)^H:O1J\Y\#9&M^'/0^#K;]&7_&O1JN?3T-JOV?1!111
M4&(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-U<@="2&!P1VIGAB*?\ L.TNKJ_N;R2ZMXI6\\KA"5R=NU1Z]\UI7G_'C/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,/'>FV75-/N-2OY![M</&GZEC6QXMMX+CX8W!N)EMS#:)/%,QQLD0!DP?4L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP(?M$#;_ +,#RK2*!T(/4=._6O8X9XKF!)K>1)8I%#(Z-E6![@CK63X319/
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M^K-JGPP]/U84445!B%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;5NUA>'_ /D.>*?^PJG_ *16U;M !1110 4444 %%%% !1110 4444 %%%%
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MI9"['ZL>34M%.[:L4Y2:LV%%%%(D**** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGY)LGY1[GBMO_A(-2_Z$_6O^_P!9?_)%:U]96^I:=<V-['YMM=1-#,FXC<C
MAAD<C@GI4])MMW9,I.3NSC$M+".173X8S*ZG(80:<"#ZY\^M;_A(-2_Z%#6O
M^_UE_P#)%;M%#;>XW*4MV<?J\E[K*A;CPUXEBCP 8X+NR53@Y!(\_KFGZ-XB
MNGL&-IX;\0WD:SRQ&2>>S+!T<QNO,XZ,A'X<5UM9N@Z=-I>G2V]PR,[WMU<
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M4444 %%%% !1110 52U#5K?3&A6YCO',Q(7[-937 &,?>,:MMZ]\=_0U=HH
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M2M<\3ZQHUEJ=MH6DK#>6\=Q&LFKRA@KJ& .+8C.#ZU;^U^+?^@)HO_@XE_\
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M] 31?_!Q+_\ (U;M% &%]K\6_P#0$T7_ ,'$O_R-1]K\6_\ 0$T7_P '$O\
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MJUU/4],\:VNA:I=+?PWUE)<0S^4L;1R1LH9<+P5(8$=QCJ<\=37/:?X>O/\
MA(DUO7KZ"[NX+8VMNMM;F)(U8@NQ!9B68@=P !CWKH: "BBB@ HHHH X[QEJ
MNI:!97NHR:S]FBCB9[2W@TTRJ2JCB5^>"QZY0 'KP34-CK^L^(]9;3+2Y@TN
M6TTRWNKEHT6<-/,"0@)X,8 ZCDY&",<[.KZ5KUZMY;V.L6D5I=QF/;<6/F/
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MM7T=]J'V86D306Y@CBCW;CA2['<3C)SV& *WJ "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 <1KECJ5OXSGUFUT:U\1VQM8[<VQF
M19[,@LS% _RD,&4D9!.T>@KF-2FL;NS\/Q>'/M6D>7XJC2XL+F'#6LS1LV A
MX"XY 7Y3N)KT.Z\.-_;<NK:5J,VGW-PBI<JJ+)'/M&%9E8<,!QD$<8!SBJ,O
M@6VDLP!?W'V_^T4U)K]T1G>91M&5P%"A?EP ./?)(!7/B745\-^-+PM&9M%E
MN4M3LXQ';)(NX=_F8TMAKFK^(-8N[+3;JWLQIMK;M,\EN9#--+'YF/O#"!<=
M.23U&.9K_P #_;+?6;:'6+NUM=9RUW%&D9RYC",RDC(!"KD>W&,U9;PF8;LW
M6E:I<Z?/+;1VUPT2(XE"#"OA@<. 2 >GJ#@4 <UX)U._T?2_"]I?F%;.^2ZM
MI,#_ %=TLC.N&]"JR#_@(KK/">IW>M:$-3N]HCNYI)+557&+?<1'GU)4!O\
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>img243551639_27.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_27.jpg
M_]C_X  02D9)1@ ! 0$ -@ V  #_X2',17AI9@  34T *@    @ "0 +  (
M   F   (A@$2  ,    !  $   $:  4    !   (K $;  4    !   (M $H
M  ,    !  (   $Q  (    F   (O $R  (    4   (XH=I  0    !   (
M]NH<  <   @,    >@  $9(<Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         %=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P,3$N,38S.#0
M    -@    $    V     5=I;F1O=W,@4&AO=&\@161I=&]R(#$P+C N,3 P
M,3$N,38S.#0 ,C R,CHP,CHR,B Q-CHR.#HT.   ") #  (    4   1:) $
M  (    4   1?)*1  (    #-3$  )*2  (    #-3$  * !  ,    !  $
M * "  0    !   "T* #  0    !   !E>H<  <   @,   )7      <Z@
M  @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                         #(P,C(Z,#(Z,C(@,38Z
M,C8Z,#, ,C R,CHP,CHR,B Q-CHR-CHP,P     & 0,  P    $ !@   1H
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M<"I4M2W3TOU1;1UD170AE89!'<4ZH-D[JX44 %% !10 44 %% !10 44 %%
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MNYX6=BS%6ZYS_C^E;>V;DY-;G*L*E35--Z"II<J%#_:%RV'#'+9W8[?2H3H
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MNIA.G%U%-.SL_P!"+Q3X>NM1T=H1?33?.K!74D_^.?X5I6^EWT5O&D>HA0%
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M% !10 54DS!)+/-<[82  I'"GI0!9P?[Q_2EVG^\?TH 3:?[Q_2EVG^\?TH
MCE=88FDDD*J.I(Z40R)/&)(I2R'H10!)M/\ >/Z4FTY^\?TH 7:?[Q_2F2,L
M4;2/)M102Q..!0 V&5)U)CEW[6*L1V(ZU+M/]X_I0!$MN%G:8.^YP <GC ]O
MQJ3:?[Q_2FW<459$:0Q6Z-L"QK]X[0 /K4*RV^H0RQ17)8%>2F,@'IV]C1=W
MN+E7+RHLI&40*9'8CN<9/Y"HY[6*Y55F4.$<.NX X(Z&A-IW0."E'E9+M/\
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M7/)^X>H!P0>A!J3P-XKGUB]U?2M0N$N-1L)\12>08FN+<JA68KROWV=<J<'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!0U694CB0[MS318PI(_UB]3CBK]4=2Q
M]G7T\Z+_ -&+5S=0 ZBBB@ HI,TW=UH ?12<T9H 6BBB@ HK@O'GQ.NO KRR
M2^%]2O\ 3T:)/MUL\'EEY&"*H#2!L[F4=._IS71>%]>O=>L9)[[1;K0Y%D*+
M!=O$S,, [AY;L,9)'7.5/M6\J,XP51[/S1Q0QE&I6="+?,O)_G:QMT445@=H
M44W=1N[T .HIN\<4;ATH =1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %-W>U.K!\:1,?#=Y(=2O-,MX$:>XFL57SS$JDLJ$@[21W'/'
M&#S0!N;N].KP/X=ZI;ZYKUA%9R:_H-Y<>;+&\NN/J,<_E>6766.0LOS)*OS+
MT.<-FO?* "DS2UR?Q.UO6?#O@K4]2T*"UEO+6"6<O=N0D4:1LY? !W'*@!>/
MO9R,4 =4&]J-U>/>)/B-XCBM_,TV>SMVTWPRGB"\%U;%Q=L=W[I3N78/W;\C
M/++38OBIKM]JB:K$+>/0?[=M-#.F20'[1^]BC8S>9NZAY5PNW!5?<&@#UC4C
MBW7L/.B_]&+5@'G-?&G[4GQ2\66?Q*GT2SU&^T33;&.-H5M)F@-P64,9"RD%
MADX'.!L['->D_LX_'#^W/!OV#Q)J\-QKT%RT-LMS,L<US#M0@[F(#,"7'7.%
M&<GD^[5R>O2P<,7=-2Z=4?'8?B?!U\SJ98TXRAU>S9]#T53GOI8[=)(K5YY&
MQF)74%>.>2<?E3[JZDA:(1V[SASAF5E 0>IR?Y5X1]A=/4ES^=<EXB^+7A+P
MGJ4EAJVM06-Y&%+12!L@,,CH*Z>2XE2XBC2V>2-OO2AE 3Z@G-<!\;Y9%\&^
M7]G;R_[1TX^?N7&?ML/&,Y_2NG#QA4JJ$^O;^F>?CZM6AAIUJ+5XIO779>J.
MN\,^,-(\96+WFC7R7UK'(8FDC! #  D<CT(_.MC/:JEK*_GM$;9DB505F++A
MNG  .>_>I+>XEFEE62V:%4.%=F4AQSR,'CIWK"5KOEV.RGS\BYW=];%JBJMO
M=3312-):R0,I(5&926X[8-$=U,]FTK6DB2@'$!9=Q_'./UJ34X;XZ#_BW,__
M %_Z?_Z6P5WJK^[&>>*\]^.$TC?#&>1H&C?[=IY\HD9!^VP\9SBNZDNIH;2*
M2.TDF<@9C5E!7CODXKKE_N\?\4ORB>73_P!^J?X8?G,NTM5KFXE@:();/.&.
M&964!!ZG)_E2S7$J7$<:VSR1M]Z564!/J,YKD/4)<?-[5YC\8+CQ7X;TRXUS
M1_$<=G:1R6\(L7T]).9)DC+;RV?X\XQVKT?SI/M8B^SOY.W/G;EVY],9S^E>
M=?'C4EA\ 7\4Z_9X_M=ELFDD4!_]*A) &<\#/Y&NS!_QX*U[M+:_7S/)S6WU
M*I)R:LFTTVM;>31V/A73=8TW3W36=976KEGWI,MJ+<*N!\NT$YY!.?>MO'O5
M33[XWBD^2R1#'ER[E99!ZC!/Z^M.M[J6:.1I+5X64_*K,I+<=L&N:;<I-O\
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M2T4 )BC%+10 FVC;2T4 )MHQ2T4 )BC;2T4 )MHQ2T4 )BC;2T4 )MHVTM%
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M?%.MZ?JGA^SF$PL[>-R]WM.560,-JJ3C(!;(R.^:^P_%7C32/!NEW=[J=Y%
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MI]S-=!C!'#<HS2A<[BH!^8#!SCTK.4J[WN=,LR]I9.K?YKT.%\"_L[Z#\/\
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MMH^]!KMJ=4/>I2CVL_T_4]9HHHK$Y0HHHH **** //OCK_R3F?\ Z_\ 3_\
MTMAKOHO]6OT%<!\=/^2=3_\ 7_I__I;!7?1M^[3UP*ZY?[O#U?Y1/+I_[]4_
MPP_.9)1117(>H%%%% !1110 S/?M28W CMWIVWUI=M CS'P__P 6Z^(5QX?;
MY="U]I+[3"3\L-S]ZX@]@W^L7ZR>E>E_05S'Q$\(_P#"9>&IK6"46NI0.MU8
M77>"X0Y1_IG@^H)'>G?#WQ:/&7AF"^>/[+?1LUO>VA/-O<(=LB'Z,./4$'O7
M74_>P57KL_T?S_,\K#?[+6EA7\+UC^J^3V\GY'4T4F[IGBDW>U<AZPZBBB@
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M$>2X2Y,T=J9FMW^SK<.F](#+C:)"I!QGN!U.*Y?XK?"V^\<:E]JL;71Y99+
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MG!TY.+-L/6CB*2J1Z_AW0^BBBLSI"BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_7:+_T8M6Z "BBB@#R7QY_Q3'QN^'WB#[EOJB7?AVZ<],N@N(/_ !Z!P/\
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MK*8]VQI  /G(+>] &QJ,TQC4&#$?GQ?/O'3S%YQ6G534O^/=?^NT7_HQ:MT
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M[K5?JCR,1_LM=8E?#+27Z/Y;>C\CU"BO+=2^*OBG3_$5GHQ\#,]U?+-):_\
M$TBQ(D17<W3C[Z\'UKT?3;JXNM/MI;NV^QW,D:M+;^8'\IB!E=PX.#QD=<5G
M4HSI)2E;7S3_ ".JAC*6)E*%.]X[W37YHMT4E%8':+129]*;O]J 'T4W?2T
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M_%WAWQE>Z19Z1HNIV$$YA_M*WCN&BP#@$9(9L=R!SCY=U=SY,U^P/BOQ7\5
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MG%=S\-?A_K_AGXI:KJ,NE_9=(N/M1>XNS!)*Y>4.@26,[W!Y.)5&T* ":**
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:***D8?A1FBBF%@YI<>U%% @S29HHH)N?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>img243551639_28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img243551639_28.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (N MD# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP?#>*UFMY8[@6LRF%T(?)+8&#SWK'BTC4X?"WAB_@LI9+O2F+R6C#8[(W#
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M%0H/8<&NQ(!!! (/4&N)TP:EX*,VGMI=UJ&D-*TEM-9KODB!Y*,G7KW^OX
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y#RYIO$9
M73M/N+"[BNDDOI1<+]GEB.[DH&^9F4==@(.,GCFS-%J&HZXQO]+NA:0LT=IY
M;PF,9&WSVS(&)P3@;> 3U)XZ:B@#D+;2-2N[;1=-N[,V\6F*1)<;T992L9C3
M9@EL'.X[@O3UI^GZ;J4BZ#97=D8(]).9)_,1EF*(8TV8);!SN.X+T]:ZRB@
MIKJ6 P[)_NX_J*=10!%Y3_\ /Q)^2_X4>4__ #\2?DO^%2T4 1>4_P#S\2?D
MO^%'E/\ \_$GY+_A4M% $7E/_P _$GY+_A1Y3_\ /Q)^2_X5+10!%Y3_ //Q
M)^2_X4>4_P#S\2?DO^%2T4 1>4__ #\2?DO^%'E/_P _$GY+_A4M% $7E/\
M\_$GY+_A1Y3_ //Q)^2_X5'=:C96)07=Y;VY?[HEE"[OIDU8!# $$$'D$4[/
M<+D?E/\ \_$GY+_A1Y3_ //Q)^2_X5+12 B\I_\ GXD_)?\ "CRG_P"?B3\E
M_P *EHH B\I_^?B3\E_PH\I_^?B3\E_PJ6B@"+RG_P"?B3\E_P */*?_ )^)
M/R7_  J6B@"+RG_Y^)/R7_"CRG_Y^)/R7_"I:* (O*?_ )^)/R7_  H\I_\
MGXD_)?\ "I:* (O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_\ GXD_)?\ "CRG
M_P"?B3\E_P *EHH B\I_^?B3\E_PH\I_^?B3\E_PJ6B@"+RG_P"?B3\E_P *
M/*?_ )^)/R7_  J6B@"+RG_Y^)/R7_"CRG_Y^)/R7_"I:* (O*?_ )^)/R7_
M  H\I_\ GXD_)?\ "I:* (O*?_GXD_)?\*/*?_GXD_)?\*EHH B\I_\ GXD_
M)?\ "CRG_P"?B3\E_P *EHH B\I_^?B3\E_PH\I_^?B3\E_PJ6B@"+RG_P"?
MB3\E_P */*?_ )^)/R7_  J6B@"+RG_Y^)/R7_"CRG_Y^)/R7_"I:* (O*?_
M )^)/R7_  H\I_\ GXD_)?\ "I:* (O*?_GXD_)?\*/*?_GXD_)?\*EHH B\
MI_\ GXD_)?\ "CRG_P"?B3\E_P *EHH B\I_^?B3\E_PH\I_^?B3\E_PJ6B@
M"+RG_P"?B3\E_P */*?_ )^)/R7_  J6B@"+RG_Y^)/R7_"CRG_Y^)/R7_"I
M:* (O*?_ )^)/R7_  H\I_\ GXD_)?\ "I:* (O*?_GXD_)?\*/*?_GXD_)?
M\*EHH B\I_\ GXD_)?\ "CRG_P"?B3\E_P *EHH B\I_^?B3\E_PH\I_^?B3
M\E_PJ6B@"+RG_P"?B3\E_P */*?_ )^)/R7_  J6B@"+RG_Y^)/R7_"CRG_Y
M^)/R7_"I:* (O*?_ )^)/R7_  H\I_\ GXD_)?\ "I:* (O*?_GXD_)?\*/*
M?_GXD_)?\*EHH B\I_\ GXD_)?\ "CRG_P"?B3\E_P *EHH B\I_^?B3\E_P
MH\I_^?B3\E_PJ6B@!J*5!R[/_O8_H*=110 4444 %%%% !1110 45SUIJ^H:
MAKDOV6")M.MIGM)D,P$H<$?O"NW[O! &[D-G':KL6K2OXB;2Y+)HD\AIDF:0
M$OM95X49P#NX).>#P* -2BN;TWQ7]NNK=7M8HX+E97C9+C?)&(SSYJ;1L_ M
M@X%267B26XFTY[BP$%GJ6[[)*)MSGC<N]=H"[E!(P6]* .@HHHH **** "BB
MB@ HHHH **** "J>IZK9Z/9M=7LRQ1CIGJQ] .YJOKNNVGA_3VNKILD\1Q _
M-(WH/ZGM7!:7HFI^.[_^UM7E:*P#$1HO&1_=3T'J>_\ +HHT%)<\W:*_K0RJ
M5+/ECJSG]:GO?%NNW-]8V-W+$=JJBQER@  YQP,G)_&NBL_ WBB2SB,FL&VP
MH"PF=R4'IQP/H*](M+.VL+9+:TA2&%!A408%3UO/'2LHTU9+YF<<,KWD[L\U
M;P]XYT@%['5#<J.=HF+?^.N,5/IWQ%N+.Y%GXBL'AD'#2HA4CW*'^8_*O0ZH
MZIH]AK-L8+ZW65?X3T93Z@]14+$QGI5BGYK1E>RE'6#)[2\MK^V6XM)TFA;H
MZ'(J>O+;S1]:\!WC:AI4KW.G$YD5N>/1P/\ T(?I7<>'?$UEXCM#) ?+G3_6
MP,?F7W]Q[U%7#\JYX.\?ZW*A5N^66C-JBBBN8U"BBB@ HHHH **** "BBB@
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M-WY)[_F;'D)_>D_[^-_C1Y"?WI/^_C?XU+17*;$7D)_>D_[^-_C1Y"?WI/\
MOXW^-2T4 1>0G]Z3_OXW^-'D)_>D_P"_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_
M +^-_C4M% $7D)_>D_[^-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3_OXW^-'D)_>D
M_P"_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_ +^-_C4M% $7D)_>D_[^-_C1Y"?W
MI/\ OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_P"_C?XU+10!%Y"?WI/^_C?XT>0G
M]Z3_ +^-_C4M% $7D)_>D_[^-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3_OXW^-'D
M)_>D_P"_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_ +^-_C4M% $7D)_>D_[^-_C1
MY"?WI/\ OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_P"_C?XU+10!%Y"?WI/^_C?X
MT>0G]Z3_ +^-_C4M% $7D)_>D_[^-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3_OXW
M^-'D)_>D_P"_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_ +^-_C4M% $7D)_>D_[^
M-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_P"_C?XU+10!%Y"?WI/^
M_C?XT>0G]Z3_ +^-_C4M% $7D)_>D_[^-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3
M_OXW^-'D)_>D_P"_C?XU+10!%Y"?WI/^_C?XT>0G]Z3_ +^-_C4M% $7D)_>
MD_[^-_C1Y"?WI/\ OXW^-2T4 1>0G]Z3_OXW^-'D)_>D_P"_C?XU+10!%Y"?
MWI/^_C?XT>0G]Z3_ +^-_C4M% $7D)_>D_[^-_C1Y"?WI/\ OXW^-2T4 1>0
MG]Z3_OXW^-'D)_>D_P"_C?XU+10 U$" @%CG^\Q/\Z=110 4444 %%%% !11
M10 45RUKJ=[>>*I(VO;6V,$CP?V;,&622+@^<IW88G;D87 !(SWK1CU&^_X2
MDZ=/';+;-:O/&4+,YPZKDDX SN/&#C'4T ;%%<KI'BEM1EBFFGB@@G61X;=K
M*8,ZJ">)F(1C@9( /<=LU)9:[J3-I%U>1VWV/5B1&D2,'@+*7CW,6(;*@YP%
MYH Z:BBB@ HHHH **** "BBJNI7\&EZ=/>W+8BA7<??T ]R>*:3;L@;MJSE?
MB!XB.GV TNT8F\NQAMO5$/'YGI^=:/@WPZN@:.HE4?;9\/,W<>B_A_/-<OX-
MT^?Q'XAN/$NHKE(Y/W2GIO[8]E&/QQ7I====JE!4(_/U,*:YY>T?R"BBBN,W
M"BBB@ HHHH ****  @$8(R#7F?B;P[=^&=1'B#0<I"K;I8E'$>>O'=#Z=OY>
MF4C*KJ590RL,$$9!%;4:SI2NMNJ[F=2FIHQ_#?B*V\1:<)XL).F!-"3RA_J#
MV-;->8Z]HMYX+U9==T7/V)FQ)%U"9_A/^R>Q[?E7=Z'KEIK^G+=VK8/22,GY
MHV]#_C5UZ*2]I3^%_AY$TYMOEEN:=%%%<QL%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!STNE:GJ&IK'?W,3:?:7*75NRPA99&!8A2V
M[ "\#.T%A^.;#:5J#>(DU07]J(UC, A^R-GRRP8_-YGWN.N,>U;-% '.V7A=
MK<V4%Q>K/8V!<VT(AVO\P*C>^X[L*Q' 7UI]AX<EMI=/2XOUN+33=WV2/R=K
M#@JN]MQ#;5) P%]:WZ* "FO&D@ =%;']X9IU% $7V:#_ )XQ_P#?(H^S0?\
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MM% $7V:#_GC'_P!\BC[-!_SQC_[Y%2T4 1?9H/\ GC'_ -\BC[-!_P \8_\
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M/_OD5+10!%]F@_YXQ_\ ?(H^S0?\\8_^^14M% $7V:#_ )XQ_P#?(H^S0?\
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M]]"C[3!_SVC_ .^A0!+147VF#_GM'_WT*/M,'_/:/_OH4 2T5%]I@_Y[1_\
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M]"C[3!_SVC_[Z% $M%1?:8/^>T?_ 'T*/M,'_/:/_OH4 2T5%]I@_P">T?\
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M1D'(-<U2G.F[35C6,XR5XL****@H**** "BBB@ HHHH **** "BBB@ HHHH
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MVS?ZHW:?[Q1OZBJ).ISD9%%<:?"]_ <VEU(#^"?R8T];7Q7;?<E:3'K(K?\
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MFDMIFH[E'\(8H3^'(H_M[Q)I?&H6/FH.KE,?^/+Q78^:_P#S[R?FO^-'FO\
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MC_[^'_"C=/\ \\X_^_A_PH Y;_A(M:M?^/O3L@=_+9?UZ5/#XTMS_KK25/\
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M!_\ JKT&ML11H02I1BM-W9;D4J]>3YW)Z[:LQ_\ A%=%_P"?%?\ OMO\:/\
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M/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\
MOV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__
M #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: )
M:*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^
M_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;
M/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\
MOV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__
M #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: )
M:*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^
M_9_QH EHJ+;/_P ](_\ OV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;
M/_STC_[]G_&@"6BHML__ #TC_P"_9_QHVS_\](_^_9_QH EHJ+;/_P ](_\
MOV?\:-L__/2/_OV?\: ):*BVS_\ /2/_ +]G_&C;/_STC_[]G_&@"6J6IZ38
MZQ:FWOK=)D[9ZJ?4'L:L;9_^>D?_ '[/^-&V?_GI'_W[/^---IW0FD]&>:WO
MAS7?!ETVH:%/)<6?5X\9('^VO<>X_2NF\.>.-/UT+!*1:WIX\ISPY_V3_3K]
M:Z3;/_STC_[]G_&N3\0^ K;6&:YMGBM;P\Y2,A'/N,\'W'ZUUJM"LK5M^_\
MF8>SE3UI[=CL:*\PL_%.N^%+E--UZ%Y8!PDK#<P7U4Y^8?7G^5=]INIP:O:B
MXL;V":/OM0Y4^A&<@UE5P\Z>NZ[]#2%6,].IHT5%MG_YZ1_]^S_C1MG_ .>D
M?_?L_P"-8&A+146V?_GI'_W[/^-&V?\ YZ1_]^S_ (T 2T5%MG_YZ1_]^S_C
M1MG_ .>D?_?L_P"- $M%1;9_^>D?_?L_XTCF6.-I'FA5%!+,R$  =S\U "7E
MY!86<MW<R".&)=S,?2O,[&WN?B%XH:]NE:/2[8@!.V.R?4]3_P#JI-5U&_\
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MTG_?QO\ &CR$_O2?]_&_QH EHIJ($! +'/\ >8G^=.H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:*B^S0?\\8_^^11]F@_YXQ_]\B@"6BHOLT'_ #QC_P"^11]F@_YXQ_\ ?(H
MEHJ+[-!_SQC_ .^11]F@_P">,?\ WR* ):*B^S0?\\8_^^11]F@_YXQ_]\B@
M"6BHOLT'_/&/_OD4?9H/^>,?_?(H EHJ+[-!_P \8_\ OD4?9H/^>,?_ 'R*
M ):*B^S0?\\8_P#OD4?9H/\ GC'_ -\B@"6BHOLT'_/&/_OD4?9H/^>,?_?(
MH EHJ+[-!_SQC_[Y%'V:#_GC'_WR* ):*B^S0?\ /&/_ +Y%'V:#_GC'_P!\
MB@"6BHOLT'_/&/\ [Y%'V:#_ )XQ_P#?(H EHIJ1I&"$15S_ '1BG4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]"C[3!_SVC_[Z%2T4 1?:8/^>T?_ 'T*/M,'_/:/_OH5+10!%]I@_P">T?\
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MT?\ WT*/M,'_ #VC_P"^A4M% #4D20$HZMC^Z<TZBB@ HHHH **** "BBB@
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M3T/I6C7,+>C4_$L+7-K?006,C+;*UE+B60@J9&;;M"@$@<]R3CBNGH ****
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MBK]<WX?N&U#5+G4;N"ZANY8@D<,MK+&L,2G(4LRA6<ELG!/MP,UTE !1110
M4444 %%%% !3##$9UG,:&55*"3:-P4D$C/H2!^0I]% !1110 R*&*!-D,:1I
MDMM10!DG)/'J23^-/HHH **** "BBB@ HHHH **** &0PQ6\2Q0QI'&O1$4
M#\!3Z** "BBB@ HHHH **** "BBB@ IBPQ)*\J1HLDF-[A0"V.F3WQ3Z* "B
MBB@ HHHH **** "BBB@ HHHH 0@$$$ @]0:;%%'!$D42+'&BA41!@*!P !V%
M/HH **** "BBB@ HHHH **** "F30Q7$+0S1I+$XPR.H8,/0@T^B@ HHHH *
M*** "BBB@ HHHH **** "F10Q0)LAC2-,EMJ* ,DY)X]22?QI]% !1110 44
M44 %%%% !1110 4444 ,$,0G:<1H)64(9-HW%020,^@)/YFGT44 %%%% !11
M10 4444 %%%% !1110 R&&*WB6*&-(XUZ(B@ ?@*?110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !6'XGU;4](LX9=+TS[=(\@#J YVH/F8X12?NAO?.  [$(VY10
M!PS>*M;N/'3:%;'2+?RL$VMSO,TZ!(G9T8$87]XZCY&R8FSC)VZ<WB2^3QW8
MZ$-+:*RGBF;[7,P_>LBH<1J#G:-X!+ 9/0<9K(\3^&/$.N:XD.^RFTIFWQ7,
MIVS67S0DA%"_,V8V*MD$%SG[HW='J&CW%WXLT758WB$%C%<I*K$[B9 FW:,8
M_A.<D=J ,73/%NH7>M63S+:?V3J5[=V-HJ1L)D>#?\S/N*L&\F3@*,97D\TO
MA_Q9J.I:EIINUL_L&L17,MD(4821")P%#L6(?<AW9 7:1CGK2:7X2U&TUFR2
M=K,Z3IM[=WUHZ.QF=YR^$="NU0OG2<ACG"\#FE\/>$]1TW4=-6\>S-AH\5Q%
M9-"[&27S7!!=2H";4&W +9)SQTH TM4\3VVBZS<)J5[:6^G06*W,F4D,JDR[
M-Q(&W9T'KGGI4MMXNT6YX6XGC<7,=HT=Q:30NLKC*!E=05#=F( )XSFL?Q7X
M0U#7=2O+BUFMD2;3X;51*S ADN!*2<*>-HQ]?SJ;4O"5W?W'BB03PQG4H[8V
M3@DF*:$$H[#'0.%/&>E &K=>*]'L_,$MS*SI<FT\N*VED=Y0H<JBJI9\*<DJ
M"!@YZ&H;CQIH%M9V]VUZ\D-Q"TZM!;2RE8UX9W"*3&H/!+8P00>0:PK_ ,#W
MLNGZ)+#+')J%C)--=(M[-:+.\^3*1-$-Z_.<C@@C@CTK3^!M2BT:Q@LK33A=
MQ17&98=3O+62"25RY*S@N\JY/*N!N(W<9V@ WE\;Z<FO:UI]T'M[;2[2&Z>\
M='\MU?=G!VX[+C!.[)P/E-75\6:*VG7-\US)%%:NL<R36TL<R.V-J^4RA\MN
M7:-OS9&,US6K^!M5U+^UXGOX91?Z?8I]K9FCD-S:R,X)5!PCY&65@5YP.A"1
M^!]1-I=7(CM+?4OMEK=0*^H7-Z'\@Y599I?FP=S ;4&W(/S4 ;OAKQ*?$.J:
M]$B 6MC<QPP%H7BD(,*.V]7P00S,,8'3I5N#Q3HUSK)TF*[8W>]XUS#((W=!
MET20KL9EYRJL2,'(X.*OAK2=3L=3UW4=4%FLNIW$<RQ6LC.L86%(\%F5<GY.
MN.?0=*RK#PCJEM=Z;8RR6?\ 9&F:E/J,$ZR,;B4R>:5C9"NU<&9LL&);:.!N
M. #9TCQEH6NW4-OI]W+(\\;2P,]K+&DRJ0&V.ZA6(+#(!)'.1P:SO$_BF;3=
M872[74]&TQUM1</<ZL3Y;,S,L<:@.G+%)"3DX"_=.>(M"\(:AID?A)9IK9CH
M\%Q'<;&8[C( !LRO(XYSBK/B#P]J%QJ]QJFE0:=/<7>FMILHOG9 B;BP8%5;
M<,L<IQGCYACD OW6M7EOJL=J+(3&/3Y+NZAMSODW[E6-(R=H.X^;RV/NCISB
MEH&LZWXDT*\G5+/2[^&_FMMDT1N501MC#!77<WN&Q]:L^&/#TNA+*L\ZW!2"
MVLX)?XS##$%&_P!R[2MCG[W6H+/0-2L?#OB&SAFMQ>W]S>SVK[FVH92Q3<<9
M&,C. ?;- %#3?$NMR>$KW5KEK"9Y;L6VEO%;/$LP:18DD9#(QPSDD '[N#QG
MBY<:OKVF>(-*@OSIDMKJEW);1VUM&XFA 1Y YD9L.,1_,-BX+#DXYN_V"T=O
MX?L8#&MAI;*70]7"1%(P!CH&(;MRHK-TG3/$<?B6;4]6L=*N'D=HX[A-0D)M
MK?.0D<1@ R< L=V6/? 4  LZ9XDOK_QI?:-/I;6=K!:">%YF!DFS(R;L*2%4
M[3@'D]3C.*FU3Q+;Z-K4D>H7EI!I\-A]JDW)(95/F!-V0-NSG'KGVJ9-'N%\
M;S:T7B^S/IL=H%R=^]9'<G&,8PP[_A6+XN\(:AK]]>3VLULBS:8+-1*S A_/
M63)PIXPI_'M0!T.D:_IVN&X6RDF\RW*B6*>VD@D3<,J2DBJV".AQ@\U#_P )
M7H_]JMIHN)3<J[1 BVE,;2*NYD63;L9P <J"6X(QD&DT_1[BT\6:UJLCQ&"^
MBMDB52=P,8?=N&,?Q#&">]8R>&=6B\7G4+8VME:M>FYGFM;V=?M*&/;LDM2#
M%O/R@R!LG:#@'@ $VE_$'2KSP[::M=QW5J;F25$MEM9II#Y9.Y@JIN*@ $MM
MV@G!.:T[WQ;HEC;VT\EXTL=S";B(VL$EP6B&,R8C5B$&X?,>.1S7-:;X3U[0
M_P"S;NR73;B\L4N[0137+I')!-*)%?<(R5<%0"N"""?FJ:P\)ZQX;&G3:,]A
M?7$&F?8)5O)&@0L'WB12J.<9+#9CH1\PQR 7[+QE;/K^J6%U-#Y<=W#;V MX
MWD></;QRDX7.0-Y.X  +@GUK;U36;'1HX6O)) TS^7%%#"\TDC8)(5$!9L $
MG X )-<I;^#-3L_&5_XIBGLWU&XFA5L,\<<UN(8XY59?FV'>F]<;ON@$X)K;
MU[2;^XU72=7TP6TMUIYE7[/<RM&DJ2* ?G56*D$*1\IR,CC.0 2#Q=HCMIRQ
M7;SMJ,?FVHM[>24N@(!;Y5.T L,YQCOC!JAXO\2R:)?Z39QZII.F"\,K276I
MKNC1$4=!YD?)9E'7O5;0/!][H^K:1=RW%O(MM:7B7&S()FN)UF.P8^X"&&20
M>G'IL:U:ZFUY;7>F6&CW<D<4D1^W,T3H&Q]V14?Y3CE=O/'(Q@@#+K5-0AFT
MFQM&LKR]NH)9Y'(:.*14C'*X+% 9)(N?GPI/4X-4-#\2:A->:[9W9M-5;2HT
M<S:3$4#RD/OM]K2-^\4H/XA]\9"]T\/>%+_0+011WEM)+;::EI9R/$2J/N=G
M8J"#M),8"ANB#FK.DZ3JS^)YM>UA+&VF-DMDD%E,\H90Y<LSLB'J2 N.,GDY
MX *FG>+K^X\):YJ]YIZ6UWI\UQ%':!]YW(!M1F!P6+'!P<9/'K4FJZMXBT6Y
ML;F[;2I+*XOH++[+#%)YS>80F]9"^,@DL4V'Y5/S=Z2V\+WT<%Q;2RVQ@N==
M;490&.3#N$BKT^]O5,CIC/)Z%HTSQ(_B^35;RQTJ[MXI#'8%M0D0VL)&&81^
M0096&<MNZ?*"!N+ %A/$M_)X^AT(Z6UO8-9SSBYF8;YGCDC7Y%!^5/G/+<MG
M@ #+6]8UY-'UBSCN+FUALFL[JZN \<C2[8A&=R;05P QR#R<KC/-+<:/<3>-
MM/UI7B%M;V$]LZDG>6=XF! QC&$.>?2L[Q=X8O=?O(IK66W14TO4+,B5F!WS
MK&$/ / V'/?I@&@#5TCQ/I.NSR06$\K2)$DVV6VDAWQL2%=-ZC>IVGYER/?D
M50G\76>F:IJ4.J7D"PPW4-K;QV]O-)-O>+S C *=S'!V[<\8'7BGZ;X?N[/Q
M';:C))"88M'CL&56.[S%?<2./NX_'VK-N_"&H3^*9=46:V$#ZO;7P4LV[RX[
M8Q,/NXW;CD<XQW'2@#9_X2_1/[+BU 7,QAEG:V2-;64SF520R>2%\S<-K$C;
MG STYK+T;QY9W6EO>7[D&74;JUM(K2UEEDECB=@&\M0SD[0"QQ@9[9 JL/".
MK6=VNIVCV4MY!K%U?1032ND<D4RE"K.%)5@#G(5AQCOD9O\ P@&L*UK?O);3
M7T=Y?2RP0:C<6:,ES().)HAO!4JO!!!!/H#0!U\GC'P_%#Y[ZG&(?L?V]9-K
M;'@SC<K8PQR0-HR1N''(SLQ2K-"DJAPKJ& ="K 'U! (/L>:\^NO 6J7.F:1
M9H^F6PT9?M=F$#RJ][N+?/YNYA$,L/O%B6#?*5 KM[.ZNYKF>&YM%A$21D2)
M(65V8$LHRJYVG'(ZY'0Y  ,2/QC96CW2:G=Q,_\ :$MI;1V5K/*[;%#;"H4E
MG ))VC&.G0U<D\8:(FG6=\+F:6*\+"!(+6665]N=_P"Z52XVXPV0-IP#@D5C
MV?A#4+?Q);ZB\UL88]7N[XJ&;=Y<L/EJ/NXW9Z\XQW-5]-\):UH1TV^L_P"S
M[J]M3?Q2033O%&T5Q<&8,KB-B&7"@C;@Y//'(!HV/C2TGUJ^AEN(/[/#626,
M\2LQF:X4E<D9&"<8. !WK3N/%.CVT5S))=.?LUV+*1(X))',Y56"*BJ6<[6!
M^4'C/H<<S>>#]>NKF\U"2XTV2_DN-/NXU7?'$[VYRZGABBG/!^8^HI(?".NQ
MSR:L3IIU1=;;5(;;SG\AD>W6!HV?9D,!N(8(>@X&3@ ETOQX;VX\Z>>RAL%N
MKY#NAF$K10*K @8.& )W!L'L!G(K=L?&.A:BEQ)!>LL=O;"[=[BWD@4P<_O5
M+J Z<'YER/?D5RG_  @FMSK++<3Z>L\TFI2.L<CE5-S&%0 E<G!!R>..<=A/
MKGA"5]*N7O;N.&U3PTVG2R11O*RR AMX0+EE&WH.3Z4 =3I/BC2=;NI+6QGF
M-Q%$LSQ36TL+JC$A6Q(JG!P<?G3)O%NB6]SJ,$UXR-IREKQV@D$</RJ_S2;=
MN2&! SD]LX-<UX.U.XU_QSJNJM)ID\,>F6UL9M,N#/#YGF2L5\PJN6 8$@#Y
M0RCKR;>I>"KO4K#Q;;&ZAB.KW<5S:NK-\ACCB #XP1EHOX3G!R#F@#0NO%MK
M+:0RZ=<Q12#4;:TGCO[:>)U$CJ,>65#AF#?*2-N>IQFIK3QKH-]>+:VUU,\K
MM*B'[',$D>/.]%<IM9AM;Y02>.E<Y%X&U%P]P\5I;7+ZE87# ZE=7K-#;R;R
M#+-R3R^%"J!W)SQ<T[P?J%G!X<22:U)TS5;R]FVLWS)*9]H7Y>2/-7.<#@\G
MN ;Z^)]%>WM+@7\?DW=H]]%(58+Y"!2TC$C" !U^]CK5>'QGH,]C<7:W<J1P
M",NDUK+%*1(<1E8V4.VX\+M!W'@9-8:_#^:;2_$>G7-Z@AOH9+73V4%C;0.S
MR8(.,X>3&,_=1.0:@A\$ZC+9ZDU[8Z8]S<V\4'EW&IWMX)%5]Y_>R$-%SRNU
M24;YLMTH V+WQYIT!T<VL-U<KJ.H&P;_ $:9'MV"LQWH4W!N%^5@"02PX!-2
M+\0/#;R+&EY<2,Y<1!+&=O.9&VNL>$^=@>JKD@ G& 365#X4UX6^GR37,4DE
MGK*W\5K/?RW BA\IHR@G=-[G+LXW#OMZ#-3Z-X0U#3G\.&::V;^S)[Z2;8S'
M<)F<KMRO)&X9SC\: -:;QEH4%A97OVN26*]C:6W6"UEFD=%'S-Y:*7 7@$D#
M!.#@TR_\<>'M.<+/?.^;1;[=;6TLZBW;=B4M&K )\I^8\#C/49Y9?A_JUK;:
M3-#)#/=VD%Q;2Q)J=S9*RR2^8K"6$;CC@%2,'/48&;J>!+NWM-0MK=[*..?P
MVFD1(AD"K*#,2<-N(3]X.K,>#0!OZ=XH@U'Q;J>@QV\H-C;PSBXV/LE$F[@'
M;MXP,'<=V6Q]UL377BG1K+5UTNXNV6Y+(A(A<QH[_<1Y NQ&;LK$$Y&!R,T=
M#T"^TGQ'<WCFW>UN=,M+=BLC;TEA\P8"[<%2),YR"",8YR,[4?".J7%YJMI;
MR6?]E:M?07UQ/([>?"R>7N14VE6!\E<,6&W<>#@9 -'PSXCN/$&L:\G$=G87
M7V:*)K*6*3(4$LTCD*V3N^4*"!M)/S#,&J>.+6+6=,TS3G$TT^IBRN&>WE\L
M *Y<))@(SJR@$ G'((]-/P_H]QI,^M/.\3"^U)[N+RR3A"B* V0.<J>F>W-<
MY!X1URWFTRP5]..E:=K$FHQSF5_/D1S(VPILV@@RD;MQW8!P* -70_&-A=^'
M!?ZA?VIFM]/2_O'MXI5B$3!CO0.H8K\C>IXP>:=;^+;6&/4IM0N8C'#J/V.W
MCM;:=IB3$CB-H]NYI/F8G8" OT;&'9> +^#2?"]G)=6X^PVRVFJ*A8K<1*RR
M +D<_.@'./E=_:K+^$-5M]5GUBSDLI+M-;DU&W@FD98Y(GME@978*2C<,P(#
M#@#N< %G1_'=G=:;->7[D;]2N+2TBM;66265(V.#Y2AG)"C+<#'<"M"Y\;^'
M[5+9VO9)A<VYNH1;6LLY:(<%\1JQ '?/3O7*MX!U@M:W\DEM)?17U[</;P:A
M<6B,ERRM@31C>"I1>,$$9Z<8T])\%W>FSVK@V<:1Z/<6;QQ22L!-+*)"09"S
M%<[LL3DGG S@ &GKGC/2M)TPSQW/FS2V37=OY<$DJ;,?*\A0$(A)'S,5'7G@
MX;IOC73)X-,BO)RE]=0VYD$=O*88Y95!5#( 40DD85FR<KZC.%#X+UW3=-MX
M;"3399I] @T>\-Q*ZK$T2D"2/"$N/G?Y3LSA>1S2KX,UN"XL3:/96LL4%G%)
M?VM[/%)B$*&5X #'<9 <!GVX#XQ\N2 >A45%"T[!_/CC0AR$\N0OE>Q.0,'U
M'./4U+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7(>.]6O-+.@QVU_>V4=YJ'D7$EE:BXF*>3(V%0QOGYE7HI.,UU]9.
MKZ+_ &K?Z-=?:/*_LV\-UMV;O,_=/'MSD8^_G//2@#!35GL7T,MKNLSPWE](
MC_;],2)W58)&V%?+B9%!7<&"DDC'0\7;/QQ87.C7&KSV.H6>GQ6RW4=Q-&C)
M/&V<%#&S?-P/D;#<CBK^LZ&=6U#2+M;MK<Z=</.-J!B^Z)X\ G@8WYY!Z8Q7
M.0?#=&_M(W=[:H][:?9F?3; 6A=MX?SI0&99) P!!PH&6XPV  ;R>))C933/
MX=UJ.YCD2-;-H8R\F[HRNKF/;UR2XQCG&1G)C\7/JNL>'!8&:V@N;V\M+VVF
M5"X>&-\J2I8<,N<JV#ZT_5?"6K:]IWD:MK5E=.ES%/'"VF?Z*0@8%7B,A9]Q
M;)R^,JN ,'+=%\!C1[C391J".MC?7-XL<=J(U/G1E=@ ;"A2Q(P.F!CO0!L:
MEXGLM*EU*.YAN=]A9K>$*@/G(2P"Q\\MN7&#CEE]:JWGC2QLM0GMWL[U[>UD
MBAO+U%0PVTDF-J/\VXGYDR55@-PR1SBEXHT;^V_%WAY(UN5^RNTUVXB81/ &
M5U0OC:6\Z*$[<YP&.,9S#J'PZM;SQ+=:K&VFA;N:*>?[5I<=S.C)@'RI7.$5
ME5005;!W$8)X -B\\5PV.L06%QINH1PSW2V<=\Z(L+3,NX* 7#D'&-P4KGOP
M<3Z%XAB\0"YDMK&\BMX)GA$\X0+(Z.R,% 8MP5/) '/UQSD_PY\[Q,VL"^M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ,VYMVF"-YA$3-& 21L# '! R.F10!W5%9^F7*.GV2.RN[9+>*(+]H7@@KD
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
=10 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>39
<FILENAME>verv-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-01T20:25:47.4854+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" xlink:href="verv-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" xlink:href="verv-20221231.xsd#DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:href="verv-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="verv_SuccessPaymentLiability" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="verv_CollaborationReceivable" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueAndCreditsNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationReceivable" xlink:label="verv_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="verv_CollaborationsRevenue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationsRevenue" xlink:label="verv_CollaborationsRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="verv_MaturitiesOfMarketableSecurities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProvisionForLeaseLosses" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="6" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="8" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="11" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="verv_SuccessOfPaymentLiability" order="14" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="16" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="verv_LicenseAndMilestonePayments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAndMilestonePayments" xlink:label="verv_LicenseAndMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxLiabilities" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="verv_DeferredTaxAssetAccruedExpenses" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>40
<FILENAME>verv-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-01T20:25:47.3442+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vervetx.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2022" xmlns:verv="http://www.vervetx.com/20221231" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd" namespace="http://xbrl.org/2020/extensible-enumerations-2.0"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" namespace="http://xbrl.sec.gov/country/2022"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" namespace="http://fasb.org/srt/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="verv-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" id="StatementConsolidatedBalanceSheets1">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2" id="DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2">
        <link:definition>100020 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2" id="DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2">
        <link:definition>100030 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details) 2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" id="StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100080 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" id="DisclosureNatureOfTheBusinessAndBasisOfPresentation">
        <link:definition>100090 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100110 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100120 - Disclosure - Property and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" id="DisclosureFairValueOfFinancialInstruments1">
        <link:definition>100130 - Disclosure - Fair value of financial instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" id="Role_DisclosureAccruedExpenses">
        <link:definition>100140 - Disclosure - Accrued expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases" id="Role_DisclosureLeases">
        <link:definition>100150 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" id="Role_DisclosureLicenseAgreements">
        <link:definition>100160 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" id="DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100170 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" id="DisclosurePreferredStockTrancheLiability1">
        <link:definition>100180 - Disclosure - Preferred Stock Tranche Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" id="Role_DisclosurePreferredAndCommonStock">
        <link:definition>100190 - Disclosure - Preferred and Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100200 - Disclosure - Stock-based compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>100210 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100220 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100230 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" id="DisclosureEmployeeBenefitPlans1">
        <link:definition>100240 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100250 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>100280 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" id="Role_DisclosurePropertyAndEquipmentNetTable">
        <link:definition>100290 - Disclosure - Property and equipment, net (Table)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" id="Role_DisclosureFairValueOfFinancialInstrumentsTables">
        <link:definition>100300 - Disclosure - Fair Value of Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" id="Role_DisclosureAccruedExpensesTables">
        <link:definition>100310 - Disclosure - Accrued expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" id="Role_DisclosureLeasesTables">
        <link:definition>100320 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" id="DisclosureCollaborationAndLicenseAgreementsTables">
        <link:definition>100330 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100340 - Disclosure - Stock-based compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>100350 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100360 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" id="Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
        <link:definition>100370 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>100380 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
        <link:definition>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" id="Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
        <link:definition>100410 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Marketable securities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" id="Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
        <link:definition>100430 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" id="DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails">
        <link:definition>100440 - Disclosure - Property and equipment, net - Schedule of Depreciation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100450 - Disclosure - Property and equipment, net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" id="DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails">
        <link:definition>100460 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" id="DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
        <link:definition>100470 - Disclosure - Fair value of financial instruments - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>100480 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" id="DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails">
        <link:definition>100490 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" id="Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails">
        <link:definition>100500 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" id="Role_DisclosureLeasesAdditionalInformationDetails">
        <link:definition>100510 - Disclosure - Leases - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" id="Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails">
        <link:definition>100520 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails">
        <link:definition>100530 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" id="Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails">
        <link:definition>100540 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100550 - Disclosure - License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100560 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" id="DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails">
        <link:definition>100570 - Disclosure - Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" id="Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails">
        <link:definition>100580 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" id="Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Preferred and Common Stock - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Stock-based compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100610 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails">
        <link:definition>100620 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails">
        <link:definition>100630 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" id="DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails">
        <link:definition>100640 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails">
        <link:definition>100650 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100660 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" id="Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails">
        <link:definition>100670 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails" id="DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails">
        <link:definition>100680 - Disclosure - Income taxes - Summary of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>100690 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" id="DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails">
        <link:definition>100700 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100710 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100720 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" id="DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100740 - Disclosure - Subsequent Events (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CurrentAbstract" name="CurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_LicenseAgreementAbstract" name="LicenseAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_NonCurrentAbstract" name="NonCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PreferredStockAbstract" name="PreferredStockAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AccruedExternalResearchAndDevelopmentExpenses" name="AccruedExternalResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AdditionalLesseeOperatingLeaseArea" name="AdditionalLesseeOperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_AdditionalTenantImprovementsAllowance" name="AdditionalTenantImprovementsAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AgreegatePurchasePrice" name="AgreegatePurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" name="AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ChangeInFairValueOfAntidilutionRights" name="ChangeInFairValueOfAntidilutionRights" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" name="ChangeInFairValueOfPreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" name="ChangeInFairValueOfSuccessPaymentsLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ChangeInOwnershipDescription" name="ChangeInOwnershipDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ClinicalAndRegulatoryMilestone" name="ClinicalAndRegulatoryMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_CollaborationReceivable" name="CollaborationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_CollaborationsRevenue" name="CollaborationsRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_CommercializingProfitsAndExpenses" name="CommercializingProfitsAndExpenses" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_CommissionOnAggregateGrossSaleProceeds" name="CommissionOnAggregateGrossSaleProceeds" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_CommonStockIssuedDuringPeriodValueNewIssues" name="CommonStockIssuedDuringPeriodValueNewIssues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" name="CommonStockIssuedForFullySatisfyingPreferredStockFinancing" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" name="CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_CommonStockOfferingPricePerShare" name="CommonStockOfferingPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_CumulativeProbabilityOfTriggeringEvent" name="CumulativeProbabilityOfTriggeringEvent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DebtBorrowedAmount" name="DebtBorrowedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetAccruedExpenses" name="DeferredTaxAssetAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsAntidilultionLiability" name="DeferredTaxAssetsAntidilultionLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" name="DeferredTaxAssetsCapitalizedCostsNetOfAmortization" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" name="DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxAssetsStockBasedCompensation" name="DeferredTaxAssetsStockBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" name="DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DevelopedBaseMilestonePayments" name="DevelopedBaseMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" name="DevelopedBaseMilestonePaymentsForStatedPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" name="EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_EffectiveIncomeTaxRateReconciliationOther" name="EffectiveIncomeTaxRateReconciliationOther" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" name="EffectiveIncomeTaxRateReconciliationPermanentItems" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueAssumptionOfEquityVolatilityRate" name="FairValueAssumptionOfEquityVolatilityRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueAssumptionsExpectedTerm1" name="FairValueAssumptionsExpectedTerm1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueInputsProbabilityOfTermination" name="FairValueInputsProbabilityOfTermination" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FairValueOfCommonStockPerShare" name="FairValueOfCommonStockPerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_FixedConsiderationAmount" name="FixedConsiderationAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" name="IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_IncreaseDecreaseInRent" name="IncreaseDecreaseInRent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" name="IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_InterestRateForAdditionalImprovementsAllowance" name="InterestRateForAdditionalImprovementsAllowance" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" name="IssuanceCostsOfCommonStockFromInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" name="IssuanceCostsOfSeriesA2ConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" name="IssuanceCostsOfSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" name="IssuanceCostsOfSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceOfAdditionalCommonStock" name="IssuanceOfAdditionalCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_IssuanceOfCommonStockFromAtTheMarketOffering" name="IssuanceOfCommonStockFromAtTheMarketOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" name="IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" name="IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IssuanceOfPreferredStockTrancheLiability" name="IssuanceOfPreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" name="IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_LeaseCommencementDate" name="LeaseCommencementDate" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LeaseNoncancelableTerm" name="LeaseNoncancelableTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LeaseRentPayment" name="LeaseRentPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_LesseeOperatingLeaseArea" name="LesseeOperatingLeaseArea" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_LesseeOperatingLeaseIncrementalBorrowingRate" name="LesseeOperatingLeaseIncrementalBorrowingRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_LicenseAndMilestonePayments" name="LicenseAndMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_MaturitiesOfMarketableSecurities" name="MaturitiesOfMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_MilestonePayments" name="MilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_MilestoneRelatedExpenses" name="MilestoneRelatedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" name="NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFee" name="NonRefundableUpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFees" name="NonRefundableUpfrontLicenseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontLicenseFeesPaid" name="NonRefundableUpfrontLicenseFeesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NonRefundableUpfrontPayment" name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_NumberOfInstallmentsForRestrictedSharesVested" name="NumberOfInstallmentsForRestrictedSharesVested" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_OperatingLeaseRelatedExpensesPriorToCommencement" name="OperatingLeaseRelatedExpensesPriorToCommencement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_OptionAndLicenseIssueFees" name="OptionAndLicenseIssueFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_OutOfPocketCostsIncurred" name="OutOfPocketCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PaymentOfMilestoneDevelopment" name="PaymentOfMilestoneDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_PaymentOfSalesBasedMilestone" name="PaymentOfSalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" name="PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" name="PercentageOfFutureTaxableIncomeUtilizedToOffset" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_PercentageOfTaxBenefitRealized" name="PercentageOfTaxBenefitRealized" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_PercentageSharesOfDevelopmentExpense" name="PercentageSharesOfDevelopmentExpense" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PerformanceObligation" name="PerformanceObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_PreferredStockFinancingFullySatisfied" name="PreferredStockFinancingFullySatisfied" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PreferredStockFinancingPartiallySatisfied" name="PreferredStockFinancingPartiallySatisfied" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" name="ProceedsFromIssuanceOfCommonSharesNetOfCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" name="ProceedsFromIssuanceOfCommonStockUnderIPOGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" name="ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ProductCollaborationTerminationNoticePeriod" name="ProductCollaborationTerminationNoticePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" name="PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_PublicOfferingPrice" name="PublicOfferingPrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="verv_ReductionInResearchAndDevelopmentExpense" name="ReductionInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" name="RemainingContractualMaturitiesOfMarketableSecuritiesTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" name="ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SalesBasedMilestone" name="SalesBasedMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" name="SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_SettlementOfTrancheRightLliability" name="SettlementOfTrancheRightLliability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_ShortTermBorrowingsReducedValue" name="ShortTermBorrowingsReducedValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" name="StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" name="StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" name="StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" name="StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" name="StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodShareLicensorInstitutions" name="StockIssuedDuringPeriodShareLicensorInstitutions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" name="StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" name="StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueLicensorInstitutions" name="StockIssuedDuringPeriodValueLicensorInstitutions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" name="StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" name="StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_SuccessLiabilityPayment" name="SuccessLiabilityPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessOfPaymentLiability" name="SuccessOfPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="verv_SuccessPaymentLiability" name="SuccessPaymentLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessPaymentLiabilityCurrent" name="SuccessPaymentLiabilityCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessPaymentLiabilityPayable" name="SuccessPaymentLiabilityPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_SuccessPaymentsForEachProduct" name="SuccessPaymentsForEachProduct" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_TaxCreditCarryforwardExpirationYear" name="TaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" name="TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_TenantImprovementsAllowance" name="TenantImprovementsAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="verv_WeightedAverageGrantDateFairValueForfeited" name="WeightedAverageGrantDateFairValueForfeited" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AcuitasAgreementsMember" name="AcuitasAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AntidilutionRightsLiabilityMember" name="AntidilutionRightsLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_AntidilutionRightsMember" name="AntidilutionRightsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BeamLicenseAgreementMember" name="BeamLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BeamMember" name="BeamMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_BroadLicenseAgreementMember" name="BroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CambridgeLeaseMember" name="CambridgeLeaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_DeliveryTechnologyProductMember" name="DeliveryTechnologyProductMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_FirstAmendmentMember" name="FirstAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_FirstLicensedAgentMaterialRightMember" name="FirstLicensedAgentMaterialRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_FourZeroOneKPlanMember" name="FourZeroOneKPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBoardMember" name="HarvardAndBoardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBroadLicenseAgreementMember" name="HarvardAndBroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardAndBroadMember" name="HarvardAndBroadMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" name="HarvardLicenseAgreementAndBroadLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_HarvardLicenseAgreementMember" name="HarvardLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_MassachusettsTaxAuthorityMember" name="MassachusettsTaxAuthorityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_MaterialsExchangeAgreementMember" name="MaterialsExchangeAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_NewAmendmentMember" name="NewAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_NovartisLicenseAgreementMember" name="NovartisLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OfficeFurnitureMember" name="OfficeFurnitureMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" name="OptionLicenseAgreementAndPatentLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_OutstandingOptionsToPurchaseCommonStockMember" name="OutstandingOptionsToPurchaseCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PreferredStockTrancheLiabilityMember" name="PreferredStockTrancheLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PremisesMember" name="PremisesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_PublicOfferingMember" name="PublicOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ResearchServicesObligationMember" name="ResearchServicesObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SecondAmendmentMember" name="SecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SecondLicensedAgentMaterialRightMember" name="SecondLicensedAgentMaterialRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SecondTrancheMember" name="SecondTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SeriesA2PreferredStocksMember" name="SeriesA2PreferredStocksMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_StrategicLicenseAndCollaborationAgreementMember" name="StrategicLicenseAndCollaborationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SuccessPaymentLiabilityMember" name="SuccessPaymentLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ThirdLicensedAgentMaterialRightMember" name="ThirdLicensedAgentMaterialRightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ThirdTrancheMember" name="ThirdTrancheMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ThreeLicensedAgentMember" name="ThreeLicensedAgentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwentyEighteenMember" name="TwentyEighteenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" name="TwentyTwentyOneEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" name="TwoThousandAndTwentyOneStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_UnvestedRestrictedStockMember" name="UnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_USAgencySecuritiesMember" name="USAgencySecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_USTreasuryBillsAndNotesMember" name="USTreasuryBillsAndNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_VerilyLicenseAgreementMember" name="VerilyLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_VertexAgreementMember" name="VertexAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_VertexPharmaceuticalsMember" name="VertexPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ConvertiblePreferredStockPolicyTextBlock" name="ConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_DeferredOfferingCostsPolicyTextBlock" name="DeferredOfferingCostsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" name="FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_IndemnificationAgreementsPolicyTextBlock" name="IndemnificationAgreementsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_LicenseAgreementDisclosureTextBlock" name="LicenseAgreementDisclosureTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PreferredAndCommonStockTextBlock" name="PreferredAndCommonStockTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_PreferredStockTrancheLiabilityTextBlock" name="PreferredStockTrancheLiabilityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_RentExpensePolicyTextBlock" name="RentExpensePolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" name="ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" name="ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="verv_SegmentAndGeographicInformationPolicyTextBlock" name="SegmentAndGeographicInformationPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>41
<FILENAME>verv-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-01T20:25:46.5698+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="verv-20221231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="verv-20221231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:href="verv-20221231.xsd#DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstruments1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:href="verv-20221231.xsd#Role_DisclosureAccruedExpenses" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:href="verv-20221231.xsd#Role_DisclosureLeases" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:href="verv-20221231.xsd#Role_DisclosureLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" xlink:href="verv-20221231.xsd#DisclosurePreferredStockTrancheLiability1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:href="verv-20221231.xsd#Role_DisclosurePreferredAndCommonStock" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="verv-20221231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:href="verv-20221231.xsd#DisclosureEmployeeBenefitPlans1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:href="verv-20221231.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="verv-20221231.xsd#DisclosureMarketableSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetTable" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:href="verv-20221231.xsd#Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:href="verv-20221231.xsd#Role_DisclosureAccruedExpensesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" xlink:href="verv-20221231.xsd#DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="verv-20221231.xsd#DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails" xlink:href="verv-20221231.xsd#DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:href="verv-20221231.xsd#DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="73.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="74.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="75.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="76.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="77.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="78.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="79.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="80.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="81.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="82.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="83.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="84.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="85.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="86.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationReceivable" xlink:label="verv_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_7"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueAndCreditsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="verv_CollaborationReceivable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_SuccessPaymentLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationsRevenue" xlink:label="verv_CollaborationsRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="us-gaap_NonoperatingGainsLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="verv_CollaborationsRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingGainsLossesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_32"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_33"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_32" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_33" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOffering" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfPreferredStockTrancheLiability" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SettlementOfTrancheRightLliability" xlink:label="verv_SettlementOfTrancheRightLliability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProvisionForLeaseLosses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_IssuanceOfPreferredStockTrancheLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="verv_MaturitiesOfMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_SettlementOfTrancheRightLliability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="verv_SuccessOfPaymentLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfAntidilutionRights" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAgreementDisclosureTextBlock" xlink:label="verv_LicenseAgreementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_LicenseAgreementAbstract" xlink:to="verv_LicenseAgreementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementsAbstract" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePreferredStockTrancheLiability1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityTextBlock" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="verv_PreferredStockTrancheLiabilityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredAndCommonStockTextBlock" xlink:label="verv_PreferredAndCommonStockTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_PreferredStockAbstract" xlink:to="verv_PreferredAndCommonStockTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredOfferingCostsPolicyTextBlock" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IndemnificationAgreementsPolicyTextBlock" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ConvertiblePreferredStockPolicyTextBlock" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_RentExpensePolicyTextBlock" xlink:label="verv_RentExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_DeferredOfferingCostsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_IndemnificationAgreementsPolicyTextBlock" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ConvertiblePreferredStockPolicyTextBlock" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_RentExpensePolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_SegmentAndGeographicInformationPolicyTextBlock" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementsAbstract" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexPharmaceuticalsMember" xlink:label="verv_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StrategicLicenseAndCollaborationAgreementMember" xlink:label="verv_StrategicLicenseAndCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingMember" xlink:label="verv_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_VertexPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_StrategicLicenseAndCollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_PublicOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_9"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_10"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_PercentageOfTaxBenefitRealized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="verv_SummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_IssuanceOfAdditionalCommonStock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SuccessLiabilityPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_ComputerEquipmentAndSoftwareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_OfficeFurnitureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_LaboratoryEquipmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CurrentAbstract" xlink:label="verv_CurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonCurrentAbstract" xlink:label="verv_NonCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_CurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_NonCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CurrentAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_NonCurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_NonCurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_NonCurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_NonCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USTreasuryBillsAndNotesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USAgencySecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityPayable" xlink:label="verv_SuccessPaymentLiabilityPayable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityPayable" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityCurrent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueInputsProbabilityOfTermination" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueOfCommonStockPerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_5"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAndMilestonePayments" xlink:label="verv_LicenseAndMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="verv_LicenseAndMilestonePayments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInRent" xlink:label="verv_IncreaseDecreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_FirstAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseArea" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_CambridgeLeaseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_SecondAmendmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalLesseeOperatingLeaseArea" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_PremisesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_NewAmendmentMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseCommencementDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseNoncancelableTerm" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_TenantImprovementsAllowance" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalTenantImprovementsAllowance" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermBorrowings" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_ShortTermBorrowingsReducedValue" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInRent" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NZ" xlink:label="country_NZ"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NovartisLicenseAgreementMember" xlink:label="verv_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommercializingProfitsAndExpenses" xlink:label="verv_CommercializingProfitsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_LicenseAgreementAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="verv_DeliveryTechnologyProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SalesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NZ" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_AntidilutionRightsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingPartiallySatisfied" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BeamLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingFullySatisfied" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_NovartisLicenseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_AcuitasAgreementsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfMilestoneDevelopment" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfSalesBasedMilestone" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommercializingProfitsAndExpenses" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePayments" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestonePayments" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PercentageSharesOfDevelopmentExpense" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ProductCollaborationTerminationNoticePeriod" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestoneRelatedExpenses" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFee" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ClinicalAndRegulatoryMilestone" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_SalesBasedMilestone" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontPayment" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementsAbstract" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockPurchaseAgreementMember" xlink:label="verv_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexAgreementMember" xlink:label="verv_VertexAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThreeLicensedAgentMember" xlink:label="verv_ThreeLicensedAgentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentsForEachProduct" xlink:label="verv_SuccessPaymentsForEachProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireCommercialRealEstate" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfUnamortizedFilmCosts" xlink:label="us-gaap_PercentageOfUnamortizedFilmCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndFeeIncomeLoansCommercial" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" xlink:label="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FixedConsiderationAmount" xlink:label="verv_FixedConsiderationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" xlink:label="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_StockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VertexAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ThreeLicensedAgentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_NonRefundableUpfrontPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_SuccessPaymentsForEachProduct" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireCommercialRealEstate" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PercentageOfUnamortizedFilmCosts" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestAndFeeIncomeLoansCommercial" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ManagementFeeExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_FixedConsiderationAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementsAbstract" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PerformanceObligation" xlink:label="verv_PerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchServicesObligationMember" xlink:label="verv_ResearchServicesObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstLicensedAgentMaterialRightMember" xlink:label="verv_FirstLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondLicensedAgentMaterialRightMember" xlink:label="verv_SecondLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdLicensedAgentMaterialRightMember" xlink:label="verv_ThirdLicensedAgentMaterialRightMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_CollaborationAndLicenseAgreementsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_PerformanceObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ResearchServicesObligationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_FirstLicensedAgentMaterialRightMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_SecondLicensedAgentMaterialRightMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ThirdLicensedAgentMaterialRightMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexPharmaceuticalsMember" xlink:label="verv_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesAgreementMember" xlink:label="verv_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockPurchaseAgreementMember" xlink:label="verv_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingMember" xlink:label="verv_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_3"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingPrice" xlink:label="verv_PublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AgreegatePurchasePrice" xlink:label="verv_AgreegatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommissionOnAggregateGrossSaleProceeds" xlink:label="verv_CommissionOnAggregateGrossSaleProceeds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockOfferingPricePerShare" xlink:label="verv_CommonStockOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_VertexPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="verv_PreferredStockAbstract" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="verv_HarvardAndBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="verv_HarvardAndBroadMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_SeriesA2PreferredStocksMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_StockPurchaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_PublicOfferingMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_PublicOfferingPrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_AgreegatePurchasePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_CommissionOnAggregateGrossSaleProceeds" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_CommonStockOfferingPricePerShare" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyEighteenMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_WeightedAverageGrantDateFairValueForfeited" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_WeightedAverageGrantDateFairValueForfeited" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="verv_SuccessPaymentLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_HarvardAndBoardMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_ProductOrServiceAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_EarningsPerShareBasicLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationOther" xlink:label="verv_EffectiveIncomeTaxRateReconciliationOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="verv_EffectiveIncomeTaxRateReconciliationOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsStockBasedCompensation" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="verv_DeferredTaxLiabilitiesRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetsStockBasedCompensation" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="verv_DeferredTaxAssetAccruedExpenses" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="verv_MassachusettsTaxAuthorityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_ChangeInOwnershipDescription" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_OperatingLossCarryforwardsExpirationYear" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_TaxCreditCarryforwardExpirationYear" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseRentPayment" xlink:label="verv_LeaseRentPayment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="verv_BeamMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_CollaborationAndLicenseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_OfficerMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_MaterialsExchangeAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForRent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OutOfPocketCostsIncurred" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_LeaseRentPayment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_ReductionInResearchAndDevelopmentExpense" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OptionAndLicenseIssueFees" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFees" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_DebtBorrowedAmount" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="verv_FourZeroOneKPlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsDate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>42
<FILENAME>verv-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-01T20:25:46.5953+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1" xlink:href="verv-20221231.xsd#StatementConsolidatedBalanceSheets1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="verv-20221231.xsd#StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:href="verv-20221231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:href="verv-20221231.xsd#DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLeasesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" xlink:href="verv-20221231.xsd#DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="verv-20221231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:href="verv-20221231.xsd#DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="verv-20221231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:href="verv-20221231.xsd#DisclosureEmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationReceivable" xlink:label="verv_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_MarketableSecuritiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueAndCreditsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="verv_CollaborationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="verv_SuccessPaymentLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexPharmaceuticalsMember" xlink:label="verv_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StrategicLicenseAndCollaborationAgreementMember" xlink:label="verv_StrategicLicenseAndCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingMember" xlink:label="verv_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_VertexPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_StrategicLicenseAndCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_PercentageOfTaxBenefitRealized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_IssuanceOfAdditionalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SuccessLiabilityPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_ComputerEquipmentAndSoftwareMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_OfficeFurnitureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CurrentAbstract" xlink:label="verv_CurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonCurrentAbstract" xlink:label="verv_NonCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_CurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_NonCurrentAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_CurrentAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_NonCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_NonCurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_CurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_NonCurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_CurrentAbstract" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_NonCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="verv_CurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USTreasuryBillsAndNotesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="verv_USAgencySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityPayable" xlink:label="verv_SuccessPaymentLiabilityPayable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_SuccessPaymentLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueInputsProbabilityOfTermination" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueOfCommonStockPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="verv_FairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_PreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_AntidilutionRightsLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="verv_SuccessPaymentLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInRent" xlink:label="verv_IncreaseDecreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_FirstAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_LetterOfCreditMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_CambridgeLeaseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_SecondAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalLesseeOperatingLeaseArea" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="verv_PremisesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="verv_NewAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_CreditFacilityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LeaseNoncancelableTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_TenantImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_AdditionalTenantImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermBorrowings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_ShortTermBorrowingsReducedValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PrepaidRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_IncreaseDecreaseInRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_OperatingLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_ShortTermLeaseCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NZ" xlink:label="country_NZ"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NovartisLicenseAgreementMember" xlink:label="verv_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommercializingProfitsAndExpenses" xlink:label="verv_CommercializingProfitsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="us-gaap_NonUsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="verv_DeliveryTechnologyProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SalesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_NZ" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_AntidilutionRightsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingPartiallySatisfied" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_BeamLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PreferredStockFinancingFullySatisfied" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_NovartisLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_AcuitasAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfMilestoneDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentOfSalesBasedMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_CommercializingProfitsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PercentageSharesOfDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ProductCollaborationTerminationNoticePeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_MilestoneRelatedExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_ClinicalAndRegulatoryMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_SalesBasedMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="verv_NonRefundableUpfrontPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockPurchaseAgreementMember" xlink:label="verv_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexAgreementMember" xlink:label="verv_VertexAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThreeLicensedAgentMember" xlink:label="verv_ThreeLicensedAgentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentsForEachProduct" xlink:label="verv_SuccessPaymentsForEachProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireCommercialRealEstate" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfUnamortizedFilmCosts" xlink:label="us-gaap_PercentageOfUnamortizedFilmCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndFeeIncomeLoansCommercial" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" xlink:label="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FixedConsiderationAmount" xlink:label="verv_FixedConsiderationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" xlink:label="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_StockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VertexAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ThreeLicensedAgentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockTransactionDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_NonRefundableUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_SuccessPaymentsForEachProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsToAcquireCommercialRealEstate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PercentageOfUnamortizedFilmCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_InterestAndFeeIncomeLoansCommercial" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ManagementFeeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="verv_FixedConsiderationAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PerformanceObligation" xlink:label="verv_PerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchServicesObligationMember" xlink:label="verv_ResearchServicesObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstLicensedAgentMaterialRightMember" xlink:label="verv_FirstLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondLicensedAgentMaterialRightMember" xlink:label="verv_SecondLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdLicensedAgentMaterialRightMember" xlink:label="verv_ThirdLicensedAgentMaterialRightMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="verv_PerformanceObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ResearchServicesObligationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_FirstLicensedAgentMaterialRightMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_SecondLicensedAgentMaterialRightMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="verv_ThirdLicensedAgentMaterialRightMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexPharmaceuticalsMember" xlink:label="verv_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesAgreementMember" xlink:label="verv_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockPurchaseAgreementMember" xlink:label="verv_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingMember" xlink:label="verv_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingPrice" xlink:label="verv_PublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AgreegatePurchasePrice" xlink:label="verv_AgreegatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommissionOnAggregateGrossSaleProceeds" xlink:label="verv_CommissionOnAggregateGrossSaleProceeds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockOfferingPricePerShare" xlink:label="verv_CommonStockOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_VertexPharmaceuticalsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="verv_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_VerilyLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="verv_HarvardAndBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="verv_HarvardAndBroadMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="dei_LegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_SeriesA2PreferredStocksMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_StockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_PublicOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_TitleOfIndividualAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_PublicOfferingPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_AgreegatePurchasePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_CommissionOnAggregateGrossSaleProceeds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_DividendsPayableAmountPerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="verv_CommonStockOfferingPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyEighteenMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_WeightedAverageGrantDateFairValueForfeited" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="verv_WeightedAverageGrantDateFairValueForfeited" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_UnvestedRestrictedStockUnitsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="verv_SuccessPaymentLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="verv_HarvardAndBoardMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="verv_MassachusettsTaxAuthorityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_ChangeInOwnershipDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_OperatingLossCarryforwardsExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="verv_TaxCreditCarryforwardExpirationYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseRentPayment" xlink:label="verv_LeaseRentPayment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="verv_BeamMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_CollaborationAndLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_SecondTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_OfficerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_MaterialsExchangeAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="verv_ThirdTrancheMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForRent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OutOfPocketCostsIncurred" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_LeaseRentPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_ReductionInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_OptionAndLicenseIssueFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_NonRefundableUpfrontLicenseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="verv_DebtBorrowedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RepaymentsOfSeniorDebt" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="verv_FourZeroOneKPlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_RetirementPlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAbstract" xlink:label="us-gaap_LiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>43
<FILENAME>verv-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-03-01T20:25:49.6258+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAndMilestonePayments" xlink:label="verv_LicenseAndMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PerformanceObligation" xlink:label="verv_PerformanceObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdTrancheMember" xlink:label="verv_ThirdTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember" xlink:label="us-gaap_SalesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingPartiallySatisfied" xlink:label="verv_PreferredStockFinancingPartiallySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NewAmendmentMember" xlink:label="verv_NewAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfPreferredStockTrancheLiability" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseAgreementTermsMember" xlink:label="us-gaap_LicenseAgreementTermsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredAndCommonStockTextBlock" xlink:label="verv_PreferredAndCommonStockTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRent" xlink:label="us-gaap_PaymentsForRent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ReductionInResearchAndDevelopmentExpense" xlink:label="verv_ReductionInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MassachusettsTaxAuthorityMember" xlink:label="verv_MassachusettsTaxAuthorityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ShortTermBorrowingsReducedValue" xlink:label="verv_ShortTermBorrowingsReducedValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FourZeroOneKPlanMember" xlink:label="verv_FourZeroOneKPlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockOfferingPricePerShare" xlink:label="verv_CommonStockOfferingPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAgreementAbstract" xlink:label="verv_LicenseAgreementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SettlementOfTrancheRightLliability" xlink:label="verv_SettlementOfTrancheRightLliability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommercializingProfitsAndExpenses" xlink:label="verv_CommercializingProfitsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_OfficerMember" xlink:label="srt_OfficerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USTreasuryBillsAndNotesMember" xlink:label="verv_USTreasuryBillsAndNotesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember" xlink:label="us-gaap_NonUsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyEighteenMember" xlink:label="verv_TwentyEighteenMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForLeaseLosses" xlink:label="us-gaap_ProvisionForLeaseLosses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasicLineItems" xlink:label="us-gaap_EarningsPerShareBasicLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SeriesA2PreferredStocksMember" xlink:label="verv_SeriesA2PreferredStocksMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBoardMember" xlink:label="verv_HarvardAndBoardMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInRent" xlink:label="verv_IncreaseDecreaseInRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationsRevenue" xlink:label="verv_CollaborationsRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfSalesBasedMilestone" xlink:label="verv_PaymentOfSalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThirdLicensedAgentMaterialRightMember" xlink:label="verv_ThirdLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_USAgencySecuritiesMember" xlink:label="verv_USAgencySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementsAbstract" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AgreegatePurchasePrice" xlink:label="verv_AgreegatePurchasePrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BroadLicenseAgreementMember" xlink:label="verv_BroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockTransactionDate" xlink:label="us-gaap_SaleOfStockTransactionDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesBasedMilestone" xlink:label="verv_SalesBasedMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamMember" xlink:label="verv_BeamMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalLesseeOperatingLeaseArea" xlink:label="verv_AdditionalLesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_RentExpensePolicyTextBlock" xlink:label="verv_RentExpensePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommissionOnAggregateGrossSaleProceeds" xlink:label="verv_CommissionOnAggregateGrossSaleProceeds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInOwnershipDescription" xlink:label="verv_ChangeInOwnershipDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondTrancheMember" xlink:label="verv_SecondTrancheMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionsExpectedTerm1" xlink:label="verv_FairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseNoncancelableTerm" xlink:label="verv_LeaseNoncancelableTerm"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOffering" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfAntidilutionRights" xlink:label="verv_ChangeInFairValueOfAntidilutionRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LicenseAgreementDisclosureTextBlock" xlink:label="verv_LicenseAgreementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentsForEachProduct" xlink:label="verv_SuccessPaymentsForEachProduct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationOther" xlink:label="verv_EffectiveIncomeTaxRateReconciliationOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockMember" xlink:label="verv_UnvestedRestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ClinicalAndRegulatoryMilestone" xlink:label="verv_ClinicalAndRegulatoryMilestone"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueRevenueRecognized1" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsMember" xlink:label="verv_AntidilutionRightsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain" xlink:label="us-gaap_CreditFacilityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_InterestRateForAdditionalImprovementsAllowance" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstLicensedAgentMaterialRightMember" xlink:label="verv_FirstLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetAccruedExpenses" xlink:label="verv_DeferredTaxAssetAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageSharesOfDevelopmentExpense" xlink:label="verv_PercentageSharesOfDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonCurrentAbstract" xlink:label="verv_NonCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadLicenseAgreementMember" xlink:label="verv_HarvardAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaterialsExchangeAgreementMember" xlink:label="verv_MaterialsExchangeAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityTextBlock" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AdditionalTenantImprovementsAllowance" xlink:label="verv_AdditionalTenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardAndBroadMember" xlink:label="verv_HarvardAndBroadMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestoneRelatedExpenses" xlink:label="verv_MilestoneRelatedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ThreeLicensedAgentMember" xlink:label="verv_ThreeLicensedAgentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProductCollaborationTerminationNoticePeriod" xlink:label="verv_ProductCollaborationTerminationNoticePeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_WeightedAverageGrantDateFairValueForfeited" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationAndLicenseAgreementMember" xlink:label="verv_CollaborationAndLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockPurchaseAgreementMember" xlink:label="verv_StockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OperatingLossCarryforwardsExpirationYear" xlink:label="verv_OperatingLossCarryforwardsExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityPayable" xlink:label="verv_SuccessPaymentLiabilityPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseCommencementDate" xlink:label="verv_LeaseCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StrategicLicenseAndCollaborationAgreementMember" xlink:label="verv_StrategicLicenseAndCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireCommercialRealEstate" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingPrice" xlink:label="verv_PublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" xlink:label="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CollaborationReceivable" xlink:label="verv_CollaborationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TenantImprovementsAllowance" xlink:label="verv_TenantImprovementsAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LetterOfCreditMember" xlink:label="us-gaap_LetterOfCreditMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VerilyLicenseAgreementMember" xlink:label="verv_VerilyLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ConvertiblePreferredStockPolicyTextBlock" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FirstAmendmentMember" xlink:label="verv_FirstAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiability" xlink:label="verv_SuccessPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockAbstract" xlink:label="verv_PreferredStockAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexPharmaceuticalsMember" xlink:label="verv_VertexPharmaceuticalsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsDate" xlink:label="us-gaap_SubsequentEventsDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndFeeIncomeLoansCommercial" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsAntidilultionLiability" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_UnvestedRestrictedStockUnitsMember" xlink:label="verv_UnvestedRestrictedStockUnitsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PercentageOfUnamortizedFilmCosts" xlink:label="us-gaap_PercentageOfUnamortizedFilmCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsStockBasedCompensation" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FixedConsiderationAmount" xlink:label="verv_FixedConsiderationAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DevelopedBaseMilestonePayments" xlink:label="verv_DevelopedBaseMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OptionAndLicenseIssueFees" xlink:label="verv_OptionAndLicenseIssueFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFees" xlink:label="verv_NonRefundableUpfrontLicenseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondLicensedAgentMaterialRightMember" xlink:label="verv_SecondLicensedAgentMaterialRightMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredOfferingCostsPolicyTextBlock" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockTrancheLiabilityMember" xlink:label="verv_PreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PublicOfferingMember" xlink:label="verv_PublicOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AntidilutionRightsLiabilityMember" xlink:label="verv_AntidilutionRightsLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutOfPocketCostsIncurred" xlink:label="verv_OutOfPocketCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_VertexAgreementMember" xlink:label="verv_VertexAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:label="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt" xlink:label="us-gaap_RepaymentsOfSeniorDebt"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameDomain" xlink:label="us-gaap_RetirementPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_NZ" xlink:label="country_NZ"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityCurrent" xlink:label="verv_SuccessPaymentLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CambridgeLeaseMember" xlink:label="verv_CambridgeLeaseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NovartisLicenseAgreementMember" xlink:label="verv_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent" xlink:label="us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PreferredStockFinancingFullySatisfied" xlink:label="verv_PreferredStockFinancingFullySatisfied"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PercentageOfTaxBenefitRealized" xlink:label="verv_PercentageOfTaxBenefitRealized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesTable" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LeaseRentPayment" xlink:label="verv_LeaseRentPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfAdditionalCommonStock" xlink:label="verv_IssuanceOfAdditionalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_BeamLicenseAgreementMember" xlink:label="verv_BeamLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OfficeFurnitureMember" xlink:label="verv_OfficeFurnitureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontPayment" xlink:label="verv_NonRefundableUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" xlink:label="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DebtBorrowedAmount" xlink:label="verv_DebtBorrowedAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CumulativeProbabilityOfTriggeringEvent" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFee" xlink:label="verv_NonRefundableUpfrontLicenseFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LaboratoryEquipmentMember" xlink:label="verv_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingGainsLossesAbstract" xlink:label="us-gaap_NonoperatingGainsLossesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ComputerEquipmentAndSoftwareMember" xlink:label="verv_ComputerEquipmentAndSoftwareMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_LesseeOperatingLeaseArea" xlink:label="verv_LesseeOperatingLeaseArea"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare" xlink:label="us-gaap_DividendsPayableAmountPerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_TaxCreditCarryforwardExpirationYear" xlink:label="verv_TaxCreditCarryforwardExpirationYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_CurrentAbstract" xlink:label="verv_CurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueOfCommonStockPerShare" xlink:label="verv_FairValueOfCommonStockPerShare"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueInputsProbabilityOfTermination" xlink:label="verv_FairValueInputsProbabilityOfTermination"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ManagementFeeExpense" xlink:label="us-gaap_ManagementFeeExpense"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_DeliveryTechnologyProductMember" xlink:label="verv_DeliveryTechnologyProductMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ResearchServicesObligationMember" xlink:label="verv_ResearchServicesObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MilestonePayments" xlink:label="verv_MilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessPaymentLiabilityMember" xlink:label="verv_SuccessPaymentLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SecondAmendmentMember" xlink:label="verv_SecondAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_NonRefundableUpfrontLicenseFeesPaid" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PremisesMember" xlink:label="verv_PremisesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SalesAgreementMember" xlink:label="verv_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanNameAxis" xlink:label="us-gaap_RetirementPlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_PaymentOfMilestoneDevelopment" xlink:label="verv_PaymentOfMilestoneDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessLiabilityPayment" xlink:label="verv_SuccessLiabilityPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_MaturitiesOfMarketableSecurities" xlink:label="verv_MaturitiesOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="us-gaap_DefinedContributionPlanTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_AcuitasAgreementsMember" xlink:label="verv_AcuitasAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionDeferredRevenue" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidRent" xlink:label="us-gaap_PrepaidRent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_SuccessOfPaymentLiability" xlink:label="verv_SuccessOfPaymentLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_IndemnificationAgreementsPolicyTextBlock" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="verv-20221231.xsd#verv_FairValueAssumptionOfEquityVolatilityRate" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAndMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PerformanceObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third tranche</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third tranche.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Third Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs of $25,098</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock financing partially satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Financing Partially Satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingPartiallySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock financing partially satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NewAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfPreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease space build out cost prior to commencement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Related Expenses Prior To Commencement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease related expenses prior to commencement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred and Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred And Common Stock [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredAndCommonStockTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred and common stock disclosure text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in common stock capital shares, reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase In Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in common stock capital shares, reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReductionInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction In Research And Development Expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Massachusetts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Massachusetts Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MassachusettsTaxAuthorityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Massachusetts Tax Authority [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Short-term Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit reduced value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowings Reduced Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ShortTermBorrowingsReducedValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term borrowings reduced value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">401(k) Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Four Zero One (K) Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FourZeroOneKPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">401(k) Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockOfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockOfferingPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Offering Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License Agreement Abstract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from common stock, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock Under I P O Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds From Issuance Of Common Stock Under IPO, Gross.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, immaterial effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows related to operating leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP(shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for partly satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Partly Satisfying Preferred Stock Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for partly satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares of common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of tranche right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of Tranche Right Lliability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfTrancheRightLliability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of tranche right liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant Date Fair Value Per Share, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nature of the Business and Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NatureOfOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nature of Operations [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harward.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommercializingProfitsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercializing Profits And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommercializingProfitsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercializing Profits And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommercializingProfitsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercializing profits and expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_OfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Officer [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Treasury Bills and Notes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Bills And Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USTreasuryBillsAndNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. treasury bills and notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adopted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adopted [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of additional common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Share Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuances of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-US</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonUsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-US [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Twenty Eighteen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Eighteen [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyEighteenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty eighteen</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProvisionForLeaseLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Provision for Lease Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of common stock under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Earnings Per Share Basic [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of equity offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of equity offering costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Financing and Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payment of Financing and Stock Issuance Costs, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common shares, net of commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance of Common Shares, Net of Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from issuance of common shares, net of commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short term lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Purchase Commitment, Category of Item Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A2 Preferred Stocks [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series A-2 Preferred Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SeriesA2PreferredStocksMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A-2 Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard And Board</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Board [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBoardMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard and Board.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance or sale of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance or Sale of Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash&#8212;beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash&#8212;end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of installments for restricted shares vested.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Installments for Restricted Shares Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from At-the-Market offering, net of issuance costs of , (In Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS SHARES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS SHARES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series A convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs of Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IncreaseDecreaseInRent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase decrease in rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInRent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in net loss per share attributable to common stockholders, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationsRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationsRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationsRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of sales based milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfSalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of sales based milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThirdLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third licensed agent material right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Agency Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_USAgencySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. agency securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option License Agreement And Patent License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option License Agreement And Patent License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option License Agreement and Patent License Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration and License Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction costs on issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding stock, reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average grant date fair value of stock options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AgreegatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreegate Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AgreegatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreegate Purchase Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AgreegatePurchasePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreegate purchase price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Broad License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of common stock closed date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockTransactionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Transaction Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Based Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesBasedMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales based milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beam</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beam [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beam [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Earnings Per Share Basic By Common Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share attributable to common stockholders, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share attributable to common stockholders, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalLesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Numerator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rent Expense Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RentExpensePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy of rent expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommissionOnAggregateGrossSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commission On Aggregate Gross Sale Proceeds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommissionOnAggregateGrossSaleProceeds_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commission on aggregate gross sale proceeds.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average share price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible preferred stock (See Note 10)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Ownership Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in ownership description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInOwnershipDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in ownership, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present value of operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Tranche Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondTrancheMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Second Tranche [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumptions expected term 1.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Noncancelable Term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Noncancelable Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseNoncancelableTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease noncancelable term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from At-the-Market offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum annual contributions per employee, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of antidilution rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Antidilution Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfAntidilutionRights_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of antidilution rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of common stock from initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Common Stock From Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs Of Common Stock from Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LicenseAgreementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentsForEachProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payments for each product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentsForEachProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success payments for each product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentsForEachProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payments for each product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of Operating Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure - Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Available For Issuance Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Available For Issuance Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock available for issuance under ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non-Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non-Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the issuance of common stock in connection with the Vertex Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Issuance of Series A Preferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Twenty Twenty One Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Twenty twenty one employee stock purchase plan member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred provision</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match Upto Three Percent Of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ClinicalAndRegulatoryMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueRevenueRecognized1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue, Revenue Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilution Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Rights Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution rights.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, value per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross unrealized gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents, and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-Term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average number of common shares, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average common shares used in net loss per share attributable to common stockholders, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount due as a result of termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Due to Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Due to Related Parties, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation, Executive compensation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Executive compensation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Executive compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Credit Facility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Credit Facility [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of success payments liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Success Payments Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of success payments liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares issued upon conversion of preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Improvement allowance interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Rate For Additional Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_InterestRateForAdditionalImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Interest rate for additional improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to terminate, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Terminate [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and development expense of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense of antidilution rights liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Depreciation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First licensed agent material right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Asset Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Asset Accrued Expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A-2 convertible preferred stock, net of issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from purchase of shares through employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series A2 convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series A2 Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance costs of series A2 convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Share Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock to licensor institutions (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsidiary Sale Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent of Match Upto Two Percent of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage Shares of Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Shares Of Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageSharesOfDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage Shares of Development Expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Increase in operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Deferred Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard and Board</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard and Broad license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in accounting principle, accounting standards update, adoption date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change in Accounting Principle, Accounting Standards Update, Adoption Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Materials Exchange Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Materials Exchange Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaterialsExchangeAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Materials Exchange Agreement [Member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Liability [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock tranche liability disclosure text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuances of common stock to licensor institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net amortization of premium (accretion of discount) on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Amortization Of Premium (Accretion Of Discount) On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net Amortization Of Premium (Accretion Of Discount) On Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Tenant Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AdditionalTenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional tenant improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard And Broad [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardAndBroadMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard And Broad.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Schedule of Future Minimum Lease Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Related Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestoneRelatedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone related expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThreeLicensedAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Three Licensed Agent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ThreeLicensedAgentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Three Licensed Agent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and unpaid interest paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Increase, Accrued Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product collaboration termination notice period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Collaboration Termination Notice Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProductCollaborationTerminationNoticePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Product collaboration termination notice period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-Term Lease Commitment, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCommitmentAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Rent Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant-Date Fair Value, forfeited | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted-Average Grant-Date Fair Value, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_WeightedAverageGrantDateFairValueForfeited_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted-Average Grant-Date Fair Value, forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed base milestone payments for quarterly period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Base Milestone Payments For Stated Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed base milestone payments for quarterly period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Professional fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration And License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationAndLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration And License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on available-for-sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OperatingLossCarryforwardsExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A Preferred Stock in payment of licensing fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value by Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability, Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease Commencement Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend true/false, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common stock under ESPP (In Share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Issuance of common stock under ESPP Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Issuance of common stock under ESPP Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StrategicLicenseAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Strategic License and Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StrategicLicenseAndCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Strategic License and Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Restricted stock units forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments to Acquire Commercial Real Estate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireCommercialRealEstate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Commercial Real Estate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lab equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized loss on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated expected cost reimbursement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecovered Production Costs, Excess of Estimated Average Unit Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment and Geographic Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment And Geographic Information Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accounting policy related to segment and geographic information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CollaborationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible, conversion ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of derivative liability by issuing common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement of Antidilution Rights Liability By Issuing Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of Antidilution Rights Liability By Issuing Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in Right-Of-Use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Right Of Use Of Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease In Operating Lease Right Of Use Of Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TenantImprovementsAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements allowance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of Credit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LetterOfCreditMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter of Credit [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Verily License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Verily License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VerilyLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Verily License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FirstAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First Amendment Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Benefits [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares issued and sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Assets, Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Grant-Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other expense, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Impairment, Long-Lived Asset, Held-for-Use, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of stock, price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive (loss) income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining contractual maturities of marketable securities term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining Contractual Maturities Of Marketable Securities Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining contractual maturities of marketable securities term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denominator:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareReconciliationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease obligations, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development tax credits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand And Twenty One Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value of Financial Instruments, Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of shareholder loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance costs of series B convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Costs Of Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance Costs Of Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reconciliation of cash, cash equivalents and restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions Used for Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agencies Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Agency Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee Lease Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Lease, Description [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease, rent expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease incremental borrowing rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Incremental Borrowing Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease incremental borrowing rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock abstract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Pharmaceuticals [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VertexPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex pharmaceuticals member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event, Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent event, date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Required fee payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Fee Income, Loans, Commercial</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndFeeIncomeLoansCommercial_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Fee Income, Loans, Commercial, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilultion liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Antidilultion Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsAntidilultionLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Antidilultion Liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Preferred Stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_UnvestedRestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PercentageOfUnamortizedFilmCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of profit/cost share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PercentageOfUnamortizedFilmCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of Unamortized Film Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Servicing Liability at Fair Value, Other Changes in Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets, Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsStockBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Harvard License Agreement And Broad License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Harvard License Agreement And Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Harvard/Broad License Agreement and Broad License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FixedConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed consideration amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FixedConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed consideration amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FixedConsiderationAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fixed consideration amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Regulatory Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed base milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Developed Base Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DevelopedBaseMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Developed base milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Depreciation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public Utility Property, Plant, and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average period over which unrecognized compensation is expected to be recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average remaining contractual life (in years), Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option And License Issue Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option And License Issue Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OptionAndLicenseIssueFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option And License Issue Fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input, Expected Term [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Refundable Upfront License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non Refundable Upfront License Fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issued for fully satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued For Fully Satisfying Preferred Stock Financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock issued for fully satisfying preferred stock financing</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Estimated Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of property and equipment estimated useful life.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series B convertible preferred stock, net of issuance costs of $241</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series B Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series B convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Over-Allotment Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second licensed agent material right [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondLicensedAgentMaterialRightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second licensed agent material right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (See Note 7 and 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Treasury Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">U.S. Treasury Bills and Notes [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Offering Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredOfferingCostsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Tranche Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation Arrangement by Share-based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority, Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Public offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PublicOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Public offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilution Rights Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilution Rights Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AntidilutionRightsLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilution rights liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Out-of-pocket costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Out Of Pocket Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutOfPocketCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">out-of-pocket costs incurred.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual license fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromLicenseFeesReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from License Fees Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equtiy (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of future taxable income utilized to offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of future taxable income utilized to offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes, net of federal benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VertexAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vertex Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VertexAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vertex Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_VertexAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vertex Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized research costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayments of Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of Senior Debt</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RepaymentsOfSeniorDebt_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Repayments of Senior Debt, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_NZ_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">N Z</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_NZ_lbl" xlink:role="http://www.xbrl.org/2003/role/label">NEW ZEALAND</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of stock options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Payment Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A Preferred Stock in payment of licensing fee (shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cambridge Lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cambridge Lease [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CambridgeLeaseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cambridge lease.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized costs&#8212;net of amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Capitalized Costs Net Of Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Capitalized Costs Net Of Amortization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis License Agreement Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis license agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match After Three Percent And Before Five Percent Of Employee Salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Common stock under ESPP value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Issuance of common stock under ESPP Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock Issued During Issuance of common stock under ESPP Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment additions included in accounts payable and accrued expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment Additions Included In Accounts Payable And Accrued Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment additions included in accounts payable and accrued expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reimbursement received related to reduction to research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Received for License Agreement Reimbursement of Costs Incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment received for license agreement reimbursement of costs incurred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock financing were fully satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Financing Fully Satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PreferredStockFinancingFullySatisfied_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preferred stock financing fully satisfied</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets valuation allowance increase (decrease)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfTaxBenefitRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of tax benefit realized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PercentageOfTaxBenefitRealized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of tax benefit realized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued expenses and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock from At-the-Market offering, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Repayment of Loans to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares available for future grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted average exercise price, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted average exercise price, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares series a convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseRentPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Rent Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseRentPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Rent Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LeaseRentPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease rent payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfAdditionalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of additional common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfAdditionalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Additional Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement with Federal Government, Costs Incurred, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash paid for amounts included in the measurements of lease liabilities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash paid for amounts included in the measurements of lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Beam License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Beam License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_BeamLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Beam license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in fair value of preferred stock tranche liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Preferred Stock Tranche Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of preferred stock tranche liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease not yet commenced, lease term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing and finnacing activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office Furniture</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Office Furniture [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OfficeFurnitureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Office furniture.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from initial public offering, net of underwriting discount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Uncertain tax positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unrecognized Tax Benefits, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unrecognized Tax Benefits, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Computation of Basic and Diluted net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount of Deferred Costs Related to Long-Term Contracts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount of Deferred Costs Related to Long-Term Contracts</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowed amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Borrowed Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DebtBorrowedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Debt borrowed amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of Preferred Stock, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Preferred Stock and Preference Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">IPO</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of options, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Category of Item Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Category of Item Purchased [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Changes in Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cumulative probability of triggering event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cumulative Probability Of Triggering Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CumulativeProbabilityOfTriggeringEvent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative probability of triggering event.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Unvested RSUs, beginning balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Unvested RSUs, ending balance, Unvested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non Refundable Upfront License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront License Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront license fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of options, Outstanding, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of options, Outstanding, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Fair Value Liabilities Measured on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per common share attributable to common stockholders, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per common share attributable to common stockholders, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued External Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued external research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingGainsLossesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Gains (Losses) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingGainsLossesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A convertible preferred stock and settlement of tranche right liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance of Series A Convertible Preferred Stock and Settlement of Tranche Right Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Series A Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Freestanding Financial Instruments and Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Freestanding Financial Instruments And Derivatives Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Freestanding financial instruments and derivatives.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of additional shares issued to licensor institutuons.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Additional Shares Value Licensor Institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional issuances of common stock to licensor institutions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series A Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series A Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment and Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment And Software [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ComputerEquipmentAndSoftwareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Computer equipment and software.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Area</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_LesseeOperatingLeaseArea_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease area.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee compensation and related benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Dividends Payable, Amount Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DividendsPayableAmountPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cumulative dividends payable per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax liabilities, Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax liabilities, Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right of use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward expiration year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward Expiration Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_TaxCreditCarryforwardExpirationYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax credit carryforward expiration year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Permanent items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective Income Tax Rate Reconciliation Permanent Items.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_CurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock (per share)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair value of common stock per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueOfCommonStockPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock per share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Outstanding Options To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Outstanding Options to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value inputs probability of termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Probability Of Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueInputsProbabilityOfTermination_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value inputs probability of termination.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed transaction price consisting upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ManagementFeeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Management Fee Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Delivery Technology Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Delivery Technology Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_DeliveryTechnologyProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Delivery Technology Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchServicesObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchServicesObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research services obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ResearchServicesObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer Contribution amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success Payment Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Payment Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessPaymentLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success payment liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employers matching contribution, annual vesting percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product and Service [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Second Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Second Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Second Amendment Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-refundable upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-Refundable Upfront License Fees Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_NonRefundableUpfrontLicenseFeesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non-refundable upfront license fees paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockConvertibleConversionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible, conversion price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unvested Restricted stock vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premises</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premises [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PremisesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premises.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized losses on marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetirementPlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retirement Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of milestone development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment of Milestone Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_PaymentOfMilestoneDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of milestone development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of options, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success Liability Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessLiabilityPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success Liability Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Success payment liability, payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturities Of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_MaturitiesOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturities of marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value, Expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental Cash Flow Information Related to Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of supplemental cash flow information related to operating leases.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, non-current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueAndCreditsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue and Credits, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Convertible, Terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, convertible terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease payment term, lease not yet commenced, terms and conditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Variable Lease Payment, Terms and Conditions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Mandatorily Redeemable Preferred Stock, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross unrealized losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of Individual</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of Individual [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acuitas Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Acuitas Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_AcuitasAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Acuitas agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition, Deferred Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of transaction price separate performance obligations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to extend, lease not yet commenced</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidRent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock to common stock upon closing of initial public offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of RSUs, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment estimated useful life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessOfPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Success of payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessOfPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Success of payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_SuccessOfPaymentLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Success of payment liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indemnification Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Indemnification Agreements Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_IndemnificationAgreementsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Indemnification agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assumption Of Equity Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="verv_FairValueAssumptionOfEquityVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value assumption of equity volatility rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LicenseAndMilestonePayments" xlink:to="verv_LicenseAndMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PerformanceObligation" xlink:to="verv_PerformanceObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ThirdTrancheMember" xlink:to="verv_ThirdTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesMember" xlink:to="us-gaap_SalesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockFinancingPartiallySatisfied" xlink:to="verv_PreferredStockFinancingPartiallySatisfied_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NewAmendmentMember" xlink:to="verv_NewAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfPreferredStockTrancheLiability" xlink:to="verv_IssuanceOfPreferredStockTrancheLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OperatingLeaseRelatedExpensesPriorToCommencement" xlink:to="verv_OperatingLeaseRelatedExpensesPriorToCommencement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredAndCommonStockTextBlock" xlink:to="verv_PreferredAndCommonStockTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance" xlink:to="verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ReductionInResearchAndDevelopmentExpense" xlink:to="verv_ReductionInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MassachusettsTaxAuthorityMember" xlink:to="verv_MassachusettsTaxAuthorityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="us-gaap_ShortTermBorrowings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ShortTermBorrowingsReducedValue" xlink:to="verv_ShortTermBorrowingsReducedValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FourZeroOneKPlanMember" xlink:to="verv_FourZeroOneKPlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockOfferingPricePerShare" xlink:to="verv_CommonStockOfferingPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LicenseAgreementAbstract" xlink:to="verv_LicenseAgreementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross" xlink:to="verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing" xlink:to="verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SettlementOfTrancheRightLliability" xlink:to="verv_SettlementOfTrancheRightLliability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardLicenseAgreementMember" xlink:to="verv_HarvardLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommercializingProfitsAndExpenses" xlink:to="verv_CommercializingProfitsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OfficerMember" xlink:to="srt_OfficerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_USTreasuryBillsAndNotesMember" xlink:to="verv_USTreasuryBillsAndNotesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonUsMember" xlink:to="us-gaap_NonUsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwentyEighteenMember" xlink:to="verv_TwentyEighteenMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForLeaseLosses" xlink:to="us-gaap_ProvisionForLeaseLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicLineItems" xlink:to="us-gaap_EarningsPerShareBasicLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions" xlink:to="verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SeriesA2PreferredStocksMember" xlink:to="verv_SeriesA2PreferredStocksMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBoardMember" xlink:to="verv_HarvardAndBoardMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount" xlink:to="us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NumberOfInstallmentsForRestrictedSharesVested" xlink:to="verv_NumberOfInstallmentsForRestrictedSharesVested_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IncreaseDecreaseInRent" xlink:to="verv_IncreaseDecreaseInRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CollaborationsRevenue" xlink:to="verv_CollaborationsRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="us-gaap_ResearchAndDevelopmentArrangementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentOfSalesBasedMilestone" xlink:to="verv_PaymentOfSalesBasedMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ThirdLicensedAgentMaterialRightMember" xlink:to="verv_ThirdLicensedAgentMaterialRightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_USAgencySecuritiesMember" xlink:to="verv_USAgencySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember" xlink:to="verv_OptionLicenseAgreementAndPatentLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CollaborationAndLicenseAgreementsAbstract" xlink:to="verv_CollaborationAndLicenseAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="us-gaap_DefinedContributionPlanDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AgreegatePurchasePrice" xlink:to="verv_AgreegatePurchasePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BroadLicenseAgreementMember" xlink:to="verv_BroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockTransactionDate" xlink:to="us-gaap_SaleOfStockTransactionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SalesBasedMilestone" xlink:to="verv_SalesBasedMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BeamMember" xlink:to="verv_BeamMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AdditionalLesseeOperatingLeaseArea" xlink:to="verv_AdditionalLesseeOperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_RentExpensePolicyTextBlock" xlink:to="verv_RentExpensePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommissionOnAggregateGrossSaleProceeds" xlink:to="verv_CommissionOnAggregateGrossSaleProceeds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInOwnershipDescription" xlink:to="verv_ChangeInOwnershipDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SecondTrancheMember" xlink:to="verv_SecondTrancheMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueAssumptionsExpectedTerm1" xlink:to="verv_FairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LeaseNoncancelableTerm" xlink:to="verv_LeaseNoncancelableTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering" xlink:to="verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfCommonStockFromAtTheMarketOffering" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfAntidilutionRights" xlink:to="verv_ChangeInFairValueOfAntidilutionRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering" xlink:to="verv_IssuanceCostsOfCommonStockFromInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LicenseAgreementDisclosureTextBlock" xlink:to="verv_LicenseAgreementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentsForEachProduct" xlink:to="verv_SuccessPaymentsForEachProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_EffectiveIncomeTaxRateReconciliationOther" xlink:to="verv_EffectiveIncomeTaxRateReconciliationOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_UnvestedRestrictedStockMember" xlink:to="verv_UnvestedRestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan" xlink:to="verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent" xlink:to="verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember" xlink:to="verv_TwentyTwentyOneEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ClinicalAndRegulatoryMilestone" xlink:to="verv_ClinicalAndRegulatoryMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueRevenueRecognized1" xlink:to="us-gaap_DeferredRevenueRevenueRecognized1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AntidilutionRightsMember" xlink:to="verv_AntidilutionRightsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent" xlink:to="verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfSuccessPaymentsLiabilities" xlink:to="verv_ChangeInFairValueOfSuccessPaymentsLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_InterestRateForAdditionalImprovementsAllowance" xlink:to="verv_InterestRateForAdditionalImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability" xlink:to="verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FirstLicensedAgentMaterialRightMember" xlink:to="verv_FirstLicensedAgentMaterialRightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetAccruedExpenses" xlink:to="verv_DeferredTaxAssetAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodShareLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodShareLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageSharesOfDevelopmentExpense" xlink:to="verv_PercentageSharesOfDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonCurrentAbstract" xlink:to="verv_NonCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBroadLicenseAgreementMember" xlink:to="verv_HarvardAndBroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate" xlink:to="us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MaterialsExchangeAgreementMember" xlink:to="verv_MaterialsExchangeAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockTrancheLiabilityTextBlock" xlink:to="verv_PreferredStockTrancheLiabilityTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodValueLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities" xlink:to="verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AdditionalTenantImprovementsAllowance" xlink:to="verv_AdditionalTenantImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardAndBroadMember" xlink:to="verv_HarvardAndBroadMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MilestoneRelatedExpenses" xlink:to="verv_MilestoneRelatedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ThreeLicensedAgentMember" xlink:to="verv_ThreeLicensedAgentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProductCollaborationTerminationNoticePeriod" xlink:to="verv_ProductCollaborationTerminationNoticePeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="us-gaap_ShortTermLeaseCommitmentAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_WeightedAverageGrantDateFairValueForfeited" xlink:to="verv_WeightedAverageGrantDateFairValueForfeited_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DevelopedBaseMilestonePaymentsForStatedPeriod" xlink:to="verv_DevelopedBaseMilestonePaymentsForStatedPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CollaborationAndLicenseAgreementMember" xlink:to="verv_CollaborationAndLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockPurchaseAgreementMember" xlink:to="verv_StockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OperatingLossCarryforwardsExpirationYear" xlink:to="verv_OperatingLossCarryforwardsExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiabilityPayable" xlink:to="verv_SuccessPaymentLiabilityPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LeaseCommencementDate" xlink:to="verv_LeaseCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StrategicLicenseAndCollaborationAgreementMember" xlink:to="verv_StrategicLicenseAndCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireCommercialRealEstate" xlink:to="us-gaap_PaymentsToAcquireCommercialRealEstate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PublicOfferingPrice" xlink:to="verv_PublicOfferingPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost" xlink:to="us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SegmentAndGeographicInformationPolicyTextBlock" xlink:to="verv_SegmentAndGeographicInformationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CollaborationReceivable" xlink:to="verv_CollaborationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="us-gaap_PreferredStockConvertibleConversionRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock" xlink:to="verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset" xlink:to="verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TenantImprovementsAllowance" xlink:to="verv_TenantImprovementsAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_VerilyLicenseAgreementMember" xlink:to="verv_VerilyLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ConvertiblePreferredStockPolicyTextBlock" xlink:to="verv_ConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FirstAmendmentMember" xlink:to="verv_FirstAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm" xlink:to="verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="us-gaap_EarningsPerShareReconciliationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans" xlink:to="us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TwoThousandAndTwentyOneStockIncentivePlanMember" xlink:to="verv_TwoThousandAndTwentyOneStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities" xlink:to="us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock" xlink:to="verv_IssuanceCostsOfSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock" xlink:to="verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiability" xlink:to="verv_SuccessPaymentLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LesseeOperatingLeaseIncrementalBorrowingRate" xlink:to="verv_LesseeOperatingLeaseIncrementalBorrowingRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockAbstract" xlink:to="verv_PreferredStockAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_VertexPharmaceuticalsMember" xlink:to="verv_VertexPharmaceuticalsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsDate" xlink:to="us-gaap_SubsequentEventsDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndFeeIncomeLoansCommercial" xlink:to="us-gaap_InterestAndFeeIncomeLoansCommercial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsAntidilultionLiability" xlink:to="verv_DeferredTaxAssetsAntidilultionLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses" xlink:to="verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_UnvestedRestrictedStockUnitsMember" xlink:to="verv_UnvestedRestrictedStockUnitsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PercentageOfUnamortizedFilmCosts" xlink:to="us-gaap_PercentageOfUnamortizedFilmCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue" xlink:to="us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsStockBasedCompensation" xlink:to="verv_DeferredTaxAssetsStockBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember" xlink:to="verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FixedConsiderationAmount" xlink:to="verv_FixedConsiderationAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities" xlink:to="us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DevelopedBaseMilestonePayments" xlink:to="verv_DevelopedBaseMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OptionAndLicenseIssueFees" xlink:to="verv_OptionAndLicenseIssueFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFees" xlink:to="verv_NonRefundableUpfrontLicenseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing" xlink:to="verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:to="verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SecondLicensedAgentMaterialRightMember" xlink:to="verv_SecondLicensedAgentMaterialRightMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredOfferingCostsPolicyTextBlock" xlink:to="verv_DeferredOfferingCostsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockTrancheLiabilityMember" xlink:to="verv_PreferredStockTrancheLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PublicOfferingMember" xlink:to="verv_PublicOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AntidilutionRightsLiabilityMember" xlink:to="verv_AntidilutionRightsLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OutOfPocketCostsIncurred" xlink:to="verv_OutOfPocketCostsIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="us-gaap_ProceedsFromLicenseFeesReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset" xlink:to="verv_PercentageOfFutureTaxableIncomeUtilizedToOffset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_VertexAgreementMember" xlink:to="verv_VertexAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfSeniorDebt" xlink:to="us-gaap_RepaymentsOfSeniorDebt_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameDomain" xlink:to="us-gaap_RetirementPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_NZ" xlink:to="country_NZ_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CommonStockIssuedDuringPeriodValueNewIssues" xlink:to="verv_CommonStockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiabilityCurrent" xlink:to="verv_SuccessPaymentLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CambridgeLeaseMember" xlink:to="verv_CambridgeLeaseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization" xlink:to="verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NovartisLicenseAgreementMember" xlink:to="verv_NovartisLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary" xlink:to="verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue" xlink:to="verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses" xlink:to="verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesNoncurrent" xlink:to="us-gaap_MarketableSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred" xlink:to="verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PreferredStockFinancingFullySatisfied" xlink:to="verv_PreferredStockFinancingFullySatisfied_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PercentageOfTaxBenefitRealized" xlink:to="verv_PercentageOfTaxBenefitRealized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SummaryOfSignificantAccountingPoliciesTable" xlink:to="verv_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts" xlink:to="verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock" xlink:to="us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LeaseRentPayment" xlink:to="verv_LeaseRentPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfAdditionalCommonStock" xlink:to="verv_IssuanceOfAdditionalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet" xlink:to="us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract" xlink:to="verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_BeamLicenseAgreementMember" xlink:to="verv_BeamLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities" xlink:to="verv_ChangeInFairValueOfPreferredStockTrancheLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OfficeFurnitureMember" xlink:to="verv_OfficeFurnitureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontPayment" xlink:to="verv_NonRefundableUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts" xlink:to="us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DebtBorrowedAmount" xlink:to="verv_DebtBorrowedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration" xlink:to="us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CumulativeProbabilityOfTriggeringEvent" xlink:to="verv_CumulativeProbabilityOfTriggeringEvent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFee" xlink:to="verv_NonRefundableUpfrontLicenseFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LaboratoryEquipmentMember" xlink:to="verv_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AccruedExternalResearchAndDevelopmentExpenses" xlink:to="verv_AccruedExternalResearchAndDevelopmentExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingGainsLossesAbstract" xlink:to="us-gaap_NonoperatingGainsLossesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability" xlink:to="verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock" xlink:to="verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock" xlink:to="verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions" xlink:to="verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ComputerEquipmentAndSoftwareMember" xlink:to="verv_ComputerEquipmentAndSoftwareMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_LesseeOperatingLeaseArea" xlink:to="verv_LesseeOperatingLeaseArea_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableAmountPerShare" xlink:to="us-gaap_DividendsPayableAmountPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="verv_DeferredTaxLiabilitiesRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_TaxCreditCarryforwardExpirationYear" xlink:to="verv_TaxCreditCarryforwardExpirationYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="verv_EffectiveIncomeTaxRateReconciliationPermanentItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_CurrentAbstract" xlink:to="verv_CurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueOfCommonStockPerShare" xlink:to="verv_FairValueOfCommonStockPerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_OutstandingOptionsToPurchaseCommonStockMember" xlink:to="verv_OutstandingOptionsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueInputsProbabilityOfTermination" xlink:to="verv_FairValueInputsProbabilityOfTermination_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ManagementFeeExpense" xlink:to="us-gaap_ManagementFeeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_DeliveryTechnologyProductMember" xlink:to="verv_DeliveryTechnologyProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ResearchServicesObligationMember" xlink:to="verv_ResearchServicesObligationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MilestonePayments" xlink:to="verv_MilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessPaymentLiabilityMember" xlink:to="verv_SuccessPaymentLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions" xlink:to="us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage" xlink:to="us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SecondAmendmentMember" xlink:to="verv_SecondAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_NonRefundableUpfrontLicenseFeesPaid" xlink:to="verv_NonRefundableUpfrontLicenseFeesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="us-gaap_PreferredStockConvertibleConversionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PremisesMember" xlink:to="verv_PremisesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SalesAgreementMember" xlink:to="verv_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="us-gaap_MarketableSecuritiesUnrealizedGainLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetirementPlanNameAxis" xlink:to="us-gaap_RetirementPlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_PaymentOfMilestoneDevelopment" xlink:to="verv_PaymentOfMilestoneDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessLiabilityPayment" xlink:to="verv_SuccessLiabilityPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_MaturitiesOfMarketableSecurities" xlink:to="verv_MaturitiesOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="verv_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock" xlink:to="verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueAndCreditsNoncurrent" xlink:to="us-gaap_DeferredRevenueAndCreditsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTable" xlink:to="us-gaap_DefinedContributionPlanTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure" xlink:to="us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_AcuitasAgreementsMember" xlink:to="verv_AcuitasAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionDeferredRevenue" xlink:to="us-gaap_RevenueRecognitionDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRent" xlink:to="us-gaap_PrepaidRent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_SuccessOfPaymentLiability" xlink:to="verv_SuccessOfPaymentLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_IndemnificationAgreementsPolicyTextBlock" xlink:to="verv_IndemnificationAgreementsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="verv_FairValueAssumptionOfEquityVolatilityRate" xlink:to="verv_FairValueAssumptionOfEquityVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094261904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 27, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">VERVE THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VERV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 557.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,833,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">82-4800132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">201 Brookline Avenue, Suite 601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">603-0070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Portions of the registrant&#8217;s definitive proxy statement that will be filed for the 2023 Annual Meeting of Stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Annual Report on Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst & Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093625072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 115,412<span></span>
</td>
<td class="nump">$ 64,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">439,396<span></span>
</td>
<td class="nump">296,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CollaborationReceivable', window );">Collaboration receivable</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">7,339<span></span>
</td>
<td class="nump">6,686<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">563,159<span></span>
</td>
<td class="nump">367,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">18,778<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">91,877<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long term assets</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">679,223<span></span>
</td>
<td class="nump">384,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,424<span></span>
</td>
<td class="nump">7,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">20,767<span></span>
</td>
<td class="nump">12,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligations, current portion</a></td>
<td class="nump">11,904<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">35,095<span></span>
</td>
<td class="nump">22,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liability</a></td>
<td class="nump">70,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueAndCreditsNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">20,014<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long term liabilities</a></td>
<td class="nump">283<span></span>
</td>
<td class="nump">377<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">128,291<span></span>
</td>
<td class="nump">26,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (See Note 7 and 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Convertible preferred stock (See Note 10)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equtiy (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">895,801<span></span>
</td>
<td class="nump">544,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive (loss) income</a></td>
<td class="num">(694)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(344,237)<span></span>
</td>
<td class="num">(186,850)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">550,932<span></span>
</td>
<td class="nump">357,352<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, and stockholders' equity</a></td>
<td class="nump">$ 679,223<span></span>
</td>
<td class="nump">$ 384,124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueAndCreditsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueAndCreditsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CollaborationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CollaborationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093605680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093656976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CollaborationsRevenue', window );">Collaborations revenue</a></td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">130,095<span></span>
</td>
<td class="nump">68,202<span></span>
</td>
<td class="nump">35,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">37,533<span></span>
</td>
<td class="nump">18,865<span></span>
</td>
<td class="nump">5,256<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">167,628<span></span>
</td>
<td class="nump">87,067<span></span>
</td>
<td class="nump">40,627<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(165,687)<span></span>
</td>
<td class="num">(87,067)<span></span>
</td>
<td class="num">(40,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingGainsLossesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities', window );">Change in fair value of preferred stock tranche liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfAntidilutionRights', window );">Change in fair value of antidilution rights liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(25,574)<span></span>
</td>
<td class="num">(5,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities', window );">Change in fair value of success payment liability</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="num">(7,815)<span></span>
</td>
<td class="num">(2,387)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">6,867<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="nump">8,353<span></span>
</td>
<td class="num">(33,247)<span></span>
</td>
<td class="num">(5,077)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(157,334)<span></span>
</td>
<td class="num">(120,314)<span></span>
</td>
<td class="num">(45,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (157,387)<span></span>
</td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.91)<span></span>
</td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.91)<span></span>
</td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares used in net loss per share attributable to common stockholders, basic</a></td>
<td class="nump">54,023,653<span></span>
</td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares used in net loss per share attributable to common stockholders, diluted</a></td>
<td class="nump">54,023,653<span></span>
</td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (157,387)<span></span>
</td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(466)<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (157,853)<span></span>
</td>
<td class="num">$ (120,550)<span></span>
</td>
<td class="num">$ (45,705)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingGainsLossesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingGainsLossesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfAntidilutionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of antidilution rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfAntidilutionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfPreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of success payments liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfSuccessPaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CollaborationsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CollaborationsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091169488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Preferred Stock</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="num">$ (19,553)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="num">$ (20,832)<span></span>
</td>
<td class="nump">$ 25,480<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,854,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,421,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,749,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock', window );">Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,888<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock', window );">Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,348,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions', window );">Additional issuances of common stock to licensor institutions</a></td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions', window );">Additional issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,849<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(45,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2020</a></td>
<td class="num">(63,909)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,616<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="num">(66,536)<span></span>
</td>
<td class="nump">$ 125,160<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,585,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,519,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock', window );">Issuance of Series B convertible preferred stock, net of issuance costs of $241</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock', window );">Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,163,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">218,919<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">218,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (218,919)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256,682,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of $25,098</a></td>
<td class="nump">281,584<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">281,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions', window );">Issuances of common stock to licensor institutions</a></td>
<td class="nump">32,490<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">32,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions', window );">Issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">537,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">966<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">7,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(120,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,314)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2021</a></td>
<td class="nump">$ 357,352<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">544,381<span></span>
</td>
<td class="num">(228)<span></span>
</td>
<td class="num">(186,850)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">48,511,735<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of $25,098</a></td>
<td class="nump">$ 242,826<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">242,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions', window );">Issuances of common stock to licensor institutions</a></td>
<td class="nump">39,986<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">39,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions', window );">Issuances of common stock to licensor institutions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares', window );">Issuance of common stock from At-the-Market offering, net of issuance costs of , (In Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts', window );">Issuance of common stock from At-the-Market offering, net of issuance costs</a></td>
<td class="nump">42,900<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">42,899<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">743,638<span></span>
</td>
<td class="nump">743,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Purchase of common stock under ESPP</a></td>
<td class="nump">$ 1,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Unrealized loss on available-for-sale securities</a></td>
<td class="num">(466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(466)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(157,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(157,387)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">$ 550,932<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 895,801<span></span>
</td>
<td class="num">$ (694)<span></span>
</td>
<td class="num">$ (344,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">61,730,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS SHARES</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional common stock to licensor institutions (in shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of additional shares issued to licensor institutuons.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodShareLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock to licensor institutions (in shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodShareLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B convertible preferred stock, net of issuance costs (in shares)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueLicensorInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Value Licensor Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueLicensorInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A-2 convertible preferred stock, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares series a convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series B convertible preferred stock, net of issuance costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099441008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability', window );">Issuance of Series A convertible preferred stock and settlement of tranche right liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesAConvertiblePreferredStock', window );">Issuance costs of series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock', window );">Issuance costs of series A2 convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceCostsOfSeriesBConvertiblePreferredStock', window );">Issuance costs of series B convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceCostsOfCommonStockFromInitialPublicOffering', window );">Issuance costs of common stock from initial public offering</a></td>
<td class="nump">$ 15,924<span></span>
</td>
<td class="nump">$ 25,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceOfCommonStockFromAtTheMarketOffering', window );">Issuance of common stock from At-the-Market offering</a></td>
<td class="nump">$ 1,722,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfCommonStockFromInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs Of Common Stock from Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfCommonStockFromInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance costs of series A2 convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesAConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs of Series A Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesAConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceCostsOfSeriesBConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance Costs Of Series B Convertible Preferred Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceCostsOfSeriesBConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfCommonStockFromAtTheMarketOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfCommonStockFromAtTheMarketOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series A convertible preferred stock and settlement of tranche right liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091032176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (157,387)<span></span>
</td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
<td class="nump">1,328<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForLeaseLosses', window );">Non-cash lease expense</a></td>
<td class="nump">3,907<span></span>
</td>
<td class="nump">1,842<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities', window );">Net amortization of premium (accretion of discount) on marketable securities</a></td>
<td class="num">(1,027)<span></span>
</td>
<td class="nump">1,508<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">22,477<span></span>
</td>
<td class="nump">7,072<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities', window );">Change in fair value of preferred stock tranche liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,507)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfAntidilutionRights', window );">Change in fair value of antidilution rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,574<span></span>
</td>
<td class="nump">5,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities', window );">Change in fair value of success payments liabilities</a></td>
<td class="num">(1,486)<span></span>
</td>
<td class="nump">7,815<span></span>
</td>
<td class="nump">2,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Collaboration receivable</a></td>
<td class="num">(1,012)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9,436)<span></span>
</td>
<td class="num">(7,528)<span></span>
</td>
<td class="num">(1,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(5,216)<span></span>
</td>
<td class="nump">6,829<span></span>
</td>
<td class="num">(1,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">7,041<span></span>
</td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">6,071<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessOfPaymentLiability', window );">Success of payment liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">20,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(3,011)<span></span>
</td>
<td class="num">(1,940)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability', window );">Deferred rent liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(122,332)<span></span>
</td>
<td class="num">(77,880)<span></span>
</td>
<td class="num">(35,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(13,232)<span></span>
</td>
<td class="num">(4,359)<span></span>
</td>
<td class="num">(3,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(479,401)<span></span>
</td>
<td class="num">(371,494)<span></span>
</td>
<td class="num">(98,484)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_MaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">336,678<span></span>
</td>
<td class="nump">136,755<span></span>
</td>
<td class="nump">50,781<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(155,955)<span></span>
</td>
<td class="num">(239,098)<span></span>
</td>
<td class="num">(51,127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">93,759<span></span>
</td>
<td class="nump">92,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock in connection with the Vertex Agreement</a></td>
<td class="nump">39,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions', window );">Proceeds from issuance of common shares, net of commissions</a></td>
<td class="nump">286,509<span></span>
</td>
<td class="nump">285,214<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Payment of equity offering costs</a></td>
<td class="num">(783)<span></span>
</td>
<td class="num">(3,630)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">2,175<span></span>
</td>
<td class="nump">966<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP', window );">Proceeds from purchase of shares through employee stock purchase plan</a></td>
<td class="nump">1,069<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">328,956<span></span>
</td>
<td class="nump">377,089<span></span>
</td>
<td class="nump">92,627<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">50,669<span></span>
</td>
<td class="nump">60,111<span></span>
</td>
<td class="nump">6,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;beginning of period</a></td>
<td class="nump">69,567<span></span>
</td>
<td class="nump">9,456<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash&#8212;end of period</a></td>
<td class="nump">120,236<span></span>
</td>
<td class="nump">69,567<span></span>
</td>
<td class="nump">9,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing and finnacing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses', window );">Property and equipment additions included in accounts payable and accrued expenses</a></td>
<td class="nump">1,706<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SettlementOfTrancheRightLliability', window );">Settlement of tranche right liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering', window );">Conversion of convertible preferred stock to common stock upon closing of initial public offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">218,919<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock', window );">Settlement of derivative liability by issuing common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">32,490<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 83,417<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForLeaseLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to estimated loss to be realized from lease transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.11)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForLeaseLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfAntidilutionRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of antidilution rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfAntidilutionRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfPreferredStockTrancheLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of preferred stock tranche liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfPreferredStockTrancheLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInFairValueOfSuccessPaymentsLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in fair value of success payments liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInFairValueOfSuccessPaymentsLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_MaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_MaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Amortization Of Premium (Accretion Of Discount) On Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of common shares, net of commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property and equipment additions included in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of Antidilution Rights Liability By Issuing Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SettlementOfTrancheRightLliability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement of tranche right liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SettlementOfTrancheRightLliability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessOfPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success of payment liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessOfPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095691920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Nature of the business and basis of presentation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Organization</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Verve Therapeutics, Inc. (the &#8220;Company&#8221; or &#8220;Verve&#8221;) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#8217;s principal offices are located in Boston, Massachusetts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Liquidity and capital resources</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">554.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> as of December 31, 2022, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#8217;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Basis of presentation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;GAAP&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Update (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099358816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ummary of significant accounting policies</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">circumstances. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the Company's initial public offering ("IPO")), stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#8217;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.855%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.815999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.103%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115,412</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,824</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,237</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120,236</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#8217;s investment managers and consist of U.S. treasury bills and U.S agency securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#8217;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">accordance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the stock offerings as other non-current assets until the offerings were consummated. After consummation of the offerings, these costs were recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2022, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.073%;"/>
          <td style="width:48.958%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Office furniture</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company has determined that its obligation to issue, and the Company&#8217;s investors&#8217; right to purchase, additional shares of convertible Series A Preferred Stock (&#8220;Series A Preferred&#8221;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#8220;tranche liability&#8221;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities were settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#8220;Harvard&#8221;) and The Broad Institute, Inc. (&#8220;Broad&#8221;) (&#8220;Harvard/Broad License Agreement&#8221;) and (ii) Broad (&#8220;Broad License Agreement&#8221;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#8217;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 815")</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#8217;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#8217;s option in either cash or shares of the Company&#8217;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company enters into collaboration agreements which are within the scope of ASC Topic 606, "Revenue from Contracts with Customers" (&#8220;ASC 606&#8221;), under which the Company licenses rights to certain of the Company&#8217;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The promised goods or services in the Company&#8217;s arrangements typically consist of license rights to the Company&#8217;s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consideration is unconditional.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical, clinical and regulatory expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s stock-based compensation program allows for grants of certain equity awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#8216;&#8216;ASC 718&#8217;&#8217;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8216;&#8216;Black-Scholes&#8217;&#8217;) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock unit awards. The Company estimates the fair value of the Company&#8217;s restricted stock unit awards on the date of grant using the closing price of the Company&#8217;s common stock on that date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#8217;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) using the revised modified retrospective approach, which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was no impact to the Company&#8217;s results of operations and cash flows from operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (&#8220;ROU&#8221;) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022, 2021 and 2020, the Company&#8217;s only element of other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss was unrealized losses on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> operating segment operating exclusively in the United States.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard became effective for the Company on January 1, 2023. Based on composition of the Company's investment portfolio, current market conditions, and historical credit loss activity, the Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093603392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3. Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.601%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.763%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">440,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">439,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.601%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.763%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,781</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The remaining contractual maturities of all marketable securities were less than 18 months as of December 31, 2022 and 2021.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The unrealized losses on the Company&#8217;s marketable securities of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">as of December 31, 2022 and 2021, respectively, were caused by interest rate increases which resulted in the decrease in market value of these securities. Because the decline in fair value is attributable to changes in interest rates and not credit quality, and because the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity, the Company does not consider those marketable securities to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">other-than-temporarily </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">impaired at December 31, 2022 or 2021. None of the Company&#8217;s marketable securities have been in a continuous unrealized loss position for </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> or greater as of December 31, 2022 or 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182044464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4. P</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">roperty and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.941999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.079999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">826</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;">&#160;</p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.436%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.568%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.568%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.657%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095825248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Disclosure - Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5. f</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">air value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The antidilution right liability was fully settled in the year ended December 31, 2021.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial instruments by level within the fair value hierarchy: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"/>
        <td style="width:1.228%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">544,699</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">439,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"/>
        <td style="width:1.228%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">354,239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash Equivalents</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;Cash equivalents of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> as of December 31, 2022 and 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable Securities&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution Rights&#8212;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO in June 2021. Refer to Note 5, Fair value of financial instruments, for additional discussion.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success Payment Liability</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#8217;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million (after termination of the Broad License Agreement).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#8217;s common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company remeasured the liability at fair value with increases of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> recorded to other expense for the years ended December 31, 2022, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The primary inputs used in valuing the success payments liability associated with the Company&#8217;s realization of a certain valuation threshold through either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.173%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2020</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2020 the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company applied a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% probability of termination of the Broad License Agreement at December 31, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.061%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.793000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.804%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.196%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution<br/>rights<br/>liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,490</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,490</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,574</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,815</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095825248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.851%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.105%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,124</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and milestone payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,992</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095526448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leases</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Boston, Massachusetts.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or ROU asset has been recorded.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"/>
        <td style="width:1.635%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.489%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,946</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">747</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,245</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"/>
        <td style="width:1.635%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.489%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,050</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022, the Company&#8217;s operating leases were measured using a weighted-average incremental borrowing rate </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.89</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% over a weighted-average remaining lease term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#8220;Landlord&#8221;), pursuant to which the Company leased approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">104,933</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#8220;Boston Lease&#8221;), further amended in January 2022 to include an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">249</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet, for a total of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,182</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet (the &#8220;Premises&#8221;). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Premises were first made available to the Company in August 2022. Upon commencement of the lease, the Company recorded an operating lease ROU asset of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">91.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and a total lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s obligation for the payment of base rent for the Premises began in January 2023 (the &#8220;Rent Commencement Date&#8221;). Base rent is initially $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million per month, and will increase by approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% per annum.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Boston Lease has a term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Under the terms of the Boston Lease, the Landlord made $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in certain tenant improvements to the Premises to suit the Company&#8217;s use (the &#8220;Tenant Improvement Allowance&#8221;), which amount is included in the base rent set forth in the Boston Lease.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which may be reduced to approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, which is equal to the first month of base rent. The Landlord has the right to terminate th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e Boston Lease upon customary events of default.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022 the Company notified its landlord under its prior lease of its intent to terminate that lease prior to the expiration of the term lease. As of December 31, 2022, there was no remaining ROU and lease liability for the prior lease.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, the Company entered into a sublease for </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,931</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and has an initial noncancelable term of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12 months</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Therefore, this sublease is treated as a short-term lease. The total fixed lease payments over the sublease term were approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and the Company was also required to pay its proportional share of operating expenses.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.936%;"/>
        <td style="width:1.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.143%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,306</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,563</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,868</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">62,736</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">119,162</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37,245</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182044464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LicenseAgreementAbstract', window );"><strong>License Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LicenseAgreementDisclosureTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> License agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Harvard/Broad license agreement and Broad license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#8220;license agreements&#8221;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">agreements without cause upon four months&#8217; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in non-refundable upfront license fees and also issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. Additional consideration under the license agreements is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, respectively, and which amounts were settled through issuances of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">121,411</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">187,867</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#8217;s IPO. The settlement amount totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and was settled through issuance of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company is required to make success payments under the license agreements as further described in Note 5, Fair</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">value of financial instruments. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts were settled in cash in November 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Indemnification agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">46.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">108</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and sales-based milestones, respectively. In 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the first milestone was triggered and amounts due to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. These amounts remain payable as of December 31, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Beam license agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In April 2019, the Company and Beam Therapeutics, Inc. (&#8220;Beam&#8221;) entered into a collaboration and license agreement. Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#8217;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#8217;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four initial gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of a final patient in a Phase 1b clinical trial of a given licensed product for the initial gene targe</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ts, Beam has the right to opt in to share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">product </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product for the initial gene targets, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">276,075</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock with a fair value of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. To the extent there are sales</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> of a licensed product, the Company is </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development and regulatory-based milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. Due to the submission of the Company's clinical trial application in New Zealand, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered in 2022 and subsequently paid by the Company to Beam. Additionally, due to the first patient dosing with VERVE-101 in a clinical trial, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered and paid by the Company to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The parties have also promised that in further consideration for the licenses granted under the parties&#8217; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> expense has been recorded for these milestones as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the &#8220;Amended Beam Agreement&#8221;).</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam&#8217;s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company is responsible for the development and commercialization of products targeting the additional gene target, subject to Beam&#8217;s opt-in right. Following the dosing of the final patient in a Phase 1b clinical trial of a licensed product for such additional gene target, Beam has the right to opt-in to share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam is entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Amended Beam Agreement also clarified intellectual property rights with respect to the Company's GalNAc-LNP delivery technology; grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology; terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Amended Beam Agreement was not probable as of December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Acuitas agreements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Development and option agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, whi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ch agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million during the year ended December 31, 2022, and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the year ended December 31, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. Under the terms of the agreement, the Company allowed the development and option agreement to terminate upon reaching the third anniversary of the agreement in December 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">License agreement</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent achieved, the Company is also obligated to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">D</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ue to the first patient dosing of VERVE-101 in a clinical trial, a milestone payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was triggered and paid during the year ended December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Novartis license agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2021, the Company entered into a license agreement with Novartis Pharma AG (&#8220;Novartis&#8221;) to obtain a non-exclusive license to lipid technology the Company is using in connection with the research and development of certain product candidates, including VERVE-201. As consideration for the license and rights granted under the agreement, the Company mad</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e a one-time, non-refundable, upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million during the year ended December 31, 2021. The license agreement requires the Company to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in clinical and regulatory milestones and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in sales-based milestones for products that incorporate the licensed lipid technology. The milestones have not been achieved and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> expense has been recorded for these milestones as of December 31, 2022.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, the Company was required to mak</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">e a one-time, non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to Novartis. This amount was recorded as research and development expense and was paid during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement Abstract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LicenseAgreementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LicenseAgreementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095637056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure [Text Block]</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Collaboration and License Agreements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Vertex Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Summary of Agreement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company entered into the Strategic Collaboration and License Agreement (the &#8220;Vertex Agreement&#8221;) with Vertex Pharmaceuticals Incorporated (&#8220;Vertex&#8221;) for an exclusive, four-year worldwide research collaboration focused on developing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, the Company entered into a stock purchase agreement (the &#8220;Stock Purchase Agreement&#8221;) with Vertex, pursuant to which the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,519,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to the Vertex Agreement, the Company is responsible for discovery, research and certain preclinical development of novel </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> gene editing development candidates for the target of interest. The Company&#8217;s research activities are focused on (i) identifying and engineering specific gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex is obligated to reimburse the Company&#8217;s research expenses consistent with a mutually agreed-upon research plan and budget (&#8220;Research Plan&#8221;). The research term has an initial term of four years and may be extended by Vertex for up to one additional year (&#8220;Research Term&#8221;). The Research Plan is overseen by a Joint Research Committee (&#8220;JRC&#8221;) as detailed in the Vertex Agreement. Any material amendments to the Research Plan are required to be mutually agreed to by the JRC.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the Research Term, Vertex may select certain gene editing systems and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> delivery systems directed at the target to become a licensed agent. Upon the designation of the licensed agent, Vertex shall receive a license to exploit the licensed agent, and the licensed agent will continue to be developed under the Research Plan in order to achieve certain development candidate criteria agreed to by the JRC. Following the Research Term, Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the licensed agent.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company received an upfront payment from Vertex of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and is eligible to receive (i) success payments of up to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for each product candidate (up to a maximum of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">66</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million) that achieves the applicable development criteria, (ii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">175</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in development milestones and (iii) up to an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">165</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, with the rate dependent upon the type of product and subject to specified reductions. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the first patient dosing of the first Phase 1b clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, it will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">40</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% (with Vertex retaining a minimum of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">60</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, depending on the profit/cost percentage elected by the Company and the Company&#8217;s licensed technology included in the most advanced product candidate at the time it exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days&#8217; notice.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company assessed the promised goods and services under the Vertex Agreement, in accordance with ASC 606. At inception, the Vertex Agreement included the following performance obligations: (i) the research services obligation which relates to the research and development services to be provided under the Research Plan (the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8220;Research Services&#8221;) and (ii) three licensed agent material rights related to the options to obtain licenses to exploit a licensed agent, at a discount.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company identified $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of fixed transaction price consisting of the $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million upfront fee offset by a discount of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million related to the </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,519,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares sold to Vertex under the Stock Purchase Agreement when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred associated with the delivery of services under the Research Plan. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">pany considers this estimate at each reporting date and updates the estimate based on information available. As of December 31, 2022, the estimate of the expected reimbursement is $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million based on expectations as of such date. Additional consideration to be paid to the Company upon reachi</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ng certain milestones are excluded from the transaction price as that consideration may only be earned subsequent to an option exercise.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has concluded that the variable consideration related to the cost reimbursement of the Research Services obligation will be allocated entirely to that obligation as the cost reimbursement relates specifically to the services being performed under the Research Plan. The reimbursement of Research Services is considered to be at a market rate and therefore depicts the estimated amount it would expect to receive for this obligation. As a result, the Company allocated the fixed consideration of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million to the three licensed agent material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">willing to pay an equal amount for each licensed agent license on a standalone basis before being adjusted for the probability of the option becoming exercisable upon the successful completion of research activities to identify the licensed agents. The Company reached this conclusion after considering (i) the downstream economics including success fees, milestones and royalties related to each licensed agent being identical and (ii) that all licensed agents are targeting the same gene. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.673%;"/>
        <td style="width:1.994%;"/>
        <td style="width:1.131%;"/>
        <td style="width:26.23%;"/>
        <td style="width:0.972%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research services obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">First licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second licensed agent material right</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The amount allocated to the Research Services obligation will be recognized on a proportional performance basis over the period of service using input-based measurements of total cost of research incurred to estimate the proportion performed and remeasured at the end of each reporting period. The amount allocated to the licensed agent material rights was recorded as deferred revenue and will commence recognition upon exercise of each option or, if an option is never exercised, it will be recognized in full upon expiry of the Research Term.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of revenue associated with the Vertex Agreement related to research services performed during the period. As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company has recorded $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million as non-current deferred revenue.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Costs incurred relating to the Company&#8217;s collaboration programs under the Vertex Agreement consist of internal and external research costs, which primarily include: salaries and benefits, and preclinical research studies. These costs are included in research and development expenses in the Company&#8217;s consolidated statements of operations during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099353168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PreferredStockAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PreferredAndCommonStockTextBlock', window );">Preferred and Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Preferred and common stock</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">has issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">101,170,571</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series A preferred, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,838,461</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series A-2 preferred, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77,163,022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Series B preferred and common stock.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company amended and restated its certificate of incorporation to authorize </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of preferred stock, which shares of preferred stock are currently undesignated, and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">200,000,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.001</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> par value per share.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16,141,157</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,105,368</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for aggregate gross proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">306.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million. The Company received approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">281.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27,720,923</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock, and the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,519,756</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company&#8217;s common stock to Vertex at a price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.03</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share, for an aggregate purchase price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company completed a follow-on public offering of common stock, pursuant to which the Company issued and sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,583,334</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock, including </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,250,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock sold pursuant to the full exercise of the underwriters&#8217; option to purchase additional shares, at a public offering price of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">27.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share. The Company received net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">242.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million after deducting underwriting discounts and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In July 2022, the Company entered into an Open Market Sale Agreement (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) as the agent pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of the Company&#8217;s common stock. The Company agreed to pay Jefferies a commission of up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022, the Company sold </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,280,168</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of its common stock under the Sales Agreement for aggregate net proceeds of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">42.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, after deducting commissions and offering expenses payable by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The holders of c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ommon stock are entitled to one vote for each share of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredAndCommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred and common stock disclosure text block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredAndCommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182254288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11. Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;), adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#8217;s employees, officers, directors, advisors, and outside consultants for the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> issuance or purchase of shares of the Company&#8217;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,885,653</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan (the &#8220;2021 Plan&#8221;), which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. The shares reserved for issuance pursuant to the 2021 Plan are subject to an annual increase through January 1, 2031. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> the Company had reserved </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,057,629</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock for issuance of stock options, restricted stock, and restricted stock units, of which </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,025,807</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> remained outstanding for future grant under the 2021 Plan. On January 1, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,086,541</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.359%;"/>
        <td style="width:1.406%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.006%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,486</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,242</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock options</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.835%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.247%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.143%;"/>
        <td style="width:0.823%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.238%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.633000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.823%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.042%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.839%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of<br/>options</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,119,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,561,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">743,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">324,131</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,612,826</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">63,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,551,841</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.52</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected to vest after December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,060,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022 the weighted average grant date fair value of the stock options granted </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.39</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> per share.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> The aggregate intrinsic value of stock options exercised during the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> was approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million while the Company received $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million in proceeds for the exercise of these options.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted stock and restricted stock units</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In 2018, the Company issued </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,150,537</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of restricted common stock. The restricted shares vested in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">48</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company granted </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">688,700</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">four-year</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.119%;"/>
        <td style="width:1.184%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.077%;"/>
        <td style="width:1.866%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">688,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">677,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, there was $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of 3</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> years.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">2021 Amended and Restated Employee Stock Purchase Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The shares reserved for issuance pursuant to the ESPP are subject to an annual increase through January 1, 2031. As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">134,107</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares had been purchased by employees under the ESPP and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">784,326</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares remained available for issuance under the ESPP. On January 1, 2023, </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">617,308</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock were added to the amount reserved for sale under the ESPP.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095860080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12. Net loss per share attributable to common stockholders</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.184%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.838%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.828%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.967%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">157,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54,023,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,872,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,250,093</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units, and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.329%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19,387,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">537,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">677,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,612,826</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,119,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,888,823</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,290,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,151,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23,814,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2022, an aggregate of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million was earned relating to these success payments, which the Company settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099358592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income taxes</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company's losses before income taxes consist solely of losses from domestic operations, which totaled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">157.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for the years ended December 31, 2022, 2021, and 2020, respectively.</span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income tax expense (benefit) is summarized as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.662%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.629999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.629999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.876%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.004%;"/>
        <td style="width:0.984%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.348%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Executive compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#8217;s deferred tax assets and liabilities as of December 31, 2022 and 2021 are comprised of the following</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.941999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.079999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">43,779</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized costs&#8212;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,095</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,669</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">533</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">135,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">56,480</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">881</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109,636</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55,080</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has incurred net operating losses in each year since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#8217;s net deferred tax assets, which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#8217;s history of cumulative net losses in the United States and estimated future tax losses and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2022 and 2021. The valuation allowance increased by </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> in 2022, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Realization of the future tax benefits is dependent on many factors, including the Company&#8217;s ability to generate taxable income within the net operating loss carryforward period. The Company&#8217;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#8217;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">163.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">148.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of state net operating loss carryforwards The federal net operating losses have an indefinite life and can be utilized to offset </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of future taxable income, while the state net operating losses will start to expire at various dates through </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2042</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">. Additionally, as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had approximately $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of federal and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million of Massachusetts tax research and development credits that expire starting in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2042</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2037</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, the Company had </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">t recorded any interest or penalties for unrecognized tax benefits since its inception.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, Pennsylvania, and Wisconsin. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095751952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">14. Related party transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An executive officer of Beam was a board member of the Company until August 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the years ended December 31, 2022 and 2021, respectively, the Company recognized $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts, which sublease terminated in December 31, 2022. Total rent payments under this sublease were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the year ended December 31, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182114576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">15. Employee benefit plans</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of employment. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">tutorily prescribed limit, equal to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> in 2022 with a catch up contribution limit equal to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> Since January 1, 2020 the Company matches </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of each participant&#8217;s annual contribution to the 401(k) plan up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the participant&#8217;s salary and then </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of each participant&#8217;s contribution up to </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% of the participant&#8217;s salary. The match immediately vests </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%. The matching c</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ontributions by the Company to the 401(k) plan were $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, and $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million for the years ended</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> December 31, 2022, 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">, and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI https://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094245744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16. S</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ubsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094301344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Principles of consolidation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">circumstances. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the Company's initial public offering ("IPO")), stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Cash and cash equivalents</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Restricted cash</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#8217;s leases of its corporate facilities. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span></span></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.855%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.815999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.103%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115,412</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,824</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,237</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120,236</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Marketable securities</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#8217;s investment managers and consist of U.S. treasury bills and U.S agency securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#8217; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#8217;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#8217;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Concentrations of credit risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#8217;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">accordance </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">with the Company&#8217;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredOfferingCostsPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Deferred offering costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the stock offerings as other non-current assets until the offerings were consummated. After consummation of the offerings, these costs were recorded in stockholders&#8217; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair value of financial instruments</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">ASC Topic 820, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Fair Value Measurement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3&#8212;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#8217;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2022, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2022 and 2021</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Property and equipment, net</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment are stated at cost less accumulated depreciation. </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span></span><span style=""/></p><div style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.073%;"/>
          <td style="width:48.958%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Office furniture</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Impairment of long-lived assets</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">recognized </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> impairment losses recognized during the years ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock', window );">Freestanding Financial Instruments and Derivatives</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Freestanding financial instruments and derivatives</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Preferred Stock Tranche Liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company has determined that its obligation to issue, and the Company&#8217;s investors&#8217; right to purchase, additional shares of convertible Series A Preferred Stock (&#8220;Series A Preferred&#8221;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#8220;tranche liability&#8221;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities were settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#8220;Harvard&#8221;) and The Broad Institute, Inc. (&#8220;Broad&#8221;) (&#8220;Harvard/Broad License Agreement&#8221;) and (ii) Broad (&#8220;Broad License Agreement&#8221;) (see Note 8, License agreements), the following financial instruments were issued by the Company.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Antidilution Rights</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#8217;s initial public offering. These antidilution rights were accounted for under ASC 815, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Derivatives and Hedging </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">("ASC 815")</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The obligation was satisfied in full upon the issuance of an aggregate of an additional </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">878,098</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> shares of common stock upon the closing of the Company's IPO in June 2021. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Refer to Note 5, Fair value of financial instruments, for additional discussion.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Success Payments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#8217;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#8217;s option in either cash or shares of the Company&#8217;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionDeferredRevenue', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Revenue Recognition</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company enters into collaboration agreements which are within the scope of ASC Topic 606, "Revenue from Contracts with Customers" (&#8220;ASC 606&#8221;), under which the Company licenses rights to certain of the Company&#8217;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The promised goods or services in the Company&#8217;s arrangements typically consist of license rights to the Company&#8217;s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#8217;s control or the licensee&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#8217;s collaboration arrangements.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#8217;s right to </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">consideration is unconditional.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Research and development costs</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical, clinical and regulatory expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Stock-based compensation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s stock-based compensation program allows for grants of certain equity awards. Grants are awarded to employees and non-employees, including directors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Compensation-Stock Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (&#8216;&#8216;ASC 718&#8217;&#8217;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8216;&#8216;Black-Scholes&#8217;&#8217;) for stock option grants to both employees and non-employees. The fair value of the Company&#8217;s common stock is used to determine the fair value of restricted stock unit awards. The Company estimates the fair value of the Company&#8217;s restricted stock unit awards on the date of grant using the closing price of the Company&#8217;s common stock on that date.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#8217;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Leases</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, &#8220;Leases&#8221; (&#8220;ASC 842&#8221;) using the revised modified retrospective approach, which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was no impact to the Company&#8217;s results of operations and cash flows from operations.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#8217;s control over the use of the identified asset(s), if applicable. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (&#8220;ROU&#8221;) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Income taxes</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#8217;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">50</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Comprehensive loss</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Comprehensive loss includes net loss as well as other changes in stockholders&#8217; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022, 2021 and 2020, the Company&#8217;s only element of other </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">comprehensive loss was unrealized losses on marketable securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Net loss per share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company&#8217;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022, 2021 and 2020</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SegmentAndGeographicInformationPolicyTextBlock', window );">Segment and Geographic Information</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Segment and geographic information</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#8220;CODM&#8221;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#8217;s Chief Executive Officer. The Company views its operations as and manages its business in </span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> operating segment operating exclusively in the United States.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Subsequent events</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Recently issued accounting pronouncements</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;font-style:italic;min-width:fit-content;">Financial Instruments&#8212;Credit Losses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard became effective for the Company on January 1, 2023. Based on composition of the Company's investment portfolio, current market conditions, and historical credit loss activity, the Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredOfferingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredOfferingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Freestanding financial instruments and derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SegmentAndGeographicInformationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policy related to segment and geographic information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SegmentAndGeographicInformationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095493408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:66.855%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:12.815999999999999%;"/>
          <td style="width:1.0%;"/>
          <td style="width:1.613%;"/>
          <td style="width:1.0%;"/>
          <td style="width:13.103%;"/>
          <td style="width:1.0%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash and cash equivalents</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">115,412</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">64,330</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted cash</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,824</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,237</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total cash, cash equivalents and restricted cash</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120,236</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">69,567</span></p></td>
          <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Schedule of Property and Equipment Estimated Useful Life</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
        <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
         <tr style="visibility:collapse;">
          <td style="width:48.968%;"/>
          <td style="width:2.073%;"/>
          <td style="width:48.958%;"/>
         </tr>
         <tr style="height:10.0pt;">
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Asset category</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Estimated useful life</span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment and software</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Office furniture</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Laboratory equipment</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5 years</span></span></p></td>
         </tr>
         <tr style="height:10.0pt;">
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
          <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shorter of useful life or remaining lease term</span></span></p></td>
         </tr>
        </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reconciliation of cash, cash equivalents and restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of property and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095860080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities by security type consisted of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.601%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.763%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,432</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">13</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">301</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,658</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">68</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">474</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">440,090</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">775</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">439,396</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.989%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.738%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.414000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.601%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.124%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.763%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amortized<br/>cost</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>gains</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Gross<br/>unrealized<br/>losses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,559</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">218</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,781</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,340</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,112</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The remaining contractual maturities of all marketable securities were less than 18 months as of December 31, 2022 and 2021.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094165184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net (Table)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net, consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.941999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.079999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lab equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,379</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,567</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">266</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">566</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Computer equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">826</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">158</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23,765</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,557</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less accumulated depreciation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,987</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,333</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,778</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,224</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock', window );">Schedule of Depreciation Expense</a></td>
<td class="text">
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:31.436%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.568%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.568%;"/>
        <td style="width:1.0%;"/>
        <td style="width:2.257%;"/>
        <td style="width:1.0%;"/>
        <td style="width:18.657%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Depreciation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,804</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,535</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,328</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 980<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84167750&amp;loc=d3e42232-110370<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095444288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Instruments, Assets and Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following tables set forth the fair value of the Company&#8217;s financial instruments by level within the fair value hierarchy: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"/>
        <td style="width:1.228%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">228,144</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">211,252</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">544,699</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105,303</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">439,396</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.302%;"/>
        <td style="width:1.228%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.132%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.218%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.419%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As of December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair<br/>value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 2</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Level 3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Money market funds</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Marketable securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. treasury bills and notes</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">277,341</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">U.S. agency securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">18,771</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">354,239</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">58,127</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">296,112</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success payment liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The primary inputs used in valuing the success payments liability associated with the Company&#8217;s realization of a certain valuation threshold through either a sale of the Company&#8217;s preferred stock, an initial public offering, or a company sale at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022, 2021 and 2020, were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.173%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.356%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.919%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">At<br/>December 31,<br/>2020</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Fair value of common stock (per share)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19.35</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36.87</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Equity volatility</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">105</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cumulative probability of triggering event</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">70</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">n/a</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.50</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Changes in Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.061%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.793000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.378%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.804%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.39%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.196%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Antidilution<br/>rights<br/>liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Success<br/>payment<br/>liability</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,916</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,806</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,722</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of Series A Preferred</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,490</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,490</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Issuance of common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,250</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,574</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,815</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,389</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,371</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in fair value</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,486</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Balance at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,885</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094124800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses consist of the following:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.851%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.818%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.613%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.105%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Employee compensation and related benefits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,124</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,050</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued external research and development expenses</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,919</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,041</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Professional fees</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,193</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,109</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">License and milestone payments</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">310</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,221</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">792</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,767</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,992</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567090978352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Operating Lease Cost</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The components of operating lease cost were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"/>
        <td style="width:1.635%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.489%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,946</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,923</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Variable lease costs</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,601</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">747</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Short term lease costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">698</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,278</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,245</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4,948</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock', window );">Supplemental Cash Flow Information Related to Operating Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Supplemental cash flow information related to operating leases was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.4%;"/>
        <td style="width:1.635%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.477%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.489%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2021</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Cash paid for amounts included in the measurements of lease liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Operating cash flows related to operating leases</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,050</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Future minimum commitments under non-cancellable leases as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 were as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:79.936%;"/>
        <td style="width:1.922%;"/>
        <td style="width:1.0%;"/>
        <td style="width:16.143%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Years ending December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,306</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2024</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,563</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">10,868</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2026</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,183</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2027</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,506</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Thereafter</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">62,736</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">119,162</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: interest</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">37,245</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">81,917</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of supplemental cash flow information related to operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099745216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of transaction price separate performance obligations</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is as follows:</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:69.673%;"/>
        <td style="width:1.994%;"/>
        <td style="width:1.131%;"/>
        <td style="width:26.23%;"/>
        <td style="width:0.972%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Performance obligation</span></p></td>
        <td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Amount</span></p></td>
        <td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research services obligation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">First licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,667</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Second licensed agent material right</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,667</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Third licensed agent material right</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,666</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099406432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.359%;"/>
        <td style="width:1.406%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.719%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.396%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.006%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,486</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,830</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">494</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">General and administrative</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9,991</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,242</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">356</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total stock-based compensation expense</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,477</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">850</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used for Options Granted</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The assumptions used in Black-Scholes for stock options granted were as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:56.835%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.475%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.989%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.247%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended<br/>December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">77.7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">84.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-average risk-free interest rate</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected term (in years)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.0</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table provides a summary of stock option activity during the year ended </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:45.143%;"/>
        <td style="width:0.823%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.238%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.633000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.823%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.466000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.042%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.839%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Number of<br/>options</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br/>average<br/>exercise<br/>price per<br/>share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted<br/>average<br/>remaining<br/>contractual<br/>life (in years)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Aggregate<br/>intrinsic<br/>value</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"><br/>(in thousands)</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,119,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">9.44</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,561,300</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28.49</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">743,638</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.92</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">324,131</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.37</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding at December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,612,826</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">16.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">63,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Exercisable at December 31, 2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,551,841</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.52</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7.6</span></span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Expected to vest after December 31, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&quot;Arial&quot;, sans-serif;position:relative;min-width:fit-content;">(1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,060,985</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.43</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.6</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29,495</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div><div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A summary of the status of and change in unvested restricted stock units as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31, 2022 was as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.119%;"/>
        <td style="width:1.184%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.077%;"/>
        <td style="width:1.866%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.877%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Shares</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted-<br/>average grant<br/>date fair<br/>value per share</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36.58</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units granted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">688,700</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22.65</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,375</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">35.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Restricted stock units forfeited</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">36,500</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24.32</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units as of December 31, 2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">677,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23.10</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095691792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted net Loss Per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> &#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.184%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.838%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.828%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.391%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.967%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands, except share and per share amounts)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">157,387</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">120,314</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">45,704</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Weighted average number of common shares, basic and diluted</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">54,023,653</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">26,872,036</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,250,093</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net loss per common share attributable to common stockholders, basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2.91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20.31</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.329%;"/>
        <td style="width:1.007%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.774%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.085999999999999%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Convertible preferred stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">19,387,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">537,633</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">677,825</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">32,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Outstanding options to purchase common stock</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">7,612,826</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,119,295</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,888,823</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8,290,651</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,151,295</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">23,814,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567095727248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Income tax expense (benefit) is summarized as follows:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.662%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.629999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.629999999999999%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.401%;"/>
        <td style="width:1.0%;"/>
        <td style="width:10.876%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total current provision</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred:</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred provision</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">-</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:57.004%;"/>
        <td style="width:0.984%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.338000000000001%;"/>
        <td style="width:1.0%;"/>
        <td style="width:0.994%;"/>
        <td style="width:1.0%;"/>
        <td style="width:11.348%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Year ended December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2020</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Federal statutory rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">34.7</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">31.3</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">29.6</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.3</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Executive compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Permanent items</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">State income taxes, net of federal benefit</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">8.4</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.1</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6.8</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5.6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">4.5</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">0.0</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Effective income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Taxes</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">: </span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.756%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:12.941999999999998%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.611%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.079999999999998%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;"> &#160;</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">December 31,</span></p></td>
        <td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(in thousands)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2022</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2021</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">43,779</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">33,409</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized costs&#8212;net of amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">11,095</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">12,395</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Research and development tax credits</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">20,835</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">6,098</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Capitalized research costs</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">28,650</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;"><span style="-sec-ix-hidden:F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">3,669</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,117</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Other</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">174</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">76</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Lease liability</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">22,285</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">533</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Accrued expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">5,024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">2,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">135,511</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">56,480</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Property and equipment</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">881</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">899</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Right of use asset</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">24,994</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">501</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax liabilities</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">25,875</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">1,400</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Total deferred tax assets, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109,636</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55,080</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Less: valuation allowance</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">109,636</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">(</span><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">55,080</span></p></td>
        <td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182254288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and marketable securities</a></td>
<td class="nump">$ 554.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567183491808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 115,412<span></span>
</td>
<td class="nump">$ 64,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,824<span></span>
</td>
<td class="nump">5,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 120,236<span></span>
</td>
<td class="nump">$ 69,567<span></span>
</td>
<td class="nump">$ 9,456<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091035376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PercentageOfTaxBenefitRealized', window );">Percentage of tax benefit realized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 81,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">91,877,000<span></span>
</td>
<td class="nump">1,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">91,877,000<span></span>
</td>
<td class="nump">1,839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">81,917,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">$ 10,000,000,000.0<span></span>
</td>
<td class="nump">10,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IssuanceOfAdditionalCommonStock', window );">Issuance of Additional Common Stock | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessLiabilityPayment', window );">Success Liability Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IssuanceOfAdditionalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of additional common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IssuanceOfAdditionalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageOfTaxBenefitRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of tax benefit realized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageOfTaxBenefitRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Liability Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093638416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember', window );">Office Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property and equipment estimated useful life</a></td>
<td class="text">Shorter of useful life or remaining lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_OfficeFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094208832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CurrentAbstract', window );"><strong>Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">$ 440,090<span></span>
</td>
<td class="nump">$ 296,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</a></td>
<td class="num">(775)<span></span>
</td>
<td class="num">(228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">439,396<span></span>
</td>
<td class="nump">296,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Bills and Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CurrentAbstract', window );"><strong>Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">228,432<span></span>
</td>
<td class="nump">277,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</a></td>
<td class="num">(301)<span></span>
</td>
<td class="num">(218)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">228,144<span></span>
</td>
<td class="nump">277,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CurrentAbstract', window );"><strong>Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Debt Securities, Available-for-Sale, Amortized Cost, Current</a></td>
<td class="nump">211,658<span></span>
</td>
<td class="nump">18,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</a></td>
<td class="num">(474)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Debt Securities, Available-for-Sale, Current</a></td>
<td class="nump">$ 211,252<span></span>
</td>
<td class="nump">$ 18,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091160816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable securities - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm', window );">Remaining contractual maturities of marketable securities term</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized losses on marketable securities</a></td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining contractual maturities of marketable securities term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091172480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and equipment, net - Schedule of Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 23,765<span></span>
</td>
<td class="nump">$ 9,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="num">(4,987)<span></span>
</td>
<td class="num">(2,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">18,778<span></span>
</td>
<td class="nump">7,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">20,379<span></span>
</td>
<td class="nump">8,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,294<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 826<span></span>
</td>
<td class="nump">$ 158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099359680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Schedule of Depreciation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 1,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091152432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and equipment, net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 1,535<span></span>
</td>
<td class="nump">$ 1,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567096867344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">$ 544,699<span></span>
</td>
<td class="nump">$ 354,239<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">105,303<span></span>
</td>
<td class="nump">58,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember', window );">U.S. Treasury Bills and Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">228,144<span></span>
</td>
<td class="nump">277,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember', window );">U.S. Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">211,252<span></span>
</td>
<td class="nump">18,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember', window );">Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">105,303<span></span>
</td>
<td class="nump">58,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">105,303<span></span>
</td>
<td class="nump">58,127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury Bills and Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">439,396<span></span>
</td>
<td class="nump">296,112<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury Bills and Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">228,144<span></span>
</td>
<td class="nump">277,341<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">211,252<span></span>
</td>
<td class="nump">18,771<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">2,885<span></span>
</td>
<td class="nump">4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury Bills and Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Agency Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialLiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=verv_USTreasuryBillsAndNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=verv_USAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091115584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 105,300<span></span>
</td>
<td class="nump">$ 58,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentLiabilityCurrent', window );">Success payment, current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember', window );">Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FairValueInputsProbabilityOfTermination', window );">Fair value inputs probability of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Harvard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Success payment liability, payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember', window );">Other Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentLiabilityPayable', window );">Success Payment Liability, Payable</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 7,800<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueInputsProbabilityOfTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value inputs probability of termination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueInputsProbabilityOfTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success Payment Liability Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiabilityPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liability, payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiabilityPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091025088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FairValueOfCommonStockPerShare', window );">Fair value of common stock (per share)</a></td>
<td class="nump">$ 19.35<span></span>
</td>
<td class="nump">$ 36.87<span></span>
</td>
<td class="nump">$ 8.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CumulativeProbabilityOfTriggeringEvent', window );">Cumulative probability of triggering event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Equity Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FairValueAssumptionOfEquityVolatilityRate', window );">Equity volatility</a></td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CumulativeProbabilityOfTriggeringEvent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative probability of triggering event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CumulativeProbabilityOfTriggeringEvent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueAssumptionOfEquityVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assumption of equity volatility rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueAssumptionOfEquityVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value assumptions expected term 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FairValueOfCommonStockPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FairValueOfCommonStockPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091486240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">$ 4,371<span></span>
</td>
<td class="nump">$ 9,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">$ 1,486<span></span>
</td>
<td class="nump">$ 33,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Change In Fair Value Of Success Payments Liabilities<span></span>
</td>
<td class="text">Change In Fair Value Of Success Payments Liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember', window );">Antidilution Rights Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">(0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember', window );">Success Payment Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning balance</a></td>
<td class="nump">4,371<span></span>
</td>
<td class="nump">2,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series A Preferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">1,486<span></span>
</td>
<td class="nump">7,815<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Ending balance</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement in which net income is reported that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Issued During Period Value New Issues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_AntidilutionRightsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=verv_SuccessPaymentLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093812672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Employee compensation and related benefits</a></td>
<td class="nump">$ 9,124<span></span>
</td>
<td class="nump">$ 6,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AccruedExternalResearchAndDevelopmentExpenses', window );">Accrued external research and development expenses</a></td>
<td class="nump">8,919<span></span>
</td>
<td class="nump">5,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">1,193<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LicenseAndMilestonePayments', window );">License and milestone payments</a></td>
<td class="nump">310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,221<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 20,767<span></span>
</td>
<td class="nump">$ 12,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AccruedExternalResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued external research and development expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AccruedExternalResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LicenseAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License and milestone payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LicenseAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567090105536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LeaseCommencementDate', window );">Lease commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LeaseNoncancelableTerm', window );">Lease noncancelable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset', window );">Increase in Right-Of-Use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,011)<span></span>
</td>
<td class="num">$ (1,940)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,917<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,877<span></span>
</td>
<td class="nump">1,839<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LesseeOperatingLeaseIncrementalBorrowingRate', window );">Operating lease incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,050<span></span>
</td>
<td class="nump">2,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">698<span></span>
</td>
<td class="nump">$ 2,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=verv_NewAmendmentMember', window );">New Amendment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AdditionalLesseeOperatingLeaseArea', window );">Additional Lease Area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember', window );">Premises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LesseeOperatingLeaseArea', window );">Lease area | ft&#178;</a></td>
<td class="nump">104,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Lease not yet commenced, lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend', window );">Option to extend, lease not yet commenced</a></td>
<td class="text">five years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_TenantImprovementsAllowance', window );">Tenant improvements allowance</a></td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IncreaseDecreaseInRent', window );">Increase decrease in rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember', window );">Premises | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Letter of credit issued</a></td>
<td class="nump">4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ShortTermBorrowingsReducedValue', window );">Letter of credit reduced value</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AdditionalLesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Lessee Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AdditionalLesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Operating Lease Right Of Use Of Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IncreaseDecreaseInRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IncreaseDecreaseInRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LeaseCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Commencement Date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LeaseCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LeaseNoncancelableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease Noncancelable Term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LeaseNoncancelableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LesseeOperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease area.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LesseeOperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LesseeOperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease incremental borrowing rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LesseeOperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ShortTermBorrowingsReducedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term borrowings reduced value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ShortTermBorrowingsReducedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TenantImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant improvements allowance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TenantImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=verv_NewAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=verv_NewAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=verv_PremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099255472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Components of Operating Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 5,946<span></span>
</td>
<td class="nump">$ 1,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease costs</a></td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short term lease costs</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">2,278<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">$ 8,245<span></span>
</td>
<td class="nump">$ 4,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567182133408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurements of lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows related to operating leases</a></td>
<td class="nump">$ 5,050<span></span>
</td>
<td class="nump">$ 2,021<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurements of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567097007936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, to be Paid [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 12,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">10,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">10,868<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">11,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">11,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">62,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">119,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(37,245)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 81,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567088210288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 05, 2022</div></th>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 242,826,000<span></span>
</td>
<td class="nump">$ 281,584,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration', window );">Derivative Liability, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,095,000<span></span>
</td>
<td class="nump">$ 68,202,000<span></span>
</td>
<td class="nump">$ 35,371,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember', window );">Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PreferredStockFinancingPartiallySatisfied', window );">Preferred stock financing partially satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PreferredStockFinancingFullySatisfied', window );">Preferred stock financing were fully satisfied</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing', window );">Common stock issued for partly satisfying preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing', window );">Common stock issued for fully satisfying preferred stock financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember', window );">Harvard and Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Success payment liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommercializingProfitsAndExpenses', window );">Commercializing Profits And Expenses</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PercentageSharesOfDevelopmentExpense', window );">Percentage Shares of Development Expense</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_MilestoneRelatedExpenses', window );">Milestone related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Delivery Technology Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfMilestoneDevelopment', window );">Payment of milestone development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Sales Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember', window );">Beam License Agreement | Sales Member | N Z</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_NovartisLicenseAgreementMember', window );">Novartis License Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFeesPaid', window );">Non-refundable upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_MilestoneRelatedExpenses', window );">Milestone related expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFee', window );">Non Refundable Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ClinicalAndRegulatoryMilestone', window );">Clinical And Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember', window );">Acuitas Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFee', window );">Non Refundable Upfront License Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ClinicalAndRegulatoryMilestone', window );">Clinical And Regulatory Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SalesBasedMilestone', window );">Sales Based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NonRefundableUpfrontLicenseFeesPaid', window );">Non-refundable upfront license fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember', window );">License Agreement | Acuitas Agreements | Sales Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PaymentOfSalesBasedMilestone', window );">Payment of sales based milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember', window );">Antidilution Rights | Broad License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ClinicalAndRegulatoryMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical and regulatory milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ClinicalAndRegulatoryMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommercializingProfitsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercializing profits and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommercializingProfitsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for fully satisfying preferred stock financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for partly satisfying preferred stock financing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_MilestoneRelatedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone related expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_MilestoneRelatedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontLicenseFeesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-refundable upfront license fees paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontLicenseFeesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PaymentOfMilestoneDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of milestone development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PaymentOfMilestoneDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PaymentOfSalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of sales based milestone.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PaymentOfSalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageSharesOfDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Shares of Development Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageSharesOfDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockFinancingFullySatisfied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock financing fully satisfied</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockFinancingFullySatisfied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PreferredStockFinancingPartiallySatisfied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock financing partially satisfied</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PreferredStockFinancingPartiallySatisfied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SalesBasedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales based milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SalesBasedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_HarvardAndBroadLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_BeamLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=verv_DeliveryTechnologyProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=verv_DeliveryTechnologyProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_NZ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_NZ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_NovartisLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_NovartisLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_AcuitasAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_AntidilutionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567096775872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Additional Information) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jul. 18, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireCommercialRealEstate', window );">Payments to Acquire Commercial Real Estate</a></td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=verv_ThreeLicensedAgentMember', window );">Three Licensed Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_FixedConsiderationAmount', window );">Fixed consideration amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember', window );">Vertex Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock from initial public offering, net of issuance costs of (in shares)</a></td>
<td class="nump">1,519,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Price Per Share</a></td>
<td class="nump">$ 23.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock', window );">Aggregate purchase price</a></td>
<td class="nump">$ 35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NonRefundableUpfrontPayment', window );">Non Refundable Upfront Payment</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentsForEachProduct', window );">Success payments for each product</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireCommercialRealEstate', window );">Payments to Acquire Commercial Real Estate</a></td>
<td class="nump">175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfUnamortizedFilmCosts', window );">Maximum percentage of profit/cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueRevenueRecognized1', window );">Deferred Revenue, Revenue Recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts', window );">Amount of Deferred Costs Related to Long-Term Contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember', window );">Vertex Agreement [Member] | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentsForEachProduct', window );">Success payments for each product</a></td>
<td class="nump">$ 66.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndFeeIncomeLoansCommercial', window );">Required fee payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember', window );">Vertex Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PercentageOfUnamortizedFilmCosts', window );">Maximum percentage of profit/cost share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndFeeIncomeLoansCommercial', window );">Required fee payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember', window );">Vertex Agreement [Member] | Stock Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet', window );">Fixed transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Fixed transaction price consisting upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount', window );">Upfront fee discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued and sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,519,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost', window );">Estimated expected cost reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred costs for long-term contracts and programs. Includes, but is not limited to, initial tooling costs and deferred production costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueRevenueRecognized1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously reported as deferred or unearned revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueRevenueRecognized1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized loan commitment, origination, and other costs (fees) and purchase premium (discount) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10152-111534<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6378536&amp;loc=d3e10092-111533<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndFeeIncomeLoansCommercial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and fee income related to commercial loans including industrial and agricultural, real estate (commercial and residential, construction and development), trade financing, and lease financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndFeeIncomeLoansCommercial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireCommercialRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of property as primarily intended to generate income for its owner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireCommercialRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PercentageOfUnamortizedFilmCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of unamortized film costs for released films, excluding acquired film libraries, that it expects to amortize within three years from the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54434-107959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PercentageOfUnamortizedFilmCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from repayment of loans for purchasing common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of manufacturing or production costs and any related deferred costs (for example, initial tooling costs) that exceeds the aggregate estimated cost of all in-process and delivered units on the basis of the estimated average cost of all units expected to be produced under long-term contracts and programs not yet complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_FixedConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed consideration amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_FixedConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentsForEachProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payments for each product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentsForEachProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=verv_ThreeLicensedAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=verv_ThreeLicensedAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_VertexAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099755952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 25,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=verv_ResearchServicesObligationMember', window );">Research services obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">5,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=verv_FirstLicensedAgentMaterialRightMember', window );">First licensed agent material right [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">6,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=verv_SecondLicensedAgentMaterialRightMember', window );">Second licensed agent material right [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">6,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=verv_ThirdLicensedAgentMaterialRightMember', window );">Third licensed agent material right [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PerformanceObligation', window );">Performance obligation</a></td>
<td class="nump">$ 6,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Performance obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=verv_ResearchServicesObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=verv_ResearchServicesObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=verv_FirstLicensedAgentMaterialRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=verv_FirstLicensedAgentMaterialRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=verv_SecondLicensedAgentMaterialRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=verv_SecondLicensedAgentMaterialRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=verv_ThirdLicensedAgentMaterialRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=verv_ThirdLicensedAgentMaterialRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091166432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock Tranche Liability - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567090915264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred and Common Stock - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, value per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of Preferred Stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 93,759<span></span>
</td>
<td class="nump">$ 92,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="nump">61,730,816<span></span>
</td>
<td class="nump">48,511,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommissionOnAggregateGrossSaleProceeds', window );">Commission On Aggregate Gross Sale Proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses', window );">Proceeds from issuance of Preferred Stock, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 281,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,105,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PublicOfferingPrice', window );">Public Offering Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross', window );">Proceeds from common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,720,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_StockPurchaseAgreementMember', window );">Stock Purchase Agreement [Member] | Vertex Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">1,519,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 23.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_AgreegatePurchasePrice', window );">Agreegate Purchase Price</a></td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=verv_PublicOfferingMember', window );">Public offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of Stock, Number of Shares Issued in Transaction</a></td>
<td class="nump">9,583,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions', window );">Underwriting discounts and offering expenses</a></td>
<td class="nump">$ 15,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_CommonStockOfferingPricePerShare', window );">Common Stock Offering Price Per Share</a></td>
<td class="nump">$ 27.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of Stock, Consideration Received on Transaction</a></td>
<td class="nump">$ 242,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=verv_HarvardAndBoardMember', window );">Harvard And Board [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,170,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series A-2 Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,838,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,163,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,583,334<span></span>
</td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,141,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series B Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary Sale Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,163,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.13(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_AgreegatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreegate purchase price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_AgreegatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommissionOnAggregateGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission on aggregate gross sale proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommissionOnAggregateGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_CommonStockOfferingPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Offering Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_CommonStockOfferingPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock Under IPO, Gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PublicOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Public Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PublicOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=verv_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=verv_VertexPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=verv_VertexPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=verv_HarvardAndBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=verv_HarvardAndBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_SeriesA2PreferredStocksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_SeriesA2PreferredStocksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567090087552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Instalment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">7,057,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="nump">$ 2,175<span></span>
</td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of stock options granted | $ / shares</a></td>
<td class="nump">$ 19.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised | $</a></td>
<td class="nump">$ 21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options | $</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock-based compensation cost | $</a></td>
<td class="nump">$ 64,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation is expected to be recognized</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized stock-based compensation cost | $</a></td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,150,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_NumberOfInstallmentsForRestrictedSharesVested', window );">Number of Installments for Restricted Shares Vested | Instalment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyEighteenMember', window );">Twenty Eighteen | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="nump">6,885,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,086,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="nump">3,025,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Purchase of common stock under ESPP(shares)</a></td>
<td class="nump">134,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan', window );">Stock available for issuance under ESPP</a></td>
<td class="nump">784,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted</a></td>
<td class="nump">688,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember', window );">2021 Stock Incentive Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grant</a></td>
<td class="nump">688,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance', window );">Increase in common stock capital shares, reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">617,308<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in common stock capital shares, reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_NumberOfInstallmentsForRestrictedSharesVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of installments for restricted shares vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_NumberOfInstallmentsForRestrictedSharesVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Available For Issuance Under Employee Stock Purchase Plan</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwentyEighteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwentyEighteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwentyTwentyOneEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567093682032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Summary of Stock Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 22,477<span></span>
</td>
<td class="nump">$ 7,072<span></span>
</td>
<td class="nump">$ 850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">12,486<span></span>
</td>
<td class="nump">3,830<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,991<span></span>
</td>
<td class="nump">$ 3,242<span></span>
</td>
<td class="nump">$ 356<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099255344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.30%<span></span>
</td>
<td class="nump">77.70%<span></span>
</td>
<td class="nump">84.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted-average risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094663552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr><th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, Beginning balance | shares</a></td>
<td class="nump">6,119,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options, Granted | shares</a></td>
<td class="nump">2,561,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of options, Exercised | shares</a></td>
<td class="num">(743,638)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of options, Forfeited | shares</a></td>
<td class="num">(324,131)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options, Outstanding, Ending balance | shares</a></td>
<td class="nump">7,612,826<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options, Exercisable | shares</a></td>
<td class="nump">2,551,841<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of options, Expected to vest | shares</a></td>
<td class="nump">5,060,985<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Beginning balance | $ / shares</a></td>
<td class="nump">$ 9.44<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">28.49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="nump">20.37<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Ending balance | $ / shares</a></td>
<td class="nump">16.10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable | $ / shares</a></td>
<td class="nump">7.52<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Expected to vest | $ / shares</a></td>
<td class="nump">$ 20.43<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life (in years), Outstanding</a></td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), Exercisable</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life (in years), Expected to vest</a></td>
<td class="text">8 years 7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value, Outstanding | $</a></td>
<td class="nump">$ 63,790<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable | $</a></td>
<td class="nump">34,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate intrinsic value, Expected to vest | $</a></td>
<td class="nump">$ 29,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1],[2]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567096908832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details) - 2021 Stock Incentive Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, beginning balance, Unvested | shares</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of RSUs, Granted | shares</a></td>
<td class="nump">688,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Unvested Restricted stock vested | shares</a></td>
<td class="num">(6,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Restricted stock units forfeited | shares</a></td>
<td class="num">(36,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested RSUs, ending balance, Unvested | shares</a></td>
<td class="nump">677,825<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested | $ / shares</a></td>
<td class="nump">$ 36.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant-Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">22.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, Vested | $ / shares</a></td>
<td class="nump">35.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_WeightedAverageGrantDateFairValueForfeited', window );">Weighted-Average Grant-Date Fair Value, forfeited | $ / shares</a></td>
<td class="nump">24.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested | $ / shares</a></td>
<td class="nump">$ 23.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_WeightedAverageGrantDateFairValueForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-Average Grant-Date Fair Value, forfeited</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_WeightedAverageGrantDateFairValueForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=verv_TwoThousandAndTwentyOneStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099118016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (157,387)<span></span>
</td>
<td class="num">$ (120,314)<span></span>
</td>
<td class="num">$ (45,704)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares, basic</a></td>
<td class="nump">54,023,653<span></span>
</td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares, diluted</a></td>
<td class="nump">54,023,653<span></span>
</td>
<td class="nump">26,872,036<span></span>
</td>
<td class="nump">2,250,093<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share attributable to common stockholders, basic</a></td>
<td class="num">$ (2.91)<span></span>
</td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share attributable to common stockholders, diluted</a></td>
<td class="num">$ (2.91)<span></span>
</td>
<td class="num">$ (4.48)<span></span>
</td>
<td class="num">$ (20.31)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094696432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">8,290,651<span></span>
</td>
<td class="nump">6,151,295<span></span>
</td>
<td class="nump">23,814,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,387,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember', window );">Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">537,633<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">677,825<span></span>
</td>
<td class="nump">32,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember', window );">Outstanding Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities</a></td>
<td class="nump">7,612,826<span></span>
</td>
<td class="nump">6,119,295<span></span>
</td>
<td class="nump">3,888,823<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=verv_OutstandingOptionsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567098938880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">$ 4,371<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=verv_HarvardAndBoardMember', window );">Harvard And Board | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicLineItems', window );"><strong>Earnings Per Share Basic [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_SuccessPaymentLiability', window );">Success payment liability</a></td>
<td class="nump">$ 6,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_SuccessPaymentLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Success payment liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_SuccessPaymentLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=verv_HarvardAndBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=verv_HarvardAndBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567089903600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes - Summary of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567090763424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(34.70%)<span></span>
</td>
<td class="num">(31.30%)<span></span>
</td>
<td class="num">(29.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent', window );">Executive compensation</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_EffectiveIncomeTaxRateReconciliationOther', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Executive compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_EffectiveIncomeTaxRateReconciliationOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_EffectiveIncomeTaxRateReconciliationOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation Permanent Items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091052736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 43,779<span></span>
</td>
<td class="nump">$ 33,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization', window );">Capitalized costs&#8212;net of amortization</a></td>
<td class="nump">11,095<span></span>
</td>
<td class="nump">12,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credits</a></td>
<td class="nump">20,835<span></span>
</td>
<td class="nump">6,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized research costs</a></td>
<td class="nump">28,650<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredTaxAssetsStockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,669<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities', window );">Lease liability</a></td>
<td class="nump">22,285<span></span>
</td>
<td class="nump">533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredTaxAssetAccruedExpenses', window );">Accrued expenses</a></td>
<td class="nump">5,024<span></span>
</td>
<td class="nump">2,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">135,511<span></span>
</td>
<td class="nump">56,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="num">(881)<span></span>
</td>
<td class="num">(899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(24,994)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(25,875)<span></span>
</td>
<td class="num">(1,400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Total deferred tax assets, net</a></td>
<td class="nump">109,636<span></span>
</td>
<td class="nump">55,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(109,636)<span></span>
</td>
<td class="num">(55,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Asset Accrued Expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Capitalized Costs Net Of Amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxAssetsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Stock-based compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxAssetsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax liabilities, Right of use asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567091118224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Income (Loss) from Continuing Operations before Income Taxes, Domestic</a></td>
<td class="nump">157,400,000<span></span>
</td>
<td class="nump">120,300,000<span></span>
</td>
<td class="nump">$ 45,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets valuation allowance increase (decrease)</a></td>
<td class="nump">$ 54,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_ChangeInOwnershipDescription', window );">Change in ownership, description</a></td>
<td class="text">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Uncertain tax positions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">163,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit amount</a></td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_PercentageOfFutureTaxableIncomeUtilizedToOffset', window );">Percentage of future taxable income utilized to offset</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 148,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_OperatingLossCarryforwardsExpirationYear', window );">Net operating loss carryforwards expiration year</a></td>
<td class="text">2042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit amount</a></td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_TaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward expiration year</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_ChangeInOwnershipDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in ownership description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_ChangeInOwnershipDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_PercentageOfFutureTaxableIncomeUtilizedToOffset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future taxable income utilized to offset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_PercentageOfFutureTaxableIncomeUtilizedToOffset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_TaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_TaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=verv_MassachusettsTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567099754288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 130,095<span></span>
</td>
<td class="nump">$ 68,202<span></span>
</td>
<td class="nump">$ 35,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_LeaseRentPayment', window );">Lease Rent Payment</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember', window );">Beam | Materials Exchange Agreement | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_LeaseRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease rent payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_LeaseRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=verv_BeamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=verv_MaterialsExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=verv_MaterialsExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140567094676448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum annual contributions per employee, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember', window );">401(k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary', window );">Defined contribution plan employer matching contribution percent of match upto two percent of employee salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum annual contributions per employee, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary', window );">Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary', window );">Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage', window );">Defined contribution plan, employers matching contribution, annual vesting percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans', window );">Defined contribution plan, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $20,500 in 2022 with a catch up contribution limit equal to $6,500 for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer Contribution amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of defined contribution pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>verv_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanNameAxis=verv_FourZeroOneKPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>verv-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:verv="http://www.vervetx.com/20221231"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="verv-20221231.xsd" xlink:type="simple"/>
    <context id="C_57a4273e-e500-4784-b24f-2d7cd8c95f12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_10db78b5-9531-4269-b673-ed6a44209efb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1338186f-d03c-4d8a-a4c8-31af991b82fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0cb67e6f-2894-4db6-9521-909923920eff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_5e543a38-cef8-457e-8d21-0bec7784e4f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_bac8d82c-d5da-4a33-90e9-09318020506e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fc34a2a2-051c-4d86-b8ad-adf3902f2be3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3c170bb7-edb6-442d-8788-b1811c3e3301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_8f2608f6-1835-45a9-8887-c4db04550843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1f9a1d59-c482-4313-96a8-40ac3152c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ThirdLicensedAgentMaterialRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_01e0a48b-6d98-43b9-9faa-58583e0071a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_59c54d37-04e4-4cc3-9af1-28ee8d5dcf07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyEighteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_bec200da-6561-47c7-ada8-88c14ff8512c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_c513a636-9c59-4d55-ad2f-c703f327678f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_94979cff-1f2a-464c-857e-c9995bec9c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1f3707ed-9eee-4702-833d-a6141f5a0cf1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7c63f0f3-4bd5-489e-af2c-513202741f0b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7175e0b6-9535-4c9e-8e30-3ebf8ac9de8f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_80d92420-5853-477a-a2f9-78d029bbafe0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="C_0445a9ca-bc9f-4e03-ba8a-fb18a059a14c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_aab4db61-ccdc-4683-9f00-31e18b63c0b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:NZ</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_86e5cc33-d110-47af-ada1-8665901d8afd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1eb38d59-c0ac-4039-ba0c-18ac2f3c88af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9dbed675-16ab-43ad-92de-56cb1fea30b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_40e18ed5-64dd-4a21-8cc0-7eb7d48b6faf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0d68b3a6-6891-4343-9cac-092f95f5b426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_70c6c44c-62b4-4951-beb7-990103810b72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2732e9b1-8a6e-408c-9326-ef2e6692329b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_87908575-032d-4129-a33d-db396e918336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_caa34b87-6d61-41fe-980c-8d45934c3138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2b381c95-04aa-4fba-8306-9a71bc42bac3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_3c178253-f282-45ba-a2bb-8b3a3328bf26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4e417686-fb62-4c06-b6fd-6b68c1256e22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f27beec5-2375-455d-9c1c-624e6dbd8e18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:NovartisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d8970451-3d27-43fa-9ddd-5d84fc44e22a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d159b9f9-0a0b-4be3-8ded-15481d15c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_67250595-6ef1-4d88-b28c-b2e432497a69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_101c4b75-a6d1-40e5-b320-d63b7c3de7e7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_37ef4e5c-ee38-4746-8f83-e39d97e60aa9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_fa5f0add-d465-41c4-9cb6-bd0f9bb41f41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_3188091a-eb34-4e3d-9630-e21db1a73318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e616ea55-8674-4e50-833f-8f6bccf6e730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_63860296-a4f0-4e1a-9241-b6d773d5b067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_e3e444f8-82bf-4a8e-a308-5343180b3425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">verv:NewAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="C_5a628f3e-c8f6-4620-953c-b4cae63925d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_f0f69b44-4afb-469a-88cb-446f929e64b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_595a69e0-a981-426d-a6f1-79798dc73b95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0bedcb64-f835-4169-aae4-e6de370db89e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_57662c72-eee2-4c4f-951b-40edfc12c8d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_279982b2-44db-49b7-a99b-e765968a154b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:AntidilutionRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_2c9c2b5b-d0e5-4156-b918-deac7e15a723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_eab2ba07-0259-4573-8347-1b9098fe2136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f440c691-328c-490a-b5a2-6550bd63dd18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f5c58be5-49fc-43e9-a294-cc491cbf767a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ac822c00-7c16-4ab3-98ac-86f18f43dbac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:OfficeFurnitureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_70871dfe-f33d-4493-9391-2c839d284371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="C_50163530-3d32-4277-baac-6dd493e6a3c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9ac9284d-7074-4f13-885b-3fd225b5738d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_fb1c32eb-3cf9-4efd-b9f9-ef61f34a3d24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1235d3e0-b5c0-47c5-9f20-b1afa841a242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_2e1ed61d-8951-4d1b-b942-435100437cc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_645da17b-a2fa-4382-926c-98c8f1d57914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_959c970c-a6c2-451b-acea-26466d2da446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a1b1686d-7c2d-471e-b953-e9208218d02c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1bf4fef6-d58f-4313-8771-beb6b446dd32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b573d06e-feb8-4e52-95a0-9b02cf165de9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d8289e27-62a6-4835-8e99-588f8ef3162f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="C_24f24102-d3be-4e87-98e7-0dfd0698620a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f6e04a3c-5788-44a1-b5df-375dfe290497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:VertexPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_97838a2e-40af-4778-a7e5-dbade0a2d74e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ab3f67d4-0906-4241-abd4-7bdebb98d719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_d7b83b22-0b4c-4a86-a0f7-f54ef4b0daf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_899016e2-2a07-4bd4-8bcc-57974930a3bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">verv:VertexPharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_a18baa7c-e6c9-43fd-b0ab-55458b1c2d27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_42e3df2c-8ff1-469a-8a07-db72c7a21989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="C_28918730-6ac5-404a-a56f-497ecef921d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_24f6e06a-2bf4-411d-b931-999829f73aa4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6dce68af-09ea-451e-8aa9-bbbf481d2537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_51f6cfff-f169-440d-8129-93e247a0bd28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_910510d8-3c53-4144-8d2f-5bf2ee890957">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_fc3d1cc1-733b-4bd6-a6d6-e0509cce03f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="C_549dd0a2-a1f7-47be-962d-821373cb96d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_69ead165-eb9d-4003-9e73-6dde8148295a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9e4fa60e-e2a1-48fa-9006-8da2fef90e88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_79adf0ca-6cf4-4e27-a49b-9bf797059526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8840dc16-dd94-470b-ae47-6f49752ffb5d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e4a312ba-6931-4d91-b541-fb2e420d6d93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_5c084e08-8487-4c71-bcce-ce2e7baea2d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="C_88c35c5e-d77b-4780-9fe2-eff887d461de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4353a489-6849-4ba4-97a8-7fc091cf5f01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-05</startDate>
            <endDate>2022-07-05</endDate>
        </period>
    </context>
    <context id="C_e5fb7e70-f89c-46e0-8d34-d37cadafb70e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">verv:HarvardAndBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_1a914828-67e8-495a-9b12-2c48154e0de5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4e91dace-0a68-4bad-a0fd-32815efdc68c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3cbafceb-7d5c-4f1a-8167-31d9b2611fff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_e450d3c0-fb5f-4751-a200-b7af8109fa84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_5632b0e3-72a0-490d-b288-cdfcbada6292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6df26867-2d6b-46b4-b508-092bafb9230e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_f3934e3e-c3eb-462e-aef8-a427f8923a25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_8a7a03b0-4e2c-4c61-8591-8ea00dfc50ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_7ea5b1c4-02d7-4d08-83fa-e232cce51d59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="C_b22cbc9c-7068-4848-a684-7dd33933fb13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a8c752a7-a423-48c6-a1b6-94dbe8e1f488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fc740280-5fd2-4e74-a2d7-888d97ae217e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2023-02-27</instant>
        </period>
    </context>
    <context id="C_dcad783b-c139-4ff0-8e9c-6423e1ed3d39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_014a8cde-c8d4-4025-be72-d973721b5175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_0e5b7c24-a5e8-4c36-8628-c7caf3267a19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5533c143-e11b-4687-bab9-616ee25f12a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_25b472d9-741d-43a8-b055-7f86620a197c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a2029774-b097-49be-abf0-6584c59d9b9d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_bdcae62d-bb8e-473d-9798-be656594f6aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_6c1812ca-014b-4804-9c67-8987654bfa75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:HarvardAndBroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f2189d68-ff46-4307-87ca-ccad5ed5d257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-19</instant>
        </period>
    </context>
    <context id="C_02d7b42f-eec4-4cd5-861d-bf55e78340ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_80a0f724-7529-472e-8067-5943bc65251c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_62529372-4437-4f8a-a2e2-7adb297a1ce7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_d5267666-4c65-44f3-9936-fcf70ee31d7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_eca01a0b-4203-4974-86fd-df6598a8bcb7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_84d11930-e66f-4233-9020-576b7dc6f3ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_dd1cb871-5f3e-4054-bc64-84e70cd6064d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_467087e6-7c15-4d2a-b5aa-9b131364dec6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">verv:BeamMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:MaterialsExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_336f1e13-611b-497c-ba64-333f8e899c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_ce21619d-19f7-43cd-b8d5-a7b052f3bd59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aea2e412-934b-4a07-a049-22c9f1b5ea0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_80fe8138-eecf-486b-bd60-cbf5bf880dae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">verv:DeliveryTechnologyProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BeamLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="C_966c03b1-7109-4952-a069-3bb673a98824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9e463725-1023-4ed8-9f1a-3d4cf8b31389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3fdd3360-eab0-4708-a04c-8b89365954ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_808142c2-b5e3-4524-9ea6-da21e029cba1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b6c51c82-3c32-4a05-9b39-deffe3ffdec3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-31</instant>
        </period>
    </context>
    <context id="C_dc7fb957-db9b-4919-85c0-f2b666593c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_17d2fd0e-b2d9-4c3d-8c72-65febc814137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_811d34f0-c7b1-4e6e-ab97-bb9220268914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_69bde097-9b90-4143-bf28-ce208cea2c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_146d0396-0c40-4489-aa98-b2e85e1a984e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ResearchServicesObligationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4507e5e6-86e5-49af-9e91-39416a49e6de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:FirstLicensedAgentMaterialRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_787fb8f2-564a-4ad4-9e81-6ab4543c8745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c8436e03-c1f0-4e91-a1b2-e9f92451d6ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="C_bcc724c9-3022-47b5-8ad1-b152262e7aba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_042eaa61-5d4c-48a9-bc1a-4987ee4f1dc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_1fa2bdd3-e60a-48e3-89d8-47c5490b909e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_0d7d5bec-d770-4173-b7fa-5da0ea98f60b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_875f1476-cc60-4a70-a9cc-ff85d743c58f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_199a8315-5928-47de-86f7-85c75d05000c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_0561a53b-a5ef-42c6-abb0-89bfc7201442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-18</instant>
        </period>
    </context>
    <context id="C_a76866af-dd3c-4049-b8fe-63fdc94162b1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_3d29fbc3-5622-4165-a232-e591a91a09ce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7a8149ba-0367-4d16-9824-0138611d7cd9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d5b798c-354b-494c-aca5-76cbed28659a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5977f77c-03e7-4fcd-8eb7-0857be233fcb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_aa0bb9fe-96a8-4b16-bddc-1ab940b85d65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_830a7292-f023-456a-aa51-b7b87abe1927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwoThousandAndTwentyOneStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_34a36f82-56c7-4f23-aefa-cbf18563b2c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:SeriesA2PreferredStocksMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4c419fcc-8948-4d11-ad8c-bc4acd187a2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8d200ccf-3e5b-4292-a74b-e614b3ce55e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_28ec8de1-aead-4024-b68e-b6f0436f3e8c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a90ac7d2-282e-440c-801e-9a2c12563c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">verv:TwentyTwentyOneEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_29085c5c-8572-4342-8193-f44746b659b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_38705494-508f-4282-b760-eb63eae1915e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanNameAxis">verv:FourZeroOneKPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_045cb64e-47d4-4a6a-8f5f-0799d3c6d0ca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_42d8066c-ec6d-457c-92e0-ad6208d5c754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">verv:MassachusettsTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_8c22a27c-1726-4bbe-9663-4f3fa7321495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_d49a8d56-7215-4b6b-85ee-c2345d8966fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:UnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_1bf70619-a638-4c23-8216-60415235bbb2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a3dbf855-2073-449b-a0a1-57d11e804ae3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:NovartisLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_b1a6ad37-f5ef-49b3-be24-86dec915f36d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:StockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="C_84658634-9c24-4121-9463-34ea37f01b51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_6b8656ae-4c34-40f1-ae35-56f5f8a895dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_346778ed-ab28-463d-a0c6-1e76673dd790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">verv:OutstandingOptionsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5ac36620-71e8-4db8-856c-7631ba94d156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7f3b431e-5ee8-4828-90a9-812944400c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5476f53e-8810-4a5b-afa1-3ba7403c605f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:ThreeLicensedAgentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_10236809-a80e-4e09-9626-2b295f8196ed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_52a4a369-ae67-4de2-82c2-3426ee972653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_a53dba14-9b85-4825-a901-caab2a81e8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_9d9b46b8-dcc4-4ea7-bf1b-5b347b2d06e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">verv:SecondLicensedAgentMaterialRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_deea9644-67bd-4520-bcd2-358aa23d9d50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_0ca2fc95-4cb8-4120-8d3b-72c64d65a515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ab5cdc4-68f7-4336-be12-9a43b519475c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_d9d32810-8547-4214-94fc-56f99ab953c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_06dbfcce-3022-4b09-89dd-3eef6740f46e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_727f645b-7b13-42e1-8111-8ed8a5b4c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_df58c0aa-a8ae-4c98-9b38-70834ce1e110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-31</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="C_72c91c7c-a0cb-4506-8c90-233e59c44e9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_dd53e7c9-c890-4a7b-9181-75e01d01947a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_4d7ab199-9fb8-4980-b91e-4d41f59ce3e9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:BroadLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_9af85f91-63b3-41d0-b819-c7632790919e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_345d25d5-d53c-4618-b2d5-0ad9f68dc335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">verv:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_66ae070f-26c2-44ff-92ab-c5483d69abea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-19</instant>
        </period>
    </context>
    <context id="C_ce0e9729-f513-4bf1-8488-e529d1be5407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0deae6b1-45ca-4fba-96bb-c6dc6d5add88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:SuccessPaymentLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_43ffe065-4842-415c-88bd-7c2bb5a6e05d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_b2ed33c7-4d15-43a9-aa3d-221d32e3b104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_8f639dd3-36f0-4110-95b1-083a24288e33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_c0f7b69c-0978-4971-a704-73743e494290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_e3fcf3c5-2b24-43ee-a2b3-55105e54c465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">verv:AntidilutionRightsLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_e9d5bc3b-5c96-4d9f-b2f1-b89dbdfe1151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:AcuitasAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_604ef497-9ecd-45dc-bf27-276566041fda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_1f7382e3-ab33-42f1-8d80-f3c02882b1e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="C_0e2c72aa-22a4-4e86-9784-5469e1b2efbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4ef51bcc-9dfc-45c1-9eee-f5566e195c5b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b8d60c32-c672-429e-9168-9e517a3b0c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="C_7857b09d-9c1b-40bd-8d2b-001c0847756a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_69a15539-dd92-45a4-b854-128562acce6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_3ebb779e-eadf-4f21-b115-8bc997a90a32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">verv:USTreasuryBillsAndNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ef2c8bcc-a458-4df0-ac7a-cb2750615042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">verv:VertexAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-18</startDate>
            <endDate>2022-07-18</endDate>
        </period>
    </context>
    <context id="C_2df5c335-7703-4efb-9c6f-ac0c13ef2ed0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_cbef945b-b67d-4d13-994e-026951a49f6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840574</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">verv:PremisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-19</startDate>
            <endDate>2021-08-19</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Instalment">
        <measure>verv:Instalment</measure>
    </unit>
    <unit id="U_Segment">
        <measure>verv:Segment</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_61ee6742-2a51-4098-a058-1a9dd746d7b1">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_966c03b1-7109-4952-a069-3bb673a98824"
      id="F_4e655ade-06f9-4904-b02d-66b61f8a751c"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_6bd918bc-c341-4101-91d6-aa85e1089ebc">http://www.vervetx.com/20221231#ChangeInFairValueOfSuccessPaymentsLiabilities</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList>
    <verv:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      id="F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_966c03b1-7109-4952-a069-3bb673a98824"
      id="F_37a3732c-67b8-46fa-a2d3-2aa2597e06dc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      id="F_1581fec8-0bf5-40f2-be75-6ab97ee8bb15"
      unitRef="U_USD"
      xsi:nil="true"/>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_caa34b87-6d61-41fe-980c-8d45934c3138"
      id="F_e0722370-e756-4380-b190-71e49f255f38"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      id="F_ff5d24c9-5ffa-4c7d-adf1-18e4911abf8a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DeferredRevenueAndCreditsNoncurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      id="F_16e89c46-c096-4d76-8afc-fed6bca8d8cc"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_e3a6ec9a-5c47-4978-aa82-c8c00b6f48a0">0001840574</dei:EntityCentralIndexKey>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_29085c5c-8572-4342-8193-f44746b659b7"
      id="F_8bfc5d9b-0194-447d-8d63-2e05dbf8ee1e"
      unitRef="U_USD"
      xsi:nil="true"/>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_bec200da-6561-47c7-ada8-88c14ff8512c"
      id="F_bfddd2a3-f9a3-4e13-bcf7-0bf43949f96f"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      id="F_34d72d37-b190-41b5-ad0e-3ad3cb160e08">http://www.vervetx.com/20221231#ChangeInFairValueOfSuccessPaymentsLiabilities</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList>
    <dei:AmendmentFlag
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_d1f0b311-5b89-4607-814f-03d3a360452f">false</dei:AmendmentFlag>
    <us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      id="F_ff58d8b0-898f-4781-8d83-6a9291f25557">http://fasb.org/us-gaap/2022#NonoperatingIncomeExpense</us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_57262f8f-91c8-4da2-8965-8ef6140c8e90">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a527e3c1-99d0-4b89-bd23-8fa38a336953">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_b93028c5-c6ba-4f95-8bd8-cf11bec4795d">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_ae3138f1-3b69-4cea-8e7a-2af8cb0cea44">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_38e7ca92-45c0-477c-b131-bc819c515177">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_85d31b85-c9b7-47ae-9709-34c597f111ec">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_763ee878-6120-4c16-bb03-bbc6718302e1">001-40489</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_cab5972b-04ea-4803-a296-46773c77a64c">VERVE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_49b15578-ef35-477f-91e6-e8e357c7fade">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_86a4d2ca-ad68-40d6-a049-714ee9d6bc40">82-4800132</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_38311786-fea5-4d52-9962-e79cdde7d9a0">201 Brookline Avenue, Suite 601</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_102cc5e4-b08c-4a1c-a20b-7448cd454dad">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_448381ca-19e3-42e8-b8de-0d78f121d6a3">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_9c8c11b3-b159-4615-a8c7-37cbd2e7f107">02215</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_30425964-9aad-4d39-a3bf-8e5781d17d63">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_37800150-02f4-4693-aff8-1c49e2aaaa9a">603-0070</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_14369adc-2df8-429f-94d3-1145d519113e">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0d38ff46-4c61-4b70-be32-ce9795926485">VERV</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_4cd65674-c8db-4413-a049-5bbc0ff032ab">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_f02e2a12-270e-47ba-b13a-74457f118614">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_bbfd52de-ec9f-463e-af36-a566fe184041">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_87706536-e4ff-4de1-ac07-50a8df1c86bc">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a8ed1cb3-c64d-4e59-b9a6-c35b982b253f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_6e9ebc9a-0511-40d0-a3c7-9640d0d5fcde">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_24a22007-e39e-43e1-ba06-774284151ce8">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_d12e5ad2-caa2-464d-832a-fce6aefb9ac2">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_bf782cd6-4854-45bc-afa8-670697d31ca3">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0f610a30-1c7b-45ba-91e0-7c137b43d6a8">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_5c920c8f-10ad-4c16-9a25-995eb7fe159b">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_fc3d1cc1-733b-4bd6-a6d6-e0509cce03f2"
      decimals="-8"
      id="F_4463efea-1505-4014-a07e-b041a1c14406"
      unitRef="U_USD">557600000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_fc740280-5fd2-4e74-a2d7-888d97ae217e"
      decimals="INF"
      id="F_33b9253e-e9c4-40cc-a55d-911e21181869"
      unitRef="U_shares">61833265</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_99f09b40-7617-4371-9e60-4fc8f5670a69">&lt;p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.25pt double;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Portions of the registrant&#x2019;s definitive proxy statement that will be filed for the 2023 Annual Meeting of Stockholders &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;which the registrant intends to file with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December 31, 2022, are incorporated by reference in Part III of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_64beefc9-e5a1-4446-99bf-deceffe645ac">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_1030352e-bfef-4404-b077-c54e8b4c6d00">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_2a058221-4ceb-4fe1-b951-0fd7e2d49233">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_9851625f-c0f9-4110-985a-89fe6da298d8"
      unitRef="U_USD">115412000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_3f54d0f4-04e8-4be5-b274-a57139cc9f69"
      unitRef="U_USD">64330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_81b8ccc3-7a44-4ae3-b322-890fdbc02b95"
      unitRef="U_USD">439396000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_2002c219-7612-43ba-a08d-2c19e5a4860b"
      unitRef="U_USD">296112000</us-gaap:MarketableSecuritiesCurrent>
    <verv:CollaborationReceivable
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_beced71f-2315-4cb6-9273-4235f39b5ed1"
      unitRef="U_USD">1012000</verv:CollaborationReceivable>
    <verv:CollaborationReceivable
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_a4d750a7-5824-427e-ad00-64c8ae587ea9"
      unitRef="U_USD">0</verv:CollaborationReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_3aded3a2-7dde-4b75-b8d6-827a1a5e1c80"
      unitRef="U_USD">7339000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_bf54e838-d295-463b-bf49-2d31d97f7068"
      unitRef="U_USD">6686000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_947059e9-a760-470b-8c21-b91faa575f2d"
      unitRef="U_USD">563159000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_ab2cf234-dd9c-48b7-b9fc-d8b1c7fcb295"
      unitRef="U_USD">367128000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_1c9648bd-1cf6-4dbe-916d-d70561288a8c"
      unitRef="U_USD">18778000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_d0ee4a1a-c408-4bfb-8897-68dbb9b85441"
      unitRef="U_USD">7224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_52012e07-e356-4166-88aa-21e262daf94a"
      unitRef="U_USD">4824000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_6026aa54-01c6-4542-adf2-eae34ed1d162"
      unitRef="U_USD">5237000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_8199d238-e4c6-4758-becc-3477f6b8858c"
      unitRef="U_USD">91877000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_3f18ad4f-cba9-45ff-9a2c-4fb1dc66b729"
      unitRef="U_USD">1839000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_d6a283ca-cf1f-4170-ba04-7f592bcc02c8"
      unitRef="U_USD">585000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_57d721ac-c2dd-4a01-a3a4-8b6f028a60c1"
      unitRef="U_USD">2696000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_dfbaf8c0-e375-402b-9c7b-63f3fea9d0d7"
      unitRef="U_USD">679223000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_5ccf52e4-0aa6-44d6-8a0a-42255e6e2335"
      unitRef="U_USD">384124000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6872a8e3-52c9-489f-a218-4feeb1644241"
      unitRef="U_USD">2424000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_dc1c7b58-63df-43a8-97f9-d1b1e419a654"
      unitRef="U_USD">7077000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_e59a86b4-99cb-4edb-b7f0-7416cae4d4cd"
      unitRef="U_USD">20767000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_7ece1c90-a5dd-44fc-bd08-714df10bb8f7"
      unitRef="U_USD">12992000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_529b3c92-9a0a-417f-bbf3-d6ca1487cbdb"
      unitRef="U_USD">11904000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_12127e48-cba2-498c-aa9c-08f297e603fb"
      unitRef="U_USD">1955000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6fee6a0e-e62c-4424-ae3c-e228a1d79059"
      unitRef="U_USD">35095000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_276787d8-3eff-4232-bc7e-bf5a502c69ed"
      unitRef="U_USD">22024000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_cb31bef9-ecf6-4283-af01-c65f57a8d71e"
      unitRef="U_USD">70014000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_cd718b82-f599-473f-91b5-1f1f6c681b0f"
      unitRef="U_USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <verv:SuccessPaymentLiability
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_3db9d4cb-c1cd-490c-9119-108248281191"
      unitRef="U_USD">2885000</verv:SuccessPaymentLiability>
    <verv:SuccessPaymentLiability
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_4a9695c0-a4c2-44b9-96ea-e5b6ab90783c"
      unitRef="U_USD">4371000</verv:SuccessPaymentLiability>
    <us-gaap:DeferredRevenueAndCreditsNoncurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6d06b2d1-be82-45e6-8732-022b0a2c111a"
      unitRef="U_USD">20014000</us-gaap:DeferredRevenueAndCreditsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_0fe2656e-75f3-4f6d-90d1-657dfe04a93b"
      unitRef="U_USD">283000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_111b4c10-edf3-419a-b527-33dc384ae144"
      unitRef="U_USD">377000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_414c6645-8db6-4a1b-bd95-a512c1247d47"
      unitRef="U_USD">128291000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_50d9933b-3d1a-4d62-ba9e-6bff97431d0f"
      unitRef="U_USD">26772000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="3"
      id="F_3d7b18a6-c8c3-4904-a15e-c2c6eecfe4b4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="3"
      id="F_8d593876-ca3e-4123-8634-da6dedb5d8cb"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_38676506-7e61-468f-9334-2b7d85864a5a"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_ab45f6db-d2ee-4efa-a319-a38c68b3cf05"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_40553e9e-ba05-4393-8912-193018c96a7b"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_615ee81e-3b14-40bc-b662-97ccf5a3010f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_a179e1b2-b86b-4b68-9fec-0c4d0cc6555e"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_89fd7564-33d9-48cf-b6dd-37e1bc63134f"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_d1efc996-a59b-467d-922b-b7b402e8acff"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_83e969f9-d91b-4b7a-b4e3-4ffdee3d1b83"
      unitRef="U_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="3"
      id="F_7292bb0d-0a30-408d-b4b0-92bae6d55ed7"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="3"
      id="F_1f277c11-f977-4241-a884-d353f9101ffe"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_202c4397-e9e6-4c97-834c-e7c8bd5c2821"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_7635ba99-b3b6-427e-8780-7a524774c0b3"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_f7da2d67-e681-4b4d-a6d9-5208efc81130"
      unitRef="U_shares">61730816</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_6f317949-b895-4b1b-91c7-ef745fef3bcc"
      unitRef="U_shares">61730816</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_1b1a17dd-7287-474a-9819-0a0f0951ff6f"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_db79e715-924e-468b-a638-7d9f26aea04c"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_e288892d-bc41-4159-9de3-5afb8bd61330"
      unitRef="U_USD">62000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_29d51bea-29c0-48c6-9941-4dbb85b119c4"
      unitRef="U_USD">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6b8135ff-04b9-4f91-a1df-02422c71faee"
      unitRef="U_USD">895801000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_d93d4f3c-4333-4693-b617-b027f4350bfe"
      unitRef="U_USD">544381000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_79f27d40-0235-4782-bdd7-c53984ebd2a5"
      unitRef="U_USD">-694000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_a21e5251-8096-4745-b9c6-cc3694a85878"
      unitRef="U_USD">-228000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_d8767003-d2e7-4310-afd9-db9700919abc"
      unitRef="U_USD">-344237000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_9d2ac2a1-2e3f-4161-9365-66d0f9e7a374"
      unitRef="U_USD">-186850000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_638ed02a-8191-4482-9f6a-af4d393b82f5"
      unitRef="U_USD">550932000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_29dee816-b3b7-4533-b35e-72d27e69e0b2"
      unitRef="U_USD">357352000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_65f9c83a-b720-4257-869f-eeb021d3b292"
      unitRef="U_USD">679223000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_9d5e8cee-b37f-4a47-ab1b-ac4b2166da2d"
      unitRef="U_USD">384124000</us-gaap:LiabilitiesAndStockholdersEquity>
    <verv:CollaborationsRevenue
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e854c35e-64d7-4a37-ab1d-ed9a41a3551e"
      unitRef="U_USD">1941000</verv:CollaborationsRevenue>
    <verv:CollaborationsRevenue
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_39328ca9-d15e-4df2-b7ba-543555df3f3c"
      unitRef="U_USD">0</verv:CollaborationsRevenue>
    <verv:CollaborationsRevenue
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_b43a995d-b680-4ad8-852b-8ebfc738af77"
      unitRef="U_USD">0</verv:CollaborationsRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e460d576-13bf-42c8-9ea3-b56d8921a117"
      unitRef="U_USD">130095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_9d6ca096-18a2-42b1-aad6-dfc0f53de6b0"
      unitRef="U_USD">68202000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_89074011-498b-47c6-a78a-b497248b9d42"
      unitRef="U_USD">35371000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_17726326-e122-41e5-846c-058882168aac"
      unitRef="U_USD">37533000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_4eb26a83-a55d-4369-a985-d87750e7008d"
      unitRef="U_USD">18865000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_6bf8583b-fa89-43bc-b4ae-f78aef2b5201"
      unitRef="U_USD">5256000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_c84d1a28-e9d5-47e6-9d90-e294c6788d19"
      unitRef="U_USD">167628000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_53b8e2e6-e54a-4577-95e7-f3260698addd"
      unitRef="U_USD">87067000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_879ede04-614d-42ba-81ae-ca2d0b97def8"
      unitRef="U_USD">40627000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_81d5c2de-502b-4f65-976b-10bc872af8bb"
      unitRef="U_USD">-165687000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_6170d16a-5b4d-40ac-bfbd-4cabcb50f125"
      unitRef="U_USD">-87067000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_5cdbd4e8-c442-4530-9809-e495af17e7a6"
      unitRef="U_USD">-40627000</us-gaap:OperatingIncomeLoss>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_857bb3c2-f492-4e81-9fb4-79d2eef4a017"
      unitRef="U_USD">0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_6192b8de-e14f-4736-8237-b38e881e1a66"
      unitRef="U_USD">0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_2907ea69-7614-4b40-a6ed-4b03ae201a72"
      unitRef="U_USD">2507000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_3a5bb4b8-9624-4f1a-8c83-24d58756891c"
      unitRef="U_USD">0</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_3353ba66-f29e-452a-8b4f-6d653f903a0c"
      unitRef="U_USD">25574000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_2fc1c215-ed56-421f-bef3-38157be95c03"
      unitRef="U_USD">5359000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_608a5bd7-0528-45f1-95e8-c69dbc21cdf0"
      unitRef="U_USD">-1486000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_fdd82c5a-bb79-46c0-b432-762ecd665000"
      unitRef="U_USD">7815000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c5aef96f-6e4c-4166-abb4-09fe8290f879"
      unitRef="U_USD">2387000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_1aaae682-4e1d-4bc7-8129-1f689c09f9eb"
      unitRef="U_USD">6867000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_da86b3c6-77cb-4888-9686-817d2ebb635e"
      unitRef="U_USD">142000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_3929f763-cf74-4027-80d1-7bce85f59e97"
      unitRef="U_USD">162000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5e5535aa-4371-4aab-9e2b-859689d53b0f"
      unitRef="U_USD">8353000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_49e9cf9d-c7d5-400e-9d89-8929d641e554"
      unitRef="U_USD">-33247000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_57cb69f4-21bd-4e02-a3a5-c715d597be7d"
      unitRef="U_USD">-5077000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_692e480f-41b9-438e-97a4-5f3fe709ebff"
      unitRef="U_USD">-157334000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_738b08b1-5139-48cf-9fe6-59653498a1db"
      unitRef="U_USD">-120314000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c4c681b9-0a38-4cb9-b765-e4251ade31fe"
      unitRef="U_USD">-45704000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_9911a604-d5d1-4929-9f96-cab7abba8ccc"
      unitRef="U_USD">53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_dbdc269a-c4d5-4cab-b8c0-19451a4439ba"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c96683b5-06b7-429d-892b-7376501c17e8"
      unitRef="U_USD">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_50036402-44e9-4157-8a4d-8b484890b0fc"
      unitRef="U_USD">-157387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c9ecf0f3-7bbb-49c9-9a36-e2324972ef79"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_ce006019-11b3-435d-b817-dcd953e04851"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_8d036191-a4d4-48af-b85a-8c816dab2c1e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_22f0db4b-486b-48b7-8cc3-c92a84dae5a5"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_972b23f0-b1c7-43e0-a4ea-7b71ceb5cdf1"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_4610ec76-8a43-4aaf-adca-f1b77594ae58"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_81e3895d-2fbd-48ad-a713-899c738e15c8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_c0abe8f7-1448-4014-bf40-554c27165798"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="0"
      id="F_b069a948-20cc-43e3-8c83-74eb57970e3b"
      unitRef="U_shares">54023653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="0"
      id="F_fc27ba8d-b642-4042-a6b9-beaae94f58ea"
      unitRef="U_shares">54023653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="0"
      id="F_3d5d4fbf-be06-48e2-a89e-77c4de11771d"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="0"
      id="F_b91c6a16-5d13-4b37-9e58-2b22ac5eee91"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="0"
      id="F_eea929e6-fe6b-47d8-bb4a-f335ac7e226a"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="0"
      id="F_fd6e8501-24cb-419f-b5fd-9a191e5c96e0"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e0d83797-f6d7-4b7a-afe1-11d059314540"
      unitRef="U_USD">-157387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_4f3f95f2-afed-4982-b4f6-b34c6d05a2fa"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_796322bf-75a7-4ba9-8709-112034254452"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_22cbcbd9-1132-44de-88f3-812a878abd40"
      unitRef="U_USD">-466000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c25263a7-5890-4e8f-9c2e-5b7873373717"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_f2b19a85-aaf6-4846-97de-2555e080689d"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_0b2da8bb-1867-4c51-a641-8717058f864b"
      unitRef="U_USD">-157853000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_e0bee16f-7650-4e14-b589-ced1e2efa6eb"
      unitRef="U_USD">-120550000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_fb3701f0-b063-4875-9ded-86b4dfb719fc"
      unitRef="U_USD">-45705000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6dce68af-09ea-451e-8aa9-bbbf481d2537"
      decimals="INF"
      id="F_a5185005-ea28-49d6-ab20-a3041c598424"
      unitRef="U_shares">51421404</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_6dce68af-09ea-451e-8aa9-bbbf481d2537"
      decimals="-3"
      id="F_5c4c84b6-bb64-44ca-9141-d82088cc6528"
      unitRef="U_USD">25480000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_0cb67e6f-2894-4db6-9521-909923920eff"
      decimals="INF"
      id="F_72d4deff-5ecd-4eba-bf49-19365d8e0178"
      unitRef="U_shares">1854438</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_0cb67e6f-2894-4db6-9521-909923920eff"
      decimals="-3"
      id="F_abf2aa3a-8d5f-4bb9-90af-f5445541db2b"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b1a6ad37-f5ef-49b3-be24-86dec915f36d"
      decimals="-3"
      id="F_0d3ef2d5-68b7-4569-a57a-06c0906a1abc"
      unitRef="U_USD">1268000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a76866af-dd3c-4049-b8fe-63fdc94162b1"
      decimals="-3"
      id="F_149dc535-762d-4807-9261-d24536feaea3"
      unitRef="U_USD">9000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_aa0bb9fe-96a8-4b16-bddc-1ab940b85d65"
      decimals="-3"
      id="F_87636f79-bec2-4555-ab63-52978c8db9c5"
      unitRef="U_USD">-20832000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_deea9644-67bd-4520-bcd2-358aa23d9d50"
      decimals="-3"
      id="F_e43aca8d-0c7a-4c7d-8ccd-54f94f145b0a"
      unitRef="U_USD">-19553000</us-gaap:StockholdersEquity>
    <verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-5"
      id="F_6206bf80-aa4c-4064-bb71-be252e1a9357"
      unitRef="U_USD">7000000.0</verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability>
    <verv:IssuanceCostsOfSeriesAConvertiblePreferredStock
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_9d500aed-e35d-404f-8404-f344a719cf91"
      unitRef="U_USD">22000</verv:IssuanceCostsOfSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock
      contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f"
      decimals="INF"
      id="F_d9f2d4f5-0b19-4bae-aeb6-842884d8f76c"
      unitRef="U_shares">49749167</verv:StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock
      contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f"
      decimals="-3"
      id="F_2e2e138c-4d6c-4e5e-94d0-57e5877ce5eb"
      unitRef="U_USD">36792000</verv:StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock>
    <verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_7b914781-cbf8-4b33-a652-e2d031a2a3f3"
      unitRef="U_USD">112000</verv:IssuanceCostsOfSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock
      contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f"
      decimals="INF"
      id="F_9c74fe62-9d78-4e9f-9c56-e5514927ba20"
      unitRef="U_shares">78348461</verv:StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock
      contextRef="C_c513a636-9c59-4d55-ad2f-c703f327678f"
      decimals="-3"
      id="F_a59ea273-34ab-4e79-9dd4-05ccd954fe88"
      unitRef="U_USD">62888000</verv:StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions
      contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495"
      decimals="INF"
      id="F_f8e0e83e-e4a0-41f1-a873-c5cc755b0de0"
      unitRef="U_shares">187867</verv:StockIssuedDuringPeriodAdditionalShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions
      contextRef="C_69a15539-dd92-45a4-b854-128562acce6a"
      decimals="-3"
      id="F_ed174823-0718-4a8a-bfab-1187bdd42cea"
      unitRef="U_USD">487000</verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_aa62c320-c389-4691-9a95-ab7ccb5238e2"
      unitRef="U_USD">487000</verv:StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495"
      decimals="INF"
      id="F_04553481-4e2d-491e-b3b6-64584f9555b9"
      unitRef="U_shares">537635</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495"
      decimals="-3"
      id="F_037c4b7c-a451-4c6e-8213-3c7091acc60f"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_51d04407-56cc-4fcb-8fc2-d5ef6d611820"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4ef51bcc-9dfc-45c1-9eee-f5566e195c5b"
      decimals="-3"
      id="F_0f10f157-19bb-4468-ac9d-f1abae661886"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_951c7c84-46d4-49d2-8feb-8413ca32f50a"
      unitRef="U_USD">-1000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_69a15539-dd92-45a4-b854-128562acce6a"
      decimals="-3"
      id="F_5241b08b-8d2b-4e16-8e70-4208226b6340"
      unitRef="U_USD">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_0ff598c8-c644-406c-853d-8458f757a1ea"
      unitRef="U_USD">850000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_8c22a27c-1726-4bbe-9663-4f3fa7321495"
      decimals="INF"
      id="F_5569f708-63f8-426a-b2f1-f317cbc96eb3"
      unitRef="U_shares">5849</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_69a15539-dd92-45a4-b854-128562acce6a"
      decimals="-3"
      id="F_cd3a51dc-0bf5-4889-8ac2-4ae63be78e2e"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_321cbd70-6d6f-4ff3-a52d-e457f5055eec"
      unitRef="U_USD">11000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="C_f0f69b44-4afb-469a-88cb-446f929e64b4"
      decimals="-3"
      id="F_713eb786-feeb-42ec-b3d3-5613dfad4531"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_918e0813-4071-4881-af46-b253c46be841"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3188091a-eb34-4e3d-9630-e21db1a73318"
      decimals="INF"
      id="F_2c1b2a1f-c87c-4956-a771-a5c6b1f361f6"
      unitRef="U_shares">179519032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3188091a-eb34-4e3d-9630-e21db1a73318"
      decimals="-3"
      id="F_ebe6a7cf-a2f5-49da-b8bf-a4ff2eca03f6"
      unitRef="U_USD">125160000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_959c970c-a6c2-451b-acea-26466d2da446"
      decimals="INF"
      id="F_fa96cf6d-bbdd-4781-92df-f65014dca3c3"
      unitRef="U_shares">2585789</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_959c970c-a6c2-451b-acea-26466d2da446"
      decimals="-3"
      id="F_54932679-2480-4b78-bd94-2d0c516a2fb2"
      unitRef="U_USD">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_dcad783b-c139-4ff0-8e9c-6423e1ed3d39"
      decimals="-3"
      id="F_bfa64a8f-f497-480e-b6d3-74842584a687"
      unitRef="U_USD">2616000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_4e91dace-0a68-4bad-a0fd-32815efdc68c"
      decimals="-3"
      id="F_a23e70aa-4a48-4cf0-925e-1d72e990b14f"
      unitRef="U_USD">8000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_eab2ba07-0259-4573-8347-1b9098fe2136"
      decimals="-3"
      id="F_ddecf8a9-12cc-4125-b4e8-e463df76d3d0"
      unitRef="U_USD">-66536000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"
      decimals="-3"
      id="F_c65dc68f-fbe2-4a49-a2cd-d294ec2921bc"
      unitRef="U_USD">-63909000</us-gaap:StockholdersEquity>
    <verv:IssuanceCostsOfSeriesBConvertiblePreferredStock
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_35031a35-0d36-4c46-acb3-2f82bbea67a3"
      unitRef="U_USD">241000</verv:IssuanceCostsOfSeriesBConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock
      contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93"
      decimals="INF"
      id="F_94694d44-ca83-4300-b06f-aa238ce08d07"
      unitRef="U_shares">77163022</verv:StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock>
    <verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock
      contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93"
      decimals="-3"
      id="F_5275c8b9-8d08-488a-9cdd-edf3f03010a4"
      unitRef="U_USD">93759000</verv:StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93"
      decimals="INF"
      id="F_dac2f3d7-ffda-42ae-abce-8fde89d57a3d"
      unitRef="U_shares">-256682054</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_cdf1c4dc-0c33-4ede-9369-8c3a6ae46c93"
      decimals="-3"
      id="F_c16bd781-a17c-4898-a062-bec440feccbc"
      unitRef="U_USD">-218919000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_976e596e-1169-479a-a8bd-78724eca2b8b"
      unitRef="U_shares">27720923</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="-3"
      id="F_a96c5449-3406-4a25-99e8-e34ebe187c36"
      unitRef="U_USD">28000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_ff659e31-b53d-4ab3-b52f-75f37bb667c6"
      unitRef="U_USD">218891000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_6e43854c-583a-4ca8-bcb1-7410bfcef3e5"
      unitRef="U_USD">218919000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <verv:IssuanceCostsOfCommonStockFromInitialPublicOffering
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_d9906afd-412a-46aa-a6fb-f5dcaaf3d771"
      unitRef="U_USD">25098000</verv:IssuanceCostsOfCommonStockFromInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_7ec262b9-4f12-42f6-9a41-798573adb005"
      unitRef="U_shares">16141157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="-3"
      id="F_803a569d-f3d2-477f-be19-b929a6efb35b"
      unitRef="U_USD">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_1454f55b-7fd6-4c26-b845-4be8f00691c1"
      unitRef="U_USD">281568000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_03634fc9-d379-4fe1-b05e-709fddd2437f"
      unitRef="U_USD">281584000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:StockIssuedDuringPeriodShareLicensorInstitutions
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_606a3517-f910-4ef8-8bf4-920de34da201"
      unitRef="U_shares">878098</verv:StockIssuedDuringPeriodShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="-3"
      id="F_ce9b4590-7e0c-4744-88a1-71c2fba7e3ae"
      unitRef="U_USD">1000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_ed04d6e0-c28a-4a5b-8068-0e70d60cebec"
      unitRef="U_USD">32489000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_b5da0a9c-0390-4590-bd7c-0740c054d7d1"
      unitRef="U_USD">32490000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_399d5473-faef-4401-8e86-6bf2a39ccbbd"
      unitRef="U_shares">537633</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_e53e2abf-72bd-4eaa-a0e0-c466fad36f02"
      unitRef="U_shares">599838</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="-3"
      id="F_c662a1d1-bcd4-474b-a570-13d29ab9201a"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_bca1ff08-bd68-4723-9deb-768ba92b508b"
      unitRef="U_USD">965000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_11ccc1e4-c211-43f1-83c3-7142a523bc6f"
      unitRef="U_USD">966000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_54e2c76b-3d3a-45a4-b191-30bd7ba3fa5e"
      decimals="INF"
      id="F_79f069c7-a403-4e20-af90-527ab0c0e5f9"
      unitRef="U_shares">48297</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_d3b62596-df38-41d3-a7a1-2ca4580d46f6"
      unitRef="U_USD">780000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5ff03cab-fc6e-498f-8ccb-86765c4c82b1"
      unitRef="U_USD">780000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_29085c5c-8572-4342-8193-f44746b659b7"
      decimals="-3"
      id="F_0b65dd60-61aa-4d45-a45c-8ce17fc34ec5"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_4c661dc4-2795-4589-a1c9-0ca0834ec84b"
      unitRef="U_USD">-236000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5c5fd496-848f-49a7-8a5f-9ba017bdecb0"
      decimals="-3"
      id="F_9223fca9-8ab0-4d54-9890-c65c5eef6d67"
      unitRef="U_USD">7072000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_1cc073ac-fc6c-4426-8b56-a0709852bc54"
      unitRef="U_USD">7072000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_966c03b1-7109-4952-a069-3bb673a98824"
      decimals="-3"
      id="F_b7f773a0-b6c7-43d4-a5bb-b2d7a40f289d"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_cc839563-44b9-4272-890e-519297563e56"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_57a4273e-e500-4784-b24f-2d7cd8c95f12"
      decimals="INF"
      id="F_84efc436-065b-4ba9-8073-291872e65a5a"
      unitRef="U_shares">48511735</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_57a4273e-e500-4784-b24f-2d7cd8c95f12"
      decimals="-3"
      id="F_184e88e1-5e78-42c6-89d5-5de91a3ed324"
      unitRef="U_USD">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_bac8d82c-d5da-4a33-90e9-09318020506e"
      decimals="-3"
      id="F_a250a535-8b85-4415-b98f-5208628a17ae"
      unitRef="U_USD">544381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d8970451-3d27-43fa-9ddd-5d84fc44e22a"
      decimals="-3"
      id="F_10452936-65ab-4f30-8dd9-f8f2e137cfd1"
      unitRef="U_USD">-228000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_17d2fd0e-b2d9-4c3d-8c72-65febc814137"
      decimals="-3"
      id="F_b5edcff7-abc8-4a4d-b137-e97d2db6ad3e"
      unitRef="U_USD">-186850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_fa5a0706-8ded-457b-bdd9-30fc017f0580"
      unitRef="U_USD">357352000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_1882a776-6648-4eaf-be5c-ac163261b87e"
      unitRef="U_shares">743638</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_2dc7409d-f23b-4dff-8f21-6e48b4e198c3"
      unitRef="U_USD">2175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_bbe1053c-bcb1-44af-a1c5-85690dcaa9dc"
      unitRef="U_USD">2175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_34b9eafd-d052-4966-9340-1eaa59806eb0"
      unitRef="U_shares">6375</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_3abdbe5b-0995-45ab-942f-5a66da60b54c"
      unitRef="U_shares">85810</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_bb3bc6c8-90e0-45ee-a058-d34413de8b18"
      unitRef="U_USD">1069000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e662193d-b859-498d-87d8-7a82a1ede38f"
      unitRef="U_USD">1069000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <verv:StockIssuedDuringPeriodShareLicensorInstitutions
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_9fddaf20-6faa-46b0-8bd1-b99b36148ce7"
      unitRef="U_shares">1519756</verv:StockIssuedDuringPeriodShareLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="-3"
      id="F_878cd9ea-506c-4fe9-be6b-284a64a40dc2"
      unitRef="U_USD">2000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_b4cd3495-3225-4d82-89d4-57087a27aa8e"
      unitRef="U_USD">39984000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:StockIssuedDuringPeriodValueLicensorInstitutions
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_cb3a4b1e-eb4f-46e8-a0f9-831e493e29c2"
      unitRef="U_USD">39986000</verv:StockIssuedDuringPeriodValueLicensorInstitutions>
    <verv:IssuanceCostsOfCommonStockFromInitialPublicOffering
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_219fea34-b95d-49da-a824-7853a843bce8"
      unitRef="U_USD">15924000</verv:IssuanceCostsOfCommonStockFromInitialPublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_ca432409-d6e3-4bb1-a621-ac55a0614cf1"
      unitRef="U_shares">9583334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="-3"
      id="F_3947ad30-084e-4add-a4d1-c8167e664a2b"
      unitRef="U_USD">10000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_87226227-d06c-4dca-a0cf-71b0ea9fa8ae"
      unitRef="U_USD">242816000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_b5f17bba-5611-4376-9283-91652c9665da"
      unitRef="U_USD">242826000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:IssuanceOfCommonStockFromAtTheMarketOffering
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-6"
      id="F_b000cfbb-f4d3-4df2-a261-0290ea106a3f"
      unitRef="U_USD">1722000000</verv:IssuanceOfCommonStockFromAtTheMarketOffering>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="INF"
      id="F_e7314891-c160-4f33-b272-913ac3fb0be9"
      unitRef="U_shares">1280168</verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_84658634-9c24-4121-9463-34ea37f01b51"
      decimals="-3"
      id="F_eb982c5a-323d-4880-a973-a9213e70ad05"
      unitRef="U_USD">1000</verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_8dc82a35-3ff8-4612-9dae-c89caa0c4e2d"
      unitRef="U_USD">42899000</verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts>
    <verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_1d13fae1-2367-4811-b655-4b0632f57f3b"
      unitRef="U_USD">42900000</verv:IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_caa34b87-6d61-41fe-980c-8d45934c3138"
      decimals="-3"
      id="F_66f09700-1691-4de0-9ac6-fd906d76f489"
      unitRef="U_USD">-466000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_f961da72-5947-4c1b-bddd-972e4f2a09cc"
      unitRef="U_USD">-466000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2eeedfd3-7d33-4efb-80ea-d4e4ac3ba722"
      decimals="-3"
      id="F_b0d7606a-7ae4-4590-ac71-7403ca6924ec"
      unitRef="U_USD">22477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_4651f551-6f3b-4e58-8d4d-6148a2e1c39b"
      unitRef="U_USD">22477000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_bec200da-6561-47c7-ada8-88c14ff8512c"
      decimals="-3"
      id="F_59d0086d-7768-40d3-9a05-f326403c6b6c"
      unitRef="U_USD">-157387000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_38fa8211-8c4c-40b9-b262-85df65062302"
      unitRef="U_USD">-157387000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_2e1ed61d-8951-4d1b-b942-435100437cc4"
      decimals="INF"
      id="F_ffedc230-2ad6-4061-83b6-d25c40926d38"
      unitRef="U_shares">61730816</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_2e1ed61d-8951-4d1b-b942-435100437cc4"
      decimals="-3"
      id="F_7a83fc28-a27d-438e-b4a1-7e817eacdff5"
      unitRef="U_USD">62000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_80a0f724-7529-472e-8067-5943bc65251c"
      decimals="-3"
      id="F_c4a2df5c-cd35-4fff-8214-62f484053026"
      unitRef="U_USD">895801000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_06dbfcce-3022-4b09-89dd-3eef6740f46e"
      decimals="-3"
      id="F_f4091fd1-c2fd-4781-905c-43d3149d1cd3"
      unitRef="U_USD">-694000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5632b0e3-72a0-490d-b288-cdfcbada6292"
      decimals="-3"
      id="F_dde9cd6b-5b35-4deb-bfeb-b386a9f09600"
      unitRef="U_USD">-344237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_f39598ad-32b0-498f-bfd6-f27732e7faec"
      unitRef="U_USD">550932000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_dad2c109-596d-49a0-8916-a063b17c8798"
      unitRef="U_USD">-157387000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_bafffd2e-0268-40cd-bc41-5c1a384cc37b"
      unitRef="U_USD">-120314000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_598406c1-04d3-4c3e-8e7a-4a3bad8a6b30"
      unitRef="U_USD">-45704000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5669de4b-3cd9-4ede-acd2-d543ac23b4b9"
      unitRef="U_USD">2804000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_eff59e1e-acc3-4f7b-9839-369ab4d56be5"
      unitRef="U_USD">1535000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c8f9a12e-d8d0-4880-b870-582d2467ac89"
      unitRef="U_USD">1328000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_2cf08f2c-b310-4ff8-a76a-e0a34073f19f"
      unitRef="U_USD">3907000</us-gaap:ProvisionForLeaseLosses>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_0b5d6291-4ce0-4911-b5ef-c6718c01c862"
      unitRef="U_USD">1842000</us-gaap:ProvisionForLeaseLosses>
    <us-gaap:ProvisionForLeaseLosses
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_caa1b79a-0927-4c15-a069-a90ff1dfbfa0"
      unitRef="U_USD">0</us-gaap:ProvisionForLeaseLosses>
    <verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_4cdf0b06-ec3e-433b-a4e6-5920c0c2a75f"
      unitRef="U_USD">-1027000</verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities>
    <verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_efa157df-dfb0-4a89-9697-1ff5191336c2"
      unitRef="U_USD">1508000</verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities>
    <verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_27623de9-c21a-41f6-a4d9-e15c953c891b"
      unitRef="U_USD">380000</verv:NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities>
    <us-gaap:ShareBasedCompensation
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_84db891d-bac2-4836-90d0-06ebf26c294c"
      unitRef="U_USD">22477000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_33570b93-e6a8-427d-9c4c-7147286680bb"
      unitRef="U_USD">7072000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_784e13bf-5508-4155-b8c2-a0b374dd5981"
      unitRef="U_USD">850000</us-gaap:ShareBasedCompensation>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_961e464a-6fb9-4118-93af-cd288cfb3541"
      unitRef="U_USD">0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_8f320521-507e-4976-ac71-0de7a634527c"
      unitRef="U_USD">-0</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfPreferredStockTrancheLiabilities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_8cbcafab-2fd2-42b7-a303-2b1640b58f40"
      unitRef="U_USD">2507000</verv:ChangeInFairValueOfPreferredStockTrancheLiabilities>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_93b1e448-d2dc-4501-a58a-365d1097c627"
      unitRef="U_USD">0</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_d00ebd0b-be29-46f3-b876-afd3d68a8b02"
      unitRef="U_USD">25574000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfAntidilutionRights
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_256e60dd-9bab-4165-b199-a6e421a76b38"
      unitRef="U_USD">5359000</verv:ChangeInFairValueOfAntidilutionRights>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_061d760d-a920-4a70-94a7-d0469355b736"
      unitRef="U_USD">-1486000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_011bafcf-f674-4da1-8b4b-85a669ec024a"
      unitRef="U_USD">7815000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <verv:ChangeInFairValueOfSuccessPaymentsLiabilities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_20c50464-7dde-43c3-aefe-0acac705c433"
      unitRef="U_USD">2387000</verv:ChangeInFairValueOfSuccessPaymentsLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e4381816-7e01-4954-8c51-f7898b67f1d1"
      unitRef="U_USD">1012000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_9ec41e7b-afc0-4448-af66-b10ac04b538a"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_04703dc3-cade-4f46-bef6-9206c53eb841"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_6e4ed932-cd8f-4cf6-ba7f-dae727a39d84"
      unitRef="U_USD">9436000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_95f27264-a487-4f78-81d6-df515823a63d"
      unitRef="U_USD">7528000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_0d06b577-ba48-4b2c-97c6-83c2a1e3081e"
      unitRef="U_USD">1582000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_132d39c5-a042-49f1-8be5-690ce9688fa0"
      unitRef="U_USD">-5216000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_1fc498ed-ceeb-425b-8cd2-d27cc72b41a9"
      unitRef="U_USD">6829000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_aebd1226-dbbb-4b2f-9375-314f5b143091"
      unitRef="U_USD">-1898000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5de46ccf-f3bc-42c3-8611-d62e63e7a467"
      unitRef="U_USD">7041000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_b48ffaf3-f495-4110-a22d-a0fc9e346dcd"
      unitRef="U_USD">5977000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_1a8a5637-6e59-41c0-8822-075dc1d9e76c"
      unitRef="U_USD">6071000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <verv:SuccessOfPaymentLiability
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_60e3bb29-a3f6-4a1b-8b31-1915453d929b"
      unitRef="U_USD">0</verv:SuccessOfPaymentLiability>
    <verv:SuccessOfPaymentLiability
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5ae27e2c-a24c-4137-a4ec-04c702aef090"
      unitRef="U_USD">6250000</verv:SuccessOfPaymentLiability>
    <verv:SuccessOfPaymentLiability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_cf47a255-a5ce-4921-8dc4-6f59eb904f0a"
      unitRef="U_USD">0</verv:SuccessOfPaymentLiability>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_6f096d18-e061-4fde-961c-7067ea1d6a07"
      unitRef="U_USD">20014000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_a5a798db-4d52-4a61-a9cf-c962092e0e0f"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_aa74b251-1fa0-48df-8005-75ac87cd3cbd"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_f24941da-d356-42bc-b15b-47996f3b4647"
      unitRef="U_USD">-3011000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_d6bb2b48-d539-4c0a-ad33-05b915db2ce6"
      unitRef="U_USD">-1940000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_6ced8a7d-f547-4ff3-83cc-2d230429420d"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_3ee7ffa4-0fc9-47c3-b2e4-7a4313e34971"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_7dbf57da-9340-4037-9e64-c63c82685825"
      unitRef="U_USD">0</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_dfb093ba-8cbe-43da-a2a6-f41c5d5121bd"
      unitRef="U_USD">51000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5ff582de-e38b-4ede-ae1a-f5179965cd7d"
      unitRef="U_USD">-122332000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_ef890573-19db-4942-8503-7da88fb82436"
      unitRef="U_USD">-77880000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_64fae1f4-79ee-4a8b-8b6c-72fb5f596a82"
      unitRef="U_USD">-35265000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_9acb560e-1b03-4033-9ef8-1dd7df39b2b0"
      unitRef="U_USD">13232000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_ccbb0a87-c552-4c9e-bd02-e29dacd80331"
      unitRef="U_USD">4359000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_b003221d-4327-459c-83f0-b764ac64365a"
      unitRef="U_USD">3424000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_8e5b0825-460f-427d-8d72-b9e600db55f5"
      unitRef="U_USD">479401000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_8423f51a-8cda-4913-b46d-3e84e29c0e18"
      unitRef="U_USD">371494000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_e6dfdf9b-cfb7-4e72-b295-54224768ab4b"
      unitRef="U_USD">98484000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_a47b3633-e2c4-459c-a61f-48bdec0a777d"
      unitRef="U_USD">336678000</verv:MaturitiesOfMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_df5e3f13-ea51-4638-b2f3-8a08301c325c"
      unitRef="U_USD">136755000</verv:MaturitiesOfMarketableSecurities>
    <verv:MaturitiesOfMarketableSecurities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_d235c0a1-d03d-48c2-830f-6ca40d915428"
      unitRef="U_USD">50781000</verv:MaturitiesOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_3f578893-df4f-4665-9590-938f8dc745c3"
      unitRef="U_USD">-155955000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_a8517180-8dd8-4727-8d45-9ed0f630e79a"
      unitRef="U_USD">-239098000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_e9493223-8b79-4733-8a7e-7d26cf8be37e"
      unitRef="U_USD">-51127000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_3e268be3-fbea-4016-b9bf-7b7d0002d879"
      unitRef="U_USD">0</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_607ce61c-b08d-4afc-927d-d9fc1787e70b"
      unitRef="U_USD">93759000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_50363257-ba11-4ef6-8aab-3ade28056b4b"
      unitRef="U_USD">92616000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_27ab7d67-b9c9-464b-ae04-073f7f7607ef"
      unitRef="U_USD">286509000</verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions>
    <verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_1aab6fb0-c394-4c97-8fcc-21a1339dd98b"
      unitRef="U_USD">285214000</verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions>
    <verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_fb95f27b-1fe2-4052-8298-82ad6864cae8"
      unitRef="U_USD">0</verv:ProceedsFromIssuanceOfCommonSharesNetOfCommissions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_80e00c95-68a6-495f-a748-cea88767b629"
      unitRef="U_USD">39986000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_511d722d-6528-4567-a787-cc2cb805d6b4"
      unitRef="U_USD">783000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_69b73bee-b2a8-4fac-b9fe-8b9b30154a46"
      unitRef="U_USD">3630000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_eb5d9e7a-993a-480b-97c6-c7de64c30729"
      unitRef="U_USD">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_78055706-9613-4b72-ac07-a54a1d82e5fd"
      unitRef="U_USD">2175000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5fb61bcb-5e21-4e97-a837-d94f075594d0"
      unitRef="U_USD">966000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_99f1e6c9-2058-48fd-8e7b-8d2e6f72f532"
      unitRef="U_USD">11000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_76859f65-f0b8-4e6f-a6f5-008b49a00b75"
      unitRef="U_USD">1069000</us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_7cbb3916-3008-4bf4-a07c-e201634a57a6"
      unitRef="U_USD">780000</us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP>
    <us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_e8ec729c-56d4-4abf-8bb4-f5cd62a308e9"
      unitRef="U_USD">0</us-gaap:EmployeeStockOwnershipPlanESOPCashContributionsToESOP>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_88324299-556e-460d-a92b-5d1a3370e2ce"
      unitRef="U_USD">328956000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_90be98a8-c876-4878-a420-9096adcb5cf3"
      unitRef="U_USD">377089000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_6146cdee-eef9-4c6a-82de-9e78fe8beaf2"
      unitRef="U_USD">92627000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_85ec9337-0bfe-4ac2-9146-9c46b2be2e8e"
      unitRef="U_USD">50669000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_12d8f849-34ef-440d-9c0e-5f296891c940"
      unitRef="U_USD">60111000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_b73c42b0-190c-4ba8-bc1d-4d68349d6abf"
      unitRef="U_USD">6235000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_4a941aaa-76d4-46ba-89f9-3c200a8253f7"
      unitRef="U_USD">69567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"
      decimals="-3"
      id="F_16191e6b-4993-4025-b2a6-20254003b222"
      unitRef="U_USD">9456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_deea9644-67bd-4520-bcd2-358aa23d9d50"
      decimals="-3"
      id="F_2e8c0797-4a01-42a1-b032-34fbfc0f5bf9"
      unitRef="U_USD">3221000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_2efae4e4-27e0-47c5-b8ee-c5dbf110efd0"
      unitRef="U_USD">120236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_4bac0285-d268-4308-bede-0b3c1d95bfcd"
      unitRef="U_USD">69567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"
      decimals="-3"
      id="F_381ed482-4369-4b1f-b5ce-babce48cb6eb"
      unitRef="U_USD">9456000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_2fbad431-4718-4ed0-923c-f3b523f22aa5"
      unitRef="U_USD">1706000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c8c46344-597a-485a-8fd4-069d1b36c2a3"
      unitRef="U_USD">503000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_ef8c748e-3203-4dae-b297-09d748524db2"
      unitRef="U_USD">86000</verv:PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_fe6cc1ac-55ff-48a9-b5a5-d2f261d1c166"
      unitRef="U_USD">0</verv:SettlementOfTrancheRightLliability>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5ddd98d9-c391-4177-b6f8-88fbb7e441ab"
      unitRef="U_USD">0</verv:SettlementOfTrancheRightLliability>
    <verv:SettlementOfTrancheRightLliability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_5b0a5dd8-22bb-49e9-9a42-d37bc0be1697"
      unitRef="U_USD">7064000</verv:SettlementOfTrancheRightLliability>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_ca49b137-f90b-4928-b2a9-8f32df1b1f75"
      unitRef="U_USD">0</verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c01121fc-30c1-486e-a0fb-f4f1a9eadf68"
      unitRef="U_USD">218919000</verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering>
    <verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_363045de-8789-47df-a00f-d345532bcc89"
      unitRef="U_USD">0</verv:TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_a00a0f59-e6ed-4939-9cf7-5ba5dc4ce844"
      unitRef="U_USD">0</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_927041a0-caab-49dd-b4a5-5a58b63a2dc6"
      unitRef="U_USD">32490000</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c5869e38-4027-41ac-8b0a-7e7c1a39396c"
      unitRef="U_USD">487000</verv:SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_cc3f7eed-61ef-4838-a529-1cbf4abd15ed"
      unitRef="U_USD">83417000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_0b6eac18-f481-40ad-bf81-30177afa26c1"
      unitRef="U_USD">809000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_d0fdb5b0-b6aa-4319-9c50-5a235cee0e34"
      unitRef="U_USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:NatureOfOperations
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_2b67ca67-636b-40c3-bb43-93129b8b12a9">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Nature of the business and basis of presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Organization&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Verve Therapeutics, Inc. (the &#x201c;Company&#x201d; or &#x201c;Verve&#x201d;) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The Company was incorporated on March 9, 2018 as Endcadia, Inc., a Delaware corporation, and began operations shortly thereafter. In January 2019, the Company amended its certificate of incorporation to change its name to Verve Therapeutics, Inc. The Company&#x2019;s principal offices are located in Boston, Massachusetts.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Liquidity and capital resources&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Since its inception, the Company has devoted its efforts principally to research and development and raising capital. The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry including, but not limited to, technical risks associated with the successful research, development and manufacturing of product candidates, development by competitors of new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Current and future programs will require significant research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. The Company expects that its cash, cash equivalents and marketable securities of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;554.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; as of December 31, 2022, will be sufficient to fund its operations and capital expenditure requirements beyond the next 12 months from the date of issuance of these financial statements. The Company will need additional financing to support its continuing operations and pursue its growth strategy. Until such time as the Company can generate significant revenue from product sales, if ever, it expects to finance its operations through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. The Company may be unable to raise additional funds or enter into such other agreements when needed on favorable terms or at all. The inability to raise capital as and when needed could have a negative impact on the Company&#x2019;s financial condition and its ability to pursue its business strategy. The Company will need to generate significant revenue to achieve profitability, and it may never do so.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x201c;GAAP&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-5"
      id="F_dc1ef3e1-61d2-4d57-9503-1c88cd9b0dc3"
      unitRef="U_USD">554800000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_e43678ed-c59e-4abb-b295-c321a41ae90a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2. S&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ummary of significant accounting policies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;circumstances. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the Company's initial public offering ("IPO")), stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.855%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.815999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.103%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;115,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;accordance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Deferred offering costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the stock offerings as other non-current assets until the offerings were consummated. After consummation of the offerings, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2022, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.073%;"/&gt;
          &lt;td style="width:48.958%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Tranche Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities were settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 815")&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The obligation was satisfied in full upon the issuance of an aggregate of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock upon the closing of the Company's IPO in June 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Refer to Note 5, Fair value of financial instruments, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company enters into collaboration agreements which are within the scope of ASC Topic 606, "Revenue from Contracts with Customers" (&#x201c;ASC 606&#x201d;), under which the Company licenses rights to certain of the Company&#x2019;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of license rights to the Company&#x2019;s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;consideration is unconditional.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical, clinical and regulatory expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of certain equity awards. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock unit awards. The Company estimates the fair value of the Company&#x2019;s restricted stock unit awards on the date of grant using the closing price of the Company&#x2019;s common stock on that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) using the revised modified retrospective approach, which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was no impact to the Company&#x2019;s results of operations and cash flows from operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (&#x201c;ROU&#x201d;) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022, 2021 and 2020, the Company&#x2019;s only element of other &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;comprehensive loss was unrealized losses on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Segment and geographic information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; operating segment operating exclusively in the United States.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Subsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard became effective for the Company on January 1, 2023. Based on composition of the Company's investment portfolio, current market conditions, and historical credit loss activity, the Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a4b241d9-59fc-4ee3-9fde-b48f202e01fd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Principles of consolidation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The accompanying consolidated financial statements include the accounts of Verve and its wholly owned subsidiary, Verve Securities Corporation. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_d5779824-712a-4bc5-af4c-79b9c4f5053c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Use of estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses, and the disclosure of contingent assets and liabilities as of and during the reporting period. The Company bases its estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;circumstances. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair values of common stock (prior to completion of the Company's initial public offering ("IPO")), stock-based compensation, and the liabilities for antidilution rights and success payments. Actual results could differ from these estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_14c8396f-eff6-4370-848b-41a0e8b2d948">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents consist of standard checking accounts and money market account funds that invest primarily in U.S. government-backed securities and treasuries. The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. Cash equivalents are stated at cost, which is substantially equivalent to fair value.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_baeb31aa-da6d-4fb1-90ee-11d171ef0018">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted cash represents collateral provided for a letter of credit issued as a security deposit in connection with the Company&#x2019;s leases of its corporate facilities. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.855%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.815999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.103%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;115,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_22f473dd-e247-4491-ab7f-690a299cbb0e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation of the cash, cash equivalents, and restricted cash reported within the balance sheet that sum to the total of the same amounts shown in the statement of cash flows is as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:66.855%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:12.815999999999999%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:1.613%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
          &lt;td style="width:13.103%;"/&gt;
          &lt;td style="width:1.0%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;115,412&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;64,330&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,824&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,237&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120,236&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;69,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_f253885e-e5ea-4f54-8eeb-f2986d5b268f"
      unitRef="U_USD">115412000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_ef973bd0-e420-4308-bd58-3b288660dee8"
      unitRef="U_USD">64330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_4b8448fb-74e1-486a-aa96-8088968cd25f"
      unitRef="U_USD">4824000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_39594492-0036-4c4c-893a-91813a9081a9"
      unitRef="U_USD">5237000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_047760ee-a6db-473b-a5b8-69dcd638ee6f"
      unitRef="U_USD">120236000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_30b696eb-3bd4-4920-9179-b3f9dfda3661"
      unitRef="U_USD">69567000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a2b5bf73-4ba2-45cd-ab24-3beeabeb0d3f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company classifies marketable securities with a remaining maturity when purchased of greater than three months as available-for-sale. Available-for-sale securities are maintained by the Company&#x2019;s investment managers and consist of U.S. treasury bills and U.S agency securities. The Company classifies investments available to fund current operations as current assets on its consolidated balance sheets. Available-for-sale securities are carried at fair value with the unrealized gains and losses included in accumulated other comprehensive income (loss) as a component of stockholders&#x2019; equity until realized. Any premium or discount arising at purchase is amortized and/or accreted to interest income and/or expense over the life of the instrument. Realized gains and losses are determined using the specific identification method and are included in other income (expense).&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company reviews marketable securities for other-than-temporary impairment whenever the fair value of a marketable security is less than the amortized cost and evidence indicates that a marketable security&#x2019;s carrying amount is not recoverable within a reasonable period of time. Other-than-temporary impairments of investments are recognized in the consolidated statements of operations if the Company has experienced a credit loss, has the intent to sell the marketable security, or if it is more likely than not that the Company will be required to sell the marketable security before recovery of the amortized cost basis. Evidence considered in this assessment includes reasons for the impairment, compliance with the Company&#x2019;s investment policy, the severity and the duration of the impairment and changes in value subsequent to the end of the period. The Company evaluated its securities for other-than-temporary impairment and considered the decline in market value for the securities to be primarily attributable to current economic and market conditions. It is not more likely than not that the Company will be required to sell the securities, and the Company does not intend to do so prior to the recovery of the amortized cost basis. Based on this analysis, these marketable securities were not considered to be other-than-temporarily impaired as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_3699f3f7-7e68-4110-9ac3-72b320853792">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Concentrations of credit risk&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash, cash equivalents, marketable securities, and restricted cash. Periodically, the Company may maintain deposits in financial institutions in excess of government insured limits. Management believes that the Company is not exposed to significant credit risk as the Company&#x2019;s deposits are held at financial institutions that management believes to be of high credit quality, and the Company has not experienced any losses on these deposits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company generally invests its excess capital in money market funds, U.S. treasury bills and agency securities, all of which are subject to minimal credit and market risk. The investment portfolio is maintained in&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;accordance &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;with the Company&#x2019;s investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <verv:DeferredOfferingCostsPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0b1dbe5f-c5b4-4fc2-810d-2b8b2d841971">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Deferred offering costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company capitalized incremental legal, professional accounting and other third-party fees that were directly associated with the stock offerings as other non-current assets until the offerings were consummated. After consummation of the offerings, these costs were recorded in stockholders&#x2019; equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</verv:DeferredOfferingCostsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_89ccf48a-7074-4b09-91e5-1dbb472231fd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ASC Topic 820, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Fair Value Measurement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the assets or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the price that would be received to sell an asset or paid to transfer a liability, in an orderly transaction between market participants at the measurement date. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tiered value hierarchy that distinguishes between the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&#x2014;Unobservable inputs for the asset or liability (i.e. supported by little or no market activity). Level 3 inputs include management&#x2019;s own assumptions about the assumptions that market participants would use in pricing the asset or liability (including assumptions about risk).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgement. Accordingly, the degree of judgement exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;There have been no changes to the valuation methods utilized by the Company during the years ended December 31, 2022, 2021 and 2020. The Company evaluates transfers between levels at the end of each reporting period. There were no transfers of financial instruments between levels during the years ended December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_6f08e60a-898d-4ad2-bbcd-cc6ea68335d5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment are stated at cost less accumulated depreciation. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.073%;"/&gt;
          &lt;td style="width:48.958%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance are charged to expense as incurred.&lt;/span&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_eec8ab08-69af-401d-81d2-00fddb45e674">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense is recognized using the straight-line method over the estimated useful life of each asset as follows: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
        &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
         &lt;tr style="visibility:collapse;"&gt;
          &lt;td style="width:48.968%;"/&gt;
          &lt;td style="width:2.073%;"/&gt;
          &lt;td style="width:48.958%;"/&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Asset category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Estimated useful life&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment and software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Office furniture&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5 years&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
         &lt;tr style="height:10.0pt;"&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
          &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shorter of useful life or remaining lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;/tr&gt;
        &lt;/table&gt;</verv:ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7"
      id="F_e1126bb9-959b-494a-bb20-cc4dd35c1f6b">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_ac822c00-7c16-4ab3-98ac-86f18f43dbac"
      id="F_f803d9fc-c89b-4171-9428-f81f316d4012">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_2b381c95-04aa-4fba-8306-9a71bc42bac3"
      id="F_f8dbdbe0-e1e7-4cda-8820-f7ae20f948f1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_10236809-a80e-4e09-9626-2b295f8196ed"
      id="F_da8e76d5-2ece-436b-8dc0-a57b0cb91285">Shorter of useful life or remaining lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_59274c14-d6d2-4e3a-a8af-c142e34fc9d2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company evaluates its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;recognized &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. There were &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; impairment losses recognized during the years ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="INF"
      id="F_a4d707ce-7386-4004-a996-b51a6c29ad50"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="INF"
      id="F_e1f63fe4-991f-4252-b859-77ab78be2b39"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_8b1fd97e-3b5a-42e5-90c1-dd1717d1a801"
      unitRef="U_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_ad52d1f1-6349-4d93-a22d-3aec66761698">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Freestanding financial instruments and derivatives&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has identified the following financial instruments, which are recorded as liabilities in the balance sheet and separately accounted for at fair value.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Preferred Stock Tranche Liabilities&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company has determined that its obligation to issue, and the Company&#x2019;s investors&#x2019; right to purchase, additional shares of convertible Series A Preferred Stock (&#x201c;Series A Preferred&#x201d;) pursuant to subsequent closings represent a freestanding financial instrument. The freestanding preferred stock tranche liability (the &#x201c;tranche liability&#x201d;) was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss. The tranche liabilities were remeasured at each reporting period and upon the exercise or expiration of the obligation. As of December 31, 2020, all Series A Preferred closings occurred, and all preferred stock tranche liabilities were settled. Refer to Note 9, Preferred Stock tranche liability, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Pursuant to license agreements with (i) the President and Fellows of Harvard College (&#x201c;Harvard&#x201d;) and The Broad Institute, Inc. (&#x201c;Broad&#x201d;) (&#x201c;Harvard/Broad License Agreement&#x201d;) and (ii) Broad (&#x201c;Broad License Agreement&#x201d;) (see Note 8, License agreements), the following financial instruments were issued by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The antidilution rights represented the obligation to issue additional shares of common stock to Harvard and Broad following the completion of additional financings, including the Company&#x2019;s initial public offering. These antidilution rights were accounted for under ASC 815, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Derivatives and Hedging &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;("ASC 815")&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and were initially recorded at fair value with a corresponding charge to research and development expense. The liability was remeasured at each reporting period, with changes in fair value recognized in other income (expense) in the statement of operations and comprehensive loss while this instrument was outstanding. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The obligation was satisfied in full upon the issuance of an aggregate of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock upon the closing of the Company's IPO in June 2021. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Refer to Note 5, Fair value of financial instruments, for additional discussion.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company is obligated to pay to Harvard and Broad tiered success payments in the event the Company&#x2019;s average market capitalization exceeds specified thresholds ascending from a high nine digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control of the Company or a sale of the Company, the Company is required to pay in cash within a specified period following such event. Otherwise, the payments may be settled at the Company&#x2019;s option in either cash or shares of the Company&#x2019;s common stock. The success payments are accounted for under ASC 815 and were initially recorded at fair value with a corresponding charge to research and development expense. The liability is remeasured at each reporting period with all changes in value recognized in other income (expense) in the statement of operations and other comprehensive loss. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2021, certain success payment obligations were triggered, and amounts paid to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; These amounts were settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022. The Company will continue to adjust the liability for changes in fair value until the earlier of the achievement or expiration of the remaining success payment obligation. Refer to Note 5, Fair value of financial instruments, for additional discussion&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</verv:FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock>
    <verv:IssuanceOfAdditionalCommonStock
      contextRef="C_63860296-a4f0-4e1a-9241-b6d773d5b067"
      decimals="0"
      id="F_f45a659f-4d5d-4933-9187-03f463d62357"
      unitRef="U_shares">878098</verv:IssuanceOfAdditionalCommonStock>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_5533c143-e11b-4687-bab9-616ee25f12a3"
      decimals="-8"
      id="F_eda14cfc-83a2-4620-8831-f8fbe5344485"
      unitRef="U_USD">10000000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <verv:SuccessLiabilityPayment
      contextRef="C_b22cbc9c-7068-4848-a684-7dd33933fb13"
      decimals="-5"
      id="F_5d121da6-eb88-45ac-ba27-fbfbf4fc77a3"
      unitRef="U_USD">6300000</verv:SuccessLiabilityPayment>
    <us-gaap:RevenueRecognitionDeferredRevenue
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_2ba1e0f6-94bc-4e07-a16f-c261dd71cd7e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company enters into collaboration agreements which are within the scope of ASC Topic 606, "Revenue from Contracts with Customers" (&#x201c;ASC 606&#x201d;), under which the Company licenses rights to certain of the Company&#x2019;s product candidates and performs research and development services. The terms of these arrangements typically include payment of one or more of the following: non-refundable, upfront fees; reimbursement of research and development costs; development, regulatory, and commercial milestone payments; and royalties on net sales of licensed products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine the appropriate amount of revenue to be recognized for arrangements determined to be within the scope of ASC 606, the Company performs the following five steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Company only applies the five-step model to contracts when it is probable that the entity will collect consideration it is entitled to in exchange for the goods or services it transfers to the customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The promised goods or services in the Company&#x2019;s arrangements typically consist of license rights to the Company&#x2019;s intellectual property and research and development services. The Company provides options to additional items in the contracts, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the customer. The Company evaluates the customer options for material rights, or options to acquire additional goods or services for free or at a discount. If the customer options are determined to represent a material right, the material right is recognized as a separate performance obligation at the outset of the arrangement. Performance obligations are promised goods or services in a contract to transfer a distinct good or service to the customer and are considered distinct when (i) the customer can benefit from the good or service on its own or together with other readily available resources and (ii) the promised good or service is separately identifiable from other promises in the contract. In assessing whether promised goods or services are distinct, the Company considers factors such as the stage of development of the underlying intellectual property, the capabilities of the customer to develop the intellectual property on its own or whether the required expertise is readily available and whether the goods or services are integral or dependent to other goods or services in the contract.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the number of potential payments and the likelihood that the payments will be received. The Company utilizes either the most likely amount method or expected amount method to estimate the amount expected to be received based on which method best predicts the amount expected to be received. The amount of variable consideration which is included in the transaction price may be constrained and is included in the transaction price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s contracts often include development and regulatory milestone payments which are assessed under the most likely amount method and constrained if it is probable that a significant revenue reversal would occur. Milestone payments that are not within the Company&#x2019;s control or the licensee&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. At the end of each reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment. To date, the Company has not recognized any consideration related to the achievement of development, regulatory, or commercial milestone revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any consideration related to sales-based royalty revenue resulting from any of the Company&#x2019;s collaboration arrangements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company allocates the transaction price based on the estimated stand-alone selling price of each of the performance obligations. The Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company utilizes key assumptions to determine the stand-alone selling price for service obligations, which may include other comparable transactions, pricing considered in negotiating the transaction and the estimated costs. Additionally, in determining the standalone selling price for material rights, the Company utilizes comparable transactions, clinical trial success probabilities, and estimates of option exercise likelihood. Variable consideration is allocated specifically to one or more performance obligations in a contract when the terms of the variable consideration relate to the satisfaction of the performance obligation and the resulting amounts allocated are consistent with the amounts the Company would expect to receive for the satisfaction of each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The consideration allocated to each performance obligation is recognized as revenue when control is transferred for the related goods or services. For performance obligations which consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upfront payments and fees are recorded as deferred revenue upon receipt or when due until the Company performs its obligations under these arrangements. Amounts are recorded as accounts receivable when the Company&#x2019;s right to &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;consideration is unconditional.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionDeferredRevenue>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_f21ffaa4-1411-4d2b-b648-c4bed32a66e2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Research and development costs&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development costs are charged to expense as incurred. Research and development costs consist of costs incurred in performing research and development activities, including salaries and bonuses, stock-based compensation, employee benefits, facilities costs, third-party license fees related to technology with no alternative future use, laboratory supplies, depreciation, manufacturing expenses, preclinical, clinical and regulatory expenses, consulting and other contracted services. Costs for certain research and development activities are recognized based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a95d179f-67b2-4496-9e97-1fde462ca4d2">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation program allows for grants of certain equity awards. Grants are awarded to employees and non-employees, including directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Compensation-Stock Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (&#x2018;&#x2018;ASC 718&#x2019;&#x2019;). ASC 718 requires all stock-based payments to employees, non-employees and directors, to be recognized as expense in the consolidated statements of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x2018;&#x2018;Black-Scholes&#x2019;&#x2019;) for stock option grants to both employees and non-employees. The fair value of the Company&#x2019;s common stock is used to determine the fair value of restricted stock unit awards. The Company estimates the fair value of the Company&#x2019;s restricted stock unit awards on the date of grant using the closing price of the Company&#x2019;s common stock on that date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s stock-based compensation awards are subject to either service or performance-based vesting conditions. Compensation expense related to awards to employees, directors and non-employees with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Compensation expense related to awards to employees with performance-based vesting conditions is recognized over the implied service period when achievement of the performance-based milestones is deemed probable. The Company uses judgement to determine whether and, if so, how many awards are deemed probable of vesting at each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The estimation of fair value for stock-based compensation requires management to make estimates and judgments about, among other things, the estimated life of options and volatility of the Company&#x2019;s common stock. The judgments directly affect the amount of compensation expense that will be recognized.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prior to the Company's IPO in June 2021, there was no public market for its common stock. As a result, prior to the IPO, the estimated fair value of the Company's common stock was determined by its board of directors as of the date of each option grant, with input from management, considering the Company's most recently available third-party valuations of common stock and its board of directors' assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of grant. Following the Company's IPO, the fair value of its common stock is determined based on the closing price of the Company's common stock as reported on the Nasdaq Global Select Market&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_685bbf25-bfd8-4172-bf83-fc79a0c7a245">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the quarter ended September 30, 2021, the Company early adopted ASC Topic 842, &#x201c;Leases&#x201d; (&#x201c;ASC 842&#x201d;) using the revised modified retrospective approach, which uses the effective date, or January 1, 2021, as the date of initial application. As a result, prior periods are presented in accordance with the previous guidance in ASC 840. As a result of the adoption of ASC 842, the Company recorded (i) an operating lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million determined using an incremental borrowing rate as of the effective adoption date and (ii) an operating lease right-of-use asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, net of the unamortized balance of prepaid/accrued rent as of the transition date. There was no impact to the Company&#x2019;s results of operations and cash flows from operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company&#x2019;s control over the use of the identified asset(s), if applicable. If an arrangement is determined to be or contain a lease, the lease is assessed for classification as either an operating or finance lease at the lease commencement date, defined as the date on which the leased asset is made available for use by the Company, based on the economic characteristics of the lease. The lease liability is measured at the present value of future lease payments, discounted using the discount rate as of the lease commencement date. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. The Company recognizes a corresponding lease right of use (&#x201c;ROU&#x201d;) asset, initially measured as the amount of lease liability, adjusted for any initial lease costs or lease payments made before or at the commencement of the lease, and reduced by any lease incentives.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s leases consist of only operating leases. Operating leases are recognized on the balance sheet as ROU lease assets, lease liabilities current and lease liabilities non-current. Fixed rents are included in the calculation of the lease balances while certain variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_8f639dd3-36f0-4110-95b1-083a24288e33"
      decimals="-5"
      id="F_fbd807d9-48f5-4382-b5f3-750996494295"
      unitRef="U_USD">2600000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_8f639dd3-36f0-4110-95b1-083a24288e33"
      decimals="-5"
      id="F_03bab5c8-42a6-4819-8d5b-5009179f4830"
      unitRef="U_USD">2400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_7e488b7b-9fb7-413f-8070-61d35d424abe">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the Company&#x2019;s financial statements and tax returns. Deferred tax assets and liabilities are determined based upon the differences between the financial statement carrying amounts and the tax bases of existing assets and liabilities and for loss and credit carryforwards, using enacted tax rates expected to be in effect in the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if it is more likely than not that these assets may not be realized. The Company determines whether it is more likely than not that a tax position will be sustained upon examination. If it is not more likely than not that a position will be sustained, none of the benefit attributable to the position is recognized. The tax benefit to be recognized for any tax position that meets the more-likely-than-not recognition threshold is calculated as the largest amount that is more than &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% likely of being realized upon resolution of the contingency. The Company accounts for interest and penalties related to uncertain tax positions as part of its provision for income taxes.&lt;/span&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <verv:PercentageOfTaxBenefitRealized
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="2"
      id="F_c1046b2d-a183-4d9b-a77c-67fe050f73e1"
      unitRef="U_pure">0.50</verv:PercentageOfTaxBenefitRealized>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a59b9e65-c8c7-4235-9624-494499b6f187">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Comprehensive loss&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Comprehensive loss includes net loss as well as other changes in stockholders&#x2019; equity that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022, 2021 and 2020, the Company&#x2019;s only element of other &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;comprehensive loss was unrealized losses on marketable securities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_b062ae17-87a1-4e14-bb01-c837d055a161">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Net loss per share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company follows the two-class method when computing net loss per share, as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to receive dividends as if all income for the period had been distributed.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common shares assuming the dilutive effect of common stock equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s convertible preferred stock contractually entitled the holders of such shares to participate in dividends but did not contractually require the holders of such shares to participate in losses of the Company. Accordingly, in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022, 2021 and 2020&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <verv:SegmentAndGeographicInformationPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_6a9ed9e1-bcab-40be-8049-5e6a711f7642">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Segment and geographic information&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker (&#x201c;CODM&#x201d;), or decision-making group, in deciding how to allocate resources and in assessing performance. The CODM is the Company&#x2019;s Chief Executive Officer. The Company views its operations as and manages its business in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; operating segment operating exclusively in the United States.&lt;/span&gt;</verv:SegmentAndGeographicInformationPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_5ecf37c2-38df-4e0f-b4d9-3ecf025bee5b"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_4e39e517-71ef-4a47-aba3-cb2a36836a20">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Subsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company performs an evaluation of all subsequent events after the balance sheet date through the date of issuance of the consolidated financial statements to ensure appropriate disclosure of events both recognized in the consolidated financial statements and events which occurred subsequently but were not recognized in the consolidated financial statements.&lt;/span&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_1118cb64-e14c-4847-861c-9620047175ef">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Recently issued accounting pronouncements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Jumpstart Our Business Startups Act of 2012 permits an emerging growth company ("EGC") to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. As an EGC, the Company has elected to take advantage of this extended transition period for certain new accounting standards.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Financial Instruments&#x2014;Credit Losses&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; (Topic 326): Measurement of Credit Losses on Financial Instruments. The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard requires allowances to be recorded instead of reducing the amortized cost of the investment. The new standard became effective for the Company on January 1, 2023. Based on composition of the Company's investment portfolio, current market conditions, and historical credit loss activity, the Company does not expect the adoption of this standard to have a material impact on the consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_c967e66f-9a3f-4a34-9aa9-3e9b5b9f018c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3. Marketable securities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities by security type consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.989%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.601%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;440,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;439,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.989%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.601%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The remaining contractual maturities of all marketable securities were less than 18 months as of December 31, 2022 and 2021.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The unrealized losses on the Company&#x2019;s marketable securities of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;as of December 31, 2022 and 2021, respectively, were caused by interest rate increases which resulted in the decrease in market value of these securities. Because the decline in fair value is attributable to changes in interest rates and not credit quality, and because the Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity, the Company does not consider those marketable securities to be&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;other-than-temporarily &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;impaired at December 31, 2022 or 2021. None of the Company&#x2019;s marketable securities have been in a continuous unrealized loss position for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; or greater as of December 31, 2022 or 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_1257b10e-7eba-403a-a202-838b0901f7ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities by security type consisted of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.989%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.601%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,432&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;68&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;440,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;81&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;775&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;439,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.989%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.738%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.414000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.601%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.124%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.763%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amortized&lt;br/&gt;cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Gross&lt;br/&gt;unrealized&lt;br/&gt;losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,559&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;218&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The remaining contractual maturities of all marketable securities were less than 18 months as of December 31, 2022 and 2021.&lt;/span&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2"
      decimals="-3"
      id="F_c0d2203f-399a-481e-a6ac-33c7101a6264"
      unitRef="U_USD">228432000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2"
      decimals="-3"
      id="F_5004769b-46a4-4df2-913e-14ab18ad3dba"
      unitRef="U_USD">13000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2"
      decimals="-3"
      id="F_0399ab24-ac3a-40e8-9c26-da8aa6e6b539"
      unitRef="U_USD">-301000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_4b4400f2-b3fd-4809-ba30-74f51821ebc2"
      decimals="-3"
      id="F_969c4db1-1633-425e-97a4-9445eb8d3464"
      unitRef="U_USD">228144000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c"
      decimals="-3"
      id="F_b8ddb1c7-1c7f-4d9b-913a-436b4f93715b"
      unitRef="U_USD">211658000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c"
      decimals="-3"
      id="F_d23320f4-7d5d-417a-bd7b-db1dad8a1a47"
      unitRef="U_USD">68000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c"
      decimals="-3"
      id="F_1922d3a0-5de5-49b3-81f6-38ce7b9ffe57"
      unitRef="U_USD">-474000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_b1c02b0f-8db2-48c7-85d0-5f0b5774ca9c"
      decimals="-3"
      id="F_85959c45-6b72-4f01-801f-16169ae6bfad"
      unitRef="U_USD">211252000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_d468a87b-d12e-498f-bd5f-0def3d3c2f07"
      unitRef="U_USD">440090000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_c3b05824-c4af-4569-ab8e-547ff94ea9d2"
      unitRef="U_USD">81000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_8fdc89a0-4f59-48b4-a819-ed5144f8e3bf"
      unitRef="U_USD">-775000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_1db5b4b7-7fef-45bd-b1f8-23470d25faa7"
      unitRef="U_USD">439396000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e"
      decimals="-3"
      id="F_cf28c627-f3a8-47af-8987-af64ee6ae655"
      unitRef="U_USD">277559000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e"
      decimals="-3"
      id="F_812b7301-7c24-4c0c-bde4-a8fd49ca3a8d"
      unitRef="U_USD">0</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e"
      decimals="-3"
      id="F_9dd1cae9-5188-4b74-8683-d3725a493118"
      unitRef="U_USD">-218000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_9af85f91-63b3-41d0-b819-c7632790919e"
      decimals="-3"
      id="F_5208ae9a-80c8-4196-b4ff-29356483c63f"
      unitRef="U_USD">277341000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec"
      decimals="-3"
      id="F_011d38fa-5eee-4030-b2f2-16c8101683ea"
      unitRef="U_USD">18781000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec"
      decimals="-3"
      id="F_21b1f656-88b3-403c-a9ed-2f6463455ae8"
      unitRef="U_USD">0</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec"
      decimals="-3"
      id="F_6544f520-5b46-4417-b987-7294c1097125"
      unitRef="U_USD">-10000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_84d11930-e66f-4233-9020-576b7dc6f3ec"
      decimals="-3"
      id="F_9ec8852d-b5a7-4dd5-8ebc-ab7555a9442e"
      unitRef="U_USD">18771000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_f742011b-354e-4e1c-adbd-b27f24cff40f"
      unitRef="U_USD">296340000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_b9060291-3240-4597-87f1-01b78294ff50"
      unitRef="U_USD">0</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_2113f6eb-7eec-4f5c-a6a2-130d011d55e5"
      unitRef="U_USD">-228000</verv:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_85f7e11c-5876-4f63-8ed6-5b639e45e757"
      unitRef="U_USD">296112000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-5"
      id="F_2b8f4f30-8873-4d7e-886f-a6e7f5026e57"
      unitRef="U_USD">800000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-5"
      id="F_5d738990-4278-454e-a8f5-9a5570283c61"
      unitRef="U_USD">200000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_01ffdddb-e434-48cc-aec8-afae36b4fc43">P12M</verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm>
    <verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      id="F_f7b1000f-1dcd-4d2b-b4be-2eb6e75d33c2">P12M</verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0321d383-f688-4d15-8809-bc645fe6a119">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4. P&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;roperty and equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.941999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.079999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&#160;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.436%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0f83f37b-b989-42b4-b305-ef34a9c6751d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment, net, consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.941999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.079999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Lab equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;266&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;566&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;158&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23,765&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,557&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,987&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,333&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,778&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,224&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_bdcae62d-bb8e-473d-9798-be656594f6aa"
      decimals="-3"
      id="F_fe1da35a-91b0-43a3-8d26-2c98eb22f33d"
      unitRef="U_USD">20379000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_0d7d5bec-d770-4173-b7fa-5da0ea98f60b"
      decimals="-3"
      id="F_9ea92045-3590-4ad9-bbb8-174231bbd24f"
      unitRef="U_USD">8567000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a53dba14-9b85-4825-a901-caab2a81e8a6"
      decimals="-3"
      id="F_9f5aed75-5f52-4784-b157-ffdc26bbd329"
      unitRef="U_USD">266000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_1338186f-d03c-4d8a-a4c8-31af991b82fc"
      decimals="-3"
      id="F_9b20e52a-c6ce-4d9f-9c12-2acce064c27e"
      unitRef="U_USD">266000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8a7a03b0-4e2c-4c61-8591-8ea00dfc50ed"
      decimals="-3"
      id="F_f5df9103-98bc-4d54-acdc-b15ca6da65c9"
      unitRef="U_USD">2294000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8840dc16-dd94-470b-ae47-6f49752ffb5d"
      decimals="-3"
      id="F_05e77bb3-92f1-4cd9-8cc1-bf1e5b47b6e3"
      unitRef="U_USD">566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_25b472d9-741d-43a8-b055-7f86620a197c"
      decimals="-3"
      id="F_94e2bdea-0860-4e45-b6b7-1bc1230ac0e1"
      unitRef="U_USD">826000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7f3b431e-5ee8-4828-90a9-812944400c44"
      decimals="-3"
      id="F_a7423f49-d3da-4b75-a12d-5bc4e68f974e"
      unitRef="U_USD">158000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_9122738e-fe28-45a0-9a38-68a7f9ff865e"
      unitRef="U_USD">23765000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_242d5ec5-ecb1-4f40-9461-6f9975cb6085"
      unitRef="U_USD">9557000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_0931092d-8558-4411-b09d-4030158e6819"
      unitRef="U_USD">4987000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_bfc3c485-1c81-410c-8452-f668e78fba09"
      unitRef="U_USD">2333000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_00c9f150-3b8d-4959-9b58-6703c876ab3a"
      unitRef="U_USD">18778000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_1ed17e59-4107-4f98-ae47-14f976f3217e"
      unitRef="U_USD">7224000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_9be33448-1c7b-4a6e-b52d-0621decd7d75">
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:31.436%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.568%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:2.257%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:18.657%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Depreciation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,804&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,535&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock>
    <us-gaap:Depreciation
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_1fa55e03-1c1b-4dd3-888c-bf9547d3a4c3"
      unitRef="U_USD">2804000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_4d544f07-ed47-4a9f-a846-22f779089678"
      unitRef="U_USD">1535000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_f3b2aec8-255f-4b08-a30c-c5cfa4e641cf"
      unitRef="U_USD">1328000</us-gaap:Depreciation>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_5cc0f60f-91f9-4ea3-ae84-85aade2bf62c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5. f&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;air value of financial instruments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s financial instruments that are measured at fair value on a recurring basis consist of money market funds, marketable securities, and a derivative liability (success payment liability) pursuant to the Harvard/ Broad License Agreement and the Broad License Agreement. The antidilution right liability was fully settled in the year ended December 31, 2021.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.302%;"/&gt;
        &lt;td style="width:1.228%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;544,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;439,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.302%;"/&gt;
        &lt;td style="width:1.228%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;354,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash Equivalents&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;Cash equivalents of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; as of December 31, 2022 and 2021, respectively, consisted of money market funds and are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable Securities&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company measures its marketable securities at fair value on a recurring basis and classifies those instruments within Level 2 of the fair value hierarchy. Marketable securities are classified within Level 2 of the fair value hierarchy because pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Antidilution Rights&#x2014;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;This obligation was satisfied in full upon the issuance of an aggregate of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock upon the closing of the Company's IPO in June 2021. Refer to Note 5, Fair value of financial instruments, for additional discussion.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success Payment Liability&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014; The Company is obligated to pay to Harvard and Broad tiered success payments in the event its average market capitalization exceeds specified thresholds for a specified period of time ascending from a high nine-digit dollar amount to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; billion, or sale of the Company for consideration in excess of those thresholds. In the event of a change of control or a sale of the Company, the Company is required to pay success payments in cash within a specified period following such event. Otherwise, the success payments may be settled at the Company&#x2019;s option in either cash or shares of its common stock, or a combination of cash and shares of its common stock. The maximum aggregate success payments that could be payable by the Company is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million (after termination of the Broad License Agreement).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The success payments liability is stated at fair value and is considered Level 3 because its fair value measurement is based, in part, on significant inputs not observed in the market. The Company used a Monte Carlo simulation model, which models the value of the liability based on several key variables, including probability of event occurrence, timing of event occurrence, as well as the value of the Company&#x2019;s common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company remeasured the liability at fair value with increases of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; recorded to other expense for the years ended December 31, 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In September 2021, multiple success payments were triggered and amounts due to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. These amounts were settled in cash in November 2021. The Company will continue to adjust the remaining success payment liability for changes in fair value until the earlier of the achievement or expiration of the obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The primary inputs used in valuing the success payments liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020, were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.173%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Equity volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cumulative probability of triggering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At December 31, 2020 the fair value of the Company's common stock was determined by management with the assistance of an independent third-party valuation specialist using methods consistent with the AICPA Valuation Guide. The computation of equity volatility was estimated using available information about the historical volatility of stocks of similar publicly traded companies for a period matching the expected term assumption. In addition, the Company incorporated the timing and probability of future events in the calculation of liabilities. The Company applied a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% probability of termination of the Broad License Agreement at December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In February 2021, the Company provided written notice to Broad of its election to terminate the Broad License Agreement, which termination became effective in June 2021.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.061%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.793000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.196%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Antidilution&lt;br/&gt;rights&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success&lt;br/&gt;payment&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Issuance of Series A Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_27e51a39-dc0f-4188-ae31-b9bdfdfe262f">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial instruments by level within the fair value hierarchy: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.302%;"/&gt;
        &lt;td style="width:1.228%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;228,144&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;211,252&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;544,699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;439,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.302%;"/&gt;
        &lt;td style="width:1.228%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.132%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.218%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.419%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair&lt;br/&gt;value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Money market funds&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Marketable securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. treasury bills and notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;277,341&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;U.S. agency securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;18,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;354,239&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;58,127&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;296,112&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success payment liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0deae6b1-45ca-4fba-96bb-c6dc6d5add88"
      decimals="-3"
      id="F_9b837163-41c6-477a-872a-74180f165243"
      unitRef="U_USD">105303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_595a69e0-a981-426d-a6f1-79798dc73b95"
      decimals="-3"
      id="F_ea70d8ba-5467-4497-9239-7e25b5112f28"
      unitRef="U_USD">105303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1f7382e3-ab33-42f1-8d80-f3c02882b1e1"
      decimals="-3"
      id="F_25bc5f91-8b21-4e0a-ace6-ab4575acab50"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_045cb64e-47d4-4a6a-8f5f-0799d3c6d0ca"
      decimals="-3"
      id="F_e7c66b8d-1b05-4e8c-9a7a-7fd1299f285d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_37ef4e5c-ee38-4746-8f83-e39d97e60aa9"
      decimals="-3"
      id="F_498a3f85-c31c-4e14-bb93-1860201ae6fb"
      unitRef="U_USD">228144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b573d06e-feb8-4e52-95a0-9b02cf165de9"
      decimals="-3"
      id="F_65d3a9ac-d030-44e7-90a0-5730024ff460"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b2ed33c7-4d15-43a9-aa3d-221d32e3b104"
      decimals="-3"
      id="F_e73446c8-ccdd-44e1-b048-9bc324a5eb4c"
      unitRef="U_USD">228144000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_43ffe065-4842-415c-88bd-7c2bb5a6e05d"
      decimals="-3"
      id="F_5bca2d4c-9841-4061-baa8-53403299ab8b"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1bf70619-a638-4c23-8216-60415235bbb2"
      decimals="-3"
      id="F_8eb804d3-a827-4d5b-b33c-d58ca0ab8cdc"
      unitRef="U_USD">211252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_fa5f0add-d465-41c4-9cb6-bd0f9bb41f41"
      decimals="-3"
      id="F_7c93ce3b-dd6e-4df8-be8f-1e77cd702a26"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_7a8149ba-0367-4d16-9824-0138611d7cd9"
      decimals="-3"
      id="F_77696267-a3d0-4ed7-ab47-9232b5792575"
      unitRef="U_USD">211252000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ab3f67d4-0906-4241-abd4-7bdebb98d719"
      decimals="-3"
      id="F_18b513b0-719c-447c-bfb8-83295526518d"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_45b368f7-e2a1-4151-ba1c-66102b0146b4"
      unitRef="U_USD">544699000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7"
      decimals="-3"
      id="F_3e7ae860-733f-4f07-9eae-3b40a2a641ef"
      unitRef="U_USD">105303000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1a914828-67e8-495a-9b12-2c48154e0de5"
      decimals="-3"
      id="F_5021c6a2-4d94-4bc3-a274-7f72d1c90af4"
      unitRef="U_USD">439396000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461"
      decimals="-3"
      id="F_78cd3d4d-94b7-4aeb-a092-1067c09360fc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_5e543a38-cef8-457e-8d21-0bec7784e4f7"
      decimals="-3"
      id="F_5895f8db-9e1a-4f0b-a4cf-bd11cae09260"
      unitRef="U_USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_d7b83b22-0b4c-4a86-a0f7-f54ef4b0daf4"
      decimals="-3"
      id="F_a543e197-4c6e-4cf3-ac8c-fbd0c3dc1a9f"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_3fdd3360-eab0-4708-a04c-8b89365954ae"
      decimals="-3"
      id="F_b2077f7a-82f9-47b2-a0be-9bb7a84f7f8e"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_9dbed675-16ab-43ad-92de-56cb1fea30b1"
      decimals="-3"
      id="F_7f5dfe82-5927-4a18-9119-e17cc6e5b583"
      unitRef="U_USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_b654fc46-0903-45b6-9e63-a34b58f13df1"
      unitRef="U_USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_80d02e4e-eda4-4b30-8e84-19cc49c309d7"
      decimals="-3"
      id="F_f2febaf1-eda8-4ea1-ac6a-0c380f2d065c"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_1a914828-67e8-495a-9b12-2c48154e0de5"
      decimals="-3"
      id="F_94b4a385-a951-42a0-b295-4c945cc844e3"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_07ec7d65-d5fa-4a1c-9cd1-e87012cda461"
      decimals="-3"
      id="F_c2423655-f042-498a-9844-f80d70bdefe7"
      unitRef="U_USD">2885000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0ca2fc95-4cb8-4120-8d3b-72c64d65a515"
      decimals="-3"
      id="F_f6896f1a-eab3-4ff0-b256-cddda6ba7bb3"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1fa2bdd3-e60a-48e3-89d8-47c5490b909e"
      decimals="-3"
      id="F_0cf8a642-4b5b-4832-ad96-83520ba68178"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_8f2608f6-1835-45a9-8887-c4db04550843"
      decimals="-3"
      id="F_741c6c86-141e-475b-b619-6f0abd9cf1dc"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_2df5c335-7703-4efb-9c6f-ac0c13ef2ed0"
      decimals="-3"
      id="F_f31b3652-cdf9-49c4-ab15-50c49cea0f11"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_dc7fb957-db9b-4919-85c0-f2b666593c29"
      decimals="-3"
      id="F_3161836b-69a5-41bf-bbe0-265de40a0ffd"
      unitRef="U_USD">277341000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_0e2c72aa-22a4-4e86-9784-5469e1b2efbb"
      decimals="-3"
      id="F_1a48a6ab-f24b-476e-8343-f3211730cbc4"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_808142c2-b5e3-4524-9ea6-da21e029cba1"
      decimals="-3"
      id="F_010cdd80-9568-4f07-8b64-f46142683e46"
      unitRef="U_USD">277341000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3ebb779e-eadf-4f21-b115-8bc997a90a32"
      decimals="-3"
      id="F_81c9614b-2d88-4b0f-bc6b-8519e2850d7a"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_6b8656ae-4c34-40f1-ae35-56f5f8a895dc"
      decimals="-3"
      id="F_60eaeb50-c8a9-4343-9c49-427331129a0a"
      unitRef="U_USD">18771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_69ead165-eb9d-4003-9e73-6dde8148295a"
      decimals="-3"
      id="F_5d6ef1a7-8c67-4824-b6a0-f18ae6df158f"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_9e4fa60e-e2a1-48fa-9006-8da2fef90e88"
      decimals="-3"
      id="F_8d28d841-f668-45db-b3d0-2811c90a7982"
      unitRef="U_USD">18771000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_87908575-032d-4129-a33d-db396e918336"
      decimals="-3"
      id="F_8b82acb9-0c36-4ff8-b15d-86fc74373528"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_770636b5-8ced-4a2b-83df-e3dbd42a4c24"
      unitRef="U_USD">354239000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5"
      decimals="-3"
      id="F_92b96805-d483-43cc-88a2-1d19d6aecffe"
      unitRef="U_USD">58127000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_24f24102-d3be-4e87-98e7-0dfd0698620a"
      decimals="-3"
      id="F_c12af2fd-daff-44a4-a027-318dea527b2b"
      unitRef="U_USD">296112000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47"
      decimals="-3"
      id="F_a621d1b0-25f5-4664-ac66-bc037f00d0f6"
      unitRef="U_USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd"
      decimals="-3"
      id="F_19aa62cc-8436-4221-a9d1-db5e4041713e"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_9e463725-1023-4ed8-9f1a-3d4cf8b31389"
      decimals="-3"
      id="F_dd423e60-5861-4583-87fd-c52a267dd08f"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_e3e444f8-82bf-4a8e-a308-5343180b3425"
      decimals="-3"
      id="F_cb83e825-5cbb-4aea-9a98-d30c480fc281"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_727f645b-7b13-42e1-8111-8ed8a5b4c112"
      decimals="-3"
      id="F_76ece1f3-a591-4a1e-aa1f-982715e99c86"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_df7e6e2a-b8f1-4366-b732-775732d92b76"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_ac9fb557-bcbb-4618-9bab-dd2c8b86d5f5"
      decimals="-3"
      id="F_df077667-b880-45cc-a32a-117390aeb214"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_24f24102-d3be-4e87-98e7-0dfd0698620a"
      decimals="-3"
      id="F_ed24c70a-5fab-45f2-b009-a2352af4b236"
      unitRef="U_USD">0</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:FinancialLiabilitiesFairValueDisclosure
      contextRef="C_49ef605b-f2ea-49cd-8c5b-910c6cb13f47"
      decimals="-3"
      id="F_e3341aa5-f80b-4269-aff8-be50767fce99"
      unitRef="U_USD">4371000</us-gaap:FinancialLiabilitiesFairValueDisclosure>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-5"
      id="F_52843c5e-485c-447d-a537-77cc6beda7c6"
      unitRef="U_USD">105300000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-5"
      id="F_b1e3be7e-12c3-4007-b558-3c9cabd20d96"
      unitRef="U_USD">58100000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_549dd0a2-a1f7-47be-962d-821373cb96d0"
      decimals="0"
      id="F_030be572-0c3e-4185-9d6e-5f6e549e6519"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_6c1812ca-014b-4804-9c67-8987654bfa75"
      decimals="-8"
      id="F_e416d487-2865-46a4-8897-159a72a346b9"
      unitRef="U_USD">10000000000.0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_645da17b-a2fa-4382-926c-98c8f1d57914"
      decimals="-5"
      id="F_f9fce782-8914-421a-bbf3-31af8cbb8e24"
      unitRef="U_USD">31300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <verv:SuccessPaymentLiabilityPayable
      contextRef="C_1bf4fef6-d58f-4313-8771-beb6b446dd32"
      decimals="-5"
      id="F_95712f54-898b-4a1b-be09-ea00c3a23455"
      unitRef="U_USD">1500000</verv:SuccessPaymentLiabilityPayable>
    <verv:SuccessPaymentLiabilityPayable
      contextRef="C_10db78b5-9531-4269-b673-ed6a44209efb"
      decimals="-5"
      id="F_cb08d904-2a65-4ffa-ba1d-76d994cec09d"
      unitRef="U_USD">7800000</verv:SuccessPaymentLiabilityPayable>
    <verv:SuccessPaymentLiabilityPayable
      contextRef="C_a8c752a7-a423-48c6-a1b6-94dbe8e1f488"
      decimals="-5"
      id="F_741bb4ff-6724-44d5-9bd4-2f61ed31900d"
      unitRef="U_USD">2400000</verv:SuccessPaymentLiabilityPayable>
    <verv:SuccessPaymentLiabilityCurrent
      contextRef="C_d8289e27-62a6-4835-8e99-588f8ef3162f"
      decimals="-5"
      id="F_e66db3cf-8399-423a-b2f5-abd65cd0b853"
      unitRef="U_USD">6300000</verv:SuccessPaymentLiabilityCurrent>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_1fba3920-306b-4863-b9d7-0693d1a9ae36">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The primary inputs used in valuing the success payments liability associated with the Company&#x2019;s realization of a certain valuation threshold through either a sale of the Company&#x2019;s preferred stock, an initial public offering, or a company sale at &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, 2021 and 2020, were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.173%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.356%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.919%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Fair value of common stock (per share)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.35&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36.87&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Equity volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cumulative probability of triggering event&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;n/a&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.50&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="2"
      id="F_8e8ccf3a-b750-4a5d-b1aa-84d5d1464dc9"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.35</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="2"
      id="F_c87da60c-81d4-4f5c-ad3b-5f005da3023c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.87</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueOfCommonStockPerShare
      contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"
      decimals="2"
      id="F_d46da72a-83d1-4884-bf4c-b9f0a31bb127"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">8.24</verv:FairValueOfCommonStockPerShare>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_6df26867-2d6b-46b4-b508-092bafb9230e"
      decimals="2"
      id="F_d73ec22f-9590-4b9d-b57c-41afc8b2c1f8"
      unitRef="U_pure">0.84</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_199a8315-5928-47de-86f7-85c75d05000c"
      decimals="2"
      id="F_9572fb3d-289f-439e-9bad-520aed09b1eb"
      unitRef="U_pure">0.77</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:FairValueAssumptionOfEquityVolatilityRate
      contextRef="C_7c63f0f3-4bd5-489e-af2c-513202741f0b"
      decimals="2"
      id="F_19434ca7-2ce2-46ef-9eab-6ad0ce4dd23d"
      unitRef="U_pure">1.05</verv:FairValueAssumptionOfEquityVolatilityRate>
    <verv:CumulativeProbabilityOfTriggeringEvent
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_27a0e8fa-6a6a-4a9a-a460-6079a31b753d"
      unitRef="U_pure">0.70</verv:CumulativeProbabilityOfTriggeringEvent>
    <verv:FairValueAssumptionsExpectedTerm1
      contextRef="C_5ac36620-71e8-4db8-856c-7631ba94d156"
      id="F_964d5134-b2df-448f-9d72-60816486c0c6">P0Y6M</verv:FairValueAssumptionsExpectedTerm1>
    <verv:FairValueInputsProbabilityOfTermination
      contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f"
      decimals="2"
      id="F_b20436c0-352e-4016-8408-9b88b6504c14"
      unitRef="U_pure">0.90</verv:FairValueInputsProbabilityOfTermination>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_6d5932fc-b2c9-400d-9132-96213aecfb88">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The reconciliation of changes in the fair value of financial instruments based on Level 3 inputs were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.061%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.793000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.378%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.804%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.39%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.196%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Antidilution&lt;br/&gt;rights&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success&lt;br/&gt;payment&lt;br/&gt;liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,916&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,806&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Issuance of Series A Preferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Issuance of common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,574&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,389&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,371&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,885&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_eca01a0b-4203-4974-86fd-df6598a8bcb7"
      decimals="-3"
      id="F_dd7d88bf-7ead-4f3b-b537-9fac13cf474b"
      unitRef="U_USD">6916000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_69bde097-9b90-4143-bf28-ce208cea2c64"
      decimals="-3"
      id="F_58b18aeb-40ed-4016-83f9-d3ff0cf7d7bd"
      unitRef="U_USD">2806000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012"
      decimals="-3"
      id="F_7fabdca3-3f76-4b67-8b55-d58f8654f018"
      unitRef="U_USD">9722000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f"
      decimals="-3"
      id="F_14601ad6-7bf3-41d2-babb-f0345205b5af"
      unitRef="U_USD">32490000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72"
      decimals="-3"
      id="F_5f6af83e-f3f3-47f5-8164-fe675e28a162"
      unitRef="U_USD">0</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_55867969-ed42-4226-a512-15e67ebcb5f6"
      unitRef="U_USD">32490000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f"
      decimals="-3"
      id="F_913aa5a7-42ed-4d78-84dc-60bb3ac1fe4e"
      unitRef="U_USD">-0</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72"
      decimals="-3"
      id="F_cd4cdd6f-9023-42ab-8e0a-deee8a3f2f53"
      unitRef="U_USD">6250000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <verv:CommonStockIssuedDuringPeriodValueNewIssues
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_ea34e681-f9bd-4239-87f6-3c073303ad38"
      unitRef="U_USD">-6250000</verv:CommonStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_d5267666-4c65-44f3-9936-fcf70ee31d7f"
      decimals="-3"
      id="F_fc6e9847-86ce-4bec-828f-00a7030befb9"
      unitRef="U_USD">25574000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_70c6c44c-62b4-4951-beb7-990103810b72"
      decimals="-3"
      id="F_e90a82ef-503b-4a23-97f9-a141670f0341"
      unitRef="U_USD">7815000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_cc21fcba-459d-443b-bf8f-e4159e47145d"
      unitRef="U_USD">33389000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_24f6e06a-2bf4-411d-b931-999829f73aa4"
      decimals="-3"
      id="F_7bcbb35c-1b7e-4e96-b8b8-dfa2cd964c0d"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_89ebc076-e2cf-451b-b68d-a1e6c63264cd"
      decimals="-3"
      id="F_4080fa68-bb03-401a-846e-4b3ef04b46b5"
      unitRef="U_USD">4371000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_f78e9abc-a529-457d-a1e8-39d1c36a5362"
      unitRef="U_USD">4371000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_1235d3e0-b5c0-47c5-9f20-b1afa841a242"
      decimals="-3"
      id="F_80034555-f040-4401-b8ea-eb974ac489c8"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_2c9c2b5b-d0e5-4156-b918-deac7e15a723"
      decimals="-3"
      id="F_9291e721-0507-42dc-8a6d-e670642f8ab8"
      unitRef="U_USD">1486000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_39ec6d80-80d4-43f4-bfbc-0b2907c959fc"
      unitRef="U_USD">1486000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_e3fcf3c5-2b24-43ee-a2b3-55105e54c465"
      decimals="-3"
      id="F_b6aa82e9-e1bb-46c9-9d73-2e808424e8c9"
      unitRef="U_USD">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_5e543a38-cef8-457e-8d21-0bec7784e4f7"
      decimals="-3"
      id="F_d5153d4f-9d20-48fa-874f-fdedd300a01e"
      unitRef="U_USD">2885000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_a5899e66-df41-4ef1-ac9d-60306bdb5bc6"
      unitRef="U_USD">2885000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a5617269-c4fa-4ef4-b077-1cee42841885">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.851%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.105%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;License and milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_94286fa0-3890-4112-b3cc-3e176d0cfe1f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.851%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.818%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.613%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.105%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Employee compensation and related benefits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,124&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued external research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,919&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,041&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Professional fees&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,193&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;License and milestone payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;310&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;792&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,767&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,992&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_c2a0885c-2fba-49a3-8d7e-b33053afd2d0"
      unitRef="U_USD">9124000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_1af9c2c0-ce9e-4ba5-8d0f-3ada1c761f59"
      unitRef="U_USD">6050000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <verv:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_dea098f1-4af0-4a4b-9df4-e1e011a0c49f"
      unitRef="U_USD">8919000</verv:AccruedExternalResearchAndDevelopmentExpenses>
    <verv:AccruedExternalResearchAndDevelopmentExpenses
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_580e0786-9ae9-4711-904d-9fe6398e03e9"
      unitRef="U_USD">5041000</verv:AccruedExternalResearchAndDevelopmentExpenses>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_d23d902e-6641-43dc-ac18-9873e77f6b0c"
      unitRef="U_USD">1193000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_f4080458-c94e-4fcb-bb64-b5466fff0fd4"
      unitRef="U_USD">1109000</us-gaap:AccruedProfessionalFeesCurrent>
    <verv:LicenseAndMilestonePayments
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_4fce9de4-79b7-41b9-839c-907a327ac5de"
      unitRef="U_USD">310000</verv:LicenseAndMilestonePayments>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_98d8cd9c-7512-417e-9573-ce559742af74"
      unitRef="U_USD">1221000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_0f89f66d-067b-4154-9015-2e07de6a9418"
      unitRef="U_USD">792000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_3f26c351-8b72-4679-969c-c9dc22a31c29"
      unitRef="U_USD">20767000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_029093c0-8805-46da-b167-c7f5fafc1dec"
      unitRef="U_USD">12992000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_19bfb865-65a1-4923-a7ca-f0581e73ae55">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Leases&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s operating lease activity is comprised of non-cancelable facility leases for office and laboratory space in Boston, Massachusetts.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has also entered into multiple contract research and contract manufacturing service agreements with third parties which contain embedded leases within the scope of ASC 842. The embedded leases are considered short term leases, as the contractual terms are twelve months or less. Accordingly, no lease liability or ROU asset has been recorded.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The components of operating lease cost were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;"/&gt;
        &lt;td style="width:1.635%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Short term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;"/&gt;
        &lt;td style="width:1.635%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurements of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating cash flows related to operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022, the Company&#x2019;s operating leases were measured using a weighted-average incremental borrowing rate &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.89&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% over a weighted-average remaining lease term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;On August 19, 2021, the Company entered into a lease agreement with ARE-MA Region No. 87 Tenant, LLC, a Delaware limited liability company (the &#x201c;Landlord&#x201d;), pursuant to which the Company leased approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;104,933&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; square feet of office and laboratory space located at 201 Brookline Avenue, Boston, Massachusetts (the &#x201c;Boston Lease&#x201d;), further amended in January 2022 to include an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;249&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; square feet, for a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;105,182&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; square feet (the &#x201c;Premises&#x201d;). In June 2022, the Company entered into a second amendment to specify separate target commencement dates for certain areas of the Premises.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Premises were first made available to the Company in August 2022. Upon commencement of the lease, the Company recorded an operating lease ROU asset of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;91.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and a total lease liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;80.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s obligation for the payment of base rent for the Premises began in January 2023 (the &#x201c;Rent Commencement Date&#x201d;). Base rent is initially $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million per month, and will increase by approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% per annum.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Boston Lease has a term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years, measured from the Rent Commencement Date. The Company has the option to extend the term of the Boston Lease for a period of an additional &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Under the terms of the Boston Lease, the Landlord made $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in certain tenant improvements to the Premises to suit the Company&#x2019;s use (the &#x201c;Tenant Improvement Allowance&#x201d;), which amount is included in the base rent set forth in the Boston Lease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In connection with its entry into the Boston Lease and as a security deposit, the Company has provided the Landlord a letter of credit in the amount of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which may be reduced to approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million on the expiration of the 36-month anniversary of the Rent Commencement Date so long as there are, and have been, no defaults by the Company under the terms of the Boston Lease. The Company also paid a deposit in the amount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, which is equal to the first month of base rent. The Landlord has the right to terminate th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;e Boston Lease upon customary events of default.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In July 2022 the Company notified its landlord under its prior lease of its intent to terminate that lease prior to the expiration of the term lease. As of December 31, 2022, there was no remaining ROU and lease liability for the prior lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2021, the Company entered into a sublease for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,931&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; square feet of office and laboratory space in Cambridge, Massachusetts. The sublease commenced in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and has an initial noncancelable term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12 months&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Therefore, this sublease is treated as a short-term lease. The total fixed lease payments over the sublease term were approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and the Company was also required to pay its proportional share of operating expenses.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum commitments under non-cancellable leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.936%;"/&gt;
        &lt;td style="width:1.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.143%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;62,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;119,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;81,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_fb7534bf-e1af-4a84-9412-454503f099a5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The components of operating lease cost were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;"/&gt;
        &lt;td style="width:1.635%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Variable lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,601&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Short term lease costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;698&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,278&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4,948&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5be36d59-e922-44b5-8bc9-4839e8d70aed"
      unitRef="U_USD">5946000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_f14955c0-1616-43a8-9cd5-dd3907ff86b0"
      unitRef="U_USD">1923000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_ceded3dc-6afa-4f63-a956-7c3a5972ed36"
      unitRef="U_USD">1601000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_51aebbf6-53bb-4d23-a034-39b7be682b47"
      unitRef="U_USD">747000</us-gaap:VariableLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_1d9e1db0-bfbb-47b9-9503-5c5f49a981ae"
      unitRef="U_USD">698000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_cc25e3e4-3232-467d-8007-0318919a64ae"
      unitRef="U_USD">2278000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_2b3fa915-ddbe-45e2-b050-e808cd6f95e7"
      unitRef="U_USD">8245000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_ac2524e8-3851-46ce-b518-ba4e6d9227a5"
      unitRef="U_USD">4948000</us-gaap:LeaseCost>
    <verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_14d8a440-bdb2-4b0c-85e8-c5492ceea4a8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Supplemental cash flow information related to operating leases was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.4%;"/&gt;
        &lt;td style="width:1.635%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.477%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.489%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Cash paid for amounts included in the measurements of lease liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Operating cash flows related to operating leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_13716d9c-134c-47b8-b491-2d6b950e354a"
      unitRef="U_USD">5050000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_3670a76f-f422-4c97-b052-5dd4a3bdde30"
      unitRef="U_USD">2021000</us-gaap:OperatingLeasePayments>
    <verv:LesseeOperatingLeaseIncrementalBorrowingRate
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="4"
      id="F_82810f5b-da45-47bf-886c-d8eebcac21a5"
      unitRef="U_pure">0.0789</verv:LesseeOperatingLeaseIncrementalBorrowingRate>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      id="F_23aa5bdb-d623-44dc-9dfb-f54aad354bdb">P10Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea"
      decimals="INF"
      id="F_638ce54d-df86-4aae-8edf-0a9e6a3598b6"
      unitRef="U_sqft">104933</verv:LesseeOperatingLeaseArea>
    <verv:AdditionalLesseeOperatingLeaseArea
      contextRef="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8"
      decimals="0"
      id="F_368c83c0-1e7c-44ad-9f6a-778c875555ba"
      unitRef="U_sqft">249</verv:AdditionalLesseeOperatingLeaseArea>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_4f22d3c8-4f36-4861-92dc-ea9676a09aa8"
      decimals="0"
      id="F_af8c6c28-b85f-4c57-8400-c8d37bad0fd4"
      unitRef="U_sqft">105182</verv:LesseeOperatingLeaseArea>
    <verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset
      contextRef="C_70871dfe-f33d-4493-9391-2c839d284371"
      decimals="-5"
      id="F_e69f5c29-c4ea-4f2d-95d2-c0ed80d25129"
      unitRef="U_USD">91800000</verv:IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="C_70871dfe-f33d-4493-9391-2c839d284371"
      decimals="-5"
      id="F_ee12db91-cd93-4c25-8c94-6a0c34bb4d26"
      unitRef="U_USD">80800000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:PaymentsForRent
      contextRef="C_79adf0ca-6cf4-4e27-a49b-9bf797059526"
      decimals="-5"
      id="F_d89c742a-5631-4f28-a9c0-783846f95efe"
      unitRef="U_USD">800000</us-gaap:PaymentsForRent>
    <verv:IncreaseDecreaseInRent
      contextRef="C_79adf0ca-6cf4-4e27-a49b-9bf797059526"
      decimals="2"
      id="F_a3acb574-c85f-4da7-9aa6-49bb859464d4"
      unitRef="U_pure">0.03</verv:IncreaseDecreaseInRent>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1
      contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea"
      id="F_f0a34839-3af8-4bc7-a0ea-910fd9fb7dc7">P10Y</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend
      contextRef="C_cbef945b-b67d-4d13-994e-026951a49f6f"
      id="F_d44440a6-eb87-434e-b1e9-286bf266dd9e">five years</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend>
    <verv:TenantImprovementsAllowance
      contextRef="C_66ae070f-26c2-44ff-92ab-c5483d69abea"
      decimals="-5"
      id="F_a0a4639f-fd0d-48a1-b48d-2e282e115c4a"
      unitRef="U_USD">21000000.0</verv:TenantImprovementsAllowance>
    <us-gaap:ShortTermBorrowings
      contextRef="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e"
      decimals="-5"
      id="F_f6777a3c-7924-4e1d-9fc4-ed372df2ff22"
      unitRef="U_USD">4800000</us-gaap:ShortTermBorrowings>
    <verv:ShortTermBorrowingsReducedValue
      contextRef="C_4de1da01-6e8e-458b-bbae-54c3f8cba18e"
      decimals="-5"
      id="F_43cb707a-8537-4bac-a77b-d858a510ff47"
      unitRef="U_USD">3500000</verv:ShortTermBorrowingsReducedValue>
    <us-gaap:PrepaidRent
      contextRef="C_d159b9f9-0a0b-4be3-8ded-15481d15c220"
      decimals="-5"
      id="F_3362e8ab-df17-4eeb-bd2f-8879e9e2e81e"
      unitRef="U_USD">800000</us-gaap:PrepaidRent>
    <verv:LesseeOperatingLeaseArea
      contextRef="C_c8436e03-c1f0-4e91-a1b2-e9f92451d6ed"
      decimals="0"
      id="F_ace36a61-8e8b-48e8-9e5b-634a25a6cbc8"
      unitRef="U_sqft">11931</verv:LesseeOperatingLeaseArea>
    <verv:LeaseCommencementDate
      contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165"
      id="F_1bc8cb4f-7281-4c5f-acd2-a28d014f206c">2021-12</verv:LeaseCommencementDate>
    <verv:LeaseNoncancelableTerm
      contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165"
      id="F_3b48d262-581b-4327-9f26-d206b7e38221">P12M</verv:LeaseNoncancelableTerm>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_2e1e720d-1d97-4f90-afd3-bbc0575e9165"
      id="F_81100b91-937b-47bb-946b-74bb1570b0ed">The Company had the option to extend the sublease for one extension term of three months by written notice not less than six months prior to the expiration of the sublease term. The Company did not exercise this option.</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:OperatingLeasePayments
      contextRef="C_c0f7b69c-0978-4971-a704-73743e494290"
      decimals="-5"
      id="F_47c05f77-f004-4450-a44e-28b124ae15a9"
      unitRef="U_USD">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_9a693a25-3523-40da-a497-a30ec67ba7dc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Future minimum commitments under non-cancellable leases as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 were as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:79.936%;"/&gt;
        &lt;td style="width:1.922%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:16.143%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Years ending December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,306&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,563&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10,868&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,183&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,506&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;62,736&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;119,162&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;37,245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;81,917&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_aebf1b71-8d3d-463d-8262-e78f38c532f7"
      unitRef="U_USD">12306000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_a503ecbc-bddd-48af-8ab5-2011a8fe8eee"
      unitRef="U_USD">10563000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_75ba1621-bd60-4d58-99cf-6c9997933d18"
      unitRef="U_USD">10868000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_1f986db2-4a49-4f4c-bb92-25d9d7f12b6f"
      unitRef="U_USD">11183000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_055b9760-6681-4787-9f1c-2755492f5b90"
      unitRef="U_USD">11506000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_0ae794b7-6057-4030-84ee-1924a2e09b77"
      unitRef="U_USD">62736000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6533c169-8735-4ba8-bf46-53ae8c3b5aa6"
      unitRef="U_USD">119162000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_843c8db3-a9e9-4db8-bff5-5f9358c92a5e"
      unitRef="U_USD">37245000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_bb0b6029-1f7f-41f2-9281-8d474fc83769"
      unitRef="U_USD">81917000</us-gaap:OperatingLeaseLiability>
    <verv:LicenseAgreementDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_81bc5bc4-8f9b-4a90-a702-d08dbc57322d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; License agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Harvard/Broad license agreement and Broad license agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement (the &#x201c;license agreements&#x201d;) for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. The Company agreed to use commercially reasonable efforts to develop licensed products in accordance with the development plans, to introduce any licensed products that gain regulatory approval into the commercial market, to market licensed products that have gained regulatory approval following such introduction into the market, and to make licensed products that have gained regulatory approval reasonably available to the public. The term of the agreements will continue until the expiration of the last to expire valid claim. The Company may terminate either of the license&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;agreements without cause upon four months&#x2019; prior written notice to Harvard and Broad, unless terminated earlier. In February 2021, the Company provided written notice to Broad of its intent to terminate the Broad License Agreement, which termination was effective in June 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As partial consideration for the rights granted under the Harvard/ Broad License Agreement and Broad License Agreement, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in non-refundable upfront license fees and also issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. Additional consideration under the license agreements is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Antidilution Rights&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The initial shares of common stock issued to Harvard and Broad were subject to antidilution provisions. The antidilution rights associated with the Company achieving a defined aggregate level of preferred stock financing were partially satisfied in 2019 and fully satisfied in 2020, which settlement amounts totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, respectively, and which amounts were settled through issuances of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;121,411&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;187,867&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock, respectively. The remaining antidilution rights obligation was fully satisfied in June 2021 upon the Company&#x2019;s IPO. The settlement amount totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and was settled through issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Success Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company is required to make success payments under the license agreements as further described in Note 5, Fair&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;value of financial instruments. In September 2021, certain success payments were triggered and amounts due to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. These amounts were settled in cash in November 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Indemnification agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, contract research organizations, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and its executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. The Company has not incurred any material costs as a result of such indemnifications and is not currently aware of any indemnification claims.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other Payments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;The Company agreed to pay an annual license maintenance fee ranging from low-to-mid five figures to low six figures,&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;depending on the particular calendar year, for each of the license agreements. The Company is responsible for the payment of certain patent prosecution and maintenance costs incurred by Harvard and Broad related to licensed patents. To the extent achieved, the Company is obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;46.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;108&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in development and sales-based milestones, respectively. In 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the first milestone was triggered and amounts due to Harvard and Broad totaled $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. These amounts remain payable as of December 31, 2022 and will be settled in cash. If the Company undergoes a change of control during the term of the license agreements, then certain of the milestone payments would be increased by a mid-double-digit percentage. To the extent there are sales of a licensed product, the Company is required to pay low single digit royalties on net sales, for each of the license agreements. The Company is entitled to certain reductions and offsets on these royalties with respect to a licensed product in a given country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Beam license agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In April 2019, the Company and Beam Therapeutics, Inc. (&#x201c;Beam&#x201d;) entered into a collaboration and license agreement. Pursuant to the Beam Agreement, the Company received an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology, gene editing, and delivery technologies to develop, make, use, offer for sale, sell and import base editing products and nuclease products using Beam&#x2019;s CRISPR associated protein 12b, or Cas12b technology, in each case, directed to any of four initial gene targets, including the PCSK9 and ANGPTL3 genes, that are associated with an increased risk of coronary diseases. In addition, the Company granted Beam an exclusive, worldwide, sublicensable license under certain of its delivery technology to develop, manufacture, sell and import product candidates and products, except for base editor products licensed to Verve.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Both parties may conduct certain activities in accordance with an agreed-upon research and/or development plan. Following the dosing of a final patient in a Phase 1b clinical trial of a given licensed product for the initial gene targe&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ts, Beam has the right to opt in to share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share profits and expenses of commercializing such licensed&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;product &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;in the United States on a 50/50 basis. If Beam exercises its opt-in right for a given licensed product for the initial gene targets, which we refer to following such opt-in as a collaboration product, it will be obligated to pay for a specified percentage of the development and commercialization costs of such collaboration product and will have the right to receive a specified percentage of the profits from any sales of such collaboration product. The term of the Beam Agreement continues until the last to expire of any royalty term for any product. The Company has the right to terminate the Beam Agreement as to any licensed product, but not for any collaboration product, by delivering a 90-day termination notice to Beam, provided that Beam has elected not to exercise its opt-in right or the period to exercise such opt-in right has expired.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company is responsible for all costs and expenses incurred in the conduct of activities under the research plan, any development plan and any costs and expenses for the development of a licensed product for which Beam has not elected to opt-in.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As partial consideration for the license rights granted by Beam under the Beam Agreement, the Company paid a one-time, nonrefundable fee through issuing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;276,075&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock with a fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. To the extent achieved, for each licensed product, the Company is also obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in development and regulatory-based milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in sales-based milestones. To the extent there are sales&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; of a licensed product, the Company is &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;required to pay low-to-mid single digit royalties on net sales. To the extent achieved, for each collaboration product outside of the United States, the Company is obligated to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in development and regulatory-based milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in sales-based milestones. To the extent there are ex-U.S. sales of a collaboration product, the Company is required to pay low-to-mid single digit royalties on net sales. Due to the submission of the Company's clinical trial application in New Zealand, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million was triggered in 2022 and subsequently paid by the Company to Beam. Additionally, due to the first patient dosing with VERVE-101 in a clinical trial, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million was triggered and paid by the Company to Beam.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The parties have also promised that in further consideration for the licenses granted under the parties&#x2019; respective delivery technologies, each party will pay to the other party development-based milestone payments up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for each delivery technology product of such paying party to achieve the corresponding milestone event. The triggering of these milestone payments was not considered probable as of the transaction date, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; expense has been recorded for these milestones as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;On July 5, 2022, the Company entered into an Amended and Restated Collaboration and License Agreement with Beam (the &#x201c;Amended Beam Agreement&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Pursuant to the Amended Beam Agreement, Beam granted the Company an exclusive, worldwide, sublicensable license under certain of Beam&#x2019;s base editing technology to develop and commercialize products directed towards an additional liver-mediated, cardiovascular disease target. The Company is responsible for the development and commercialization of products targeting the additional gene target, subject to Beam&#x2019;s opt-in right. Following the dosing of the final patient in a Phase 1b clinical trial of a licensed product for such additional gene target, Beam has the right to opt-in to share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of worldwide expenses of the development of such licensed product, as well as jointly commercialize and share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the profits and expenses of commercializing such licensed product worldwide. If Beam does not elect to opt-in, Beam is entitled to receive milestones and royalties on the same basis as other collaboration products as provided in the Beam Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In exchange, the Company granted to Beam an exclusive, worldwide, sublicensable, fully paid-up license under the Company's intellectual property, including under the Company's GalNAc-LNP delivery technology, relating to a preclinical program developed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Amended Beam Agreement also clarified intellectual property rights with respect to the Company's GalNAc-LNP delivery technology; grants Beam, on a target-by-target basis, the option to obtain a non-exclusive, worldwide, sublicensable license to the Company's GalNAc-LNP delivery technology for the development and commercialization of certain base editor products, as to which Beam would owe the Company a fee upon exercise of each option, certain regulatory and commercial sale milestones as well as low single-digit royalties on net sales for base editor products using the GalNAc-LNP delivery technology; terminates the Company's rights and economic obligations under the Beam Agreement with respect to the undisclosed genes, allowing the Company and Beam to independently develop and commercialize products directed to such gene targets; and concludes other licenses that applied under the Beam Agreement with respect to delivery and other technologies developed by the parties for the development and commercialization of base editor products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent there are sales of a delivery technology product, each party will pay the other party low-to-mid single digit royalties based on the annual aggregate worldwide net sales resulting from the sale of each delivery&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;technology product of such paying party; provided, however, that such royalty payments will not apply to net sales of the collaboration products or licensed products. The Company concluded the receipt of any milestone or royalty payments under the Amended Beam Agreement was not probable as of December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Acuitas agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Development and option agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In December 2019, the Company and Acuitas Therapeutics, Inc. ("Acuitas") entered into a development and collaboration agreement, whi&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ch agreement was amended and restated in October 2020. The Company agreed to reimburse Acuitas on a quarterly basis for its services performed related to the program activities based on an agreed upon number of fulltime employees committed to work on the program at an annual rate per employee, including reimbursement of reasonable external costs. The Company recognized research and development expense of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million during the year ended December 31, 2022, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the year ended December 31, 2021, respectively, related to the reimbursement of research and development services provided by Acuitas and technology maintenance fees. Under the terms of the agreement, the Company allowed the development and option agreement to terminate upon reaching the third anniversary of the agreement in December 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;License agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2020, the Company paid Acuitas a non-refundable, upfront license fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million (less a previously paid target reservation fee) to exercise an option with respect to a licensed product and a licensed genome target and entered into a non-exclusive, worldwide license with Acuitas, with a right to sub-license through multiple tiers, under the licensed LNP technology to research, develop and commercialize the licensed products using the LNP technology in connection with the PCSK9 gene target for all human therapeutic or prophylactic uses.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;To the extent achieved, the Company is also obligated to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in clinical and regulatory milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in sales-based milestones. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;D&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ue to the first patient dosing of VERVE-101 in a clinical trial, a milestone payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million was triggered and paid during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Novartis license agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2021, the Company entered into a license agreement with Novartis Pharma AG (&#x201c;Novartis&#x201d;) to obtain a non-exclusive license to lipid technology the Company is using in connection with the research and development of certain product candidates, including VERVE-201. As consideration for the license and rights granted under the agreement, the Company mad&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;e a one-time, non-refundable, upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million during the year ended December 31, 2021. The license agreement requires the Company to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in clinical and regulatory milestones and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in sales-based milestones for products that incorporate the licensed lipid technology. The milestones have not been achieved and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; expense has been recorded for these milestones as of December 31, 2022.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2022, the Company amended the agreement to include three additional licensed products to the scope of the non-exclusive license. In consideration of the additional licensed products, the Company was required to mak&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;e a one-time, non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million to Novartis. This amount was recorded as research and development expense and was paid during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</verv:LicenseAgreementDisclosureTextBlock>
    <verv:NonRefundableUpfrontLicenseFeesPaid
      contextRef="C_910510d8-3c53-4144-8d2f-5bf2ee890957"
      decimals="-5"
      id="F_8527fcc8-0f5b-445d-add1-d5cf8ed68d3f"
      unitRef="U_USD">300000</verv:NonRefundableUpfrontLicenseFeesPaid>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_811d34f0-c7b1-4e6e-ab97-bb9220268914"
      decimals="INF"
      id="F_9ca33862-5545-4000-89f5-31d29cdde527"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257"
      decimals="-5"
      id="F_d5c93566-3272-4110-8058-264d823db1f6"
      unitRef="U_USD">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:PreferredStockFinancingPartiallySatisfied
      contextRef="C_0bedcb64-f835-4169-aae4-e6de370db89e"
      decimals="-5"
      id="F_ef89b253-4c7d-465c-862b-0f07f503df62"
      unitRef="U_USD">100000</verv:PreferredStockFinancingPartiallySatisfied>
    <verv:PreferredStockFinancingFullySatisfied
      contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f"
      decimals="-5"
      id="F_69514149-ea3f-4bcf-96e7-4aeaa007ef64"
      unitRef="U_USD">500000</verv:PreferredStockFinancingFullySatisfied>
    <verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing
      contextRef="C_0bedcb64-f835-4169-aae4-e6de370db89e"
      decimals="INF"
      id="F_c90e3323-783d-4576-8577-8541b4f8f203"
      unitRef="U_USD">121411</verv:CommonStockIssuedForPartlySatisfyingPreferredStockFinancing>
    <verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing
      contextRef="C_69b359b5-45e4-4728-8962-f83fa4cd4c5f"
      decimals="INF"
      id="F_06ab9a15-e5b6-44b4-8dd1-d5cabf915e70"
      unitRef="U_shares">187867</verv:CommonStockIssuedForFullySatisfyingPreferredStockFinancing>
    <us-gaap:CommonStockValue
      contextRef="C_279982b2-44db-49b7-a99b-e765968a154b"
      decimals="-5"
      id="F_9fc38b4e-5e23-40a7-86ba-5a6ad69b2ad9"
      unitRef="U_USD">32500000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_279982b2-44db-49b7-a99b-e765968a154b"
      decimals="INF"
      id="F_40111d18-0d9b-41fb-b29d-12709aeddac2"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:DerivativeLiabilities
      contextRef="C_d8289e27-62a6-4835-8e99-588f8ef3162f"
      decimals="-5"
      id="F_240815a4-5667-430f-a4c3-bd1578c90679"
      unitRef="U_USD">6300000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="C_6c1812ca-014b-4804-9c67-8987654bfa75"
      decimals="-5"
      id="F_aae41d4f-fdd2-42ad-bc88-30893db37e9b"
      unitRef="U_USD">6300000</us-gaap:DerivativeLiabilities>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257"
      decimals="-5"
      id="F_18dd4035-2f56-4de9-a798-55a7d83c474a"
      unitRef="U_USD">46200000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_f2189d68-ff46-4307-87ca-ccad5ed5d257"
      decimals="-6"
      id="F_310c73a4-3b35-415e-8626-e165e1089ee0"
      unitRef="U_USD">108000000</verv:PaymentOfSalesBasedMilestone>
    <us-gaap:DerivativeLiabilities
      contextRef="C_0445a9ca-bc9f-4e03-ba8a-fb18a059a14c"
      decimals="-2"
      id="F_e3cf4efc-60cb-4a6e-9a19-423613e99252"
      unitRef="U_USD">300</us-gaap:DerivativeLiabilities>
    <verv:PercentageSharesOfDevelopmentExpense
      contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b"
      decimals="2"
      id="F_00b67ba0-d0db-46a2-9778-3bf0ba60d22b"
      unitRef="U_pure">0.33</verv:PercentageSharesOfDevelopmentExpense>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_67250595-6ef1-4d88-b28c-b2e432497a69"
      decimals="0"
      id="F_42974ac0-e2af-41f3-82e3-1a3ca9397d21"
      unitRef="U_shares">276075</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b"
      decimals="-5"
      id="F_1332dec6-e4d9-470f-ac5a-fac5e17b15c6"
      unitRef="U_USD">300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b"
      decimals="-5"
      id="F_a34fb85c-046c-4f4b-874e-c9d780ae1900"
      unitRef="U_USD">11300000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_ebce5e30-7636-4eb4-9e4f-77d0ca04271b"
      decimals="-5"
      id="F_48848996-244a-4e7d-bf2f-c3f55613b26f"
      unitRef="U_USD">15000000.0</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_fc34a2a2-051c-4d86-b8ad-adf3902f2be3"
      decimals="-5"
      id="F_dc0f4744-e179-435a-8ff9-646de881207a"
      unitRef="U_USD">5600000</verv:PaymentOfMilestoneDevelopment>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_02d7b42f-eec4-4cd5-861d-bf55e78340ce"
      decimals="-5"
      id="F_8fd22913-8ada-43e6-853f-be2fd724e32a"
      unitRef="U_USD">7500000</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_aab4db61-ccdc-4683-9f00-31e18b63c0b5"
      decimals="-5"
      id="F_1acff290-a05b-415b-bdca-2e5117d1cd9d"
      unitRef="U_USD">300000</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_f5c58be5-49fc-43e9-a294-cc491cbf767a"
      decimals="-5"
      id="F_ddf23cc1-5306-4449-b48a-1582557a60a1"
      unitRef="U_USD">200000</verv:PaymentOfSalesBasedMilestone>
    <verv:PaymentOfMilestoneDevelopment
      contextRef="C_80fe8138-eecf-486b-bd60-cbf5bf880dae"
      decimals="-5"
      id="F_e99a72a5-86fd-43da-b7fd-9efe621f0732"
      unitRef="U_USD">6000000.0</verv:PaymentOfMilestoneDevelopment>
    <verv:MilestoneRelatedExpenses
      contextRef="C_ce21619d-19f7-43cd-b8d5-a7b052f3bd59"
      decimals="-3"
      id="F_7eefc329-57c7-47c0-bd2d-c1ef2a0cd071"
      unitRef="U_USD">0</verv:MilestoneRelatedExpenses>
    <verv:PercentageSharesOfDevelopmentExpense
      contextRef="C_4353a489-6849-4ba4-97a8-7fc091cf5f01"
      decimals="2"
      id="F_5e2f78be-612f-4de5-a136-8bacfd5228b7"
      unitRef="U_pure">0.35</verv:PercentageSharesOfDevelopmentExpense>
    <verv:CommercializingProfitsAndExpenses
      contextRef="C_4353a489-6849-4ba4-97a8-7fc091cf5f01"
      decimals="2"
      id="F_00a1f844-3862-4ce7-a30a-7081cac66b6d"
      unitRef="U_pure">0.35</verv:CommercializingProfitsAndExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_e9d5bc3b-5c96-4d9f-b2f1-b89dbdfe1151"
      decimals="-5"
      id="F_8c9e2b67-3f44-467d-a83e-1e74f33d1230"
      unitRef="U_USD">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_51f6cfff-f169-440d-8129-93e247a0bd28"
      decimals="-5"
      id="F_50e91d14-d427-4e3d-867c-7aa4f3253fb7"
      unitRef="U_USD">1000000.0</us-gaap:ResearchAndDevelopmentExpense>
    <verv:NonRefundableUpfrontLicenseFee
      contextRef="C_4d7ab199-9fb8-4980-b91e-4d41f59ce3e9"
      decimals="-5"
      id="F_8f4b2f22-c032-4855-9a54-7792729930f0"
      unitRef="U_USD">2000000.0</verv:NonRefundableUpfrontLicenseFee>
    <verv:ClinicalAndRegulatoryMilestone
      contextRef="C_a1b1686d-7c2d-471e-b953-e9208218d02c"
      decimals="-5"
      id="F_ccf1e521-2fc7-478e-988b-aed4e524dbcd"
      unitRef="U_USD">9800000</verv:ClinicalAndRegulatoryMilestone>
    <verv:SalesBasedMilestone
      contextRef="C_a1b1686d-7c2d-471e-b953-e9208218d02c"
      decimals="-5"
      id="F_7429ce50-8e06-4b26-bace-f7cf0cbfa361"
      unitRef="U_USD">9500000</verv:SalesBasedMilestone>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_a18baa7c-e6c9-43fd-b0ab-55458b1c2d27"
      decimals="-5"
      id="F_4c208566-00e0-4c7f-8917-cc92d51f5819"
      unitRef="U_USD">800000</verv:PaymentOfSalesBasedMilestone>
    <verv:NonRefundableUpfrontLicenseFeesPaid
      contextRef="C_f27beec5-2375-455d-9c1c-624e6dbd8e18"
      decimals="-5"
      id="F_8b774fea-8301-4c57-b8ba-ff8f392cc766"
      unitRef="U_USD">800000</verv:NonRefundableUpfrontLicenseFeesPaid>
    <verv:ClinicalAndRegulatoryMilestone
      contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3"
      decimals="-5"
      id="F_cd0494cd-4469-41cd-b0ce-b9a1f0816c6b"
      unitRef="U_USD">10000000.0</verv:ClinicalAndRegulatoryMilestone>
    <verv:PaymentOfSalesBasedMilestone
      contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3"
      decimals="-5"
      id="F_5d80cde6-f82b-431c-b589-97a883612cf5"
      unitRef="U_USD">35000000.0</verv:PaymentOfSalesBasedMilestone>
    <verv:MilestoneRelatedExpenses
      contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3"
      decimals="-3"
      id="F_e0fedea8-4681-45dd-aa17-95dcf32e4537"
      unitRef="U_USD">0</verv:MilestoneRelatedExpenses>
    <verv:NonRefundableUpfrontLicenseFee
      contextRef="C_a3dbf855-2073-449b-a0a1-57d11e804ae3"
      decimals="-5"
      id="F_c73a4f75-c148-4ed8-a3ad-bbabd228b65e"
      unitRef="U_USD">2800000</verv:NonRefundableUpfrontLicenseFee>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a712488b-cb1b-4be2-b683-bb4387701ac5">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Collaboration and License Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Vertex Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Summary of Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In July 2022, the Company entered into the Strategic Collaboration and License Agreement (the &#x201c;Vertex Agreement&#x201d;) with Vertex Pharmaceuticals Incorporated (&#x201c;Vertex&#x201d;) for an exclusive, four-year worldwide research collaboration focused on developing &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; gene editing candidates toward an undisclosed target for the treatment of a single liver disease. Additionally, the Company entered into a stock purchase agreement (the &#x201c;Stock Purchase Agreement&#x201d;) with Vertex, pursuant to which the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,519,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock to Vertex at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Pursuant to the Vertex Agreement, the Company is responsible for discovery, research and certain preclinical development of novel &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; gene editing development candidates for the target of interest. The Company&#x2019;s research activities are focused on (i) identifying and engineering specific gene editing systems and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; delivery systems directed to the target and (ii) evaluating and optimizing development candidates to achieve criteria specified in the Vertex Agreement. Vertex is obligated to reimburse the Company&#x2019;s research expenses consistent with a mutually agreed-upon research plan and budget (&#x201c;Research Plan&#x201d;). The research term has an initial term of four years and may be extended by Vertex for up to one additional year (&#x201c;Research Term&#x201d;). The Research Plan is overseen by a Joint Research Committee (&#x201c;JRC&#x201d;) as detailed in the Vertex Agreement. Any material amendments to the Research Plan are required to be mutually agreed to by the JRC.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the Research Term, Vertex may select certain gene editing systems and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;in vivo&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; delivery systems directed at the target to become a licensed agent. Upon the designation of the licensed agent, Vertex shall receive a license to exploit the licensed agent, and the licensed agent will continue to be developed under the Research Plan in order to achieve certain development candidate criteria agreed to by the JRC. Following the Research Term, Vertex will be solely responsible for subsequent development, manufacturing and commercialization of any product candidate resulting from the licensed agent.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company received an upfront payment from Vertex of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and is eligible to receive (i) success payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for each product candidate (up to a maximum of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;66&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million) that achieves the applicable development criteria, (ii) up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;175&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in development milestones and (iii) up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;165&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in commercial milestone payments. The Company is also eligible to receive tiered single-digit royalties on net sales, with the rate dependent upon the type of product and subject to specified reductions. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Such royalty payments will terminate on a country-by-country and product-by-product basis upon the later to occur of (i) the expiration of the last to expire valid claim under the patent rights covering such product in such country, (ii) the period of regulatory exclusivity associated with such product in such country or (iii) ten years after the first commercial sale of such product in such country.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Prior to the first patient dosing of the first Phase 1b clinical trial for the first product candidate developed under the Vertex Agreement, the Company also has the right to opt-in to a profit share arrangement pursuant to which Vertex and the Company would share the costs and net profits for all product candidates emerging from the collaboration. If the Company exercises its opt-in right, in lieu of milestones and royalties, it will be obligated to pay for a specified percentage of the development and commercialization costs, and it will have the right to receive a specified percentage of the profits from any sales of any product candidates advanced under the collaboration. At the time the Company exercises the option, it may elect a profit/cost share of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;40&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% (with Vertex retaining a minimum of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;60&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%). In order to exercise its opt-in right, the Company is required to pay a fee ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;70&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, depending on the profit/cost percentage elected by the Company and the Company&#x2019;s licensed technology included in the most advanced product candidate at the time it exercises its opt-in right. Under all profit share scenarios, Vertex will control the worldwide development and commercialization of any product candidates resulting from the collaboration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Vertex Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature. The Company and Vertex each have the right to terminate the agreement for material breach by, or insolvency of, the other party following notice, and if applicable, a cure period. Vertex may also terminate the Vertex Agreement in its entirety for convenience upon 90 days&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company assessed the promised goods and services under the Vertex Agreement, in accordance with ASC 606. At inception, the Vertex Agreement included the following performance obligations: (i) the research services obligation which relates to the research and development services to be provided under the Research Plan (the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x201c;Research Services&#x201d;) and (ii) three licensed agent material rights related to the options to obtain licenses to exploit a licensed agent, at a discount.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company identified $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of fixed transaction price consisting of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million upfront fee offset by a discount of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million related to the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,519,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares sold to Vertex under the Stock Purchase Agreement when measured at fair value on the date of issuance. The Company is also entitled to reimbursement of costs incurred associated with the delivery of services under the Research Plan. The Company utilized the most likely amount approach and estimated the expected cost reimbursement to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million at inception. The Company concluded that these amounts do not require a constraint and are included in the transaction price at inception. The Com&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;pany considers this estimate at each reporting date and updates the estimate based on information available. As of December 31, 2022, the estimate of the expected reimbursement is $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million based on expectations as of such date. Additional consideration to be paid to the Company upon reachi&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ng certain milestones are excluded from the transaction price as that consideration may only be earned subsequent to an option exercise.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has concluded that the variable consideration related to the cost reimbursement of the Research Services obligation will be allocated entirely to that obligation as the cost reimbursement relates specifically to the services being performed under the Research Plan. The reimbursement of Research Services is considered to be at a market rate and therefore depicts the estimated amount it would expect to receive for this obligation. As a result, the Company allocated the fixed consideration of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million to the three licensed agent material rights based on their relative standalone selling prices. The estimated standalone selling price for each material right was based on an adjusted market assessment approach. The Company concluded that the market would be &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;willing to pay an equal amount for each licensed agent license on a standalone basis before being adjusted for the probability of the option becoming exercisable upon the successful completion of research activities to identify the licensed agents. The Company reached this conclusion after considering (i) the downstream economics including success fees, milestones and royalties related to each licensed agent being identical and (ii) that all licensed agents are targeting the same gene. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.673%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:26.23%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research services obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;First licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Second licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Third licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The amount allocated to the Research Services obligation will be recognized on a proportional performance basis over the period of service using input-based measurements of total cost of research incurred to estimate the proportion performed and remeasured at the end of each reporting period. The amount allocated to the licensed agent material rights was recorded as deferred revenue and will commence recognition upon exercise of each option or, if an option is never exercised, it will be recognized in full upon expiry of the Research Term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of revenue associated with the Vertex Agreement related to research services performed during the period. As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company has recorded $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million as non-current deferred revenue.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Costs incurred relating to the Company&#x2019;s collaboration programs under the Vertex Agreement consist of internal and external research costs, which primarily include: salaries and benefits, and preclinical research studies. These costs are included in research and development expenses in the Company&#x2019;s consolidated statements of operations during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3"
      decimals="0"
      id="F_735ff689-21f7-4735-a60e-739220c71a8a"
      unitRef="U_shares">1519756</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7"
      decimals="2"
      id="F_bf7c0095-003e-4bd4-ab2e-6f24eb2aff83"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock
      contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3"
      decimals="-5"
      id="F_68f06b91-4c6e-4641-b9df-ed56b3147209"
      unitRef="U_USD">35000000.0</us-gaap:ProceedsFromRepaymentOfLoansToPurchaseCommonStock>
    <verv:NonRefundableUpfrontPayment
      contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3"
      decimals="-6"
      id="F_36cad7b6-801c-428e-ba51-35df525bc448"
      unitRef="U_USD">25000000</verv:NonRefundableUpfrontPayment>
    <verv:SuccessPaymentsForEachProduct
      contextRef="C_f6ffb5cf-0a1f-43c8-9898-e064bfa132c7"
      decimals="-6"
      id="F_2e58115e-b5c1-4dce-9991-d40e3020ddf9"
      unitRef="U_USD">22000000</verv:SuccessPaymentsForEachProduct>
    <verv:SuccessPaymentsForEachProduct
      contextRef="C_b6c51c82-3c32-4a05-9b39-deffe3ffdec3"
      decimals="-6"
      id="F_20c7e244-9a28-4a3d-a294-cd038ee90e26"
      unitRef="U_USD">66000000</verv:SuccessPaymentsForEachProduct>
    <us-gaap:PaymentsToAcquireCommercialRealEstate
      contextRef="C_28918730-6ac5-404a-a56f-497ecef921d3"
      decimals="-6"
      id="F_3f826ae0-2109-4d6f-842c-7f39a1da2334"
      unitRef="U_USD">175000000</us-gaap:PaymentsToAcquireCommercialRealEstate>
    <us-gaap:PaymentsToAcquireCommercialRealEstate
      contextRef="C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea"
      decimals="-6"
      id="F_909972f2-2544-4b81-b6a4-30fcb0ffff09"
      unitRef="U_USD">165000000</us-gaap:PaymentsToAcquireCommercialRealEstate>
    <us-gaap:PercentageOfUnamortizedFilmCosts
      contextRef="C_80d92420-5853-477a-a2f9-78d029bbafe0"
      decimals="2"
      id="F_58ce054d-e452-46c1-9a3d-bd1f483d0865"
      unitRef="U_pure">0.40</us-gaap:PercentageOfUnamortizedFilmCosts>
    <us-gaap:PercentageOfUnamortizedFilmCosts
      contextRef="C_42e3df2c-8ff1-469a-8a07-db72c7a21989"
      decimals="2"
      id="F_02d14aa9-00d4-4b7c-9f84-e5ce761a4684"
      unitRef="U_pure">0.60</us-gaap:PercentageOfUnamortizedFilmCosts>
    <us-gaap:InterestAndFeeIncomeLoansCommercial
      contextRef="C_5c084e08-8487-4c71-bcce-ce2e7baea2d4"
      decimals="-6"
      id="F_08365053-dede-4158-ae7c-74cb727432b5"
      unitRef="U_USD">25000000</us-gaap:InterestAndFeeIncomeLoansCommercial>
    <us-gaap:InterestAndFeeIncomeLoansCommercial
      contextRef="C_ef2c8bcc-a458-4df0-ac7a-cb2750615042"
      decimals="-6"
      id="F_d8e10f28-3b87-4336-9e3a-8ff40da06fda"
      unitRef="U_USD">70000000</us-gaap:InterestAndFeeIncomeLoansCommercial>
    <us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
      contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9"
      decimals="-5"
      id="F_93696961-877b-4aa1-821d-2cc352af3961"
      unitRef="U_USD">20000000.0</us-gaap:ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet>
    <us-gaap:ManagementFeeExpense
      contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9"
      decimals="-5"
      id="F_a7834795-84bd-450a-a814-d977a54c5ec3"
      unitRef="U_USD">25000000.0</us-gaap:ManagementFeeExpense>
    <us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount
      contextRef="C_0561a53b-a5ef-42c6-abb0-89bfc7201442"
      decimals="-5"
      id="F_417a3ee0-bfff-4467-8eaa-754a869e1888"
      unitRef="U_USD">5000000.0</us-gaap:FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_957ab491-c1ea-4ea7-9cc0-25da870db3a9"
      decimals="0"
      id="F_5f300d5d-73dd-4c93-b275-5b00269353a6"
      unitRef="U_shares">1519756</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost
      contextRef="C_0561a53b-a5ef-42c6-abb0-89bfc7201442"
      decimals="-5"
      id="F_e7b8b6ba-3dfc-432e-a250-a00ec864d8c0"
      unitRef="U_USD">5800000</us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost>
    <us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost
      contextRef="C_7ea5b1c4-02d7-4d08-83fa-e232cce51d59"
      decimals="-5"
      id="F_7db542e2-6b76-42de-8b69-2105a483f92d"
      unitRef="U_USD">5800000</us-gaap:UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost>
    <verv:FixedConsiderationAmount
      contextRef="C_5476f53e-8810-4a5b-afa1-3ba7403c605f"
      decimals="-5"
      id="F_bdf2874d-a81d-4063-8cb5-df2f920fda83"
      unitRef="U_USD">20000000.0</verv:FixedConsiderationAmount>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_3fff0d5e-7552-405b-aac1-7ad155e92991">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As such, based on the relative standalone selling price for each of the three material rights, the allocation of the transaction price to the separate performance obligations is as follows:&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:69.673%;"/&gt;
        &lt;td style="width:1.994%;"/&gt;
        &lt;td style="width:1.131%;"/&gt;
        &lt;td style="width:26.23%;"/&gt;
        &lt;td style="width:0.972%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Performance obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:0.5pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:0.5pt solid rgba(255,255,255,0.01);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research services obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;First licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Second licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Third licensed agent material right&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <verv:PerformanceObligation
      contextRef="C_146d0396-0c40-4489-aa98-b2e85e1a984e"
      decimals="-3"
      id="F_1c969452-1013-43f7-9e2e-cccfd7d4fe90"
      unitRef="U_USD">5845000</verv:PerformanceObligation>
    <verv:PerformanceObligation
      contextRef="C_4507e5e6-86e5-49af-9e91-39416a49e6de"
      decimals="-3"
      id="F_7de77cf9-8a2a-470c-ae34-e893b70f8ce7"
      unitRef="U_USD">6667000</verv:PerformanceObligation>
    <verv:PerformanceObligation
      contextRef="C_9d9b46b8-dcc4-4ea7-bf1b-5b347b2d06e3"
      decimals="-3"
      id="F_3c1de9db-11d3-405e-9c12-013545818f32"
      unitRef="U_USD">6667000</verv:PerformanceObligation>
    <verv:PerformanceObligation
      contextRef="C_1f9a1d59-c482-4313-96a8-40ac3152c220"
      decimals="-3"
      id="F_6be3192b-463e-4f5d-9049-257f516411b6"
      unitRef="U_USD">6666000</verv:PerformanceObligation>
    <verv:PerformanceObligation
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_ecd731b3-1c89-490d-be7a-f9b167f094d4"
      unitRef="U_USD">25845000</verv:PerformanceObligation>
    <us-gaap:DeferredRevenueRevenueRecognized1
      contextRef="C_97838a2e-40af-4778-a7e5-dbade0a2d74e"
      decimals="-5"
      id="F_46d08463-f32a-4e8c-8606-5aae847c260e"
      unitRef="U_USD">1900000</us-gaap:DeferredRevenueRevenueRecognized1>
    <us-gaap:AmountOfDeferredCostsRelatedToLongTermContracts
      contextRef="C_014a8cde-c8d4-4025-be72-d973721b5175"
      decimals="-5"
      id="F_276c9093-441a-424a-9168-3f72589d65c8"
      unitRef="U_USD">20000000.0</us-gaap:AmountOfDeferredCostsRelatedToLongTermContracts>
    <verv:PreferredAndCommonStockTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_f7403a9b-2c9e-46b7-9cf8-75428665bca1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;10. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Preferred and common stock&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;has issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;101,170,571&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Series A preferred, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,838,461&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Series A-2 preferred, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77,163,022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Series B preferred and common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2021, the Company amended and restated its certificate of incorporation to authorize &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of preferred stock, which shares of preferred stock are currently undesignated, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;200,000,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.001&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; par value per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2021, the Company completed its IPO, pursuant to which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16,141,157&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,105,368&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, for aggregate gross proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;306.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million. The Company received approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;281.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in net proceeds, after deducting underwriting discounts and offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;27,720,923&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock, and the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;878,098&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock to Harvard and Broad as final settlement of its antidilution rights obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In July 2022, in connection with the execution of the Vertex Agreement, the Company and Vertex also entered into the Stock Purchase Agreement for the sale and issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,519,756&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company&#x2019;s common stock to Vertex at a price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.03&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share, for an aggregate purchase price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In July 2022, the Company completed a follow-on public offering of common stock, pursuant to which the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,583,334&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock, including &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,250,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock sold pursuant to the full exercise of the underwriters&#x2019; option to purchase additional shares, at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;27.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share. The Company received net proceeds of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;242.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million after deducting underwriting discounts and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;15.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In July 2022, the Company entered into an Open Market Sale Agreement (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) as the agent pursuant to which the Company is entitled to offer and sell, from time to time at prevailing market prices, shares of the Company&#x2019;s common stock. The Company agreed to pay Jefferies a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the aggregate gross sale proceeds of any shares sold by Jefferies under the Sales Agreement. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022, the Company sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,280,168&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of its common stock under the Sales Agreement for aggregate net proceeds of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;42.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, after deducting commissions and offering expenses payable by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The holders of c&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ommon stock are entitled to one vote for each share of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</verv:PreferredAndCommonStockTextBlock>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_8d200ccf-3e5b-4292-a74b-e614b3ce55e4"
      decimals="0"
      id="F_8e788149-df07-4719-98ba-0c4752d2d469"
      unitRef="U_shares">101170571</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_34a36f82-56c7-4f23-aefa-cbf18563b2c3"
      decimals="0"
      id="F_eeafbb24-bab8-42f8-ab31-85e5a7aeb937"
      unitRef="U_shares">7838461</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_042eaa61-5d4c-48a9-bc1a-4987ee4f1dc6"
      decimals="0"
      id="F_8453954c-76a8-4acb-86ad-d902226d2aa7"
      unitRef="U_shares">77163022</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_875f1476-cc60-4a70-a9cc-ff85d743c58f"
      decimals="0"
      id="F_32aba145-eeca-484c-9ee9-3a41b8086927"
      unitRef="U_shares">77163022</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_8d5b798c-354b-494c-aca5-76cbed28659a"
      decimals="0"
      id="F_82aff6e5-7ab5-4a5d-8bbc-99d225ac8636"
      unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464"
      decimals="0"
      id="F_8bbd4342-8f52-4788-8908-1a17d702c14d"
      unitRef="U_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a8da6f07-7d32-4b46-aa4f-fdbea2a92464"
      decimals="3"
      id="F_52f899d7-f5a4-47d6-8d7f-c04e3ceddbb6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_f3934e3e-c3eb-462e-aef8-a427f8923a25"
      decimals="0"
      id="F_8546e994-f208-4ae9-85c4-4aea6a80fd47"
      unitRef="U_shares">16141157</us-gaap:CommonStockSharesIssued>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_6ab5cdc4-68f7-4336-be12-9a43b519475c"
      decimals="0"
      id="F_a3c0a434-268c-4197-ac8d-7d6e6ba9e036"
      unitRef="U_shares">2105368</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <verv:PublicOfferingPrice
      contextRef="C_0d68b3a6-6891-4343-9cac-092f95f5b426"
      decimals="2"
      id="F_53ca0415-c9b0-4455-9199-36b13ac3c0df"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.00</verv:PublicOfferingPrice>
    <verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross
      contextRef="C_6ab5cdc4-68f7-4336-be12-9a43b519475c"
      decimals="-5"
      id="F_4f71c243-50e6-4eea-9a83-2c463a363599"
      unitRef="U_USD">306700000</verv:ProceedsFromIssuanceOfCommonStockUnderIPOGross>
    <verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses
      contextRef="C_72c91c7c-a0cb-4506-8c90-233e59c44e9f"
      decimals="-5"
      id="F_2e5ee0eb-ea07-435f-be0d-75f111b44662"
      unitRef="U_USD">281600000</verv:ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_fb1c32eb-3cf9-4efd-b9f9-ef61f34a3d24"
      decimals="0"
      id="F_4ca846ac-17a3-4a46-a3c1-25184911a6ff"
      unitRef="U_shares">27720923</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e5fb7e70-f89c-46e0-8d34-d37cadafb70e"
      decimals="0"
      id="F_d50ca6e7-bcb5-4127-9cd4-b1701003832d"
      unitRef="U_shares">878098</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_899016e2-2a07-4bd4-8bcc-57974930a3bc"
      decimals="0"
      id="F_92d4bc5c-653d-44ba-97c3-86d1b3745ca4"
      unitRef="U_shares">1519756</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_899016e2-2a07-4bd4-8bcc-57974930a3bc"
      decimals="2"
      id="F_075a2b47-59d5-4024-9707-51f970306f0b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.03</us-gaap:CommonStockParOrStatedValuePerShare>
    <verv:AgreegatePurchasePrice
      contextRef="C_f6e04a3c-5788-44a1-b5df-375dfe290497"
      decimals="-5"
      id="F_f94b07d1-c7f2-4a00-819a-2f924204a8c4"
      unitRef="U_USD">35000000.0</verv:AgreegatePurchasePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8"
      decimals="0"
      id="F_b20cb342-314c-4fab-9e9f-d4e668f7123b"
      unitRef="U_shares">9583334</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e616ea55-8674-4e50-833f-8f6bccf6e730"
      decimals="0"
      id="F_a04e4bb7-4ca2-4e5b-ba5f-d4013ad076b3"
      unitRef="U_shares">1250000</us-gaap:CommonStockSharesIssued>
    <verv:CommonStockOfferingPricePerShare
      contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8"
      decimals="2"
      id="F_f82c0071-6d2d-4394-a5c6-3a678b71428b"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">27.00</verv:CommonStockOfferingPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8"
      decimals="-5"
      id="F_632531d6-5d2e-4e7d-9ef1-9a8dfbd981bb"
      unitRef="U_USD">242900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions
      contextRef="C_d9d32810-8547-4214-94fc-56f99ab953c8"
      decimals="-5"
      id="F_52020d16-bc3a-4e45-a315-a11954fe7289"
      unitRef="U_USD">15800000</us-gaap:InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions>
    <verv:CommissionOnAggregateGrossSaleProceeds
      contextRef="C_df58c0aa-a8ae-4c98-9b38-70834ce1e110"
      decimals="3"
      id="F_a3ab8473-a617-43a4-963d-dd299406ae2e"
      unitRef="U_pure">0.030</verv:CommissionOnAggregateGrossSaleProceeds>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c"
      decimals="0"
      id="F_90da0151-a32f-4b15-b890-68b596458438"
      unitRef="U_shares">1280168</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c"
      decimals="-5"
      id="F_301f0591-6e24-450a-89db-5b05bdb7e44b"
      unitRef="U_USD">42900000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_5eba59d4-c964-448e-9810-26f64fdf0d5c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11. Stock-based compensation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;), adopted by the board of directors in August 2018 provided for the grant of qualified incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock and restricted stock units to the Company&#x2019;s employees, officers, directors, advisors, and outside consultants for the&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; issuance or purchase of shares of the Company&#x2019;s common stock. The maximum number of shares of common stock that were authorized for issuance under the 2018 Plan was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,885,653&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2021, the Company's board of directors adopted, and the Company's stockholders approved, the 2021 Stock Incentive Plan (the &#x201c;2021 Plan&#x201d;), which became effective on June 16, 2021. The 2021 Plan provides for grant of qualified and nonqualified stock options, stock appreciation rights, restricted and unrestricted stock and stock units, performance awards, and other share-based awards to the Company's employees, directors, advisors and outside consultants. The shares reserved for issuance pursuant to the 2021 Plan are subject to an annual increase through January 1, 2031. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; the Company had reserved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,057,629&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock for issuance of stock options, restricted stock, and restricted stock units, of which &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,025,807&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; remained outstanding for future grant under the 2021 Plan. On January 1, 2023, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,086,541&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of the Company's common stock were added to the amount reserved for issuance under the 2021 Plan. Upon effectiveness of the 2021 Plan, the Company ceased granting additional awards under the 2018 Plan.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.359%;"/&gt;
        &lt;td style="width:1.406%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Stock options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The assumptions used in Black-Scholes for stock options granted were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.835%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.247%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;84.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table provides a summary of stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.143%;"/&gt;
        &lt;td style="width:0.823%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.238%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.633000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.823%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.042%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.839%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,561,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;743,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;324,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,612,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;63,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,551,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;34,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected to vest after December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,060,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;29,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022 the weighted average grant date fair value of the stock options granted &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19.39&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; per share.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; The aggregate intrinsic value of stock options exercised during the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million while the Company received $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million in proceeds for the exercise of these options.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;64.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;Restricted stock and restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In 2018, the Company issued &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,150,537&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of restricted common stock. The restricted shares vested in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;48&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; equal monthly installments, commencing on January 1, 2018. The restricted shares were fully vested as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;During the year ended December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;688,700&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; restricted stock units under the 2021 Plan. These restricted stock units vest in substantially equal installments over a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;four-year&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of and change in unvested restricted stock units as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.119%;"/&gt;
        &lt;td style="width:1.184%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.077%;"/&gt;
        &lt;td style="width:1.866%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;688,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;677,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;At December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of unrecognized stock-based compensation expense related to restricted stock units that are expected to vest. These costs are expected to be recognized over a weighted-average remaining vesting period of 3&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;.5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt;2021 Amended and Restated Employee Stock Purchase Plan&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;font-style:italic;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In June 2021, the board of directors adopted, and the Company's stockholders approved, the 2021 Employee Stock Purchase Plan, or the ESPP, as amended and restated, which became effective on June 16, 2021. The shares reserved for issuance pursuant to the ESPP are subject to an annual increase through January 1, 2031. As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;134,107&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares had been purchased by employees under the ESPP and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;784,326&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares remained available for issuance under the ESPP. On January 1, 2023, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;617,308&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; shares of common stock were added to the amount reserved for sale under the ESPP.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_59c54d37-04e4-4cc3-9af1-28ee8d5dcf07"
      decimals="0"
      id="F_d4014bca-e280-48cd-9b2e-f55358d6b783"
      unitRef="U_shares">6885653</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="0"
      id="F_0cc86586-b562-408e-8dd3-266a04970cd8"
      unitRef="U_shares">7057629</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3"
      decimals="INF"
      id="F_7e3c155a-640d-410b-8cf3-cc68df78f85e"
      unitRef="U_shares">3025807</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_830a7292-f023-456a-aa51-b7b87abe1927"
      decimals="0"
      id="F_8ce055a3-ac2b-400c-8da5-31e0757626a8"
      unitRef="U_shares">3086541</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_f9f13f7f-9a7e-41f9-828a-da710b47aaaa">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation expense recorded in the consolidated statements of operations and comprehensive loss is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.359%;"/&gt;
        &lt;td style="width:1.406%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.719%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.396%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.006%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,486&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,830&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;356&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,477&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;850&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_57662c72-eee2-4c4f-951b-40edfc12c8d7"
      decimals="-3"
      id="F_31af9e00-5298-40f7-ba53-99e42b1e515f"
      unitRef="U_USD">12486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_604ef497-9ecd-45dc-bf27-276566041fda"
      decimals="-3"
      id="F_f122ca6d-5e81-47d0-967d-d84c076fd14f"
      unitRef="U_USD">3830000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3cbafceb-7d5c-4f1a-8167-31d9b2611fff"
      decimals="-3"
      id="F_a43a61f0-7ba8-4aa2-bed4-3064c9a39a9f"
      unitRef="U_USD">494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_aea2e412-934b-4a07-a049-22c9f1b5ea0f"
      decimals="-3"
      id="F_6202f341-4268-4ea2-a7af-9775cf1aad84"
      unitRef="U_USD">9991000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_86e5cc33-d110-47af-ada1-8665901d8afd"
      decimals="-3"
      id="F_636d72bd-4e44-4995-bf42-fe4d87e63b75"
      unitRef="U_USD">3242000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ce0e9729-f513-4bf1-8488-e529d1be5407"
      decimals="-3"
      id="F_24dc9c66-c26d-4bae-ad14-9550eb8acb1a"
      unitRef="U_USD">356000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_9845443a-a81a-4be6-8bb2-dc3c75f93d1a"
      unitRef="U_USD">22477000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c38a29c1-933e-4c48-9ab3-53d11de2b32a"
      unitRef="U_USD">7072000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_e583497c-50b5-46a0-a8f8-fd790d9edf55"
      unitRef="U_USD">850000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_a6410f78-02df-4d3f-8121-e970ade903c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The assumptions used in Black-Scholes for stock options granted were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:56.835%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.475%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.989%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.247%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended&lt;br/&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;77.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;84.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-average risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_2d51ff62-4beb-49f2-a011-4ba0d66bb987"
      unitRef="U_pure">0.773</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_87751413-32a2-44e2-b51f-ec4faea52037"
      unitRef="U_pure">0.777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_b6544811-6541-41d6-98f9-948ff168bfdc"
      unitRef="U_pure">0.848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_fcaa3184-841d-4178-b19c-187f7d643412"
      unitRef="U_pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_d6617667-8296-470b-bb45-b606f57bcf5e"
      unitRef="U_pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_4224c5d9-8cd3-40fd-8048-71f041f62c18"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_56d47e8f-aa7e-4966-9f13-22977e3dcee8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_723539be-cb87-463b-8d8b-9442e86bba40">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      id="F_d7d9f2a0-f9df-4a02-a772-441b307975f5">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      id="F_b05dd4c8-8a49-44ca-aa5c-7bc52ee687cc">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_e6148835-322e-4742-bb64-9ba503c14de3">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table provides a summary of stock option activity during the year ended &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:45.143%;"/&gt;
        &lt;td style="width:0.823%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.238%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.633000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.823%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.466000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.042%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.839%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Number of&lt;br/&gt;options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;exercise&lt;br/&gt;price per&lt;br/&gt;share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted&lt;br/&gt;average&lt;br/&gt;remaining&lt;br/&gt;contractual&lt;br/&gt;life (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Aggregate&lt;br/&gt;intrinsic&lt;br/&gt;value&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:bold;font-size:6.7pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;position:relative;min-width:fit-content;"&gt;(2)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;9.44&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,561,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28.49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;743,638&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.92&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;324,131&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,612,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;63,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,551,841&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.52&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;34,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Expected to vest after December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;position:relative;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,060,985&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.43&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;29,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="text-indent:0.0%;display:flex;margin-top:0.0pt;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;text-indent:0;display:inline-flex;font-size:7.5pt;font-family:Arial;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="INF"
      id="F_d15a022f-0e67-4abf-8c9f-b7320801dca1"
      unitRef="U_shares">6119295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="2"
      id="F_243a2172-f455-4889-bf6d-3cdddf228bf6"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">9.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_f682e5cd-1004-4024-a345-40c979c17437"
      unitRef="U_shares">2561300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_810fd13d-6310-4761-94e3-488759456c1d"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">28.49</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_e270a080-07e8-41e7-a76c-f581dc2a1982"
      unitRef="U_shares">743638</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_75fa504e-94b1-41b0-9a44-ba8760020af2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">2.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_18f8c341-cc10-4ec9-b6c1-6bbe758d694f"
      unitRef="U_shares">324131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_8da5c371-86c2-4d9e-9af6-bba004979c59"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_76da6e34-8259-4dd1-9d6d-fef59f17f320"
      unitRef="U_shares">7612826</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="2"
      id="F_3ad1dd59-f2cb-4da0-af2c-886026b03526"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">16.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_3d235212-484b-4e5a-92de-60c509efce7d">P8Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_3e8d2871-8d7c-41d2-a82b-315398b036e2"
      unitRef="U_USD">63790000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_97311c9c-61b4-4e18-a3f0-2ad32a6c4f61"
      unitRef="U_shares">2551841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="2"
      id="F_38be8608-8859-4956-9595-0e55be9a3985"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">7.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_c31804f4-757a-40fc-84fc-127c9515ac06">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_09a7fb2b-0c8b-414b-a38f-15fe81be641f"
      unitRef="U_USD">34295000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="INF"
      id="F_f13bbc0a-1453-4f66-a849-7ec20406a08c"
      unitRef="U_shares">5060985</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="2"
      id="F_0a599922-8081-4710-9bde-35868f890597"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">20.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_ee2714e4-37d2-461d-909b-8a096b25efba">P8Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e"
      unitRef="U_USD">29495000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22"
      decimals="2"
      id="F_1c93bcc7-9c60-475a-ac0f-becfd10e8aa2"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">19.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22"
      decimals="-5"
      id="F_8b6d50d0-48af-4d05-8321-fb8f57bc8fb5"
      unitRef="U_USD">21200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22"
      decimals="-5"
      id="F_d5cac074-c2cd-4971-8744-2f60cebd80f8"
      unitRef="U_USD">2200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_40e18ed5-64dd-4a21-8cc0-7eb7d48b6faf"
      decimals="-5"
      id="F_32a0ff97-a519-45e8-ac5c-cfd5bd595c0e"
      unitRef="U_USD">64400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_4e417686-fb62-4c06-b6fd-6b68c1256e22"
      id="F_55391a03-f69a-46a1-9ba7-dec7eba1c73e">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_345d25d5-d53c-4618-b2d5-0ad9f68dc335"
      decimals="0"
      id="F_9ccda87d-46df-46e6-9510-4b03d920ea42"
      unitRef="U_shares">2150537</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <verv:NumberOfInstallmentsForRestrictedSharesVested
      contextRef="C_3c170bb7-edb6-442d-8788-b1811c3e3301"
      decimals="0"
      id="F_64549902-7136-46ac-9cd3-ffb22dc77e62"
      unitRef="U_Instalment">48</verv:NumberOfInstallmentsForRestrictedSharesVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_e4a312ba-6931-4d91-b541-fb2e420d6d93"
      decimals="0"
      id="F_17230d37-f24f-47cb-a8fd-104181155b68"
      unitRef="U_shares">688700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="C_bcc724c9-3022-47b5-8ad1-b152262e7aba"
      id="F_b5e252f1-e8b6-4c17-9355-8c4bfe5cbd9f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_db394905-e39e-4aee-8694-0a2d5575d125">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A summary of the status of and change in unvested restricted stock units as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022 was as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.119%;"/&gt;
        &lt;td style="width:1.184%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.077%;"/&gt;
        &lt;td style="width:1.866%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.877%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted-&lt;br/&gt;average grant&lt;br/&gt;date fair&lt;br/&gt;value per share&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36.58&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;688,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22.65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,375&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;35.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Restricted stock units forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;36,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24.32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units as of December 31, 2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;677,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23.10&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_f440c691-328c-490a-b5a2-6550bd63dd18"
      decimals="0"
      id="F_fd546605-1393-454b-a785-6469fc69293f"
      unitRef="U_shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_f440c691-328c-490a-b5a2-6550bd63dd18"
      decimals="2"
      id="F_fb2c8569-4061-446e-b9ce-0a9590adfd08"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">36.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="0"
      id="F_84e0715a-4625-4bc8-ba55-db40d59260dd"
      unitRef="U_shares">688700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="2"
      id="F_04da067d-67a5-496c-92bf-a784f9c4bff8"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">22.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="0"
      id="F_b808e5bd-6911-4218-9726-9bb053e3a134"
      unitRef="U_shares">6375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="2"
      id="F_2de18436-4318-4299-a7a9-fae1d95d6339"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">35.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="0"
      id="F_c65b205d-fcad-4525-b00b-de44251f369e"
      unitRef="U_shares">36500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <verv:WeightedAverageGrantDateFairValueForfeited
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="2"
      id="F_b343dc6d-9cd9-4eb7-86a1-49c0558db798"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">24.32</verv:WeightedAverageGrantDateFairValueForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3"
      decimals="0"
      id="F_7f2f3bf3-ace7-46e3-809b-b522f2e9dba2"
      unitRef="U_shares">677825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_5a628f3e-c8f6-4620-953c-b4cae63925d3"
      decimals="2"
      id="F_12602417-6890-46b4-bc0c-44f3be6dfc1c"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">23.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_4c419fcc-8948-4d11-ad8c-bc4acd187a2f"
      decimals="-5"
      id="F_b183dd08-963c-42cf-bb3c-05e3d71812b1"
      unitRef="U_USD">13600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_7175e0b6-9535-4c9e-8e30-3ebf8ac9de8f"
      id="F_c053f0ca-3840-4ce2-be5b-3e9a8e7d31a8">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="0"
      id="F_78ce48a1-0634-4d79-9bb5-596e234fcd3d"
      unitRef="U_shares">134107</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan
      contextRef="C_e450d3c0-fb5f-4751-a200-b7af8109fa84"
      decimals="0"
      id="F_cddc92e9-5135-4c1f-8c3f-8ff1c63dd64c"
      unitRef="U_shares">784326</verv:StockAvailableForIssuanceUnderEmployeeStockPurchasePlan>
    <verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_a90ac7d2-282e-440c-801e-9a2c12563c84"
      decimals="0"
      id="F_558c5416-0af9-4ca2-a5bc-8e7718b6e9ae"
      unitRef="U_shares">617308</verv:IncreaseInCommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_805672b9-e8d4-4cd8-90d9-1eca26080b80">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12. Net loss per share attributable to common stockholders&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.184%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.838%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.828%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.967%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;157,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;45,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted average number of common shares, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;54,023,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;26,872,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,250,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company&#x2019;s potential dilutive securities, which include convertible preferred stock, unvested restricted stock, unvested restricted stock units, and common stock options, have been excluded from the computation of diluted net loss per share as the effects would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.329%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19,387,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;677,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,612,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,290,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,151,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23,814,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As part of the license agreements with Harvard and Broad, the Company is required to make success payments. The Company may elect to make these payments by issuing shares of the Company's common stock. As of December 31, 2022, an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million was earned relating to these success payments, which the Company settled in cash in November 2021. No success payments were triggered or paid during the year ended December 31, 2022.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_57c6bb96-d856-4792-a989-df9a7841e033">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The following table summarizes the computation of basic and diluted net loss per share attributable to common stockholders of the Company:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.184%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.838%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.828%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.391%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.967%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands, except share and per share amounts)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;157,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;45,704&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Weighted average number of common shares, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;54,023,653&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;26,872,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,250,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net loss per common share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2.91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_e8640443-3ea8-44e9-a748-a9fbcf872417"
      unitRef="U_USD">-157387000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_c1d63082-8072-4f11-b0d7-518fa1f769f3"
      unitRef="U_USD">-120314000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_ccd037ac-5a75-41ac-93a4-ff951d97f160"
      unitRef="U_USD">-45704000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_70795245-c44a-4a13-8dd3-f465f06773e9"
      unitRef="U_shares">54023653</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="INF"
      id="F_cd6cdba3-9572-47f3-9f12-e62b1482bc87"
      unitRef="U_shares">54023653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="INF"
      id="F_e8eb7313-3415-474a-9a8c-36873211c36b"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="INF"
      id="F_db255bd4-d5a6-4865-9952-b931e9ddeea6"
      unitRef="U_shares">26872036</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="INF"
      id="F_733d71e0-4a3f-4851-8371-70d3b1206622"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="INF"
      id="F_662aa3c0-3431-440a-97c3-639d70cb5716"
      unitRef="U_shares">2250093</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_a9ea0d04-5ec1-492c-9cd5-0b253366eed4"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.91</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_6b85571b-2059-459e-b0e7-45b837b714af"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-2.91</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_11667e64-9733-4f0f-aa82-f4cb56bb611f"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_1d897b1a-9344-42f4-b40c-7443fc8e047e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-4.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_b2c37d5e-1e72-4e8d-b297-51ed2d1aae3e"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_e400fe90-27c7-4bd2-92cd-d9c15e5b9080"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">-20.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_deb2eea3-e480-4f2e-9343-8016bd87cdde">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.329%;"/&gt;
        &lt;td style="width:1.007%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.774%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.085999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Convertible preferred stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;19,387,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;537,633&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;677,825&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;32,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Outstanding options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;7,612,826&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,119,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,888,823&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8,290,651&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,151,295&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;23,814,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5977f77c-03e7-4fcd-8eb7-0857be233fcb"
      decimals="0"
      id="F_4cfe3138-f788-4b6e-8d5b-a7283f48b493"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_787fb8f2-564a-4ad4-9e81-6ab4543c8745"
      decimals="INF"
      id="F_a8726c12-de1f-4c95-90da-91cdbcd54fc5"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_336f1e13-611b-497c-ba64-333f8e899c92"
      decimals="INF"
      id="F_a884cfb9-541c-4d4a-a019-c0b4b4e7b234"
      unitRef="U_shares">19387544</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d49a8d56-7215-4b6b-85ee-c2345d8966fc"
      decimals="0"
      id="F_3ccc0d01-0bd8-4bd6-b26f-3bb661fba63a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0e5b7c24-a5e8-4c36-8628-c7caf3267a19"
      decimals="INF"
      id="F_3da0561d-cd56-4c6f-8c0a-9996a69b4d87"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_101c4b75-a6d1-40e5-b320-d63b7c3de7e7"
      decimals="INF"
      id="F_89bb5089-5fca-4e4f-a6ec-16bb47267781"
      unitRef="U_shares">537633</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_01e0a48b-6d98-43b9-9faa-58583e0071a6"
      decimals="0"
      id="F_60355410-ee73-43a4-96cd-e88d26fe6822"
      unitRef="U_shares">677825</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_9ac9284d-7074-4f13-885b-3fd225b5738d"
      decimals="INF"
      id="F_04fefb94-3bff-4d93-a34c-d63fc846e082"
      unitRef="U_shares">32000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_28ec8de1-aead-4024-b68e-b6f0436f3e8c"
      decimals="INF"
      id="F_295bc431-4d67-4ca1-abc9-8136a680aa51"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a2029774-b097-49be-abf0-6584c59d9b9d"
      decimals="0"
      id="F_27621f8f-701c-445f-bfec-63b403fd730c"
      unitRef="U_shares">7612826</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_dd1cb871-5f3e-4054-bc64-84e70cd6064d"
      decimals="INF"
      id="F_61526d5c-c8ae-4428-b286-095aa1f6c4b1"
      unitRef="U_shares">6119295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_346778ed-ab28-463d-a0c6-1e76673dd790"
      decimals="INF"
      id="F_fac084ea-22d4-45be-b828-dc656f59a118"
      unitRef="U_shares">3888823</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="0"
      id="F_a4c0ed46-9030-4c35-965e-34c228611a6e"
      unitRef="U_shares">8290651</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="0"
      id="F_dd1b979d-62e6-4bb1-8f90-9b519cf518da"
      unitRef="U_shares">6151295</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="0"
      id="F_fa53a679-1ae3-46b8-b179-0ee6263acf70"
      unitRef="U_shares">23814000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <verv:SuccessPaymentLiability
      contextRef="C_94979cff-1f2a-464c-857e-c9995bec9c94"
      decimals="-5"
      id="F_d8dd2350-db46-4d7c-a85c-6a996e1c798e"
      unitRef="U_USD">6300000</verv:SuccessPaymentLiability>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_28c35ebb-ce84-498e-92d6-78c7ebcbc095">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;13. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company's losses before income taxes consist solely of losses from domestic operations, which totaled &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;157.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;120.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;45.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; for the years ended December 31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income tax expense (benefit) is summarized as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.662%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.629999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.629999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.876%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total current provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.004%;"/&gt;
        &lt;td style="width:0.984%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;34.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Times New Roman&amp;quot;, serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company&#x2019;s deferred tax assets and liabilities as of December 31, 2022 and 2021 are comprised of the following&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.941999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.079999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;43,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized costs&#x2014;net of amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;135,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;56,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has incurred net operating losses in each year since inception. Management has evaluated the positive and negative evidence bearing upon the realizability of the Company&#x2019;s net deferred tax assets, which are comprised primarily of net operating loss carryforwards, tax credits, and costs capitalized for tax purposes. Management has considered the Company&#x2019;s history of cumulative net losses in the United States and estimated future tax losses and has determined that it is more likely than not that the Company will not recognize the benefits of the net deferred tax assets. As a result, the Company has recorded a full valuation allowance at December 31, 2022 and 2021. The valuation allowance increased by &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;54.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; in 2022, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards, tax credit carryforwards, and increase in deferred tax assets associated with current year temporary items.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Realization of the future tax benefits is dependent on many factors, including the Company&#x2019;s ability to generate taxable income within the net operating loss carryforward period. The Company&#x2019;s ability to utilize these federal and state net operating loss and research and development credit carryforwards may be limited in the future if the Company experiences an ownership change pursuant to Internal Revenue Code 382. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; As of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022, the Company has not completed a study to assess whether a change of control has occurred and whether the net operating losses and credits are limited due to a change in ownership. To the extent that an assessment is completed in the future, the Company&#x2019;s ability to utilize tax attributes could be restricted on a year-by-year basis and certain attributes could expire before they are utilized.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;163.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;148.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of state net operating loss carryforwards The federal net operating losses have an indefinite life and can be utilized to offset &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of future taxable income, while the state net operating losses will start to expire at various dates through &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;. Additionally, as of &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31, 2022&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million of Massachusetts tax research and development credits that expire starting in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2042&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2037&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;As of December 31, 2022 and 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, the Company had &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; uncertain tax positions. The Company recognizes both interest and penalties associated with unrecognized tax benefits as a component of income tax expense. The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;t recorded any interest or penalties for unrecognized tax benefits since its inception.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company files income tax returns in the United States, California, Connecticut, the Commonwealth of Massachusetts, Pennsylvania, and Wisconsin. The Company is not currently under examination by the Internal Revenue Service or any other jurisdiction. All tax years remain open to tax examination. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period.&lt;/span&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-5"
      id="F_646dd7ef-1990-4173-8f52-0ee37f863648"
      unitRef="U_USD">157400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-5"
      id="F_0623b21a-1e89-473f-8a9a-076b46b28d6a"
      unitRef="U_USD">120300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-5"
      id="F_e9c800cf-ea63-4a11-82a7-2e65663029fa"
      unitRef="U_USD">45700000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_cdd01b56-fd44-49c9-8cc8-fbe5d76a98c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Income tax expense (benefit) is summarized as follows:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.662%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.629999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.629999999999999%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.401%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:10.876%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total current provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:7.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:7.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred provision&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_fc4a6355-3a88-4757-90aa-decd3ae25fe5"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_9e45147e-4150-42c8-853f-c8f2921157fd"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_a8420aa0-7a32-499c-8531-79821f1b9204"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_8d3f18bc-fbc3-4aee-8e7f-e3a84e982882"
      unitRef="U_USD">53000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_ba0bd889-8f76-4bd8-9f90-5150e3a4d143"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_f5bfe00b-18b7-44a8-a2f9-359369c596ba"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_8d1de571-8382-431d-982a-b7e52a011ed1"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_57ea769d-ee65-416c-a133-dea9ce2def64"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_5a7002e3-919f-41d5-93fd-3b9b0a441d36"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_10d942ee-85f8-4611-936c-0276033cd9f8"
      unitRef="U_USD">53000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5e7d2535-6c41-4feb-9713-8dfcbc813812"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_c113d7a8-1cda-4230-8796-f45081285b50"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_0df4ac71-3bcf-49cc-8701-750fdbebe9dc"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_a60ae281-d8a1-4777-8cdf-aa2e89b9ced6"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_32cade3f-d6d8-4c85-bc2c-99c2afb57e42"
      unitRef="U_USD">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_fdfca671-7079-474b-af79-316b8f7fef97"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_08bc33de-d0f2-4f93-88ba-1974627478c3"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_28872d9c-22a3-4ef4-8a62-53ec39c85035"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_ae151fce-8e44-4b12-bed3-8c96b565038d"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_e05878cc-4844-491c-aa7c-e08a2a6679db"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_cb52b461-258d-4bfe-befa-0b89774fd7cb"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-3"
      id="F_5155164f-33e2-4192-a111-878bca103e23"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="-3"
      id="F_5749a672-5a3e-4a78-bd57-1876e3a472f9"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="-3"
      id="F_4c04605c-5658-47c3-be9d-abd4b98778a8"
      unitRef="U_USD">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_03ef9407-ffff-489c-b80f-7a6bf637e1c0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;A reconciliation of the income tax expense computed using the federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:57.004%;"/&gt;
        &lt;td style="width:0.984%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.338000000000001%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:0.994%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:11.348%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="10" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Year ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Federal statutory rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;34.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;31.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;29.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Executive compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Permanent items&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;State income taxes, net of federal benefit&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;8.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5.6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;4.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Effective income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_a6bf8734-dd29-44f2-9830-d6e4104d3e65"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_ce915678-f911-468f-a79c-26e136be9779"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_44a14dde-3a88-4a40-9fe7-6697c674fc2c"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_eb03c9d8-182a-4393-8adb-4d431a7e6859"
      unitRef="U_pure">-0.347</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_46056b0c-17c7-4a34-ae85-3572d75aa38a"
      unitRef="U_pure">-0.313</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_1c4dde36-8c0b-4937-83ca-c756bbc667be"
      unitRef="U_pure">-0.296</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_d44b11c3-9b48-4cd9-a759-6fa7c7ae510f"
      unitRef="U_pure">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_76a3dd0e-93b8-4519-845e-a1fb4a9a13d6"
      unitRef="U_pure">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_2e72ca1d-abf8-48cb-8855-92e17c2321c8"
      unitRef="U_pure">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_e7ff60eb-c61a-4fa1-b81a-b271e29372cf"
      unitRef="U_pure">-0.008</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_7c1d96cf-4e52-4f0a-b8fd-de711a87a908"
      unitRef="U_pure">-0.011</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_94fe7169-bb45-4bf8-82cc-05f9d0ffa92d"
      unitRef="U_pure">0.000</verv:EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_989f04b4-841e-42ad-b717-a0a8eab2fa47"
      unitRef="U_pure">-0.002</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_1437d3cf-73c5-4589-a615-a9f4eaac08fd"
      unitRef="U_pure">-0.001</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <verv:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_74f496b8-e7bd-4184-a14d-95de73170163"
      unitRef="U_pure">0.011</verv:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_773f687f-08e6-404c-92d1-f4bdc3ba47a5"
      unitRef="U_pure">0.084</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_af883616-978c-4683-b84f-8d26a0584514"
      unitRef="U_pure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_5b37fdcf-5c7f-4bb9-bd2b-a8b54014fe38"
      unitRef="U_pure">0.068</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_9ee549e9-b4ab-4b3f-9bc8-51fc7ce9dca2"
      unitRef="U_pure">0.056</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_f1f48748-f926-43f7-b493-39bb39ac4b70"
      unitRef="U_pure">0.045</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_5e7a52da-d099-4b88-b7fd-6df246113389"
      unitRef="U_pure">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
    <verv:EffectiveIncomeTaxRateReconciliationOther
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="3"
      id="F_1f6c0015-a89f-4192-9413-f1ba993802d2"
      unitRef="U_pure">0.010</verv:EffectiveIncomeTaxRateReconciliationOther>
    <verv:EffectiveIncomeTaxRateReconciliationOther
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="3"
      id="F_3f844f8e-1296-42fc-ac11-de9dc8b7a5f5"
      unitRef="U_pure">0.000</verv:EffectiveIncomeTaxRateReconciliationOther>
    <verv:EffectiveIncomeTaxRateReconciliationOther
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="3"
      id="F_c06222f9-41b7-4235-bf72-d9ddef8bface"
      unitRef="U_pure">0.000</verv:EffectiveIncomeTaxRateReconciliationOther>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="2"
      id="F_50952bb5-05e4-4c39-a600-7e00438a28fa"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_7857b09d-9c1b-40bd-8d2b-001c0847756a"
      decimals="2"
      id="F_f9775c3e-fae7-48d0-9dd2-fd990e5438fd"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3d29fbc3-5622-4165-a232-e591a91a09ce"
      decimals="2"
      id="F_ff983ae7-b84b-446a-b512-96ace5729d87"
      unitRef="U_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_78f2bbd6-dae5-4b87-87c3-8d5c99aa47dc">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;: &lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:6.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.756%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:12.941999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.611%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.079999999999998%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="border-top:2.25pt solid rgba(0,0,0,1);background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;43,779&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;33,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized costs&#x2014;net of amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;11,095&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;12,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Research and development tax credits&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Capitalized research costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;28,650&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="-sec-ix-hidden:F_fc68c0bd-4fb1-4f7f-9054-7fc7f7df2d80;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3,669&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,117&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;174&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;76&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;22,285&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;5,024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;135,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;56,480&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;881&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Right of use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;24,994&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;25,875&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1,400&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Total deferred tax assets, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(255,255,255,1);text-indent:28.0pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Less: valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;109,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;55,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(255,255,255,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_fe9089e2-82de-44dd-af59-db461ff44ca1"
      unitRef="U_USD">43779000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_78d4d0ba-1b86-4c72-8944-f9ffc06bedc0"
      unitRef="U_USD">33409000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_0532ba67-52d3-4020-9eb4-8e691b7906fa"
      unitRef="U_USD">11095000</verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization>
    <verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_8105dcb3-7277-4124-bf79-3fc982738adc"
      unitRef="U_USD">12395000</verv:DeferredTaxAssetsCapitalizedCostsNetOfAmortization>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_7c42cf3b-1e6d-4e2b-9315-c6b85b92f788"
      unitRef="U_USD">20835000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_15bd770e-cad5-4930-ad29-7cb5569faef3"
      unitRef="U_USD">6098000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <verv:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_ab039620-6de0-4aa6-8abb-3b6dc804d655"
      unitRef="U_USD">28650000</verv:DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <verv:DeferredTaxAssetsStockBasedCompensation
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_2aafece1-0184-4d36-a49a-da38e52dada6"
      unitRef="U_USD">3669000</verv:DeferredTaxAssetsStockBasedCompensation>
    <verv:DeferredTaxAssetsStockBasedCompensation
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_9d42f7d4-cb16-4e00-a6eb-03032d9fc8dc"
      unitRef="U_USD">1117000</verv:DeferredTaxAssetsStockBasedCompensation>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_1eea6d0f-474f-4daf-aad4-e21b00757b0a"
      unitRef="U_USD">174000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_3192279b-8bc5-4d27-9bc6-1eb6af271744"
      unitRef="U_USD">76000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_5f10d659-2aed-44a8-a919-09277b73d945"
      unitRef="U_USD">22285000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_af8df070-6722-4854-8399-6b4a5e05b00b"
      unitRef="U_USD">533000</us-gaap:DeferredTaxAssetsRegulatoryAssetsAndLiabilities>
    <verv:DeferredTaxAssetAccruedExpenses
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_e1c43fc8-e786-40f2-a5e5-0c852f75f7e0"
      unitRef="U_USD">5024000</verv:DeferredTaxAssetAccruedExpenses>
    <verv:DeferredTaxAssetAccruedExpenses
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_60887a7d-ce52-4349-9a5d-24454446d54e"
      unitRef="U_USD">2852000</verv:DeferredTaxAssetAccruedExpenses>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_6ed11926-7e1e-4968-a081-f3377a504159"
      unitRef="U_USD">135511000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_b63ba75e-c7eb-4e72-8b54-53303c1fe119"
      unitRef="U_USD">56480000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_2a390555-4775-437e-9552-160a4e2db0ff"
      unitRef="U_USD">881000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_00c30542-18d8-4c61-8799-7a5f51d35c63"
      unitRef="U_USD">899000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <verv:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_79291490-2f10-49ba-8aa6-3c75b6d6e623"
      unitRef="U_USD">-24994000</verv:DeferredTaxLiabilitiesRightOfUseAsset>
    <verv:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_214a0ddd-a3e5-44e9-8137-806f88c56815"
      unitRef="U_USD">-501000</verv:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_7152d2b3-b9d7-4d09-b33a-776695153d55"
      unitRef="U_USD">25875000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_0f40ebaf-80d3-4047-8939-a78635f404bc"
      unitRef="U_USD">1400000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_899b3e9f-085d-4be3-8fd4-32cd195eca37"
      unitRef="U_USD">109636000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_f01728b3-3e8c-41be-86a3-e146d26c0210"
      unitRef="U_USD">55080000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_010c1983-e9d0-40f0-8e1f-e10cc5baf748"
      unitRef="U_USD">109636000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_84d15b33-298f-4d89-a8d1-dc121003e1e6"
      unitRef="U_USD">55080000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_0ff3debc-9f6c-4997-8e8f-26a16c9c05da"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_8babecbb-2e85-4e97-bf86-c14346b00e27"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-5"
      id="F_e900c522-2c2c-4112-b126-ac97732f90b0"
      unitRef="U_USD">54600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <verv:ChangeInOwnershipDescription
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_f34e87c8-8442-4ecc-8ae6-5cda16abade2">An ownership change occurs when the ownership percentages of 5% or greater shareholders change by more than 50% over a three-year period.</verv:ChangeInOwnershipDescription>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_dd53e7c9-c890-4a7b-9181-75e01d01947a"
      decimals="-5"
      id="F_47507c25-78ee-4354-be2f-a53215082af7"
      unitRef="U_USD">163900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018"
      decimals="-5"
      id="F_ec8be912-2917-4d1c-abbb-8763497af48c"
      unitRef="U_USD">148000000.0</us-gaap:OperatingLossCarryforwards>
    <verv:PercentageOfFutureTaxableIncomeUtilizedToOffset
      contextRef="C_ae9a1b92-1fd7-4378-a219-aeb6c0ec3018"
      decimals="2"
      id="F_d12840a8-b2da-4f1c-aa2f-c117c2012d75"
      unitRef="U_pure">0.80</verv:PercentageOfFutureTaxableIncomeUtilizedToOffset>
    <verv:OperatingLossCarryforwardsExpirationYear
      contextRef="C_62529372-4437-4f8a-a2e2-7adb297a1ce7"
      id="F_0df0e8b7-2337-4044-bd6d-d516a275df84">2042</verv:OperatingLossCarryforwardsExpirationYear>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_dd53e7c9-c890-4a7b-9181-75e01d01947a"
      decimals="-5"
      id="F_ec4317c1-1869-4feb-98c1-49451b4d398a"
      unitRef="U_USD">14400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_1eb38d59-c0ac-4039-ba0c-18ac2f3c88af"
      decimals="-5"
      id="F_a5e82df4-c171-4a7f-a019-69fad5666f98"
      unitRef="U_USD">8200000</us-gaap:TaxCreditCarryforwardAmount>
    <verv:TaxCreditCarryforwardExpirationYear
      contextRef="C_b8d60c32-c672-429e-9168-9e517a3b0c68"
      id="F_446fd862-0ad1-4f79-8f95-3535ade0a892">2042</verv:TaxCreditCarryforwardExpirationYear>
    <verv:TaxCreditCarryforwardExpirationYear
      contextRef="C_42d8066c-ec6d-457c-92e0-ad6208d5c754"
      id="F_893be8b9-13ac-4055-b712-4bacc9487882">2037</verv:TaxCreditCarryforwardExpirationYear>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_52a4a369-ae67-4de2-82c2-3426ee972653"
      decimals="-3"
      id="F_f7b22f09-6203-4443-8736-cdb0c2fa27f3"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_50163530-3d32-4277-baac-6dd493e6a3c1"
      decimals="-3"
      id="F_e7375e70-8b54-4c95-9851-e7f65c6a11e6"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="0"
      id="F_ca364bc8-e72b-45d9-b815-a0ac8a182c87"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_abd2f758-8de1-4f15-9088-083813defb61">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;14. Related party transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;An executive officer of Beam was a board member of the Company until August 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In October 2020, the Company and Beam entered into a materials exchange agreement wherein the parties agreed that Beam would provide certain mRNA, gRNA, and protein to the Company and that the Company would provide certain gRNAs to Beam at an agreed upon price per each material provided. For the years ended December 31, 2022 and 2021, respectively, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million as a reduction to research and development expense related to reimbursements received for materials sold to Beam.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;In December 2021, the Company entered into a sublease agreement with Beam for laboratory and office space in Cambridge, Massachusetts, which sublease terminated in December 31, 2022. Total rent payments under this sublease were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the year ended December 31, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;An executive of Broad was a board member of the Company. The board member resigned, effective May 2021. In March 2019, the Company simultaneously entered into the Harvard/Broad License Agreement and Broad License Agreement for certain base editing technologies pursuant to which the Company received exclusive, worldwide, sublicensable, royalty-bearing licenses under specified patent rights to develop and commercialize licensed products and nonexclusive, worldwide, sublicensable, royalty-bearing licenses under certain patent rights to research and develop licensed products. Additional consideration under the license agreements include antidilution rights and success payments. See Note 8, License agreements.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_467087e6-7c15-4d2a-b5aa-9b131364dec6"
      decimals="-5"
      id="F_1cbd2163-2811-4142-b311-80d37ddc0db1"
      unitRef="U_USD">400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_88c35c5e-d77b-4780-9fe2-eff887d461de"
      decimals="-5"
      id="F_cf3d249f-23e5-49cc-9439-318d1dbb6ff8"
      unitRef="U_USD">200000</us-gaap:ResearchAndDevelopmentExpense>
    <verv:LeaseRentPayment
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="-5"
      id="F_9d01ae64-6dec-4aca-8be3-3fa820400f0d"
      unitRef="U_USD">1800000</verv:LeaseRentPayment>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_0305bacf-6b59-41f7-9500-3e24ed5d8d06">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;15. Employee benefit plans&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company has a defined-contribution plan established under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;), which covers substantially all employees. Employees are eligible to participate in the 401(k) Plan beginning on the first day of employment. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the sta&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;tutorily prescribed limit, equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;20,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; in 2022 with a catch up contribution limit equal to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;6,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; Since January 1, 2020 the Company matches &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of each participant&#x2019;s annual contribution to the 401(k) plan up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the participant&#x2019;s salary and then &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;50&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of each participant&#x2019;s contribution up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;% of the participant&#x2019;s salary. The match immediately vests &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;%. The matching c&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ontributions by the Company to the 401(k) plan were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; million for the years ended&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; December 31, 2022, 2021&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;, and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
      contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"
      id="F_82437b18-6945-4459-a243-7b3f0a5c9869">The 401(k) Plan includes a salary deferral arrangement pursuant to which participants may elect to reduce their current compensation by up to the statutorily prescribed limit, equal to $20,500 in 2022 with a catch up contribution limit equal to $6,500 for those 50 years of age or older, and have the amount of the reduction contributed to the 401(k) Plan.</us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"
      decimals="0"
      id="F_3da0a082-127d-4c57-bd4c-ba092fce9573"
      unitRef="U_USD">20500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      decimals="0"
      id="F_fbe15966-9ce5-46e4-bb0e-245863f02abf"
      unitRef="U_USD">6500</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary
      contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a"
      decimals="INF"
      id="F_abf3499c-2f50-4442-81b8-0364e16ce35e"
      unitRef="U_pure">1</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary
      contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"
      decimals="INF"
      id="F_5c55c6af-fddd-487c-b15f-284b40ea6536"
      unitRef="U_pure">0.03</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary
      contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a"
      decimals="2"
      id="F_5034f149-290b-409d-bc6e-a9c1ba764e46"
      unitRef="U_pure">0.50</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary>
    <verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary
      contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"
      decimals="2"
      id="F_1d721bff-e883-4f6f-b1ba-145ddc742fdd"
      unitRef="U_pure">0.02</verv:DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary>
    <us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
      contextRef="C_9966a6e7-5328-4db3-ad1c-4825b3952f9a"
      decimals="INF"
      id="F_6d94f22b-e2e5-4ea6-a5ee-f59cb24f2e3a"
      unitRef="U_pure">1</us-gaap:DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_3c178253-f282-45ba-a2bb-8b3a3328bf26"
      decimals="-5"
      id="F_bc874398-00e8-414b-8e42-50683c38885f"
      unitRef="U_USD">1000000.0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_1f3707ed-9eee-4702-833d-a6141f5a0cf1"
      decimals="-5"
      id="F_c647a9c2-cfb6-4061-9f9c-4132a99eb16e"
      unitRef="U_USD">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_38705494-508f-4282-b760-eb63eae1915e"
      decimals="-5"
      id="F_2071132d-26eb-4dfe-99df-dc75f0a788c4"
      unitRef="U_USD">100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_2732e9b1-8a6e-408c-9326-ef2e6692329b"
      id="F_57093492-f965-401f-afe8-0e6a9b0d40c7">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;16. S&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;ubsequent events&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&amp;quot;Arial&amp;quot;, sans-serif;min-width:fit-content;"&gt;The Company evaluated all subsequent events and determined there are no material recognized or unrecognized subsequent events requiring disclosure.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_0a599922-8081-4710-9bde-35868f890597"
          xlink:label="F_0a599922-8081-4710-9bde-35868f890597"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_f13bbc0a-1453-4f66-a849-7ec20406a08c"
          xlink:label="F_f13bbc0a-1453-4f66-a849-7ec20406a08c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e"
          xlink:label="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_ee2714e4-37d2-461d-909b-8a096b25efba"
          xlink:label="F_ee2714e4-37d2-461d-909b-8a096b25efba"
          xlink:type="locator"/>
        <link:footnote id="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xlink:label="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">This represents the number of unvested options outstanding as of December 31, 2022 that are expected to vest in the future.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0a599922-8081-4710-9bde-35868f890597"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f13bbc0a-1453-4f66-a849-7ec20406a08c"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_ee2714e4-37d2-461d-909b-8a096b25efba"
          xlink:to="FNT_247ca409-7f5d-47a8-8c48-39a833c8dcd8"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_09a7fb2b-0c8b-414b-a38f-15fe81be641f"
          xlink:label="F_09a7fb2b-0c8b-414b-a38f-15fe81be641f"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3e8d2871-8d7c-41d2-a82b-315398b036e2"
          xlink:label="F_3e8d2871-8d7c-41d2-a82b-315398b036e2"
          xlink:type="locator"/>
        <link:footnote id="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xlink:label="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.5pt;font-family:&quot;Arial&quot;, sans-serif;min-width:fit-content;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of December 31, 2022.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_09a7fb2b-0c8b-414b-a38f-15fe81be641f"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3e8d2871-8d7c-41d2-a82b-315398b036e2"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_1b04ada1-6a5e-4208-8e56-2e88f0fc6d7e"
          xlink:to="FNT_cbfa0a0e-19c5-4a4c-98d4-6e84510cdcd3"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>116
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M.U94=XJJHWAAC^4%5_J0M\U4W\- F #]?,FY>NZ8D[ZYV45_ %!+ P04
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ML$*H3_388)T)2G9"LK(9##,H\^KP39X:1YP,<,.! ;@9@/L#_($!7C/ >^D
MOQG@*\\<J"@_K(@DBRO.'A&OT6"M_J&<J48#_;RJXWXG.?R;PSBY6+)*L")/
MB:0INI/P!4&5 K$-^G5+.:F#(Q"I4K1D)6165H=\3]'/3 @T19_O5NCUJS?H
M%<HK]"EC.P%0<363,+7Z ;.DF<;-81IX8!HN1A]8)3.!OJ]2FIX;F &GEA@^
M$KO!5HLKFEP@SWV+L(.Q84++EP]W#<-7+Q_N6-AX;9@\9<\;L/>^2EA)NP"A
MW]^MA>2P:OXP.?M@S#<;JTO)I=B2A%Y/(**"\CV=++[]Q@V=[TR.&M/8:B1C
M9T[T6R?Z-NN0ZT5!UNR8U)SN:;6C)O\=[$3*3ETY]PMW[D,:[$_]HH.<<\3*
MACAC$+0, FL:-$NRND?T"2J_H.+2-/U@S/"/:6PUDK$SYX6M\T)K^#^"1<*3
M3%6S%()?L&V]EDP>/%@*3Q/ <YQYT$L!'1;&L.)[::"CO,"+7',J1"V;R,KF
M1UI!+A2*#$FA,^1U/:B;J(E/I$\A"CRO1T='N7$<]DBO=%2 @]#,)F[9Q%8V
MGY@$+DQ+;Q.76)]E&(4X[I'187'DA%&/C([RG1!'9C;SELW<RD8UQPUGY9$1
ME!L3D[GV\*D;!F'<F^32@#-Q,< L9%RGDPB.O>K(C')H\*H%O6Y"\\98>1I+
M(Y6>4:VMQK)V[L43H>7:NT]&JGM:ZZ0-R3G:DV)':YD%#]M0SD%^@=A+'A"L
MX@K4/2IRLLZ+7'XU^MG58MUK/LOG(2L#! ?.4+[@CBG^5TQ))?,T+W9*\/-:
MD(MG6.+G6>J0*0Z"R.]3-> "+Y@/<.UTF6M5+(-<Q2Y)*%2!+?FJ])J=IZ>7
M-#\.^U1UU#2*W7YY-L&P%P]%M1-/KET]O:\DA74A5<=A)R7A+:JHL8DV!L_;
M8[]J+0THU^^W4!,HQ .4.C7E6O7&L>LH+DU9&R83Z/T$VGB?C(Z:>A[V^Z7:
MA(.5-Q2D3N*X=HVC.L^:;ABG4%C8/E?OYW!Y+-^2/)F[JJNKE*D;1)[G]RF:
M@-CQ7&W)&8!^$#G^ ,E.^;AVZ7/[SX@9](H6-AVCU4H;Y)Q()WI<N^KYA4)A
M@(@9IQUK+P\J'IHX, *-\3  ;?'HU(YKESM'&@C$#H)@E! 9D1%(02(ES]<[
M2=8%1(BU?]:-+F-%2KEX6V_;Y(G1!8?'SL\JV<6\_QYF@OD7?MRG;[+F7'@#
M.AQW\@A;A<-_I:\Z8G_+H]GA<%[D !/,X "C-8L#.F6#[<KFB]I<H^F4[$'M
M0C<\=8) .P':!AID=>JG,?(#Z_(E\!WLA=KZ-B QR&Q8)6'?208D:")G[@UX
MJ5-%V*Z*_F<OV=)(USY#?M*10WXR(*U^ZA05MF]UZ?N,QC<-/.H>UZC65F-9
M._=@I]2P7:G9V@K6]Z3,;<4(-+45$]#25G"GSO SFUU*ER5GZ5 ,IL.H>UZC
M6EN-9>W<CYTFQ'9-^+GBE!3Y7U!?5&&!TE$2_D /]4309,=SF9O%$S9IN+#_
M9F)"8;UDF(3C0))T6A#;M>!22P\CC<B8];%> $U [ 1!7PZ:@'76!SU"LY.C
MF9+R>W7$)2"K=Y4\'&:T=]MCM'?J\*AW_\:]7!T.PSHSA[.Y#X3?YQ6\2M,-
MF'0N(D@W?CCN.EQ(ME4'0&LF)2O5SXP2:!LU /[?,":/%_4#VD/'Q=]02P,$
M%     @ W3MB5A</ E.@"P  L6H  !@   !X;"]W;W)K<VAE971S+W-H965T
M-2YX;6S-G5MSV[@5Q[\*1\VTR4RT(BZ\I;9G$HE$\["M9[W9/M,2;'%"B5J2
MLK/[Z0M2C"A<!)'VR4Y?;%V WP%Q#D#BCT/JZKDHOU9KSFOGVR;?5M>3=5WO
M/LQFU7+--VGU4['C6_'-0U%NTEJ\+1]GU:[DZ:JMM,EGV'7]V2;-MI.;J_:S
MV_+FJMC7>;;EMZ53[3>;M/SC$\^+Y^L)FGS_X)?L<5TW'\QNKG;I([_C]9?=
M;2G>S8Z45;;AVRHKMD[)'ZXG']$'YN&F0EOBMXP_5R>OG>90[HOB:_/F\^IZ
MXC8MXCE?U@TB%?^>^)SG>4,2[?B]@TZ.-IN*IZ^_TY/VX,7!W*<5GQ?Y?[-5
MO;Z>A!-GQ1_2?5[_4CS_BW<'Y#6\99%7[5_GN2OK3ISEOJJ+35=9M&"3;0__
MTV]=1YQ40.1,!=Q5P$,KD*X"42K@X$P%VE6@2@42G:G@=14\U<*Y@_:["KYZ
M#/Z9"D%7(6B==>C=UC6+M$YOKLKBV2F;TH+6O&C]V]86'LFV32C>U:7X-A/U
MZIMYL:V*/%NE-5\Y=[7X)^*LKISBP1%?/?&RSNYS[MR* .%EV98IEE^==-N]
M6A?YBI?5/YSX]WU6_^&\7?"';)G5[YRI\^5NX;Q]\\YYXV1;Y]=UL:]$M>IJ
M5HMV-]9GRZZ-GPYMQ&?:^&M1I[FAVMQ>;5YL-B+8VV8::B_LM3^N5EDS6-+<
MN4VSU?3SUIFGN\S<DO@":[G<;_9YV\?_J=>\%'V[$3/'NAG23]SYO%T6&V[@
M)L.Y7;\;(,P.45PK V8BG(XQA8\QA5LB/4/\Q!^S[3;;/HI)(D^W2^ZDM6C?
M\B>'H/<.=E%DBH$#,VB9S03Z=#-%D>>1J]G3J<_U8E@NL=!+(.R'<J%8+Q3)
M)1)#>[ ;$L4:,[3'HZ%[+"7U(#GV(!G9@V_%$*K6:<FK=X-ZT\IOSF\?JEVZ
MY-<3$885+Y_XY.;O?T.^^T_3.#O _-,>#3U*B=*I"TBC,20L@80QO3L\1#&B
M+C5[G1Z]3JU>_UQ5^];98O*]XV7&*^>CLSR9A7?'H5H=9^&*UW7>3MI-M;H4
M@#5WRN8,[.19>I_E8EI^[VQY^WWVW<2RJ&KC5&QMXMC @80M(&$Q)"R!A#&J
M32C$#R)L#BWO&%K>_U=HG4Y8IC"S-G=LF$'"%I"P&!*60,*8ITUB- IHA/S
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M3_/L3W$FR(M*7"ING?0IS?)4K#.G#T4YK5*QX*SX<E^*ZTING@JHYM*I-A6
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MG9%;(YQW9/6!W1\EA?22$@+X"NT^'T85&Q^2?>2($4*5*&R@1OU=NQ[]FVW
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M/1QB5;H;F!_0N$:XLJZI:>  LJ@E8/.RS8<]' ^>_2KBJ67X0&F@1F&Z@%F
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M3Y(]<Y;7?#+<FG&>@.'_?\1H#T+*(N['9DH>,50^]U,\:.>7<2"2:H'X2LE
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M2(T QW?$FAO'TZ///,ZY7;:7X+C3F[KR W_HT=\FAFD4!WH3065I8YB:K,S
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M0AJ>Y6,X(8F%29+ R>#(A5%HPSP<CW,2QB%CZ> '<N+GB@;^Z\;<$-/E[G'
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M_4OVZL:JW'T$6REK5>HNMP)@HVD"GJ\5.NORAC:HOXK>_@]02P,$%     @
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M-!X5F2\W"D.,)0&\7QGCZQO:H/DT??=?4$L#!!0    ( -T[8E80PKQQ0!,
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MH[=+,0IMSZ<?Y;-3%GY0Y7N$QQY@TP,J?7]-9@FVRP1NJ[W;[^T29^>S]G!
MV'*W&23O NBQY/M%2"DSL4>DXEFW(<*W^E9@1ZEIL90$R=I,S#K97.(]D+TJ
M/<JR@WU&[UZI:VPA@=:-;TIV]!X#C<3J?.X XOM28,#_)]CZ9=)F#;68NT,>
M[P9^YF"ZMR491IK>E?2C3FU,GKB+)Z/]R+&#]^J WEE<$1]*XO7*J)30OI0
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M P>7E^GL$XA&63;8TK&@LN\AJR1^)C:-EIP%+(^$R^3+M,^>C^)M>066D;@
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M )"QMMMN)),V0X-ZSZ!26B^,ILK<D8;XWY/C<I#@! ":E4]<.@]I94/#&J=
MEK1-'AM'-J/ #VT<AUO3*U%C%K?2^*C^ S6IJI.J0P$4BN.(L-^"Q'0TJ'RA
MV!=Y-AE[%<3)GP,/JMDZF;4MY:3)+$]Q"L'"F&81[!Y<+W.=9@?@="$7R!A^
MD\(EABC/DNE,C%6.P#SSB:/"Y4#PT_:-2D;=]T8(\J0W0'M&FVY[M@D164LZ
MH0%_I1&F+LF)B+%4O]7FCO*'DJT SQVXKEQ,('%LQ%--U!7H#QYJ\TLXV:?D
MH+\@!HU@BIJ,(@X@LB45@VD8S:=YLY/HU&C>SY%#8#Z;>/*W_7CT@6BL$"U;
MX1%B,<9@,7S;!?(,4&@X^'WF_EJ9RQH7:VKWZM'UWFWBBOWTT6/.V69PD,$]
M>?3Y4'F-W#=[\>SBT4\\PSH8]>)R=GGY_-$-V;C^KJU?UMI^S\[+1U^,QPH5
MI,P-^6,JET8D,]^?38":9M5Q&<91B3#CDH/S=:GD$*,TX=R:749EB<&%-_K]
MX(^#K\3R-$_H/?/.*:F,OUQ>DD.G6B2&?.2ER$0<"ZJL?#E!=,S+5M&46LU#
M6OH&?A.:DHYLS?4O?>NDF%F+9HK>$'%;'V81;<N=:%2I#ZU"44-D#B-P&3OC
M'CD7&]31*])P.E%/9GJ%K>"X0+0FT>^UW>P4$?2N:/*FCU]VAE>C.Z6@F*;%
MXJH?Q=G\9=DW9<GW= ,[K6X!5KO=ZVC5>N0R&>V!FG6+T75IGZT\C4>=Z8[9
MN_@EV-1T]&G/I+T)H!;2VKY1V/2+%GCGRLKVT* @M9+Y\X0NXC&]HN8?Q=<R
M/%H-33P@#QE7-WG2]HK&HUB)N6 !9*;IZ2R^]QB_JQAU[)%38C7A\NQZJU]Y
M<#J0W_3'IF97$S0/XI$95RA^#'+3Q\+)E48]Z'KS?=^"G12?\]$<G3]:=.'5
M1/BR+Z_F[R*OPN> X_;P4>4ODL;P3C1JB:.G\^<71R&\TP]O>OXX<&&\-RW_
MN5825J4->+XTQJ<?=$'^6O3=_P%02P,$%     @ W3MB5I!!Z^W<!0  "1
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M$5KM[F/7TX3FCN-SY*TJ%VCFX20V;3>,W3@\1S_?[]48_B'!M.K(#8,_:5G
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MHO$T2&93\:I=Q6&01*-N-1H'TQ"+WANJ-,J^A?CB>PR\D#= 79&H&N\+_-V
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MMFFG\';A=.TG7W0\S-'^,<>'"QD6P/Y2HQEU"P;8?@K-_P=02P,$%     @
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M,Z&9YQ;>6V[$*K2HA@=@.)9UD?($13N8<KE"&$<#@0"G*#>$ &-D&YT\*/Q
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M, J/#T\+V'H@-0<"_K4W;=D49X2:*]E\E,<=D=/\H@![VQ+D: N2K2(PV](
M@0 % FEDMUE99>N*"1/>O<U@FJ%+-D!332LX*7L@I*HTMS ^H'&-<&5=4].'
M TBTEH#-RS8?=K ]2']G@4"=AP^T$*HHIDT8!4CA8!Y+D_4 ^ 0,UTV?()7C
M%WV3$CB;K&QA/=6@C+W;P0(!%?GGY'@/RVQQ,<A(E5$JZQUV_X;3P-; S/MA
M#2(1?M\8VIGCHW<??CLZ.4EYM%/<AX)& AH@BG5DX&\Q$"H\[X'5JX%F;%%I
M,DZZ(0>L=<D^NZ<U J_G_0"3 QF#BNU@^*$"VB@1B&33-CO!ED7M$B^_L+S\
M8I$3K[)N2^#0/WX$+@($(C@QICYPJ!S_8=Q0R?PON/- K+@32$9%UL)+6Y-_
M1JQ;88J?PE::>V#H]C.8;O)+L@%:5)*M@5A[$"* F[8$20O4]>GL^BRY:6Y-
M6R.*8=ORSRA]G:RE34/:A@=(PCZS$6Q ZO 6".$M[!R,6I4 ?2&S,6V2%,J
MFF!S@78K ++'\>^9OEIC$'BT!8 :*MSRC,4-TCN^LQ_:? L4):PV1M(9X\]'
M&W( <4>!8^5-UZ? WF6^3<J.E$N/5)>APG&?X?".19:(YQM+/-\L[OA'P &(
M&00#@8Z1S.( <:-A-&HR_AM$)+[+Y%-5@(466;9M;F&W"N8YP',/STD,M*8
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M(EK!<"FKBE^!YPE\4.?WWK1G<_CQY:PS75"0#3C=T+9$S&#C9&(1=_:IF%W
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M=:63V";)")]<_" 3O3S'4(16G_HMT8Z=PEO48F;??4=.\^CXAM:,SV+7.TY
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M&>@0%IT8YV&=F%N2NRMWH<)J^4*%JR U\QY8-R9]EP>)WZ40CDQ"(?+('G!
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M<6B\ NUOM';'B3^@?S67_P%02P,$%     @ W3MB5BLYN 17!0  HPX  !D
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MOIA01>OVSF\'5M7^GETK2[>V[Y;T3$+M%M#_C5+V>> <= ^OY7]02P,$%
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MRMUPW(N1"WNK>)0&[RAV.,=+(2@RP.]3*<WVA3;HKYF3_P!02P,$%     @
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M:;"-<9\%]HV@[ 9<SR6JNAO8 $,GNOH74$L#!!0    ( -T[8E8%QI(3 P4
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M%XE5HLP$DY\2&2>&LRQ! %V &5G&9$%\% LP\GV:Q(+$2S"E(?$)YN :C(*
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M+,W?!:5U,.=+(?36L!?T_ZOT#U!+ P04    " #=.V)6(/_<SX("  "I!@
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MKIZ1Y2LDU^Y)-EULX)%BI8VL.S!F4#/1ONECUX<=0'C\"B#J -%+0/(*(.X
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M#!A]%DC&443$QQT-^;ION=9FX268+Y1>L >])9G3,56ORV<!=W:.,@TBRF3
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M6"GVNQ7-3KQ2!8U@8N%64R W8(5OW[B^\Z'+[G\2>V:^UYCOG5(/;[."BQT
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M<D4X))CG7 :X>&1U[54=+8KRYE@*C?=0V4SQ2P&D"<#Q1 B][YC+J/GV"/\
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M#:LVNZT.>+XIMTY]R#G/T_+CFH8193*!^'Z5Y_SM0&:PVW+X^B]02P,$%
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M-44BFPNIF6A1UI? 5&ASI=3#E;G$4=H%YOU""/TZL?=*][<@_PM02P,$%
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MP=J^")65SUW*.4NK]*0>NJ+E,X@ZD_V3H9Y)E[1,CXJF:]_X8]MLD%W 2:-
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M[S2%:-I=,U&\M!UCPY7N/W:8Z2\$"%.@]U/.U6%BFE#WS8E^ U!+ P04
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MP>ZR87?9Y3W:9\?B05V0):PSSC.^QB+"/QS#Q3Y_OAS5M*)0!0EM$'/$;*,
M3QQO[&Z/8!LTV :=V#Z6Q1*D2>P*W%O4^QR0P0&0<#0:GD(2-DC"5ZJT+Q=E
M*^(5VH0'D'IA,!P<1S1L$ T[$1T *6W=X@6P@NP<HN$AHB <G!)IU$ :_4@J
M 4]^/(]&A[]O.!S1$V)=-<BN.I%]LJ<^)+WI%B3>8E4F$3R*@;QAF22/+"_Q
M3,-DLU5\K@[VQ\PQ#A66JW8MA/W!Z#@%W]M? =Y/D.A]1Z)=)=TPZW!^T )*
M:3\\H;7?NJO\7ZSVX^N$K>-^@S@8] ?!"<1TCYC^$FG;U74&*CTB[F4_H">@
M[B\CO_,V^ EQ.^KP#(?@()%IT/>_8^"VNIH"Y-KV;@J[E)+KJL%I5IO^<%IU
M1?OM57/Y@4FL.D5R6*&IUQ_B82ZK?JV::+&Q/=)2:.RX[##%'A>DV8#?5T+H
MEXD)T'3-T5=02P,$%     @ W3MB5LC64$YO P  $@P  !D   !X;"]W;W)K
M<VAE971S+W-H965T-C,N>&ULM5==C]HX%/TK5K:J6FE*OA.8 M(PV6I7:JM1
MV6F?36*(-8E-;0>Z_WZOG9 &QB >V)<A=LXY]KF^OKDSW7/Q(DM"%/I55TS.
MG%*I[;WKRKPD-98COB4,WJRYJ+&"H=BX<BL(+@RIKMS \Q*WQI0Y\ZF9>Q+S
M*6]411EY$D@V=8W%OPM2\?W,\9W#Q#>Z*96><.?3+=Z0)5'/VR<!([=7*6A-
MF*2<(4'6,^?!O\\F&F\ WRG9R\$STDY6G+_HP=_%S/'TADA%<J45,/SLR".I
M*BT$V_C9:3K]DIHX?#ZH?S+>P<L*2_+(JQ^T4.7,&3NH(&O<5.H;W_]%.C^Q
MULMY)<U?M.^PGH/R1BI>=V3804U9^XM_=7$8$/SD#"'H",$I(3I#"#M">"TA
MZ@B1B4QKQ<0APPK/IX+OD=!H4-,/)IB&#?8IT\>^5 +>4N"I^5?(K,]<2O1$
M!%J66!#TH)2@JT;A5460XNB1US6<T%+Q_*7D54&$1!_0$A*P: #!UQJQ!;PY
M2!@NL*0YPJQ &:T:10K$7J_R+B,*TTJ^!ZWG98;>O7F/WB 72?U6(LK0,Z-*
MWL$D//]3\D:"HIRZ"ESKO;MYYW#1.@S../0#](4S54KT)RM(<2S@0KCZF 6'
MF"V"BXH9R4<H].]0X 6!94./U]-]"SV[GNY=<!/V&1 :O?!<!C0U$5AQ<6^+
M;<N-[%Q=D^[E%N=DYD#1D43LB#-_^X>?>!]M<;FE6'8CL:.817W,HDOJYM94
M.I_QR5W)V[LB!W?%%M56/37JNC#OYA_\. W'Z=3=#0-FPP5>Z$?'N,R"B^+4
M^PT[<AGW+N.+F9$1QJ'DG,V-^):Y<4NQ[$9B1U%+^J@E%W/CA_G40-'#.[A7
M&X)84Z^@[$%A/&2'*7%W^GM%<UM@VP62P7'&D1>$21R>Y,=K8)",4\B0Y"1!
M+, @]KQ):,^0M/>:WLAKT7X);&[3:]V^!IYQ:P%><CONW8ZON_5;L#CT=TT9
MN'#<[:J3X>T-1A/_Q+T%%8VB\8EUFY8W"GV[\TGO?/)_.K]P^).KO%M0%N\V
M+8MW=] MP:=O8[I."3MOF&J;@'ZV;VP?3#]W,K^ AK?M3W_+M-WR%RPVE$E4
MD35(>J,4"I)H.]!VH/C6]&0KKJ##,X\E-.U$: "\7W.N#@.]0/]OP/P_4$L#
M!!0    ( -T[8E;+I5-%. 0  /$5   9    >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;,U848^C-A#^*Q:53JUT73 $DFR32$G84T^ZNXTVW?:AZH,#DV M
MX-0VR?;?UR8L"0G+;4Y^V'U8P,Q\]GPS7[!GM&?\220 $CUG:2[&5B+E]M:V
M191 1L0-VT*NWJP9SXA4CWQCBRT'$I=.66J[CA/8&:&Y-1F58PL^&;%"IC2'
M!4>BR#+"_YM!RO9C"ULO P]TDT@]8$]&6[*!)<C'[8*K)[M&B6D&N: L1QS6
M8VN*;T,<:(?2XD\*>W%RCW0H*\:>],/G>&PY>D600B0U!%&7'<PA33626L>_
M%:A5SZD=3^]?T#^5P:M@5D3 G*5_T5@F8VM@H1C6I$CE ]O_#E5 OL:+6"K*
M_VA?V3H6B@HA658YJQ5D-#]<R7-%Q(F#"K3=P:T<W'.'WBL.7N7@O=6A5SGT
M2F8.H90\A$22R8BS/>+:6J'IFY+,TEN%3W.=]Z7DZBU5?G+R3976%R8$6@!'
MRX1P0%,I.5T5DJQ20)*A.<LRE:&E9-%3PM(8N$"_H@63D$M*TOJ]=A8?T4QE
M(49J8)JQ(I<"W1=22)+'--\@(O5$E,7H+H_1'M1T=\]16L3*Y1-G&9():,"M
MFKZL"[9&(4T+J=[_X%)_#D$2FHI?U*)%N<:1+15S.GX[JEB:'5AR7V$)N^@K
MRV4B]+(A;@+8BO*:=_>%]YG;B1A"=(,\_!&YCNNV+&C^=G?<XAZ^W=WIB,:K
MJ\@K\;Q7\*:J$F*=)J5AM(2HX%12$&>Y/<WK_1K=$9ZKFCC-Y]]?%##Z+"$3
M_[1EZ;"*7OLJ]$_DK=B2",:6^@T4P'=@33[\A /GMS:&38*%AL :[/=J]GM=
MZ$WV1<U^&X$'H* $TI^$W63@#IW 5S6T.^7FTB[ /G:'?M,NO+1SO0'N.8Y3
M&S9"\NN0_,Z0YBS? 9=4ZWJAO@3 N:JB4M=M876"75L7)L%"0V -$H.:Q.!=
MJ#(PR;Y)L- 06(/]?LU^WY0J^Q<J<L[T^%V+\-("#[U!W^_UVI4XJ,,8=(;Q
MJ(0H].?W05TXC627#CNAKJT$DV"A(; &A<.:PN&[T.'0)/LFP4)#8 WVL7/<
MXCJFE%@A=4GQ^R9ABXGO]0//:Y<B/MFLXQ\3(WK,J6R/J!/QVJHPBA::0FNR
MZ1[9=-^%+JMEF$J!2;30%%HS!<=S ^[<&%\E3>]R3]KO#US_7)^7=IY[NB&M
M K\T>V7/BH_[<-R]$3\]Z=YO=<4(] =#BX)'B3H5-XZGK2%VPE]=*";10E-H
M36J/YP'LOP^M&CU*&$4+3:$U4W \3>#.[?)56@TNQ-4/L#MP@W.Q7AH&& \O
M#YHMAMY _;GGWU3[I!>6 =^4/46!(MV+.K1GZM&Z;SDMNW5GXS/=SRQ[;$>8
M0S/T*^$;JJ2=PEI!.C=]E1=^Z"\>'B3;EAVW%9.29>5M B0&K@W4^S5C\N5!
M3U!W>2?_ U!+ P04    " #=.V)6/EA%Y:4"   /"   &0   'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6RU5FM/VS 4_2M7&9I VLBK#8BED?K8!!*;*CJV
M#],^N,EM8^'8F>VT(/'C9R<A:D>I0.J^-'[<<WS/\;7=>"WDG<H1-=P7C*N!
MDVM=7KBN2G,LB#H5)7(SLQ"R(-ITY=)5I422U:""N8'G16Y!*'>2N!Z;RB06
ME6:4XU2"JHJ"R(<1,K$>.+[S-'!#E[FV VX2EV2),]2WY52:GMNQ9+1 KJC@
M('$Q<(;^Q3BR\77 #XIKM=$&JV0NQ)WM7&4#Q[,)(<-46P9B/BL<(V.6R*3Q
MI^5TNB4M<+/]Q/ZEUFZTS(G"L6 _::;S@7/N0(8+4C%](]:7V.KI6[Y4,%7_
MPKJ-]1Q(*Z5%T8)-!@7ES9?<MSYL /S>"X"@!02O!80M(*R%-IG5LB9$DR26
M8@W21ALVVZB]J=%&#>5V%V=:FEEJ<#KY9@KE6B@%4Y0PRXE$&&HMZ;S29,X0
MM("Q* IC^$R+]"X7+$.IX",,LXS:C2 ,KGA3379;CB>H"67JQ(3<SB9P?'0"
M1T Y?,]%I0C/5.QJD[==W4W;'$=-CL$+.4XP/870_P"!%P0[X./7P_UMN&O<
MZBP+.LN"FB]\@>\SD9SRY:9E(Z)H"K^N321<:2S4[UTJ&]K>;EI[7"]425(<
M..8\*I0K=)+W[_S(^[1+\X'(MAP(.P?"?>S)K$I3-#53D@=SH#4P2N:44?VP
M2W5#=593V3MEE03GY_W876VJ>1[4"\_\+F@KRUZ796]OEI=$KHC,8,@S& G;
M>H1KFIH;"'?EN9?LK;MS(+(MW?U.=___U&?_D X<B&S+@:AS(#I<?4;/2B\*
M/>^?^MR[WEO5N!O7M7TJOQ*YI%P!PX6A]T[/C'>R>7Z:CA9E?8//A3;O0=W,
MS8N-T@:8^840^JEC'X7N/T#R%U!+ P04    " #=.V)66/H)ZR<#  "O#
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MI</SQJW<=IC-%]=7*]?];MYYEE!="9XU@F>]3$]O$)>F+@_)[>=1'LT[TCX
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MJ$,R<&V@WJ\8DZ<;?0QKCMVS_P!02P,$%     @ W3MB5KS5^4& !0  !1X
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MR97BL;G< ,5=K07P^8IS]7RC#903_MG?4$L#!!0    ( -T[8E:XK64.2 ,
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( -T[8E9VJ'B)<@4  #,O   /
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #=.V)6F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M -T[8E8!D$: B@@  *\T   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #=.V)6636F^H@&  #G&@  &
M            @('-$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#
M%     @ W3MB5K?2!*+O @  Y0D  !@              ("!BQ<  'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -T[8E8\\KN-(@8  ( <
M   8              " @; :  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q0
M2P$"% ,4    " #=.V)6%P\"4Z +  "Q:@  &               @($((0
M>&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ W3MB5B^Q/VUX
M P  :PT  !@              ("!WBP  'AL+W=O<FMS:&5E=',O<VAE970V
M+GAM;%!+ 0(4 Q0    ( -T[8E:(2NU5:@D  .LL   8              "
M@8PP  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #=.V)6
MNW6>W? '  #Y$@  &               @($L.@  >&PO=V]R:W-H965T<R]S
M:&5E=#@N>&UL4$L! A0#%     @ W3MB5NGA_)[>)P  H(8  !@
M     ("!4D(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (
M -T[8E:QL*:F@ 0  +T*   9              " @69J  !X;"]W;W)K<VAE
M971S+W-H965T,3 N>&UL4$L! A0#%     @ W3MB5DG\)8WS @  HP8  !D
M             ("!'6\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"
M% ,4    " #=.V)6^IY_VJ *   A'0  &0              @(%'<@  >&PO
M=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -T[8E:DY5EQP0(
M .P%   9              " @1Y]  !X;"]W;W)K<VAE971S+W-H965T,3,N
M>&UL4$L! A0#%     @ W3MB5ON,\I#G"   IA8  !D              ("!
M%H   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #=.V)6
M$,*\<4 3  ![00  &0              @($TB0  >&PO=V]R:W-H965T<R]S
M:&5E=#$U+GAM;%!+ 0(4 Q0    ( -T[8E89-@S^: X  #DJ   9
M      " @:N<  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%
M  @ W3MB5I!!Z^W<!0  "1   !D              ("!2JL  'AL+W=O<FMS
M:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #=.V)6!:;'!4<)  !$&@
M&0              @(%=L0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+
M 0(4 Q0    ( -T[8E8HT/S=,@4  !8-   9              " @=NZ  !X
M;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ W3MB5F2IA<8$
M"@  9AH  !D              ("!1,   'AL+W=O<FMS:&5E=',O<VAE970R
M,"YX;6Q02P$"% ,4    " #=.V)6G2?;<I,$   9"P  &0
M@(%_R@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( -T[
M8E:2^X[4 P0  "@)   9              " @4G/  !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL4$L! A0#%     @ W3MB5K>ZIK%( @  -P4  !D
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M=#(W+GAM;%!+ 0(4 Q0    ( -T[8E8K.;@$5P4  *,.   9
M  " @><* 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @
MW3MB5@%3-LW- @  [04  !D              ("!=1 ! 'AL+W=O<FMS:&5E
M=',O<VAE970R.2YX;6Q02P$"% ,4    " #=.V)6(%4Y]<<#  "$"0  &0
M            @(%Y$P$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4
M Q0    ( -T[8E8H>$<_T (  (8&   9              " @7<7 0!X;"]W
M;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ W3MB5I"3>/&V!0
M<@X  !D              ("!?AH! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6Q02P$"% ,4    " #=.V)6@4SZ.E $  "5"@  &0              @(%K
M( $ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( -T[8E8%
MQI(3 P4  (X,   9              " @?(D 0!X;"]W;W)K<VAE971S+W-H
M965T,S0N>&UL4$L! A0#%     @ W3MB5@K6F0Y, @  GP0  !D
M     ("!+"H! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -T[8E9)C$&FE0(  ,T&   9              "
M@:(\ 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ W3MB
M5D<*<]23 P  -!$  !D              ("!;C\! 'AL+W=O<FMS:&5E=',O
M<VAE970T,2YX;6Q02P$"% ,4    " #=.V)6*I>KOHH"  "[!@  &0
M        @($X0P$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0
M   ( -T[8E8@_]S/@@(  *D&   9              " @?E% 0!X;"]W;W)K
M<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ W3MB5H_PM;\"!P  U#H
M !D              ("!LD@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q0
M2P$"% ,4    " #=.V)6V(Q1"'4%  !/)@  &0              @('K3P$
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -T[8E:@[Y5T
MF@,  ,0/   9              " @9=5 0!X;"]W;W)K<VAE971S+W-H965T
M-#8N>&UL4$L! A0#%     @ W3MB5O2>$[;?!   <A8  !D
M ("!:%D! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " #=
M.V)6U.D*C_<"  "'"   &0              @(%^7@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( -T[8E;TU-3[$PD  'Y8   9
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M970U,RYX;6Q02P$"% ,4    " #=.V)6>E4'$2,'  #_-   &0
M    @($ZA $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    (
M -T[8E9SP +7L (  *@(   9              " @92+ 0!X;"]W;W)K<VAE
M971S+W-H965T-34N>&UL4$L! A0#%     @ W3MB5J9#]-MH @  ?P8  !D
M             ("!>XX! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"
M% ,4    " #=.V)6'@@AH(D*  #Z;@  &0              @($:D0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -T[8E:ASP\BX <
M %]$   9              " @=J; 0!X;"]W;W)K<VAE971S+W-H965T-3@N
M>&UL4$L! A0#%     @ W3MB5F912V54 P  )@X  !D              ("!
M\:,! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #=.V)6
M'P*5]0L#  #""0  &0              @(%\IP$ >&PO=V]R:W-H965T<R]S
M:&5E=#8P+GAM;%!+ 0(4 Q0    ( -T[8E9:.*DH; 4   X5   9
M      " @;ZJ 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%
M  @ W3MB5MD_[5:- P  00L  !D              ("!8; ! 'AL+W=O<FMS
M:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #=.V)6R-903F\#   2#
M&0              @($EM $ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+
M 0(4 Q0    ( -T[8E;+I5-%. 0  /$5   9              " @<NW 0!X
M;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ W3MB5CY81>6E
M @  #P@  !D              ("!.KP! 'AL+W=O<FMS:&5E=',O<VAE970V
M-2YX;6Q02P$"% ,4    " #=.V)66/H)ZR<#  "O#   &0
M@($6OP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( -T[
M8E8V?%0DR ,  +P-   9              " @73" 0!X;"]W;W)K<VAE971S
M+W-H965T-C<N>&UL4$L! A0#%     @ W3MB5BRWXB0T!   @@\  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( -T[8E9VJ'B)<@4  #,O   /
M  "  4[= 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #=.V)6L 4 O38"
M   <*@  &@              @ 'MX@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #=.V)6X<M&R/T!   ]*0  $P
M@ %;Y0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5  ")YP$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>232</ContextCount>
  <ElementCount>416</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100080 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Property and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Fair value of financial instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1</Role>
      <ShortName>Fair value of financial instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</Role>
      <ShortName>Accrued expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100160 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Preferred and Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock</Role>
      <ShortName>Preferred and Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Stock-based compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-based compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Net Loss Per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Property and equipment, net (Table)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable</Role>
      <ShortName>Property and equipment, net (Table)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value of Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables</Role>
      <ShortName>Fair Value of Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Accrued expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables</Role>
      <ShortName>Accrued expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Stock-based compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-based compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Marketable securities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails</Role>
      <ShortName>Marketable securities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property and equipment, net - Schedule of Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Property and equipment, net - Schedule of Depreciation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails</Role>
      <ShortName>Property and equipment, net - Schedule of Depreciation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Property and equipment, net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and equipment, net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails</Role>
      <ShortName>Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Fair value of financial instruments - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails</Role>
      <ShortName>Fair value of financial instruments - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails</Role>
      <ShortName>Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Leases - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails</Role>
      <ShortName>Leases - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails</Role>
      <ShortName>Leases - Summary of Components of Operating Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails</Role>
      <ShortName>Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100550 - Disclosure - License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails</Role>
      <ShortName>Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails</Role>
      <ShortName>Preferred Stock Tranche Liability - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Preferred and Common Stock - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails</Role>
      <ShortName>Preferred and Common Stock - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Stock-based compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-based compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-based compensation - Summary of Stock Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100680 - Disclosure - Income taxes - Summary of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income taxes - Summary of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="verv-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100730 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-EntityWellKnownSeasonedIssuer-Value] In submission type 10-K, EntityWellKnownSeasonedIssuer value "No", is not equivalent to header element wellKnownSeasonedIssuerFlag value "true" in the Required Context. verv-20221231.htm 96</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate -  verv-20221231.htm 8</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 3 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration, us-gaap:FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList -  verv-20221231.htm 8</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="verv-20221231.htm">verv-20221231.htm</File>
    <File>verv-20221231.xsd</File>
    <File>verv-20221231_cal.xml</File>
    <File>verv-20221231_def.xml</File>
    <File>verv-20221231_lab.xml</File>
    <File>verv-20221231_pre.xml</File>
    <File>verv-ex10_22.htm</File>
    <File>verv-ex10_5.htm</File>
    <File>verv-ex10_7.htm</File>
    <File>verv-ex23_1.htm</File>
    <File>verv-ex31_1.htm</File>
    <File>verv-ex31_2.htm</File>
    <File>verv-ex32_1.htm</File>
    <File>verv-ex32_2.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img243551639_0.jpg</File>
    <File>img243551639_1.jpg</File>
    <File>img243551639_10.jpg</File>
    <File>img243551639_11.jpg</File>
    <File>img243551639_12.jpg</File>
    <File>img243551639_13.jpg</File>
    <File>img243551639_14.jpg</File>
    <File>img243551639_15.jpg</File>
    <File>img243551639_16.jpg</File>
    <File>img243551639_17.jpg</File>
    <File>img243551639_18.jpg</File>
    <File>img243551639_19.jpg</File>
    <File>img243551639_2.jpg</File>
    <File>img243551639_20.jpg</File>
    <File>img243551639_21.jpg</File>
    <File>img243551639_22.jpg</File>
    <File>img243551639_23.jpg</File>
    <File>img243551639_24.jpg</File>
    <File>img243551639_25.jpg</File>
    <File>img243551639_26.jpg</File>
    <File>img243551639_27.jpg</File>
    <File>img243551639_28.jpg</File>
    <File>img243551639_3.jpg</File>
    <File>img243551639_4.jpg</File>
    <File>img243551639_5.jpg</File>
    <File>img243551639_6.jpg</File>
    <File>img243551639_7.jpg</File>
    <File>img243551639_8.jpg</File>
    <File>img243551639_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="703">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>122
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "verv-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 703,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 232,
   "dts": {
    "calculationLink": {
     "local": [
      "verv-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "verv-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "verv-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "verv-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "verv-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "verv-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 720,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 9,
    "http://www.vervetx.com/20221231": 3,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 16
   },
   "keyCustom": 108,
   "keyStandard": 308,
   "memberCustom": 39,
   "memberStandard": 37,
   "nsprefix": "verv",
   "nsuri": "http://www.vervetx.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Property and equipment, net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Fair value of financial instruments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1",
     "shortName": "Fair value of financial instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued expenses",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses",
     "shortName": "Accrued expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - License Agreements",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LicenseAgreementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Collaboration and License Agreements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredAndCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Preferred and Common Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock",
     "shortName": "Preferred and Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:PreferredAndCommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Stock-based compensation",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-based compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Net Loss Per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "24",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Property and equipment, net (Table)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable",
     "shortName": "Property and equipment, net (Table)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value of Financial Instruments (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables",
     "shortName": "Fair Value of Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Accrued expenses (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables",
     "shortName": "Accrued expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Collaboration and License Agreements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables",
     "shortName": "Collaboration and License Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Stock-based compensation (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-based compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "ix:continuation",
       "span",
       "p",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Property and Equipment Estimated Useful Life (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_bf015cb8-73af-4e9c-8184-18d43e6ec0c7",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Marketable Securities - Schedule of Marketable Securities (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - Schedule of Marketable Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:CollaborationsRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:CollaborationsRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Marketable securities - Additional Information (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
     "shortName": "Marketable securities - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Property and equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
     "shortName": "Property and equipment, net - Schedule of Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Property and equipment, net - Schedule of Depreciation Expense (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
     "shortName": "Property and equipment, net - Schedule of Depreciation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Property and equipment, net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and equipment, net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
     "shortName": "Fair value of financial instruments - Summary of Assets and Liabilities Measured at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Fair value of financial instruments - Additional Information (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
     "shortName": "Fair value of financial instruments - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "verv:FairValueOfCommonStockPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair value of financial instruments - Schedule of Fair Value Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "verv:FairValueOfCommonStockPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_UnitedStatesOfAmericaDollarsShare",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_50163530-3d32-4277-baac-6dd493e6a3c1",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100490 - Disclosure - Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
     "shortName": "Fair value of financial instruments - Schedule of Reconciliation of Changes in Fair Value of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_ebd810ed-a6eb-48f2-a9aa-c82bc1bab012",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Accrued expenses - Schedule of Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
     "shortName": "Accrued expenses - Schedule of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedEmployeeBenefitsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2e1e720d-1d97-4f90-afd3-bbc0575e9165",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LeaseCommencementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100510 - Disclosure - Leases - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
     "shortName": "Leases - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2e1e720d-1d97-4f90-afd3-bbc0575e9165",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "verv:LeaseCommencementDate",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_deea9644-67bd-4520-bcd2-358aa23d9d50",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_deea9644-67bd-4520-bcd2-358aa23d9d50",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Leases - Summary of Components of Operating Lease Cost (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails",
     "shortName": "Leases - Summary of Components of Operating Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "verv:ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails",
     "shortName": "Leases - Summary of Supplemental Cash Flow Information Related to Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails",
     "shortName": "Leases - Summary of Future Minimum Commitments under Non-Cancellable Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - License Agreements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
     "shortName": "License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "verv:LicenseAgreementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_02d7b42f-eec4-4cd5-861d-bf55e78340ce",
      "decimals": "-5",
      "lang": null,
      "name": "verv:PaymentOfSalesBasedMilestone",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireCommercialRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Collaboration and License Agreements (Additional Information) (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements (Additional Information) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_892c3a29-24ed-4d2e-b11b-37fbb577f9ea",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireCommercialRealEstate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:PerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails",
     "shortName": "Collaboration and License Agreements - Schedule of transaction price separate performance obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:PerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Preferred Stock Tranche Liability - Additional Information (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
     "shortName": "Preferred Stock Tranche Liability - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Preferred and Common Stock - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
     "shortName": "Preferred and Common Stock - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "verv:PreferredAndCommonStockTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_94ae7f16-bc4b-4ceb-ae9c-2e324421a03c",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Stock-based compensation - Additional Information (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-based compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Stock-based compensation - Summary of Stock Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-based compensation - Summary of Stock Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_3d29fbc3-5622-4165-a232-e591a91a09ce",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100070 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_3d29fbc3-5622-4165-a232-e591a91a09ce",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "verv:IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails",
     "shortName": "Stock-based compensation - Schedule of Assumptions Used for Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_50163530-3d32-4277-baac-6dd493e6a3c1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Stock-based compensation - Schedule of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
     "shortName": "Stock-based compensation - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_50163530-3d32-4277-baac-6dd493e6a3c1",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_f440c691-328c-490a-b5a2-6550bd63dd18",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
     "shortName": "Stock-based compensation - Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_f440c691-328c-490a-b5a2-6550bd63dd18",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Schedule of Computation of Basic and Diluted net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "verv:SuccessPaymentLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
     "shortName": "Net Loss Per Share Attributable to Common Stockholders - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_94979cff-1f2a-464c-857e-c9995bec9c94",
      "decimals": "-5",
      "lang": null,
      "name": "verv:SuccessPaymentLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100680 - Disclosure - Income taxes - Summary of Income Tax Expense (Benefit) (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails",
     "shortName": "Income taxes - Summary of Income Tax Expense (Benefit) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Income Taxes - Schedule of Deferred Taxes (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_52a4a369-ae67-4de2-82c2-3426ee972653",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100080 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "-5",
      "lang": null,
      "name": "verv:LeaseRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Nature of the Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "verv-20221231.htm",
      "contextRef": "C_2732e9b1-8a6e-408c-9326-ef2e6692329b",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "country_NZ": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW ZEALAND",
        "terseLabel": "N Z"
       }
      }
     },
     "localname": "NZ",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r647"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r644",
      "r645",
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r212",
      "r213",
      "r318",
      "r325",
      "r612",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r345",
      "r551",
      "r579",
      "r606",
      "r607",
      "r625",
      "r631",
      "r639",
      "r690",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r345",
      "r551",
      "r579",
      "r606",
      "r607",
      "r625",
      "r631",
      "r639",
      "r690",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OfficerMember": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Officer [Member]"
       }
      }
     },
     "localname": "OfficerMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r264",
      "r552",
      "r626",
      "r637",
      "r686",
      "r687",
      "r692",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r264",
      "r552",
      "r626",
      "r637",
      "r686",
      "r687",
      "r692",
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r332",
      "r345",
      "r380",
      "r381",
      "r382",
      "r526",
      "r551",
      "r579",
      "r606",
      "r607",
      "r625",
      "r631",
      "r639",
      "r685",
      "r690",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r332",
      "r345",
      "r380",
      "r381",
      "r382",
      "r526",
      "r551",
      "r579",
      "r606",
      "r607",
      "r625",
      "r631",
      "r639",
      "r685",
      "r690",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r212",
      "r213",
      "r318",
      "r325",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r350",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r231",
      "r350",
      "r653",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r265",
      "r266",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r627",
      "r638",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r265",
      "r266",
      "r592",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r627",
      "r638",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r231",
      "r350",
      "r653",
      "r654",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r678",
      "r799"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASC 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r636"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Employee compensation and related benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r72",
      "r179"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less accumulated depreciation",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r185",
      "r575",
      "r587",
      "r591"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive (loss) income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r20",
      "r23",
      "r119",
      "r510",
      "r582",
      "r583",
      "r660",
      "r661",
      "r662",
      "r670",
      "r671",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r389",
      "r390",
      "r391",
      "r670",
      "r671",
      "r672",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r218",
      "r219",
      "r220",
      "r221",
      "r231",
      "r270",
      "r271",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r389",
      "r390",
      "r391",
      "r412",
      "r413",
      "r414",
      "r415",
      "r428",
      "r429",
      "r430",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r554",
      "r555",
      "r556",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r101",
      "r102",
      "r352"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountOfDeferredCostsRelatedToLongTermContracts": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred costs for long-term contracts and programs. Includes, but is not limited to, initial tooling costs and deferred production costs.",
        "label": "Amount of Deferred Costs Related to Long-Term Contracts",
        "terseLabel": "Amount of Deferred Costs Related to Long-Term Contracts"
       }
      }
     },
     "localname": "AmountOfDeferredCostsRelatedToLongTermContracts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r140",
      "r153",
      "r181",
      "r208",
      "r258",
      "r260",
      "r262",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r435",
      "r439",
      "r464",
      "r636",
      "r688",
      "r689",
      "r801"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r174",
      "r187",
      "r208",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r435",
      "r439",
      "r464",
      "r636",
      "r688",
      "r689",
      "r801"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets",
        "totalLabel": "Assets, Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r274",
      "r293"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r61",
      "r273",
      "r293",
      "r570"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair value",
        "totalLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r60",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r60",
      "r177",
      "r293"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r176",
      "r610"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r46",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-Term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r38",
      "r45",
      "r48"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r38",
      "r130"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents",
        "totalLabel": "Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and finnacing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": {
     "auth_ref": [
      "r168",
      "r169",
      "r217",
      "r270",
      "r271",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r412",
      "r428",
      "r429",
      "r442",
      "r444",
      "r445",
      "r455",
      "r465",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r554",
      "r555",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether accounting standards update was adopted.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adopted [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, adopted"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": {
     "auth_ref": [
      "r168",
      "r169",
      "r270",
      "r271",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r412",
      "r428",
      "r429",
      "r430",
      "r442",
      "r444",
      "r445",
      "r446",
      "r449",
      "r455",
      "r465",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r481",
      "r484",
      "r485",
      "r486",
      "r487",
      "r505",
      "r506",
      "r554",
      "r555",
      "r580",
      "r581",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Adoption Date",
        "terseLabel": "Change in accounting principle, accounting standards update, adoption date"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": {
     "auth_ref": [
      "r218",
      "r230",
      "r272",
      "r285",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.",
        "label": "Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]",
        "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r208",
      "r235",
      "r236",
      "r239",
      "r241",
      "r248",
      "r249",
      "r277",
      "r307",
      "r310",
      "r311",
      "r312",
      "r316",
      "r317",
      "r322",
      "r323",
      "r326",
      "r327",
      "r330",
      "r464",
      "r608",
      "r651",
      "r665",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r144",
      "r158"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (See Note 7 and 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r670",
      "r671",
      "r791"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common Stock, Shares Issued",
        "totalLabel": "Common Stock, Shares, Issued, Total",
        "verboseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r636"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total",
        "verboseLabel": "Issuance of common stock, value"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r24",
      "r196",
      "r198",
      "r203",
      "r571",
      "r576"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r152",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r322",
      "r323",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r1",
      "r2",
      "r82",
      "r85",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion of preferred stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockTermsOfConversion": {
     "auth_ref": [
      "r1",
      "r2",
      "r82",
      "r86",
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of conversion terms for preferred stock.",
        "label": "Preferred Stock, Convertible, Terms",
        "terseLabel": "Preferred stock, convertible terms"
       }
      }
     },
     "localname": "ConvertiblePreferredStockTermsOfConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r668",
      "r786",
      "r788"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r668",
      "r786"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r409",
      "r420",
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r668",
      "r786",
      "r788"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "terseLabel": "Accrued and unpaid interest paid"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r293",
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r293",
      "r679"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r668",
      "r787",
      "r788"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r114",
      "r668",
      "r787"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r43",
      "r114",
      "r410",
      "r419",
      "r420",
      "r668"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueAndCreditsNoncurrent": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total carrying amount of consideration received or receivable as of the balance sheet date representing potential earnings that were not as yet recognized as revenue or other forms of income in conformity with GAAP, and which are expected to be recognized as such after one year or beyond the normal operating cycle, if longer.",
        "label": "Deferred Revenue and Credits, Noncurrent",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "DeferredRevenueAndCreditsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueRevenueRecognized1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously reported as deferred or unearned revenue.",
        "label": "Deferred Revenue, Revenue Recognized",
        "terseLabel": "Deferred Revenue, Revenue Recognized"
       }
      }
     },
     "localname": "DeferredRevenueRevenueRecognized1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r668",
      "r787",
      "r788"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseBenefitDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r404"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r113",
      "r785"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Total deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r784"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets, net of valuation allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r113",
      "r785"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r113",
      "r785"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsRegulatoryAssetsAndLiabilities": {
     "auth_ref": [
      "r113",
      "r785"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences derived regulatory assets and liabilities.",
        "label": "Deferred Tax Assets, Regulatory Assets and Liabilities",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsRegulatoryAssetsAndLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r405"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r107",
      "r784"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred tax liabilities",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r113",
      "r785"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Contribution Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Defined contribution plan, employer Contribution amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employer's matching contributions to a defined contribution plan that vests in a given year.",
        "label": "Defined Contribution Plan, Employers Matching Contribution, Annual Vesting Percentage",
        "terseLabel": "Defined contribution plan, employers matching contribution, annual vesting percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Defined contribution plan, maximum annual contributions per employee, amount"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTable": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.",
        "label": "Defined Contribution Plan [Table]"
       }
      }
     },
     "localname": "DefinedContributionPlanTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlans1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r43",
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Total",
        "verboseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosurePropertyAndEquipmentNetScheduleOfDepreciationExpenseDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r43",
      "r70"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r19",
      "r120",
      "r135",
      "r188",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "negatedLabel": "Success payment liability, payable",
        "terseLabel": "Success payment liability, payable",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total",
        "verboseLabel": "Success payment liability, payable"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r189",
      "r190",
      "r463",
      "r614"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Success payment liability",
        "totalLabel": "Derivative Liability, Total",
        "verboseLabel": "Success payment liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes derivative liability.",
        "label": "Derivative Liability, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of defined contribution pension and other postretirement plans.",
        "label": "Defined Contribution Plan, Description",
        "terseLabel": "Defined contribution plan, description"
       }
      }
     },
     "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r354",
      "r385",
      "r386",
      "r388",
      "r393",
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Non-cumulative dividends payable per share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r143",
      "r159",
      "r309",
      "r310",
      "r311",
      "r315",
      "r316",
      "r317",
      "r514",
      "r669"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Amount due as a result of termination",
        "totalLabel": "Due to Related Parties, Total"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r204",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r232",
      "r235",
      "r239",
      "r240",
      "r241",
      "r245",
      "r453",
      "r454",
      "r572",
      "r577",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share attributable to common stockholders, basic",
        "totalLabel": "Earnings Per Share, Basic, Total",
        "verboseLabel": "Net loss per common share attributable to common stockholders, basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share Basic [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareBasicLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r204",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r235",
      "r239",
      "r240",
      "r241",
      "r245",
      "r453",
      "r454",
      "r572",
      "r577",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share attributable to common stockholders, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total",
        "verboseLabel": "Net loss per common share attributable to common stockholders, diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r51",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r242",
      "r243",
      "r244",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r398"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r210",
      "r398",
      "r422"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r783",
      "r789"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": {
     "auth_ref": [
      "r783",
      "r789"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r782",
      "r783"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r783",
      "r789"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes, net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which unrecognized compensation is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r781"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r781"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCashContributionsToESOP": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the amount of cash contributions during the period made by the entity to the Employee Stock Ownership Plan (ESOP).",
        "label": "Employee Stock Ownership Plan (ESOP), Cash Contributions to ESOP",
        "terseLabel": "Proceeds from purchase of shares through employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCashContributionsToESOP",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r81",
      "r170",
      "r200",
      "r201",
      "r202",
      "r214",
      "r215",
      "r216",
      "r219",
      "r227",
      "r229",
      "r247",
      "r284",
      "r331",
      "r389",
      "r390",
      "r391",
      "r414",
      "r415",
      "r452",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r510",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r456",
      "r457",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r457",
      "r523",
      "r524",
      "r525",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Disclosure - Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstruments1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r319",
      "r333",
      "r338",
      "r457",
      "r523",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r319",
      "r333",
      "r338",
      "r457",
      "r524",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r457",
      "r525",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r124",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Changes in Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r319",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r523",
      "r524",
      "r525",
      "r623",
      "r624",
      "r628",
      "r629",
      "r630"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r459",
      "r461"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in fair value"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r122",
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r128",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement in which net income is reported that includes gain (loss) from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability), Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationNetDerivativeAssetLiabilityGainLossStatementOfIncomeExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r294",
      "r295",
      "r296",
      "r321",
      "r329",
      "r443",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r621",
      "r680",
      "r681",
      "r682",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "terseLabel": "Total liabilities",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount": {
     "auth_ref": [
      "r268",
      "r269",
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized loan commitment, origination, and other costs (fees) and purchase premium (discount) on financing receivable recognized as adjustment to yield. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount)",
        "terseLabel": "Upfront fee discount",
        "totalLabel": "Financing Receivable, Unamortized Loan Cost (Fee) and Purchase Premium (Discount), Total"
       }
      }
     },
     "localname": "FinancingReceivableUnamortizedLoanCommitmentOriginationFeeAndPremiumDiscount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r300",
      "r553",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering",
        "verboseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r43",
      "r69",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment losses",
        "totalLabel": "Impairment, Long-Lived Asset, Held-for-Use, Total"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r67",
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r209",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r137",
      "r145",
      "r161",
      "r258",
      "r259",
      "r261",
      "r263",
      "r573",
      "r620"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r399",
      "r402",
      "r408",
      "r417",
      "r423",
      "r425",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r211",
      "r228",
      "r229",
      "r257",
      "r397",
      "r418",
      "r424",
      "r578"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Income Tax Expense (Benefit), Total",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r199",
      "r395",
      "r396",
      "r402",
      "r403",
      "r407",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Collaboration receivable",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r663"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r615"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r663",
      "r797"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Increase in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Increase (Decrease) in Other Current Liabilities",
        "terseLabel": "Increase in liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred obligations classified as other.",
        "label": "Increase (Decrease) in Other Deferred Liability",
        "terseLabel": "Deferred rent liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherDeferredLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndFeeIncomeLoansCommercial": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest and fee income related to commercial loans including industrial and agricultural, real estate (commercial and residential, construction and development), trade financing, and lease financing.",
        "label": "Interest and Fee Income, Loans, Commercial",
        "terseLabel": "Required fee payments",
        "totalLabel": "Interest and Fee Income, Loans, Commercial, Total"
       }
      }
     },
     "localname": "InterestAndFeeIncomeLoansCommercial",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions": {
     "auth_ref": [
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees and commissions from banking, advisory, brokerage, and securities underwriting activities. Activities include, but are not limited to, underwriting securities, private placements of securities, investment advisory and management services, merger and acquisition services, sale and servicing of mutual funds, and other related consulting fees.",
        "label": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions",
        "terseLabel": "Underwriting discounts and offering expenses",
        "totalLabel": "Investment Banking, Advisory, Brokerage, and Underwriting Fees and Commissions, Total"
       }
      }
     },
     "localname": "InvestmentBankingAdvisoryBrokerageAndUnderwritingFeesAndCommissions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r64",
      "r138",
      "r151",
      "r162",
      "r609"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r501",
      "r635"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r798"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Operating Lease Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee Lease Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee Lease Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease not yet commenced.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]",
        "terseLabel": "Option to extend true/false, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to terminate operating lease not yet commenced.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Terminate [true false]",
        "terseLabel": "Option to terminate, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedExistenceOfOptionToTerminate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease that has not yet commenced. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Option to Extend",
        "terseLabel": "Option to extend, lease not yet commenced"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "terseLabel": "Lease not yet commenced, lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions": {
     "auth_ref": [
      "r796"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of basis, terms, and conditions on which variable lease payment for lessee's operating lease that has not yet commenced is determined.",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Variable Lease Payment, Terms and Conditions",
        "terseLabel": "Operating lease payment term, lease not yet commenced, terms and conditions"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedVariableLeasePaymentTermsAndConditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r795"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r208",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r436",
      "r439",
      "r440",
      "r464",
      "r619",
      "r688",
      "r801",
      "r802"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r142",
      "r156",
      "r636",
      "r667",
      "r683",
      "r793"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r175",
      "r208",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r436",
      "r439",
      "r440",
      "r464",
      "r636",
      "r688",
      "r801",
      "r802"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-term Purchase Commitment, Category of Item Purchased"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "terseLabel": "Fixed transaction price consisting upfront fee"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MandatorilyRedeemablePreferredStockFairValueDisclosure": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of shares that an entity is required to redeem for cash or other assets at a fixed or determinable date or upon the occurrence of an event.",
        "label": "Mandatorily Redeemable Preferred Stock, Fair Value Disclosure",
        "terseLabel": "Preferred stock, fair value"
       }
      }
     },
     "localname": "MandatorilyRedeemablePreferredStockFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r28"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized losses on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected Term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r792"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Equity Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r250",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureNatureOfTheBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r38",
      "r41",
      "r44"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r44",
      "r146",
      "r160",
      "r173",
      "r194",
      "r197",
      "r202",
      "r208",
      "r218",
      "r222",
      "r223",
      "r224",
      "r225",
      "r228",
      "r229",
      "r237",
      "r258",
      "r259",
      "r261",
      "r263",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r454",
      "r464",
      "r620",
      "r688"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r232",
      "r233",
      "r238",
      "r241",
      "r258",
      "r259",
      "r261",
      "r263",
      "r620"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingGainsLossesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Gains (Losses) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingGainsLossesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Schedule of Status and Change in Unvested Restricted Stock and Restricted Stock Units"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r258",
      "r259",
      "r261",
      "r263",
      "r620"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r495",
      "r635"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r794"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNoncancellableOperatingLeasesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of operating lease liabilities",
        "totalLabel": "Operating Lease, Liability, Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfFutureMinimumCommitmentsUnderNonCancellableOperatingLeasesDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease obligations, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r491",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows related to operating leases",
        "verboseLabel": "Operating lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfSupplementalCashFlowInformationRelatedToOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r500",
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r180"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long term assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r191",
      "r192",
      "r193"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "totalLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Comprehensive Loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r115",
      "r116",
      "r118",
      "r195",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized loss on available-for-sale securities",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option [Member]"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedLabel": "Payment of equity offering costs",
        "terseLabel": "Payment of equity offering costs",
        "totalLabel": "Payment of Financing and Stock Issuance Costs, Total"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRent": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments to lessor's for use of assets under operating leases.",
        "label": "Payments for Rent",
        "terseLabel": "Rent paid"
       }
      }
     },
     "localname": "PaymentsForRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Transaction costs on issuance"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireCommercialRealEstate": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the acquisition of property as primarily intended to generate income for its owner.",
        "label": "Payments to Acquire Commercial Real Estate",
        "terseLabel": "Payments to Acquire Commercial Real Estate"
       }
      }
     },
     "localname": "PaymentsToAcquireCommercialRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PercentageOfUnamortizedFilmCosts": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of unamortized film costs for released films, excluding acquired film libraries, that it expects to amortize within three years from the date of the balance sheet.",
        "label": "Percentage of Unamortized Film Costs",
        "terseLabel": "Maximum percentage of profit/cost share"
       }
      }
     },
     "localname": "PercentageOfUnamortizedFilmCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Preferred stock, convertible, conversion price"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted.",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Preferred stock, convertible, conversion ratio"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionRatio",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, value per share",
        "verboseLabel": "Preferred stock, value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total",
        "verboseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r636"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Convertible preferred stock (See Note 10)",
        "totalLabel": "Preferred Stock, Value, Issued, Total",
        "verboseLabel": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r659"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r611",
      "r622",
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from initial public offering, net of underwriting discount"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from the issuance of common stock in connection with the Vertex Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of Preferred Stock, net",
        "verboseLabel": "Issuance of preferred stock tranche liability"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from Issuance or Sale of Equity",
        "terseLabel": "Proceeds from issuance or sale of preferred stock",
        "totalLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Annual license fee"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow from repayment of loans for purchasing common stock.",
        "label": "Proceeds from Repayment of Loans to Purchase Common Stock",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r100"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r173",
      "r194",
      "r197",
      "r205",
      "r208",
      "r218",
      "r228",
      "r229",
      "r258",
      "r259",
      "r261",
      "r263",
      "r277",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r316",
      "r317",
      "r434",
      "r437",
      "r438",
      "r454",
      "r464",
      "r573",
      "r620",
      "r633",
      "r634",
      "r662",
      "r688"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r76",
      "r594",
      "r595",
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r71",
      "r178"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r73",
      "r157",
      "r574",
      "r636"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r73",
      "r594",
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Property and equipment estimated useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForLeaseLosses": {
     "auth_ref": [
      "r148"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to estimated loss to be realized from lease transactions.",
        "label": "Provision for Lease Losses",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "ProvisionForLeaseLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r339",
      "r513",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r131"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Related Party Transaction, Expenses from Transactions with Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r339",
      "r513",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r800"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r511",
      "r512",
      "r514",
      "r515",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities": {
     "auth_ref": [
      "r35"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for debt, mandatory redeemable security, and principal payment for finance lease obligation.",
        "label": "Repayment of Long-Term Debt, Long-Term Lease Obligation, and Capital Security",
        "terseLabel": "Repayment of shareholder loan",
        "totalLabel": "Repayment of Long-term Debt, Long-term Lease Obligation, and Capital Security, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebtAndCapitalSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Debt",
        "totalLabel": "Repayments of Senior Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and Development Arrangement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet": {
     "auth_ref": [
      "r136"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of research and development costs incurred for a fixed-price, best-efforts research and development cost-sharing arrangement with the Federal Government.",
        "label": "Research and Development Arrangement with Federal Government, Costs Incurred, Net",
        "terseLabel": "Fixed transaction price"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r104",
      "r164",
      "r809"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r45",
      "r48",
      "r176"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r593",
      "r656",
      "r664"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r89",
      "r155",
      "r586",
      "r591",
      "r636"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated Deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r170",
      "r214",
      "r215",
      "r216",
      "r219",
      "r227",
      "r229",
      "r284",
      "r389",
      "r390",
      "r391",
      "r414",
      "r415",
      "r452",
      "r582",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanNameAxis": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r631",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Axis]"
       }
      }
     },
     "localname": "RetirementPlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanNameDomain": {
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r631",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of plan designed to provide retirement benefits. Includes, but is not limited to, legal name of defined benefit and defined contribution plans.",
        "label": "Retirement Plan Name [Domain]"
       }
      }
     },
     "localname": "RetirementPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueRecognitionDeferredRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing unearned income or deferred revenue related to transactions involving the sale of a product or performance of services.",
        "label": "Revenue Recognition, Deferred Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r499",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of Stock, Consideration Received on Transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of Stock, Number of Shares Issued in Transaction",
        "verboseLabel": "Shares issued and sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share",
        "verboseLabel": "Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SaleOfStockTransactionDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the subsidiary or equity investee issued or sold stock, in YYYY-MM-DD format.",
        "label": "Sale of Stock, Transaction Date",
        "terseLabel": "Sale of common stock closed date"
       }
      }
     },
     "localname": "SaleOfStockTransactionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales Member"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potential Common Shares, Based on Amounts Outstanding at Period End were Excluded From the Computation of Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Taxes"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTable": {
     "auth_ref": [
      "r50",
      "r53",
      "r235",
      "r236",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The table contains disclosure pertaining to an entity's basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule Of Earnings Per Share Basic By Common Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of transaction price separate performance obligations"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Instruments, Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Lease Commitments under Non-Cancellable Leases",
        "verboseLabel": "Schedule of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetScheduleOfPropertyPlantAndEquipmentDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of public utility physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation expense and method used, including composite depreciation, and accumulated depreciation.",
        "label": "Public Utility Property, Plant, and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Depreciation Expense"
       }
      }
     },
     "localname": "ScheduleOfPublicUtilityPropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r132",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r105",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r351",
      "r353",
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r93",
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used for Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r78",
      "r79",
      "r80",
      "r82",
      "r83",
      "r84",
      "r86",
      "r87",
      "r88",
      "r89",
      "r182",
      "r183",
      "r184",
      "r248",
      "r322",
      "r323",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r625",
      "r651",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [
      "r657",
      "r658",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A preferred stock.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock",
        "verboseLabel": "Series A Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [
      "r657",
      "r658",
      "r691"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B preferred stock.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServicingLiabilityAtFairValueOtherChangesInFairValue": {
     "auth_ref": [
      "r539"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from changes in fair value classified as other for a contract to service financial assets under which the estimated future revenues from contractually specified servicing fees, late charges, and other ancillary revenues are not expected to adequately compensate the servicer.",
        "label": "Servicing Liability at Fair Value, Other Changes in Fair Value"
       }
      }
     },
     "localname": "ServicingLiabilityAtFairValueOtherChangesInFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r632"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Description",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Restricted stock units forfeited",
        "terseLabel": "Restricted stock units forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of RSUs, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant-Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested RSUs, ending balance, Unvested",
        "periodStartLabel": "Unvested RSUs, beginning balance, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted-Average Grant Date Fair Value Per Share, ending balance, Unvested",
        "periodStartLabel": "Weighted-Average Grant Date Fair Value Per Share, beginning balance, Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Unvested Restricted stock vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted-average risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares of common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of options, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Number of options, Forfeited",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of options, Outstanding, Ending balance",
        "periodStartLabel": "Number of options, Outstanding, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Ending balance",
        "periodStartLabel": "Weighted average exercise price, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Number of options, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share weighted-average price paid for shares purchased on open market for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Per Share Weighted Average Price of Shares Purchased",
        "terseLabel": "Weighted average share price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding stock, reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r358",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r392",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Aggregate intrinsic value, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedForOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r99"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life (in years), Expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r0",
      "r141",
      "r154",
      "r636"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Letter of credit issued",
        "totalLabel": "Short-term Debt, Total"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "terseLabel": "Lease Rent Payment"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r496",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r49",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r182",
      "r183",
      "r184",
      "r208",
      "r235",
      "r236",
      "r239",
      "r241",
      "r248",
      "r249",
      "r277",
      "r307",
      "r310",
      "r311",
      "r312",
      "r316",
      "r317",
      "r322",
      "r323",
      "r326",
      "r327",
      "r330",
      "r464",
      "r608",
      "r651",
      "r665",
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r18",
      "r81",
      "r170",
      "r200",
      "r201",
      "r202",
      "r214",
      "r215",
      "r216",
      "r219",
      "r227",
      "r229",
      "r247",
      "r284",
      "r331",
      "r389",
      "r390",
      "r391",
      "r414",
      "r415",
      "r452",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r510",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r247",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r81",
      "r82",
      "r89",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Purchase of common stock under ESPP(shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs of (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r81",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of options, Exercised",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfStockOptionActivityDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r18",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Purchase of common stock under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock from initial public offering, net of issuance costs of $25,098",
        "verboseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r2",
      "r3",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r18",
      "r81",
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r58",
      "r636",
      "r667",
      "r683",
      "r793"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equtiy (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r480",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r480",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r480",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsDate": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the event occurred after the balance sheet date but before financial statements are issues or available to be issued, in YYYY-MM-DD format.",
        "label": "Subsequent Event, Date",
        "terseLabel": "Subsequent event, date"
       }
      }
     },
     "localname": "SubsequentEventsDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r517",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary Sale Of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "negatedLabel": "Issuance of Series A Preferred"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r275",
      "r276",
      "r321",
      "r329",
      "r443",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r680",
      "r681",
      "r682",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r218",
      "r219",
      "r220",
      "r221",
      "r231",
      "r270",
      "r271",
      "r281",
      "r282",
      "r283",
      "r284",
      "r286",
      "r287",
      "r389",
      "r390",
      "r391",
      "r412",
      "r413",
      "r414",
      "r415",
      "r428",
      "r429",
      "r430",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r465",
      "r466",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r481",
      "r482",
      "r485",
      "r486",
      "r487",
      "r488",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r554",
      "r555",
      "r556",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r790"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r617",
      "r628",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agencies Debt Securities",
        "verboseLabel": "U.S. Agency Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r617",
      "r628",
      "r630",
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "US Treasury Securities",
        "verboseLabel": "U.S. Treasury Bills and Notes [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r394",
      "r401"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance",
        "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "totalLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of manufacturing or production costs and any related deferred costs (for example, initial tooling costs) that exceeds the aggregate estimated cost of all in-process and delivered units on the basis of the estimated average cost of all units expected to be produced under long-term contracts and programs not yet complete.",
        "label": "Unrecovered Production Costs, Excess of Estimated Average Unit Cost",
        "terseLabel": "Estimated expected cost reimbursement"
       }
      }
     },
     "localname": "UnrecoveredProductionCostsExcessOfEstimatedAverageUnitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r251",
      "r252",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Deferred tax assets valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r497",
      "r635"
     ],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease costs"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesSummaryOfComponentsOfOperatingLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r234",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares used in net loss per share attributable to common stockholders, diluted",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total",
        "verboseLabel": "Weighted average number of common shares, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r232",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares used in net loss per share attributable to common stockholders, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total",
        "verboseLabel": "Weighted average number of common shares, basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersScheduleOfComputationOfBasicAndDilutedNetLossPerShareDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_AccruedExternalResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued external research and development expenses",
        "label": "Accrued External Research And Development Expenses",
        "terseLabel": "Accrued external research and development expenses"
       }
      }
     },
     "localname": "AccruedExternalResearchAndDevelopmentExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AcuitasAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Acuitas agreements.",
        "label": "Acuitas Agreements [Member]",
        "terseLabel": "Acuitas Agreements"
       }
      }
     },
     "localname": "AcuitasAgreementsMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_AdditionalLesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional Lessee Operating Lease Area",
        "label": "Additional Lessee Operating Lease Area",
        "terseLabel": "Additional Lease Area"
       }
      }
     },
     "localname": "AdditionalLesseeOperatingLeaseArea",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "verv_AdditionalTenantImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional tenant improvements allowance.",
        "label": "Additional Tenant Improvements Allowance",
        "terseLabel": "Additional tenant improvements allowance"
       }
      }
     },
     "localname": "AdditionalTenantImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AgreegatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreegate purchase price.",
        "label": "Agreegate Purchase Price",
        "terseLabel": "Agreegate Purchase Price"
       }
      }
     },
     "localname": "AgreegatePurchasePrice",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AntidilutionRightsLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilution rights liability.",
        "label": "Antidilution Rights Liability [Member]",
        "terseLabel": "Antidilution Rights Liability"
       }
      }
     },
     "localname": "AntidilutionRightsLiabilityMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_AntidilutionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antidilution rights.",
        "label": "Antidilution Rights Member",
        "terseLabel": "Antidilution Rights"
       }
      }
     },
     "localname": "AntidilutionRightsMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non-Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Non-Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxNonCurrent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current",
        "label": "Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Non Current"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxNonCurrent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_BeamLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam license agreement.",
        "label": "Beam License Agreement [Member]",
        "terseLabel": "Beam License Agreement"
       }
      }
     },
     "localname": "BeamLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_BeamMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Beam [Member].",
        "label": "Beam [Member]",
        "terseLabel": "Beam"
       }
      }
     },
     "localname": "BeamMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_BroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Broad License Agreement [Member]",
        "label": "Broad License Agreement [Member]",
        "terseLabel": "Broad License Agreement"
       }
      }
     },
     "localname": "BroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CambridgeLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cambridge lease.",
        "label": "Cambridge Lease [Member]",
        "terseLabel": "Cambridge Lease"
       }
      }
     },
     "localname": "CambridgeLeaseMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurements of lease liabilities.",
        "label": "Cash paid for amounts included in the measurements of lease liabilities [Abstract]"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementsOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "verv_ChangeInFairValueOfAntidilutionRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of antidilution rights.",
        "label": "Change In Fair Value Of Antidilution Rights",
        "negatedLabel": "Change in fair value of antidilution rights liability",
        "terseLabel": "Change in fair value of antidilution rights"
       }
      }
     },
     "localname": "ChangeInFairValueOfAntidilutionRights",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInFairValueOfPreferredStockTrancheLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of preferred stock tranche liabilities.",
        "label": "Change In Fair Value Of Preferred Stock Tranche Liabilities",
        "negatedLabel": "Change in fair value of preferred stock tranche liabilities",
        "terseLabel": "Change in fair value of preferred stock tranche liability"
       }
      }
     },
     "localname": "ChangeInFairValueOfPreferredStockTrancheLiabilities",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInFairValueOfSuccessPaymentsLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of success payments liabilities.",
        "label": "Change In Fair Value Of Success Payments Liabilities",
        "negatedLabel": "Change in fair value of success payment liability",
        "terseLabel": "Change in fair value of success payments liabilities"
       }
      }
     },
     "localname": "ChangeInFairValueOfSuccessPaymentsLiabilities",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ChangeInOwnershipDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in ownership description.",
        "label": "Change In Ownership Description",
        "terseLabel": "Change in ownership, description"
       }
      }
     },
     "localname": "ChangeInOwnershipDescription",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_ClinicalAndRegulatoryMilestone": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestone.",
        "label": "Clinical And Regulatory Milestone",
        "terseLabel": "Clinical And Regulatory Milestone"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestone",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And License Agreement [Member]",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration And License Agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements",
        "label": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "verv_CollaborationReceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration receivable",
        "label": "Collaboration receivable",
        "terseLabel": "Collaboration receivable"
       }
      }
     },
     "localname": "CollaborationReceivable",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CollaborationsRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaborations Revenue",
        "terseLabel": "Collaborations revenue"
       }
      }
     },
     "localname": "CollaborationsRevenue",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CommercializingProfitsAndExpenses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercializing profits and expenses.",
        "label": "Commercializing Profits And Expenses",
        "terseLabel": "Commercializing Profits And Expenses"
       }
      }
     },
     "localname": "CommercializingProfitsAndExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_CommissionOnAggregateGrossSaleProceeds": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission on aggregate gross sale proceeds.",
        "label": "Commission On Aggregate Gross Sale Proceeds"
       }
      }
     },
     "localname": "CommissionOnAggregateGrossSaleProceeds",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_CommonStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Issued During Period Value New Issues",
        "label": "Common Stock Issued During Period Value New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "CommonStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CommonStockIssuedForFullySatisfyingPreferredStockFinancing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for fully satisfying preferred stock financing",
        "label": "Common Stock Issued For Fully Satisfying Preferred Stock Financing",
        "terseLabel": "Common stock issued for fully satisfying preferred stock financing"
       }
      }
     },
     "localname": "CommonStockIssuedForFullySatisfyingPreferredStockFinancing",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_CommonStockIssuedForPartlySatisfyingPreferredStockFinancing": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for partly satisfying preferred stock financing",
        "label": "Common Stock Issued For Partly Satisfying Preferred Stock Financing",
        "terseLabel": "Common stock issued for partly satisfying preferred stock financing"
       }
      }
     },
     "localname": "CommonStockIssuedForPartlySatisfyingPreferredStockFinancing",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_CommonStockOfferingPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Offering Price Per Share",
        "label": "Common Stock Offering Price Per Share"
       }
      }
     },
     "localname": "CommonStockOfferingPricePerShare",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "verv_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer equipment and software.",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer Equipment and Software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible preferred stock.",
        "label": "Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_CumulativeProbabilityOfTriggeringEvent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative probability of triggering event.",
        "label": "Cumulative Probability Of Triggering Event",
        "terseLabel": "Cumulative probability of triggering event"
       }
      }
     },
     "localname": "CumulativeProbabilityOfTriggeringEvent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_CurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current [Abstract]",
        "label": "Current [Abstract]"
       }
      }
     },
     "localname": "CurrentAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_DebtBorrowedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt borrowed amount.",
        "label": "Debt Borrowed Amount",
        "terseLabel": "Borrowed amount"
       }
      }
     },
     "localname": "DebtBorrowedAmount",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredOfferingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs.",
        "label": "Deferred Offering Costs Policy [Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredOfferingCostsPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_DeferredTaxAssetAccruedExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Asset Accrued Expenses.",
        "label": "Deferred Tax Asset Accrued Expenses",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "DeferredTaxAssetAccruedExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsAntidilultionLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Antidilultion Liability.",
        "label": "Deferred Tax Assets Antidilultion Liability",
        "terseLabel": "Antidilultion liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsAntidilultionLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsCapitalizedCostsNetOfAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Capitalized Costs Net Of Amortization.",
        "label": "Deferred Tax Assets Capitalized Costs Net Of Amortization",
        "terseLabel": "Capitalized costs\u2014net of amortization"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedCostsNetOfAmortization",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs",
        "label": "Deferred Tax Assets Deferred Expense Capitalized Research And Development Costs",
        "terseLabel": "Capitalized research costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxAssetsStockBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Stock-based compensation",
        "label": "Deferred Tax Assets, Stock-based compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsStockBasedCompensation",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax liabilities, Right of use asset",
        "label": "Deferred Tax liabilities, Right of use asset",
        "terseLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match After Three Percent And Before Five Percent Of Employee Salary",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match after 3% and before 5% of employee's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchAfterThreePercentAndBeforeFivePercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match Upto Three Percent Of Employee Salary",
        "terseLabel": "Defined contribution plan, employer matching contribution, percent of match upto 3% of employee's salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoThreePercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan employer matching contribution percent of match upto two percent of employee salary.",
        "label": "Defined Contribution Plan Employer Matching Contribution Percent of Match Upto Two Percent of Employee Salary",
        "terseLabel": "Defined contribution plan employer matching contribution percent of match upto two percent of employee salary"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatchUptoTwoPercentOfEmployeeSalary",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_DeliveryTechnologyProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Delivery Technology Product [Member]",
        "label": "Delivery Technology Product [Member]",
        "terseLabel": "Delivery Technology Product"
       }
      }
     },
     "localname": "DeliveryTechnologyProductMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_DevelopedBaseMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed base milestone payments.",
        "label": "Developed Base Milestone Payments",
        "terseLabel": "Developed base milestone payments"
       }
      }
     },
     "localname": "DevelopedBaseMilestonePayments",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_DevelopedBaseMilestonePaymentsForStatedPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Developed base milestone payments for quarterly period.",
        "label": "Developed Base Milestone Payments For Stated Period",
        "terseLabel": "Developed base milestone payments for quarterly period"
       }
      }
     },
     "localname": "DevelopedBaseMilestonePaymentsForStatedPeriod",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Executive compensation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Executive compensation, Percent",
        "terseLabel": "Executive compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationExecutiveCompensationPercent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_EffectiveIncomeTaxRateReconciliationOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Other",
        "label": "Effective Income Tax Rate Reconciliation Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOther",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation Permanent Items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueAssumptionOfEquityVolatilityRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumption of equity volatility rate.",
        "label": "Fair Value Assumption Of Equity Volatility Rate",
        "terseLabel": "Equity volatility"
       }
      }
     },
     "localname": "FairValueAssumptionOfEquityVolatilityRate",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueAssumptionsExpectedTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value assumptions expected term 1.",
        "label": "Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "FairValueAssumptionsExpectedTerm1",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_FairValueInputsProbabilityOfTermination": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value inputs probability of termination.",
        "label": "Fair Value Inputs Probability Of Termination",
        "terseLabel": "Fair value inputs probability of termination"
       }
      }
     },
     "localname": "FairValueInputsProbabilityOfTermination",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_FairValueOfCommonStockPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock per share.",
        "label": "Fair value of common stock per share",
        "terseLabel": "Fair value of common stock (per share)"
       }
      }
     },
     "localname": "FairValueOfCommonStockPerShare",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "verv_FirstAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Amendment Member.",
        "label": "First Amendment [Member]",
        "terseLabel": "First Amendment"
       }
      }
     },
     "localname": "FirstAmendmentMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_FirstLicensedAgentMaterialRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First licensed agent material right",
        "label": "First licensed agent material right [Member]",
        "terseLabel": "First licensed agent material right [Member]"
       }
      }
     },
     "localname": "FirstLicensedAgentMaterialRightMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_FixedConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed consideration amount",
        "label": "Fixed consideration amount",
        "terseLabel": "Fixed consideration amount"
       }
      }
     },
     "localname": "FixedConsiderationAmount",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_FourZeroOneKPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "401(k) Plan [Member]",
        "label": "Four Zero One (K) Plan [Member]",
        "terseLabel": "401(k) Plan"
       }
      }
     },
     "localname": "FourZeroOneKPlanMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureEmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Freestanding financial instruments and derivatives.",
        "label": "Freestanding Financial Instruments And Derivatives Policy [Text Block]",
        "terseLabel": "Freestanding Financial Instruments and Derivatives"
       }
      }
     },
     "localname": "FreestandingFinancialInstrumentsAndDerivativesPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_HarvardAndBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard and Board.",
        "label": "Harvard And Board [Member]",
        "terseLabel": "Harvard And Board"
       }
      }
     },
     "localname": "HarvardAndBoardMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardAndBroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard and Broad license agreement.",
        "label": "Harvard And Broad License Agreement [Member]",
        "terseLabel": "Harvard and Board"
       }
      }
     },
     "localname": "HarvardAndBroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardAndBroadMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard And Broad.",
        "label": "Harvard And Broad [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "HarvardAndBroadMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardLicenseAgreementAndBroadLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harvard/Broad License Agreement and Broad License Agreement [Member]",
        "label": "Harvard License Agreement And Broad License Agreement [Member]",
        "terseLabel": "Harvard License Agreement And Broad License Agreement"
       }
      }
     },
     "localname": "HarvardLicenseAgreementAndBroadLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_HarvardLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Harward.",
        "label": "Harvard License Agreement [Member]",
        "terseLabel": "Harvard"
       }
      }
     },
     "localname": "HarvardLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Operating Lease Right Of Use Of Asset",
        "label": "Increase Decrease In Operating Lease Right Of Use Of Asset",
        "terseLabel": "Increase in Right-Of-Use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseOfAsset",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IncreaseDecreaseInRent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in rent",
        "label": "Increase decrease in rent",
        "terseLabel": "IncreaseDecreaseInRent"
       }
      }
     },
     "localname": "IncreaseDecreaseInRent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_IncreaseInCommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in common stock capital shares, reserved for future issuance.",
        "label": "Increase In Common Stock Capital Shares Reserved For Future Issuance",
        "terseLabel": "Increase in common stock capital shares, reserved for future issuance"
       }
      }
     },
     "localname": "IncreaseInCommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_IndemnificationAgreementsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indemnification agreements.",
        "label": "Indemnification Agreements Policy [Text Block]",
        "terseLabel": "Indemnification Agreements"
       }
      }
     },
     "localname": "IndemnificationAgreementsPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_InterestRateForAdditionalImprovementsAllowance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate for additional improvements allowance.",
        "label": "Interest Rate For Additional Improvements Allowance",
        "terseLabel": "Improvement allowance interest rate"
       }
      }
     },
     "localname": "InterestRateForAdditionalImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_IssuanceCostsOfCommonStockFromInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs Of Common Stock from Initial Public Offering",
        "label": "Issuance Costs Of Common Stock From Initial Public Offering",
        "terseLabel": "Issuance costs of common stock from initial public offering"
       }
      }
     },
     "localname": "IssuanceCostsOfCommonStockFromInitialPublicOffering",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance costs of series A2 convertible preferred stock.",
        "label": "Issuance Costs Of Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series A2 convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs of Series A Convertible Preferred Stock",
        "label": "Issuance Costs Of Series A Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series A convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceCostsOfSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance Costs Of Series B Convertible Preferred Stock",
        "label": "Issuance Costs Of Series B Convertible Preferred Stock",
        "terseLabel": "Issuance costs of series B convertible preferred stock"
       }
      }
     },
     "localname": "IssuanceCostsOfSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfAdditionalCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of additional common stock.",
        "label": "Issuance of Additional Common Stock"
       }
      }
     },
     "localname": "IssuanceOfAdditionalCommonStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_IssuanceOfCommonStockFromAtTheMarketOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING",
        "label": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING",
        "terseLabel": "Issuance of common stock from At-the-Market offering"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromAtTheMarketOffering",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS",
        "label": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS",
        "terseLabel": "Issuance of common stock from At-the-Market offering, net of issuance costs"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCosts",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS SHARES",
        "label": "ISSUANCE OF COMMON STOCK FROM AT THE MARKET OFFERING NET OF ISSUANCE COSTS SHARES",
        "terseLabel": "Issuance of common stock from At-the-Market offering, net of issuance costs of , (In Shares)"
       }
      }
     },
     "localname": "IssuanceOfCommonStockFromAtTheMarketOfferingNetOfIssuanceCostsShares",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_IssuanceOfPreferredStockTrancheLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of preferred stock tranche liability.",
        "label": "Issuance of Preferred Stock Tranche Liability",
        "terseLabel": "Issuance of preferred stock tranche liability"
       }
      }
     },
     "localname": "IssuanceOfPreferredStockTrancheLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A convertible preferred stock and settlement of tranche right liability.",
        "label": "Issuance of Series A Convertible Preferred Stock and Settlement of Tranche Right Liability",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability"
       }
      }
     },
     "localname": "IssuanceOfSeriesAConvertiblePreferredStockAndSettlementOfTrancheRightLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_LeaseCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Commencement Date.",
        "label": "Lease Commencement Date",
        "terseLabel": "Lease commencement date"
       }
      }
     },
     "localname": "LeaseCommencementDate",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "verv_LeaseNoncancelableTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Noncancelable Term.",
        "label": "Lease Noncancelable Term",
        "terseLabel": "Lease noncancelable term"
       }
      }
     },
     "localname": "LeaseNoncancelableTerm",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_LeaseRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease rent payment",
        "label": "Lease Rent Payment",
        "terseLabel": "Lease Rent Payment"
       }
      }
     },
     "localname": "LeaseRentPayment",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_LesseeOperatingLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease area.",
        "label": "Lessee Operating Lease Area",
        "terseLabel": "Lease area"
       }
      }
     },
     "localname": "LesseeOperatingLeaseArea",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "verv_LesseeOperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease incremental borrowing rate.",
        "label": "Lessee Operating Lease Incremental Borrowing Rate",
        "terseLabel": "Operating lease incremental borrowing rate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_LicenseAgreementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement Abstract",
        "label": "License Agreement [Abstract]"
       }
      }
     },
     "localname": "LicenseAgreementAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "verv_LicenseAgreementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement",
        "label": "License Agreement Disclosure [Text Block]",
        "terseLabel": "License Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDisclosureTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_LicenseAndMilestonePayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and milestone payments",
        "label": "License and milestone payments",
        "terseLabel": "License and milestone payments"
       }
      }
     },
     "localname": "LicenseAndMilestonePayments",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureAccruedExpensesScheduleOfAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_MassachusettsTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Massachusetts Tax Authority [Member].",
        "label": "Massachusetts Tax Authority [Member]",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MassachusettsTaxAuthorityMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_MaterialsExchangeAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Materials Exchange Agreement [Member].",
        "label": "Materials Exchange Agreement [Member]",
        "terseLabel": "Materials Exchange Agreement"
       }
      }
     },
     "localname": "MaterialsExchangeAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_MaturitiesOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maturities of marketable securities.",
        "label": "Maturities Of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "MaturitiesOfMarketableSecurities",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_MilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments.",
        "label": "Milestone Payments",
        "terseLabel": "Milestone payments"
       }
      }
     },
     "localname": "MilestonePayments",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_MilestoneRelatedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone related expenses.",
        "label": "Milestone Related Expenses",
        "terseLabel": "Milestone related expenses"
       }
      }
     },
     "localname": "MilestoneRelatedExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Amortization Of Premium (Accretion Of Discount) On Marketable Securities",
        "label": "Net Amortization Of Premium (Accretion Of Discount) On Marketable Securities",
        "terseLabel": "Net amortization of premium (accretion of discount) on marketable securities"
       }
      }
     },
     "localname": "NetAmortizationOfPremiumAccretionOfDiscountOnMarketableSecurities",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NewAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New Amendment [Member]",
        "label": "New Amendment [Member]",
        "terseLabel": "New Amendment"
       }
      }
     },
     "localname": "NewAmendmentMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_NonCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-current [Abstract]",
        "label": "Non-current [Abstract]"
       }
      }
     },
     "localname": "NonCurrentAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesScheduleOfMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_NonRefundableUpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront license fee.",
        "label": "Non Refundable Upfront License Fee",
        "terseLabel": "Non Refundable Upfront License Fee"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFee",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Refundable Upfront License Fees.",
        "label": "Non Refundable Upfront License Fees",
        "terseLabel": "Non Refundable Upfront License Fees"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFees",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontLicenseFeesPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-refundable upfront license fees paid",
        "label": "Non-Refundable Upfront License Fees Paid",
        "terseLabel": "Non-refundable upfront license fees paid"
       }
      }
     },
     "localname": "NonRefundableUpfrontLicenseFeesPaid",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront payment",
        "label": "Non Refundable Upfront Payment",
        "terseLabel": "Non Refundable Upfront Payment"
       }
      }
     },
     "localname": "NonRefundableUpfrontPayment",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_NovartisLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis license agreement",
        "label": "Novartis license agreement [Member]",
        "terseLabel": "Novartis License Agreement Member"
       }
      }
     },
     "localname": "NovartisLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_NumberOfInstallmentsForRestrictedSharesVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of installments for restricted shares vested.",
        "label": "Number of Installments for Restricted Shares Vested"
       }
      }
     },
     "localname": "NumberOfInstallmentsForRestrictedSharesVested",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "verv_OfficeFurnitureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office furniture.",
        "label": "Office Furniture [Member]",
        "terseLabel": "Office Furniture"
       }
      }
     },
     "localname": "OfficeFurnitureMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesScheduleOfPropertyAndEquipmentEstimatedUsefulLifeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_OperatingLeaseRelatedExpensesPriorToCommencement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease related expenses prior to commencement.",
        "label": "Operating Lease Related Expenses Prior To Commencement",
        "terseLabel": "Lease space build out cost prior to commencement"
       }
      }
     },
     "localname": "OperatingLeaseRelatedExpensesPriorToCommencement",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OperatingLossCarryforwardsExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards expiration year.",
        "label": "Operating Loss Carryforwards Expiration Year",
        "terseLabel": "Net operating loss carryforwards expiration year"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationYear",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "verv_OptionAndLicenseIssueFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option And License Issue Fees.",
        "label": "Option And License Issue Fees",
        "terseLabel": "Option And License Issue Fees"
       }
      }
     },
     "localname": "OptionAndLicenseIssueFees",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OptionLicenseAgreementAndPatentLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option License Agreement and Patent License Agreement [Member].",
        "label": "Option License Agreement And Patent License Agreement [Member]",
        "terseLabel": "Option License Agreement And Patent License Agreement"
       }
      }
     },
     "localname": "OptionLicenseAgreementAndPatentLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_OutOfPocketCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "out-of-pocket costs incurred.",
        "label": "Out Of Pocket Costs Incurred",
        "terseLabel": "Out-of-pocket costs incurred"
       }
      }
     },
     "localname": "OutOfPocketCostsIncurred",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_OutstandingOptionsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding Options to Purchase Common Stock",
        "label": "Outstanding Options To Purchase Common Stock [Member]",
        "terseLabel": "Outstanding Options To Purchase Common Stock"
       }
      }
     },
     "localname": "OutstandingOptionsToPurchaseCommonStockMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_PaymentOfMilestoneDevelopment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of milestone development.",
        "label": "Payment of Milestone Development",
        "terseLabel": "Payment of milestone development"
       }
      }
     },
     "localname": "PaymentOfMilestoneDevelopment",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PaymentOfSalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of sales based milestone.",
        "label": "Payment of Sales Based Milestone",
        "terseLabel": "Payment of sales based milestone"
       }
      }
     },
     "localname": "PaymentOfSalesBasedMilestone",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment received for license agreement reimbursement of costs incurred",
        "label": "Payment Received for License Agreement Reimbursement of Costs Incurred",
        "terseLabel": "Reimbursement received related to reduction to research and development expense"
       }
      }
     },
     "localname": "PaymentReceivedForLicenseAgreementReimbursementOfCostsIncurred",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PercentageOfFutureTaxableIncomeUtilizedToOffset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future taxable income utilized to offset",
        "label": "Percentage of future taxable income utilized to offset"
       }
      }
     },
     "localname": "PercentageOfFutureTaxableIncomeUtilizedToOffset",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PercentageOfTaxBenefitRealized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of tax benefit realized",
        "label": "Percentage of tax benefit realized"
       }
      }
     },
     "localname": "PercentageOfTaxBenefitRealized",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PercentageSharesOfDevelopmentExpense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage Shares of Development Expense.",
        "label": "Percentage Shares Of Development Expense",
        "terseLabel": "Percentage Shares of Development Expense"
       }
      }
     },
     "localname": "PercentageSharesOfDevelopmentExpense",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "verv_PerformanceObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance obligation",
        "label": "Performance obligation",
        "terseLabel": "Performance obligation"
       }
      }
     },
     "localname": "PerformanceObligation",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PreferredAndCommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred and common stock disclosure text block.",
        "label": "Preferred And Common Stock [Text Block]",
        "terseLabel": "Preferred and Common Stock"
       }
      }
     },
     "localname": "PreferredAndCommonStockTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock abstract.",
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.vervetx.com/20221231",
     "xbrltype": "stringItemType"
    },
    "verv_PreferredStockFinancingFullySatisfied": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock financing fully satisfied",
        "label": "Preferred Stock Financing Fully Satisfied",
        "terseLabel": "Preferred stock financing were fully satisfied"
       }
      }
     },
     "localname": "PreferredStockFinancingFullySatisfied",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PreferredStockFinancingPartiallySatisfied": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock financing partially satisfied",
        "label": "Preferred Stock Financing Partially Satisfied",
        "terseLabel": "Preferred stock financing partially satisfied"
       }
      }
     },
     "localname": "PreferredStockFinancingPartiallySatisfied",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PreferredStockTrancheLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock tranche liability.",
        "label": "Preferred Stock Tranche Liability [Member]",
        "terseLabel": "Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "PreferredStockTrancheLiabilityMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_PreferredStockTrancheLiabilityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock tranche liability disclosure text block.",
        "label": "Preferred Stock Tranche Liability [Text Block]",
        "terseLabel": "Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "PreferredStockTrancheLiabilityTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosurePreferredStockTrancheLiability1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_PremisesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premises.",
        "label": "Premises [Member]",
        "terseLabel": "Premises"
       }
      }
     },
     "localname": "PremisesMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ProceedsFromIssuanceOfCommonSharesNetOfCommissions": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of common shares, net of commissions.",
        "label": "Proceeds From Issuance of Common Shares, Net of Commissions",
        "terseLabel": "Proceeds from issuance of common shares, net of commissions"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonSharesNetOfCommissions",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProceedsFromIssuanceOfCommonStockUnderIPOGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock Under IPO, Gross.",
        "label": "Proceeds From Issuance Of Common Stock Under I P O Gross",
        "terseLabel": "Proceeds from common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockUnderIPOGross",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses",
        "label": "Proceeds from Issuance of Preferred Stock after Deducting Underwriting Discounts and Offering Expenses",
        "terseLabel": "Proceeds from issuance of Preferred Stock, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAfterDeductingUnderwritingDiscountsAndOfferingExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ProductCollaborationTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product collaboration termination notice period.",
        "label": "Product Collaboration Termination Notice Period",
        "terseLabel": "Product collaboration termination notice period"
       }
      }
     },
     "localname": "ProductCollaborationTerminationNoticePeriod",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment additions included in accounts payable and accrued expenses.",
        "label": "Property And Equipment Additions Included In Accounts Payable And Accrued Expenses",
        "terseLabel": "Property and equipment additions included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PropertyAndEquipmentAdditionsIncludedInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public offering [Member]",
        "label": "Public offering [Member]"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_PublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering Price",
        "label": "Public Offering Price",
        "terseLabel": "Public Offering Price"
       }
      }
     },
     "localname": "PublicOfferingPrice",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "verv_ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation of cash, cash equivalents and restricted cash.",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash Table [Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashTableTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ReductionInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction In Research And Development Expense.",
        "label": "Reduction In Research And Development Expense",
        "terseLabel": "Reduction In Research And Development Expense"
       }
      }
     },
     "localname": "ReductionInResearchAndDevelopmentExpense",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_RemainingContractualMaturitiesOfMarketableSecuritiesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining contractual maturities of marketable securities term.",
        "label": "Remaining Contractual Maturities Of Marketable Securities Term",
        "terseLabel": "Remaining contractual maturities of marketable securities term"
       }
      }
     },
     "localname": "RemainingContractualMaturitiesOfMarketableSecuritiesTerm",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureMarketableSecuritiesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "verv_RentExpensePolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy of rent expense.",
        "label": "Rent Expense Policy [Text Block]",
        "terseLabel": "Rent Expense"
       }
      }
     },
     "localname": "RentExpensePolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expense of antidilution rights liability",
        "label": "Research and development expense of antidilution rights liability"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseOfAntidilutionRightsLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ResearchServicesObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services obligation",
        "label": "Research services obligation [Member]",
        "terseLabel": "Research services obligation [Member]"
       }
      }
     },
     "localname": "ResearchServicesObligationMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales Agreement.",
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SalesBasedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales based milestone",
        "label": "Sales Based Milestone",
        "terseLabel": "Sales Based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestone",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of property and equipment estimated useful life.",
        "label": "Schedule Of Property And Equipment Estimated Useful Life Table [Text Block]",
        "terseLabel": "Schedule of Property and Equipment Estimated Useful Life"
       }
      }
     },
     "localname": "ScheduleOfPropertyAndEquipmentEstimatedUsefulLifeTableTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of supplemental cash flow information related to operating leases.",
        "label": "Schedule of Supplemental Cash Flow Information Related to Operating Leases [Table Text Block]",
        "terseLabel": "Supplemental Cash Flow Information Related to Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToOperatingLeasesTableTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_SecondAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Amendment Member.",
        "label": "Second Amendment [Member]",
        "terseLabel": "Second Amendment"
       }
      }
     },
     "localname": "SecondAmendmentMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SecondLicensedAgentMaterialRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second licensed agent material right",
        "label": "Second licensed agent material right [Member]",
        "terseLabel": "Second licensed agent material right [Member]"
       }
      }
     },
     "localname": "SecondLicensedAgentMaterialRightMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SecondTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Tranche Member",
        "label": "Second Tranche [Member]",
        "verboseLabel": "Second Tranche [Member]"
       }
      }
     },
     "localname": "SecondTrancheMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SegmentAndGeographicInformationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting policy related to segment and geographic information.",
        "label": "Segment And Geographic Information Policy [Text Block]",
        "terseLabel": "Segment and Geographic Information"
       }
      }
     },
     "localname": "SegmentAndGeographicInformationPolicyTextBlock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "verv_SeriesA2PreferredStocksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock.",
        "label": "Series A2 Preferred Stocks [Member]",
        "terseLabel": "Series A-2 Preferred Stock"
       }
      }
     },
     "localname": "SeriesA2PreferredStocksMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of Antidilution Rights Liability By Issuing Common Stock",
        "label": "Settlement of Antidilution Rights Liability By Issuing Common Stock",
        "terseLabel": "Settlement of derivative liability by issuing common stock"
       }
      }
     },
     "localname": "SettlementOfAntidilutionRightsLiabilityByIssuingCommonStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SettlementOfTrancheRightLliability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of tranche right liability.",
        "label": "Settlement Of Tranche Right Lliability",
        "terseLabel": "Settlement of tranche right liability"
       }
      }
     },
     "localname": "SettlementOfTrancheRightLliability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ShortTermBorrowingsReducedValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term borrowings reduced value.",
        "label": "Short Term Borrowings Reduced Value",
        "terseLabel": "Letter of credit reduced value"
       }
      }
     },
     "localname": "ShortTermBorrowingsReducedValue",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockAvailableForIssuanceUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Available For Issuance Under Employee Stock Purchase Plan",
        "label": "Stock Available For Issuance Under Employee Stock Purchase Plan",
        "terseLabel": "Stock available for issuance under ESPP"
       }
      }
     },
     "localname": "StockAvailableForIssuanceUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Issuance of common stock under ESPP Shares",
        "label": "Stock Issued During Issuance of common stock under ESPP Shares",
        "terseLabel": "Issuance of Common stock under ESPP (In Share)"
       }
      }
     },
     "localname": "StockIssuedDuringIssuanceOfCommonStockUnderEsppShares",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringIssuanceOfCommonStockUnderEsppValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Issuance of common stock under ESPP Value",
        "label": "Stock Issued During Issuance of common stock under ESPP Value",
        "terseLabel": "Issuance of Common stock under ESPP value"
       }
      }
     },
     "localname": "StockIssuedDuringIssuanceOfCommonStockUnderEsppValue",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodAdditionalShareLicensorInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of additional common stock to licensor institutions (in shares)",
        "label": "Stock Issued During Period Additional Share Licensor Institutions",
        "terseLabel": "Additional issuances of common stock to licensor institutions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalShareLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of additional shares issued to licensor institutuons.",
        "label": "Stock Issued During Period Additional Shares Value Licensor Institutions",
        "terseLabel": "Additional issuances of common stock to licensor institutions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodAdditionalSharesValueLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodShareLicensorInstitutions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock to licensor institutions (in shares)",
        "label": "Stock Issued During Period Share Licensor Institutions",
        "terseLabel": "Issuances of common stock to licensor institutions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A-2 convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series A Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee.",
        "label": "Stock Issued During Period Shares Series A Preferred Stock In Payment of Licensing Fee",
        "terseLabel": "Issuance of Series A Preferred Stock in payment of licensing fee (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesAPreferredStockInPaymentOfLicensingFee",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period Shares Series B Convertible Preferred Stock",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "verv_StockIssuedDuringPeriodValueLicensorInstitutions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Licensor Institutions",
        "label": "Stock Issued During Period Value Licensor Institutions",
        "terseLabel": "Issuances of common stock to licensor institutions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicensorInstitutions",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series A-2 convertible preferred stock, net of issuance costs.",
        "label": "Stock Issued During Period Value Series A2 Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A-2 convertible preferred stock, net of issuance costs of $112"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesA2ConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares series a convertible preferred stock.",
        "label": "Stock Issued During Period Value Series A Convertible Preferred Stock",
        "terseLabel": "Issuance of Series A convertible preferred stock and settlement of tranche right liability, net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesAConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee.",
        "label": "Stock Issued During Period Value Series A Preferred Stock In Payment Of Licensing Fee",
        "terseLabel": "Issuance of Series A Preferred Stock in payment of licensing fee"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesAPreferredStockInPaymentOfLicensingFee",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series B convertible preferred stock, net of issuance costs",
        "label": "Stock Issued During Period Value Series B Convertible Preferred Stock",
        "terseLabel": "Issuance of Series B convertible preferred stock, net of issuance costs of $241"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueSeriesBConvertiblePreferredStock",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_StrategicLicenseAndCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic License and Collaboration Agreement [Member]",
        "label": "Strategic License and Collaboration Agreement [Member]"
       }
      }
     },
     "localname": "StrategicLicenseAndCollaborationAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SuccessLiabilityPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Liability Payment",
        "label": "Success Liability Payment"
       }
      }
     },
     "localname": "SuccessLiabilityPayment",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessOfPaymentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success of payment liability",
        "label": "Success of payment liability",
        "negatedLabel": "Success of payment liability"
       }
      }
     },
     "localname": "SuccessOfPaymentLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability.",
        "label": "Success Payment Liability",
        "terseLabel": "Success payment liability"
       }
      }
     },
     "localname": "SuccessPaymentLiability",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedBalanceSheets1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiabilityCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success Payment Liability Current",
        "label": "Success Payment Liability Current",
        "terseLabel": "Success payment, current portion"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityCurrent",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability.",
        "label": "Success Payment Liability [Member]",
        "terseLabel": "Success Payment Liability"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfReconciliationOfChangesInFairValueOfFinancialInstrumentsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_SuccessPaymentLiabilityPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payment liability, payable",
        "label": "Success Payment Liability, Payable"
       }
      }
     },
     "localname": "SuccessPaymentLiabilityPayable",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SuccessPaymentsForEachProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Success payments for each product",
        "label": "Success payments for each product",
        "terseLabel": "Success payments for each product"
       }
      }
     },
     "localname": "SuccessPaymentsForEachProduct",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "verv_TaxCreditCarryforwardExpirationYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax credit carryforward expiration year.",
        "label": "Tax Credit Carryforward Expiration Year",
        "terseLabel": "Tax credit carryforward expiration year"
       }
      }
     },
     "localname": "TaxCreditCarryforwardExpirationYear",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "verv_TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity, Conversion of convertible preferred stock to common stock upon closing of initial public offering",
        "label": "Temporary Equity Conversion Of Convertible Preferred Stock To Common Stock Upon Closing Of Initial Public Offering",
        "terseLabel": "Conversion of convertible preferred stock to common stock upon closing of initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityConversionOfConvertiblePreferredStockToCommonStockUponClosingOfInitialPublicOffering",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_TenantImprovementsAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant improvements allowance.",
        "label": "Tenant Improvements Allowance",
        "terseLabel": "Tenant improvements allowance"
       }
      }
     },
     "localname": "TenantImprovementsAllowance",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "verv_ThirdLicensedAgentMaterialRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third licensed agent material right",
        "label": "Third licensed agent material right [Member]",
        "terseLabel": "Third licensed agent material right [Member]"
       }
      }
     },
     "localname": "ThirdLicensedAgentMaterialRightMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsScheduleOfTransactionPriceSeparatePerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ThirdTrancheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third tranche.",
        "label": "Third Tranche [Member]",
        "terseLabel": "Third tranche",
        "verboseLabel": "Third Tranche [Member]"
       }
      }
     },
     "localname": "ThirdTrancheMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredStockTrancheLiabilityAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_ThreeLicensedAgentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Licensed Agent",
        "label": "Three Licensed Agent [Member]"
       }
      }
     },
     "localname": "ThreeLicensedAgentMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwentyEighteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty eighteen",
        "label": "Twenty Eighteen [Member]",
        "terseLabel": "Twenty Eighteen"
       }
      }
     },
     "localname": "TwentyEighteenMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwentyTwentyOneEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Twenty twenty one employee stock purchase plan member",
        "label": "Twenty Twenty One Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "TwentyTwentyOneEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_TwoThousandAndTwentyOneStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "label": "Two Thousand And Twenty One Stock Incentive Plan [Member]",
        "terseLabel": "2021 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneStockIncentivePlanMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_USAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. agency securities.",
        "label": "U S Agency Securities [Member]",
        "terseLabel": "U.S. Agency Securities"
       }
      }
     },
     "localname": "USAgencySecuritiesMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_USTreasuryBillsAndNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. treasury bills and notes.",
        "label": "U S Treasury Bills And Notes [Member]",
        "terseLabel": "U.S. Treasury Bills and Notes"
       }
      }
     },
     "localname": "USTreasuryBillsAndNotesMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsAndLiabilitiesMeasuredAtFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_UnvestedRestrictedStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock.",
        "label": "Unvested Restricted Stock [Member]",
        "terseLabel": "Unvested Restricted Stock"
       }
      }
     },
     "localname": "UnvestedRestrictedStockMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units [Member]",
        "label": "Unvested Restricted Stock Units [Member]",
        "terseLabel": "Unvested Restricted Stock Units"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNetLossPerShareAttributableToCommonStockholdersPotentialCommonSharesBasedOnAmountsOutstandingAtPeriodEndWereExcludedFromComputationOfDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_VerilyLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verily License Agreement [Member]",
        "label": "Verily License Agreement [Member]",
        "terseLabel": "Verily License Agreement"
       }
      }
     },
     "localname": "VerilyLicenseAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureLicenseAgreementsAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_VertexAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex Agreement [Member]",
        "label": "Vertex Agreement [Member]",
        "terseLabel": "Vertex Agreement [Member]"
       }
      }
     },
     "localname": "VertexAgreementMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_VertexPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vertex pharmaceuticals member.",
        "label": "Vertex Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "VertexPharmaceuticalsMember",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndBasisOfPresentationAdditionalInformationDetails",
      "http://www.vervetx.com/20221231/taxonomy/role/Role_DisclosurePreferredAndCommonStockAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "verv_WeightedAverageGrantDateFairValueForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-Average Grant-Date Fair Value, forfeited",
        "label": "Weighted-Average Grant-Date Fair Value, forfeited",
        "terseLabel": "Weighted-Average Grant-Date Fair Value, forfeited | $ / shares"
       }
      }
     },
     "localname": "WeightedAverageGrantDateFairValueForfeited",
     "nsuri": "http://www.vervetx.com/20221231",
     "presentation": [
      "http://www.vervetx.com/20221231/taxonomy/role/DisclosureStockbasedCompensationScheduleOfStatusAndChangeInUnvestedRestrictedStockAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.11)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.13(b))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "980",
   "URI": "https://asc.fasb.org/extlink&oid=84167750&loc=d3e42232-110370",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54434-107959",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d)(i))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=6378536&loc=d3e10092-111533",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/subtopic&trid=2235116",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL120154346-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918705-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r641": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r644": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r645": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r646": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r647": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r648": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r649": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10152-111534",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e21216-110875",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>123
<FILENAME>0000950170-23-005713-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-005713-xbrl.zip
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M9*=8V7^0YZ_S")9YT.LFY@EP$AB69L(07GSA*RGUXO0[J=]%;E^_,O7!]A,
MU=D)U25N8G'0BJQ+3O U$94:7"1Y(AG(@?CJZU'-#PRSV3'$YKW^U7#9P:A
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M#KE@IFGR'3V0[T=_@]5DKHH0-4P:*O1EI"-XXPFP^F+*\2XQ8YJXR[J*QW;
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M,2\PQ2U+B@M+VA. [H;$40%$]:<S_"+',^"H59%]4N]S_>=9;&[(<1[;>Y\
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M:07%3+'$FJ5JVBYW..A91\D,/5 *,;VZ]^3G4UIJS&]D=4B^J7$YK&GERC
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M>;G\C-3EGBF,[M&[5NX>6615XO<=G3!<A\%Z#_>V(;L?QV6<Z3>/TR+']$\
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ML&WOI8T,JAG5!<.1'/5-O#D1G _)M!6!OTNEM)0_EW2;". A^YJ<F>**RDA
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M"USMVO!;< !9,)P;,#T>?EDS,N,@[!='6=T0]89.C1HYMB'-?#AQ9-;Z;)!
M6GCMXY;RYV8)X7!W@9H?S@0]A;$YUF#,X\PMD";[CU^WZ].#>F[KKE'1AP;7
M^[KCS:J%V^;/XS6$.[@XQF09^;ZU13<-:F7Y:&S.3B[">*;KP88#6O&8S]S[
MX-=%08..4AW(EE@"")T)74G&(2K<R=._H+8YBF/]]X_B0E\,T9L@Q#.PTDO\
M@2(GEX_J)>/##71)WU9PCHJ:FF)#,RENZ^/7791P!K:?XDFJ%IM<?(/OJ[&6
MO*Q TG?&X;6)W3I8D")7Q$Z;5!!3L=Q?F"5ZVM ^]CHL3M1(T#']W*.,KG%]
M)[=O'>&@=@Z6R-;[XFH0T'IXUZ)!3#:]8RC>#9/UJ #W;P[]@GSU2H\)=(\8
M/3(\BYS5LU-/13TCA%*RE-?5O$)Y9*]JL@WY2\"(FK\TO1U-YQ>ILS:I$@#[
M\?UF%A!"B.IC)+45Z:HG[J/DUBD'WL#NFF(NG/S[3MXYPU+9C!_CI->_AF5?
M^4_VE@M>/J?'S:]SS*-))8&V>?25/L=W!$4U8-V@>HM(8EAHK#E_KV:TO 0+
MRA!V9SLD&QX$V/HF#]"\HS$4VYC*]_J5+!Q]2,99GT<YZCD_F19(J=QRS'HM
M5#,X'&"54?VH(VR12]-E,1FJ&B=ZMO9!2?Q*S_S)&$3(I'X_Z8ZJ0&\FZ;)"
MZ@6<2V+.48+ WRO]QY%2X5!E;/U[%%V1>$7DH\@:_RB^XE^W"Q)WP>_5M8\<
MC7;@UF>2[?0_^6W?N@4^K6TMV)D-;;6%L'(5<+&$)&G6(UE(?PH%;0FV*+TX
MWBIWF7=[=1R5&& VS]OEY]E'OY)<EQ^W!IHSAT&?1F@.36W=FB(G4)T&0>QU
MS8W$MWDL$97%Z$JK([$[!X8!6H5&QENBK=4BL?W+F*+;?G=4Q=Y!]")7$Z#<
M-)O% !\)C7H#YFPFA#-W>0U50 E4"'^#F=_RHS(B9-5_KOP&??TQJ\?DK;Q:
M'/+5J.17_V"F.7!8A^C<M@PHVZY@*X@04=\@H''G#A@/J2)?R( :"L BC69-
M[796M*Y-J52/O[R)UAT>2]89<_8T$7#T+>AD4=B@M\65SDE&F [U_:ZR>NP&
MTC'<UHD:5CT*B7#0).H"\W*>U_(!JVGP,I^X<_6IMR<E-*_:(QT;)M*S=Z)=
MN&R'^J\U$5%3<QI0QD@K?9LBC>2ET$#N.'%R,:9H"#SWJ]ESUV)>'2=AU*#C
M]NOMV>^1W]FKJC-?7NMOI#,9U]^.2JYME'$<<?GX7=TM(O7!1!U$G0,L$-W;
MU4V'M:3:S[IF2H$4VCXP=$ASQ/"DQYZ(00-XT?&KJIE7-7? K>R>/C["-UG
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M$FE5W@NE@C=#D"&T@>\75[22NHT^X&X..^5Z86(?FL2^49R&9P,W_DQ<+UT
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M]V;#%/4M6&X!.?]LIR"3?;^W*$%*#OIH/FG9@!H$])%OQ%=91%^LU^\148P
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M&*\08&30;_NU^ "VDP20;3^T^"$<,OGC_7OC^$=:Q?DM^_D\O$9<[Q"#&DG
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MQ0"&E9>K:E*$PZTM(JDRROWP@/,F1E,!(GMM[*;-1@$=BUJCC'&X>FC6D<P
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M'HAM83IWDQP>#3TSIO/N>6PT;3MH%V^1TEW5FF)Q7_!=NVBNP5&$6>,.VZ%
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M5K#F8[NUY@/;I,1RA71-XX,D4Z:&\IHZ]'"UF8APM./G>DNKT3)75<=66L?
MC?W4ZDEH,M;I(\,5VZ%G+SS0](\NEY H#'GLR#YU7O(CKE)D4MD*5+G,F'BD
MM\KCTH59(_2:)N<<Z1P#-%E0>X>R)=<FCBK5KAIV^9K]+G^"F!%M[I7UR!4A
M?;$[S4S-0QN;+54\<;UA9HZ?*T)#YXLMX+1C@4+%/ATJ)_:5J;9!"WN2H?:3
MD^2LDV]>L4Y'3I@8O[,-',/%\Z04[NSK[L#.+<'?7#9L"A>*1<R2=9:'RDZK
MR8%$)%!2UB*WS_6PRVKW9?4L"TUF3)AVM)L"3,Y%W& '/SMKP@QF,\DV<<G
M#94JX2P87A539.?#-%AUPL.W43WHG7,E&IQQ#4$.NU+-'8WH)X4NE?4-?@-D
MN?:%+(%CH8L1LMIC6)XNQ68*M*K>CH$+!OKGW4WEKF3.$?M\4*MM.+E7<<P?
M-[E@(9H9X_=]NN3ZPCF0\[;B)L5;A\GEGCM%B3Y]29:/X$:T3\2?,:O7F'0X
M)3WX3-GM-7BY4$)@ P0=O[J^=1N>+9"C!XV.O-P,I[D;-DYZ=VI,P=@J, JK
MN"(Q6SU2<KI?L)Q/_54X/BP9<).Y@Z6B86A\P]6&?G37,U( 60S7[C_EEOA2
M$<@PVAJ4$\C;/\/OEOV0*S3Z93H&2U\+A!636=1#& IW+-%#&RW78%8( Z&5
M[1<7*B/>]Q9 /_@4'HC8AK\ J9T$>LKV0+,? RSDPB;#M#Y_IU^RC1@@@BX"
ML33[J?$#R&EWN2? ^*$EOE3]%Q?R(WXG=U,%AGS(5RLMZ_0@Z3M?6*4B=^K*
MJ%#^(,.[3O$WMGOVKUV*5U@?TJL+_16MNSAS 1P_-HC\GK!]SM=/N(.A'^(*
M4*J??G0NA;\YB$0+D#LZPUC^1AT5HE':&*#>[I,D ^A;=V%C^J<Y!:_&U+54
MU)"IYI>M8ZIH='T+^IGM#S1W[3O-A:J#'=/ 7A?^G>?AS>ZP\1(<M,X(;IW[
MOK/;ML/0A!K)N&&#;7QS^:*\F84K]:6&N]4%X6^^\:^Z".<S:Q!PA;VU2K)J
M%I0ALQX=FKS!GL+!<KD<-P[_0:C78;%XZ_9TS^)(8M5 M/7[]-? \G"DT:/O
M"QHYYWB,=>H+S3' 0(CAP=_5]P%=65<K5(&]K%FUIU$@3G+\0:&KW/H47-,4
M2*>DE#]@C0P&FDYIG([/K!4JC87S9O>3[)?I6('+UM!DTR)_O(/VRG+CMSF#
ME-UTEO3TWH<,?7<D[OL*KX"4A3/$S/#R45C,LZSCZ]=?T$AN3.L77EGK75O6
M\3,)S"=Z^BS%G*GTH?[8C*]PWBDS[VU4 H4FT(5NA!R/98PE>T2CE>_%H3R@
M>\4<F[VAT%84C4,94ON4X2R?9!Z/MEEZY*+E"ON^*>P5A*],I+8WJ=\< !7O
M##@W4_"/%>;:5'*0F"B<^OAW("4RJ8X PQ454L0A^"Y+T7J4BU:6/HT4B$\C
MJ]=/;GV*V+F\TB4< PJ)TA6"F(.]+C;\M',-&2(>@7*"=NLJ/+)1GS?-]4Z#
M=3;EPL;J89>,8:'0!1\PKAZU71<B/::JW$)\4U_@BMAY@8R88$-Y]6A#@I#=
M*QB  OD1+@$2DI=XWU!.M@-%&S"T#-7L05M!9EV6-*M;"B5(9-3!^9<J@B$?
MF7$NV"UL  8?55\V,7O>LJ ]"(,/0E&X^ASSI,>0?3/$0?3Q8$0KVE(+S=U\
M+[AGAQ09DA"!>F@[6#1['HSKZL 8<0P_EV'@X5'DI(<%6LY;$-T4?:Q797GT
M0^4>3Z]A*AVH@I%8QCFE1#7B"]N3K.G*"H<Q)]?;RTF<WBU/!J_!PW88*@?M
MKFC;4,527%<Z5!?JG YX[-)1!;CJN45^-N+FMW)0>=+!QA:MQY&?RN-\]:%H
M4;&18?#HJ%Q5"G[]);\ !_*G44:KJS*T^_J2PH^[ K-BI[^<<W2D'W0P/GX>
M\)#$@QYB.)JJ75E9%;RTIDGD;&$#TQ(,!K)_WO@8+R*F/9S! *WBE:/E167'
M&L1=0U IQ^]H]U?E?Z+K_RO1M75$^M29R^'"=&J6O4-^HJ++*3&%!C[,_&&4
M%I=>$95(%CE,UUK@;HNE$460W#Y.\%\[?ZS!J]Q(MOF6^HLSON=2?3T(9E/?
M-/H.@]C<];0DE^29R-"=%)5J6**]$F<!0RZ>JNS SAJ1BNMPR.N\226GI#MW
M#CZ"&E1AY7V8&\OV_$L"\S7YA8O^_0L7^,=VT\[^3)5OHZ^PG)"HP1:+H A^
MN[N_/FVS5WH!]O$6&+^4$J!=5ZJ635E!)8@'O8PI*1*N_+@BDW@'*F]4% $B
M3&>5)WH%[5IJP B&7Y&V>Z@!Y%IFO4CN3JGV@!#L&/LV;*P2AB L86N#[FKN
M@^+==D01CMEG@G=>^(!N.MV DW.2!N^-BCAU$?Z@7\V!7!3(1"IY"?3<\TA$
MRR4KH&M3E[CTRAM50?CK!>\P5M^CT)RFU3X:RY^UANSRV<P>;*9VZD-.X:%2
M'7&0T$",@Y;;D$ W#1V?G4>"D,AR& 0.OD*G8PXF* YM@PEX]8Z!:(GE#79F
M6&GW)SCE;=J0!C'D_@)UQO2_.AZ3[Z<B]K^#Z">/#V@%%!6ZR1+]*','&D_>
M$L(7?[?B"6@RS$NGXZ2M++S6"MWEM84>O,OO>&0,@MT,-2@F,] EEEJB=8L-
MI'^NJKC$YK:_#V;/DM&'N"Q-F1G;4E'&#AEQ%7&J[F'1X;];J5V3<Z/HE0[)
M][Q@$R1<<_@HBHI7YSA=Q8%K-=4+6(G;C,B6DRJBTGR5P.K*Y!\)'\W6H)!A
M -IX *OF$'.FL%NLG$PR!8NRFOWG2:%A9F_;K_*KG.8&?24U"^_ NOXR-_BK
MY"2%*]\QWC2X:*"Y]ZMZUCR'+AA5(6K0S^P&?WE%$<F]EHF\!L+!_=^C\5)=
M!E*TLCNJ=N1O($#WYT9"M^2?&PG[)W_]^6OD'XSFYUB\0:?2[)AC #8N=KJ9
MJU-][Y1Y])? YD?-OI'NEO)NQR%]J= -76!;_;PI#-!1U+()630U^<IW#/"A
MW.- ?/@3"J9^W MHT1'J.^:HAAXLL^T*J^1_'[4G= 1ZDM.8^6YVEX\-Y0J"
MVECA7X;J.9#?$=$GSR9U5_O4*';BCH-_ZQ0!0WET(=O^AEE7@MF+U)B^I_0C
MR$P3380R6"K+SY.?<WM%(J\&2(GO&1Y$%-$%\A7Q4=+D5C]K2:27?,/Z<'PK
M'"8.J)-TX+KM!;):X:MV&_:_^WC(9 4W=#$JZ@XW^-#N7.N,[_U6,J+8:L7O
MZT)S?12'>8!GS0?RW"4<:C:&<L\V.PU\>L/+0W(/^7CG8VT4S05:=6->+3Z.
M?+JJOUZT$&"SR7O9@"W1^FY(U?52&7SU?.3:!CE6%QQQ^7ESTC?-#J97JF2X
MW0N6G4U!;:X4_\"\?KDE^@/Q*94K%=]A0[[JXD-LPY8-M:>3J1V#$ +3?S*?
MTX-?ZL@0_=3-B&5=AH$J:)A72M _0Y8&>PA:)A9RL %!^W$%@?>^\@:QG>ZW
M5$E\#&1.92#6CJMU=I=[#7K0"H*\8=4/? @D6H,@T5([D0%7\[$::+./T-=!
MA:2&=:(R8&-%(^-_"48YT(O'\0-HKN/H4;<6T*F=VT+,C60:@&0?Z<O7 @_1
M57!1?**X(<D#:G1*- A3D:?TK4X=[!8#@ H]5I3:6]]R#M:9FP56LD[!5+L=
ML@M=:3F L^UE@QRK,QMI\*2+(G$.<DPE#$%\&<DV:+X$CM%%$[068C6)C*\[
M+-7;'<A@A!7J,=MNL>W''RN?C)*JI$7(->68L>O$+)M&> U%OU$S.:NM;QHG
MX3P-EQ=%C!D8)Z5PUH6OB!L:)0H8)ZF<3+'@L8;[E]Z083 ,9:=A"\^)C52\
MA_N(1>A[CO3OCVV,%SV&'-,*.R+F'3% Q6C;+P_'Z ZW+%"Y@[>!UBTKO#0#
M^I=(A[&U6019J=(O+Q6S;%<41&S/@@"0D)E^"@ 8H(:V2><1])AC]G#^=[MW
MA,ZWSZ/K:G9+KV[#D"$B+=M\2W9#6W_QJ:W%#ZPB-@1D%>)\)P10]#/.C9]W
M)?\6X5VO P,Y ]@4]%-CPWNS7< ,L<6'?FZ:^=<YP#_-W_F[^3^ P7O5%VQ1
M/R7^?HN2!A;^:A_1M)0- 2KTH[%7'A)HN=-3CZ6_4?C?8?#GY-[WCG-7,<#!
M/-\>Q=_ *H$]HTS4[S3M7'$@I6A32'>>SI.)3Z)BDB+= .%W6]75AGAB,W[\
M6%FP5TRLP^$5%N5S=W=/1]8XD\1S,6<5\MYNK!I6&4XL37@Z4-)[1BJ5:X;2
MCR3\9V<S_[[\JQCHVFD,5"YY&@.-?(^!FOXG!OHOC('H; =NY/?<CYPHJA#;
M$\;"@K)+G9W?0B?#&TMXK0_B6[,7:M7+&W#OO<;B+F9C@#[CLX#+,"2@!GH]
MX,:;-4*[2K8U9$64K<T[W%E<YZ6-7RUOEP2Y5#K PZV9KKX#(KR !=8Z@X'L
M.D&9N1F1<IF-Y*EEQL;Y4@L3AIZV=1$G21$SFZ1YKS/8%N%JZDW&3!?. )%#
M$[&^8BA*NWBD;*'42.GGK-TOC&:O(1&I2<$K_T-2_CN2E&EU]90EN\>%2J-T
MA=Z3*B6+]QS2(M[JQ5C"ZT,1#_B5R*OS:*HCI=?+ULG96?NQ/7PH1:+,5%FD
M>B8=7\9,ACX$&'RQ*QUX-S:P$X/TKG:<:Z@K2B5IK)'?11N%>#;WKP&^U1>M
MVPGO$ K7RLN3*@-+"H%6448Y8>G\,1'K75,.]@V)Q_.#546\O-)C+E8NS)^V
MGYDSETP%]%$?4 NSV+AQ[Y951PCD=+QMU\NJJO#K,3#7ND9?(4C)>A(M0W_8
M4K):(_YX0LZIWD)2F<IFC=7,=LV.Y:>SNRN_//+X(UDQ#3%UG5,_YH@U._B"
M 7HK<QO$K\Y>W+]7_R=?.4U'I1Y3ED*G(;T%$IFV,-H#J8L*(#Y<?H%Z#+ZG
M!<\] :'N,N0TCX9_FG9SFX BGW)#X1.G,( S'](VU.AJ[LZM+7F],Y\_W4'E
M.X#Y-<G'Q6<:F()Q7Z35J?MG.PX&%_2,ZPODR0QL-EI'N/2"X:QU3>R;R>GC
MJ'9=ES/M=HKM^H8,Y[.%6=>]FI^"&GL(AONFJ\CG3NBK8"\GIWNN!H5O^F7-
M2%>_^!'6W/+?+X&>$A#KU .XL!6(;[U>_V^$5#34*7,2Q=B?>>ZW+LXLWL=-
MXVNX[+7)(%WU>4S0_BM*JW>7(ZVIO/6ZG,;H1E3)NW!%!W5RK,&\B30K4>H>
M'AQ1&KC<OW&4XG^0Z+\#$A5KM1_:G4AT7:F9!9RJ[SCM641&9-N.2*!$>&28
M8HT"#ZT8;_4P^M1*]N,17Q#+'':]X<)ZY6M6:/UU0MUC#_C4Z+36T'ZAO6#O
M59KXG$O)V3')X?@$5TI^VU]0"&I9( !'_0(#R//8C?Y<_652#NLG4&BB;(2W
M@O/A;H&_PP#)-NINC\R;V5:Z7/_$A2HX2QMTE\<45@]-UG&7'T8+KWE=^8G"
MN.5;8X!=7)!:E9Z>6";3MV.KZ^ +>DZNJ?BR5/H/$F+J;^K]1SQ2DK)T!(L
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MTGS^.=F+= !'S_J_\C^C_>\J.)C/_Q]02P,$%     @ W3MB5MXZY3*+M0
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MND\10UWN63IE8 ?'"V-[EV  L"BD3'":XFO=-GCDYD).JCE4^'/4EOHQ%B]
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M'N4QP9UFPS?13+X#--!L!J5@7(JCX?I7.MY^\Z"Z,BBI255WF<+VS,L;&\<
M_=&J(VZ5YC:54P<PM,% *$:?;"A]D)LH;\TY3(UEAX9(DJ6MHK"HCYD:%\?@
M#C#<K'"E4(Z^$M>;Q[<C@I@WGJQ;7C/G_?37MZJ"VMT!21=?%S;YV\F?PGM
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M56O+RRV,>*:XFNMUC/Q\%15?BAYL!_B?](JP0 I)-!YK"J6WN+-','%.$/5
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MFNF L%$1FZO^3@D[%I*;"VF]H5QQ-+Y%[N,#Q&*%MOZEMB15E%\/>PC?9]C
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MHW2KHV_=K[C^0W+@_R4Y:,__I22E"3QN5MD<'VL*3L*(V<.X(2#-[0_U5I]
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M<E46/57\5TP+^5NV8+ X<H$L944W4GCGH%,.I2Z/5VKAP1Z)0"+L"%_'6GT
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M\ W$U>52@G8GT,DAIU:>1)Q"QNC>V+J)ERJOM*;V9+*",*3=BN<?LLL9>1@
M%L)N P=ON50C<ZAI"9?S1;&4([XH#@MLFMA;8B[QV*=36X^\5'=Y4FJ7TA!_
M9K$@<JZ#U)5H+[<AJR[*'PD-6H_^KBBIE+@Z-1TY%ZF;3I+".A>+PW%.FN]6
M/,0R>V[]0*=B1\<1B;HP0N6L?-Q&,QC?"NX_FQF%/^M(=K'_XM6U6B+.%.<[
M"#TO%9Z5-.72;&BJ#]!='?G&WD-K&DIQL9ICY!1=*;M,F4W_[-V2B?+*@K?R
MM2,Y;C3R62SALB'HB; 05%BM&*N/XTIX+$-)<=;??=FD6P]G;5Y6X'1Z1IJ'
MP@"6 I72#$C9S,0XAA9\9847!R$>CF@ET[Q7M&TP, $GD=C!Q#,EN7MU# \3
M.M;LX]"MV.5]9234<?T :'Z.[$!J/GZ, 3#I@L[7%I%4<*:KG.(M7Q<5'140
M5HQ/IFWF/)7B*]-<4>RHCY[K]M2S?.BC_^#2!>M[K-A9/;9/#\Q9NGUANJ/E
MAK^04#U^(HX^U.R""(.NKB>Q2W$&VFJHU.PE?["LV!'B4PU['U^AZA/J_SY>
MMGF&\K+RS[1WNG,^;X9_'2J.5=?R<Y4!.7[^PBV?S:6Y)E=EJD@KO9#72(4]
M?W,'@F^. _^*Y)[YU/7TA?ZIZ17'_O['DXT42FW149%J;GSILJI@&/4BKJ&"
M50 C"?Z(M_(<3>)PL;,THEYHA-W.KD9RJ#0?\(6F5YE2?.SA8S=]>\'$/0R
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M!P=V)-^T_SJ=FOV?R=O)6(2(H'=:9852\+EG4\0;?20DHT^48Q.7[%Y\=EG
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M:FQ<ITY\-]N"X:9ZQ)2J+'.5O47(*K);XJQ,)].Q$)+=;MHA4!S<*K) -8%
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MSN=)BQ_EC9A^K.$[/$[7^S*-8IN+VR8UOZ QHEIG-KF:8MVZ553/VLLN9QQ
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M"',EF]NH5?24:&Q2#S62JT-LW)"\ O]DXWOI\M%#=%@R)H28)[KW\R%52M%
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MP.>L=<F3LB_[.#(S^QUB6*DVVVQ.$N.,T?A<#/3_@Z:(_V_#5&>'2.>AQ+Q
M5U."X_ KY9)I+^MV,9)"5Z79_Z2WF2/L-56_G"K+(RP^B5-ZI,C@$JS/I^T"
MV?_[_>C_'?]W_&\>2(^S_P-02P,$%     @ W3MB5F%&.>3H+@  ,SP  !,
M  !I;6<R-#,U-3$V,SE?,3,N:G!GO7MU7)S)LO80( /!">[!/;@[8;#@[L%E
M& ANP8.[!Q+<&1P&"!K<W0="@EOP("$!/K)[[CV[>^\YWQZYI^=7?[UOO]TE
M7?545<_=PMUG +8"2!X$0'@  "#<_P!W2P!I ,K#A\"'R"A (! 5%>41.AX&
M.AH:.C'N8RP\<A)*"G(2,C(J6G8&*FI6&C(R1GXF5@Y.'AX>2@9!40$N$79N
M'JZ?'T% 145%1T,GPL @XGI"]H3K'QYW'P X* B]"-.("-2 !S@(B#@(=ST
MROM](B/\,@!_&0@/$)&0'P)14!^AW;\ PP8\0$!$?("$B(R,A'3_U/?^.0 )
M!QGW":?DP\=JID!J)SRNP(1<%!JIFDY\]<EC6FXSYR#41P2$1,0D=/0,C$S,
M/+Q\_ *"0M+/9$"R<O(*&II:VCJZ>OKF%I96UC:V=BZN;NX>GE[>P:]#0L/"
M(R(3DY)34M/>I&?DY1<4%A67E);5UM7#&AJ;WC=W=??T]O4/# Y-3<_,SLTO
M+,)7U]8W-K>V=W;W3D[/OIY?7%Y]N_[)%P( $>&_QO_*%\X]7P^0D!"1@#_Y
M0GC@\?,%'"3D)YP/<275@*9.CZFY E'PI!)R:SI1:;C5C_'-G"<?$=#RK-*=
M_&3M%\[^'&-!_Q1G_\W87_F" ] 1$>Z5AX@#$ =<7C/F!3SZ21;M+R)^Y!0]
M)\]MME[)E@&X7!+ZT=8WI*X9^'+TXQ*^J!630V0@TYXMN /8U86N.WSB1%P7
MY>+6.J_ZAO#I#C#?<@?8H<^\?SI ,7S;Q'"*A^ <R9CSX#])Z4P)9BZXH?&(
M,/D/#/LJ>0&"ONI'/4H%*ZBN+;S17=_?&&X$!B=--?)D?T-<])]'NI5Z6^$_
M@'D'N&W;N -,*%E?F>O$7O>R;D14'+'EJQZ_WZ@4<-K#("!1@N9[WR\@*8.G
MBO"?HN<IF6;N,?Q-2&7;Q&+IQ9,29.VE)>"J@A76#!)J(D-NWU+ER> Q%JFI
M,;YIUJJ\QEC%'<B#KA'W;68Q=5]N;=C?4@N&,([-=;U^6VZ":J\(I-:3\NC9
M>@EOOEY&QJBIH^CM6TN\^6=0A4P2+7()\95^A;KB/8+KPFB=U*IFIH>R9E@O
M9<V88+/X=!>IO66,>0G_07&D4WL\8_^ BT>A>ZVQDX-IKC5[SL03U0MYL(F?
M^U)WF +OQ=E<P]?_J=I[*4CR'##<2ER8G'>*Q^>@I41!/X[GL>K$&^3O[O5\
M++ ]*Q'OXYPGW[<+0B 2B;2-91]7JY%+>I;8UYDPPU5]B"6M7&[P=NDCMT'X
M\W:'-+<&'@MER,9EOY98&]0N-'0=(A7)6""G)H,'^#\DA+"U-QM"K]0+>Q)0
MMJ.3I6.^O12\*/\>P@W?NXY.PZ6;+3^,C]] Z5I'I+BY<3$2[:WG?_E-(\=U
MP)Y2U5E<OX(OKGC9Z*;(P,+6&95!)&&:)K<7X'+0?-JO.5-IE4C:8D5-11:(
MB8?3_YYAWXA'8\!U9]MSL8 3R%FE[O3N4>BZ;'5S,R&W <UPG_RXP&["2I4J
MD*YR/R.Z&>.+^S7Y5V<>5OX!* PDR)#]?$XEX)5SXRH/1"F59>!6US F3T+8
MO^W'/FRN8P/H?P<P/KH#Y&2LOE+\; K=:<BH3&XW+B9#&8'V9P:(GQQY-SFW
MT3K*+K9T^7I?B%)'?A8!KF<?\)* *E>,"PF'RG]X-7WQAU?>)N>M?1DH5=;<
M'*8J-Q*#@,:UWRJW83DAI:?"]\E;\GUB^YLJRB*W*.L-%+'>G'R+U/$FX]IN
M$JM/HF>'<^FSL$C[RINFCFM(32UQ:+VG='?[\LG$Q'LV%_I(8:Q3!D\=^_]8
MGP -.G]FAB0PWX3R+#'#[D]G%:/3P\*>X$5Y85S4DNOTOB(<,?A/&30F?[\Q
M\NW,6%4!%HM&W):ELLBR!T7,C]U7/P7G1J)<MF)<3#A$W'3F= >HT_$Q]EWO
M0"3=@H!!#T5!XIF3 F><R_ZP'_NZ@_+. _O%ZKPT7\I^9#M> 7,F#?D#15XV
M+TLKS;R1+>WA/'/:"KS_A'?DH1T=(:&5RTPQL_-F@K3.]"?U:ANSIL05MR=K
M*9A\3;O9:GM,UQ;SS@L];BC:I-4H"?BUJ$!BBOZJ=1T6&H-I=O9H?OBK=N-\
M<!+!^ND EJ:C^;6Z_@Z.QZ5>E8PL>KO9:F2$)A8GHK5MOT+B_Z6+Z4WE]Y!Q
MLY)"9!2I\K-!^*HF \ ;M,!Y=LIAAH<K%9W]X5='<\+VKEEF PSQ0^O:0],7
M( N>6?O?]/)+#-$XGJL"E^PF2.-89*WPZIG&0]S6@^.D%R9-"^#O8??+THRU
M>GSV:'*IW GH]<?Y1.MTTD'9(PZ_=<O];$):'$Y%P-]S+VM!8!P/YOJG&1VP
M,60]#FFH+AO;!B&O-?Q;8B\A<O@MW>4Y^5\59OZE[%7Z+H\.^6=_4IDU89-:
MHY0XC?!7^Q-RXJWB)95]=<F&1NGCZN]*AU-!HG-)7&#5O8Q74605KUMBSAHL
MOOBOD,?823IAS$CITLF;T\8,+!*3VRGTQBG'R<RPPX@.M<G%M+@,)71"_(^J
MBGPB^='.6$1'RY@2%,DF:6N$6AT069@&J+/E O(B&0'_9D($]EP_UZ]H)3U"
M;HVOL<#\KJVBNAP<5VAYI:@0]$FS[;TGTN-#--RH*AZN V*:+) OV,-HDA4&
MU9T[0]MH<O4_O-Z>(4D<EIHJ9R D2.609N<@)P0^#."QR8L$,"4.5/><"G;E
MT,9S]XI% K;<3/!LN6T)$PI."3R-)$[)G"4OH',DD/(YN$..&24X]*,6+5*0
MI'$8N8S^7,!M=\?ZK=$?CZ(MK$9#8>YVT84NY(NXQ4S>9B[#D_GO.SYQF_KG
M>!.H^.E\!4N/"EHDF;(51B>/> E2#3"TEZ/>2%!O<7Y_/S_C3:FFXJNFQ%#&
MNY,7^8S">CT.60GR\I7,ZO&D8<^*18U,Y_CE_'7DRK%*S(L3MIS&)A:"0MS;
M4[' _LNTZ\A]Z,@KR.?2+Y5QX3^$FYG6Q'Y. +8PWIK!HI/G66,'E'GSO^PY
M3MY&?]T#:;DQ#Q'+=2)9X!AF![VR!4:4_TB/["U])NY%J;3^?=@(8C4=52=8
MC"IE6+O<W1 ZWS4A5_NQ=D%1 )LFEHKMA^#MH;=UH8,FOW:U,7P0XD(RB!ZI
M-=N,H]=0M[038YD_[L(31UT=I!>VTG_L<-Z_'<E_#CP"SRSD13)AX_T\9O]&
MTIH)(N?[+ ^Y2%YPP93X=) TU73 +BIC[3%UKBA7S4__AN$L\!PY3J6KV1&G
MK7:'7][#N>%D* 0QRTOT(9!A5U>,*'9E7<\+0EN'(]G64$ OV/[J!;;$-Y!
M#N:@LR8!D;TSD\T]0+:OI>7D2>2;D="+RRE6FPL0S-3I%6*%RVRH?>H;.Q8J
MZ=R(]X6"Y>\ \:)I-R]5-IA%+;%M/.X S'> _I:+.X#%3(;*C\ O'?M!_D\D
M")G1AC7;ZE/A(#=Y0EO&)5V?8'AQ7H ^T;5IQ[1I*H;^&M.3\$",)0X-ZJS
M?BN*MGVSW);ZH.LY17!)JJX%D85I9WG)(T\395-?7]H&12I=8QFZ/(T/Z-TE
M%$50YULV[[>NZC3EX971Q+H6V,XHA:54IT<D5WSKBJUW@-=)W2UYB7QG=)%B
M93ZU<2IJ1N)!/RP=UWRP$_&C5"/\?0C\+K\K'ABI$=^CH=-Q8D^^?9GV7Z:]
MS;=9&DDEN@.$S08<BLI "(K>6[Y?1.VK]\U4NA:?S"K6/!?E6M*N!1L4TJ&B
MEQ>C1PMQB(:7BS^\ZEOJ)1" U)CTB/L2>-\!ZMMG9[25!%JX,]12!/5V)C,A
M9=(WQ?1)#&\:.4'E12;?[-L65?R\YV(T6Z<A558-&39G;/59%LJ8C[*?7U.L
MY4R=>YX3-@7FV[ ?9%M4"VYX<YPCN?)XY=CM[4S]NTWLQ540VES'U&&%/<;>
MDG!='[D.4B7"]DG91;=&VPEOX9=K:3U9/"Y9VAAFSE?KB,%[& YV.F$JTP[L
M/2"-1P0+F-Q://L55E[)*[KP;H?AS,DQP^U&HAP,_9])EWTBK5I](H>F6JKY
MQ".W)PB!2 ^P5&T0LV9;9?,5\U?Z*8KMQR8$M'#1DX+UX?]M/5KG;X4M)Y^&
M-X;C.%P] 5XJZ4[Y;V!9W@$,'W][!'C_,[8I)?*D\L4^TP$169K&RPA% GJ2
M>U>->/U&P2)SBDQ<R) ^)-$/>YK>F"D5$!>,S58/@M/RZ@%^EM(!ZL(^$(;Y
M'O617&.H$?T8$YN9E>V!N5'YAU,%]P%!@2,5Y]NG&F;Q 9)(%A0Y,]II:BMP
M&1?,(W8M]);DTA^2NQKJ-.9#K\Q72:NP3.X 78JK4Y/A2Z]J&(Z]XX5+#UGJ
MCL.B(*UJ16'(YJW19IXN$]=QYD:/&=V8/^#3(%&\UDGRK.J:S\*="0O_(:1'
MI3U2\U3,I(I\YC:EU@Z<:I!9G5A%:2T>E7]#O*\%.IS%E><E]7F6IBJG()NZ
MU.H&5YFK:V5:@ZK@V7;9A,?N AY+9FE>QZD9G"<ILX]LVJFF9&UB,&@%Z]00
M8@=%H\J;.9#PDVO&J>GLLVAR[;J??MJ]X!Q^\O*2,1^+&B%(%HKPH^P\9;,]
MUQI_MCQ(SL)HJ"NT.5?>M[!&%$]-+O[?%>/$#5-17(4'V4W/<G4C;,YB5A8K
M_:5JE;@-&B/!I'*;[P.S"!M2WMH0#5!E.XVZU;$J(45Q:.!HM(H_]Q@UWTEM
M1F>=MA63M^5J28D0 ,9S+_BH/OR(IR:!3-/<%_(QJ"PZ41F 5Q]=MJ<58'DO
MXM  3EY?:\4D4/NS&0AQ!A" FISHGNT]\1L3RH?NZGO;-(XT\'6^QI3$P<2<
MUJG_;[@3P/[;K"2AW, .3*L#-]P81NG6%^QQJ2JN\R:9"G7D)7RY^$1UE)@J
M9=Q<?4X,FC?HXD*16[SLFZ86#L&E4)<YK!2.VU3Q);8MM1F-!.<-1,?FIH2B
MT%!%5F'F0M@V4J5<^9T8;:G)L+'\G;1+<:=E$SWSNPE7,&;ZPUN%]" I=:R*
MXVE9.;$[_@I'KUC6WM[K/,]33O'UFHW\)M:5]GJ>(JDL=>B]_=]_\E3EL:?#
M':"3I.0$&#:,IK28R#D0)RKYJUGEU2U_B4ZE%DFZ:A:[?7X.[YEUM)HH"%H3
MP-[58W&F4<F@5L'J5]O_-N5IWG/AQS"MO?4Q:"0'-9<AV?'XLJ(6D0D= 5C"
MF];U9<Q 0&%*HKPR<":HG OED F,J[CT4=A8CEUSN-@HOEHN8N1I7//"%Q^2
MI5PH:M_/)(.6\1Z'_*N47]Z+=\V[[#)&%9$G7""*YYUMM]G*S>JA/U2?EAH]
M&4'">)!OVN+.)4]3C/B@&0M'$7BAV9 D*.T<7;:B]I*#.Q'9VH:D<'3TU&"P
M1$8(97RH005'X"BI%^#VBP>,[M2LPP9L),%3,W9J:6A*+$V#L*08$9_J=M1!
M"+YI'SYXC@G Q?33T/ZKB=3Q0H#R<: VU^D*K50@57B?9&>%Z&\2\.0_>%AK
M.WVV]GP>0N0LTA)25Y>>EQ\\@#.4"G*\4"]>K_K!A(-#C3<]P0\L;T\I[@ *
M4V67?'R-<6C+4K4B[+0Q<9JFRR0>A^HILP6Z1?*X2H]EF%GZUM'O-5#^%F+F
M"7.?=F-Q0D_DY*NC?^[RM,B'@US&?F(VL+?GE!+'TT/UF+Z2]P:I<:'1[U0L
M%^&6X-S$;W8GB_B$+3NBOK>YX8FE,?WK+/.?FO8RB_7,8E(SYB?5T[7 ,9:I
MVA&*Z[YY 6XFY=;E-ET7"0%>&=QD2\-A2IK:/IE.B3WL>J^,*/UI%E &RHV8
M(2#XK2^W*I90]*"C)V&8E-^^-\>-C'!W%G7M"?N;1O>84#)%''$>R X8=+&P
MHJ?D0)_XF#H%%_1RR%?&LB%ZLR[**9$AKXY''D;0X..KS&KX84GDLYA>OS7E
MC/=<)D,NF]["O3$@_:O!SG(__MD%FQ/OYL?ZEP^^0+)M'1W>S2D'4Z/MM"[%
MJ"HRO(%BS)3MGZX+?M@?J!BUDS.=K%Q9>RKTA/@CA5.3KX\O^,WQ3D-8#WM-
MQ+;L&2[Q9K8?L7O:AWYEB7$8P+W^YR*/ Y-D^.2F;#($\;@XG@0>,CX(K6.U
MENYX\.P.$.=Q^^1F6GU7_!18>P>H1/T18KZW0C1I.GED$:<<8D3EK@Z40JB(
M^3NF]).>J"X,[$Y<:XME75=DY5WP#\UKCZ8%G4@@81T*G'^EJ;"?-B*06R2S
MU,66+2E*EU^2G"4[EG%![!0!TZH_*(^^-QQ?L:EM2:\I UB2[+.GI,][!H%E
MV\VW>0UFJ8)Y>F9NGLN6>LJ2>+PO[,:E!W@S:=2OG"HKJPI2DYZG5 ]X(]ST
MW8:V"4O,E[?*%-$=O-V@H."^S'>4UJFL>-'6D C?HDLE)@3GHP>Q#,",GFI<
M@2LQ-!39^-*X35/>$]VN^TOK0W\:D&VYPF9:7\?C&5BFF)'4 !ML>.GCLRXY
M"XT/I@NQG[]2%T]OO<_H(VP-D'35N4QXB(0X';R[ K71/\@.=QTX*L]F7A:B
M;(U9)HG2FV:WS,*058JGN^E ,%REEYXEO:;HJSNUYLWN9,.(9!8HEE>D<N4J
M$NG11LJE$>"EDW_SK]:J9'6;P$H4AVXA5DPX8@;HP><7E8[=\QH8QBPZO@)E
MJ*HRD(=S<4@N\P$N5W/%X4>5%=O5]0VM0>,'K-^WTB4!S-MD)Z/F5QYJ3=DZ
MM5D&P[9+JJ&@5,9)R3 K#B[!?M$=Q(9?8Z=%3?FDB#)7[*.$ PE\WK]1\<2/
M*KLRD N3:TUADW,-651YLXR-U0:Q_:N- 0S_1F1&(-::@0*&0"@TP;H3"]VK
M)4_93<%A-7< 738:HUN]HVJW_E?:LWC33 IP5ZJZUL89-O-F6(IEJ&2*)4^C
M>[R)OB+8#7<8O4QK,E02/U.T^(*M[>-<P@NZ5#VDV@]5]?RE:A-D?FZ.SV?9
MW,"<+G8;E>ZUU=TTF&7=-7@&9:3:E_DU&]<QH:7'X\8DH5G&OO16G1H3<8>-
M';E5FI-N4%$?I=CK(8G)ZF]IS12?O\]&+;'X@L84#9I2=6E_Y@=5-&UULWY$
M^UT7 _77SPZ"BG,I/SJ"R&/ A3);;O0US./K)G$_'D\[NFK[:I.K=SE!W%'T
MFH;&*?.QU!;N$]^TB\8^RX9T"QL+SH'\H&AA'%4;^&A62U&_KR65Y[+S/9;#
M:N,SHD HIX>BR>-_4*\-OU9N"\:\^@(6IW<1W\RZ!^(EN]ZPR@K$00=='@=U
MN7<0SP5W4WB5YA=I)6&.>_'^LR4VA(@UEC:*.0',N@?R: 3PL;=!\>+I!5-W
M@%52_H!=?[/O\AJW!1@+1]JP,Y(='6=YNS1J@6&43&=4_(@\0R+86T^"O;YO
MUH$%3R$/<L.(#H7)+K_F8#;4Z!AD&4F!;2 T+'@K:E9-6K273[SG9ETR4E.<
MW%A/>HO@3"G=;)\=TX5<]K,+ 0;OY_6)'="UU94@=DO6;SA(55YA%I/OZY%;
MR+A20=&#A",_9"O/F!GL"UM$?&YSOG5I1[<,P$CX5$Q440B3J35XWIA*@[-!
M1F9.;O,  WPK<9\HGA\QW ;9_A7FZWH7A]1?N48-$BAV#:)5CPXGQ&.U.?P9
MP_V%RC\JHVTT<.U22!F&G9'PJR*ME*F8^8(5(A^3N'LP[:;UJ];(KZP8>'%I
MK26;IH2I'9V7/BV'P%B8(.QK>B]2W&MA&G/V[(?YD;YBNSFMC73Y2#\2O:%Q
MTM=:PX(;J2LT+B2=SJK<W:V<&N?D,N(\&K<67OBC#=#C;A-"OMY#GJC03F ^
MEO1.=TV5SI0;6-11.?)Z2(V6"ZM7Y:4OAGR)[45S872#1P)KM0+'D/^;RRK:
M5#:#5;^.;9GV;=DF^Q=?37=\B?Q@52>$Z;-%= 8'5?VWJ'M)NR<&'\?+X$N.
M[9SVS!7UBK$!%^-M[ G0I7V"4-U@VA)W);3C$W$WZNQ"N]2,L4S\\^0\.0MB
M8)-8V,2,Q[&*(W+O2AH$T80#.3C:*\>=89X<PWICS/%PV 44F5NP%[]W(>4Y
MN^Y&1Q<I&1K3K\7K5[CS+Q@K EEB3VS"P![)\Q!M<9^Y.GMVGH%S5(C] 0&0
M]<- _&L]8K_C@3T9Z37+]XESC&NRG#7"<('6/B2L-,1&T>_J-M<B#3HL+EQA
M7H]9]09M%M:I,,/$VCRW>1!:?BU?#IKC]IRD6J*C#+W#^<J#H*%_!X@GOP/<
M^ S^++"[)]T!J'R>7G_.'M"FAZXNF$T]I24)+5@R=0EM-L,"EE2T_7_BZ&\)
M/ZG<9O35B;'>Z 5$ >M<PPW)0YM\9@Z&-UV]SD#HJA5T0<Q.,EH4O0**G.HK
M+O*)LU-25(+-?OUF7T6-*\G8"6QL^LK[L#!?ND3%T;56M&VSQ4IP_?O"8?$,
MI;0*;/; P8TT1H0P=@^KC2P8.>W[\![CF8S!P;/3%(C.JD<X']]^)L5FTU?3
MFWN+V/=VSP>7+?1Z63.FHH*TPD[%SBDJ"A;WO5T;^&N H9)7I5\DOX"'J+(U
MKTS6*.O&V]?OS2E(B..<(EI4>*Y9T]A:^TW*S?G5?3X@JJ(3I4K0!6%:-PC_
M-&+S!EU9N%0TKDUO^@CC)EJ''O6%-26/>B6QBA0&6\QY0Z$E_L<"*"MNY:9E
MV3VO.0<8%VF"A'S?[@"R[C?+>]ZE7\5"[\,J\_Q';Y*OFB_E+$.()_HV)6T&
MD4I%8YD5$O^9GB9ZA;GZ^[K$J;D^HHV69BO='W-/\!@'&<CF_(+7T/:72BK.
M27W<N%'1U264^9]T,P&_S=PRA@I"*N!;78I03>>I5M9GU7> ^J:-V/=EUZ1P
MPY4/KF^12=S*(20K8LX;65+62>/J-HA%?PFG)181$\)/7H V]T1[ 9J_:]?\
MUIHH2G.4"!(\MPUFWK&RN]?G X,[UW[35/U=AO@W24NX@FOJ= N^I7L'\+=?
MRDN01Q<%R:H=Z##^K**F%(/!;OYBV6ZHL/;P1&KS!&IW-]'^TU)8)L6XT;1%
M37NXB+* Z,P%U06OF8]N88+5Z3H_3BB.W'#BZ\BQR7-PQ"'=-(Q1)%,*IRD9
M.)PB+)2]"X>.$M[LV)J/'#C 3$))3F#-&$X%RHM(KC3?NR?#G(S?6_HXEBSV
M>M@R#R-!WQOYS/J"9>KFZQ=9'<TQ2&_F#L-J*,XWW0GAQ=ULG@LFCMGRF;5$
M]W.'=WQE;.]#JFM]#?/^KR&5EXUYM6IMEF?QF0[T=0)9-KO-V:6N=VQ??6YS
MZ&JA7*&LYUN+R&(Z@XE)6P_D\W(/[:GRZH&6A)EC&;5LD$:Y3"G\.62;DG55
M=EC(F^.</,9R8\S@D[PK+V-9*DE*94$B;_W;:&7S!+E[K-#C#G6-L*T@NI<H
MRC^2-':=(/'I> BY92YK"*8O,\5J$$D0LBH+?2U706-[K5_.YE@T#L;HDH/0
M@H.Z9#1"AR[.*ZIP):T]+PAT<)3/5#AUX:A\7.BO^L7>'#S3OM 6HZZ#&7AA
M%Z8K6GU,AF.- ,YW1P&.OZJ:2].6VE6'<00%72C.&U#Z-[I8Y:(:H(XX^5;W
M^2IR;4(ZA4K2X'Z%Y?]1U_HSI&KT89ZOMI=L%"DV1%N3DHM236-2@@V]@F!=
MW683-DNUY.0@%17R/2EV1!2KI'@_@SPMG&>^MBW..4NM?P5TCB]6:$I1:$Y7
MGBA/9(]]TC"G+HA$6:$SM=G6T*#+ZV7*'2'25*C=G\79V6]^<*"U%?.T2L35
M.FVW.;7T>-I0R+V  L)L-53[M?\R[=.,3B7\HZ0/F'RT'LK*Q6CA)HBDQ>8C
M57N"F4X7LV:IPKA^!/H87L4Q"8,HKO8UPT'E)$I<VD--&P@WY[=Y]>XEE8U"
M^KIOSI[&^#&4*!9V$A3!ZQ_M.U,S[Q)_>...+IRP,/VU0O^3#NPL=SFVV**Z
MJ;NGNZP:^E(%?P15!)<U0>Z7WDRI$1Q-VJW4]L)IL$3$5(ZM<;1?0J6JS;)]
MF^TH?WDRK\16"-9>8[W=^5Y/>=#,*2RB7\MT7V>7UTS?=C$$3TTBZ$\Z*TR/
MWC@R-;U1LJ2BG,0DNR=1(U8"WP*-U\EM)B#;,W11AJUMBFF<>"'4T7E]J-^:
M1 [7*4,,YWB@T.]1PF^%9V$9"^_1)[T"#HEV$U1MO/D*"ZIC(5KL;*'KFV@O
MPYP$QYQ]=Q#=?UF+*1':JES3WD\58F\-G,?[3>CK^#V$RJA,+Z=/\!ROK,L)
M&7ZZ&.] )&+UF][=GW-5_^VR1%44&V;+X?!=><-#'8U0$#FQBAGS)IX]#]P#
M9 2;O[!P=R?)/!WV8+*(57_[:L1U'++0/Y>^)HZYZ)GV'"P,Z\8T2_;=69K1
M&I55;IBU7YD[%#UII(I]E-5#T>,]JW+ R//V+1O7P9:8&7+DGB$D(>PXZ>9H
M6[.E8CC*8RMV.\/&>ZOP^%)/B+V^_-JE05UR0-4_PK=-QOL+MXS+ R7T*%KE
M7_1=VRJ_.BR.NQMCZ]KD-*(>> 9:R?_!,O9*O&I/#&$.,Z0RE _]4TM2B81_
MA/_B.3D4E"+C]GZ:L5QJ*ZYWUN-,E%\C\A!-SX'G#61T\<5A;--9P"W9]7IN
M:7T;2%2]ESU?GF9,:SWAY4!WB;A"'5XICR*K<A5IP-"0,\IY^8$5F^)0[+9B
MLM<$^:C#PI+0I;H/I;2>8^X0[%*O5$;2]J5#!75F;B*!&U(_53?35UY1:HK
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M)C\[=?3@X9<9U-+JP0(EM%1G1J<>/$+WRAI]2NN#W^%?H57=8$_4CKQ3GWV
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M6"!;:5<:>!Q3@ IE9L,"!<]1.9I%>=!I^PT6]%/R&5UX2=FU;+M-HXBH)UB
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MLN>2D!IA?I!-C@+TT\/XG8'ETR?H)Z^<[6O<G,E%8C\0(.(5=ZPQP!CY1'6
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M=NSL@)>PA1ZT1:8'%/4+V& -PQQ&TAP+V(/2_?[F5]T&:M?]A';#,A8?N[U
M3.-"EJH12!I;398C)QH*D^9P+V&-]354=%78 2$Y^E25XA.,](H"IL;LL'3F
MX/7[=H.LN/K@'"CE]9??L<!?/3VZ__6>GGR3^J%U=-'@)XT@_#@>IY/NTV>6
M91T,)$W<?30Q+=[TMU6NF+,]S3CUSF6N?^<=\;!>@& S_6TIU_7SJIF$[X5L
MLQ>&C#&-UV(4 V?>7TW$.TT^%8P1LOI1W;[2]U=PT7"T9R$O$ C\QWHZ(&(L
MW$TPTF\AF/+ GC]=<G$UR*E8.V&'E%#K"^]3\B%4A]64US'T7<X).9)JMZR;
ME 87+8BR?/YZ]!?( .0@8U_-7VHKO04#6N572&MF?\5Z'^;V%JC' :!/S]M@
M67-_@OG$<^B^BW]UA>T(%%_E7UO+38E_8$(2+MNY)N$MVV?#OCG6DC%&_$8[
M6:FXXL3%,:>PNZ>\P F<TT/L<GO>PDAI&8$A]!8#A64.+YG/K^.)LM\%(%G\
M(:CVB?_&2*-Q**D_=9/E7O"=UB*>K#B+,7V\/08#,B9I!K?^\Z=7B3*]#=!T
M^)B+^5:(AYAVV')7D;[]B/=&HKT2 #I=<M(V-Z%<OT7%S\/9#!H1?H3L$8N6
ME#:'38&:]W*PP'F#LYA:<!S2<.N?S@$CT [#B,.0T^.MU4V?6#8O#6,!D-L@
MZ0ON';E2]^E>UD30S?:<[Y Q4<Q57=D)"PV6"80&,NXH](+F^ _DS4E7H(-E
M>FV+54#J)4_HKA^6UI0PU<DYGHIF)360YJ6GH&]C+07)O6$7*B?@1R%BD&6[
M7LMF,FR?!@Y![D!G])5 ]C%M^!YT@JSID)-O_Z='%TE5=*36Y^"F.AN;=/3T
MNUF9[\CL;O067)H)5'AS)^F:GFN;W_V36X8QO5KGD[Y^)35++J]2K?I<)?3I
M??@*<()%^1Y/P8^*#$G!+WJ]_K>L^G^TK/IQXW)X@Y5VU\Z-N:Y-HJ]],]^V
M9\MRWF[(A5XQN5JY&O(YU^9D%+3-Y\/6NY/5@D(G2AT\5C?"\RC"O66<(B+F
M<3'P"G5G2_Q*Q:KL;&^BX<)H//RP2@^-Q1\^]UC+IAY-*&Q3%)R,(6@'*0RE
MG+@\?^3<KM6!U@L2UNUZS9 _5O3M1-@^K3-HSI/<M2W6W[P0L]9:9_^BT4-F
M^G9'DD#W6"CYR5':,4U'8#GAKP*HADS:?Z7JV3D$F29VP\PH94*;N9= OH#Q
M4;:&;9X ";1C1C]DFL;E,%0%,3')F>M1#;3Y[SV:$_\T^1.Y-][^$LIL!.E/
MNPYGJD#/O)T_6TJP6<Y1*I8=/S,^7'T5G%'*J'0I%08N/+?083 (G>HE1^Z'
M[?<;<OS1,LFKGN=L36PH[O+O5DL-YT@P%\W<?9^N7%1P8 PU;3PE6TUR^C%S
M@OIUQJ\[C\ND&(TN3_#6ZTQUN^2(HZPO!CB&L+X[Y_@A_#'C?4>G/N9MO3H;
M^M(H4]>>*'C@1XJ[IJ:F#+??.*OH\!3<QKB'CFER<3><^?8XS4^*V6>TF^!X
MCE]CA*>AVA=F(C,_PR[3J.&O$M&@,D"OI]&S_@$+I$) =+L[_$R0'SKU:0I3
M(;)9P+/>D$MG2%NB,ZD#6)P3L7LUE V&P$V^36A'NQE#DPF6?5I>Z!@433+X
M?D]G0'KXS;91UE-+<7<Q6@>\H;1KG\"P',Z/W S,T[#["^7=>N(-REO1"'67
MVE\GA4J/E ,X#H,6?FWH$(4\Y"0UX@7(">2/PK>5?-@'V.;5O2CT/#0B9;D0
M"[15>'AE#F^ R_ZRL@SMR((\G<L$P4B5(K9;H#%VOR/=+U&X&2A^V'P06V;J
MGMV0 3BF\05Y\4 E/[3+.!*-B?:,%4%Q/44(0 /&-[G"D/M!^_TT1UDVW2=?
M\@E^+23.O%>,R408*@"D:D8@,9J7R4GT7]"\?@94BT3$]G=^S(N'4&+0"D\B
M"_J7,Y,#FZ?_Z!H4-1"1P_1&4E,4Z3:>^>BP<S]W_+*8R5*#FT;CP[-]!M+"
MA5(5.M5PK5;<JRT<3.X+!F\!:DWC)?N:Y6Y\]*A>V1T#C\R63W,<2ZHZ5D;6
M<6U/'I\S#U8XXTBVM3V5H=)4 ]SZ>\*_=8.G ,7F\7+TZK0(_4Z>]O\R\?]^
M)FY7/U2:;&TMIMM_;77T>RQZ.&*$N88G-9=G?[IHD/GQ2GX^;^HS=J_;9CNE
MC_')7B"[3ZS0FRBR?GW@_E4X0<(TQE:)36( F90LZT 69ALG]>(#HY_8.<H[
MA*,DIV(QR&O$=F(?[5YQ9YXSA17( W!I<R:#>$X2S;!+?3R70YCNT=P[V>DP
MZN7B.C9[[8WVZFG,JC3)R2F?&_0@K+$%([:_P9!7<HP+4^Z/78[V)D?B.D.V
M>G+,GYVKC* =5NY\MRQ!%3KP=B* [?K9OG[QU4U_^AR12KZWF:T7JN!R^J05
M[%N9*T\E4[_<C=+3D64,V)6/:EK2<+%FX&#68W!I/-(; _]RU(7T^=<'@J9-
M>\'AK^Z87+0TOXGWDU?\U?!0UDD()[./I).")=/$<XO$W0Y9?X>P5N(6YHJ<
M,C4O WXGN_]4"H9_\B2T&J%I\4L'DBG4M8_[%0M4J"VR;)ZJ/.R$!S&[NY*Z
MU! Q_2^WU\@]M9N]_2,QHP9ZC,%_> ROOSR&JC5D8XD0_;0)M0BA^H-ZT6;K
MI6C;L?R[W8X-J_9=D^:R+Z<C>5EEM),B^?"]97F>1W@3+?AT/C'.WM-1I:Y^
M?ONNB0N!]JR _[[4HJ>X<;YU\>)E78X=SZ*NBD(NGO)DI&_SUZT.M?7@1+.0
MCY&6# ^N$H1,;I:2O"W7)S&]W\L^%BL8SQ$H%>W"72?:+!19R^1-&[,R&RML
M'C(UNCQQBH0L(T)/4/F$@AY-65DLUYG6OBN/M8-M.0J8?$U&%V@9O(I3Y:P?
M%8J][8](3-33DCW>0NFUBY'@@RQ%0;F_LQ"!<RNTQH"&-V]>(_Z;"R5AGSJS
M(74@^Q5>+/-%3*=80;=GF'2RQV@/2>%ABB;:1<%<=\]L 9F2]TL/8E!VM KM
M</TPPO*H P-4E3VY-!3'$I)!@^4Y9-KBW^K)JNI>('>*@-7#UFZA0EC,PC &
M;7W;,D-AH.BE!Q!+X2"B^-X']6R3% X*5 &5\Z0)/&%='-]NAL[?? _RIWT"
M,"P:NH!1E_U&\_]T$;D8#H_N*XA[U5^VIF>UL6COH#9@<[/#;ODBW)R37=^6
M*<QDOYN S-]"Z.T6L6MIHUL(K$.OA2F!^4 ;QX"].W7CU31^UA8[E+NUN&^;
M$.&]I)+XM;8]..(2D8S<ATM?KOND/5(F$.L^?S6A!1.JWS+C2S\J0]ZQH/FH
M9!;^2H&W[F[+&3^)?.&,;0DRSVPT-4['WAOI/D2ARUE$409LYNI:2Z>G=?*/
M$(/GZL^5:FJ<V:,>J!5<[HBZ>NCV.B3&:K!W=#4+T>(EHWATBXFAT=%R@WJ7
MJ9G10S!"B'%_@O;ZD19&O+49Y/!'#"U!=BC>[ ]^52\3SMDH%A_!R N#\M5G
M!PG\$&B?(@?^^UH)([]V4Z^WKA14>T+4VJHO@#P"=)8&,X=!A>-[U/'S;",J
MH9R-HH+?[.JR#OJMO[I;RVZFMQ>Q)0O[JZP0]>?F$PT%5TNU*:_4Z\?C#-!:
MCM6HI17;'2 L+5Y2TM3J9WZD\4R[LH,\S?6LW[S,^T9[,"7@4#X7>7)K*\\J
M*5OWXQ.K[JH/1=LA:<HCY/FD %^(F]!.U(GV;R<9&<,O$^$_<U@%("%TE?HB
M]TOE.RH,]%$?3CN*2JA7>DZ[[<@YG(H)">(D1,?RH+D[ -/TX W\R+/%3!_X
M=*7.?!R3@O#;^M!8'P@,E$R_CX0(X"M7:6\WZ"<_$SL@)C: -$0U69^J#S$.
MOK'J!G?^.6+YAR\5.5)CSF]]C])X!WFYY5L4.J\GT%X4<,KVH&(%YI%Y34[8
M6D9>B,J"/PO:S+J&J1D_!/_2\4UB?TPY.9H@N;^:+E]O0<NQ95*%W>'#<LN.
ML@B0&I'0MXRBRN_*&*G<B^:6D+^)CF;$%7?)$RR=TZIHV^!O0H48'0M7 O#Q
M)C;O$>X\.Y25W9[>33NR^8 ,^(=R,U>G<P85+5UW^Y%#_EOCIZ6HQ:,)M"<]
MY_%B/C9>8T@TZW)BL:0QZ$K/(,UKH^^Q?19Q\@MZ,1ZCW1GG$D"%O@4]C5E1
M*MC#JXL5IYGIJ(G*+4Q7WU^UAU+IWIHH\PT,VR*<AG;5PZ8TW#\/#:O*74-4
M];47_^6&C-W_<D,&^;",$4M7"AU=&54B/PHY#KQ%Z["-#K\LOK)4(TND<UG.
M(Q:/%)RAT?Z&,;>K:1>X.W8KWN8><BZ6[>\LWS-12G^4 W6SK,H8-LI>*$Y4
MO=3J"O83R&JS>+[7!U??X$M)&_T21J*?]/K4ZG?UR1(%D^3+E@VE9:MA<C_Y
ML6SQ2P)Z\QY/!;+DV,I"#)2,J7&YM^_O2NP_O<MU&8>#,5Z7B_)'+V)4-@C]
M6N D"OS!^-4&5/OC;]R@6_LS2KFR'H8*HD6L03!^UGT%OWS[#NK28@I*9!&A
M9IOCK@<:^6$.264@/F_BD&G"T(]EU4O-"OP,8=G_>L8__G]RQE]YL QJ8O#H
M[7WC5Y17/K"$V=T=0&9D-[]?T"+K?81S?3<6=*),DE[1.%T/XRW[X-I&5W1K
MFEXU#EP4L+U+PN+EZ+06N&0=O#[-E;'T78^W/])_M"I^E#M6^:2T[3L^#^?\
MSA^1CT#UWXO..HE_WY#XCES@&/9K_%EV_M]"\[_>-)I809J'*5V7NPA[U%U_
MILTQNWUZ"X\CS24F+!O:!#*@@-,U^[)K7DIM\4!<76^3L*_5AC2UG)]R.+KS
MC+=L82.4H2\737GM9<E+RL4KU"D.5X*?OBL\Y[ 2V/V/C")(@"(:C9#K2N@S
M X7:"T?#C3]WREW='O^S/^N&$%\,:!-!_,@)%HPWSS7]*,W$L<W&/GF=E'C:
M$'/KF'LZ=P[*N^@SYK];93'5I,U&OY=FE+K[:<8H')@G],AY:-VV"OTH_# Y
M,(KM; -TDV>19;L-.?@)_7$K%TH#ZD%!)G2(?TF/>)>P%W9S_$.-T3POM<H=
M'_(&EHTI"U AWO];5QDG*-FS$"3:_\>>43M3O3VZ]L.MMW_NE_VG?90G#L;W
MULM!M55$Y;0_!;63M:'@H MT&/%;2[^[T@LA%@?Y/RFRH'_D&*,U/PI7O*^M
M)^(R%D/+_K4N&R[9B8MQZ[""><MCC%;N"&()>L9"]MWXE?Z339(J+,_4L8#O
M=S2%J0LUC!2YA-@^0'/)JLBMC^>#8981HC>LJ!&\@3]N]ECN.V/O+;@(K\#Q
MOD*\E;JYIYR$NK (*H(D>6_N4_"F"$GHTJP1FFC J1O-W53'LD\UA*D]9$8A
MY!,/(!,0#>3;&&H5'<;G/QHGD%.Y'A>F2FYJ4"1D+6Q#[B%\'VJ06DTJ&# O
M/GS&E]6HY:86/(70!=J*_3K;U'M75F+%\&ZQK>H0TYAX:R/GTJU3\M4^.6E+
M2S;D2NDZ-CT:D[K%:@+Q.YF?_R^"%%_H+;I E.*YD&D>T7UE4UB:(KKX  MP
M'%S?;1]!V'9^:;2,_9//9B%FC;% F1(ZL<RU8EY^:,#9*)*[ZWQ</>9,>.-&
M;-5!Z&59IJ6!GS(L <O!5\[*]FU+Y!SIK2R4.-)UN9A6 3<*>3WX*\2JGOT5
MT57O2@KQG%I _I]^>H$$%O@K>9[+1#9FB1+)V-=RU)N\[@HX[?=7/M4JXV%K
MR>HZJ!B33-(*SZ"QL>J8.]M2M2V(^N<I]L[T.>'CR9=<14.%[8%';/#:T#$Q
M-^\PVI5Z/H_!KTZU_/P[1,]\VL.\=%Z8?7'H QRO]@GB9*3<'6)0%RA9N4;Y
MH;FMI)!$5AZA[NS=I/"L&I>LRH2XS&IZ9:KL3$[_CXT.QPDJ#].1#4>/_O9<
M&@*10-!>M/H/^SKR? ]\%K0Q/.#8C90/$PJ#I72KY&G7?1'/P?A.ES,Y@H E
M$#+5V(5!//BWB +4,&9AZ/8!.2B%Z+'FLG7^5^ 07A[J)<-!J? G/!-O#_/W
MB)("]6I6=S->\1MEN!+<A9T3P=^#/0:77Q8U]I2WOC\7O).M/#]X&G26]C#V
MJ6F^>A+G1B467X"6+NP"_&.%&:\=CTQG"DZA3X+KDH[:$JUX*#Q5UOJ*&]4U
MBO>A$J7;- @[.YI<5DYE5K*!M]F D,%9/(SAKPJ"D,U+NK\J"!Z[DL>V7IP=
MMCZ>C5:L_(N(:5K]%=VK?HFMI??PROQ7"W_17I26T)-(C%_,$2+6'W,TNI?]
M8H(%XARWT"KPWVWH&?M-$IEB[X32GA&DA_8HP$7_!7R<!Y?L]E3WC^WER>0^
MDCBFYO<]Q?+)L& +[V=8T_H9^;HQM%08JNU_VZ?3_.?3 EK20XG:(R]K,"E>
M#P1F.RN<XU^\*857%F?B0J(G'"_O3\/N:J#%5Q=63?QF[Z1^SZM?-#&H$F/A
M5TNL\<SN[KO4T%.^2=?.GKC7\BW!N:M&?/#38'-%V<OSMAGL&PO+DIEXY/7#
M8S!T6.:7_;FNS=?"R[8(?2W9/ZN"-T"B:*TRA=$^TKTA>G:<8,_GX(D*H@].
MS)E<%>7UA2: )<T"^DED$K8"+OF!?-T*B]DXPL3F"^+,PI#0HE (%KB:](]B
M7$],<F9GYB3'3)E)7,FZQ<M[5>GC5N*^T84Z';,V(=I42*UW/=)W4V<J0N0C
MW^8_%@YQ(,VQ5NV<.&TE$ S+,\*,]ET-*Y6-SYK8>/T/.%R<*6<9<:LFWW;8
M00[F#UD\ZIUU8RMRB9JD#9QWS+,[C^_&.)3Z[SY4@J-[[C#&USR6=-:Z-E%5
M_@@E47 M1LV!$Y]+8G4GCR)_(?<.'7ZXO6SLJ%>,X[WEL533V>6 ?\;K]+7\
MB2"4&6Q)?8?MZ/G'V]&3C2@O_VA'?_9'S3&U!POT@P,>Z@?'(/M'%D .]$>9
M(+ 79(%$LZQ_[$E;?]FQA'0!9%T+%5J)!=!.0<BA=YHN(F*%Q],!3LR<E:>5
MK&O5 \)C0V*_I6Q]G+*<K/1HJ'S?/Z05N]G\I:B%(8DJA_+*0F@_SA-Y/N<J
M)[8UXXJOLW9=*&(\2,RM[,6+@U\'"8U*<!%<!DTGGGUSDUCG0@I%5WK%D.:V
MA[#:7E);W:S?6.G0+2_U6Z2B;F8B-UGI[B:X4)H&=9L9N538(+)&+!'AY,L&
MY+MSV$M:R_"JGD^IR]2'\3+1O $2J+;2Q"5];KQ_1="M8,$A)NGHD3#0('V;
M*!LW\P-@?P*X;XGT+4V9;)F&1WGP1G)=NS/WQ&/HEO9"4_!?!5#J0\@^>N"$
M3"+V:;;)P8#9^H'7-Z36E<D..P4#*N5BD9W)Z8M]M!M5UU_EO6$R4>QG:2VN
M]7Y,XZ@I@O]<O6]&R"&.U153PM\C37-1]L(DD]7@Y)G[@3Q-[OE3;@VIKW#T
MHMY6#TEE+)8.)V*!XH#&=HN.YU.H,ISX*FDUJT'>5C[A.Z!_BOSS29/_=,LD
M+OI(XQO%D<8W#Y??7+!D\7VK#O4#XSB;@2-EMV*-:MY#%3]DAYR+L>WP];:^
M;5F]7P-HE=VOHV#JE/4HA3VEH2W!; @NM+EK4FDW"2.3>JR]XGH;"ZH*I*DA
M!;_EBYJ[OTVB9H9]X(9^VL>\+#I2?$LY4I0#@1OZ*:[M.\<Q[JAV-&V:])13
M&4.Y#7W'_%/ES:KB;]4Y__7WL'58-OI>:R!G;NB-GY\@^!_;-1.Z8/'$DG98
M.M3XNJS9* [2+9=_V=/I0&%E?'APS"UJ&D29@K-.L#6/(5EIP65U\ZE"TNS.
MV.8R@=QBG.^5?-U*O>E@>%'\W,X_+LO-12@?P5NI?[>/6MO_1*BG50C"&RXR
M6,#;]#)=*U2T36Z&I-3I^5 I1'?K]850ZO%+@4&+3;COE]?R" .VA464;2[7
M^<R2>>W66&6P90LM"F*!%GH/R/-59[3'N'KE('O50YH8C90FPG&AH3_13Y6'
M)]/L?JN,%.&YWD1WH3=13U[=2TU?8VNHEIPDO5@G?R YL.S06GQ'/OR>P+A\
MH=FD 2U/SFXD\H*.^>B+K.G[3[1R/;W;(!L+A.@#E@GM8=Z8'"N/;FOM.W0W
M2!I%]T]8=]&YF>2,],4)YF*PP!XAQS?TS3[5O0 'R82V2T;W1RH\W4YM,1G3
M\PDJ[!FK;LK9L;*&3F<!&B_S;+[9]$A1/Y(1>(F392TFOSH_EZ4B+R_WZ+'P
M:\) P15A8J4]&0XHE^OJ]W"+[71+Q[V7M^S/KX]NAI7(E0=$VSS:1/AZS!CO
M66,D[;# \GF'PV +8>G\-013Z#P2B(*VSU539%AU+R'AF+3T%M,RBG?2KJ21
M5^>MJY(# Q1>C\YFB8@Y74X.Y+[S\S->_ED7W,\/.GO@=_'1JVZ8:K)OH*#8
M;8WK==3(7SZP$LA]JX6Y62F"?@K!!%D-'CL#$$] #DC'LMV"B'D<]@(ZK0T:
MS&,PXKQJ^/9W5_YJN'KCHO>C&@]!;H;F'H6%M&+>IP(@"QK<^U5Z*W_D-Z$F
M)XJ]%^0E:%+N(_7W+.XCH!!6U(0%^&86D"G6ORN+:-3\CGJQK9^"K=="DR\=
M::7B_*O#2F5'>WP];1/5<J0^HGZ4;7$:G:*&O  #?,*?6ZCR_]9FE82ZQ('B
M6$2H%24'\K"%_RR[_V#O*M._\7Q\$>'WAC<?E =<"$Z(<8A01TPP@WY[_BQ(
M+[P:+'ON+5LI/FIL8KC%T,3@*WU&@PG(4)$^3\._M=5OK#T=[^Z=,$M_BFHO
ML"WLD^:5:]5NNMXE(17-%7:OD/'CR?$VU!GLN:\"A3/UHYZ'6CY,CCBO?5CR
M"-/# @=$^M!Y\](<NCJCC24H%GA '(8FZ=,3&/K4D0T&%+]Z5.;1S6.?<X]E
M:_Z#CPW3M(6SR5K3K3&+QIOIO+TGG.'UA"RAFR#F6$)$;>NUJ357:UR\4$S]
MB3<7NIVGM^<D!H@KA*S?M-$WAM\H"Z\@<)GCEMU^1UKUN_S(ZESU@'E9[/F4
MRWR^3G,%#OJ)01,K3@J]#XH])0W""R\5\Y')00;S>3E+G-42U!D\AQ;UCZ51
MA*K%T]K:"RU37QFU/6VO9C!@DQLL6:,V6.Q*]P]]XO+RW&M'HC5%.9WH;-E8
M>339F]]HO8MN27QI2JK!EXOAS7WUS6<ZR_$#/_8Y*]HV*9;!;42OWGZN<#(N
MGG6(-R!#--O5L^6HDXSM95+=H;HD;LG)%/4ZVC'5!QD85S=L#D]>'$Z;CG\8
M87>*1N.U8Y74TGZ/B[F6Q&/V K0!0^+OLS%A%$VYUE[,U7W&O<%V]L]OE2P]
M;X;T%MMLY5F-]7*^421LNY$:$/<^2:C-^ $X&+N"??*C>6.;!/&TE5RWRY85
M(8WJKZ/5QVC[X&_Q#FYU]$F,PY5F\[]$VYQ9D!68>6CKL..HQ7(T:Y/K7M2F
MLT$;?.E!GT0Z9>J;1#,VG_@"H?0"._PHN?0)-M6.@+AWU!<K5(DZN>.UUG[5
M$M-@D=.%J\#\)CKB%I^YH5^N^[TNG?75EY<N]J*&**O?1)KAS8HEP5N[Y1V<
MAQ&'61X:^<[%S<?RH]I"E<_#&Z4?P>YQKQQ]E+2F3.GW4I@]59=/V_ G]?LB
MJ+HP76 HN<*_/$&_T-M23_E[JM:S0N[3>&%Q[\Y\)*S(T15,6AVX7Q[[L*/<
MLJW"IFC:H>O6;I%D)F[3SRV//.1Z-O=V/FTVDEY^'W/J4KH9,%?+[8(8H*&&
MFD#P6)8&GPG-Y\)6F-0PST!=A?:^$_^Z5ZNGM.SV7??J.6:/K4Y./-? %DS/
M &2>! OLHCF/O,33/7J%FWIP;6Q33Z-G^KN)M"OXT4=3^PS :'(1M,1%"8D'
M06,!7<B?+^6!P:-7Y+V9'#%/ KXI,K5]N.$PQT]/3XU3)0W&H \785L$T -,
M-/3/5SA66.">WOJ;?+X'7V#; C9=@YEZ[L:#/<6D,TB?\^$%L+HK8NP;8VE'
MAD9L8XM9EC?NF;ZN'D)E[G+0:F_Y-1I$H]?'?B.&760XJ#W@8G1/DJC%]^@5
MYO)4N;1CL".@:1KR6KD*YU.^ %3\0TVD<VU"]?>T:F\\SJ]A7'+GII@D.P!G
M=2T^CENLJ;M1?*\8E"[:"?E-"D_-+C[F#]/7;"C9#4H>:>\6')(1NO3"EQTC
MB&-P-/&B)5J00VJSA@6*R!K+M%WWEQ+\."!Y!L?7O-E&2>VVN?C5;R2P\3QI
MZSPKNMC"T;J4BE#IT=3.E,#C2RY_?,D+;84\98:'=:9[$F0IZ8PY#)^9]M9E
M+ZK=8LQ*N=ZDW':P/?_X_VKK.H":7K;^/T&JM%"\$(-$BI0 4J4H$%IH%P((
M! (H&$J03E20H@$NJ$ "A*X(D1900I->-$@3$$2D2$">2A4)(DT%\3Y\WS??
MN^]^;V;/S.[LS-G=L^?L_LZ<W3E4OKL(N7WSPRN)JO$G\(_MDK_4J7R7$3Q;
M;D_K&BA+L1(]]JEUPI4?:%!R!>IF7=$A.J(# ?:NADP]V@'H5[-,\M_5PQX7
M3-3B019^"[\);"KAA!46"GB*_LU\YQ?SOP[\J(DPBQ;6&JYL]@P5:0E,NR /
M'OYE+T? JJC#[0  -L#S7_Z0N55?QY17@+]T;:%V6]# B7DBC#=U>:J9#OB[
M,4TN;W4@$S23S =&;-#N38D5;_G.K]GLWO',YLUO85"T/S-^"A<:6JWB@>*,
M?'MK-9Z22OU'G Y3#M:H%)LLK:%@-JJT_W?BRR\X&AT(Q&)-?+B3!8U_\UM8
MSI$I&A_?&8DDV!5:5ZY=',GAFHIQ&/Y99RZ)^.DGL8$HH8+34^,%H@+K2]4:
M**J.%THG^6ET^G!S=OF@Z[0S2H&TI-_K(F_8HS9&/%/%DJIK(#,!T[!4>3DM
M?<_($+N6EH 4RXX!Z803CO6QFS3JS=U'-X@\Y$B'#W,6WD=*DYUJHZ'6]_+H
M</_RH(I.&\_+S-IVDE?]752"HE_T)=ZD,^?CB\@:2 E>-1E!<UX<5[(H845A
MA_1^V'AI;]"L53SRHF=NVAPOF+O_>&M7?]3T?Z80(#?8([GC"M[Y31*!%:#L
M?[$CD6D:DK.1L*SDJTKHFUTN<^Z8# PLM%C,NW[[WB!_RX@AG9#VZ/*9-AI3
M;$C!WTK3]81U#WIH,6.B]>=U*O_(+\94:PO*KELCYW"VJ-ARJDK8CV&GEBFE
MH+?S&I49XHXUY4M,@=?ZL8BBV@DM,2V78R%ZF);P7+4G9Y+67N$J^B^&1 %K
M^$-HH\@5^#Y^Z4-DEY"M43C:G9>GA% ]7=P1.I(4] '.S>!EL.1FI.DX_%[V
M=E2#JLWR<Q7SSY.!;#!B^'G)KOY-*G];LH)X?*4O'%"W9"&/VF&9)GA9P?AS
MTU#G@9<O^D_5[TA<TPB2P5ZIF IT%83QJF]&?96FX9S.Z5?,GGD@FQ);[!;[
MQ#LD+$U-WP37%&7':?-WE&*!U#=3%@'N8<28:A^3L;_DJD 93#<=L^BRC\I$
M\E_E3Z65\$*3QR81"!?6@R/F4):=;625#=K-+<4GS38[KQ9#.*']/;IVQNCG
MR8_HC;<'O8R6QKRS9:TG',<.%4)'X.?HX4+X5N4KJH.]&N+*[^^B2F1&P;/(
MW#-C7?!3NG8E0%B7F&9M3ZT)S$+U]@/,"@?B_D1C2",U:=#U=YZAY<XZ#N/4
M5H?"Z4^8<[H5[O^8UFES'SBZML7Y):W[:4TG$/C*#-/1V5Q[:[@U"Y7?9P,H
M+Y9B=BG8$>YDHR1@/KF EQ>C_&@U+>+4C#_-#9^?8][(=+< 9^G?6#[5N(WX
MN".AJ+N.<\H32K5;=$E(3<,AH8[V3M4UK*J.IPTOZCY[/BHZ?Z"_ @I>>]])
M$O*T*DV1>C>?'J[8&PXMIQ,(BK/8(<U05&G/)28R"R:I7?B;Z)A_1,C-\BZ"
MS(7SSUM]6(4%T1$BH.#_2'UA;!QO"?!;ZC],G%AXC-_T\#=2D5&,>1(9'!KV
M:8XH/=&(JH>8!&=8$C1$C*199G#A+4EJE8T<NG9*YC<!CM<!)P&89!899T 5
M[MKNM2S#9\P5-=C&?'N3HZ'350!;]#9YE;4MU7:43X]/[Y1%A!"K-9]L.<^V
M"?  =3"UWJ_23CI'TW49*PK;Y$_0WZ[Q4+TIH>P^EW-?&Z1_A;I5=1!?0GCM
MH[,EGF]3N7;NN\RT,8U$SG?<?O'!%5S]ZFNNX=QRF1]^S[>HJA2::=[2VW:R
MXV;5[S'MMR[I^<W,W2^+C!(O%K(5'8TW(9M^7_2&;U:?G3+R\>%+K(V'S<NF
MJ U<.E0MX5)_<5F(8[,#YT6Z7DEA))UZG9:!(W&XYFVP^P1LS9)TH4P4><[D
M#HT4<<["?([M:> >#Y" G30-M_2'05X*]2ZA\P%E<1G!0GJO6<G*KG:YLDN?
MQ-LS%',ASQ\UY+Y<],8LBF^*JZ[)P!XRF"2Y^8I[T5+L0S,]J/AQ$WE.= ;*
M"T(**4H%,Y/;R;8<ZK'^/41U6W8S_9XS==\S!S/@\X0F]DN19.M\:KR\[V85
M;7 @-.$:]SYU_ALZ7![,%^#F?)W541;@TG3'1V"?X;9>?SH&VEBRTF345P$W
MR[F*4>0</%Y0'\56,'ZM$-H<$/,2$H_J@O0QOLM]B]?^BJ8%3F[;RZC)V%>X
MO#)^2";RQQ-%(=(>=<7%>_(,VG_++/3KW0;:85SZ=6!9:]A3SQ%&*!I^PWV'
M=5YVW&%(4_5YC9+.'/5@+(K-O10:.UE382V[;KIJ9>C;*"W#OK;"^*D)Q$E-
M-7*OG?8B^7ES7)1MEI?.RC@^!8.L(2H;:YL:DG3F$P&3=..TSME]QV-16O=)
MW6APT*5VX[2VA"><@7='J>"*U;L4_R:2"MN31;MV8A>.:+FF,5?X-443<Q0G
MH^'>1X-\EHRN-<@>_MCFWI;%(EQYL2F\/R 1NM*=E)BU,;""!^7L3N[M'/26
MS<IG/AM"B(TL6G+HGG_K@DNS"ZA*&IM["[F4* @_&:KG5ZW82<[TIPW)Y*P8
MA1$%S"X:L3!M!"2[[RJ3]D:*Y.48?<<=%3=SN1*>[K(+<\R\H-^7>U@69ZW8
MN#9O.'OU8Y>W.\4N"QV_EZ.!:%K.GCI$)W/)I@:W'H@ PWJ#+R]&"#V#T$_Q
M UU,]!S:^(]-1%4RDTO4U%YJS>-1W&B4(_1&?DAY53PPG;Z8GZ8CP3EZ[5%@
ME^-C06 ADTD\5G\UUHF.103@W^=\"&)P>_,D!',?V4N/%#DPWG.]DD\;<U61
M@?F(J;&UGBCEG\@HPZMYG"X*:\+GY6Q9''J4Q' C'\.KXU\/YR)G\WIG//E+
ML>'*",ZC.\?88%Y@ET",[?STT*(DY2S$,1T$O]IO%=_W3,* 3>0LV=+75U<I
MU@;[_[+I_ \I(E+R@N#^U3(N\Q>J^HBRU03W22>LFVFB;.(E(=L^)/]8V&94
M[;F)&L'A*TW<"V=[0T[.G/M2O4RR6.7<VGYX]V;2@X#80ZM1$[.'L#L]72X6
M'ERX1F4?TTPYWI?B@N^V5O2JU_'EO+4;K%N=:"]\5A0C)\<F;M P%("G*U.X
M,(%X57;AV:X R?QSE4)^Q^_7RH,=D$<RB6>GU.@!E[$?!)0-!CA>*;7_O'H)
MA#%;!_7=W)LPO%W:>E?G9)*]:-:? ,*V)'+VQFKS/N<#*<I4]YF70?O?4E6Z
M#["J!IBOV6[[M-=->+"-M-EC2XYRN&-.:+T(+#$F?.ACD=6,Q9C6#%2QICB5
M1YHD1<*9\22K FL*F>Y=P:^4ZA4U:^I J\,K\F"4YT/7VT"XI3XB:[*QDR6_
M67)L=XOKQ]ATF-P1B<[19<Y/SC&HTWXM\:.BY#';/ZH7<W[_<GQ/8:<RZ(<&
M?G+^)2GCWOVX.'E:570['; I77$^=G;]9#./KX$G:J&_A;?"(+OZ8<4#>^,*
M,>#PB $A 4]^H**LO3G>E.P_3UK8?_@"%%(&6(U4J+\0N3*@4WW6;G)R/?*N
M-?Y' L+LF)N2A8[/U36!;TYT7\00RR/(AX1E[^YFBQV*^^$:\MZK4/''!=AC
M\*G<*Q2%(36&.FA4]W/:E A()9?ZYF/HN= >KIB#+YD-!2R#%CH2$&,#_G:$
M$+[>I9-IL+:8@3")AC5/MW35U/E:_=:=3W8K3)\7V"QMA?!-1D;]@&'^YNPU
MD!U,WMVIM4./@H9;5^(:<NR5FAC@LK@1H]76SVY(=C$ M"(/^H5UEK7XC/E<
M_K%2TS;I\R?@)%.RD%4M-C\>]GR;AC\SQ;'G]KF^US]$4Y''^#T%P_F9J!?6
M3P_R<)V94U3NL=J'Z0E/N%R!CV__*W(P[#[WYELR<VGVI6S!KD,^FX7.=^[C
M&Y$^S[7\C%]7*ZL$^Q"D9EJ<S"@AJNV\2^C A3 LX>-NLT:W9FTE1<A*VUAC
M/#KM\F,DNU%$A"BI*E>C#D(=8 SL@<Z_]A R8ZY6Z;U+'>74J+A@\G"F][J0
MU#!.;4M994/;;Q%.#KW^;C(GSD<_NVI(4XIKSN&+VV>^10561K_[AD)0@_<M
M#.5[JDE\76D8BR$G4_=3&MOP]\#'_Y&SQVXK.VGHV2@:?L=DY$NYJ14A_J;T
M6"-"?=]<6QNURERU=IT^U\I3X26U)QA-[B.JDF__OGAE:. 4AU,VS*;!C>/L
M'1W=V+>/F>V@L4?3KKU>?GP-\+4[8'!4.H?NHU^?2$OH;M.7(2ZSI7=@7Q9F
M!5K^* #0@7N3C>;G(.Z,C6'H@#"IJDJ=B\I_WN:U"FX\J#B92^3-H+/U\SPV
MJ1/7U'?D,EAS;7O>JJ6"I?;5XTA1%(%!&P6Y,,EE/K+[*Q$W F_B;]TQY['V
M#GK[9B/ E]K^N/E)4W1T7H[%K&<"$K:>73IK4CG3H7U:R7F?XOJ#<0RI [G=
MQ>@GK"(JR_NA/7&"GCQ7 0E$4>OXVLYSE8:RZW -TV<*]T/K/=]E[RRU\3=F
MQC[HC8X(@4/,17Q<G_5O-;W.!K7S[E!Y]$0;AU:E]M=JL<]& S.?ASI<.^)%
ME%!+F"H,*"TI^^\2_Z4\L*W^H!"9S:8W\PYKL8"XULA%#^RG#"4'2X-[! X5
MK^M9GC4V;U:B?L(PEDK^FFB19'$)J_K"=Y-.Y?'*ZY[73\L6'O<<.N( VF2;
MDJM\9\>F>?1H"JJ5@E:#9R7 '&R63G JV=IJ3(&;5HJ)4%:=^.V149OP7+TL
MO;?TSFW[XI=^*A=&UG"A80U7YPLVHC!N=EKWV^=D9TR?1"D@#S:BHT?9^< C
MT0A="OX/KBV-WI"G$12:I(JY1/A-Z.2A'26MOP]26FKQ4:H[&5Y2R1@F1!CB
MIN8;)Y37?9/L]W.:91!-U]6VOKKL[6$<D=*<9<X>!A.G"[]< D?8574_T?..
MVA]E]^ 9^3!D W'/;&E7[W-_FD,K7M</PUZQ1XHT2E@IZ\GXD2V]TUD6Q>Z/
MPS*_@]P/-A(<6I/WF%Q:7#7T'M3;-XAJ=4:EOL#P\SV,O2;$-M&;)*F(61)_
MM_,0B\K2G,C/SRB[W_TT]T2/.P XK:G*@V/5N5D-[?C@HIB/8IC 93G1X+^$
M>/Z<_B=02P,$%     @ W3MB5EN)U%5&'P  *#,  !,   !I;6<R-#,U-3$V
M,SE?,34N:G!G[7IY.)3M^_=MWY.MA*)0=MDJDD%V3\:N$$D1(A$AC*4LD[)3
MR(@8^U2V[ JI;-DCV7<1@PS&S'N/%C//]_F][_-[C]_W.-[O>SSCN/^XYC;7
M7.=Y?L[/^3G/N?&?\"/ 7AT-;0V C!P R, _ /\9. O04E/34%/1TM#0T-'1
MTC.R,S$R,# >8&5C9C_(Q7OH(!</#Y^ Q#&^(V+\/#Q")X7%CDO)RLKR'I,_
M<TI:44)&5IJP"1D='1TC R,G$Q.G]&&>P]+_[1>^#F"A)7,G>T!!=@0@9R&C
M8"'#-P"\X#FIR'9>P,\7&3D%)14U#2T=/0/X#R5[ 7(R"@IR2@HJ*DI*\*X?
M>!^@9*%B/2RE0LUF8$-SY":[=&#T4UI^U1>O.0P[E@1D+KL%T='OV\]Y@$OP
MZ#$A81%9N1,G3\DKG%53U]#4TM8Q,C8Q-3M_P=SVRE4[^VL.CNZW/#QO>WG[
M!-^]%Q(:%@Z/B8V+3TA\]#@I/>-99A8R.R?W95%Q26G9J_**-_4-C6^;WKW_
MT-G5W=/;]ZE_8'1L?&)R:GIF=FX9O;*Z]GT=L[%)L(L,H"#[]?I+NUA N\@I
M*2DH:0AVD9'?)OP#"R7582EJ5A4#&IN;;$>D VG95:.?OGA-QR]CN,1QV:V#
M?I^ [*C@,L&T'<O^GF%!_U>6_39LUZX!@)&"# P>!0L  =8WA=(#Z*>,SE?A
M>EB*(XP6SK%)QF^E!7C"OMTQ.W<A0ZUXO^HENP&!%34K&W3]YL*L,GN!!\.8
M&$KP,1=WN0ZG:N!SGH77<S[N2=VUW0NR[SIUR_]PG':,BNB'!,BQ<\EE5G>V
MI3I\TM7DUM+1@!KF?31!D\V1I3'.'X3]T>U2T^KD9N6<^9VS7X_&7WFM0*0^
MA6Q<EP> ?,S$ Q]CRH2 =/B_]:)@'<=IZO)NHA/Q@*K.YWS=R(V#8K#Y#];;
M=*(N ?0$W_P;+RD)R,2M%W@ )0Q;%2BH:'B%!Z([FW!5.\:7SOS/&5J%!QIK
M64."<TN3;:^5L:E'RGUYGNM'K= ['(R]R S_>N4F<[0['?GYHNAV5>9,B[LQ
M4R?BZ:-#3YL?%&<WT+_,;J .$%^7+6'O9FWQ@)4A'IC1MO (OXD'^#,CM[UU
M\<!30>>/9.KL^G]]N:4*+R\B1N_?*_%Z5EYI\ZKA+E/&8$\M Z:BOO$$^DQN
ME9%ZI/0!A8CU0^EY,:;5Q;*W[)ZV.^\)@@OER- +H11JEVO#0L,\#IX^UW4]
MZV'']T6WNO'AI.S&9EN=6YF&W\_L@R]]VXM57E8LX[UR.Q+J5;/YV5Y@6_LH
MRNMV$T[DU;T"OJ !G%;(N, &4V1=1&_J6]/RCTMR[-Z%#_%  TZN2U'"%CZA
M+=<0[-:X3YHF9S5'469L^W2CE);SR299R_>,P8PTV6L<$TJBI7UK?MHE%@NG
M^*7%[CBCZ\@68ARMZ=3'Q%F72T29Y'DJ.+\/LJ9%9JGD?C>8&#:ROXO\BH+=
MZ5Y/$HU:LH9[2.Z].'=BX$%!%:LY!V?H&3WWE-C9BWXV EU%IX[1T+D]3X<O
MS]\__<3Z+=>J<ZY5793EWOOL=QFY;D9*&>>()%:61%HF33%<95+L:*"KDWCM
MOM$=$ ($T9ZA125YU!8WYD*=;KHK#IV--Q*-N6F1RO&\LF<!.9PSK,(C($([
M<:K@(K?HX'P"E09/FW5@%V9^; \2Z13CX&.43SY,KJU#+=9@3Z%HFS2(N3/.
MC6!5N>GLG^M24'=#2H,BY_M:X3']);'8D\G4:6B=INF3/+&8GOO,5-Q:*]LY
M[NPM2NYD TQ&QAO.W9WZ]166>?[31096MY=Z"MF,^YSM*E)'+T6S,!9J?[,*
M/Z^C6-B$,$44)8J_>;[H:S.Z=?JQ>*&<EFW2B8$9]RB8R"#J<.GSXNKER+":
M'F?VSR[47^93;NJQZ*U+/#C5MGAQSSJ.#<$()HK5\!H>H(>,RB^U;U,MX 'K
M)11M'_T3NUE#VE$U-WC8*X!^3G&_@WVVPXIX3P0K)X*!G^\]3<GUF4;1)[&O
MN^[*?[YJS6,QNYZT.I"0F//9LM'MK )U/?_M^6XS[27TM[-+/4\:^C9;LRO*
M^:5R!(X\#$CQF"J$V3A 5O>4XH':RX%/'>3Q0)1'V?86NSSRD,&'_*O0_LK/
M$[?-[<JRYH^<15YL<N7GD_]C.>DC2A'CP'4V!P,_]?&(^(=[)IS Y>H]SY,F
M/36IK@F=:Z1B-S"\\B/']+F;;=S$6Y;#([%%@S(;^I2KQL*W;P@LD$.Y=6J]
M*1CA27^?/#*2O)S'I:$B:L&8)P&\!7O;F1HN:PEJZZ]>N:0YJWP^!BZ41@X7
M_5#"I-N0.'2\5RS?(ZLDI%>9@W[B4F!=;H3W P=##\F"?)\"CI$DQ'TL%.G(
M.@!ST1:.&'F932$'4^W%FA3F#YF%F1^]?\#TCXE#:QGIG=5MH8$QD3(Q92WE
MR_QO?/*'#L>:%)7&3 UYZ ^=?Z]*?5PST\E7<JDF(U/7(\?Z3>^8,4L3V_:8
M3$KT0.Z&E11((RFPX0I%!"=H3!ODVQ<+YZ:$F?X/>HDOIZS#Y^+,*$8.&IE5
M]);<.6BX78AK+A9E"4087%RS$4)7\G (5[A-VEB9V(.DU!X.F<_% ^9KYN@\
MR,8A7VT\<-%LL\>H/VGT.P(Y%^8Q3&\Q?Y)\TNXX-$+J[5D_QZ'0M,\SKA5O
MI[2O;*&/SW\]DV<.+[1WXJHHNCE9$Z@[%!/8^RP(5=^^<4"1L!?;9E^ZV1.L
M(NC[V ;$6@>DP$=0!,'"B1CS39S@F#3E12MX)>-JG'J</N2#X5H^N>W;%=+B
MY8><W4QO>YHV6_$LR*+2KY/LP5RC]B%,GF>"Y_<3\U3%NCRZ'>I0]=/5]]UB
M36\HI\.%:?.6ON$T)%GQ0-]5G+-5.)A4)&MU:%B$V;+2MW>B'V2'-W@(A[.F
MV##+ZXMSJ$6?\DK$U="@T[FE1G$'-OTSUB ,#@,%[0."S#S(;[+VW#4E&38V
MSED#!27Y=_AY-F/\SEU(SWM<8JLI+_=A*%!Y7IVB0%N =P]L0G(,NKEI/6D5
M;.6W-(U3Q0F \,O$F<S(YOIJ>"'&((D3('Q5 @S4V0$S09=$T\UD#0JY^B$9
M:5D@*!2SO@5;RRM(#Y"WX S95N@7ORCI/&67JOKHS4J,1<W7WN_I2???!NLE
MT2(@4H\9R,^\,!-*VV,U<$9;T=9I.T.N*O_Z9/_$4TO?YI2I"OB_P#WK@*U1
M\!&*F?-&\TTE!R7$;9L&!LW8+$74C+,?JE8[CAYR;LWN-*K^DG_;7V#Y;>QH
MF1;2/G7T[2C[*0%F0Q_ZDM%O'+.I L4.!8)"'2G:[%72>."!%RI<\:32$T^!
M4FUDR:7C$XM\FUPEHR@&;9^74%\)OK (#992&5[KS.NS9Q/63UOMBWPY-=6W
M.>/H>Z&J/+EAKWGQW?Y\L@Q]?\.&E-AONDL)Z"EQG[%N+?5DY8O=B+CC_#3S
M[_.81AY(_'$C8>%%UZUR7%S.R -QI8DRI]3*JTVKR-9#>H;;F9*V7VO/]NU3
M@[V:^S0?G.3AC:B_<]-^[(%/AT#T>#@_P]2)\>Z^+#/%C ]?O4L<MN3=D*XH
MT3+0/6!) R$)BT(9DZYSD=U]S,7;$&-;3/#KE>$Y9F]; =O6R8ZVXWXJ!3>8
MKM&<+8UMC3K3T'!#]"/91_K!](+6$MO;YBX\D9?2X2*,\%0R<+/Z!L0W<1]Q
M[[X V(3K\K&M9JO[! Q"EY5TT?3$R=:7VQ=_ 0^\6P&Q,U?;"[\CM9-Z#RJ$
MTH." GOA-.9 WM(*3@/*"NM3PY7,Q$_#F"$35Y:/;=^"SEN%ZR ;-(YA$((;
M5-XFH=B'J4=!R"41TIEYXZ#B.1#ELJ-%AW@=-OVS/X-L)R24#@?^FZFB^U>I
MDMKB!0OQ1^14@K)%7U^A0WE>>:\O@>=K04:9A<7[,'FOUR,V&#"QN)K$#;.T
MSISE V.P,)QUE($Z!S69.@==9>E^U>YVSI2(L'6F3YOZE-U_5SQ97>#%QD'V
M;K-6ZU6]A&P(^1_>%'2 YG2%#E@A<D]<2X?3$[2C,(89IVG-@@<J>5?D9GJF
ME2C H/0UP!:;L*T^<AQ*1Z0@#1N2H(U@29R $;QI/2':0[(40G;O,%&&(U@"
MTD#OD2-W@VGE,<)+X!$<NB^]PVB,GPT+C<$&5>6VXS018*1,<"5S)9.F,+0B
MZ($*U!K!83M[N1#V2O-(#^P-$"'E1>]A$MHTS%EF"<<=>^^O8F5B [H &5X[
M/U5M6I5;C].$LL'Z6D]=;PH=\ =-GOEIL@CV-+C?_8;:M7Y8LAF!=TG6!N I
M.;#02A!^#T[B-)D) :_#F<RM37+=P#X\) @")Q";C031,@KBSZ5#G9V=?4^Q
MOL)'RK]/;8&:Y_V2C%LG#RBXRC3Q3XVG*BRW<T0^^V39[,&T_3Y&S7,XZ$14
M'8<IWTI0[;;/[/D%0S]JIT@EX1[;XI)*)R?JD/&;)MH/OPJ)P7@H,!]I;-6E
M#U!^;!+BW/,T0&EU$R"@]T_,-D_:H:21_\:$SQ/O*S"T/O;LJDXGP@C)7%P-
M,;Z^8Q6(,J,E7NS#&GX\X F9<NK(:_.E 5V,"L,#7R(WDE8=17S5+L/"T=91
M9O&?P=S$ Z#U,[7OS'))UP;0[*4M:->:1@^[@8H*F I44 "\/3H&74^HWE<U
M7P<!$R9V>Q*EGDZ4I@ALI!+HOL*\[9VZ!P+.&P2<A_6\^IE'/[;[0MANIZX
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MZNQB>3LK!VX??\%IK<[%?6/<6Y4E3V(&U:D_E1X,I1$[X\51ONLH_N,F8@T
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MJ>52OWC+C0#XJ+EU%K_RA_ LB@3VUX5ZN(ME0PY9=:G0]IC;%G*/NQH 4>!
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M<W[DR'G1A]M7X(&T/-CZMV(R4EM7<I[,A8FQSJ;UQ^MQ\E.S'?S\'C1$OI1
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M+"@.7;SS843/U*1_/$%A-(?]H\^)FSC1G:*H<FO(5N<=/-#$DDYV*Z,!UWK
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M06CY? /4095S.M2PJ5=WX4\BUH\=+G<_?*4(OL^LO(;[O9S<8;DV]XO@"D>
M*VQYB$)Z#IO@66N$X%HXP16VS$O;S,2Z"13C4&1J6Y(%U0UG\  ;(7CR2V)
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M<OY^"\W;3EUH0$-PMR+(<.\V8(N5I>?!:9BU/$2ORX?H9=A8_@Z<:U9K<"I
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M+SY 5'M+@3-!!CK8*OB^4&$;=*R) 1Q1$(C;8V8@!O8GP0@\<>$S4VF[W;
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MS>FG/>$8?U[XRH0:E@BA=\@+77[CA>]M0;U(U 0:]8!LGS<Q"S[D:L,@5W/
M B,O<*+[+Z<A3R$*>XP0#3FJ7?:9S@&7+4L?=C-A/?]8+#QAV2>-$@_TI!UX
MX0&[TT?C> O+1Y]O3Z)!)CD5-:.];?9J"T6I8=J/5/@D30>>;;U#WGP5MDU@
M>GE:;8^VTF$?"_9.5F@-]V>YW^;2.O.Q+M)]$#S@]!KK+/ STYL66ILD@\W*
M@JYQK1078;O8"_=KA,D[;O0=S,);\("@.P[$698KA_*8+@U[:?A."=0,R0].
MR0[%(7#V:J_X/_3M8PQ@Z-L8Q"EAH[#.AP$&I%X2^BB$9?T- GE UQ8WCY,
MG_V+8 A%^/8MEQX5], >SBH%Q&?/_"W,A]-'Z9Z'CF=IB]K>!10()-6XD-"*
M4HR M\.&0=M1*R/''7Y^84/F[TE/"0]BE-MCR/^3\%Z]V2'ZV?[5GJ/ID=X]
M@T3PKI1U*F"7?=-F[^H=96I]T$]-Y'B@<P?<RL9K\.3A;(>I<F^S#38DIC]E
M4PVG )*S5?J+N/#XFN55WY]B@3HJW^3 $QC */M3(T=K5OC^26:96:>5(&R2
M;6F?);*D%92ND4C89W$S+ V5(^JG6&!Q 89DJ0UVVC0P[0C?:R2;WL7X6J>A
M/B[LM9IZ:"F@K9/9-UBV,%]^;N"/M/'!G^7A@<AP-MP>HUI_JL<_S$K/)OS$
M]DP+?PO8G3D,V)5RY('X0=)S'$/I\*>1O1*6'Q3.87_ED,+5P\)@2.ZEPTT+
M:EQND*!&,*[4ICCLYGG"7LWI-'XSV[M*"\$Z@YVYI:0O=/39J.^;;Y"EV51/
M/TXA"_-3X"Y<K_SO7NGJ.SR=?_P-\@0+N_432VMTFM8#)1(>V%\BQD5%-D0=
M?F(0!A[>-P$@:!FB^HY$$'5@(<<<(9VY*_N9[<OS1YGBG1+K(R%#$S+S)B.!
ML;_C>^NFAVO$>1BX\^G$A=EN&,ZW>G-M(?& __[S<7!3O0"Y:"\\SNLPXC6K
M>!@SI(<<ECOS[X0%Y7QFL*X, M.Y*SB%I]HBO_%$K;_=FBAD5$O',SK[<,X7
M_A:9*\U6&&=4WBM X"2G0'D Q11&G1E"OL7F(K%*T GOH]SLJ=X10EC0AKG:
MT/K---=O]/>8H8K&W^*'*B8*6;M2"W\>UEM+)3L,8,H>4A:0&T/;4/ ]&A?8
MP4ECT'F,E"@S7HKB)<88@*NHK+,Z20J9E3G\):.:<5]JI0-ZE&\-3_N2O2J!
MH#D1F+XK/T47\W7&_\ Z"^+LJR18-C(/Z__EIY$?#7Z4/"HN^W%_FOVS,O['
MN_>1\U IEOTU;O>;^OQ#"+ B>X/%^\=/#T=XFM.ARYIU#<.]VX0M=D,S_S0<
M>(]QICPR[6 V4KSQA\*N Q4V&8C1#25'GT',%C[\Q4:@B1?6.1^"F^O;"OT;
M\GP'UT&TL.\:.!>\IS G07(E_./GD#^2O8;6*3(,; 6&>C^VUV.:9@P*K^ ^
M3AJ,&Q+S'/2]_ET_AZ8</:-:[82W# +G23^-U4N8R%^:C9$V27;L,X1A.$D)
M1]9QN*B-XD:8B<FY"0KZB@0W-]ZW$Z/2)5Y8 %44+&G';!,O,AJ8>C_0*[<J
M);I\EOS1*=2"&#@7?N*CK9N^24[Y:)]8-8*2]&CV$+5-_N099*^]A@RU[@B+
M2:PB@O=^XL?EX4MA3I_?O"-FD6HLB(\@Q>7.</;:[GP:O4%TY3V1_5M@CW=[
M9>] M\&4>6!N*'NP=U3.[;P=GPH2%*QN$*^-8O%_QA\4_6)MOUC;+];VB[7]
M8FV_6-LOUO:+M?W/8FUWT0FJ\%0C>C5Y_=FFP93W<M=:NDKJ]7T\]:Y99:)C
MM=_@VAL'8SI:5#*EVCXVEQW?M3.%ZK6)NPRX%UQU;M2HV$%0ALP2LMWFX*N8
MO?3\<^>*06+V&B:5G-9E;JG&<N1$&O=[$0&%:C=V1-G*8"/@*47U$6VGVZH_
M(@A]X/#6H(+WF$ \7]#MN.X%&AH,-"/]K(@98LV%KKLBC)L 5?C2R'P]_.0,
M9-V%,7>DP&8?$KHMQ3^/<IB*N!>1K2I"*GZ79)4H.3(E9'^PTH$<[6=[$?[Y
MN:&<)=2YJ@A)]FKN_@F8,"/6\],&=C>$L4WSB[M_L88F&9]YL/?'4\!UZ:?/
MO9"BL^K$LCGC4CL)4!<N^8N);*[A>(" )5HW[[_\CZ7+O%6@+D['8PV,I'ID
M7>;%63A2FHQ*?.\3Z]*OV(8",TV](/OZ=&$%AP,/:B>'$1V]$JI1VJ#BR]KT
M$UVW&"5F)L+S>5/&J442>@9R@/FOS_I^?=;WZ[.^7Y_U_?JL[]=G?;\^Z_OU
M6=]_YV=]7AW"=50C,4_;W$Z,LGEW,C,FB[QYUT?_!AKM^.T&"<7H2D+5-&$C
ME::\++L-C3*YT5+D2W M&6[V\B0(&@KN9SU77*5@X9<G[HE[1.S;.>RU7>2P
MYK"?8[8'0L]H'F'Y)V?Y@0OS*DD=3?7UL1\27662WEP'-#X1&+9]L]BX6N+0
M&=/51$<N=SG8Y*N"_7?Q /,^9/I9-\VFC;Z=^&(ZZ ?N_]/>=T8UM75K!Q!1
M0% 1%02" H* HB*"M(A(DZ/TWE14FH#T3D1%%(&(BB@M2A&D1:2$'@'IO2M(
M[P2$4$,(X=NQG$OB*^><>]_[W3O&S8\U1O9:R<[.SEYS/O-9SYQK<0_MX'UQ
ME\#+<KNI)62HAN;3X/26#?8A2*?T==!-4?GA\Y,2.E7\THM#B7EIJFK,6-^&
M-J-R\VO5R"U5@5-]FAYBL+BNDEAO^;S6A;*<FJ^UTX=W?M:^M>J^,%.)>O>*
MJ>)? #QZ,C6?)N",83UJA&)BD%RI9_FWBYCL*T_/P#HJA=Z);;0S>-%/-98H
MU@"UF4 M[ 30!0I-$.MM/LOEVQ46M+S7H<3#7CC8R_Z>BO;3U>&I'2Y<&X'>
MIU0H*[2*"H4>[ .>[020^08\I[U1O?>,J@4+^&U;/4+A&P!![;BL"P0.P!.J
M^Y/%HP5I;2;+2]?:#/IE)6(JVRIWX=EPD*H57*  (@_")?L4$2DT(;GROI 1
M/HU':4UA$PE @-/=MVJI1\;GF4'(>PQOK(/*8&]AC%#VQ%A\(SPI-G )]D36
M;[8/0)5J:Q[$$N'T&.;=T*KV%&CG5!^.#6&_R1B=,$%&#?UVR0/ <]',Z->1
MICVSRX3S,A!"%S'T1>Q"V&&!Z/\0%WP=9 M8)CU%6SPM&B<*NP_MXR/L6XFK
M7$2LL(D!H3+@],='DUV< ,L<^A2X)>^"&PDAUHG&#.9+[GB!)>CO 5P1SV:"
MOG1#LXKPQGGI*<AJNQI\]+)>,IZ7Z-^)-N 1=/Q%"M&] S\)^2<N2X .1 Y!
M[S3PDP P(2CIH;(W0]-X EX")U+U79+R&WJO"T\T.4Y_?ET@J?3O(-X*:A(B
M"9G1 B Q#W41 S$*M8$N-G2OU)MZF?K/!A @V2C<F"U^-$T(NB-R<!WD)Q(^
M&C0#6$\IX%&Y//[->NJ9DY&!R6;40LQX 1S7QC.DDGXJ[O=#@02I,W&$%1&U
M9@X7,J $(Z4!;?7Z+2[Q8#473A&^A=[K(..OT"BQL;!Q$I7=?$T$I.S\=R/:
M0'("*U+<)[K)F#C>^8K(<A7.-VB^9DH6@.)5,_QK=XE98:%Z8#(>L OQH2%*
M:39AW!GUIZJ.FZBJ(VHT?S)V.XF,G8>.(AA[0U^D/\YK$U[/@8N6^+?&03L-
MH OGP[K_ R4&$E&B-3\>N/LF=6AHD7PKOE$P[0<R).(Q(C0L(>_HA=(L2 $6
MA\D4-B?#3\K<72V"DW6\+_,&BX93X?>A<8=&-Q/CN0Q[;H;U6E+PRBP/"3(0
MLW8N$;U3T)7]6?#5;4;0\1%@ZI'RA>->G'.?8WH&^U9V9Z-6Z;Y QW,0M A/
MC#W^H2& TKY"%HST[G2>/C!@ 0_',[=M0%Y]1*KKD"*1* 1N'_"VVR:_YP*%
M9L#H=Q@X*\1L3IK]]0:Q7\3&@TD9UKR%=V30S4>05+QG[&Z:&!8^#0F?5#6=
M!T#4RNY3D%4Z '#%=A2R%Y%Q>+K\ PJC8.I%Z:U_TH;)AH$;7D_*\.?-R&Y&
M["%ND@@ 3?G)0)>C.G;8PQTRV(B;U$3<(.J*#]'"UER(&'C&5-2T?K:5<)X!
MC$,3S58O@F76NQYX56**&O4X38H*+Z23R@"U4UPR/H/]N>I_+(O\.*7#$&I%
M@+URS?D1X#653&&;C1IGH8)%X*,>GZ#+R7!(W8=_='T.9D0*S^4GA1>27DE*
M!2:(^!T8^+;P\#WF+2#:UK-$UYX2]4W8E_53V&<"WH0:!( >9Q0 ^/MX'=HG
MX22P;\2%K ,PVIG$19OH[_'?\C%HE,X&&^0XME)NZG$)-MOL_ETO_'U%A$!<
M]$A#165/+(Z"MT$!& O,ZG3=O@;#!=PP J_HH=\XA H?OA,HD,ITEAQK,'S,
M7^QXTN&:?SV\6P1A<D_CJ9\_FSD.=F&,+LC;@"_+Z7" -4^$_&[E1O_>_>G;
M>RKK3C2<M'G3N6 3?0Y]J:@U?2]# =M#S:&#H>\XW,9H\(NI@*?>9H-D44OL
MMKY5&6MLS/9YV]K@=20K!]0KM![DQ@I/L\S))\"7I(AJX%[PLNW=4&!ZI-$+
MT !(W?_**\\>X&8U$UCC8MU%59M$ZD?\X/4"YK+F=XXKR\:TZVEA1M+NIXCY
M9_N/3.6,[<XZ\CBQ)77<5)C0W;8#L:0S\H9'9/12KNFV(70]R/G4O\BA((-E
MUB3E-;^EZO[M1L;!7<V@D&D4,HU"IE'(- J91B'3*&0:A4S[6V0:707[8L@;
MX4,9&.KN+H_*Z1L]#?B=IZ.8E-&A7YF8! .6+ * N>X*@&94>\:@">1<,T].
M8&-9QW)X9XCF-NHAB4FU=U5O;)X;'O9WN+HLR^&7:B%ED0M "?7*_8U(L_ER
MD-LW@9Z>I-NCM&PT.HU5^-"=@3D=&*[NUOZ[S1D30<MI%QD(NQ'3-&NH)<C[
M%0LNI=Z>4%A9VI7:!)$@;XWD;NNNH-DR<^Z0 Q+&1WC T"T<8YW@EE2LU0%Y
MC']CP#2B=ZG*\&&;<G=$CQ^-G5)&HUT<!C3]WUR=NY)$]59.BL4$:-@WRMO>
M)-G)+B+6?+NAX\.OF,(_0N>$K'^DFU(COT&KG)_0ZIT =0PP^;A59W#+0'@J
M)]9.9,9,?C)CCA&_E<$E0$)DWTC ^AN;"4J-;1H*/M58S$*T]V<SE<[ZL/YK
M -P:P<$MRB%S8X3>=5#WN6)2OFH%1];1*D[@\/G#W1S;+K-OU'M-88]>EG<H
M64+K _>G!,4T(P+J!G!Q]5[030;=SUA@)J$F:IF-ZZ OXU 3QJZEF0#4W$$B
M.=!)M CNP61(+%_4OE_$K#G*6Y2P(C*+JN>"I$&KJHDF1!$P(4IB6BD1G?B@
M",#$V$$7G'0D^XW F94#2IGX385L$^ =D&'X)\#XJL+6P'P>J+^R*7H#_/A'
MGC]S28F*)Q(TE@:X3D9BII.#+,GW )B:]-A0OM\T0$%DH++95^G[M/\=H97>
MN5GZZA7F(57<E /@]CSAB2O[6<?-@*!KE1ASN?8U6,]WD2(Q*R/LS;Y]^.W>
MJ%,6WF0)J=\LW@8"3$<3NTN?F!]&>@JRSZ6!-QE,U<-\K@<O5WOZ/AA*^=L(
M9R-&0D@CY$F!F'8S@9W_A^2$[ QJ&U1Q!O#?#Z&&XK9#BY5:%RQB]$BR47-Q
M9!R8;KOO5N=!B+^(? )1^GJH%PY8?5IBNGMGF%[R+T@L^?@ZJ.QD"93V0.^F
MU);-@\UR6#4@0TJXKQ9&:Y-<\%$/G>_*.1CP /,149KN#O*.>2SX]6<]K.,"
M-'0"0L)<#;%.K8/(>IX?Z%^)RF7N1YDU[]O(5B&,R?-9>385PX69#9Z-4L-,
MX A)&$_R;%=@,FZ$=/*?9I[7+<T0;VT8,=54%G#("MGN1[TZR:%8WKL^!FD\
MJM\W7OQWB:B%U+_GQ33,W(';$A"$?8L#;GA_^XX^O ?P(>/N%>T-K_4TQM,:
M$P+(%&X3&LM*+<76&[)+ATH7I5-15GB4IB$YTNIO)R.RK#,@]"+'L?O>]I_^
M29YIMOW)HVEV:DS(-'IL3FYY66R6Q_HDH)*GMH28KMNI&4:*9# 12_9  ,FM
M#_S+1K UKD5W^-U1&QB!?A$P6=79&PFV9!TWXJ,83EP.\&\D!%LG&*6%5.$%
MOIV &(%^.^$\C#0\A6XR.)* MR*:QH8R(/C37B'<H/T'%Q=(GI3J"B'EP=*.
M>&_K^\:ZO]TL#W6<L#DIIJ^$G1I*)*SPA"#(X1M"Z)<NHA'?05RPJ)OY+I'-
M<\(/;K!$J^&0!L'Y&F?H_4>E4&H(I#[FVY+ (@HW8HL?0:@ACI.A,#[HH&A-
M!903C^(%P,]E1W+N9K_OX:9T%\MINU.UKVV2#,YX>>A?<SPNMR3!A;I0;LM0
M+HE6LAF4*M!?6+S54@E:22AID(3"+TS+;U6OD=,\N4UZEX$Z-N5<;N'>=Y//
M&T4YDVEF*YNX N9?[; &L,EQL1G:"=F#N?OV60GK[0?5TM#>H.GDOKNBD\9<
MYFD?\-JY-?9@?,6*\=<;>.BK-,.?;-RU^:-%A4\E^,S/#3/ETIP"X83H(7OB
M,U)#K=@SXQA3CN;(<;T:1?1-+N%<"C6-A2-'!R4TQ)7'FI@-044*%A/Y[3F)
MO!F*[\ND]4_*2=YTH2L6.O?OWN2#E.$*R] G$9:!*C;@K+?)!V!%-C]*APC0
M))#F$P 3D2SA )0(S,NJW:N$HF$ KEQT\25Z:+V?C)CQFTU F97:$.QM" ]6
M%+#'Q*0 ,T=?Z6_Y!<1$ W<V2/>*;^)GC!H>@-!(U%(3@KS 1['O+UU9]>N@
M + 6UWZ"F)K""IR8N3 -YO6A&4"ML#K#?VP-/<A%7(5+(98(_HQ:$#7MVW24
MR0#O">_4FII?!RU+@COE3Y/R7*8\I,N.Z4'=6(;.!0LP(['@!%YD7@F&)DTL
MF!PERSS(W5LYA<%J !YH,XCEJ?0CJ&LA!FG5IO:;<^KD5)=>V"^KCQ< 'RQ>
M <1U46HDWT1<1B;K>(S=][I9%>NP8!;ZG?S^;1F0[&\F8O0_OI>5Y#KUY;$M
MA (.9VAOX@1!D9:4JRI<(EF#--0E'! 'HD%J,Y%ZMKYO]#R,4-*\@?;?4#9$
MNWB++ABKL2"S\0P&I)]2^OT0*][526EMSA0>*S'YMY?WR)8(&X6:R-8A3T'O
M/_QN^*))3T'"F758;#)FCQTO-9L)75AC&PO[VY3<Q"\\U^0O*Y%!D-FZ=V8E
MBLN;U@$9E/Y&72D"?^_[;]05\C_@'2L1WK6I89L)!2^!O] S('$E1L?H!Z #
MGF(5(J*[2]Y12* ;=]4A<!2!ASW52$I]N)=[0<@ZKM_'REH<H\&*="XHD!!4
MG;)\T&H("KBLQ]!Q++IJ83. EJ"'?<S/@O?T125+FY+E%VB3)R T+4F-9,H4
MD!%=IHNDBY'I-\5+&R$B6/#;#6@)A<TDG ^V)Y0 MP]X$^CWY4/:]'HAG5>&
M9 5]4</N8O(;*#*2@S9/(:>)*^1H"Z?MT[R B$B##C6 <:.HFMS9(C4AD2ZH
M2-MS\I5&=S%R+BQ5K?11G2SMI/N./^N,:&>S;GC=YJGF1)ZX0%8*Q/0SV0JG
M&BE4&GZ-J9J;A9;#%]L2R);R"F^0D4VF_/TK$<"K.T70NCE;DAP#$_(<!%VT
M^7L(O4SD#\W%CS,.D0@RP)L,_KI"\ \N;O ;5X[^L]S'#P)^0^&0"V;4XM\+
M%?W"6)WY)I% 38&)"HE\R"9E1#IV$:0D (A>K#R4\LL*9@WZERZB$?]6YTF*
M)-_@IRGZD8T0#1Z(G85_@#7.6[PF([KJ9,E6(ZO-L$%S&?!*J$@U +GT.?S(
MMU;A2;(Z:=7\Q0#K2Q Y-GA:L67T!7/AB1</1YB1AS(6/KD<=5)38VXXU7W"
M/OMZW<UPY62ENF3WZ@\K?CP14#P/,N-3?:+J0-*Q&4XX>Z:QP!?])[R0C]L:
MU:S1=M(0^R2KG'>3?[28=%<D(T.CGZ10U0HQ*:J=HDHCJ:KKUI54<&=>S4:H
M]@JO9OE2RH.<<Z@C;"(Q=*@B.ZWKP8<?#H;)Q]U)C;\E-WV6(ZWBI=>5@;:B
M1P;/+MI0/]-_X4%[MI\JQ%$J)C%[ITG1<F"63618%U^&\-UWC\=<(?3 7+EW
MX>/@Z1A,FE]5MNC3G7A)0K:;>O.TV/Y#(3J6073'JQEL 2O2 QE+."YJ 5@W
M?]L1"\A563N9DP[P2G""LQC\S7A'EWFML*UP:VWP?,-JS^WIB*9X*NW"-#T"
M5'@=-+L+A1TQB;TMFO5:L#'I48#2TVEYX0?:X!ZE3T_Q:$72K<12LO[15@ZZ
MD(U%XW*$P)3R;Y3R;Y3R;Y3R;Y3R;Y3R;Y3R;Y3R;R2+>Z$/MUT(BKHE8TD=
MMH1\8Q7$HHY"(AU/[AJF>H!S2?PTF<,>\32Q5\X).;,MGE%O4DJ/)O8SUDMG
M-J&=@!*V3ZIJ$:M[4INCW,UOM]6]GY%I328Y3L["?$"&_Z/KB4='31+H,SY^
M9 @ZHWEZU2]&8FSB+-?;_^R.JO\4!BD];%$YM7V+AHJ0<-/I3X\+=AX^=XN.
M'\1BN*!.MVL) !1P&<!'@0X#\_=(ZO7<F':>S.+&KOZKAC4ZH.W:3U3402 6
MD_H]5)'_3/,UE6VCA&JVOSD@^-[8J'KW7FGJFK.-2+&*29)J&].GNMS.UP@Z
M./BH :?SUTJ'-G8 ,344F(,/X@BLEX Y!S&$KN&AA$-%CH$+J.P3G)U?W"&3
M2W29JZ4_5&'H:D)?[:)TPS\$3E<HP(D"G"C B0*<*,") IPHP.D_7S=W8*!5
M^L"@F93V<SYD&!,Z-_[91W.[U0KWL5ST8E*V&LNX4Z^!D:6GD?6R[IE5P?/W
M%/;)P;TONU867<7&Z<^&/]!(?&AG:X_Y6 LJ6Y5HA)BB:A!8F\&M#Q.M5&DK
MHFZ.F!Z8RKCSWFNQP3</UT07O]G6G?^U_0G^5=-N3P,<MT)1UKWD:@=[W@OZ
MLPQ':&2_=$+68 !6V0%9!U$#QB183T\!Y+ < ^X\EFJ!G,M:F(^[UK.4*%%5
MX3"B=^7'!>K5AQ$%5:9+:DL$L[>8*,!/'8-.SZQE"8V#B=M?IA#+ISV#X$ (
M> I93YHH=*"RK>P^)%BKV=>"*,_R4JH&DTK=W0,>0H:MVU'H)?LUQD[D)F-W
MGT.Y$A?;5J7706L- 8M-]>09@@_(\4O<:0+UXAI;91EDYLDZB '?'.TQFZE2
MU';,KD^]+<[K9<P-;?><^Z["#B^J*]32 ,]-3ZQ\].H-,&U] &-4@2Z,+?;J
M:LS#*778B&19C$L*<X&;K[0>Y7VN__J8?)W<58-''/U4[3!K3!^)5F!9<):T
MHY.I._+FQ >D8(L]<C+H+ZJ((1%XT4R*M(HBK:)(JRC2*HJTBB*M^CO2*HXU
MY(.%U4@97<S1!SFM!L^JU'T7DL;LY_ *EZT()]J^=/=->O+N'._4?/#$?>4:
M[Q!_C**2,7U#_GL,:TP _SW;K(=\#T?Y1-2CT[BFOT1=]N7O9D4.2AU!93@C
MMG_JKC[R0O']I;B1X)W!=5 N2YKL32HI4)/D]FF3[<#Y+ZN]_I,F!$PK?Z\!
M*&XK=/@C"J_CG*7[.$437G*XB-%Z8+P#F7TGK "P(J+D;W,X_[@T]-PC#LO7
M&GLN"W""./TE _EU$]1"+N(R-,N:XZ#7:0\LJ?@JU3_34/ IP:[\3VJ^.8_N
MT3 [Z7N;=:"8Q.5_U2'K:+V/[7L]?GT=]-$7GGQ<B*P< 5$WLI$K&0> !9("
M+"C @@(L*,"" BPHP.)O 0LW__AVO%P2M%3.Q=?\7=\AHT])_0B>HW>#8-[+
M$TJ/#K=[RR0=1MGXMNC/*(]E7*F0O.Y1H=;O&QOI,1"M=;'M,)0>'?J9(?SD
M :D@5D;/L"I(+28A9S8$D=1;XC#88V+/@_29L*4?8&"Z-PL)'SK+&;9)\O]_
M=3_OO]GHZI_IV:^#Z!.!YQ*>!B$0(.N@74IXP6@G@F\6X+2QZR"\@@^L\]8Z
MJ %6LPYZ[] W/Q$3MJD0>3K>4.;^(W.+$[I/>GLEHE[WAZDSR>0BMF/X\<&&
MR#7?^G70ZXBYN8IHZV"H(5SAXY'*[0H0]%_JE:.^ZY69_]0KJRKLT:N#OZ)U
MMR?QQ5YA[JC@A>A+]IS6F483AO<PRI@]3PZH\.I2[R\IT>%)XIE-CQ*O6&.6
M![4DS70O*ATE3[\_32CO@(QO3UX']1?;$PX700:N1_>$!R">+[4,MO>N16L.
M[@T.7-$(&K@M4<4SFX;.KG(UYXW>>\OW+[!&&8 U+E*P!@5K4+ &!6M0L,;_
M::S!I681-X'KO)>]PTNSP"D9&7D2+L'(R@9BOG0"GU(P6XS@[/.?.EQ8$-1P
ME:JV2GPWTTD?;#)X-JT0\"G2_.L@5 4,J]L+_"TQ+.N@/@!+7/^?QQ+?FAF$
MA"'PH2'K\#)0PO"->X<#E[T5GH(/^DO&H. [8Q!C\8O?_WDK189\^+4B*PU3
M.W"ZKZ4UI15X[[>HL-Z^?_R6CO+D-KP0P^H^X%%\=1B8=W=64-@(W-[ R9"#
M\6$P18D)14'I @ZUTEJI A%FLZ.+">4I1?.2"1^/'F"=BV,K SD\5AHP!I/#
M"U*\H</FI'VSD'<MP4,U?TW#CZ0<(4*&5">AVXZZWU!'V9J$LC4)96L2RM8D
ME*U)_@>W)OFK]F^LX_=7S:+VE>7\A;GZ^$_5/!D6;CGG]&/BHQQMS@4FU6A\
M#A4X!]V=%[D.VM9+C+9M@0"=2@LON%B4M?<YFC;^1 G]V$T';AVV,Q(TO?&Q
M 6=4%<O9M?MG]B?,T0O$QC>1+"B$=A1S6$7T9CN]_6)FO;/643O_'&::5EV@
M8I@_-F2Q4T.'3:(@=D!3NV=PZA9T-FD!BJ.W1BU_@>#MD-(G^M%@^FK7)7%Q
MO1W..\_D7I/87K"_*V5MWH26]5+\<.KG^)3VB)&G39AU$%G9W;?N0R7LJ >%
M"IR$2+XG'X]J[C[&YVQ;\[4G-+<L< PUH.L>3O"<,,.R +B&/;W+A?O54XNT
M<T4"+8&.IS;S;?E](*RJYFP=[EE$7!>RZSEKD%%58[#_?'0-JH^UFBPN'6Q-
M[SJ1*-"X]XLK<CQ$<G,M'C)E5A1!U.*QD]7G72"5#%X$#\3>^IZM1O+Y+)+T
MVI>_'XHD2!X/7QWV@2AZC/S-$L*2Y(5Y/1%D>L$X9KRH\+Y9C>^N2GS-Y9NK
M,D']^38$\+9<V*:%Y%@(IZ#IHRZHWM<3!(LPW>^YMT3)'E%,>+F#]-@>XH?C
M#(,&B"BM<#TE+>5F>L*TD;S'X$HQ\\O:VP2&Q;5=3ILZN3F9WZ?23N@0>+=_
M7 =QP1&3L'TDT6>[)'ETZBP3LG*ST8ZL+F\1F50P<L=L9F,M@6YR8VHK>2FX
ME _'_E3Y <%!.7R.UP:ZQ 0GQK>LR[#%3^Z-@7#$"M<.]0T>].+& Q>NP"\X
M?=+4V.(P4I^8+BVB55.[!*]=Y".3 IKN(*_;F\(R&SO/[.<90[.A[-Q1A8T'
M+EQ/OY 'M(.>&V1Z>CGNFU61RQ/P=I0N!&,LUER.Z)$J[1!LY&5Q]1YB96\
MK_H19O/2D63!IYX+:7":_VD*5@J[\:<P^MLI)4AETTJ;C?Y2N_R?7)X$@K0F
MW/<2X?H_\E]S)UO"/P3/KH-*8:_)2NF258%+AVWT9GF-1 NH\/.L]Z A#9+0
MF2<2DZ3ZPKE\TN,6U.SG8G&L< -IT/G3YGP/21,!^%WX'7Y_(_XV5N.=9R;3
M"CKJ$7BD4RTP?;5S<@I[=.FX_TE>PG^/7.^_TE@?IKI#Y#MGGL_H9'HDZG^4
MZQA4)JBKT-!_<#%?Z>C9TVK5P\IVX1C&]8P95C<&@"FOG%'8 X##W*>W *4;
M]Z2=-[72M6><9GM08*S"7Z/,>^5%2#)$L#OV;5ND[DVD86I8%+S7H['<AJ&[
M-IISZJ9=>L>I7";;Z5Z3^!<9T:^&)"!AM\"?\BO7J,3,\/OJUT$?.YNR=-^E
M#W 9<9[*"(G:<S0#B&,8%^H5.RMV7W1+-.U66&)CJ<O-=N]T>')RJSZ3.R3,
M"/LA@;<YG8/5__QXRRY_1N_W5#(GS^7092P@+L:&YZR-R3S$M2[5I"C5@VT
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M=W=W>)SN\]XYW7U?W_ON'7?T'6_N47_V6F.N655?U5>SYGSX]; (/)>1D)8
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MF\Y=V/.M0]^W475\/FSM_<&+J]Q&<52$ZHU^3,5*Z="IM!)%;A&6-.647$8
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M231=H(@*NP;XX+12J<9V _WR!\ZE^!>HDGSBN,PFV>&J_P%?'4+'?!@WR _
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M:B,SH!5 YT53*TR2O=%3UME!"#7@I>O#":]&]'QN91CZMBBI'FQ_%.:AX?4
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M !=\TF4#&F#['(Y3SK*+R->OP-4[WV3*93/$?=;A6'>>7FUM0_Q^+5*<,<G
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M_S#:.F],-+Y!)6:VCWWU2.ZEPWAN'L5,QJGS\F&0:,R-]+4/+;,0GH/Y.FT
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M_U=>Y&A>F-C86-AX?_#"P/3Y8P Y-@ZS$.[=)UIXEF[W6(3?XU,\C<NI^D'
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MSP'KOPHX)!;:L:HU)N$IGHIZT0T_,1[]Q#..?#E^F@;[P!"NPV76>T?8#?%
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M'/28F]07K_'TQJ&NXLUQ/W;5#S?6[%?$][!969<@FOX,*BP-2O4F7P4>*,_
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ML'&^Y(% ('3/A<0$P:+<O!#PWY^@8&-CX^'BD3]]2@YFH&8 _Q^GWST (BQ
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MS<2K>4IJX3&#0P:"?&,^^TOM'\S^-6+A_U?,_IW8?^.U"L!#0_DS>6A$  G
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MU+%RQ"];,45[ 5(M2&;> _R4IK?STE<S2!$-NKKD%5%MCS'$1D:72T[<#N!
MBPLFK9;EMBU/["J>W<!W"<$>>FN"T>$JD8K:ED?MSD3*3AY ZU]&@,UZ:C<C
M.B)Z1OL5[F]R8RO>/#<C+T+@+,:W=OG2^?Z%'5_@X=V(\XGAMV*>'PDL8E68
M6B>\NE?';,WQM,K ) ON$5_P#H"<VO*T5IC-4V3==%9/]8X\*^$=HJMKKCQN
M&,>P*9-4ZTD_@S&JL'=-ET0?V#[,5ZSS=$UN&Y6H<TH*[;G@?93WI=9>X%.=
M+-WVP>^4&,7NY?L$(5X-_;8DY(7ZT)&ZGCI]Y$>Q*)5R/W%'D7%%J[86QDTV
M)ALH/P'WM_@)1=$E$UD!?JUZ@1#>M.;3Q4I+FKB6F^NOCO#0U6@_1?GWX6#>
MW!Y843H!SL;^T")2]7.<Z5 RJ%[4*%GEN"T'E6=:Z<"N=&KPN,P]JRQ)O'P[
MB)_EPF@\CD9.@W:Y5.=G4G!'U5[A-T4^;&^KP&8C1P0U%)7F;"17: H+4>IU
MJ3'5OZ:L[,4#$2.Z7"EK:[OC-58H%)"N$=<X;,N[0OL>D)M[O+[*7XQ'N/$Y
M$Z35W\F4%#X>+OR+\GM%<>;[5:4;H4,U/%PVKV'83H?A..><2$*6;2*A6BM+
M:>/I1J>/F6W78*]1)C=A7)T CZOA>A',!K\F7RNE[;1TI^R,[!PCW/%K"Z?F
M*P70E7SOKOUB,$G6JIV58XS<I.2F$PP,1&U;!3M6%<%\))Q%]"^.'<8U%)O%
M>-5(1/66<%^D+PY'@UP87R-<:88<=5TQ7>;K0 9<._#V#RH@3R8RS+A0*31,
MFD'O5"UD$.;QKB,3A^KL"2>?LUR(N$!S1Z(2R1O\6CA^>R]U@*[&Z5XI1FV(
MKS-_UMG&!//@9(./*:!'Z+JN"FH\D::IN+[S0Y0KA#,@JK:[$-7 =(J;QI38
MQ,P-A);WCI1O.-I%?QKTS!TT6<%\9(U@EIN)+\_[LUO^CIHWVPQOC(^@F:KD
M-R Q84TI4HS?>6VQTB$ \LO^\4NTK0!NA=B$-3V8O;I"LZ9@Y_* H^%/.QQX
M?>64G_3FN8C17?:\=6!'2Z8O2Y\>P-;5)9>CN BJLK$>.YZYSEH$?14%U)!\
M\F]P>V2<8YGOM"<Q&'O3W?*1UTC"^=LO.LO9#JA*=8?/3 ?YE%!57,V)B5";
M2/'8]J?V^8*\;Y9D&1Z'7^(;N5^Y -&2UJUTRQKP2_%;0N!U6VV6I29./+)-
M:&A".WL=/]A%D19(D4^^5Z6L<1YC)0@*IF8]^)*E;<S2*W=3FIEFW!$OW,/Z
M!AE76X!?9Y2X578*@$=\/3^@N?+KROY70BZ;KC88UE3. :5<S]1CVB( ^,=3
M]D+-!!&.226#/(1=U.T]-PYDJOU-BN/F75WR=>9/+N_2K5JC-W?1;7>3A-;%
M>NG&*DT<LW*N7QZXJX#M?\6OX/2IO1B+TMO]^='G1$PE@!#&1ZZMS@/#=%62
M =I(<!:E[K=2!VNSU?7K%'6/]LMX5YFP)+C\2DTJN6DL2*>0:1H@3*1H"/?<
M;'YK0JX KW31V)LK^*3;0<YUOA4Z(1+JIN(5SCK/JC__Y*Z-1CSU' 6=*#&0
M4JBY+=?,'P*CO%:F,1O032@<'?"YP!U_KP%'YSBO?#/D.3?;Y)7+)G4:^#X[
M_2NPT0GLGH@RC,@)XI@E9MW69(I7IRV48WMEQ_\-Z'S7Z?5+"]D2Q7ZM:[;X
M&[#G;O@;L/I\_A(W5]9J+NV%DH5([GA\)[$D.>A,AXMO?+3Y#MNR(U7>,^!4
MT17T+4:=0/_L_')KJ4 8%(%?U2_42U$6PX!O_"KL(G=-SMZSVHG9P'"2&M74
M ?O;@_ !0J]#P95[S'C=]N'5FVP [0H]WAQHT1O+J1G%,41LH?& #;O=ME\>
M6U+Q*4P((7A3=W"GIGQHQC29_@2/G-S(]3>@1@NR0;NDW)K.&J%@XW'>6>XI
M$CB'-'E__:5Y5=!HJ+UCEJNL<QY$EGC@CK4'0_IK"TXA ;:8A3>UGVD4F.8N
M8\G\+-'4XV)MJ1+?UHY>D2Y@,1+]M "M/&P4TZ5Q#%)#21&Z&BO1LMQ!&K0K
M)B).;C?"\*]O6NC6^#];IY_*>_J7ETVS^>R@>KBG;%:NJ+S+/[I)?IWLV""/
MS.\<TUKZM53(U8D3A<X3Z5(%-)^+Y D%Q ,P15D/U7)]*&N2FQ-$9@F6-Q>Q
M3G;])5IIF!7IF.4%MRZGS0*:RC8.-,K>OUU-FSCV]82\P(M/91= )&C /4V^
MII!M;QJZ/ <=4TS2&IH#H( =<Z]?ZLC@T,/R+Q?' KIMZ8A7OHLN5EWMG1S^
M=JIDXE2[:S! SZ^E(EV(.%5S@@;L7/'$UN]#IS)GIK;EU_7S@,7)UUF!1+KN
M*<:%LD#MS"?__1;^ _+-YT2Y%)VS;C0** (N3#D6^=]6T+-LL0ACR4FQGM&%
M5MQ+,?_B9+-ULC5 8T*AW:ISA^=+"@E=5[Z5<.8KR[L^KZ0UGB*%'G.WWPT$
M?D$]J/7*X$]PY0B[B*"$D1\+3EK+^K*]FMP=A8N(_H3Y,IGOH,&$AH(X*HM"
M>6OV.AZ'%%_9^/]<KEM3KD/ 4T[:(!L2FNUMW7FS)Q-&XT![^H'"7CQ]G]\
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M)'6IWC1DWE&J&32@%@8CV/L_BZH_85E<T#"6Z7X)/?\DR( B2'Y5BUU7>]R
MG*8VV.\*G49J8[QS(=56Y)[E81UY^"&$3#![K?.SMJ!M.!='$98]3ZV.H1?M
MHUR80S@R-SWR72JIJBYS:YR&5^?.0YGI&#04/^-Y?_ U&L@=WRP),'X-H/GL
MM]"D1YD,=7CAR393KE&I:%(+%: T?N8[ZBG\#B<;E6C8>"^;-I<3W!9]7-SJ
M8WO>AQ8><!YHFZ,;!6S?=218&;II^&,2L=:Y2VT2P?!J)D8Y(E7>95]DK3)W
M)#<EFNC=@#F&R,LIE)'1V@#V+OA=RE5 $/29L.>X.^B+,1S#"IL;R+_%&Q=
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M)N;P'-^TC+1"6-=7=2\7J&&0\\V T,]5K?F38TSPEV31/$L+GWZ!MFF^>EF
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MQ1FD=A,/L/]7+]3_(PQG@;SEDTC7BM)[(;\&/[=TM&5AY2TPO]Y3CEPE!W@
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M'V)A8I%B8Y/RT%+2\OR7+W@S@(^!!$8.1D&B Y#QD5#PD>#M  BQS@=(?U[
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M@0"7[KMC.T<K@W:"+PDR5"2.V[O0%#4#&:Y'-D<&!6G3C%]FKT<?&OB:Q#)
M=/<SALI[RJ?*K]E7;+4E\#MEY[JR,^D\( KA2MZHI2%Z(F@NL&.J?G$7Z@6!
MAEI8%8D:(L)X[<(:$N' \V*1Q[8DU*3#Y;85I56C?$ )Q]#<KVHA8-/OE5=(
M1!<[-F:.U;1;K%A7IGJ\]&C6Z.-74>/D(Z)O0\[T73I>FD<2YN5P:*D%N3<V
MC9^+Z!M%FK:2$B]LO:!7%G3"U3\?5*CQ2CB?#XNP)'C91^&3-3&S)\V07>8O
M'&ZS7?Q>)&/G&?NDFTH?FU_=H"JZJ?=H,2\5)XS%K+HT: *_4IS[IQ>66_8
M]&)X5&GW4(@VGSWE*(2O8GWITV(/UJ(U))%6J;>K$5M N\X[2-2,M)I'BBHJ
M0'E:0^2UX[:!RP)HQ'(TJE61]%6!I9-L%9)2SF56Q_(\$ZD]+;23(6P9U2DO
MC,H'F[*;2)O#[MYPD]8N6XHYV(65>L6<*ZN@7D&B-V\)UT%%J2IN]_6X:8I6
MW'W];$/)@MX\^H<37W76*;>BUE7)4<Z$\:RRT)DAI(=BRCAM)SEIB-W&WJH+
M5PJPP*[G%\3>07\Y//!Y/^V2[6K"VNZ.WH>=A]>)\Q?/=_S30O.*C)FJX',]
M>3[,;F/H"/%#K$R9%5R^24.=V1WB<%M7O#B2SC4Q'!S9'=:2[8L2PU=N$3G)
MYNJ1MZ5A_E&QD=_96#KG(<M-W;U'=F.7R:05<1N:<2HUF"4]@J9HMB)M)'BS
M'A_;*T][(Q4<1(>*IA@?A<EX:ZE8OG'(GN5H*)!DB8DB="$3XE-2.8)%Y_66
M+DQU\.8]I0RA]#)7<76C/*XO+A-TKW'.\NB%#5BH1^V+YJX*#@#H:!7$(DF@
M#G)!*.QDR7#VY2C#"#%6[X= ='O;7&'Q9)?!O6%K@NE5:H4BXDP?\0G%?-NL
M@)<3O7V8EQ(R..!'[[>J=,13Q@O">1O4($N8A1:;VM7>/8.'-,_>?]SL[$]N
M2Y@:.RAV>/_2I37>SNY!@0.EYB0RP5J8=G(VU9/TQ-8$PI-^]H2W#S;6!X13
MC IUQGC%!-3Q@_ODUKE#Z/']TT=YKX<-%\ I?6;A-=':=B"%JMJZA(<I*B=Q
MYC'/RM^O,KQ3LHD\T^;PI=V.I*BKZDCLJ97O,95R&<S.*:JVNO%JL4.>Z2S1
M W][]*%5(">S?H2=Z\"XIK9"GLEO@UE,,UY(?-KE5'"7C,NL\ABMJ,I=3=&2
M=P73::U3\.Q0>5M6RR3+:":QA^';V"##)73X5_8A4+,4-K5M,%\14/CUZ_-'
MJ=]^19E=?3UGRIWU<) MKR=QNWG/_0M'(\9G= ?]N:PPKAV5BV"_S<6*Q[F!
M)B+X8@KULB]:(Q'%^&GU'32>_V#\I'8G];,Z:L75\ZWH"6H&=HM?\\5%$72U
M39AO;%21[]/+4V?:K@7QZO/< Q<[X1-OZP,.,T^[DK6:G:_I2>B5H05AR*O[
MBU,"":4V5;F..!G#[6E*D5J^W&'WWA.M%(44'4I8 E5:K/P)EQR4)R2_H!Y=
MF2[[:=O]EHP_*J10HSP+DH(WA>YVS$QL'*+.6K/6Z;G9DUJCORMO?)A04G07
M/7V5J%L_NG>N9^9Q6=I=<"+OUJAH?I)LZ+%:I3L:->*CIG7\-%JU(5#$() A
M4#45Q/X=#ISG9QAA6_7X7'2,+C\^6*S&73GO>CE>/EI('[>C'B UOSH(7FQN
M'ER62M@B**:8Y]K93/X"J2BZHW7W=A6,6R$A$.[5.@C#.&-N*O0RWM:)]O"6
MKRZM*HOKY?>?VR $MYP5/@4 '/\LU9HD7:A;E=(I D9G=+.D08%_GW+YBXT;
MW>S5O^K++#D'TM/X6"'O$TF?!V,LA5E4&T196@/?5XNIQQVIWH2:RV"%\&!L
M20/"4)94Y/\?*7_0^T%IMWF$!=]"KY#@C0:T<\RE+O'^-;\[R PEL@[UG1-W
MF'.7[QA2IK4[U7YU D>+/$T@*<U'_R=T!L(['*JV4QS#8R_#(@,QZ]_.*)6@
M3U3L[0=DEDH\BFC@+UH<R4[%\:*@N%6,;]13>3+ @ U$X'(YFSMYB D5*CX1
MXCC[NH^5:?[0?_>.X<;GF995*@Y7^T?]$?$._L2<05?NR"!_B3IS#=7V=V(/
M'#R\VXF3:4<[^FMFZ>Y*6Q>]^,]X$[+O LN-;O:98<$VZ^_ETQ<\'#3@P*=@
M25)-\/93W-JV.6]8; 9=5HU7[""%KJXG'$B)7]_RPB:*7H8#>+H>GY5(^/LK
MN@C:_Y#&5Z@\JLO-N[+7"F7)H$F#LB 5:<MT.-916F99TW&:JEXMR(IX603)
MF#A6^:K?-3:.Q:W:U1O+KB_+]B0GCR$Q_ED8_!V)2$EUU'2<PW>0-[JS[J-]
MH&1H5W5!^)44.WCS4AT.-'=E%8Y5YU3D"PNGY^]89UA'+=0KL4BFFYHQ1 &=
MOA5?DW%^RFJ2)'RCV40[/M9\KY0]F+OU>'J6U9HJ&L5MU&\IV==O5%[?6NK;
MDRUIW*!E'>9PY?(4)0^3TV-^G#5T5/^'AS-QL^W);Z&6(X>%J2Z<T=T?K0'+
M[Y1A8C8-@Y\X4E[50\FR;7-7,)BK([JU4)^"7D*3)S:-XLT?;_,?T_T@D#L-
MU!)<M:)<NAV]]"(>(Z_%Q"7PJ7](\K(^;'K5FK[:^-%3%-&EXQ0OU^R@PL/D
M?HZEV.05+K$N4+62EC@L-LCLQPZW#2MCY5>7[DHY3GS.J@[^Y\T:@Y27*YE'
M"Q]R/#SM)#LV.EQ)];9F)'29R=I0YMPZ^-/4?[P>Z$R*AQK7UWSP[7(FJNB+
MJ:J)E.F1&T3Y'K*TRE?LZ&UK'5ZN+TW\G-X;*4)XDM9NN2YKO)!05]'ZC;63
M)<7!7<?2=U254?'[)Y9:(T;*D^S9ME8;5= %<[LKFF=VLRTWY*]DUGJ?;FA:
ME&M5EO6:0E=8&5 <-=[)45<D9EQ%C6HWU9?["Q$5AF,MF:I\MS=Z&Z*)JHN3
MG:T[I6AF1EKW^744^LQ.=K]I=<_AW.9,BLGRO*U"XP@S@9X252TIHUR\V5M[
M>89D.='A/NK5BW=E8UMG#?:#&E5A<AGJD2T.C%\=  (A4(">_\7$^CQ--51&
MJ1[_ UWU/+CMQK\H"35!7W/?EB%*T:F4\XU:W?IJLO. K6R;[AM8BM<N8W&T
M1<E;%=;0[Y1G6/6Q-Z=2T*T.X7=:UDG2A"K*QD1DUN)#) _7[08-G575'\C.
M?O04W>M*3/Y^EOIPZU^$P2>8[1OJ_C,2;VZ%N]\O4S5_IJ=\WQYVG^]6@WBQ
M>AOM:N2FUZM\EJGGUT)/,/:$H<#P\.<[A15:1@DGB3@'OI+DNE)GK5VNMN$"
M7<D'S!ONIJ)EI*K:4<C)$E3YJG^V;'CXE*ZQK9K.9Y3NB<?S&:S9[2BA9*3&
M'X>@O>/@-;XT.#!I#3[3TVP /.-JTA:O%+7(.T/:7W1M2%UJ0UR;?A2-MC4R
ME!]C?XL"S<_)MD_L7T; @<\--H.H6D_KG]%XS)G$7!8+3;P7<_QA(^]M]FYB
MC5+*>0I20G,@MINI6UIVU<1#. YVRVX;OCCQ-8K_L:VN);1\2)B533MZN'++
ME$_:)ZE$@'M(>_ DO<@MP<VB-#BX[(]&##UC5]3U?&CVP?D=*\?QA<?%8>=P
M*!SP/LZ,62$1J311ZM\^E$>:=R C\/RF<KI*T;"%K/!O=JW^;RBKATZ:0I[^
M@309>Q?P"' ETL16Z%TW^%$;U.JS0NIXGF\@(\V?,*<@O^,/A2I^I4.M[_XA
MIQ8]E.R?F6E<BY#Q(>#W<*0EXKL GC@X@0-+5) D[1S,\,I/IS73*4^H/'<3
M@.1_F5AJ4@ASH+:*F5&'ORAB&-QE"#MYY,4K1C5E&J<J0SRK\/W;04QS"DI4
M+>B$P"%.*7]4'6$10P2_Q:G3;-CK@VN^?!U?:H*B<()?81G//BV2AL3.N26E
M9Y,6/KR# RSWWSL9]C>09;<E"%3TIR>+B>@MB;O#3AXDFI5&-!P);52E5<N4
MZ\QH]Q+.&2CUG=\HH[GEP@':0A)8G3P<2)NIV$4^@8T<Z@_'+6R0:2O2TE(2
MH,>--TD\D!7%UV\]^O5AU3%0DY(\"LJ/5IPN"@<,CVZF/\DO/+<*3=2;@@,3
MN@+&/IH5HN 5ZX"1K9GE%TV=QM5JMW69>[T^/OFY4;P)_&'2."%/>V6>$[7;
M+E KZCD31O:(Q]9Y$<(!/8O%!:GM?0/6O+Q!R" ,=\.2[):H3\SDJ@N&ON:N
MKH6;=I5EQRGG<N_V)NZA8,78Y(&"&&@XOPJ+3(H5%3]"UJM5Q='-8B2T8EXL
MQ9%A,.:*#0<'T^7.FK8G0("(F3)V^TJ%Y==KY,#>E)C+BPP_H@]($I^03L(^
MSF1$_;W][,D"Q^CS8($@QD$=PLCPUAQ/1/U^=Z\#6<R" ^23:;FO>R?HU,>2
M#F"GC*:3[MB3FMJ#X%J'XWSR]G=]F:_CT9[CHS@&.;5%#K"=$UZ?*_UL2%BW
MN;T4W$Y6S'^R1?S<F;R55%_Z85 I[IQXO;.JX8)"4*).D40@RZ^W;QP6+,D$
MN_H/$W8!P!AX0*%UFWY2Z%.[9W)NZ?!E+5NS*D6=E6'%(HX8*!%2"XF\R^NC
M2#UTO4A,ZLOYTNX=-O_I0XB7EGPY=6L([G/%64_"GS#(1#;8S)%MUX(Y0>>R
M[J2H1=G9KUL&/4O:A?<KV0":DI?N@-.&>TFAH. 3?D(5Z>>I*BH&!!Q,]/[X
M3;'&UH;4H_8N^=:9 3.R(<^X(VO 28!+C";XCIY<Z>ZVZO[.X3@=AA_*#/.9
MA<$$KH;0.EZXWQ>\']Z;'KTJ2UG7092PUN#3@\7+XZ;.:!B^';W;81GEV>#7
MQ54)"MY_3PQ1.!S Z(R& ^+[< !"<6=3E+T\SX/-N:.][.H2]$TNLAJ!3U'2
MTE)+&:9FHYS>5\ TQ/YL*1(-7"68<]A1GSE2',015Y\X80AN[AH0.2?3A2T[
M<# &[DCCQI[0E>M\ZT;=3%$ 1H;)^4?2N&5*LO0>E7FFY\(XS]T\[K88@CU?
M[6@YG9.=Y>DRV%''??AU&_P,),Y-81Y]1^\G]D3&CZ4R67.!U*[(O$H[WG@&
M"=7[X^)"=F4Y=**?0\69@'-.0.AF[$P9C>F' ZKP M0TD)?)FD=# @[$V>FY
M1N9!NFVEX4#1"&2KLM#KS\3#BH&*)_-\AQ6!%?6TCJJY?TW@=Q[U_9I0A0/Y
MT7,0ETFQK(6=&:PL*A&?^5)0RLO:MZ]([IW-+@.\-%3&7((Y5(":+R0@-^GE
M^"U;5PUYW>P%2R)AH];9LMGUZ6]>[L%GH3K4N'R%!_X1%V6P@^=[S_0JFS&M
M6O-99IZ2KD%7*R#8<YXO]&>E\_58NBTI+$.\ JEL>3I9][^9#=_).UHRVXJ]
M$N!:LG)Q*# 8MJD@$Q'HOA5K?'F6\"3<P+:CDL:G3#+P!GR]_8:+ PX@\9Y=
M?<CN;.'#I)+IN0WBZ$$Y)HJGY[]XYFV[Y5JN2505<B?BXDA=^);BMFA6:5>W
MQ$CW]8^TVH"6[4H):]Z)-4$%D;0.0DMZ*"O!_TUW^3\B*5<X0.V,R+?\, TM
M23@0015_[T1DLPL3W43LC=U=7E$ '* 1X;I98T&^%D2]T20ZR,Q1RIYG;(B9
MN*16$W7B)J7B'LS=#+=9*.C74B\ICUKHW'\9>/S)]&D-*3.9^$<FOZ>!N>Z$
MK\SM.>EK;+^D1<E/&_7)HAZ@.@YP#Q:RCO&I0Y?CUA2)OF]P"="^_X7GZV#(
M(WC8;Q\J(E=5E=#7_8'^S2E#R"5*S5WNQ*K"%RE+].EFE4;!%JHN7>!-<B;%
M]NCK4WN/F/K$P*$:,E"@R,23JVCE;RJT@:29)'C(>H)6:W! S-8>?82NLEK;
M<$X2A^FZ5&@U(? )U2/)B1+&NK( TP^E<H9)M\IH':H3X#5,;SB@#[HFKT4#
M4%+S=+ON/CA =C_" 7J)QSJ0KH"F>R>C=;4Q8J/C90<$8_RU^MF?YP*:)$'X
M;XB5_=(L8ZZ=1+/XI,HW&9Q'*^PG9.K#AF>)*VX-\KI?#@6H:ALO^?G@9@+@
MMI,@ET\T>!KS..:<#[&>TX:K;.O&)OT(@I2F\^2ELG?RZK_/C2YW[)3HL!I"
MDB941I/Y%UF.'E$G1$P$PP&###@P;*?[MW7\(TWCT#F1LC[R-1OR'I=_R\%'
MH4[B*.T<"Q(R;)+27.L)_4GXG1)MR[<\PI]6HC?/L=OPX_8K_J2AA%<Z7U\M
MYW+(VSU1J:Z  UEOW;/7O-1T#PU+5:MJ7;2&+KV=>^" 7\)63J%8&82@Z7RN
M:XKQ2 "D=#*UUK\8X(JR;CBEU\+LF@Q\/LU.0?'0W?*,N[ F$SVLBOEXMYM>
M75Y99U"%)\L"!^R>%P2)LAJ3-B0.6MP[HW["[<U5P+687-'-#PH<0*"YZV^;
MS>^D^Y/+\O52;J[9P?3/CSJ;,." S+'=\$4<$5W1?7"[)N3X,*?-[>.5_6/T
M4T*(W4Y<T_%]6O^'\?TIP>P>YJ-R.%#,T]C >)S5@*@=?Z7Q+E)(@%T+MT\A
MDU:X9ZD"82NWP]O/X$"M#B3)NFVE@4EFEJ$?Y5(GH@A,'9O[8+^P^Q<)MQQX
M^IT-(UG72OB2OJ-R\H0ECZL1N?3EG8@ES;EBB>P=PP)M\+U[ "?NO5,,GVNY
MNC-G9_*(F&D3Z%2(Z^KEH1FHZ2CKY\<Q&0R8R^>NBR!8G<(X'1SP6KQ[4I06
MW/73>11FU+XVN<*$>-$XQ*?)X(#-.!QHS33Z0DWI<.WS!L%* AJI-<UKPT*Z
M@084%((.9UH7M5O2CO<HQ^K 33"DL&3^HUF$>H;3D$6[IH%L)2(K I]^TVXX
M,&NBF2(SLG9[8Y?H8ZQVSU9W9209?6C-G_+)6.7@\T%]'_<N^=NFG</]Q&V6
MW(F#:=A^N^S62DG&D6Q@QNW,"U"@[ F?02/(P_BDUBKD)B,$7$B]I1OO?@EI
M$5:AHP[+WK*>MXV% P'>:;CG=MXDM_'LK-G-_&;WFH4%+[SMZGAUQ=KB4DY]
M04>O2Z%KG_T/'M]K!;G^H=&KQ8'P*VG7:C@P=E5[YBW*-J;CCB,'$5@:J(2N
MR7Q8Z89M0B_A0)--TTC\+;AS.#Q:9Q3AYD41^'<YZP9MT\4;1N'75'9$/:C'
M:SX6PYD(EZQ.W_<5"G'.LBZ% W7<1AM6ZZ>X;S8:3PO3:KCVP\ED865M_ =B
MJL=6XDS'6)#=]\R.<.#M!O8]RYK)WIOUR_0_^*Y>.@SYWK;6_H0#CBBJD%9/
M CA0.%3Q!0XL5,&!W>$>FHMG>ZYC6DSBM%:[L%J*+<ABE<.VDM&79 IFM!,-
M\+Y>-2S&2?&G-WE*[T 6=#.Z2YPB.BL7(:7^$1S@5LL.KA=CGI]@AP-D$IF]
MMP3;KUPLQHE2J!LR%&'%:F4.&7TP/A.NO?7;>&6!$0FK,L:.PF%3J%74L^&Q
M>VP6FC.ZB( T* OP;Q R1?'5:0JLINHDKY;DSF^O:3<B/_I'U,(+*ATY4*SI
M5&75&S/LJHNWN.LL!HM6G1 %8*'(6^-HK&JR]0!;4NY[_^/22HQ'GT4=)W/O
M;!9GSIMN'K3 @0_@>QOQR4(X,,2)>_<0807E!TKXVHK>KF94I=T,;MPOE\6-
M:$Z6DJ>;NR;2Q<EB7<G,=<R>BF:IF\IYS)*2DJ[A%AK=&B+,)U$-/F)&V%/^
MHM]6$-;W$7Q^ F[UXXENG;00FM"Q*V-7Z72,(LT_8 C!2:^P>IXVZ%"<./42
M7X^;,=*3(S+LD^,Y6M9?!,G^OD1@XO=@K='X^XK52<(+YZ>5'.Z_(5_GJ(&M
MMR/#%8 )A)^$8T)NUIIZLW,*T[EUVRA\UB2R=QXH_JTF<FYDTF'67M7F=,MM
M\;@P^8A,BOWKJ>/B0BW;AJL@:L):J>$V"7E =8 F-K0@SW.^A3[Y^Q!:5H##
MA1VW6G<48# E30/DL+\69# MSW_2-CQ('!$Y2%AB%]GNV.O4FQ@VY"E6\GH2
MKZ$ M(W?G"\<9TV9]W/37QJP'M;/<'=\O17O[),\3!]!W\7]D.%#2<3T9IA$
M8;^X7MSPC[@7/$KK:T\HB<]Z+DE3']W\UB>;+++W#MZNV*<TT.:H#3*G_=1R
M\KYR-;4HZF]5MRO%[-G8_EZ!YJ)+9'G(J&4(R.:EQ^?)UW?)07!@S:8,$2TM
M8:856RCTU+3GHTW,Z7_[*GR_6FB^DS"68.8_\_ZD54=9+J0:47::">U*8)L?
MH^1J"CNJ/I6ACJ2?7)5^ >M_E Z8;(DS5)(\T'W8T7@1:O^4_UD.0\ZF6/BZ
MFO:N\F+/NBQ%$-)U/,T^*;H02$4"?[5=O-9][<SLSZ]S+Q_)@1F70.^OJ[&P
MG3+CA'"E<0[79^\XOJ:4]9J^#W$"9P(:75]\7 Y[MM]R\:'D];QY7PD'V.DT
MK)QW0R@G*LRS[T*C$(#F*V+_MU!T$?4J1E:E_[);/ZH3KJRR+0\$<^LT:=$<
MO^HRW;3Z+M\4FC.@,AW)]BZE/?HI>)D\"G1U.GYH<H9U.^9+Z!/=CI"]4T&A
M%P'>+/=6VM8[T[BU=IU<LSSWX K<'2Y#N95J5\9=M'XZ(&:2"/J1#B/0H5O9
ME6T*'BOP_KRI=Z:R3W<9OD'=:VO=E!3">VP?H?<V6O35-L-;<*9>L,%(UFW\
MD2\G^FG^(*$3EJA-VU#(N#RO 8]#DXF]4G'<,^EM\= '^46Y=PGWBMQS+4]_
M.<O @8.??!RF/<NOR*522M^"]T2X3OA([NCB$%F9^K)J"%(C<#7<]^H^&Q&C
M<6SZ/(H1^:%)VAABO(,/!W(FB[JROZ*H7( (I"_Y;#UETYO13]*GNS+B5V'/
M]RVJ/MZ!?RVF_10=)&SW_/SZJ_<S%-F+K ;033^6_"%EV\WPGI%,X]'%;A[$
M66"K &5%!&'BR2WW?-C2XEVN;#![_+U=Q1[XL%F:NC/;^*:?LV AK42M(^')
M.P=DD(P,:*10MFA;];[O"DS2=9KKDE7U,M,P>D;QD)<EA^!FQ.C<71E\6XJB
MAH;%@P%6B$N8&^:]((:R9#S]([HUG^7,+)#<#G4N:J!EI/FQB<=F*\)*6\>;
M%@*4SO(&EQNP81>19G# EQ"B,):6-*V@JO<,^XYJ>5O\(MKNBA,<JQ7=+$X6
M713W\7Z:$J*[S9+=S[G.5D$R8\GF2^WQ'I(?N *^9'8XSDH!K-ON-6"YB%PF
M>_>D("W,TQU4F3N' )'+&.9P0&-%S-HG=, :O$PPKG:O!#U_  =\I+3TI"GW
MQ,IO8;(,HB(K'G!@_*I6"G:?EK(K>V$4LGJ;<)_1=#B+=!?@6JXRT#:K6'H;
MV8,AZ@Y2[*<SNHSL.B$DNW,%Z8DA?AA\/N6;&)85B/ V.BBN7@O,716$P3Y8
M<]W&TT"$<;_4*X%N!C%JX(#3MM)94254*-[X(A*F<04'OO5 6O7RLF\.']F@
MW+>2AU^]5H 4'AV4IUP<INP:V!$:N.%X0+A6!EZ^EQC5NG<-R\8MNC7K8+D*
M7IY;WDP&7Z8Z'!7E ^?($5T4KM)@%>G5*2$$WGQR"P>6*/=\Q8Y^)?'Q@0YE
M5J^A/Y.YC_:2^&Q-SM]"A$>CE<KB[]]D8,/.C,<MCV"AS(LC!8F[R A,0+UE
M&&]Y__Z3$KY5J4^_[A]H!%%KD/],*$IAGFNL=,C(@Q2J0!YZ^-QL74 ^26AX
MBF(OUPAO.X9?ZGP^X?7^<5O\S-,BJ%/UA<E>\VBIF&V\PV=?"F:Z 0WPWASX
M:A2\;+B-"<OROH+,58,G@F6KG49AEG\ DUZ_G-MW#@R;%J)S9YN9SN C_\ZF
MG8I]&_"E/>1FW%EN:'W$57+$5CAVBYN2L<W^^:#^S=#( 3.IGKPONI0TH?JW
MOW3&3'9K ].SY_0:ZB0X$FDOVP^F$5#CHK"W:S+S.T<Y?Z%@=6RW=%"K)0HS
M0U@,DMF+VJC+EXI!S/+3\XWF(:D@[E7T9&%GK6FB25L6DRT9VV=M,*,+Y2E&
M+(8(Q8W*C5,!JFGZ8J%"!< $RO/CI8VZ"^F2VM:_Z(\6ZY#_'N+_;,%A_25@
M[])!KLD+$(D.L;BOB%HZW]OLP4V:4G4 @Q\%Y2K9O4V^U7+16Z6$5Q6YUJ*5
M:_6?TQ_O1]E^+[?]4J]6:S5AFU7WADVEBN'%NY9:.Y0*:ULMW>]> <WE-1[I
M@2PZZB](N1%(]R+UX<H0DV+U>%'$E-2[2>[VQYMS3N]>>R%W)M]0+KXEP3?
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MZV NAW)+:(1IH*0^?HIRGHH-#?16]$YJ=&%EZL*I"WS7]J/@\$JF?/&@'PY
M$N^LX, GVU>PO<7+ZZ9./W:C[: <?5W1$1#;@A*O=/G[ 6$"K^.$V/(^YKI;
M-3T92S$CRF1N]:9E\E%(G< ]S.$X!_>SRV#EIU.F@5_7AK;.@X;E2*D)_(GD
M/Q4%_8P)0UR!-=R!# /A?H=72U7A^^@P7;.$3#B ,9%X/]UT> H)!1V%6C?-
M)\(04/EJ"*WA=V?)_YV/WL/LI2M;#ZM:"YK%)D(K"JZKHRJ$#13O\KQLZ+K(
MTT+8_("+[+\E5VW=[,\'7 ?9<50O9C-6Q+;7 GND8H7$S^ND@>?65.V:O?%:
MR"LJW[OQF"!(:L/2@,7"O '%>6DY=_Z7E[]&L/R1FD%)KZQ]H[>#O)GH51-3
MAATGKU4\LZ6\=O9.NNC\ZU;L,G)W<"MTH*1+ ;2ADIT?;8I34W$L52;/<OGL
MZ*0;0@J<NO67CK#>BHG9JL$(#"A@D-6[\"OU^ DE\<RL0?*B/D^JC,$?DN@[
MME*F<,#%5QT)@2$?<H8B@.0Q3/:.!;$I\3((;'>%B-8PHMP22"V8C9_K4G9=
M@@QR%+6U> H'0&N0UO K>1>':\1+= )>UDTDN4T_2?^OBN/QB)<]F24Y^O@Q
MM'GU>"4*1+"-3#B?(ZE'&8,.^DR4[HZ;9"EJE5^S^@:DRAI'O+&H5!4H;;!-
MGF\V]@C(_5]:]._BHF$$/H11:#^(954&09DV>T8'X;TYNM/UND4_WNTTZL,,
M!Z\>+0VA&OW/K> _*8X5-^A,)60''^OH63)$87RJ:1X4:[FCJ>3*&!FDA3?'
M'IXL2(@$NF.H%;A#((MKT%'Z/WN.9E8';.LNY\][ $2^:55,APS>02+AP"/P
M,N-PTR8,W T' FS>_J%]:/#]\+4RFM'?051DI$)DN<M9*E;)B@^1WY.<%\^W
M9""M\;^Y] Q?XK351>5HWG5)JF87/9_W_[(_&QU%;]55P@$KZ<@!H<&3S+^R
M,FBJ<C8XNFF\C_] 3UV#&JU+\<=#4K&:?GNP[&]V*WSUARU5_GP T/<76820
MWRPW]J<Y_RO">L69A]7-=_!QYC;O6"&_&5XQ;UILOI[U49&FQYK0JM\T'^1_
MV:*_BXOP2)$VB<QY(9LS>*59](<CY85%6EQX>02^,8"9AW:)DC#X!OK1_CT-
M]=^QNE+Y^-MSS)6X>.5>8M%2/W<<K_LGLG_JK2$QW7/?6.7'\DG/T_>VRL*/
M]]]+M/UUXP$%HVRS/6P2/S9=Z=?0I\Z7'G=8Y:,I-Z_A1]CRG"K$>19A"="Q
M'"@S]*HQ?.A4W_SX\5#7Y@<>6PCP] ' \1N<('(X5&U%HF=UL\#X@D$1= D.
ME;<6T9\M* 3%O?8U:&E24=[11%'^\-CI<]AS.A*#OL@=D;!73(DF%Q@,DCO]
M#($R4W7JCZ=PQI#<?JM<'EU62?;VVD93=-.KSN*9?]>0YW.#DA:1#RB5\?S@
ML3<4\+9D)LN?Q/>\*&U+:C0E&LR2><)1'ESF:.,[^5AOENY30!K8 X*_69R=
M";P=_FW,0O/%S(FTHR/N])OYQVG(4\H=91^CAQP7*G:9+F5LZ[YE/68YQ;+L
M<YG[;.]ADOR\'] ?/=2$30Y@])P2T41XHE/BMQ#9Y%E7RK1.]O"@,P:_SZ_0
M$HMQ([+_YR[2#TB.O'$A;;DG3:B[/%UI"*[QZU=&!?U22G7UM4$C&XQ5X1LG
MACQ2 KEKEM0Q2/0[D46YV-#.O8&,LK"@3@GQJ_SS&!?!P'2BE5=LI=TCP@<,
MW'055O]T:IQ3Q.AAPD7)I G;,@:KJ8X)J"CR/J"+Q ^_''6*G,.7(!O>379*
MD[)FB,<Z:-1V;9X=.QC@UB5VE_=&X /C ,>A<^JT,MIAILJ'C UCC@,%][3W
M4YHPO)I5D.Y(2;D>A>#^>/!;RI(=>2$F/_;?YE.08IG*.3;-:RL]U.D%[7KG
MN'+00R[R-4G"/<(&D8+MGV+F0^A;\AYO*7GRAKJ*OC&@>@BE"EDZFW,>8.M,
MRJR(;2_K87AY /T*Y>)X)Q(9'2U!KOY;]:PRSB=X5N? MVJMG8PO'#EW#V2D
MJ'A[9\ASZ$N>8$P8]/6("0XXJNS4LNLF"/'T4!:2A?"4-),-*EB-VH=EQ7.Y
M4D:T U#FD*COQM\WXQ"%0/YO+0D4<U<H?^04&PMCT-X31M=S;^EO=N98IU\U
MJ/Q/1*(\$%# EFJ_;+:_SLQ,Y#4N.E_,>Y%*DA<UB[5+_94NIWB;)60;?KQ[
M7,2P?DXB,A3+=?LIF*M%WO:$16</#8_G)P+G$*3D9C<BF[_/)*=5)";/9]6^
M,<O(UT7,RA5C9L?$Z<YO*#_-E;N%MC3+J)R&_^@'W+[LTAW(8#6FKJGE?RB]
M]?V6U653[(GJF.&_V/>E)$YB#FTU>Q(Z>LKG5GMJGK ,'J4+^*%QC<P3NIDM
M(;]9 ;CJ3;XS:'-<PQJ9?&AF[5XY;Y9\(60<>.@<(X3=(*<?.72^6FBMLV@C
MJU/^N/R$H21K:_S1EY-OC*5//2_1_(3=HOA<95RQYI%$$Y1;ROQQ<'">A$_2
MXN_V.Q)B.XN0-OO;FO9.=;&L'MQN1)-'&^A+$\;S#W_CS/AE'1(AL^"(*)-2
M<7JAZR;U8X;;XJ,<<TY?E6?;(]]'4=4?"JZFZ)MF'>T/9#HZ+=I&28H6+W31
M?2_XMG_R(=PD 5@DT=R[13TF&>#_3-:OJ!^8G1WLHZA14UZ&R:/SI(U..HIA
M;B[\(G>R;)?XQE\OX]0.(Y",3)Z &\R_QWKCEHI3"5WA8AYW8&CPXQN2-ZE6
MHQX]B;VM%NP2[_H^EG>3R$9A6S<.Y;;_@N4CA24D!(+E 7LY13PKI]J!O$&9
M-2>:.M&#,^X$%&L#A,?A]C;.G#_MJ;6JOY.N5QE\2:%' PEMPX&=5)R"GX_D
M:9#&AC!H\)ZC1]A^'?T1!<;:B=NSIW[C&3A-N!GE&*X?KE 4FB=++A>MG]=Z
M45(@(JY:0"CN,5@\XB>\OUWEMCX[*;22E/Q,GT!OKK.LC&/ ?#1#/;A/!!/-
MGCO\):BS4-$Y3\G7;FR>P:&1.-RZV> SEF!SSV4JSD!$:9$ 'L\['J^$Y?T#
M5SF[ F.H8DR(1!J_B[WY .G3&27J*]+\Q_+>XL7(^@V32=2IGWNTPV/HJ4CY
MP86 &^_?<UQ1TT6XOSQKU]=4CA3[<+C3,7*WFR[)H4!G#I5..4OFC<1BA[\,
M1 %HDK:$V%M/?^'HK?JZPC>#J_H0])G*1BI?^\O+)NM7/RHO=\]2,<LUS7;=
M>J@2G]+OZSQ)!@#S*!O'?&WB1YS1C.ZXF8!^6I[>3IR6ZI?4:EGG[TC[FEO_
MUM#-_QIEO)D+<)*1X1%1':%<6BVV 3K$J4<+XP1TJ-$DT.# LT,\*63G17IP
M4'96@,VRN5X0PW75P7R$GN-;F/DP!"V="4KC\:.NUJ*-)P?I.=@#[0!]5R.N
M$R;$\:,"JF@KN(IA2L )M SXG(;%(/$U?D:?7CXM2I GTGRZ7$TKA9T.N[&)
MXT!>>*#$IJ/Z LSN=X+&C2@H]+9U8RO\.RCXUTQ*,%D?B:;Q".[6C_?=VBGM
MN97,*+&^&?PNQ7GBV,4<A@WHVC&A5?D3#%82FE.>2&%1CJENQ97):61&V^)M
M/)TC1D'*8[%SV%\=>Q3OF3DS7";8(KA)'3//,P)[LBB^]VP_:%AGBIC^'0VE
M+R^2&Q7_ FO<"[-:(:PD[YCIP67-N!5BU3YV<YSE /-[Z,G&J!H':'J]=AFO
MFL'8+$K,IJ$SQ9$7F+6.G!$^N)9B9NXSQJ5TI?,39K,_;Q8)?-B\66BAHV?4
MX5'ZBCV4PK-N^"M>T]/I#V?]*MPV3[<E&2NM$A:]#^<*Z];?XB\*=0 NTGXT
M!#Q>N+I(Z((TJQ^A&W&S>E'<="0@5M:-VG@RC4&Q4F=YJK 2?#/2;T1KEB@#
MKUJ"2#F]0]P(D4:12<WQ9',RB^Q%.$PQ5L-XU#_$LBW1E;@Q_-QYCNJ25V)H
M(_&L@^&0W9OD;0@90T04*1:.F.,LLI]P59Q@R89<;C+::LB0Q1<A*3HT% 9[
M,I2)DG-;D:"W=ONJ0X;<!E&OUZ5HNA@LK\*WE<43G>)?KO2\F:57>,-9$_LH
M@EYHLWJWBQ"IX>++^Q+F).K6=Q3O.GTK&)WZ,@TJ:N69$@*"Y0S'>% ?^#W2
MJD03;]A-*PU:*@UDI7!. [H6_)C_5]V?&4A1T&5!X310\\G,_$6[*F^I;L)F
M1V.)_G'D1XJN!R=G).WI"Y&YI&83#>7O7O<[$PD81?0G&T$,4G><J>$3D7:I
MTC,_9=#XEUBVMV]P>_U8#&U!%@W0:;NUB-K\J/149L+N<VN9;Q=!:4J"OTS5
M)>68&7"F]W4=4%5YGK6']/1&I>[?*-LMLW2;2A:XXY<;I^@"@R/G2E5D&^\9
M:,W>8'?.A3GY5JANJC7 .@2(?P5:U)P,149HN8%C[8(]4.U( \5"GFI9M1"F
MD<;QA<A\(*%09VF^44870 ^R\#Q@Y+8/\*>PNHB8:N%(Z89IO+OZQ,)#84K#
M4:+GSEB)OGTF6&A16>48Z,\C-J2:Z*&P_[2K:M2JZR6$DP6%!$; 8\K.\:Z[
M8 3-IX'"@6Q7;<'PI4-'[;RL->G'_H7=),3KI_0\S+?"8E6NM/:D/0*[Y'M>
M,<H)D8V>A\4CQB"&1TX_8BC)@2YJFE^E+R+(%);H/_K=[1_"@<E\8=_BB]M<
M.N(1NJ)W:Y3FE)3CRW: TPIIFP##/AGO>B!#9(;<L 'L] &0DIN*XR5FL[.P
M/+)6$'9 S*=:A\%5CM<<Q3V'KY8=A-)':3JB*7B_,?S]?8<'?;&4KM/VA#,R
M]0+X6ULE(78[9<C-6)/%1^X4)M&N2W&5DWLQ%A2^<_G,H2(',^G0.'H&#^,N
MTN[N/9^\A!VOS *HY:=Z:88(]-8:C4?RJV(]A>=5 43C)J$: ]H/ (&)[\/I
M]VMJ+91A73FI6%K'> 2]06\'PZN=0[MHJ)MTM28S0S/F+4]DH[3EIYZJW21,
M$$\L!V/0SWDEI3-]-_FRR4T[:!3CO.#WS)6BYD=3%10S@$<(M'7K57S,+;12
MNC9^#BKM9U=K'5P3[5" Y,TLV5TR6!8[&E#,Z"GR]#/6*[&=N4G(W5E+EZ/\
M:N>&G1[>I6_<W RAO4[,4W+.[2&\C=7)4'_)B3;15>1S3;5K__5G>VEY/L%#
MBL!WZ<P[UG^=[/X?)B3X]/\!4$L#!!0    ( -T[8E;/F2I2&KT  * F 0 3
M    :6UG,C0S-34Q-C,Y7S(P+FIP9^R<=51<79>G+^XNP2%0"01W+2P$"P$"
MP3TXP=T]N$. !-< P5V#4UB0X.ZNA00*']YO]?1,OR/=/;-6O]_7G<MZ^*<N
M1>TZ9Y_]V_N>LQ]F'E8 W-=2LE( '#P P#W^  _S@ 2 BHR,@HR$BH*"@H:&
MBHY)B(6)@8%)BD^ 0TA)1DU%249!00-BI:>A9::CH&#@>\',SL'-S4U-+R#,
MSPEFY>+F_.--X-#0T# Q,$FPL$@XGU(\Y?QW7P_M !XJPA&R,@(<+0"/!X>
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M<UU3#SFG)MY=(OFRW3!QG!_-DC10PC)8@;:%WT6ZF(:9YA@MY8D.,)3I]XB
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M&#.!(N=K\*"9L\A[]6'W]-C;@C+452GASL[KY7?CI>4'&V<L-CFRV=YY-E)
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M /,S[>(OAFM2=:BJVDV;GXVC8<."SHA8BPC=*69AUF3>@@X0,)JA\]P)/E>
M*$=<K)V=P@M^6:8:[$_K5*8U/(5E<CJPN-5%]#4Y"_JDK:T7X$;:NC>'_-M;
MAH3KV4 \#LG*VF4(V"@7EJVA\7K?+N+[X99N67&:660PI8"R?5P:03@%*/$
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MZZ"51%T)._M8CU-1068A(9WJQ[^CR:FN731=[KKFODZ?<.C'%))@IB$6^LP
MD:'4<,V3]Y2_AU1/VM@\WM4<!8HJR].X/SU"E^4?%C*K+!@X=/@$FASC+LP)
M?Q7T5V>)_QGXMV6ZAK#B;CPWRY<I5U>?[H\6>9.P7B 6"O.O)/2M4,&^/KJU
M?41"%?4:-?[N$FF5=NJEH6Y=+Z;!D]C+=I"=4$+OFAC8Z@$@X?[5'&5]7OR%
M)1K<#XI3FLZPRZ4YN1\=J=<Z+=[?3W]]H3W8GV(9INW8[$Q_C=WN!%\\;65W
M(K<D_-J-X=GQAQ'OT5::':U?\UH]H+IJ^TJ;SH(460AA,$W:>G0!V"S-F>=T
MR%.]R_:);.FLR!=?+ME";=9-%SWC"/_XQ1F"P#1CO(F-*57ST^+N+KR@#9W1
MF6.F!%CR8R;T "@_ !XX=Q2)4^KT)VSWLO?Y]^?4UP),9+YDOP3,'P!\D<)N
MJ$WM:F$KI;:FY9-K2\2S%$NY$&FCL/20HV%98522_G6B0?,G?()F0;?O2W;1
MK6NNJ(0L#:[.Z!:?(Z-:%=.^%M@&1?N\RXAIOT>!'E6O8C#=W""G;*DE>]Y]
M51U^YDS!!#>*OG<KOSK1"E4]BLKO(&I]"\;M# _7U)$AQ 86I+CF!4K3UO*F
M7<N7G)MB(Q<\O]O6;9EUWCT7%NV +KHS)S\9'NO3%7LFSNAGG]XL]G[Z.%YP
MHDX/PYJM=WE>RSCI(L5RGC!IBK]]D +K6Q90?)IK)K" 8UKB&]S*/,9RRY#B
M_>NN]%-=E<ARS1N"(6G#U> #[!(I./YV>E(B;[!UX8=6YI3>KKJW>X+6I<TU
MIW=CITC>V2"6&B9V2<3 S,^1A4-O/EWEO5I7GU-8'A.@QMPC7L8&RWE_W5?#
MU(3&Z>>8*C*Y(%CWW\U2<\S'H](<T2#MUPRRH;G%]'!8SK'F&;;5/<M Q3,\
M$SQRC1JW7]RR9CO?IHWB@NA1GPBG=U.!:L=+GM=E4AM/&*N1(I"'?/[&A] H
M Y$2V&.*F3ATLJ2FW,&#<;3L>G6[(SXQU1@9&7=C[MK$:2O$"(QN;!;@\Z9>
M,1]/=95_O4S;<W=7]N4$HCT_.T5N_CC77!X B3M9,"  6GEW*_Q-&[:^QMXX
MR0K"FR-.EJ_M4T72P,49NH0BQ'(U%&TP^GVP]'@CN WYPKT?&&J207OGKEJO
MSM2!:/Q"9SMRN]9)%/=<_T#_X $@W*F0M!7)I 45D\R4I#&:(=KQ1_IQJIZD
ML;RSE)S,28UIIBICNKY*O.<(>^/!8-H@1WL:IL7#3%21JL )Y]UJ"D<GRD>7
MLE?KYL5![W^DFUME3<:0YS:4 U$EWR*-@+U*#4.XRU4%RZTIXHRLI%K>O9[:
M.I.;T'S2[Q>UVNC%2V%0]!(5I;#',=Y-NET+$7<_63"O'HHU@LG"S<GR\UW4
M-R)Q+WQ.KIAC^Y0A2\+T<\[HBO#$R=2KY'O<#Z7.6;H6\1RFU9\$<9%'XXU7
MJ/*.-7%$<C.Z:J9KW6HHL8_??7%E:3)Y![(UM"N.Q>;LQER/W&K4_WC]*L7U
M8]2/$UI93[;/434A'$CHC7V[L3\$(T4\4S+7HM.?/0"!>N:7!":".I]4%AOM
ME%K]4)@5<^YIC1.*;3ZJ*"71+K(:^EK<OKKO>XR@!2/C(AT;W@4'0J*;2<O?
M(\T*1F*X1):[M+7:(EA96TEDUUB8OZ=W66$T,'VRY9=:,<:57NJ@^XH-]W57
M[_E/ Y@E0K^CF8.UTT:PMJR)*AM-: Q#T=$\"3:V-!UMPZ+@E*6O_W5+?'F_
M\+G#JUEJP;"G+[U;C=^/Y)OGI$YJOU,EHB^QMGBV9]ZUIDB])T(A[S-K_;2B
MZJ/L\\/(2T_^V+@9^$@9<GY^I&@LUWN2$\KZ<&[GMGJIJ,26QAP;KT8 ,?*2
MA"9PQY/"/^$!X':\WWP [NK+^#JHJ+Y/M]"Q5T[;<A>]GS >%!NJ$S.,"$8?
MD"4A$5BGCW9+R@4M31D/L*=I6TC]V&U]$?7>BV][1H]9T ,K^:<9#H.KY%OL
M\5Z6N+A8^Y'7PS KGGTVG'0I]ZGUEW*>P?65_@B*6VAH_.12LD^A?-0MHBB6
M>H23->7PEKN.98N66+02C&&#."\,$SSC&N=A[NO4KM\UH<'?YEP[GWRO46EH
MJ(K>C#0(K/P8O<S?MP)/$KE-R2DS.#X[:UEX?@&NK)Y:GKY*7!'%KSWF>EO;
M6/_S<,.!MKHQ$D62PI?PS7(81$$&P-/6Q_'2I@_GMD!:6JZ?2]1\'>D>WK7I
MP.&G0((K5 2&1[*;\PTYS\3=45SS)8:E6%6WN"WY=:M4OCA#[J?;4E'506@7
M(,J%&D/,IB,9U6AI&$HZPB,'_60 ?&$QTG/";:*^VY:VXD0UO L'E_F!Y1CE
MLJBU$0K8U\ZE<2FW^Y_ .W>/D^X\KI94-[#5W).CKP=%MZ[..'ANR=TB]*T_
MP4P\I25JU/LVFR]=^84T'93\KL( Z^U!$"]_[LKT;3B?[Z];WW,5U8&:\1A*
MRWH/JJ("<_Q>[MB^N:"Y-4-CZTV^IRN?,*6%9%=65H3H>>.U"->?*,M*6EQ?
MWF&)8C7+K2^^4SY1W2CZ9EZW.4&;R9+[RCCNI%[(;F %JY$3'X7_B<$)6Q18
MTU'X.'BEKF[<&F10)-(Y'DMX99N6WHWKHYME0^<CQL,;M-IL.@J68RDK-RFU
M3(DJB6#2:C$Q<B>*'A5?=TSHG\.>7#%L]$5QD^ALI?N9U]@Z<<1R_/Z,:HV#
MF0'1".4'W*?TSR9(,7;FE[KSNYO7"!O6_>=5\^>\Q[=*I6X)G5I3:5AEF<46
MG>\*I5#G>1HTB27%7-/;_;"Q!7&[7!!%T:UKMUT:ZK[[<W,WV3M:M=NZGB8C
M>GWI?7$KD;T^I8\-<Y7,&.Q^ *!1Z<IKQM69BM*-YBUA7SH> +4! /PM+9[?
MP',JIF-VS1?[ QYSJ+'VV";<54"-18#TX]R]HGX-&OL8_[)PG<Q!27]<:.CE
MA3"??%/;%]V<NJ M.S]BQJR$R,NUEF.921]:6$ _S_SS,?P)%)5J$QH=HC[Z
MM%A78\RFR,*^7OJ6Z?+#FB'TT]/3,>UFC?6[<SPIBBHJ<D891$!68!V8_CP+
MDY:;,&B8NJ5;2QY/-&#CYI117=E(CY<I(278['W:>G103Y3(73+/GI4[L) \
M5)R.W5RFKW_+V-36/'[?ZU5*X2CN:)&(M4W3)ZN.B"M.06%&"E*G7']?-K1R
MB']ZY"F>TT+<R>2&2Q>&U?@L%,/_U@")!JX^?-06[X,>+4RB9+!H2S:K,9A#
M9%)WI9_ P#_FL]E-ED'YNY142$4_6\<(-K=]<XG]/%>B\LM FP&T<U(#D3R/
MJ5&=4C:NK_$;%MJ'HGT[ZEK3+919BTMN=7O3;UWBE/NMI4@7@I^1'*AB! W;
M*2[MMY?$'&:&QNU20Q.,WB1U:H"/JQ[3M'?$BTNFG#CB:;9&9]Y+G2,]-9;+
M*+.Z<S+CVA%!7KW!D<5T2 [VXR# ,;"M$<*Q">7SRQW-U-1U.=*6?!>5($::
M:7/,#!]X^=$7K:,H/*HQ9;EO."4P_%-2Z<5]B8=-8'%/N;E+2AI3K=F;*N/T
M:&Q2![%A$KPTQ\BI*(=[N/&:&VI,4)/!!/'2J50#_"U#0BPA]2<C1!JZ,O$1
MCSVF#-D7W-&"82]J L(9BFC^.1_YS;\;II%[W@>@_^FT[^'R _":KESLSP5^
M/V'XEK9UBBK4&K? BJ@44V.4 *EV-*I<^C.>/:+N6X71O,D6_GJ7DV)%@R$F
M?)B(VG(F9=BJHO"G]=%=R7SNV5:RUSSOS$)^2A+M9,RH:T*G-.E.%@-RJTHB
M&!M0X$*2>E$FC!%^P3<*GMM^O"9,)BMI6J@LJJ]3"W_.-I(B-@P<$&:T+9&,
MF'\;"VR,II553APQ^);R-=FL9'=L1K]K6UNNWL/69!CU_4"LA[_:3CF/$!6M
MM5#.U^3\V9TY)S5BW"O>GS8SJ;.5\1JGW1EYDTT,V<V!ULW5J9->2*M#AIME
M-MPG% <=&3*4N<MG-D(!:?@+ 3.+@1.XJ.-CW)1LXO7LNTE*VL7>%SK)/K+D
MGS=32?G[^0^UN%4%9(MYWQ7QEBR%")>ZT8E-'QDW?:^F/7HU8Q:N)D5"@N7G
M$B^L0>7G@,SH3=^IA1VZ)B\J%R"0&,$\\@6D$TDAA-]N5,&_<9TREQ/MKC6-
M8R'DL"Q!=X\717V/3WUX7$5]"-X>/M._214Y<KE;$E2+6BSAFW*<T_D*HX_*
MB>.4VGP?P"E 0982KFZEH.S2/--7#X7$6&</YO2:*Z2_>)85KQZ+F0;5B&\Y
MZR !1[N76-H&BQ#7M7IF5O0S,$?&#G)Q6]3/"QAXAC +V?&7=89_<-!]K6I:
M;OH+W;A2VAZCB]L"I/Q"6OJMZB>H.$IAP4]E4P?\6TYHS5S$8NTG?U(9WETN
MT/NPX14X1 \#RH9#7:R+J((]0?&Q,FN5&2+5T[>?V]'%W_+&^:%2"C/^(E)P
M\*Q:E&W6/7AW/UAU#[GO._4=]1FYL&6R?P#4ZVT6MH7YAQV5S.>(4U=OI&O'
M#G_@M@2KO:,3T?#C2@*=*UVI11&673SA+K6,3&(X>NIF&@4*EV38V4.ORD"E
M^44T9-&&<RN:9UFQ-\5[)LG-\4GFQX\^M#Z6,Y/J "FN&*LS74G"%SPY[TD'
M7N1="DA USL+E+67#VHQT8QPXUJ^@@(XOT"04>=$=/!1P4:6"J-.B\]/KX\@
M\P,9UXJ<JRT0Z\,D@0X0MF:34:GY3_EA11<^90<UZR]SK(%?81Y#A]S-MK0H
ML7V#6UR;%<@.W1GAHHRG+YY6_3SZA0;VS?[@.NV@<]L4B2_8\US]*+#Q"0DI
MR38*B6Y#N4W.-R(*[;9WKYT7M&VUK_8O,T2S=W&7W=:E)\!<.7M-JA]EMX;L
M/8+BIE&.;$"4 RX;'#>S@'7_$0];2"OII#-R:^-XWY>-LV>GFTZ:V*@;"/[]
MBW$!,ANGCA-*K[[U-Y?"NX7U+YHKC3EYB[ZL)/:PKNI 7ML49]:,498%)8PZ
M> ""Z.W46+="5&VVQ1*(%2WX:&I+?-W:'7U61G0H%"\P3J,YTG[5J!3U6_V8
ME/TZY_F__?('EV[YH/F_YA9$DBK9K3X%2$616$-XB^"D)4Y7-IPWMHMS@N@I
M/^<*2*RZ<&Y"CQ)8_;AYJY6^^N7V29GL=/CW"0ROQCO&>VSS<*?P9K*&<KNS
MJ)Z?H'<^-53 $\,8=HSS#TP+X$J;W'OAR+Z=[)@^ZD60Y^:T)V=>U8^=[<_\
M!$D7/FJ981WTON\J['GA ]!9#DU.&Z,4E%)[FXTUT4#IX-@,WG#F7S' =IQ1
M4CU\YKE0;JU\N?5>DE"%]'<-Z#^D_D,(MY7!!-.E')3US"(*-S5UK7'II!*4
M[AUP$*02V,LR; @#PZU]/GH:5!,F-]ALH8GWR<#XR,"N=99.N'B'D<EM.DTU
MNM"(45+;L1<L"BU^V]2P7,8W<YA,-Q@N::&Q8H1H(K:]<!+IF/*KF9S<FG>
M28A?C=PM^0/M.<)UQL:OYR5*FL-Y!8V)6N/?[E9RPE?OF3Z\V[W'FL6PUFX.
M"E!&0S&=<D#&\?XLL!(@[:$4PR638N<8'[[WJ((Z+58S:^]2;URZ?$:X7#/
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M,"K.NHQ77FR<^7?TIGN)0R&)J^48%O@6;\D]"UFG.)Q*P[0W7!9^<"0TBJ/
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M:TI5U?9\SWW5R6M_^:K!N_2G!&4(C?>"O9KHZE/8]@/PTC3D ?!-?M2H# _
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MZ.Q9,QJY*)]0&+KB8#,"O)_P<%=W"FO!-SV+),'\O,L+!>6UQ6=(HU&-ZT5
M!6(T7!\X #G?3;0GG07,=R+4X7$9<E"WYUIO5:4]WS0?D8S_M,, 98@^;>#'
M;!_$<WOICR#Y*%U@NFTXHCOO'_4*4\P]W^-44CTN/S@?%&!C.UJIJ8TAW\H0
M)V.506!V(P7A0!I\_^7M>O8GY6OT05ZZ*_-"6#BJ-[H3'@%O^B_<C3I1-Q W
M)[!+1 6!:ZKP[5NTQR3FK$O_ KWV ?@IIXOT>X;_ _"X$)YC4!/"?,XD)Y(D
M+)S\]0>M2_)P!]JO@X&SN%Z::*:N9S"B]0@LJ>Y=/8;*C&FY3_(%J?6)7LE]
M#J^T==6W25?25@AV]9)/'"&N2ZA0I;9QNL@EG066/.4V6OR!H38;]FY$?I3(
M6 6QCK,;Q4"JYR=FP27TTZTTBS_H)1N)?VA=@$"4^3J#M=%3>\@"_" ',4$<
MQ%O:B9(6<9306\LRV9(/239(*>Y#X ]9O!C<Q0VQ/S3%(&.-_2-4C7K4V3XC
MU#,93\=Y;&&OO8XK%GL<-WW-#I<KNZQ'/MNG&?'S'#UJB<<L!P^,9P8]UHF
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M@1GE9M#"$Y<J,^-1&9!4!\UJ" HB'NPM4OCO$LO?)0B9)P41S+=$JYZE'T[
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MJ#%(@_<>7";LS^E<J34O7]Y1SJI%(H\7R)(:T'=V4L1A"_]9Q&.BLJ&CN'*
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MO /[-\/<_4#MC[\9[#YW3X/E,H1_WD3K@DOI77LJ)Q3_1RD^#,SY&8-"6O3
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M9$=+!#K2$9^R"AUU#UDH2; "\>\\EO#*29R&XOS[F,&T90S>L8]C,H.S+9T
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MP^I-C(T7R")M,/SY&]H*Y3V[S$;%&6^^/MM]5]YK+:")B7\B@RE&-YAOGPH
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MQH,R;'/]*,)\ :CPUO.7.?GM,P\S":L1]JJXX'KW'3Z5\QG".:"2QVV"=:5
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M9+0! T2P@7YO:)!SKQDJ ?-G(C'GQ<]KMRR'[V_XD+/B6A'$U*UD&<"LL!=
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M*ZHM;P\KM/?8Q?GLD(($O%1L(M/J:,=> )20L[73H/UM!BCDUC_+U=WGE&L
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MIDKKH*U.3\GKF.)R)@=(<$8/@=-:NQG!N1D5X7)^'Q'2Q]7+&2B%@:N@OHC
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M2JB(Y;P9#H+$6-G2P<1#0YL11:U^C1UUR9>><\57&S;D2VW+!WS)7KAR&%\
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MY["<U@=@]P.H/QGJ\P"\N(&KK($NQGYBLB!-/P#;BOZ/S_OD]P P.TI!]VG
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M^\Z4 G!2RJ@/\XW6?C/GG.ES'0CEKB=D3,NX["ZD8K\C9T7[P&Q\I\J6RY3
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MD$%YF[<4LB!&ULEYHV@V[(X9*-A+N<+WSN)BQ"Y[G*=K)MFE]NREJ4F> +P
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MUENX[7+YO(B+O''R\-@,8Y%)-N (J-C7Q6M\^\'D%/'P(_/[^XX8O#B![>F
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M]%8^F(4(GDS%U1!%N[$.BP)&!99I7\@1:\=57Z'I8#8>^XT).XS)[?G-N;'
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MF1,/-TW6I4H6+J(4/^?HIWY7W&NPK]BAL/QCMW, DG6<-(Z;>UK\\J3M_;U
MR75(6<F"3HW<>LQ(C\^W$G-MDW=Y;T#-R!G6Y\5I!=WVK,OM[-=92G+'$[^2
M402'USQIF^JMZ.-AXE\Q, O&L6=7K&#IQ=^+C66]G*A./^2=U:J;)%?P<2T4
M3V#75&G8<*>0EH7*G6TEO-;NFF?Y$E^T0^@[DV1'E^YH=<*6A+4:NJG"CDK0
MZ)UF-V=HZ,X@+#()/BXO*+C'&LV_7BTI/]@T/T6=E0J]TV_$_<Q=F&<I ['+
M"V"LV+X^XUJJQ+LLF\C2F&"%6NA<;=J/M,E2J8\+#1ZNR=324F$GL'@O+6.F
MG.^AA]:^C.IIO=H2&U1"ND7".'^T=#6R& 2V#%T3F,YX/^\R3L^O&M\+GU:0
M_S JBC-V#Q8+?T/37-N8KOGPPTYG0YEJE%T.R?2MM1UBGAG758P$=,1N5*&=
MV^V/HZ@3O]M$HZ.E-)USDE>7C4VZ%) 1,K1.:TI;KD[> E]J)+?D62-Y:DDJ
M+.K(<U#P4HOQZB/02T+4>UNB]QK7XS+M6TW,VA$BN5EM);<<U2NJV,8!:FAJ
M0$F<.@CF ?N:Z?.U6+=B^=RBD:*GUB_AI@_244C%GUTI '(!5/;FDV;B3'#Q
MB;;T(Q"23Q:ST=24I?&^(107_2"LV4@=98V#B77"*9I"Q0L@-E72H,G3#"L6
M)DY0C=12ZN').B3)^YUSA/2;2+,JR7W.C4DC=*[ KDA5 1,JAE\],QL9TQG"
M FZK_A!<4^RS^\:RI8FWL(K9:9Z+ITN1+I$FEOC-<H<54V"0$P+M86R'"&UO
M=["^H8Q:7._7X9)NLV."(*'PTB5$)UX'QD&*-[C\)@CM?<*/P#WG<6B*;(I2
MK/JT:8TNA0_]=/:"!67*L)0FAWV< _1OI[@54":#WWIIO[&ZSV*TOZTC2NUG
M^TBF7^/IKQNGZ*;2J"+?!CDCO>SC2F:+CU.F 48.(@5G#_E6TY51:RX_P3[D
M%Y+5D$^NUE@EX]5%6R0.P(.PY4AUL.+6"0K3+PU..O6Z;>:_E)TB'%.EZNG$
M9M9Q(2YX'-4S,!9_-D#7@-*Q(-)>KHJ)]2^8_SY_68>R(;UKT58'0=A*$WJO
MD4:K&3FH0<G=+JGV8@-=CK9MKGQJ_+<43\..*-+LQJG,>S=#(YWWF+:X*C^Y
MY5W0FVTWH!>AG/4;<))66U#1D'<$'1)LS^0<3>UQ2A098%-57T)U 8CM!\!H
MOJVS 6?-A7#J.^44TRE5*<J7?P\!8"R1V6U#EE))V@4,9D*P0:/^WX7@4Z]@
MWWT037[ .^V-K6;:W:K5FDJ[7+Y[I1;*DTJ]@7^8I+LI<-'>PQ6<=O<FT%CX
M87P):8J;1&MT#>^#_18?.]M<C:=;O8;1DGX</!;Z:U/QC< ,\TRFG$BE$U]_
MKHD..;F!R#N%TQW3G;@YNS37'\9!]FP4Z J;W[1E#-RH*'302P17UD68QIJ)
MUDC49KNO_ BF:F3=ZS]_BSEBN@R3$$RVSQ& DW61$4HA??_B-)I,-[#4O*TR
MR>&B:$[=O3EJ%[O)XT:UR3+?37%H T 4S@#I>S>_?6"HJ_S(+3:OA=7K;%W$
MS$3]C9/W, ]=B>LJD=AGYG);R]J1L:2!+O<^]8)G,X,P)&^F3J77V9XS$<(
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ME0(\>?!-)IQV*9<F[QW$.0"!?#UMI.HZ?E7[#CU+K\'LL(!Y7 HY/W&TO@^
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M6#'&N5;O]+Z*4)>=JG$DOO;O$9LW,L"EI9YFB6"&69".C"Z'2;5OBMEXDQ#
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MU_3FYN:$'9^<NDZOZU23AD1?]A]( .MK$4S)FCT!0%/B3UI4IN5?Q("Q(4/
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MTRWR%C%=1=# 00@=)H1AZIS"6H>4WY="V7Q&DET#+950=BTNU X46+#5&,\
M*G7]_%*_L&/XN1FK^<[N2S.H_<O;G8AO%HJZ<QO"]%FC:=_A$@_J=#4<G;CR
M@B:(YWS^HYDI@*,#^].*R@#[@.\=@OVY]@0?]1J&H:G_NK%9:OU=A KQ'D;]
M<>WU"U.S90RMZR+[+:+(]0W#C"_(6"43K4+2DTJV3M/.+C^K*+\.4^+"9B5
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MTR<ZV@M9PC!XVR%V9Y2R'(BSY5!2F'8I=''18?JL+*ZU?*;N0C#.(E=V@T9
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M'&Q/QDLYLZH$%F(3:A>8?4RRK!/B,G=VXK6U$F)X K[-4W:2/ YU#B=3BU"
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M!URE[<E<7JAV\\YQ#=*IDZ,IR2B@'2D8H+;SX3C[>DE3R4%GQ@AML3D!)0;
M)Q ND,ZTQP S[3/H"@A"2#4QAO>-1[-V38<Q\?2ER<Q1I_,+D8^7NKA+\V].
M05'/=B:VAY0/">%FNAI[PRW/T#PU8(*1R7^\_2$,>P9!L"WKHB<Q0$^ 8Q+S
M>E-LMMZR_MMHBU"1P&;JJ)&JNF<LX!70[^2'A-IB;Z&M#"WH<@Y$7NI(8)#=
MI1N]']:0=%:IP=&WA'/YSD!;"UVWC1?T2P)FR/=I>6MS4,MI&ZQ+WD[;8MRR
M&"#R0M"A5PL&2 ZNTBB&[F/K0.'54"1A3DG,U^FX;R E2OV0*V#5;O:5131A
M@N9!?BL)>4I69C)A6%[570XKUJNG< /PI_8&BE4ESG@>=T>=$S,)/"=M"$)\
M'(1A)?2\8=Z)V0V[N25D6@3]#J2Q[J)5KS3-/6I5:9Q+Q]VN?.T4M'4B&[Q!
M"!W[9>@1+,R3KU6';ZI.>S_ 0SH"%6'$ 6;UGVJ,JE-;T+(%I\$+373[AY/R
M6:R1OIECH$]S<JY),R]BUS7 ]LD>Q:-K93=MMK@V)X(@"(8-OD/OB/G!18UL
M;YE'?_.%>BN6%2$($NFP8KCJJ$> [%1&U[Y&#NU!_:%L'8T8@!;6C;@&6CDE
M@%I5HO4$1//53^"WXS1*EQP/O4;%V+V'@*$KRA %E]:542$3.^/*2T9Y'AC@
MK#HH[36TYIPX$4A,7NC1MD,ND_6BP334)<^"@<7,U& )&K()E(<!%,Z!EGEW
M#'""/9<[,  )!IB5+075_X !%F6J&&9JZ3! :X0=!C T!T$4YB8D)'[1_%=H
M^QF6\H.F"5#/D+"#)QA BJ;;F@6!#X:.?")4C@Z*P! RB0(/KU*KRF&_KS;!
M *Q-\$'H&_LANE#(K$XELF S.Z(Q)'VC96 KCP4M$<>RO<:"]N=:5>L%Y20"
MKS?: .5DS1]2=@[6!U/S2X2<F?:S.@_F8SOP;EO<%)D\-;[=*GOA>YXSZ29@
MXB\=JB#N=BNROE8]-%*"8ROYU-"_F8.7Y\#V61R@*V.0R/RAXY/$:XBM0]66
MT .6:>,807 1WX.F>/RB6A@#L/GF8  #.%+;S,#]1.XMJMQ<0S?+0[<^D8/Z
M= QC1@5&JF;@??#G&&#E?>[2MVYM\N)#B(9]KS0U-;5[:O@6EO%4-RJP6A$#
M&+/MEWC2>*R=0*"F.)NH\@9+!X+X&-7NE%_&.;3( &]1.K3UAM1#HN:FH2'*
M"_N,8%&B A:^R??/XH#>:SYQZ%V&H!F$7YJ$[.,;@@)U@.YD:/X<S1/DCP'<
MGY,MH#R408U&][5?['&@I=<.'#BV"K3 \B3B$BCP:R@7 H8+@J4& ]C-HF.O
M[.DN]Z*I:[277314I<\1!ZZA1?,A*Z!%V=0UKD,WYIS 9\'V&:QHYS!   9
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M'<  7UF0%/E><J"#"44<.BK/&9+_'+!:A7NG*J'U^^B $3"UQ3-YU("6#BD
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M*RN& 0A?&&]1#]2MK6, 8L@450C:/R'^$,TR94A&;1@0U=DPN>+E]9PC1&U
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M>S']68S=3SI5%G<M7$E1];Z)/VD#K*]2@7/>IR%6/!#W+*V^E=H95SLE-LD
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MWUU57U5U574OD%/()< 362D9*0#:/0  #?4#0,X") #8F)A8F/>QL;"P'CS
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M-W'RQQ6?QK'2,^=*-1RN,Y[4-%T-@76-QUT).EUH2]#*,6%ET4*R61VN=N/
M7[A9F (V.&[%?HS-X\0=3*:F!7V6Q'#KP3< I[[&"R3 !6=2US;',E'5<Z+>
M-8=@E6PE0+WB_%YN8N>(Y>V5[8<XVQ @Q^K]FK1UYTGR#)'M^H@4.,-D1.&
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M.E>0@#M[ \1"0HO>8D".MC 7Y33=ET1M_/Z3JU '&W)V=)J1>ED *F?Y@YB
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M<=H_WL\I=S>U:\IH\.*JR&X\Z-(:C]/G]83PFM1!D\.[OUO9X*#Q[UZ(PW1
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M8_Z4\;U/%=71\_LC$_>#>]A(.^_5>*VY\'P,UX/5WJ7Q53)2,"DRD:8^4JD
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MKF6!*OWU.>+H=O<+Y?VCY*UDU-SQ".[E);:'&5^H;A_8'^?V41X>H(8#YT#
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M'F/=KYZ"P3NR);CM'>H@1OY.H,]&WEZ3SKG3('-+7C>AB[L,P@CWLB%,D"P
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MPY)QOB0;>1^F)VJ%J,QLP<==#0>G\FHHT"+]B/LKTRQLJ@NKS4YU)V^8>=6
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MJCR+!C_^O--+OA_/.7FLV9*VCI,: 9E"LJ5HY*7.^'!V=7Q$=:<+G74C;G]
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M<2^LS^L27G>AC_U,\9UZO7D349LN1?=,*N^=B'9.K7D6<8=[M8=8FE/%#?<
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M5:WKNI???,5?GY^_Z>FCB,CO&T]I,/ (]QU:?X&J&7008?;_-P%02P,$%
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MUWAO.6/W\O0K\8;/&"NMZU'QA+M.7:PK0G0F>""R+ @/F#GA@?01?ZG%]%!
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M#92T_=>QL5'TLGJI3_WISI.-P,6F@5J"4,!*EHKV>3#WB%28);QO7R"5ZJ#
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MW1VR8ZG06>DIEY-]_=*4]4)A093UL=G U$1&'@/$=]9>+RM-$&!@[1KAE_'
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MF/F7_]\QWL11,NB)NMR<TC]>S56GG] Q< Y1,*GRIL3K5>3JN8IZY4&B,*P
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M1!@#K8<??OT^U[YH>2?.8\>].[/9%T$?]$10O*><(;91/X"SL:A4!,VR978
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M/;B[/?*?<\^UL]YZ[YZWSKUKO;]FU4SO/=WU=755=U7OW0\_'I: I[*2,I(
M'!P<X/'X 1Z6GUY*>%B9 X"\/$ / , 3 !%. (!_+&$_7LB&6@&(CV6XQ[).
M6OKO7X < )Z.;Y,"*(_W,!ZOA1\9(-W^H^V?]"?]27_2G_0G_4G_GY*<L8L9
MI;R]DYV9L:NMR^,-I#B$/S(*W,?,H3 .\6_EYH3X/\H('!P D)#PK^5_S2Z>
MI/V6^&=V\2?]27_2G_0G_4G_?Q,[*SL'/RL[/QL7)1LK/QLO/ROGW[WWF(<
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M(*9DX6"A9Z>E9Z#_+00.Y<D3-%0T7'1T7'I20E+Z_VMZ: =PGL M(*$@P+T
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MO\E'AB)ND*A% ,,;'HT^'3;G"=.%B?W:[CZ@*8$+C/)_>J EA;^NHM*2F&D
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M Y!&^)<<1^L X;\>'<#XC_G ?TX9_H%C"7_E.%;[1M%-4DV$E?I6RH'EIK/
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MMU0_DSR/Q-&L-T$>FZ A[U&4'%:LN=@S$:ZXV3?0Y]QWNS8O )=L:5P'1Q)
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MS2*.C#S<3E+.;L>EW.P$$;.4/@$9WA90G8&X?C\R&_80^!NM27.HB5>(YVU
M6Q!61E#RBXVJS*K06D==?9:V:_.]V)A2+FRDH14ZJH]#X5%@^_AFX:6OONSN
M+!L,!61\%:R3IPVU;6$:C4RE_D>,T^54S0P_#;"_] J=%W'NB7<2GUZG3U9N
MW>0D6)C9[Q6I4B:(PI!1)NIX%(3(HE^*?:Q1J?:J4)@M2Q\5GZQCT*=53#B^
M5F0F[!,TK=K-<J<Y1/$:&+_51RY8OF$"[59WV+L[,;4[L7]H>*,(N<7N;6"R
MF^V&J3=:<VCK#)GE_HA]P<="U%SDYC-^.E0_ 'S\;NIDW0]MK;I4-,LWU)7
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MG:!HJ7NA-K=%D7[#B?4K4<&5VG0^5;?X,NOG.<S:V7MXBC<:HW<"%P7W+Q^
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M'A%'YC8)=V;_4,]CQF4U/S^+5L3,LSG8GZG!GV.HERVSI=<QMK,4?<>YB"O
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M;\FR2IS863<&>A[\#K8N%IW)PDOM/IPAK__HM:DRT3VY0>=&E0RHU)TK3F\
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M[.JIK+YLS>Y]C8U-E1#K6S':B 1$X-LU&#R#4, I0N<3]W46I]0LF+*-"(@
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M5I+60AC.V]-54-QM^,C=C9AC_R-)+N_FAE, 22/5R.=Y5["=*H=9],,J40V
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MLR?AAWI3?T6]/ :X]W6S49]4.O&5-G%S[[2\DP?;80#_[K-'*^)S]71M_W-
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M:[[;GM.-$1J]JT/*](*I]8"TUO8 'T(BRKZ9T'Z3N^NM6,_30+&\ ]V?)TB
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M7(&DA6H_\@?  [A[&MX<!Q@BV(HB=-M>@DW_V,J.QNTL,[25>C2S@!:>I/[
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M5WD) 3W7[_=PJC(9S 9.](^>^ T1#K@8S<GJ#Q2<]/2YJ[>^; A^A&)L%RS
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MQOMZ[*+\5$L/Z1U&&<=+P3<Z:I M&<8^=:HJ^_ @#^?IBJ+G[(7U^+&^[3'
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M7E!6%NGWV@\Z*7) 3?$8<%FI^3?1D!=UG $:6M^XR*SU$^#JC=_#"R9M+9.
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M4M0[U"H* G!VK0E-[43DI0 Q?+QX]>"JW@H2% E *5*,Z+$^D%,#(@2+<EZ
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MVDE=;<'B@!?HQ0&'',O%46SIV5 3'T6P\XRR+4LB#X-T+L5?-= &O?,^^4^
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M<CBVA,, YZ4Z&F/P8U/^K@JS=M0]_N@@(3,8@3+-XKSXH.+0A<1/N-?]B&J
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MM3QR;,):^^$ [L(33E]]X%%H@'UO&5F9HP1Z?6E,'M9Q_PE0DZP'F%79LT,
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MWPUQB=9^!GU+8QLLXO.DV$]== ]9Z[/5RC":_B> Q&Z=^#Y8]'962:D/67&
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M7]YTV.'TX&"OJ1$BG>%Q_7,_Z,PRUI*KRKX<SC?#YU1#G#?"JEHW*1K7J:0
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MY B)<33X?J2;Z3UF<[6%X!'U>-0QEJ62NYLXN)-(VW7Y;.BC/T:5 +XYI?,
M/;@+T9_K7R6=P,8^$L%(/%R<87D 4HO'8^)&Z<WEDN>QXB<(2WD"%Q/O9V.Q
MEZP\E?M);XZ0?ABM<"WL-9K5U>8M[L[N'8(<0_C42+/-A"0D!6?Y[%;1-;WE
MW(H&/%R$H"/^5=Q58]1;OH9N."L<:]?*O(+C*!KWM+=UL;G7;MW\/<-N^,0_
M#?CG>3\_?&^68[2Q+42P=[,0DN!7.;A7@8KE7UOHMV6\A[KLUT,WJZ7\\3L-
MO:N@TS&N(:-.<9_P/&?;XSF)Q4.JBWJ\\G_E/N"\J/MY9H1AM5VWCC5C\OOS
MYOFAK,DJ\%ONQ ';)<-133J.@U :U<^RLOZ7$<,^W61?H\6)*,G9^U%-_NWF
MP&^7+/K8^%I:VL+9>$%UCE+'9J;5;QE<T/*J8G*M3$;Y__Q#,[&N@K9;>9<X
MN!FM1%V*%=0\[7UAJ):8$%V,.M4"<(RY;JEE:GDK.7YI19^J!-G47=;508;\
M_-Q@>=]2@O<;C^+#;GQ@K"(VL77;_-!::!S>#%89W !T5O_A9?/Q1PNY.RE=
MYS'>0PVH+_F $2=Q?ET!M%S21^@@F:/]#V6B!.:PK1!D5CR'<U,\U(Q$RI.W
MP;*G1?179WNH2CPA*[_-!FW8;[RJMPYN')J$SC\1-/.4+2\"Y[>#B^LS?-ZO
MF3:\?#L:KKK8@.3?'H)*B I8;Y3I'A<4OM4[RB\VT*6%YY=(13LP.WA8XA%8
M4Q73^*,6\]%D7$,;_TW_.X+4&P<<U[)6J%C03%U(K]0< #62!?=K1K:=_RSZ
M11+@4/-;MH)@GVVMQ:!'747\2HCC9ET6Z365);4]>/A!+#,EA)<4$9LKGZ+K
M%#\5*PP_JSA+S)5U<@)4^8'*@),^M8F$QW6NB=2V8/$:S0K*148E)$T]7LM4
M[2+4%N.]M=B1P1GOBEB-?12'0#WNC\9#SO*<4BN\<8^0A]#43MANA0C@?WMC
M'[,QS/H@*L*]: A $=UNVK>"[\'?;_1+*_+OE+\<<>311X9(<>EQC"F#5R3@
MK'(]TRB+-24ZY,:]=_X(E4OR'#_WV']*$HOA2.($?U$LR<U"RLI"_=?^3"J*
ML/H&&#JP2-IP< $B-4$8"\[DI:98T\7U99V!W@M#PI<?2H2 ZJ%R$YL-P2@S
MYHSFAE\=L<C\+]#WQ-VT9R+G,P+]C$ .5U:VT,U@NH5,YJK8)B*RCY#>^A-3
M%7<FF7'XSE"F-/XQT&5KQV9\ Y@X1AGCR,%+'POW_U#;1FR=@=<Z7>.58M+6
M="?4/._378G\!-!C2_CRU?ZE.DD]$G6TY^*/&2XF;%)L[#TWJEN25"0/.T=C
MS24M7:9L] X*CAB'C*SMDN7K%[5MATQ0UP<*I>9PANP,.&:$=:7P!6/9L/3*
MP,!.(5Y^P;7GKJ#$_!', W/F;/XA[@T((9QW8ZD!C,[./(S*MPH0D@;\^J_$
MXDQLW?-]]]3+!-.U=LPR-H?+:I%IJ(:\1(?QX=,EC1GI=J6[&MHN9\FPQK#L
M1-$.QBY4U,IM?SX!/1VMR=I,S+YB:U2E0#U)Z<2<+_A3+YL[M@X!![Q&(<R>
MI+,@W=[T-:;OM2P<^UHS!(K$@G)DX?FP! W'0[9WBPLKEKV?E 9X+W9__>.<
ML8R">(\?'+M&IJ X"2'<JJU),J()=%!7Z^^\$ G;&(=?&EU7?)GV%LM9M'+5
M#H8FMBQB8W9 1@H<"4T8OWS#!7L&?B*<]:5NBQ-!M5+4(_%:>?U%7Z<V2I:J
M#_7[EN@+-YQ/1,@8&4P<!H1[5[?#&;C K%O_F9PJ/?$<O66QKAT[1I0N2D#%
MI^9 ,+L.</50M,PY6D2]]G%\@M G8(\)7PU]Z\:FZEW",0;_6G)609M_DE1>
MDX_8([V=+R1ZH9M0E+&\QX#-[;8E1:^I>D"@>@2@=7)4[/O,K:[]5.J!788_
MQEXLE)0.D/J?K %T0U3ZD:A)/2]F(K*O?6I&Q!2GC\N3SI6GM01OXMC>(V9U
M4M%M4V+$#]#$>>Q&E?S#7JO-5B77@5W\+(]MK!48"GB3^> 47)E3W6Q#Q(;W
MVT0O%WTE %[^TM[S\-JRY>O$FM+SPO*@DIAV*DD"G!M]DU>R[P4</Z_)9+P:
M$Y1U6&TQW^F1*]?=]_39C*V\P^6!F,;10IX /TKYHY;+)8[M>4O='K$;('>J
MR7_,J/>267/)??X(VL;Y?,#VUA:!L +U72A@@Z\?13AL/5WAF<$I_?H]EH=.
M)CRY6N9 $R)=&-F/%U%\ P!XU]/3Q^I)!E["3WD"+Y:,I;J5]=J)O^A_#<6,
MM@D,'WE.%FAK%HII3UJS(-IC%I@)IP.@G1"IKZIF-\G 8&,.-ZPT]:N(O/E?
M_+0%R87%.EY20=+UFS$"F4[3#Y:(E_]2JH-WO-$$Z=2\V/]^:*OE0#K9M5U"
MH=>4+))N'[8^!*7H=G,]M]9HC$HL3W'P<GK(-ZVK8A*?&NBVU)-:BD-"Z!L9
M<4L>EW,R8>:&.6H-=VUF<*J;"M<;BMY+7L\*>],*YY=U%;E#'C$_+>C(@9"Y
MKPJ6$ <!,75Z0S@H_/Y"#$A8%&_W;O53UM*]5-MX7"'G$C#\5AG&!:)W5F\'
M*5$V;+'6YZX*M-US=12P?PF_;V@^AUX"^[,SY<_&)9&5&U09.L22#)(%PE S
M4 E__C@1C'D"F"Y8>WYOFZHQN#Z!<7=0O$-[G_C[]9UJS(?2/2>YZA,2G:Y"
MJUGB[YGBDT?B(^F%<Z>49C0YS4W@2V5W!-4TC/A%I!__<*W,-WMG5OR&=Z1
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M0(Y/@$/[.?<  :!L[<^)(6.:N-<2+Z.Z&(AVCDM7,SNKH<W(SNKTG?,Q4TE
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M>,9*+<#0_\53!C)/*N#T^"IG:-1-W^8L 6M9D 5:+Y17C%\$>VIL&V[\5-$
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M ]PM/O\NZ@(V 0 9&8 6   D !E !6#O-:K[DX\P6 #<O0YS_P%@" "$WSJ
M5 1#^$^]$H;FCS3WN6!8_IFW$8;UMXY]KR\%@ 'X/]*?0HD Q/LCVOVY&P!@
M1A%!?W,?Y$$>Y$$>Y$$>Y/]040-;&5D[VY/)FUD[6).)&H$=K.W(6)@9F1E9
MF)E96!A9.-FXV7\EO/==?GD3_SC^UW*Q,K.R\C*S\K*RDK%P\K)R\[)SW_L=
M$7!_>BF89A'P_]0]HB)_ZW <+  0%?4O/0WF7QY1&NR?7@WLCS2X/W68F']Y
M.,C:OPK[X.$\R(,\R(,\R(/\GRW_X85P\C*S_>VU>WD$ _>'K_'HWU=?,!?^
MM?J"N?'OJR^P,'_Z()C[L/_T33!&_T"__<?Y/XYW/^^F 1$ Z=$CQ$<(2(B(
MB,C(2"AHV(_14%'1\+&>8F 3$Y"2$!,0$9%1,%*3O: G)R*BX7I)S\S"SLY.
M2LTCP,W*S\C&SOKK(3#(R,AHJ&AXCQ_CL3XG>L[Z/RQWWP!,),#FWK.">0[
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M@7%*W2,=B2>G5Z@,IQJ3EWX:A@!PXBLZ4O$X[Q@4B1OPCC7(G85O"F$RU&I
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MQO0A%8N)'Z8(G$!2Z#'9C#-F]51V=+<$>1;LX*(. W+CY!<+4N]*=_Y*U9P
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M.D[= 9H$TH^EGV2J?BYFC H_*3@TH?;W &>>#WZ;W>0*MLF;I@R/B7U&A.T
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M !B ^1#AVEY!OD7,D[/:^/1NTY0X648)<BTM30"YYJT3EBDAH\MGF_!1.0R
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MTTCJ^2()X?+ET51V:=782G5DB+VE-SSHR5OB-%>MEH4:Y:A(G33E7==..<^
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M6G<]:ZLY5E6G $9:G$^=QE[E"!9YMJRD8;.E(&@]IN^.._E(MMA2O[]C#V<
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MLFHB]Z9E!LGM&$(_*OXT2LM!:RU+X791E,UMUQH4YY*9?G3;C Z8/F'PTSO
M /P%2_ V-]]EZ>IMGIJ/TCK>%=CNTM@W7+!:C--O>$<NH=(TM"]M$JZ3V"4:
M+]S(KY$UU3J'U@[NV;(844H4@/!X1<+434(O7]\>^3-=\=N$@*F;-G#_EY?Z
MD"_/)OB?W/-FTF<?X669_(F4*\XDJH[/[3$0>A\JZ U]=KLPT&A0R29 TF-
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M9@[[W<T[RL[3^0<6_EJ6_\ NY*RQU[_A=&;_-QH$T][_FT06Z^P=C!Q>_J^
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M>M<S'26ND[-2!P84UQ,2=0IR['[8/0]J^5[$$'1F*KH/,;A;-X2^:UQ4&G$
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MN5U^RWEH%BX40I!VE57'8J#&2>#WNTA0?3HH&L047.&@/RG^4\-#5%SY$F#
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M(OLYPP!OI,AK5>753YF.=V>0<YY\%@K[SQZ=C940$%=E1JU^H7/X\]:6&O-
MM&,0Z.H*6E5AL(HE>%;PU-D0U$8->*+QEP0[]]JZEU_J&:</*:&H,B>(GAQ4
M"=YCHN;"1?=Y@5/_]]O$@?PC',W]Z0[Z^1#N#Z/X _D_NSK&+^H7B*T-QW.^
M9F40]/Q$W-#(8/KA/E/J,[0%4.Y$A;O42N(0KFXH6MO6'GE,K+AP2QZRO9[2
MXO9D^E&7GZ6[$&[<WB'/*1NE04VX?.,12$DG,OL>QV9AH1O[Z5.[&,D^K(:D
MNB.]((@82?WX.0)99#U_]KLIT//OX;GKBNKN+#$9=GD[Z%%@H$:G;4>JPQ7T
M)\M"K$NU*C/CY/FYL]6Y\#H$;T46YW+F<8'A+ Q@&0^!N_"M4DS@ATK;+;A6
M>VS-;2M:#,'BNTR/1T1Z+RE73TI@P*_JND P)\ZX:):8O?(B!NS7+-]W@.V<
M_D[YK)CL>J]MJG97=O:$35-7:W&6OJ.HAYN-LR2 )K>4J7;481%AGN<@:40N
M)Q95W!TO7!(XAA[!@%TUN[2KC*%VPDX991LFA(T7T@=RDY&'&N-M)R7.0ETW
M<WDJ#>NQ(7,9&:=Z4(\UR"3$Y->,>=(8'/+]P9ZD89CD-?YN%X5_S_Y$@AQO
M;4-2#PUN2!W^SG<S^I:V73W3>)/E6':_KBSN9)+)I0>-!'DS.L5,+,/T\>E^
MP.MR/BW(D-#>=HN3]D&GW:%:7MJ]KZ;5A#6*\UK36N(V;.X]!D$JBPP,=)@I
M+AE8O-\G=K0*W9A-2NB'XEELF!K6UM:\HX=XS((!II8I%NCPYETLCI!0S;6!
MHX?=KBKC+YCP_R0!7A+HW05]N=./WE9',%JE20@4<LNC6LR@QHDZ:73FCG.V
M]%;D'#E\.L4?E?# P&3.S/ 2H+H2/Q<22Z20/)KK@51HD&[X%NXH%.P0%@M)
M7M*'//D@PBE .S69,:Q"(LUV[/C.E,?(9="[8-'9_KZ0+]V%[T$'8UO7F6C*
M8F]]GK!:]H#7(1W#724,P)P(R\[1-*L.M70B/!-!7_Y\XSLU&6=V\R9WF7D\
MP4'0/W; J_\5_QF=;>X9*-L277!_]]#3R#8JI_K'.3_[WD'9FG8']9D:":1@
MX,.-473FE7^WCFE<>3J4/PLA@6M+DL#\%DVG' :$R]SM"#)&A/\X5I=F8QNR
M>SFJ)JDC;@N:H62 E^J8;R(L]F'!@+31U>-H6HOZKX96MUI4Z?C^#O9JY,+&
M?+-<%R;0@89<H>/=I%6>D;:"*6UP0:-?>,X1SOHS(G3DMR&^ZJYQ?MP#8BQE
M'BE*$!M,G';[XM;G)&@TP<&?TQ4TS38^[PPF-E*$$4\YA[?%FPO(CN=!"<C\
M12;S(,PRLL?9R3UX"^E5<3ERC'*3-:LZ(D9FFJC)!8C&'UERH9I=)S4P0.^X
M1*YP/+L8PW1ZS^'.*,:2N4MWUTY"X($R#EEAIBW)F^>Y:CB/O4M,WAB-E&B:
M5$3YYM_D+T')QQMP2+M:>L999S#04,;(/6GS[LPR0Z1.)K1+CVY[8C%Z[!3<
M^XYOPZJ#_6<.%DZH62M[F%PSC7)**N%C1"8K]#0C^$G@WX(+YB&(Y8IY4$G+
M,OEPFTA_[OL!*EVP%U@)!DP6@TFODDQ(G:*M%K<O ;CG-$4!]T3EP-DJ1^Q^
MB:]K!+-O8EMJ21#J./(WH3<B<*BON9>)/AI>G=KC9$1 MW&7Y&F4ZB?,A19@
M?Y3%O"#-Q=URRWA!56R/KZ!=D93+\,3*DCBO\%%&,)/$SZU(RU3/*>BO2OPH
MQ(=Y "*V+#.$HPL#K*[LR^F,[2-*A=#<L7=WA#P$764)JDA'L@ZJ=QHB%1,2
MQEJ/6H(M&R6-(P-+::F: D!71^=4O36[@^XJRXFA#TZA#UB!+R'&[L./;E.*
MT"X]),^VQZX,VB<6:+^>$N'-2P )Y&>BF5,3,7E=<3,C5V":)P.+46Y0HWU\
MY8>ZFG U65(;#+J<N[?.RY!1_OB8-P8'TG@=,(R?.IEMK'TU"(2P%F<9?9L9
MP05$:TG2L#."E[A#]10]C  KP\\RC]0DWDE@;(9-[>K<_7W(3E+"1O+CRAEI
M[<Y)<\H3'W%^&&!,,GAPU24]7,+6>3'3IE15/LK.RD-F:OW>NOPS#)"J8*UM
M,!:8P= _9>2W>/\#33$A)Y7^N%SF5K5!>P,E_K4OA:?V1NRLTM?&E%>LUL6Y
ML>SGD1U,%0S\:TA=/)NA?(GXJA<CF:G5<]R"FORWLHW%C2YASWKDG9)P.6K=
M^P&"TJPA0Q>/9>>SC="LBNH('18/?=2GV=I@#/8PG \F2-49P>9Q@(4*Z) 7
ME)Z&IJ!@E0IUZ8(!8)PKA7KP]2;5'03TR]/FO^C_D^AC=F($_>R8QT61_#/=
M/QUOJ=\*)>#@;3,)? FWUGZ RT35,JMDFU.N^M%<E(O4J?"C]0@G8BC]Q2YD
M-^.H)915^)D/1O7LHG?_RR/H#CA7K]C>#0Y^4VS@$+T-2M!Y%=?:,F.;N,_Q
MKK()S>;>&DO 9"[6(=P/*.D>]S/LT?(,APPZ82BYCUWL.9[UT(2IS-*9[6ZU
M\6PF\(59V_=%9CM'H6K(^SUL00$OM I0[>-,%CL=OSEM+V^GCN(E4=6P1;_@
M+V(:3F8P)?V>953)F?K=U6"N,MOPWAOWKU-ZZZD3Z8G?)G#Z%0=(;OSAZL%)
M#@[25^'@- #". ^"G(9#H51'19\$[):%;@T21630H,BI?=PI<L%%T#U_0ZI]
M9K"H>?YO%3/MX>[5(.CV"OS=2\#ZZE55H=[5[6@Y&I@U[GQ;J6U5Q@Y:/Z(,
M VQ\P<)JXK\-J/R 60W5;M%^%@QPWX0!AFGW.)PSI:*+]DG.[$$CL5LF@KW[
M*3(:6L18C<SAZ;M2[ $6]+OZ]U*5XP-."*3UT+5:..)"X(I9._P.-4=!436J
MGHGSL\[*7B_7E<3.B%SE5MQ 2J^6Z8T5.55G0@KC!'<<GMD$_60.Q(+AF)PT
M$8I[6YMH3Y27>TR5E^V!UG[/3W2A/'TGQ^@1%/E='25.S$)($IC@DN(3V6"Q
M+I.>[^V %CN!*5\:3B4Z.=RX+[+OCIX7QB5TINH_D+*S#R[WZ#>L\>!(6#$^
MRLE3+ZN4@*M*JS1/#8)$NQS9M\M6EC.<;;1.KE7G6477'@Z0P+AQLOJ-L]%3
M&.#E&EHU1A2[*]+XB4YV.#:[5'"DU,%2<.X38W+Q]*>W;75V/TZO7"<BCOT@
MD@^G.PZ]^B"G6IV*-8U53Y,,P#9;CO9J-,(6-@->(*F66U(GR.,VJ/<F%+ZT
M+WB,C#64'3P4%R5&'S?7@>@,_-!B13Z[)7R#XZ!I\&8K?#$N0JMLH0R-J>TU
M3]' -(.4+YE[&.J&2O6["++IT7@&]X(2H\+KJUB<Y:1KC]\TL >>*]3C1U\J
MI(2TI5'ME9Y"S$>90ZJ.WQ/RVFC.FGI3![W(N)X'X#*-#H6F5@6'%[7<F16<
M-V65EFO=BQ%5L<K5%[>Q7C6% ?X3>.?OS-".BX^W8@NO'MZ9)P\R.UKD#^R%
M'02??FIYJ*?WXJW+L$+]1^*A:K.FE$P[TWI&:]GZ&@:ZU9NQ6W6MQ'AUS][L
M:Q>=.QRY'.&R=BZZ8-_Q,.:AQFTKM,-&,4(< Y;4/ORMLSN>1,Y=U?W4%Y([
MXNS6,M=Q"R!]M6N]N<%>2[O7OH<+[> YH998LX\+[*,&,$"U0AH\K8TS-J',
MJTL13G:P''=WFP2F)TC'7*#TO5,?Y=H9^1DMN)\/ SAOVZ;&H&J7!*F=#_JE
MM4QO@Z"GA$-+*'9HLG7#)8\G:2I2NI_0?1GW21.IOO%P+KGF:1(A,M-19SQ[
MZ'WW1$MK=$U"LN&KH;Y/\0=TVM%L;0Z\L*09D7,:=9>6BBORDK":YB<U+JOC
MY<&S.B2SMJD.VP,68DL-#AMN=7IW'?<AI]HZ9];+LAX\(J@K&,6&_.;.V8O>
M\Z]VP\5FKV]0PH.*2HLR:T^+T]@$@ETN!%-?H!>;NS'.R$?9>)K!^_ZDLW!$
MP4GW9<25L71 :H5+P/A4ZFBVB9BAN34T9X81!LP_8\J]F(^#0.%*[PH?]#WA
M9CU*8M":Y97\&\*U!YZ^Y!.4$Q3#I>7YD-(#=DE32_QB%L=CNM#Q<8#A.+\P
M;K31%.L@DZ)PAEN&V4)RL2%ZE)9@3'FD^$U!(T67II\TVSB!3S!C\6N?7SWW
M]. )8BN&%.[VBHCW%M&UWMYG2X[Y>?_':.#_+6$6V[7->+:8K^N*GWK?UL4%
MR*5#8UHK1>FNP!S.6OL)"E82&'+M#F*'H[NZN3\_UU9'S'KK.Z<FSO(RK>Y]
M*66G4E;60:4QA<$QLT1#"K%A\,9\5BO;3C9^JB*VS6'P7F%OJ2B1F8P=1T5#
ME9OGZW<2;S=_4')<;928IO"-G3&GYUPES"C5>/.*?A"1,Z)</2_>6<X?T,,^
M7#.\5QX6H[#-K>+&O*LC,6YEL2F5;A460 L#BLPZ/E2.5@C6W&/,B/CMTVIQ
MGD8B1D)G@YCGW=CI ;N*P\^P7JK_H&%404)0?GO/ 5\>^8&&9K\=:R4[].SM
MN-,P=^YN[JPG'@*DX,[@*DXOH&U&9EZ4U.A:/QSDTM+JP!U#H"C]1*>\J2BM
MU(W<.NSQZ)YA@-2(Q>CM"U7%?E]ZA*W,.;AS6VSORN>[MW]6JZ3X:9_HHU5,
M7P2"B#_ZDBJ[5R5)20G=\>/<>(;X(%_GS932.S084-"$6MVND(Z<+\$L.Q^[
MIEBJ*Y?<LUM=!+?!']7$X>"4  8TST),?EZ^_*?+G^$'9>*V'KKA)^QU9'=&
M-:<M35\6CX)-4D]70(=P<Q7* *%Q98!<P8 U-3BPG<D(+QR&BE]2WQFU_*PJ
MMXQ%\*-@IOP!OV%,.8A37!+'YRSP1X!4ML#MT&.<[> MD^QS3:(6FMN \_J+
M&J';?J2E>6(8T$>"-B(F*WI_!.>H7S1*34R<O> 'G"O:Q"X,$+H=M(/B)C-
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MK4&Q\X<,0Q2MJIZ5ZBJ#D$7[3D]?/T$F!$?I.IK";,AJ;ROH3I]0"6.%3,&
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M3G>ATVA:CCFHZ BMLH*@ON1O+MDR=QGF</Z,LJZS/L.DM4D,]#BLKS8[@@9
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MYZBUJTGJ!3]>NB%>E9P-RS$BJ.NK,-]LBD%'DV"99F3'2Q]:>LU+G..U"JB
M1/O*;W;B/G)?7"M52B$ \2(#NO%<SA>%INI ='D'FJ?Q]8TL[W].F4OHO-P>
MOYV4U<$E:=Y>KIAH'@AWDG'-D8"%!J:)++_@S*Z@:_(<+$EXG?ID5Q0&B\]*
MV%[6 -N%0XA?^9],-%A8P#WX=($I3^IQ^LBN8B.)5$EI![UV?_D$>97UE:W\
M^F#3W(04\!X3XJL[9JB/[E-??O35J1I^0B)#M-<D($>\OWALM(Z6#6U"SR,"
M@)?W*7&!KOL*;UM$URDQY'_$N[C4%D><T'V<5@FBSKU-+*1-W5+5H4@C'KQ(
M1C@<9E^H?7']B?]3D,3$Y$ATD?_AJD^N3HU>H1<['G!%%K:+Y[3;G".IF_4V
MA%.;+GS9W+GE=K9/('-/CE>-;5@@(L!*CI45?[T[_A,5VO_+\_;Y,[&L=OI?
M_ +>RZFM+^3K<YB%.VRH2#X5)2\T VQKHVW/)PO@ILY^R'6(*?I%$,[8\UPO
M F"1,%6<H2DB?SD2N(:Q8[.B(-X0A?I9RU=;+<@/BI*H^ZJ*E'WMVT]AW<!X
MFJC@@DGB$6'H)D?Z4%]VS%WM1.@55*E"J2DF\6CN7ORRR0G6J(@Q8@6,W])6
M#F-I^16<Z(B \:&A)2N(I^:]'!DE['"=#CXZ$1UA1P67'=%K*?K 1&)I.7.8
MBFM"X=%8^8K6N4H9[39YO>'*.&UWJ@XWGGNPS?8/#\/BB\=<ZR:)3-^2 /Z)
MI@6FUP2T#OT"%3Q=MSI DVU@+]I=&QAA?*Z"ZF8L1K<468:$.,N.D*\<.K/G
MJ^J4R"7=)2@MB9#3=RF8I?;U'%NS1U3OL)V@0R:R0-1@3-'71[LI%!A*O&&M
MH(@QBB0E+J?UI^3;?71-?VQH6OQ>J*;I(\\$GB6XS%3&JE>U)>"D?=+-CL>O
MEI+SL*6*&\_,*7GXV-+RV7O$@_PL4T+V!8NJ2](*5.J=^C"P4O]>[NHZR)GT
M5+-+^Y/--.(A3WJ%C<E5TO?R\4>W!8]&'L9(E=GZ4(U3E1__0)+) $BB4%!
M'+J9H2'DRT>9&^.[P;47QC>QW2X+<4[M0(KS.H\%O/M\\L9*E%FZ9;#/^2L/
MA.V'#50:L^5,Y?0Q7F$*].W->&5Q!AO8YJ.-*P!3WU<$8PS@[MX7,;H<+&L"
MWXV>*ED>8=\MF;K7\/[8',M'CH=6LAHWB4@R^0"+9-BOF:L^.W/)E:5?KS??
M$7EM12Z()V4K;W MQ;)QKKP7)NU&ZBRS^AA7.>1P'!H #7[7$J(>DOF6K[(N
M8-L 1YUO\4V,Z?-<T6_-P605J\<6^#/-LH?8:<9&%7QP2BZ^D$^8)=--TDUC
M<<__W/QT$R=^KA*P$\_,(43E6UCH:@7 :B<'RUT#SA\_*7[JD"YV.%]3XUD<
MK-?@[?'BP6';Q>AZD<V0LX(I/*F$._]_P>_*_[=AI/:93YQ?XY60HW&W3=L:
M_?B:,>^DJAH;8M>0,@O<3M#.F_E3Z\ZP#OF<?KGUW9I[P3+V XY[Z'FT__)C
ME.!]3M9?P&=XG'6O H]]/.2S5O'B<IN]XY,$[3P\AMR4!2)Q3EZ9Z.^&I:DP
M>4]NZTSV5$Y3-LL46VGLP CM6J'&<^/8=TWQ4CXP9UK@TR\CN.-7L5Q#N_JU
M'^5<:"FV%/X"KNZ$_P*6'.7D90]UB0WS+ANGV3H1J3?.8LF23RO;"_2$JK,9
MKN5)M5]!-,:"#EZC9@-@GVQ6PS%X7F7;EP_+Q?-FHS;FKG?KNAMB--IG7%'Z
MZ7-) VE<^]/_F-<;9X3R=N2G4&E6GPT107'&JR2-G"V,]Z!/R9^"%17E-O*"
M%^@E965X8V:;\$OG^?7^  6K"Y#A0_P#C8,%'0L]Z/LJGFRB2SQ401/2)Z.Z
MIOJ[)L,?PZ\MJ2+=8WO#_6%'ZV<\1#>@:3P_4V.F9\A3-YSBPG,M#1S#^AS$
MZ9'!1]:PX1T;+Y,URGKJVT&'OX"9.33<$\*1PE^8BOUT?%+=CR$VOJT:\HL]
ME,H!R:<UHT8U[/?D506K</*RE&(*X VRF<M':L_?2.7I^#DBO5UK]WBH;"&S
MS5QJ9@D4M%N7?-IG0=088.__<13K:>!'-$3^6V8\\O6WQW41"^&H"Q\*KASO
M$9L MJG1;@<\A^<?!?!IK[?"9$=Y8V2<(8??5M=OM/,"Q*^CB6#2UH3JHF$*
M=J]MOEK0Y^F;$KM:-CN<N910\\/[1XB,W%QKHMC:;5ZF]K+L>DW)><4 KD?_
M\:+(&K-1:UN[\X.)"GB>3>K$2L![$^QT7!3W7O!R*(,5W 3=DN%7NK:U%R2U
MUX9CB;2+5M[C>5I%-O9Q%,%BS:_$^!&1J.SC!@5EV;7R/3.G:'<8V4<P-?VR
M R-.R(GC=7[$)<,.$T7DAW!;-:#<"F.;=SEJ:GXF9P*IWD$O>//M$DMW =GV
M>/*XRC^,;!M:J2]#2D>W(*2G%;9M'ZSX;*+WG5VP!-I;L@&!]LT WSEC,B]'
MA[0;23/?%+[8]'A9WFJ9YS&E5GY%L!:*,4GY\%@!7GC=G-7<^UE+, "1<[K8
M"A 5U)/>L4\H%\-@S]GM*G!(,VH(2.SR;<&?)"'%RRTLJV'6GLG<$R3N#2UK
M[Z5;!19ELC61]]2<^^^7X\UF06UFS X)*@\7* X3Z<LGVA".X9+I+U_/A('I
ML0#N2L.',"7&>:J\4O.BLB6VAO86#?]"PIO(C? V@(365B=I=[7#?TA/>P5.
M)M18.!&+QY?M]"AA*HHC&;RFC4+OV;HX_P+RIQXU-1ZI1N14U$=*-!L;:)T\
M8UP+U0S^I,3Z/5\ZVS2=.J<!_C&LO#+MX*[.VDJ@3<G>F=JSU:X 73TX0Q[)
MUBG^ J;M_P(X2OX"GHS2?IMHG[5#]DZ#/>?5'$T]_!/ F8.7E[(]TZ:B_'TN
M+@6,_H/:<T^F9II"/*=T3&N;%64 ^,*_:WYOQQ>V53W0Z$9\;UQ96II$KA!F
M.5?9ONB<*4T<W Q,(@Q=YW-N^+HKM:9;/V"4;<FK:GPMNWRJ-Z89Y-V>_7*!
M'+]PF-.+*0>/4>T?GJIY5)M +!Z2P'F3]'XGGY>L5]S;%S$K\FZBX<3.6G,_
M.\T>6!NCEP><;TQLVC*V^N,^B7"0(=Y]!&ZGR/VLK/() GD<2;0$EI1V\O0G
M0YJKZ(.2GH2;P)J5Z,-DOUZL6,L &1G60+,;N0XEF8:7(#(-;D3R:%R\E*/$
M*;._C_S1_%F5=5ESW;=6DXGQ<*G6?S%,AN1?#/.J<+_).X>9B4>>(%=7VSY0
MSX^JTX%T@L==L%AVDH1C"O]PU 8Q+RJ,$9;D9C#&:'B(#LIM54[P6-+[/BF3
M"T%.F0-\:= YI=E6D,_,P?W1V_$2L'4LSB?Y28 CCP&%(9WFN7S':INURCU)
MHA)36A\C(T#%#5MKC>OLV4^WZU-GG;IOAID]RZ_KE]L[1/%&1KGXF^O<E>3Q
MRJMD<.:,+9ZA2I?Y2*5CAW#Z-2GCH]N#>^ 8:/!@2)2'$IVQV4V.O1>(XO7=
ME@Z2=C. FB4 9TF98$A1F,%KMJDJJZX52GYL@&AKZ(#MMP>E6ZRM[IJF]/2L
MX%+&0G]',V!E>YG2H(/&! KCRLR[6FY[3P7E4EG95DK4TVA5"!.-V;KQQ#!6
M9\P9;\+M-;5V%E^[+ILDC*7H1D2#8X7UI G#?[.MSQ:A^/3Z3EO&K$&!'G,G
M:*EWSRLW/G2PT!ZIN5YC'% :YQ$K"%=E_ 4TN'9O,D@"[SB7F%W_ OB('U5%
M$8HG/_<9#Y&' ]ZV]LU98_%G 2<N]LB=MNA!52H+<69./6,0=$JK,$P6DJ.*
MGN2M<*53WVK6%C$6EIANY8R(E=12FN09K?,A*F.)C=FJO:[Z<OR6G.TPBPXJ
MLS[RL727G$=Q]!,MNQ8>TSS.8PY#HTE38*!:";V$2M2;9Z:ITG[W0Z.:\%@U
MU2'KB"D6QE,J#?4HC1"F26Y74*MWI'*J^KC+O0]/ -[BU;&Q Z PQF;T!_9G
M>A=?/:I.$BDQP!\;I(H;,,F16HS1-!['<^CY!8GVO6;WI97V>>5M+M."3=AO
MA-6N\E3:OFCHP0M*C(7E564_Y@PW'O5.D3*I"N=/=><W+?6-+Q27)'WT>;D5
M;Z=^5H4N6CS[A_ZUCZ_!CY08TT>!U:D)CC=5O^_3);'7#!"<94I.RB$N"U5V
M#1&R*OLX@(U2C^SK(^?<.;%VU&S3'>3[0O5#$04XS!S_:C+DVV6(4^17F=0O
MU1:XC:UMX7U:,+X= _NKKZT.2+8J$F.F,#K 43Y*[.ZSH)YL\01LH->E/*%6
MSW\(+S>;+C)8I53\ZVV4:1(^V9OQU%E6]+IW) \!'EXBZ:O=0F2S/-N)9D@)
M8=8_)[NI"P(V<P2M9TA2H=O?6VU7W#T$I;3'/UQK&GV?\:'OE.9'#DL:C3?B
MK8]R\0![=$C4%?65&'URZVU#W&_..[[(L'A1GG<((J16J'I ]K'QW#>9)3D_
M)^8[F[; T+<V8TUQ97FZ4R^0TRC<(C_QO3)HA<GBFER@"\7P(,213:1=@%K<
M"",]241+2$BZ,M,PJK[(R>PU@EHX?>=SM>M.N%W&%V$1/,MZW[C=WR-8H=M*
MC-BYH-FBE)D:9A=/_%Q+["A*5URB E\2=;Q<4KS,]J @MS+3,3_O1W,RHG8<
M_@_70([6'TT:EANFU^#KL=]NLWB()<;L)%!D ]8G0QXUV03IXT'_:DU;G!]A
MMAI XKUC;P-_W"L._!V,[&LQC I<A+5G&C%9*[\;8B(:/=H@</;)\DT_4P!6
M_74UW89@M>N9-8II29Q^+A<-0+Y!TY:L-9S'M%/P-B6Y=P;ESDZ5=32N##WD
MN?L,SMT/"[[F>][7\33XY!U+PNY2;AOM2#[))/IR[;3,!+3V[FL?)S;4'8,M
MMX-,?P%/(7':]%?2VIBFT#K8JQ,4/_>!O>WR"T\K0$(I-%$"/"'O?9CV H43
M#4NRQG#6@$I V)]4WZW&[._QA44D**],X[WQ*%=Q*S==DFE+.G[_'="#%O&:
M@-2(-^7(W!G/HA944^6E-$0U&%*K*5_^=H[83102 >P U'^@\AMFUG:;(!JK
M"FI-B+9.?8;ZEEZF[=THO+C60='>GGR2O4IS)S+($;6O5HW-M_6Z,"&)V.PK
M\X_4VHPM:4PE9>::)<O: ?20AYP2PJL\]MAWY*,T[GC81 G5HG>B!A (>R,B
ME^++E4-U(G1F^C=KPCE3.EZ95A$EQMJ,18AXA^^-WJJC! V=4U_):X0GF S!
MSZI;1[ZXMAG!N/(0 (SJ4PM7%W]!W-R96MR2V-FA"P$#B<GX][! #N_MGI#(
MXX(G ('R5!\VC9R/9>-<7_)RE AF5@;"7TD4/BKE_2*K_O._5/S*0Y@E)4B$
MZW^;SDZA-D)O;H^74%%Q\)\ZC&40"4/ZGT6)Q0MG/^,"^!W\A[^,_UW0>6.Z
MO ;7\&"ZH*P2\51EU%+>7BO[G^]S\>Q;2]0-"N*<CE*WU:N)FXXPV)P^8:'8
MY/#-5>1><_[,'I)]7Y#Q67?*BE<U!A"_AE\-+41$2JB08ZLP?B7"T/L?&?[Q
M__&_#:%_E_X=4$L#!!0    ( -T[8E;!!LXL(4P  -=2   2    :6UG,C0S
M-34Q-C,Y7S,N:G!GO+ME>!S;DB5:(@LL6V Q2R5F9F:PF*62+&9F)EM@66 Q
M,S,S,S,S,S-+3SY]N^?<Z3O=_>;'[/KB3V96U8[<$2O6BIWY-O^V#D"4%)40
M!8"! P!@[Q_ VQ) " #SX0/T!R@8:&AH6%@8.'B43_ ?/\)C(G]!0,'%PL?#
MQ<+!(2"F)2,@H@;BX)"S45#3,S S,^.3<?"P,W+3,C$S_OD1,%A86/B/\!B?
M/F$P$N(0,O[_'F_M "08,"%P=@@P(@ X$A@$$MA;-P#_?9Y08'\-P#\&&#@$
M)-0':!A8N(_O%]0@ L#!("# (2&@H" AW\]ZOI\'0")!(1,R"'SX(J\+362+
MPN@;D0$#%*SH0%68."=FTK/S@X5#0\? Q"(A)2.GH&1F865CY^ 4$A81%1.7
MD%144E9155/7T#<P-#(V,36S=W!T<G9Q=?O^PS\@,.AG<&14=$QL7'Q"8F96
M=DYN7GY!8655=4UM77U#8V=7=T]O7__ X.34],SLW/S"XL;FUO;.[M[^P>'%
MY=7US>W=_</C'[_  !!@_S[^I5]([WZ!0T)"0$+_\0L,W/G/!4B04(0,'Y %
MY*%U;;\0,?K"H A&9%1TP *9%,Y1]>PFX-"(F3=(+OZX]I=G_S/'_/ZO//L/
MQ_Z77XL > BP]\6#0 +P >X>R3-]X/X[H\*6GS&NG".H%2=)I:#)_IU-COG]
M@QR"=G)BSZ3CB>CK(R'+4+8 T$C)E_4J^91XVPM5DG:.62E[9G0T>$/LUVE>
M72L#B/3.P%TZPC"6B4"0WNM*/ZU;.:/ [ Y+"9UA[4&SC'<4\V3.GH)]B.X\
MXD V(N:8N(X+CB(?4U]NI,&GPT*?;#9%3@]%7@3P_\;4T3FSQ^^+9"=GY+IL
M+9F+^_+)Y>"]UT1]6/8S@P'D_\*R>$Y^< 9W40?1<<<:@@QKG?MV'E4$IKD9
M^^=(V6M[G= O90?=]'-H^@+/=F=E<NLFJ$HZN6T?7%\60U!7I@V8G,Y4DD03
MJG\-\;&PC=E<%MG[?#SM*)IP9 4%+T82/]+T=*/=?Q]%?)@ DL*E ].L^'-[
M"DVB/B -?42@YUM9KV"'YW$]4Z]K16]M:4D]J(&9'B+$AO0DHJK";KS>PSA2
M7#%Q"\O*>0,8:XU8E-/VJ 3:&,FY\O;A1:L[XV;DYI[43+-%)!#8[&.4;HQ'
MS*&R*$[1&%562)FFX A+]O8S1)]$'*E28OZJN7Z/"%\H%'G^?S;?Z JY]HAI
MB,G8OX5.MA-,R%YF2") @XITK)LUSJ[7GR1P1&&B^CN8SUU1U*&*2L/5:68X
M-+0]V-@#44J"#*/,+(V\<ELU]>O4K7=USY[E2I7-*.=NPDM)W@.1=:W03I7%
MIR8_3_(J=*IC4*:/'2-Y-D%F,#D@L_Q9P-W5G.4'J\6A<41,K2AN.4HJ&'"R
M*JF[$@%1+ \[/Y*QR.HI:N\+XS8KIXX-PZ%9M"9S*(6$%JXE:C?()5"N?.J[
ME#?$\H ]M6DK03JQ\%[&H0WTEN:B3"4+U4)[)!-8, 41X.J*5G8V$"V04D%R
M=P1U$.02?$O<HNP_$'S?7F7Q '[1<;>;67WQ:5J#937+E<,RWZ/&9$;5:3,+
M$B>1 \,=4V-/5\0F?+.IMK*.RB57?%;7EAC1U3<!IJ/710%FMW8]33E*HSI
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M#?>LS@_>2-^U_3>L\=5<?O84%]QJ'MMBX[QSN4;O'-=/<0$W)9+#*PL'52.
M5Q8(Z(/4FN02FN:-Z&I[T07H#!64'1GD^<)X,Y8O\A,/^#(3:GB?YV2#N#F@
MEN.?!+U.K>\"O?N^:][TSZ0D; W2,MIZOA/(;'%Y$13 ?V6JA&7>_0^9;X"Y
MF+%7?US'FW[SM4M>D[:;'?L_#%*1SS\&X2>6@[R(78JN"(K<'VJ.H3 A]?4/
M.Q400:ENWWE67;^OV7F2KJ)F.Z3'>'F?ZAL Z^KCRT>E*4.&E?GAM!,HZKQ]
M$?<67%$$X&0CQ28)E.5$"[=P>DDCKW?P[.'IN@C*EQ&&5\3L6JK6\[(NJ:*?
M6TUS7P;J%.LUC7>][UJ@'!,5U1'PM$5C+VG6%E"J?5L%&ZYO#K0\'0:;S*5A
MN_7)SGO4S(AZ@X,RE$4!N( \>1$=UX[WR8+]NX'"RF/1M3FG]&.VV51NQXBZ
MY5 HE^T\W>:T0 6N1A<M\^Z0PGXSRK3!*2-1R<:YG!/NI)9"F];]=;8Y!W?B
M!;:&UD2$@T6B]+PQV]I<4XM=/6R?ZI"6P2CQ^N9NRDR*^5#NK>B0#EI5A)WE
M/<;[W?&%CLU,E+=CFW =*"]EM<(4Q6<L6'C KD.)%K$Y,CY2]3BEZH'TOT=R
MC-I>%W&^UAANN/\:JQ*P>NP9*HKX$AF!F&ZE.^4, @/1O\Z=IQ9JFB]J459"
M4W5 U[/$CDYRB1]KS>\DA$GPUBRG)[4)%>A.Q9QED(P,W\4Q@I8')T<(ET_W
MB!-7SVF3'\-_'2NK4D \G'J"7SU?J#5ZI;@6KM#4A#:-4>'H0D,<NJO6NS!U
MVM[KR_#JJM/E=20*C+N1WZ(H)8988!1.Y'V(/3YX%\=;W (8_@I]Z9AE%!=K
M(7,*$TDRM35-=<A2@:Y1)HZX@27.KY2Q[,T,7H:-3Y35(A['7ZI3.3^;C[X2
MF)Y9;K3 %P<H^7I4[G'OV"&PY'#94Z7$BXL,L"U_\Z]%0Q=23+Q=Q>1N\6%.
M1TR_.=+02$UR-B[R+&P700$."P]S;1E:Z)M"^W%LEC]_O)6]%_40N[V..7$B
M2RQ_N>0I2I_YU@6[S@,\D?L6RC;,9\S?+8XP<M>F,?L-LT7SR?C."VH-;M^F
MX_.* H8!%WCO5"^ZNY41E]+M@[_K6.C)1OE%S+5*1#&Y/Z;R!_"4]&TOE@/.
MMENDZ6=F*YT65YLT?9.K&K&AT#= CNM:-]T#[@W"/?2K'WGN4LQ@9^WA%6_1
M#4]4E]MWLU:<\A;O-FK*;R^G 37F$!TJ9^;K)ZP<8/!Z\ (GJ>9>#3M-W(L_
M*:K](N(I8\D \)&FYDS=B@+0@8[0#3&9@?TZH]^)#?1]5_V+2"E/@(QSO;/(
M)5N@I14-DOSE20D\Y3AV2*2.XC',^RBIEG.:J04S)(Y&,"+ Y;UN/4)GK0.5
M.$TSA[XY-J8.8H$BT<NZZ[87<V*MOV'!@;T&MAIJ,/U//["*<-MP-Y3-G(H9
M5!DFF26FGF<Z>TOC34VJI)H5E*^:5DP-?BE95SUNMW%E@HF*B_<!!NA&ZL!(
MQIPZ.FT?AP[4C:LNEIBE#G*3/?_;B/&"#TUGD"ZE"\TB/*,U-A6RS!3(XBXJ
MNAUDXZE4A<56I<YZ!_:EC@7[]/=1@G[$ =@^$>F+A>7U "_E'6VRB;R99A%7
M[^P>G-@H>D-;HE(9CO7?[[FX^08(NKVUE=#/[*_20JHIA5X./S@T[\_6!U9'
MXH[V4?=%2E/*F2MRDV"*7BV^O &RW=$[7SC?@6=:OSF$J#JH'R+@V'[\A:JU
M5&QC-.B1+P!I5SIJI2ZY/8S_%>G!_GY.2TW).8J= 7FWB!1%7D0@Z+_'QM(W
M0/_3/X%CVR7O_K\"1X$_.,.?&1O?&1M,COCGVPH3(O1P&I(:@*S<E[97Y*>2
M";IYWN&F;R8#%M=C&@=%D5-$=7C<S=%:41S5_):WJ1_<]O+> *6-BX>:0*PW
M /K NU;_YSFJDN46AV_BVJVOY7334!()AVD.4C;[<6$=#K03WY:R=988<W.&
MKB3;98ZY _D2VR/MI]T5XMI']D](K2<G1.QCA>Q-+=W18QPA[<GN#.3,(R_H
MOCOX3P['JM365CU,O%Y*P)6RV7&P[S9)=EP$5;T3=<>1BWA^TJ T,NRJIK":
M$@H6$B,M#@D)XM'$/MGJJ74D#4TAN'4#T73C9[,91J)<%*J4)E&F ]F2SZRG
M-W]Z2CACH:>$X>)U=:G#*S0ST[86RZJ8/'8\E%KVHH'J$WE3W^"*ZT/;ZKLR
MLN=&KA-7?Z$6[_^&U9"*7H5@].V#CAK+,54:69SEU'O0QW9+I<HSU^CSM::C
M]F\65,>P_D)(L)6!-X,>Q&V8?Q\V2J79?S+)GGV%/JCPV4:LK,7MMB+]8/&D
M/OAUF0/?2:"+;GP.MNB9*6!TUCR?11='OO081 =QV/5,E8N:0>9JY:Q8(JJP
M&UD=<L]+>J1R>]Y9KA[S$YR"(7D=WFV*V9+QJ>^5TOVI?H;FC@K42(L.T"&_
M8R]-$[M7SG.U65[[-N!4FG$KS)K1/Z:=[:6\CZ;"VNA8J*G>_KLSS1%11S%&
MO&]]N3>7*)KN.+9E( *-68D?/+\=HOR]4MFGVJCR;4DL(L"#4"HU.X\CXM4E
M(-$ >ZCCJER;';;DD^NUK5*J[CW+\$E?@YEB\-HD;9<GXWI#R>7$($T*$2E]
M4!QP'/(F1/04.1#078AH/)*&1-7HVCO(3H=N[N[*:*:Y>8I,(U&:RE, 6S:@
M@D>D;P)P3)J*9>1%5@Z3/3*)M?L/BU.2TW0&2(OSRY)]E:+F$\W \TGQ4F#;
MG.#.Y^T::.['BM>8@X@W0-&W'-Z:&*/9'S-],F83*@!Z>DYY$=2?W?]MZU4%
M/=AK/);U2L"9&9PK?HA:#$^'^@/L4;A9=\#FF50#'17+]!7WT9<^K\G0=F0F
M_*^VX6: 4ZK?<][;GA/>1X-[;P#!L)0LF0//[/BRW4;S):/8 SR%#1FP9>CS
MYS5:*#:M-T#$G<@;H(PJ[06.,^&9.M]#?"HSF"KZD'(L?TES&08W>:!7L'>D
MCH>1?^NB8%)MQ9FJ +1%<%><(ME[:+[&.8D<N<%?+S%XCD XAZ&K9#!^.E)1
M%P:C+"0N ++KWF8#^E[OULC_TDPD[UU*X16UC4B3U$D%4@D3:QTV!5VC!BV2
M=.#ID->1&NG3GCI%0V ^[J9K81W3HHW"R&6;$A5]H*LKV-;SA[G[K+Q\<,DC
MQH(EC5/)"0PP.<?XO+!;KC]^ZI\]^*H>=WR$X\WVE0F9:1Z1OT@ET>' .K]0
M"#>A'B1<4>N$6S^V)Q1\2H:Z/)6ZBVWR=;(5$9'Q@RNW/GA._Q89YD'B'E_Y
M3H*XN3BAP([7D=?Z<![)HV,?:H:G,7%BLC.^8=@A$EY[V)-'[4I*UWE6C/.7
MX%-3/UAV8%CKM($Q)N;1;$/.^)FVQ-<B#&32!0#!!ZZK>3>WF9B)/2UMB3 -
M?"8/=TD?="M6/*;POA9>Y66/HH8REI6:Y@CBJ3YL25L,H]ZM$Q4JG_M :^I&
MIRA(UF/B5<$>_)&ZL.^H.>LG?-VQ-F6W.8._0![E$E?B?'AKDEX#=O;+>=)V
M]J#Y*1*?^\M+0L.?_IE1]O7/73P,4V^ &2U#>PV3MG<4ZCQRV+?P&F[26V7$
MYK&=FTL\,%>NY*#R^/:'C#+\?5<#DXFQ T@PY$\BUDJ5<#[>_-I19RE(''PR
MQ!P<A&)0<<Q>8HW$;7OO+&>:]\3M)01!RU0%Q.PQWG<Z,L]0ZXQ\*"PO)>YE
M V=*3$R#G9!P#WU(1)&74D-!#=\,2'&@^%23N#*T2TID<N?'YMA78Z%"%[S%
MZ.)FJ-E3Q37^,"P.L7O0QSW3M2D4V!V62_257%VP=B(&MZ7@!@?_X@Q]K&T;
MGZT,UTQR?OO/5#FX(@R=+V#%(_5=#8W]DD3;<?8X;DH&>Z=2W<._F"N,Z/R&
M- C@J$6<S,=KZ;%4<>0%YFJA_U81"_Y4?SZ:;C4IYB/L7&P,[Q50<\3U[4GV
M]M/9_*:Z%7=6!:80N%?@=TD^9)CW))B$E\Z<CQ>B%EUE] T3U\K"O"NJ496^
M"HLSL4(D7I5T#?X 7CL1X7NF4F3<,$8S_UYD?J .'HT8\OVZII*8-&J0970)
M1JK6\48L+6P82'R4Q;8T-WB"5'&5"/ZT-&0'X7BPF'AH+K5I/9 X_7ZC?-Z_
M#V;&=V-^G:>H_P90J3Z<P:3_7P+\7QI$_(5_4WS)::TFQLP/"R-GN:8@S,'?
M@,>I9U(TIGS^-B-=E$+N(6-CT<'O,S_W$ALV(7#0O$UC-UW&D3"%0R3+HE80
M- HV3HQ6U==D+F,QT:.5Z^@#3EUX'CZ4':? UDGV"5#+#R>1B#CVL^NFB@CA
MI1A^FEH1,T>6>0.X\:=_43')YQB\O46+K1P@::F6YPZD[4]'*]7_9T0Y.OIG
M+,KU_DB)C\S\SHQW.#LKZ%BH@EBX@N0K405"70#XU'4L=?(UU0B$$1F">T5(
M UOX@Z4T-+V)FO&U&B/M:ADN&L9*(8," R2]=EPZBFOJ3287.$C9FYOLBV3$
MB,7S+YXB9DG8BI22.K(, &7=7L"!].MPY>4*[PC>'&&\_0 T\*9P-URO(6M^
M.$[3-4L>W,(ADB5^CPLVRO3;^&N,\=>9-+D([XE!(2)TL;T0O,"U Q6:ZGW+
M6:WYF)VX$2=#")I>/FJX1&PI%V)70G_YM#.DU8 M<V+2=Q,Q=Z:^<V;@:>JM
M*(?K=NS_4$7K6%1SI?".$881@EE1D3D5:4+W*J\,RC))>L(--2$/;=X<>\EO
M ,XOX4K$,S>B6K---FDF:KHA&SC=#^PD;KO9X<J-))GBRKN,[%QK.UKY&%OX
M&A-8CHFQ1(O<]83UAP@:D51<)OQ([<$?;'T/&9[S=\-UKT27H+*'G$VM'<LA
MB,W6\22WC5'U$H,J,C/)E>5]H/DI9HB9@%^EZ.YERW -HU>QF3]A?OM-Z[8W
ME^-8,V3Z3MC.DU;RYI$4CW^]QE3O-#PU'&A).UR+LKS21;[GW7?$O\=>VD7)
ML%,K6B/C(G;V[VPCZHB486CY$74_EN!%\@DG2@*Y5I_/,9H];=;N7.S%M,B8
MQ(W\.\D4AJ<?W%XH3T2T(CEUSPF*7YSE/8%"3=/ 4 ,3%'I1;CS^UYHL]5;"
MJ9V9ZH]#,)@JZN.4L?L<T(\JMC4S@Z$-,;=,#GS8IECC:L]KE<MI#X8,O5Z!
M&45X=.9*YR-#JR+$Y1\$55@7)<9P9KW\US_125*P]#]93EYB]@WFS:OT!;W.
M,W],.[Z?.769+P;#]41 +=J^_16E+S9P@D[:)V"F7+Q.#B.$%0.=CU%02&7-
M=%S^D [+2GO."1%FII'E?XKRPU^A>QTLTM0LML(1-S;4U9XQ-HQ=/4&@ XA+
MSA^S$H+P$?@2<+A1-GEC19OM$('Q^WUM$I>YP3VA#.ZUR8G.9\(7,ETR(_GH
M@;7B*V.D->&48C6&;*Y,N=Y?V%>H-FE3[.UN$X-?P@Q_IWM5U'[FO"T90XRG
M;:;Q$-D4^=CI/8ER"G"[ *W&G,_.6!DTSNP\"3&';$)N?)!QY3G*FLNLKCQ/
MN?8V0##'@71%2FG ^XY+I6YG3RND_L3K>#S20JCLH(DJX;&#=N%+=M<[,;:E
M2AD6TO^(ESHAK!>R)*K":*=DB8%Y6S2]N@=?IRN"HH"H2I';A])*.T>[U7H5
M_&!338"T@\@4+G2OJ@J*\\^I:WJ=:0GH7V*N*RV+)7/59K.?##RO,M.42(&B
M05$1_(O 5^$_UCPJ%E3\18$X:T2__E==]S_6=T$1ZF!G(+'RHV#G 1XUYLXC
MC\QWK$1IW&'SBF5GV1E\QX"F5?-'E"OE!R^9#X">;Q<?4EB+<I),N"-?]5H7
M?LZWXZQO)4I_D8V3#5".G>T%'_E-\U'G8@U8HOPR94A<L%10)(*B%.]OAW7V
M'-Y(]^(*>@/LR\]] P4TO0& I[_> -JJ?(\HCDSWZG+W$7DB*'"[G#TYV3GI
M?ZD4*8D_[1L*$\"?(^\B0P2<R6$F[?6+9BU;O\X3Y>:<-Z7]7>T;0..0*G+J
M4]PSV9RO@G7M2R@; ]!H^1;7?K*Q4]!/ O!9@F5F E/UOE5<@VK40^)"$)LC
M=4KT)RVQ8D#*ZSIO5XMMY+/@!7>E-59XW.N@:/V+B#D6HUMB%Y2*V1/>E8C+
M;<2%HF)MC**B'U>^&YI 35];1IGBI*,[C5D'';41LO"*I](CTOST8')60PR(
M^\!#O.7=9XP_6T,X><%H@UO?QFE*B6.LT(Q2446@-$W.#C11XPJX)UTF>X%Z
MH9!.HYO;&8,,6X#K$HW1T@/<;T;D[X)$/4BCY\+ 9FCCUTQ] ^N$)78.G*8U
MKU]M$7Y/.(HV>IMK2>L45NY7#J S;V8I/O([RG-B(V;)UL(\30O7>Y_!?S;K
M49E:^"9=8Q@^I B'F+:"@:.<.)-<9E-LC<ISZ6)W]L2B7#H/%<+*,("Y?NY2
MDKCS;!);9WO@YMDSU7FUFM6+RF9-,0 ]F>Q,&]D\4615'#L!!& 00$- L!>0
M'TB!=OR-C]K,7CM;GKY -5R&QZKY@#V[E, -7E *D 4XHC1$9/YH7UI1)89W
M<RX,V[>YCZC(=7T#++!ZFQ*,;9/%B])KFHS)NM4I,0L@CCM<0,3]T!1%FM<I
M7Z07+[JI6N[4+,\,IH Q&%:!Q12'1_DMT3Y*E7K>N18*AS:=HTZ;DK 0[4<O
MBQ/VR<0E;/.C]6<SY.6F;*(/R_V,[4AA4"KC-+J5YR_^S? CR)U-F &PT*EB
M6\*M7TP\/CTD,LM+J<.\A[Z.>OB+Q@O%]/P[@2N;3-$ DOYWZD#7''UM8;''
MOV>Z4BSOQV\F<A+A9,NUL/E1BD>HH57I_&7@X*R";))1-%)$M56O=R!'C[D$
MM?RZ%!&M.P,$2TH6*.^L>B<BEU4 <523UTB5HW#?U+U+7R68O( );IME[0'?
MX=^WH$I;&SXYOXJMH+\VEWI?DQ\:GU=F7 !E8H.A[''U)D10_LP?H$&>&0_(
MR8SU@=,0D.+_LS</_\*^ZMVI[X U Y6VH&KQJO:NWU=>J- W X,,IJ[WJYN,
M*6CF245QA?7K-LTTAWZ-?.DQE@\;/7RDBH<4)!>#$3B4%0#Q=6L66#6#=ETT
MR">9E3 A8X[27FN<Y26J+27C6 S):L*D:J$<%F]3\MH"F4NL9;X?'[%:[OWB
MP-,+;^:M,7]%DH:[)QE-VS0W*0GV.W#L#G*_Z#7/^B4R^2RBFWV0R'(),GWT
M[+5&W#'PN+$]F6TD8<GB+%0--BTZ:-A)*,UJ3R6($KJ )Q_U&G#HI%!*!>/!
M/F<YPFKSOY8*179WKJCS8PZ*B4"D"(<H-6]'B7&D=(74F<"D_)F>I\(>SZ)_
M\$C)92==+=)Z(9 VF%W*U/T7@566(+[H>5ZSEB *FP$^,38,LMI'<JKTZ.Q7
MJFNY?-=NK M6BI:ID!Q=@%?RACG1G$GY%G04&ZLM3F&"HF+P43V5Z$GU&3C7
MIANCUW#Y!G Z[N#G4VPOX>R[T%AJ\W=$;7(%?A_@6F09 COF>B?5(D*;8D+Z
MN][&2Z[#6-\HG,LYAG0,IF]4OR*%D@X+#T\\P%:7=P!->LUFS$:-ZU7I2B2K
M7/K$J]RAHL6P1VFQ^9IXV$\>YN1!@[\*FDU=R9;DCS?JE-".2"4;]DC<Y2LM
M)L-.'K"NJ^75X*G8NFFJNAJ_>R:#]#[P2D C],EPE%".S0F/I*]]=)V%;8Y=
MH&(=#\2U7RSDRGP/("%1RT?<[Z[@\$N]'NGLLM&V8SG:A1K\T2:S1*8_)A]@
M6T4L.T8GHE)OG&K=XZ6<WF.>$ ./,5'-@X4ORJC.$IAM1"K8[M>.S%\"HSKD
MQPR'0NE;_:[IB]O0BJ<^T:Y^O*YQI4-9;U DP(G!.-+8*Z$X#IUK;]65$D&%
M_ .&OQC^K2PEX2^C'$Y@EO]W?#OIXE/FH5M*;FILK)W,1'. >WQ=T#@B/70!
M:<[Y-(71W"SIY.S'7ZXHXK<#%890 BI]^L'<@HVPB1#%@MK2>4-$;'K0WDWR
M+J#YESP%+,NZ&!-<5K;80= )YM-RJMGKP$19Y6M3[,W3TA%0Y[8,J_-./.I4
M:WC0G2['H*_TD%YCT2QJ.$K :1*ABA)L9YT!A)=W>I5X2%N\T:PV:T@-C# $
MX>@&2N9]\,U;6GG)(-(3/8FHBHR(?5I231]S^YX\-L7RB5_K(,V\07UK.IT1
M$LG_4M/J&)RSE'TO>4;Z;]E]Y-0G5#%5"G\./(.39VO0Q8I**418P>LLK_D[
M)!2D=0X&=H=R:I"7ZN?_27\*DZRCR7@H&OO95J!8XDF.2R*J:"S43U^]0AN!
M.VZDFZ*/Q5H?;VO<O^S6KM$2$IS"$M=2+A.K$H<F:G0G*=?+?NKSOLP>'D08
M^MU@X7#VM:YMVJH46*6J]JLJIL&D7 M]0M:- \..R2NXLZUI^EB#D/H'/V)<
M0_"G+2?O(&^8/EL)\Q)9U\(Q??RXISRC53%D F4"N@+BJWWR;:?Z!MQ2:WDU
M#9D"1]M\,4L["5-"4\ROFMRQD. -IQQ'"E)E\<^=M9_WBZBLK@#]H>7+WG0:
M'+C'.&&WK%7:KA=L$LY2EAHD)/IX2O7'7/@'6GRW^Z]K4O+$^$;4A#IJUE=P
MISAN^N$EG*-/3S*KV-*"PQ9-/_LYH P@\ONL9AP>"@;$&SVFM[-=K*!S0%..
M7"U$CUQ#F"&*A(><2/MBMEHJ;>>7CZ.J29(?#N>3@ZZN\NKJ2R4U/\Z_IXPS
M;-T9VD\?_#"JR9 MEBP>\E%4M$#336_,4.^NW_'6VS4-9$,-%?*7]:_GUK)F
M>QX461*E+L&S,TKQ,=U1>!U@>\^4EM@=B:NU_>,:S"HG8VEL@_4WN"/N^ '<
M=,8;OQ!($59E2>&GD(;2]GF*."3I5<1(-*KW!3JQDWQT )QP[XNKV ]'GF^U
M0E25LNT95%%A=(UQQ ],.K]H<Z$CF=83WW%O@(.28TSHC JKJ5!+1:H+7NM2
M\</.LL<^M:50:*J4U9^LHZ)X_GJ4UMT9&TPI_EZ0J1COS>4,:C1S$9/Y!]7X
M:J%):\R9NJ6H[NWEU*Q4%H5@EYC>06(Z=7KK@N@=)(RE2:J+&"=@?OHS86 L
M78;QP=4H,[=T250AD,<T1P_[;#.T[[%8U;DG3RY319P?5#3.L(P(CDNW2I51
M"I'22X9O]%F9%T<$]QX7-?@0(RB"YOQ?9Q<IASPM<5NF*YL:B2!?@7[\9\$)
M'M2SJ1$6"YG!5 1PPQ<8=;S8TUXSNZYX0M:7%TT8)XE3A5@;T29LO3!HKAZQ
M2U]HU_=P&5:3G=_1560%LM.#+\\SR3OBUN36^FE^D2'-;;R0DR%Z/Y;41)CQ
M ;:11"OC,S3&B6J1<4-(ZY_"3B2CJNU.\:R;H3Z"4F+G)Q64H 8%@K?CFKTQ
M&'2$Y381$DQ;N%CTJ#S!7)4%\IAK1S]BMT1>OE>/]-\YX)&IY$B,GATRN7G_
M(^#Z#RL5^]_4>5'$'-]_4N<L[]F\R^D73&'JH\ )+2JZHZ83;J9!#IXPZ7 ;
M"F2U\1>AK)=C!V)LE:%,9,[[OI;<;;,E-)_V8^"\L!==5S^DV5[Q[CB6UVHJ
MU2 AD,!0IO[ "=9L8J<3=#V4(EP.RX//FY\))F]"74A=I/F5F1>[H>RT+NZE
M.P<]FXOEF-Y+(/^3>R)LQ(?I 4 Y@_*09K/K.3B[Z-E2?,9LMJH/;V5$S3]J
MPS0NYW DF/.5RJ\TVYUCR,NH1%[RF'907[(<*?J)6(UNU]ADI8ECU.TF<TFJ
MNCI>"EY$#;PHEIB<QX;+J%1>YA@T3!G66"&1;@9K<UJ>Y/1YD)&_3U?UL#0G
M[;BI69B45]'K)$#H8C+HU(\K<RT0GJPKT7MA916?4) I!)EAM?J(K N9N15S
M:N4D=B%$B+[P]Y>E#S5%.:?VLIM_A!,Q%5UW'-%8EUMHE\"MSV\&!ONKBZDP
M<X7R9Y U=*"Q)NSDQP #96>;9C3,[;L>]E,M%M=LL<P^'#>2X!Z$WZF2$6CV
M=<#W>]D?$XFBRF&3SG##OIN-.GIC-+*R_+XXD*@QF]95;X!.AH*7$@-S;\+F
M#LPNI!.-&B'05>]W#TM=];Q+S:'0.!O]@[#KK0O"ODW1L.#QVD ]'7A">M+V
M%UO?V3)E&H)A!W,F6XPP:Q+G= PXVRG<PA.K._K8X^$+E(F.C16!G7JT01W#
MJR R72#@XJ8P$;=N_IH*VYMK; $NG"TM+:QYFI>M/H .(8B6!FN7JV#+I[=8
MM6#4CC>F (O:EHB\L] '.OV]2(3JY_"I< :3%_^@,38_:NM:]'M)U]S]\')!
M#+E5AOI'[=.7!;*@U8=F_]!L<%#TZ\(%.Y'YPPZ(7@.:''!Y/"YX:<9=TR/Q
M=W"N-%!3TIGI-DXX2K9,-E@/*C"V\]O74V^R-'F&C2_HWPDZLETBR$9J\\7I
ME&J*J2P.HJ?:%PF"_9IE7)5G0SVS"2MGVXG/T-5:ZUND1V>SU5Z. PO3?5AP
M(A<4BASEUSXP2?(<%##&EPDI\38'A=D W;]OA/]7!@IK^"?Q.*<*+/7^V^[7
MUU<T)5YB,WD1U&''=VVL^"X?4:K?,Y+"!/'?-JAH_L'II;X*R&M1L60?AE>$
M6 9<LQ\I3)$".L@M3LCMP[\J\@>X2(W@H95_T<I9]H4QG;@+V+Y[UV[*H_>8
MQTN=3GX]AFHHE;X44*T7UZ7!C89-#$47;7+O_X+I;[?*AL:T>##+5L;XDGL#
MZ:7P/1;G*G6FR'N3!_NK7EQB:+,,9X9'^3,TRY!9*^VD(XVSB-^DN<3&%_1(
M=8$/1-"07T*P\O,:6K#L=Q4J9E.E47S\P" 1W8,U=C'>'?"AXOLF$O6^LLR;
M*U_AX?OXR-IP9D.-CT:0[[WE3#<9NPGT+K[[=4VQR*]\YD.FVY=$%RA73AL#
MA^K.XF/#=2V!&SX_ZG[%F5K%")''0#=#&Y /U^B?]2+8U^ N@4THS5,,D+)M
MPE><;.30=!(%128O!C<8=QN]W.#B?>20)S(=6@8?BI7C@I@[+V&:;>X]ZUM4
M/@LZKC&UI$/1 !+ULB:?GLTV66)W/\HT,AC:<2\;=+X!J,*[VC8459!5QO=C
M,#LI]^=S,H.[NRECJV[#CS77*LG-PTF:R]L1-7$<-TMGG5HC!C9.1$BCNY#J
M;";!4K)P;5<+N3+>TRH@],_U=#4^=7B2KCX @(7]5'"+>BN^6E17HUT70R*A
ME:\!$#N <[-,EEMEO'FJOZ+[._6Q#:!$>U?A/H%$S*:')L=0IQCQM]HZ1-A-
MN]D; /68)L>D>DBUB=)VEV$^\&!Y]M-8#]?0D,1)[E0FTK _K 0,$(A9I)3[
MB(O4J>PV?]9,6Y?%[UL#.^L>:&1WV.$+>>''SE(!<O9KELT"F<:Z"2-S,W5@
MB(19@+\!A,;G]-5&6,CLS'IZK?8IVA7 9 J8T*(5%/V92?^$_.1GO]ABG_]9
M-=FY?@.@2'!?)N75!C!?R495=/\@=?MR&=4GP(\K8L>Y][?NRFQ82HG6F*-1
M7.R$".JSJ*8^=J3HAY.2L[KD\!QC\[3_O"T<G1D9VS":GAFL : PI3 !H%3+
M_Z4GH?ZA?!G>DT@.3,A87\=@?5U>4E0 EY$</._'IXWSQX]+AK71XNNB%3\P
MQJ#!ZXJBS@UG0DNC'*T<36CQJ!*P1&GJ=&C:.4ISC'Y.:)&(JCQETQ.\4)5J
M)JBH).%K*VZUX8%XEA-%PRF$A2I-I\ZXO!UE<YQYR>=HKDL^O\SN$CK]3HDX
MP[YT@<9UG_,WN153F 'Z[S*$)ZJ30) (^G6'>U%IR'W[PEGNH'>FX$XD+2;<
M-I6A^2M'$+.V0ATBVL+87#^CATUZPII%.>(DECY(\#22WZ=B/XM'VOK;FOI]
MX-<F*76C,#7$E8%6%'D.$+A:V85>0L[*H@F6<G-<.'7NU0L)D5I,+&,>W!N
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M$8WG:9K;]#&51WYTK'0E*?:G8&',.XH\1-P:$^S-M4F6?7HMH%FF+SD$%VF
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MB;X'%>3M[)U$Y29,[C<)1+:KP@@7;[$ 648>QAG-N2'HAUF*N1KVDJQ( ?@
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M, :(Q_W\-_O]?VZ0W=%_ E!+ P04    " #=.V)6=NO_H-,>   F*0  $@
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M0V\F5MZ] 1,^ %:&<&Z]K7S .QY%D;:?RO!E^#;_GE@WF"X[>+>PO+.ZY@-
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MT3(7I B6%FVC4Y2&6F=D(&Z,ARBW301@P'3D_W'ZB(,>^7]02P,$%     @
MW3MB5B<U98I'+   52\  !(   !I;6<R-#,U-3$V,SE?-2YJ<&>]>F54'<NZ
M;</"W=W=W9W@$(*[!;<@"Y?@&H($3W!W#>Y)<"<X"PMNP=T?>Q^YYYZ[[WWR
MX]4:<XSN535ZU*S/9E7W\_SS+P!#459!%H""!@"HEQ_PO A( 0AP</!PL CP
M\/"(B A(*#BH*,C(*(18V.@XI$3D9*1$)"04-&ST%%0LU"0D#/R,+!R</#P\
MY/2"H@)<(FS</%Q_/ 0*$1$1!1F% !65@(N2A)+K_[H]?P,P$8 !J"L0%!4
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M/,>W2(8^_Z*/J&_>\-?Z*[PDLH']R#\3F2-E,TPWDSR\>C0:4SV>8YIJ8W-
MO<!K/-/I*1X#*>O";FQIZD1R#M!*<%+A2/W$1%X4(QZ.F@SP'U!&*XP*)XY0
MR[*!FE;GAE$?D0"5\D CP+CQ /7_,I 2N 0F?[Y<?R:$!U%WL.( :C+_,]1A
MM6C"@*P"M/IZ52@9:JZ\%"L ;3NU9!3 T9 J=0D*7QO$V0<8\J+^"48 B0,
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M_]G.&C^)-U*,_=C(Y\;&C%U55QZJ2[H$F1*88>=M]+E.JRC^_:ILO",HSEW
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M8(&@^ (L *T,^8F$(S*_7RI;X^@99R\6^(.&/S0@5?SP+%E]C+V8\X\J?M_
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M+$#5PIKX=1,V8T"DP!7U>*FA8?&U#A%95/?_P]Y[AT69;/O"K2 ($@R@9%!
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MJ_L%' 5Z]=^*NK$2/S.*/#H22UE.GER>V 8O;X'/3\ MX173:$#O)*:!.VA
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M*)M0-[8TYW!K<3&X:EB&RDU]D8B<VET VXO&BN]8(=Y]DQJV\-;+@JR50;;
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M?^/Y&\_?>/X='A?"UD8#O*RI:N=&030@=A4-.*G>9*E#[/CP](TLDV,(S#3
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MQ<KK:T&(2J#6C]KZBF+__KIJOWG6%:_A>SIPDXD$R64[O$O+G;?58V>89UA
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MA/I/UX4B 1V"[<DE U2!-AS[]W_B3;TQ_>KKZ_%.A9#\3H?PH;S65G#C%(0
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MA=;;85G:>-6@+C[XN)43O9SH5:C *MI IE)A5'6&O;V2G:[N +D%WHIZHWJ
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M1.E<+X+*S\G-M")2B$ZB0N!K?O&T8V*R.TAGE&-Q[ZZT7U+YZGQ?W;($FL#
M7#_G7K R_ S(=\,S<<9P3=G0B T;WN_>8H'.3;P92'Y0J+2CW!C@_&0P(X25
MJ+M4>X-"/6K/MTYYN3JE5;"T0_BII7V+S==TSX@[Y #]1%_/%+V;AZ=DC0\V
M72?8[.VS4Z,;CM1-!A8S'CHO?#F5/F 9&%FY'=Z5_9R%D=TM#O;V2#&'](SH
M=[>X SVWZ.P&U!MKKTXH[<ET^Z?5PG)F<XOYB&_GNCMY(]/O?XOHL).9$%UB
M-*P\:H?^]LY-?[US4X#Y3/:2KDP#Z=#ZR'*))W%?G80#(^T3S\1/*>,IV9ND
M>M'O)PC5TDA(>#FQ.VA"6U>*<W*#/R\N1ZE?PQ8<+4E4M9R->4?*Y"Y<I\=G
MC*4"&8NX+WQ_=P^'_?2M<]"R64'AZ_*(*@7/Q%3$J_C50IT$H;@TASNC#J'9
MD^&B-_FC9U2/MTBA3<GG72:QQ/,DWR(.RH,1W)%NQN(Q[2ST)?IEK3-#!%,^
M=DJB72"MTZT5IK9<[G/)F[ 4:+1Z+M&]L2)ZV,Z"+-N)\+6"IO#+9:QK779-
M(_U2P#OCJ.-@V$3N^9YJ80'K7GD2^OJ#!\EK<5ED)XF\=SJL'5A&J=Z.F(XF
M*$2.Z6V%I[_DI,XE>\>2Z+22J2B/[N;-&SW2Q/SSXXF^P"\LY_107ZF+1GT@
MJYA,<K[#6D6"B]96G@?XV#R9K1PFG2]&,(K:W#-S7TCS!_63V-ZA10MMO/52
M+K++&!Y1'-E[7C,R+:[(5O)=*D]HJ1T3@;M TVAYZKBDBYM>%5* &[/4TA5K
M)'U73K1?/7<K4-OND45EN/PC7MRO&[JEZ'0!E'&T$?TX%$W99W!O9<CPR:V(
M"1)@;(0W+ ETKCTY;M0[/S;'*-BJT8LSR.I0-HGWY)^65@A>ME[<9TOD* 16
M[<@,I09ICI?O@91<K-Y!'P0"K\6E5D\ONE";36AS;54=3>H;_*&LY%0SA:(X
M\D2TY <"5%\$(0\M8A5_DH\_B[EWO'*[XDLDT"ZZ$>DQ>NM"7@=S/<@\1S3V
MPKZ-;RA+,8'WYZ:FY@?DAR>V1D^L:&M&GP6VL3^O*:^L)6-=K<8E^0AJB00*
M.<UU*$NZ^YQ7Q@K*W%V?IG$,@"8;_.0,?V7_T=>[\3-Y_&G'84,0W6<764,2
M7WKV#R_1[YU=E26['4QZ/*0Y; \B^%PI:4@5P8+^7I(V8F2=0=AQH?HL#W[+
M,I=]Z[QP>A7WFU)*(^MA5S85>R.>VJE-O3QLZ-M'!3](+27M*J7M8+2%==Z+
M+VN!)Z%<GJK2^5A"-@RBU;ZOS:O-P'XW&X\_V,^0!Y[VX&!OD9HGG4L3C_3K
M1MK277#8GSS]N2\TIG)H[C\"UA6^6T!,Q7.2<KW]S7YT9 H)2$YROM54[MKA
M,9GHNQ',SDR#G;[UX1U][.^W_A947_V< '#R:>*T\\8JP,]TT'F/^<RZ"/H,
MM\ 5??UN0O^+-6]Q3)&*+5>X;&C6(7"5$OP1)G%2##B:I/3 +K?4D@TMNML"
M <3APAAG53Z-Y%!/ !_),+5$0 \<820?H'KY^22T8]4^6CLSJ^\'M;P#NY$
MA</U;!O7;).$!.FJ8DRTCYT;N8A]^U KWL=R6 -/-R>*; B2BIF3M5"V)+H
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M/;G^/^: O65R9-<1]+M.$N<,@8V;CK\$+IZ0%2,RW 6?"Z3\LQ/*R&G3/Q5
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M!Z!EO!M:\Y856^F6])I4]^ZCX:?1_2]<3;Q71L93QFG6U2<,32J&%V*+>D^
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M<WT^5U@;R_!YY!AN<Z^UVZ'HVKGJ,/8D3_JJA(&\:@\]_!-02P,$%     @
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MHA\FB825:Y1#@]*Q'7.^T1%;Z1+5+Y1H)#(Z$JG\17VM%;L'SFXG:QZ;\#?
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MG5^TO^4?Z/2,^5]Q3_94C5AW9#I4D!2_KX[G^1/;\@V)A&%SA:CMXI@JPH;
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M! M;0[!L? :_8^M*% ,(F\U!A> Z/J/G:U-+MH90#=L/D3 ]LD+9V(2II?Y
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M2!X$S#@=M X\//O(1?[2#>X&88?CVAS43AQLAND$._<7(_SD6[HCVP9%FB$
M%ZKU^,9YYV4C]S1Z9FY$I3<F=Y*_?O45"&RG7V.8F_24TS";+&5(9F!]O_4-
M1W]EDE$Q;MR[>SJ'6GJE[\6+72C$J=ULJOQ3ZD1VZMA8E6J#BK<ZL[;F6VK?
M].K!F6_W/Y-+P$U$JB[I%#=6,YZ)V4X.4)1(<^.-X1<PNL@P@="T=*A^[L-T
MD 6:6_&I]O0%QG=RJC5\5D \9A,\$.[TQ#E.=:!>GF TG#00NVFZNBZS'+4J
M@FJY<4<PR(7G;17-DYAB*VJGY-.ZO>:8NN0+H)P7$E.VTA#6?L?0)/'D,?08
MX7I5/>^)HW]X[U.RUD+_FF_"T/:#FT=P69E$9_HY^VWQ<SNDMVD?VH[ETL;2
M?(Y*5_(DIE4UJ:OD@6+DH4) [IDTJ*2H;AW2J^0*;<P$L1$HN2MIC"K^,O N
MO.RI4 1A=V,K@@#_L6CX4$P?.]?X'^X*.3H>LO$<716D3%$.#^7+3L6&NW'3
ME=AA'KS;KQC:$<?9L&O)]L.P'D<I[$M$D)1.23%M>.73)O\>^[V*(RG%:SVX
MZ6P_&7H,=+GJ=P][EEA%?0&TLYSCY+*$G7!FGWU-WW13400AT:EC_!%N+'L!
MS,GI[^F.V*_ /22=/ 5L/?]X[N*CA[S1I\QK2Y+Q(M@.H7<6_<4MO?55N$1O
MZ8""-]^#\@<K??@W;^] 5RI$^(_PI!G0<H3 W)H11JZS/DIT7$7H1J&<4HI)
M6LA,G(;XN_!LUR$.19"M4Z#3,]"K_^B#E[EI./>HPD7:]&^%3X+B5@QB:<S<
ME;GT#[R%6CN\:[PL5/4-#V+-GTM@[0[2KL;'00SVF]"(8QPK+ZE&K0Z5*QGQ
MMDG:.AT[ESNG24[]YW<8_$?MIA>13XMNQEMC>6"EFE2NN)QZMGPUII4WU[R"
M:)]:JZ?1+V((03'G*2=CEV554""?2K:L%LUTL71)8PX.SD@)M_W/_ @3L;FI
M&M5:;X(D&_ZLU*!$<%XV4XV7&W$\+=4SIV,!5W5^[LD\X=KG^5[67T*)Q9=/
MZ132,W@UJD1NS:AT6=_@^GOL+V[-'O>9*B&.$RDRS528RKH]'X?POP\Q-X^=
M[B0-EN)/U]X3*79+1]QY1H+FH(VT /2TRQI%+?Q7,/_EG[9(X&D!Z7)@0A:L
M+L;0M[4)(]^?E!"5VU-<D*+TO-3&"> ]I\D.DT4LZO;(XG'JB_/1B7A'O2V+
M71@$6E^CO YVI<^2NB1F>*@AV 6?0%"X=;*^5#VX.UIGOL<%H:5*@AXUV/&;
M-GS,][UP;ZM)B^MC(S89 3\V(G";V$=>^(>=B6Q=V$%^^6J);0E<;!LEX0 #
MTE0'^67@$MJRX\JDF*ZB2"RM@C$)MWFN\NE-:()VO(;>ZD <XA\X$RPM-T+=
MW-'$I[2S]24Z5=5G8N<>M?%'0?.L1-)5KP'R#C=>GLO2K-T'FJ2;)F(<RA#W
MD 9AI\)2$+8Z[XRC&^1<U3GJ_B+ACO#H(*3Y=<$KSH',IK3WS]II"R9DJCZ/
MY>^/$OT]+S>__CUG"XK/\+37']K)RXSU3J^FG^Z:ZE@-?\#F_-F9:?($HO[8
M4!*H0E4UE=89!UI>CY@;8C3SNH(Z:$K&05IJ:N(V=<>=4+H\\O^L"U5TXZHV
M.U[BQHJ"(_=)J-8(*DM3TILLMUMN;HH00"K;9/UEYZP86U%4"DAN4^_ZFN*L
M_^^G9UD6%$CQAKN[*>*IK7BKCS'F<Q&J#<_RR8FN7#K5I.5O*?N&Q&A<TBM^
M\:B(W=+(1((>OKI453JZ7##QY>X@#C4W<#5#$<2IBQ]=EA.901H7^IOO-?K>
M:#]CX3Z/7_C\%AIK]V&]<!D%%F856"WD>*KFI^SK_CP"D8RH6IW'MJQT*W2)
M8\8G32?LEBQ3:H2IA\Y3N*\(("+%C&46NC#)83#/R7+)R>&H%W)BK];4T]1S
M%#\47^P9'>%(?)DVF#:T_(">*T>@75 \K1065DW!%C[+H1=,R1)PK*W,7$T[
M/W2R)#_,.R9]\.D7W&^C>&A37*[2TC+ZGD(@\-P%=2Q*>W*S&6S:H,\JQ_OG
M_:'5 \:@R#&KCDM"D%WV-*[$^01/"H_U)K<@H$RZ.D5K4YV_H#/E1\IRB:MJ
MY](>7S8XLI,7C<"-,3N/?99S65'W!YA/=M[67KVKMTJJ-8  %8:79[M*0+E0
MUY*4J*6M6M5R74%\+1K1<Z9'0@!+5WO C@T)"F+8]_+7S#=W=>[)F30S#^(T
MFWGD-X=\D.<#=6?RO?I!\YGKC&.%<)(\?MK(*S$7N9#&Y\3)]\Z'LQ=,J-9X
M>F7:,L'YX2F9\2?R'U8E3U-YI .M)-H 3EG'YT6=,\X_J:XET;_R>9%BTGYY
MJ3U&RZ>VOBDWE16V6&U^LG!ST.^V$9B?$S_KK!INOQC&2M^U'+?"K3XZWX:O
MMD850>(9_>A!K I<9MY>]]K /J52=WV601+5E$2'@2=V*UB4; 6'G A-VES7
M.@OO+PXM%(FSINQL'R3UCO,>D6Z'WP>6UAR@3QQ&%U@;_(&U1Q%$$E!-ZI]R
M5IMB[NEHM.@/?9NU S8,(X[<2)\H%ED;(/^$T:V$Q?Q4!<1V>/X]IN\ RK;I
ML5ATRL@+%C=3-=#T.47*=2I=&PJ9KI/%WMI6$[*PQD&BM1\32C&&>MY:;HS.
MKQEULZ-04K%V$%_\-H_Z@LI$NK$5Y9295;#G:3]9NL!.FW3H.$%:^HMX>C]>
M;/73:TZ^?5U@80:67Q&OZH3PP:C^)KB^C.+D6;HLY@6@]PIH*75;K:_U M4?
MA-*+>>Q0(?UCZ^7W3Z]0_* XYC3_,?R9X143K)Z5-665=^O:A1T_O@*Q K:_
M"OE_*D 2 9G\]E"3WVZ2]2'-;::=]02_A!I*H81@QQ2M)2!2#RE=6!>6Y@!G
M]7 ]VYV'6F_'TLR5\6W")__N)(YXMKJ^T=V<7M>/SS_6;$U'*O;.+YB](YQ=
M8G"FMC00D:8(MUQ6L74MVU@F.+S<UV/YLP2.YI=@>/ O3W0B>FLW6.#G)<S=
MB-D6S8?\W.Z"?Y.VI]JYRW<V^5OU=7L^=FK/X[&2\R[&3#V3(-@<3GGO\6=G
M*D9P[- D[6V[.2N"#!S?]KC9<9QW89^U5$)*0 ;2WA)622VM=L'^/E2K,@6(
MVDP2C-1PY":;9+\V"?>OHHAVDVP3J;O5Q^7IQ;8DL :,(X7B<@J;B\%.'@JQ
MX 3M5'*#^0XD)"3$^(;T(%=U>PLW[GJOCM;T$9"1I^<SYZ+*J$"5Q6B.!]6&
MUUQVJ<Z(>:;^TN(+H R*Y+PAX-MC[(ZFVC0C\#$!KY[TZ[JXN#5 (H-SHHDQ
MIL8V,\87'=-!3Z9(I.B1=[K+4IV>.O6"C!F)8&\NJJ]4EZ>0EC2O)JL(U%4N
M-LF9:C0I,DG5WLI((8KXUO1G6F?)W JH0*/# X:&X#>?+3X/YP[MIS/]\'(#
M(7+8(?G0>@^9;_*_WSQOMS+@&]?[\1@I5/9FJDH8,)CCX(#W927%48#+45E0
M!G311DPL2/_#FO[-UK-HT_VF .@UIDX"(:L)=Z@3"3TW2>.W;?+G_*\0WO\'
M\%^H4]GVWTD5Q# 5NSV8)6;V%;'%P("P%>#592@7OE2D2"L$" 43JY-D:.RS
M@B5/B"N+S$>8?K\ (ERGU*8.>$ ]3,,,:]-2O3:'KUCQ:%V;:HIPI!NJ6F='
M^5HG\_$?O^P'\LH]%FWWF._?&TQ;=R,J$Z@MO6$?:[50E%-44C,*3]&*71H>
MOW2__*G!&'[.0S1F'24B/WV9,UT:3^,8GL_PRZR&+E_^1FUSHGOFZ>HIKY[=
MV9M4D 9)-7J ,J4:"SI14KF.AGF$6,W<^6D1SMC/&Z@4K+[ #5SVRSXTR@:3
M%SE9U7'=Z)LE;;W3,4<L4Q<N<C>Q(HQ:".S]M6FGV]K:>L!79ND%/9P)MVS4
MRJ[B0Z4O\..91K0OPC9?2-4B"&2SS*H/S4WZ',E)8.[T#0C4/Z.."OZ#^"?1
MUF2=R.+. W.RXJ;,41!-^4Q@R&M=DQ"HL\W$1=/IN^AQ#-90=IP^5(+*)-D.
MW<\U"T?9Y"667@H*':C^<&BC[C9X ;1X3D$6GUF%N1\IU1:],3J6=7%::W"C
M&7%_Y["R?!;Q59H9?*N+OD(!7(M:?:(<;G%;1WL2$Y4!/KU;[Y3G^!CS$]O:
M%6?)W:Z;3_ ZSMS.KN#3) B6LG>DUA<5YD#31W#\I+84%YF1\IWD]R#3Y4A6
M:"UW  ?X .C<4ADN3VR5I]$F#@_@@SH&Z"C-+<_F[(%D9/563^6*H.OJG0MU
M*4[9[K'[5$<8_1=X%P=*"&?K&.VV$_I/V2@XW[/NV9B0:A+6(P>+5O;5M)S-
M9!8;;*8<O_8!GG7!/VPH>Q(V;%X (1,K[-/6F1W"J;*6?VP(43[?2#$]_7H!
MQ"<HX>W,N68JZFHDYY)L0>1O*4;.D.1BY8$RU:U3FT>;$H'"IY0]XE_%UN=]
M+ 18L2WGY(6(+LMB\;/JPR70+=]AKH%0A:6]+3(1?@>'0&^-;UX DMO":^Q3
MEX\DX*Z$CSTK8.-MND>^68E<L)9KO=V.Y8T46U1+QEK"/K]*:LBAYRQWT:TX
MP3&DAB,Q,KF0A4*C0?W:4&HR;%&DMY1WC]JN_V"W3%[BS#K,LTDB)!-7*^IS
MPK.F_#&FL:ZITR S\W AJ,\^"TK_[K\/#_Z5RW[_? ()2-1=Z'GOB<;R,?K.
M@4Q'14ZGTK%V*/^-!]W*+)=%2=2;VHN]YO+Z=]IT^B<X-Z6>'Y@M"N'7!FB)
M_CK1I/E7!B-*A+2(V:R5"K(P9\5_]H!W#W>^X?0<4ZB98HP]7G!?05+H\'\C
MU/:C?H9K(?5'G5L,8X7DQT'(F-8:]:TJ<EQ/7JT;0G.:42^DG--! :QN9H,@
MIUB3FJ@F$U+;'C8SL=<MX%H8:BH7#-C<.8-MY6II[[ 6H-U 6\5<R8+C)?VR
M:5#'AYE)5E#6K']FPJ<R9&B*TC9MLL:4O6/73-I94XB[F4W:6_MGZ8=QE?C(
M:UXG6\]RUV-UH%Z9\Y3IMCAQ/OSX[2S3?"J\51W%+#R3575:,GLC4^B>!JE;
MOI(Q?,XC,^"?58%69GQ6*.!!S0;X8$_3E5[QFBJE<.A=/ K_23/>:#YYN[KK
MD*HLZ3>QPNN/0OFC$O[,#Y@U*>!M8V-H29J?MZI%%XC]Q7@E' #'2X*@<]:6
M+I2_)E/L9:&E60\LHAO@$2PZ"3[:CNI2PYVM- (% 'LW>*XI:AS"(DJLSMXZ
M*__PO'Q.A,C-<K1J?;S&.Y7#-'5('ZSA<RE3>P%T>)(\IMG-^XP(6]K\[%W-
M59''O(V2PY]XE#[!WR/9]/KV*,'Y/:N)G9-!:4'MZ@7PS;FI-\ZP6*.%+[!*
MGM"ORTV59Q_3ZB(JF)1PXDH1XN9E10OVBH@!DB60>) <^!RU.)'$=<1?2+.6
M?-$,D.#I& 4FG@H%>A5;XKU)&AE)+9:_Z $ &OMTKHL#J#*F1XL<%;-9(+)<
MC7M-08TYNV=FU_<KR^K?<H-\?N)\6Q&"[@U:W ME%G";H51"V&?R*D[-@O,'
MML/D:^17M./9N ^T!XM"L+ 9(J&OGL9A2,%+[#U0BAQ\;H+H>PRG0GJ9+FB#
M;.*\29V:&HZ<]&)? +U)QN#X"&.2,/IXUHN-U/E[4N ,_RQ!MKOGS?-[&VV5
MJ0PQ.+_HXRXD^'"'2YP<%;4ZSLP0Z/:/6#4)&W.(9:$VTTA<MU/G,L$;D$89
MS47GY%Z];*&[$:1RZ<I+">+$7<=/.'7Z H#^F=X"$S5$1!;CO=.6ZO6>NL$)
MV--6K10HDDEZ<W F(8ZH@>GYYRMFL?Z^#\-LS_)D$Z4AN7&G866T4-S*;/SM
MZ,Q&IQ!EL/X$LQHOBT[Q8DQ*VJ,;TMVX%+V>H&8I?*Z[BQ=IQG%EMN0A#K;I
MSTO8AE*UYTFEL_2 8^LRRC1$CT_.O 3X)>#F=N+;HM4'GKWT^>OS,\;P7!$R
MY<6%LKHPS.!'J3]'0KBKE;G,+X 5(T19'?*L*\\7P"]FCA_<G@=W[),%6=#A
MB_]B@U-IRD7&AHW\!MUQU06OL!AW%FMY4<(!BX8741RD-,/A?N4>HR<>D4U5
M#),^6JHQGQOX0ZU?2@5_X!A,M3-Z4EFL\I0$7F=\7>(+H]4$VHBKDI4>P'B,
MVEX?!-YK8ZM(8R5TAP5*B:VYOH+(DF]_'6@@>>0VI\F_GK%$8=2-3D-3ZU%Y
MU8")8O:(^P8-GM_OV$YYH03$Z-0=V[U_UK!4DD\>I?5S4G&::826=X#VPZ7!
MO8H;U@!3367/ATAQ4:R^TQ1[\,@E&I.=GM^N[FWL-4&IN84I]",,_J[3B59G
M.K>B.'W/0#.5IV#/=&N.+-/P61?AE;G!*S6ZZ57>5ZX-#BR-6%HF/>K]$+4J
MN/?AE"9N.]3.M'F*BN38C%%8>O?H**,FT+ ^D"+4DX(9 4SHH+TO4RPG_*;\
ME-59'AV4K\.5Z<VN;U7E>//.J7Y>PE#[4E&+VRG>Z<?RYBNISI%\!>J O\"Z
MW/W#H9(V;.0!8_*;'D8)DF]%N&U4?AK9%\8.E!]<485.=.P]=H&F,01QB2)T
MCCF1P0L9-D+C"63FX22!,*@P@*N^'7DQR0:M$>RH$*;XCV/H13Y*ZL#H$C:B
M4BSP.(=AKM_GCJX_?N^W&80:^ZSJ21.,L5%0%WHJ 7!T@JQ)[I4U;\J8LI9R
MXO@11022.(B<'W"$ZS*Q)"A%Z-Z5[7KZ7.0!=OR<?D\R<>[:FM0'9CHGJ:"K
MDP>.2CZKVCUP_99Y7\+0IIR@J@!8$F>_ZN"DT-3JH^B//P.6B58H(&>+Z*76
MD4_7>#%9#2^LBE+)K]F&!T^13H_V>)?><F/IY225A?-H!Q#$8SW_/@969,5'
M:,;)5?MM>99U\^FUYAY\#&6T,TH(_[$<I%\@ !WO<5P(]G>6%5=FU[I[_SV=
M:[F.;!*:)T#I;=<3%5I+EU UN&* D_Q:YWP\6<SM5)]!R6-_:VMN7>/R141U
MM]+P+ZN6IRSVB]48VC<(J!<H<H)9R,OM7$?_%QW/T?\Y(RKB7NA-S9.WPSB:
MLA^P7S3"?)2X5XB[)I3=#9M2U-2CBKR7Q]2#F,O]ULVR$]?+)UX/*#M$T9V;
M[K@LJE](C4Q&2;H^QG_KY@;'V6F1))>]3D*X\ QYOT]$HU/C\#50WB%IIN94
M*,R..Y5#:67DZ:$0[3D5"#&*/RSTHN/*96IFN>"5Q],=6._5%0--YI_77#':
M10VTO+'/+NS3VFTCZ\D?R"B]JK&VW32J9^MWXQ?V\086:XP;8Q4Q9."C(B(*
MLGZIJZVO#ANL"^(Q'G7MS10'@W-)54!?U 6%S>+:RW)JU&B*UV&R]N,K5D1E
M4^?GB?O9*Y_P/;UFEH'$HQA4JPHYYAKCJ7,,!0.T%;DEF'A]#B[9N1$EZ_2V
M.Y*>+O 7EZ_V=F)MQX8V15:)EP4S_'KK#>++K@_OLL'^O)F%0.6%&AO#:#).
MW?U.C'Q0,A??"\M?Q5GVW>2GB@>2^!< BX.CB76LK,6XW,:VI>-?5)<>^1^G
M&"EU3K?2F@D3W<1<R#XN]71EWM_@E(,X#E5,Z80L6N7D5KN;\H,VM>7?BTXN
MFEM[AJ-%2SP8SU3F);$0?I6ID]21R9LC]_YU.K=SQ5/^J3%\!,PAHAB6#2 V
M,2<V:Y!%6IN+G)#BE,H-NLJAUIK0;58+Q-^?";^D6Z<_;QR2J%^=Z<LCGB5;
M9[DC^PI\?FSO5Q$^A>Y7G%FN%U_J=2IN0[2&O4CD^OKTB'5EU/B"=B",/_VL
M-])2P3Q*6VX-2IO-6W&7W@^D^2!L-7/\_UIO"Q:Z(R!?K#LG!<\ULA6,$+91
M7FMAP3UI1:@ER_.TO=[\K??0K527@,$J7]R0^#.UZH1VMERUBZRX#$%I=CCM
M2;UI(L%9N*L>6#JCL:JNA?XZ1$TTW3EM.K;VBL]HPO/'"Z#>YFL7@=2-'6O9
M^R=C.#^\='TM*-G;12*7>.=8X;M=URV%:$FD5=ARH523@]I28TJJ<_[OW^^2
M0!.'V)G:DKXBM3YZ?D5G#*>'Z@DZ?OCU GBH6]Q]1'3#_G6\>7FMUD;J%N8Z
M&4:PYNCJKBO\Z_FZ-".T4)40NH"/G\F<;?^D#Z8UZ?I%JTV0BQ[BDR#EDN[J
M(=@=#7DOE21+?C' 3.!O.QM%6BYHD2W4L4Q2C)^7NS9H,V-[O_+J-Y.]9XVH
M0_M#_#O7LUZ'Q[$=G;[(*Q*U01XE#.XC3^.H2[^,8R0!YSU%'MZ>7D)V:53F
M$N?? S9*\EC=SJ6J:A9Y2EAQGUC[8;JF3P(3JF4SE^<'>^(GO"N_SY&NICH6
MEXPXGVN[>WUNEDD./+\9NO PN%IPZ)N:V--J70UDM&OA]S*[KE>NVTPAS3_8
MBUROZ30\8/ 9+9YN;SCH;2A2<MZH:FW::PNNR*GLEY3"@EZA_EIO6,:\\>$_
MXY#J9*<*P#PQQAES=]0.J>VG"IVCB)TD/GU/_%T7R9];7Z;X(#('[2%["]+0
M@GI8&'S]SNKF]ZF]QEC)V@XWD?-CXO0X".?G?]A<_3="W/T".%>YC+J__'Y'
M> +V2W^63ONK-10+H=0] NF.3PL'D?XO.D-5Q6=$:K=M)W^=M_'_M[UAN,0S
MLUJOW*<T?I&MDP&V:&2>(QV?6I<7  ISJ#O+N.QTCIF7QP]C"WC8_+F9A/ K
M;]%)32S]W1.G'&9"^@]4K#P[,9-IO8UYZ4JSI7D3-1@4ZSPT_'FQ^BV#?,S'
M/TO6@LN*BZ!Z)X4'OU6F<?):7U7JOX3 Z8\4N@OU>LS50-%-HY1K-CC';=!1
MTX+]]3S^0'"UYCOP@CEY?#K<[,X_^.",M7D2'KFDBC/1BC>W)?J5*+X3'.4I
M@\98N5;NJ/FK$M8]$/=]DR(4/!0[!D'8RB==7%3';AD&M5G0%CT.ZL!^L^\P
M17<X?ZM_KN=EQ>"K C>\+N+ADK8V!BV^F0VA)A%!R(8JSI4>YOQ[LQ^VH9S+
M=HZ04.&FU2/,F7+=93%3JQN\-^\X"&AGY[QFF%KKBM?U5P: <Y9]QUG>.Z3/
M[8/ILK*%/8/,#T1*RXNBBZ8-05R7'@#A4I7X^7).,'^N^\K$,HFOVJB) .8D
MQY PQJUWFK:[R<5VR+H"S8#R,;^2CCL?O#%7H@MGSD;FBJ2POI5.?RXR;?8C
MAI;H)_A8 '$L&+=+M='OUC*I"?E8_KY1 HWE=?I3.3PCRSFB*[R($(Q*(%LE
M+P#YX_(#N5[;[W(3C M@-<+ S?@9)[3@$#/Q<%/EN;3$>[5 Y4GG9B:*N<4Y
M[1)67,9/Q[(ZF7?OA;0?FE_C3#+Z[W%1IJWS HBYZ%S]1X.?<PB<?B[DKOUT
M!XG.BPSG/A.2/S>'_+7?\4&'^]OS]BNK->2%Y+IQ=KEC'H/;K]\GW"L_H._F
M/O)^C6R"TI6$4*0MH.6@"-!3^$?CFZ6%Q+RRLB)$ !Q N2#K> 8G[AA;S;:V
MZ+4<+)1DL; NUWUS)TL5RSH8*A:(^=E2^-860.P'Y%9#_9HP-:^8'%PC(V8$
MI2M%]RNRTHIH^YXO[^V\9ACH1@;Y)#BBD611NN:1%V,<BJ@Y]P=&AU**-O+*
MV;LLC;3J:YG[@XI_^T19"F]ZC /T-K<*J.'^O9O0)+04S-J2)'@V%I_-9,%^
MGN)IU(HX<;YR/\]L0R.5Z1"]ZXA<0,CA'OX%.AY3DTF,M0?=ICDUJ&T$IR(I
M-4QL&<='"%D,O "<+TMSD8=L$(X*IVY;9V])DHKR7(O*/(_P1\S "V]2RRV/
M$#/Q%[*!W.+A]_XZK25MW(W@D/6IRYFWTD;FL30#Y"Y/5NJG9?E%%7S/S9S=
MND>E??'!9P=*A1PGCD]S_(U/LP+77@\C)"PU8.]/RY:8=%*VAE]2&S<1R_7'
MJ2H20#4V'_W-*&$%T.T%O?=^[Q%^);2[=G:U#Q/]:+38<7^?[IDV,X,&-*FK
M#34*1,3!RRC=HAJNQ ]1A2JJU6^\ ."37D$2[[]]S>D_DC=&D#L&3XDG3ZG'
M"+?:#OD7 +7\7_O24L(Q9==99;O[Z5V8\M,IW('"F^9GZD\^+X (E^G^6^5G
M<0@.9/;D=E974_4VHOBKOMLFMB)()/HO2 VO7E>])&.'TRTOH'] J3;$,J5R
MM:U'74=*<.N;9Q7/J'YTOFYQ,14+YX/$>S^;-SW*)5665TM?D#,Y'HBMJBNA
M5#-A;=+2FFCDBT1U<TV:EPE,S%FLHG-/UY6%D_ *MVN,?EUAW-P$@<D3 B)%
MMZ[;_"PX_7I$*0+<K3%1*G9?5)($:V=#76+6!>4H<6J^6EZ7/E(^["S-*KI8
MVGE;7]\HY/QNZ*(,]]=E0!$?+E0-Y.Z??GAE:9<LQ3F5B.+J$4$B2.03!:C-
M*@BDWPS4WPE0>^<VVF$>.,WWS1Y>^)P+=TUD523TWD>$JV/M>QJ!Z/J-W]OV
MB&7=?Y3&T)72'IX]@P1QI-IV[+3%,-&$.M:;PY'V3:DG=)3IR%QC"&LW)7F_
M(;AAA ;?)'LZ>I:Z[?V99\G7?!0I6K("R7T6=B3W\2^U7;&X]WY.O48+TUB8
M0V> B4B7EUX@W:^>FN I4-9)Q]O;U:Q+0RNVV*Z+H?*=PC81P#I2FI;EEJN;
ML*:HJA&M$!=2D)/5SO&8J%VN>X7'OOAX#B3@[M.]H_2JA?)D.A(T8QYA7[)2
MEWU80!$ 8 "ST"B(8_9=>W8&#\5>':L9/5#@2'BP<;?V!4!FX75XPA$TI?&^
MRCY@YTP/XPVS7/^QBLY$N-8X2[?-5=.MW?ITV%PEUOYGCW'_IV/,V]D"=>B2
M<,BEW5LM]VK]R215\P[EOG@^F*BUZQ'/X[ABS0.MKVYU;*$?("/RF201..^K
M3-<SCO#:XML3E;N3M/:U5 )@:0/L0H-U(NV%Q[3*L_52Q:2#W,@'_&*-\_[8
M0^+LZI>M[PDWO]+[YB\A//C9)3S?D<W\X.+5JUF^)YI2!+'_NXW2_^8"R!OU
M?K^^CONCA.TV%;#9OF,)K"W6^EUA8B--.9%-C-@X*>U"KJ8=E=E0D^N2MJ"8
MX1_=%-]O2%:='-M%O-R9XWS1SC^P772E;Z[?[G/UHMQ8]PO3=Q1PC% L2K_S
M(/K9N)5<)@@4S6IL\AM<D$E.5*,S)C W_H9@.8#'#+8RR1?2^WQ)72+HU.-I
M&QR2ZR2X81]?$3':=Z^&G31:NSYK4?-QP2<AA?/2?^?[4X?6 G>0\_);/#]V
MIB'OA\0V<^.K(UW%7!N3=YOY9R>+C\.0PU+CGMB2^SLN3WO^[,DL6^U)CQ>
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M%)I T?XQ+^]:#^NC<<[&237E@YW+B!HYZE3/1'A[R^H.&2#?_WHC0L+W(&&
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ME?G&6L;$ZNUE$H>PO<O+U9I SOTU?'NML3PL4YO5Q;WT$0XO(K7<Q':'@5&
M:3ZR-")@%<LS8A.?9<@X7+N6KBL";L*B2EZ]SWW^*N2A;>BL6?^X0EX%2;PO
M.T(RR-:L!O<([+=NXFYZ?4G7P8>O?[N39%FAC&O_FHE.MUMB$TPU,.6S? ,
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M9-,H>MC1;)0[_=THC\(Z OC#)&$1BQ^_BGO\>. FPJQCPII.'OXW4$L#!!0
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MEO#[W*L.]+U?*_--28K%E'"?.,A34N'W5./M1MH--ST?('F1_/U8JD:J83^
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M8!SA.CR!BAR [:["XK,?'Z1FT@M,1N6A6HLUY6RO9(2QX0BUHA4682M]H#^
M0H5,MZ"RH-"<P\MK>7SB3=UG2.PP0"CZH9$U&"*9^J"[R[!D$,7V((K_>*[[
M#Z%340?1 16%EXQ'OW!/APXQNJCP;\8L&7,K"%X8;9KKO-B<$BY@J)7PZ&5"
M182O4[;PV2JC+QO)8VV;ZK3PSLL6#GP=)-D>GK37Y9RI(JD&!!GJ,K&S,K)>
MSL[&!H4(JR4\2AX6V.D\9" Y]DV=YRR&\]X"/>,DUN6"Z%1N(MM4Z+X\B::&
MA8:XZF& +:@2N+:,*H/I0@PP&Q"#KI:C<IQ;K*<NAC;4W)8O\EQSW*GA8=,T
MT*-N!?-+OKA.]V2_IL17RVBIE<*<;$>E1B7W58NG.G1"N4ZRZ0[$>8U78K%;
MZ07*TL^4+#]^E2V=+?.-E*O#K6-,U30C\UG,[* 'A9PJ1^)+0>=#>CAL91"F
MO+H2WETSZUL!YG[S8\Z/[URA%W?DRWF#3*?-C>2:4%'>J;OK-3U5OM,\T%F_
M3^!3GNB7YF6OTBRDF@Y>S;:+L66\PPYC2R.4H@<5[;V- >#G4(U>.E\/_- *
MJNKH<MYMBB'=^ZD1OKS-]WFG:O0.0\@UC1;NZ)%,BW!C@)+OEZ1S%/?YV$C$
MG^^A+$2 A8&JL!E>N+6QUOQR-WQ:7^;[[3>'K[]\=4\ %@4E)8M'6)_X%CM>
MO5^W0)B3;=?+*)XNHZ:DX6NQD]-UTL4\PQ!6,TN)?QP@C0$R\9QT?[\%BV:&
MR+6L3_W%*_=O;--1$26=+QG_Z:W[!I4ND?T\5=#FZ:9&Y2C.9<1\^ 2);<Q2
M(=<^WH,FXW3R!6SXBK=7:8+/D9&)?<5P$3*A2I#Q?OB]CK1]^5K4"MF=[@*#
MYJIQ)5+96+LLKAKEY?!8Y;#;-EQ+E8)&[+R?G$.^<\V&%F0$MR;+ST,GJ/--
M6%*F)Y2XL:Q8ZJK.ISN(RW1SMY0TC3SHW5=XWNBZ"P^B$9E44.U1+.Q3'LG+
M$Y$OY.\+(\V7@#+U'&LV'Z@IQ#0*B2<GXE4F@:Y?:  G%+_OB++)YN+CLM<)
M)>1+(?8NZ8QXD93),K)K(V^HVOLH;0RL<6]2-!T$HQ7H!-#EDEZGQE:/#R8R
M41%_>KRF'$5:$&A6HD'0ZD6@U;WAP^6O?XTS?Y"4Z__?'3F,+?_"241.?0-K
M/O@AD\\XV]77!A7U!%VMODTQK'TW@ UYI1;%CP'("']YF=>IJN@ZF%@?"]C"
M0@/>1)!KZI[ "(^8!JV0GXK<8^BI$ILYY2S+?*![2 <=L*"O4308@8'-!US2
MRC%G&9QQ!JU0U8G<-UV2I_'Q/2.P"LJ[U9L1QO'EA&YG3GT_I(- D9,U;7I6
M1LY/:F8]P+6N!)VL-]8F] "1@7H2A*;9A;T&=[[#,\1GMT$3TM\;+?C,)< #
M/1"!?XL4K';)>LJ39;Z.^S@S%T4I._A5^1_-11$3OJV_#KBOC"0 JU. -)5F
M(+F9C<C,0*JF(<!M3CCRDG&J6EZL7]+BMI@5_&!J^XTH.[WKEV6E53S MOO.
MMOT^S>P1)*.E=),K9MT_9YZZ;O-;$YQ33?QI5HG*\R\W%VD%7&NITXBB?NOS
MP[T;$%X]2UW,WJ3B-.77*6JA#_3D;N"YT5\#@T"^ @;PS"^$RS9,;$%L,<!Z
MB8=Y3>@6+/I;!/KRKFD"-P(ZG<B96&5K@FN':[DNMP(B/6PX:90Y*SQ?2\=L
M$IG4%'*/IV VP2<Z,^*5K>YDS(JQ)/GM7&%1=SZ-C+>UTM2.(##@,>@9&)-Q
MH\O:J1N+T".IU'Q(G?-MQ(ZT$>PI=-:U%[H2C##_->ZI?^#<C9;]"B/V+6RK
MD"/7#2)DRPC\.S(>KK:Y@P&NUQ[7; 8\Y8P< /'C]1%T 0M4NQ>DR0&V):[_
M@\=:Q]%,!X3?[PR2 IVG^Z?SC/ >,J2#3]]&17CU-PS!FH]/TL*L0^G;$\Y+
M]0?E=4TH0T5I_,@0GD,(ZGQ8\^[)4POR?TA\#)V60X)!]J3'?"8@'E1VZH?$
M1J_8QJ74+:D37MRF9Z<9>I"Y&(R_T8JZ]>_S1[9Z9UYYJO9T- LR05!3[L[)
M41'YWZ:!MPTHE>XSYR9?';S6(W4%18PM'/L5[L#'RY]%'=)_AZZ,P;)/,A55
M9Q&:Y5! #?1# /1M[*C?D>WZ^?>LD,(Z8_)LB_[<@7/_#VHF.H!K26H4N!'W
M)OIUC/Y3UN=[DS1&4U3;*&.'0DG.SO:X;$]WYEH(R^?'HL;SVZ[4#]"KK"),
MA?0OL<:E*6.<:?4[&LZE&A%FYMG&#6=4B49?LPV7D8M^?,:]BS2A&LLK2.":
M<"Q-4:_(?%8:D4WWM1O?''SFF(NX;J^KS@6%6])NN*XD]!XQGVDS$+3?P"5=
M-7^N3636UZ>!SSU-1W/K8U%9PG#=.+7<*)5'.+:4ZWAEPC^6R9S/-X51$0;0
MHP)C_]/@SR1&J<>@(F\Y;R#R4-U.86P%N"='E%9EJ,A*]:,(5(0W1?VI,57J
MQR7D^W^A]K\-:O&S?=9:[%UO<4<DU]EN*;K?0]B>$PI8+C.N646DT\=^*8WB
MBA-V]F1Y6;I7] VO*MZ-"(YJGA@S;P2\78ED J]](7_P.:4/&8G+-](04D9Q
M@V!W.BOMA$;]1\>K%21DL.;^3 Q0V8] 7/V+N%R?:#B$-L]^Q0 @/MHO+6:$
M=?W8^;\M 31_!$JB:[N2L+\C!%S"7X\99B5L3B#<^O*OY$UR2+\*6QE;*85?
M^VMX @SU;2*&$0Q N1A4ON:,5G" @K5^&\+"R*L,M$-)ZK$?P[R=^6?6Q:;P
M Z;E&OXU<DV#LR>9L?VD,X \P<//SD#7#U3)_P%CZ>!AV#0L3>\7PHR33V'/
MXT^1%FAF4S#7-IQXF<TI@!F9_(8]JM0PJ:?7840U#77E^1C@D '<CT)-XX)3
M7#Q<:&O'_(\R.U..7"?PA%W(RI]T(!;0U4]VX!WE[:>X0;AZ0_4%L\\$)WR>
MDF%+<AR&J,0 RFLKIRIBS<?C)@_#CT"),8*@9=Z?>"[;:7JL1W.:'>A/!T 6
M:ZY.UCP^-IT']7%/-O.A:&S<&_A8M3&7I>N-P_5X4DWJYETW?;%U:M1*L42P
MD7%*1.$=(P,5O)3$SV.66FAS8K:[Y^_,# >*4UELF45*+-P-^?;]H7J6:B/E
M?:RB9OKBXO]4&?L+7\A9"55P'W6CT"MZ\C0'J:R'M*\GI@IU#C/&?MJQU?F0
MSB-UG^;P\CKGDU]C#CZH3>^N^:/QG$(0&1C@ JQYY@T,@0^O.W63_8-[/@D_
MH0?Q;C^CI77MB0=''?M5@V'HU)@J>68);1Y\!)L&J]??#B]6'7Z+=5S"#<=4
MFZFX_GKSQAEAG-(GP8.Z]!3?S \]#3[-T'$0''[J*/4=PAD(&&/^"((K'T]W
MH,+_D$D$:WBV \:C'P'S6 "M4/]#9-@:Y[->Z.R#$]+Z&MZ3>5+NG2&9.HE'
M?X4TSA(X!P9 *RQ!5_I.H!'.ERB+4MD5M/T)C=.-%P1U)HA[=U!X/5+/!@R7
MKS*(?G1A3O%-X^K3T /9;!=?J@5*9<LZ^2>;9?BM13+S0!)<RIL<#&!$>1BV
MFB^A_K6:<E:"<F,B'W72*'9_]U]H%/\K _[/S( GQB37O&-R]46C$'-GY=9-
M=F?*Q#+\HS$7OI4;-,5ZG.YSSE7&,ANA9J7A(^4QU.(^5KLL^0&B3H]C:#^K
MQWO/YE.U.K;.1*>,=IWQ_JU(UV. CR_W&ABR#+R,VT@L=[]23A*5Y-7H1?ZO
M@/0_.B!Q$+Q;@QL)#FPV?S&[I*%((4F.169X8^Y</0T5>EZ;KD8Y#J0G)(VF
M6^>"T357,$!W4!GG[[=LP*F:U'.W^7XB6KZ X7@ 'BZ\*:6^)<I7<]+[D*MD
MRRC^T52(F]@26X*N"V]!1O7._QIK_VB?UA-4JYMVX[FB0=G13;= 3R$Q#CE]
MI_+CM(B$&@4!Z<[<7W0'I%=5#,A]7]#6?PU/^AZ]J/I_<N2S]F^/?*K^BH'W
M:F8#3MH=6Y 1/3*K$ZN>F#OZCR[-!;.]U(/418I3#12$S>G>"M4?(JDP0"@E
M2$^*?H 2^:N#HD=YNK<BSSH=E4'$4']B\;]0H^=@I(,!4%$],,3;3.)/U506
M0D\.7BW;@@'5[,1Q-$Z'*+C :38%(I+W)M7_]7;C?^''O?^*,O^3H\R_:,^_
M:,]_2'O^N'[_?=P__%J.XE=V^7RJ:.]^C&;]AE:X)GS@T!]@6_;3GOPC: 5C
MUN.O8-4;-G5J'*X^M'-\QUPX=P5,"] &ABV1I=3=VI7WO\9+YI^%%S' U9F?
M/TKXT]__Z0&<&7KBH :L^T\!HNKR;UU\,'E!Y25L:AET#E_9_NPF.)XNSJ=/
M91WMN]Y@4J#OQ0!DQ]CE[89HA;<_\H48:*9^T$P_,DGF'R+K&389CT$/_=%-
M@/YV.C9]ZN ,M*@F6/P?6*&O4?QJU:\Y_ 46<C K9!)9@^NY>*QZ^6=:^-L3
M[+Z[ 2R+P7@;*B#@3M7F>LZGLLY)Z4]D ZI_$16?\[/V5Z@',[\];+<6C&PM
M_W#8W$FV62AW2(*'$EX&O0[<^Z25$VO^\%!GB&=)BF+/L'X#![W7K8!5^M3;
MJYPRPOH6^A?FJ,YHB0?K"_OZ?Q^&C[=/$GB%??"I:+G %QWYZ7+-'E5D I<2
MC.TF8TN1[A>J93&-,\YA\A[ET)4MDF,J3J?W#+5([;Q+LEZ3%UP0/#YT) ;>
M*$9?;]1.-0;X D:WR\ 82'/24BEL45[V/1C@D;H:!DAY57- C@%F-&N"!4/I
M3*3=.FH\$Z:^,<@F],2J*1E]K>9UH-=&YNSS51D>Y6QE.L \T#JLJ*O#ZL>2
ML$D5#! AI(Z_I$)#NO<N4!WUH.:@WT]G4/+5Z[&"X]Y#S9*:2AA'>MK]NW5'
MLB45%0ZE"7(L4<.TWDP#Q1A@ZGP/;&D% V";HFSW\M_[\0I0/Z07ZKD/=:V)
MAD]7?#^0*8;Q68ZXS_...1=+*73-9_W#DI4+U/Q\KFIF+6T[5-5,1@S/H&X0
M;$;&@YE18Q=4]VQ*,@:0Y(5ML&. KYFP,W87%3^(5-AH!K:[S$8U">9JS\8V
MF;PJ#E/:55^W\"K;5Y^3'T OH?+4#V2+4Y&^X)Z] O?,\C-)3QRE^=Z[$&98
MUE_J)?ZQ&;X,+;FV)I2]WSTX.1.#/:Q?7.D(Z)I)[2B&3A'_HW+7+L"FQ(O
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M&AJP4;F@0'IF2:3A%O1@S4FQHG@9DXS#.U<<4#>G 9S=.U^L*HX1+0+HQB!
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M'<RV\BT^]9U%J1,G'299+29;/6]:>*)I]6_SMNY2'?NPOFJV[V=@2^7W\$O
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ME&T8;8J?)$1WT Y.'EH*?2/%#CYL@X*G+W*VM W;^9;QJL$.[#;+6ILD:U=
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M -<@/7+_CY;HSEJBGX6$)R(Q<-)LH)^4O8A-YVM:O-E:MYUX]^N&8O1]S#>
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MFV!<;G[9KK=L9IF8I:9/SDHSFM%[9$;#A.]0^3\=RI"*HNF<+L$8S5:V08#
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M-U1U-97*U+KA!*UTG[U^^58:QNI9"S'Y6$8O3!Y%T8=THZ2M34+ <1(3)L@
MA"%H9JLYIN/,B2,OO#>V98218RY/1QCY5X&1CR?;WUU\>I"\4AE@MIN3D$G5
M.E0%^9OIN:F0$2JJ>=>J%4V]3X:@,Y8PBTTGS5,JR(XXZRG.9>QLT:^_>?(
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MSLC!K:LM_;,HB_6:SN0V/(BN$BE@=&]-11?YZ0#4]IM:8P)V$H+1I?TXQ\Z
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M($7MHV4DI\.VT]U!@4XO"&0M(XO$Y^NF6*'/4&9N:2BFJK/MYK;UYXT!W!C
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MV,V6-9VPP2-'DF1Y9ZS'$79O.!5)K2."?KQ CZLEI)-F$\E3TN][@J<A*5U
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MP2*3YKF0P4D-M[1 )<Z%>=;RL#H=)9H'2XICN>X/0@TKIU@QG6TMH(G.Q6*
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M)G>0(TR=4*/J[&"FWDS1I.WZ&'QK"!=:71?A6"$:]\V=WC?NS&F=>F^LU(M
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MCA^>G)X>/3IY\I]'![^L%W^!GOCP'VRZBZ_\Z/'Q^M-W2QGR\3=/Z!](S=W
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MT\=%@IO&?I[0'SL94E?:Q3YT(XC_],UIK^J[SYKTBL4/AXK%XQ8?M_A=W>)
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MF;JAX.G^-"?>8*:U483EIA/3??GI^AP#W9-]#'1/!ACH'AZ=> :ZD].3F\Y
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M^YYHASS7[3'J[F!,8R)5INR8CJ'''\(%N3O*^R;7M8YUP#?=V+FY=<"/!^N
M'_>2S@3-)0\?7U('_%?3SK>'*OG;Y6??7*(ZV;,*%.C-]5QNEZ;[+3F'36LJ
M8$FRZHR1AA* HXDNMXK.RTULEH;OB#F-\;O;H_?OHI4:9MU!3"W(2Y]RM_&4
M**V/>$@0YY%0*B!&Y."<%4MN5NK#^:0Y/AT='!X_X8%L.#[<3?#>VH%^N>C!
MDXLX5,H-8AA2?\SQV7;<E-,#%MO5$[OJB S+.LJELZMMD \XV\[*;#Y)DXT4
MOP/_?UE0JR=4E>3;.V,WCG5[7+?W\UBW-];M?9^]A]@T)]+S>I(/1L=;G51:
MDK03:+H_6]$B3-*L3%>F^DEP-2%2O\EMT$[4?L3 )@77>4^\OC^%==^'X'^Z
M.R[WN'=1%G5*>GHU.3HX.F)=JID4,Y<8*O.]M9/X(7F :'X&<^M.][LZ,EK8
M@$W0Z*+),]Q_CEP0TCQN[T\Y1X;=VN-S!'T[9%;K9E5GLFMI@80!AQ-O[@LQ
M>*H.HQW0Y8!&-MD\0<K8]<Y]\>P4TW3I[;;IHXEB6Q@F]895S<T9:+)T%<YR
MV4+%*(^!AIFYL*N;G/9YPR3,$DH))%.Q@W0!=6B6SV ')EYI023LWI^XT_J,
MK%9:R!X;BB$?= .\9YAI@9SK&Y-1[H.DDBI[@HB^OW>+L*&[B?I1A[E?1MD6
M]Y66G?^:.F9V^R?H* P*0#=%9OC%U&8MWTI?R4+JCNB#!KP3?$P^T5Z\OZ&[
M)G5)EW3W(@_;^G2"PE<=-,QAY%H7$.RCX35V"\O%"8&\+[@\H9)$*(;+<G!/
MI68(K.O(\!V%9U0I:[M#<L*&VXQ(.H0[D9 4J1O=8I*4;8V^/_G%AMTED>TE
M0M5%%OL-<<;\-63"3\JL^MB:.3LEM-SK8NXP:C:K5#2K.3?3#CJB<#XGX8KA
M(LUDF9R$FH/"QS8/']7;:*)^X3KT1SB/#H8BG/:;.,+Y*& Z?'#X\TUG.KQU
M]@PBX,)"5&B&MV#9@#B9II596GA]P^UP$4JQ;<5(Z[- 9LE4_3ULR_&.#!2%
MK2#;R%\I*(Y+<5=%ZNLFR)KAY/9@)&0H>L&WB>6_+4KCFVT';C;*MINVU;]/
MP9@C.@AL9"V0')N=?YU.2G.0EA7, A$8O94K^Z<K&E@ACO^!0:: F9"IN#_Y
MK;B@ <KI9$E&I)AD4B;[B7XI;X[M/UQ%X@,5_VI GKY_^L]G74.K0M38_5)X
MSG)#4U>73J4D6$JS#4D@,L1,.6C'LS>@I;CT!+4RR?M.CX\/]M#B>3>M'(SV
M!= X4NA;P(1;B8L56OS<X6Z/+5+[ 'TT;U)E=!!VBT^">WD^2&YWMJTFA]/)
M\8$TWCW@!W#\,YU&A"3BQ9HG3P[-#MT0#Z:3!P]YC$<GXE*XG[K.B/)C6I(K
MA*[#%MN6",]W)G3S.M=^E[J)U-.V:R%O*&S1??3XGNNZ35,^?NC^?/!P.CDY
M=G\^.I'.O/[WCP^&N&055+5<PN75,NT-;1,VXIV L1V(0_68LLUN/8HDX,ST
ME/C.G;B$L3/BP P(-WRHC:=R/90I8W2=H^N/Q^CZ#^FZ' ZZ+H>7N2Y'/]]X
MU^4NO_#;*VPBW>/4#J>*N6$QJ@(ZD>:/9HLX3Y+7R5+4D- \P?[J\)JSP]=K
MAUV3UAC?XG^?.OMRM?4^MV_MS"\UZ%?#Y@1,0WI%Y"Z;&O[RK\GJ=9+NT:MD
MG@&S6-!;,DR:;SN3!E9&I2DM#,<FR%0M#C8/HO0;#?;SHWN^&;2WN.@?%]EJ
MOE=O-T9)N=3 Y^TE,7F>V*E,3"="C]0U>[)<*N>=2:Q.@E#?P'9T&]WWD6;S
M2F.=W?MLV93GQ9S19IY/FEH [-C3D2'%H7^.:-AE+O)KVM^C>KYE%23?+@IQ
M9I*RWCOTT?<:0XY2]7KV+A(^_2N,0C@IDU,X65Z2:]02>P_(^YVC74 <0?C-
MO/AM<G&F6900@<BQ!994-EJJA3[<RH&#GH--"N/TI/52?=C!1F19<FW.$EJS
ME/G^ZBR5K)H3SYP-ED9JMM<#:?Y,^B^_>O9J[ZGFPF0E+%F!]'G;T'(%@+C[
MIS]Y*L:D(O>,B]XEVE"4,E=Q*Z5"\?XOR.,A5 &FQ2*W\1R^(BW.Z)HIJPTN
M$0X>$#<F?467\4+3VU!6,ZU77DGVRADQ*PXKTV8R#9*3/#X>\/Y3GD"QT7$K
M@\#+P/U)2RPSD)%%=Z>O.;XS"2[B3]^BD/_4ET/)320"(W--]'Y!1$A3N5=Z
M@OW)LT9(5AO6A_2MOE+-Q"_!O GE#48A.LG_:] F4,DMZ2Y_Y!GN\3\TQKQ8
M@ZT2F= MG3^3(C7(>Z&@<UJI5D0"6/6L$JJF? WOL_.DS(JF:N<5"UTWWL93
M/4@2WM$@%Z9G8#OJ_<=0^QT2NY:-W;$2IBL2PDG -O#TPVG5@KM<<3\S1""?
M_*.AP^- .$F>T]JD(7OP(BLK)[BY!8WL= Z"MK 6F73]Z-<4GEQ> LQLC0LW
M83M6Z^\;R(TPRK9G*AK7\KB6$7IYX.;/63&Q'"%[GN40K&O?@^<*JR9L#JM$
M!147>=)=!)/L=9-5*O-MG@!,(( F)-!(%D>2\*\\DETH%9-GR6K!$=B#H^/1
MF[RF QAWNQ7X%MRXBZ2<2^S\)9T89>5\FU05;PG.ZYZ90'/1>V%CA[LW\7?V
M.CH.K[(4^#9E+SY-4W SO$WJLXMDRT"UEZ].WTYM]O>/_YG\;J,&?,%OM&7K
MLQ2;6?N<5I-W5KUM)Z?D^Z8R#B[__;=WIV*T],W<$AZP:RI\(@9:1\F2-;,M
M\U&[(UM7JNR,-/^=U)GP_G'O6?$W%TD*%8=OK21)Y#GQ._<XNJ/C0Z<>YL+L
MP:ZB(7(6&273'7/35IKV3(;'-S@-; I5_-#^3Q[($:J41FB"0N23G1L,PX9L
MT11'CQ9WDALS'P_5]6FUJIDI\3STQ<O7S^ PK"PGF%0<L?63M(6>+5>)TIW
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M:G./#,304VT<J1)ML'HO"IZ/Y^KNG:NP'T^W$8^F32RO2,F4<EEIV'-58O5
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MRG('P%!#U)@^96$$F:4BRN8(\?%'LVW)J1M,TS@&5&^SHC]^. 94;W>CNH&
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MUQ^^'0;C<=[ =UO42$+H0ZV3?P,$'^VKJ6R89$4JH;7C=!\&.]-2I<(92A-
MH-$YAMY%W6C42$Q'-C5I 'KXU+Z=33,C:T;^60KBWP$#PC'NCCH9A1^<'->6
MTVTNVC<)=H3M(6D##[S?.5#9_04.NI41T?D6"<(E0Q"*'!2U\,)%EI,'(E0
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MCZ$LO;=AV@L=Z=G$^K5B:TUL-HA>W0(34//34>+DEM5'?L\L6#8G(IK2BI'
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M:L":PZ&MW%Q W9 X;"P/K>)[0QJHA8'2>:'$LW,0I*RX@X;59I59ZJ06X9:
M,[LH5EFA/5XXDXRE6Q47H_RX<?*C'7W_>BDX5Z*"@_W5L@=?;_YW;&-\Q7R"
MX.V62>F"6/]\_NZ?S_<.#P[M_F :I*NJ'Q4R%3?(M1*;97N/,<SB[IQYQ,A.
M-;D3_I'%#)%,1BZ9/=Z"TEX.(2^R)!X&]%[/0WF-!SBT887E.NH.5E)(!X:*
MZ2/X8G*!<X8C #L E<F<6LI XAT8[E10+*9Q>H/16XTRAD?.3NTA#-QN/+5=
M)>SU^-'M"?S>]0*):<C*C_BP8/' 0$:*VV^8&<AM.#=E:3A'/7WCQ/%?U7.#
M5KX'GMXHO3R^]N^EA8^^@1:>1C_2YB,*N7O[],-W5=A'7ZJP[5$:5?:HLD>5
M?8-SOK<=C_=*(.2Z&<(JU619&F','>%Y-VLO?/UZ_8FP#G+MLB=R7MF]XG9&
M5+Y\X6HW;/!SVIL-";%O?=E3CGC&N0(N'W#5#OV72>#8Y88M3GW/8EPB?>?Q
M?,K_FI7,H<AY.JM625S:*A:]=V6[*[D8;49OWO4!\'3B+H(Z6VD! ,<[&TD?
M66[%5@M!)I;D0*[T.JJW&RDSZUGXN&CYYN[_&P8U&Z'<7].0>AHK$#H1G9TK
MI2B_F&0=5;G<&%]QC.%^<Z7S,I^<;LIL9<OXS&[VC$NVE:*4S>1-F=&ZD2SF
MS79J?SF5Y+N"JYWF0CE<=LXH!!+/Y*A53*=\492K^053AU;<OH1N*_W8= ;:
M[4WS6"2K<3?/TQ'JDBA?&60;.PUB7-HQ!L*[;O=H//&19L3P\@+M7J1&+5EA
MFCPJT!:,!8UGX#A,N5M.BS3$]I*/G\!6>U55D4J)G*TK/CR:"0-&4AV"7BO*
MQDY, A^3BR$=30G>ID S%BY+J^G7=J?/;IX6OV:0O:+3@QD)3Q? ,&F))YJ[
M&O6T*(L<& >MS*S<]G#6A.=*_@/P7//)I+XITO ^THRIF"@,WA$DO._&(+7R
MC 1;,CIE+BV-Q3'GC2,-A25#?/3HX?3@T0FW7C(NC@!X;X&#7:0?<3DF<7?\
MLU$Z0CK^HQ'BMB,I[EA+K8JP,G"\;+YSHS+JG$6J PIPB"D8YYT=IZO!K8-X
MND/4VJ'B&^]/W@:2=OAW4_G;GI&F^C8R.!"HNPCW ^%UD91SX,_$-V$9O8=R
M7JS<=* 47.7;5"@7?.'.L(QS@!0GH>3Y=KQBQPM"^V$#.835L2(HY/YH/V=B
M!9TGMX["D&X*;5'MQ7O8E39>]V*#@RXB<'_R_%-J-B@Z IU 6F8S"^286GB<
MM(.[[!&\.Q10<OL5&MB*-R1:]"-4"#PX&"L$Q@J![[/W7EB%8WF+2)X%G'U.
M0'D.1A8?$OE6>V[! M22R@3D.&UV/(:_=82-F-I(H,2W9($#]BAG]G$J3&0@
MR%EAUDV.C^]A6*?2M,^*V'L]HHYOU)Y"Y#W\N\@LX6V@OIA(BN](URRRVK>U
MLS<+?^]R0EW)VLOJ#--@<G+PMY,#*-<,V#Y+L<6J,5B9;_0N0G+ \.97?"LG
MW_JMZ!VU\OG+7Y"?\^@4W"$Y^%)L7#BKM$,X+EW'!A<?C62RS%!0T=VJ0=P#
MX0,Z"?Z8\D;3L9@8+HZ_N#&RVI52:)A;/-Q-LM6[:R=BW)CF:;B5;=^1ZC=+
MTZ*2?+JFJWLF(:R?ODUP>,@UHG/)-.SIXZ0#@A.(HEQR5S*W!?!0V3"^6,/]
MRW0AYY[?%T\UB/,GL)X% X!:^CVZ:%W$V3=T"2A*ZS* -BO--KS4F.DER],G
MO0<"8*TYXH%LV<C)02BL9((D:,UB@0"3DO3/E5J OK9%=[U+]X)1%#U?(33#
M14?RY]YLNV<?@Y4,J+FXAYE.I?50ZD1T=J+3(^(ON[YC=/K(Z2UR>=G-1H)3
MM.Y+ %EJOLU_G>P_Q ]7K@$V-L?>C$-,5QK@T?Z)'6 4T'=(0/\KD*R0*EW#
M:E'8O*FS4903]'[V$W-K@#"OML4A(N>[8K[ [^F";!&,H[^>=WX^M?< HJF4
M*[P$(GN%[VE-))27V'/O*T+8@)E?67X+!V:I8BO@6^Z-0PQ;5@FM2;ZW0ZCP
MI8._N52Z!%&FKR)*#@_WC_^:+#D\V3\8A<D=%"8?1/=SM58MV0-M :JFRH")
MME-C<K?/X?/2.@_6T(N4/1T)<MSP5UELDU6M62J6*@D9!GP;--[&J5=4AP'-
M)+W8O75&1X"^(!MFGBVSNF6;Y::6YYN& 49OR;F.#.@GCI,O4]A:2:65KZAZ
MXWZK<OH9VEEN<?KUGR*?AH0"A\YYTMPN'G(Q31L&PT!*RUO99&42)HQ6254'
M%7U"',!%ND&<,J(K$.R*L[T#ZTUM.Y[J5"0]7XW^,'-I4^S$D V9<R%>*SFV
M:US5(33TX<%D:Q+N[&Q[G$ISFY#;)K0Z!T:\P7B4VW7RR8P(4H=RL*Z4&YEJ
M-'V39/,]TB=QJF208"/,POJ?_IJL7I^F>Z]>O^U)36^5X4S;TB915Q7+*1FQ
MG ($Y6P5$4'NB5H3!5'1'HB*E$F;#[9BL%=V-$&R)D+CAHP8MB,'8%IB,9PS
MI@J'5V8B2"SQ*-%(.6-9)G-@3VPNHL"QFTJ:WEM S!0K=HI W>@=C*?@&E&)
MUCMEQ[3K[+O-+^PQSH*T=#"!#K%Y0NR44A@5*JL%SJ5UB?8\#D?U_K@0F#/?
M1I98Y!]G_ZO:I4<Y%DJZQT40^_-2NG.WP:[Q<_=HO]':NT.[_</P;K&Z0)/O
ML&@DT W+15LZL.$BI"[DPVFVV9+,Q<+V"JEUK>;9K0$^+]5LSU]0O1(X:4GE
MHU(2CF*VA.+",#  5 (*:+ N,0W)0D&>=AJ<;]]C/IJ+F#"!RQ7$[:$1Q"K=
M$ZO46[9T3V>4QCCAX $40H7%V+UFXY&^0T?ZCTO@"9JG4L.FLI'6*D"B*;<Z
M LXPDUIL9]Q^JYI4Q<KEKA@3XA2EF/$: YHU-0>86$8X@#K;1(MLI?RMJA%Y
M#B;D/>.[02B$=YLZ'TI=M+3EX5R&T)C:"+=ZN1LX;K42!\6XDD!7^L:9@;:4
MN5\$3^_-2V<P^ >-'])Q<':=-&\0]\E J\F5)B:ZTA81.M5NC?DKXU9&*?'C
M2XEV4FDGMZ!-,$>>E3J(\\D_F?HP*3-)MDL<5ZMZ_$&B 5$B*)WT1,2$]2I^
M<R;^E+*;/^ ["MTMWS'GT?($U2G<E\O"8R,XFS>J;<I\T&.3D*FWXN77Q45N
MRNHLV_0]O0@!YSE4("K3]H2PX)=% 6(\A@ZKT5'HCV;DY'D@FE#U0N.3T.!0
M5B@V^AC&\6SV!6&*\U@>W)U3/2+F&#%W."+F1L3<]_,FF?IM=QS"UB%"ZM?9
MJB^.K?R2-L[.@S+,HR>]&1N?SNCRT?A=(9%J*&GJ+5=[WP'(Q6QK333ID/?X
M8&^>;-WM\5L:)4N--<2FK>"/3Z5J#I;-Y4ORL$%@/OQI"*>1WTJ.%HLZWQ]
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MR CD&Q:]S9V[#S9$3!C@Y91$0A/(@^0&]\'UWB+226;TVYI!H'C4*1!N9+@
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M)^"MJD0E-@RY"&MAS>>UJ:T]>Y%PAYXP8'SI/?%00_<-!0'?3I--O@*51Y$
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MA;=<> @ET/?RMZFXU@SHM*F:U39L$V=K:K?<\LTJ*BA")8*B4;QJ>(,,#WM
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MP"3\J;RH3A?/*>&[#8-5&&\^(^)KQJG(&(EWG=9J4OYB45< >P?P-M*718,
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M\W L_< /RN<0GC%]*XR\HIQ[6%C!V"@61_U81=?8P..H9]CC>\OV :21MB_
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M@F7-(PETCEH4,3"/VP"2YB9Y7<VH%:,9Y9@,X2LYR>NR)O%#3C? O-;GS4%
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MH&+^S4>@RA'J5JXG]4D6B4\0.2:7X\EA(WAXU7;76'14CV?7/4G;S,7J3]^
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M2DV0Q9@W#?V'CO$L1R8I"Z.$HU;*DO$4^]^:%ES-PWM,:R6$!85$)4+V+0B
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MS'U!_,8E]9S1*[OI):&="&]X4;5AVU0P+/'A4HM*;L2;W]5M&5[RI=_6YN:
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M-_R!F%&A9NX<LI/V]U/KD5N.-V@(@>[9"!)P-:-"_RXB0AR[]H@ P/K[<P*
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MA_#F.8;KDAQ_J21T52F]<9BE4%PT<S[RD!9/Z-YZ0@G>E/AYVV8-+G)S)E@
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M+^V?!_!'LI,8RG!<$[VF($ZZ<(F(A)YW-7"FDGN]NGR_'$&+Y=Q9RWF>$T,
MGT$^F-HW/<$\*4$ HP%-5U"_*/?Y3BE**.4-2EOIB@RP31Q,3W[Z1O33S%'$
MV7H:+N4P3EC5DBGXN=U#_G6=2)"N&L(OB* '%5 HX(^21MF*.2&V052Q'41R
M,>AL90'76_Y'PW[V5U@[@W)!2M##_GU(XH<<$265L-0VPM=<<!4+&0WO]F3<
MGC)V?_)-VW34P.J'?2 HAF2_;)G*IOG*6C)6]""2XN!X@S-QH\S<0?70SE=/
ML:R%R]C]#C,)2Z/&+VC4>+0T:BR-&K_-VI,N>MTJB:K,[ZV'2VH>B]5]XM=
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MGT"JM&QE:/SNL,9T$LYUXQ.N)3LE;:SDT&Q2,,13@F@AJD;P?.BTRGB#17U
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M82)-8DE+$LW%4>EU(L%X0_HE@82"SP*<"'.]/XLA+X9\#PQ9I!Q"F]Q;JCE
MJV&QE<56[K*M"-:<$$C>1C(]-@I&GQM ?P"BO]%17,ZAQ;86VPK]A5K)GI&<
M5\!@XC(N2<O%+NZL78SH/HW\/('YA*(Q 8A:TP",:YM?^1\-W!%'5[_*J^5
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MP(+W8N8B\>N-26QX3O.-H!UFB5T#\06Q,/FM*A)@S"](Q;9/X RYDFDJRE_
M>_[IT'.S1BEDW8"8EKFMR:<,:#O6EIO2L"_P\P7 ]$N *4\"S+0=4L+IL@;M
M!3685:[>:8\*++_NRBOA^NNDD0]*C*&6"<X5X,@3C<2H7ACE$F]0/-1JVRD@
MZD2JL!O6("#JWX]:X0(5^GTZ$&7W"IL?\-=#RSU;+D=Q_"1-DVBHO)&<B=BH
MA*?N#3I=Q%H7!4%6(GF&LYOD#+M 6'0#SI2@03B*E;*JL%3/P6R$+QBG<+9Z
M^IWQ :B#HR734_ZP>;< CPW%.7I4^CQUFQ\/2@28OR*PMW_PH\O;SNA3$W8
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MX2[O#C_K&-Z6A%[CW6!3*ML5.NVDQL)&YT:TRM+/O&&I%_IX4&:A?%+9%F<
M^!\M%W,KEV=<Q+6+:A.)5&$JV1@8:Q?VV<6([[H13SOTFU!N'[&RO;VQ&R8#
MUEFJ=XX)ZO8 2.%&T&BA]IRD/0%^1UD;K\%FC-XQ4>U2#O_SCY#("V19$[QQ
M)+O$2C ,.PSIG"050[K1 -&D_P6;/#?4W<2A10J7 +W,$]A@(Q>4M$+>F.<P
M76\@X%BXYA9K^#G\6V&[BWFWV]-0"9W++/G3F"PD!?7WKMTS\9,2=<U1#.AW
M V4C69(0A\];C+9JBME$3J'K@'-;G8KX+!-P9$2X?1R8,[*&J6A$FH[N\\8
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M\C:X.2%$EEK!Z?AP[8X-\3PU7=00V@QMZUC1#8/9'RI"!91A/)$2()+95,?
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MMG*69@N!&L'R+:BQD23C\5,-9OB9<CE?P^V*EC+\.[?/Y#S%L6'_G]<)0*\
M5BY":=NB(=-(;:DL($"1:5\Q;S62?,.BSU<(5H<8907?(\])+S+\XN#34SY)
MJIMS<C)TNW;*U$HB"H;JM6XF'"R?SB+"K/_VZ/FU F+DDLC)7"8AJ31SGWSH
M>_;=6;]?P0&MRA.=JU57GMZ @\0R(^.I*.?>TKF*KYWSTL;,JS_:QLW0-W7I
MSW5I_+6IV,!NI2 IOA<[!D:M:?K*F,T97^[D&]J%#SM]UY-Z67@H;G$/F@GX
MCLG[,7X)<]!*O[ H(D67'3LNY.KLJ.M>.P8FFL%Q<HR(Q'-J'BWVA[IM"_$
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M^P:#ESAN4'[$J2D18JNL=%W&/Q,M73B@6-V8+DR';4ZQZI7P$6',IKC""5P
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M18*Z*5T-$U:VU,9('#'=26DM#.8K\R3-Z 7L#WDQ]GE2<X"*6F!=9N+8#]]
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M>8YPB4X[>/158+BF[:^GQ3*'#4VI,B)75-TQ2DEY#?*JWR]A[#"+@[P*/K?
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MI 48DLV$R9%>3>-]Z)Q&R:PH%R/@&9RB3)(0/J[#4K(L&PHA[0HV&X8?$LO
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M^WDN3M\_Y41P:9PM#\UZ9\E VUE];#Y#XHF,X+.6=*"6@)9"5.5+$'_I+CN
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M/ZO\@#@6ZG+KP564:!"[D)TI=%TF.84+\;8>4PF&D=(SPRRL' Z0<_M+.^Y
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M?A 4:G^K8O+S:?#!;<<_KU52()3LDOIB,RS/__:452-ER4Z3JRE-1B\6,-Z
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MG4K5R+&9=0J$^8D5BH2$,;NZZ:ARV"E%S& >H^KAFJIFN?A3V:!M<4!NOT
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M\Q^5:]K$.!?>@XXL @:2S]Z$R<-<!\IW0Q3G)(3/D:U*4?!$K^H\ E[?QE5
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MHEGU>W1;5[+'CRY_1=T(!"WS<DYJO2!F;EI[!9B>/O=ZM=P@M%2=7*SG<M(
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MQXZ,'?>MZL H*A^K*X,R</R'8HX,#3;P*QANF?QN$+&.7R?/DH>)_67!CH_
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MB_/0^+XM=TAX\1@19QUU-W2P"\=XE[_ETDZ<=+N%[=:W.M"290N866"-L7H
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MQ@T(/-JV(<4M /,^?>8W>VBW3K_!],_3@;S1280[1^4=S$Z)EE;8SSTI-]*
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MR8)#(<U:^&I)ID"15D'L42]>?O-=)TK=QK9.J4G3&P/#YSJ(F23%:^C<(6]
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M3"[QH9_RN:XPWMGOXMEV:(*G \;WP#J<C@ZX[04*%TTKH9G'SJ>#%4P$;]K
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MTPZ,AB-X<0S@:=2-G(OU.60E+T9<IXZYC;&*MHR9YAN>(F79G%_:_;RTOD8
MA'"3,6,E";E@@-FI)J'[\=KG=J])-QZA*4><-L4M$YTN=CH57$8/Y,N<WN8/
M+6U%AC@Q?VN VC\(NEV&]*/4,E!4L:SD$#]?HM+OVU)*2*^E?3Q9SS0GS:NZ
M)C^6K_UUN<)XB3:P70J*TO?YX>J&6UO"I4X%F[R"UZ^^^6+Q^?C+P^PY\.[1
M-<-<+;YLQ%U=?N&:[/%82=GX6Z'\9,"?^6*3 _=XB/\];K+WO>,VO3@'N_?6
M"SPUE\O]^SJ@9SF&".7*#>^X+KJ6>)YN4SPCN<!P3RTM]#;W8[FM\2W<M(R"
M>0>D<(FO6QSOOMX5!TF)YYJ.D?647;Q+I@-(($V2H82DC(*B,7X41=F?3&&&
M<I_%W*1>4<XNSU)L^1E;&3?(K5W28+L\?Z&!9RF'CJ=PZHI5J)CD$W>..7R?
M9'(I?_]GW@>9$4*A OT"357)>"K?T!@OKO.RXEJQ!V8S2#\(,?I_4&3 #$+-
M4&,):4LZW!OG7;0RK7N5:9ISXK%L)6%2=*X_/"5%X[M@XG13?8A6VILPC$H?
MNCA,A83MTIO?@YE?"5]*?&'=]ELY?TY_T=TJM'(H\T:S6RK3EG;MR$?LK(D3
MC:MT6025/*_JIJ8=Q2)Z48K0DT!O1-BL$^J6".0B(I8O;:IND-!-;Y4[[ML1
M'0Q*]\ 7<(BDIG7R2 XZT2-M!S2J+/ I^!M%5:^#V8MF29N XDF1MU4ZRNCL
MM^A2WD!!D@BL=Y$.EK&@[%5CJ*.;>K&E>&%!RP;,CKZ."O%P4RB6NM>\9@>T
M#"N@FNA\NBJJ?0(KRO! 0,(JPJ#:GMPI-A93CX>S5L$GJNF]!F@*-[ZJH)K(
MX:^D4X%T:QB,AS"0<M9Z4/V$J ;F1EQNQ'WQR=R(.S?B_EI459Y?+OK\@"V@
M1PQTJW>+9CD=__H;D,$E@>=&>U9#\&!6- -6".G<C/.%K1I,[I%\;_/ZTZSK
M. *YRM\K\)",@02V$ZN2-J$$9+?F+4IVB(&<%#&2@^ II\;_PJ!?!.C$K.^I
MZ.,@&$2THC&GH<0#F7M<>?%21=D(&8\-[0?"5@Q_5X6T.\5V5H.B[/JV;9C>
MI-&@"#N&_PX>QM.Q<K.6^6N SIX,,BTV'(MB@T9_Q-D_1N)+R8C%I$-KX.=P
M]>/?)8==0W*+?_=*F,Q2Q-ZQHW7>N339J"]>%S(A!A>+-\YS]CZX!K1E5?7B
MK7,T')00PSU9%26X@9:SGTBIN !"E9L!+7CGG LOD<,O7.,9@P=X)@_Z1%NS
MU\VJQW<8$/T*NVMW59]UX2IZ 5_)4G7^F7FZ3?5U?UBA[]$2@/&Q4_23]+ES
M)DJB!]HW>^VQNEA<CG2/5YJ8GW6:?-LHHIS3>D%C#9,C7?F.3$]]N *M4LX!
M'B?C.5)01M$ J\+ (1PX4%PAOYK5UQ-27[YF(+,O$47QCK6#"-7"P,<H9'O4
ME2$XM#&),^,A_V7;0LW(W9-[LKLPNB$]5^.3[\"<!$M![ILB)A.\B=LWS->S
MT@$JSDA_,MI+LE8TTW_3M 52$EF2^LM.Y&S4>4QN&&9G;"ZE5+J'6"DX29#"
MV^=^1F\4@V.,6 -CPEA1PZWW "JT5X'U"T/OTMF%AP[#M=V H5AR 3?NQ(B3
M)562B?=WMIDQCO1X#,FI$LD^DL2-JB-W?I(1YX>]7^L:GWH \>[U@/F\E8\
MF&E%:345_5',(J>-!3.Y/Y%>V0MSVZQRGY#*/4$B[^5*:I;^E+'&(M?C=D0.
MZ<:^T&MPEOBZJ7K2"(PCSN=MD9<[@=83WR@,%'EV]+:1,;NV8 A/DLZ.,X8,
M>3?H$]1S+\!C"E30[ ](&H[#LJ(6)"\?9P':K3,/#>Y2&$99!"H9A@"%N[SO
ME^3P+*YXW$>",'0@A+CPKN&M6"[;DPUYC)WDDP<W/P"T[^!X7OEU>+HE<;RA
M"#IP[ CP()3YX4K=J^#W3B,QH$-,39JDI^VWYM*7XJ!RV(!/>2,.#@ VJOU!
MHMSNW+DS8:A;P),(SRJ4M\.WQ8CLVH\=J0PF@"1<G8X?\\ 0>&'":V/M^"6_
MF3LT>R\\DS?2H:V@%$:]3B^0418%KTTKI?R0V630Q8@5NZ(XZ/1=3 8$:B8&
MO1.+J169LV=.']S!\$KS K+UEC+P"+A6JUGE>T&&W;A()P DKRH2T&XBOS*A
M&2Q1HMN/#$2,KUY^]<WW% 2(4>K;A$^K$6K- %G,SV(5@V5?5FNF@ZZ*-9VI
M_ J1$5_S#F\NT[3-FMYTL^W%J?3:8WU=PMH?%F^+8W+B2*_2MC:UQ5@C<>:Y
MFTUD@9=SY52))7V4-\L%CZ6QT J]$R94]%""#E)'&M6SB",C"'>[KM="4,FE
M\%%-.D!,R_MA3&1R:$A3YUON'G22<1"X9)P>3%9455%!\4[M#[\0/G".^<3I
M2OT>9J$%#9G#?,/&%)R8E2S,<4R8QS9M9<[V\&<C]R?.6%L?9>Y'4>[+G<,&
M>7<NI%TB!L'X<8*#35N&Q*NPCPEG,)ZC*M^2#KAJ1$4GQD_\_'/G??;9GI#/
MIF$RTFTXU?N^)8T0'#)14MWAF8Z+_>-_9#(J'EA1O)SO@4<D0HD_3K@Z.GLC
MQ(568(U5ZWSQ_/>?/%OG7A' V@V:8")$$N>TZV"9KG'N?5N=+F8O;74<JK[Z
M^O+["_Y_>(J=0:**BI4\'L_W)6A4J1:R+%M\5$>A&YL-\?RKJV(GQ0R2]@/7
MP:V,#D<A_@Q?CCCWUI1-+P-<D6L_O_ROH.4$/]&9Y3UM&\R=ZZ.0]U>*P,//
M.,8Y9VQ"%N>)^;W25;XLEJV,H_^.Y]$_)=6OVE)U';*[_#[M5?(U>$]MNDI-
ML:*IJ#)OAIC)JM*XTB$@&^Q96U^2%:]4?3-T]R1._[0QH8_SLLNKN2WW [?E
M3B-3-^T>N5ENA"G>D51T('4Y!DM\*[+;9"\JGSM_.5N (1Q: B0.4\KQE-/"
MXRG:7K_;%S[#?H_9X1F'\*,S@_\(,,O?R;G]'.?V<G4X57)RK*OL!?OC'DKG
MVL8&Y65$):-J.@P<<W]-UJ$O0X79YR1@5PJ%F>A2;%%91H@AM*,38C 9WUXL
M_F[P6 +6-$GL QV>/J)W1A.6035.8GHV9=M-PFQ;Q<=QN\3$0RE$@\,T=I:4
M^9#TAE&M%&O%%7SB_9RB,*-H/"/='32%C>*$"SX9QWAN\I(FK^=SD]?<Y/4K
MH2VZ)(RIRR[?10V8_#'-U*W3'R+1BZA&5&1 G,7EX;.IYD2!G;TM9;@Y19)S
M&'YE:%%P>>^BV?4G\ZL*8V@3J,#G*-\YDAW'=F"E**0Y17V'W";7XZ;-4S88
M*B\W0SN2L-73W^D]\+YTC;5/<"3H'RDIC?W8=P<FCY\3)T](/@-R]:![1?-K
M)Z(?Q$?UL-:ER4<F##I**G]3UA,@H=R-*=V0)V>Y8FLEVO?5J107+J0N8KL.
MDTD5-]9)\^(3VMA//N&[4 #?"]YDW2M\ZL3,:VB18%J<)J3L=>63JXFN'D5U
M7!8\M5T.=I]+&Y!6;?1)$K]WB3EM%\\$D:'!213!H5BE^V^4EH@<=6Y!F8 8
MW59SP.)Y3^&S!G7M//Q77CL%@"H&TZ-W<R-(KC5I&&$UPN>2S%W]A2^%AY4_
M",K"0K-&G0L'1AMB2%/ 7ZSZ=_9J^72_XQLS%[B;W_"S<(R=)Y4#N/LU'U?R
MZK<]!0QH=NCZ[;:P:1:4A0X*)2J4-3507&@W;@0Z%#;+,EP.)X\+%'%C91(%
M2(:!%PU)^K+F@R7?6A6N'8]$&%?GAI)K1J,<-DNPM9-9N6$$UX47%P- O-$D
MUM&OW&*:HPBX1DJ3%-=Z4>4RM!=$W<_[]&Q$VP#N*_%E=]7<&!\;^O3:3":%
M!@2.;[G-4JI]/+AB&&O(W5K/8(ZBXW<GS@O/8:+T UXC3-FX1Z&+(G8:MH9*
M04JJ09LFZ;E:W.2=+Z6L"[=<O;+CYVWQJ'UM^24M>3A&JG_W*#*.*>XX-:LE
M4>GZMB_8<$\HK)\.P6>;_J1L.NG1/XK(OR3OKI7Z0<>(KGK>7Q=I=?A2"NKR
MP^@+O+Z\D']DRN'0:,,J:45@)6*$HHR7C06Z@ TZX*5-:=$RJ[:6K<$1BMC:
MR)P?/)3*NZ;>39>HP PTGY7Q RI@5&1<HD&>%1W#4?VMY8>)SDO$R;?.6(7V
MA&&Z6$@B[KM=33JJ6U3%MNS44X'ZD/:S[^FU"(+*#VV_V\,.?$[7Y=&]%W\4
MP-XL*"!%^1KP5B/0(.TYO2T.V?'D &2LPIQ(B^F0=\)3R <"&R*G!< ,@=_Z
M6!QDH#+L*P_1H* ECPW \%D;/1UM9)XU#E]01@S1*2T"= 1UK+^8RES+L-$A
MD&V'PJ)Q;BK&@$X^1"<4: MMSW);,60(QQ4!/CI4#%]2",,?7NXIH*\B@N7S
MYV157Y;MJB^Y;^(-6IA$.C]Y\9QC&W,-L_ C=5MQ/7,EK&FH6S7[0NC*73Z7
MO3SZWL =GK#AP3VVX8/8Z$&293\_Z0*$G\O<LOFQ:)\QE1RQ$S0*5)JPZ*N[
MI Q=&R35X;(_7/4!F18[:K[A.COIOSL%Q?U>Y/ZTR4--SMH-9R;NL+;+BDR=
M]7L7;NH[:&;FCF_HU2GG (H20$:7:,U.#3_?,2H[O@:K1H/>KO(;\C\C&KK@
MR>/_#T$.ZJ;GR44Y.<R_<3B@'+TLCHV-C-MA,1(,G%&8GW@AKE);EUCLXX.L
M# VO=.L?!=8.[^+95$B/"TN'99N4\9-FRN1EP@,V/7]!UFM?B$S .>9U*U.M
M<[(3%0"GGL=YT#[GKGM*UK,$-5=/,<+3-4]P*K4#WL;3,3%S27^\L]\66Y5I
MZ0H-_8.:$< XJK77Q(&XI#;94FPIG7:C7UBT3\>XR%L2"XXK!T?0;LW4X'M/
MUJAPW!.#.G/I_J$?X0](0()$:FRD=840AWK/9'DP-/PGG,>0>=(\A%@ARPQ8
M.+98%56E6<Z4:MHAV O[9TCJAK6$^[/!6;.2MVH$-+T>=.GQSG7>4FW)2?EQ
M*C[Z3M+\H@8\20A?,<&&N@-HX]5['I!07$=:7J#S,B0^>S+2IBTF]-95P&_J
M:^2?,OIG079?R;[+W:YIP0!.O\HB[/X!O08^_1WRK]O<.I!'6V+Z2![8AAT4
M10:!XZ6HD;"IR0..=,R P:BHT60X)##PHW#X@;UH_SK[/5[DU;$C,POGDEX%
MJ<!RR3C]FC0MVYAQ$FI57(&]VQ 19VZ<08-P/;3N0-R)#9,<PYZ^G"E*DL.D
MSZ9F)R0'%KR4([_.O*+/UVAR)L$L\Y:?)'HS!IV6XH@-T<F>CB<Q:^&_0E(B
MN?VU=2>Q&O).*4]W3OL84B+@$"&/7Y)<-F-A>0^6KH.B0\T:.(43$7D 6P7K
M(&8LDY@OG?]Y'U)H2:B9%+C^14Q5K0KGRP,UJWB7 \8ODTS/)XAA6*$L>NY-
MEA$2:"2##MSU+8H?VWRWRY]1/(D&)-*<5K<(';VTV]O6>K*"?FF+)=+S!XMQ
MKI"AA^&*2<7/O[W,9&NU80JE?MSAAK[V3%X$3R"IIN3:R"%I:&X+'0!=Y5I=
MJHK^;;$K\ZA\Y5><\?.#H<8'8\V<T/5]A5;? W0RZ6HN280.TA,3&E:#DHD,
M[MV4A1^.9S"OXT&,++P<D?8U<X])#\30Y_38*LZ]Y7,5BTQ:Y/*#'F<F3$0X
M"F"G+PMM:8\L!&K-D0,Y13&1MZZ@R!WN"+!;R[(.3B@WT)V::@?3!4-!PLBV
MH2"82_&Q%=]B9/K)VJP0AA^>C&J?.^&D$^[%W DW=\+]2IUP4O -G01,Y@36
MVM6J;XV^U-2N,BXU(5LP\ND!DVS:,;5V<L7L?1T#2\<KUI%%7A,6,.;=KF"N
MUX%7"[E>3[DZ=((L:ADX08QHLM<AF2<$;S-G[L8[&[NAE!\./E'%?!!P74*D
MB*-EPZ63_,+G!W3"<(Z57V1\.V$G;NIMD^;0APUOP5VS^G4*CLOD).1V](*-
M0%X=_7@5^'^.,N6_0/U6'Q>1:^:;1AQ5T*#5SG.D_(K4QG.F\:,S1)=34I%V
M,YZ4*X&NWL:.HWA6=0@-J25$"3QO&^?&?8HE"Y%#)J;K4'8AT40_V#4Z5 ZL
MN&LA)0^(4*']<8("3XMA'.NXB(3;0P*DFJMP1BBM:2ITCC&Z(KV:X3DPWGP7
M8E\',">7Y V(.^A!)G0N%A24&6,O<X-+(*8*M;MX5[+F?P=2A%\(:(D/FGY3
MME,#=,["']CKX RDY I:@&<T4J5#K$1GPO*3;4$?KT4[&3J?AJN#^V[S=FU5
M[2';:<<Y QFHCOE$!:*BZ[\MBCW]=I!AD'B_6@MJ=>ZZ1_[V]24W\@CSD$*B
M-'5Y:%JWCT,72&:JD?DK*U6_^61#'9!$&$@Q83RAF\:6X,-QK_V+F #N+(H-
MN5!.0MJ0\*@3E$%;M@T=8'![/^OW"ESN:JLQ1!\\!3[L]S(8]OSWSS!.D$P_
M^!V;V9+N;6 E'CQN8N>.4:5;K04/ X@L5:')F(3^E.5?M"=K&#\J:)P_6A6?
MW]C]O#'M7 @O+E@(D_>0I^(VX@E[%9OPI^@Z3_+1\(R$M5:'[VO]P)DE=O,L
M<5S[B5%:+3=<I!T6 W8269.$6?JL#NG*N:V9]LGP(1OEY%9DCS 0D)HER_TQ
M %#?7A=D505R-:I9Z8=D\P:=[3BTW6J?3M@VNY!_O5S!E-.Y8>1V<C%V7 Z\
M4\QFO;,GYJD]5<@ML=N-4CRR7YC<4:D?^];5+MDUREFL8D]^-^ZBDJB-1PTQ
MAU 7D3M>$?3(%T ..^_$:PJ>8P0L]@6'1.,$I22Y>7T^+WARLX$_Q^F>F^+$
MTW)"G6&4M/+ "Q'DS($??H(Z.#MS\55,Y8C#/QUK)W&Q87;6\+:G?6M[0]G"
M//ODME;SR7P8&\!LCH,F&I>24N2\-$".A?-<ZW!I?)ROKABBEI?2L?ZT"4K^
MCL.S$O7;<6YLR#D[N=>!:NYN)<',L9M*'8C^-%$C#-$28^'-6;,'J']_N=S(
MSPGIH^@XER64P+78;0(-)6V-TW*IS"IJ8[_'Y\)(I^85R[V,.B(P&ZJJ$\I)
MQZEN"@]$W->X\*K<LQ-%3T*J;Z==(,-$62%Q=;FQ%#NM?I=4(>=\V(,7IE]F
M0&&<#<(T,X[MJFK8@.AGRM:0*'PG6SZ1Q9T1$4(NH(39?*'T*D4OOU8PUB2H
M&<*JP0UA)\PQGE\I8EG(2257L"CH(G;#NP0-I->:OIQ9W4@GO4POK_7C (*P
M'[)#QKP>D$GK!;M(FV?\9[Y.IC\M64(W!>?/#$2._OECO]X*8-[Y')V]E7+'
MTQ905A12<Y..5UQUZNS%=DA/V^8S6LEJ,U,;-\5T#K[<N/E:1=:L:T8@Y?'@
M#B<LO)RR';^,;%IS%@+H+#T^J] D&5<7C]ID.G-3K+DMAEVZ@Y#?N"OJ[GDO
M%=?XO$!+IQ7^_AMX$"MQZ3__[K\O%O\LFU@&X7OJ7;YL&GK^[RWLED&?;L=Y
M,)O@D74Q?O]A?.<OR8LL%B^E79/AJGQR4X^:2A.G]F+66!H*^63N#>HUMF-R
M[B:0AM37B':WL8<+X*[A/S>+:WO"3@ %AINH\'P8,B8SF/?:O;)$7V.5WW3N
MJWC__4XFH0_"KLI?X=GM=)(HGG5NW^FN,&;/D^C)] :TA4F@E*V.>VE@"CPG
M86+9CX?(E#KWU:3S2 '#2]LRQS!?,Z?Q_4WDQGE]F9 ' P=:NHYZ@&T<M:]%
M=9YT:9)>K$2]92<37(5\9MGPN_E=&4O0L2S(.[S.A6 G1"1!?O_\$08>Z_+Z
MY$FF][*O\N.?-U7Q;GR*!23G:-?F;Y&[1FKS+WQ6G]$S[KH_ ]B!U'LQ>;+C
M*E]<O/C3'__/PS[J UD-NWYFPY,]#1M:UMB19[RO9^\[U YG]GRTE6A:(AO_
MXD5H6W+O.EW)P]KF]SW20S_'UT;?1R_\)<H&[93^_T^5D=_-,C++R,.5$8&G
M\;4@<Z(%1UYCM%DD9I%X2B*1=G"T,1R8!6(6B,<O$"[1+"UD'&0-RN2##NB3
M$C%/9_R<Z8Q/Y^F,GSF=,6OD62-_]!IY590*&YJWM?KJO:'D5P5CY<P^R2P!
MCU4"7+%=*RVQ?#BHOL]B,(O!8Q6#MMCTG7+$*D2QX8LE+==)/W;GOKY.OR?D
M;3JX,4O.+#F/6'(PKY+TG<S'?3[NC_6X;X1]$KE-T MPD5UX&K9-NPV3[-+1
MR_9"QV!GH9B%XK$*1==W>Y#(2DX_#2DF>OAG49A%X2F(@O: *[3#7=/ZLQ#,
M0O"1"X&+IO=H Y5&4?1/,[(X9BN:-B#^S''#+!*/7B3"^&51_J=O"V%&F(_[
M?-P?YW$OZQ_[.H[TF?KO2IOI6)77)2->K]IRQP,(86KOXGX;'N:1 ![9=.#"
MR6P*NZD832G6@YF4*K\9@([UG1M:!W$*H]G4RI4K"#F&.\:P$,RL97! N%(
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M97(4P<8GM;GIP1_6-=Q6Q;C/#<7$P@@BA"B*<R'Z6&+:75^KTP)_B;Z&? #
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M3)6T;,:O:_1M*T;AVV?WY2N2\RCY==( ^(5Z!B89_K673 >D"VC1"BZNBS3
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M!TV5AGC]'P$/ NUC8QTF/$4962L4?1W$ \VI3$7Y]FF!.056FA@$\)0P/K0
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M80WQA(?=QF6+[_SG=T;BGNE7=2!H^=&O!J*W"O#.CEDR'U952;M@\;AI+_$
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M?;%KRH[\PEU95?*KX@OM*,2WKYKV)9AJRJI7^DX90-(-E0?.9L^9HUH*;9;
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M;5["/N)T/6XRWA$'\&UWL^9MSZG6O)""3P:IE[STA]KU@!Z.%9)MD].'JA(
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M((.B%Y;2C+Z!U#DG1I1DFNPKU\<OG 1@G(%0R4HNDTNR(EP[DJV4BTMW5MT
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MZ>*G!A#(\&:4<Z*(U;ZD-8),2UOB)4O/NB@H5@&DM4-/&8#ZP&E).W?ZX4E
MEZ(S+2!3QBA#E,+F/WGV5%+<DE\FJSS^F)?QVU/0YTX$?RIAQT\_9 8KC-&Z
M_.JS9)P0X9,R EV;/3XFM]F4.S&Z_Z*7[EXMGK&>'.W1'KJ5';?M^3V#&\KG
MYECF#MG/GXY3.2CX&IJ2!7"0%Q>MNP"/Q'KQE\\^B3#<O!GHH7GO)[#F(SO-
M3'*\EVBK7H+TI:)I".7!T<?2_3.?I.\ZXZWF?<+H,BQ?3/A>L?GPI'HG[]X4
M3&4-1 P_W"P@A5#[=OK%V.KJ18(//L'K<_VA3;_JQ;S3>T)K,1^J7A"RHD7+
MV7$.ZAF6+S_[VR$+?@RK&[7UT#_N:7/#V<>?GCX('0]_.3N_=WK?;Q3^\%\>
M?'SZ:?A$G*-[?3-$#OE685:!;"P3F@FCR?T'#T[/?5O%;,;OSN;EU2N<.V%E
M^YX<79:??!KL-2W+SSX-?3FZ*N]%!OVW;(#A4O[%17N=!UOR'I>HE3V6:$/Z
MP8KB.():.)B#C0JMYZ:N-<22Q&Y]T0R]YN"\>@2% 2^F'&F.!*]\:6S!!*)?
MGYS=.S,GSVZQH=G8GYP%!=T]OZ@OPL/I.3>IL,O'(,<:=V9CSOA4P:<^F/&I
M?PH^=3X8OAS+R'_AK9S/<@Z%YO<- Z<F9<*_(*>K!<S/<J5<?4@R&W5#?Q@4
M2'VB(U0?AMF/H!:N"0-/9L,@,O=2J^X@7(AS%;'LVL2S!!2;&/7S>V<2DL>6
MV7]>"R'\<2VA?K%@[ /G_#+AKRSH,*3#46*43#1QBBS.O1Q/O(3#YXO%I@1G
MV['D2QW-/WVWXS./#IK>)TM#ZH<U&=G'SK1YU5Y$P>F4<MGO)4!+,!(XD+=;
MUS(DDU:<M++%SK8VHHOH4;-$UC.Z/M>_+OGHBX<1+CEXG9(64^&@%1*L_6Y'
M#[':\'7Y;:_0/9DH[UG:.;KL?[B=5:DQUO&@XW=^;/@""H&R9!B_))^BQ&!>
M9:+>E FG0)D#>1( K+I:#8 3(SV[0[=W6Y50LK<&B([FLS1+B)>>^;%';SXS
MUKWX]<C%W7H-#@]DC"*Y)B2Q)2RV8.W.N!BSB?\R O$B2(3J)(M+QGGJ1-J7
M'DS+1_&R5!\V\KJ]&!BWD;LXRWA@^?E]60D !#IIXD&OM)"-J#YV\(^G!D >
MS 4O$9OU 8/Q" ]2NI;SA+59TF>LT#3(E'*;O%ON W ZUA^S-#W@>$A-&_,&
MFPNC"Z<7K6*TN#/#8,H5HUS8 +8M-_EO(WP)KBP[$/;)I.!"9C:F[4%9[DJ2
M+GV-? ;S*W.VS:?+^1)BNCP:38@)(@%1[5AF=-M.=$BY#M5%>G4+'%<(@.CP
MS0^L(;<M]YE42!V@\X[AAD81>_14\N&2-EB_UE31YRY:O'[>!(*<LV,;5A1D
M"U,N"!?;>#&CWA<H[R2'>.0Z  M4EW\2T<X':%J^"MI_H*WHZ35S&?-(0P&3
M[C8KZ93'EI@\WT9KGF$FY4K0(V1*8(#^+WMOWMTV<J4/?Q6<'O>,/0=B<]%J
M37*.O'3BI+OML3K)F_<?GR)0)!&#  >+).;3_^Y252APD2B)D@"RYDS'MH2E
M4'7WY;E 7U/$&<%75SEN$R4@!2^YZG]DA!Z.VE7/%,&$LLBP@A&.YT53$H36
M1Q!"Z@X*=JJK5\<A%Z24XB?&3J09D/KAL=3,/!)1S."/"Q?0%]6^.B]SXNS:
M"HF3;4D,UG7$-0V)Q=#54VJ!!UML%P9W!"N48CZMFBQ8Q_WI<E^6,R-VG]?O
MBCLC K_/./RH:;E@-;?$+Y&D#5TW\EX='1UV3BN@GU6SM^4-N"GL\MWS!<3S
MDEFA)-V"RM&F83L*2AZ5TJOT0["'R@HVFQ4YH8I2_D%BBMS3*""P$T<5L) N
MN(MR]'[('R/&1<CQF;92X/.06]'-D H/]CI+=<:7 ,M0M<F;"8A8WHIJ3KA>
M:%50D*=IHI$ C9E$29DU=M)0SE.-3#Y+(X97K6Q#8VM8AN&"*03J6 '%XI>!
MN.AXE[)J]_HE@HT+46C96VM6W-$M8'LC1%R?U"<U?'CDO?_\]T\?#GIGBX.(
M70=5LRCAZ7CJ4U6$A9DA0Q U>$+AC7G"! ;6)):'JN;-?V _D?=GZM[Q/G/U
M435(IM"I:+S4/-D\0QM%N;(N<XJHU=QA%2_A]B >3@-WI70W0F1CH348;+C9
M7 "(Z^'>)OP=NGLCY??"%:,2-1&#6,,K67RN7AOJA!#T38"59VB^)N9?>G1W
M;6[W^A'=J[JU2;Z'<D9=TV9,CV5^6]7=JOG$6/"^C2>N(.PXC(@Q.6P1KFQU
MU(6^B1IDN.QZP"^UCBSGWK9?/^=5M9.YS?B:*^[XBG>@ILLB-:1$3K%>*5/%
MO;P7JAK=Q! 1QA A"POQO0JP'N0!5A18Q>F*CN0-&!08JV![O<K<Y4494I/T
M/R8(U+E8A,:6  ],8B8"[@G16O)7M,+CQ],;^9MP^PFG%_9_FB91D1ILL,B(
MT-7TP_-9ZO5P>Z-AG5BE,ATJR0;O;C&MOD!2C'"I,M<;T!59X]-9G,ZELI?)
MI"1*-K6==AGF)^0B%>NQX_68CQB1S/P.]OE5!&:O*12OO<14Z?CH[J/84'#7
M'+^C,!6Z_691.AV/$HFE$]C+B#F@YQZ0^8YH!0S3D"8'-$&(E4! ?:<J;*8*
M'*+,^U<ZK!6[5O$&EBNA5)-OX'C@DG^;B..M2_$)CX#\"GC2E<BH )SB(]3\
M4*A:7U5QOO!MN7ZBG<'*)!;'4?0QQK+] TXQP",H*:/BD+#?E'3"#%2F@HV^
MF0145=_RS9R=*A1(,/I"L]5G913I76?0\7B" -;S6\Y%]2"2G#P$JBK+6'^D
M\#Y-"$K&LUCF$(X5*\$6$XOR%<63;B<4Y'P]]6MBQ_H5;)V@(I7"N&JKJUA(
MP6@0=I'KX(R9PY1F-*D2*\]#AJ488_*2>4&40*?:4\Y4]#R4'(KA3U.*;2AS
M'MX$BRM,,>4"H]:95%< \]Z!0-)?KC]X?U1&>YRRY9U<LY$+ZS=;NMENMM6W
M_(52+U(5!5N)&4^,,\GQ&^==-IVDMV@&D1I)P8T;*XN<)Q!I31MO0"^D,E"*
MVPUE=M825@A"E\""L72!>^80Y%R'"[DFN32X$V@%@1K(TCDXEB3;DZH(?DVY
M0FV&"-HN]@*I/1[[TTIN-E)YC16E#%6CDYV*ZR!(5JU& 6OXL[!JMZ_>AC*D
MBN^]4]I$MPEOPH &]DFE4*D7ZPMH(^^3SV.U>AN@>3GMM&\5DD>N0O)%*B3;
M8QT]E4:F*;,)R=JJB7,YXN8LBV:3P]/A-'SEDH G(X"FH_^UAB2>3C_];/7"
MK&^%N9;D[H/Q^&^XX%6O<V:::6@2E6TQJ3H3BF*L[XI;:JE;V1FGC- $%V=9
MHF42:PS1DDKUKFW0!RR]50.SENJ.UU?+<E0HH:*1:9J9ONAEHW9_3+C6\,?S
M"9[/2]47NRH]^YW^\8FCCWNKU#7UI;M.+KLC3)Y.*M])'(0K'N4%:]6<-*!J
M\<9R2I[JO3&R">?J5;CB;0NU5AA=K26U,,IGL9B_'<7RQB:S0UK+O\J\B$9S
M_6RZ"IO^L^*<B.D 9S+D;[':#6'95I)>M4H4A6<_-IL6'Q YK^VIV= HP1TY
MH'V]];V+['O+GB]M)7KZ-VA;&E_?.NOZ2IJUS?<E:4JS(K FY@)5OP-5?7+C
MG0[EYMPZOA+02 .1JN2O'H+X!='E0FW8_BP1A8<\^S^+[ I['-^#62['#(ZH
M?N93E<\[!#/S/B5P7$6)I48XY)XNH]_XWCLIIC0$4H'YYM85$@%Z+H(2=$9>
MN\9ZC/HUYQA_ ^LZ*Z)<8?1X%W^B:_2/_?HH #;R311:#6+0T&2+YKQEQYMP
M=DY5G1Q+#L\KD0($IO[7B18G6G9 M"P8"!86A)HDP19";;8Z_$(A9EWHQ,:Y
MXQ#'(;O)(:9-^4 SAS:T[1$PN8A%1@;S,$U*^N50)A(>I8?8I,%WA42,@25X
M $>Z,&)4U:K(9"S&;*BOM<Y'9<(U-4XO.:[;5:XSSJSMNRX"&Z$FTI 7<[]6
MG5S#AU@!%UII-@,56C$S%TI850;J;1$8Q 07+BUH?_2VRQCKYG/?E&WC'"A=
MSNS8U+'IKK*I\4QIT UQF4974:,R- INO?V!4#!S1B+!!FI5,[NBOX Y68W+
MX5X2[JFO(8PMC&.K%I6):S,C+?=*A<Y_:Q-_%?URG.LX=Q\X5R5>,0)"L$.:
M[0R+& YB."#'%8XK=I,K[/:44*(ZBJJN2FXBJ+R_6FI$-2UR'TD<IT'-521%
M9U08!6ZEZDH?V;T<C.Z9EQG^KK..T5SN[.%5T>I$UJM_CHB)RO/H>+^E2281
M.X&P!S0\H(DO:RP>JI3&@QZG::@FXV97D1YW0.4O,KJRIJJR*6,901L8)=3Z
M@H4T6<ACR& /9R*J:(V[</5/&2:&[U)7\/ RZIS1$0IN%,K+*7QN"W-\CB$>
MWH1.0Z1Q)HXWFP@U?*^&1W2KL:RXA4J=X)EF! AW.Z:C _A_>!UB;QF+WG18
M8UD7./3@"/ ,"I:;&J&HFFO$H)/G/(@$ <[K&.MSB2 <XQ+'=<+N:X^C D-*
M:(H-^?D'P_F!^BMC!SERWR-R7UL[L2!>L6D !Z^HWDO3-TC#2VNXW1JE9RV#
M5"CC"#VP /)-;;2W0/<OP&[7AU0QH.HRGBORCC7[9%44S-\,'-;G&3TK_'<;
M?M:OH<UN,,R'>U.Q25OM(L'-ZCA>M94U/$_:8XZ_5\"A+'UH9\UN"D*;7<!\
MM%YTYTG9H01M#-1AV]8%\_W%I0P1VV@2Y8A?@$? 4&/<&*XVWN"F,>:[W1"L
M*<=*RM7[K;B+:EY9(O 7+3YKT4I>]O4DG>JW45<,$XNJ'H!-"_ZOC/*HLG=G
M*]K!Z*),JJ%Q&K10I]Q=G>L^B]>+@CO7$/?%5VBGJ*"1&]*$1M-6>&"9]SU)
MK[DT&T<>(BX(@QMR UU>]:-K0<"&MD(RU(;#7&$U<ZTV3]C<* _@;U#,[5.-
M^=HJ;OP*+9#9[+;&!JX:4K9"7N=+0#/XI(A^$ZI&^JUA2]:#I#QU"_ZU+W5]
MQR[:Y*)-S2%I"]!567/CC#!D1IO),)>I<%RR'UP"VF^HQEJ FS"3M[*(<9$(
M,29 Q"4,1Q!(NV,4QRB[RBAZF.S"*(-\C:E\GW*9%6-R'!\Y/MI-/K)Q]D?>
M*(JU@:9F2*BT791<H3<[5D-Q@,NNO3 KU63CWS[XZ$G&P%$58B<-O\@XP)=F
M\!U)[1H5&4>GS$SDUERHT>K7E\ 82+I5,ZT<MSINW5UNM:(N/&Z<(ZLRR=(X
MKN:%L>;3@ -U[EG+(@ZXZ#' 1<<.N.B1P$5.1#L1W7(13;,[U  ?>_90BLDF
M NMC1"G"<+''":\R=HQW3\:2'M F$.X]5"8;HBNKL1N,; LO2338BZC- L-H
M^H&J@^%10[$!EJ4B+2RRF8$^024R2V>8).!A9VOA"E6&37E1SO1R?+TG?%U#
M3U+D[V^08 MY?-<B^%(U?-5?ESS3E1.<WJ?"NM X4Q127^9<QY".(?>$(6F$
M,A?R$P]^E_/UY2_6$&7'((Y!=I-!=-?+<KD$]9+6 ]]HW]T^//U:5G5OF54:
MI2KO:N-Q'5LYMMI5MEK0.];(>QNF:&5#]0&6*,ZM\E(<RX%V7=4(BBUI<Q/=
M7HQZUU'=ZW6J-#I[C>U(\VW)$G4(/XXW=Y<W*9N%$\_9TS)Y+=1N9K9LFE6S
MRBVEY9LI$698NS77?;&<<-U;JJ)EJV5*9I)@%ASK.=;;5=:[52VJN,A*O#XS
M<DQ5XEO!$WD#+)=CV=_\EH0OQSX3&F:N/+V15&T4J]^H:OFY$$1$4V>O.L;<
M%\:L!1L-<#P9CS3@#J.3VE3$MF\>7BIBA?1.R$0V>CV/-<6+'!<Y+MH7+JK\
M/-/F&-JI-L[*X?3?6&;Z/I6C X<NF)O\V_IN&=.Q8I((#I'$,=DN,YGJ?[MU
M/*L#"MEZ)Z,>\$Y0VW.U\^ 'X_1$E&8JA(7S<-54&JM14,.555[URJF&"$IM
M#5/$K">_U$2I:RV15Y$1FG?'KJDX8NFMU'F-Q0D)7)UQQE4AHI$WPE,!5H^U
M65GML%#LL#/=OFYNR4-F?/R)!C-Q-X$(X:HH+] DOI)N<DEKR.7I.&\#\C"S
M2V99-&50&*Q]7X)@5M)Q)?[R)K#+/HFT"DA"84+*&QF4N"!_W1P% P52:ZM>
M\44&I;GC;?+=!(>AH<1B.4:A*S7V@QK>OCIPP_F/;);22+2I* KX*I]L:5BG
M:@.2JE@&S'&$@Z+4B"@9H0.4C+A1CR$H6]I/A5SE5W!D1B5E CY=H7ZL CU3
M>&;S)<!L"T4M-2.PZ*D[HSB<'-@(A0W,G2B(9H(0&Q2$SG@#-JGCJ]1AU*@"
MC:M!]17A)H!J2W T%!&JX?10U%0_<G7]P%"2G>;-RB$H$^[T2>;+6#*8$UED
M0I\YWJ_97IA&$3>&APR4W.*+M=O-KYC.XHB8E7[WF\A#\7_TK$N0;%D%,OCQ
M1MF:[]/I-"(Y01U*EQ_?XS*HD$'-O&8>3[G[-D5?G9!C%J0"(Q=B1Y2Z4FT$
M"S"LQW.,WDQ&?\:YAR3Z@2/2J?1>*Z9^LZLFH?,A'K*U[XW?/1)1ABCBI>1$
M<A&%45SR>%A.5L7:(]Y5$MH=(?-TTAI1EU811X;PO3DVT5%]N9>".N)>75+J
M>5Y*N[HOGXB,P2\Q&Y0F[#K@I7H4&BHUGGI61:$Y4F.W%<)+1Y(&5O #1A'B
M_,*UMO6+^A7SM^9W&DSX6H"=3@7PZ*?DHPB>4\Y2MG.".,U5607:2Y^^?.YX
M!+F%[()A=K4$_$%5:^73OPVKF)KY57N&KZ^@90N;!4V@B4##;?S9NP#U.(<F
M";5V"B94F?'#I0@P@(8&&XT$@%-.E4W#MHFU%O3/5BH/W+=8JCT >['D^A("
M)"V+O!#4%+0S5H?3*=O4*:KC1)<E.7W2'N)Y6N\T4PZATAD*SUC,5ZL#<*I(
MWM>IR0R>QP'U[.&**W!PQQBDR;Y+C*+/Z%#_S5I)WF P/M>PQZ2V0+9.@(30
MZPLD]S=2DZ0@T$ OP41;&(VCP@NQ B%3<-^XSE>X(Q[0<ZQ]NUQ4N57EGW*E
M+<;<0JF*%R)>2:[233@NM%H'09=:'S7"9"]S%VG.I,C2>/$=Z!"N>CE!1#*:
M.?F;9I?Q)N/W+O H%EN(?$)Z@G+-U78I#5)I9QK11"OM>.1[7$>(<VHA!E2'
MA5F,(?Q<%D7,^HD:46=F3R+2/_1NW$MC+J@/,B:#S]\+/QJ">C=H T*5?:V_
ML?,[35R<*E]^EB)!8DFS&(,R1S)<7C4%3SB3-)0&_G4X]TK6@:_Z1T $4R8"
MLA;NM!36"46"D94U[/EM&@BX6HZAW,=*R!YA)2# YB[:" Z;8D-LBA.'3?%(
M; IG9#QP-S_(F5+G*6>>4(:JS!2%M&MVZFUB>6XZJ#$+A/4(*3]8^U!UJU?/
M*F&9J?->( ,+U9F#BFFF; $::(BZ9127F'5"#52K5R!;1(EDU-WTMYT1I,[9
M>H@C\@E5@\P+*]RQJ(Y]+Y&%\[&:3C-/.79F'8U4>7]5"2!#QMI3-X AB2AX
M2FJR(\75I?7\%C]T&H';!'Y1(A$Y7;V"2DYU0K%,K.D*;)%CZ,A(0"?,&DB8
MSRG,B&0*<>/$5=.IX@FK0<DL^B #22C4@Y[O8>FQFD(%YI$,J7(!M)I5V!*G
M.:-^_O;Y%S"D1);-1VEV+;*0'O>J=SSHG&G?7%4KH8D%EZ^Z^O#4]N0Q5J!?
MNWP#C<82&+<(Y0@1$3$!,&+1!Z8;Q@K*(L)N%Y9[HU$.2S_M_DB IZJ<0MR0
M8&6IZ5LN]+IE4G$&2%9"'2FH5!;%+I>[:E"$?O>P3Q47M,8J3$!IC\H,9A14
M*C 08X%..TEGW.%0)UBH;"F'E9M!&8L3,=3P#+!^L:R)YHZ 4Z<C;CLCVY_!
MXW\IT;Z\\(?MXU<%,5=S;YY,IF]KU7LFP9\Q(T1 S%'.8= Y6)6YQUA_2U*>
MA";\I><L@*;3S],6&5A9?_8XRBFZ*O_&:#[/E5N6,";;OAF)M7$.4WMBH<MT
M_.#.MS7Q4$48O!KU ;C0MZ(LTO,AFCH9K0]G;G7/Z?*#6,S3LH#'W\CPG%_5
MZ](&JANHN7B6R[>Y1/3XPG0;4M4&/_L'?#\LP(2PKZ(\X@#A6WV_N@BN"LV.
MT>N.3CJ]7A^;ZO[GIR)<<U&O,SB[\Y+N75=T.Z>]P\<_9DMK.3NZ^ZN;NQ;X
M2[9X[!-F?\5PRP>N2 I9L-_I'^%4WC2.0J\N7E8+Y_[1D:__0QD$C^(DR5M.
ME> /5DNF*[#*$;-)\2[S-'[*.N&A^;1!TN/I,BDKC]P=5-,/"C8<?_.''XY_
M:.*AJ;68C5VWFI5IW9<Z;M)H;7 UUM',/\'.8S/O?X:9]],?;5NO32R_.]33
M$&G1OC.V7P>;!&]T>N!6/=!OI!YPA]82=G0'M7!0#_)OFB Y#>$T[$C;9$B]
MINKIM(1+P_S-G7SLCKW)G+Q63S;JV)IOR[:)@3&PW2ZV;?[Y-X23&WEZ3N@Z
MH>N$KI6G;@?;-O_\&\+)C3P])W2=T-U[H<OMY>UBW.93P,OS<@/C3[#=39.Y
M[2KD>E\#ZL^P.;QL".LV[%Q?GO^>X B2M#T'\ #&>AX>>M4,?FF^"FN7:.SY
M9X?/Y3RVB0_;+O.<VGGQ(V@3N3NUX]3.<ZH=FN/2.W2LZ#2/TSQ[3>Y.\SC-
MXQR>E^?#M@99NR=^_[ +9])W0=879:S/!@-#X^R\?2";;>M(F\EH#;$X-D]7
M;ODXFJ_0&G)"[E3V_E2<Z'*BRS&).Y46GHH374YT.29QI]*D6$$]?F-O;^^0
MGK2]\(&- Z0>W@ IV*Z(PM<U(R2:$9AU"LX%4/<H;]=\5=4NX=8;P!K.CAPC
M[1LC-6RWG=YPY.[T1GOTQO&IW^\^5X^]XZ/&\%'#=MNI#4?N3FVT2&WT_-.S
M@>.C':U[<K',AO/?GV1"8WMHZFT(5T5Y@>525P_M0W7INA=7>?<]@EO%8DO!
M-]I^)GN#K- N<3DX\8\&#S57'%\ZOFSFJ3BUUI*#:ON9.+762+76._5/CQ^:
M\W-\Z?BRF:?BU%I+#JKM9^+46E/5VO'QJ>/+=O#ELQ34]D^?, BM'MZ @VL7
MG_Z>%B*VAM7K1MUFI/P:QI.M,&I<9JZY>^TRW,]KA!R?^,?]AUHACI%:RT@-
MVVVG-QRY.[W1'KUQ>N)WCT\<'^T;'S5LMYW:<.3NU$:+U$;7/SIV0(*[$\MT
M0((-X:S/Q41FWFL5G'SC14F03J4#$VRPU>!@;1H,H.)@;=RI.-'E1)=C$G<J
M+3T5)[J<Z'),XDZE2?$"!R;8JJ@"SVOVHL0;B2CSKD1<2B\=>2(IHC"*2QX-
MBXO(O3@2PRB.BGDS0K=.^[D(J\M4-$B/M4ORN5E[^\I)#=MMIS@<N3O%T1[%
M 0?D'YT<.D;:QCD^SY&]:08G-NRXG.)QBL<IGO8H'J=WFL!'#JS0Q4KKL=*\
M# *9Y]Y,S'$.RZ/CI"Y+^.*:<*O=]PT[@+;OM;,ZGGDR_.'IL6.C?6.CANVV
MTQJ.W)W6:(_6>'WBG_8: >G7,#[:N1BITSNMDX5MXI>V[[73.\^J=\[\0?>A
M[:>.C9H7(G7EI*UBOT\HPF1>T$"7E#I6N4_5]Q+I)E2WUL+8:O;(H9$V,5OK
M4()?: 2=?]H,G"7'EFUFRX:=BM-J+3FHMI^)TVJ-U&J]PT8,XW9,V6:F;-BI
M.)W6DH-J^YDXG=9(G7;LG_0?FM)T;-G>&/3Z,ETWSJ6!;*K&N5C!YPHU\3%A
M:)?H?G%%ZH9B-<^X<</J=L*X.?4'1VZRN&/+W3H5I]5:<E!M/Q.GU1JIU5X/
M!G".#TVO.L9T]<I.,;9'".\B_[7]3)QB;*1B/.SYQ]VNX\MV\.63%52[>3XO
MQH&_I'GN#>4HS:0WR]*K*$>H7?BG#EH7XL;-(&^O\>( =YJ[UZXIZWF]\-[1
MB3\8..BJ/7"OG>9IG31L$[^T?:^=YGEFS=/O^H.>TSQ.\SC-TSQIV"9^:?M>
M.\WSS)G'$[_;?VB$=9<9J5V*QXU2W[W0ZY=MAUM=:?"+JT.7DVJ>B>)RQ;MA
MRKC"X+TQ=YK+U0T[5J<46W)0;3\3IQ0;J10?.3[4<:;CS&:>BE-L+3FHMI^)
M4VR-5&S.V]L?;\_5%>]></LW67AQFC>D<KBE;-P*(\AA"C58WKYJ%_\Y*^HI
M2IY/';#S#K)V0PK46GJL3K6VY* :RW].M>ZY:FU.3;=C;:=:FW.L3K6VY* :
MRW].M>ZW:L6B]9.'QO\=9S>8LV^-_\.?8AA+^NNZW?RQ/?ILX=5FE^ZGU!Z^
M&;W^8W>CDF;M%2:]P].%W9R8)--,C"4+AP,Q@B]]*^)K,<_/?_!^VA4B?+11
MU:Y].'X97NQW^L<GM^_&\LH:FA,<IG'X&,KB6W%];Z,"EAZLW=_W:1P+T+"B
MP":8K_)*)J7<"NFU9K.?3N[5-S?CS?6N1>Z]ZG7./'ARK%N/BHGTYE)DGH3M
M#;T/,I#3H<R\0<_W^MU^W_=$''OIR(//"2;PK%@4<%V1PE]SN ]^!FNYB@+8
MX9G,X)%3^#7LD^1G_QU,*WGC78PS*:>PNH[W#^F%8$,E:0&/",#&\D0R-XO<
M8$V]CJ83^X0:=@2>$QU/)3J^:L+#"<\AT$V<SI"T/#5B(]\:>3S?-VU$+D[T
M;3!Z98(R)([3ZR@9>^13>'DYA>^&U^1>6F:5X%I'/S4AE*^3C'0[BJ.WNR*.
M]M2J4T3"J['''XFR2'44 -<'%/6V>TZ7'\1BGI8%//Y&AN?\JEZ7-E#=$* .
MGN7R;2YG C2QU'M#01I^]@^+E6_8$SR,XJB8O]7WKZA_X]<=G72Z1_T?<3M7
M14C4FCJ#L[NOZ=YU1;=SLL&K[GS,=A8#E\!65_^W,PM[4"TD4QMR)U@3ZT)4
M>XE7\R(J?ZT WC!CX8ZS<5&0^D'!AN-O_O##\0]-/#27MW@)[OZG\5;_9YAY
M/_W1-A;;Q/*[0ST-D1;NC'?_C(U&Z+=:(SAUOV,,[ ZT^;UF[3[2-IEHKZ/$
M*R9I"9>&N2OR:S<GK]6[C3JVYEM0;6)@C+FWBVV;?_X-X>1&GIX3ND[H.J';
M[??:Q;;-/_^&<+([O3:?GI/#>R6'WT]$,I:.EW>-EQVV_^Z5H'V<SN)T+N6!
M+I9=K$MTT/Z-XL'GQI5KV $TME_LH9V@6^:7YJNQ=HG'PV/_<'#F&''?T%0;
MMMM.[SB]X_3.'NF=WIE_>N3TSM[IG>;SD5-%3A4Y5;1'JJA_[!^=/G0PZRXS
M8EMCKPYZOB&<]?$&I%,BXJJ75^1Y&D04A[V.BHD'"PKB*,%-AT\LPZ@&7#"<
M>VE9Y%$H/7AH7L:%2(K<QPFM,5R++<63"$YW)K)B[KW_^KDA(/<-(YI66#2[
M/.&Z[7OM#)+G-DC.CIZKNM+Q46/XJ&&[[=2&(W>G-MJC-GHG_O'I<]6'.CYR
M?+1;(57' <W=Z]9S0+LTR9G?/W&*9'<"HJX8M2&,]55<>U,! @IN\X(T+W+"
M+91WQDEA=\J1"(HRPZ@G_"6ZBHI(KH^%_OK@6*@K-'IQ]>B22LW=:V>*/&\L
MM.L?G3YTM)?CH];R4<-VVZD-1^Y.;;1';?2._>/^J>,CQT=-XR.G21P'[#<'
MM$N3#/RSHV/'1CL3"W7%H0UAK%_$T,O+V2R.'MR+[^IO7EQ[N71/<_?:60K/
MZW/V_-/31LQ*=GSDU(93&X[<G=IH@=HX](\'#^T^=&SDV&B_(Y6. YJ[UZWG
M@'8IDA,X&>=^[$ZDTE5M-H2Q?A8!30$V$*)<N?FZ*KT,)3:R1Z*(TN2ATVQ<
M <V+*SB7KVGN7CMCXGF#F5W_\-3E/?>.CQJVVTYM.')W:J,]:F/@'STX!>;8
MR+'1?@<S'0<T=Z];SP'M4B3'_EG7*9+="6:ZLLN&,-8O48 MYM1W#H^1>9$F
MTIN)^11^[PHQ6^N$N@Q.<_?:V0[/7%%SU#MR;+1O;-2PW79:PY&[TQKMT1I]
MOSMPH&>.C1K'1DZ1. [8;PYHFR(Y?#!BE6.CYH4N71UF0QCKO9X45%3XF<W(
M_C3L6%MA,;@L37/WVED,SUPUTQV<.#;:-S9JV&X[K>'(W6F-]FB-__R/FWZW
M=^@XR7%2XSC)Z1+' ?O- >W2)<X#:0 ;N7++W8M9?BXF,O,RF4N1!1.JN@SE
ME8S3&=9;/BJ&Z<IG7ERK;35=,X2K959MTM&L\/(TCD*O3LT-.ZBVG\D=;+'I
MJ3B+9-L-(+VS,\>6CBUWZE2<5FO)0;7]3)Q6:Z16&_@G9XT ^W1LZ=AR[P/
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M'..?(@PC?#-J1=PN+^8GB0(XM>>]R]+T.\6(+L!Q+:7C7,>Y>\*Y=Q6, XN
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M:6*,0(WB]-JA:S2>*IZV[,6 4'@J]EA.,?;[;Y0)&+Y6F1-DUE+9!12^1#%
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M]%I+#JKM9^+T6C/UVLF)WST]<XS9#L9\LHRTO9&]0WK2X_STAYRFC=FB%M&
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M9;ZSH#=M_C2LEIZ[\$2U$!KW]JK7.[.GKZS+.U+?;\CF<3513HV[ ,4E&!\
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MCSJNYC>OQH103AI:1>#?C>F#*C0B==5/?-\2[ -YQY:YL+0@83_7KYS!Q7V
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M(R].001DMUCFN.37$=XP0O$C<"$Q@^=%&7Q+&H@AIBAF*&L*_:9;=L;D+%1
M21-?Q[NHBJ?]S>((=@43K=>4,%6[H2):>!1WG0,L+4FQWEO%Q;A5HM97O'@:
M3G#ND>#\AU1%IUA8X 6QR/-H%,F0JXA)1EF\EX2:&T81PD&0L^8Q6RR6,QR#
M-H]!3&%Y1L0WJ<(P+!24.DNGBAOR(@V^JWK>W)O(F*P,Q$)')HTC$A/R)I 2
M1,JKDVYWH9@"Z?@O92*]01<X!^2);B] EQ?QED;<U$TUV0E&Z>&,\MQT&5'K
M=J_3/?&&ZKE8,8F/04\36QZJ#[:R'P'5L7!OT2T"9ZG@0V^CFI*,'(Y/)ME,
M&:F5C\?3X _!PF#)ZZ/^A5>]:MTCVK:ERFVR(!%Y(Y/R@,Z-I=?^L+L+7+['
MTGT"M[0T!*BC0)<2@-&>8#4\.A3_*L/QVC!^HS[+:8,M;239JE7_5N6:HA-6
MYKF>?P%7Q/,\,J46E2&#G;&1F9.A.T[QLM4M:QO91!90%TEPV)69X'P]47(6
M4CT<F4)_ZUQV5",L]7A2X?6B313!&V:QJI%1CS.12*Z)6VF;\3=Q55[EEYJ.
MVEQA<E M@&G&\RM.XLU;;&079'^I: 'Z];)*7J)J4STEH 0UDA([RJ8\1B=<
M+5>9NHU,VE856'(FML)CBC;<?T8Q055$OK?I,H3] H(!;YYD"BXGBS E['NJ
M&3 SG2U6:OA*@-K!5BJ*+.M60EUBKL%2!'4)B#Q58"<FI!Q$65!.T;\@I"G>
M-4-F3"@TFPE_ XN.V+U0'3G645 P@9XHLHQ\&C),K#U?VC!3)( &.JPNQ,I2
MT.&"O!J*G_!7*5P!VCA)C1'%XN8MD@*Q#/SO.,6ET,)5J0-7%>B/I#0 >5*>
M#C+E%K6IG:I\K=H[LHI!G9V_3Y+]'Y,H9@JT5?Q*,X!J8/(@BX8L8<G*#&4A
MHI@KF("4^[YW64ZGB"Z P8K;'[EY$MVW)8!I#QZE&#.A4I(UZ^5HR#3-P2W6
M)HXJ]*O+7HM-\LI?7U  &RWU;0NYYR%8><<.*\]AY36'I'7C8":#=)Q$=EK7
M 4,Z8M\M8@=UEY549K%Z6H7Q !P6L6."764"B@P?<,"@GNQ-PGKTF/TL^)4#
M#'8LL<LL,1)1IK(H4RDPWJ/"-/L)$/Q\+>!?E?7Y=87UZ0(46^VM7#/;E>-[
MZ/-CM%?Y[WF0SBCD:94@79H"A/=I2,$)!5>8>1>7[WWO]W06!=YQ]W@WFS$T
MI5*(4&,PZ$94D*GI5&8[T9_!Y\D'N="FI_N"*K0372BM@CQKT#UG,J, \EJS
MN]9BJQ!>3.*@A@=3S&<8C(JM)C3=9(4ES])DF75:78>ZWE(2-Y,(1\,06.4,
MSA*CS!+M_4Q&TR'V&>N'K5ULD.8%W% ;<E<UD?F+<^Z66^/8FLK2N8@9Y!P1
M;HH*>--TN>F^.-=OOB7J_AO1LR%O+#  X5;,=?3CW](4,##R4%0@)B-SM\(F
MS74-J>I<G%*%$$[OX''CBI1]KG-0>2>.O0+U8858SDD2[-X.I9Z]2SS&-2&T
M(D:TS!D2*I!83!1A.9T"D1S1%' ,TBZ]&9@(B^ 8X4CJJH@LG641@?/Q@HC"
M^4NY',)L 1>FU;C./"W4T-"K=(7>5NS!51Q?CS:/\"OR0L[RMU1?%C%$L%(E
MFF77[ZD.+^L._'.N.M.K,T^!HU-8 +<^#96>6BACPEEMDU5;O/6P.<?R:=9
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M+';\FOZ1*ZP/Z[G5YQNO.9>$J48H,1H7I 9%M0#[IN1I0!59-&Z]*IA:_IW
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MOH3DG<)) IO!?)1+3>Q#653PK8K!?S.1H]83]/N.7;?R5;:]$DI']'2SXE_
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M^/3,_C\<4;W-'3GNG-QK0V9I'M'#,AD++/!:7U/]ZVZ70OG+&">;%X;_18[
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M>SU\\[K7??,ZNGJ#3_@JQSI=?WGP5W=66SJK_P ;+<0>&_AL^& P#:@4&B]
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M:>C?EV-*/%)O^/A39V3578:9K:VNQ!IOY1@S[)-:S+' >SW>:F:9]R0"<05
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M'Y)RQ 7PV9=7P?G@)<F4R5%K<=N20>.6Y1"%406A"FJ'<7<Q_EJW":J@*G4
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MOW%.X\5MC'LK:^M%[\K,BN*G$4.U;I.]$3][KARBCX$IZR"(81-A$0S@32!
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MYHYW=0U_XR/=_(QEK\'?"F5%% *",QP$)P0\41F<8]R$1$PDEY8:A9AI$#$
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M86 4X8F&R"MH@*H-@)!4B:MCCKX237!UCE[;3)0-&IP@'$1B!%RV!"33SI-
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MUG3!YRFH9\FUF&S.9716*,N>IT!4H7Z_U)6&;('I9 N %4W4BLI::P ,4'4
M#  ,L"(8?0JX @(H6@#@D@I1=0!V ':P(@",T@4 JEZ(J@-@ &" %0%@E"X
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MZ3^4L%!CX[%X9C@>I[@98!@<$< PP#!H/\!P>3"LO%/4,(%8C IQ2=*&V)N
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M%!LF-UHF"=,SK2"3Y-A]3EEK#? *JEX@O#Y1:?VD,/)J]P]6=$Q65-9: V"
MJ@-@ &" %4&N.IP.?^%TV%SD(]U\%!S^O6Y6%^FGF#ZQ^ 3IZ%/F%A S*W6E
M)W_6.RG_!L,B]HHA"?$UI1Y)017B0M;(U*I&SE%G%19>6C[*:?6 +._C3]OV
M[F\60PGD]NSZ;0:84<ZL:\4@V>!E37T D@$D T@&D(PI "V0C+TN1]K6S(:
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M$\ /&W?_UXO?N^#?+:Z*DB\]_CCM0JB::5%FABYXL^EZL[)D D1@$F*:N$2
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MC0Y'8>->3S8?@M&2<R1KZQ$7%"/K?/J,4,90YK47N#R*P&:4ECG/!]P;U-U
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ME6CA;YU1]+J,S)"RU* ,=IF6.__EO[]+0/"DPG@XW1A?/+>RC3+D S(Y<IF
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MA*7VQ#+IJ'G4+./R(%Q@!@ . %[06@.  X #@ . /PC 0U2NYBH@1C%#W)N
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M%,IB@^I0.V)8VGI+-VI!S7/ -E>C#;9_P8YLFC&6 ]?9/&1 ,,1B'JLXO6-
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MWDB/>$S IG$(B!!/:A(BQN2 $/AK4I!T+TE&7X+(*6=9% X+5P+H36KJP%8
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M3)]/W[I*_TM?8"]N;SQ]-:]@,]9P.809=N8O],,2-K,0+BK;S.?#6]+K5?K
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M:U:;=(MD3FNW_0[CAQ!,'NAN&H_R8/;-[FG88JVV,]R7H5O/5S?O:W+G!\^
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M#' .2&1S^X^R-O)?Q3]G'KR$5NVQXM,/<>N.WT613ZD>=4K%>*F4PR50SG!
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M99<%09/1\/S9;9YA2(R!9^:,U.8;DV#X8CHO5C>+M;_4U..)2^V_SB_%\/;
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M]7 %/:$XJ1 C@"+- *TJ"7B%):@HXM A5F*Z5VT>&BLM4PC04DM G9) ,*6
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M]B/N'8L]6_VI">=E/C//0BT'X(V:7)F-ADF7C TN QM(K^8M$A6@.E2FUHX
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M2.WX+EA>W.DZ?)>KV(4D\GBW2X.[T^V^J0E:(YEAU],+>HBC:EC](@?&F#5
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M_?ZZO,!$V0*5.C3,)98B@)@:><QX3G&N<^5W$:K-:5$6!0!:4^2(<_BAE*Q
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MRY(KPX4TO1I]0EENF<-(YP9^4YH<24_AGT1Y)3A1E)]T*O,)-;U(&O+4->3
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M=*/LYVF]F$Y&V3]572MSN:S=8E%O;Z[FDBPNR\8&\\LY7!6R/-VD3>[\AYK
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MU/B3NJF?_Y#]]90.'1[RT.K;-U-RU?_^84.=-@<*OIJ#XWZE B"_5M4XDK^
MXM[4\]7*P0\VX"+[8P:V?4N#MYHZ.M#;-F(.1F$>/ &8LITCC>S=FS\R\# :
MA^5_)N340TZND#XW5"+#7>B!2L$#R"U%!CLKL*4YH;*7)H!%2:QWR#-FP6N0
M#$D6\M[ EY"6"LY*LH6<8A ?EN.5:_[W]60;1;T+K_[&_U&[-_Y%6*V#Z0/%
M5OI ?BNXDN3B,"O<Z6ZP#'X[#@L8'._.+=@N9;Q)TGY VAVA5H.H&@M"RPW-
MD3"2(X#[AG&MN:6]L-)]I+T[@/B2P/_6+=11!%W@LQ;TB\</H9]A:L"'O1D
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M*;W3=?@N5Q47A+.OO-TW-1H[P1[& ^-(/Z4^U_\WY"%GX%P$0[JYO\^UW_7
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M0//IR,%WU(%O 2?#7]EU:&^_W3UENV]LY084$#U1T3@9V'W4>,.)+M9@]?F
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M)B>^,-Y[Y$DA$><8?D.H1)(YRDN%M:7B\26=G'^!PA?$G&RW)!WM6KP]YN6
ML5A;S^[$7M^L[&ZX>",DL=.J'4S3'RL//ASLK(():C^W8SR#:0,%N_AH%YIO
MTPBW#65"]477*?&RBAU()R'R7(=63;O/#G!C ^(]F2C!$P+W=W>:?GNP[H+)
M]1NJ=-SB^FVZ(7OX9U?Z+V83K.EG1Z"(_!QNM,H>""?SJ3K\ *,*!U1,*3*8
M4<1%GB.I<H[*4M*22LFP[R%K;DNEB02 X;5 7 J,M"0.,#8G/I?&,;==A?7[
M=/)NM3Q_-(O3[O5?W7'0!CUOM/'3V-5UDV]U74V7=<>XT";;!. POVY+DYW[
MRQ;U/;Q\:[?OT$XWTI*O/_[H)M.K+E^BR?O8CJ <2N19[;WXS':KCCH"W54J
M?;W4:)7CTS)&7X5C[!FXV(L*0,-HXP!B-:R0N;)=-M%!I]$M22%;M]B3%K-S
MU] G>CJ9.+.>NW7SRHTTDA5S_.42-'/,&&@C45F3G#&[O!D'D32AN6>= ,Y3
M,6&'F/+NP9L; U]=UD<R87M-F#&>N)P21'TL)!8.22$T4LYR^)Q;;?HT0D23
M0A06E89:^ U8+RUSAIRD6% B+*9F.XF^S7(%?_G=*GOON!0G\D*<LPD+ZK1+
M%=[FOTO,=W>HEN<4@%6.D7"!Q4?3 L%K.>1+X['17K&B5RU_;R%_*/(>^60)
M[T[_+5^=_BM\@6\,S&IB&SL:S;<!W9(7!<+88<1-Z9&0I$3&2&IS< \%D7T]
M);12I4&N,('"UENDL=(HSWDN- 'E1<O'9AL[:U-\@&WLCH<W1T@S/[.TR@%-
MPFGGB?T^O0[%$/4J>M"+!">']&@Q57(;STE_!9H(R&J%WEXJ&&;VXC]#GDW#
M9-)]M^(N.5SRM5G8-:YFU=8)UHY_W 1H#D1C#AZ9;=1U=;$M ]=4MB&<7R=Y
M-+8?!GR1O:B_T#0M^BW;C=/6T:D#YVE7:F_W[M.2'+?;[6UOO#UAH]MC[;HL
MN7<*"88)8*.\1!J0#_)>>":I,671:XKE::F=,SFBK,P1SW.+I"$&%92[PFHK
M'!'WB+77;\'0)XATK$06TN1]]75ERTN^53^9(GOWCNQ9S"4W%G$>$EM(H/O#
M)D0Q%/%8D,(4NN=,,*M].,:BN&3P0ZF1PHJ@O+2$.(&YVNEM\0B1O3!-Y[Q9
M4FCOFU*^K,#&N@)Y036XOZ#==2YD9'41K"#4^/R;I?S!76;V5#MC19"X)C]K
M:*/-=#Z;SKO>ZJM#QUVHVYB/C7M%(NI03!6)-[LCHT0A>X#*&7MGG1*A#P0
MJMQ:I!0ID<RM\8PZGK->LN2]=TZBD'TD"MF'"#0EIS\X_?]83MP>9M.N_&,[
M(3.R;,1BT9"1X=PVM>1N]D37/,=,9ZO>;GL]_8OL]63'N^YR06^Y__: 0]QR
ML^//E?KS]#?+;:YU\JSOZ"B43'$/#K(A'*R!LP(IIL!;T$K;0#99Y.Z;#<&C
M9+&=M5,-6[:+$0;D$W)?KN E%NW&;DU$_/L+55/A\_"CKSZW:&?Y]^45#-W
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ML)(_52 ,[EJ-ETW3KH[$[:KI5G= *H-CW:0>9F8.+PHC[*1FW2QN5]U==)^
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MD4IQMSAV7R.QG25,FOV):/8=4ONP^YK3G9VTY"@HK<BF@-G>@!DKC+*E+I
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MP1UVH[_3/3FD0SF)'>/ [9&O;;9G]<=98Q,63[UXT?Q"YW8^F[QV39UF\\S
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M4J#!:4 #RH,W7DKDJ01\X&P$,Y]'R@N!H]/6.[+5/])'G!MR&Y0$87!. E3
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M?&>'TYP3&-?R 9>:_C]7BOYO=K99XG(UG\95C0NBZT4NOU(_J\Y89XM<.J;
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MZ,4\;DC9+U-2LA +)NVL1CMQ0$=#))KG5M4,L!RGQB"KK(%;11*,")(QTR=
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MHPJ,V*U4%D64B-C)O ,4<(Z)2$>&X1R7M/4F1/U\@M,F.[^;3!<?Y>/(AA3
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M'7Q_(7&B5=E?:+0\M?"-PC>>7@AC&._"-PK?>.H,O,1Q=#8AC0-#''.%M&%
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M^==O)L";($%646JPEQ-C6T4D$O@R$U<"2/S\CQ??LYY(Q&@8?-P[>G>X9Y'
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M#!I-JMP[C3NZB3XG=?91IV:[MJ4+[I:S7<'OZUX@L=O[6[K;F\?[*+">&NX
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MA80I3C)JWR<O_"59P9Z_H7FI\#[ Y\O?RCMO=KO>-\"3K/4R*A. B#1.#8R
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M0.C"T5;;66!IFNZ:/FVZ:]H *[2EJZ9SM#<@B(<7Y#^C:Q)$<TOR@+O@S+_
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M3\,8I2F9V;F7AF3R9,8I60:[T"9!$-+_]Z*;>)[@%?O'2Y1Y892J4!KL@^,
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M;FP6P^^.",-N!FJS>/[Y"/#4,I*;A>TOQP);'PN^64C_>BR0JEP(S,+V_;'
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MEI!'1]9;_C/]S[.7HK__?U!+ P04    " #=.V)66#R>G3CL  ".TPH %0
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M''GQL1V?XBM] 2KY4P0B^!J/)OG]JE9B.Y6:P? 6#/"8?LQ'>-08A>L[#"0
M3.1%_:/2NM70R2T 1!N%J;2Q:;<R'"'G$?QL="<7&KI1,@[OIY@K1+7.@18=
M>S)GWF^\(#C?)2#;'&2P5+5R86KVDN="L/Y!B'_^ ZUEE;&Y$TT7<$U2>+NC
M2PH3@?OV(?0V(%3@^7$=>6%VDL]C_PF:HQ)^1?%:AL-GX^\VGT3Z2L6:&!W"
MP1)ARNQ\K9DI2P(3ZMN:@]X0 <MH7H:W)\N<ECN*7P#<4%IVS!U'P +&A!8
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MB%2;AN'."_0OT=0M(5=JJV49(&Q<H59WMF[H!_4/+5[E1MM6'0>,U#)=@_:
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M57.\0#O52J)LJL7"5KV_*H%!<V+W+ASH8]NO=L!U,HXG@C'OU;C;E4V'DA;
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MSX5DU\+/#AM@13$)'^]8,==R[;]*Y#,[B)M=6*A??!P^7?O^PV .=6>I!I[
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M:/U$&7A>^,00ME_1?1(^R;K>Z#V6()9U148MCM;3L7__3(.@"8 JU\A%@%#
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M*X%;QD9'BHZ#MI0W%3TA7I@LHMM=O'QFR?J*FQ9A7.WHC.DXO=FAZ5&D[N:
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M(FECWRK^\B120U"?CM"9C";LEF:C@4KC<U\X6K?*]E*;;FZ4N;:2VE!$-#A
MX""_KDW0E V,/?4V@>]P*&^\$ $"2N([3Z5BT)'/+K[:E/%"$V=VQ/JYUK<U
MIZMFN<L:PD;%==VFA[DDL\SY)MQQI;")-<EG1Q$POZ(LOBK)AX7 M@=MJJHL
M3=NN3AQRH<=]IE>T =JOM*E!.2> HR4&$6KY'$9!]+2'95KMEC6^[Z8N+DX
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M^<8QSCEQPJD+D]E$*E(P!&]@4TRTP6+^QJQZ[/:8JBURSSWT7?:Q),\\2MH
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M>0U:E!H8P_T@BIEE+"CR-.%,1?TRQ>)$+M^V/B_P@>%"G=0X'G="%4&RLAR
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M8K$8=)&W>I!4L*J<=&252?LI,OT8V$E5E.\ECZTN@5,^58')H9]8AG<R/OE
MG_>D' #:OA96!_O03[8;YWD V6[&>"Z\B+\HWKNEN=GR3--TNHGBU/\'>R3S
M-9R-&W^W06,DY9_@.X?:Q#S,<D:R7)$NJX#52#UM=%%+ \<G[SPY _QT)>;P
M+=8EW62I*XG%A!XWZQ-D2Z,/C(&/MW)IU. L'%(MS3PD/>4ZN5F:8@S$H)>H
M!%!9_?JC3V.,T=M?8WQ>YTSX['I4A)FYZ&;ZT]CX"II9LIOBGI5@6=#0"U/C
MM76T4C,I&Z&B],J8^ L.6./$^RVF8X6UPIG3]NG9M&R41A/Q8)MIN)J%&.3K
MOU!TP8ARLIW2TUEED<- H%$S*$7O^A(A/9;)+7@2C-341)G2)KZ0D3E7.G/Z
M==T8==4H)BQA&TUW< A%\8VW.?FDYA0(DK#X(B^?Z6J'H!+E*1+MZCJBI-;I
M !.S0$%0)4=,JVL\9B4>%UF)QRM5XI'\S&9D,];6V;(%A16+UI7I),=4Q;2_
M9!S!H*.Y2< @]!).K1[QU0[C8K_XH;_9;>[P+ ED9 4^RUSN!7^H9BK<:X^8
M3X&(.8A4$[P_? $;L0M7-,9\H[,+E&V"@"E/?$I?V1J5O &%Y>'C9\7&V3;/
MY^G(#6]7;G"Z3ODHPL;=)*=A,2Y/<L=#=JZCI%N])>C/'7DB.\F*!<[@Y,7&
MS7:B"%UZA\0L.A1-K+L65=;/NG,'N!_0)(U">D<#C%,T@3.O:)*8$[6-.&^*
MB: X?T'/-L*\J?D7HP\JGX,M#)W%<TQIOC1#%WV(D9,!;:!1//40$6**A<*S
M*&.EWZJ%LBSAY5M*PU/3&2IK$F;5!CG],?&6Q[CC#!;2<?$#R2"US* X!&Z]
M.-UW+U ECS!&;LB3#DKFVT-9*82"RPI9R?1>D84@BX6;J+J"JN,NW'K^*JLA
MCW^-C#7QF!B"7D9\0B3YB<K@D"-8#+E0=NA;6,A9>.%M?5Y6>1.%G<';-2LW
M/J<S/R1+/L"8.#KT2MSR+4@$[0FQ:R6UQ]J61^VE<%(</K):+B?DG#[Y88CG
M^[D7V'''V&;\,EP=S3;TL<IS$J=_@0>2,HO8/0@['LRTJVM7TAGP=(/\3*UG
MW6;FCHL(+5$1"BLO5#-'8I(\(M]5?,T*27I+7N^C@Y4T-WS.@(SWG?XW3^]+
MGSW8G+E.UNRB(I8R0G@@;4@0%$5!; 9EE(),SF.<.E8\P6'(4A]'52['WT,V
M$N'O[OB8#?)\YH8@VAB$#R("V,;'YT&0[%'/U:K'.XI39))I/)EE>KK!H)Z3
M?;] ] RI'EB\)X13'@M'ATCE:/R51E=+&[& .?(9CKL4$XI4,) "5C$!WW(F
M,4'8.&<XD!86/$$K/!^,_!_R*_*]2*08'>O!B5R/CM'"63,4AH6#DZXP)D09
M$34G"A.95MTO3340><3W=:/LE5O=K_1W5;3'ZMUIE>N@R# .0C(#K7*DH8N=
M#V3W!K7*[0$\_"F/V6:>";=0P-V^IDG"%*<K:@1W0R=)UM2F9]@L$]),(&PW
M.3Z0K$4,#K8?<Z(<J"[FL_WS$BN&OAQDRH^*MT,%K(HMVRX3._P5#A&W?&:E
M4:_@](HOX&Q\BDXNZL I$4:*2%J#G71))5?;,Z\$<>F40-&,R--33HT=]IJQ
M>'I.^K#"7A/Z3BF/=I'MF6U5[B.#-Q;/"Y2$^SO/3?(3?#VLE&9M]LI2#GX-
MTP)B^@Q7H )KQ[BA&YK.UPOO[193PN Z3GG-&A;G%MUZ707<AS"F7N#_ V3$
M *.4X"[V7CP_0/IG(,:?)5Y/AV?/BR V,K=BYX;-!YDAN /#MH#A)T1,@.@S
M8.'!GET\N[YWB'8H&UTANP=W%D0"\[KPXG@/.QAA>Y,,G/?/U.MTB#->LV 2
M?&>6^DAZ/<4]C#4R5N5KD<4#(8>Y ?2ZBW\>'X>%8W]^Q+.T:,)0TS@Y8%-[
M9=D[INU2>^&:QJ9_L.\LAVC6P2*(FO)YU)99**33^9HKJM#GBG;-O&R$BK@7
MU>9)$<AF%JKDOOF:J"FA<<=6-*BK-<O)G(;7ZBM;JBHHK\JE\4-IM<5F@5J:
MM8VE.<BRUT"!OU / 7!6\_ .A4U<LW,O\9.','I,8$E1CIB%VUV:KQATOE<X
M2JQ4?/< 2RU+_W&OX40Q\K^@-0E:+(?%>,[,V"4,U7=TBZ(E YY,=Z=>,,+@
M)6@2191PJL/GH\1ZUQ\S#8![;)O<J7J=K!4KF_$Y[IBY)*L?P!D5:W5,-8BA
MD3/;>,=-I+<X&U(<X:(P"1O6UG6V6RYIDH@K2AT"\'>7A%Q.5%W-BNR$",*C
MX*8HT0FNY*T:9%QM;7&E<'OY0<!<O>BWB99>8+3T*Z,\LOE+OYHX)!EQ%LS(
MR/=5 I9M/!4714$LP]UQ"EAR8;]E85Z2*$- MJ4#&&%!/)**J0]YYH=!:4M]
M^G9@N5&$F"W7L<"WF*8I7 'L\5\%WM.I10 NKNZ(1,S02!*D.70><FI.OXSD
M\'P>F\N?/5:4/Q-EP+@(#Q<ZJ%U+=L-_Z)3C\O04,W<HYB1QHN2%RPW:@+^$
M59%"AL&*;]KD,#]*KB^;G\6X(.F.P2 N3W>U8LY6]E>W0"&6_Z4[6*<Y+Q .
MW$/9GK)<4/;/393^F:;R]%Y=OOE)BK_-U^921>>%C%"2QCOZ_=H+, F.%W$-
MHY3L::H._9[38JTNA;J4*S*"^75W(U9 C8^OA9@!:F?%O&'R,ZXB8:O8&Z2Q
MM'QA-HU*RGI O)?+9+OEH.VF+&L7.LPMQY2YO+^])>]F(3]4; F3O7!=HY96
M5@K0%N'>9L!Z+PO0PE[O<B%R-HKG*( !$X[XU-U_E&@T__N__.[CA__Q[ZRJ
M6;HG[U:@)BVM*$KF.#I,)\V21!]M)XF:FGZ6%"I2/4<P<_W0$(3^E0@<LKX"
M)\0)$6-(H[^4$:SA*A_;:B@62HRB(EC1NE"(;^TO0,HJRP?'X3!8UV+H=YL=
M YRHBICI'L:G#4*J@V-&R*38S]/YQ:SB/;4<D?U)[*X$N8BWN(/HZGQ_ARY+
M%#"[ N I^D0? -4_-83E<C!6N<RE8C6S:M/7M?#>9BL8W@<Q@:?P[CKL2.'G
M0E-MGBKA9$? 28G;KD=V\K5$%4("6L#9I= 1T$&$ RJZ1!(>!2=! Q/VP1]*
MH<$/C6;G1:,9EZDRU)Z$W0>+9T_@BB<JDW46'IGY5YI;H;D>I8;C\VP_6_FK
M0UZB4G"N?RZ014NLT"&TR>HH),I.JV:,T4VVLFZ5SS(S-3!#L %X>U&T_E?O
MOWO__@/9>C$WX?\[@5Z3]_Q_)FA__,UOU-^BQ+VW2Y^CF,7S>RGY1)=,7B._
M_C"!WA\_\F[O/\*?T'I+EXC8$NPGY+<?)O_CU^\GO_OP6];DWWXW^<T'_.@W
MDK#/;1Y'$/WW9J+1+F5%;E&Q/8+R<)]F'D&XRC(TX0]TN&P$N?THL*9$_ DW
M?@UW[KHAJX8!ZW7;N_)Q:+ZJY:9' #0SG&66K5J^;".<98"7J>>'='7IQ;B*
MB:9E?^+&SFZRDVXU$ 1'P4R# 60U/E8"*:MQPD129N75BL_(HH7;PD/2CKZ6
M[%D_!LUS>7@PMN:UQT/2%M_9L=F:Z[Z.T(/\<.8DCI>^%]Q1+[C$P)Q.\G%9
M?G@V!L%!"!]E9$P&[OGC.'RLKOM<E'6_!56VV_/B9>(E/<((#G?JP2AG700X
M[&?V>HVBK1EX!/C!_,M;.] ]AF8L3=*2BF-X@.KHL.GJK[N$X2_*!''#. $]
M@ZNX6@7QP.<7LPEI%27W&6YEE1KOK6$5238+9M& 67Q]ZY3###"[6-:%5&7T
MYQ9&7+THQ)NXJV=$6"PS@B/A(:B8OG5?")XSRPCN1H:$AU"]<*M=1$F:7+YA
M7LU\#0*0O_$R_,Z'T$^Q0:?')&FR5'F16Y:D)*;^YG$'[>Q>2?TQ'62GN1B0
M9",2-B0&=+(,IFA-LG61$*8X,&MG;S46T&B^GJYXA18C\1J(/RSR(L,50W9X
MV-K)U3#)1- X?XOYMSR:B#XQ1U&X^DRCI]C;/OO+68B%,)FTR0L)FRG=R$=B
M)WXV%M$&&R6+09Z[:25W1!1EMAM^T@/'Q=+BV>;=<@YE[3+0<1/MH3]ER^)G
MD[&(N'+A)5B"%G_@-?<"X@A<< :W-%+F\7#XBS;&R'@*&MB9J+W;6V'Q7(3A
M'5U2_Z5K0>5\T&*L: Z;@V#,DZ]%A+7)1)9C@T"A'0LLR^*X/118SD/&7$0A
M/(W4AR7BOR*\\QVNWLFU0'+8,*P MAQ!_H%C$#;(^-C, WM+7H5'?JGSNLQX
MC>WP*F[B- TH1_V9PB6Y\H,=>Z6P;D"B@ G.]^@,A2O44"&T;%B4\5<TAO>,
M5>Y16 48A^/S,2V#;/2]#D'9$NAC$CZHAG1SOB=B7,N5U?I>BV(P_Q#7) O$
MO=S0^ D&_!Q'K^DSFB2\L"-@MR1).$TBB Z>BY)@XMY8J43\._4:S:?@%B$+
M?Q@!!T%Q\I*@5:& G1:R2N<GRG_.PGS&,'MQY^N'!(T124([/1TY&(95,L)G
M\_79 R;](&5;:9[660P*W,F!$#:PD 7-V480060;?K !Q\IXX?P?T@+(=U0@
MX.$L&= =\V;^% 4P);R'NAL'A84[(SDR7L3FU6@31GS"';\:8STX*D\.0A>A
MVXCR1E?3<'4IK/"+"#_2<#>Z)]]P"BCA1!FNA[#YIQ%YL5K@>*@+)*5B@V I
M?*K,8*2O+WY<0%*QG?0D4$NN*&@ZAO'0!,W1S%V:BP06FB#;*P;:@H8>'(";
M;1R]B,*V01"]8F1:ER?!R1)?HTL\27CXK 0Y+G229#H>+@H"1>TSL5E95153
M9DKI.4?!/:DJ<KYL-2>+8@_' 3E7,+BV2AY;8"DH<!-);AY[X^::IK"P\_5%
M3%>^B<@Q1H^A\3"*PYYY4#[ION2S4]#9%#@UB/N[C81J$R((C3>=,.LR\0#+
M%K_S>:V%Q":VS&#6P9S@I>%T:Y/3A%N<GZ4KY"<:^\'>?(E'3K>WNHXFV0CJ
M.; - V.2E<*M[HHES0^4=Q"9=-EG8Q0K)8R,JZ"1H1XC3FPQ>>! SIC=YOU[
M?53NX1"-6?4&F<WQ":Z+KB[F*DS&#%P<=.M'K#OMK^Q;G:_\.$FGP-S*S#G/
MZ!%%<,"S#DHG;/OH,S'SPKM2Y( 3M?":9*ZOGZ)@!^/'O'IMQP(>BABO76NU
M<$?'B9=XZ^S/7IY.G\0Q*$P]/!5@7#8P.RR([22)*UN8@ 'JR22FI=1G>DBX
MNJ.ISZWYG_QD&41HV^]XAV0DB6"GGYBE3Q2NXJ4O.9MNL$3-/]B?G?#--+*C
MF'QP.&],D=D&E"EZ:"?7R4_(311N56C^*%C4,X!.Y--:IH\.O+< G3KQ>>PB
M5DSJB"9(,GJB!-.PIU\&$]@'#\KZXBD[)G?]P!\,#HA#?LQ"-A=O><H6S./O
MW.>ABV#K)5%@$X3+(F?24N1I)EOI.V,?<%X%-+4?$FVL<7*<L[T/BVT6]9 H
M:V!V27<Y,CG1G"4O(VP]!=(<2[I7C@&)VPH/,C[UH,6#Z,/'PV70<[J.8JK$
MW4_P(TG])5S25_"Y_Q0R-XV9[*O=9H/:"+Q0;N3?GGDO\8$)OA_9P-HJ@/ B
M!F<7B!A>^,CLIKK8QW;\#"00AYB#)/Z)8G"7RC%E7V*1+/5F#1[YD?.3P3Y.
MB.1));"R)JS.F/9^__/9U1X/DOA9;A'/"HLHEM\F-B#H"JJJ.7]%Q1EUXL[4
MZ<EW_IT@:?&T,\9&2=%W]E:(Z.D)"6T&9\XV6WCX/%7A.@J?KOT7V(#L\OR1
M!GA2/YS DAYPK 9@H",VT46L\!(4V9@0I'W&B//0V0E!\@P0 P88&7_Z]FO/
MI'TTCTPI84&P<$*R,[:;,LGC:8$6OZ>&/_URC7%T;)2I@2)G;\MX@9.4XPG;
M-,^JU-07JEW>F5K0W5&KC9 3C+(Q++MJ6XLL24.4LHCNI57"B?R^,[Z<$NX\
M(9=009GO#!5G[!1XW>EJ'2&!)T>6P:3U<K9L]?^W]V[-K>/(FNC[^16,.&?.
MKHK0VKV[>L[LN9R8"/FVVM->EL.65T=W/^R@)<AF%T2J>;&7^M</,G$A2 (4
M)1($Y9J7NEA@(A,$@;Q^Z1J KD,W'$"7&@(#34?7Y'K6JM+XYR=04GYFJ^*]
M_T\?B6E36'N7(P7=Q6:#@]DILIGK5ZW[XDZ5WIER@XD CP30?K#J-\; 71'2
M;V$N$-86FV\*DJ_$78.\OWX]+<2<4!4O)PVV:E80W @%B/F<9[X0M+X&VGQ!
M.2&DA)=3:J!W+K,NQUJ#6N9(O_W@,!'+)"]/,.NS_8VO]1R$H"W\CPO9HY!7
M-QO>P4/Y=1_9 ?M(V#Y:193'BLWJ%$>D8P\(3S33.E;DY%[7B@_=V0VL!%5>
M9F8O^,RL)96:U"P0_'WBI:Q896"-?<%D>=2(Y%0N<[(TV L> ER4K63Z9995
MNU&(^*)&_5RD,J2=C2]:B8:?D3!= 3C9%7DG-$'L9.V;D7?8,F$;$N#?;I(4
M%:_L+HK);4ZVO?+NY/R(P*=Q4+&T)0],A0L$%Q#OX0I@%OP-. F0%8>'I(^5
MHK5%"NV+-"M7*2]7:3/V*EVI+')V[+&E@EY]+I(;G]PV$W IAGBI5V72/]QP
M\&IQ%D^!7A6/TA+E!7C!>@%8<D4*L/7LVHJRYSAYR9BF"\H+@AI4[[?>!9U:
M?%_C)I#L! O(A1(,!<A1H+/$@19J.H/[XDG?*TCKBS<SKU[26+W9%)8/4,DU
MV/,:(+I(3025*<OO&6.\4O[D;Z\# KJ:$F&5,1]2S.I0?10=8Z1/OOH2AD!R
MNB)QLHWB,$]2AQ!.;N20^J!LJZ.")8W-.D+^]#W)2]=6OQ9DX*4"*E-CUN!_
M U;IA%G5 66FS2HMN:PX+2T=WB<J1344"\)$0ACTN8]=W;>_/.U>,&/=4436
M2EYH]!J*&(NX 0+(Q'::R3JL?+0N6K-.\=+UW2857J;8\OR&V_@A3<#I83:M
M!C$K0:U>:Q93SK3J%<(ZC%#;Y4K2N@4!IH+,C870'Y\KL)F-+@7/5FF$\<C%
M!OK<Q:"PQ?P\ PA[B-)@.0L:I0],KTI5^=,#F_744U3,%>B3!4 02EP43Y])
M\*I.QZ5?Z=+O4/JU2^DY3-%'LGQ+BHQM,B;>\H,)M%_$!'U9[%YA_QN]$Q"Q
M?SDR-)P6-?**,K[E\Q1-[%TV2R"G03<8GXA9N<0HK.NB9L=2U[&HIB-],^==
MAY5AIRLX@@[;]@-F_VMI\)I/!/Z/67 Q]I[4$I%GXA+@OJ22T4^Z4K1MD6QK
MT>8&&;5V8+Y>8U5?2 $:XC:^#'<1,[/Z-212-!%OX@O3!039$;Z:006J9/?4
MI+I54CD41DN_8GOYGLU>_D6K9,OZBV=/,,034?M_K;"B\M#9+@,=:@4<MMNR
MZO2E@<8,W4NV+OM-DD)&7F^G15GY@!T]5SKMLQ2PS5[13%(0]O+LA:T6VQ\I
M\0A=WW<"_8B7&T#>$7C#L3D5'JJE6[R/Y&H>N):Q[ !!!&&JF?;_'+M\H3PL
M,]'(BE]:@I7]6:\*M2W(LK8@R^X+<IXK4770:,N!10)O"5VSPYTFSLPYJ$4'
MA%OLIKG8/)&4"7%AQ4#K52 EIL)NI9AYE^%LP87>SZ@.AG:><M.:R#@-8O%*
MD<='[W,L<KU!PT1$+_.5'LEK!!&P.+\/MZ=&DD5R4DDK &+39=N06.6<=Y'P
MJT<?%QMHQ%AK]8C848R3""!?X;?AO 2UV"?@%C/ZLT8[2+Q)2B;P]T^S(-2X
M%@N^%LVEF#>7(N#&_PBHF^.O3B-3O+YC5KACX)\!J>V8M%PF^'WTQJ_S'#5D
MIB_W+I=7G5+K@IZ93+0F3K/Q:Y@'<@;70 INWIIF2APCIG-+P8FT.ZS5>\K#
M-#])Y@MVR\4Q]V-2-QTI1I#_.EZ?)/TUIDB[$YUW?RQ6$%,5104J;-X/VP=)
M!M(04DT^IRT"K7(ORRSNSH/[>FM-VSMP>,W5<^,&40)E"IF6$U?/(]*+#+BQ
M[?#>&TQ(:8LT<_Y&*KHO&[P8B\5Q.647,'8@\03'LM&#FVB@-@$T_%OS1'_Q
M!^=H/W[7Q!#W:ZF.YS'DLON99*>RA*."AD&Z/]:+0$\? <0Q_Q'U<J?Q_D 2
M3.0,F*<FOH._ 2F':__\]#5AMTF,._65,!N(9-6\\_[QO.>GH)PDD+,$M93S
M\Y.1'B/>"/%F5W)6,UJ?__7I7[F4^W'%XZTE[GB?697#U;NTAI,580:-\!B]
MQ083B.JRS&0NZZC2F&MXSZ-8=U@9Y'5\J/0:RF?0G.,U;5,72_= <-E>.LOF
MW OQD$*.0+Z'A#@(S8&)C*F]]R<T$M<$E731^":2J&.TPD&%T3ZHLQ>&5N68
M8?XC3XJY+L6Y/Q=QFEZNPY*-ZML:7MC2I=5%5->.K-Y=%MN;76MX!36D-!,@
M3N_NE V,N=2(?T.C#=%Z5X[>5/PLU]EPISMM.ZZ)9$"L,X,\N0%PZH\>B/]8
MLCG8BX-O'>+./#NQ5Q(L4 V [.>6F=;%'2&U4SDU[H9 -%'41D+<Z,\]]<-X
MM<*Q'UYXH[#1N94Q"/<M9:>S .M,B2LY,*C"+>BJ*+?QBI>EA?0B2=/D@_T
M&%9#EM1&Y1S!BYPD2)U NC@7M.*-J+<"#;19 C4-@IJ=H:BUZ)D0.>G\=AU&
MU;0:'T/#F2&0,T:IJ'(C!FU(8&FB,PIRQLFM-T[5B\?$M1[5N#B;19R60>$:
M AL26F6J_N]_>5E&^<D^;GP6 F2__^6GEY\=%@ ,P7.EP]A8C*M&&G#K8'"!
M__LVGJ]62<&L%K:#^H9-)"E(% %:9R2&V$B2;O"3I R Z($2[.'L!*LT.>DF
MG5L0\&I-0<^[NE8LX+YW_##<US3$AVJ!2Q *L@X4013B.TES\N.!71_;<$6*
M/%J%M%^\FU,,:B1=8S ,*$?MC0AY=C5YMJ[:S&N-M"6"[A UTV4JVX19IDUN
MQX"O*/O[7#)-*5JC=09-B5<$6C\MAN]V6YDGD!,!Q,+8S6Z'E[BEVZUOL8N7
MC/RC8-_V]3MX9Z].=UZ4I *D-<-&C--FO9I+K?@GG/^U4_[-:?#5DIWF[[WZ
M!;0DQ=<KF<RC?'06&'.=:OAO>M&24_!$8/XA3=[92;"^V$,V[FVLW&]S: ;
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M^JJ JX%'L= 3E(W2-RK1>@BU=(Q")RT,CJH-IP#P"A7<[.?/L$14.Q(#/FG
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M,CX-N#3?)=T@E(0_[0J(W:VXT(#S.'Y,E9-94"Z3"0)(,10HCM#SM')GH6A
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M=!8(,49X#_74C#*5HIK"T1M=Y]TMC) K.<1+ZI!F<GZRZ4G*!P3,0M?-GI_
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M/[+;!!GEA!Y 'J9XOR3M[NK(\9MY?EJFF'N]+VW( 9"TGP))5K--ST$*VB;
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M;QV*T,0#Y(L*]7>Q$9E<HGDXGH@]X\KZW+.@,CMN47U^N!<5!T')PBA!Y[X
MD)I'Z,\$&DZ3]9S9,^$KD9B+#Z W]P^82>I,)4/R"AV3*^9Z[.O%>=1FRHM6
MAL8.+IF(<OU6UVLX!5?Y3C5.9X%:?\&L@B$-'MS8DFW :.C!%;AH[#QB0_.(
M*>#5E-;A@>-XF$1AHVDSUW'2/L%R& L-([XL:[XL_!L-..Q;D/%U":%H6JW+
MKIH!/#+:H).%.8B9UR(_WI<9R7.JTO79I1BOWDB0PO>EDO3VH[DQ.R&M](>3
MLN&MG)5 M%T6U8G),:84%K$_L@G%R=V_OA^(R7M@HDS3,^.W=GYROCFDM2N^
MH<GITXK$(3O[H"OF*LSZP:9)(@XW]' \UUN: B67F!7HP<ZFW.3^9![U;VV&
MI78.CVFX]Q:;YXQ@@<CB)0\!G^4VOOZQPL(4]BXMF%*][B.8]DNR^5) -1VO
MU4G$W) Z3L3LZ-2-R4=0 FIS/*U1TNE'7!Q:6Y?GC/"2G6"A+<NUOBPU6)42
MB,MAIN;Z[X7(<5\FLB4VN2<YQQB_2S+V=V@;^I F[]&:K"_V3!"V8(K7.;37
M[I5N7XFME?SPREW!$6IOE'$#?X7_7D$KTR+CJUCNI5!Q\]\_]Z)1XWHI9A S
M52+5 T,_P\_8_U4R!6;K3\]\!7_6]E[)VRA.ID?"OX;K, 4'3=;_LJIF_6ZB
ME<N>]L.PKQ1A<3)(:JXUWS*Q0&)_A+1'&+F>.:!9<Z&B7\D\<9]C,XA@M&F>
MEG1'BH1_2V*RY[D>-T6\'N!#08J!R/=!FE/GGMH8'Z'5I"GXT;<K[Q0".#V:
M]=K"-XX;]UYO-@0N*<(ON&7X S*I 7LNB@MV;(J[+(G[=X(\1R'$RU$32#T
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MYB(OP,'$!:ZXK#^_N&)76FO+)\Z^KAY:97"N&?+ S"#]GAU'N?IQ2G4FW2<
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M+MW_5>9G"( K$J "*0*\%BF$RV\4LLZQ"#F,?V5SS=?O49:D^XLT^95]1J\
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M>2LINL\I'(9W6F-;4%.825/G7[^2K4(XSV"M-ZFNMJ9F?!7; B,5F%I;(H#
MA<OA[(^YRHWIK3QIMZB#JGP6F>MZ9(=>W1H+(J59@UX!+E1:-V/$852Z!^I*
MY9*0>"O39)76N!P1%<;2T":[V%=^&;*DV]KL)@LN]K5?1RS;=K@2M+8(2=LB
MS$#7&VD5C'Z;OA^;/X]3CV_/Z%=R]!5B[L!\541Y6&*<#8!](4B6&&>N,D8&
MXIW:V':-+C<0_[7\"RE'J,@ZS*.PYFN!)ZZ_U_@NB5^_W$7OZ&Z*7S%.C3ZG
MLY*('A!F!,^Q2-L0B&&P46JY(OVZX?&<$(WZ&4E"K4+,@D;:RZA5Z5KLEUW
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MT^)@;QU]KM^]^("8AK(A48[Y\#%D;D3B]=P:*B!&F]33H@*:OH#R7*0"QA/
M[_4UL(WQK=$#B 4T)D&%.]E$N5A:S,0QZNVM3WA\ XO-AJUIVOP8&S].PO-4
M]3MDK8[=]B=\.ZIU'P+_4NV:M'7PI/Q%-87@D4#*@_P1@KZ_/^Q).DS#YZ?_
M_+0$K:!(]Q<1I? %WR>Y*6__\&C?7U-9=0+@S5K!&=<"C=_3@6<FLQGK:1)W
M;:&\#H_Y=HB)+D_VA*/JB(E4B#"]@WW,L:JZ%9?=!8D)N_Y,8G1[TK<KZP0W
M_WR=[')BU.YZD/->P0LO*-TE7)W$V)LHJ;I,UA7KJN,C_@U&MM]4#+$MM&49
MZM7A:(Y8U*"1N%F5I&#E,YN@84'V)'7F]AEW< C%'&+DRP3^)$#K(*;<!L'G
MPGCKQY%O9T42/[>D(F@_^]XWQ4L6K:,PW2]2KLM\(_E;LK[E_D@"Y9>+#7X6
M['TU!LMA]KR$ >E[O]W3Z#T$.(T#0!3&@5YKFC_8M[6_QJ^%V-([38-\;\YR
M<X".QV-#HGU,2P[ZP:=\:[50=@F8]4S;X\DNV/_6'-XU#IV."75I3^AICO*]
MG5H*EZV)#4>D2+03FJR->)QIZ'OKM65FRF2<JX+\A83I\BTEQDOI:"*^/6:U
M/$U$QFDU[=N?\'W^\15>;,IZ<^%4D>D+T%3'?!YV>W2RV>.8M7%/<OZ'*,N,
M5LCQ)'R?K+*X1757,EL$]5&>V19NAHSM*M OV59J(M,8FA689#N1U"3L_F7X
MHT.RN&VL[PLAB5]A3\FK%C^*' Z)RS GKPFS)39PZ,G?UW;%\412?G.M(-%H
M_DLUT\CFEF\=[?M2,"0REF#69MVX[0GOQJ*"_CEH+9I&3B!K@9UA%PG[=WNV
M0G64]TUDN#A3;A#:HSN'G_+N;W[:AI1>%!G3X*H59Y8AOB,%8?96JZ-I5-]4
M_Z"--,8*^A#TC5HH5=5'LB*,)Z8>/,?AENE"<$[=)6%<7C2+-'IEP\%5<4-
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M1EYJ,^V5'*T/>(4U$.U'#Q;$'A[MO2I6]YM)S?HY7I>&8"O&=Q\ZOB-6H$%
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MUK44RW'-FX<+L59.5=A9_-O'DO';;8Q]@NPB 6V4O9,2-.%VNTN3=V&.F8!
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MV@\.]IU&M-VQY12U-PE32:%O"S\G_D@H?!S/9H$Z/>C[,RK/<?35L7V%._/
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M?@OSU9LLVE/M:]&IN-C@CXC5MGQC&U#\'6!'$&/T!OJ\RK&JF#.D86I$3?3
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M@2J-0'J(;J%U64BK@'J'<A!:'_9X(2, S\-;$A,>W*_?Q_7?)^F%J6(+S74
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M"D,86@0!4SR-!P^BGS<@"WTODMJ@GF..N5?U']/E:KD#D!!-BBCI,MGN(-B
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M# [#J.";U0O5F(\*N3/6,?I%F53 G:=.H2UBI8+QO/4*\_$NE6?+>:L@],J
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MR=!$:6Z;BJM7&\TVJU<L;3[X #E^<_:&L\\Q=-SDT!M+Q?/LVN-Y5[OU,F)
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M4CRL=C!Z \<,R&?\W.1&Z"H'MQG8LM:K]1.6BC\?YRUZVB0P>P9PVT@%P@)
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M@S;JND]B"0*CM+(21?V:'9!8O"$&@T_?30)Q7N#%-H$9=B2]3-(,9P,L)LS
MMM]8%A9-XS(\,SR[O87)4PX@Q];.:FTC/\*AS :FE%)*R!H'4?"THS# M$_2
MI:YC=&GO#+T\_8H$-A@3BEJ#V"<"2G/F CXLV5T;5^X"V8'9]_-M'F%U^E>8
MI.E+#$L?^E_1U78!5@D$S][[@6G36+KN3TQK[:87;I&8!?-O'KD++V5G-%(=
MQOH&WZ'_,DS<K$],:^VF%SY=XI8[G/TH7G+L"8#2U+*;2Q *O3T&FO!R^9*)
MZB@36&BOPZJ9V-MC3P 4UKX-W';K5D@IB]/A1:JKH[M;X\>$):EIQ^6984R@
M.HGR0 );3SM$LI>5Q5V"%%I@FN@Q+1Z.OQ>K&TR:J'$@=APW@86LE0%#*V-T
M%%?>DTE/+G=YGBR.+8S0[A'W<C>,)X_(&B>=+5XH(9V8,8NZ2[5*0HO@^#OJ
M/2.Z*@Q8H\^+WJ@W2'\S]ACE51QD?DRSN7ME,HV>:+H)WCT039UH6=N]R^F#
MY"PP?>S][E5HE=7DE)\+W(-J]"/;>8'0FI7J<X%H#-;XP].PT@P&EOV*,4;"
MJ8EY#KM0(F["#L./ )L:PGA=54O/O>B+EY4?I+MK/P.XI?D3]!Y+U\MA"K/&
M=J#_.FQ%I[AV:_+MW\:<#-63K/OK2!/ZXKV'VWS+G%+[]]FY=?81%>Q-6VC'
M4H#"1E$ZCW4.$ OCGH/6[R<C; SD]HZ^ %&O!0S7$8MV'8#CPA>42\%1$)3L
MX!V2<1R2^:E^)"50]@9U]'U%Q(?:E[*C()SJ>YQ%DP$M>>,]R"2R*9R8#>%<
M\CD2XZ'J4HI.<QK$47;(N32( LU;W&]*B[&4TW'P@OA)_EBM["1NK1XZK@"Z
M+ORP-$GO(D!DA#@H'1+(WYEPLV(2= WO5N)#RZ?JGEE$E]O%1A1]E<X(S>4F
M?,?_QM\"3@<;I9V[V=2X<V>UMBW :TZ(5LI$CJO,<]Y'0T0W9QV=LV9.,$<:
M*Y7<V<'$O13TB9M:+4%3=+R94VA.-=7AV4'63\Z[!X:<A"?@N3Z0RGAJS9R"
ME(884Y-R+?VHPF- \P:]?M^!.'6FK-,I&C&;V\&8=ZO)9$\B/WBXN<AQDD9,
M[T'.!3?>^>S-9V^:%U^C/CTMGKRNB$C*L^+8]*H@) D8Q_EM0+#(ZE%.[%P>
MYET#(O*FY7:Q8;6OYL/;H67\B#T\8!BO48/[)(;5?Y*@5]Y#L[[Q+8#S"-#&
MA'X&@DLOW:"IX7_@\__F19B\Z7_E/AP,&M*&?W42@WWAZ7.3QP%_<8S&-LGZ
M8E^7H+V,O#3E)7;F]K&Y"/Z1(6?D)4Y>4\2Y\5&YC9'^A7Y.$#N.BCNHNR3N
M0[WY[\ZI_^?4_R;/?/VO_P@!1*+>9G\'WD D=_AYG6TNJSR"A$B.YRAWHJ7&
MT!;C5Q8!+VM_UYR 74V3W^%$Q:,CDZP!$>G.IDME,6^*9"LJ+"WL9\,/A"J
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M%M%F>!*B/J>#A>E_P76#T;!(WGP$ ;J%L-&GP\2]$!+.>/!D82RMYV!:;SL
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M,LP'3><3G;./:$>3<#>AMFGJZO'F['J6:"[1T6U%)M+HG@?]\=P 7$].+!1
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MOO[I%.$J#PZV51N%Z_@[)PA6X?)8G)5"*DSPG\;"4/KS)PAMXSAU0KXKUOX
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M^177\^LKP^?HS[#=V!-=>!!%/X%,(W'3E,L"A1[)PK8IC-^SV#'Y3,QJL(;
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MPK+))%]=NI*B"B- BR:;D:=)+?GHA8UR8Y0; Y ;#P<C-QQ$Q0N0AZ, V29
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MF>!0,]D2>U:LV_)Y7K%X^WKM<_T$/-;I##!"B/5D-+^'97X_&[;Y_4Y]P#,
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MW5'=Z!TI4N:P_"RE*)9G80U4X)(ZO-SVE?@RCV+M/('/BIRFWME&R+K7\B;
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M;\'RS1,#=A?]&=P'!@%CX)@4N?"(B*)X)@.<^&0D3,YO'<. J8]?^K6GS_/
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MWH7"R91*\;Q63;74UAI*]411HRX2E9171K2F[9&#0R.M9OO4A):B&$T4<6_
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M]IY+"M@IM*KVA[* 56# M=;"S;O5LW>72S;&J :F)^\/6T^>=:"PKU25JC]
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MPEB&J3"0+%V?MHPD+73E@*.EN@0C^&H(_)@_&Z1 '#@-[PM+FX40!F1W[(]
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M2SR0J\K@@_#Z$&-$UW<2CXS74KF$#1-D;BR%6]#>F..'BX+[>.71X\,H5>L
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M<1']\Y?SM^>O?^KDT[#MA6M-TDG$(AFR(AY[!LYQ9XP&_(Z2^7Z929%2E3:
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M#$(ASSQ<TI&,(CD%/>VI:J=EM-,*V&F9EQ8J*^!R+Y<>_OY\[_F^V8K &/
M 0SS.6+)KH=\XX&<BC./):$'$P@%+AC\FN<LF,#(. $8B"GNL2B#?W@I4SE]
M+$>/6MH^+@;_*&%O<T^.O%^0%QJ$S]DPXG7S;@<%W& ?B3^4"J9'KX7VW=XA
M7;X3L9DL<GC.%0\/]3,/#ISK@4 12S,^R#BL.<NY-@KA:<H^ZE)D8.!$(I\-
M[-7F(K@JM%?IL5\>[!X<O/H[KM*S/%QPT2M@AKWZ1? /U7SN1*^&(?'\$\T;
M:.YZE0)+R$B$AS=PA+F+K,_:?5/X8F>H./LVH+]W\(-V9C%C$/'=(8QQ;;_8
M>_-*)(>77,&JLLBP,4S7WE]:;_,CV.GI(8!0BW:=93Z7&Y=I279$@WYD,>TK
MQ0.1"OALPU3G9X9,*%)'JCSR%2W5Y\ 1DZU"Y^'DQ(;(@\6LL))UWW^]=]BV
MYG])A_3*HE<6318CX\O[ ,;0S;*E%R*]$.F%2"]$YBW.(AYRI6W.5A=^:V.,
MS[/S+UG7K$X=K>%AKR%Z#=%KB(=GCD<H2[Z"7L 0[WF.P=;>W-QD80(_,5Q[
MAP#[ZUM2Z777=Q6>;!11;4_U4?0^BKXV$JA3)K[==3^FQ?J ;,]:?\&11C_2
MRR<L]Y#=6MG,E8"]%;ZI5E5O,G=X<?LMWG-!O\4[O;C7^#'/W^[NU_T86'*8
M</+/I\^?]E*@ Q;FJMCM*(J\2^.FB,P+><J)A)Y,"'/I0&0\Q6,F$KR2)=X)
M4$%@T,"YPO=8YJ5*7HK0X"=%LKO: $\'-WP/#E\"52\FP,UT&E7Z2!GX9ME(
MP%@B\48%,#Z#_P,9QR)'?+[QHI#K#:;:FP _YW)N(TQ%/L$#S)0'N?U>9 @]
MUCA5.M#TS;FF3#6N6(*W!A<JCW\O1#Z#^0>%$CG,IXDEK@7C?CSVMK^WM[K@
MVRL:^\;0V]T#;]>SV@J,DT>A6=;$!.E7JHNR<E$BS3V=\_:<TH%XY!/\TQ$X
MR[NA>G\.J\;R0I$^;\&)]U+Q,>JO7GKUTFLCI%>N.,^]HS $+R5;*+.4G-XR
M2-1S^Z/A@Y]FM;/ DIHU=,<;BAOV!+Y+]MRGT4@$7/7$7FD\!\NZW'BXW>OT
M=>6+7J??5:<?BWSV[#QG.7_V/R+UCF7(^]#ZLD+KZTF,^8=VA!CM52MN(L=2
M2U2M$SG^"F^LGAB34IVF;,RU/MQA(UBX 8NF;);=J5):RPNL?>V3APK NJ^W
MCO/WUF,;=88??K"06,\6:RHG[M_8!6DA58K/ YZY*,M:'9=EK7I\P7()_K-4
MWB6+"CJJAX\S 4M,J^UC.1TN4@(>P#2#"0)KX T3.8UX..:A3X !+":&8 1;
M9@QW-^)G=)6SK)FA$XK+'UJSO?GE^E>1Y6(TL[,?C")^M9-A?EW[:E7O;$9?
MB^5;HL%3DS^'H<C2B,T&(L$MNH/4N9;#KR-GDW)/W^^76MQ9P?HC.RV9CJ9,
MA83!:5-J7<F K\[*897-W[V<78IBJTM7@E>!N2P"&$LA5E$!0Z&N QDZY-5'
M!I9ED5S#61/%Y<\AO4SQ@A;$%\RR&/[+07NU5H[,> [26^43!)CE"$"[P9##
M<FMPU<:4O+C6@GV$S%G5O4!.$(G+4?J[@\-KJI!N6K4]>.6N+;R/4&A&*JX-
M%)K<6.YFHSB@DR5O&E*?>XUZM1I5C&7-,UU &+X@L5]3 QO$!0OJ^7:%(78]
M[X2!TP?,#KL>II)Q6\":#O]0-I"'"%I )MS+)DRCS!")#@:. 8__!Q8RV+\O
MXJRT88'7D26&W4L^/_CN(-1IW7R]FRL[<K.V\K%F63)N.K+(E6 O4G@UFQME
MEADV]6U]@48:U-H';9M1VS[P]#@#3\\W//!DBJ]T1"SU :85$?9"2_4,];G)
MA45#G@7 JB$E])%CAX*^643K9M-_LZR!)GTZLO5*B^ /OTQN]KV)G/)+KGSM
MWI&MT @:5A&@D#/@$7@/X)EF+JFP&=-(N3*RV8A>,K0O/!ZGD9QQCJFD,;>1
MA=:8TU":J'LHP-?(I<I\:[]DP-# Z"*.>2A8SJ,9,?V?X+<<P:-&B@7(+RS2
M%BY&6;,BHH4=*1G3,"Q-(Q&4 5F<(C;L GJQ,=Q19+P,A\UO&MIG&*I%+H +
M0SE-RH )QT?F0"L9N>$3G#=,\(LE<YM9YA*,7C'D$3A9JBV#=PM(N'"Y/O",
MLG]@;C_QA(_@ J9FOB=&]L6'$=_V<>M[W+IZQ 9#V&[(83@]9)*:?^<:RW-&
M9,IF% HPU,S9%:_W,SKGM"S>&].[R!U-ORZ0U+QQ:PQ[&>^,C)A)>"SE^2.C
MT.=.9R:BAUV=$,;SO6&A)2J\%NP8DSX-'[S8Z[W;-1)S(9ME=+I2P KBRO4N
M2^^RW*_+\F+#79:?I1IQ8;-.OR1:C6BE3:KOF&=9J77/M;'0$?%S*P?G'D!C
M'7%OGIQJ@TEKWK+ B6L7!)QEVN0$"\(Q,_W2>*3:)3K+"7[Z^"L>RH-52/55
ME,?"2Y&A>2'K9AA^A3]TW9,DQ[HG-!OSB,RWXV:^:ZI6HV>^,WY60:K0IN*V
M!)$34:>S.+! <:_J-Z6#5OA_8]RPMLI,'1$257!V9%A+ ?.B.%1>(LTOOO;8
MX2/\*<'Z#!AX)#Z5^ZD<!E/N!QFIL)*69?:"7.CD/K*&@E+LEL[+2(MJ]',<
M1PJ#P-A:/&:4_P6?U!TYOYQ2B\U?Q[FT@5#X:(1>P"4W$ZU/SC@&[M;6TYTP
MN /(,RH4;40ZALI:#ZR+FLXQ-*ZY&D2TF,WTJ$/.$UWZ"!FN/J(&-L*L3D=S
M,L?XT5G-XV7H% $)T/-H>+:^6>P1C)D$NH13XQ 5!J!1LR9*J.%+:YJ(!%Z3
MA=II@@%"+41&VETT]^H7(BI7,VM6:^J-S<=I;+[<<&/38M-T<;+$NZ#NZU4>
M\R-7%7W ?(4!\WD=DTCX%X\B+ &)D22P PT_^5Y*L'??F\Q2M 0#B@J!&#?1
M/5,7;RHRD,6P_V3&R<H<@A)('=AGQ*;UB[>P:IU6B*!IK7UGG^N"\V:DSWRK
MT 3F@V"8,3>'LS:BYB@(?"'"DWXOA VH@7V1H^I%=2*GB0Y-VM%Q<-2$O$5G
M2AW4,S/C9+%.)S+6NH7NKM2IO4SI(.JED%$MTFHT8ZGLLGE$4:^CNJ&C7FVZ
MCM*6*AY_Z*TTD5&XF2IJ4[.0UX@8]\)B!TN-C)_^#'KQQ<M#[\.GXZ]'9Z='
M/_UZHC\Y__V##$X__"KU,9Z^:E__^*>^Q/Q6#O#Y[-/GD[.+_ZX-H+\].KXX
M_7KRY=S;/WAS\/K5J[<'E[O/G=NON6J96>>]'7=7.\[&"I0C>;-*\C;ACLT8
M@K&?\-BX<>)9!0Z&?%'$0%:QF2+)13176!E_7S3\_(%G=2K9?F2<]2=<O4%W
MOP;=ZPTWZ#XWG!8=G]]$>ZY75;<LYE]%>N&7)GJFE:U\T%V!3&>U1/Q1H1*1
M3=HA,@;JU^I*]SJBUQ'WHB/>;+B.N&!7WF\L!XN_*\F"NYZS.>NZ8<$FW7^Q
M^^+%BY7M4CM\OTUOO4TMZ9Z^WV+;F[U1C\J:-M0^Y]#[6,%4W[[8&FY[)Y'^
MM3O[N.DU.W5]#*!@0OCLC#Q7<FWQ6%^#9,%]'N:FA1;!J,-+43FVK;A<PD:#
M0"P1,&T>,RMKK*#K3,4PYE'FBD<SPIC+"(]+$,R AP_EP'@;'GI(#=7-L-*H
M;HL$\RX365GN6EE-G,_(PZ1V-J;;VF:*KX(X!_Z]T.?X,"M&;KGC_+>0F9@9
MII2$3I>F&KC93M^9UK:#-6^LPT)ZXP0CP71;I"IFP10>. DJ1I(8%B_S0ECP
MO0#K4Q=_LF$&F,\S>) ^T!+V_.::5YSGI$1ZW&P@ VBJ[RXSWBF>9B%>_PQ!
M7@6GTK#XY?[!V]?4DHW%G)#VFY6.XE;(?>2"QZDW@;7$+IF(6L-GAK5Z8Z-[
MQL9PPXV-WX'5,0;=H93.&W0 @0DQ#+&H,:%;40+$>P$R@#*T#*XPLX"!;\"D
M+L:BX&VQ#[QRQ!%_&/E:^_M>) /0*V7G0IV5Y(Y:PB.&,\)G:! QBJ4)C]IK
MXK3%X8$2^DM@*XU3KL\-7Q>5.RS3I9!%!O8+O^)!D9O:7W-Y3Y9.%6(R+)1N
MJ\BC",0:K .FAB$,4!4&!*53N BA+)1)ZY_*(L+$?KRX2LQ:SFN#;LZU$49H
M4[.D#;,-7QOM.V[I'L/**,$0H9*DQ3 2 ;P%EI?1(!$VM/!2QSC+FPEC5*_*
MTE1.Q)"@K,0]H=16HBV9-I=;*#1,%7$JE+282IC#K ;-\>?>1%MB9M'TN8Y+
M^EHF;><MDS(7\J@CH@P8.6?X4K::Z699FA^,;#FRT&\PU+64.2;!<5JQ>D<6
MW '7::D5<Z;=0MUE5WN:)-K H9(@I<86H]Z"!A=9#6>'":.AY%H\N2+C%G0&
ML28H(84*M)49K(W45!ATOLVUJW/%R'A>SA D\.<.#C"W8,J-?K!RW7V:[:B=
M@IASO$'MN]-$#/1^'JP.NH629R)-GS+CH,P@*!.SW3G9!\3 66YB<9W6CMJJ
M"_PJS[B!BK1IU=>=]<^;%_I 7^C3&].).30I&#!P.:=I9>>YH,B8A7S1^5I_
MT/&HG)KRH./MAA]T_":R .072SB8M!U1#+?<HWWH85UW:7_.4?+T1^F=63_[
M&#X528$%G;N5?GV[8(2/E@"J:HK)V_.,$0N<'.,6CQ>5?T 4Q","734'T19@
MJ6%\(2B):Q/PFNF3C9R_TDK$,P4PD-!0Q SF*SRMT!D9,=AM,"!XN;'(3)W-
MYE/T(00,,1%I%=:OV5(T.<P.;*OTHY,3V[,JV0\_KW&8PD8C$9&55S]LZ25L
M]R3LI@=W[;G6R[V#KH1$C$#5)[+HXZ$0<NHY-209!O@P+8W.Z;1?!IYOG!K?
MCN0/B+)9)2Z,QU1&>ET:5B(CY.5Y\ 6FQQ=JYIWQ<6$$D,Y8"W4BG/9TMS8F
M;--!KG.K4"/[&5^=CN87^.H+*ZIE=/)M\B!9 *X*U_VE\%B;FP3%(HE0TZ9<
MQ2(W7[K1<9?&O>;JGN8*-EQSM8)(&L"HCLB6VZ&?!IZW);;IY$YAH8VZOCN$
M+\VW%-XK\455X4CX(&6VI5K"QS(7YH0+])F."I=A5!BZSZ7L<RG[7,J_EDNY
M0 'O/8#J70<MLBH!6EG["!O@8Q:!45\D&8]NA( &$TE(444B\U)&10*$AOF
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M4Y9*57*D;@.>7O^^]$NESUK@\Y>\C\J$T;+RS9 3%-U-E?K*U27'4QV8'B^
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MRYFIC5S>0P_5*VMNU&6>;1_02FKK'<3*RJH&Y5<[7G+SA VRC^","S&^V1V
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MWC?H%<C]$F/^H1M,C(WBC-ZT6!O3XMVSH0QG[__V[MDDCZ/W_P]02P,$%
M  @ W3MB5G:+26Y,#   >*8   \   !V97)V+65X,3!?-RYH=&WM7>MSVS82
M_]Z_ I<^)IF1;$FVXT1R,^,Z:L\WC9U)W-SU(T2"(AH28 '0MOK7W^Z"U,/R
M*XYEBS&FT]@"\5CLX[>+!:W=2UV>O?F.[:6"Q_"3[3GI,O%F^+]VM[.WZ3_
MX\WJ^=Y(QQ-FW203/S_+N1E+U6>\=/I?,B^T<5RY0<'C6*IQG[TJS@?/:-*B
M'N+$N6M+%0OE^IV-SH^#1"O7MO(?T>_"Y\(-_*1MIXN^;Z >"<]E-NF?R%Q8
M=B3.V >=<U5W'FGG=%[UIR5X)L>J;^0X=4#"'LY1DS#BT>>QT:6*VY'.M.F;
M\8@_[[3HOQ>#I;;NB\%9*IUHVX)'HE\8T3XSO/!TG0E<HC_26;R\E7G*?_J[
MU&YP@7[?V&)6&)D,<MC)F8Q=VD^D ]J4 RX!]</S5(ZD8S#K[MXF3KJXH?6C
MF-5D;A9?(?YN[VOE'\$ZPC1> 3X-/WP:LI-_#S_LOQ_^<7)X\+'%#H\.-H(R
M/$%EV'\W/'H[?,OVC]ZR#\./)_LG\.'H^*@]?/?^]^,_AT/V]O##\.#D^ ,[
M.'[W?GCT<?_D\/B(O3_^_?#@SZ>D,E_M/C*1+'F/JQFS C[\]'WW96>POLQ8
MA?$H;7*>K<Z9)HF(G#P5C%NF$_8?KDIN)JS;8KU.;ZO%7"J8TJHM\B+3$R%8
M+ V,T(:Z?Q(&AIZD L@6I9.1!2A6T09[CN-^^OZ\U^E&@P.=%UQ-_,=X\(+9
ME&<9@WD$KHQ=$YUE^@S")!9!9Z$L=U(K:#;X6!K<QJF,B,Q<Y"/AU\>AOVAN
M8OSP=DK9PNKT?+9V-:JBZ?Z<QHH%=4]NXU53]'ZE@%IK"FE!K6Q/R1>\;(H:
MK-BJCDO#QIIG3%KF-"N,/I6Q6,8@#?VN0$&I&&>PH!((5=PQH?@H U)*FI([
M9WCD&%<Q )[CT%V7SL+)$ ^%TWE8A TQ=S#0=TTR>& )JVPYP@%. J$.MHGT
MY=+EL >F $2M1<B&Q?0IX*(0\P#G@>_U *9-$BZ-W6#_!13-K ;6B,]$(DJ4
MQD@,"85UA*VXY]DVD2ALL4Y'GU/0<%$UG@F6<D#Q*-56*)POAJDU&TWFV @[
MO8:%9]*ER$1YCNM&W*8TL_B[E&[2'G$KX@61- >T VK?@9M^/!+9EP[HCZ[D
M[P&JROIB^.TW$E#]/LWN! -*(:S'XS,)L>9(L(++F$#R:B!"J*\#3:UFT66+
M\.C"4\&CM$)B![,L1J.* 1/@.39-,5X2G)._H!#63^NNI1:?1BD =P& "]/.
M+]-B$F!:B=G$1:$1P^/9S!?&7D=TO32W53AN^XT!VO6UG\<_(3N,1Q:3U&VD
MM(^)ZL%(&_#E1"!FJ3L#ZM[.^ 3B%)C^7,0#O]3N2V1@U1^T(..%%7TK"FX@
M;JEY0TEF/S4ENV%]4R]^*JT<R0R\>K\>7W6"7O&48[3:SO;&3N_EC\C.31=?
MT:FW\;+W^A[Z=+<W=K=O6JR[L=7KWKS8]M8]].GN;NS<W&F)(/C%U$Q?&G0#
MDE?W%'5ZI+,EU> ,A-T>&<$_]^G?-C9<;NWU<-*L>CS$HTY&/*OL(Y=QG(EI
MUYD94>>ZV6M0W0J[N\J::[MY.@FO2Y7A\>7J&1CD^JW)-=AKD&N0:Y!KD&OP
MKT&NP5Z#7(-<@UR#7+]>KO.)BIJTU*<*_67'<EKH\<6_2C?\:AVDOWS/] 2,
M.DCU'J4*,@0ZU,_/>L^:(.%=Z%PEM*O6;@%LU9F,V>(-Q^5Z<(E@'DDO'NUU
MSGO5KG=T+\;VE2IYMC<R;WX5HND(<JU^]79V6O7_,.!*10N TVPE"%(-;B2X
MD8=R(P=S+ST<JL@(?%7..Q3O6ECP*P&![G VK8['MSV<]CK;K=[6*Y)"]T%4
M!J9N='JB@6^;+?_]P=V0Y>&5)5PK/%PH&J3[--#@AV]9/2X-%!]+81[LK]E7
MK#';0$>G\RVKS9JA2O 90;I!NLV4;@/Q/40$(2+X,HW9"A'!D_09]Y=X>L@L
M94@Y/3A [)>Q=/B'K_[/^)J>R6Z$FJP)1@2Y!O._8T2Y[HH18LD5Z,IN:^>N
MH>2ZZ\N: 4EP$$&N0:[-D6L#P3PX_N#X@^-?-R!9$P<17EL*ON1+WI&<_X[#
MKTPEA:1S<V$C2#<@0KBH##'F733F9;BG#"XC2#=(-T@W! 0-4X\0$(2 H/&@
MLB8N([RX%#S*K53H2,,37P\"OZ#\0)M"XY='L]^P=(7B*A+AM::GB"!!K@$<
MPNUF"#1OJRL[=P\TUUU?U@Q(@H,(<@UR;8Y<&PCFP?$'QQ\<_[H!R9HXB#JW
M!#^Q,-6CUDS_1O"6ZN-I(\8:$S%4>VY6=FY"U<*PJJD!._ %3A.LF2?^QB].
M@W\,0%DV@7;K>);A5ZO9NEI>QJUC,9],2\U5W5MU:=785[G#OCP'ICGL:4OH
M"2M30=,I)88R0[[L'E<35FA#[RK5 ZJI9Q/.U]E3VOE:?5AY=*&2'WRBX7-%
M\ SNT1.AK6Q6A=%08/3+F>G'(Y$WU>4<4@G:4&*TL25&:>581(@E(+P^K '@
M)958F44>*DF%FG\S'(#Q,FUIH,?88'\4 )RRVIO VM2(Q56!T@I:"?$O+:TZ
M1?4Q<H7JDY:@'IQ")O E5$A:NE27'LJ5F /^I#30!K_[-4>3Q<*L,ZJ\L?*S
MZOOXX)$N:C*+TD0IM[XVMBKI:Z;1DZ3<B&FY:_0)Z!^PQK7W*S"$<?9+!B)C
M'Z-48V'O4YZ55"6UJIZ*5;OKWVE_E:N$57_8[;YN[>YLL^?0';8:E1GYM-*B
M8Z+:WCP7+!>P]1CD/I[,W%E5P-M7=BVMH'+BTSFHBZ<$MT$4T\Y]%5O8+O@R
M,:5QJ1IX(O&V!=D&7MS1%Z3:%QOLA*J >WYZ1@*'0'14XILS\+<Y30DD32@Z
M2(S.E[A (WT-6C_\5%A? GT$I@@;%N?"1-)2J,%I8[V-W=W=5S_6,U1R\>8Z
M06:1?_8D50P2*I[&&? 4ZZ#+4RS-*]H@10?>''1:QU4QVYKA7D)$+80?,J-&
METJ<5RF)%=2QFOJ"/+%W"\NP_P7:7"O]I8H^8S :CU0E"+NN&5R-F\D5,&"<
M>OIY40!X$S^05T@L+NH%4K=X7G+8:2;HULRSKMOI+/$-K95C\5\UIF .J3$Z
MNZ .?OI*&!AR46ECWZ4R';_FR.M;E&E2W&G'):.I8JU:&8A]3RV8:MHQX^%]
M9/4ES-^8BQQ>X_Y23:X$H0 0@9R*KP&^6(*;7)YCF<!SE)7GC(#,HL'!DPI
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M7&._\[ !QPR'\'PIPDTLVE.<BID=::JKCQNS?Q=SGQO2:M0:/\2DC???:],
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MDRF3L2\Y!Y4M=^5I8.^@[)=[G%L0I,^>0.S\'F=/0 T.H<(!Z;C%CS<+ LX
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M7?#('PK<R$@]#V#_!)?B.7KP<$5=GCU0O#!0# /A/.^3!DA@81 \300%4A&
M&%N-X_>MDALVEAN.#AOUH^,/!Q\;S:.#H\8A$L4.W=URICCC!@(%D./RY:=A
M7<%4/J*Y>7X3S*E##A M1O)9NLHU= #+\5 8M\B#%$]=/[BW-$L/YE,,S25U
MF"_2]!EN*T7Z@1<%I J@BU%2,&J=HJ$13% M< +"%Q,NZ4FQI]Q@@N\HTKAJ
MP*4$RG!0R$(*@HTR"!<1Y9)B)@/3<DK,"@5HX<N.^6H)_@HY"H)/H3UGST@N
M2D[9>DX)WQ:G/'LA7Z*6E2W;H3Y9E04\FV2 F(:"(7=0HU**Z0XUP#NXA8"=
M Z=0S2;X!L81-!12V#%6&*M&1K9S5.!0[HEJ071N%P*H#,> $/0SRW*= =$8
M5Q1%D=(,U?!;$GV>0JTC@6_@"L^0R% D3ZWG%" \D4%Z4[+*&D3]J[-*M.VL
MTAU2F;OE','&XYA'5@P!(V9%[0\ESS,2$W^X>B/ <0<TA*3"^.V&4.7VX;&?
MDSK1J33'O93XZ:U&$DYV:1PC<F\#T*>%G9? ?_W ?'7@LVT'_IE'UC)"\>9#
M4>N[*_<(X/D["*[@4%&4:T3@7':_T%^BC(4S^(@%]&(BZ.);#BZ"3G>6A&.@
M#UC#[\D5:D8 %G>7!&^@N!N.7I==K\F FFGY@ZN_HQO.7'[D9E\D+F,BQ2V7
MQ2V3>_*5'S#(,\FE9)*-99)B(_2PW A=W AUCP2P">%49LLO9@/S!#!;B1'(
MWU'C+.U<@%(T9\(J;::EA#L!G26)L);SE?E-J*!,P2M,@$ZN^0X0!*03!M,5
M^,9]DPF3\6^Y )4==^5IY.Z@[)9[G&L0I*^>0&S]'F='0@T.H2( Z;C%CS<+
M(L$!FD4-,-UK''%ZBTF]+\A=6N\V%-SS"Y,[C]\%^&);T-]@6;%N4P8-#9\N
MVRO(H=A] &' N=+ 2JZF,%!0F#P!N("QW#2*M&CEW=FR7EB3<'QUN&_]]F,'
MRH)8PQ): ?!QM]X#?-U#/P7.*S[/%NE0R2''9#NE_>+9)5VD"#S)I!ISN#H:
M*)\7T 46 =3_8-VQ]P >5SZO7 5W'GQ\/WE[9PK19G.#7M+Y7E>N?#_'NCW;
M%82%[SFU0F!(KIUN^))3K>7$JQ#<*@>@B#O.6GZH>LW16=$ @EC2S/# ^%W<
M*3.Y]W)\W^YE*5! 3T;';65/S\&D?2$$4FQJ+0_'H[V/'^L(P?:^90\(U?=J
MM8,G9,#IQ\VG9#[L'306!X,_]'W]!QZ+A;^6-5\-_,;A867R'Z ^B<@BVNHB
M;8W IM40%KS;P'U6\<1J3AAB*@XU<A%M/@JG?7KC%[W"9!YZE'\2;7\F"#:+
M%<\@I -"_DDUI".-"FG4&LTY8*V,I=+]C[A_S?Q+EKAR35P*G6R$/S<+SI_&
MP?JYND!OL:).C=\XS,#*^#0&6;3?RK!8X:;7"I,_[VVZEPN4?;-_[R6N57%3
M)@?EZE"ZM'3ISW!I(AB3?'M=^E)O/J^M0Q_#Z)M<K5_LW?=RG=X(!GB#I%ZZ
MM'3IAKFT7*?+=?J%?I1I('A,/D_OZ%SZ9TCF(Z(T[O]KW)TO_LEVL.N2A7<?
MRXG@&V_UK-_/+[W9G[1;S]_W&TPSYXSVN:?:*HW!<0&5(SHV+H=N[^-/*9[\
MTMYW/\'X/U!+ P04    " #=.V)6%P;-BWD%  !=+@  #P   '9E<G8M97@S
M,E\Q+FAT;>U:;7/:.!#^WE^A:R>=,&,#-I 7F\L,3>A<IM>0"?2F]U'8,M95
MEEU)#G"__E9^"RDDN;D++32>$,#6:G?][#ZK178_5!$[>X7Z(<$^?**^HHJ1
ML^%GLV/W6_D!#+>*\?XT]I=(JB4CO[Z.L)A1[B"<JO@7&B6Q4)@K-\&^3_G,
M02?)PGV=*4W**8HLE$FY3[ARVLWV@1O$7)F2_DT<"XX3Y>9*314G3GXBDPAP
M1-G2F="(2'1%YN@FCC OA:>Q4G%4R&<F,*,S[C 2*/"@KU64'LQ#JH@I$^P1
M)Q'$G N<K'NQ:O3MUS16[D!0S/*O!I*82U,200,W OMSZJO0":@R/9@'UP9&
MW[ZQCMINOZ4UG?5;R8_$0=!9N ;$%'M?9B).N0]>LU@X8C;%AVTC^VNX:^>L
MAOLP=G.B33C3F/G; '.X".F4*M2QF]:S0&J=_%],/;!#Q#Z#>CZ\F5R^OSP?
M3"Y'5^CZT\WXT^!J@B:CW4C:_0?8.D&?FN/F>1.-A^<9R%:GUS;08(P&%Z/K
MR?"B1OWY42^Q/FT?H=%[-/EMB,:#FW>#J^'8''W^??@G&IQ/](C=;MO_!O1N
ML]?I/%%.[&TL5=M G<<BPFP;N%]R! ><>(K&',VI"I$*"1IPGF*&;HAN#Q",
MO </D-4V/Z X0'\0<4O0)"3@)TD5]:2!+KG71(=Z[MLW"[MM>>YY'"68+_-#
MWVV@(!:9\H!*#Y0O"1:(0+1\=$$\$DV)0!W+@ C;MH&P!#D&8Y5/8^*E@BH*
M <+<1\.%%V(^(PCL1%1*[3^\M*2/%4'@'0%?[[F47T_E$7AM@-HOX,<'K$(J
M""!F((\(18.E@9)4R!2:(Z1BM%(6"K#RL@!^8C].%'BZ*EX*Z7P&+S+_L9AB
M3J0Y6C"R1 -/Z1&=SP:,8^5\D]8^O;W?LYDZW71BVR<'[EJ!\:E,&%XZ 2.+
M#5G^5RKU196AS\1,J;!0;I;+)J1@))TIEH113C9F_ET2:78='_Q,5+B'9P4F
MY1H,,\/T49.9L<= 7L7NN&=;QR='W5.[<]P]MGL' -RAU2CCOQ+X^W[L,[ZO
MSZ!>E 4E2!E;0N&)$J;I7%%<D*\IL#"""5*3XXYJA[B!H'Q8O4._41'JKB!4
MQ:!@E77:Z>;<C+(*X^J24?$+ "[>:YZ].)[9+X%GE =:?T8>/8+AJGPXF_&F
M)"&F E@(WDG--T,/8\803"/:)+!1)D! :12K-L?<T^=!H4\SU7H=!JF49:2+
M$V@(]'E9,K1H 9H/,&]CXV9"W+JG!^6&1$7&I[JY'[+OL-Y!/N.^@\)31C:5
M)KUUXTYCX1.1^:;W;=IN)FY"%L<I,((NH.KEIJQV5KB*"9"M#">2.)(D&.)5
ME:!LOR'7G>W_@ .BM'Y+)?R49U0MG7)^(012?H56SKM>L]OK:J[U6\I_2$A[
M])3$2><IF:-F]^B^$'P1WWH?YI0K<F;=[\W\MGL]H_P'1I?Y6.2:1;D[!T3-
MJ2#XBY.]F_K$9NK?ZIX2NMXBU_(<K'3FT!=:X6(>^AE9YMKWI,!^%;\+2&@'
MH8]8>"&RLQ\3G15:;<RE.OR/A'_'XHO6*N6.A!24[$4\]XO.[Y;.[H6Z8&^Q
MGE;@V[T$4(X9A9[H'GX;TV)#F'Y4FGR_W</M)4I+MM9V<C9E3MT>U.M#'=(Z
MI,\1THCZ/B,_;TBW=:]G9P/Z&$=?Y'J]M;M]:_=</C8OFO5ZO:N5X 46]SJD
M=4CW+*3U>EVOUUMZZ"RD)$##!?%216\)&@4!]8A8S8@:W/\*[N&UH-RC"6;K
M"#<>ZXG@4]_R^5F>U?W&=(7@WCRPNW,/+H=5RYS@&<EKK(D#X(N#V1PO9=8\
M]UOZ\?"S5_U6]ECY/U!+ P04    " #=.V)6H.Y-9G,%  !&+P  #P   '9E
M<G8M97@S,E\R+FAT;>U::W/B-A3]OK]"S4XR808#-I"'33/#)F2::1LR@72V
M'X4M8W5EV2O) ?KK>^57'I"DTX8-))X0P-:5='WN.5?7PKU A>SD$^H%!'OP
MB7J**D9.!E^-MM5K9@?0W,S;>Y/(6R"I%HS\O!-B,:7<1CA1T4\TC".A,%=.
MC#V/\JF-CN*YLY,.&A==%)DK@W*/<&6W&JU=QX^X,B3]F]@F',?*R08U5!3;
MV8G4PL<A90M[3$,BT269H>LHQ+PPGD1*16%NGTZ!&9URFQ%?@0<]/43AP2R@
MBA@RQBZQ8T&,F<#QLA?W)]W[GD3*Z0N*6?:UCB3FTI!$4-\)8?X9]51@^U09
M+O2#:X-)]SZ;!RVGU]0CG?2:\5OB(.@T6 )B@MUO4Q$EW .O621L,9W@_58]
M_:LY2^?,FO,T=C.BI[ G$?/6 >9@'M )5:AM-:Q7@=0\^K^8NC /$=L,ZNG@
M>GQQ?G':'U\,+]'5S?7HIG\Y1N/A9I!V^P$VC]!-8]0X;:#1X#0%V6QW6W74
M'Z'^V?!J/#BK4']]U NLCUL':'B.QK\,T*A__:5_.1@9PZ^_#?Y$_=.Q;K%:
MK7^53#J-;KO]0CJQUK%4K0-U'HD0LW7@?L$1''#B*AIQ-*,J0"H@J,]Y@AFZ
M)KH\0-!R#AX@L_4KBGST!Q&W!(T# FZ21%%7UM$%=QMH7W?=^SRW6J;KG$9A
MC/DB._2<&O(CD8[M4^G"V N"!2(0+ ^=$9>$$R)0VZQ#@"VKCK $.P9MI4LC
MXB:"*@KQP=Q#@[D;8#XE".8)J93:?7AI2P\K@L [ KX^<"F[G-(C\!IDS1B5
MT/$L$K>8U9%+A*+^HH[B1,@$*B.D(G0O)^1(93D!O,1>%"OP\[YY8:3)##ZD
MWF,QP9Q(8SAG9('ZKM(MFLQU:,?*?L1IC]X^+-@,S37-:NMHUUG*+AZ5,<,+
MVV=DOH+B?R527U01]]3,D H+Y:1$-H!_H;0G6!)&.5E)^SL&:6D=[KXG'3S
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MKZF?@S_YU&NFS\__ U!+ 0(4 Q0    ( -T[8E8-K%QSK3@  &]+   2
M          "  0    !I;6<R-#,U-3$V,SE?,"YJ<&=02P$"% ,4    " #=
M.V)601)!]88C  !O)@  $@              @ '=.   :6UG,C0S-34Q-C,Y
M7S$N:G!G4$L! A0#%     @ W3MB5E3J!*7](0  UC8  !,
M ( !DUP  &EM9S(T,S4U,38S.5\Q,"YJ<&=02P$"% ,4    " #=.V)68'@%
MTFLZ  #>40  $P              @ '!?@  :6UG,C0S-34Q-C,Y7S$Q+FIP
M9U!+ 0(4 Q0    ( -T[8E;>.N4RB[4   /S   3              "  5VY
M  !I;6<R-#,U-3$V,SE?,3(N:G!G4$L! A0#%     @ W3MB5F%&.>3H+@
M,SP  !,              ( !&6\! &EM9S(T,S4U,38S.5\Q,RYJ<&=02P$"
M% ,4    " #=.V)6$2SBE(!4  "M=   $P              @ $RG@$ :6UG
M,C0S-34Q-C,Y7S$T+FIP9U!+ 0(4 Q0    ( -T[8E9;B=151A\  "@S   3
M              "  >/R 0!I;6<R-#,U-3$V,SE?,34N:G!G4$L! A0#%
M  @ W3MB5F:=_Y9S<   G1(! !,              ( !6A(" &EM9S(T,S4U
M,38S.5\Q-BYJ<&=02P$"% ,4    " #=.V)62.S5EQLM  !:-P  $P
M        @ '^@@( :6UG,C0S-34Q-C,Y7S$W+FIP9U!+ 0(4 Q0    ( -T[
M8E;-%!#1$B@   HR   3              "  4JP @!I;6<R-#,U-3$V,SE?
M,3@N:G!G4$L! A0#%     @ W3MB5C:C+PW9+@  \3(  !,
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M-#,U-3$V,SE?,C(N:G!G4$L! A0#%     @ W3MB5I3R60?[1P   5,  !,
M             ( !U-H$ &EM9S(T,S4U,38S.5\R,RYJ<&=02P$"% ,4
M" #=.V)6RM.GP1U&  !:4   $P              @ $ (P4 :6UG,C0S-34Q
M-C,Y7S(T+FIP9U!+ 0(4 Q0    ( -T[8E9QP.BZ/AX  $LQ   3
M      "  4YI!0!I;6<R-#,U-3$V,SE?,C4N:G!G4$L! A0#%     @ W3MB
M5BI? X-_RP  /@,! !,              ( !O8<% &EM9S(T,S4U,38S.5\R
M-BYJ<&=02P$"% ,4    " #=.V)6X,.9F3-V  "_PP  $P
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M-34Q-C,Y7S4N:G!G4$L! A0#%     @ W3MB5DDXQ3J*S@  ,C@! !(
M         ( !I,\' &EM9S(T,S4U,38S.5\V+FIP9U!+ 0(4 Q0    ( -T[
M8E9D&OZS5Q\  /X@   2              "  5Z>" !I;6<R-#,U-3$V,SE?
M-RYJ<&=02P$"% ,4    " #=.V)6;T7T>_16   49   $@
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " #=.V)6]:A6^GQ#   8ZP0 %0
M        @ &O;0\ =F5R=BTR,#(R,3(S,5]D968N>&UL4$L! A0#%     @
MW3MB5E@\GITX[   CM,* !4              ( !7K$/ '9E<G8M,C R,C$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( -T[8E8_;/I T&<  )(*"  5
M      "  <F=$ !V97)V+3(P,C(Q,C,Q7W!R92YX;6Q02P$"% ,4    " #=
M.V)6 NSDFM]@  #@MP, $               @ ',!1$ =F5R=BUE>#$P7S(R
M+FAT;5!+ 0(4 Q0    ( -T[8E:R>G?!!1L  %4Z 0 /              "
M =EF$0!V97)V+65X,3!?-2YH=&U02P$"% ,4    " #=.V)6=HM);DP,  !X
MI@  #P              @ $+@A$ =F5R=BUE>#$P7S<N:'1M4$L! A0#%
M  @ W3MB5EL4@P?L P  D!T   \              ( !A(X1 '9E<G8M97@R
M,U\Q+FAT;5!+ 0(4 Q0    ( -T[8E:*=?NW*@D  )%1   /
M  "  9V2$0!V97)V+65X,S%?,2YH=&U02P$"% ,4    " #=.V)6.CYTC2 )
M  ")40  #P              @ 'TFQ$ =F5R=BUE>#,Q7S(N:'1M4$L! A0#
M%     @ W3MB5A<&S8MY!0  72X   \              ( !0:41 '9E<G8M
M97@S,E\Q+FAT;5!+ 0(4 Q0    ( -T[8E:@[DUF<P4  $8O   /
M      "  >>J$0!V97)V+65X,S)?,BYH=&U02P4&     "L *P#&"@  A[ 1
#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
